<SEC-DOCUMENT>0001655759-23-000010.txt : 20230223
<SEC-HEADER>0001655759-23-000010.hdr.sgml : 20230223
<ACCEPTANCE-DATETIME>20230223172622
ACCESSION NUMBER:		0001655759-23-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230223
DATE AS OF CHANGE:		20230223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARVINAS, INC.
		CENTRAL INDEX KEY:			0001655759
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472566120
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38672
		FILM NUMBER:		23661140

	BUSINESS ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-535-1456

	MAIL ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS INC.
		DATE OF NAME CHANGE:	20181001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS HOLDING COMPANY, LLC
		DATE OF NAME CHANGE:	20151015
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>arvn-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:e632b970-0fa5-4bd1-afa0-85cac57f3761,g:02db76aa-3c10-4220-82b9-6cc6c0294fe6,d:a936ede3f23041239a783a07e7f93c48--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:arvn="http://www.arvinas.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arvn-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV8yLTEtMS0xLTQ1MzM0_14b2ddae-cf81-47c7-98d5-ae5ab9d8d47a">0001655759</ix:nonNumeric><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV8zLTEtMS0xLTQ1MzM0_83b0dc65-1a21-4b72-98a6-676d092b667f">2022</ix:nonNumeric><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV80LTEtMS0xLTQ1MzM0_92aef757-4fe6-4423-9b2b-56fe02c0c443">FY</ix:nonNumeric><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV81LTEtMS0xLTQ1MzM0_1791d19b-31a7-4893-8103-14a29bdfb1db">false</ix:nonNumeric><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV82LTEtMS0xLTQ1MzM0_a4582ddb-399d-4cc0-8fc4-9158effd2106">Yes</ix:nonNumeric><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV83LTEtMS0xLTQ1MzM0_c646a26c-b17b-4f2c-a97f-40a76b70ffeb">Yes</ix:nonNumeric><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV84LTEtMS0xLTQ1MzM0_b0d9abb7-42e6-47eb-be35-d2730678a5c8">No</ix:nonNumeric><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV85LTEtMS0xLTQ1MzM0_184484c4-9e33-4461-8268-ec5d72186934">Yes</ix:nonNumeric><ix:nonNumeric contextRef="i1e801491e3064f7e8860d42f7cd1d807_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzItMS0xLTEtNDUzMzQ_80a0dda5-94ea-4289-80be-96fd1a6d6b63">1</ix:nonNumeric><ix:nonNumeric contextRef="i37df6405966e4a9bba28bd31c157a857_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzQtMS0xLTEtNDUzMzQ_c4a33286-7b0c-4eee-a3cb-a8307661d733">1</ix:nonNumeric><ix:nonNumeric contextRef="i3bd0aacedfdf49bf999f9c0416ec3008_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzYtMS0xLTEtNDUzMzQ_e0292168-c96e-4d5f-ba05-c093d7e7280f">1</ix:nonNumeric><ix:nonNumeric contextRef="ic4368412362e45bba2473a1217491133_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzgtMS0xLTEtNDUzMzQ_47d49ce6-4ac2-4cf4-8c09-4431b9c1f577">1</ix:nonNumeric><ix:nonNumeric contextRef="i672048308c094a4fbb8e393353f2cc46_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzEwLTEtMS0xLTQ1MzM0_aa113f81-e516-4bb2-97a2-1bd04a7fe144">1</ix:nonNumeric><ix:nonNumeric contextRef="ib73fa643c9664e9aa6e824a9828957e4_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzEyLTEtMS0xLTQ1MzM0_02f33142-358a-42b8-a9f4-12e89fd06b42">1</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpenseDebt" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80NTUvZnJhZzoxNzhkZTQ3NzhkNzI0ZDg1YmUwMmZjOWU3M2Q4YTRkNy90ZXh0cmVnaW9uOjE3OGRlNDc3OGQ3MjRkODViZTAyZmM5ZTczZDhhNGQ3XzI3NDg3NzkwNjk0NzU_03bdee86-5a25-4b61-b9dc-62f2284faf92">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80NTUvZnJhZzoxNzhkZTQ3NzhkNzI0ZDg1YmUwMmZjOWU3M2Q4YTRkNy90ZXh0cmVnaW9uOjE3OGRlNDc3OGQ3MjRkODViZTAyZmM5ZTczZDhhNGQ3XzI3NDg3NzkwNjk0NzU_14f68dbf-8950-42d1-92d0-caa5a47871ed">0</ix:nonFraction><ix:nonNumeric contextRef="icfabad7e7058466fb197da797a83c8d6_D20180301-20180331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQ2Mjg_cc30fc57-88bc-4fe7-a68a-ecb6f7074afc">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arvn-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2bf8d71415f4efa90cde8b45af0012e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i902528dd801a41cba33017f4bcccec14_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62b9074c6dbb4f3fbdbff41dce34d514_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f51f7f7a9845899d4dd0c5fc38d3c8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5126550f14e04feb9ca9ca6b7e02ed04_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib59969a5f0034e8e9c7010fd7f0be379_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35327f5dcba84428bcd65e20009ba82d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6be069e34bc4e4dab6470f86f377631_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2da99b1272604c40b299c7e2a492b717_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff0703d3445f4aebac374d380138baf6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a5a6b31a7ca4b5e825ff2a8e5104399_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58e74e4ca00a46a298dd26d104628c71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb59a32694da4a52a057a3d5d4602acb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9803bb2bac440b9a73f90689f2b195a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3f132181ab4f2782eda83c630d9771_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d68e78d78a7421fa07de080fcab1007_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82f79a4ab8ad48ac808ede7cafff07d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic150bcdd10a44a698d262678b95dc444_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ae1926583c8447eb7a2bf92b4691763_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i189cf08cd0b147de9ee24b6f4241c087_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c56b6a959914b1fa1a46f86145ab11e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a8a21d9b2d1414aaf530880ae2aa161_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9275d362a24c8a9d71ee61e0d22587_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20400f57ea38437d8f5a5a76227f5779_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i332f5a83e3e04dc99cf119f9afdf4c9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i515d8e18c44c4d4eb75265ed7439e978_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d0618dabaa4dde950863143d4eba01_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id43fad10517549efbe1041cf1a7ac9c6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3328081fbb1245bea8d77942437e9fda_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1c26cc298914577ad3d74291efe85aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49058d6c0fee45bc82e5a3b3d793c61b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec633905ec142408e34afcd540d6467_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbedba621b114c17bd11d5578ed1e6c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c91e2ef842a460da45c1b6475a741ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ca8da516e7499682d587c74985691c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i765b24d88e5044b0b3474cc202e4c269_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>arvn:Subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="i8f3407ea1c884292b6b1262e24808e77_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05529346f2bd43978586c86e2c968da8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2cf9012e2f3e483fb7f5830d388d4178_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1ef30395c542ec9b2036e573ee37fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93dabaf08df04303b0314c7df4d8e165_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43bf74e98bde44c59baa52f0d2d487fe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f476fc73a34c9e810fa5b3bfabf520_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8bb00294943430a85af5e662821b3fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="operating_segment"><xbrli:measure>arvn:operating_segment</xbrli:measure></xbrli:unit><xbrli:context id="i3c8b495cdfa84814911559b730f66a7e_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id72a39411b0248c680378066eb3c8a44_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia18bd320049b4bbba687aa9d1e399170_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae355cb2cbd14a7ca7ce12fab1f7f070_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49f4a72ec629422dafd039f183564403_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008bbd6d947d479fad8e8cd49d905905_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib894aa0b10644e20af715749fe409cc1_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i137647b8ea294b7f923d056ee2a3185a_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0122cacce6947ffb02e9a5170ae43e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f9942e42d3140f8a91bf2d658e6dcf3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5e7ec5fd01749818f635a4f60e5162b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1c1ec77b77045b497b74778ed6dd646_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7526a5f18544f7e93c796607abcc906_D20190601-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c577e36553475a87e391c1f798aa7b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48ac848348704c25879ff7a321b30a93_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd3db3e1a3a44d7eaadb52f8b2021f2d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic37540796dbd46e89f0413e7111cb541_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63bcebaaf3e442f0be53ff2a3cd2ab6b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id766159d435e4384b6f8955f4aa30c00_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60b38ed093ce46b7bd1daba503d94341_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ae4abd92fa47a5b59e353890bedd74_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaf06e4b711c47f79d1671a25c581273_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b133ccf8c94b249e0de13cf22af00d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a14b1ae339242c8b514f80494ac7461_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8056d73a6e7d4769acafb7929251b89d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic134f4ad0212413fb29264d3665de649_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd68967c863457f9a819376746fa6fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i877187a756224a52a50870299413f7a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:AdditionalTargetAndServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i660d8e9f27ff4dc1a01397df66df2870_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:AdditionalTargetAndServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94762668373b4b67bb84c11c71e8cdb1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759fe1462729496ba429f2526fc8aff5_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a9898905f154cf8b9795022a7300014_D20150901-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>arvn:Target</xbrli:measure></xbrli:unit><xbrli:context id="i8cc6a3e194a5420ea29436a5800706bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5473a14476bb4d1885b2439dc1d56870_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8eb28a02b3f4a66aeb3f487c3c1bb6b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i095c155f507a4c09a74c9bc2d95f96ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bbb1ec29ec94c9f87ada6000b54a3fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i247c5fdfe9cf425da9589cd446cbbdb1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ea29be677eb40da8b1cb7c47d711d2d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e801491e3064f7e8860d42f7cd1d807_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37df6405966e4a9bba28bd31c157a857_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd0aacedfdf49bf999f9c0416ec3008_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4368412362e45bba2473a1217491133_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i672048308c094a4fbb8e393353f2cc46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib73fa643c9664e9aa6e824a9828957e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11ac1a1558a74e50b590271f7dea04b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2baa9d5c1314262a04322fd5725c7b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2517bd9479df46dcac4edde8de8fbf8b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e71741f7e2c4379b7adad37f613ae6b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb3556f23c44e99bce5894aafa9c448_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46cfa718400a42c5a9f24fb1d208bf44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49bcbdd1acfc42b186645d856f68c30a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice07d9029aa84199ac8be838d60ae4a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7090b40f62334eab9ab385c427bcecdd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24c2800943e64589bfe1be38fdfcdeac_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i058eebe5acbf4e69a811a1f3713b1674_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65535f62f10e4ef4870538c48dee40d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida76e88673e6409baa83b50282beff61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a77e93668514396822e5760f192b979_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a171973241c4a65b20f085ad93852a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80ab38e360f943d6a594d05213ee4b3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i079086717708440bbc6bde6339a2c26e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i435f3577adb6471086574fa92705b9b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc16f834f8e48cca3a2cc04f3bdb2ab_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i75b6e519c7cb4a81826452584ae57c12_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PledgedStatusAxis">us-gaap:AssetPledgedAsCollateralMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i172eba417a7443088682953acc866535_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PledgedStatusAxis">us-gaap:AssetPledgedAsCollateralMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78cc6c1900c646e7a686f9fcfb72aaf7_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe4cc386917403580675ce1a278cc64_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9675174a7b047df809244be6ddfdc48_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i076af9c270b244029a1fd9d8b3982564_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6661ad55442349ec8d7ed679ec7f076a_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53fe0650f7c54cf9ae9a1454d05ebdc7_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c91c1b5ea044c539a1158ebd4047fc5_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477280be32f04a07b28c112beeada17e_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d949a3402824e308e36a3888973c554_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2470b93587642ee93b6862f8c50a373_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>arvn:vote</xbrli:measure></xbrli:unit><xbrli:context id="ib169c00592d548a6a517237266872f3e_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3746b160a6d94d569ae602cad6e75837_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i991152e66e4e40e9bc87485ec165e1ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2470ca2aeec0492f9ed6572c69865095_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b0bd17747b4688858d04a773ba7ca5_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7510f41e99a44e9ca02267aa1713991c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31413367d46d44f0931cd3029d3ff4ef_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1acbc8a7b44d439c12403bc1c92244_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec89f9a651ba481db8272f35c6c0df8e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i639e7b73e496499384ef668da7babf51_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49494ba6d0a5453c93d7b34884260277_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dcf04ef5c59465f95dac5b9e575482f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia846f83b7f644f2a8e79d0645dc59a76_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfabad7e7058466fb197da797a83c8d6_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if26c93c17a9d49abbe7e03e1fcfe3fdc_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ab2311054644dec946b5c3b15b4ac53_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf4d92b3f5524d2ca5cfdb2b7d2ecc62_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic70f3f6fa6df4c48b0dda80d2a243089_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3160983fd398465eb653ad6cd4b8665c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f56a6f1dc8a4a1cb8a2a3b2b8c32f00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if489ed4aaa6246e6bd13294c53489cff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf5f5dfe6c4149dba9168a6e138aad59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf91003a0cee40d78e7d885446a5b900_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1574e37a15e549dfb509f0a9a114356d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i354e561295fa4c89814e4858d5d58e62_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09e4011096b842ed87640ac7cc8d1cb1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia382a82cd26a4f6289ea15987b91a7b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib731e741df304e76af7f4302010536a3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a73ff779bf416cb4eebeeae68b3d11_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4ccd6ef3f64b6b9e8ca76e68ac3d86_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b0ed0665f494c7c902dffd54470764e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a433e284fc436190fc991a5d7d1826_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideae804a84b646ac95f9d6e31422f985_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife9054bd93cd4ee890d1bb3769253bbc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d25eae66f4940efbc51ec06b70565d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b0c4960152f4b068f2e7ff788c1f577_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07de6ac05c1e41a9b8b94c23de19c282_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b24196f7ab4e96948b59541f2a2454_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i825713991b7d4d6ca930134e1ea64f3b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64e8a70e80d34c36a994fb20b47a535c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9135a832bfa141bdaea8cd60e7266128_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbbd49660da24081b31f3017c1fb0202_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81e6172dea754fde956550d07bd3297c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee0ea6f5d3fd49e6bcd4ffc8b9e8f561_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba241f8483c4d27abe31fc22d087023_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19ac2aec78b54b438d208831130b52be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9391f67286954fea9ef7f855af5453c3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2942bd6c0af14feca606f6c2cf37f948_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife636ddfe9704222b932ba3a4f39e4d6_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d437e8b17c84126a8ff5f6624f1cd05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d95876f6cfe490fb65fd87f81be2616_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc24f8c5be114f76ab380633238bd2df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i808530cbe2df478ca19263be75cce162_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ce462a88c514f3db5b77585aa66ba25_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b75291c93af4cb4b6f481d140f1d96f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a596c4754f948a899d60103c138350e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfbc96733ba14eacba1def4f1f53391f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d1a440ff1814ec2b2967dbc51a0a62c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f581941be6141b8a521496421ffb373_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecde1bb80509425b97c53198d17cd282_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i462d342906254aa08ed253bed2a62c4c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ad4e65cba64ab792067ed0244886b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1330642a737d458aa14cb794d465bbbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f49b42bb24b4669b993f69de2a04054_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1938c4bd324660821a879962862c4e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98620edc8ebd468da40a2ba163c12f1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief8ca6ef40ac464c81aebbad3e910b38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cc8adccf5a84a7e82138a769bca1f6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadb5ee3cd631498e9f704ed1e3083c3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b912e140bd549c59a71222eff36d168_D20130701-20130731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-01</xbrli:startDate><xbrli:endDate>2013-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e872fdee2484e02a8eecae47bd8d71c_D20130701-20130731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseFirstLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-01</xbrli:startDate><xbrli:endDate>2013-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71af99d94a15409d814e3bc898621bc3_D20130701-20130731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseSecondLicensedProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-01</xbrli:startDate><xbrli:endDate>2013-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c4e41fe7c444302a2f4e5632b5df43f_D20130701-20130731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-01</xbrli:startDate><xbrli:endDate>2013-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bcccb8aa5c3415c94857cd84457d1c3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc0e2f0ce3a94a72a40371967158f45d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8f55863c58b46e580d64c087d73a211_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i496ab182e9bd4c7fb0d9db9b728a6798_D20220604-20220604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:FoundationMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-04</xbrli:startDate><xbrli:endDate>2022-06-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d22ed283414299b6a543fcde594e37_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i131967269d424a0a9e25495c62957e55_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia927654c60d84e7a99159c1cae642735_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008486f737c64fb5890db18235e070ff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia62bc0fe985a441ab8b2ca63ed56b425_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25d62ff1d49b406c840997107b6eae57_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccb0fc5624af4bea97bb6b0b4030e038_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e8a5c5471147159a6cf356c1ed6b90_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ad800b817ff41fc9a94dc8de9936747_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia936ede3f23041239a783a07e7f93c48_1"></div><div style="min-height:14.4pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDY3_e2de66c3-4575-454e-bef0-10f50d2807a5">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">________________________________________________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6ZjBmOWI3MGJhNTdlNDVhM2JhZGNiNDdkM2ZmMjE1MjgvdGFibGVyYW5nZTpmMGY5YjcwYmE1N2U0NWEzYmFkY2I0N2QzZmYyMTUyOF8wLTAtMS0xLTQ1MzM0_287d7dd0-cb48-4aef-9f7f-5a77b1cadaa0">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8yMzI_787d3ed9-c0f4-4e5f-ac8c-a78e3e4971b2"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8yMzI_453e4ca9-3580-4fdf-885a-ad2721154552">December 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR </span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NjFkYjRlY2I3YTk4NGIzMzg1YWM3NWZiN2IxZDZiY2YvdGFibGVyYW5nZTo2MWRiNGVjYjdhOTg0YjMzODVhYzc1ZmI3YjFkNmJjZl8wLTAtMS0xLTQ1MzM0_6f8106a4-df96-4a59-9ca9-feea10770331">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; .</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDYy_63452e43-4652-4082-bf1f-8c13d570baf7">001-38672</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDYz_cd3810f6-34eb-48eb-bfa2-0e7adade9d06">ARVINAS, INC.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its Charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8wLTAtMS0xLTQ1MzM0_f7ff6bd7-7cac-4626-91c7-f52adbbc4f4e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8wLTEtMS0xLTQ1MzM0_2aeb08dd-d3c7-482b-a1ff-7c095eb82f18">47-2566120</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8yLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MGM2ZWYwMmY1N2Y3NGY3NGIzYTEzYmJlNmU4MjhjMGVfNQ_10020a03-844a-489b-9f76-c272b8beca64">5 Science Park</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8yLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MGM2ZWYwMmY1N2Y3NGY3NGIzYTEzYmJlNmU4MjhjMGVfOA_2fddb7df-ae52-497e-a0be-d70e05514bbf">395 Winchester Ave</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8yLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MGM2ZWYwMmY1N2Y3NGY3NGIzYTEzYmJlNmU4MjhjMGVfMTI_5b0aa51c-3c4f-465d-8e76-707da5378d0c">New Haven</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"> <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8yLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MGM2ZWYwMmY1N2Y3NGY3NGIzYTEzYmJlNmU4MjhjMGVfMTY_d26c9ceb-5491-4b34-974e-ebc8d50898e7">Connecticut</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8yLTEtMS0xLTQ1MzM0_2b4944d0-59b8-46e6-a49d-3a442897cd2d">06511</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDY0_92c1d022-37a4-4ab8-ab83-78996e22b2b4">203</ix:nonNumeric>) <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDY4_3ec8e183-c0c8-4662-a6a2-5cd202f9c717">535-1456</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Title of each class)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 3.28pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Name of each exchange on which registered)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NGIwNzgwYjk0YzZmNDk4NjhlNjcxZDc0M2IwZmU5NjgvdGFibGVyYW5nZTo0YjA3ODBiOTRjNmY0OTg2OGU2NzFkNzQzYjBmZTk2OF8xLTAtMS0xLTQ1MzM0_d52d2b42-3322-4c9d-924e-a54a951bbe16">Common stock, par value $0.001 per share</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NGIwNzgwYjk0YzZmNDk4NjhlNjcxZDc0M2IwZmU5NjgvdGFibGVyYW5nZTo0YjA3ODBiOTRjNmY0OTg2OGU2NzFkNzQzYjBmZTk2OF8xLTEtMS0xLTQ1MzM0_18cd75b5-1fe9-418c-a454-8db6ac822764">ARVN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NGIwNzgwYjk0YzZmNDk4NjhlNjcxZDc0M2IwZmU5NjgvdGFibGVyYW5nZTo0YjA3ODBiOTRjNmY0OTg2OGU2NzFkNzQzYjBmZTk2OF8xLTItMS0xLTQ1MzM0_de472043-4fb9-49f8-a2af-633ff8658340">The Nasdaq Global Select Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Title of class) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> NO </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">YES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> NO </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> NO </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:20.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NWUzMjUyMDY0NGQxNDBjZWIwNjdlNzFjMzgzZGU5MmQvdGFibGVyYW5nZTo1ZTMyNTIwNjQ0ZDE0MGNlYjA2N2U3MWMzODNkZTkyZF8wLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MWZiMWM2OTYyODRjNDk1MWIxYTRjZjk4Nzc1YTY3NWRfNA_497d94bf-a3a2-4347-b78f-a5e2e49955b7">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NWUzMjUyMDY0NGQxNDBjZWIwNjdlNzFjMzgzZGU5MmQvdGFibGVyYW5nZTo1ZTMyNTIwNjQ0ZDE0MGNlYjA2N2U3MWMzODNkZTkyZF8xLTQtMS0xLTQ1MzM0_92d5f305-d5a3-4ed3-a711-0e86a6f7a09a">o</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NWUzMjUyMDY0NGQxNDBjZWIwNjdlNzFjMzgzZGU5MmQvdGFibGVyYW5nZTo1ZTMyNTIwNjQ0ZDE0MGNlYjA2N2U3MWMzODNkZTkyZF8yLTQtMS0xLTQ1MzM0_36901ca1-053d-4c8d-af3f-aba42aa55e47">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDcw_e417616e-a817-4831-8bbe-8b709283c0b6">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES &#9744; NO <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8yNzQ4Nzc5MDcyOTIz_d1f4f192-51c5-4ea1-86a4-27efa870f67e">x</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of June 30, 2022, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="ie2bf8d71415f4efa90cde8b45af0012e_I20220630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8yOTI2_c621de1c-7a77-471e-ad03-360d46ac94ec">2,175.7</ix:nonFraction>&#160;million, based on the closing price of the registrant&#8217;s Common Stock on such date. The number of shares of registrant&#8217;s Common Stock, $0.001 par value per share, outstanding as of February&#160;17, 2023 was</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i902528dd801a41cba33017f4bcccec14_I20230217" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zMTA4_9478e652-25bb-40e9-a992-7c313128a0ed">53,271,491</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDU3_7ddd66a8-a112-4f44-ab4f-a0687c9c373e" escape="true">Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant&#8217;s 2023 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December&#160;31, 2022.</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:14.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_16">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_16">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_16">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_19">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_19">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_19">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_22">Item 1B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_22">109</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_25">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_25">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_25">109</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_28">Item 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_28">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_28">110</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_31">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_31">110</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_34">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_37">Item 5.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_37">111</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_40">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_40">[Reserved]</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_40">112</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_43">Item 7.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_43">112</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_61">Item 7A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_61">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_61">127</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_64">Item 8.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_64">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_64">127</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_67">Item 9.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_67">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_67">127</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_70">Item 9A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_70">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_70">127</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_73">Item 9B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_73">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_73">130</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_76">Item 9C.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_76">Disclosure Regarding Foreign Jurisdictions That Prevent Inspection</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_76">130</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_79">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_82">Item 10.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_82">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_82">131</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_85">Item 11.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_85">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_85">131</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_88">Item 12.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_88">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_88">131</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_91">Item 13.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_91">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_91">131</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_94">Item 14.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_94">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_94">131</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_97">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_100">Item 15.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_100">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_100">132</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_103">Item 16.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_103">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_103">136</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;goals,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress and results of our current and future clinical trials of ARV-471, bavdegalutamide (ARV-110), and ARV-766, including statements regarding the period during which the results of the clinical trials will become available;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of, and our ability to obtain, marketing approval of ARV-471, bavdegalutamide (ARV-110) and ARV-766, and the ability of ARV-471, bavdegalutamide (ARV-110), ARV-766 and our other product candidates to meet existing or future regulatory standards;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential achievement of milestones and receipt of payments under our collaborations, including our collaboration with Pfizer Inc., or Pfizer, entered into in July 2021, or the ARV-471 Collaboration;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to pursue research and development of other product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to submit Investigational New Drug Applications or Clinical Trial Applications;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential advantages of our platform technology and our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our scientific approach and platform technology may potentially address a broad range of diseases and disease targets;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential receipt of revenue from future sales of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the potential market opportunity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our sales, marketing and distribution capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain arrangements for manufacture of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into additional collaborations with third parties;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of COVID-19 on our business and operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of government laws and regulations; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#8220;Risk Factors&#8221; section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our future results may differ materially from what we expect. We do not assume any obligation to update any forward-looking statements except as required by applicable law.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Cross-trial comparisons are not based on head-to-head studies and no direct comparisons can be made.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Annual Report on Form 10-K, the &#8220;Company,&#8221; &#8220;Arvinas,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; except where the context requires otherwise, refer to Arvinas, Inc. and its consolidated subsidiaries, or any one or more of them as the context may require, and &#8220;our board of directors&#8221; refers to the board of directors of Arvinas, Inc.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Arvinas name and logo are our trademarks. We also own the service mark and the registered U.S. trademark for PROTAC&#174;. This Annual Report on Form 10-K contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks that if realized could materially affect our business, prospects, operating results and financial condition. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. These risks include the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability. Our net losses totaled $282.5 million, $191.0 million and $119.3 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. To date, we have not generated any revenue from product sales and may never be profitable.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding to continue our operations. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts and raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our approach to the discovery and development of product candidates based on our PROTAC technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We are early in our development efforts. We are developing ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer and bavdegalutamide (ARV-110) and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer.  Additional product candidates are still in preclinical development.  If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Drug development involves a lengthy and expensive process, with an uncertain outcome. We cannot be certain of the timely completion or outcome of our preclinical testing and clinical trials. and cannot predict if the FDA or similar regulatory authorities outside the United States will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs. The results of preclinical or early clinical studies of our product candidates may not be predictive of the results of later clinical trials. In addition, interim top-line and preliminary data from our clinical trials that we may announce or publish from time to time can change as more patient data becomes available and are subject to audit and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">verification procedures that could result in material changes in the final data. If we are unable to obtain, or there are delays in obtaining, required regulatory approvals, we will not be able to successfully commercialize our product candidates and our business will be materially harmed.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We are developing and may continue to develop our product candidates in combination with other drugs. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, or revoke their approval of such drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of or market our products.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have, and anticipate in the future seeking additional, third-party collaborators for the research, development, and potential future commercialization of some of our PROTAC programs. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. Further, we may seek to establish additional collaborations. If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely, and expect to continue to rely, on third party research organizations to conduct our clinical trials and third party manufacturing organizations for the manufacture of both drug substance and finished drug product for our product candidates for preclinical testing and clinical trials, and we expect to continue to do so for commercialization. If the third party research organizations on which we relay do not perform satisfactorily, including failing to meet deadlines for the completion of trials, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Further, our reliance on third party manufacturing organizations may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to grow the size of our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. In particular, if we are not able to establish sales and marketing capabilities, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired, and we may not be able to compete effectively in our market.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ia936ede3f23041239a783a07e7f93c48_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. We use our PROTAC Discovery Engine, our proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body&#8217;s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines. We have a robust preclinical pipeline of PROTAC protein degraders targeting a broad range of intracellular disease targets, including those representing proteins that currently cannot be addressed by existing small molecule therapies, commonly referred to as &#8220;undruggable&#8221; targets. We are using our PROTAC Discovery Engine to build an extensive pipeline of protein degradation product candidates to target diseases in areas of unmet need, including oncology (including immuno-oncology), neuroscience and other therapeutic areas. We have three investigational clinical stage programs:  ARV-471, a novel PROTAC estrogen receptor, or ER, protein degrader for the treatment of patients with locally advanced or metastatic ER positive / human epidermal growth factor receptor 2, or HER2, negative, or ER+/HER2-, breast cancer and bavdegalutamide (ARV-110) and ARV-766, each an oral PROTAC protein degrader that targets the androgen receptor protein, or AR, for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-471</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-471 is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. We are co-developing ARV-471 with Pfizer, Inc., or Pfizer, pursuant to a collaboration agreement that we and Pfizer entered into in July 2021. We granted Pfizer worldwide co-exclusive rights to develop and commercialize ARV-471. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In preclinical studies, ARV-471 demonstrated near-complete ER degradation in tumor cells, induced robust tumor shrinkage when dosed as a single agent in multiple ER-driven xenograft models, and showed superior anti-tumor activity when compared to a standard of care agent, fulvestrant, both as a single agent and in combination with a cyclin-dependent kinase, or CDK, 4/6 inhibitor. In 2019, we initiated a Phase 1 clinical trial of ARV-471 designed to assess the safety, tolerability and pharmacokinetics of ARV-471, which also included measures of anti-tumor activity as secondary endpoints and in the fourth quarter of 2020, we initiated a Phase 1b cohort expansion of ARV-471 in combination with the CDK4/6 inhibitor Ibrance&#174; (palbociclib). In 2021, we initiated VERITAC, the Phase 2 single agent expansion cohort of the ARV-471 clinical trial. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the third quarter of 2022, we initiated TACTIVE-E, a Phase 1b clinical trial with ARV-471 in combination with everolimus in patients with metastatic breast cancer. Also in the third quarter of 2022, we initiated with Pfizer a Phase 1b trial of ARV-471 as a monotherapy in Japanese patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the fourth quarter of 2022, we presented initial data from VERITAC at the San Antonio Breast Cancer Symposium and we initiated, with Pfizer, the VERITAC-2 Phase 3 trial with ARV-471 as a monotherapy as a second-line and later treatment in patients with ER+/HER2- metastatic breast cancer. Also in the fourth quarter of 2022, we initiated the first of two arms in the ongoing Phase 1b umbrella trial of ARV-471, with ARV-471 in combination with each of the CDK4/6 inhibitors abemaciclib and ribociclib (TACTIVE-U). We initiated the second of two arms in the first quarter of 2023. In addition, in the fourth quarter of 2022, we initiated a Phase 2 clinical trial with ARV-471 as a monotherapy in patients with early breast cancer in the neoadjuvant setting (TACTIVE-N).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In the first quarter of 2023, we and Pfizer requested a meeting with the U.S. Food and Drug Administration, or the FDA, to review the proposed update to the trial protocol for the VERITAC-3 first-line, metastatic ER+ / HER2- breast cancer Phase 3 trial of ARV-471 in combination with IBRANCE&#174; (palbociclib) to determine the optimal dose of palbociclib as part of the trial design. Following correspondence and alignment with the FDA, we and Pfizer determined an approach to the planned Phase 3 trial to enable trial initiation in the second half of 2023, which includes a Phase 3 lead-in to evaluate the optimal dose of palbociclib (100 mg or 75 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mg) in combination with 200 mg ARV-471. This approach follows the recent analysis of data from the ongoing Phase 1b combination study of ARV-471 with palbociclib, in which an increase in palbociclib exposure was observed relative to historical palbociclib pharmacokinetic data.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first half of 2023, we expect, with Pfizer, to provide an update with preliminary data from the Phase 1b combination trial with palbociclib (Part C of the Phase 1/2 trial) and in the second half of 2023, we expect, with Pfizer, to submit and present data from the Phase 1b combination trial of ARV-471 with palbociclib at a medical congress and. Also in the second half of 2023, we expect, with Pfizer, to initiate a Phase 3 trial with ARV-471 in combination with palbociclib as a first-line treatment in patients with ER+ / HER2- locally advance or metastatic breast cancer. and initiate additional arms of the TACTIVE-U, Phase 1b combination trial with other targeted therapies, during 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bavdegalutamide (ARV-110)</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bavdegalutamide (ARV-110) is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the AR, for the treatment of men with mCRPC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, bavdegalutamide demonstrated activity of AR mutation or overexpression, both common mechanisms of resistance to currently available AR-targeted therapies. In 2019, we initiated a Phase 1/2 clinical trial of bavdegalutamide designed to assess the safety, tolerability and pharmacokinetics of bavdegalutamide and also included measures of anti-tumor activity as secondary endpoints, including reduction in prostate specific antigen, or PSA, a well-recognized biomarker of prostate cancer progression. In 2019, we also received Fast Track designation for bavdegalutamide for mCRPC. In 2020, we initiated ARDENT, the Phase 2 single agent expansion portion of the bavdegalutamide clinical trial. In 2021, we initiated a Phase 1b clinical trial of bavdegalutamide in combination with abiraterone for the treatment of men with mCRPC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we announced completed Phase 1 and interim ARDENT data for bavdegalutamide at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to initiate a global Phase 3 trial with a confirmed dose for bavdegalutamide for the treatment of men with mCRPC with AR T878/H875 tumor mutations in the second half of 2023. Also in the second half of 2023, we expect to complete enrollment in the Phase 1b clinical trial with bavdegalutamide in combination with abiraterone.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-766</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-766 is an investigational orally bioavailable PROTAC protein degrader designed to target AR with a different profile than bavdegalutamide, as a potential treatment for men with mCRPC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, ARV-766 degraded all tested resistance-driving point mutations of AR, including L702H, a mutation associated with treatment with abiraterone and other AR-pathway therapies. In 2021, we initiated a Phase 1/2 clinical trial for ARV-766 designed to assess the safety, tolerability and pharmacokinetics of ARV-766, which trial also includes measures of anti-tumor activity as secondary endpoints, including reduction in PSA. In the second half of 2022, we initiated a Phase 2 expansion trial of ARV-766 for the treatment of men with mCRPC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to share data from the Phase 1 dose escalation trial of ARV-766 for the treatment of mCRPC in the second quarter of 2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate initiating a Phase 1b or Phase 2 dose escalation trial for either of bavdegalutamide or ARV-766 in patients with AR-dependent tumors who have not previously received novel hormonal agents, or NHA, such as enzalutamide or abiraterone, and who may benefit from bavdegalutamide or ARV-766 therapy, in the second half of 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of  ARV-471, bavdegalutamide and ARV-766 has demonstrated potent and selective protein degradation in our preclinical studies. We believe favorable clinical trial results in these initial oncology programs could provide validation of our platform as a new therapeutic modality for the potential treatment of diseases caused by dysregulated intracellular proteins regardless of therapeutic area. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been a leader in the field of directed protein degradation using chimeric small molecules since our founding in 2013. We have assembled a scientific team with extensive know-how and translational medicine expertise to develop PROTAC targeted protein degraders with features not previously disclosed in published third-party studies. Our management team draws on extensive experience in all phases of drug discovery and development gained at large pharmaceutical and biotechnology companies to continue to advance our product pipeline and expand the capabilities of our platform. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have designed and optimized our proprietary PROTAC Discovery Engine for the discovery of PROTAC therapeutics to address diseases caused by abnormal proteins or aberrant protein expression. We engineer our PROTAC targeted protein degraders to tag a target protein for degradation through the ubiquitin proteasome system, one of the cell&#8217;s natural protein disposal systems, and then to iteratively degrade additional target protein molecules. The PROTAC Discovery Engine includes advanced screening capabilities, including in-house high-throughput and deoxyribonucleic acid, or DNA, -encoded library screening abilities that are tailored to the needs of incorporation into PROTAC protein degraders and to optimize their drug-like properties. Following selection and identification, we use tools including predictive computational modeling and privileged linkers that allow the potential for increased potency and selectivity. Finally, we have utilized our own proprietary PROTAC-specific optimization strategies, which we refer to as the Arvinas Rules, to create PROTAC degraders that, for example, are capable of being delivered through multiple routes of administration, including oral delivery, as well as PROTAC targeted protein degraders that are able to penetrate the blood brain barrier. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our clinical product candidates, we are expanding our pipeline by utilizing our platform to potentially address historically undruggable targets. Unlike existing small molecule inhibitor therapies, our PROTAC targeted protein degraders can degrade proteins using any available binding site, including low-affinity active binding sites or non-functional binding sites, bringing biological utility to ligands that would otherwise be ineffective. While some gene-based medicines are also seeking to address undruggable targets, we believe that our PROTAC targeted protein degraders confer the advantages of traditional small molecule therapies, such as broad tissue distribution, multiple routes of administration, including oral delivery, a well-established development pathway and relative ease of manufacturing. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are further diversifying our pipeline by developing new PROTAC targeted protein degraders against targets for which we believe protein degradation offers advantages to existing therapeutic modalities, including PROTAC degraders that are designed to reach targets in deep brain regions and are capable of being delivered through multiple routes of administration, including oral delivery. We have engineered PROTAC targeted protein degraders that, in preclinical studies, have successfully achieved blood-brain barrier penetration, a key step in developing drugs with the potential to treat neurodegenerative disease. We believe there are many other indications for which our PROTAC technology may be advantageous. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By year-end 2023, we expect to submit an investigational new drug, or IND, application or clinical trial application, or CTA, for our PROTAC degrader designed to target each of the BCL6 protein, a protein mutated in patients with different forms of Non-Hodgkins Lymphoma, or NHL, including Diffuse Large B-Cell Lymphoma, or DLBCL, and the LRRK2 protein, a protein kinase that has been genetically linked to some forms of Parkinson's Disease, or PD. We also expect to progress at least two additional PROTAC protein degrader programs in IND-enabling or CTA-enabling studies by year-end 2023.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to discover, develop, and commercialize therapies that improve the lives of patients suffering from debilitating and life-threatening diseases. We use our proprietary PROTAC Discovery Engine Platform to engineer PROTAC targeted protein degraders that are designed to harness the body&#8217;s own natural protein disposal system to selectively and efficiently remove disease-causing proteins. We believe that our proprietary PROTAC technology is a new therapeutic modality with the potential to provide distinct advantages over existing therapies and to address a broad range of targets, including undruggable proteins. The key elements of our strategy are to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Advance clinical development of our lead programs, which address the well-understood oncology targets AR and ER.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our strategy for our PROTAC platform includes the initial pursuit of oncology targets with well-understood biology, well-characterized disease models and established biomarkers. We have one product candidate in Phase 3 clinical development and two product candidates in Phase 2 clinical development. We are focused on creating potential therapies for patients in both oncology and neuroscience and we believe favorable clinical trial results in these </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initial oncology programs would validate the broader therapeutic potential of our PROTAC technology and PROTAC Discovery Engine.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Utilize our PROTAC Discovery Engine platform to address historically undruggable and difficult-to-drug targets.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are applying our platform to develop treatments for diseases associated with historically undruggable targets. Our platform enables us to build PROTAC targeted protein degraders with the potential to degrade these proteins through the cell&#8217;s natural protein degradation process using any available binding site, including low-affinity active binding sites or non-functional binding sites, bringing biological utility to ligands that would otherwise be inactive. We also believe that many &#8220;difficult-to-drug&#8221; targets, where prior approaches are inadequate, will also provide opportunities to apply our PROTAC Discovery Engine.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Selectively collaborate to realize the full potential of our platform. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are using our PROTAC Discovery Engine to build an extensive pipeline of product candidates. Our co-development/co-commercialization collaboration with Pfizer has the potential to accelerate and broaden global development and commercialization of ARV-471. In an effort to realize the full potential of our PROTAC technology, our ongoing strategic collaborations with Bayer AG, or Bayer, Genentech, Inc. and F. Hoffman-La Roche Ltd., or Genentech, and Pfizer address targets across multiple therapeutic areas. In addition to these collaborations in human therapeutics, in 2019 we established a joint venture called Oerth Bio LLC, or Oerth Bio, with Bayer to pursue our PROTAC technology in agricultural applications. We have and plan to continue to selectively pursue collaborations with leading biopharmaceutical companies with specialized capabilities or know-how, including global development and commercial expertise and capabilities for those products for which we retain full development and commercialization rights. We believe this selective approach to collaboration will further broaden the therapeutic reach of our PROTAC technology, as well as complement and expand our internal development expertise. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Develop new therapeutics with distinct advantages over existing modalities, including gene-based medicines. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to address targets for which we believe protein degradation and the tunable features of our PROTAC targeted protein degraders offer advantages compared to existing therapeutic modalities. For example, unlike gene-based medicines, our PROTAC targeted protein degraders confer the advantages of traditional small molecule therapies, such as broad tissue distribution, multiple routes of administration, including oral delivery, a well-established development pathway and relative ease of manufacturing. In addition, we have engineered PROTAC targeted protein degraders that, in preclinical studies, have successfully achieved blood brain barrier penetration, creating potential opportunities for our PROTAC technology in neurodegenerative diseases. We also believe there are many other indications for which our technology may be advantageous, including autoimmune, anti-infective and inflammatory conditions. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Continue to expand the capabilities of our PROTAC Discovery Engine and the breadth of our intellectual property portfolio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are investing in our research and development activities to expand the capabilities of our PROTAC Discovery Engine and the breadth of our intellectual property portfolio. This includes: research into novel E3 ligases, key proteins in the ubiquitin proteasome system, that may have tissue-specific or disease-specific features; the discovery of novel binding ligands; the discovery of orally bioavailable and blood brain barrier penetrant PROTAC protein degraders; and improvement of our PROTAC targeted protein degrader design and optimization processes. We have exclusive worldwide rights to our platform technology, as well as issued patents for composition of matter in the United States and other countries for ARV-471 and bavdegalutamide and patent applications pending for composition of matter in the United States and key countries for ARV-766 and patent applications pending for composition of matter in the United States and other key countries for our exploratory programs. We also have patents and pending patent applications for broad platform coverage for other PROTAC targeted protein degraders using specific E3 ligases. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Focus </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Role of Proteins in Disease </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human cells produce tens of thousands of different proteins, the entirety of which is referred to as the proteome. Proteins are responsible for many structural, functional and regulatory processes in cells. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proteins are large, complex biomolecules made through a series of steps based on instructions carried from DNA, the genetic &#8220;blueprint&#8221; within the cell. Generally, sequences of DNA are converted into messenger ribonucleic acid, or mRNA, during a process called transcription. mRNA provides the template that specifies the assembly of a particular sequence of amino acids into proteins during a process known as translation. The amino acid sequence dictates, among other things, the conformation, or 3-D shape, of the resulting protein. Proteins can have complex shapes, with multiple chains of amino acids folding together in some cases to reach a final form. The final form of the protein, as well as the timing, location and concentration of its expression within the cell, is essential to the protein&#8217;s intended function. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In healthy cells, the transcription and translation processes contribute to producing properly folded proteins in the right amounts and at the correct times to ensure normal cell health and function. This balance can be disrupted by a variety of events and factors, such as cellular stress, genetic mutations and transcriptional or translational errors, which can then lead to cellular overexpression, abnormal production rates, misfolding or mutations of proteins. When proteins are overexpressed or mutated, a wide variety of diseases can result. For example, it is well documented that overexpression of androgen receptor, a nuclear hormone receptor, is implicated in prostate cancer. Similarly, overexpression of estrogen receptor is known to be associated with breast cancer. In neurodegenerative diseases, abnormal deposition of misfolded or aggregated proteins in the brain, including the intraneuronal aggregation of the microtubule-associated protein tau, are associated with Alzheimer&#8217;s disease. Recent genomic advances continue to implicate the role of specific proteins in many disease states. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are multiple therapeutic approaches, both approved and in development, to treat diseases caused by abnormal proteins or aberrant protein expression. Each operates at a different point in the lifecycle of the protein, as illustrated in the following graphic: </span></div><div style="margin-top:12pt;text-align:center"><img src="arvn-20221231_g1.jpg" alt="arvn-20221231_g1.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:460px"/></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Small Molecule Inhibitors, Gene Therapy and Gene Editing </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Traditional small molecules seek to block or inhibit the expression or function of an errant protein. While there are numerous examples of safe and effective small molecule therapies, their efficacy can be limited by weak or incomplete binding of the therapeutic molecule to the relevant binding site on the protein, the cell&#8217;s ability to counteract the inhibitory effect of the drug by producing more of the protein, mutation of the target, or evolution of the cell to rely on alternate pathways. These cellular responses often result in a need for higher dosing levels, which can in turn introduce safety challenges from off-target and toxic effects, or drug resistance. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy approaches act by augmenting the errant protein with normal protein by using viral vectors to introduce DNA from an exogenous source that codes for a functional protein. While there have been promising advances in this field, the fundamental approach is limited by delivery, expression efficacy, pre-treatment conditioning, durability and manufacturing challenges that curtail the practical utility of gene therapy. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene editing or gene silencing approaches such as CRISPR/Cas9, RNA interference and antisense act by either correcting or inactivating, or knocking out, the gene that would otherwise be transcribed and translated to express the errant protein. By correcting or knocking out the gene, the errant protein is never made, preventing its downstream negative effects. In the case of CRISPR/Cas9, the resulting modification of the gene occurs at the DNA level and is believed to be irreversible. While there are examples of approved therapies in this field that have the potential to correct specific genetic defects, gene editing and gene silencing approaches generally face delivery, stability, biodistribution, specificity and selectivity challenges, in addition to significant manufacturing hurdles.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protein Degradation </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When proteins become old, mutated, misfolded or simply have served their purpose, they are naturally degraded by the body through the ubiquitin proteasome system in which cells mark or tag a particular protein for disposal by attaching several molecules of the small regulatory protein ubiquitin to the protein to be disposed. This process generally proceeds along the following steps in rapid sequence: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The E1 enzyme activates ubiquitin, which is then transferred to an E2 enzyme. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An E3 ubiquitin ligase, or E3 ligase, transfers the ubiquitin from the E2 enzyme to a specific target protein. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Once a chain of at least four ubiquitins are attached to the target protein, the proteasome recognizes the polyubiquinated protein. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The proteasome breaks down or degrades the protein into its amino acid components. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several therapeutic approaches work at the protein level by modulating the ubiquitin proteasome system to harness the cell&#8217;s natural protein disposal system to degrade and remove a protein. Degradation can be induced by inhibiting chaperone molecules such as HSP90, which are known to facilitate correct protein folding, resulting in tagging misfolded proteins for degradation. HSP90 inhibitors, however, have shown limited efficacy in the clinic to date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some degraders use an approach that causes a conformational change in a specifically targeted protein, resulting in a misfolded protein, which triggers the cell&#8217;s innate protein degradation system to dispose of the misfolded protein. Although these compounds have shown efficacy, they only induce the degradation of those proteins able to adopt a non-native state, leaving a wide array of protein targets unaddressed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chimeric small molecules use a different protein degradation approach. Instead of causing improper folding or inhibiting molecules that facilitate proper folding of the target protein, chimeric small molecules directly recruit an E3 ligase to tag specifically targeted proteins with ubiquitin, signaling the proteasome to degrade the targeted protein. Our PROTAC targeted protein degraders take this approach to protein degradation. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PROTAC Targeted Protein Degraders &#8212; Our Approach to Protein Degradation </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engineered our PROTAC targeted protein degraders to utilize the cell&#8217;s naturally occurring protein disposal system, directing the proteasome to recognize and degrade specific proteins associated with disease. Our PROTAC targeted protein degraders are chimeric small molecules with two operative ends&#8212;one, a ligand that binds to the protein targeted for degradation, and the other, a ligand that binds to an E3 ligase. These two ligands are connected by a chemical chain linker. Our PROTAC targeted protein degraders bring the targeted protein and the E3 ligase together into a three-component grouping known as a trimer complex to facilitate the transfer of ubiquitin to the target protein. Once four ubiquitins are attached in a chain to the target protein, the proteasome recognizes and degrades the protein. The entire cycle from the formation of the trimer complex, which can occur in a period of nanoseconds, to degradation of the target protein by the proteasome happens over a period of minutes. After our PROTAC targeted protein degrader facilitates the tagging of a target protein molecule with ubiquitin through formation of the trimer complex, it can move on to another target </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protein molecule to conduct the degradation process again, potentially completing this cycle hundreds of times before eventually being metabolized or eliminated from the cell. We refer to this recycling as our PROTAC targeted protein degraders&#8217; iterative mechanism of action. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The figure below depicts our PROTAC-induced cycle from E3 ligase binding and target protein recruitment, to trimer formation and ubiquitin transfer, to degradation of the target protein by the proteasome, to the release of ubiquitin and PROTAC targeted protein degrader for further degradation cycles</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:center"><img src="arvn-20221231_g2.jpg" alt="arvn-20221231_g2.jpg" style="height:341px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Discovery Platform &#8212; PROTAC Discovery Engine</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designed and optimized our PROTAC Discovery Engine for the discovery of PROTAC targeted protein degrader therapeutics to address diseases caused by abnormal proteins or aberrant protein expression. The PROTAC Discovery Engine includes advanced screening capabilities, including in-house high-throughput and DNA-encoded library screening abilities that are tailored to the needs of incorporation into PROTAC protein degraders and to optimize their drug-like properties. Following selection and identification, we use tools including predictive computational modeling and privileged linkers that allow the potential for increased potency and selectivity. Finally, we have utilized our own proprietary Arvinas Rules to create PROTAC degraders that, for example, are capable of being delivered through multiple routes of administration, including oral delivery, as well as PROTAC targeted protein degraders that are able to penetrate the blood brain barrier.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Design and Optimization of our PROTAC Targeted Protein Degraders </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As genomic knowledge and advances in genome mapping have increased, the understanding of proteins implicated in diseases has similarly increased. We undertake a rigorous evaluation process to prioritize protein targets for which we believe our PROTAC approach can achieve differentiated clinical outcomes for patients over existing modalities. Our PROTAC Discovery Engine is built from over 20 years of experience, know-how, and intellectual property and comprises three stages:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ligase Selection and Ligand Identification</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.53pt">E3 KnowledgeBase </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The human body has more than 600 E3 ligases, and we select ligands for E3 ligases from our proprietary library for incorporation into our PROTAC targeted protein degraders. We continue to research additional E3 ligases that are expressed in specific tissues or diseases, and identify or discover associated binding ligands, to create novel PROTAC protein degraders that recruit E3 ligases with targeted expression patterns, such as tumor or central nervous system-localized E3 ligases, that may be beneficial for the development of targeted cancer and neurologic therapies. To enable targeted protein degradation via alternative E3 ligases, we have discovered and characterized novel small molecule ligands targeting the E3 ligase KLHDC2. We have functionalized these novel KLHDC2-targeting small molecules into robust and potent KLHDC2- PROTAC degraders and demonstrate KLHDC2-dependent degradation of target proteins across cell lines. Furthermore, we have leveraged biochemical studies to understand mechanistic assembly of the KLHDC2 holo-E3 complex together with its cognate adapter proteins in addition to structural studies to show the dynamic tetramer formation of KLHDC2 E3 assemblies induced by small molecule engagement.  In doing so, we have expanded the arsenal of E3 ligases that can be targeted by small molecules and may be hijacked for targeted protein degradation. We</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> believe our success with the diverse set of E3 ligases that we are currently employing and the binders of other E3 ligases that we are researching provide us with a competitive advantage as we develop a range of products with different technical characteristics. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Advanced Screening Capabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We select ligands for incorporation into our PROTAC targeted protein degraders from a variety of sources. The ligands we select, which target the desired protein for degradation or E3 ligase for incorporation into our PROTAC targeted protein degraders, may include (1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> de novo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ligands discovered through high-throughput screening, biophysical directed binding approaches, virtual or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">computer-based screening, and affinity-based hit identification through our in-house DNA-encoded libraries that that are tailored to the needs of incorporation into PROTAC protein degraders and to optimize their drug-like properties or (2) ligands that are known to bind protein targets but may have faced therapeutic limitations that we believe our PROTAC technology can overcome, such as lack of potency or function, metabolic instability or off-target effects. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rapid PROTAC Design</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Zone of Ubiquitination - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bringing the targeted protein and the E3 ligase together into a trimer complex is necessary but not sufficient for degradation. We use structural and biochemical information to predict precisely which lysine residues on the target protein can be &#8220;tagged&#8221; with ubiquitin, and we design PROTAC degraders to exploit this knowledge.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">ANGLE: Arvinas Next Generation Linker Evolution</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We connect the selected protein-targeting ligands and E3 ligase ligands with our privileged chemical linkers. Linker selection is critical for rapid identification of protein degraders and can introduce function and selectivity to a nonfunctional or nonselective binding ligand upon incorporation into a PROTAC targeted protein degrader molecule. Linker composition can also be used to modulate properties of our PROTAC targeted protein degraders, such as membrane permeability, aqueous solubility, metabolic stability and biodistribution. We select from a proprietary library of conformationally privileged linkers to enable the efficient formation of the trimer complex essential to ubiquitin transfer and protein degradation. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Predictive Computational Modeling -</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We use trimer structure-based computational modeling, sometimes aided by structural biology-generated insights, and design algorithms to rapidly identify potent degraders.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Proteomics - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A PROTAC degrader is often more selective than the targeting warhead. We have proteomics capabilities that enable us to understand that specificity in precise detail and iterate quickly to optimize the selectivity of our PROTAC degraders for the protein target.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Turning Degraders into Drugs </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Arvinas Rules - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Optimization of traditional small molecule agents tends to focus on guidelines that increase the chances of such molecules having sufficient permeability and solubility to make them orally bioavailable. Chimeric small molecules, including our PROTAC targeted protein degraders, are larger than traditional small molecule therapeutics, such that the conventional optimization parameters prevalent in traditional drug discovery do not readily apply. As such we have developed and apply our own proprietary Arvinas Rules for our PROTAC targeted protein degraders. Through our Arvinas Rules, we have made PROTAC targeted protein degraders that are orally bioavailable and that cross the blood brain barrier.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Deep knowledge of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> PK/PD and efficacy relationships - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our understanding of molecular features that impact PROTAC biodistribution and target degradation, in the body, enables us to create PROTAC degraders with drug-like properties and activities. We can use this understanding to rapidly progress from target identification to PROTAC optimization and development. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Features of Our PROTAC Targeted Protein Degraders</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the design, optimization and development of our PROTAC targeted protein degraders, we focus on the following key features that we believe are critical to successfully engineering PROTAC targeted protein degrader therapeutics with potentially robust application across multiple indications and therapeutic areas: potency, selectivity, and deliverability and versatility. We have harnessed these features to successfully target and degrade a wide range of protein classes, including nuclear proteins, transcription factors, epigenetic modulators, membrane proteins, cytosolic proteins and high molecular weight neuroprotein aggregates. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Potency </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potency of our PROTAC technology is driven by two key characteristics: the iterative mechanism of our PROTAC targeted protein degraders and the ability to turn weak binders into potent degraders. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Iterative Mechanism </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our PROTAC targeted protein degraders behave iteratively to repeatedly induce the ubiquitination and subsequent degradation of proteins. As a result, protein degradation may be observed with PROTAC targeted protein degrader concentrations much lower than those required for typical small molecule inhibition, even operating at picomolar concentrations. We expect that the high cellular potency of PROTAC targeted protein degrader could provide the possibility of removal of proteins at levels equivalent to the knock out effect intended by gene-based medicines currently being explored. Our PROTAC targeted protein degraders offer potentially significant therapeutic advantages, including low doses, low drug exposures and practical dosing intervals, potentially mitigating toxicity and tolerability risks. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The iterative mechanism of our PROTAC targeted protein degraders potentially leads to more complete and lasting inactivation of downstream signaling in cells. In oncology, this translates into improved inhibition of tumor cell growth and reduces the likelihood of cell compensation through activation of alternative proteins, a common risk associated with small molecule inhibitors. This enables PROTAC targeted protein degraders to operate in a broad therapeutic space between desired degradation-induced pharmacology and unwanted inhibition-induced effects. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the pre-existing reservoir of the targeted protein is depleted, our PROTAC targeted protein degraders only need to degrade newly resynthesized protein to maintain their effect. Depending on the resynthesis rate of the protein, this may be achievable with low tissue concentrations of PROTAC targeted protein degrader, which could lead to safety benefits and opportunities for flexible dosing regimens. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weak Binders Become Potent Degraders </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our platform and know-how, we are able to engineer potent PROTAC targeted protein degraders that do not require a high degree of binding strength to their targets. This contrasts with small molecule inhibitors, which require strong binding to a target protein and function by continually occupying the protein&#8217;s active site. The potency of our PROTAC targeted protein degraders is determined by a number of kinetic </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors: formation of the trimer complex, rapid ubiquitination, trafficking of the ubiquitinated target to the proteasome and release of the PROTAC targeted protein degrader to enter another iterative cycle of degradation. As a result, a PROTAC targeted protein degrader with a low level of target protein occupancy can maintain a deep and prolonged suppression of protein levels, leading to the desired pharmacological effect. This provides opportunities to use our PROTAC technology to repurpose small molecules that only weakly bind to their target to create potent degraders as PROTAC targeted protein degraders. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we have published experiments where we built PROTAC targeted protein degraders from the known protein kinase inhibitor foretinib, which is a relatively weak binder to the protein p38&#945;, a protein implicated in immune disorders and heart disease. We constructed a foretinib-based PROTAC targeted protein degrader we refer to as PROTAC 1, which happened to further weaken the binding affinity to p38&#945;. Binding affinity is measured by K</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or equilibrium dissociation constant. In this case, we observed that PROTAC 1 exhibited a tenfold reduction in binding affinity relative to foretinib, decreasing from 1 micromolar, or &#181;M, to 11 &#181;M. Despite the significantly weaker binding affinity, PROTAC 1 achieved potent degradation of p38&#945; with a DC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a concentration that results in half maximal degradation, of 210 nanomolar, or nM, which means that its degradation potency is approximately 50-fold better than its binding strength. The figure below shows a western blot of cells treated with increasing concentrations (left to right) of foretinib, the PROTAC 1, and an inactivated (non-degrading) version of PROTAC 1. The decreasing presence of the p38&#945; protein is depicted by a lighter shade of the p38&#945; band in the western blot as the doses of the PROTAC 1 increase. This demonstrates our ability to use a weak binder to create a potent PROTAC targeted protein degrader. Based on our experience, we believe that with additional medicinal chemistry effort, the degradation potency of this weak-binding PROTAC targeted protein degrader could be further increased.</span></div><div style="margin-top:12pt;text-align:center"><img src="arvn-20221231_g3.jpg" alt="arvn-20221231_g3.jpg" style="height:150px;margin-bottom:5pt;vertical-align:text-bottom;width:560px"/></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selectivity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a ligand is incorporated into a PROTAC targeted protein degrader, the trimer complex initiated by the PROTAC targeted protein degrader often causes the ligand&#8217;s selectivity to increase, meaning that the degradation profile of a PROTAC targeted protein degrader can be even more selective than the binding profile of the ligand alone. By minimizing the binding of a ligand to off-target proteins and maximizing selectivity for a target protein, our PROTAC targeted protein degraders may reduce the potential for incidental degradation of normal, healthy proteins and unwanted drug effects and toxicity. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We published experiments in which a ligand binding to 133 kinases degraded fewer than ten proteins when incorporated into a PROTAC targeted protein degrader with limited additional modification. The figure below on the left depicts foretinib binding to 133 protein kinases as measured by a competitive binding assay. The figure on the right depicts cells treated with a foretinib-based PROTAC targeted protein degrader degrading </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">only a small subset of cellular proteins (lower left quadrant of the graph) as shown by mass spectrometry analysis. </span></div><div style="margin-top:12pt;text-align:center"><img src="arvn-20221231_g4.jpg" alt="arvn-20221231_g4.jpg" style="height:230px;margin-bottom:5pt;vertical-align:text-bottom;width:460px"/></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With further modification, and based on our experience, we believe it is possible to engineer promiscuous binders such as this into more selective protein degraders, and when starting with less promiscuous, yet still unselective, binders, identify very selective PROTAC target protein degraders. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This selectivity allows for engineering of PROTAC targeted protein degraders that degrade only the mutated and unwanted protein, while sparing the normal, or wild-type, protein that may be necessary for healthy function. For example, we have demonstrated degradation of abnormal, but not wild-type, forms of the BRAF protein using a PROTAC targeted protein degrader. Wild-type BRAF helps transmit chemical signals from outside the cell to the cell&#8217;s nucleus and is part of a pathway that regulates cell proliferation, differentiation, migration and apoptosis. Mutations of BRAF, however, have been associated with a number of different cancers. As shown in the figure below, our PROTAC targeted protein degrader degraded BRAF mutants, as depicted by a lighter shade in the columns labeled 300 nM, representative of each of the three classes of BRAF mutations, while not degrading the wild-type BRAF, as depicted by an unchanging shade in each of the columns shown on the western blot. </span></div><div style="margin-top:12pt;text-align:center"><img src="arvn-20221231_g5.jpg" alt="arvn-20221231_g5.jpg" style="height:115px;margin-bottom:5pt;vertical-align:text-bottom;width:460px"/></div><div style="margin-top:12pt;padding-left:72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1hMito is a protein this particular PROTAC targeted protein degrader is not targeted to degrade, and is included as a control to ensure total protein is equivalent in each lane.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deliverability and Versatility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our PROTAC targeted protein degraders have the potential for delivery through multiple routes of administration to reach target proteins, and certain of our PROTAC targeted protein degraders are capable of penetrating the blood brain barrier. In addition, the broad expression of the E3 ligases we target and the potential to turn weak binding ligands into potent degraders allows the application of our PROTAC technology to develop treatments for diseases associated with proteins that cannot be addressed by existing small molecule therapies. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deliverability </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed PROTAC targeted protein degraders that are capable of being delivered orally, intravenously, subcutaneously and intrathecally, among other routes of administration, as well as PROTAC </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">targeted protein degraders that are able to penetrate the blood brain barrier. The multiple routes of delivery for our PROTAC targeted protein degraders potentially provide many attractive clinical dosing options. For example, oral delivery can offer a differentiating, competitive and commercial advantage over other therapeutic approaches such as gene-based medicines which require parenteral administration. Further, oral administration avoids risks of adverse events associated with intravenous or intramuscular administration, such as the potential for infection and blood clots at the infusion site. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Versatility </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our PROTAC targeted protein degraders may have potential application in a wide range of therapeutic areas because the E3 ligases we currently target are expressed widely across tissue types. Ligands that bind to some proteins may be of only weak affinity. However, we believe that our PROTAC technology will allow the degradation of proteins through such low affinity active binding sites or non-functional binding sites. Our ability to design weak binding PROTAC targeted protein degraders that nonetheless initiate rapid ubiquitination and subsequent degradation of targeted proteins has the potential to expand the number of disease-causing proteins targeted for drug development to include undruggable targets. We believe that rendering these targets druggable for the first time represents the true breadth and potential of our PROTAC Discovery Engine. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted an experiment designed to demonstrate that non-functional binding sites, analogous to those that may be present on proteins considered undruggable, can be used to target proteins for degradation by PROTAC targeted protein degraders. The figure below depicts a structural model of the Abl tyrosine kinase. This protein kinase possesses an enzymatic active site that is inhibited by the marketed small molecule, imatinib. The Abl kinase also has a second, non-functional active site, called an allosteric site, in its structure that can bind a different small molecule, named GNF-2, which despite binding allosterically (with a relatively weak K</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 500 nM), inhibits only the wild type protein (C-Abl), but not BCR-Abl-a mutated form of Abl implicated in chronic myelogenous leukemia.</span></div><div style="margin-top:12pt;text-align:center"><img src="arvn-20221231_g6.jpg" alt="arvn-20221231_g6.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:460px"/></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When GNF-2 is converted into a PROTAC targeted protein degrader and used to treat cells, both BCR-Abl and C-Abl are effectively degraded. The figure below shows western blots of cells treated by increasing concentrations of our PROTAC targeted protein degrader and shows decreasing presence of each of BCR-Abl </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and C-Abl protein (depicted by a lighter shade of the BCR/Abl and C-Abl band in the western blot). Downstream signaling, as denoted by reduction of phosphorylated Stat5 (pStat5), is subsequently inhibited.</span></div><div style="margin-top:12pt;text-align:center"><img src="arvn-20221231_g7.jpg" alt="arvn-20221231_g7.jpg" style="height:230px;margin-bottom:5pt;vertical-align:text-bottom;width:460px"/></div><div style="margin-top:12pt;padding-left:72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1Tubulin is a protein the GNF-2 PROTAC targeted protein degrader is not targeted to degrade, and is included as a control to ensure total protein is equivalent in each lane.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PROTAC-induced degradation may offer a solution for historically undruggable proteins because only binders, not functional inhibitors, are needed to facilitate E3 ligase recruitment and initiation of the degradation process. The probability of finding a suitable ligand using binding-site-agnostic screening is increased because the function of the ligand itself is not required. As a result, there is the potential for PROTAC targeted protein degraders to generate therapeutics from poorly selective ligands, weak-affinity ligands, or ligands that may not be intrinsically biologically active. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Pipeline and Programs </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platform has generated several promising degradation product candidates that may be capable of targeting diseases in a wide range of organ systems and tissues. We and our collaborators have initiated programs across multiple therapeutic areas with the goal of developing and delivering life-changing therapies to patients in need. Our lead therapeutic programs are summarized in the table below.</span></div><div style="margin-top:12pt"><img src="arvn-20221231_g8.jpg" alt="arvn-20221231_g8.jpg" style="height:371px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ER+/HER2-, estrogen receptor+/human epidermal growth factor receptor 2-; mCRPC, metastatic castration-resistant prostate cancer; BCL6, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B-cell lymphoma 6 protein; KRAS, Kirsten rat sarcoma; HPK1, hematopoietic progenitor kinase 1; mHTT, mutant huntingtin. IND, investigational new drug; CTA, clinical trial application</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">These agents are currently under investigation. Their safety and effectiveness for these investigational uses have not been established.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8224; Denotes historically undruggable proteins</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the programs above and our early-stage development collaborations with Pfizer,  Genentech, and Bayer, we are conducting exploratory research and development work on multiple other undisclosed targets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Clinical Stage Programs</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-471 for the Treatment of Patients with Locally Advanced or Metastatic ER + / HER2 - Breast Cancer </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing ARV-471, an orally bioavailable ER degrading PROTAC targeted protein degrader, as an alternative to, and potentially more potent degrader than, the intramuscular injection fulvestrant and other selective ER degraders currently approved or in development for the treatment of patients with locally advanced or metastatic ER+ / HER2- breast cancer. We have chosen ER degradation as a therapeutic focus given the well-documented biology of ER signaling as a principal driver in a high percentage of breast cancers. ARV-471 has demonstrated activity in ER+ breast cancer preclinical models. We are clinically investigating ARV-471 for use as a single agent and in combination with CDK4/6 inhibitors such as palbociclib, abemaciclib and ribociclib, everolimus and other targeted therapies. We believe ARV-471 has the potential to improve clinical outcomes over current standards of care for patients with locally advanced or metastatic ER+ / HER2- breast cancer as well as in earlier treatment settings. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Breast Cancer - Patient Population and Market Opportunity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breast cancer is the most common cancer diagnosed among women in the United States and the second leading cause of cancer death in women. The American Cancer Society estimates that in 2023 there will be approximately 298,000 women diagnosed with invasive breast cancer in the United States and that one in eight women in the United States will develop breast cancer in her lifetime. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 67% to 80% of all breast cancers are ER+. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment options for breast cancer depend on many different factors, including the stage of the cancer and whether the cancer cells contain hormone receptors. Patients with locally advanced or metastatic breast cancer are treated with systemic therapy, including hormone therapy, chemotherapy and targeted therapy, either as single-agents or in combination. Patients with locally advanced or metastatic ER+ / HER2- breast cancer are often treated with hormone therapy, such as an aromatase inhibitor, sometimes in combination with targeted drugs such as CDK4/6 inhibitors. In patients with aggressive disease or whose disease continues to progress with a hormonal treatment regimen, chemotherapy may be prescribed. Treatment with chemotherapy is generally postponed for as long as possible due to the potential for severe side effects including neuropathies, nausea, diarrhea, decreased mental capacity and increased risk of infections. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A current standard of care for patients with ER+ / HER2- locally advanced or metastatic breast cancer is fulvestrant, an ER degrader administered as a monthly intramuscular injection, either as a single-agent or in combination with another targeted therapy. While fulvestrant has validated the importance of ER degradation as a therapeutic intervention, up to 50% of ER can remain when compared to baseline levels after six months of treatment with fulvestrant, providing an opportunity for more potent ER degraders.  In January 2023, the FDA approved the ER degrader elacestrant for postmenopausal women or adult men with ER+ / HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preclinical Development </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted a comprehensive preclinical program to study ARV-471 as a potential treatment for patients with locally advanced or metastatic ER+ / HER2- breast cancer. In our preclinical studies, ARV-471 demonstrated superior ER degradation compared to fulvestrant. ARV-471 has also demonstrated superior tumor regression when combined with a CDK4/6 inhibitor compared to fulvestrant and the same combination partner. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> models, ARV-471 has induced ER degradation in multiple cell lines typically used in breast cancer research. In </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> experiments ARV-471 has achieved superior tumor growth inhibition and degradation compared to fulvestrant. We have tested ARV-471 for tumor growth inhibitory activity using an industry-standard MCF-7 xenograft mouse model. MCF-7 is a well-characterized estradiol-dependent ER+ / HER2- cell line that forms tumors when implanted in the mammary fat pad of female mice. ARV-471 resulted in very high tumor growth inhibition when dosed daily orally at 10 mpk and more than 80% tumor shrinkage when dosed daily orally at 30 mpk for 28 days. At both doses, ARV-471 demonstrated superior activity compared to a clinically relevant dose of fulvestrant, which is 200 mpk twice per week for two weeks and then once per week for two weeks. After 28 days of dosing in this efficacy study, the MCF-7 tumors were removed from the mice and processed for western blots to observe the level of ER degradation induced by oral dosing of ARV-471. ARV-471 reduced ER by 85%, on average, at 10 mpk as compared to the control tumors and by 89%, on average, at 30 mpk as compared to the control tumors. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have also conducted preclinical studies to test ARV-471 in a tumor line derived directly from a patient, referred to as a patient derived xenograft, or PDX, model. This model is derived from a tumor with an ESR1 mutation (Y537S), which is a mutation in the ER that occurs in patients who have been treated with standard-of-care agents such as tamoxifen or an aromatase inhibitor, such as letrozole, and has been cited as a mechanism of resistance to those drugs. These studies included a comparison with fulvestrant. In this 28-day dosing study, oral ARV-471 inhibited tumor growth by 99% at the 10 mpk dosing level and by 106% at the 30 mpk dosing level which was observed to be superior at both dosing levels to a clinically relevant dose of 200 mpk of fulvestrant. Further, ARV-471 was shown to reduce ER by 79% and 88% at the 10 mpk and 30 mpk dosing levels, respectively, compared with 63% at the 200 mpk of fulvestrant dosing level. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also conducted studies of ARV-471 in combination with palbociclib, a CDK4/6 inhibitor that is standard of care when used together with fulvestrant. In these studies, we have achieved significant tumor shrinkage with ARV-471 in ER+ / HER2- MCF-7 xenograft models. As shown in the figure below, in a 28-day dosing study in MCF-7 xenografts, ARV-471 at 30 mpk daily in combination with palbociclib was superior in shrinking tumors, as compared to either palbociclib as a single agent at 60 mpk daily, or the standard-of-care combination of palbociclib at 60 mpk daily plus fulvestrant at 200 mpk twice per week for two weeks and then once per week for two weeks. </span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="arvn-20221231_g9.jpg" alt="arvn-20221231_g9.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that ARV-471 may also show compelling activity in combination with other targeted agents currently used or in clinical trials for locally advanced or metastatic breast cancer including PI3K and mTOR inhibitors and have tested and plan to continue to test these combinations in preclinical models. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Our Clinical Trials</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we initiated dosing in a Phase 1 clinical trial for ARV-471. The trial is an open-label dose-escalation study in which we dosed with locally advanced or metastatic ER+ / HER2- breast cancer who had progressed on at least two prior endocrine therapy regimens and a CDK4/6 inhibitor. Eligible patients may have also received up to three prior regimens of cytotoxic chemotherapy. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we amended the protocol for our Phase 1 clinical trial for ARV-471, to include the Phase 2 expansion cohort and a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1b cohort expansion of ARV-471 in combination with Ibrance&#174; (palbociclib), respectively.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dose escalation portion of our Phase 1/2 clinical trial of ARV-471 was designed to assess safety, tolerability and pharmacokinetics, or PK, of ARV-471 in patients with locally advanced or metastatic ER+/HER2- breast cancer, as well as measures of anti-tumor activity as secondary endpoints. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we initiated VERITAC, the Phase 2 cohort expansion portion of the ARV-471 clinical trial. We announced initial results from VERITAC in the fourth quarter of 2022. In VERITAC, patients were treated with either 200 mg or 500 mg ARV-471 with a primary endpoint of clinical benefit rate, or CBR, (rate of confirmed complete response, confirmed partial response, or stable disease &#8805; 24 weeks). Secondary endpoints included overall response rate, or ORR, duration of response, or DOR, progression free survival, or PFS, and overall survival, or OS, as well as safety and pharmacokinetics.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of the data cut-off date of June 6, 2022, 71 patients with locally advanced or metastatic ER+/HER2- breast cancer in the VERITAC expansion cohort were treated once-daily with oral doses of ARV-471 at 200 mg (n=35) or 500 mg (n=36). All patients were previously treated with CDK 4/6 inhibitors; 79% of patients were previously treated with fulvestrant; 73% of patients were previously treated with chemotherapy; and 45% received chemotherapy in the metastatic setting. Patients in VERITAC had a median of four lines of prior therapies.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the time of data cutoff, ARV-471 administered at 200 mg (n=35) and 500 mg (n=36) demonstrated antitumor activity in all CDK4/6 inhibitor-pretreated patients, as measured by a CBR of 38% (total n=71) in all patients, 51.2% in patients with mutant ESR1 tumors (n=41), and 20% in patients with ESR1 wild-type tumors (n=25). At 200 mg, ARV-471 achieved a CBR of 37.1% (n=35) in all patients and 47% in patients with mutant ESR1 tumors (n=19); and at 500 mg, a CBR of 39% (n=36) in all patients and 55% in patients with mutant ESR1 tumors (n=22).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ARV-471 also demonstrated preliminary median progression-free survival, or mPFS, of 3.7 months, a secondary endpoint, in all evaluable patients (n=71) and 5.7 months in patients with mutant ESR1 tumors (n=41) For the 200 mg cohort, ARV-471 demonstrated mPFS of 3.5 months in all evaluable patients (n=35) and 5.5 months in patients with mutant ESR1 tumors (n=19). At the time of the data cutoff, data for the 500 mg cohort were immature and therefore not included in a separate analysis.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ARV-471 was well tolerated across both dose levels. Treatment related adverse events (TRAEs) were primarily Grade 1 and 2, with five patients experiencing Grade 3/4 TRAEs. In the 200 mg cohort, TRAEs were: Grade 1 (n=13): 37%; Grade 2 (n=13): 37%; and Grade 3 or 4 (n=2): 6%. Grade 3/4 TRAEs in the 200 mg cohort were Grade 3 QT prolonged (n=1) and Grade 3 thrombocytopenia and Grade 4 hyperbilirubinemia (n=1). In the 500 mg cohort, TRAEs were: Grade 1 (n=11): 31%; Grade 2 (n=9): 25%; and Grade 3 or 4 (n=3): 8%. Grade 3/4 TRAEs in the 500 mg cohort were Grade 3 fatigue (n=1), Grade 3 decreased appetite (n=1), and Grade 3 neutropenia (n=1).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There was one discontinuation due to a treatment-emergent adverse event, or TEAE, and no dose reductions in the 200 mg cohort. There were two discontinuations and three dose reductions in the 500 mg cohort.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the third quarter of 2022, we initiated TACTIVE-E, a Phase 1b clinical trial with ARV-471 in combination with everolimus in patients with metastatic breast cancer. Also in the third quarter of 2022, we initiated with Pfizer a Phase 1b trial of ARV-471 as a monotherapy in Japanese patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fourth quarter of 2022, we and Pfizer initiated the VERITAC-2 Phase 3 trial with ARV-471 as a second-line treatment in patients with ER+ / HER2- metastatic breast cancer, which trial is actively recruiting. In the fourth quarter of 2022, we also initiated with Pfizer TACTIVE-U, the Phase 1b trial with ARV-471 in combination with ribociclib and abemaciclib, in two of the combination arms. In addition, we have initiated  sites and are actively recruiting patients for TACTIVE-N, a Phase 2 clinical trial with ARV-471 as a monotherapy in patients with early breast cancer in the neoadjuvant setting in the fourth quarter of 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the fourth quarter of 2022, we presented initial data from VERITAC at the San Antonio Breast Cancer Symposium and we initiated, with Pfizer, the VERITAC-2 Phase 3 trial with ARV-471 as a monotherapy as a second-line and later treatment in patients with ER+/HER2- metastatic breast cancer. Also in the fourth quarter of 2022, we initiated the first of two arms in the ongoing Phase 1b umbrella trial of ARV-471, with ARV-471 in combination with each of the CDK4/6 inhibitors abemaciclib and ribociclib (TACTIVE-U). We initiated the second of two arms in the first quarter of 2023. In addition, in the fourth quarter of 2022, we initiated a Phase 2 clinical trial with ARV-471 as a monotherapy in patients with early breast cancer in the neoadjuvant setting (TACTIVE-N).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2023, we provided an update from the most recent analysis of data from the ongoing Phase 1b trial of ARV-471 in combination with palbociclib. The following were observed:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An approximate increase of 50% in mean palbociclib exposure (i.e., pharmacokinetic area under the curve and Cmax) in the fed state was observed relative to historical palbociclib pharmacokinetic data in the fasted state.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Grade 3/4 neutropenia, a known dose-related adverse reaction associated with palbociclib, was 76% for 200 mg ARV-471 with 125 mg palbociclib (n=21).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As per the U.S. Package Insert, or USPI, the starting dose of palbociclib for patients with ER+ / HER2- metastatic breast cancer is 125 mg. As per the palbociclib USPI, a Grade &#8805;3 decrease in neutrophil </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">counts was reported in 66% of patients receiving IBRANCE plus letrozole in Study 1 (PALOMA-2) and 66% of patients receiving IBRANCE plus fulvestrant in Study 2 (PALOMA-3).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There was no increase in the rate of infection reported in the ARV-471 with palbociclib Phase 1b investigation relative to the rates reported in the registrational Phase 3 studies of palbociclib.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The neutropenia events in the ARV-471 Phase 1b trial were manageable with standard dose reductions of palbociclib.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the arm combining palbociclib with 200 mg ARV-471, one of 21 patients discontinued.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2023, we announced updated guidance related to the anticipated initiation of the VERITAC-3 first-line, metastatic ER+ / HER2- breast cancer Phase 3 trial of ARV-471 in combination with IBRANCE&#174; (palbociclib). In the most recent analysis of data from the ongoing Phase 1b combination trial of ARV-471 with palbociclib, an increase in palbociclib exposure was observed relative to historical palbociclib pharmacokinetic data. In light of the recent data analysis, in the first quarter of 2023, we and Pfizer requested a meeting with the U.S. Food and Drug Administration, or the FDA, to review the proposed update to the trial protocol for the VERITAC-3 first-line, metastatic ER+ / HER2- breast cancer Phase 3 trial of ARV-471 in combination with IBRANCE&#174; (palbociclib) to determine the optimal dose of palbociclib as part of the trial design. Following correspondence and alignment with the FDA, we and Pfizer determined an approach to the planned Phase 3 trial to enable trial initiation in the second half of 2023, which includes a Phase 3, lead-in to evaluate the optimal dose of palbociclib (100 mg or 75 mg) in combination with 200 mg ARV-471. Based on this modified approach, we and Pfizer expect to initiate the trial, as anticipated, in the second half of 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first half of 2023, we expect, with Pfizer, to provide an update with preliminary data from the Phase 1b combination trial with palbociclib (Part C of the Phase 1/2 trial) and in the second half of 2023, we expect, with Pfizer, to submit and present data from the Phase 1b combination trial of ARV-471 with palbociclib at a medical congress and. Also in the second half of 2023, we expect, with Pfizer, to initiate a Phase 3 trial with ARV-471 in combination with palbociclib as a first-line treatment in patients with ER+ / HER2- locally advance or metastatic breast cancer. and initiate additional arms of the TACTIVE-U, Phase 1b combination trial with other targeted therapies, during 2023.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bavdegalutamide (ARV-110) and ARV-766 for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing bavdegalutamide (ARV-110) and ARV-766, each an orally bioavailable, AR degrading PROTAC targeted protein degrader, for the treatment of men with mCRPC. Both bavdegalutamide and ARV-766 demonstrated activity in preclinical models of AR overexpression and AR mutations, both common mechanisms of resistance to current standard-of-care agents in men with prostate cancer. We believe that the differentiated PROTAC pharmacology of bavdegalutamide and ARV-766, including their iterative activity, has the potential to translate into significantly improved clinical outcomes over current standard-of-care agents. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prostate Cancer - Patient Population and Market Opportunity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, prostate cancer is the second leading cause of cancer death in men. Current estimates predict that one in eight men will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that in 2023 there will be over 288,000 new cases of prostate cancer in the United States and approximately 34,700 deaths from the disease. Men with mCRPC have a poor prognosis and a predicted survival rate of fewer than two years from the initial time of progression. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment options for prostate cancer depend on many different factors, including the stage of the cancer. Castration-resistant prostate cancer is defined by disease progression despite androgen deprivation therapy, or ADT, and is often indicated by rising levels of PSA. In making treatment evaluations, physicians monitor disease burdens in several ways, including changes in PSA levels. Increased PSA blood levels are considered by many physicians as indicative of cancer progression, and alternative treatment options may be considered. Current standard of care for men with castration-resistant prostate cancer provides that patients should initially receive a combination of ADT and either abiraterone, which works by decreasing androgen levels, or enzalutamide, which works by blocking androgen binding to AR. If the disease progresses despite these second-generation hormonal therapies, chemotherapy is considered the next treatment option. Treatment </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with chemotherapy is generally postponed for as long as possible due to the potential for severe side effects including neuropathies, nausea, diarrhea, decreased mental capacity and increased risk of infections. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AR remains the principal driver of castration-resistant prostate cancer progression during the transition from localized to metastatic disease, with AR gene amplification occurring in 40% to 60% of patients, amplification of a transcription regulatory region upstream of the AR gene occurring in 70% to 87% of patients, and AR point mutations occurring in approximately 15% of patients. Between 15% to 25% of patients do not respond to either abiraterone or enzalutamide and the vast majority of the responsive patients will ultimately become resistant, resulting in limited survival. There remains meaningful unmet medical need in the treatment paradigm of mCRPC, including a significant underserved set of patients who are or become resistant to current therapies. Based on our preclinical data, we believe our AR-targeting PROTAC protein degraders may overcome these known resistance mechanisms and create meaningful clinical benefit for patients. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bavdegalutamide Preclinical Development </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted a comprehensive preclinical program to study bavdegalutamide as a potential treatment for men with mCRPC. In </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">models, bavdegalutamide degraded 95% to 98% of AR in multiple cell lines typically used in prostate cancer research. Bavdegalutamide is also highly selective for AR. A proteomic analysis of VCaP cells treated </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with bavdegalutamide at a 10 nM concentration for eight hours demonstrated that only AR was degraded from the nearly 4,000 measured proteins. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Importantly, in addition to AR degradation and selectivity, we have observed in preclinical studies the ability of bavdegalutamide to potently inhibit prostate cancer cell growth and reduce PSA levels. In addition to guiding treatment decisions, reduction in PSA is often an indicator of the effectiveness of treatment in clinical trials, however, it is not recognized as a surrogate endpoint for purposes of regulatory approval. For example, bavdegalutamide demonstrated equivalent reduction in PSA to enzalutamide at ten-fold lower concentration levels in an </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inhibition study of PSA synthesis in Lymph Node Cancer of the Prostate cells, which are androgen-sensitive human prostate adenocarcinoma cells, that have been engineered to overexpress AR. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mouse models, bavdegalutamide has inhibited AR-dependent tumor growth in a statistically significant manner. Bavdegalutamide exhibited superior tumor growth inhibition compared to enzalutamide in both castrated and intact (non-castrated) xenograft models derived from VCaP cell lines. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To assess the ability of bavdegalutamide to treat enzalutamide-resistant cancers, we conducted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">studies of bavdegalutamide in an enzalutamide-resistant VCaP xenograft model. These VCaP tumors acquired resistance to enzalutamide after being continuously propagated in castrated, enzalutamide treated mice for approximately three years. This resistance can be seen in the figure below, as tumors in mice dosed with enzalutamide grew at nearly the same rate as tumors in mice dosed only with the drug vehicle - a control similar </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to dosing a placebo. Orally delivered bavdegalutamide significantly inhibited tumor growth, described as tumor growth inhibition, or TGI, in these enzalutamide-resistant VCaP tumors. </span></div><div style="margin-top:12pt;text-align:center"><img src="arvn-20221231_g10.jpg" alt="arvn-20221231_g10.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also conducted preclinical studies of bavdegalutamide for enzalutamide-insensitive tumors. We conducted an </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> study in a PDX model that is derived from a tumor from a patient not treated with enzalutamide but that is insensitive to enzalutamide. This insensitivity can be seen in the figure below, as tumors in mice dosed with enzalutamide grew at only a slightly slower rate than tumors in mice dosed only with the drug vehicle. In contrast, orally delivered bavdegalutamide significantly inhibited tumor growth in these enzalutamide-insensitive tumors, achieving a TGI value of 100%. Further, PSA levels in the plasma of mice </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following 20 days of bavdegalutamide dosing significantly decreased in comparison to those dosed with only the drug vehicle or enzalutamide. </span></div><div style="margin-top:12pt;text-align:center"><img src="arvn-20221231_g11.jpg" alt="arvn-20221231_g11.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the activity of bavdegalutamide in the above VCaP and PDX models may closely reflect enzalutamide resistance or insensitivity in the clinic and shows the potential for treatment of patients whose tumors have become resistant to, or demonstrate intrinsic resistance to, a current standard-of-care agent. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bavdegalutamide has also reduced the levels of PSA in plasma comparable to levels achieved with enzalutamide in a different VCaP xenograft mouse model but at a lower dosing level. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bavdegalutamide: Our Clinical Trials </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we initiated dosing in a Phase 1 clinical trial of bavdegalutamide. Our Phase 1 trial was designed as an open label, dose-escalation study of bavdegalutamide in men with mCRPC whose disease had progressed on at least two prior systemic therapies, one of which must have been enzalutamide or abiraterone. The Phase 1 trial was designed to primarily investigate the safety and tolerability of bavdegalutamide. Secondary endpoints included characterization of bavdegalutamide&#8217;s pharmacokinetic profile and preliminary assessment of biochemical and clinical activity based on evaluation of PSA levels, and radiographic measurement of evaluable lesions. The anti-tumor effects of bavdegalutamide in measurable lesions were assessed using Response Evaluation Criteria in Solid Tumors, or RECIST, a standardized set of rules for response assessment based on tumor shrinkage which is widely used in oncology clinical trials. We also evaluated exploratory markers of disease burden, such as circulating tumor cell enumeration, as exploratory endpoints of the trial. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A potential drug-drug interaction between bavdegalutamide and rosuvastatin, or ROS, was identified during the trial. One patient receiving 280 mg bavdegalutamide experienced a Grade 4 dose-limiting toxicity of elevated aspartate transaminase/alanine transaminase, or AST/ALT, liver enzymes followed by acute renal failure. A second patient, receiving 70 mg bavdegalutamide, experienced a Grade 3 AST/ALT elevation, which resolved after the removal of ROS, and the patient was retreated with bavdegalutamide. Follow-up exploratory findings indicate that ROS concentrations, but not bavdegalutamide concentrations, were elevated in both patients who had liver function test increases. Subsequent </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transport pump studies indicated that bavdegalutamide inhibited breast cancer resistant pump transporter, of which ROS is a substrate. Following the initial data that supported a potential interaction with ROS, concomitant use of ROS was precluded. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we amended the protocol</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for our Phase 1 clinical trial for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bavdegalutamide to</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include the addition of a Phase 2 expansion cohort. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our observations of a molecularly defined, late-line population with a particularly strong response to bavdegalutamide in the Phase 1 portion of the trial, we designed our Phase 2 dose expansion to assess bavdegalutamide in four specific subgroups: patients with tumors with AR T878X (T878X = T878A or T878S) and/or H875Y mutations but excluding other AR variants; patients with tumors with wild-type AR or AR alterations other than T878X, H875Y, L702H, and AR-V7; patients with tumors with AR-V7 or L</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">702H, which are variants of AR that, preclinically, bavdegalutamide did not degrade, or did not degrade potentaly, respectively; and patients with biomarker agnostic tumors treated with no more than one prior novel hormonal agent, or NHA, such as enzalutamide or abiraterone, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had no prior chemotherapy. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fourth quarter of 2020, we initiated the ARDENT Phase 2 expansion portion of the trial at a dose of 420 mg once-daily, the recommended Phase 2 dose, or RP2D. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In February 2022, we announced completed Phase 1 and interim ARDENT data for bavdegalutamide with a data cut-off date of December 20, 2021 at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium. We reported that bavdegalutamide showed reduced PSA levels of greater than or equal to than 50%, or PSA50, in 46% of the 28 patients with tumors harboring AR T878X/H875Y mutations. These results also demonstrated PSA declines and tumor regressions in patients without tumors harboring AR T878X/H875Y mutations, suggesting an opportunity to develop bavdegalutamide more broadly in prostate cancer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of the data cut-off date, 195 patients were enrolled across the Phase 1/2 clinical trial (71 in Phase 1; 124 in Phase 2).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Phase 1 dose escalation trial evaluated bavdegalutamide at doses ranging from 35&#8211;700 mg, once-daily, or 210&#8211;420 mg twice-daily, in patients with mCRPC and two or more prior therapies (including abiraterone and/or enzalutamide).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Patients in the ARDENT trial received a median of four prior lines of therapy with 100% receiving at least one NHA (64% abiraterone, 75% enzalutamide or other AR inhibitor, 39% both abiraterone and an AR inhibitor) and 31% receiving at least one chemotherapy regimen.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Efficacy Measures</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We presented efficacy measures on a combined basis for patients in both the completed Phase 1 dose escalation trial and the interim analysis from the ongoing ARDENT Phase 2 dose expansion trial. In the biomarker defined (&#8220;more pretreated&#8221;) subgroups, we observed the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In eight patients with tumors with AR T878X and/or H875Y mutations but excluding other AR variants, PSA50=75%; PSA decline of more than 30%, or PSA30, =75%</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In 44 patients with tumors with wild-type AR or AR alterations other than T878X, H875Y, L702H, or AR-V7, PSA50=11%; PSA30=20%</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In 25 patients with tumors with AR L702H or AR-V7, PSA50=4%; PSA30=20%</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the biomarker agnostic (&#8220;less pretreated&#8221;) subgroup comprising 27 patients with no more than one prior NHA and no prior chemotherapy, the PSA50 response rate was 22% and the PSA30 response rate was 26%.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In biomarker-evaluable patients treated at or above the RP2D and with tumors harboring AR T878X/H875Y mutations (across all subgroups and thus regardless of prior therapy regimens or other mutations; n=28), the PSA50 response rate was 46% and the PSA30 response rate was 57%.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Of seven RECIST-evaluable patients across the Phase 1 and Phase 2 trials with tumors harboring AR T878X/H875Y mutations, two had confirmed durable partial responses. These patients were on treatment for approximately nine months (ongoing as of the data cut-off) and ten months; the duration of treatment ranged from eight weeks to 44 weeks, with three of the seven patients continuing on treatment as of the data cutoff of December 20, 2021.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Twelve (43%) of the 28 patients with AR T878X/H875Y-positive mutations received bavdegalutamide for 24 weeks or more, with nine patients ongoing as of the data cutoff.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PSA reductions and evidence of anti-tumor activity as measured by RECIST were observed across all subgroups regardless of mutation status, including tumors not harboring AR T878X/875Y mutations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RECIST responses were seen in patients with tumors lacking AR T878X/H875Y mutations (one confirmed and three unconfirmed RECIST responses).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The &#8220;less pretreated&#8221; subgroup (n=27) had a similar molecular profile&#8212;as assessed by circulating tumor DNA analysis&#8212;to the more pretreated, biomarker-defined subgroups in the ARDENT trial. These similarities included both AR variations (point mutations and AR-V7 splice variants) and non-AR mutations frequently associated with poor outcomes (e.g., TP53, BRCA1). Six of the 27 patients (22%) had PSA50 reductions, and this PSA50 rate was similar to that observed collectively in the &#8220;more pretreated&#8221; subgroups (16%; n=77). Four of the six &#8220;less pretreated&#8221; patients with PSA50 declines had tumors with AR T878X/H875Y mutations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Safety and Tolerability</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bavdegalutamide had a manageable tolerability profile at the RP2D. The majority of treatment-related adverse events, or TRAEs, were Grade 1/2 and there were no Grade 4 or greater TRAEs in the 138 patients treated at the RP2D.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TRAEs that occurred in 10% or more of patients treated at the RP2D were nausea (Gr 1: 30%; Gr 2: 16%; Gr 3: 1%), fatigue (Gr 1: 23%; Gr 2: 12%; Gr 3: 1%), vomiting (Gr 1: 20%; Gr 2: 5%; Gr 3: 1%), decreased appetite (Gr 1: 14%; Gr 2: 11%; Gr 3: 1%), diarrhea (Gr 1: 14%; Gr 2: 4%; Gr 3: 2%), alopecia (Gr 1: 13%; Gr 2: 1%; Gr 3: N/A) AST increased (Gr 1: 9%; Gr 2: 3%; Gr 3: 1%), weight decreased (Gr 1: 7%; Gr 2: 5%; Gr 3: 0%), and anemia (Gr 1: 4%; Gr 2: 1%; Gr 3: 5%).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TRAEs at the RP2D led to dose reduction in 11 (8%) patients and discontinuation in 12 (9%) patients.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Phase 1b trial of bavdegalutamide in combination with abiraterone for the treatment of men with mCRPC is ongoing. We expect to complete enrollment in the Phase 1b trial in the second half of 2023. Abiraterone is approved, in combination with a corticosteroid, to treat patients with mCRPC or with high-risk castration-sensitive prostate cancer. Up to a third of patients treated with abiraterone develop primary resistance to this drug and nearly all patients experience disease progression. The Phase 1b study evaluates the combination of bavdegalutamide (ARV-110) with abiraterone at the initiation of progression on abiraterone (PSA progression without radiographic progression) to test if the addition of bavdegalutamide will overcome resistance to abiraterone and re-establish the AR pathway blockade in patients with prostate cancer. The primary objectives of the trial are to evaluate the safety and tolerability of bavdegalutamide in combination with abiraterone and determine the RP2D and schedule of this combination (based on the incidence of first-cycle dose-limiting toxicities and the frequency and severity of adverse events and laboratory abnormalities).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to initiate a global Phase 3 trial with a confirmed dose for bavdegalutamide for the treatment of men with mCRPC with AR T878/H875 tumor mutations in the second half of 2023. Also in the second half of 2023, we expect to complete enrollment in the Phase 1b clinical trial with bavdegalutamide in combination with abiraterone.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARV-766: Our Preclinical and Clinical Development </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing ARV-766, which has a different profile than bavdegalutamide, to target and degrade wild-type and mutated AR including at least one additional, clinically relevant AR point mutation, the L702H point mutation.The L702H point mutation in the ligand-binding domain of AR results in activation of the AR by glucocorticoids and can cause resistance to a standard of care regimen. Recent studies have reported that between approximately 2-9% of patients with mCRPC had an L702H point mutation. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we initiated a Phase 1/2 clinical trial for ARV-766 designed to assess the safety, tolerability and pharmacokinetics of ARV-766, which trial also includes measures of anti-tumor activity as secondary endpoints, including reduction in PSA. In the second half of 2022, we initiated a Phase 2 expansion trial of ARV-766 for the treatment of men with mCRPC. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to share data from the Phase 1 dose escalation trial of ARV-766 for the treatment of men with mCRPC in the second quarter of 2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate initiating a Phase 1b or Phase 2 dose escalation trial for either of bavdegalutamide or ARV-766 in patients with AR-dependent tumors who have not previously received novel hormonal agents, or NHA, such as enzalutamide or abiraterone, and who may benefit from bavdegalutamide or ARV-766 therapy, in the second half of 2023.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Next Generation AR Degraders</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing additional PROTAC targeted protein degraders capable of degrading certain AR splice variants. We expect that results from our Phase 1/2 clinical trials of bavdegalutamide and ARV-766 will provide further data on the role of androgen receptor splice variant-7, or AR-V7, in prostate cancer. Bavdegalutamide and ARV-766 bind to full-length AR at its ligand-binding domain. AR-V7 is a truncated form of AR that lacks the ligand-binding domain necessary to bind with bavdegalutamide and ARV-766 and which bavdegalutamide and ARV-766 therefore do not degrade. AR functions as a dimer, a complex made up of two individual AR proteins. AR-V7 can form a dimer with a full-length AR, and such non-identical protein dimers are called heterodimers. We believe that bavdegalutamide and ARV-766, by degrading the full-length AR component of the heterodimer, could successfully inactivate AR-V7-directed signaling. Although shown to form a heterodimer preclinically, there is uncertainty as to whether AR-V7 and AR form a heterodimer in patients&#8217; tumors. It is also possible that AR-V7 signals through V7-only dimers, which would be unaffected by bavdegalutamide and ARV-766. Although the presence of AR-V7 has been shown to correlate with a lack of response to enzalutamide and abiraterone, a published study demonstrated that approximately 40% of patients with AR-V7 expressing circulating tumor cells show a PSA response to enzalutamide. Given the evolving potential role of AR-V7 in prostate cancer, as a follow-on to bavdegalutamide and ARV-766, we are exploring the identification and development of a PROTAC targeted protein degrader that can degrade AR-V7 directly, as well as other AR splice variants. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Preclinical Programs Addressing Other Oncology and Neurodegenerative Disorders</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have active preclinical programs to evaluate additional established targets in oncology for both solid and hematological malignancies and neurodegenerative disorders. In line with our strategy, we assess potential exploratory programs on a target-by-target basis to decide whether our PROTAC targeted protein degraders provide a compelling differentiated approach over standard-of-care or other, existing or potential competing mechanisms of action directed against a specific target. In the case of currently or historically undruggable targets, we assess whether the features of our PROTAC targeted protein degraders, including their potential to degrade proteins via sites other than enzymatic active sites and the ability to initiate the degradation process using only weak binders, offer us opportunities to degrade those targets. In 2023, we expect to submit two IND applications or CTAs for two of our preclinical programs and to have two additional preclinical programs in IND- or CTA-enabling studies. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncology</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exploratory and research activity in oncology includes programs directed to the B-cell lymphoma 6, or BCL6, protein, a transcription factor implicated in B cell lymphomas; Kirsten rat sarcoma, or KRAS, an oncogenic cell growth regulator; Myc, an oncogenic transcription factor driving tumor cell proliferation; and hematopoietic progenitor kinase 1, or HPK1, a suppressor of T cell activation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In particular, we believe our BCL6 PROTAC degrader has the potential to be a first-in-class potential therapy for the NHL subtype DLBCL and believe additional opportunities for a BCL6 degrader exist in Burkitt's Lymphoma, Follicular Lymphoma, Angioimmunoblastic T-cell lymphoma and solid tumors. BCL6 is genetically mutated in up to 85% of DLBCL, a subset of NHL. More than 18,000 people are diagnosed with DLBCL each year. Treatment for DLBCL is largely devoid of oral options and there are currently no approved BCL6-targeted therapies on the market or in the clinic. BCL6 may also be a clinically relevant therapeutic target in various solid tumors including breast cancer, non-small cell lung cancer and glioblastoma.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our preclinical models, complete tumor stasis, which correlates with 95%-100% degradation of measurable BCL6, was achieved when our oral, BCL6-targeting PROTAC clinical candidate was taken at low, oral daily doses. We saw similar activity in multiple DLBCL models, including for activated B-cell and germinal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">center B-cell lymphoma. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This program is currently in GLP toxicity studies. We expect to submit an IND application or CTA for our BCL6 PROTAC degrader by year-end 2023.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neurodegenerative Diseases </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurodegenerative diseases are generally progressive in nature and result in the degeneration and often death of neurons in the brain, leading to cognitive decline, functional impairment and eventually death. These diseases affect a rapidly growing patient population and represent one of the largest unmet medical needs of our time. Alzheimer&#8217;s and Parkinson&#8217;s diseases encompass the largest patient populations among the neurodegenerative diseases</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Alzheimer&#8217;s Association estimated that 6.5 million Americans aged 65 and older, about one in nine individuals, were living with Alzheimer&#8217;s disease in 2022, and the Parkinson&#8217;s Foundation estimated that nearly one million Americans are living with Parkinson&#8217;s disease, or PD.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Alzheimer&#8217;s disease is marked by the progressive accumulation of aggregated tau protein, while aggregation of alpha-synuclein is thought to cause PD.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhibitor-based therapies targeting the proteins thought to be the cause of these neurodegenerative diseases have failed to show clinically meaningful benefit to date. While some existing products provide symptomatic relief to Alzheimer&#8217;s and Parkinson&#8217;s patients, they have significant side effect risks and over time gradually lose their effectiveness in treating the symptoms of the disease. Further, there are no approved disease-modifying treatments for Alzheimer&#8217;s or Parkinson&#8217;s. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Developing PROTAC Targeted Protein Degraders that Cross the Blood Brain Barrier </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Engineering PROTAC degraders that cross the blood-brain barrier is necessary to achieve targeted elimination of disease-causing proteins from the central nervous system. The ability of a targeted therapy to cross the blood-brain barrier is a highly desirable characteristic in developing effective therapeutics for patients with neurodegenerative diseases as compared with therapies delivered directly into the central nervous system, or CNS. Any product candidates for neurodegenerative disease must reach their intended targets in the brain at exposure levels that will provide a therapeutic effect, while having an acceptable safety profile. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Importantly, we have achieved brain penetration in preclinical models following parenteral administration of PROTAC degrader molecules designed to specifically target pathologic oligomers of mutant huntingtin, tau, and &#945;-synuclein, for the treatment of Huntington's disease, Alzheimer&#8217;s disease (tauopathies) and Parkinson&#8217;s disease (synucleinopathies), respectively. These PROTAC degrader molecules achieved concentrations in the brain sufficient to induce degradation of the aggregated proteins, widespread penetration into different parts of the brain, and brain/plasma ratios of 0.5 to 5.0, comparable to approved therapeutics with CNS activity.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Developing PROTAC Targeted Protein Degraders that Degrade Proteins Associated with Neurodegenerative Diseases </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted preclinical studies to establish the potential of our PROTAC Discovery Engine in the CNS for the treatment of neurodegenerative diseases, including tauopathies, the largest of which is Alzheimer&#8217;s disease. We have demonstrated that tau PROTAC protein degrader molecules could be dosed peripherally and degrade pathogenic tau in the brain of a mouse tauopathy model. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, we have demonstrated that alpha-synuclein PROTAC degraders can specifically degrade aggregated forms of the protein. We have conducted in vitro experiments in cells expressing the A53T mutant form of alpha-synuclein, a mutation that causes aggregation of alpha-synuclein and early-onset Parkinson&#8217;s diseases in patients. We treated these cells with alpha-synuclein targeting PROTAC degraders at 1 &#956;M for 48 hours. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our tau and alpha-synuclein programs, our neuroscience pipeline includes a program directed to mutant huntingtin, or mHTT, a key protein target for Huntington&#8217;s disease. We have identified novel ligands that when incorporated into PROTAC protein degrader molecules induce potent and selective degradation of mutant mHTT protein without impacting wild-type HTT protein in preclinical studies. This selectivity differentiates these ligands from other small molecule splice modulators that reduce both mHTT and wild-type HTT protein.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parkinson's Disease, or PD, is the second most common neurodegenerative disease, affecting approximately 10 million people world-wide. It is commonly thought of as a movement disorder because patients can experience tremors, slowness of movement, stiffness and difficulty with walking and balance. In addition, Parkinson's patients can have other non-motor type problems such as constipation, depression and memory loss. The disease results from the loss of dopamine-producing cells in the brain and is likely caused by a combination of genetic and environmental risk factors. No disease-modifying therapies have been approved for PD.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mutations in the LRRK2 gene are one of the most common genetic risk factors for Parkinson's disease. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LRRK2 is a multidomain GTPase/ kinase that acts, in part, as a scaffolding protein to interact with components of downstream signaling pathways regulating lysosomal function, mitochondrial processes, neuroinflammation and alpha-synuclein accumulation to negatively impact neuronal survival. Human genetics and preclinical animal model data suggest that a reduction of 50% of LRRK2 protein, but not kinase inhibition, may impact pathology and dysfunction in PD. Therefore, reduction of LRRK2 in the brain may be beneficial for the treatment of PD. We have identified potent, selective, orally bioavailable LRRK2 PROTAC protein degraders that cross the blood-brain barrier in preclinical species and biodistributed to deep brain regions impacted in PD. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our oral PROTAC LRRK2-targeting protein degrader clinical candidate has been shown preclinically to broadly bio-distribute to deep brain regions in non-human primates and degrades LRRK2 more than 95%. This program is currently in GLP toxicity studies. We expect to submit an IND or CTA for our PROTAC LRRK2 degrader by year end 2023.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to secure and maintain patent and other proprietary protection for our platform protein degradation technologies, including our PROTAC targeted protein degrader programs, product candidates, and know-how related to our business, defend and enforce our intellectual property rights, in particular our patent rights, preserve the confidentiality of our trade secrets, and operate without infringing valid and enforceable intellectual property rights of others. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions for biotechnology companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protected or remain protectable by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. <br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 30, 2023, our patent estate that we own, co-own and in-lic</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ense includes 36 issued U.S. patents, 92 granted foreign patents, and 492 pending patent applications (83 domestic and 409 foreign). </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PROTAC Patents and Patent Applications </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our PROTAC patent portfolio is generally organized into two categories: PROTAC platform patent filings, and PROTAC product candidate or protein target-specific patent filings. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PROTAC Platform </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 30, 2023, our PROTAC platform patent estate that we own, co-own, and in-license, and that covers our various E3 ubiquitin ligase constructs, includes three issued U.S. patents, 32 granted foreign patents, seven pending U.S. patent applications and 63 pending foreign patent applications. This patent estate covers constructs that have ligands for the Von Hippel Lindau, or VHL, E3 ubiquitin ligase, the cereblon, or CRBN, E3 ubiquitin ligase, the inhibitor apoptosis protein, or IAP, E3 ubiquitin ligase, and the human mouse double minute homolog, or MDM2, E3 ubiquitin ligase.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclusively license from Yale University, or Yale, a portfolio of patents and patent applications describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds comprised of ligands for the VHL E3 ubiquitin ligase, as well as claims to associated methods of use. Patents have been granted in Australia, Mexico, Russia, South Korea, and the United States, and patent applications </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, Mexico, South Korea, Russia and the United States. If all appropriate maintenance fees are paid, each granted patent will expire in 2033 without taking potential patent term extensions into account. We also co-own with Yale patent applications describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds comprised of ligands for the VHL E3 ligase. Two patents have issued in the United States, three foreign patents have been granted, and patent applications are pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, Mexico, Russia, South Korea and the United States. Our rights to this patent and these patent applications are governed by the Yale License Agreement described below under </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses and Strategic Collaborations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own one patent family with three pending U.S. patent applications describing composition-of-matter claims covering the CRBN E3 ubiquitin ligase ligand generically, the chemical linker group generically, and a small molecule or peptide ligand that binds to a target protein generically. We own granted patents in Australia, China, Europe, France, Germany, Great Britain, Hungary, India, Italy, Japan, Mexico, the Netherlands, Russia, Spain, Switzerland and South Korea. Patent applications are pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, Russia, South Korea and the United States. If all appropriate maintenance fees are paid, each granted patent in these families will expire no earlier than 2035 without taking potential patent term extensions into account.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own a patent family describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds comprised of ligands for the IAP E3 ubiquitin ligase as well as claims to associated methods of use. Patent applications in this family are pending in Europe and the United States. If granted, and all appropriate maintenance fees are paid, the expiration of these patents would be in 2036 without taking potential patent term extensions into account. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own a patent family describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds comprised of ligands for the MDM2 E3 ubiquitin ligase as well as claims to associated methods of use. Patent applications in this family are pending in Europe and the United States, and granted in Australia. If granted, and all appropriate maintenance fees are paid, the expiration of these patents would be in 2036, without taking potential patent term extensions into account. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PROTAC Product Candidates </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product or protein-specific patent applications were created to pursue more focused patent exclusivity around PROTAC targeted protein degrader compounds designed to target specific proteins. As of January 30, 2023, our PROTAC product patent portfolio covering AR and ER, and those patents that we co-own and in-license (including protein targets other than AR and ER) includes 20 U.S. issued patents, 92 granted foreign patents, 83 pending U.S. patent applications, 14 pending Patent Cooperation Treaty, or PCT, applications, and 388 pending foreign patent applications. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own 13 patent families describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds addressing AR and associated methods of manufacture and methods of treating cancer. The first patent family has three issued U.S. patents, six granted foreign patents, one pending U.S. applications, and 12 pending foreign patent applications describing composition-of-matter, synthetic intermediates, and method of use claims covering bavdegalutamide. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2037 without taking potential patent term extension into account. The second patent family has two issued U.S. patents, two pending applications in the United States, seven granted foreign patents, and 14 pending foreign applications describing alternative composition-of-matter claims. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2036 without taking potential patent term extension into account. The third patent family has two pending U.S. applications and 11 pending foreign applications describing claims directed to additional methods of treating cancer using bavdegalutamide. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2040 without taking potential patent term extension into account. The fourth patent family has one pending U.S. application and 39 pending foreign applications describing composition-of-matter claims directed to ARV-766. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2040 without taking potential patent term extension into account. The fifth patent family has one pending U.S. application and 12 pending foreign applications describing claims directed to additional methods of treating cancer using bavdegalutamide. Any patent granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account. The sixth patent family has one pending U.S. application and 31 pending foreign </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applications describing claims directed to methods of manufacture, crystalline and ultrapure forms, and dosage forms of bavdegalutamide. Any patent granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account. The seventh patent family has one pending U.S. application and one pending PCT application describing claims directed to methods of treating cancer with bavdegalutamide in patients with specific AR mutations. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account. The eighth patent family has three pending U.S. applications describing methods of treating cancer with ARV-766. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2043 without taking potential patent term extension into account.  The ninth patent family has one pending U.S. application, one granted foreign patent, and 15 pending foreign applications describing alternative AR-based PROTAC compounds and methods of use to treat cancer. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2038 without taking potential patent term extension into account. The tenth patent family has one pending U.S. application describing claims directed towards dosage forms of bavdegalutamide. Any patent granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2044 without taking potential patent term extension into account.  The eleventh patent family has one pending U.S. application describing claims directed towards additional methods of treating cancer using bavdegalutamide. Any patent granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2043 without taking potential patent term extension into account.  The twelfth patent family has one pending U.S. application and one pending PCT application describing alternative composition-of-matter claims. Any patent granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account. The thirteenth patent family has one pending U.S. application and one pending PCT application describing alternative composition-of-matter claims. Any patent granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own 13 patent families describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds addressing ER and associated methods of treating cancer. The first patent family has three issued U.S. patents, three pending U.S. applications, seven granted foreign patents, and 22 pending foreign patent applications describing composition-of-matter and method of use claims covering ARV-471. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2037 without taking potential patent term extension into account. The second patent family has one pending U.S. application and 23 pending foreign patent applications describing claims directed to methods of treating cancer using ARV-471 as a monotherapy, and combined with an additional anti-cancer agent. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2040 without taking potential patent term extension into account. The third patent family has one pending U.S. application, one pending PCT application, and two pending foreign applications describing claims directed to crystalline forms of ARV-471. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account. The fourth patent family has one pending U.S. application, one pending PCT application, and one pending foreign application describing claims directed to methods of treating cancer with ARV-471 in patients with specific ER mutations, and methods of treating cancer with ARV-471 and additional anti-cancer agents. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account. The fifth patent family has one pending U.S. patent application describing oral dosage formulations of ARV-471 and methods of preparing such oral dosage formulations of ARV-471. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2042 without taking potential patent term extension into account. The sixth patent family has one issued U.S. patent and three pending foreign applications describing alternative ER-based PROTAC compounds and methods of use to treat cancer. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2037 without taking potential patent term extension into account. The seventh patent family has two issued U.S. patent, one pending U.S. patent application, one issued foreign patent, and 13 pending foreign applications describing alternative ER-based PROTAC compounds and methods of use to treat cancer. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2038 without taking potential patent term extension into account. The eighth patent family has one pending U.S. application and one pending PCT application describing claims directed to methods of manufacture of ARV-471. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2042 without taking potential patent term extension into account. The ninth patent family has one pending U.S. application directed to dosage regimens of ARV-471 as a monotherapy to treat cancer. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2043 without taking potential patent term extension into account. The tenth patent family has one pending U.S. application directed to dosage regimens of ARV-471 combined with an additional anti-cancer </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agent to treat cancer. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2043 without taking potential patent term extension into account. The eleventh patent family has one pending U.S. application directed to methods of treating cancer with ARV-471 to reduce any potential drug-drug interactions. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2043 without taking potential patent term extension into account. The twelfth patent family has one U.S. application directed to methods of treating cancer with ARV-471 to reduce any potential drug-drug interactions. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2043 without taking potential patent term extension into account. The thirteenth patent family has one U.S. application directed to a method of treating advanced breast cancer with ARV-471. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2043 without taking potential patent term extension into account. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Yale co-own five patent families describing composition of matter claims of PROTAC targeted protein degrader compounds addressing certain discovery and other potential protein targets, and associated methods of use. One or more U.S. patents have issued in each of these families and patent applications for four of these families are pending in the United States. In addition, 37 foreign patent applications are pending for two of the families. Patent applications are also pending in the European Patent Office for each of the families. Our rights to these patent applications are governed by the Yale License Agreement described below under </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses and Strategic Collaborations </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We co-own with Genentech two pending U.S. patent applications, two pending PCT applications, and 30 foreign patent applications and one granted foreign patent directed to PROTAC targeted protein degrader compounds addressing a specific protein. Our rights to these patent applications are governed by the Genentech License Agreement described below under </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses and Strategic Collaborations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent covering a drug approved by the U.S. Food and Drug Administration, or FDA, may be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering bavdegalutamide and ARV-471 may be entitled to patent term extensions. If our product candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term extensions in any jurisdiction where they are available; however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States also offers Patent Term Adjustment, or PTA, whereby a particular patent&#8217;s term is automatically extended beyond the 20-year term if the United States Patent and Trademark Office caused delays during the underlying patent application&#8217;s examination. However, potentially available PTA will be reduced by any amount of delay caused by the applicant. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets, technical know-how and continuing innovation to develop and maintain our competitive advantage. Our policy requires inventors who are identified on any company-owned patent applications to assign rights to us. We also rely on confidentiality agreements with our employees, consultants and other advisors to protect our proprietary information. Our policy is to require third parties that receive material confidential information to enter into confidentiality agreements with us. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademarks </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own a U.S. service mark registration for PROTAC for pharmaceutical products development of new small molecules aimed at degrading disease-causing cellular proteins for treatment in the fields of oncology, immunology, inflammatory diseases, and central nervous system disorders. We also own a U.S. trademark registration for the mark PROTAC for small molecule products aimed at degrading disease-causing cellular </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proteins for treatment in the fields of oncology, immunology, inflammatory diseases, and central nervous system disorders. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own U.S. trademark and service mark registrations for ARVINAS in word and logo form for pharmaceutical preparations and pharmaceutical products development of cellular proteins for treatment in the fields of oncology, immunology, inflammatory diseases, and central nervous system disorders. The ARVINAS word mark is registered for pharmaceutical products development services in Australia, China, the EU, Japan, Norway, South Korea, and Switzerland, and is pending registration in several other countries. The ARVINAS word mark is also registered for pharmaceutical products in Australia, Brazil, Colombia, the EU, Hong Kong, India, Indonesia, Israel, Japan, Mexico, New Zealand, Norway, Singapore, South Africa, South Korea, Switzerland, Taiwan, and the United Kingdom, and is pending registration in several other countries.  The ARVINAS logo mark is registered for pharmaceutical products development services in the EU and the United Kingdom, and is pending registration in several other countries.  The ARVINAS logo mark is also registered for pharmaceutical products in the EU, Hong Kong, and the United Kingdom, and is pending registration in several other countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own U.S. service mark registrations for our &#8220;degrading dots&#8221; logo mark in both black and white and color form for pharmaceutical products development of new small molecules aimed at degrading disease-causing cellular proteins for treatment in the fields of oncology, immunology, inflammatory diseases, and central nervous system disorders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we own pending applications in the U.S. for the PROTAC mark for bi-functional small molecules that mediate targeted protein degradation through the ubiquitin proteasome system for agricultural and pesticide use and agricultural products development services.  These applications are licensed for use by Oerth Bio.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licenses and Strategic Collaborations </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Yale University License Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2013, we entered into a license agreement with Yale pursuant to which Yale granted us an exclusive, worldwide license under specified intellectual property rights for the treatment or prevention of any human or animal disease in which a product mediates degradation of one or more target proteins, which we refer to as the Field, subject to certain exceptions. These licensed intellectual property rights arose from the research conducted by Dr. Craig Crews at Yale.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to use commercially reasonable efforts to implement a written plan we agreed to with Yale setting forth a description of any research and development, testing, governmental approval and commercialization activities relating to licensed products and our financing plans. We must update this plan on an annual basis to indicate progress to date on the plan and a schedule of major events required to commercialize licensed products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the license agreement we paid to Yale an upfront payment of $0.1 million. We are responsible for paying Yale an annual license maintenance fee in varying amounts (ranging from the low tens-thousands of dollars to the mid to high tens-thousands of dollars) until the first sale to a third party of any licensed product, which is creditable against our royalty obligations for the given year. As of December&#160;31, 2022, we have paid a total of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.6 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in license maintenance fees to Yale. We are required to pay Yale, subject to the achievement of specified development and regulatory milestones, payments aggregating up to approximately $3.0 million for the first licensed product and up to approximately $1.5 million for the second licensed product. We are not required to make any milestone payments for any licensed products beyond the first two. While the agreement remains in effect, we are required to pay Yale low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions. Yale is guaranteed a minimum royalty payment amount (ranging from </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.2 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.5 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for each year after the first sale of a licensed product that results in net sales. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he agreement requires that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we must also pay Yale a mid-single digit to mid-double digit percentage of certain consideration we receive from a sublicensee for the first licensed product we sublicense. We are also responsible for costs relating to the prosecution and maintenance of the licensed patents. Finally, subject to certain conditions, all payments made by us to Yale (except patent costs) will be tripled during the pendency of any patent challenge made by us against Yale. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license agreement remains in effect until (a) for certain products, the date on which the last claim of the licensed patents expires; and (b) for certain products, 10 years after the sale of such products. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expiration of the last to expire patent right licensed from Yale, if it issues as a patent and all appropriate maintenance fees are paid, is currently expected be in 2039. Either we or Yale may terminate the agreement for the other party&#8217;s uncured material breach of certain provisions, we may terminate the agreement for convenience upon six months&#8217; prior notice, and Yale may terminate the agreement if we fail to make a payment when due, fail to obtain or maintain adequate insurance coverage or fail to achieve specified financing or regulatory milestone events. The agreement will automatically terminate if we become insolvent. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech License Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we entered into an Option and License Agreement with Genentech focused on PROTAC targeted protein degrader discovery and research for target proteins, or Targets, based on our proprietary platform technology, other than excluded Targets as described below. This collaboration was expanded in November 2017 through an Amended and Restated Option, License and Collaboration Agreement, which we refer to as the Restated Genentech Agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration is managed by a joint research committee and a joint project team, each of which is comprised of representatives from us and Genentech. Decisions of the joint research committee and joint project team are made by consensus, with each party having one vote. If the joint research committee is unable to agree, and the parties&#8217; executives are not able to resolve the dispute, then Genentech has final decision-making authority, subject to specified limitations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Restated Genentech Agreement, Genentech has the right to designate up to ten Targets for further discovery and research utilizing our PROTAC platform technology. Genentech may designate as a Target any protein to which a PROTAC targeted protein degrader, by design, binds, to achieve its mechanism of action, subject to certain exclusions. Genentech also has the right to remove a Target from the collaboration and substitute a different Target that is not an excluded Target at any time prior to us commencing research on such Target or in certain circumstances following commencement of research by us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a Target becomes subject to the collaboration, we are obligated to use diligent efforts to undertake a research program in accordance with a research plan agreed to by the parties for such Target. We are responsible for funding our activities under the research program for each Target up to the amount set forth in the budget for such Target agreed upon by the parties in the research plan. For costs incurred in excess of the budgeted amount, Genentech has the option of either having us continue the work on the Target and reimbursing us for our costs in doing so or terminating the work on such Target. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research program for each Target contemplates that the discovery and research work will occur in two stages: Stage 1, in which our objective will be to identify a PROTAC targeted protein degrader that demonstrates in vitro protein degradation of the Target; and Stage 2, in which our objective will be to demonstrate certain </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> research and development activity, but not to complete toxicology studies or other necessary IND-enabling studies. For each Target, at the conclusion of Stage 1, Genentech has the opportunity to continue the research program for such Target or terminate all activities on such Target. At the conclusion of each stage, we are obligated to provide certain deliverables to Genentech, including a data package at the end of Stage 2. Genentech has an option to obtain an exclusive worldwide license to the applicable PROTAC targeted protein degraders directed against the applicable Target, which we refer to as Licensed PROTACs. Each such option must be exercised within a specified time after we deliver the data package for such Licensed PROTAC to Genentech. Once Genentech exercises an option, it is responsible, at its cost, to use diligent efforts to develop and commercialize the Licensed PROTAC through first commercial sale in the United States, the European Union and Japan. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Restated Genentech Agreement, we and our affiliates are not permitted, either directly or indirectly, to conduct any activities in the design, identification or discovery of any small molecule pharmacologically active agent directed against a Target included in the collaboration, including certain PROTAC targeted protein degraders whose intended primary mechanism of action is, by design, through induction of proteasomal degradation of such Target. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Restated Genentech Agreement, we received $11.0 million in 2015 and an additional $34.5 million in 2017 in upfront payments and expansion target payments. We are eligible to receive up to an aggregate of $27.5 million in additional expansion target payments if Genentech exercises its options </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for all remaining Targets. We are also eligible to receive payments aggregating up to $44.0 million per Target subject to the achievement of specified development milestones; payments aggregating up to $52.5 million per Target (assuming approval of two indications) subject to the achievement of specified regulatory milestones; and payments aggregating up to $60 million per Licensed PROTAC subject to the achievement of specified sales milestones. These milestone payments are subject to reduction if we do not have a valid patent claim covering the Licensed PROTAC at the time the milestone is achieved. We are also eligible to receive, on net sales of Licensed PROTACs, mid-single digit royalties, which may be subject to reductions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Restated Genentech Agreement will expire upon the expiration of all royalty periods for any Licensed PROTACs. The royalty period for each Licensed PROTAC expires on a country-by-country basis upon either (1) the expiration of the last-to-expire valid patent claim covering such Licensed PROTAC or (2) ten years after the first commercial sale with respect to such Licensed PROTAC, depending on whether the sale of the Licensed PROTAC is covered by an applicable valid claim. The expiration of the last to expire patent right licensed to Genentech, if it issues as a patent and all appropriate maintenance fees are paid, is currently expected be in 2042. We could also obtain rights to additional patents, including through the issuance of pending patent applications, with later expiration dates, or new Licensed PROTACs could be added to the agreement that are subject to additional royalty terms with later expiration dates, which in either case could extend the term of the Restated Genentech Agreement. Genentech has the right to terminate the Restated Genentech Agreement for convenience in its entirety or with respect to a specific Target on 60 days&#8217; prior notice. Either we or Genentech may terminate the agreement, in its entirety or with respect to a specific Target, if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either we or Genentech may terminate the agreement in the event of specified insolvency events involving the other party. If Genentech terminates the agreement for convenience or if we terminate the agreement as a result of Genentech&#8217;s uncured material breach or Genentech&#8217;s insolvency, all licenses we granted to Genentech terminate (either in its entirety or with respect to a specific Target, as applicable based on the nature of the termination). If Genentech terminates the agreement as a result of our uncured material breach or our insolvency, all licenses that we granted to Genentech terminate (either in its entirety or with respect to a specific Target, as applicable based on the nature of the termination), except that Genentech has the right to elect to retain its licenses, in which case it would no longer be obligated to use diligent efforts to develop and commercialize the applicable Licensed PROTACs and its payment obligations to us would be reduced. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into a Research Collaboration and License Agreement with Pfizer setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of Targets using our proprietary platform technology that are identified in the agreement or subsequently selected by Pfizer, subject to certain exclusions. We refer to this agreement as the Pfizer Research Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pfizer Research Collaboration Agreement, Pfizer has designated a number of initial Targets. For each identified Target, we and Pfizer will conduct a separate research program pursuant to a research plan. Pfizer may make substitutions for any of the initial Target candidates, which substitutions are limited subject to the stage of research for such Target.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer are obligated to use commercially reasonable efforts to complete our respective activities set forth in a research plan, including, in our case, the obligation to provide certain deliverables at the end of each stage. Under the research plan, we are required to provide compound formulation and conduct pharmacokinetic/pharmacodynamic and drug safety research and development activities in support of screening and other activities conducted by Pfizer relating to a Target. Following the provision of the deliverables by us for a stage, we will suspend the conduct of any further activities until Pfizer has exercised its right to proceed. If Pfizer does not exercise such right within the applicable time period, we will cease activities for such Target and such Target will no longer be part of the collaboration. Each party will bear its own costs in the conduct of such activities, except that any additional work that we agree with Pfizer to perform outside of the research plan will be paid for by Pfizer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer has the right to exercise an option to obtain an exclusive worldwide license with respect to each Target for a specified period of time after receipt of the applicable deliverables for such Target. If Pfizer does not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise its option for a Target, such Target is no longer subject to the Pfizer Research Collaboration Agreement. If Pfizer exercises such option, Pfizer will have an exclusive license to develop and commercialize compounds directed against such Target, subject to certain diligence obligations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Pfizer Research Collaboration Agreement, we and our affiliates are not permitted, either directly or indirectly, to develop or commercialize any pharmacologically-active agent whose primary mechanism of action is, by design, directed to a Target, or grant any license, covenant not to sue or other right to any third party for the conduct of such activities. There are no restrictions on Pfizer from developing, manufacturing or commercializing products, programs, technologies or processes that are similar to or may compete with any covered by the Pfizer Research Collaboration Agreement, subject to certain limitations on Pfizer&#8217;s right to use our confidential information or know-how.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2018, we received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in exchange for use of our technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. We are eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. We are also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as mid- to high-single digit tiered royalties, which may be subject to reductions, on net sales of PROTAC targeted protein degrader-related products.  In 2021 and 2020, we received payments totaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2 million and $4.4&#160;million, respectively</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pfizer also selected additional targets and initiated additional services totaling $1.0 million and $3.5 million in December 2022 and 2021, respectively, which were included in accounts receivable as of December 31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 and 2021, we received payments totaling $3.5 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2 million, respectively,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for addition targets and services. In addition, Pfizer selected an additional target in 2022 totaling $1.0 million which was included in accounts receivable as of December 31, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Pfizer Research Collaboration Agreement will expire upon the expiration of all royalty obligations thereunder. The royalty period for each product developed under the Pfizer Research Collaboration Agreement will expire on a country-by-country basis upon the later of (1) the expiration of the last-to-expire valid patent claim that claims or covers the composition of matter of a compound contained within such product or (2) ten years after the first commercial sale with respect to such product. Pfizer has the right to terminate the Pfizer Research Collaboration Agreement for convenience in its entirety or with respect to a specific target on 60 days&#8217; prior notice. Either we or Pfizer may terminate the Pfizer Research Collaboration Agreement, in its entirety or with respect to a specific target, if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either we or Pfizer may terminate the Pfizer Research Collaboration Agreement in the event of specified insolvency events involving the other party. If Pfizer terminates the agreement in its entirety or as a result of our uncured material breach or our insolvency, Pfizer retains its license with respect to Targets for which it has exercised an option (unless Pfizer elects otherwise), subject to reduced payment obligations.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Collaboration Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we entered into a Collaboration and License Agreement with Bayer setting forth our collaboration to identify or optimize PROTAC targeted protein degraders, that mediate for degradation of Targets using our proprietary platform technology, which Targets will be selected by Bayer, subject to certain exclusions and limitations. We refer to this agreement as the Bayer Collaboration Agreement. The Bayer Collaboration Agreement became effective in July 2019.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the identified Targets, we and Bayer will conduct a research program pursuant to separate research plans tailored to each Target selected by Bayer. Bayer may make substitutions for any such initial Target candidates, subject to certain conditions and based on the stage of research for such Target.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Bayer are obligated to use commercially reasonable efforts to complete our respective activities set forth in each research plan, including, in our case, the obligation to provide certain deliverables at certain stages of the research plans. The joint steering committee established under the collaboration shall determine </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether the research program with respect to a given Target has been completed. In the absence of any such determination by the joint steering committee, and unless otherwise agreed by the parties in writing, for each Target for which research program activities have commenced, if no research funding is allocated to such Target for the 12 month period commencing on July 1, 2019 or any anniversary thereof, and we refer to each as a Research Program Year, the research program with respect to the relevant Target shall be deemed completed as of the end of the last Research Program Year for which funding was allocated to such Target. Bayer shall pay to us research funding payments of $3.0 million dollars per year in each of the first four Research Program Years. If our costs for its research activities under the research plans exceed the research funding provided by Bayer for any Research Program Year before completion of all relevant research program activities in such Research Program Year, and we have complied with its reporting obligations to Bayer with respect to research program costs, we shall not be obligated to carry out further research program activities for the given Research Program Year unless Bayer has agreed in writing to fund such additional activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Bayer Collaboration Agreement, we and our affiliates are not permitted, either directly or indirectly, to design, identify, discover or develop any small molecule pharmacologically-active agent whose primary mechanism of action is, by design, directed to the inhibition or degradation of any Target selected or reserved by Bayer, or grant any license, covenant not to sue or other right to any third party in the field of human disease under the licensed intellectual property for the conduct of such activities. There are no restrictions on Bayer from developing, manufacturing or commercializing products, programs, technologies or processes that are similar to or may compete with any covered by the Bayer Collaboration Agreement, subject to certain limitations on Bayer&#8217;s right to use the Arvinas&#8217; confidential information or know-how.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Bayer Collaboration Agreement, we received an aggregate upfront, non-refundable payment of $17.5 million in August 2019. Bayer is committed to fund a total of $12.0 million in research funding payments through 2023, of which $10.5&#160;million was received from inception through December&#160;31, 2022, subject to potential increases if our costs for research activities exceed the research funding payments allocated to a Target and certain conditions are met. We are also eligible to receive up to $197.5 million in development milestones and up to $490.0 million in sales-based milestones for all designated Targets. In addition, we are eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Bayer Collaboration Agreement will expire upon the expiration of all royalty obligations thereunder. The royalty period for each product developed under the Bayer Collaboration Agreement will expire on a country-by-country basis upon the later of (1) the expiration of the last-to-expire valid patent claim that covers the manufacture, use or sale of such product or (2) ten years after the first commercial sale with respect to such product. Bayer has the right to terminate the Bayer Collaboration Agreement for convenience in its entirety or with respect to a specific target on 60 days&#8217; prior written notice. Either the Company or Bayer may terminate the Bayer Collaboration Agreement, in its entirety or with respect to a specific target, if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either we or Bayer may terminate the Bayer Collaboration Agreement in the event of specified insolvency events involving the other party. If Bayer terminates the agreement in its entirety as a result of our uncured material breach or the Company&#8217;s insolvency, Bayer may elect in writing to retain its license with respect to any Targets previously identified and delivered to Bayer, subject to reduced payment obligations.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Joint Venture</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we, Bayer and Bayer CropScience LP, or BCS, formed a joint venture, Oerth Bio, a Delaware limited liability company. We and BCS each received an initial ownership interest in Oerth Bio representing 50% of the ownership interests. Oerth Bio was formed for the purpose of researching, developing and commercializing PROTAC targeted protein degraders, or PROTAC Products, for applications in the field of agriculture. A 15% ownership interest of Oerth Bio was reserved for the future grant of incentive units to employees and service providers of Oerth Bio and, as a result, the Company's ownership interest totaled 46.5%, 48.4% and 49.4% as of December 31, 2022, 2021 and 2020, respectively, as a result of vested incentive units.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the ownership interests in Oerth Bio, we made an in-kind intellectual property contribution to Oerth Bio and BCS made an in-kind intellectual property contribution to Oerth Bio. In addition, BCS committed and subsequently made cash contributions to Oerth Bio totaling $56.0 million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the joint </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">venture agreement, we have no obligation to provide additional funding and our ownership interest will not be diluted from future contributions from BCS.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and BCS&#8217;s ownership interest in Oerth Bio, and the accompanying rights and obligations as members of Oerth Bio, are governed by an amended and restated limited liability company agreement, or LLC Agreement, by and among us, BCS and Oerth Bio. Oerth Bio is generally governed by a board of managers, or the JV Board, which is comprised of four voting members, two of which have been designated by us and two of which have been designated by BCS. JV Board decisions will generally be made by majority vote of the managers, with each manager having one vote. Certain matters will require the consent of both BCS and the Company or both of their designated managers on the JV Board. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Oerth Bio is jointly controlled by us and BCS, we account for our ownership interest using the equity method of accounting.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and BCS also entered into separate service agreements, or the Services Agreements. We and BCS will provide services to Oerth Bio as agreed from time to time by us and BCS, as applicable, and set forth in statements of work to be delivered under the applicable Services Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and BCS each also entered into respective intellectual property contribution agreements, each, an IP Contribution Agreement, with Oerth Bio. Pursuant to the IP Contribution Agreement by and between us and Oerth Bio, or the Company IP Contribution Agreement, in addition to certain non-exclusive licenses, we granted to Oerth Bio an exclusive, worldwide, fully paid-up, royalty-free license, including certain rights to sublicense, to use certain of our PROTAC technology to research, develop, manufacture, use and commercialize and sell PROTAC Products in the field of agriculture.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the IP Contribution Agreement by and between BCS and Oerth Bio, or the BCS IP Contribution Agreement, in addition to certain non-exclusive licenses, BCS and certain of its affiliates granted to Oerth Bio an exclusive, worldwide, fully paid-up, royalty-free license, including certain rights to sublicense, to use certain of BCS&#8217; or its affiliates&#8217; intellectual property that covers ubiquitin ligases or moieties that bind ubiquitin ligase complexes, and linkers that attach ubiquitin ligase binding moieties to moieties that bind to a target, to research, develop, manufacture, use and commercialize and sell PROTAC Products in the field of agriculture.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company IP Contribution Agreement and the BCS IP Contribution Agreement also contain a non-exclusive, worldwide, fully paid-up, royalty-free license grant from Oerth Bio to each of us and BCS, respectively, under various forms of intellectual property developed by Oerth Bio to research, develop, manufacture, use and commercialize products outside of the field of agriculture, in each case excluding intellectual property licensed by the other contributing party to Oerth Bio.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We, Oerth Bio and BCS also entered into an option agreement, or the Option Agreement, pursuant to which the parties agreed to certain procedures for, and preferential rights relating to, the possible transfer to BCS of PROTAC Product candidates researched, developed and commercialized by Oerth Bio under the joint venture. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we, BCS and Oerth Bio terminated the Option Agreement and the commitment agreement entered into in connection with the formation of Oerth Bio. In addition, we, BCS and Oerth Bio amended and restated the Arvinas IP Contribution Agreement and BCS Contribution Agreement. We and BCS also amended the LLC Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer ARV-471 Collaboration Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into a collaboration agreement with Pfizer, or the ARV-471 Collaboration Agreement, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound ARV-471, or the Licensed Products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ARV-471 Collaboration Agreement, we received an upfront, non-refundable payment of $650 million. In addition, we are eligible to receive up to an additional $1.4 billion in contingent payments based on specified regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer share equally (50/50) all development costs (including costs for conducting any clinical trials) for the Licensed Products, subject to certain exceptions. Except for certain regions described below, we will also share equally (50/50) all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be the marketing authorization holder and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. We will determine with Pfizer which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of all profits and losses for the Licensed Products based on the role each party will be performing. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the ARV-471 Collaboration Agreement will expire on a Licensed Product-by-Licensed Product and country-by-country basis when such Licensed Products is no longer commercialized or developed for commercialization in such country. Pfizer may terminate the ARV-471 Collaboration Agreement for convenience in its entirety or on a region-by-region basis subject to certain notice periods. Either party may terminate the ARV-471 Collaboration Agreement for the other party&#8217;s uncured material breach or insolvency. Subject to applicable terms of the ARV-471 Collaboration Agreement, including certain payments to Pfizer upon termination for our uncured material breach, effective upon termination of the ARV-471 Collaboration Agreement, we are entitled to retain specified licenses to be able to continue to exploit the Licensed Products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to specified exceptions, we and Pfizer have each agreed not to directly or indirectly research, develop, or commercialize any competing products outside of the ARV-471 Collaboration Agreement anywhere in the world during the term of the ARV-471 Collaboration Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products. While we believe that our technology, expertise, scientific knowledge and intellectual property estate provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. Not only must we compete with other companies that are focused on protein degradation, but any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Moreover, our industry is characterized by the existence of large numbers of patents and frequent allegations of patent infringement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platform and product focus is the discovery and development of protein degradation therapies using our small molecule PROTAC targeted protein degraders. Other companies researching chimeric small molecules for protein degradation include</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accutar Biotechnology, Inc., C4 Therapeutics, Inc., Cullgen Inc., Foghorn Therapeutics, Inc., Kymera Therapeutics, Inc., Nurix Therapeutics, Inc. and Proteovant Therapeutics, Inc. Further, several large pharmaceutical companies have disclosed preclinical or clinical investments in this field, including AbbVie, Amgen, AstraZeneca plc, Boehringer Ingelheim, Bristol Myers Squibb Company, GlaxoSmithKline plc, Genentech, Novartis International AG and Sanofi SA. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2020, some of these biotechnology and pharmaceutical companies have announced the initiation of clinical trials for targeted protein degraders. Additionally, other novel targeting mechanisms could ultimately address similar patient populations, such as CYP11A1 inhibitor (which is being developed by Orion/Merck) and an AR N-Terminal Domain inhibitor (which his being developed by ESSA Pharma) in prostate cancer. In addition to competition from other protein degradation therapies, any products that we develop may also face competition from other types of therapies, such as small molecule, antibody, or gene therapies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidates target oncologic indications. The most common methods of treating patients in oncologic indications are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy. There are a variety of available drug therapies marketed for cancer, including prostate cancer and breast cancer. In many cases, these drugs are administered in combination to enhance efficacy. Some of the currently approved drug therapies are branded and subject to patent protection, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. In general, although there has been considerable progress over the past few decades in the treatment of cancer and the currently marketed therapies provide benefits to many patients, these therapies all are limited to some extent in their efficacy and frequency of adverse events, and none of them are successful in treating all patients. As a result, the level of morbidity and mortality from cancer remains high. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to currently marketed drugs, including the selective estrogen receptor degrader elacestrant, there are also several product candidates in late stage clinical development for the treatment of oncologic indications, including for mCRPC and metastatic ER+ / HER2- breast cancer. These products in development include, in the case of metastatic ER+ / HER2- breast cancer, selective estrogen receptor degraders and may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain market approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved for the indications for which we expect to conduct clinical trials, they will compete with the foregoing therapies and the currently marketed drugs and potentially any drugs in development. It is also possible that we will face competition from other biologic or pharmaceutical approaches as well as from other types of therapies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of all our programs, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization Plans </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet established our own commercial organization or distribution capabilities because our product candidates are still in preclinical and clinical development. Other than our discovery collaboration agreements, we have retained commercialization rights for all of our development programs including global co-commercialization rights for ARV-471 through our collaboration with Pfizer. If any of our product candidates receive marketing approval, we will need to develop a plan to commercialize them in the United States and other key markets. We currently expect that we would build our own focused, specialized sales and marketing organization to support the commercialization of product candidates in the United States for which we receive marketing approval and that can be commercialized with such capabilities and we are beginning that building process, including through the hiring of John Northcott as Chief Commercial Officer in 2022. We expect to utilize a variety of types of collaboration, co-promotion, distribution and other marketing arrangements with one or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more third parties to commercialize our product candidates in markets outside the United States or for situations in which a larger sales and marketing organization is required. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As product candidates advance through our pipeline, our commercial plans may change. In particular, some of our research programs target potentially larger indications. Data, the size of the development programs, the size of the target market, the size of a commercial infrastructure and manufacturing needs may all influence our strategies in the United States, Europe and the rest of the world. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely on and expect to continue to rely on third-party contract manufacturing organizations, or CMOs, for both drug substance and finished drug product as well as for the synthesis of compounds in our preclinical research and development activities. We have engaged third-party manufacturers to supply the drug substances and building blocks for those substances for ARV-471, bavdegalutamide and ARV-766. We have also engaged third-party manufacturers to develop and manufacture finished drug product for ARV-471, bavdegalutamide and ARV-766 that we are using and plan to use in our ongoing and planned Phase 1/2 and pivotal clinical trials. We currently obtain our supplies from these manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there are a number of potential replacements, although we may incur some delay in identifying and qualifying such replacements. Under the terms of our collaboration, we expect Pfizer to manufacture commercial supply of ARV-471.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are organic compounds of low molecular weight, generally called small molecules, but which are larger than traditional small molecule therapeutics. We have selected these compounds not only on the basis of their potential efficacy and safety, but also for their ease of synthesis and reasonable cost of goods. In particular, our lead product candidates are manufactured using reliable and reproducible synthetic processes from readily available starting materials. The chemistry is amenable to scale up and does not require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities or with partners. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approvals</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other jurisdictions, such as the European Union, extensively regulate, among other things, the research, development, testing, manufacturing, pricing, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, sales, reimbursement, post-approval monitoring and reporting, and import and export of biopharmaceutical products. The processes for obtaining marketing approvals in the United States and in foreign jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approval and Regulation of Drugs in the United States </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States, drug products are regulated under the Federal Food, Drug, and Cosmetic Act, or FDCA, and applicable implementing regulations and guidance. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products, and for their regulatory approval, is typically referred to as a sponsor.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The failure of a sponsor to comply with the applicable regulatory requirements at any time during the product development process, including nonclinical testing, clinical testing, the approval process or post-approval process, may result in delays to the conduct of a study, regulatory review and approval and/or administrative or judicial sanctions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor seeking approval to market and distribute a new drug in the United States generally must satisfactorily complete each of the following steps before the product candidate will be approved by the FDA: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical testing including laboratory tests, animal studies and formulation studies, which must be performed in accordance with the FDA&#8217;s good laboratory practice, or GLP, regulations and standards; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of the manufacture, under current Good Manufacturing Practices, or cGMP, conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">design of a clinical protocol and submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication, in accordance with good clinical practices, or GCP; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation and submission to the FDA of a new drug application, or NDA, for a drug product which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling for one or more proposed indication(s); </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review of the product candidate by an FDA advisory committee, where appropriate or if applicable; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of third parties, at which the product candidate or components thereof are manufactured to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of any FDA audits of the clinical trial sites to assure compliance with GCP and the integrity of clinical data in support of the NDA; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payment of user fees and securing FDA approval of the NDA to allow marketing of the new drug product; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategies, or REMS, and the potential requirement to conduct any post-approval studies required by the FDA. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Studies </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Before a sponsor begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish rationale for therapeutic use. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as other studies to evaluate, among other things, the toxicity of the product candidate. These studies are typically referred to as IND-enabling studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the United States Department of Agriculture&#8217;s Animal Welfare Act, if applicable. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The IND and IRB Processes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved NDA. In support of a request for an IND, sponsors must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">among other things, must be submitted to the FDA as part of an IND. The FDA requires a 30-day waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, or thereafter, the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold or partial clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin or recommence. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. The FDA imposes clinical holds whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, nonclinical, and/or chemistry, manufacturing, and controls, or CMC. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, such studies must be conducted in accordance with GCP including review and approval by an independent ethics committee, or IEC, and informed consent from subjects. The GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group provides authorization as to whether or not a trial may move forward at designated check points based on certain available data from the study to which only the DSMB may access. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving business objectives and/or competitive climate. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expanded Access to an Investigational Drug for Treatment Use</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational new drug products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational drugs for patients who may benefit from investigational therapies. FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">size patient populations; and larger populations for use of the drug under a treatment protocol or Treatment IND Application. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no obligation for a sponsor to make its drug products available for expanded access. However, if a sponsor has a policy regarding how it responds to expanded access requests, it must make that policy available. This provision requires drug and biologic companies to make publicly available their policies for expanded access for individual patient access to products intended for serious diseases. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 study; or 15 days after the drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. We received Fast Track designation for bavdegalutamide for mCRPC in 2019. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without needing FDA approval under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients under the Right to Try Act.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Human Clinical Trials in Support of an NDA </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator in accordance with GCP requirements which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written clinical trial protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may also be required after approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information about the investigational drug product&#8217;s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. Phase 2 clinical trials are well controlled, closely monitored and conducted in a limited patient population. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 clinical trial may be designed to deliver </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a drug: such Phase 3 studies are referred to as &#8220;pivotal.&#8221; </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Moreover, as noted above, a pivotal trial is a clinical trial that is believed to satisfy FDA requirements for the evaluation of a product candidate&#8217;s safety and efficacy such that it can be used, alone or with other pivotal or non-pivotal trials, to support regulatory approval. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may approve an NDA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of a larger number of patients in the intended treatment group and to further document a clinical benefit in the case of drugs approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FDA finalized guidance entitled &#8220;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#8221; which outlines how sponsors can utilize an adaptive trial design in the early stages of oncology product development (i.e., the first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to product development and reduce developmental costs and time.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, with the passage of Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product.  These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products.  Specifically, actions plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them.  In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggest a significant risk to humans exposed to the product; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCPs and the integrity of the clinical data submitted. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the U.S. National Institutes of Health, or NIH.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. The failure to submit clinical trial information to clinicaltrials.gov is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. Although the FDA has historically not enforced these reporting requirements due to the Department of Health and Human Services&#8217;, or HHS&#8217;s, long delay in issuing final implementing regulations, those regulations have now been issued and the FDA has issued several Notices of Noncompliance to manufacturers since April 2021.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing and Other Regulatory Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the FDA&#8217;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and some state agencies, and they are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the manufacturing process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval before being implemented. The FDA&#8217;s regulations also require, among other things, the investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements upon the sponsor and any third-party manufacturers involved in producing the approved product. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Studies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, or PREA, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The sponsor, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For drugs intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of a sponsor, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, the FDA will meet early in the development process to discuss pediatric study plans with sponsors and the FDA must meet with sponsors by no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than ninety (90) days after the FDA&#8217;s receipt of the study plan. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The law requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. It further requires the FDA to publicly post the PREA Non-Compliance letter and sponsor&#8217;s response. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although FDA has recently taken steps to limit what it considers abuse of this statutory exemption.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA Reauthorization Act of 2017 established new requirements to govern certain molecularly targeted cancer indications. Any company that submits an NDA three years after the date of enactment of that statute must submit pediatric assessments with the NDA if the drug is intended for the treatment of an adult cancer and is directed at a molecular target that FDA determines to be substantially relevant to the growth or progression of a pediatric cancer. The investigation must be designed to yield clinically meaningful pediatric study data regarding the dosing, safety and preliminary efficacy to inform pediatric labeling for the product. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of an NDA </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain approval to market a drug product in the United States, a marketing application must be submitted to the FDA that provides sufficient data establishing the safety and efficacy of the proposed drug product for its intended indication. The application includes all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the drug product to the satisfaction of the FDA. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The NDA is a vehicle through which sponsors formally propose that the FDA approve a new product for marketing and sale in the United States for one or more indications. Every new drug product candidate must be the subject of an approved NDA before it may be commercialized in the United States. Under federal law, the submission of most NDAs is subject to an application user fee, which for federal fiscal year 2023 is approximately $3.25 million for an application requiring clinical data. The sponsor of an approved NDA is also subject to an annual prescription drug product program fee, which for federal fiscal year 2023 is approximately $394,000. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation, an exception from the program fee when the program does not engage in manufacturing the drug during a particular fiscal year and a waiver for certain small businesses. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following submission of an NDA, the FDA conducts a preliminary review of the application within 60 calendar days of its receipt and it must inform the sponsor by that time or before whether the application is sufficiently complete to permit substantive review. In the event that FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the sponsor. The FDA may request additional information rather than accept the application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which the FDA accepts the application for filing, and 90% of applications for NMEs that have been designated for &#8220;priority review&#8221; are meant to be reviewed within six months of the filing date. For applications seeking approval of products that are not NMEs, the ten-month and six-month review periods run from the date that the FDA receives the application. The review process and the Prescription Drug User Fee Act, or PDUFA,  target action date may be extended by the FDA for three additional months to consider new information or clarification provided by the sponsor to address an outstanding deficiency identified by the FDA following the original submission. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its review of an application, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA submission, including component manufacturing, finished product manufacturing and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Under the FDA Reauthorization Act of 2017, the FDA must implement a protocol to expedite review of responses to inspection reports pertaining to certain applications, including applications for products in shortage or those for which approval is dependent on remediation of conditions identified in the inspection report. Moreover, with passage of FDORA, Congress clarified FDA&#8217;s authority to conduct inspections by expressly permitting inspection of facilities involved in the preparation, conduct, or analysis of clinical and non-clinical studies submitted to FDA as well as other persons holding study records or involved in the study process.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a condition of approval, the FDA may require a sponsor to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events and whether the product is a new molecular entity. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a novel product to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to expedite the review of applications in several ways. Under the Fast Track program, the sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, priority review and accelerated approval. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Breakthrough therapy designation. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Priority review.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Accelerated approval. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Drug products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials. With the passage of FDORA in December 2022, Congress modified </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">certain provisions governing accelerated approval of drug and biologic products.  Specifically, the new legislation authorized the FDA to: require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to FDA every six months (until the study is completed); and use expedited procedures to withdraw accelerated approval of an NDA or BLA after the confirmatory trial fails to verify the product&#8217;s clinical benefit.  Further, FDORA requires the agency to publish on its website &#8220;the rationale for why a post-approval study is not appropriate or necessary&#8221; whenever it decides not to require such a study upon granting accelerated approval.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Regenerative advanced therapy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> With passage of the 21st Century Cures Act, or the Cures Act, in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of these expedited programs changes the standards for approval but they may help expedite the development or approval process of product candidates.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA&#8217;s Decision on an NDA </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a Complete Response Letter, or CRL, or an approval letter.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reach this determination, the FDA must determine that the drug is effective and that its expected benefits outweigh its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the product&#8217;s safety and efficacy in the NDA. This assessment is also informed by other factors, including: the severity of the underlying condition and how well patients&#8217; medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary to manage specific risks.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this assessment, the FDA review team will assemble all individual reviews and other documents into an &#8220;action package,&#8221; which becomes the record for FDA review. The review team then issues a recommendation, and a senior FDA official makes a decision.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time- consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six month extension to respond.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has committed to reviewing resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has taken the position that a CRL is not final agency action making the determination subject to judicial review.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">That is, the approval will be limited to the conditions of use (e.g., patient population, indication) described in the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Regulation </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA may have imposed as part of the approval process. The sponsor will be required to report, among other things, certain adverse reactions and manufacturing problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or withdrawal of product approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. In the United States, health care professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as off-label uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of off-label uses. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug product. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug product. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug product. Further, with passage of the Pre-Approval Information </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exchange Act in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval.  Previously, such communications were permitted under FDA guidance but the new legislation explicitly provides protection to sponsors who convey certain information about products in development to payors, including unapproved uses of approved products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the HHS, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 505(b)(2) NDAs</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NDAs for most new drug products are based on two full clinical studies which must contain substantial evidence of the safety and efficacy of the proposed new product for the proposed use. These applications are submitted under Section 505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section 505(b)(2) of the FDCA. This type of application allows the sponsor to rely, in part, on the FDA&#8217;s previous findings of safety and efficacy for a similar product, or published literature. Specifically, Section 505(b)(2) applies to NDAs for a drug for which the investigations made to show whether or not the drug is safe for use and effective in use and relied upon by the sponsor for approval of the application &#8220;were not conducted by or for the sponsor and for which the sponsor has not obtained a right of reference or use from the person by or for whom the investigations were conducted.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 505(b)(2) thus authorizes the FDA to approve an NDA based on safety and effectiveness data that were not developed by the sponsor. NDAs filed under Section 505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the 505(b)(2) sponsor can establish that reliance on the FDA&#8217;s previous approval is scientifically appropriate, the sponsor may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) sponsor.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Abbreviated New Drug Applications for Generic Drugs </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress established an abbreviated regulatory scheme authorizing the FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs. To obtain approval of a generic drug, a sponsor must submit an abbreviated new drug application, or ANDA, to the agency. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, bioequivalence, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are &#8220;abbreviated&#8221; because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, in support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug, or RLD. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, the strength of the drug and the conditions of use of the drug. At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221; Upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. This interpretation was confirmed with enactment of the Ensuring Innovation Act in April 2021. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the sponsor may submit its application four years following the original product approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety, provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product. The FDA typically makes decisions about awards of data exclusivity shortly before a product is approved. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA must establish a priority review track for certain generic drugs, requiring the FDA to review a drug application within eight (8) months for a drug that has three (3) or fewer approved drugs listed in the Orange Book and is no longer protected by any patent or regulatory exclusivities, or is on the FDA&#8217;s drug shortage list. The FDA is also authorized to expedite review of &#8220;competitor generic therapies&#8221; or drugs with inadequate generic competition, including holding meetings with or providing advice to the drug sponsor prior to submission of the application. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Patent Certification and the 30-Month Stay </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the sponsor&#8217;s product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. The FDA&#8217;s regulations governing patient listings were largely codified into law with enactment of the Orange Book Modernization Act in January 2021.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">When an ANDA sponsor files its application with the FDA, the sponsor is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA sponsor is not seeking approval. To the extent that the Section 505(b)(2) sponsor is relying on studies conducted for an already approved product, the sponsor is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA sponsor would. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the sponsor must certify with respect to each patent that: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the required patent information has not been filed; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the listed patent has expired; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the listed patent is invalid, unenforceable or will not be infringed by the new product. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the sponsor does not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the application will not be approved until all the listed patents claiming the referenced product have expired (other than method of use patents involving indications for which the sponsor is not seeking approval). </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the ANDA sponsor has provided a Paragraph IV certification to the FDA, the sponsor must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA sponsor. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the Section 505(b)(2) sponsor is relying on studies conducted for an already approved product, the sponsor is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA sponsor would. As a result, approval of a Section 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) sponsor. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Exclusivity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of regulatory exclusivity to the term of any patent or existing regulatory exclusivity, including orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation and Exclusivity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition, generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a product available in the United States for treatment of the disease or condition will be recovered from sales of the product. A company must seek orphan drug designation before submitting an NDA for the candidate product. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not shorten the PDUFA goal dates for the regulatory review and approval process, although it does convey certain advantages such as tax benefits and exemption from the PDUFA application fee. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same drug for the same condition for seven years, except in certain limited circumstances. Orphan exclusivity does not block the approval of a different product for the same rare disease or condition, nor does it block the approval of the same product for different conditions. If a drug designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period of market exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the disease or condition for which the product has been designated.  Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if the company with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orphan drug exclusivity is not able to meet market demand or the subsequent product is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan drug exclusivity regardless of a showing of clinical superiority. Under Omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical superiority applies to drug products that received orphan drug designation before enactment of amendments to the FDCA in 2017 but have not yet been approved by FDA.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of market exclusivity, the term &#8220;same disease or condition&#8221; in the statute means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, FDA announced that, in matters beyond the scope of that court order, FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Restoration and Extension </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patent claiming a new drug product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of the IND for the clinical investigation is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The United States Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Law and Regulation </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable state and federal fraud and abuse laws and regulations (including anti-kickback and false claims laws), patient privacy laws and regulations, and other health care laws and regulations that may constrain business and/or financial arrangements. Restrictions under applicable federal and state health care laws and regulations, include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchasing, ordering, leasing, arranging for, or recommending the purchasing, ordering, or leasing of, any good or service for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the civil False Claims Act, and Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or knowingly making, using or causing to made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or making false statements relating to health care matters; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and the regulations promulgated thereunder, including 45 C.F.R. Parts 160 and 164, imposing rules regarding privacy, security, and data breach notifications; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Foreign Corrupt Practices Act, or FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal physician transparency requirements known as the Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the Affordable Care Act, or the ACA, which requires manufacturers of drugs, medical devices, biological and medical supplies covered by Medicare, Medicaid, or State Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within HHS, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to health care items or services that are reimbursed by non-government third-party payors, including private insurers. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Insurance Coverage and Health Care Reform </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated health care costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of health care costs also has become a priority of federal, state and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and biologics and other medical products, government control and other changes to the health care system in the United States. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA. In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2030 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. These Medicare sequester reductions were suspended and reduced through June 2022, with the full 2% cut resuming thereafter. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard this case on November 10, 2020 and, on June 17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden rescinded those orders and issued a new executive order that directs federal agencies to reconsider rules and other policies that limit access to healthcare, and consider actions that will protect and strengthen that access. Under this order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID&#8209;19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and under the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, President Trump issued several executive orders </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which has been delayed until January 1, 2026 by the Infrastructure Investment and Jobs Act.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 9, 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of pharmaceuticals.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Order directs HHS to create a plan within 45 days to combat &#8220;excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, HHS released its plan to reduce pharmaceutical prices.  The key features of that plan are to: (a) make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; (b)  improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase transparency; and (c) foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden.  The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of enrolling in a plan providing outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).  The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D.  CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 additional Part D drugs in 2027, 15 additional Part B or Part D drugs in 2028, and 20 additional Part B or Part D drugs in 2029 and beyond.  This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition.  Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also caps Medicare beneficiaries' out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription pharmaceutical and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Medicinal Products in the European Union </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, a sponsor will need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. Specifically, however, the process governing approval of medicinal products in the European Union, or EU, generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial Approval </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, the Clinical Trials Regulation (EU) No 536/2014 became effective in the European Union and replaced the prior Clinical Trials Directive 2001/20/EC. The new regulation aims at simplifying and streamlining the authorization, conduct and transparency of clinical trials in the European Union. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one Member State of the European Union, or EU Member State, is only required to submit a single application for approval. The submission is made through the Clinical Trials Information System, a new clinical trials portal overseen by the European Medicines Agency, or EMA, and available to clinical trial sponsors, competent authorities of the EU Member States and the public. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the main characteristics of the new regulation include: a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new regulation did not change the preexisting requirement that a sponsor must obtain prior approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. If the clinical trial is conducted in different EU Member States, the competent authorities in each of these EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the sponsor may only start a clinical trial at a specific study site after the applicable ethics committee has issued a favorable opinion.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the EU at the EudraCT website: https://eudract.ema.europa.eu.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRIME Designation in the EU </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises, or SMEs, may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated Agency contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies, or CAT, are appointed early in PRIME scheme facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Studies </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining a marketing authorization in the European Union, sponsors must demonstrate compliance with all measures included in an EMA-approved Paediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are laid down in Regulation (EC) No 1901/2006, the so-called Paediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Paediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. Before an MAA can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing Authorization </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain a marketing authorization for a product under EU regulatory systems, a sponsor must submit an MAA either under a centralized procedure administered by the EMA, or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure or mutual recognition procedure). A marketing authorization may be granted only to a sponsor established in the EU. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the EU, sponsors have to demonstrate compliance with all measures included in an EMA-approved PIP covering all subsets of the pediatric population, unless the EMA has granted (1) a product-specific waiver, (2) a class waiver or (3) a deferral for one or more of the measures included in the PIP. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across the European Economic Area (i.e. the EU as well as Iceland, Liechtenstein and Norway). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products and products with a new active substance </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. The centralized procedure may at the request of the applicant also be used in certain other cases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a product and for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 15 calendar days of receipt of a final opinion from the CHMP, the European Commission must prepare a draft decision concerning an application for marketing authorization. This draft decision must take the opinion and any relevant provisions of EU law into account. Before arriving at a final decision on an application for centralized authorization of a medicinal product the European Commission must consult the Standing Committee on Medicinal Products for Human Use. The Standing Committee is composed of representatives of the EU Member States and chaired by a non-voting European Commission representative. The European Parliament also has a related &#8220;droit de regard.&#8221; The European Parliament&#8217;s role is to ensure that the European Commission has not exceeded its powers in deciding to grant or refuse to grant a marketing authorization. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission may grant a so-called &#8220;marketing authorization under exceptional circumstances.&#8221; Such authorization is intended for products for which the sponsor can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the sponsor cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sponsor must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of a marketing authorization of a medicinal product under exceptional circumstances, however, follows the same rules as a &#8220;normal&#8221; marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission may also grant a so-called &#8220;conditional marketing authorization&#8221; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products), if (i) the risk-benefit balance of the product candidate is positive, (ii) it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data, (iii) the product fulfills an unmet medical need and (iv) the benefit to public health of the immediate availability on the market of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU medicines rules expressly permit the EU Member States to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the products we have in development do not make use of embryonic stem cells, it is possible that the national laws in certain EU Member States may prohibit or restrict us from commercializing our products, even if they have been granted an EU marketing authorization. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mutual recognition procedure similarly is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of other EU Member States. The holder of a national marketing authorization may submit an application to the competent authority of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Data Protection in the EU </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement for medicinal products authorized in accordance the centralized authorization procedure. Data exclusivity prevents sponsors for authorization of generics of these innovative products from referencing the innovator&#8217;s data to assess a generic (abridged) application for a period of eight years. During an additional two-year period of market exclusivity, a generic marketing authorization application can be submitted and authorized, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Periods of Authorization and Renewals </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five-year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (in case of centralized procedure) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause). </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Exclusivity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a sponsor obtains a marketing authorization in all EU Member States, or a marketing authorization granted in the centralized procedure by the European Commission, and the study results for the pediatric population are included in the product information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate, or SPC. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation and Exclusivity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation (EC) No. 141/2000, as implemented by Regulation (EC) No. 847/2000 provides that a drug can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the sponsor must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once authorized, orphan medicinal products are entitled to 10 years of market exclusivity in all EU Member States and in addition a range of other benefits during the development and regulatory review process including scientific assistance for study protocols, authorization through the centralized marketing authorization procedure covering all member countries and a reduction or elimination of registration and marketing authorization fees. However, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the 10-year period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Extensions in the European Union and Other Jurisdictions</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union also provides for patent term extension through SPCs. The rules and requirements for obtaining a SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a drug. These periods can be extended for six additional months if pediatric exclusivity is obtained, which is described in detail below. Although SPCs are available throughout the European Union, sponsors must apply on a country-by-country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the European Union.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements after a Marketing Authorization has been Obtained </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization studies and additional monitoring obligations. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU notably under Directive 2001/83EC, as amended, and are also subject to EU Member State laws. Direct-to-consumer advertising of prescription medicines is prohibited across the EU. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Brexit and the Regulatory Framework in the United Kingdom </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom&#8217;s withdrawal from the EU took place on January 31, 2020. The EU and the United Kingdom reached an agreement on their new partnership in the Trade and Cooperation Agreement, or the Agreement, which was applied provisionally beginning on January 1, 2021 and which entered into force on May 1, 2021. The Agreement focuses primarily on free trade by ensuring no tariffs or quotas on trade in goods, including healthcare products such as medicinal products. Thereafter, the EU and the United Kingdom will form two separate markets governed by two distinct regulatory and legal regimes. As such, the Agreement seeks to minimize barriers to trade in goods while accepting that border checks will become inevitable as a consequence that the United Kingdom is no longer part of the single market. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law whereas Northern Ireland continues to be subject to EU rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law the body of EU law instruments governing medicinal products that pre-existed prior to the United Kingdom&#8217;s withdrawal from the EU.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since a significant proportion of the regulatory framework for pharmaceutical products in the U.K. covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit may have a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the U.K. For example, the U.K. is no longer covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA, and a separate marketing authorization will be required to market our product candidates in the U.K. Until December 31, 2023, it is possible for the MHRA to rely on a decision taken by the European Commission on the approval of a new marketing authorization via the centralized procedure. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, while the Data Protection Act of 2018 in the United Kingdom that &#8220;implements&#8221; and complements the European Union&#8217;s General Data Protection Regulation, or GDPR, has achieved Royal Assent on May 23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the European Economic Area, or EEA, to the United Kingdom will remain lawful under GDPR. The United Kingdom has already determined that it considers all of the EU 27 and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the EU/EEA remain unaffected. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Data Protection Regulation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the GDPR which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The EU initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022. It is unclear if and when the framework will be finalized and whether it will be challenged in court. The uncertainty around this issue may further impact our business operations in the EU.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing Decisions for Approved Products </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between low-priced and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Management </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had approximately 415 full-time employees. Of these full-time employees, approximately 330 employees were engaged in research and development activities, with 300 employees possessing advanced degrees, and approximately 85 employees were engaged in general and administrative activities. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We believe that we maintain good relations with our employees.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that identifying, attracting, incentivizing, integrating, retaining and promoting talented employees is vital to our success, particularly as we continue to grow. We aim to create an equitable, inclusive and empowering environment in which our employees can grow and advance their careers, with the overall goal of developing, expanding and retaining our workforce to support our current pipeline and future business goals. Our efforts to recruit and retain a diverse and passionate workforce include providing competitive compensation, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including equity incentive compensation, and comprehensive benefits that provide resources to help employees manage their health, finances and life outside of wor</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k. As of December 31, 2022, and for the last several years, our company turnover rate was and has been lower than the industry market average. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Training and educating our employees is key to our organizational success. We endeavor to provide in person and virtual trainings, as well as experiential learning through cross-functional exposure via presentations or shadowing opportunities. In addition, we value our employee's opinions and thoughts and provide virtual and onsite forums where our employees can provide feedback on corporate initiatives, recognize each other&#8217;s contributions and accomplishments, and provide other suggestions for improving our evolving workplace. We prioritize employee feedback, and conduct an employee survey to measure employee engagement and to inform future talent initiatives. Similarly, we have introduced technology that enables employees to provide anonymous real-time feedback. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are committed to our employees&#8217; health, safety and well-being. In March 2020, in response to the COVID-19 pandemic, we adjusted our workplace policies to allow employees to work from home and we remodeled our work paradigm to one that is flexible and designed to accommodate a range of work profiles from office based to hybrid to fully remote, allowing us to maximize productivity and performance. We leveraged remote hiring supported by virtual processes through which we provided a high level of interpersonal engagement and continued to expa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd our robust onboarding program to ensure all new hires are grounded in our business and culture.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also committed to diversity, equality and inclusion and we are committed to increasing representation of under-represented populations at our company, particularly in leadership roles. Over the last two years we have made conscious hiring decisions to significantly grow the number of women and diverse employees, particularly in positions of Director or above. In addition, as of December 31, 2022, five members of our board of directors identify as female and/or from a diverse racial and ethnic group.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the goal of ensuring every employee is included, supported, and treated equitably, our employees formed a committee to support and guide us as a diverse, inclusive, and culturally intelligent workplace. This committee is comprised of a mix of employees from various functions and positions. Since its launch in 2021, the committee has worked to identify areas for growth and education in order to develop processes, systems and actions that will enable us to continue to build an inclusive workplace and a diverse workforce. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also believe in the importance of our employees engaging in our community. In 2022, we hosted our first ever IMPACT day, a company-wide community service day benefiting organizations in the Greater New Haven area. Giving back to the communities in which we work and live is an integral part of our corporate values and over half of our employees participated in person or virtually. The activities selected support important priorities for Arvinas, including science, technology, engineering, and math (STEM) initiatives, and the Greater New Haven and patient communities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 5 Science Park, New Haven, Connecticut 06511. Our telephone number is (203) 535-1456. Our website address is www.arvinas.com.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We make available, through our website and free of charge, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the U.S. Securities and Exchange Commission, or the SEC. In addition, we regularly use our website to post information regarding our business, product development programs and governance, and we encourage investors to use our website, particularly the information in the section entitled &#8220;Investors &amp; Media,&#8221; as a source of information about us. The information on our website is not incorporated by reference into this Annual Report on Form 10-K and should not be considered to be a part of this Annual Report on Form 10-K. </span></div><div id="ia936ede3f23041239a783a07e7f93c48_19"></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face a variety of risks and uncertainties in our business and investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K, before deciding to invest in our common stock.  Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also become important factors that affect our business. If any of the following risks actually occur, our business, prospects, operating results and financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might lose all or part of your investment. </span></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need For Additional Capital </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses totaled $282.5 million, $191.0 million and $119.3 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. As of December&#160;31, 2022, we had an accumulated deficit of $965.4 million. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests, proceeds from our collaborations, grant funding and debt financing. We are still in the early stages of development of our product candidates, and we have not completed development of any product candidates. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially if and as we: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue a Phase 1/2 clinical trial of our product candidate ARV-471, a Phase 1b clinical trial of ARV-471 in combination with palbociclib, a Phase 1b cohort expansion in combination with a standard of care agent, and a Phase 3 trial with ARV-471 as a second-line treatment, and initiate a Phase 3 trial of ARV-471 in combination with palbociclib, each in patients with locally advanced or metastatic ER+ / HER2-breast cancer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue a Phase 1/2 clinical trial of our product candidate bavdegalutamide (ARV-110) and a Phase 1b clinical trial of bavdegalutamide in combination with abiraterone for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC, and initiate one or more additional Phase 1b cohort expansions of bavdegalutamide in combination with standard of care agents and a Phase 3 clinical trial, in men with mCRPC;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue a Phase 1/2 clinical trial of our product candidate ARV-766 in men with mCRPC;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">apply our PROTAC Discovery Engine to advance additional product candidates into preclinical and clinical development; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand the capabilities of our PROTAC Discovery Engine; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we may obtain marketing approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand, maintain and protect our intellectual property portfolio; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional development, including clinical and regulatory, and scientific personnel; and </span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel to support our research, product development and future commercialization efforts and support our operations as a public company. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or other regulatory authorities to perform trials in addition to those that we currently expect or anticipate, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our current or future product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated revenue from product sales and may never be profitable. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never generated revenue from product sales. Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, product candidates we may identify for development. We do not anticipate generating revenues from product sales for the next several years, if ever.  We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. To become and remain profitable, we must succeed in developing, obtaining marketing approval for and commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, establishing arrangements with third parties for the manufacture of clinical supplies of our product candidates, obtaining marketing approval for our product candidates and manufacturing, marketing and selling any products for which we may obtain marketing approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding to continue our operations. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we continue our ongoing and initiate our planned clinical trials of bavdegalutamide, ARV-471 and ARV-766, advance our other oncology and neurodegenerative programs and continue research and development and initiate additional clinical trials of and potentially seek marketing approval for our lead programs and our other product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. We continue to incur significant costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms or not at all, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents, restricted cash and marketable securities of approximately $1.2 billion as of December&#160;31, 2022. We believe that our cash, cash equivalents, restricted cash and marketable securities as of December&#160;31, 2022 will enable us to fund our planned operating expenses and capital expenditure requirements into 2026. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, costs and results of our ongoing clinical trials for ARV-471, bavdegalutamide  and ARV-766 and any future clinical development of ARV-471, bavdegalutamide and ARV-766; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and development programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of, and development requirements for, other product candidates that we pursue, including our other oncology and neurodegenerative research programs; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaborations with Pfizer, Inc., or Pfizer; Genentech, Inc. and F. Hoffman LaRoche Ltd., collectively referred to as Genentech; and Bayer AG, or Bayer; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, for the development or commercialization of our product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives. Adequate additional funds may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our collaborations with Pfizer, Genentech and Bayer, we do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights as common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be acceptable or favorable to us.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for our stockholders to evaluate the success of our business to date and to assess our future viability. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies, establishing arrangements with third parties for the manufacture of initial quantities of our product candidates and conducting Phase 1, Phase 2 and Phase 3 clinical trials for our product candidates.  However, we have not yet demonstrated our ability to successfully complete any clinical trials, obtain marketing approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, as a young business with limited operating experience and no history of revenue-generating commercial activity, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, stockholders should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax law may adversely affect our business or financial condition. The Tax Cuts and Jobs Act of 2017, commonly referred to as the TCJA, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, significantly revises the U.S. Internal Revenue Code of 1986, as amended, or the Code. The TCJA contains, among other things, significant changes to corporate taxation, including a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% and the limitation of the deduction for net operating losses to 80% of current-year taxable income for losses arising in taxable years beginning after December 31, 2017 (though any such net operating losses may be carried forward indefinitely). In addition, beginning in 2022, the TCJA eliminates the option to deduct research and development expenditures currently and requires corporations to capitalize and amortize them over five years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to the CARES Act, as part of Congress&#8217;s response to the COVID-19 pandemic, economic relief legislation has been enacted in 2020 and 2021 containing tax provisions. The Inflation Reduction Act, or IRA, was also signed into law in August 2022. The IRA introduced new tax provisions, including a 1% excise tax imposed on certain stock repurchases by publicly traded corporations. The 1% excise tax generally applies to any acquisition by the publicly traded corporation (or certain of its affiliates) of stock of the publicly traded corporation in exchange for money or other property (other than stock of the corporation itself), subject to a de minimis exception. Thus, the excise tax could apply to certain transactions that are not traditional stock repurchases. Regulatory guidance under the TCJA, the IRA, and such additional legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen the impact of these laws on our business and financial condition. In addition, it is uncertain if and to what extent various states will conform to the TCJA, the IRA, and additional tax legislation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In the future, we might not be able to utilize a significant portion of any net operating loss carryforwards and research and development tax credit carryforwards we may have. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had no federal net operating loss carryforwards, $63.4 million of state and local net operating loss carryforwards, no federal research and development tax credit carryforwards and $1.9 million of state research and development tax credit carryforwards. During the year ended December 31, 2022, we fully utilized our previously held net federal operating loss and credit carryforwards due to taxable income resulting from revenue recognition for tax purposes from our ARV-471 Collaboration Agreement and the mandatory capitalization of qualified research and development expenses incurred on or after January 1, 2022 under the TCJA. We expect in to incur net operating losses in future periods as a result of additional product development. To the extent net operating loss and tax credit carryforwards expire unused, they will not be available to offset our future income tax liabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Section 382 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be limited. We believe our federal net operating losses are subject to an annual limitation as a result of changes in the Company&#8217;s ownership, as defined by Code Section 382, in July 2018 and December 2020. Notwithstanding the limitations, we expect the federal net operating losses to be fully available under Section 382, subject to any other limitations under the Code. In addition, we may experience ownership changes in the future as a result of subsequent changes in our stock ownership, some of which may be outside of our control. If we determine that an ownership change has occurred and our ability to use our historical net operating loss and tax credit </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that due to regulatory changes, such as suspensions on the use of net operating losses, or other unforeseen reasons, our existing any future net operating losses could expire or otherwise become unavailable to offset future income tax liabilities. As described above in &#8220;Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,&#8221; the TCJA, as amended by the CARES Act, includes changes to U.S. federal tax rates and the rules governing net operating loss carryforwards that may significantly impact our ability to utilize our net operating losses to offset taxable income in the future. In addition, state net operating losses generated in one state cannot be used to offset income generated in another state. For these reasons, even if we attain profitability, we may be unable to use a material portion of our net operating losses and other tax attributes.</span></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of product candidates based on our PROTAC technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our PROTAC technology platform is a relatively new technology. Our future success depends on the successful development of this novel therapeutic approach. Prior to the initiation of our Phase 1 clinical trial for bavdegalutamide in 2019, no product candidates that use a chimeric small molecule approach to protein degradation, such as our PROTAC targeted protein degraders, had been tested in humans. No product candidates of this type have been approved in the United States or Europe, and the data underlying the feasibility of developing chimeric small molecule-based therapeutic products is both preliminary and limited. We have not yet succeeded and may not succeed in demonstrating the efficacy and safety of any of our product candidates in clinical trials or in obtaining marketing approval thereafter. We have not yet completed a clinical trial of any product candidate and we have not yet completed assessment of the safety of any product candidate in humans. As such, there may be adverse effects from treatment with any of our current or future product candidates that we cannot predict at this time. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our PROTAC Discovery Engine, or any similar or competitive protein degradation platforms, will result in the development, and marketing approval of any products. Any development problems we experience in the future related to our PROTAC Discovery Engine or any of our research programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our current or future preclinical studies or clinical trials or from commercializing any product candidates we may develop on a timely or profitable basis, if at all. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are early in our development efforts. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in development. We are developing ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer and bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer.  Additional product candidates are still in preclinical development.  Our ability to generate revenue from product sales, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. The success of our product candidates will depend on several factors, including the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully completing preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt and related terms of marketing approvals from applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining third-party coverage and adequate reimbursement; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of the products following approval; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have product candidates in clinical development and preclinical development. The risk of failure for each of our product candidates is high. We are unable to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned INDs in the United States or similar applications in other jurisdictions. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or similar regulatory authorities outside the United States will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome. A failure of one or more clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical trials for various reasons, including noncompliance with regulatory requirements; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate the trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen global instability, including political instability or instability from an outbreak of pandemic or contagious disease, such as the COVID-19 pandemic, in or around the countries in which we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conduct our clinical trials, could delay the commencement or timing of completion of our clinical trials;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate and could be exacerbated by macroeconomic conditions such as inflation; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate, or their cost could increase dramatically making them financially infeasible. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not obtain marketing approval at all; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have the product removed from the market after obtaining marketing approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will also increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, cancer therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. Our current clinical trials for bavdegalutamide, ARV-471 and ARV-766 are in patients who have received prior treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but any product candidates we develop, even if approved, may not be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse events, undesirable side effects, or unexpected characteristics are identified during the development of any product candidates we may develop, we may need to abandon or limit our further clinical development of those product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidates we develop are associated with serious adverse events, or undesirable side effects, or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the adverse events, undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations, and prospects. Many product candidates that initially showed promise in early-stage testing for treating cancer or other diseases have later been found to cause side effects that prevented further clinical development of the product candidates or limited their competitiveness in the market. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. There can be no assurance that our PROTAC technology will not cause undesirable side effects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A potential risk in any protein degradation product is that healthy proteins or proteins not targeted for degradation will be degraded or that the degradation of the targeted protein in itself could cause adverse </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">events, undesirable side effects, or unexpected characteristics. It is possible that healthy proteins or proteins not targeted for degradation could be degraded using our PROTAC technology in any of our ongoing, planned or future clinical studies. There is also the potential risk of delayed adverse events following treatment using our PROTAC technology.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Positive data from preclinical or early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive data from our preclinical or early clinical studies of our product candidates in our future clinical trials, we will be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical studies may not be predictive of the results of clinical trials, and the results of early-stage clinical trials may not be predictive of the results of the later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. In particular, the small number of patients in our ongoing early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. For example, even if successful, the results of the clinical trials of ARV-471, bavdegalutamide and and ARV-766 may not be predictive of the results of further clinical trials of these product candidates or any of our other product candidates. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Our current or future clinical trials may not ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for product candidates proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business and results of operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have published and may in the future publish interim top-line or preliminary data from our clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For example, the initial safety, tolerability, pharmacokinetic and efficacy data that we have disclosed in connection with our ongoing Phase 1/2 clinical trials of ARV-471 and bavdegalutamide (ARV-110) may not be indicative of the full results of those trials obtained upon completion. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our reputation and business prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. In particular, we are conducting several clinical trials, including a Phase 1/2 clinical trial and Phase 3 clinical trial with ARV-471 as a second-line treatment,of ARV-471 for patients with locally advanced or metastatic ER+ / HER2- breast cancer, a Phase 1/2 clinical trial of bavdegalutamide for men with mCRPC, and a Phase 1/2 clinical trial of ARV-766 for men with mCRPC. We cannot predict how difficult it will be to enroll patients for trials in these indications. Therefore, our ability to identify and enroll eligible patients for ARV-471, bavdegalutamide, and ARV-766 clinical trials may be limited or may result in slower enrollment than we anticipate. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment is affected by other factors including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility criteria for the trial in question; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the product candidates under study; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of competing therapies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the burden on patients due to inconvenient procedures; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced that, as a result of the COVID-19 pandemic, two trial sites for our ongoing Phase 1/2 clinical trial of bavdegalutamide had publicly announced pauses in patient enrollment for clinical trials, including our trials. In addition, one trial site for our ongoing Phase 1/2 clinical trial of ARV-471 had a pause in patient enrollment for clinical trials, including our trial. While the pauses at each of the trial sites have been lifted, we may nonetheless face difficulties recruiting or retaining patients in our ongoing and planned clinical trials if patients are affected by the virus or are fearful of traveling to, or are unable to travel to, our clinical trial sites because of the outbreak. For example, we experienced a short delay in the enrollment for one cohort of our ARV-471 trial as a result of screening slowdowns attributable to COVID-19. In addition, we may engage in conversations with regulators regarding clinical trial protocols, which could result in delays to our anticipated timing to enroll patients in our studies. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing and may continue to develop our product candidates in combination with other drugs. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, or revoke their approval of such drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of or market our products. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting clinical trials of  ARV-471, bavdegalutamide and ARV-766 and intend to conduct other clinical trials for each of  ARV-471,  bavdegalutamide and ARV-766 and potentially other product candidates, in combination with other therapies. We did not develop or obtain marketing approval for, nor do we manufacture or sell, any of the currently approved drugs that we are or may study in combination with ARV-471, bavdegalutamide or ARV-766. If the FDA or similar regulatory authorities outside of the United States revoke </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their approval of the drug or drugs in combination with which we determine to develop ARV-471, bavdegalutamide or ARV-766 we will not be able to market ARV-471, bavdegalutamide or ARV-766 in combination with such revoked drugs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If safety or efficacy issues arise with any of these drugs, we could experience significant regulatory delays, and the FDA or similar regulatory authorities outside of the United States may require us to redesign or terminate the applicable clinical trials. If the drugs we use are replaced as the standard of care for the indications we choose for bavdegalutamide or ARV-471, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. In addition, if manufacturing or other issues result in a shortage of supply of the drugs with which we determine to combine with bavdegalutamide or ARV-471, we may not be able to complete clinical development of bavdegalutamide or ARV-471 on our current timeline or at all. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if bavdegalutamide or ARV-471 were to receive marketing approval or be commercialized for use in combination with other existing drugs, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the drug used in combination with bavdegalutamide or ARV-471 or that safety, efficacy, manufacturing or supply issues could arise with these existing drugs. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our other product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We plan to conduct clinical trials for our product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We plan to conduct clinical trials of our product candidates outside the United States, including our planned global Phase 3 trial for bavdegalutamide for the treatment of men with mCRPC with AR T878/H875 tumor mutations . Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are risks inherent in conducting clinical trials in multiple jurisdictions, inside and outside of the United States, such as: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or limit our ability to conduct our clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign exchange rate fluctuations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, customs, shipment and storage requirements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cultural differences in medical practice and clinical research; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that the patient populations in such trials are not considered representative as compared to the patient population in the target markets where approval is being sought.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional potential product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to apply our PROTAC Discovery Engine to address a broad array of targets and new therapeutic areas. The therapeutic discovery activities that we are conducting may not be successful in identifying product candidates that are useful in treating cancer or other diseases. Our research </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval or achieve market acceptance; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may not be effective in treating their targeted diseases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. If we are unable to identify suitable product candidates for preclinical and clinical development, we will not be able to obtain revenues from sale of products in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face and will continue to face competition from third parties that use protein degradation, antibody therapy, inhibitory nucleic acid, gene editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities, such as small molecule inhibitors. The competition is likely to come from multiple sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public and private research institutions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several biotechnology companies focused on developing chimeric small molecules for protein degradation including Accutar Biotechnology, Inc., C4 Therapeutics, Inc., Cullgen Inc., Foghorn Therapeutics, Inc., Kymera Therapeutics, Inc., Nurix Therapeutics, Inc. and Proteovant Therapeutics, Inc. Further, several large pharmaceutical companies have disclosed preclinical investments in this field, including AbbVie, Amgen Inc., AstraZeneca plc, Boehringer Ingelheim, Bristol Myers Squibb Company, GlaxoSmithKline plc, Genentech, Novartis International AG and Sanofi SA. Since 2020, some of these biotechnology and pharmaceutical companies have announced the initiation of clinical trials for targeted protein degraders. Additionally, other novel targeting mechanisms could ultimately address similar patient populations, such as CYP11A1 inhibitor (which is being developed by Orion/Merck) and an AR N-Terminal Domain inhibitor (which is being developed by ESSA Pharma) in Prostate Cancer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Dependence on Third Parties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our collaboration with Pfizer is not successful, we may not be able to capitalize on the market potential of ARV-471. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into a collaboration agreement with Pfizer, or the ARV-471 Collaboration Agreement, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound ARV-471, or the Licensed Products. Although pursuant to the terms of the ARV-471 Collaboration Agreement, we and Pfizer share equally (50/50) all development costs, including costs for conducting clinical trials, for the Licensed Products, subject to certain exceptions, our control over the amount and timing of resources that Pfizer dedicates to the development or commercialization of the Licensed Products is limited. Our ability to generate revenues from the ARV-471 Collaboration Agreement will depend, in part, on Pfizer&#8217;s ability to successfully perform the functions assigned to it in such agreement. We cannot predict the success of this collaboration with Pfizer, and we cannot guarantee that this collaboration will lead to development or commercialization of the Licensed Products in the most efficient manner or at all. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this collaboration with Pfizer does not result in the successful development and commercialization of Licensed Products, or if Pfizer terminates the ARV-471 Collaboration Agreement, which it may do for convenience subject to certain notice periods, we may not receive any of the $1.4 billion in contingent payments based on specified regulatory and sales-based milestones for the Licensed Products under the ARV-471 Collaboration Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently depend, and expect to continue to depend, on collaborations with third parties for the research, development, and the potential future commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have, and anticipate in the future seeking additional, third-party collaborators for the research, development, and potential future commercialization of some of our PROTAC programs. For example, in September 2015 we entered into a research collaboration with Genentech, which we amended and restated in November 2017; in December 2017 we entered into a research collaboration with Pfizer; in July 2019 we entered into a research collaboration with Bayer; and in July 2021 we entered into a development and commercialization collaboration with Pfizer. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies and biotechnology companies. Any such arrangements with third parties will likely limit our control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any collaborations involving our research programs or any product candidates we may develop, including our current collaborations with Pfizer, Genentech and Bayer, pose the following risks to us: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations. For example, our collaboration with Genentech is managed by a joint research committee and joint project team, which is composed of representatives from us and Genentech, with Genentech having final decision-making authority. Similarly, our research collaborations with Pfizer and Bayer are managed by joint research committees composed of an equal number of representatives from us and our respective collaborative partners, with the collaborative partner having final decision-making authority. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators may not pursue development and commercialization of any product candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition or business combination that diverts resources or creates competing priorities. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Genentech, Pfizer and Bayer have broad rights to select any target for protein degradation development on an exclusive basis, even as to us, so long as not excluded by us under the terms of each collaboration and may select targets we are considering but have not taken sufficient action to exclude under the collaboration. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators may not properly obtain, maintain, enforce, or defend our intellectual property or proprietary rights or may use our proprietary information in such a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation. For example, Pfizer, Genentech and Bayer have the first right to enforce or defend certain intellectual property rights under the applicable collaboration arrangement with respect to particular licensed programs, and although we may have the right to assume the enforcement and defense of such intellectual property rights if the collaborator does not, our ability to do so may be compromised by their actions. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. For example, each of Genentech, Pfizer and Bayer can terminate its agreement with us in its entirety or with respect to a specific target for convenience subject to specified notice periods, in certain cases as short as 60 days, or in connection with a material breach of the agreement by us that remains uncured for a specified period of time. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished, or terminated.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaborations do not result in the successful development and commercialization of products, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, marketing</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval, and commercialization described in this Annual Report on Form 10-K apply to the activities of our collaborators.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of any product candidates we may develop. These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek to establish additional collaborations. If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To realize the full potential of our PROTAC Discovery Engine and accelerate the development of additional PROTAC programs, we plan to continue to selectively pursue collaborations with leading biopharmaceutical companies with particular experience, including development and commercial expertise and capabilities. We face significant competition in attracting appropriate collaborators to advance the development of any product candidates for which we may seek a collaboration. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator may also have the opportunity to collaborate on other product candidates or technologies for similar indications and will have to evaluate whether such a collaboration could be more attractive than one with us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical companies has reduced the number of potential future collaborators. Our existing collaboration agreements limit our ability to enter into future agreements on certain terms with potential collaborators. For example, we have granted exclusive rights to Genentech, Pfizer and Bayer for the discovery, development and commercialization of PROTAC targeted protein degraders directed to certain protein targets, and during the terms of those agreements, we will be restricted from granting rights to other parties to use our PROTAC technology for those targets. Any collaboration we enter into may limit our ability to enter into future agreements on particular terms or covering similar target indications with other potential collaborators. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to negotiate collaborations on a timely basis, on acceptable terms or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue from product sales, which could have an adverse effect on our business, prospects, financial condition and results of operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect to continue to rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely and expect to continue to rely on third-party CROs to conduct our ongoing and planned clinical trials. We currently do not plan to independently conduct any clinical trials of bavdegalutamide, ARV-471 and ARV-766 or of our other product candidates. Agreements with these third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that would delay our product development activities. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols in the applicable IND. Moreover, the FDA requires compliance with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, these third parties may have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party CMOs for the manufacture of both drug substance and finished drug product for our product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely on and expect to continue to rely on third-party CMOs for both drug substance and finished drug product as well as the building blocks used to manufacture drug substance. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to establish agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on the third party for regulatory, compliance and quality assurance; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible breach of the manufacturing agreement by the third party; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have only limited technology transfer agreements in place with respect to our product candidates, and these arrangements do not extend to commercial supply. We acquire many key materials on a purchase order basis. As a result, we do not have long term committed arrangements with respect to our product candidates and other materials. If we receive marketing approval for any of our product candidates, we will need to establish an agreement for commercial manufacture with a third party. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. Some of our manufacturers are based outside of the United States, including the manufacturers of the building blocks for our drug substances which are based in China and India. As a result of the COVID-19 pandemic, there has been an increased risk of supply interruption with our manufacturers and, in the first quarter of 2020, the production of certain building blocks for the drug substance used in the manufacture of ARV-471 was delayed at one of our China-based manufacturers. While this production delay did not delay the overall clinical development of our product candidates, other delays in the manufacture of building blocks, drug substance or drug products for our product candidates could arise, which could have a material adverse effect on our clinical development.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement manufacturer or be unable to reach agreement with any alternative manufacturer. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </span></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Product Candidates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current cancer treatments, such as chemotherapy and radiation therapy, are well established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenue from product sales and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including, but not limited to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages as compared to alternative treatments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects of our product candidates, in particular as compared to alternative treatments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer our products for sale at competitive prices; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing, sales and distribution support; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of any marketing approval in relation to other product approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">support from patient advocacy groups; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products together with other medications. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales and marketing capabilities, we may not be successful in commercializing our product candidates if and when they are approved. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of biopharmaceutical products. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish sales, marketing and distribution capabilities, either ourselves or through collaboration or other arrangements with third parties. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect that we would build our own focused, specialized sales and marketing organization to support the commercialization of product candidates in the United States for which we receive marketing approval and that can be commercialized with such capabilities. There are risks involved with establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our products on our own include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain adequate numbers of effective, knowledgeable and experienced sales and marketing personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of such sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage to companies with more extensive product lines; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services, our revenue from product sales and our profitability, if any, are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to market and sell our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of these third parties may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government healthcare programs, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, government authorities and third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the FDA or similar regulatory authorities approve the drug outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for any product candidates or products that we may develop;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of any marketing approval, recall, restriction on the approval or a &#8220;black box&#8221; warning or contraindication for an approved drug;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to enroll clinical trial participants or withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced resources of our management to pursue our business strategy; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any products that we may develop.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We currently hold $10.0 million in product liability insurance coverage in the aggregate, with a per incident limit of $10.0 million, which may not be adequate to cover all liabilities that we may incur. We will need to increase product liability insurance coverage as we expand our clinical trials and if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </span></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired, and we may not be able to compete effectively in our market. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection in the United States and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and other jurisdictions related to our novel technologies and product candidates. Any disclosure to or misappropriation by </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Moreover, the patent applications we own, co-own or license may fail to result in issued patents in the United States or in other foreign countries. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or at all. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned, co-owned or licensed patents or pending patent applications, or that we were the first inventors to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or the USPTO, or in addition to interference proceedings, may become involved in opposition, derivation, reexamination, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review, post-grant review or other post-grant proceedings challenging our or our licensors&#8217; patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our owned, co-owned and licensed patent estate includes patent applications, many of which are at an early stage of prosecution. Even if our owned, co-owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned, co-owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned, co-owned and licensed patents may be challenged in the courts or patent offices in the United States and other jurisdictions. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned, co-owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws or patent jurisprudence could diminish the value of our patents in general, thereby impairing our ability to protect our product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first-inventor-to-file provisions, became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. Furthermore, for applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years limiting where a patentee may file a patent infringement suit, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors, or other intellectual property, which could be expensive, time-consuming and unsuccessful. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our issued patents, the patents of our licensors, or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive, time-consuming and unpredictable. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours or our licensors is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Even if we successfully assert our patents, a court may not award remedies that sufficiently compensate us for our losses. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms or at all. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of a third party to commercialize our own technology or products, in which case we would be required to obtain a license from such third party. A license to such intellectual property may not be available or may not be available on commercially reasonable terms, which could have a material adverse effect on our business and financial condition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. We may not be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, reexamination, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review proceedings before the USPTO and oppositions and other comparable proceedings in foreign jurisdictions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference, derivation, reexamination or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review proceedings before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found by a court of competent jurisdiction to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. In addition, even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in our current and future intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a license agreement with Yale that provides us with the foundational intellectual property rights for our PROTAC targeted protein degradation technology. This license agreement imposes diligence, development and commercialization timelines and milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations, including achieving specified milestone events, Yale may have the right to terminate this license, in which event we might not be able to develop, manufacture or market any product that is covered by the intellectual property we in-license from Yale and may face other penalties. Such an occurrence would materially adversely affect our business prospects. For a variety of purposes, we will likely enter into additional licensing and funding arrangements with third parties that may also impose similar obligations on us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of any of our current or future in-licenses would reduce or eliminate our rights under these agreements and may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology. Any of the foregoing could prevent us from commercializing our other product candidates, which could have a material adverse effect on our operating results and overall financial condition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above risks, intellectual property rights that we license in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we do not have the right to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. For example, under the Yale license, any patent applications and issued patents under the agreement remain the property of Yale, and Yale has the right to choose patent counsel. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees, consultants, contractors or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at universities as well as other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We have received confidential and proprietary information from collaborators, prospective licensees and other third parties. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and reputational loss and be a distraction to our management and other employees. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Such assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent offices, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and patent offices in foreign countries in several stages over the lifetime of the patent. The USPTO and patent offices in foreign countries require compliance with a number of procedural, documentary, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of a patent or patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain patent term extensions in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for our product candidates, our business may be impaired. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one of the U.S. patents covering each of such product candidates or the use thereof may be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Act. The period of extension may be up to five years beyond the expiration date of a patent but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA-approved product. Similar patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Nevertheless, we may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product may be shortened and our competitors may obtain approval of competing products following our patent expiration sooner, and our revenue could be reduced, possibly materially. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We only have limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In-licensing patents covering our product candidates in all countries throughout the world may similarly be prohibitively expensive, if such opportunities are available at all. And in-licensing or filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates may be prohibitively expensive or impractical. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection or licensed patents to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the European Union. These products may compete with our product candidates, and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may decide to abandon national and regional patent applications while they are still pending. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications may be rejected by the relevant patent office, while substantively similar applications are granted by others. For example, relative to other countries, China has a heightened detailed description requirement for patentability. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or regulations in the United States and the European Union, and many companies have encountered significant difficulties in protecting and defending proprietary rights in such jurisdictions. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets or other forms of intellectual property, which could make it difficult for us to prevent competitors in some jurisdictions from marketing competing products in violation of our proprietary rights generally. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, are likely to result in substantial costs and divert our efforts and attention from other aspects of our business, and additionally could put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly, could increase the risk of our or our licensors&#8217; patent applications not issuing, or could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, while damages or other remedies may be awarded to the adverse party, which may be commercially significant. If we prevail, damages or other remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition in those jurisdictions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some jurisdictions, compulsory licensing laws compel patent owners to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties under patents relevant to our business, or if we or our licensors are prevented from enforcing patent rights against third parties, our competitive position may be substantially impaired in such jurisdictions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval and Marketing of Our Product Candidates and Other Legal and Compliance Matters</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval process of the FDA is lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained marketing approval for any product candidate to date and it is possible that none of our existing product candidates, or any product candidates we may seek to develop in the future, will ever obtain marketing approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to receive marketing approval for many reasons, including the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its proposed indication;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials may not meet the level of statistical significance required by the FDA for approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data collected from clinical trials of our product candidates may not be sufficient to support the submission of a New Drug Application, or NDA, to the FDA or other submission or to obtain marketing approval in the United States;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. The FDA has substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of any or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advertising, promotion, sale and distribution, export and import are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities outside of the United States. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company, we do not have experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party clinical research organizations or other third-party consultants or vendors to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. New oncology drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the United States and in other jurisdictions, is expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may increase costs or cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed outside of the United States and may limit our ability to generate revenue from product sales. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our products in the European Union and in other jurisdictions outside of the United States, we, and any collaborators, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. We, and any collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many countries outside the United States, a product candidate must also be approved for reimbursement before it can be sold in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. Obtaining non-U.S. regulatory approvals and compliance with non-U.S. regulatory requirements could result in significant delays, difficulties and costs for us and any collaborators and could delay or prevent the introduction of our product candidates in certain countries. In addition, if we or any collaborators fail to obtain the non-U.S. approvals required to market our product candidates outside the United States or if we or any collaborators fail to comply with applicable non-U.S. regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects may be adversely affected. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the withdrawal of the United Kingdom from the EU, commonly referred to as Brexit.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom is no longer part of the European Single Market and European Union Customs Union. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to European Union rules under the Northern Ireland Protocol.  The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines.  The HMR has been incorporated into the domestic law of the body of European Union law instruments governing medicinal products that pre-existed prior to the United Kingdom&#8217;s withdrawal from the European Union.  Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling outside of the United States; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, and, as a result, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. As of May 26, 2021, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and review timelines could be extended, thus, the FDA may be unable to complete such required inspections during the review period. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we, or any collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. We, and any collaborators, must therefore comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we, and any collaborators will not be able to promote any products we develop for indications or uses for which they are not approved. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our third-party manufacturers, any collaborators and their third-party manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, assuming we, or any collaborators, receive marketing approval for one or more of our product candidates, we, and any collaborators, and our respective third-party manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, and any collaborators, are not able to comply with post-approval regulatory requirements, we, and any collaborators, could have the marketing approvals for our products withdrawn by regulatory authorities and our, or any collaborators&#8217;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations in the United States, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek certain designations for one or more of our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA, including the Fast Track designation we received in May 2019 for bavdegalutamide for mCRPC.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, even if one or more of our product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we, or any collaborators, obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and we, or any collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products when and if any of them are approved. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we, or any collaborators, obtain marketing approval, as well as the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA, EMA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a risk evaluation and mitigation strategy. New cancer drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales of the product. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product, including the adoption and implementation of risk evaluation and mitigation strategies. The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we do not market our products for their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown side effects or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on such products, manufacturers or manufacturing processes; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions and warnings on the labeling or marketing of a product; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on product distribution or use; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to conduct post-marketing studies or clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters or untitled letters; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of the products from the market; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications that we submit; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall of products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, restitution or disgorgement of profits or revenues; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of marketing approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to relationships with any potential collaborators; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable press coverage and damage to our reputation; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to permit the import or export of our products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation involving patients using our products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs applicable to drug manufacturers or quality assurance standards applicable to medical device manufacturers, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, and any contract manufacturers we may engage in the future, our collaborators and their contract manufacturers will also be subject to other regulatory requirements, including submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements regarding the distribution of samples to clinicians, recordkeeping, and costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product such as the requirement to implement a risk evaluation and mitigation strategy. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Similar restrictions apply to the approval of our products in the EU. The holder of a marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules, which can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory; and the marketing and promotion of authorized drugs, which are strictly regulated in the EU and are also subject to EU Member State laws.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with health care providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other health care laws and regulations, which could expose us to civil, criminal and administrative sanctions, contractual damages, reputational harm and diminished future profits and earnings. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any drugs for which we obtain marketing approval. Our future arrangements with third-party payors, health care providers and physicians may expose us to broadly applicable state and federal fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. These include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-Kickback Statute, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchasing, ordering, leasing, arranging for, or recommending the purchasing, ordering, or leasing of, any good or service for which payment may be made, in whole or in part, under a federal health care program such as Medicare or Medicaid; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">False Claims Act</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - the federal civil and criminal false claims laws, including the civil False Claims Act, and Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or knowingly making, using or causing to made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any health care benefit program or making false statements relating to health care matters, and apply regardless of the payor (e.g., public or private); </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA and HITECH - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which impose obligations on HIPAA covered entities and their business associates, including mandatory contractual terms and required implementation of administrative, physical and technical safeguards to maintain the privacy and security of individually identifiable health information; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Transparency Requirements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - the federal physician transparency requirements known as the Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the ACA, which requires manufacturers of drugs, medical devices, biological and medical supplies covered by Medicare, Medicaid, or State Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous State, Local and Foreign Laws</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - analogous state, local and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader than similar federal laws, can apply to claims involving health care items or services regardless of payor, and are enforced by many different federal and state agencies as well as through private actions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and/or administrative penalties, damages, fines, individual imprisonment, disgorgement, exclusion from government funded health care programs, such as Medicare and Medicaid, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other health care providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded health care programs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union Member States. In addition, payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the U.S., EU and UK. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, California passed into law the California Consumer Privacy Act, or the CCPA, which took effect on January 1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the General Data Protection Regulation, or the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which went into effect on January 1, 2023 and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities. In addition, other states, including Virginia, Colorado, Utah, and Connecticut already have passed state privacy laws. Virginia&#8217;s privacy law also went into effect on January 1, 2023, and the laws in the other three states will go into effect later in the year. Other states will be considering these laws in the future, and Congress has also been debating passing a federal privacy law. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.   </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the laws in the U.S., there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in EEA, and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May 2018 and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR places restrictions on the cross-border transfer of personal data from the EU to countries that have not been found by the EU to offer adequate data protection legislation, such as the U.S. There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the U.S. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the U.S. While we were not self-certified under the Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the U.S. generally and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in October 2022, President Joe Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The EU initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022. It is unclear if and when the framework will be finalized and whether it will be challenged in court. The uncertainty around this issue may further impact our business operations in the EU.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the withdrawal of the UK from the EU, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, through separate &#8220;adequacy&#8221; decisions, that data transfers between the two jurisdictions are in compliance with the UK Data Protection Act and the GDPR, respectively. Any changes or updates to these adequacy decisions have the potential to impact our business.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and the sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions.   </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the U.S. regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any FDA approved product. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for prescription drugs purchased through a pharmacy by the elderly and disabled and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this statute provides authority for limiting the number of drugs that will be covered in any therapeutic class, subject to certain exceptions. Cost reduction initiatives and other provisions of this statute could decrease the coverage and price that we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors. In March 2010, then-President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. These Medicare sequester reductions were reduced and suspended through June 2022 with the full 2% cut resuming thereafter. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the ACA, there have been and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts for Jobs Act, or TCJA, in 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA and therefore because the mandate was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard this case on November 10, 2020 and on June 17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden rescinded those orders and issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans&#8217; access to health care, and consider actions that will protect and strengthen that access. Under this Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents. This Executive Order also directs HHS to create a special enrollment period for the Health Insurance Marketplace in response to the COVID-19 pandemic.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our drug products, if and when approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have been delayed until January 1, 2026 by the Infrastructure Investment and Jobs Act. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, on August 16, 2022, the IRA was signed into law by President Biden.  The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of enrolling in a plan providing outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).  The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D.  CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 additional Part D drugs in 2027, 15 additional Part B or Part D drugs in 2028, and 20 additional Part B or Part D drugs in 2029 and beyond.  This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition.  Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations.  Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare beneficiaries' out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In other jurisdictions, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we, or our collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the FCPA, the Bribery Act, and other anticorruption laws that apply in countries where we do business and may do business in the future. The FCPA, the Bribery Act, and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA, the Bribery Act, or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States, United Kingdom, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, which we collectively refer to as Trade Control Laws. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act, or other legal requirements, including Trade Control Laws. If we are not in compliance with the FCPA, the Bribery Act, and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. The Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges, including the Nasdaq Stock Market, for violations of the FCPA&#8217;s accounting provisions. Likewise, any investigation of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by U.S., U.K. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Although we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain workers&#8217; compensation insurance to cover costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, train, retain and motivate qualified personnel. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the research, development and clinical expertise of our management and scientific teams. Although we have offer letters or employment agreements with each of our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms or at all given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. These consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract, train, retain and motivate high quality personnel, our ability to pursue our corporate growth strategy will be limited. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size of our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, manufacturing, regulatory and medical affairs and compliance and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Any future growth will impose significant added responsibilities on members of management, including, but not limited to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, recruiting, training, integrating, retaining and motivating additional employees; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our internal development efforts effectively, including the clinical and FDA review process for bavdegalutamide, ARV-471, ARV-766 and any product candidate we develop, while complying with our contractual obligations to contractors and other third parties, including our partners and collaborators; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improving our managerial, operational and financial controls, reporting systems and procedures. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to advance the development of and, if approved, commercialize bavdegalutamide, ARV-471, ARV-766 and any other product candidate we develop will depend, in part, on our ability to effectively manage any future growth. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of any collaborators, contractors, consultants or other third parties that we work with, may fail or suffer security breaches, which could damage the integrity of our clinical trials, impact our regulatory filings, compromise our ability to protect our intellectual property, and subject us to regulatory actions that could result in significant fines or other penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of any collaborators, contractors, consultants or other third parties that we work with, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult, time consuming and costly to detect and we have experienced certain attacks, though minor, related to third party vendors. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any material system failure, accident or security breach to date, if such an event were to occur, it could result in diversion of management's attention and a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be materially harmed and the further development and commercialization of our product candidates could be delayed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading laws, which could materially harm our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA or similar foreign regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">healthcare fraud and abuse laws and regulations in the United States and in other jurisdictions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">violations of U.S. federal securities laws, including those related to trading in our common stock; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failures to report financial information or data accurately. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations regulate a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Other forms of misconduct could involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could, among other things, result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct and implement other internal controls applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties. In addition, the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any legal, regulatory or administrative actions or proceedings are instituted against us, and we are not successful in defending ourselves or asserting our rights, such actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diversion of management attention, general costs of litigation or proceedings, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock is volatile and may fluctuate substantially, which could result in the loss of all or part of our stockholders&#8217; investment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and likely will continue to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree of success of any competitive products or technologies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of or developments in preclinical studies and clinical trials of our product candidates or those of our competitors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our product candidates or clinical development programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to discover, develop, acquire or in-license additional technologies or product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems in the United States and other jurisdictions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;Risk Factors&#8221; section. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the foregoing factors were to occur, or if our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, companies that have experienced volatility in the market price of their stock have frequently been the subject of securities class action and shareholder derivative litigation. Such litigation, if instituted against us, whether successful or not, could cause us to incur substantial costs to defend such claims and divert management&#8217;s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to significantly influence or control all matters submitted to stockholders for approval. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers and directors, combined with our stockholders who own more than 5% of our outstanding common stock, in the aggregate, beneficially own shares representing approximately 53% of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence or control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could significantly influence or control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay, defer or prevent a change in control; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entrench our management and the board of directors; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our organizational documents and under Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide for a classified board of directors such that only one of three classes of directors is elected each year; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from our board of directors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide for advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue "blank check" preferred stock, which could be issued without stockholder approval, may contain voting, liquidation, dividend and other rights superior to our common stock, and could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our charter or bylaws. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our trials or operating results fail to meet the expectations of analysts, our stock price will likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a significant portion of our total outstanding shares are sold into the market, the market price of our common stock could drop significantly, even if our business is doing well. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our outstanding common stock can be traded without restriction at any time. As such, sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Holders of a significant portion of our common stock have rights, subject to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we issued 1,346,313 shares of our common stock to Bayer. On October 1, 2019, we filed a registration statement on Form S-3 covering the resale of these shares. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued 3,457,815 shares of our common stock to Pfizer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant number of shares that are subject to outstanding options and restricted stock units, and in the future we may issue additional options, restricted stock units, or other derivative securities convertible into our common stock under our equity compensation plans. The exercise or vesting of any such options, restricted stock units, or other derivative securities, and the subsequent sale of the underlying common stock, could cause a further decline in our stock price. These sales also might make it difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Such sales of our common stock could result in higher than average trading volume and may cause the market price for our common stock to decline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently have on file with the SEC universal shelf registration statements on Form S-3 which allow us to offer and sell registered common stock, preferred stock, debt securities, depositary shares, units and/or warrants from time to time pursuant to one or more offerings at prices and terms to be determined at the time of sale. In October 2019, we entered into an Equity Distribution Agreement, or the Distribution Agreement, with Piper Sandler &amp; Co. (formerly Piper Jaffray &amp; Co.), or Piper Sandler, pursuant to which we sold 2,593,637 shares of common stock in at-the-market offerings for aggregate net proceeds of $64.1&#160;million. We terminated the Distribution Agreement in August 2021. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into an Equity Distribution Agreement with Piper Sandler &amp; Company, or Piper Sandler, and Cantor Fitzgerald &amp; Co., or Cantor, as agents, pursuant to which we may offer and sell from time to time, through the agents, up to $300.0&#160;million of the common stock registered under the universal shelf registration statement pursuant to one or more "at-the-market" offerings. During the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, no shares were issued under this agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of substantial amounts of shares of our common stock or other securities by our stockholders under our universal shelf registration statement, including pursuant to our "at-the-market" offering program, or otherwise could also dilute our stockholders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market and other applicable securities rules and regulations, including those promulgated by the SEC, impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and have made some activities more time-consuming and costly. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404 of Sarbanes-Oxley, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. To achieve compliance with Section 404, we are engaged in a process to document and evaluate our internal control over financial reporting and internal controls, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and carry out a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in harm to our reputation or an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adverse reaction in the financial markets and it could restrict our future access to the capital markets due to a loss of confidence in the reliability of our consolidated financial statements which would materially harm our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders. Our certificate of incorporation further provides that the federal district courts of the United States are the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. These choice of forum provisions could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or other stockholders. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty owed by our directors, officers, other employees or stockholders to the company or our stockholders, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law or as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware, or any action asserting a claim arising pursuant to our certificate of incorporation or our bylaws or governed by the internal affairs doctrine. Our certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, other employees or other stockholders, which may discourage such lawsuits against us and our directors, officers, other employees or other stockholders. Alternatively, if a court were to find this provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. Neither of these choice of forum provisions would affect suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder, jurisdiction over which is exclusively vested by statute in the United States federal courts, or any other claim for which United States federal courts have exclusive jurisdiction.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we have never paid and do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders&#8217; sole source of gain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of gain for the foreseeable future. </span></div><div id="ia936ede3f23041239a783a07e7f93c48_22"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ia936ede3f23041239a783a07e7f93c48_25"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties. </span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease approximately 63,000 square feet of office and laboratory space in New Haven, Connecticut under leases, as amended, that expire in December 2024. In May 2021, we entered into a lease, which was amended in August 2022, for approximately 160,000 square feet of office and laboratory space in New Haven, Connecticut which we expect to begin occupying in 2024. We believe that our facilities are sufficient to meet our current needs and that suitable additional or alternative space will be available as and when needed on commercially reasonable terms for our future growth.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings. </span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of business and regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. We are not currently a party to any material litigation or legal proceedings.</span></div><div id="ia936ede3f23041239a783a07e7f93c48_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ia936ede3f23041239a783a07e7f93c48_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol &#8220;ARVN&#8221; since September 27, 2018 in connection with our initial public offering, or IPO. Prior to that time, there was no public market for our common stock. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of February&#160;17, 2023, there were approxima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tely 24 holders</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of recor</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any securities that were not registered under the Securities Act of 1933, as amended, or the Securities Act, during the year ended December&#160;31, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form 10-K. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance graph shown below compares the quarterly change in cumulative total shareholder return on our common shares with the Nasdaq Composite Index and the Nasdaq Biotechnology Index from September 27, 2018 (the first date on which shares of our common stock were publicly traded) through the quarter ended December&#160;31, 2022. The graph assumes an investment of $100 on September 27, 2018 in our common shares, the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes that any dividends are reinvested. All index values are weighted by the capitalization of the companies included in the index. The comparisons shown in the graph below are based upon historical data. The stock price performance included in this graph is not necessarily indicative of future stock price performance. The following performance graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, or SEC, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, nor shall such information be incorporated by reference into any future filing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Exchange Act or Securities Act, except to the extent that we specifically incorporate it by reference into such filing.</span></div><div style="margin-top:12pt;text-align:center"><img src="arvn-20221231_g12.jpg" alt="arvn-20221231_g12.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div id="ia936ede3f23041239a783a07e7f93c48_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="ia936ede3f23041239a783a07e7f93c48_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis is meant to provide material information relevant to an assessment of the financial condition and results of operations of our company, including an evaluation of the amount and certainty of cash flows from operations and from outside sources, so as to allow investors to better view our company from management's perspective. You should read the following discussion and analysis of financial condition and results of operations together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K, our actual results may differ materially from those anticipated in or implied by these forward-looking statements. </span></div><div id="ia936ede3f23041239a783a07e7f93c48_46"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. We use our PROTAC Discovery Engine, our proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body&#8217;s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines. We have a robust preclinical pipeline of PROTAC protein degraders targeting a broad range of intracellular disease targets, including those representing proteins that currently cannot be addressed by existing small molecule therapies, commonly referred to as &#8220;undruggable&#8221; targets. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are using our PROTAC Discovery Engine to build an extensive pipeline of protein degradation product candidates to target diseases in areas of unmet need, including oncology (including immuno-oncology), neuroscience and other therapeutic areas. We have three investigational clinical stage programs:  ARV-471, a novel PROTAC estrogen receptor, or ER, protein degrader for the treatment of patients with locally advanced or metastatic ER positive / human epidermal growth factor receptor 2, or HER2, negative, or ER+/HER2-, breast cancer and bavdegalutamide (ARV-110) and ARV-766, each an oral PROTAC protein degrader that targets the androgen receptor protein, or AR, for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-471</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-471 is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. We are co-developing ARV-471 with Pfizer, Inc., or Pfizer, pursuant to a collaboration agreement that we and Pfizer entered into in July 2021. We granted Pfizer worldwide co-exclusive rights to develop and commercialize ARV-471. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, ARV-471 demonstrated near-complete ER degradation in tumor cells, induced robust tumor shrinkage when dosed as a single agent in multiple ER-driven xenograft models, and showed superior anti-tumor activity when compared to a standard of care agent, fulvestrant, both as a single agent and in combination with a cyclin-dependent kinase, or CDK, 4/6 inhibitor. In 2019, we initiated a Phase 1 clinical trial of ARV-471 designed to assess the safety, tolerability and pharmacokinetics of ARV-471, which also included measures of anti-tumor activity as secondary endpoints and in the fourth quarter of 2020, we initiated a Phase 1b cohort expansion of ARV-471 in combination with the CDK4/6 inhibitor Ibrance&#174; (palbociclib). In 2021, we initiated VERITAC, the Phase 2 single agent expansion cohort of the ARV-471 clinical trial. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the third quarter of 2022, we initiated TACTIVE-E, a Phase 1b clinical trial with ARV-471 in combination with everolimus in patients with metastatic breast cancer. Also in the third quarter of 2022, we initiated with Pfizer a Phase 1b trial of ARV-471 as a monotherapy in Japanese patients.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the fourth quarter of 2022, we presented initial data from VERITAC at the San Antonio Breast Cancer Symposium and we initiated, with Pfizer, the VERITAC-2 Phase 3 trial with ARV-471 as a monotherapy as a second-line and later treatment in patients with ER+/HER2- metastatic breast cancer. Also in the fourth quarter of 2022, we initiated the first of two arms in the ongoing Phase 1b umbrella trial of ARV-471, with ARV-471 in combination with each of the CDK4/6 inhibitors abemaciclib and ribociclib (TACTIVE-U). We initiated the second of two arms in the first quarter of 2023. In addition, in the fourth quarter of 2022, we initiated a Phase 2 clinical trial with ARV-471 as a monotherapy in patients with early breast cancer in the neoadjuvant setting (TACTIVE-N).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2023, we and Pfizer requested a meeting with the U.S. Food and Drug Administration, or the FDA, to review the proposed update to the trial protocol for the VERITAC-3 first-line, metastatic ER+ / HER2- breast cancer Phase 3 trial of ARV-471 in combination with IBRANCE&#174; (palbociclib)  to determine the optimal dose of palbociclib as part of the trial design.  Following correspondence and alignment with the FDA, we and Pfizer determined an approach to the planned Phase 3 trial to enable trial initiation in the second half of 2023, which includes a Phase 3 lead-in to evaluate the optimal dose of palbociclib (100 mg or 75 mg) in combination with 200 mg ARV-471. This approach follows the recent analysis of data from the ongoing Phase 1b combination study of ARV-471 with palbociclib, in which an increase in palbociclib exposure was observed relative to historical palbociclib pharmacokinetic data.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first half of 2023, we expect, with Pfizer, to provide an update with preliminary data from the Phase 1b combination trial with palbociclib (Part C of the Phase 1/2 trial) and in the second half of 2023, we expect, with Pfizer, to submit and present data from the Phase 1b combination trial of ARV-471 with palbociclib at a medical congress and. Also in the second half of 2023, we expect, with Pfizer, to initiate a Phase 3 trial with ARV-471 in combination with palbociclib as a first-line treatment in patients with ER+ / HER2- locally advance or metastatic breast cancer. and initiate additional arms of the TACTIVE-U, Phase 1b combination trial with other targeted therapies, during 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bavdegalutamide (ARV-110)</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bavdegalutamide (ARV-110) is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the AR for the treatment of men with mCRPC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, bavdegalutamide demonstrated activity of AR mutation or overexpression, both common mechanisms of resistance to currently available AR-targeted therapies. In 2019, we initiated a Phase 1/2 clinical trial of bavdegalutamide designed to assess the safety, tolerability and pharmacokinetics of bavdegalutamide and which trial also included measures of anti-tumor activity as secondary endpoints, including reduction in prostate specific antigen, or PSA, a well-recognized biomarker of prostate cancer progression. In 2019, we also received Fast Track designation for bavdegalutamide for mCRPC. In 2020, we initiated ARDENT, the Phase 2 single agent expansion portion of the bavdegalutamide clinical trial. In 2021, we initiated a Phase 1b clinical trial of bavdegalutamide in combination with abiraterone for the treatment of men with mCRPC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we announced completed Phase 1 and interim ARDENT data for bavdegalutamide at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to initiate a global Phase 3 trial with a confirmed dose for bavdegalutamide for the treatment of men with mCRPC with AR T878/H875 tumor mutations in the second half of 2023. Also in the second half of 2023, we expect to complete enrollment in the Phase 1b clinical trial with bavdegalutamide in combination with abiraterone.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-766</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-766 is an investigational orally bioavailable PROTAC protein degrader designed to target AR with a different profile than bavdegalutamide, as a potential treatment for men with mCRPC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, ARV-766 degraded all tested resistance-driving point mutations of AR, including L702H, a mutation associated with treatment with abiraterone and other AR-pathway therapies. In 2021, we initiated a Phase 1/2 clinical trial for ARV-766 designed to assess the safety, tolerability and pharmacokinetics of ARV-766, which trial also includes measures of anti-tumor activity as secondary endpoints, including reduction in PSA. In the second half of 2022, we initiated a Phase 2 expansion trial of ARV-766 for the treatment of men with mCRPC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to share data from the Phase 1 dose escalation trial of ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer in the second quarter of 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate initiating a Phase 1b or Phase 2 dose escalation trial for either of bavdegalutamide or ARV-766 in patients with AR-dependent tumors who have not previously received novel hormonal agents, or NHA, such as enzalutamide or abiraterone, and who may benefit from bavdegalutamide or ARV-766 therapy, in the second half of 2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are further diversifying our pipeline by developing new PROTAC targeted protein degraders against targets for which we believe protein degradation offers advantages to existing therapeutic modalities, including PROTAC degraders that are designed to reach targets in deep brain regions and are capable of being delivered through multiple routes of administration, including oral delivery. We have engineered PROTAC targeted protein degraders that, in preclinical studies, have successfully achieved blood-brain barrier penetration, a key step in developing drugs with the potential to treat neurodegenerative diseases. We believe there are many other indications for which our PROTAC technology may be advantageous. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By year-end 2023, we expect to submit an investigational new drug, or IND, application or clinical trial application, or CTA, for our PROTAC degrader designed to target each of the BCL6 protein, a protein mutated in patients with different forms of Non-Hodgkins Lymphoma, or NHL, including Diffuse Large B-Cell Lymphoma, or DLBCL, and the LRRK2 protein, a protein kinase that has been genetically linked to some forms of Parkinson's Disease, or PD. We also expect to progress at least two additional PROTAC protein degrader programs in IND-enabling or CTA-enabling studies by year-end 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Operations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced operations in 2013. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies and clinical trials and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests, proceeds from our collaborations, grant funding and debt financing. Since inception through December&#160;31, 2022, we raised approximately $1.3 billion in gross proceeds from the sale of equity instruments and the exercise of stock options, and had received an aggregate of $780.5 million in payments primarily from collaboration partners.</span></div><div style="text-indent:30.6pt"><span><br/></span></div><div style="text-indent:30.6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage company.  ARV-471, bavdegalutamide (ARV-110) and ARV-766 are each in Phase 1/2 clinical trials and ARV-471 is in a Phase 3 clinical trial, and our other drug discovery activities are at the research and preclinical development stages. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Since inception, we have incurred significant operating losses and expect to incur increasing operating losses for at least the next several years due to costs associated with our ongoing and anticipated clinical activities for  ARV-471, bavdegalutamide and ARV-766, development activities associated with our other product candidates, research activities in oncology, neurological and other disease areas to expand our pipeline, hiring additional personnel in research, clinical trials, quality and other functional areas, increased expenses incurred with CMOs to supply us with product for our preclinical and clinical studies and CROs for the synthesis of compounds in our preclinical development activities, as well as other associated costs including the management of our intellectual property portfolio. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate revenue from sales of any product for many years, if ever. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research or product development programs or any future commercialization efforts, or to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. </span></div><div id="ia936ede3f23041239a783a07e7f93c48_49"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. Our revenues to date have been generated through research collaboration and license agreements. Revenue is recognized ratably over our expected performance period under each agreement. We expect that any revenue for the next several years will be derived primarily from our current collaboration agreements and any additional collaborations that we may enter into in the future. To date, we have not received any sales-based milestone payments or royalties under any of the collaboration agreements.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech License Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we entered into an Option and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, collectively referred to as Genentech, focused on PROTAC targeted protein degrader discovery and research for target proteins, or Targets, based on our proprietary platform technology, other than excluded Targets as described below. This collaboration was expanded in November 2017 through an Amended and Restated Option, License and Collaboration Agreement, which we refer to as the Restated Genentech Agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Restated Genentech Agreement, Genentech has the right to designate up to ten Targets for further discovery and research utilizing our PROTAC platform technology. Genentech may designate as a Target any protein to which a PROTAC targeted protein degrader, by design, binds to achieve its mechanism of action, subject to certain exclusions. Genentech also has the right to remove a Target from the collaboration and substitute a different Target that is not an excluded Target at any time prior to us commencing research on such Target or in certain circumstances following commencement of research by us. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time we entered into the original agreement with Genentech, we received an upfront payment of $11.0 million, and, at the time we entered into the Restated Genentech Agreement, we received an additional $34.5 million in upfront and expansion target payments. We are eligible to receive up to an aggregate of $27.5 million in additional expansion target payments if Genentech exercises its options for all remaining Targets. We are also eligible to receive payments aggregating up to $44.0 million per Target upon the achievement of specified development milestones; payments aggregating up to $52.5 million per Target (assuming approval of two indications) subject to the achievement of specified regulatory milestones; and payments aggregating up to $60.0 million per PROTAC targeted protein degrader directed against the applicable Target, subject to the achievement of specified sales milestones. These milestone payments are subject to reduction if we do not have a valid patent claim covering the licensed PROTAC targeted protein degrader at the time the milestone is achieved. We are also eligible to receive, on net sales of licensed PROTAC targeted protein degraders, mid-single digit royalties, which may be subject to reductions. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into a Research Collaboration and License Agreement with Pfizer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of Targets, using our proprietary platform technology that are identified in the agreement or subsequently selected by Pfizer, subject to certain exclusions. We refer to this agreement as the Pfizer Research Collaboration Agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pfizer Research Collaboration Agreement, Pfizer has designated a number of initial Targets. For each identified Target, we and Pfizer will conduct a separate research program pursuant to a research plan. Pfizer may make substitutions for any of the initial Target candidates, subject to the stage of research for such Target. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2018, we received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in exchange for use of the technology license and to fund Pfizer-related research, as defined within the Pfizer Research Collaboration Agreement. We are eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. We are also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as mid- to high-single digit tiered royalties, which may be subject to reductions, on net sales of PROTAC targeted protein degrader-related products. In 2021 and 2020, we received payments totaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2 million and $4.4&#160;million, respectively</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pfizer selected additional targets and initiated additional services totaling $1.0 million and $3.5 million in December 2022 and 2021, respectively, which were included in accounts receivable as of December 31, 2022 and 2021.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Collaboration Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we entered into a Collaboration and License Agreement, or the Bayer Collaboration Agreement, with Bayer AG, or, together with its controlled affiliates, Bayer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of Targets, using our proprietary platform technology, that are selected by Bayer, subject to certain exclusions and limitations. The Bayer Collaboration Agreement became effective in July 2019. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Bayer Collaboration Agreement, we and Bayer conduct a research program pursuant to separate research plans mutually agreed to by us and Bayer and tailored to each Target selected by Bayer. Bayer may make substitutions for any such initial Target candidates, subject to certain conditions and based on the stage of research for such Target. During the term of the Bayer Collaboration Agreement, we are not permitted, either directly or indirectly, to design, identify, discover or develop any small molecule pharmacologically-active agent whose primary mechanism of action is, by design, directed to the inhibition or degradation of any Target selected or reserved by Bayer, or grant any license, covenant not to sue or other right to any third party in the field of human disease under the licensed intellectual property for the conduct of such activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Bayer Collaboration Agreement, we received an aggregate upfront, non-refundable payment of $17.5 million. Bayer is committed to fund a total of $12.0 million in research funding </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments through 2023, of which $10.5&#160;million was received from inception through December&#160;31, 2022, subject to potential increases if our costs for research activities exceed the research funding payments allocated to a Target and certain conditions are met. We are also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated Targets. In addition, we are eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer ARV-471 Collaboration Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into the ARV-471 Collaboration Agreement with Pfizer, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound ARV-471, or the Licensed Products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ARV-471 Collaboration Agreement, we received an upfront, non-refundable payment of $650 million. In addition, we are eligible to receive up to an additional $1.4 billion in contingent payments based on specified regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer share equally (50/50) all development costs (including costs for conducting any clinical trials) for the Licensed Products, subject to certain exceptions. Except for certain regions described below, we will also share equally (50/50) all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be the marketing authorization holder and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. We will determine with Pfizer which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of all profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the ARV-471 Collaboration Agreement will expire on a Licensed Product-by-Licensed Product and country-by-country basis when such Licensed Products are no longer commercialized or developed for commercialization in such country. Pfizer may terminate the ARV-471 Collaboration Agreement for convenience in its entirety or on a region-by-region basis subject to certain notice periods. Either party may terminate the ARV-471 Collaboration Agreement for the other party&#8217;s uncured material breach or insolvency. Subject to applicable terms of the ARV-471 Collaboration Agreement, including certain payments to Pfizer upon termination for our uncured material breach, effective upon termination of the ARV-471 Collaboration Agreement, we are entitled to retain specified licenses to be able to continue to exploit the Licensed Products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to specified exceptions, we and Pfizer have each agreed not to directly or indirectly research, develop, or commercialize any competing products outside of the ARV-471 Collaboration Agreement anywhere in the world during the term of the ARV-471 Collaboration Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs. </span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with third parties, including CROs and other third parties that conduct research and preclinical activities on our behalf as well as third parties that manufacture our product candidates for use in our preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of laboratory supplies and developing preclinical studies and clinical trial materials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party licensing fees. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use our employee and infrastructure resources across our development programs, and as such, do not track all of our internal research and development expenses on a program-by-program basis. The following table summarizes our research and development expenses for our AR program, which includes bavdegalutamide and ARV-766, ER program, which includes ARV-471, and all other platform and exploratory research and development costs: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AR program development costs</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57.5&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41.8&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.4&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ER program development costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other research and development costs</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">185.4&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107.7&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66.5&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total research and development costs</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">315.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">180.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">108.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we continue to conduct our ongoing clinical trials for ARV-471, bavdegalutamide and ARV-766, including our Phase 3 clinical trial for ARV-471, and continue to discover and develop additional product candidates. Research and development expenses related to ARV-471 are shared equally with Pfizer from July 22, 2021, the effective date of the ARV-471 Collaboration Agreement. The ER program development costs in the table above reflect the cost sharing with Pfizer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot determine with certainty the duration and costs of future clinical trials of ARV-471, bavdegalutamide and ARV-766 or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt and related terms of marketing approvals from applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining third-party coverage and adequate reimbursement; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of the products following approval; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies. </span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support increased research and development activities relating to our product candidates. We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and Securities and Exchange Commission requirements; director and officer insurance costs; and investor and public relations costs. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Income (Expense)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our cash, cash equivalents, restricted cash and marketable securities. Interest income increased in 2022 as compared to 2021 primarily due to a full year of an increased marketable securities balance resulting from funds received in July 2021 under the ARV-471 Collaboration Agreement and in September 2021 under the Pfizer Stock Purchase Agreement. Interest expense consists primarily of interest paid or accrued on our outstanding debt with the State of Connecticut.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2013, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in any year or for our federal or state earned research and development tax credits, due to our uncertainty of realizing a benefit from those items.  During the year ended December&#160;31, 2022, we fully utilized our previously held federal net operating loss and federal credit carryforwards due to taxable income resulting from revenue recognition for tax purposes from our ARV-471 Collaboration Agreement and the mandatory capitalization of qualified research and development expenses incurred on or after January 1, 2022 under the Tax Cuts and Jobs Act. We continue to carry state net operating losses and credit carryforwards. The revenue recognition and capitalization of research expenses are timing differences for tax purposes and deferred tax assets were established. We have provided a valuation allowance against the full amount of the deferred tax assets since, in the opinion of management, based upon our earnings history, it is more likely than not that the benefits will not be realized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, Arvinas, Inc. had four wholly owned subsidiaries organized as C-corporations: Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc., Arvinas Estrogen Receptor, Inc., and Arvinas Winchester, Inc. Prior to December 31, 2018, these subsidiaries were separate filers for federal tax purposes. Net operating loss carryforwards are generated from the C-corporation subsidiaries&#8217; filings. We have provided a valuation allowance against the full amount of the deferred tax assets since, in the opinion of management, based upon our earnings history, it is more likely than not that the benefits will not be realized. </span></div><div id="ia936ede3f23041239a783a07e7f93c48_52"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue under Accounting Standards Codification, or ASC, 606, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, we evaluate whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. We have determined that these services within our existing contracts represent combined single performance obligations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC 606. We continually assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized ratably over our expected performance period under each respective arrangement. We make our best estimate of the period over which we expect to fulfill our performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgement is required to determine the duration of the performance period. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the transaction price allocated to the combined performance obligations identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on our best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. In accordance with ASC 606-10-55-65, we recognize revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale, or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). We anticipate recognizing these milestone and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in our accompanying consolidated balance sheets. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Contract Costs and Accruals</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors in connection with clinical development activities; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CROs and investigative sites in connection with pre-clinical, non-clinical, and human clinical trials</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base the expense recorded related to external research and development on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that supply, conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment streams. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on new accounting standards, see Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></div><div id="ia936ede3f23041239a783a07e7f93c48_55"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the year ended December&#160;31, 2022 totaled $131.4 million, compared with $53.6 million for the year ended December&#160;31, 2021. The increase of $77.8 million was primarily due to $72.5&#160;million of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue from the ARV-471 Collaboration Agreement entered into during the third quarter of 2021 and $3.7&#160;million of previously constrained deferred revenue related to our Oerth Bio joint venture.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> totaled </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$315.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compared with $180.4&#160;million for the year ended December&#160;31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase of $134.6 million was primarily due to investments in our platform and exploratory programs of $77.7 million and increases in expenses related to our AR and ER programs of $15.7 million and $41.2 million, respectively. The increase in spending over all of our programs was primarily due to increased personnel and personnel costs utilized across all of our programs of $42.3&#160;million, which includes $11.2&#160;million related to stock compensation expense. Clinical trial costs and related drug manufacturing costs increased by $37.0&#160;million as we continued to expand our AR and ER programs into additional clinical trials. ER program costs include a year over year cost sharing increase of $16.0&#160;million in accordance with our ARV-471 Collaboration Agreement with Pfizer. Direct expenses related to our platform and exploratory targets increased by $28.7&#160;million as we expanded the number of protein targets in the exploratory and lead optimization phases as well as more investments in our platform discovery efforts.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative exp</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enses totaled $79.6 million for the year ended December&#160;31, 2022, compared with $61.6 million for the year ended December&#160;31, 2021. The increase of $18.0 million was primarily due to an increase of personnel related costs of $15.0&#160;million, which includes $7.2&#160;million related to stock compensation expense, and professional fees of $5.6&#160;million.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income totaled $12.2 million for the year ended December&#160;31, 2022, compared with $4.3 million for the year ended December&#160;31, 2021. The increase of $7.9 million was primarily due to higher interest income of $10.2 million from marketable securities as compared to the prior year period on a higher average investment balance, partially offset by lower refundable research and development credits from the State of Connecticut of $1.0&#160;million, as we are no longer eligible to receive a cash refund for research and development credits in the State of Connecticut, $0.3&#160;million of higher year-over-year realized losses and forgiveness of debt of $1.0&#160;million in 2021 equal to 50% of the then outstanding loan balance, related to the State of Connecticut loan upon our satisfaction of certain jobs criteria.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense totaled </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compared with zero for the year ended December&#160;31, 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily due to current income taxes resulting from revenue recognition for tax purposes from our ARV-471 Collaboration Agreement and the mandatory capitalization of research and development expenses incurred on or after January 1, 2022. Under the Tax Cuts and Jobs Act of 2017, qualified research expenses incurred after 2021 are no longer immediately deductible for tax purposes and instead must be capitalized and amortized for tax purposes. As a result of these items, we expect to fully utilize our federal net operating loss and credit carryforwards in the current year, resulting in current income tax expense for the period.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss from Equity Method Investment </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from equity method investment totaled </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compared with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $3.7 million was due to increased operating losses incurred by Oerth Bio.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations &#8212; Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discussion and analysis of the results of operations for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020 is included under the heading "Comparison of Years Ended December&#160;31, 2021 and 2020" in Part II, Item 7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, in our 2021 Annual Report on Form 10-K as filed with the SEC on February 28, 2022 and incorporated by reference into this Annual Report on Form 10-K.</span></div><div id="ia936ede3f23041239a783a07e7f93c48_58"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of equity interests and through payments from collaboration partners, grant funding and loans from the State of Connecticut. Since inception through December&#160;31, 2022, we had received an aggregate of $780.5 million in payments from collaboration partners, grant funding and forgivable and partially forgivable loans from the State of Connecticut and raised approximately $1.3 billion in gross proceeds from the sale of equity interests and the exercise of stock options, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">October 2018: completion of our IPO, in which we issued and sold 7,700,482 shares of common stock for aggregate gross proceeds of $123.2 million, before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">July 2019: sale of 1,346,313 shares of common stock to Bayer AG for aggregate gross proceeds of $32.5 million; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">November 2019: completion of a follow-on offering in which we issued and sold 5,227,273 shares of common stock for aggregate gross proceeds of $115.0 million, before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">September - December 2020: sale of 2,593,637 shares of common stock in an &#8220;at-the-market offering&#8221; for aggregate gross proceeds of $65.6 million, before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">December 2020: completion of a follow-on offering in which we issued and sold 6,571,428 shares of common stock for aggregate gross proceeds of $460.0 million, before fees and expenses; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">September 2021: issuance of 3,457,815 share of common stock to Pfizer for aggregate gross proceeds of $350.0&#160;million.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into a lease, which was amended in August 2022, for approximately 160,000 square feet of laboratory and office space to be occupied in 2024. In connection with the signing of the lease, as amended, and at our election to increase the landlord&#8217;s contribution to the tenant&#8217;s improvement allowance, we issued a letter of credit for $5.5 million, collateralized by a certificate of deposit in the same amount. Once occupied, the base rent will range from $7.7 million to $8.8 million annually over a ten-year lease term. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into the ARV-471 Collaboration Agreement with Pfizer, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound ARV-471. Under the ARV-471 Collaboration Agreement, Pfizer made an upfront, nonrefundable payment of $650.0&#160;million. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into an Equity Distribution Agreement with Piper Sandler &amp; Company and Cantor Fitzgerald &amp; Co., as agents, pursuant to which we may offer and sell from time to time, through the agents, up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$300.0&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the common stock registered under the universal shelf registration statement pursuant to one or more &#8220;at-the-market" offerings.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the years ended December&#160;31, 2022 and 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares were issued under this agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents, restricted cash and marketable securities totaled $1.2 billion and $1.5 billion as of December&#160;31, 2022 and 2021, respectively. We had an outstanding loan balance of $1.0 million as of December&#160;31, 2022 and 2021. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for the period presented: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash (used in) provided by operating activities</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(273.5)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">559.4&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(89.7)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">242.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,313.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">164.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.7&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">278.6&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">504.6&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(26.0)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(475.6)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">579.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2022 totaled $273.5 million, primarily due to our net loss of $282.5 million and a decrease in deferred revenue of $116.8 million, driven largely by the ARV-471 Collaboration Agreement with Pfizer, partially offset by non-cash charges of $91.6 million and a decrease in accounts receivable of $14.0 million, related to payments pursuant to the ARV-471 Collaboration Agreement. Non-cash charges were primarily stock compensation expense of $75.5 million, depreciation and amortization of $6.3 million and net accretion of bond discounts/premiums of $5.7 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities for the year ended December 31, 2021 totaled $559.4 million, primarily due to an increase in deferred revenue of $695.5 million driven largely by the ARV-471 Collaboration Agreement with Pfizer, a net increase in accrued expenses and accounts payable of $27.9 million, and non-cash charges of $72.1 million, partially offset by our net loss of $191.0 million, an increase in accounts receivable of $14.0 million related primarily to the ARV-471 Collaboration Agreement, prepaid expenses related in part to clinical trials and drug manufacturing contracts of $13.6 million, and the payment to obtain a contract of $12.9 million related to the ARV-471 Collaboration Agreement. Non-cash charges were primarily stock compensation expense of $57.1 million, net accretion of bond discounts/premiums of $9.4 million and depreciation and amortization of $4.8 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December 31, 2020 totaled $89.7 million, resulting from our net loss of $119.3 million and a decrease in deferred revenue of $13.3 million, partially offset by non-cash expenses of $35.6 million and an increase in accounts payable and accrued expenses of $12.8 million. Non-cash expenses included $30.2 million of stock compensation expense. The decrease in deferred revenue is primarily due to $21.8 million of revenue recognized, partially offset by $8.5 million in payments received and an accounts receivable from collaboration partners. </span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December&#160;31, 2022 totaled $242.8 million, attributable to maturities and sales of marketable securities in excess of purchases of $249.6 million, partially offset by purchases of property and equipment of $6.8 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December 31, 2021 totaled $1.3 billion, attributable to purchases of marketable securities in excess of the maturities of marketable securities of $1.3 billion due in part to funds received as part of the ARV-471 Collaboration Agreement and purchases of property and equipment of $4.7 million, partially offset by sales of marketable securities of $7.2 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December 31, 2020 totaled $164.3 million, attributable to the net maturities and sales of marketable securities in excess of purchases of $170.7 million, offset by the purchases of property and equipment of $6.4 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December&#160;31, 2022 totaled $4.7 million, attributable to proceeds from the exercise of stock options.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2021 totaled $278.6 million, attributable to the proceeds from the issuance of shares of our common stock to Pfizer of $260.0 million (after allocation of a portion of the proceeds to deferred revenue), net of expenses, and proceeds from the exercise of stock options of $18.6 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2020 totaled $504.6 million, primarily attributable to the proceeds from sales of our common stock from our public offering and at-the-market offering of $496.3 million, net of combined underwriter discounts from the public offering and offering costs of $29.3 million and the proceeds from the exercise of stock options of $8.3 million.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we advance the preclinical and clinical </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we anticipate that our expenses will increase substantially if, and as we: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">continue a Phase 1/2 clinical trial of our product candidate ARV-471, a Phase 1b clinical trial of ARV-471 in combination with palbociclib,  Phase 1b cohort expansion in combination with a standard of care agent, and a Phase 3 trial with ARV-471 as a second-line treatment, and initiate a Phase 3 trial of ARV-471 in combination with palbociclib, each in patients with locally advanced or metastatic ER+ / HER2- breast cancer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue a Phase 1/2 clinical trial of our product candidate bavdegalutamide (ARV-110) and a Phase 1b clinical trial of bavdegalutamide in combination with abiraterone for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC, and initiate one or more additional Phase 1b cohort expansions of bavdegalutamide in combination with standard of care agents and a Phase 3 clinical trial, in men with mCRPC;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue a Phase 1/2 clinical trial of our product candidate ARV-766 in men with mCRPC;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">apply our PROTAC Discovery Engine to advance additional product candidates into preclinical and clinical development; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand the capabilities of our PROTAC Discovery Engine; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we may obtain marketing approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand, maintain and protect our intellectual property portfolio; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional development, including clinical and regulatory, and scientific personnel; and </span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel to support our research, product development and future commercialization efforts and support our operations as a public company. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents, restricted cash and marketable securities of approximately $1.2 billion as of December&#160;31, 2022. We believe that our cash, cash equivalents, restricted cash and marketable securities as of December&#160;31, 2022 will enable us to fund our planned operating expenses and capital expenditure requirements into 2026. We have based this estimate on assumptions that may prove to be wrong and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, costs and results of our ongoing clinical trials for ARV-471, bavdegalutamide (ARV-110), and ARV-766 and any future clinical development of ARV-471, bavdegalutamide, (ARV-110) and ARV-766; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and development programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of, and development requirements for, other product candidates that we pursue, including our other oncology and neurodegenerative research programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaborations with Pfizer, Inc., or Pfizer; Genentech, Inc. and F. Hoffman LaRoche Ltd., collectively referred to as Genentech; and Bayer AG, or Bayer; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, for the development or commercialization of our product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these anticipated expenditures, we will need to obtain substantial additional financing in connection with our continuing operations. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our collaborations with Pfizer, Genentech and Bayer, we do not currently have any committed external source of funds. Adequate additional funds may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. </span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, we entered into an Assistance Agreement with the State of Connecticut, or the 2014 Assistance Agreement, under which we borrowed $2.5 million. Borrowings under the 2014 Assistance Agreement were forgivable if we maintained a minimum number of full-time jobs in the State of Connecticut for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a minimum period at a minimum annual salary. Effective in March 2016, the full principal amount under the 2014 Assistance Agreement had been forgiven. While borrowings under the 2014 Assistance Agreement have been forgiven, we remain subject to an ongoing covenant to be located in the State of Connecticut through January 2024. Upon violation of this covenant, we would be required to repay the full original funding amount of $2.5 million plus liquidated damages of 7.50%. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we entered into an additional Assistance Agreement with the State of Connecticut, or the 2018 Assistance Agreement, to provide funding for the expansion and renovation of laboratory and office space. We borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that we be located in the State of Connecticut through September 2028 with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received. As of December&#160;31, 2022, $1.0 million remains outstanding under the 2018 Assistance Agreement.</span></div><div id="ia936ede3f23041239a783a07e7f93c48_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents, restricted cash and marketable securities. Interest income earned on these assets tota</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">led </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2022.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. As of December&#160;31, 2022, our cash equivalents consisted of bank deposits and money market funds and our marketable securities included interest-earning securities. Such interest-earning instruments carry a degree of interest rate risk. Our outstanding debt totaled $1.0 million as of December&#160;31, 2022 and carries a fixed interest rate of 3.25% per annum. </span></div><div id="ia936ede3f23041239a783a07e7f93c48_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements, together with the report of our independent registered public accounting firm, appear on pages F-1 through F-28 of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">his Annual Report on Form 10-K. </span></div><div id="ia936ede3f23041239a783a07e7f93c48_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia936ede3f23041239a783a07e7f93c48_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2022. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the company. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company&#8217;s principal executive and principal financial officers and effected by the company&#8217;s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). Based on that assessment, our management concluded that, as of December&#160;31, 2022, our internal control over financial reporting was effective.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deloitte &amp; Touche LLP, the independent registered public accounting firm that audited the consolidated financial statements included in this Annual Report on Form 10-K, has issued an attestation report on the effectiveness of internal control over financial reporting as of December&#160;31, 2022, included below.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended December&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal control over financial reporting due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 pandemic on our internal controls to minimize the impact on their design and operating effectiveness.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To the Stockholders and the Board of Directors of Arvinas, Inc.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Opinion on Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have audited the internal control over financial reporting of Arvinas, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2022, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by COSO.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December&#160;31, 2022, of the Company and our report dated February&#160;23, 2023, expressed an unqualified opinion on those financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Deloitte &amp; Touche LLP</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stamford, Connecticut</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2023</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia936ede3f23041239a783a07e7f93c48_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspection </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III </span></div><div id="ia936ede3f23041239a783a07e7f93c48_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2023 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics that applies to our officers, including our principal executive, financial and accounting officers and our directors and employees. We have posted the text of our Code of Business Conduct and Ethics under the &#8220;Investors and Media &#8211; Corporate Governance&#8221; section of our website, www.arvinas.com. We intend to disclose on our website any amendments to, or waivers from, the Code of Business Conduct and Ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K. </span></div><div id="ia936ede3f23041239a783a07e7f93c48_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item (other than the information required by Item 402(v) of Regulation S-K) is incorporated by reference from the information that will be contained in our Proxy Statement for our 2023 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </span></div><div id="ia936ede3f23041239a783a07e7f93c48_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2023 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </span></div><div id="ia936ede3f23041239a783a07e7f93c48_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2023 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </span></div><div id="ia936ede3f23041239a783a07e7f93c48_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2023 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ia936ede3f23041239a783a07e7f93c48_100"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits, Financial Statement Schedules. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Financial Statements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The following consolidated financial statements are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_115">Report of Independent Registered Public Accounting Firm (PCAOB ID No.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMDAvZnJhZzpjNWZiYjgyZTA4ZTk0YzYwOTE5MDkxMzkzMTkxZDkxMy90YWJsZTphMjIzMTAwODMwNzc0OWY2YWY2YTQ1YzgwZGI2YmUwYi90YWJsZXJhbmdlOmEyMjMxMDA4MzA3NzQ5ZjZhZjZhNDVjODBkYjZiZTBiXzItMC0xLTEtNDc5MTkvdGV4dHJlZ2lvbjo2M2IxODg4MGFjNDk0YjY0ODM4NDUzZGI4MmI5YjNjNV83Mw_a19e24c1-2731-41f7-aacc-a31e9b3beb51">34</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_115">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_115">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_118">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022 and 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_118">4</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_121">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2022, 2021 and 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_121">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_124">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2022, 2021 and 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_124">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_127">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2022, 2021 and 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_127">7</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_130">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_130">8</a></span></div></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Financial Statement Schedules</span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the consolidated financial statements or the notes thereto.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Index to Exhibits</span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex31.htm">Restated</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex31.htm"> </a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex31.htm">Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on October 1, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex32.htm">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on October 1, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex41.htm">Specimen Stock Certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018)</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019009357/arvn-ex42_866.htm">Registration Rights Agreement among the Registrant and the other parties thereto, dated September 26, 2018 (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 26, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex43.htm">Second Amended and Restated Put Agreement among the Registrant, Connecticut Innovations, Incorporated and the other parties thereto, dated March 29, 2018 (incorporated by reference to Exhibit 4.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-2271121) filed with the SEC on August 30. 2018)</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000156459020011004/arvn-ex44_268.htm">Description of the Registrant&#8217;s Securities Registered Under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518262944/d564688dex101.htm">Incentive Share Plan, as amended by First Amendment, dated October 16, 2015, Second Amendment, dated December 22, 2016, Third Amendment, dated September 8, 2017, and Fourth Amendment, dated March 29, 2018 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">).</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518262944/d564688dex102.htm">Form of Incentive Share Award Agreement under Incentive Share Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">).</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex103.htm">Form of Restricted Stock Agreement under Incentive Share Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">).</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex104.htm">2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex105.htm">Form of Stock Option Agreement under 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019009357/arvn-ex106_781.htm">Form of Restricted Stock Unit Agreement under 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 26, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex106.htm">2018 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September&#160;14,&#160;2018)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/arvinas-formofrsuagreement.htm">Form of Restricted Stock Unit Agreement under 2018 Stock Incentive Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/arvinas-formofrsuagreement.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/arvinas-formofrsuagreement.htm">(incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-36874) filed with the SEC on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/arvinas-formofrsuagreement.htm">May</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/arvinas-formofrsuagreement.htm"> 5, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/arvinas-formofrsuagreement.htm">).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex107.htm">Form of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018)</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex108.htm">Employment Agreement between the Registrant and John Houston, Ph.D., dated September 13, 2018 (incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.11+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex109.htm">Employment Agreement between the Registrant and Sean Cassidy, dated August 28, 2018 (incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.12+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex1010.htm">Employment Agreement between the Registrant and Ian Taylor, Ph.D., dated August 28, 2018 (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.13+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000156459020019266/arvn-ex101_177.htm">Employment Agreement between the Registrant and Ronald Peck, M.D., dated July 18, 2019 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on April 28, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1012.htm">Lease Agreement between the Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated December 31, 2017, as amended by First Amendment to Lease, dated May 23, 2018, and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1012.htm">S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1012.htm">econd Amendment to Lease, dated September 4, 2018 (incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312519076853/d723460dex101.htm">Third Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated March 12, 2019 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on March 15, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000156459020011004/arvn-ex1014_313.htm">Fourth Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated January 31, 2020 (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000156459021009857/arvn-ex1034_590.htm">Fifth Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated January 4, 2021 (incorporated by reference to Exhibit 10.34 to the Registrant's Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 1, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000156459020011004/arvn-ex1015_406.htm">Lease Agreement between Arvinas Operations, Inc. and Science Park Development Corporation, dated November 15, 2019 (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000156459020011004/arvn-ex1016_407.htm">First Amendment to Lease between Arvinas Operations, Inc. and Science Park Development Corporation, dated February 27, 2020 (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000156459021009857/arvn-ex1035_591.htm">Second Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated January 4, 2021 (incorporated by reference to Exhibit 10.35 to the Registrant's Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 1, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000156459021041688/arvn-ex101_99.htm">Lease between 101 College Street, LLC and Arvinas Operations, Inc., dated May 4, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-36874) filed with the SEC on August 5, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000054/a101collegearvinasfirstame.htm">First Amendment to Lease between 101 College Street, LLC and Arvinas Operations, Inc., dated August 5, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-36874) filed with the SEC on November 9, 2022).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.23&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1013.htm">License Agreement between Yale University and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated July 5, 2013, as amended by Amendment No. 1, dated May 8, 2014, Amendment No. 2, dated October 23, 2014, and Letter Amendment Number 3, dated April 1, 2015 (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.24&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019009357/arvn-ex1016_955.htm">Amendment No. 4 to License Agreement between Yale University and Arvinas Operations, Inc. (formerly Arvinas, Inc.)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019009357/arvn-ex1016_955.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019009357/arvn-ex1016_955.htm"> dated January 9, 2019 (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 26, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.25&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019028501/arvn-ex107_143.htm">Amendment No. 5 to License Agreement between Yale University and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated June 3, 2019 (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 5, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518262944/d564688dex1014.htm">Amended and Restated Consulting Agreement between Craig Crews and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated October 16, 2015, as amended by Amendment No. 1, dated August 27, 2018 (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018)</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.27&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex1015.htm">Corporate Sponsored Research Agreement between Yale University and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated July 1, 2016, as amended by Amendment No. 1, dated April 1, 2018 (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.28&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1016.htm">Amended and Restated License and Option Agreement among Genentech, Inc., F. Hoffmann-La Roche Ltd and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated November 8, 2017 (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018)</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.29&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1017.htm">Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated December 22, 2017 (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018)</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.30&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000156459020011004/arvn-ex1024_312.htm">Amendment No. 1 to Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated December 9, 2019 (incorporated by reference to Exhibit 10.24 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.31&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm">Amendment No. 2 to Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated January 14, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm">(incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm"> to the Registrant&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm">Quarterly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm"> Report on Form 10-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm">Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm"> (File No. 001-38672) filed with the SEC on M</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm">ay</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm"> 5, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm">).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.32&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvinaspfizzeramendmentno3.htm">Amendment No. 3 to Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc (formerly Arvinas, Inc.), dated December 21, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.33&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019028501/arvn-ex103_145.htm">Collaboration and License Agreement between Arvinas Operations, Inc. and Bayer AG, dated June 3, 2019 (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 5, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.34&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1034arvinasbayeroer.htm">Amended and Restated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1034arvinasbayeroer.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1034arvinasbayeroer.htm">I</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1034arvinasbayeroer.htm">P Contribution Agreement between Arvinas Operations, Inc. and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1034arvinasbayeroer.htm"> Oerth Bio LLC f/k/a</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1034arvinasbayeroer.htm"> P</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1034arvinasbayeroer.htm">rotag LLC</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1034arvinasbayeroer.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1034arvinasbayeroer.htm">effective December 20, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1034arvinasbayeroer.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.35&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521221390/d160222dex101.htm">Collaboration Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521221390/d160222dex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521221390/d160222dex101.htm">by and between Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521221390/d160222dex101.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521221390/d160222dex101.htm">dated July 21, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521221390/d160222dex101.htm"> (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-38672) filed with the SEC on July 22, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.36&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000027/arvinasfmicdxagreementre.htm">Master In Vitro Diagnostics Agreement between Foundation Medicine, Inc. and Arvinas Operations, Inc., dated June 4, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000027/arvinasfmicdxagreementre.htm"> </a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000027/arvinasfmicdxagreementre.htm"> Exhibit 10.</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000027/arvinasfmicdxagreementre.htm">1</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000027/arvinasfmicdxagreementre.htm"> to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000027/arvinasfmicdxagreementre.htm">4</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000027/arvinasfmicdxagreementre.htm">, 20</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000027/arvinasfmicdxagreementre.htm">22</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000027/arvinasfmicdxagreementre.htm">).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.37&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019028501/arvn-ex105_115.htm">Stock Purchase Agreement between the Registrant and Bayer AG, dated June 3, 2019 (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 5, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.38&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019028501/arvn-ex106_114.htm">Investor Agreement between the Registrant and Bayer AG, dated July 16, 2019 (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 5, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312519259952/d811610dex12.htm">Equity Distribution Agreement by and between the Registrant and Piper Jaffray &amp; Co., dated October 1, 2019, (incorporated by reference to Exhibit 1.2 to the Registrant&#8217;s Registration Statement on Form S-3 (File No. 333-234035) filed with the SEC on October 1, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.40&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521221390/d160222dex102.htm">Stock Purchase Agreement, dated July 21, 2021, by and between Arvinas, Inc. and Pfizer, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K (File No. 001-38672) filed with the SEC on July 22, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.41&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521221390/d160222dex103.htm">Investor Agreement, dated July 21, 2021, by and between Arvinas, Inc. and Pfizer, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K (File No. 001-38672) filed with the SEC on July 22, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521239250/d204994dex11.htm">Equity Distribution Agreement, dated August 6, 2021, by and among Arvinas, Inc., Piper Sandler &amp; Co. and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.1 to the Registrant's Current Report on Form 8-K (File No. 001-38672) filed with the SEC on August 6, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvn-20221231x10kxex21_1.htm">Subsidiaries of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="consent-form10kfy22.htm">Consent of Deloitte &amp; Touche LLP, independent registered public accounting firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvn-20221231x10kxex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvn-20221231x10kxex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvn-20221231x10kxex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvn-20221231x10kxex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000156459021009857/arvn-ex991_751.htm">Audited Financial Statements of Oerth Bio, LLC, as of December 31, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div id="ia936ede3f23041239a783a07e7f93c48_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARVINAS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February&#160;23, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David K. Loomis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;David K. Loomis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President and Chief Accounting Officer</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Date</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ John Houston, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;John Houston, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(principal executive officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Sean Cassidy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Sean Cassidy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(principal financial officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ David K. Loomis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vice President and Chief Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David K. Loomis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(principal accounting officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Timothy Shannon, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;Timothy Shannon, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Linda Bain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda Bain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Everett Cunningham</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Everett Cunningham</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Wendy Dixon, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Wendy Dixon, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Edward Kennedy, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;Edward Kennedy, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Briggs Morrison, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;Briggs Morrison, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Leslie Norwalk, Esq.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;Leslie Norwalk, Esq.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Laurie Smaldone Alsup, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laurie Smaldone Alsup, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ John Young</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">John Young</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_115">Report of Independent Registered Public Accounting Firm (PCAOB ID No.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMDkvZnJhZzplNjVmZmUzOWM5M2M0Yjc2ODg0NWQyZTMzMTFkZGU0NC90YWJsZTo5MmNjMTc5YzRjYWI0MTRhYTFhNzI2YThkYWIyOTIzNy90YWJsZXJhbmdlOjkyY2MxNzljNGNhYjQxNGFhMWE3MjZhOGRhYjI5MjM3XzEtMC0xLTEtNDUzMzQvdGV4dHJlZ2lvbjozODJhOTJmNTIyMGI0NWY1YTIxMGUwYzcwZDExNzRiMF83Mw_a19e24c1-2731-41f7-aacc-a31e9b3beb51">34</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_115">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_115">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_118">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022 and 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_118">4</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_121">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2022, 2021 and 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_121">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_124">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2022, 2021 and 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_124">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_127">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2022, 2021 and 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_127">7</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia936ede3f23041239a783a07e7f93c48_130">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia936ede3f23041239a783a07e7f93c48_130">8</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 1</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the Stockholders and the Board of Directors of Arvinas, Inc. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have audited the accompanying consolidated balance sheets of Arvinas, Inc. and subsidiaries (the "Company") as of December&#160;31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash flows, for each of the three years in the period ended December&#160;31, 2022, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021 and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December&#160;31, 2022, based on criteria established in </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Internal Control &#8212; Integrated Framework (2013)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February&#160;23, 2023, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical Audit Matter </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prepaid and Accrued Research and Development - Refer to Note 2 in the Consolidated Financial Statements </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Critical Audit Matter Description</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has entered into various contracts with third parties to perform research and development, including clinical research and contract manufacturing. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company makes estimates of the costs incurred by third parties during the period and the outstanding obligations to those third parties as of period-end. Estimates of costs incurred during the period that are included in period-end prepaid or accrued expense balances are based on a number of factors, including the Company&#8217;s knowledge of the research and development programs and clinical manufacturing activities associated with project status and milestones, invoicing to date, and the provisions in the contract. Significant judgments and estimates are made by the Company in determining the costs incurred during the period that are included in prepaid or accrued expense balances at the end of each reporting period. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We identified the measurement of the accruals and prepaid expense related to these types of research and development costs as a critical audit matter because of the judgments and estimates necessary for management to determine the status and progress of each contract. The expense recorded related to external research and development is based off of estimates as to the services received and efforts expended pursuant </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to quotes and contracts with the Company&#8217;s contract manufacturing vendors and contract research organizations that supply, conduct and manage clinical trials on the Company&#8217;s behalf.  Assessing such estimates required an increased extent of audit effort and a high degree of auditor judgment when performing procedures to audit the prepaid and accrued expenses related to these costs.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">How the Critical Audit Matter Was Addressed in the Audit:</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit procedures related to the management&#8217;s estimation of costs incurred included the following, among others:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Testing the effectiveness of controls over the accounting for prepaid and accrued research and development expenses, including the Company&#8217;s assessment and estimation of the costs incurred for significant research and development activities performed by third parties</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On a sample basis, we tested the accrued and prepaid expense balances by:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">inspecting related contracts and agreeing key provisions of the contracts to the Company&#8217;s analysis of estimated expenses incurred to date;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">inspecting correspondence from the third-party vendors to the Company, including status reports, and comparing such information to the amounts used in the Company&#8217;s estimates;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">meeting with clinical and manufacturing operational personnel within the Company to understand the status of significant research and development activities for a sample of project activities, and comparing such information to the amounts used in the Company&#8217;s estimates;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">comparing the estimated accrual balance as of December 31, 2022, to the invoices received after year-end to evaluate the Company&#8217;s ability to estimate the accrual.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTUvZnJhZzowMGRlZmU4MmNlMTY0MWZkOGE2OWJlNzM3MmE3MmUwYS90ZXh0cmVnaW9uOjAwZGVmZTgyY2UxNjQxZmQ4YTY5YmU3MzcyYTcyZTBhXzk2NTQ_126c3cb9-8a5d-4165-8f98-7a9c8b5fd1dd">Deloitte &amp; Touche LLP</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTUvZnJhZzowMGRlZmU4MmNlMTY0MWZkOGE2OWJlNzM3MmE3MmUwYS90ZXh0cmVnaW9uOjAwZGVmZTgyY2UxNjQxZmQ4YTY5YmU3MzcyYTcyZTBhXzk2NTU_3c3613cc-1728-496b-9790-2800e450091f">Stamford, Connecticut</ix:nonNumeric></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2023</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2016.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 3</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzQtMS0xLTEtNDUzMzQ_7d630db4-0cf1-4f4b-ad96-ed3ba03417a8">81.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzQtMy0xLTEtNDUzMzQ_91e0e4df-0163-4019-adbe-4dbb1a8c0c85">108.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzUtMS0xLTEtNDUzMzQ_5c7b3744-1709-4c5b-9a29-b5b837faa9a0">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzUtMy0xLTEtNDUzMzQ_efcfb5cb-ea26-4417-9023-f0ba1835ef01">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzYtMS0xLTEtNDUzMzQ_10585f4a-12c4-4d1e-8f27-423a26adaac9">1,124.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzYtMy0xLTEtNDUzMzQ_92d79028-cb55-49a2-9fac-16a60d9d6d41">1,394.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzctMS0xLTEtNDUzMzQ_7674b7ed-1456-4c65-9c5d-5dfb16e4b6ce">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzctMy0xLTEtNDUzMzQ_d723fe78-3caa-43f0-9732-da88e422c97a">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzgtMS0xLTEtNDUzMzQ_d2b39128-77b7-41cc-8923-8328024f4aff">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzgtMy0xLTEtNDUzMzQ_0d7a2df0-8cea-4207-b190-a172ca5c1e70">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzktMS0xLTEtNDUzMzQ_12d249f0-7e12-41b5-a4af-37acd0027312">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzktMy0xLTEtNDUzMzQ_671e780c-8b93-45e4-9029-a85ea7dc3c42">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEwLTEtMS0xLTQ1MzM0_c452fcb9-a1c5-47f2-a65c-c68b463df5f8">1,240.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEwLTMtMS0xLTQ1MzM0_4479638b-d4df-4235-843e-59c4775f0b84">1,552.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzExLTEtMS0xLTQ1MzM0_ef879659-d858-49d7-ac91-13c5271726ce">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzExLTMtMS0xLTQ1MzM0_dbae5bb3-6436-46f5-bd81-930b4de99435">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEyLTEtMS0xLTQ1MzM0_c0d6267c-11a7-478a-9c53-a8846f4a0ade">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEyLTMtMS0xLTQ1MzM0_69732df3-7b30-4c32-9329-89263bc17f6f">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Collaboration contract asset and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEzLTEtMS0xLTQ1MzM0_9bed69a2-c8c9-450c-bf72-206e16f3974f">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEzLTMtMS0xLTQ1MzM0_0b52fa6c-8a64-41b2-932b-4a9756a95193">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE0LTEtMS0xLTQ1MzM0_00a102e3-9fe7-49f1-9224-1538ccc4b888">1,268.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE0LTMtMS0xLTQ1MzM0_7aaec7fd-19a0-451a-818a-887af4eed829">1,581.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE3LTEtMS0xLTQ1MzM0_170d2020-47b8-49d4-bf4a-089e78075832">74.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE3LTMtMS0xLTQ1MzM0_d4c7525c-4874-4adc-b4bf-d0dbea49dd45">54.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE5LTEtMS0xLTQ1MzM0_5d66fe7c-47a6-4fc2-a57d-892eccfd266c">218.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE5LTMtMS0xLTQ1MzM0_e75fecc0-a798-42e0-babc-f58bd85eca11">206.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIwLTEtMS0xLTQ1MzM0_982e2938-6d96-403c-a0ba-5e21ba81c255">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIwLTMtMS0xLTQ1MzM0_88182e5b-5060-4805-9024-4f6d85408926">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIxLTEtMS0xLTQ1MzM0_0eb74118-2736-4157-9fbb-12d434d3bdec">295.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIxLTMtMS0xLTQ1MzM0_1b70b382-85d3-474a-a49c-3f180490a39d">261.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIyLTEtMS0xLTQ1MzM0_96d8a2de-f977-4e23-a6d8-e33f9cdfaf75">405.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIyLTMtMS0xLTQ1MzM0_83ca210f-1933-4be5-9830-fdc6d63f608a">534.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIzLTEtMS0xLTQ1MzM0_ee804a72-d939-448f-a498-fc7b35bd748e">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIzLTMtMS0xLTQ1MzM0_b1f93221-b0ad-41c6-a768-3990cdbe1c74">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI0LTEtMS0xLTQ1MzM0_c3899974-2878-41e0-9564-b019d8dbe296">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI0LTMtMS0xLTQ1MzM0_4e99eb0c-eed4-4f9f-a4d7-fcbc52574796">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI2LTEtMS0xLTQ1MzM0_408491ac-2b72-4b6b-8e43-e5518920a2a4">703.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI2LTMtMS0xLTQ1MzM0_2af84360-cc94-4c24-8930-151ba931a934">799.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI3LTEtMS0xLTQ1MzM0_04c58906-f550-4b74-b63d-9e9e65257f7f"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI3LTMtMS0xLTQ1MzM0_59d0e93f-cb66-42ed-890c-950219792799"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMTg_18ddcf86-68c9-4d6f-93d8-2a993901645c"><ix:nonFraction unitRef="usdPerShare" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMTg_6c783322-1ccd-4f3e-af23-07b9d280ada5">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMzI_37f07f9a-70d4-4bf0-b3a3-87484135b89a"><ix:nonFraction unitRef="shares" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMzI_f71d868a-cec6-445a-9578-16d4de938e45">53.2</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMzk_31d73e62-680e-4952-b705-efe6d518efc5"><ix:nonFraction unitRef="shares" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMzk_92114ab0-e6ac-4c19-b707-6a999d55b60a">53.0</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTEtMS0xLTQ1MzM0_228b1ce3-42d1-4b97-865c-0ca28546075b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTMtMS0xLTQ1MzM0_4a4a55cf-4eca-470e-b092-e4891c8bf335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMwLTEtMS0xLTQ1MzM0_d69c8117-f0f2-4edc-96c6-0cd3af3a655c">965.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMwLTMtMS0xLTQ1MzM0_f906eee9-5366-4fd5-9326-264f1bb68714">682.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMxLTEtMS0xLTQ1MzM0_11661960-4da6-4789-8f2e-d5aa353117c8">1,549.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMxLTMtMS0xLTQ1MzM0_6dd6356e-377e-45c0-92b4-0f2f06979c83">1,469.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMyLTEtMS0xLTQ1MzM0_3e2be126-1d67-4d2f-8345-a43c78bcf907">19.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMyLTMtMS0xLTQ1MzM0_5ccec8c0-f755-4f99-a58f-5b51b69878e3">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMzLTEtMS0xLTQ1MzM0_1026699b-dc96-4bdc-a584-13da55626c66">564.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMzLTMtMS0xLTQ1MzM0_cf926d79-5f6f-49c4-835c-869615d4169e">781.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzM0LTEtMS0xLTQ1MzM0_595dbc32-f946-4a0e-be4a-e32e9eb272e7">1,268.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzM0LTMtMS0xLTQ1MzM0_50e89839-7f50-4718-b4f4-66bd1a2afd45">1,581.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 4</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Consolidated Statements of Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzItMS0xLTEtNDUzMzQ_d0405cc0-07aa-43c3-8810-b7a1de8a365c">131.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzItMy0xLTEtNDUzMzQ_27a59a41-3e9c-4eab-afae-c430694b37ce">53.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzItNS0xLTEtNDUzMzQ_f9a1ace6-82c7-4de5-810c-d5eb7311cd95">25.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzQtMS0xLTEtNDUzMzQ_cd3e1da3-022e-4748-a0b2-7ac906e7d18c">315.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzQtMy0xLTEtNDUzMzQ_c027d036-b38e-43c4-bc25-527c736bcbf5">180.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzQtNS0xLTEtNDUzMzQ_f7f47707-c662-436f-8d81-2e0e0a55df1b">108.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzUtMS0xLTEtNDUzMzQ_5cc2bbfe-5249-477d-9f6d-26255ed94aa8">79.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzUtMy0xLTEtNDUzMzQ_6fcaa43d-56c1-4a45-9e5b-ed8503f720ae">61.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzUtNS0xLTEtNDUzMzQ_39990306-7772-47c4-9a1f-11f049c0d8e8">38.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzYtMS0xLTEtNDUzMzQ_3b9079a0-681d-45e0-bbaf-12787a49bbbc">394.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzYtMy0xLTEtNDUzMzQ_8f202e88-356e-456a-a08a-66ea0a2ea9a8">242.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzYtNS0xLTEtNDUzMzQ_801b3f6d-095f-4e38-9f26-42649de442b2">146.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzctMS0xLTEtNDUzMzQ_81206a4a-120f-430f-abc5-db5e0aaec504">263.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzctMy0xLTEtNDUzMzQ_3dcfb84a-265d-433b-a546-c5465acd7f4f">188.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzctNS0xLTEtNDUzMzQ_f4a5fefd-dacd-4063-bade-d324e8839210">120.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzktMS0xLTEtNDUzMzQ_d8d7c3d6-305b-4b61-88bf-736218a4dcd6">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzktMy0xLTEtNDUzMzQ_575457af-c91d-484f-9370-981597b4d3ba">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzktNS0xLTEtNDUzMzQ_9c3d2455-7a73-4151-944c-4ff3d348132e">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzExLTEtMS0xLTQ1MzM0_4ce8f9db-bda2-4c7f-9d90-c7bdb7e373eb">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzExLTMtMS0xLTQ1MzM0_7fff2e59-0ad4-40e6-85b9-d45d668def3e">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzExLTUtMS0xLTQ1MzM0_9064661d-d49b-4a1d-9c5f-a52b3fffb831">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzEzLTEtMS0xLTQ1MzM0_7751f4b2-85fc-4ce4-9449-ac03644efd77">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzEzLTMtMS0xLTQ1MzM0_58dd0523-1baf-4c8b-b7c4-9b3f5e8955bd">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzEzLTUtMS0xLTQ1MzM0_ffb3873e-30e7-4f53-a7c2-feedf6b6b06a">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss before income taxes and loss from equity method investment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE1LTEtMS0xLTQ1MzM0_767b6a89-dbd8-4bc2-885b-1cafe0841e45">251.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE1LTMtMS0xLTQ1MzM0_82f80a0a-34ed-48a9-b14c-160bd6edf1d3">184.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE1LTUtMS0xLTQ1MzM0_fa0dc6b5-f030-4913-a9ea-5de101a68c3c">115.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE2LTEtMS0xLTQ1MzM0_1ac26cb4-281c-41af-bd72-ba11758c04a5">20.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE2LTMtMS0xLTQ1MzM0_28473b9b-1bad-473d-a61c-e7f67f44a36f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE2LTUtMS0xLTQ1MzM0_36dfbb22-190e-4a81-ac80-97dc5cebb38d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTEtMS0xLTU5OTkx_d35c8fc0-052e-4803-b466-fd4b5d7ea055">10.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTMtMS0xLTU5OTkx_0ef31a79-4a0c-4654-ae3a-4e8e45b8f226">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTUtMS0xLTU5OTkx_4a677249-be61-4d21-903d-3627317af8b8">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTEtMS0xLTQ1MzM0_f4edae02-d9c4-4b6f-adc1-baef9e24af3b">282.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTMtMS0xLTQ1MzM0_ea199ab6-2983-4ecf-bc87-e989203e0782">191.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTUtMS0xLTQ1MzM0_b1a1f235-82eb-4793-8672-496ce3abe554">119.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTEtMS0xLTQ1MzM0_c3ddecca-f25c-431f-9a36-b96a59fbd564"><ix:nonFraction unitRef="usdPerShare" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTEtMS0xLTQ1MzM0_ef7dae64-ccac-4817-8592-dd4f206f8054">5.31</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTMtMS0xLTQ1MzM0_30c7ba46-1e7f-4bde-bd5f-718f18b2b76a"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTMtMS0xLTQ1MzM0_65359610-9344-4823-9c02-79da7ecd2e8a">3.82</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTUtMS0xLTQ1MzM0_10f3a8f8-b885-4347-b063-b8c928b18562"><ix:nonFraction unitRef="usdPerShare" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTUtMS0xLTQ1MzM0_7d6ada07-31b0-4e14-a465-8dbb9544d463">3.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTEtMS0xLTQ1MzM0_1b763ebb-02f1-4cfe-813a-cb59a5a69362"><ix:nonFraction unitRef="shares" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTEtMS0xLTQ1MzM0_1c7017bc-0aa2-4c4d-8aeb-3f206265d4b7">53.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTMtMS0xLTQ1MzM0_8a2f453f-1e4d-4951-99aa-bff5e0fe3b17"><ix:nonFraction unitRef="shares" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTMtMS0xLTQ1MzM0_e68f69d5-d3e6-46b4-baf6-7869500b88c1">50.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTUtMS0xLTQ1MzM0_0b1b4bf1-eaf3-4b52-87af-718db97964fc"><ix:nonFraction unitRef="shares" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTUtMS0xLTQ1MzM0_d0df61f3-4182-4446-a38d-c9204ea757e8">39.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Consolidated Statements of Comprehensive Loss</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzItMS0xLTEtNDUzMzQ_f4edae02-d9c4-4b6f-adc1-baef9e24af3b">282.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzItMy0xLTEtNDUzMzQ_4320c9a9-107b-4efb-a453-b082b7b848cc">191.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzItNS0xLTEtNDUzMzQ_b13ed757-aac5-434b-99e3-463b4b6cb6bb">119.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized (loss) gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzQtMS0xLTEtNDUzMzQ_fc04699e-d656-43fa-ae44-2cc6bf3a76c0">14.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzQtMy0xLTEtNDUzMzQ_1179620d-17cb-40f6-9897-e2852e4d5ffd">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzQtNS0xLTEtNDUzMzQ_182bfea1-1a96-48ca-97c5-5ca9f64e8004">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzUtMS0xLTEtNDUzMzQ_bd63c642-de19-499c-9fc9-5e894e400231">297.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzUtMy0xLTEtNDUzMzQ_bbc1e1f5-c48e-493c-8649-062cf528f3bb">196.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzUtNS0xLTEtNDUzMzQ_5dc3ee13-28a5-4ab5-8274-69dbd558153f">118.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 5</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC AND SUBSIDIARIES</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders&#8217; Equity </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.796%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Common</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated Deficit </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Additional<br/>Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated <br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i62b9074c6dbb4f3fbdbff41dce34d514_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktMS0xLTEtNDUzMzQ_18c82c5b-16aa-4ed4-81f6-bbe2d522c4ba">38.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i62b9074c6dbb4f3fbdbff41dce34d514_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktMy0xLTEtNDUzMzQ_82f4a1d7-b80b-43d6-aa48-1787ead37789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i00f51f7f7a9845899d4dd0c5fc38d3c8_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktNS0xLTEtNDUzMzQ_35f9f3a9-1aa7-42f7-a432-695de65df1b7">372.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5126550f14e04feb9ca9ca6b7e02ed04_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktNy0xLTEtNDUzMzQ_b3377c13-6fbb-4725-ade8-01c123d3a284">599.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib59969a5f0034e8e9c7010fd7f0be379_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktOS0xLTEtNDUzMzQ_c4887f5a-99bf-4910-bfec-8177d489b053">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i35327f5dcba84428bcd65e20009ba82d_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktMTEtMS0xLTQ1MzM0_4266bff4-17fe-4492-b259-9380e5b8ae4d">226.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuances of common stock, net of underwriters' discounts and issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEwLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MTNlZmQzZWI1NjA3NDk1NThjOWE5NDRkZjNjNTc1YjdfMTY0OTI2NzQ0MTc1Ng_3b54a662-3c7e-4f46-b93a-44d66b9d9cde">28.1</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id6be069e34bc4e4dab6470f86f377631_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEwLTEtMS0xLTQ1MzM0_eb297cf9-ba04-4ecb-aede-b347ed841121">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2da99b1272604c40b299c7e2a492b717_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEwLTctMS0xLTQ1MzM0_d3b295f8-951c-4786-b627-52ffeb32503b">431.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEwLTExLTEtMS00NTMzNA_3af37ad2-4766-429c-bfd4-7a785dd0d412">431.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2da99b1272604c40b299c7e2a492b717_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzExLTctMS0xLTQ1MzM0_6aa049da-d176-45c8-94cc-11271f58e879">30.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzExLTExLTEtMS00NTMzNA_6e098030-a801-4f2a-882f-60bce2be5937">30.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iff0703d3445f4aebac374d380138baf6_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEyLTUtMS0xLTQ1MzM0_8a886243-2bac-4a31-ac77-cea97c6dff08">119.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEyLTExLTEtMS00NTMzNA_1ecebc59-7eda-4a57-8cfb-d618e664d198">119.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Restricted stock vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id6be069e34bc4e4dab6470f86f377631_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEzLTEtMS0xLTQ1MzM0_2edcfc61-d2df-40a9-a28a-d77cfe64dd3d">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id6be069e34bc4e4dab6470f86f377631_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE0LTEtMS0xLTQ1MzM0_f9b068ef-83f0-4d0a-a13e-27b764816d3c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2da99b1272604c40b299c7e2a492b717_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE0LTctMS0xLTQ1MzM0_946bc83a-4b1c-4f66-9ccb-57dd211c3cc1">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE0LTExLTEtMS00NTMzNA_791d4f7a-9d33-4455-b9d0-b98c893d6c8d">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Common stock issued in at-the- market offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="i0a5a6b31a7ca4b5e825ff2a8e5104399_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE1LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MjQ4OWExZDgxNDZlNDNmN2I3Y2IxMjM2OThlZDAxZGJfMTY0OTI2NzQ0MTc0NQ_9b03368f-2073-4371-ab5d-91082a0c1bad">1.6</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i58e74e4ca00a46a298dd26d104628c71_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE1LTEtMS0xLTQ1MzM0_abe69aa4-b85f-428c-b788-d68ca4357028">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ifb59a32694da4a52a057a3d5d4602acb_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE1LTctMS0xLTQ1MzM0_60b2de46-517e-4164-bc5f-ed8773d82790">64.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0a5a6b31a7ca4b5e825ff2a8e5104399_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE1LTExLTEtMS00NTMzNA_1d5e7bc2-6478-4376-9f28-2b9a680b629e">64.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unrealized gain on available-for-sale securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie9803bb2bac440b9a73f90689f2b195a_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE2LTktMS0xLTQ1MzM0_f9a75ec3-105c-4699-bb96-5f52cc1266d0">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE2LTExLTEtMS00NTMzNA_306f8a31-47de-4a46-a4b0-e634c4dd2d4f">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i2c3f132181ab4f2782eda83c630d9771_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTEtMS0xLTQ1MzM0_7179a22d-8bbd-4506-8190-df1b15ffcaab">48.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2c3f132181ab4f2782eda83c630d9771_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTMtMS0xLTQ1MzM0_91cb7518-0f30-4af9-a117-2b696a0d9fb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i4d68e78d78a7421fa07de080fcab1007_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTUtMS0xLTQ1MzM0_388dda17-c7d0-44c7-81b7-641c18d8c089">491.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i82f79a4ab8ad48ac808ede7cafff07d1_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTctMS0xLTQ1MzM0_85e0a7e3-1d51-459d-9768-cfb3c96fcbad">1,133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic150bcdd10a44a698d262678b95dc444_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTktMS0xLTQ1MzM0_b7b5f695-ddef-47e0-82be-83e519968a6b">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTExLTEtMS00NTMzNA_11b70b55-cd78-4036-b4bb-40aad42d486d">642.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5ae1926583c8447eb7a2bf92b4691763_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE4LTctMS0xLTQ1MzM0_69669f4f-14ba-4c3d-947f-b728b794eb5d">57.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE4LTExLTEtMS00NTMzNA_552cf142-29a3-45f3-b09f-0dbb7e56ac3b">57.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i189cf08cd0b147de9ee24b6f4241c087_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE5LTUtMS0xLTQ1MzM0_f32fa8f3-e7a7-4be2-8181-d3d590796288">191.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE5LTExLTEtMS00NTMzNA_cbad353f-289e-44ca-985f-194581d609de">191.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Restricted stock vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i7c56b6a959914b1fa1a46f86145ab11e_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIwLTEtMS0xLTQ1MzM0_c5a4dd73-be8f-4bbe-9dae-09fc3d6f4820">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i7c56b6a959914b1fa1a46f86145ab11e_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTEtMS0xLTQ1MzM0_f337cb5f-6158-47a7-b58d-0fa64b01e2c8">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5ae1926583c8447eb7a2bf92b4691763_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTctMS0xLTQ1MzM0_a8c9803a-dc52-462f-8457-b982097c902b">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTExLTEtMS00NTMzNA_63dc6636-e882-4d59-81fd-d75d658aff58">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Common stock issued, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIyLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MjdhZWNjOGJkMDk4NDAzZWJkMGEwY2FjZmI1NWI5OGNfMTY0OTI2NzQ0MTcxOA_9bd5dfd9-d3a0-4296-ab40-916e529d522f">4.6</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i7c56b6a959914b1fa1a46f86145ab11e_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIyLTEtMS0xLTQ1MzM0_d6525b4a-b6bc-4437-9b29-f4a94ad24929">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5ae1926583c8447eb7a2bf92b4691763_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIyLTctMS0xLTQ1MzM0_3500a271-36fd-40a6-a6b6-fd4797814aed">259.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIyLTExLTEtMS00NTMzNA_6343187a-da76-4519-b8c1-12ebcace7d9b">259.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unrealized loss on available-for-sale securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i3a8a21d9b2d1414aaf530880ae2aa161_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIzLTktMS0xLTQ1MzM0_7382e925-8cc7-445a-b070-93aafb2aa41a">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIzLTExLTEtMS00NTMzNA_0e497622-14e2-44f4-9938-159d309fed6c">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i5e9275d362a24c8a9d71ee61e0d22587_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTEtMS0xLTQ1MzM0_1c4c21b7-5aea-4346-be5b-3aed6b0a5dc7">53.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5e9275d362a24c8a9d71ee61e0d22587_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTMtMS0xLTQ1MzM0_d8fa987c-23bb-4c0a-b3d8-43a1cb49db74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i20400f57ea38437d8f5a5a76227f5779_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTUtMS0xLTQ1MzM0_c547ef64-213b-40fa-be2d-8cf360d42117">682.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i332f5a83e3e04dc99cf119f9afdf4c9a_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTctMS0xLTQ1MzM0_a5a9267b-54bb-42ed-9189-7d72ef595989">1,469.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i515d8e18c44c4d4eb75265ed7439e978_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTktMS0xLTQ1MzM0_8a9846b2-2895-4aa4-944c-b844298d2a3d">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTExLTEtMS00NTMzNA_a36ef835-9649-4ad1-b1c8-906c80b0e671">781.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i36d0618dabaa4dde950863143d4eba01_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE4LTctMS0xLTQ2NzUy_00ffe07a-c1fa-4d74-a1c2-5b29f10b7429">75.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE4LTExLTEtMS00Njc1Mg_5ba8ecc4-1335-4737-85f9-661071ac07e1">75.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id43fad10517549efbe1041cf1a7ac9c6_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE5LTUtMS0xLTQ2NzUy_c96741c2-5ed6-4c10-8fda-84dad8584f00">282.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE5LTExLTEtMS00Njc1Mg_1798a75f-f11f-4fbf-88c9-dff831c25c99">282.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i3328081fbb1245bea8d77942437e9fda_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTEtMS0xLTQ2NzQ0_6dacf8a4-fbac-4333-bd39-878687602ecf">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3328081fbb1245bea8d77942437e9fda_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTMtMS0xLTQ2NzQ0_02f09ff0-3bdf-4755-88a1-8cb0755cb026">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i36d0618dabaa4dde950863143d4eba01_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTctMS0xLTQ2NzUy_b8efbb94-ea0f-44af-839a-8aa0f3626df8">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTExLTEtMS00Njc1Mg_9be8212c-7694-4136-baae-de11ed6c1caf">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unrealized loss on available-for-sale securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic1c26cc298914577ad3d74291efe85aa_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIzLTktMS0xLTQ2NzUy_7ea6a979-6913-446c-a33c-0525110a25d8">14.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIzLTExLTEtMS00Njc1Mg_37606047-0ea6-4103-8567-0e1df77dda30">14.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i49058d6c0fee45bc82e5a3b3d793c61b_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTEtMS0xLTUwNDE0_97f05a2b-cb7e-4570-b051-ef18ae4da903">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i49058d6c0fee45bc82e5a3b3d793c61b_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTMtMS0xLTUwNDE0_c4c5e69b-4207-4ed8-9b4b-192d0751e31d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="idec633905ec142408e34afcd540d6467_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTUtMS0xLTUwNDE0_0081c87b-b5bc-4047-be59-87b52964754c">965.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="idbedba621b114c17bd11d5578ed1e6c5_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTctMS0xLTUwNDE0_56df5bac-379c-4a1c-a6df-5a210db508bf">1,549.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9c91e2ef842a460da45c1b6475a741ca_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTktMS0xLTUwNDE0_d03da82f-d436-423a-ab7e-b9d291c8500d">19.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTExLTEtMS01MDQxNA_e76faf5c-d748-45b2-b281-94d28fbcb887">564.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 6</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="background-color:#ffffff;color:#2e2e2e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="background-color:#ffffff;color:#2e2e2e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. AND SUBSIDIARIES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMtMS0xLTEtNDUzMzQ_f4edae02-d9c4-4b6f-adc1-baef9e24af3b">282.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMtMy0xLTEtNDUzMzQ_1699a791-4dc5-41d5-93b1-5f3891430fa1">191.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMtNS0xLTEtNDUzMzQ_d040fc6c-fb59-4e64-a5f4-2678888c9720">119.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzctMS0xLTEtNDUzMzQ_5ee1f321-966e-4b4c-8bae-aa66a335577a">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzctMy0xLTEtNDUzMzQ_a58d3356-8cb9-44d6-b031-7d02ea5ce159">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzctNS0xLTEtNDUzMzQ_1ba28c20-02b1-4075-a318-fe9cd2a40070">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net accretion of bond discounts/premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzgtMS0xLTEtNDUzMzQ_2bc25cbf-52b3-4fda-80fb-afcad42c0a97">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzgtMy0xLTEtNDUzMzQ_e7275afc-9b36-473e-a680-fe335870169d">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzgtNS0xLTEtNDUzMzQ_b0530c34-031b-4aff-89ed-3c401eb5a815">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Forgiveness of debt income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="arvn:DebtInstrumentLoanForgiveness" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzktMS0xLTEtNDUzMzQ_6e939b72-70d3-4e8b-9223-61d08ea2f3d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="arvn:DebtInstrumentLoanForgiveness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzktMy0xLTEtNDUzMzQ_b6204d81-ad6a-435e-abae-316ca1865bbb">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="arvn:DebtInstrumentLoanForgiveness" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzktNS0xLTEtNDUzMzQ_fd96c6e9-663c-4cee-88f5-9ab1ac5aac52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Loss (gain) on sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEwLTEtMS0xLTQ1MzM0_f67c9c8a-c8c0-4361-8f61-df45589a7947">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEwLTMtMS0xLTQ1MzM0_4febaec1-4332-4547-9649-32e04d6102e1">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEwLTUtMS0xLTQ1MzM0_550b6fe9-2c84-43ac-8285-eb541a7c7a13">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzExLTEtMS0xLTQ1MzM0_5cc02937-4c41-4380-869c-f3d2da4e262b">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzExLTMtMS0xLTQ1MzM0_5a7b1734-1123-4a0f-80c6-b05983ba0523">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzExLTUtMS0xLTQ1MzM0_cf8228f8-71da-4105-8668-96b847f115e5">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Amortization of collaboration contract asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEyLTEtMS0xLTQ1MzM0_10af3333-02ef-4a7b-9614-e8616de5472c">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEyLTMtMS0xLTQ1MzM0_23e95f18-f797-4b82-ba5d-cd5dbcb8abc7">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEyLTUtMS0xLTQ1MzM0_cd6f4550-ac16-4472-86e4-80aabf1d50f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEzLTEtMS0xLTQ1MzM0_c86a0506-746c-44e6-82c1-f225be0cc735">75.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEzLTMtMS0xLTQ1MzM0_2c0bc726-2530-4baa-8742-a4a74ab803da">57.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEzLTUtMS0xLTQ1MzM0_8e24c7d5-70b6-4bb7-bb77-a0ab9d7c5cae">30.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE3LTEtMS0xLTQ1MzM0_c3f0c585-7397-4290-a33b-46064cad966d">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE3LTMtMS0xLTQ1MzM0_9d1264de-3e9d-4bbc-a081-e456d89f37f2">14.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE3LTUtMS0xLTQ1MzM0_b1ed8c65-e79d-4d5c-9f1c-5598b93dfb02">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE4LTEtMS0xLTQ1MzM0_eceb95bb-7339-4082-a0f0-2343d17824ab">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE4LTMtMS0xLTQ1MzM0_a14af4ab-42ba-4dab-a393-5b87571ed1de">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE4LTUtMS0xLTQ1MzM0_a2821e10-f1d7-4935-b951-3304f09fb20a">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE5LTEtMS0xLTQ1MzM0_667aa357-8f06-49c1-b5da-c80a1210bf64">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE5LTMtMS0xLTQ1MzM0_fd329bd9-de3e-4f00-9161-f0b7ad1da17f">13.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE5LTUtMS0xLTQ1MzM0_4715e2cf-0830-46de-bd0d-3afcb79e429a">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Collaboration contract asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIwLTEtMS0xLTQ1MzM0_2af7841a-1940-4dac-9a91-c848a0ad0916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIwLTMtMS0xLTQ1MzM0_d18725c1-f3ed-4ee1-80ce-20e95ada24e7">12.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIwLTUtMS0xLTQ1MzM0_07a623c8-ed7e-4fbe-923e-7aeefd7cd3b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIxLTEtMS0xLTQ1MzM0_de4b521b-2817-4fbc-9bb9-cd28fff21959">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIxLTMtMS0xLTQ1MzM0_da9199cb-f9c0-4320-8b06-d8ac09f27076">27.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIxLTUtMS0xLTQ1MzM0_3c4b1779-96d6-4684-83d1-903dc50c465b">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="arvn:IncreaseDecreaseInOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIzLTEtMS0xLTQ1MzM0_58d9a003-5828-4692-94ec-eadf34f8a0c0">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="arvn:IncreaseDecreaseInOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIzLTMtMS0xLTQ1MzM0_8dc0e5ff-da14-4cbf-be7b-fa4a9f5946a9">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="arvn:IncreaseDecreaseInOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIzLTUtMS0xLTQ1MzM0_72b7e21e-3883-49c8-8292-072e803f0b53">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI0LTEtMS0xLTQ1MzM0_3aebddc1-ad4a-40e8-b723-bbd1618dfe12">116.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI0LTMtMS0xLTQ1MzM0_8a5b1a53-e378-4590-a378-4d54ea0558fb">695.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI0LTUtMS0xLTQ1MzM0_fc10bca3-a45c-4e90-a05b-659ba78431ff">13.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI1LTEtMS0xLTQ1MzM0_99288040-b475-4ace-b694-f1e3f13e771f">273.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI1LTMtMS0xLTQ1MzM0_05f629a6-40b3-404d-861d-d207fd8aef8a">559.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI1LTUtMS0xLTQ1MzM0_71c42d6b-5777-4240-99ef-bf56b3bc6d54">89.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI3LTEtMS0xLTQ1MzM0_5378c39e-49b0-4382-a2fe-017fea4c6128">886.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI3LTMtMS0xLTQ1MzM0_738db541-45e7-4644-beb3-7ceaae96612b">1,744.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI3LTUtMS0xLTQ1MzM0_4e38b4b0-bb41-47c9-9ac9-0691ad67be4f">41.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI4LTEtMS0xLTQ1MzM0_cf1cd835-5758-4df5-8c72-904da749689d">1,076.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI4LTMtMS0xLTQ1MzM0_c7de9af1-485a-4fc0-895e-02720e4b45f8">428.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI4LTUtMS0xLTQ1MzM0_c3bda442-3334-4989-b92c-4933e67e748e">174.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="arvn:ProceedsFromSaleOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI5LTEtMS0xLTQ1MzM0_0e123029-11d6-4f3e-a0ea-6d259b5ed8c2">59.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="arvn:ProceedsFromSaleOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI5LTMtMS0xLTQ1MzM0_12eb7009-0250-4801-9400-859173be374e">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="arvn:ProceedsFromSaleOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI5LTUtMS0xLTQ1MzM0_9b9cbb66-9142-4675-979a-33c8fc583228">37.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Purchase of property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMwLTEtMS0xLTQ1MzM0_f1bb0f3c-1391-4819-8749-51c079da0897">6.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMwLTMtMS0xLTQ1MzM0_0eb7cada-2375-42f1-b963-e7bdc924b242">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMwLTUtMS0xLTQ1MzM0_27394e63-d171-4aa3-afcc-4d8aade3cb08">6.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMxLTEtMS0xLTQ1MzM0_96da0a27-9444-4bee-b3a2-e0912a02ee91">242.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMxLTMtMS0xLTQ1MzM0_44949d3a-d7c2-46d6-aff1-cceab791116d">1,313.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMxLTUtMS0xLTQ1MzM0_c77e0ae8-f37a-4c5c-b831-4cfd20118f0d">164.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM1LTEtMS0xLTQ1MzM0_1fdd5953-66da-49dd-ac84-f6a58e5f5582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM1LTMtMS0xLTQ1MzM0_fa02bcc7-f4ae-415e-8e7b-4af9b22ae2b6">264.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM1LTUtMS0xLTQ1MzM0_7f25dbb8-5ff3-4040-a2ef-cc1254ad6d83">460.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Payment of common stock offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM2LTEtMS0xLTQ1MzM0_7edda06c-7088-4df7-ad66-754be3033e11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM2LTMtMS0xLTQ1MzM0_dafa4932-1725-498c-bf78-7884952a11ff">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM2LTUtMS0xLTQ1MzM0_dd9c23de-c05c-434b-81bc-508ae5f3acb7">27.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds from sale of common stock in at-the-market offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i49ca8da516e7499682d587c74985691c_D20220101-20221231" decimals="-5" name="arvn:ProceedsFromIssuanceOfCommonStockGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM3LTEtMS0xLTQ1MzM0_997b5f24-e328-46ac-af5c-633da37c2778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i765b24d88e5044b0b3474cc202e4c269_D20210101-20211231" decimals="-5" name="arvn:ProceedsFromIssuanceOfCommonStockGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM3LTMtMS0xLTQ1MzM0_0bfa1fe0-1bef-485a-9459-d9f2e1ee210e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0a5a6b31a7ca4b5e825ff2a8e5104399_D20200101-20201231" decimals="-5" name="arvn:ProceedsFromIssuanceOfCommonStockGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM3LTUtMS0xLTQ1MzM0_62dde33d-847a-4650-8bfd-c8dd467724de">65.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Payment of common stock offering costs for at-the-market offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i49ca8da516e7499682d587c74985691c_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM4LTEtMS0xLTQ1MzM0_88e59a95-5de4-4075-ab39-fda06ebe6911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i765b24d88e5044b0b3474cc202e4c269_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM4LTMtMS0xLTQ1MzM0_e4f651a0-b325-4d15-b11e-68fbb77d9de2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0a5a6b31a7ca4b5e825ff2a8e5104399_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM4LTUtMS0xLTQ1MzM0_340472e6-033e-4acc-a9f1-8844334377f6">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM5LTEtMS0xLTQ1MzM0_dcd38552-e125-494a-9199-876a930ea5c6">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM5LTMtMS0xLTQ1MzM0_4079c156-378a-43a4-b226-bd21fda52a08">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM5LTUtMS0xLTQ1MzM0_02759320-fac3-462e-a947-fa83041490b2">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQyLTEtMS0xLTQ1MzM0_09245a8c-6806-4eea-b556-25e6dbf80929">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQyLTMtMS0xLTQ1MzM0_c4ce39de-e200-442b-9d9d-68aabfb99de9">278.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQyLTUtMS0xLTQ1MzM0_ac21b24c-cc2c-4caa-93aa-02573b5c2c7d">504.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQzLTEtMS0xLTQ1MzM0_77cb38fe-76ab-45b0-b0ea-9e16f7f21c15">26.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQzLTMtMS0xLTQ1MzM0_8ade6a0a-5c32-4dbe-98e1-915cfce4db2e">475.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQzLTUtMS0xLTQ1MzM0_7427119a-0696-4f39-805d-35d48fa334f3">579.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ0LTEtMS0xLTQ1MzM0_9ad3843d-d048-491b-88b4-edadc8fc0426">112.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ0LTMtMS0xLTQ1MzM0_56d5c293-d918-432f-b1e7-3b1a12417302">588.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i35327f5dcba84428bcd65e20009ba82d_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ0LTUtMS0xLTQ1MzM0_c27401a8-1152-4529-bda8-f612b1b9daa1">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, end of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ1LTEtMS0xLTQ1MzM0_db33a401-59ff-4763-b466-cbee6ca26c78">86.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ1LTMtMS0xLTQ1MzM0_db5a9b33-6229-4d8a-992b-163a057828cd">112.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ1LTUtMS0xLTQ1MzM0_cf67020f-493e-49d0-a5e6-575872be1fbf">588.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Purchases of property, equipment and leasehold improvements unpaid at period end</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ3LTEtMS0xLTQ1MzM0_5458fed0-3723-4217-a952-83527ccddadc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ3LTMtMS0xLTQ1MzM0_c9f0f6c3-35ff-4c48-a7f5-4674d66f4101">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ3LTUtMS0xLTQ1MzM0_5f0d31af-fb22-4e03-bc2d-2360dd745f71">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTEtMS0xLTQ1MzM0_19de77b2-c929-4199-8cb2-e62405f231bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTMtMS0xLTQ1MzM0_b7362366-90ed-4a8e-a971-862616100190">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTUtMS0xLTQ1MzM0_f7d1abde-e51d-49dd-81e0-6d20986a6d4d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash paid for taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTEtMS0xLTQ2MzI4_6b3bfbdb-8240-4292-b4c9-efa803e397c0">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTMtMS0xLTQ2MzI4_b6876f7c-e6ab-46e1-afac-d46bdb5e0495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTUtMS0xLTQ2MzI4_5e8b1156-a247-49b0-ac7c-22c0ba315b25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 7</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="background-color:#ffffff;color:#2e2e2e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="background-color:#ffffff;color:#2e2e2e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. AND SUBSIDIARIES </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div id="ia936ede3f23041239a783a07e7f93c48_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzMvZnJhZzoyMGVmZGQxOGQwYTY0Nzg0Yjg1MTA2ZDQ5ZTdmYWQzMy90ZXh0cmVnaW9uOjIwZWZkZDE4ZDBhNjQ3ODRiODUxMDZkNDllN2ZhZDMzXzMxMDc_d2d3837b-ba0d-4cd9-91d5-5b0faaa0c694" continuedAt="i5145205d7907433aa32fca663f5f1667" escape="true">Nature of Business and Basis of Presentation </ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5145205d7907433aa32fca663f5f1667" continuedAt="if34e8f8759264d2fbc77edba04e58908"> </ix:continuation></span></div><ix:continuation id="if34e8f8759264d2fbc77edba04e58908"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases throughout the discovery, development and commercialization of therapies that degrade disease-causing proteins. Arvinas, Inc. has <ix:nonFraction unitRef="subsidiary" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="INF" name="arvn:NumberOfWhollyOwnedSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzMvZnJhZzoyMGVmZGQxOGQwYTY0Nzg0Yjg1MTA2ZDQ5ZTdmYWQzMy90ZXh0cmVnaW9uOjIwZWZkZDE4ZDBhNjQ3ODRiODUxMDZkNDllN2ZhZDMzXzM2NQ_0cdbe1ad-6694-4a67-8204-64b09cffc34d">four</ix:nonFraction> wholly owned subsidiaries; Arvinas Operations, Inc. formed in 2013, Arvinas Androgen Receptor, Inc. formed in 2015, Arvinas Estrogen Receptor, Inc. formed in 2016, and Arvinas Winchester, Inc. formed in 2018 (collectively, "Arvinas" or the "Company").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated upon consolidation. The accounting policies used to prepare the Company's consolidated financial statements are the same as those used to prepare the consolidated financial statements in prior years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior period financial information in order to conform with current period presentation. Accounts payable and Accrued expenses have been condensed into Accounts payable and accrued liabilities, Interest income and Interest expense have been condensed into Interest income, net and in Note 11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, within the reconciliation of U.S. federal statutory income tax rate table, a portion of the stock compensation rate effect was reclassified to return to provision.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified and recorded an adjustment to prior periods related to the accounting for its investment in Oerth Bio. See Note 10,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity Method Investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further details.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the Company&#8217;s revenue recognition, uncertain tax positions and research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other biotechnology companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of equity interests, proceeds from collaborations, grant funding and debt financing. The Company had cash, cash equivalents, restricted cash and marketable securities of approximately $<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-8" name="arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzMvZnJhZzoyMGVmZGQxOGQwYTY0Nzg0Yjg1MTA2ZDQ5ZTdmYWQzMy90ZXh0cmVnaW9uOjIwZWZkZDE4ZDBhNjQ3ODRiODUxMDZkNDllN2ZhZDMzXzMwOTY_0a445600-5872-4810-8f42-a2ea5d082a5f">1.2</ix:nonFraction> billion as of December&#160;31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 8</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzI3_3aea5069-53cf-48a3-9d82-dfdded15df8b" continuedAt="ic80474ce717844c68182251e16b3b249" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic80474ce717844c68182251e16b3b249" continuedAt="ie8a8781febbb4414bec1757dbff89dfa"> </ix:continuation></span></div><ix:continuation id="ie8a8781febbb4414bec1757dbff89dfa" continuedAt="i2046319ac7db44c1ba6214c5d0a8ebdd"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE1_8ed964e9-f334-41b6-b423-5f4673075352" continuedAt="i5251d411164944d19986c859d756f917" escape="true">Cash and Cash Equivalents </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5251d411164944d19986c859d756f917">The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents and are considered Level 1 financial instruments.</ix:continuation> </span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE2_ab4ac742-50d3-4ee2-b4a3-aa09afe44e11" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease entered into in May 2021 and amended in August 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI3NDg3NzkwOTUxMzA_28f9ba78-7a84-46ff-846e-d94f26ad00d8" escape="true"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI3NDg3NzkwOTUxMzA_96d93159-0d1f-4338-bbdd-4630f4798dc4" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzItMS0xLTEtNTk1MzI_7d630db4-0cf1-4f4b-ad96-ed3ba03417a8">81.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzItMy0xLTEtNTk1MzI_91e0e4df-0163-4019-adbe-4dbb1a8c0c85">108.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzItNS0xLTEtNTk1MzI_ca2a5900-11e4-454f-9331-de715c0d5d57">588.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzMtMS0xLTEtNTk1MzI_5c7b3744-1709-4c5b-9a29-b5b837faa9a0">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzMtMy0xLTEtNTk1MzI_efcfb5cb-ea26-4417-9023-f0ba1835ef01">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" xsi:nil="true" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzMtNS0xLTEtNTk2MDI_b0c19611-9520-4385-bf12-417d9aa736ad"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzQtMS0xLTEtNTk1MzI_0d803d43-e319-455f-be93-a150b44ae38b">86.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzQtMy0xLTEtNTk1MzI_f73329a0-1b81-4dfb-9685-c18c350ef145">112.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzQtNS0xLTEtNTk1MzI_6a1c1043-8f1f-4294-8e52-a681003d1834">588.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzI4_1f4a17e6-2fdd-4199-bc33-df19f4af8e47" continuedAt="i8ffb9aedf3054281a3afe48d2cdde185" escape="true">Concentration of Credit Risk </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8ffb9aedf3054281a3afe48d2cdde185">The Company maintains its cash in financial institution accounts that may at times exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $<ix:nonFraction unitRef="usd" contextRef="i8f3407ea1c884292b6b1262e24808e77_D20220101-20221231" decimals="-3" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzkzNA_ece569a1-8550-46ef-ad02-3cb526de0e84">250,000</ix:nonFraction>. Cash may also be maintained at commercial institutions that are not insured by the FDIC.</ix:continuation> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and 2021, one collaborator represented <ix:nonFraction unitRef="number" contextRef="i05529346f2bd43978586c86e2c968da8_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzExNDA_262e9aef-f1b8-4acf-b0de-865db3927b55">88</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2cf9012e2f3e483fb7f5830d388d4178_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzMDQ3OQ_1e2c84b0-91d1-4d52-8526-2c5e3e2c0d19">68</ix:nonFraction>% of the Company's revenue, respectively, and for the year ended December&#160;31, 2020, three collaborators represented   <ix:nonFraction unitRef="number" contextRef="i6c1ef30395c542ec9b2036e573ee37fb_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzMDQ1Ng_e1652582-1033-4b41-9c29-3c1b201849c6">37</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i93dabaf08df04303b0314c7df4d8e165_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzMDQ2Mg_925e0a94-c58a-4960-98e2-9d9848bc080a">32</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i43bf74e98bde44c59baa52f0d2d487fe_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzMDQ1Mw_8394ab9f-1106-4524-93ad-102779bcaf99">31</ix:nonFraction>% of the Company's revenue. For each of the years ended December&#160;31, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, one </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborator accounted for the entire accounts receivable balance.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE0_35ff9273-5bf9-467c-a9f4-963afff41aef" continuedAt="i4bdc8ab789ed4cc6bbed29989d86ba8f" escape="true">Marketable Securities </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4bdc8ab789ed4cc6bbed29989d86ba8f">The Company's marketable securities are classified as available-for-sale securities and are carried at their fair value based on the quoted market prices of the securities, with unrealized gains and losses reported as accumulated other comprehensive income (loss), a separate component of stockholders' equity. Realized gains and losses on available-for-sale securities are included in other income in the period earned or incurred.</ix:continuation> </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzIx_fa7e37c3-0870-4426-8221-7e4abf8e19eb" continuedAt="i8bed3c9f697248c093a3f5592cb1b2ec" escape="true">Property, Equipment, and Leasehold Improvements </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8bed3c9f697248c093a3f5592cb1b2ec">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from <ix:nonNumeric contextRef="id3f476fc73a34c9e810fa5b3bfabf520_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzIxMjA_8b16caad-53bb-4683-b75e-6ac07c6346d8">three years</ix:nonNumeric> for office equipment to <ix:nonNumeric contextRef="id8bb00294943430a85af5e662821b3fc_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzIxNDc_12694f5d-3e33-4592-a0a0-21dbae363519">five years</ix:nonNumeric> for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation is removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2046319ac7db44c1ba6214c5d0a8ebdd" continuedAt="i62ffea71f8084035a5a64bada437117e"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzEy_6c6fba3b-2880-405e-aa0b-bda6580b219c" continuedAt="i1ae02860380c47dda4dc63fd5ac0c84c" escape="true">Impairment of Long-Lived Assets </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ae02860380c47dda4dc63fd5ac0c84c">The Company evaluates the carrying value of long-lived assets when indications of potential impairments are present. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than the carrying value.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI5NTI_12793652-4314-4f7b-a536-f9561b4e3359"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI5NTI_7068ddfa-5383-4d41-89a1-afeb6c19244e"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI5NTI_c607be03-7599-4428-878c-d73769877ccc">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> such impairments were recorded during 2022, 2021 or 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzIy_7ece1e0c-8a37-4dcb-991f-ef5ad7ea7d55" continuedAt="ie51a2ce1a7f546afb37ea6355b075efc" escape="true">Segment Information </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie51a2ce1a7f546afb37ea6355b075efc">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in assessing performance and allocating resources. The Company, through its Chief Executive Officer in his role as chief operating decision maker, views Company operations and manages the business as <ix:nonFraction unitRef="operating_segment" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzMzOTg_97b7671a-bc76-4abb-b2b5-1d3d8fe12c9a">one</ix:nonFraction> operating segment. All of the Company&#8217;s tangible assets are held in the United States and all of the Company&#8217;s revenue has been generated in the United States.</ix:continuation> </span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzIz_aa2c2cbb-3c96-4684-ab29-cc1743c32914" continuedAt="ifede06a588d84993a92ab63fb11a251b" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition and Deferred Revenue </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues from Contracts </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, the Company evaluates whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent combined single performance obligations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company determined that the most likely amount to be recognized was zero, against which no constraint was applied. The Company continually assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company&#8217;s performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the transaction price allocated to the combined performance obligation identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on the Company&#8217;s best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale, or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i62ffea71f8084035a5a64bada437117e" continuedAt="i71c185a450114f7f8b27c5417e72c72c"><ix:continuation id="ifede06a588d84993a92ab63fb11a251b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s accompanying consolidated balance sheets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses direct and incremental costs to obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as collaboration contract assets and amortized as general and administrative expenses over the total estimated period of performance of each underlying contract.</span></div></ix:continuation><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzI0_f5121e0c-8af7-400f-ac8f-5422ecf74729" continuedAt="i5f988cf0b9734275a4c5324594992097" escape="true">Equity Method Investments </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="i5f988cf0b9734275a4c5324594992097" continuedAt="i258fc8eff0cd41efbb935f1d4955a54c"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Equity Method and Joint Ventures</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i258fc8eff0cd41efbb935f1d4955a54c">. The Company recognizes its pro-rata share of income and losses in the investment in &#8220;Loss from equity method investment&#8221; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment in the consolidated balance sheet until such investment is reduced to <ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2Xzg2NDM_1c8ca365-e5e2-4a90-ab4d-55461c51975d">zero</ix:nonFraction>.</ix:continuation> </span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE5_9b6e74cb-b53a-4132-a5b7-5f01f7527236" continuedAt="i2a368d1420954a0586c55b73f5392cfc" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. The Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2a368d1420954a0586c55b73f5392cfc">The Company follows the authoritative guidance for recognizing and measuring uncertainty in income tax positions taken or expected to be taken in a tax return. The Company recognizes interest accrued related to unrecognized tax benefits and  penalties in tax expense.</ix:continuation> Management has evaluated the effect of ASC 740 guidance related to uncertain income tax positions and concluded that the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has no sign</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ificant uncertain income tax positions as of December&#160;31, 2022 and 2021.</span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzIw_0d19a17d-6ca1-400a-8115-d45d55633867" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures employee, board of director and consultant equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards. Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies equity-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="arvn:DefinedContributionPlanPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI3NDg3NzkwOTUxMzM_679ca02c-86a8-4be1-8f33-722193e8ad5b" continuedAt="ibf0073b4cf794f5083f6bd46c2fbe269" escape="true">401(k) Savings plan</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf0073b4cf794f5083f6bd46c2fbe269">The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis.</ix:continuation> Under the 401(k) Plan, the Company made discretionary matching contributions on behalf of eligible employees totaling $<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzODIzMQ_6f6c682e-4936-49be-ad54-f1074e969890">2.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzODI0NQ_fcfff923-c70a-4fb5-9603-06d6d90a1220">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzODI1OQ_1cc38a55-63b0-41de-a166-d585b5c6532e">0.9</ix:nonFraction>&#160;million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i71c185a450114f7f8b27c5417e72c72c" continuedAt="i18a78e08eb7f44ca884692ffd6688e29"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE3_158e9632-40f4-4264-b5ce-04d22f8551e1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites and consultants; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into consulting, research and other agreements with commercial entities, researchers, universities and others for the provision of goods and services. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE4_17f1cc0d-a34a-463a-baba-d46c81e12a20" continuedAt="i87a6c0e6d9bc4ed6bc91a3b7de44915b" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires disclosure of the fair value of financial instruments held by the Company. ASC 825, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;&#160;&#160;&#160;&#160;Inputs are based upon observable or quoted prices (unadjusted) for identical instruments traded in active markets.  The Company&#8217;s Level 1 financial instruments consist of cash equivalents.  </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;&#160;&#160;&#160;&#160;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#8217;s Level 2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;&#160;&#160;&#160;&#160;Inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques. </span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i87a6c0e6d9bc4ed6bc91a3b7de44915b">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</ix:continuation> </span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzI1_cea6ec44-3f2e-4690-b3a2-f0966c9894dd" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Common Share </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common shares.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i18a78e08eb7f44ca884692ffd6688e29"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzI2_4d001c28-b152-4811-a0e4-f4dd735b70a1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reviews</span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new accounting standards as issued. As of December&#160;31, 2022, the Company has not identified any new standards that it believes will have a material impact on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="ia936ede3f23041239a783a07e7f93c48_145"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzkzNDY_779a8845-90ab-4dea-b2f1-afcef64e513f" continuedAt="ifc9e8c14f14a4d1086695966da0a5714" escape="true">Research Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="ifc9e8c14f14a4d1086695966da0a5714" continuedAt="i3bd58f3383c7408e9879bdd6121febf9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-471 Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a collaboration agreement with Pfizer (the &#8220;ARV-471 Collaboration Agreement&#8221;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#8217;s proprietary compound ARV-471 (the &#8220;Licensed Products&#8221;). Under the ARV-471 Collaboration Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="i3c8b495cdfa84814911559b730f66a7e_I20210731" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ5OQ_bdf09266-52fd-41f3-9250-c227aa7bafab">650.0</ix:nonFraction>&#160;million. In addition, the Company will be eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="id72a39411b0248c680378066eb3c8a44_I20221231" decimals="-8" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU3Ng_67baaa15-a03d-4a13-be3f-91a897c7de4c">1.4</ix:nonFraction>&#160;billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $<ix:nonFraction unitRef="usd" contextRef="ia18bd320049b4bbba687aa9d1e399170_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzcxOQ_fad5213d-34e6-4243-bc56-6ed4ceea5b67">400.0</ix:nonFraction>&#160;million in regulatory milestones are related to marketing approvals and $<ix:nonFraction unitRef="usd" contextRef="iae355cb2cbd14a7ca7ce12fab1f7f070_I20221231" decimals="-8" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzc4Ng_b6c5f6e2-bbf4-45aa-95fc-bb09d602654f">1.0</ix:nonFraction>&#160;billion are related to sales-based milestones.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the execution of the ARV-471 Collaboration Agreement, the Company and Pfizer entered into a Stock Purchase Agreement (the" Pfizer Stock Purchase Agreement") for the sale and issuance of <ix:nonFraction unitRef="shares" contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzE5MzU_d8e109e9-d456-4842-92cb-037fe66f1c99">3,457,815</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;) to Pfizer at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i008bbd6d947d479fad8e8cd49d905905_I20210930" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzIwMTQ_fba5ba53-aed6-4421-881e-3c6d616359c2">101.22</ix:nonFraction> per share, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzIwNjM_28ee55e5-65c9-4c35-9d2c-e2f492754bf7">350.0</ix:nonFraction> million (the &#8220;Pfizer Equity Transaction&#8221;), less financial advisor fees of $<ix:nonFraction unitRef="usd" contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930" decimals="-5" name="us-gaap:PaymentsForBrokerageFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzIxNDA_be82301e-c190-479b-9d71-456ed02300ce">4.6</ix:nonFraction>&#160;million, which was consummated in September 2021. Pursuant to terms of the Pfizer Stock Purchase Agreement, Pfizer has agreed not to sell or transfer the Shares without prior written approval of the Company for a specified time period, subject to specified exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the ARV-471 Collaboration Agreement and the Pfizer Equity Transaction entered into with Pfizer concurrently should be evaluated as a combined contract in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined the fair value of the shares sold under the Pfizer Equity Transaction to be $<ix:nonFraction unitRef="usd" contextRef="ib894aa0b10644e20af715749fe409cc1_D20210701-20210731" decimals="-5" name="arvn:SaleOfStockFairValueOfSharesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzI3ODc_fc5367e7-c852-4e34-9a3a-b6ddbc65ecbf">85.4</ix:nonFraction>&#160;million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the sale of stock should be recorded at fair value and therefore allocated the excess consideration received under the Pfizer Equity Transaction to the ARV-471 Collaboration Agreement, which, along with the non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="i137647b8ea294b7f923d056ee2a3185a_I20210731" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzMyMjM_de32ea44-bf1e-40d9-91f4-337e06c66cdf">650.0</ix:nonFraction> million, is being recognized as revenue over the total estimated period of performance based on the Company&#8217;s best estimate of costs to be incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the ARV-471 Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $<ix:nonFraction unitRef="usd" contextRef="ia0122cacce6947ffb02e9a5170ae43e6_D20220101-20221231" decimals="-5" name="arvn:DirectAndIncrementalCostsIncurredToObtainTheContract" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzM1Njk_9c2e76d4-81b4-4960-a9cf-8369a0c5f9d5">12.9</ix:nonFraction>&#160;million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $<ix:nonFraction unitRef="usd" contextRef="i3f9942e42d3140f8a91bf2d658e6dcf3_I20221231" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzM2Njk_86d02116-d6b4-4318-a898-cf47068a2396">12.9</ix:nonFraction>&#160;million in collaboration contract asset and other assets in the consolidated balance sheet, which is being amortized as general and administrative expense over the total estimated period of performance under the ARV-471 Collaboration Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3bd58f3383c7408e9879bdd6121febf9" continuedAt="i75c10265e82f4abf90a71262a18e73d1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the "Bayer Collaboration Agreement") setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC targeted protein degraders, that mediate for degradation of target proteins ("Targets"), using the Company&#8217;s proprietary platform technology, which Targets will be selected by Bayer AG, subject to certain exclusions and limitations. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="id5e7ec5fd01749818f635a4f60e5162b_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ2MTI_84316c3d-59a7-4bb2-ae48-181d95411849">17.5</ix:nonFraction> million in exchange for the use of the Company&#8217;s technology license. In addition, Bayer AG is committed to fund an additional $<ix:nonFraction unitRef="usd" contextRef="ic1c1ec77b77045b497b74778ed6dd646_I20231231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ3NjU_ce29b8cd-2dd8-4bd6-b491-4003b364c051">12.0</ix:nonFraction> million through 2023, of which $<ix:nonFraction unitRef="usd" contextRef="if7526a5f18544f7e93c796607abcc906_D20190601-20221231" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyMzQ3Mg_e8024c3a-ae83-4717-98c0-c2fa7dba678c">10.5</ix:nonFraction>&#160;million was received from inception through December&#160;31, 2022, including $<ix:nonFraction unitRef="usd" contextRef="ib6c577e36553475a87e391c1f798aa7b_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ3ODk_21b184fc-6602-442c-b422-dce578b61a17"><ix:nonFraction unitRef="usd" contextRef="i48ac848348704c25879ff7a321b30a93_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ3ODk_be33ac64-0e93-487f-abc0-2f4a654c3874"><ix:nonFraction unitRef="usd" contextRef="ibd3db3e1a3a44d7eaadb52f8b2021f2d_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ3ODk_fcae2e43-9e5a-44da-aabb-3e8408c777a4">3.0</ix:nonFraction></ix:nonFraction></ix:nonFraction> million received in each of the years ended December 31, 2022, 2021 and 2020. These payments are being recognized over the total estimated period of performance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ic37540796dbd46e89f0413e7111cb541_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ5NzQ_03195cb7-3294-457f-8b14-2b79be58fc76">197.5</ix:nonFraction> million in development milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="i63bcebaaf3e442f0be53ff2a3cd2ab6b_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzUwMjE_1193ac6f-3eaf-4315-bfc0-2d346dccc6f3">490.0</ix:nonFraction> million in sales-based milestone payments for all designated Targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were <ix:nonFraction unitRef="usd" contextRef="id766159d435e4384b6f8955f4aa30c00_D20220101-20221231" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzUzMDQ_019f3dae-590f-458b-b66e-2cb3a9302114"><ix:nonFraction unitRef="usd" contextRef="i60b38ed093ce46b7bd1daba503d94341_D20220101-20221231" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzUzMDQ_07ad0e90-3bfc-4cff-b702-1bdcd6534ed1">no</ix:nonFraction></ix:nonFraction> development or sales-based milestone payments or royalties received through December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Bayer Collaboration Agreement and a Stock Purchase Agreement entered into with Bayer AG at the same time should be evaluated as a combined contract in accordance with ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined the fair value of the shares sold under the Stock Purchase Agreement to be $<ix:nonFraction unitRef="usd" contextRef="if3ae4abd92fa47a5b59e353890bedd74_D20220101-20221231" decimals="-5" name="arvn:SaleOfStockFairValueOfSharesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU3MzA_738ca174-7b75-4b77-8d33-91343e914d7e">2.9</ix:nonFraction> million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the sale of stock should be recorded at fair value. Therefore, the Company allocated the additional $<ix:nonFraction unitRef="usd" contextRef="if3ae4abd92fa47a5b59e353890bedd74_D20220101-20221231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzYwMzQ_0f0cc5bf-176e-40e7-9fad-5c12a7d2b6f6">2.9</ix:nonFraction> million of consideration received under the Stock Purchase Agreement to the Bayer Collaboration Agreement and added such amount to the total transaction price. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the "Pfizer Research Collaboration Agreement"). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $<ix:nonFraction unitRef="usd" contextRef="iaaf06e4b711c47f79d1671a25c581273_D20180101-20181231" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzY1NDI_1161ae91-c93c-4bcc-be4b-27671681717c">28.0</ix:nonFraction> million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized over the total estimated period of performance. The Company is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i41b133ccf8c94b249e0de13cf22af00d_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzY4NDc_11c78671-ae6c-44b6-8b53-65f86020a819">37.5</ix:nonFraction> million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. The Company is also entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="i1a14b1ae339242c8b514f80494ac7461_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzcwMjk_73a1429e-cbec-4687-80eb-21815f50f3bd">225.0</ix:nonFraction> million in development milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="i8056d73a6e7d4769acafb7929251b89d_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzcwNzY_e473dbff-449f-46ed-9f65-6c208c1e78f9">550.0</ix:nonFraction> million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. In 2021 and 2020, the Company received payments totaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic134f4ad0212413fb29264d3665de649_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzcyOTU_631ed538-a5de-4e03-8598-97e4025d83c4">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibcd68967c863457f9a819376746fa6fc_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNjE3Ng_88fc738e-451f-4947-a437-3c5a222f6ba1">4.4</ix:nonFraction>&#160;million, respectively,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which are being recognized as revenue over the total period of performance. Pfizer selected additional targets and initiated additional services totaling $<ix:nonFraction unitRef="usd" contextRef="i877187a756224a52a50870299413f7a3_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNTM5MA_a56989ed-0b69-40a5-895f-00cc0723d133">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i660d8e9f27ff4dc1a01397df66df2870_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNDk3Ng_ad8fef0c-d9ba-4e47-9598-d33fad588fd9">3.5</ix:nonFraction> million in December 2022 and 2021, respectively, which were included in accounts receivable as of December 31, 2022 and 2021. There were <ix:nonFraction unitRef="usd" contextRef="i94762668373b4b67bb84c11c71e8cdb1_D20220101-20221231" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzc1NDg_05d90269-66e1-4511-b041-41b2b3090764">no</ix:nonFraction> sales-based milestone payments or royalties received through December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Modification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the "Genentech Modification") with Genentech, Inc. and F. Hoffman-La Roche Ltd (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Genentech Modification, the Company received upfront, non-refundable payments of $<ix:nonFraction unitRef="usd" contextRef="i759fe1462729496ba429f2526fc8aff5_D20171101-20171130" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzgwMTY_f83fe5d2-548a-40b7-9691-30301c042313">34.5</ix:nonFraction> million (in addition to $<ix:nonFraction unitRef="usd" contextRef="i9a9898905f154cf8b9795022a7300014_D20150901-20151231" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzgwMzU_7bcc973a-9585-4cc7-affd-b4cd29b1c81e">11.0</ix:nonFraction> million received under the previous agreement in 2015) to fund Genentech-related research and Genentech has the right to designate up to <ix:nonFraction unitRef="target" contextRef="i759fe1462729496ba429f2526fc8aff5_D20171101-20171130" decimals="INF" name="arvn:NumberOfMaximumDesignatedTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzgxNjc_f14c16bf-ff35-41e3-9bc5-814a37da55d9">ten</ix:nonFraction> targets. The Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i8cc6a3e194a5420ea29436a5800706bc_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzgyMjA_f80cba16-237e-4e95-a233-c0b87ca6905f">27.5</ix:nonFraction> million in additional expansion target payments if Genentech exercises its options on all remaining targets. Upfront non-refundable payments are recognized as revenue over the total estimated period of performance. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i75c10265e82f4abf90a71262a18e73d1"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i5473a14476bb4d1885b2439dc1d56870_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg0NzI_dbee24ce-bff3-4fef-b879-7f05ac130ab1">44.0</ix:nonFraction> million per target in development milestone payments, $<ix:nonFraction unitRef="usd" contextRef="ie8eb28a02b3f4a66aeb3f487c3c1bb6b_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg1MjE_1b1be1ae-3404-4d46-b455-7ef230dc0651">52.5</ix:nonFraction> million in regulatory milestone payments and $<ix:nonFraction unitRef="usd" contextRef="i095c155f507a4c09a74c9bc2d95f96ab_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg1NjE_64429161-e637-4d6a-bd60-3ec8577bb0c7">60.0</ix:nonFraction> million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were <ix:nonFraction unitRef="usd" contextRef="i5bbb1ec29ec94c9f87ada6000b54a3fc_D20220101-20221231" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg2Njc_1fe6c0b0-9509-45ee-9b6d-8039f7beb9e9"><ix:nonFraction unitRef="usd" contextRef="i247c5fdfe9cf425da9589cd446cbbdb1_D20220101-20221231" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg2Njc_3d72fdbd-726b-4eee-a1d2-9b2156f14341"><ix:nonFraction unitRef="usd" contextRef="i9ea29be677eb40da8b1cb7c47d711d2d_D20220101-20221231" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg2Njc_622b2a15-cb32-48dc-bcf7-dd28b09098d8">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> development, regulatory or commercial milestone payments or royalties received through December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzkzNDQ_df76fea3-1ed3-4c30-ad11-43bc79c2b11b" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzMtMS0xLTEtNDgzMTU_28755c09-e1df-4552-8d9f-603419f109d2">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzMtMy0xLTEtNDgzMTU_4e7f5009-35f1-4b82-9b72-80e4dc765404">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzQtMS0xLTEtNDgzMTU_389a4d32-f814-4cf5-ab97-e93e3c0a5b38">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzQtMy0xLTEtNDgzMTU_b6ffeaea-6a58-4de8-b187-b938cfd2ecef">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzUtMS0xLTEtNDgzMTU_cedd0882-95f4-45fe-a6d5-5b454484bb90">20.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzUtMy0xLTEtNDgzMTU_68ed6668-4c92-4bad-a2e2-db4f7c4d9b65">5.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzYtMS0xLTEtNDgzMTU_c13833a0-2a73-4824-9f95-2527b8462529">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzYtMy0xLTEtNDgzMTU_a7eb2a74-8094-4ca7-b6d1-b3ac0d613140">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzgtMS0xLTEtNTE2ODc_a7f42c93-2ac1-40a8-9598-80aba63b80a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzgtMy0xLTEtNTE2ODc_d81c71df-06ca-453a-9c4b-c6970c68e4bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzktMS0xLTEtNTE2ODc_46105469-6487-4744-b4e4-1305686d263a">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentAdditions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzktMy0xLTEtNTE2ODc_2111bb06-371c-4bb1-b606-12a2d73656d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentPayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEwLTEtMS0xLTUxNjg3_99435c8e-4b7e-4754-bbab-679fa025c642">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentPayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEwLTMtMS0xLTUxNjg3_e6a2fe3e-9828-4d06-bd81-eed13ce5524c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzExLTEtMS0xLTUxNzMw_01b3b3e8-edfc-4a2c-830a-39a7a46ede1f">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzExLTMtMS0xLTUxNzM0_664bf915-f0a6-4eed-9d77-a660fc425ea0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzgtMS0xLTEtNDgzMTU_9d7a1eba-1707-495a-b88d-86ee68b77fd1">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzgtMy0xLTEtNDgzMTU_f497bc0d-c533-40d7-93c1-6c1df6ffbb07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzktMS0xLTEtNDgzMTU_2ff718d8-cf2c-435e-8744-04bea3cff993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzktMy0xLTEtNDgzMTU_e45aeec4-e5ae-4c00-936b-fe38cdec3513">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEwLTEtMS0xLTQ4MzE1_a0e76bbc-d408-48a3-a966-355df9fcee57">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEwLTMtMS0xLTQ4MzE1_b9ff27c6-5385-4c88-af1b-f2197357ead1">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzExLTEtMS0xLTQ4MzE1_4c3c6be4-9f02-4791-b792-50e53e084843">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzExLTMtMS0xLTQ4MzE1_adf39926-23d8-4496-8744-ea248e63d8d1">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEzLTEtMS0xLTQ4MzE1_b1ed149e-8531-4a5e-85a1-0cba33352db6">740.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEzLTMtMS0xLTQ4MzE1_a224ce2f-54cd-4685-888f-1ac28a77d8c4">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE0LTEtMS0xLTQ4NDM5_7bc9953b-43fa-408e-8f5e-37415ec0a7aa">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE0LTMtMS0xLTQ4NDM5_7b9df067-9f42-4e80-a54f-de7747a79e28">742.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE0LTEtMS0xLTQ4MzE1_3b8c1fe2-0629-49fe-80b8-89b9fbc51509">120.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE0LTMtMS0xLTQ4MzE1_60481800-6e6e-4ade-93ae-63685c35bf09">18.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances not held at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="arvn:ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE1LTEtMS0xLTQ4MzE1_4c83164f-6e7a-4aed-a7b4-fe3f2141a1ec">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="arvn:ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE1LTMtMS0xLTQ4MzE1_998ebe73-de54-48ad-9663-5a1f8ab0e8ec">28.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE2LTEtMS0xLTQ4MzE1_e1fb870b-00c8-4daf-b4c0-7e694734809c">623.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE2LTMtMS0xLTQ4MzE1_f9eab2aa-acbe-495f-8259-4a155a0a875e">740.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded cumulative catch-up adjustments from contract modifications totaling $<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNzE2NA_0ed483b7-3721-467f-b6fa-1396e8741466">0.7</ix:nonFraction> million, $(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNzE1MA_0feadc5b-3f89-4b58-91b1-8f9ffdb40de0">0.8</ix:nonFraction>) million and $(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNzEzNg_42966ae5-6b47-4943-aa9e-792205cd9638">0.4</ix:nonFraction>) million, respectively, relating to performance obligations which were satisfied in prior periods.</span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzkzNDU_30935a90-1f7a-44d5-8d73-0f1a88d045c3" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of December&#160;31, 2022 totaled $<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzkyNzg_2e3121ec-305f-42d4-8ba9-2b3cec350a49">623.7</ix:nonFraction> million, which is expected to be recognized in the following periods: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1e801491e3064f7e8860d42f7cd1d807_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzEtMS0xLTEtNDUzMzQ_124a5a12-c3d6-4b40-99f4-75487cc87d87">218.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i37df6405966e4a9bba28bd31c157a857_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzItMS0xLTEtNDUzMzQ_3cabfec8-d111-45f4-a495-834dbcaa1eea">193.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3bd0aacedfdf49bf999f9c0416ec3008_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzMtMS0xLTEtNDUzMzQ_25d4d8b9-07af-4d0c-ab2d-497d9e15dfba">90.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4368412362e45bba2473a1217491133_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzQtMS0xLTEtNDUzMzQ_ab87efdc-846d-4da5-802e-fe1c6cd0c3d8">55.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i672048308c094a4fbb8e393353f2cc46_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzUtMS0xLTEtNDUzMzQ_a5bd8f8c-1f1a-480d-bb42-59ae96f20bbe">34.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib73fa643c9664e9aa6e824a9828957e4_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzYtMS0xLTEtNDUzMzQ_3bc7672e-4721-460a-88b7-309dd225b58f">31.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzctMS0xLTEtNDUzMzQ_2e3121ec-305f-42d4-8ba9-2b3cec350a49">623.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 15</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_151"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90ZXh0cmVnaW9uOjRkZDkwNTY0YmE2MTQzNmFiM2QxMGFmYjk2M2ExMGY5XzEzODM_c217fa0c-bc69-4cf4-9a3d-50a85082e474" continuedAt="i2f27694d25da4b45ae9841be4c781498" escape="true">Marketable Securities and Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i2f27694d25da4b45ae9841be4c781498"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90ZXh0cmVnaW9uOjRkZDkwNTY0YmE2MTQzNmFiM2QxMGFmYjk2M2ExMGY5XzEzODE_1e7ecd58-a5bf-4edf-9f9b-83c78724f22e" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s assets measured at fair value on a recurring basis.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ac1a1558a74e50b590271f7dea04b2_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzItNi0xLTEtNDUzMzQ_4d5c2d74-c1ce-42bb-8f84-f8d88b10961c">802.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ac1a1558a74e50b590271f7dea04b2_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzItOC0xLTEtNDUzMzQ_5f329dc9-a982-4621-94da-29154785d7be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11ac1a1558a74e50b590271f7dea04b2_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzItMTAtMS0xLTQ1MzM0_ad9ec5ce-8226-443f-b528-efd9b94cd36d">9.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ac1a1558a74e50b590271f7dea04b2_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzItMTItMS0xLTQ1MzM0_dfa754b5-fe3c-455b-9bec-77aa95751783">793.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024 - 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2baa9d5c1314262a04322fd5725c7b6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzMtNi0xLTEtNDUzMzQ_e9bc668e-f9f9-4dca-9e59-5c88e855ad2a">205.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2baa9d5c1314262a04322fd5725c7b6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzMtOC0xLTEtNDUzMzQ_9b7298f9-7498-4d59-8d46-d4eac56dc744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2baa9d5c1314262a04322fd5725c7b6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzMtMTAtMS0xLTQ1MzM0_b700de2c-946e-4d8f-8014-856174e86baa">9.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2baa9d5c1314262a04322fd5725c7b6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzMtMTItMS0xLTQ1MzM0_8e3b75d4-c781-4ad7-af05-140f4440bf4b">196.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2517bd9479df46dcac4edde8de8fbf8b_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtNi0xLTEtNTE0NjE_86df73e9-47bf-42de-9c3e-937e15935363">61.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2517bd9479df46dcac4edde8de8fbf8b_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtOC0xLTEtNTE0NjE_f7d6e7a3-4e0e-4bc6-a8ab-6e9cbae22bc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2517bd9479df46dcac4edde8de8fbf8b_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtMTAtMS0xLTUxNDYx_d3ef11be-c25c-45f9-b45d-13e5fc6e0e1e">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2517bd9479df46dcac4edde8de8fbf8b_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtMTItMS0xLTUxNDYx_cb781a15-4938-4bbc-a544-bddb646b4d1d">61.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e71741f7e2c4379b7adad37f613ae6b_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtNi0xLTEtNDUzMzQ_6944101a-2c3f-4f9a-a619-28f6af84c873">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e71741f7e2c4379b7adad37f613ae6b_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtOC0xLTEtNDUzMzQ_3c49cdcb-6d36-42d5-8b7c-bf98b42eca48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e71741f7e2c4379b7adad37f613ae6b_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtMTAtMS0xLTQ1MzM0_c9f3e403-b82b-4d52-ba18-623fe8dfb938">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e71741f7e2c4379b7adad37f613ae6b_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtMTItMS0xLTQ1MzM0_e63d3a36-94f0-492b-9e1f-f5496a07b5ae">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb3556f23c44e99bce5894aafa9c448_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzUtNi0xLTEtNDUzMzQ_d1ef67a6-4150-4392-ae73-56d5f83ef9d1">1,143.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb3556f23c44e99bce5894aafa9c448_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzUtOC0xLTEtNDUzMzQ_14368309-fe92-408d-9d42-c8636bea6470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cb3556f23c44e99bce5894aafa9c448_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzUtMTAtMS0xLTQ1MzM0_3c8d882f-a81f-41e7-a635-7b5fca83392b">19.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb3556f23c44e99bce5894aafa9c448_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzUtMTItMS0xLTQ1MzM0_33eede96-e97e-4b30-a166-3073ab51cb9e">1,124.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46cfa718400a42c5a9f24fb1d208bf44_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzItNi0xLTEtNDUzMzQ_ba8e111c-352b-4c30-aeb2-daf5822e3e38">784.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46cfa718400a42c5a9f24fb1d208bf44_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzItOC0xLTEtNDUzMzQ_79e96c6c-33be-4e09-b07f-ab766849b594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46cfa718400a42c5a9f24fb1d208bf44_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzItMTAtMS0xLTQ1MzM0_448f9b6a-2c41-4573-a635-072e87b846fc">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46cfa718400a42c5a9f24fb1d208bf44_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzItMTItMS0xLTQ1MzM0_0f81d7e1-fcf5-4bb2-8ace-d8cc7dc8fbca">783.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bcbdd1acfc42b186645d856f68c30a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtNi0xLTEtNDg2MjM_84dbd29a-01bb-4ae8-9062-cabc460b9020">582.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bcbdd1acfc42b186645d856f68c30a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtOC0xLTEtNDg2MjM_455c6e0a-aac7-4d40-b1f3-cd48f99f3c3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49bcbdd1acfc42b186645d856f68c30a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtMTAtMS0xLTQ4NjIz_c2dd9caa-8697-4dca-9cd3-ecb74458ec34">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bcbdd1acfc42b186645d856f68c30a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtMTItMS0xLTQ4NjIz_1b0e6e63-d627-4e81-956d-7f54d8ac3004">578.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice07d9029aa84199ac8be838d60ae4a6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzQtNi0xLTEtNDg2MjM_eee08b08-e27c-47c5-bd75-69f997b97aa7">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice07d9029aa84199ac8be838d60ae4a6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzQtOC0xLTEtNDg2MjM_35114fc4-2d63-4076-a848-c17b50e492ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice07d9029aa84199ac8be838d60ae4a6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzQtMTAtMS0xLTQ4NjIz_37b22a82-5285-413f-b92b-ebd8acf1e1e3">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice07d9029aa84199ac8be838d60ae4a6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzQtMTItMS0xLTQ4NjIz_7d1e7478-826d-47f9-bfdd-46425f30ac85">32.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7090b40f62334eab9ab385c427bcecdd_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtNi0xLTEtNDUzMzQ_993ae1c8-ca96-427e-86d7-a7d7ac66c67c">1,398.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7090b40f62334eab9ab385c427bcecdd_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtOC0xLTEtNDUzMzQ_78fa3c9b-f2f6-4c4d-8d18-4fb4bd66c8dd">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7090b40f62334eab9ab385c427bcecdd_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtMTAtMS0xLTQ1MzM0_9ad265a7-d72f-4844-a4e3-ec2a32f19e8b">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7090b40f62334eab9ab385c427bcecdd_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtMTItMS0xLTQ1MzM0_c4112134-01c6-4bdc-ac2a-db4bfc2d02ed">1,394.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of accounts receivable and accounts payable and accrued liabilities approximate their </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair values due to the short-term nature of these assets and liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-recurring fair value measures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, in connection with the Pfizer Stock Purchase Agreement, t</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company valued the common stock issued to Pfizer</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at fair value. The Pfizer Stock Purchase Agreement contains provisions restricting the sale or transfer for a period of time (the &#8220;lock-up period&#8221;). The resulting fair value of $<ix:nonFraction unitRef="usd" contextRef="i24c2800943e64589bfe1be38fdfcdeac_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90ZXh0cmVnaW9uOjRkZDkwNTY0YmE2MTQzNmFiM2QxMGFmYjk2M2ExMGY5Xzg4MA_8a20a5e8-3e31-4455-afd2-f69698e5075b">264.6</ix:nonFraction>&#160;million was determined by applying the discount due to lack of marketability during the contractual lock-up period to the public trading price of the common stock, which is a Level 1 input, on the date of sale. The Company accounted for the lack of marketability during the contractual lock-up period, by utilizing put option models, which are considered Level 3 inputs. Such option models included the Company&#8217;s historical volatility and the risk-free rate based on U.S. Treasury bond rates, as key inputs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 16</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_154"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90ZXh0cmVnaW9uOjVkYTZiYzcyMWU0MTQxMDJhOTI0MjM0ZTMwMzI5MmNmXzIyNQ_c234ef06-3686-487d-aa6e-26debadd09ed" continuedAt="ib2cf420389b545e58f6574fc3a80c938" escape="true">Property, Equipment and Leasehold Improvements </ix:nonNumeric></span></div><ix:continuation id="ib2cf420389b545e58f6574fc3a80c938"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90ZXh0cmVnaW9uOjVkYTZiYzcyMWU0MTQxMDJhOTI0MjM0ZTMwMzI5MmNmXzIyNg_6ac68c49-fc98-4688-b7c8-3fa6c5394b4b" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i058eebe5acbf4e69a811a1f3713b1674_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzItMS0xLTEtNDUzMzQ_ad8d6d64-fae6-400d-8682-8dba02964dce">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i65535f62f10e4ef4870538c48dee40d7_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzItMy0xLTEtNDUzMzQ_f803ebdd-cdba-49f0-afc8-ec8e19c30de3">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida76e88673e6409baa83b50282beff61_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzMtMS0xLTEtNDUzMzQ_f12d7829-2c39-4d61-b6db-ad0020798a65">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0a77e93668514396822e5760f192b979_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzMtMy0xLTEtNDUzMzQ_b5c9e6a8-2b18-44c2-9f46-f32d048ddc22">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3a171973241c4a65b20f085ad93852a2_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzQtMS0xLTEtNDUzMzQ_dd416532-6feb-41c6-ad15-e7001ec9d29b">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i80ab38e360f943d6a594d05213ee4b3f_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzQtMy0xLTEtNDUzMzQ_5959742d-e809-4825-8562-407445035851">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzUtMS0xLTEtNDUzMzQ_5b3fc561-aeba-4355-b223-ecd4658c10e3">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzUtMy0xLTEtNDUzMzQ_76748954-2fde-4d7c-8c6b-65f219d35688">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzYtMS0xLTEtNDUzMzQ_3038be96-d1b4-48ab-b4b3-f02c86d83cd8">16.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzYtMy0xLTEtNDUzMzQ_f28b6e79-9bce-465b-9835-4049196a1ce5">10.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzctMS0xLTEtNDUzMzQ_e28cfca4-2c70-4126-bc8a-af2d4bcaedae">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzctMy0xLTEtNDUzMzQ_0b47a4d6-a6ac-4f98-9bd3-120d15677c6a">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90ZXh0cmVnaW9uOjVkYTZiYzcyMWU0MTQxMDJhOTI0MjM0ZTMwMzI5MmNmXzE2MQ_63e8b1ff-0a0e-4f51-87ed-f2ac7e3bb6b4">6.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90ZXh0cmVnaW9uOjVkYTZiYzcyMWU0MTQxMDJhOTI0MjM0ZTMwMzI5MmNmXzE2NQ_c7b92378-710b-43b5-b21b-b52513074e19">4.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90ZXh0cmVnaW9uOjVkYTZiYzcyMWU0MTQxMDJhOTI0MjM0ZTMwMzI5MmNmXzE3Mw_654c9011-59e8-4cbf-90fd-b75f27de8e57">3.2</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div id="ia936ede3f23041239a783a07e7f93c48_157"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjA_af99682b-dea5-407e-9adc-fc1c1264e336" continuedAt="i0a8b99d9596a4a56a8d8a6ce98a270b4" escape="true">Right-of-Use Assets and Liabilities</ix:nonNumeric></span></div><ix:continuation id="i0a8b99d9596a4a56a8d8a6ce98a270b4" continuedAt="i3fd701ff2d2c44f7879b0ebe2e1831fa"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commencement date in determining the present value of lease payments, which ranges from <ix:nonFraction unitRef="number" contextRef="i079086717708440bbc6bde6339a2c26e_I20221231" decimals="3" name="arvn:PercentageOfIncrementalBorrowingForLeasePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDM3NDA_fdf78db0-34b4-4bfb-ba1f-3bbfc484565a">3.0</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i435f3577adb6471086574fa92705b9b6_I20221231" decimals="3" name="arvn:PercentageOfIncrementalBorrowingForLeasePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDM3NTE_04806e0e-4d95-4b04-9863-d3eaa7fe01a1">4.1</ix:nonFraction>%. Lease expense is recognized on a straight-line basis over </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the lease term. The Company considers options to extend or terminate the lease in recognizing ROU assets and lease liabilities when it is reasonably certain that such options will be exercised. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a lease arrangement, which was amended in August 2022, for approximately <ix:nonFraction unitRef="sqft" contextRef="i5bc16f834f8e48cca3a2cc04f3bdb2ab_I20210531" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDM3NjU_38a0578d-ddfb-47b7-ad1d-c7f653b6137e">160,000</ix:nonFraction> square feet of laboratory and office space to be occupied in 2024. In connection with the signing of the lease and the related amendment, and at the Company&#8217;s election to increase the landlord&#8217;s contribution to the tenant improvement allowance, the Company initially issued a letter of credit totaling $<ix:nonFraction unitRef="usd" contextRef="i75b6e519c7cb4a81826452584ae57c12_I20210531" decimals="-5" name="us-gaap:DebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDQ3MDA_ac4b11bc-36e1-4fcb-9d6e-cc3854631ec4">4.5</ix:nonFraction> million, which was subsequently increased to $<ix:nonFraction unitRef="usd" contextRef="i172eba417a7443088682953acc866535_I20221231" decimals="-5" name="us-gaap:DebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDQ2ODg_14f2c724-00c1-4991-8474-368cc5992909">5.5</ix:nonFraction> million, collateralized by a certificate of deposit in the same amount, which is presented as restricted cash in the accompanying consolidated balance sheets. Once occupied, the base rent will range from $<ix:nonFraction unitRef="usd" contextRef="i78cc6c1900c646e7a686f9fcfb72aaf7_D20210501-20210531" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDM3OTg_6ce30116-7e2f-42e0-98ac-b2fd988c5987">7.7</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="iabe4cc386917403580675ce1a278cc64_D20210501-20210531" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDM4MjU_feb20691-af2d-44e2-9247-e86e5565f728">8.8</ix:nonFraction>&#160;million annually over a <ix:nonNumeric contextRef="if9675174a7b047df809244be6ddfdc48_D20210501-20210531" name="arvn:BaseLeaseRentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjQ_0fb40080-f91b-4191-98d9-8f33aba1055a">ten-year</ix:nonNumeric> lease term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its corpor</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ate office, laboratories and certain equipment, which expire no later than January 2026. The leases have a weighted average remaining term of <ix:nonNumeric contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjE_9aad5514-4a93-4d8b-9cc3-f54d5473970c">2.3</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjU_f90ca5ec-5140-4a96-aeee-7d8fa68d408e" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTpkM2VmOTFmM2ZjZTg0MjFiYjY5NzAxOGYyMzVhMjExZS90YWJsZXJhbmdlOmQzZWY5MWYzZmNlODQyMWJiNjk3MDE4ZjIzNWEyMTFlXzItMS0xLTEtNDUzMzQ_4ea2cf1a-0ce4-4b80-ba09-919e50e250df">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTpkM2VmOTFmM2ZjZTg0MjFiYjY5NzAxOGYyMzVhMjExZS90YWJsZXJhbmdlOmQzZWY5MWYzZmNlODQyMWJiNjk3MDE4ZjIzNWEyMTFlXzItMy0xLTEtNDUzMzQ_cc21dbc9-eb04-4686-82c4-d7afd975f483">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTpkM2VmOTFmM2ZjZTg0MjFiYjY5NzAxOGYyMzVhMjExZS90YWJsZXJhbmdlOmQzZWY5MWYzZmNlODQyMWJiNjk3MDE4ZjIzNWEyMTFlXzItNS0xLTEtNDUzMzQ_dd07eb4e-85a4-4ea2-8dfc-0bef99c6a93d">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3fd701ff2d2c44f7879b0ebe2e1831fa"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjI_38156d3a-6649-470d-a6a5-e7eea5b76cf2" escape="true"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzMtMS0xLTEtNDUzMzQ_44a41232-34dc-4a62-9b0f-7f8931ba7dfd">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzMtMy0xLTEtNDUzMzQ_abb0f647-a84e-4131-b15c-f07d7f60c620">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzMtNS0xLTEtNTU5MTg_8f16c9c6-947b-4a6e-8acd-fff82c92e57e">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzUtMS0xLTEtNDUzMzQ_bb8dd331-3196-420c-9ba0-14076372a19a">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzUtMy0xLTEtNDUzMzQ_d3fbc21c-b789-4d5d-88e8-dc0015d8fd6c">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzUtNS0xLTEtNTU5MjY_8c1173d5-3139-4d02-86c6-dead8bd13d0b">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjM_87cd55a1-092c-4a0e-9dc5-f27f2dd34243" escape="true"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of December&#160;31, 2022 were as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzEtMS0xLTEtNDUzMzQ_1ef0e1fe-7523-48f0-ba62-f82a1fac4b5a">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzItMS0xLTEtNDUzMzQ_a6010bc1-2639-40e5-8219-6614fe30cad2">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzMtMS0xLTEtNDUzMzQ_57c14298-e13c-432a-97d6-d3cd154f3ff9">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzQtMS0xLTEtNDc3Nzg_f506d7a0-35fb-46f7-8cfe-c463ed0848e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzQtMS0xLTEtNDUzMzQ_3758403b-a10a-44e4-811f-eef697bc467b">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzUtMS0xLTEtNDUzMzQ_0009160e-6d38-40dd-b65a-6f686973899b">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzYtMS0xLTEtNDUzMzQ_2ed16eac-b749-4bd7-a939-68b52b09e077">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia936ede3f23041239a783a07e7f93c48_163"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90ZXh0cmVnaW9uOmUwNmI1ZDY1ODE1NDRlNjY5ZTY2NzBjZTM4NTU1MTA4Xzcy_62d00a76-41a0-4eb2-a294-33a2801097b9" continuedAt="i66cae2dfa7b74c3aa277988dda3888c1" escape="true">Accounts Payable and Accrued Liabilities </ix:nonNumeric></span></div><ix:continuation id="i66cae2dfa7b74c3aa277988dda3888c1"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90ZXh0cmVnaW9uOmUwNmI1ZDY1ODE1NDRlNjY5ZTY2NzBjZTM4NTU1MTA4Xzcz_562a451c-c9dc-4772-8432-4862aba91f7a" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzItMS0xLTEtNDc0NTU_cc3a57e1-264f-46d8-afd3-fed0f31e10fa">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzItMy0xLTEtNDc0NTU_b31ceacf-b97f-430b-a6de-d6a50e7dc2dc">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzQtMS0xLTEtNDc1MDA_3d71c5ee-63fc-47e4-a650-df9e707de3ad">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzQtMy0xLTEtNDc1MDA_dc8ed1c3-265c-4c27-b052-6a0b376a3f67">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzItMS0xLTEtNDUzMzQ_59f92d42-798c-4ffb-853e-76f5d32f909f">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzItMy0xLTEtNDUzMzQ_af025c09-bf36-4a67-8075-cd10e56f5cf1">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzYtMS0xLTEtNTgxMjY_b6842064-4c95-46cf-b851-e65e84a9b8d1">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzYtMy0xLTEtNTgxMjY_974bdb61-fe41-4c0f-9e64-01f3b38d6809">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:AccruedProfessionalFeesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzQtMS0xLTEtNDUzMzQ_98d259b8-4cdc-4e5e-b6ac-d1f1b628692f">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:AccruedProfessionalFeesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzQtMy0xLTEtNDUzMzQ_7adc3e97-d110-4215-84c6-8833c6d74484">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzUtMS0xLTEtNDUzMzQ_b154c7b6-4acb-433c-b48b-cfe2a202f0c2">74.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzUtMy0xLTEtNDUzMzQ_3350d8ad-dea1-4c40-9797-06327df13237">54.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia936ede3f23041239a783a07e7f93c48_166"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE5OTQ_069dc3f8-31b5-4737-ae49-a732450f05bc" continuedAt="i59affbfbe3384ca7833d1a0189f976dc" escape="true">Long-Term Debt </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="i59affbfbe3384ca7833d1a0189f976dc" continuedAt="i720e8b68f16543108eb18ab10faec3a7"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into an Assistance Agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space (the "Project"). Under the terms of the 2018 Assistance Agreement, the Company was entitled to borrow from the State of Connecticut a maximum of $<ix:nonFraction unitRef="usd" contextRef="i076af9c270b244029a1fd9d8b3982564_I20180630" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM2NzQ_1232c0d2-8773-4e7d-9511-8e1a8c905f38">2.0</ix:nonFraction>&#160;million, provided that the funding did not exceed more than <ix:nonFraction unitRef="number" contextRef="i6661ad55442349ec8d7ed679ec7f076a_D20180601-20180630" decimals="INF" name="arvn:PercentageOfMaximumFundingOnProjectCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM2OTI_c0a267b3-dd3a-42c6-b88f-a2f7bb2de255">50</ix:nonFraction>% of the total Project costs. In September 2018, the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="i53fe0650f7c54cf9ae9a1454d05ebdc7_I20180930" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM3MTA_8368e3ee-ae72-41e7-9fea-d6b9cbf39d8c">2.0</ix:nonFraction>&#160;million under the 2018 Assistance Agreement, bearing interest at <ix:nonFraction unitRef="number" contextRef="i53fe0650f7c54cf9ae9a1454d05ebdc7_I20180930" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM3MzA_1502110b-6efe-4451-b0ab-8dae70e798d7">3.25</ix:nonFraction>% per annum with interest payments required for the first <ix:nonNumeric contextRef="i3c91c1b5ea044c539a1158ebd4047fc5_D20180901-20180930" name="arvn:DebtInstrumentInterestPaymentsTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzYyNA_0bfc5f40-943c-43e0-845e-31736efe7aeb">60</ix:nonNumeric> months from the funding date. Thereafter, the loan will begin to fully amortize through month <ix:nonNumeric contextRef="i3c91c1b5ea044c539a1158ebd4047fc5_D20180901-20180930" name="arvn:DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzcxNA_e82b24e5-9592-4e28-9a67-af486c7564e9">120</ix:nonNumeric>, maturing in </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2021, borrowings totaling $<ix:nonFraction unitRef="usd" contextRef="i477280be32f04a07b28c112beeada17e_D20210401-20210430" decimals="-5" name="arvn:DebtInstrumentLoanForgiveness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM5Nzk_c30da163-25bb-4de6-8060-6d6c496a8323">1.0</ix:nonFraction>&#160;million were forgiven by the State of Connecticut as the Company met certain employment conditions, as defined in the agreement. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028 with a default penalty of repayment of the full original funding amount of $<ix:nonFraction unitRef="usd" contextRef="i53fe0650f7c54cf9ae9a1454d05ebdc7_I20180930" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM4MjY_0d16d08b-3a4c-46fd-90e8-60e424a80d14">2.0</ix:nonFraction>&#160;million plus liquidated damages of <ix:nonFraction unitRef="number" contextRef="i3c91c1b5ea044c539a1158ebd4047fc5_D20180901-20180930" decimals="3" name="arvn:PercentageOfLiquidatedDamages" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM4NDU_dfee313a-d795-4aff-8c11-066f77d25d0c">7.5</ix:nonFraction>% of the total amount of funding received.</span></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i720e8b68f16543108eb18ab10faec3a7" continuedAt="i9265c3be6f9844b3805647c4f84c069a"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an Assistance Agreement with the State of Connecticut (the "Assistance Agreement") entered into in 2014, under which all the borrowings by the Company were forgiven in accordance with the Assistance Agreement, the Company is required to be located in the State of Connecticut through January 2024, with a default penalty of repayment of the full original funding amount of $<ix:nonFraction unitRef="usd" contextRef="i1d949a3402824e308e36a3888973c554_I20141231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM4NjQ_6fdafe3f-6b9c-4e24-8615-d2a3db49d7a7">2.5</ix:nonFraction>&#160;million plus liquidated damages of <ix:nonFraction unitRef="number" contextRef="if2470b93587642ee93b6862f8c50a373_D20140101-20141231" decimals="3" name="arvn:PercentageOfLiquidatedDamages" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM4ODM_99df6030-15a3-4e1f-a865-fa2aaa695a7e">7.5</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE5OTU_6f066fba-d929-4537-8e86-76f64c53e577" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt as of December&#160;31, 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzEtMS0xLTEtNDUzMzQ_d36bb1fa-ddcf-4098-968c-98e845cb7381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzItMS0xLTEtNDUzMzQ_3aae8e91-03c0-40f4-8f20-2b3158e53350">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzMtMS0xLTEtNDUzMzQ_671dfd94-6e3d-47cc-8e73-e041a6504414">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzQtMS0xLTEtNDUzMzQ_39d26d32-c671-4342-bd04-db56ee1c6e5b">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzUtMS0xLTEtNDUzMzQ_5ac83b32-f6ed-4254-9a28-e26ba9f4aa28">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzYtMS0xLTEtNDUzMzQ_fc45728f-6c5c-4ddc-b84a-0e053c4e372f">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzctMS0xLTEtNDUzMzQ_7a12c4fa-0e80-4da6-bb03-cf73dd26ae8a">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9265c3be6f9844b3805647c4f84c069a">During the years ended December&#160;31, 2022 and 2021, interest expense was immaterial. During the year ended December&#160;31, 2020, interest expense totaled $<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE5Nzc_d8363b70-ab06-4b0f-a042-dfcb7b944bb1">0.1</ix:nonFraction> million.</ix:continuation> </span></div><div id="ia936ede3f23041239a783a07e7f93c48_169"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMTY_f95b013e-36fb-41f1-a08b-b70130e174d5" continuedAt="i8fc0c29735a342ef8650b238c68c5037" escape="true">Equity </ix:nonNumeric></span></div><ix:continuation id="i8fc0c29735a342ef8650b238c68c5037" continuedAt="if596e6bd49dc4f21bf792e83a8ee929a"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 and 2021, the Company had authorized <ix:nonFraction unitRef="shares" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyODA1Nw_46d5460e-ada9-402c-ae2b-58d8e328a73e"><ix:nonFraction unitRef="shares" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyODA1Nw_d9020ae7-949b-4583-91b1-309fa44f2b8a">200,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, at a $<ix:nonFraction unitRef="usdPerShare" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzY1Mg_18ddcf86-68c9-4d6f-93d8-2a993901645c"><ix:nonFraction unitRef="usdPerShare" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzY1Mg_6c783322-1ccd-4f3e-af23-07b9d280ada5">0.001</ix:nonFraction></ix:nonFraction> par value per share. The holders of shares of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="INF" name="arvn:NumberOfVotesPerCommonStockShareHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzMyOTg1MzQ4OTc5NzU_3ad6c560-9e57-49c2-b64d-45dd023a104b">one</ix:nonFraction> vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. The holders of shares of common stock are entitled to receive dividends, if and when declared by the Board of Directors. No dividends have been declared or paid by the Company since its inception.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, in connection with the Pfizer Stock Purchase Agreement, the Company issued </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzEyMw_d8e109e9-d456-4842-92cb-037fe66f1c99">3,457,815</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of common stock to Pfizer at a price of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i008bbd6d947d479fad8e8cd49d905905_I20210930" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzE3Mw_fba5ba53-aed6-4421-881e-3c6d616359c2">101.22</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share, which resulted in aggregate gross proceeds of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyODU2Mw_ab901300-e00c-40df-91d1-80c469b7b11c">350</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, less financial advisor fees of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930" decimals="-5" name="us-gaap:PaymentsForBrokerageFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzI2OA_be82301e-c190-479b-9d71-456ed02300ce">4.6</ix:nonFraction>&#160;million, as further described in Note 3 to our consolidated financial statements</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pursuant to terms of the Pfizer Stock Purchase Agreement, Pfizer has agreed not to sell or transfer the Shares without prior written approval of the Company for a specified period, subject to specified exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company completed a public offering in which the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="ib169c00592d548a6a517237266872f3e_D20201201-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzE0MzQ_5436982f-b827-4205-b0f6-82c0e882438d">6,571,428</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c3f132181ab4f2782eda83c630d9771_I20201231" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzE0OTA_badb7957-9610-49b2-8041-961e6d1429a9">70.00</ix:nonFraction> per share, which resulted in aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib169c00592d548a6a517237266872f3e_D20201201-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzE1NTA_a06d6e33-0d22-4f5f-a88d-fbeb2f1b1dfb">460.0</ix:nonFraction> million before underwriter discounts, commissions, and offering costs of $<ix:nonFraction unitRef="usd" contextRef="ib169c00592d548a6a517237266872f3e_D20201201-20201231" decimals="-5" name="us-gaap:PaymentsForUnderwritingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzE2MTg_ac9be2b6-5e0a-4d81-ba21-cbe0f7a4f8d2">28.1</ix:nonFraction> million.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Distribution Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp; Company (&#8220;Piper Sandler&#8221;) and Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $<ix:nonFraction unitRef="usd" contextRef="i3746b160a6d94d569ae602cad6e75837_I20210831" decimals="-5" name="arvn:MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzI2NjA_a925f84c-23db-47a9-8537-96b8b5799688">300.0</ix:nonFraction>&#160;million of the common stock registered under the universal shelf registration statement pursuant to one or more &#8220;at-the-market" offerings. During the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="i991152e66e4e40e9bc87485ec165e1ad_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzI4MjA_77a773c9-98bb-46a7-a26e-8bd9051825f2"><ix:nonFraction unitRef="shares" contextRef="i2470ca2aeec0492f9ed6572c69865095_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzI4MjA_f0c8cd6f-42c0-4d0d-a9c4-b83765eb7a05">no</ix:nonFraction></ix:nonFraction> shares were issued under this agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into an Equity Distribution Agreement (the "Distribution Agreement") with Piper Sandler, pursuant to which the Company could offer and sell from time-to-time in an &#8220;at-the-market offering,&#8221; at its option, up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i96b0bd17747b4688858d04a773ba7ca5_I20191031" decimals="-5" name="arvn:MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzMxMjg_bff78faa-7486-426b-9614-e6fcddf4f5b8">100.0</ix:nonFraction>&#160;million of shares of the Company&#8217;s common stock through Piper Sandler, as sales agent. During year ended December 31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i7510f41e99a44e9ca02267aa1713991c_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzMyNjQ_be6dcc49-9abc-49bb-aa8e-572e99e221a0">2,593,637</ix:nonFraction> shares of its common stock resulting in proceeds to the Company of $<ix:nonFraction unitRef="usd" contextRef="i7510f41e99a44e9ca02267aa1713991c_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzMzMzQ_a799a8fa-90d0-470e-b45a-155aea2e6b0a">64.1</ix:nonFraction>&#160;million, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="i7510f41e99a44e9ca02267aa1713991c_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzMzNjM_49b560ae-9919-4634-94b9-7191b6da7682">1.6</ix:nonFraction> million. The Company terminated the Distribution Agreement in August 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if596e6bd49dc4f21bf792e83a8ee929a" continuedAt="i577028167b21437582ef86e383c8e8f8"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i31413367d46d44f0931cd3029d3ff4ef_I20180930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzM3NjY_87eb0f88-f3f5-4228-ad31-1c22afdf0d06">311,850</ix:nonFraction> shares of the Company's common stock. The number of shares of the Company's common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to <ix:nonFraction unitRef="number" contextRef="ibe1acbc8a7b44d439c12403bc1c92244_D20200101-20200101" decimals="2" name="arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzM5ODE_f2669101-eaa9-439a-8a3b-81c011958d51">1</ix:nonFraction>% of the Company&#8217;s then-outstanding common stock, effective as of January 1 of each year. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="iec89f9a651ba481db8272f35c6c0df8e_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQwODI_5991d666-f915-4426-9fc8-fc863ad219d3">1,986,565</ix:nonFraction> shares remained available for purchase. During the years ended December&#160;31, 2022, 2021 and 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i639e7b73e496499384ef668da7babf51_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQxNzg_8346b4c4-7aa1-490a-a54b-23489a22c25d">24,898</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i49494ba6d0a5453c93d7b34884260277_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQxODU_0d327ce0-c3ae-4ea4-9708-748d9d6f7200">19,357</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6dcf04ef5c59465f95dac5b9e575482f_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzAzMg_cf60080c-1d41-4abc-ae16-e781aff25fda">11,046</ix:nonFraction> shares, respectively, of common stock under the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Share Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Fourth Amendment to the Company&#8217;s Incentive Share Plan (the "Incentive Plan") adopted in March 2018, the Company was authorized to issue up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia846f83b7f644f2a8e79d0645dc59a76_I20180331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQ0MzQ_0e9604bb-8cd6-4388-af25-29cb70b778d0">6,199,477</ix:nonFraction> incentive units pursuant to the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQ2Mjg_cc30fc57-88bc-4fe7-a68a-ecb6f7074afc">one</span> to <ix:nonNumeric contextRef="if26c93c17a9d49abbe7e03e1fcfe3fdc_D20180301-20180331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMjE_ced4ec46-9b39-4a55-938b-c78131985f19">four years</ix:nonNumeric>. The Incentive Plan was terminated in September 2018.  In September 2018, each outstanding incentive unit was converted into a number of shares of common stock based upon the IPO price. Certain of the shares of common stock issued in respect of incentive units continued to be subject to vesting in accordance with the vesting schedule that was applicable to such incentive units through the year ended December 31, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s board of directors adopted, and the Company&#8217;s stockholders approved, the 2018 Stock Incentive Plan (the "2018 Plan"), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s IPO. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) <ix:nonFraction unitRef="shares" contextRef="i7ab2311054644dec946b5c3b15b4ac53_I20180930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTY_764b6596-119f-47b3-98df-02caf0e794f4">4,067,007</ix:nonFraction> shares of common stock; plus (2) the number of shares of common stock (up to <ix:nonFraction unitRef="shares" contextRef="idf4d92b3f5524d2ca5cfdb2b7d2ecc62_I20180930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU1NzY_4329b552-f901-4b64-aa56-67cfc849cbf5">1,277,181</ix:nonFraction> shares) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each year beginning with the year ended December 31, 2019 and continuing to, and including, the year ending December 31, 2028, equal to the lesser of <ix:nonFraction unitRef="shares" contextRef="ic70f3f6fa6df4c48b0dda80d2a243089_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzYxMzQ_9f34e2f5-7a27-45af-9833-21f725c48b2c">4,989,593</ix:nonFraction> shares of the Company&#8217;s common stock, <ix:nonFraction unitRef="number" contextRef="i3160983fd398465eb653ad6cd4b8665c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzYxNzU_7692b14d-a3b4-4278-bbc9-e93698bae51c">4</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the year or an amount determined by the Company&#8217;s board of directors. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i3f56a6f1dc8a4a1cb8a2a3b2b8c32f00_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzYzNDQ_2dd13f90-8b76-48a4-9d49-371267feee9f">2,048,284</ix:nonFraction> shares are available for issuance under the 2018 Plan. Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or cancelled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized compensation expense of $<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzY3MDU_3bc7d15c-d222-49c7-a78a-a4f16a6b3de5">75.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzY3MDk_5277b792-e536-4d7b-9274-9a8cddaf4b66">57.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzY3MTY_04e5e249-8e33-4bce-890e-9e75739b2e5a">30.2</ix:nonFraction> million, respectively, related to the issuance of incentive awards, including $<ix:nonFraction unitRef="usd" contextRef="if489ed4aaa6246e6bd13294c53489cff_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzA4MA_008f5773-09fe-491f-b516-62c3a856205d">0.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="iaf5f5dfe6c4149dba9168a6e138aad59_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzA4NQ_ce561555-45ea-47e3-9e2e-816927e88e24">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibf91003a0cee40d78e7d885446a5b900_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzA5NA_2f51eba3-0e66-496d-a0c0-c3fdc7f3adc2">0.3</ix:nonFraction>&#160;million, respectively, related to the 2018 ESPP. As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzY5MDM_216a4418-a6de-4fa3-9eec-a9748f7f6ba3">67.3</ix:nonFraction> million of compensation expense that is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="i1574e37a15e549dfb509f0a9a114356d_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNDkxNg_94da43db-3bbe-4679-b32a-cb5529934c65">1.7</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i577028167b21437582ef86e383c8e8f8" continuedAt="i6cc11dc7b28948e094595f35c616296a"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMjI_b29d0ec9-8372-4dbd-9e00-5218c259040a" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during each of the years ended December&#160;31, 2022, 2021 and 2020 was determined using the Black-Scholes option pricing model at the grant date with the following range of assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpkMDAwZTIzMmY4ZDY0NzM3YjY3NjFmZjFkNWMxMzUzMF80_209d2b24-c2a5-47b6-9900-5d35aeae7005">73</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpkMDAwZTIzMmY4ZDY0NzM3YjY3NjFmZjFkNWMxMzUzMF85_908911d2-b6c9-44ab-bdbe-5c1d9ca67339">76</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiY2UxMWNiNmU1MWQ0ZGIwYTZkYjc4MDdiYmVhYTQwNF80_f63415e1-07f5-4434-a3ce-a5d0dd83cfab">74</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiY2UxMWNiNmU1MWQ0ZGIwYTZkYjc4MDdiYmVhYTQwNF85_fca7355f-5344-4041-af01-0d843839ee4f">78</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiZDdmMmJlNTgyZWM0ZTQyOWRjMTlmMjI2ZGJkNjZhZV80_5bfafefb-52d2-4ae2-8a00-510f45194d53">70</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiZDdmMmJlNTgyZWM0ZTQyOWRjMTlmMjI2ZGJkNjZhZV85_5e35aa59-e22f-4d06-be2b-25bb7ac04d9b">75</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i354e561295fa4c89814e4858d5d58e62_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjoyMmJkMTkzZWU0ZjI0ZWYzODVmOTU0MTUzYzI0YWQzN180_2db7606c-6a59-422f-bbed-ba9e6c821c37">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="i09e4011096b842ed87640ac7cc8d1cb1_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjoyMmJkMTkzZWU0ZjI0ZWYzODVmOTU0MTUzYzI0YWQzN185_dfe8172b-72b2-46f9-ac96-cba3bd9e1a25">7.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia382a82cd26a4f6289ea15987b91a7b7_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjozOWY1YzMyMWFhM2Y0ZjE0YmFkNjEyYTUzYzg5MTAxMF80_6a71e450-f9de-4264-8294-09ca86785ae1">5.3</ix:nonNumeric> - <ix:nonNumeric contextRef="ib731e741df304e76af7f4302010536a3_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjozOWY1YzMyMWFhM2Y0ZjE0YmFkNjEyYTUzYzg5MTAxMF85_88e8cbbf-4075-46ce-bff6-b53336f46be2">7.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8a73ff779bf416cb4eebeeae68b3d11_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjowZjIxNGUzZTg0Yzk0OTI5ODJmZDcxMjA5MTQ0ZWQ3M180_20f230b3-76a1-4c05-ba64-638fe672df81">5.3</ix:nonNumeric> - <ix:nonNumeric contextRef="i7e4ccd6ef3f64b6b9e8ca76e68ac3d86_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjowZjIxNGUzZTg0Yzk0OTI5ODJmZDcxMjA5MTQ0ZWQ3M185_926a61d5-7773-4916-98eb-aa1ae168e3b2">7.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjoxNGI5NzU0Mjc2ZDc0ZmFjYTMwMDEzYjg2OTNlMDYzZl80_6a9a9b96-134f-4ca6-ba0d-e07afec20788">1.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjoxNGI5NzU0Mjc2ZDc0ZmFjYTMwMDEzYjg2OTNlMDYzZl85_be22e1e3-5c89-4592-8075-a88045406193">4.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiNzcyMTBhZTc3ODE0ZjM4YWRhMTM1ODYwYmZmYzU0Zl80_3c31b9c1-a892-4b83-a343-810bcb80da05">0.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiNzcyMTBhZTc3ODE0ZjM4YWRhMTM1ODYwYmZmYzU0Zl85_e470139f-3103-46ed-85ea-61f0c6192e24">1.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo3MWE1MzhlOTkzMmE0M2I1OGMwYmU4OTk4YWFlYzg3OV80_8ceaab11-ed26-4b78-8045-6dbc5795630b">0.3</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo3MWE1MzhlOTkzMmE0M2I1OGMwYmU4OTk4YWFlYzg3OV85_66d93768-371f-4e0f-88f0-d86e2ee264d6">1.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzUtMS0xLTEtNDUzMzQ_3b6033b6-8e78-4989-b4ee-638fac28dbdc">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzUtMy0xLTEtNDUzMzQ_40bb031f-4e3f-40b7-96cd-66379fdc1ba1">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzUtNS0xLTEtNDUzMzQ_eac6ddee-48a7-470e-8da6-24729a5acb5c">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7b0ed0665f494c7c902dffd54470764e_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo0ZmZiNWQ5Y2E2YzM0NmZmOTZhYzJjZDAxZDQ4ZGQxM180_32f2991a-6817-4335-946a-2017472f9a79">36.79</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ib7a433e284fc436190fc991a5d7d1826_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo0ZmZiNWQ5Y2E2YzM0NmZmOTZhYzJjZDAxZDQ4ZGQxM185_934dda9b-d68c-4868-990a-d5cc680b2edb">78.91</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ideae804a84b646ac95f9d6e31422f985_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo1ZWJhMTEzMzg2YzM0NjIwOGNjMTlhYWY5NWJiYzc1Nl80_6c8be5e7-952a-40e3-b058-2aaccfd3985f">66.82</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ife9054bd93cd4ee890d1bb3769253bbc_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo1ZWJhMTEzMzg2YzM0NjIwOGNjMTlhYWY5NWJiYzc1Nl85_6ced06b1-705f-405c-bfbd-252e264a4646">100.40</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5d25eae66f4940efbc51ec06b70565d7_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpmMDczMTMzNDBlMzQ0Njk4OWYzY2M3NGE2NjJmNTQxMV80_8956db7b-b343-44c8-8644-23ff6f403f9a">22.70</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b0c4960152f4b068f2e7ff788c1f577_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpmMDczMTMzNDBlMzQ0Njk4OWYzY2M3NGE2NjJmNTQxMV85_10ab2ca4-9484-48de-89b9-7fa0293b7d7d">50.00</ix:nonFraction></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the Company&#8217;s common stock has not been trading for a sufficient period of time, the Company calculates volatility of its common stock by utilizing a weighted average of a collection of peer company volatilities and its own common stock volatility. The expected term is calculated utilizing the simplified method. </span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzI3NDg3NzkwODAwOTg_c2a06dcb-d22e-408c-a3e3-1e6b7b9a9a06" escape="true"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMTk_2a82e4a6-c4de-4613-9272-c0aa9b98ba4d" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2022 is presented below. These amounts include stock options granted to employees, directors and consultants.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07de6ac05c1e41a9b8b94c23de19c282_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzEtMi0xLTEtNDUzMzQ_8395540c-5213-4bcc-9685-c614f26e475d">5,343,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07de6ac05c1e41a9b8b94c23de19c282_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzEtNC0xLTEtNDUzMzQ_eeb53283-a339-4c1b-bf80-65389d09e135">44.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzItMi0xLTEtNDUzMzQ_9d1e741f-9ba7-4094-af4e-3096668d402e">1,889,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzItNC0xLTEtNDUzMzQ_2f59df85-6fe4-4351-9289-8bcfa483325e">59.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzMtMi0xLTEtNDUzMzQ_d3a62e5c-36f4-4f44-8dcb-1917974e905d">184,160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzMtNC0xLTEtNDUzMzQ_ff3930eb-ece5-4a82-b535-130c7740c7bf">19.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzQtMi0xLTEtNDUzMzQ_093ab10c-c3f7-4e93-8115-453e09a9628e">233,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzQtNC0xLTEtNDUzMzQ_a951eab3-65ec-4234-a441-be0a0cd67433">61.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzUtMi0xLTEtNDUzMzQ_1edd45df-223c-4ccd-b6fa-9dbc964e3368">6,814,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzUtNC0xLTEtNDUzMzQ_3a6b36a5-8644-42a9-92fb-75ce70d38fe9">49.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzUtNi0xLTEtNDUzMzQ_bfaeaf4e-c6e6-4f1f-825a-a88c2b23d5c7">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzUtOC0xLTEtNDUzMzQ_28d3f07c-1e3b-41ec-9f84-25bf0ec235f4">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzYtMi0xLTEtNDUzMzQ_cb0e0f2f-f1de-4c77-b76a-5ad721b1d566">3,601,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzYtNC0xLTEtNDUzMzQ_0a8d815e-5e9d-4d57-863e-e677d49bf9a0">37.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzYtNi0xLTEtNDUzMzQ_1e8d29e6-c682-4626-bf4f-9245c66f397e">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzYtOC0xLTEtNDUzMzQ_3d2d121b-3c12-44be-a136-0436b3acdb4f">33.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc4NDA_4d28d286-015f-45b3-82f8-a4968fb31663">39.17</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc4NDQ_f79f7160-70ce-49e1-98f4-407e6a0c63e4">52.85</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc4NTE_ce729dbc-0181-48cf-9fdf-4d6f2351424f">27.45</ix:nonFraction>, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc5NTc_74571ea5-e550-46fc-9e52-48df58f36e0f">7.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc5NjE_28825a2b-4dd3-40d8-b49e-808f8be75f8c">46.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc5Njg_b50e9b7c-5f88-4376-b290-0638b9736a17">19.4</ix:nonFraction> million, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i3f56a6f1dc8a4a1cb8a2a3b2b8c32f00_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzgxNDY_17f05e70-842c-4d12-9cd7-295e724b24fd">53.8</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options granted under the 2018 Plan is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="ib3b24196f7ab4e96948b59541f2a2454_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMTc_c3eb7e77-91e0-46a6-952a-be6af744c8c3">1.6</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there w</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ere </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3f56a6f1dc8a4a1cb8a2a3b2b8c32f00_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzgzMTg_3d034661-16a6-4e6a-8555-b98c8d882709">6,540,844</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stock o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ptions under the 2018 Plan that have vested or are expected to vest.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6cc11dc7b28948e094595f35c616296a" continuedAt="i1c68202a44b54b8bb705f3b43c3430a2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><ix:nonNumeric contextRef="i825713991b7d4d6ca930134e1ea64f3b_D20220101-20221231" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMjA_4121cbf0-69d7-488a-98f4-ed2ff1a282af" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted stock award activity under the Incentive Plan as of December&#160;31, 2022 is presented below. These amounts include restricted stock granted to employees, directors and consultants. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date<br/>Fair Value Per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64e8a70e80d34c36a994fb20b47a535c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzEtMi0xLTEtNDUzMzQ_db24c702-bc4d-4375-b144-bfc4ba0d8511">30,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64e8a70e80d34c36a994fb20b47a535c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzEtNC0xLTEtNDUzMzQ_650269f2-5429-4e34-af28-5bdbdfb2d76a">16.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9135a832bfa141bdaea8cd60e7266128_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzItMi0xLTEtNDUzMzQ_1cea7725-1543-4c56-899a-db99a32f0d75">29,305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9135a832bfa141bdaea8cd60e7266128_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzItNC0xLTEtNDUzMzQ_b34ce6c7-a1e7-4f2a-8bc4-dd91a44983c7">16.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9135a832bfa141bdaea8cd60e7266128_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzMtMi0xLTEtNDUzMzQ_38821583-7716-4ae3-b282-0436081ab94c">1,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9135a832bfa141bdaea8cd60e7266128_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzMtNC0xLTEtNDUzMzQ_8e8f2c6d-fdd1-4c06-b9a2-d4f6a0e6d48a">16.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbbd49660da24081b31f3017c1fb0202_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzQtMi0xLTEtNDUzMzQ_faaddd54-8531-43bd-9a3b-db14f58d017e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idbbd49660da24081b31f3017c1fb0202_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzQtNC0xLTEtNDUzMzQ_b73ade22-00f3-4dca-82cb-bac37114929d">16.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i81e6172dea754fde956550d07bd3297c_D20220101-20221231" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMTg_94d505ab-887d-4c7c-9150-040850da293b" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity under the 2018 Plan for the year ended December&#160;31, 2022 is presented below. These amounts include restricted stock units granted to employees.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date<br/>Fair Value Per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock units as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee0ea6f5d3fd49e6bcd4ffc8b9e8f561_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzEtMi0xLTEtNDUzMzQ_391065f0-a1a9-4fe9-b877-920bb7627f7f">88,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee0ea6f5d3fd49e6bcd4ffc8b9e8f561_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzEtNC0xLTEtNDUzMzQ_e6fc6f25-144e-43f6-b69f-161af359cc5a">20.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzItMi0xLTEtNTExODA_79d83a20-9d48-4b8c-b08b-2d7be705538f">460,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzItNC0xLTEtNTExODA_407aab13-039e-4f3f-8a5e-2b98be4b8155">54.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231" decimals="INF" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzItMi0xLTEtNDUzMzQ_560befe9-6029-48b0-ab11-dde1f084af9b">42,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231" decimals="2" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzItNC0xLTEtNDUzMzQ_8ffa7807-bd09-401b-ac7f-ff4ea412d202">20.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzMtMi0xLTEtNDUzMzQ_fcec601e-304b-4f59-bf5c-46832a3082c8">17,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzMtNC0xLTEtNDUzMzQ_9b6c9633-716f-46e8-aac4-7d2e9fbd438d">53.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock units as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ba241f8483c4d27abe31fc22d087023_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzQtMi0xLTEtNDUzMzQ_95ab2bd8-e078-4c81-928d-19cd948b43fb">489,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ba241f8483c4d27abe31fc22d087023_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzQtNC0xLTEtNDUzMzQ_cb0ada9f-2b53-4229-84a4-ae6e3d159643">51.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i19ac2aec78b54b438d208831130b52be_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNDg2Mg_8802c8c2-2507-4cc8-998c-a93ca25779f2">13.5</ix:nonFraction> million of total unrecognized compensation cost related to non-vested restricted stock units granted under the 2018 Plan is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="i9391f67286954fea9ef7f855af5453c3_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNDg2Ng_83388bc4-26be-4df1-91cf-d7e756598c0e">2.1</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1c68202a44b54b8bb705f3b43c3430a2">As of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i3f56a6f1dc8a4a1cb8a2a3b2b8c32f00_I20221231" decimals="INF" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzg5Mjk_273d42e4-4486-42ba-a2b9-73e10eb7ee7c">414,450</ix:nonFraction> restricted stock units under the 2018 Plan that have vested or are expected to vest.</ix:continuation> </span></div><div id="ia936ede3f23041239a783a07e7f93c48_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzQwMTI_5a1b697c-103d-4eb0-95d0-ecc97a03a0d6" continuedAt="i725a47f81ac64685aa1a0bc23b38697e" escape="true">Equity Method Investments</ix:nonNumeric></span></div><ix:continuation id="i725a47f81ac64685aa1a0bc23b38697e" continuedAt="i42765194aa9d46d796099a7550d4f3a5"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company and Bayer CropScience LP ("Bayer LP") formed Oerth Bio, a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. Pursuant to the terms of the joint venture agreement, the Company made an in-kind intellectual property contribution to Oerth Bio in the form of a license to certain of the Company&#8217;s proprietary technology and Bayer LP committed and subsequently made cash contributions to Oerth Bio totaling $<ix:nonFraction unitRef="usd" contextRef="i2942bd6c0af14feca606f6c2cf37f948_I20190731" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzE2NDkyNjc0NDYxNzM_aa066498-07b2-4cfe-9894-ab48fb6ef1ee">56.0</ix:nonFraction>&#160;million, as well as an in-kind intellectual property contribution. The Company and Bayer LP each held an initial ownership interest in Oerth Bio representing <ix:nonFraction unitRef="number" contextRef="i2942bd6c0af14feca606f6c2cf37f948_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzE2NDkyNjc0NDYyMjE_c75d14a2-f96d-4bfe-a0a3-648372f19779">50</ix:nonFraction>% of the ownership interests. A <ix:nonFraction unitRef="number" contextRef="ife636ddfe9704222b932ba3a4f39e4d6_I20190731" decimals="2" name="arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzE2NDkyNjc0NDYyMzA_640dcbc3-f513-43ba-9de7-7a0bb1f5481d">15</ix:nonFraction>% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled <ix:nonFraction unitRef="number" contextRef="i0d437e8b17c84126a8ff5f6624f1cd05_I20221231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTg1ODA2Mg_1ca5d975-61c9-4c71-9de5-ca8749bcb7e1">46.5</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i5d95876f6cfe490fb65fd87f81be2616_I20211231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTg1ODA2Nw_6bf88a75-6a2d-46f0-bb79-3e2fd5c97a62">48.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ifc24f8c5be114f76ab380633238bd2df_I20201231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTg1ODA3OQ_73fcad42-49f0-408f-853f-41133f341100">49.4</ix:nonFraction>% as of December 31, 2022, 2021 and 2020, respectively, as a result of vested incentive units.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the joint venture agreement, the Company has no obligation to provide additional funding and the Company&#8217;s ownership interest will not be diluted from future contributions from Bayer LP. The activities of Oerth Bio are controlled by a management board under the joint control of the Company and Bayer LP. As Oerth Bio is jointly controlled by the Company and Bayer LP, the Company accounts for its interest using the equity method of accounting. The Company determined that Oerth Bio is a variable interest entity and, accordingly, the Company has evaluated the significant activities of Oerth Bio under the variable interest entity model and concluded that the significant activities consist primarily of research and development activities and, as the Company does not have the sole power to direct such activities, the Company is not the primary beneficiary.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i42765194aa9d46d796099a7550d4f3a5"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the fair value of the equity interest it received in Oerth Bio in exchange for the license contributed totaled $<ix:nonFraction unitRef="usd" contextRef="i808530cbe2df478ca19263be75cce162_I20221231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgyMDg3Nw_3ec6fe28-2003-4cd3-9415-8068b1ae663f">49.4</ix:nonFraction>&#160;million. The fair value of Oerth Bio was determined utilizing discounted cash flows based on reasonable estimates and assumptions of cash flows expected from Oerth Bio. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i7ce462a88c514f3db5b77585aa66ba25_D20190101-20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgyNTI4Mw_1291042d-6461-49f4-8f62-945597c8bad8">24.7</ix:nonFraction>&#160;million in 2019 attributable to the license contributed to Oerth Bio. In 2019, the Company also recognized $<ix:nonFraction unitRef="usd" contextRef="i7ce462a88c514f3db5b77585aa66ba25_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgyNTI5OA_af93bac1-b9a6-4e75-856f-98be292d7be3">24.7</ix:nonFraction>&#160;million of equity in net losses of Oerth Bio reducing the carrying value of the Company&#8217;s investment to <ix:nonFraction unitRef="usd" contextRef="i9b75291c93af4cb4b6f481d140f1d96f_I20191231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzIxOTkwMjMzMDA3NDU_d6ff3a96-059b-4b15-8d62-86de7baa1838">zero</ix:nonFraction>.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In connection with the preparation of the Company's consolidated financial statements for the yea</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">r ended December&#160;31, 2022, the Company identified a prior period error related to the accounting of its investment in Oerth Bio in 2019. Previously, the Company disclosed that revenue of $<ix:nonFraction unitRef="usd" contextRef="i808530cbe2df478ca19263be75cce162_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgzNjQ5Mg_91770998-506c-44dc-977e-f94df41393f9">24.7</ix:nonFraction>&#160;million was deferred and would be recognized if and when Oerth Bio recognized revenue associated with the license. The Company has now determined that the consideration received for the amounts associated with the deferred revenue should have been constrained, because at the time Bayer LP had contributed only a portion of its full cash commitment to Oerth Bio, and Bayer LP had the right to all the cash contributed, but not yet spent, upon liquidation of Oerth Bio. The constrained revenue should have been recognized upon both cash being contributed by Bayer LP and the related cash spent by Oerth Bio on research and development activities. As such, the recognition of revenue is accompanied by corresponding equity method losses of the same amount for all periods presented. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company ev</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aluated the error</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd determined that the related impact did not materially misstate the previously issued condensed consoli</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dated financial statements for the years ended December 31, 2021 and 2020. Although the Company concluded that the error was not material to its previously issued consolidated financial statements, the Company has</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined it is appropriate to adjust its previously issued consolidated financial statements for the years ended December 31, 2021 and 2020 to correct</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the error and improve comparability</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMyOTg1MzQ5Mjc4NTI_3a1f796b-09bf-4203-9a70-75f9ea019e58" escape="true"><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following illustrates the effect of the correction of the immaterial error for the period presented. There was no impact to the balance sheets, net loss per common share, statements of cash flows or changes in shareholders&#8217; equity.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as previously reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as adjusted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as previously reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as adjusted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItMS0xLTEtNjAyOTQ_b7fa807b-416d-49bc-be3e-bd9db0353033">46.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItMy0xLTEtNjAyOTQ_8c70fd93-6285-4beb-b62e-b2184cdba88a">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItNS0xLTEtNjAyOTQ_cef98cbd-de1a-4336-9c4d-0e7c88a531e8">53.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItNy0xLTEtNjA0NDA_91069843-22ff-4e28-ac92-12f75c5c94b2">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItOS0xLTEtNjA0NDA_f4270fb6-6b53-416d-b244-eea329a70297">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItMTEtMS0xLTYwNDQw_b6117a08-bd1c-4445-98be-49b934790d14">25.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtMS0xLTEtNjAyOTQ_7d9478e2-6106-49bb-ba2b-635b4798bf20">195.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtMy0xLTEtNjAyOTQ_6734c19e-5941-49ff-8bef-6feb2f1d8b57">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtNS0xLTEtNjAyOTQ_4b77cac7-d2ef-4f3d-a612-758093f35e45">188.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtNy0xLTEtNjA0NDg_939b5356-e5ab-47ff-8a37-be10b455cbea">124.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtOS0xLTEtNjA0NDg_20ad8e2b-0728-4103-9891-4bb228e6cafe">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtMTEtMS0xLTYwNDQ4_4db3c6f4-23bf-41d7-84c7-24cbd978262a">120.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtMS0xLTEtNjAyOTQ_7fad1350-443c-4405-a949-a73e64b48165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtMy0xLTEtNjAyOTQ_0a96589d-f092-450f-b45f-ed155ccdeb06">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtNS0xLTEtNjAyOTQ_b1373366-c2e9-4e1c-ae5d-9c1e67582c99">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtNy0xLTEtNjA0NTY_4f519021-fd47-41e5-89af-bfb06b83eb64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtOS0xLTEtNjA0NTY_75c0e1e7-80fe-4a7b-8286-7cf4bd1b7eb6">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtMTEtMS0xLTYwNDU2_47ab6f9c-0522-4567-ace7-ecef2f2af1a0">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtMS0xLTEtNjAyOTQ_101db2ce-6dfa-4b62-9e24-984eb4019206">191.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtMy0xLTEtNjAyOTQ_a02cbc19-cb5b-47d2-85b0-a01376b686ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtNS0xLTEtNjAyOTQ_56f5a753-85f1-44ed-a992-3220c4d6953f">191.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtNy0xLTEtNjA0NjQ_a965e58f-260f-4144-aa06-34ed3f9093e0">119.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtOS0xLTEtNjA0NjQ_bf32ce17-dc15-4af6-a0c1-0645107e8c92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtMTEtMS0xLTYwNDY0_e4ba3875-d6da-47e5-9182-005a62ce5982">119.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMS0xLTEtNjA0ODQ_1dac6700-b626-4455-9654-7f94aa7acd68"><ix:nonFraction unitRef="usdPerShare" contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMS0xLTEtNjA0ODQ_b2291695-c9a6-4c01-8de9-64a8c4557a14">3.82</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMy0xLTEtNjA1MDY_143605fa-6d36-456b-919f-41d7438da439"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMy0xLTEtNjA1MDY_a47af6ab-44a5-4794-a8a6-e5a8673ba398">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtNS0xLTEtNjA0OTA_4ec9f07f-0f25-454c-b8f7-fb25519067df"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtNS0xLTEtNjA0OTA_7287cc69-44e6-40f3-a079-1bb1301f1d46">3.82</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtNy0xLTEtNjA0OTU_631fb358-7e74-4e2c-8a5f-8383942113b3"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtNy0xLTEtNjA0OTU_9c473465-f848-491f-9050-f67d26cc9a46">3.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtOS0xLTEtNjA1MzE_03bf57d5-6413-45df-a57a-a152997952d7"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtOS0xLTEtNjA1MzE_2ff51ec5-3ad0-4c4e-9fcd-5372584b8f8b">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMTEtMS0xLTYwNDk5_64359b54-fdbb-4432-adfb-ea9a13e0c657"><ix:nonFraction unitRef="usdPerShare" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMTEtMS0xLTYwNDk5_708d9e00-5ca7-454a-b2d9-3b06879108d0">3.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctMS0xLTEtNjI4MTY_d613cc2c-36a6-44d2-bc6c-d1736b8f2c71">196.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctMy0xLTEtNjI4MTY_0cef6ff8-135d-49e0-8bd1-1e84c527a3c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctNS0xLTEtNjI4MTY_7ad94e3d-d99d-4cd3-9fcf-a7523f45c07f">196.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctNy0xLTEtNjI4MTY_1bd04a5b-9497-48a8-b37b-c9af7f84307f">118.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctOS0xLTEtNjI4MTY_9748fbd6-3410-461f-99fd-d81e1c67cdfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctMTEtMS0xLTYyODE2_403b0def-0295-4a4b-8f94-f17e18cf4f09">118.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses and net loss of Oerth Bio for the years ended December 31 2022, 2021 and 2020 totaled $<ix:nonFraction unitRef="usd" contextRef="idfbc96733ba14eacba1def4f1f53391f_D20220101-20221231" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxNzQ_3c7bb7eb-9def-464b-ad87-471831ce1796"><ix:nonFraction unitRef="usd" contextRef="idfbc96733ba14eacba1def4f1f53391f_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxNzQ_d5315e65-3027-40dd-a6c6-0f3319a45b1d">22.9</ix:nonFraction></ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0d1a440ff1814ec2b2967dbc51a0a62c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxNzg_70627fc3-51dc-472a-a763-a3647742b85b"><ix:nonFraction unitRef="usd" contextRef="i0d1a440ff1814ec2b2967dbc51a0a62c_D20210101-20211231" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxNzg_a4e31c76-b3f3-473d-b602-072a1858fa95">14.3</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f581941be6141b8a521496421ffb373_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxODU_7eb37fc2-38c1-4467-a3c8-f28af2ca169a"><ix:nonFraction unitRef="usd" contextRef="i8f581941be6141b8a521496421ffb373_D20200101-20201231" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxODU_de03e16f-401d-4adb-a3bc-e128c3a117d3">8.3</ix:nonFraction></ix:nonFraction> million, respectively. The Company recognized equity method losses of $<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgzMTE3MQ_87bfd27b-e721-4cea-b925-8277fabf8267">10.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgzMTE3OA_b1373366-c2e9-4e1c-ae5d-9c1e67582c99">6.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgzMTE4NQ_47ab6f9c-0522-4567-ace7-ecef2f2af1a0">4.1</ix:nonFraction>&#160;million for the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2021 and 2020, respectively. As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and 2021, the Company&#8217;s carrying value of the investment was zero.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides Oerth Bio with compensated research and development and administrative services through a separate agreement. The se</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rvices rendered by the Company during the years ended December&#160;31, 2022, 2021 and 2020 were immaterial.</span></div></ix:continuation><div id="ia936ede3f23041239a783a07e7f93c48_178"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzUxNTc_b78b39ec-48b5-4df1-97b1-be309b0f290c" continuedAt="i887d368345114e7ab8a0591dff244017" escape="true">Income Taxes </ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="i887d368345114e7ab8a0591dff244017" continuedAt="iadda81aac6834498acd6bd9fe3f44f9e"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzYwNDczMTM5NjIxOTA_d271598d-a408-4697-a983-dacb5edc1dcf" continuedAt="icbba04dd05d3484ebb0bd75c2235c744" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, income tax expense totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzU0OTc1NTgxOTE3OA_1ac26cb4-281c-41af-bd72-ba11758c04a5">20.9</ix:nonFraction> million, and consisted of the following:</span></ix:nonNumeric></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iadda81aac6834498acd6bd9fe3f44f9e" continuedAt="i403a830a5a4d471092fef4c4af9e8fef"><div style="margin-top:12pt"><ix:continuation id="icbba04dd05d3484ebb0bd75c2235c744"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzQtMS0xLTEtNDkwODU_403fe743-0268-4624-b6da-8554cb967687">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzQtMy0xLTEtNTk3OTU_a7b08920-f6f5-4853-8a73-66d699fc31fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzQtNS0xLTEtNTk3OTU_76380a49-94e3-4804-85e1-e4b9d0993ff6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzUtMS0xLTEtNDkwODU_01a2d31b-fd24-4c9b-8d7c-469c7b0f4069">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzUtMy0xLTEtNTk3OTU_c673126c-5d79-4a8c-8bc0-6c69f1961b87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzUtNS0xLTEtNTk3OTU_b9b1a0dd-ccd8-4b49-9fb8-5e293c23c44c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzYtMS0xLTEtNDkwODU_d80d72f4-c3db-493f-acfd-195413e61bf5">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzYtMy0xLTEtNTk3OTU_8db670cc-0f94-48ca-8829-32561d7c0883">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzYtNS0xLTEtNTk3OTU_c7b967b8-6d58-47b1-8f97-c43118fb1ee3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzktMS0xLTEtNDkwODU_312bba93-79ac-41a9-9bac-7799624f20c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzktMy0xLTEtNTk3OTU_847b73a8-fb51-4be9-a401-3fd4bcf37c83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzktNS0xLTEtNTk3OTU_23ff2359-6710-4f4a-93ab-48e26ddc69e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEwLTEtMS0xLTQ5MDg1_e18389fd-2505-47fc-8992-a5d95573b35f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEwLTMtMS0xLTU5Nzk1_d64bf7a4-0807-457a-9ca2-2b43ddba0d45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEwLTUtMS0xLTU5Nzk1_b278cbf9-894e-4799-a5e0-ab93d737f8ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzExLTEtMS0xLTQ5MDg1_494c1c3b-0c14-422c-bda2-96681c4335f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzExLTMtMS0xLTU5Nzk1_88ad1597-a844-4b80-aefd-1b576f55143a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzExLTUtMS0xLTU5Nzk1_add484eb-fd52-462a-8135-ca4d27cd255f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEyLTEtMS0xLTQ5MDg1_1605394c-d02a-4acc-8a8c-d63affb6081a">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEyLTMtMS0xLTU5Nzk1_b337b5a3-d877-4552-bd46-efc9859a0226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEyLTUtMS0xLTU5Nzk1_2dbab1fe-ad17-4555-b29e-dbb8e4333a36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generated taxable income for the year ended December&#160;31, 2022 primarily due to revenue recognition for tax purposes from the ARV-471 Collaboration Agreement and the mandatory capitalization of qualified research and development expenses incurred on or after January 1, 2022, which, upon recognition for tax purposes, would create additional deferred tax assets. Under the Tax Cuts and Jobs Act of 2017, qualified research expenses incurred after 2021 are no longer immediately deductible for tax purposes and instead must be capitalized and amortized for tax purposes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzM5_83bb080c-2fb7-4f36-9de1-17c346296621"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzM5_cffb05fb-2e48-4825-9c2c-46869ad23eae">no</ix:nonFraction></ix:nonFraction> income tax expense due to incurred operating losses. The Company had also not recorded any income tax benefits for the net operating losses incurred in each of those periods due to its uncertainty of realizing a benefit from those items. All of the Company&#8217;s losses before income taxes were generated in the United States.</span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzUxNTk_7c59cdb6-9de3-4d74-b992-6730794d390f" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2022, 2021 and 2020 were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzItMS0xLTEtNDUzMzQ_8fd68f2f-f68c-4f6d-9fc4-27b3a6bcc0fb">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzItMy0xLTEtNDUzMzQ_9eb121a1-ada4-400a-a411-e658cde89c60">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzItNS0xLTEtNDUzMzQ_91a1a12a-683c-4dd1-8cb0-7151b12d5240">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="3" name="arvn:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMS0xLTEtNjIwNjI_ac743d8d-585b-40f8-ad94-4ad2d46d3be1">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="3" name="arvn:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMy0xLTEtNjIwNjI_af3cfd5b-1db4-4a67-aa5b-e77ae39160dc">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="3" name="arvn:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtNS0xLTEtNjIwNjI_a9afea5d-e499-4a1c-9fa3-ea904f5991cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMS0xLTEtNTc3MzY_28a90526-5e38-4404-8b39-089deec04210">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMy0xLTEtNTc3MzY_c7ca9f25-0a86-4100-b8e5-5c0920255557">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtNS0xLTEtNTc3MzY_e9cb9005-d2d3-458b-9f31-2fd79155d9b6">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtMS0xLTEtNjIwNDM_d3ebcc13-6be9-45bc-9b64-b61e4ba00f8f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtMy0xLTEtNjIwNDM_b0bbebc8-842b-46b8-8e65-d79edf83f1ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtNS0xLTEtNjIwNDM_6b88b7ed-a721-4d8b-8b96-832cb64099b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtMS0xLTEtNTc3Mjg_8f4da429-441d-45ba-888b-f59c9cd5f6c6">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtMy0xLTEtNTc3Mjg_7a350c9c-d294-46a6-8ef2-7a1050bc046f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtNS0xLTEtNTc3Mjg_f9d8cfcb-9bb2-4b54-bfdf-970dd1b959b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtMS0xLTEtNTc3NDg_e871306a-4d42-42eb-8b13-5db8582eafaf">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtMy0xLTEtNTc3NDg_9402aaac-a9cd-4e4b-9fd2-1911447173e9">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtNS0xLTEtNTc3NDg_f463ac27-71b7-4b5f-88af-76c116045bed">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMS0xLTEtNDUzMzQ_d2916356-5b45-4056-8652-4ab1a1378b51">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMy0xLTEtNDUzMzQ_549278a5-82b3-47c2-96d9-23c4339b63bb">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtNS0xLTEtNDUzMzQ_8dde8bf2-a5ed-4e16-988b-1e299ad53fa9">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtMS0xLTEtNDUzMzQ_0042f7d1-45e0-4a22-b351-92345efe9af6">31.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtMy0xLTEtNDUzMzQ_aa4acd44-4b57-4fa2-b21b-e6977f0cd11e">38.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtNS0xLTEtNDUzMzQ_6a8f07ba-d9b2-4ae5-b2e1-7b7a684f2928">23.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzctMS0xLTEtNDUzMzQ_b267f625-66c5-4561-b80e-1219c3295db7">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzctMy0xLTEtNDUzMzQ_d8e0af36-1591-45c2-9023-22b526f967fc">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzctNS0xLTEtNDUzMzQ_88a3df87-58d8-41b5-8b04-c2f8a859b681">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i403a830a5a4d471092fef4c4af9e8fef" continuedAt="ieb7faca5a9324d19ab072f2ed5508fd2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzUxNjA_ca7b4408-355b-4f6e-b72e-1db5e0eedb0f" continuedAt="i5455c9af94224920ae14aa4dca7dc851" escape="true">Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities were as follows as of December&#160;31, 2022 and 2021: </ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><ix:continuation id="i5455c9af94224920ae14aa4dca7dc851"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzMtMS0xLTEtNjE4OTY_031bb08a-9dc1-4ce8-9c4b-aede3e2cb586">143.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzMtMy0xLTEtNjE4OTY_e5a164bf-cae0-454d-8652-402f747d9164">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzMtMS0xLTEtNTQ4NTU_40577d60-0eca-4c33-9c67-131c4adf4712">56.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzMtMy0xLTEtNTQ4NTU_8ddb73af-3efc-49ee-8308-17d874e7e6f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzUtMS0xLTEtNDUzMzQ_ff461316-d514-4576-84a1-6808199c4ce4">25.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzUtMy0xLTEtNDUzMzQ_36af6637-b04b-4109-94d5-a2734d246f08">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzYtMS0xLTEtNDUzMzQ_454c98dd-1286-4cdb-88b7-94d17f003616">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzYtMy0xLTEtNDUzMzQ_2a94dabb-5da5-43f1-9866-c08049f168df">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzktMS0xLTEtNjE5MTg_4a2ac154-b066-4f91-a8ff-48d78d9811c4">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzktMy0xLTEtNjE5MTg_faa4a6dd-c685-4a81-aa4b-4d590187dde9">97.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzctMS0xLTEtNDUzMzQ_fc4efd40-11c6-4b2f-b118-0742fa22c0de">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzctMy0xLTEtNDUzMzQ_fff39374-1734-4b04-9f2b-60a0cc18fb3d">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzgtMS0xLTEtNDUzMzQ_37d79aa4-d4a9-4865-9f4f-2514b72468cd">247.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzgtMy0xLTEtNDUzMzQ_6890c31d-9a4a-4d1b-b765-6d50c28ffdbb">144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzExLTEtMS0xLTQ1MzM0_afc7b5de-96d0-4d45-97fb-df32028d126e">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzExLTMtMS0xLTQ1MzM0_017870d6-9703-4fa6-bd5b-41f772220299">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzEyLTEtMS0xLTQ1MzM0_7a28ccc5-4dfa-42c3-b8e8-ac8abf50a5cc">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzEyLTMtMS0xLTQ1MzM0_ccefb878-0794-4db0-8a48-c448a5ff747f">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzEzLTEtMS0xLTQ1MzM0_626e97c1-7c6c-4cd6-ad92-67943644e230">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzEzLTMtMS0xLTQ1MzM0_028bdd74-6f04-4875-9c7d-1321f0a0523c">5.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzE0LTEtMS0xLTQ1MzM0_a29b8e44-5065-4e32-8cd5-a874468c6afe">243.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzE0LTMtMS0xLTQ1MzM0_0ad1edb5-0d61-48f9-9694-6c544b420a21">139.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred income tax liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzE1LTEtMS0xLTQ1MzM0_5d5a07a8-b9eb-413a-ab00-c300452031ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzE1LTMtMS0xLTQ1MzM0_2bb9a656-1f18-4865-82b1-8fd974a0f138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company has provided a valuation allowance against the full amount of the deferred tax assets since</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> it is more likely than not that the benefits will not be realized. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This assessment is based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All, or a portion of, the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to utilize these potential tax benefits. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="iecde1bb80509425b97c53198d17cd282_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzEzMzI_08598f9d-5c16-4082-8027-f6585c49e374">104.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i462d342906254aa08ed253bed2a62c4c_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzEzMzk_9b76c230-be8a-4fc8-823f-d7340178eb26">74.6</ix:nonFraction> million in 2022 and 2021, respectively, due to revenue recognition for tax purposes from the ARV-471 Collaboration Agreement and the mandatory capitalization of qualified research and development costs in 2022, and increases in net operating loss carryforwards, tax credit carryforwards, stock compensation expense, and research and development tax credits in 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="i87ad4e65cba64ab792067ed0244886b2_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE1MzM_34eb6349-cc3f-43be-a66a-e42445a490cf">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1330642a737d458aa14cb794d465bbbb_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE1NDA_133958c6-1b6b-42da-8da4-10769daef10a">373.6</ix:nonFraction> million of federal net operating loss carryforwards as of December&#160;31, 2022 and 2021, respectively. Federal net operating loss carryforwards as of December 31, 2017 expire at various dates through 2037 and federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such carryforwards is limited to <ix:nonFraction unitRef="number" contextRef="i0f49b42bb24b4669b993f69de2a04054_D20220101-20221231" decimals="2" name="arvn:OperatingLossesCarryForwardMaximumDeductibilityPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE4ODM_a5aaf6f2-e503-4742-8f8a-96adcc9618ad">80</ix:nonFraction>% of the Company&#8217;s taxable income in the year in which carryforwards are used. The Company had $<ix:nonFraction unitRef="usd" contextRef="i7a1938c4bd324660821a879962862c4e_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE5Nzk_d6096a61-06c2-4b58-8144-596ba25f1548">63.4</ix:nonFraction> million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i98620edc8ebd468da40a2ba163c12f1a_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE5ODY_1d401019-24fb-42b0-bb9f-a7f288198218">346.9</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of state and local net operating loss carryforwards as of December&#160;31, 2022 and 2021, respectively, that expire at various dates through 2041.  The Company had <ix:nonFraction unitRef="usd" contextRef="i87ad4e65cba64ab792067ed0244886b2_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzIxMzA_9bb72b9f-8090-4d2f-b411-3999044cb110">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1330642a737d458aa14cb794d465bbbb_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzIxMzc_eb00a9dd-5237-415a-954b-bca8f3e41ef8">15.2</ix:nonFraction> million of federal tax credit carryforwards as of December&#160;31, 2022 and 2021, respectively. The Company had $<ix:nonFraction unitRef="usd" contextRef="i7a1938c4bd324660821a879962862c4e_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzIyNjU_62d60203-4669-4890-8425-f777973ba624">13.1</ix:nonFraction> million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i98620edc8ebd468da40a2ba163c12f1a_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzIyNzI_f4255030-f5bc-48fd-afa8-083ec97e1025">4.5</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of state tax credit carryforwards as of December&#160;31, 2022 and 2021, respectively, which expire at various dates through 2037.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company performed a Section 382 analysis to determine whether an ownership change occurred for tax purposes. Based on this analysis, the Company determined that ownership changes occurred on July 31, 2018 and December 31, 2020 due to various equity offerings, vesting of restricted stock awards and stock option exercises. These ownership changes resulted in Section 382 limitations on the Company&#8217;s net operating loss and tax credit carryforwards generated before these dates. However, because the amount of the Section 382 limitations (including carryover of the unused Section 382 limitations and realized </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ieb7faca5a9324d19ab072f2ed5508fd2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">built-in gains) exceeds the amount of the Company&#8217;s carryforwards generated before these dates, the limitations will not affect the Company's ability to fully utilize these carryforwards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company complies with the provisions of ASC 740 in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. As of December&#160;31, 2022, the Company recorded net uncertain tax positions of $<ix:nonFraction unitRef="usd" contextRef="i7a1938c4bd324660821a879962862c4e_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE2NDkyNjc0NTI2Nzk_e7137c61-0b94-4913-ac4c-5c4f811b2899">3.2</ix:nonFraction>&#160;million relating primarily to state income tax filing positions in various jurisdictions. As of December&#160;31, 2021, the Company had <ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzM3Mzc_88c28761-7d3d-42d9-9620-abd557e0ca4a">no</ix:nonFraction> unrecognized tax benefits.</span></div><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzMyOTg1MzQ4OTM5MTE_6154a4ef-2b3e-445d-b4e1-90facb409e1e" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's gross unrecognized tax benefits were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period balance - gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzMtMS0xLTEtNTc5ODI_a70bc16e-9a96-45c3-af9c-741934e2b10c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzMtMy0xLTEtNTc5ODI_3df9ee3a-d864-49d0-971c-ba30585c4a9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35327f5dcba84428bcd65e20009ba82d_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzMtNS0xLTEtNTc5ODI_01366704-bc61-4ec2-90a7-ddc4c98806b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions taken during the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzQtMS0xLTEtNTc5ODI_16639f59-8087-42e7-93a7-f3bdaf6b62df">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzQtMy0xLTEtNTc5ODI_c0f75ef6-f23a-43ee-9af6-892eba1be01a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzQtNS0xLTEtNTc5ODI_370114b4-cdd0-4752-af20-997848c7effc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases for tax positions taken during a prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzUtMS0xLTEtNTc5ODI_5465b89f-2ffd-4ece-a1e9-eea56c4504cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzUtMy0xLTEtNTc5ODI_70cce9bd-11cd-4613-aff8-8cdd4028fc4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzUtNS0xLTEtNTc5ODI_977427ad-1e0c-4121-bb74-7594d0d917d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period balance - gross</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzYtMS0xLTEtNTc5ODI_42f5a7de-8aab-4752-b61f-b06b1f45f1e7">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzYtMy0xLTEtNTc5ODI_76774876-34d6-41b7-b605-d46229c20bd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzYtNS0xLTEtNTc5ODI_e55543fa-c559-474f-aae4-a6fb729607c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense. The Company's accrual for interest and penalties as of December&#160;31, 2022 was <ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzIxOTkwMjMyNjYxMzY_d2e7e562-41be-4fa4-a261-350dcc8ca8c7">immaterial</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to file income tax returns in the U.S. Federal and various state jurisdictions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Company&#8217;s net operating loss carryforwards, the Company&#8217;s federal and state statutes of limitations generally remain open for all tax years until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization. The Company does not currently have any federal or state income tax examinations in progress.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021, and 2020, the Company recorded a benefit from expected cash refunds to be provided by the State of Connecticut, equal to <ix:nonFraction unitRef="number" contextRef="i462d342906254aa08ed253bed2a62c4c_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ2NDc_0ad998e5-a0d8-47f1-af97-2ad0b1b649dd"><ix:nonFraction unitRef="number" contextRef="ief8ca6ef40ac464c81aebbad3e910b38_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ2NDc_cab7a289-dbc8-42e9-b6c5-c940d2d1911c"><ix:nonFraction unitRef="number" contextRef="iecde1bb80509425b97c53198d17cd282_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ2NDc_f9f9ab72-2275-491e-b216-838c60ff7255">65</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of research and development credits, of <ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ2OTA_400ffdc2-329f-43b6-958d-1450df17fcfd">zero</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ2OTQ_5e18b903-fac5-48c6-bcb6-89b4b2ddac8c">1.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ3MDI_d3b1bccf-db2b-4855-8d1b-5d857d8306d1">1.8</ix:nonFraction> million, respectively, which is included in Other income, net in the accompanying consolidated statements of operations and comprehensive loss, due to the Company being a state income and franchise taxpayer in 2022, and a state franchise taxpayer in 2021 and 2020. The benefit results from the exchange of the state research and development tax credit carryforwards for cash refunds. As of December&#160;31, 2022 and 2021, the Company had receivables of $<ix:nonFraction unitRef="usd" contextRef="i3cc8adccf5a84a7e82138a769bca1f6f_I20221231" decimals="-5" name="us-gaap:IncomeTaxReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzUwNjc_b54827f0-b4e4-4af3-86e9-70ae67434e79">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iadb5ee3cd631498e9f704ed1e3083c3a_I20211231" decimals="-5" name="us-gaap:IncomeTaxReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzUwNzQ_5b82fb92-a7bc-4691-a9f3-d0ae494db291">3.4</ix:nonFraction> million, respectively, relating to research and development credits due to the Company.</span></div></ix:continuation><div id="ia936ede3f23041239a783a07e7f93c48_181"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzgzMg_a4a747e5-7a0c-43ea-841c-87d827ab5000" continuedAt="ia37e78848c854c9989457afac2eaa8c3" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="ia37e78848c854c9989457afac2eaa8c3" continuedAt="i15c803a916824d1f97a96b2a83fc802d"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the&#160;ordinary&#160;course&#160;of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred.&#160;As of December&#160;31, 2022, the Company has accrued $<ix:nonFraction unitRef="usd" contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzE2NDkyNjc0NTQ0NTg_a0a7aa4c-6fbf-41fb-9cb4-e9c6ce9d7271">7.0</ix:nonFraction>&#160;million for such matters, primarily related to a contract dispute that is in early stages.&#160; Due to the early stage of the dispute, the means of resolution are unknown and could involve contract modification and, or payment of consideration.&#160; An estimate of the possible range of loss associated with the dispute cannot be made at this time and the Company has accrued its best estimate as of December 31, 2022.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical and Preclinical Development and Licensing Arrangements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i15c803a916824d1f97a96b2a83fc802d"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under licensing and related arrangements to which we are a party, we may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Yale University License Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2013, the Company entered into an exclusive license agreement, including the right to grant sublicenses, with Yale University to develop protein degradation technologies. Under the license agreement, the Company is required to pay a minimum license maintenance royalty totaling $<ix:nonFraction unitRef="usd" contextRef="i6b912e140bd549c59a71222eff36d168_D20130701-20130731" decimals="-5" name="arvn:AnnualLicenseFeePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzMxOQ_7ae996aa-ed53-41c3-b05e-1ea5ad54be0d">0.1</ix:nonFraction> million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first two licensed products for the development of the protein degradation technologies totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i0e872fdee2484e02a8eecae47bd8d71c_D20130701-20130731" decimals="-5" name="arvn:RequiredMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzU1MA_7244c149-2b66-45b4-bfe9-f6e26ca2435d">3.0</ix:nonFraction>&#160;million for the first licensed product and approximately $<ix:nonFraction unitRef="usd" contextRef="i71af99d94a15409d814e3bc898621bc3_D20130701-20130731" decimals="-5" name="arvn:RequiredMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzYwMg_96e21f8c-7758-4e6d-92f1-28658ccecf69">1.5</ix:nonFraction>&#160;million for the second licensed product, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from $<ix:nonFraction unitRef="usd" contextRef="i6b912e140bd549c59a71222eff36d168_D20130701-20130731" decimals="-5" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzgyNA_80d2f22c-4669-43d5-ad07-faefc1d87298">0.2</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i4c4e41fe7c444302a2f4e5632b5df43f_D20130701-20130731" decimals="-5" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzgzMA_8000bc70-10b2-4fcd-8681-13a246fdef50">0.5</ix:nonFraction> million. During the years ended December 31, 2022, 2021 and 2020, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i2bcccb8aa5c3415c94857cd84457d1c3_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzU0OTc1NTgzNDkwMQ_0e98b6ff-eafb-4a01-a636-cca58f4a8b6f">0.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="idc0e2f0ce3a94a72a40371967158f45d_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzU0OTc1NTgzNDkzMQ_b54079b5-0946-4107-bceb-bfbe4bbcd1a5">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id8f55863c58b46e580d64c087d73a211_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzU0OTc1NTgzNDkxNw_8a4c645c-5d75-462a-8f62-6d3ae2934d55">0.2</ix:nonFraction>&#160;million, respectively, under the license agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FMI Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a Master In Vitro Diagnostics Agreement with Foundation Medicine, Inc. (the "FMI Agreement") for the development and commercialization of one or more of Foundation Medicine&#8217;s companion in vitro diagnostic assays for use with one or more of the Company's therapeutic products.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FMI Agreement does not have a fixed duration, and the Company may terminate the FMI Agreement for convenience by providing adequate written notice to Foundation Medicine, Inc., subject to payment of applicable termination fees. Either party may terminate the FMI Agreement in its entirety for an uncured material breach by the other party, upon the bankruptcy or insolvency of the other party or by the mutual written agreement of both parties. Additionally, Foundation Medicine may terminate the FMI Agreement with respect to an applicable program, if (a) a reasonably necessary third party license is not secured by Foundation Medicine or if the Company does not consent to payments for such license (b) Foundation Medicine reasonably determines that further development of the applicable assay is not technically feasible or (c) following a certain number of years after the first commercial launch of the applicable assay for use with the applicable therapeutic product. Certain license and other rights and certain obligations of Foundation Medicine survive termination of the FMI Agreement. If the FMI Agreement is terminated in its entirety or with respect to any program, the Company has certain payment obligations remaining to Foundation Medicine and may also be required to pay a termination fee, if applicable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bavdegalutamide</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the development of FoundationOne&#174; Liquid CDx as a companion diagnostic for use with bavdegalutamide for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low to mid tens of millions of dollars, in addition to certain validation fees per sample and related pass-through costs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARV-766</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the development of FoundationOne&#174; Liquid CDx as a companion diagnostic for use with ARV-766 for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low <ix:nonFraction unitRef="usd" contextRef="i496ab182e9bd4c7fb0d9db9b728a6798_D20220604-20220604" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt-sec:numwordsen" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzE2NDkyNjc0NTAwNjQ_27728292-3df0-48ef-8873-c15dc2818e3f">ten</ix:nonFraction>s of millions of dollars, in addition to certain validation fees per sample and related pass-through costs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 27</span></div></div></div><div id="ia936ede3f23041239a783a07e7f93c48_184"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90ZXh0cmVnaW9uOjEyNmEzYWFlM2E3MDQzMzdhNzExMWIyODliYTYxODk1XzI4Mg_986253b3-14ef-4d63-80cd-de43fbf0fac3" continuedAt="i1ed941003695440db344c9f41c7e1b5a" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="i1ed941003695440db344c9f41c7e1b5a"><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90ZXh0cmVnaW9uOjEyNmEzYWFlM2E3MDQzMzdhNzExMWIyODliYTYxODk1XzI4Mw_b8c2899a-e50c-496e-a7d2-7f6c6505e3e1" escape="true"><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzItMS0xLTEtNDUzMzQ_f4edae02-d9c4-4b6f-adc1-baef9e24af3b">282.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzItMy0xLTEtNDUzMzQ_1b234317-f74f-4e32-8073-e77079a8e9b1">191.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzItNS0xLTEtNDUzMzQ_6d681472-c811-427b-bbc4-8b5889d84716">119.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;- basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtMS0xLTEtNDUzMzQ_5d8e0e19-7a4c-42ea-8414-4452563a594a"><ix:nonFraction unitRef="shares" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtMS0xLTEtNDUzMzQ_ca7357fb-7480-411c-a635-7d0763115e3d">53.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtMy0xLTEtNDUzMzQ_39b64c60-1933-42c4-9dc1-1ec7307a5ea7"><ix:nonFraction unitRef="shares" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtMy0xLTEtNDUzMzQ_782eef24-b23b-4ee3-9661-18567b9099b1">50.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtNS0xLTEtNDUzMzQ_9ccced41-83cb-4308-be44-26aba2e9b478"><ix:nonFraction unitRef="shares" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtNS0xLTEtNDUzMzQ_e492034e-c525-4161-a0f8-63dd7c35da5b">39.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per common share<br/>&#160;- basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtMS0xLTEtNDUzMzQ_0d095c59-9423-47b7-a163-cfb14774b60d"><ix:nonFraction unitRef="usdPerShare" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtMS0xLTEtNDUzMzQ_d50862b3-4dc5-4bad-95ac-ebe81214e160">5.31</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtMy0xLTEtNDUzMzQ_9f82e83c-e29d-408c-a73d-e12e8f344bf7"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtMy0xLTEtNDUzMzQ_edb18b11-8db1-4e04-80fc-007f33f14faf">3.82</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtNS0xLTEtNDUzMzQ_254167c3-8fe4-40e1-a6c0-3e2f96633a59"><ix:nonFraction unitRef="usdPerShare" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtNS0xLTEtNDUzMzQ_d20ccf03-08f7-4025-8ab3-a4d2f00235be">3.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90ZXh0cmVnaW9uOjEyNmEzYWFlM2E3MDQzMzdhNzExMWIyODliYTYxODk1XzI4NA_21e6c148-8089-4181-810f-9b605a4607d8" escape="true"><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the years ended December 31 2022, 2021 and 2020, and therefore excluded all stock options, restricted stock awards and restricted stock units from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96d22ed283414299b6a543fcde594e37_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzItMS0xLTEtNDUzMzQ_df5d4a7c-c2ef-4cb6-bef8-6fa08d3df087">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i131967269d424a0a9e25495c62957e55_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzItMy0xLTEtNDUzMzQ_907aedc2-e77b-4f05-8f89-6821a765fc53">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia927654c60d84e7a99159c1cae642735_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzItNS0xLTEtNDUzMzQ_c4db2122-9ad8-448a-853d-6cee35d99f22">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i008486f737c64fb5890db18235e070ff_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzMtMS0xLTEtNDUzMzQ_4eddca7d-7596-4e9a-bbcc-a800736c99c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia62bc0fe985a441ab8b2ca63ed56b425_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzMtMy0xLTEtNDUzMzQ_2d0688e7-3eea-48e3-9928-14367d1f8eee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25d62ff1d49b406c840997107b6eae57_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzMtNS0xLTEtNDUzMzQ_b896f662-914c-47e7-90ba-14fe3c0a6d3b">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iccb0fc5624af4bea97bb6b0b4030e038_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzQtMS0xLTEtNDUzMzQ_674cf69b-2b08-456c-8b4c-3cdefe2aebe1">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73e8a5c5471147159a6cf356c1ed6b90_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzQtMy0xLTEtNDUzMzQ_2938d5b9-2ddd-4323-afbf-f35eef105d3c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ad800b817ff41fc9a94dc8de9936747_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzQtNS0xLTEtNDUzMzQ_34130a63-ba14-4759-b1d0-278c49c26eba">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzUtMS0xLTEtNDUzMzQ_30e47cfe-d8a3-476d-a233-cc4912c5519a">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzUtMy0xLTEtNDUzMzQ_98811fa3-d2e5-41fe-89cc-506d7a489cbe">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzUtNS0xLTEtNDUzMzQ_b8e48c24-d07f-471b-b0f8-435d4a764c8b">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 28</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>2
<FILENAME>arvinaspfizzeramendmentno3.htm
<DESCRIPTION>EX-10.32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i365de30ade7b423185afe0e2f0caccf3_1"></div><div style="min-height:92.16pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.  Double asterisks denote omissions.</font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.32</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment No. 3 to Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(&#8220;Amendment No. 3&#8221;)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment No. 3 Effective Date&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">December 21, 2022</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Name of Original Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; &#160;&#160;&#160;&#160;Research Collaboration and License Agreement (the &#8220;Original Agreement,&#8221; and together with previous amendments, if any, as described below, the &#8220;Agreement&#8221;)</font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date of Original Agreement&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">December 22, 2017 (&#8220;Effective Date&#8221;)</font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;Pfizer Inc. (&#8220;Pfizer&#8221;) and Arvinas Operations, Inc., f&#47;k&#47;a Arvinas, Inc. (&#8220;Arvinas&#8221;)</font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dates of Previous Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;Amendment No. 1 dated December 9, 2019&#59; Amendment No. 2 dated January 14, 2022</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties wish to amend the terms of the Agreement regarding the nomination of a Target (as defined in the Agreement).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in order to accommodate the desired amendments, the Parties hereby agree as follows&#58;  </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Amendments to the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.6pt">Notwithstanding any other provision of the Agreement, the Parties agree that (i) Pfizer shall hereby be deemed to have issued a Target Substitution Notice pursuant to which &#91;**&#93; shall be replaced with &#91;**&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;&#91;**&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> Substitute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which Arvinas accepts as a Target under the Agreement, (ii) the &#91;**&#93; Substitute &#91;**&#93;, and (iii) the Parties shall agree on the Research Plan for the &#91;**&#93; Substitute &#91;**&#93;, as applicable, in accordance with Section 3.5 of the Agreement, and Pfizer shall &#91;**&#93; for such Target no later than &#91;**&#93;. Notwithstanding Section 5.4 of the Agreement, the payment due under such Section 5.4.2 thereof &#91;**&#93; for the &#91;**&#93; Substitute pursuant to Section 2.8 thereof shall be paid on or before &#91;**&#93;, and the Parties shall cooperate as reasonably required to ensure that the corresponding invoice is issued and paid on or before such date. For clarity, in accordance with Sections 2.2.4 and 2.2.5 of the Agreement (as amended by this Amendment No. 3), any &#91;**&#93; with respect to the &#91;**&#93; Substitute may be applied by Pfizer as &#91;**&#93; due under Section 5.4 of the Agreement with respect to a &#91;**&#93; made in accordance with clause (ii) of the first sentence of this Section.</font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Ratification of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly set forth in Article 2 above, the Agreement shall remain unmodified and in full force and effect.  The execution, delivery and effectiveness of this Amendment No. 3 shall not, except as expressly provided herein, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ACTIVEUS 197982464v.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operate as a waiver of any right, power or remedy of the parties to the Agreement, nor constitute a waiver of any provision of the Agreement.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment No. 3 may be executed in any number of counterparts, each of which shall be an original instrument and all of which, when taken together, shall constitute one and the same agreement.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SIGNATURES IMMEDIATELY FOLLOWING ON NEXT PAGE</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">Amendment 021716</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#999999;font-family:'Garamond',serif;font-size:9pt;font-weight:400;line-height:100%">ACTIVEUS 197982464v.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the duly authorized representatives of Pfizer and Arvinas have executed this Amendment No. 3 as of the date first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.153%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arvinas Operations, Inc</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#47;s&#47; Sean Cassidy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print Name&#58;&#160;&#160;&#160;&#160;Sean Cassidy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;CFO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;&#160;&#160;&#160;&#160;_January 10, 2023_______________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Duly authorized)&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:7.692%;min-width:6.692%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.155%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pfizer Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#47;s&#47; Charlotte Allerton</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print Name&#58;&#160;&#160;&#160;&#160; Charlotte Allerton</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;SVP, Head Medicine Design</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;&#160;&#160;&#160;&#160;_January 10, 2023__________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Duly authorized)</font></div></div></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">Amendment 021716</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#999999;font-family:'Garamond',serif;font-size:9pt;font-weight:400;line-height:100%">ACTIVEUS 197982464v.1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>3
<FILENAME>exhibit1034arvinasbayeroer.htm
<DESCRIPTION>EX-10.34
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia4c7f1051c3b43bc8a7f14fa355a29f0_1"></div><div style="min-height:113.04pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.</font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.34</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:104%">AMENDED AND RESTATED ARVINAS IP CONTRIBUTION AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This AMENDED AND RESTATED ARVINAS IP CONTRIBUTION AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of December 20, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by and between Oerth Bio LLC, f&#47;k&#47;a Protag LLC, a limited liability company organized under the laws of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Oerth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Arvinas Operations, Inc., a corporation organized under the laws of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Arvinas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Oerth and Arvinas are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Oerth and Arvinas previously entered into that certain Arvinas IP Contribution Agreement dated as of July 16, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to which Arvinas licensed Oerth certain of Arvinas&#8217; rights under Know-How and Patents (each as defined below) and expertise in the field of targeted degradation of proteins&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Oerth and Arvinas desire to amend and restate the Original Agreement to adjust certain rights and obligations of the Parties under the Original Agreement, all as set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the respective covenants, representations, warranties and agreements set forth herein, the Parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:10.91pt"><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Agreement, the following capitalized terms will have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Abandonment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, on a jurisdiction-by-jurisdiction basis, with respect to a Patent, any abridgement or cessation (whether by action or failure to act) of Prosecution and Maintenance of such Patent. Abandoning a Patent includes not filing an application for a Patent (except where the Controlling Party, in its reasonable discretion, elects to protect the corresponding Know-How as a trade secret or Confidential Information), withdrawing a Patent or claim of a Patent with no opportunity to refile or otherwise resume Prosecution and Maintenance of such Patent or claim, refraining from or failing to timely file a required submission to a patent office when due, disclaiming such Patent, denying such Patent, or admitting such Patent to be invalid or unenforceable. Abandoning a trade secret or Confidential Information includes any disclosure to a Third Party outside of a confidential relationship or agreement or withdrawal of security measures to protect such trade secret or Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any claim, action, cause of action, chose in action or suit (whether in contract or tort or otherwise), litigation (whether at law or in equity, whether civil or criminal), controversy, assessment, arbitration, examination, audit, investigation, hearing, charge, complaint, demand, notice or proceeding to, from, by or before any Governmental Authority or arbitrator(s).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADME&#47;PK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means absorption, distribution, metabolism, excretion and pharmacokinetics, as describing the disposition of a compound and any of its derivatives within an organism.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, any other Person who, directly or indirectly (including through one or more intermediaries), controls, is controlled by, or is under common control with such Person. For purposes of this definition, &#8220;control,&#8221; when used with respect to any specified Person, means the power, direct or indirect, to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities or partnership or other ownership interests, by contract or otherwise&#59; and the terms &#8220;controlling&#8221; and &#8220;controlled&#8221; will have correlative meanings. For the purposes of this Agreement, (a) neither Arvinas nor any of its Affiliates shall be considered an Affiliate of Oerth or any of its Affiliates, and neither Oerth nor any of its Affiliates shall be considered an Affiliate of Arvinas or any of its Affiliates, and (b) no Person shall be considered an Affiliate of a Party solely as a result of their right to designate a member of such Party&#8217;s board of directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any applicable provisions of the following&#58; (a) constitutions, treaties, statutes, laws (including the common law), rules, regulations, decrees, ordinances, codes, proclamations, declarations or orders of any Governmental Authority&#59; (b) any consents or approvals of any Governmental Authority&#59; and (c) any orders, decisions, advisory or interpretative opinions, injunctions, judgments, awards, decrees of, or agreements with, any Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Arvinas Assay IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How and Patents Controlled by Arvinas or any of its Affiliates as of the Original Agreement Effective Date, between the Original Agreement Effective Date and the Effective Date or during the Term that (a) claim or Cover (or in the case of Know-How, are directly related to) ADME&#47;PK assays and&#47;or data analysis directed at PROTAC characterization and&#47;or predictions, and (b) are necessary or reasonably useful for the Research, Development, Manufacture, use or Commercialization of Oerth Products in the Field.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Arvinas Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Arvinas Assay IP, Arvinas Ligase IP, Arvinas Linker IP, Arvinas PROTAC IP and Arvinas Target IP.  For clarity, Arvinas Background IP includes all Improvements to Arvinas Background IP and Developed Improvements to Arvinas Background IP (as defined in the Arvinas MSA).  For further clarity, all Arvinas Background IP is Confidential Information of Arvinas.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Arvinas Ligase IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How and Patents Controlled by Arvinas or any of its Affiliates as of the Original Agreement Effective Date, between the Original Agreement Effective Date and the Effective Date or during the Term that (a) claim or Cover (or in the case of Know-How, are directly related to) (i) ubiquitin ligases or (ii) Ubiquitin Ligase Binding Moieties as independent components of protein degrader compositions, and (b) in each case of (i) and (ii), are necessary or reasonably useful for the Research, Development, Manufacture, use or Commercialization of Oerth Products in the Field.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Arvinas Linker IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How and Patents Controlled by Arvinas or any of its Affiliates as of the Original Agreement Effective Date, between the Original Agreement Effective Date and the Effective Date or during the Term that (a) claim or Cover (or in the case of Know-How, are directly related to) Linkers as independent components </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of protein degrader compositions, and (b) are necessary or reasonably useful for the Research, Development, Manufacture, use or Commercialization of Oerth Products in the Field.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Arvinas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the MSA as amended by that certain Amendment 1 to the Arvinas Master Services Agreement of even date herewith, and as further amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Arvinas Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Patents within the Arvinas Background IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Arvinas PROTAC IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How and Patents Controlled by Arvinas or any of its Affiliates as of the Original Agreement Effective Date, between the Original Agreement Effective Date and the Effective Date or during the Term that (a) claim or Cover (or in the case of Know-How, are directly related to) PROTACs, and (b) are necessary or reasonably useful for the Research, Development, Manufacture, use or Commercialization of Oerth Products in the Field, including for clarity the Licensed Yale IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Arvinas Target IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How and Patents Controlled by Arvinas or any of its Affiliates as of the Original Agreement Effective Date, between the Original Agreement Effective Date and the Effective Date or during the Term that (a) claim or Cover (or in the case of Know-How, are directly related to) (i) Targets or (ii) Target Binding Moieties as independent components of protein degrader compositions, and (b) in each case of (i) and (ii), are necessary or reasonably useful for the Research, Development, Manufacture, use or Commercialization of Oerth Products in the Field.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, the occurrence of any of the following&#58; (a) the filing of an application by such Party for, or a consent to, the appointment of a trustee of such Party&#8217;s assets&#59; (b) the filing by such Party of a voluntary petition in bankruptcy or the filing of a pleading in any court of record admitting in writing such Party&#8217;s inability to pay its debts as they come due&#59; (c) the making by such Party of a general assignment for the benefit of such Party&#8217;s creditors&#59; (d) the filing by such Party of an answer admitting the material allegations of, or such Party&#8217;s consenting to, or defaulting in answering a bankruptcy petition filed against such Party in any bankruptcy proceeding&#59; or (e) the expiration of &#91;**&#93; following the entry of an order, judgment or decree by any court of competent jurisdiction adjudicating such Party a bankrupt or appointing a trustee of such Party&#8217;s assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bayer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Bayer AG and any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bayer CropScience</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Bayer CropScience LP and any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bayer IP License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain Amended and Restated Bayer IP Contribution Agreement by and between Bayer CropScience and Oerth of even date herewith, as may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a day other than a Saturday, Sunday or other day on which commercial banks in any of (a) New Haven, Connecticut or (b) Durham, North Carolina are authorized or required to close.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to market, promote, distribute, offer for sale, sell, have sold, use, import, have imported, export, have exported or otherwise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commercialize a compound or product. When used as a noun, &#8220;Commercialization&#8221; means any and all activities involved in Commercializing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; of a Party means (a) information, including all Know-How, in tangible form disclosed by or on behalf of such Party to the other Party that is marked as &#8220;Confidential&#8221; at the time it is delivered to the receiving Party, (b) information, including all Know-How, disclosed orally by or on behalf of such Party to the other Party that is identified as confidential or proprietary when disclosed and such disclosure is confirmed in writing within &#91;**&#93; from the date of such disclosure, (c) other information, including all Know-How, whether in tangible form, disclosed orally or in writing by or on behalf of such Party to the other Party that the other Party should reasonably understand is confidential to such Party, (d) other information which is deemed Confidential Information of such Party pursuant to the terms of this Agreement, or (e) Confidential Information (as defined in the Prior Transaction Documents) of such Party disclosed to the other Party in connection with any of the Prior Transaction Documents&#59; provided, however, that the above information shall not be deemed Confidential Information, to the extent the receiving Party can establish by competent written proof that such information&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure, and without breach of any legal or contractual obligation to any party&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;was generally available to the public or otherwise part of the public domain, other than through a breach of a legal or contractual obligation by the receiving Party, at the time of its disclosure hereunder to the receiving Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;becomes generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;is independently developed by the receiving Party without reference to, use of or access to any Confidential Information disclosed by or on behalf of the disclosing Party&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) &#160;&#160;&#160;&#160;was subsequently disclosed to the receiving Party by a Person other than the disclosing Party who is not subject to any legal or contractual obligation to any party with respect to such information which the receiving Party should be reasonably aware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specific information shall not be deemed to be within any of the foregoing exclusions merely because it is embraced by more general information falling within those exclusions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Know-How, Patents and other intellectual property rights, possession by a Party of the power and authority, whether arising by ownership or by license or other authorization, to grant and authorize the licenses or sublicenses, as applicable, under such Know-How, Patents and other intellectual property rights of the scope granted to the other Party in this Agreement at the time such Party would be required hereunder to grant the other Party such license or sublicense, without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be first required hereunder to grant and authorize such license or sublicense. Notwithstanding anything in this Agreement to the contrary, a Party will be deemed to not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Control any Know-How, Patents or other intellectual property rights that are owned or controlled by a Third Party, following a Change of Control (as defined below) of a Party involving such Third Party, or such Third Party&#8217;s Affiliates (other than an Affiliate of such Party prior to the Change of Control), (a) prior to the closing of such Change of Control, except to the extent that any such Know-How, Patents or other intellectual property rights were developed prior to such Change of Control through the use of such Party&#8217;s technology, or (b) after such Change of Control to the extent that such Know-How, Patents or other intellectual property rights are developed or conceived by such Third Party or its Affiliates (other than such Party) after such Change of Control without using or incorporating such Party&#8217;s technology. Additionally, notwithstanding the foregoing, with respect to any Know-How, Patents or other intellectual property right acquired or in-licensed (other than the Licensed Yale IP) for which a Party would be required to make payments to any Third Party in connection with the license or access granted to the other Party under this Agreement, such intellectual property will be treated as &#8220;Controlled&#8221; by the licensing Party to the extent that, and only to the extent that and for so long as, the other Party agrees and does promptly pay to the licensing Party all such applicable payments to such Third Party arising out of the grant and exercise of the license to the other Party hereunder pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.5(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlling Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Party having the right, responsibility and direction under this Agreement to initiate, conduct and control (a) Prosecution and Maintenance, (b) any Action against a Third Party for any actual or suspected Infringement of any Patent rights that constitute intellectual property rights covered by this Agreement, and&#47;or (c) defense of any Action alleging Infringement or misappropriation of a Third Party&#8217;s intellectual property rights, in each case of (a), (b) and (c), as and for so long as such Party maintains such right.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Covers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (including variations such as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Covering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the like) means, with respect to a Patent and a product, that the manufacture, use, sale, offer for sale or importation of such product in a country would infringe a Valid Claim of such Patent in such country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEL Screen Binder Company IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Know-How that is (a) developed, conceived, first reduced to practice or otherwise made pursuant to activities in the DEL Screening Services that is specific to any Ubiquitin Ligase Binding Moieties identified by the DEL Screening Services, and (b) (i) was assigned to Oerth as Company IP pursuant to the MSA and the IPMA, or (ii) is assigned to Oerth as Oerth-Owned Developed IP pursuant to the Arvinas MSA and this Agreement, including any and all Patents claiming, and other intellectual property rights in and to, such Know-How.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEL Screening Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any performance by Arvinas of DNA-encoded library screening for Oerth pursuant to the MSA prior to the Effective Date or pursuant to the Arvinas MSA after the Effective Date. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to develop a process, compound or product, including work comprising the following activities&#58; conducting preliminary formulation activities for field testing, producing field test materials for such testing (meeting minimum requirements for field handling, handling properties, stability, use rate, quality control, safety), performing field testing (including physiological and soil analysis, formulation (prototype development and field validation, formulation optimization) and field trials (demonstration of biological efficacy of an Oerth Product for expected phenotype compared to control treatments and reproduced for multiple genetics&#47;geographies (in view of defining the business case))), developing commercial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">formulations (as included in the regulatory dossier, fully compatible with other active components), completing toxicity studies needed to obtain regulatory approval for an Oerth Product, and dossier generation and submission for regulatory approval. When used as a noun, &#8220;Develop&#8221; means any and all activities involved in Developing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the first paragraph.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all agricultural purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreground IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How developed, conceived, first reduced to practice or otherwise made by or on behalf of Oerth or any of its Affiliates, whether solely or jointly (including by or with any Subcontractor), in connection with the Research, Development, Manufacture, use or Commercialization of Oerth Products in the Field, including any and all Patents claiming, and other intellectual property rights in and to, such Know-How.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of law), or any arbitrator, court or tribunal of competent jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Grantback Ex-Ag Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">&#8220;Improvements to Arvinas Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) that subset of Know-How included within Foreground IP that is an adaptation, enhancement, modification, and&#47;or improvement of any Arvinas Background IP, wherein the making, using, selling, offering for sale, or importation or exploitation of the same would infringe one or more issued claims of Patents (or would infringe such a claim in a published Patent application if such Patent application were to issue) within the Arvinas Background IP  that were in effect at the time of the activities conducted under this Agreement that resulted in such Foreground IP, but excluding Oerth Products, and (ii) any Patents claiming or Covering any of the Know-How included in clause (i).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Infringe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any intellectual property right, any activity that, directly or indirectly, violates, encroaches, or trespasses upon the exclusive, exclusionary, or other proprietary right protected by such intellectual property right, including, without limitation, infringement of any Valid Claim of any Patent, infringement of any copyright (including, but not limited to, by unauthorized reproduction, distribution, creation of derivative works, and public performance or display of a copyrighted work), and theft or misappropriation of trade secrets (including, but not limited to, by unauthorized disclosure, taking, or using of trade secrets). Any grammatical variation of &#8220;Infringe&#8221; (e.g., &#8220;Infringing&#8221; and &#8220;Infringement&#8221;) has the corresponding meaning set forth in this definition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">In-License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an agreement with a Third Party licensor under which Arvinas or any of its Affiliates obtains Control of any Arvinas Background IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all proprietary information, inventions (whether or not patentable), improvements, practices, formulae, trade secrets, techniques, methods, procedures, knowledge, results, test data (including related reports, structure-activity relationship data and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statistical analysis), analytical and quality control data, protocols, processes, models, designs, computational processes, and other information regarding discovery, development, marketing, pricing, distribution, cost, sales and manufacturing. Know-How shall not include any Patent or any information disclosed in a Patent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Yale IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How and Patents licensed to Arvinas by Yale University pursuant to the Yale Agreement included in the Arvinas Background IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Linker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any linker that attaches the Ubiquitin Ligase Binding Moiety and the Target Binding Moiety.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to make, have made, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store a compound or product or any component thereof. When used as a noun, &#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved in Manufacturing a compound or product or any component thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Oerth Foreground IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Foreground IP other than Improvements to Arvinas Background IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Oerth IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, (a) all Oerth Foreground IP, and (b) any other Know-How and Patents Controlled after the Original Agreement Effective Date, between the Original Agreement Effective Date and Effective Date, or during the Term, by Oerth or any of its Affiliates that are necessary or reasonably useful for the Research, Development, Manufacture, use or Commercialization of Oerth Products in the Field.  For clarity, all Oerth IP is Confidential Information of Oerth.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Oerth Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Patents within the Oerth IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Oerth Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a specific Target, a PROTAC whose primary mechanism of action by design is the binding to and degradation of such Target.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original Agreement Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means July 16, 2019.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the first paragraph.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Patent(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all patents and patent applications and any patents issuing therefrom or claiming priority to, worldwide, together with any extensions (including patent term extensions and supplementary protection certificates) and renewals thereof, reissues, reexaminations, substitutions, confirmation patents, registration patents, invention certificates, patents of addition, renewals, divisionals, continuations, and continuations-in-part of any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association or other entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prior Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) that certain Commitment Agreement, dated June 3, 2019, by and among Arvinas, Oerth and Bayer CropScience, (b) that certain </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Second Amended and Restated Limited Liability Company Agreement, dated October 1, 2019, by and among Arvinas, Oerth and Bayer CropScience, as amended by that certain Amendment No. 1 to Second Amended and Restated Limited Liability Company Agreement, dated September 13, 2021, and that certain Amendment No. 2 to Second Amended and Restated Limited Liability Company Agreement, of even date herewith, (c) that certain Option Agreement, dated July 16, 2019, by and among Arvinas, Oerth and Bayer CropScience, (d) that certain Bayer IP Contribution Agreement, dated July 16, 2019, by and between Oerth and Bayer CropScience, (e) the Original Agreement, (f) that certain Intellectual Property Management Agreement, dated July 16, 2019, by and among Arvinas, Oerth and Bayer CropScience (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IPMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (g) that certain Bayer Master Services Agreement, dated July 16, 2019, by and between Oerth and Bayer CropScience, as amended by Amendment 1 to Master Services Agreement dated June 16, 2020, and (h) that certain Arvinas Master Services Agreement, dated July 16, 2019, by and between Oerth and Arvinas (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prosecute and Maintain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, (a) with regard to a specific Patent, the preparation, filing, prosecution (including the bringing or defense of oppositions, interferences, reissue proceedings, reexaminations (including in the foregoing challenges of validity, enforceability or patentability) and other post-grant actions or proceedings before a patent office), and maintenance of such Patent, (b) with respect to a specific copyright, the preparation, filing, prosecution, and maintenance of such copyright, and (c) with respect to specific trade secret or Confidential Information, documenting, retaining and safeguarding as proprietary and confidential such trade secret or Confidential Information. For clarification, Prosecution and Maintenance or Prosecute and Maintain will not include any other enforcement actions (including any such actions to abate Infringement) taken with respect to a Patent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prosecution Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the reasonable out-of-pocket costs and expenses paid (or payable and accrued in accordance with GAAP or IFRS) to outside legal counsel and other Third Parties, and filing and maintenance expenses, incurred in the Prosecution and Maintenance of any Patent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PROTAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a molecule that contains a Target Binding Moiety and an Ubiquitin Ligase Binding Moiety, linked together via a Linker or chemical bond, and whose primary mechanism of action by design is the degradation of the protein target(s) of such Target Binding Moiety.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Research</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to identify, research or discover a process, compound or product, including work comprising the following activities&#58; chemical synthesis, chemical optimization, developing in vitro screening assays and model plant assays, generating genetic tools for Oerth Product candidates, conducting comparative genomics on a structural and functional level, cloning and expression of genes and pathways, engineering cellular functions in view of use case, enzyme design and analytics, and testing the performance of an Oerth Product in model plants. When used as a noun, &#8220;Research&#8221; means any and all activities involved in Researching.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a consultant, subcontractor, contract researcher, contract manufacturer, academic researcher or other vendor engaged by a Party to conduct activities on behalf of such Party or its Affiliate under this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to sublicense, grant any other right with respect to, or agree not to assert, directly or indirectly, any Know-How or Patents licensed to a Party under this Agreement. When used as a noun, &#8220;Sublicense&#8221; means any agreement to Sublicense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Third Party other than an Affiliate to whom a Party or an Affiliate of such Party grants a Sublicense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any protein identified by its UniProt number, including all splice variants, mutants, natural variants, etc. reasonably associated with such UniProt number that could serve as a molecular target for a PROTAC or other Targeted Protein Degrader, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Target Binding Moiety</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a moiety that binds to a Target and, for clarity, does not include a Linker or a Target Degrading Protein Binding Moiety.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Target Degrading Protein Binding Moiety</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a moiety that binds to a Target degrading protein. For the avoidance of doubt, Targeted Degrading Protein Binding Moieties include but are not limited to Ubiquitin Ligase Binding Moieties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Targeted Protein Degrader</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a molecule that contains a Target Binding Moiety</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and a Target Degrading Protein Binding Moiety joined by a linker or chemical bond, whose primary mechanism of action by intentional construction is the degradation of the Target(s) of such Target Binding Moiety.  For the avoidance of doubt, Targeted Protein Degraders include but are not limited to PROTACs. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period starting on the Original Agreement Effective Date and ending on a Termination Event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">&#8220;Territory&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means all countries of the world.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any entity other than Arvinas or Oerth or an Affiliate of either.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any non-financial encumbrances, obligations, restrictions, or limitations imposed by an In-License Agreement, including field or territory restrictions, covenants, diligence obligations or limitations pertaining to prosecution or enforcement of intellectual property rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ubiquitin Ligase Binding Moiety</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a moiety that binds to an ubiquitin ligase complex.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a particular country, a claim of an issued and unexpired Patent that has not been (a) rejected, revoked or held to be invalid, unenforceable or unpatentable by a court or other authority of competent jurisdiction, from which decision no appeal can be further taken, or (b) finally abandoned, disclaimed or admitted to be invalid, unenforceable or unpatentable, including through reissue or disclaimer. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Yale Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain Agreement between Yale University and Arvinas dated as of July 5, 2013, as previously amended as of May 8, 2014, October 23, 2014, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">April 1, 2015, September 30, 2015, December 19, 2018 and June 3, 2019, and as may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Yale Letter Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that letter agreement between Yale University and Arvinas, dated as of June 3, 2019, and attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:10.91pt"><br>LICENSE GRANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">License Grants to Oerth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">License Grant to Arvinas Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms of this Agreement, Arvinas hereby grants to Oerth a worldwide, royalty-free, fully paid-up, transferable (in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">exclusive (even as to Arvinas and its Affiliates) and sublicenseable (solely as permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) license under the Arvinas PROTAC IP, Arvinas Ligase IP and Arvinas Linker IP to Research, Develop, Manufacture, use and Commercialize Oerth Products in the Field&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">non-exclusive and sublicenseable (solely as permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) license under the Arvinas Target IP to Research, Develop, Manufacture, use and Commercialize Oerth Products in the Field&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">non-exclusive and non-sublicenseable license under the Arvinas Assay IP to Research, Develop, Manufacture, use and Commercialize Oerth Products in the Field.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of Arvinas and Oerth hereby acknowledge and agree that the licenses to Oerth of the Arvinas Background IP pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement at any time that Oerth is classified as a partnership for U.S. federal income tax purposes are intended to be treated as a contribution of property pursuant to 26 U.S. Code &#167; 721.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">Oerth may grant a sublicense of its rights to the Arvinas PROTAC IP, Arvinas Ligase IP, Arvinas Linker IP and Arvinas Target IP, under the license grants to Oerth of Section 2.1.1 only in the following circumstances and to the following entities&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.63pt">to Research and Develop any Oerth Product in the Field to a Subcontractor or research collaborator assisting Oerth or its Affiliates or licensees in performing Research and Development of such Oerth Product&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.58pt">solely as necessary to Manufacture an Oerth Product in support of Oerth&#8217;s or its Affiliates&#8217; or licensees&#8217; Research and Development, use or Commercialization of such Oerth Product in the Field&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">to a distributor or importer assisting Oerth or its Affiliates or licensees in Commercialization of any Oerth Product in the Field.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">Provided that Oerth is licensing Know-How and Patents it Controls (other than Know-How or Patents licensed to it under this Agreement) in the same transaction, Oerth may grant a sublicense of its rights to the Arvinas PROTAC IP, Arvinas Ligase IP, Arvinas Linker IP and Arvinas Target IP, under the license grants to Oerth of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) to Bayer or one of its Affiliates or (ii) to a Third Party, in each case of (i) and (ii), to Research, Develop, Manufacture, use and Commercialize Oerth Products in the Field.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each such Sublicense granted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> will be subject and subordinate to, and consistent with, the terms and conditions of this Agreement and will require each Sublicensee thereunder to comply with all applicable terms of this Agreement and Third Party Obligations under Arvinas&#8217; In-License Agreements for any in-licensed Arvinas Background IP being sublicensed. Oerth will, as soon as reasonably practicable thereafter (and in any event within &#91;**&#93;), provide Arvinas with a copy of an executed Sublicense with a Sublicensee (which copy may be redacted to remove provisions which are not necessary to monitor compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">). Notwithstanding the grant of any Sublicense, Oerth shall remain primarily liable to Arvinas for the performance of all of Oerth&#8217;s obligations under, and Oerth&#8217;s compliance with all provisions of, this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.18pt">Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Oerth may engage Subcontractors to perform its activities under this Agreement&#59; provided that (a) each contract between Oerth and a Subcontractor entered into after the Effective Date will include confidentiality and non-use provisions that are substantially similar to those set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (or such other terms as are otherwise agreed by Arvinas) (but of duration customary in confidentiality agreements entered into for a similar purpose, provided that the duration of confidentiality for any information which constitutes a trade secret will be for as long as such information remains a trade secret under Applicable Law), (b) Oerth will remain at all times fully liable for the acts and omissions by such Subcontractor under this Agreement as if they were acts or omissions by Oerth, (c) Oerth will be responsible for the effective and timely management of and payment of its Subcontractors hereunder and (d) each contract between Oerth and a Subcontractor entered into after the Effective Date will provide that Oerth will obtain ownership of, or a fully sublicensable license (any expenses of which will be borne by Oerth) under and to, any Know-How and Patents that are discovered, developed, invented or created by such Subcontractor in the performance of such agreement and are necessary or reasonably useful to Research, Develop, Manufacture or Commercialize such Oerth Product in the Field&#59; provided that Oerth will (x) use commercially reasonable efforts to obtain ownership of any such Know-How and Patents rather than a license to such Know-How or Patents or, (y) if Oerth cannot so obtain ownership, obtain an exclusive license to any such Know-How and Patents or, solely with respect to an academic institution, university or non-commercial Subcontractor, a right to an exclusive option to obtain or negotiate such license.  For clarity, the foregoing requirement to obtain ownership of, or a fully sublicensable license will not apply to any improvements to the proprietary core or platform technology owned or in-licensed by any such Subcontractor or its Affiliates unless such improvements are necessary or reasonably useful to Research, Develop, Manufacture or Commercialize those Oerth Products with respect to which such Subcontractor or its Affiliate conducted its activities under such contract.  The engagement of any Subcontractor in compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.3(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> will not relieve Oerth of its obligations under this Agreement.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">License Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Oerth hereby acknowledges and agrees that its rights and obligations hereunder, including its rights pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, are subject to and limited by Third Party Obligations of any In-License Agreements for Know-How or Patents within the Arvinas Background IP, including, with respect to the Licensed Yale IP, the terms and conditions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition, on &#91;**&#93; basis, no later than &#91;**&#93; during the Term, Oerth will deliver to Arvinas a high-level report of the Research, Development and&#47;or Commercialization activities relating to Oerth Products for the &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">In-Licenses&#59; Third Party Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">In-License Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.63pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1.5(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as of the Effective Date, Arvinas is not a party to any In-License Agreement for Know-How or Patents included within the Arvinas Background IP existing as of the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Existing Arvinas In-License Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Third Party Payments under In-License Agreements. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.63pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof and to Section 3 of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Arvinas will be responsible for all payments associated with any Existing Arvinas In-License Agreements as a result of the grant to, and exercise by, Oerth of the license under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.58pt">In the event that, after the Effective Date, Arvinas in-licenses Know-How or Patents that would be deemed Arvinas Background IP for purposes of the licenses granted to Oerth under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> but for Arvinas owing payments or other consideration under the corresponding In-License Agreement for such Know-How or Patents, Arvinas will notify Oerth of the existence of and anticipated amounts of such payments and Oerth will have the right to decline a sublicense to such in-licensed Know-How or Patents or take such a sublicense.  If Oerth elects to take such a sublicense, Oerth agrees to comply with any obligations of Arvinas, under any such In-License Agreement with respect to such Know-How or Patents, that apply to Oerth and of which Oerth was informed by Arvinas, including any obligation to make such payments.  Further, in the event Oerth elects to take such a sublicense, Oerth will make such payments, or deliver such other consideration as may be mutually agreed to between Arvinas and Oerth, within &#91;**&#93; of receiving an invoice from Arvinas for the same.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Oerth License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the terms of this Agreement, Oerth hereby grants to Arvinas a royalty-free, fully paid-up, perpetual, worldwide, transferable (in accordance with Section 10.1), sublicenseable (through multiple tiers and without Oerth&#8217;s prior consent), non-exclusive license under the Oerth IP (other than the subset thereof licensed by Bayer CropScience LP to Oerth under the Bayer IP License Agreement or by Bayer under the Collaboration Agreement) for the Research, Development, Manufacture, use and Commercialization of products outside the Field (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Grantback Ex-Ag Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for any such Oerth IP that is in-licensed by Oerth, if Oerth&#8217;s rights are for a field that includes the Grantback Ex-Ag Field and to the extent permitted under the terms of the corresponding In-License Agreement therefor and subject to Arvinas&#8217; compliance with the rest </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> then Oerth hereby grants to Arvinas a non-exclusive, worldwide, transferable (in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), sublicenseable, sublicense in and to such in-licensed Oerth IP for any and all purposes in the Grantback Ex-Ag Field&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">but, further provided that,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Arvinas will have the right to decline any such sublicense grant in writing to Oerth and, if Arvinas does not so decline, then Arvinas hereby agrees to comply with any obligations of Oerth under any such In-License Agreement with respect to such in-licensed Oerth IP that apply to Arvinas and of which Arvinas was informed by Oerth, including any obligation to make payments for Arvinas&#8217; use of the same in the Grantback Ex-Ag Field, and to make such payments (or deliver such other consideration as may be mutually agreed to between Oerth and Arvinas) to Oerth within &#91;**&#93; of receiving an invoice from Oerth for the same. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All rights in and to Arvinas&#8217; and its Affiliates&#8217; Know-How, Patents and other intellectual property rights not expressly licensed to Oerth under this Agreement are hereby retained by Arvinas or its Affiliates, as applicable. All rights in and to any Know-How, Patents and other intellectual property rights of Oerth and its Affiliates not expressly licensed to Arvinas under this Agreement are hereby retained by Oerth or its Affiliates, as applicable. Except as expressly provided in this Agreement, no Party will be deemed by estoppel or implication to have granted the other Party any licenses or other right with respect to any of such Party&#8217;s Know-How, Patents and other intellectual property rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Transfer of Certain Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Oerth may request at any time during the Term for Arvinas to disclose and make available to Oerth any Arvinas Background IP comprising Know-How that Oerth reasonably believes is necessary or reasonably useful to Research, Develop, Manufacture, use or Commercialize any Oerth Products, in each case that has not previously been disclosed to Oerth.  Arvinas shall consider Oerth&#8217;s request in good faith and, to the extent such request is reasonable, Arvinas will provide any applicable Arvinas Background IP comprising Know-How in a reasonably prompt manner and in a form or format mutually agreed by the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Additional Arvinas Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If, during the Term, (a) Oerth identifies any Know-How or Patents Controlled by Arvinas or an Affiliate thereof, other than Arvinas Background IP, that claim or Cover (or in the case of Know-How, directly relate to) Targeted Protein Degraders and (b) Oerth notifies Arvinas in writing that it wishes to include, in the licenses granted to Oerth under this Agreement, rights under such Know-How or Patents to Research, Develop, Manufacture, use and Commercialize Oerth Product(s) in the Field, then Arvinas agrees to enter into good faith discussions with Oerth concerning the terms of an amendment to this Agreement pursuant to which such rights to such Know-How or Patents may be included herein, provided that (i) Arvinas shall not be required to continue such discussions with Oerth for any particular Know-How or Patent(s) for more than &#91;**&#93; following receipt of such a notice from Oerth with respect to such Know-How or Patent(s) and (ii) Arvinas shall not in any event be obligated to include rights to any such Know-How or Patents under the rights granted under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Materials Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">Either Party may, at its election, from time to time provide to the other Party certain materials for use by the other Party in connection with such Party&#8217;s rights and obligations hereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). All such Materials (including, as applicable, any progeny, expression products, mutants, replicates, derivatives and modifications thereof that are made by the receiving Party and that include the Materials </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the supplying Party), to the extent such Material is not generally available from a Third Party, will be used by the receiving Party in accordance with the terms and conditions of this Agreement solely for purposes of performing its activities under this Agreement, and the receiving Party will not transfer such Materials (including, as applicable, any progeny, expression products, mutants, replicates, derivatives and modifications thereof) to any Third Party unless to a Sublicensee or as otherwise expressly contemplated by this Agreement, or upon the written consent of the supplying Party, including, as applicable, any academic or research institution. For clarity, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> will not restrict either Party from using Materials that are publicly available from a Third Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each Party agrees it will not, and will not attempt to, and will not permit any Affiliate or a Third Party to, or attempt to, identify or determine in any way the chemical, physical or structural characteristics or identity, fragmentation sequence or composition of any of the other Party&#8217;s Materials nor modify or make derivatives or analogs of the other Party&#8217;s Materials, including that it will not reverse engineer, reverse compile, disassemble or otherwise attempt to derive the composition or underlying information, structure or ideas of any of the other Party&#8217;s Materials, including analyzing such Materials by physical, chemical or biochemical means.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">Any Materials provided by a Party to the receiving party (including, as applicable, any progeny, expression products, mutants, replicates, derivatives and modifications thereof) will be used by the receiving Party solely for purposes of this Agreement and any unused Materials will be returned to the supplying Party (or destroyed as may be requested by the supplying Party in writing) promptly following the end of the Term or earlier upon request by the supplying Party. All information that specifically relates to such Materials, including any improvements, modifications, and derivatives thereof, will be Confidential Information of the supplying Party. The receiving Party agrees to use all such Materials with prudence and appropriate caution in any experimental work, since all of their characteristics may not be known. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE MATERIALS PROVIDED HEREUNDER ARE EXPERIMENTAL IN NATURE AND ARE PROVIDED &#8220;AS IS&#8221;. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE SUPPLYING PARTY MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND EXPRESSLY DISCLAIMS ALL SUCH WARRANTIES, INCLUDING WARRANTIES OF NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE MATERIALS PROVIDED HEREUNDER.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Parties acknowledge and agree that the terms and conditions of this Agreement shall apply to the Materials provided by Arvinas to Oerth under the Material Transfer Agreement dated November 1, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pre-Existing MTA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as well as any Materials that were provided by Arvinas to Oerth prior to the Effective Date.  The Pre-Existing MTA is hereby terminated, and the terms and conditions of such Pre-Existing MTA are hereby superseded by the terms set forth in this Agreement.  </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:10.91pt"><br>INTELLECTUAL PROPERTY MATTERS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Inventorship&#59; Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.8pt;text-decoration:underline">Determination of Inventorship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Solely to the extent the same is conceived, first reduced to practice or otherwise made after the Original Agreement Effective Date, the inventorship of Foreground IP will be determined in accordance with United States patent law. To the extent that an inventor may have any rights in or in consideration for an invention under Applicable Law of the country where the inventor made the invention, such rights will be governed by such Applicable Law notwithstanding the foregoing provision.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.18pt;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.63pt;text-decoration:underline">Oerth Foreground IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Oerth shall own all Oerth Foreground IP.  Arvinas agrees to assign and hereby assigns to Oerth all right, title and interest of Arvinas and its Affiliates, and its and their employees, agents or independent contractors may have in and to all Oerth Foreground IP generated by Arvinas or an Affiliate thereof under the Arvinas MSA.  Notwithstanding anything to the contrary in this Agreement, all Oerth Foreground IP shall be deemed Confidential Information of Oerth and not Confidential Information of Arvinas.  Arvinas shall promptly, but in no event later than &#91;**&#93;, inform Oerth of any Oerth Foreground IP generated by Arvinas or an Affiliate thereof under the Arvinas MSA and provide written information in reasonable detail, including data and results of research related to such Oerth Foreground IP sufficient to permit an understanding of the nature of such Oerth Foreground IP by a practitioner reasonably skilled in the relevant technical or scientific area.  Arvinas agrees, from time to time and as necessary, to execute, acknowledge and deliver to Oerth, at Oerth&#8217;s request and expense, all such further acts, assurances, deeds, assignments, transfer, conveyances, agreements and other documents reasonably necessary to give effect to the assignment in this Section 3.1(b)(i).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.58pt;text-decoration:underline">Improvements to Arvinas Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Arvinas shall own all Improvements to Arvinas Background IP.  Oerth agrees to assign and hereby assigns to Arvinas all right, title and interest of Oerth and its Affiliates, and its and their employees, agents or independent contractors may have in and to all Improvements to Arvinas Background IP.  Notwithstanding anything to the contrary in this Agreement, all Improvements to Arvinas Background IP shall be deemed Confidential Information of Arvinas and not Confidential Information of Oerth.  Oerth shall promptly, but in no event later than &#91;**&#93;, inform Arvinas of any Improvements to Arvinas Background IP and provide written information in reasonable detail, including data and results of research related to such Improvements to Arvinas Background IP sufficient to permit an understanding of the nature of the Improvements to Arvinas Background IP by a practitioner reasonably skilled in the relevant technical or scientific area.  Oerth agrees, from time to time and as necessary, to execute, acknowledge and deliver to Arvinas, at Arvinas&#8217;s request and expense, all such further acts, assurances, deeds, assignments, transfer, conveyances, agreements and other documents reasonably necessary to give effect to the assignment in this Section 3.1(b)(ii).  For avoidance of doubt, Improvements to Arvinas Background IP do not include Improvements to Bayer Background IP (as defined in the Bayer IP License Agreement on the date hereof).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Prosecution and Maintenance of Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.8pt">Arvinas Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the rest of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Arvinas is the sole Controlling Party for the Prosecution and Maintenance of Arvinas Patents, and Arvinas will consult with Oerth, with respect to such Prosecution and Maintenance of Arvinas Patents.  Arvinas will be responsible for &#91;**&#93; percent (&#91;**&#93;%) of all Prosecution Costs incurred in connection with such Prosecution and Maintenance activities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.18pt">Oerth Patents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to the rest of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Oerth is the sole Controlling Party for the Prosecution and Maintenance of Oerth Patents, and Oerth will be responsible for &#91;**&#93; percent (&#91;**&#93;%) of all Prosecution Costs incurred in connection with such Prosecution and Maintenance activities. Oerth, in its capacity as Controlling Party, will use commercially reasonable efforts to avoid creating Patents (whether at filing or during subsequent prosecution) that disclose Confidential Information of Arvinas or claim any subject matter other than Oerth IP.  Oerth will not grant any right to Bayer or any of its Affiliates with respect to the Prosecution and Maintenance of, or any right to enforce against Infringement or threatened Infringement by a Third Party of, any DEL Screen Binder Company IP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.8pt">Process and Procedure for Prosecution and Maintenance of Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.63pt">A Controlling Party with respect to Arvinas Patents will use commercially reasonable efforts to Prosecute and Maintain all applicable Patents during the Term. A Controlling Party will provide to the other Party all patent office papers promptly upon receipt, and drafts of responses to office actions from and other substantive filings with any patent offices regarding all applicable Patents reasonably sufficiently in advance before their submission to enable review and reasonable comment by the other Party, and a Controlling Party will consider in good faith all comments timely made by the other Party. The other Party will bear its own internal costs (i.e., those costs that are not Prosecution Costs) with respect to its Prosecution and Maintenance activities relating to such applicable Patents.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.58pt">If a Controlling Party chooses (whether by action or failure to act) to Abandon any Arvinas Patent Controlled by such Party, prior to such Abandonment taking effect, the Controlling Party will notify promptly the other Party (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Election Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). As between the Parties, the other Party will have the right (but not the obligation) to assume control of any such Patent.  If the other Party desires that such Patent should not be Abandoned, then the other Party will provide reasonable written notice thereof to the Controlling Party, and the other Party will determine and implement a Prosecution and Maintenance strategy for such Patent, at its sole expense, and the Controlling Party will transition any such activities to the other Party in an orderly manner.  Such assumption of responsibility shall not otherwise affect the rights and obligations of the Parties set forth in the other provisions of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">In the event there is a dispute between the Parties with respect to which Party is the Controlling Party for the Prosecution and Maintenance of a certain Patent, an outside law firm agreed to by the Parties will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be appointed to continue the Prosecution and Maintenance of such Patent at issue in a manner so as to protect and optimize the Parties&#8217; intellectual property rights until such time as a resolution can be reached. The Parties will cooperate in good faith with each other and with such law firm to reach such resolution, which may include dividing the subject matter of the Patent at issue into multiple applications to the extent consistent with applicable practice and the maintenance of broad coverage. The costs and expenses of such law firm will be shared equally by the Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.13pt">The other Party will provide the Controlling Party all reasonable notice, assistance and cooperation, at the Controlling Party&#8217; cost and expense, in the Prosecution and Maintenance efforts provided for in this Section 3.2, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Defense of Claims Brought by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Oerth will inform Arvinas of any potential Infringement of, or any claim of Infringement made against Oerth with respect to, a Third Party&#8217;s intellectual property rights resulting from Oerth&#8217;s practice of the Arvinas Background IP in the Field. At the request of Arvinas, Oerth will discuss such information and how to handle such matter&#59; provided, however, that Oerth will be solely responsible for defending any Action brought against it alleging Infringement of a Third Party&#8217;s intellectual property rights in connection with such of its activities. This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> will not be interpreted as placing on a Party a duty of inquiry regarding intellectual property rights of a Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Enforcement of Patents Against Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">Notice of Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If a Party learns of the Infringement or threatened Infringement by a Third Party of any Patent or any non-patented intellectual property right that constitutes Arvinas Background IP or Oerth IP, such Party will promptly notify the other Party in writing and will provide such other Party with all available information in such Party&#8217;s Control pertaining thereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">Enforcement of Arvinas Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   Arvinas will be the sole Controlling Party, at its sole cost and expense, of any other Action against a Third Party (but without obligation to bring any such Action) for any actual or suspected Infringement of any Patent or non-patented intellectual property rights that constitutes Arvinas Background IP, and Arvinas will retain any and all monetary damages awarded or recovered in any such Action. For clarity, Arvinas will have the unrestricted right to settle any such Action as Arvinas sees fit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">Enforcement of Oerth Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Oerth will be the sole Controlling Party, at its sole cost and expense, of any Action against a Third Party (but without obligation to bring any such Action) for any actual or suspected Infringement of any Patent or any non-patented intellectual property rights that constitutes Oerth IP, whether occurring in or outside of the Field, and Oerth will retain any and all monetary damages awarded or recovered in any such Action. For clarity, Oerth will have the unrestricted right to settle any such Action as Oerth sees fit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Joinder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party agrees to assist and cooperate with the Controlling Party, at the Controlling Party&#8217;s request, as may be reasonably required in order to facilitate the Controlling Party&#8217;s enforcement and defense of an Action under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bringing an Action as permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> agrees to reimburse the other Party for all documented and reasonable out-of-pocket costs, damages and expenses (excluding attorneys&#8217; fees and expenses unless such other Party are unable to use the same legal counsel due to conflict), that such other Party incurs in connection with providing assistance with or joining as party-plaintiff any such Action, including any award of costs against such other Party. Any such costs, expenses or damages hereunder to be reimbursed will be paid by the owing Party within &#91;**&#93; of receipt of an invoice therefor, including reasonable evidence that such costs, expenses or damages have been incurred. The Parties agree to use commercially reasonable efforts to cause Third Parties to be joined as a party-plaintiff where necessary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">No Other Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as otherwise expressly provided in this Agreement, under no circumstances will a Party or any of its Affiliates, as a result of this Agreement, obtain any ownership interest, license or other right in or to any Know-How, Patents or other intellectual property rights of the other Party, including tangible or intangible items owned, controlled or developed by such other Party, or provided by such other Party to such Party at any time, pursuant to this Agreement. Neither Party nor any of its Affiliates will use or practice any Know-How, Patents or other intellectual property rights licensed or provided to such Party or any of its Affiliates outside the scope of or otherwise not in compliance with the rights and licenses granted to such Party and its Affiliates under this Agreement, except to the extent the same is otherwise available to the public through no fault or breach of a Party obligated to keep confidential such publicly available Know-How or other intellectual property rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Unauthorized Use of Arvinas Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Oerth will institute reasonable procedures to prevent the Arvinas Background IP from being used, practiced, sublicensed or otherwise exploited outside of the Research, Development, Manufacture, use and Commercialization of Oerth Products in the Field. After receiving notice from Arvinas alleging a specific breach, Oerth will investigate (with Arvinas having the right to participate in such investigation) the use of the Arvinas Background IP, and if Oerth identifies any unauthorized use of the Arvinas Background IP, Oerth will immediately cease, and will cause to immediately be ceased, such use, and will implement, and will cause to be implemented, reasonable procedures to prevent such unauthorized use of the Arvinas Background IP in the future.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:10.91pt"><br>REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Representations and Warranties of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of Arvinas and Oerth hereby represents and warrants to the other as of the Original Agreement Effective Date that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">It is duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">It (a) has the requisite power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder and (b) has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">It has the requisite resources and expertise to perform its obligations hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">The execution, delivery and performance of this Agreement by it (a) constitutes a legal, valid and binding obligation, enforceable against it in accordance with the terms hereof, except to the extent that the enforceability may be affected by bankruptcy, insolvency, and other laws of general application affecting the enforcement of creditors&#8217; rights and by general principles of equity that may limit the availability of equitable remedies, and (b) will not constitute a default under or conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, or violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">It has obtained all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons or entities required to be obtained by it in connection with the execution and delivery of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Additional Representations and Warranties of Arvinas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Arvinas hereby further represents and warrants to Oerth, as of the Original Agreement Effective Date, or, to the extent specified below, as of the Effective Date, that, except as otherwise set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt;text-decoration:underline">Schedule 4.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> sets forth a true, correct and complete list of all patents and patent applications within the Arvinas Background IP, as of the Effective Date, indicating for each such patent and patent application whether it is the subject of a registration or application issued, filed with, or recorded by any Governmental Authority, and specifying, where applicable, the jurisdiction in which such patent Controlled by Arvinas have been issued or registered or in which jurisdiction such patent application Controlled by Arvinas for such issuance and registration has been filed, including, as applicable, the respective registration and application numbers, the names of all registered owners or applicants, and the filing dates and, if applicable, issue dates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">With respect to the patents and patent applications within the Arvinas Background IP for which Arvinas controls prosecution and maintenance, Arvinas has (a) to the knowledge of Arvinas, complied with all Applicable Laws in connection with the prosecution and maintenance of such patents and patent applications, and (b) timely paid all filing, issuance, maintenance and renewal fees payable for such patents and patent applications. Arvinas or one of its Affiliates has obtained an assignment from each inventor of the inventions claimed by the Arvinas-owned patents and patent applications within the Arvinas Background IP, and all such assignments have been recorded with the Governmental Authority where such patents have issued or patent applications have been filed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">Arvinas owns or has the right to use the Arvinas Background IP existing as of the Original Agreement Effective Date, except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, free and clear of any liens, charges and encumbrances (other than licenses granted to Third Parties that are not inconsistent with the rights and licenses granted to Oerth hereunder and other than the licenses granted to Oerth hereunder)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the foregoing is not a representation of non-infringement of the intellectual property rights of another Person, which representation is solely set forth in Section 4.2.7 below. Arvinas has the right to grant sublicenses to Oerth of the scope contemplated under Section 2.1.1 under the Licensed Yale IP, and any other in-licensed Patents or Know-How included in the Arvinas Background IP, in each case, existing as of the Original Agreement Effective Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">No Person has challenged in writing the scope, validity or enforceability of any Arvinas-owned patent within the Arvinas Background IP (including, by way of example, through the institution, or written threat of institution, of interference, cancellation, opposition, reissue, reexamination or similar invalidity proceeding before the United States Patent and Trademark Office or any equivalent foreign Governmental Authority). To the knowledge of Arvinas, the Arvinas-owned patents within the Arvinas Background IP are valid and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">(a) To the knowledge of Arvinas, no Person has infringed, misappropriated or otherwise violated the owned Arvinas Background IP existing as of the Original Agreement Effective Date, and (b) neither Arvinas nor any of its Affiliates has filed or made any written claim against any Person alleging any infringement, misappropriation, or other violation of any owned Arvinas Background IP existing as of the Original Agreement Effective Date, in each case of (a) and (b), where such Person is engaged in activities that are reasonably similar to the Research, Development, Manufacture, use and Commercialization of Oerth Products in the Field.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">As of the Original Agreement Effective Date and to the best of Arvinas&#8217; knowledge, neither Arvinas nor any of its Affiliates Controls any Know-How or Patents other than the Arvinas Background IP, as the same exists as of the Original Agreement Effective Date, that would be necessary for Oerth to Research, Develop, Manufacture, use or Commercialize Oerth Products in the Field as contemplated under the LLC Agreement as of the Original Agreement Effective Date, excluding commercially available software and commercially available laboratory materials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">As of the Original Agreement Effective Date and to the knowledge of Arvinas, the Research, Development, Manufacture, use and Commercialization of Oerth Products in the Field using the owned Arvinas Background IP as contemplated under this Agreement does not infringe any duly issued and unexpired patent of any Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt">As of the Original Agreement Effective Date, none of the Arvinas Background IP owned by Arvinas and existing as of the Original Agreement Effective Date is subject to any pending or outstanding injunction, order, decree, award, settlement, judgment or other disposition of dispute that (a) would reasonably be expected to adversely restrict the use of the same within the scope of the licenses granted to Oerth pursuant to Section 2.1.1, or (b) otherwise would reasonably be expected to adversely affect the scope, validity or enforceability of any Arvinas Background IP owned by Arvinas and existing as of the Original Agreement Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14pt"> There have not been any, and, as of the Original Agreement Effective Date, there are no pending or, to the knowledge of Arvinas, threatened in writing, action, claim, demand, suit, proceeding, arbitration, citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, against Arvinas or any of its Affiliates, in each case, in connection with the Arvinas Background IP owned by Arvinas and existing as of the Original Agreement Effective Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nothing in this Section 4.2.9 will be interpreted as requiring Arvinas to have undertaken any inquiries or to have obtained any freedom to operate opinions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Arvinas Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Arvinas hereby covenants to Oerth that, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.5(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and except as expressly permitted under this Agreement, it will not amend, modify or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate any In-License Agreements in a manner that would have a material adverse effect on Oerth&#8217;s rights hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Oerth Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Oerth hereby covenants to Arvinas that, in the event that the Yale Agreement is terminated and, notwithstanding such termination, Oerth retains its sublicense under the Licensed Yale IP as included in the license granted to Oerth pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Oerth will comply with the obligations applicable to Oerth under the terms of the Yale Letter Agreement. The foregoing will in no way limit Oerth&#8217;s continued obligation under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY NOR ITS AFFILIATES MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. OERTH AND ARVINAS ACKNOWLEDGE AND AGREE THAT ANY OERTH PRODUCT WILL BE THE SUBJECT OF ONGOING RESEARCH AND DEVELOPMENT AND THAT NEITHER PARTY CAN ASSURE THE SAFETY, USEFULNESS, TECHNICAL OR SCIENTIFIC VIABILITY OR COMMERCIAL SUCCESS OF ANY OERTH PRODUCT.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:10.91pt"><br>TERM&#59; TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Agreement Term&#59; Expiration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement is effective as of the Effective Date and shall terminate upon expiration of the Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Termination Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement will be terminated upon the occurrence of any of the following events (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Parties mutually agree in writing to terminate this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">Upon the occurrence of a material breach of this Agreement that is not cured within &#91;**&#93; after written notice thereof to the breaching Party, at the election of the non-breaching Party upon delivery of written notice to the breaching Party (including a breach by any of its Affiliates) of its intent to terminate this Agreement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; provided that if such breach is not reasonably capable of cure within such &#91;**&#93; period, the breaching Party may submit, prior to the end of such &#91;**&#93; period, a plan that is reasonably calculated to cure the breach, in which case the non-breaching Party may not terminate this Agreement for an additional &#91;**&#93; so long as the breaching Party is using commercially reasonable efforts to implement such cure plan. If the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided by the other Party, and such alleged breaching Party provides the other Party notice of such dispute within the applicable cure period, then the non-breaching Party may not terminate this Agreement unless and until it has been finally determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the alleged breaching Party has materially breached this Agreement and such Party fails to cure such breach within &#91;**&#93; following such court's decision. During the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">Upon Bankruptcy of a Party which is not dismissed or otherwise resolved within &#91;**&#93; of the filing or commencement thereof, as applicable, at the election of the other Party upon delivery of written notice to such Party of its intent to terminate this Agreement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Consequences of Termination of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">Termination of Licenses to Oerth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon any termination of this Agreement, all licenses granted to Oerth under this Agreement shall cease.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of this Agreement, any Sublicense granted by Oerth under this Agreement shall, to the extent provided for in the terms of such Sublicense, survive and shall be assigned by Oerth to Arvinas such that such Sublicense becomes a direct license between Arvinas and such Sublicensee, to the extent applicable to the rights granted by Oerth to such Sublicensee, provided that such Sublicense was granted in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and that such Sublicensee is in compliance with the terms of the Sublicense (and did not cause Oerth to breach its obligations under this Agreement).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary, termination of this Agreement for any reason shall not release any Party from any obligation that, prior to the effective date of such expiration or termination, has already accrued.  Subject to the limitations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement, neither Party is precluded from pursuing any rights and remedies it may have under this Agreement at law or in equity which accrued, or are based upon any act, error or omission occurring, prior to the effective date of such termination. The following Articles and Sections of this Agreement will survive termination of this Agreement&#58; 1, 2.2, 2.3, 3.1, 3.2(b) (last sentence only), 3.4.2, 3.4.3, 3.6, 3.7, 4.5, 5.3, 6 (for the duration set forth therein), 7, 8.1, 9, 10, and 11.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:10.91pt"><br>CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly provided in this Agreement, each Party shall keep completely confidential, shall not publish and shall not disclose any Confidential Information of the other Party, and shall not use any such Confidential Information for any purpose, in each case, except for the purposes contemplated by, and as permitted under and in accordance with, this Agreement.  Each Party shall maintain in confidence such Confidential Information using not less than the efforts such Party uses to maintain in confidence its own confidential information, and in no event less than reasonable efforts.  Without limiting any provision of this Agreement, each of the Parties shall be responsible for the compliance by its employees, executives, directors, officers, subcontractors and any other recipient(s) from it of the other Party&#8217;s Confidential Information of the confidentiality and non-use obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party&#8217;s obligations with respect to nondisclosure and limited use of Confidential Information under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> apply during the Term and continue for &#91;**&#93; thereafter&#59; provided, however, Confidential Information that is a trade secret under Applicable Law shall remain subject to the obligations of confidentiality and non-use obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for so long as such Confidential Information remains a trade secret. All Confidential Information disclosed by or on behalf of a Party under the Original Agreement shall be deemed to have been disclosed under this Agreement and the confidentiality and non-use obligations of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall apply to such Confidential Information.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing confidentiality and non-use obligation, each Party may disclose the other Party&#8217;s Confidential Information&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">to its Affiliates or to its or their respective advisors and accountants strictly on a need-to-know basis, if such Affiliates, respective advisors and accountants  and other permitted recipients are bound in writing by confidentiality and non-use obligations no less restrictive than the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or have a fiduciary duty of confidentiality, and provided such Party will be responsible for compliance of each such recipient with the confidentiality and non-use obligations set forth in this Article 6 and this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">to the extent such disclosure is reasonably necessary in connection with&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.63pt">Prosecution and Maintenance of Patents as permitted by this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.58pt">prosecuting or defending litigation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">complying with Applicable Laws, governmental authorities and governmental regulations, stock exchange rules, court orders, and administrative subpoena or orders&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.13pt">submitting information to regulatory authorities as required in connection with any regulatory filings for a product that such Party has a license or right to develop in a given country or jurisdiction&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">complying with a valid order of a court of competent jurisdiction or other governmental entity&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.13pt">for external audit purposes&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.08pt">submitting information to tax authorities&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.03pt">upon prior written consent of the disclosing Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided that if a Party is required to make any such disclosure of the other Party&#8217;s Confidential Information in subclauses (i), (ii), (iii) or (v), it shall give reasonable advance notice (e.g. which will be sufficient to enable such other Party to apply for patent protection for inventions to be disclosed), to the extent possible, to such other Party of such disclosure and, shall cooperate with such other Party, at such other Party&#8217;s reasonable cost and expense, in any effort by such other Party to secure a protective order blocking the disclosure of, or otherwise affording confidential treatment to, such Confidential Information, and will limit any disclosure to the minimum information that such Party reasonably determines is required to be disclosed.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">Notwithstanding anything to the contrary in this Agreement, either Party may disclose this Agreement and the other Party&#8217;s Confidential Information to the Party&#8217;s actual or potential financial investors, acquirers, and&#47;or other financing (including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">debt) sources or to actual and&#47;or potential collaborators, licensees or licensors to&#58; (i) provide financing to, or monitor its or their investment in, the Party, (ii) to assist the Party in evaluating the transactions contemplated or in fulfilling its obligations or exploiting its rights hereunder, or (iii) in connection with any tax, accounting, finance or other reasonable business purpose and, in each case (i) &#8211; (iii), who are, prior to receiving such disclosure, bound by written or professional confidentiality and non-use obligations for such purpose substantially similar to those contained herein (but of shorter duration if customary).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Archive Copies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon any expiration or termination of this Agreement, or upon one Party&#8217;s written request, the other Party will promptly return to the requesting Party or destroy all copies of its Confidential Information, to the extent not prohibited by Applicable Law.  It is understood, however, that in the event that computer archive copies of such Confidential Information exists, such copies may be retained by the other Party so long as such computer archive copies are incapable of being accessed by any employee of such Party or by any third party without permission provided by its IT systems administrator, and that if such IT systems administrator shall receive any request for access of such computer archive copy(ies), no access shall be granted without express written permission of Party owning such Confidential Information.  Each Party may allow its internal and&#47;or external counsel to access the other Party&#8217;s Confidential Information for the purpose of determining compliance with such Party&#8217;s obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Information Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties will make commercially reasonable efforts to&#58; 1) have in place and maintain personnel security safeguards in accordance with generally accepted industry standards and any Applicable Laws or regulations&#59; and 2) maintain a security position through the application of security controls, policies and associated procedures that protect information-related assets from internal, external, deliberate or accidental threats. The Parties will review the overall implementation of security controls against regulations, policies and associated risks on a regular basis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Privileged Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither Party is waiving, nor will be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges as a result of disclosing information pursuant to this Agreement, or any of its confidential or proprietary information to the receiving party, regardless of whether a Party has asserted, or is or may be entitled to assert, such privileges and protections. The Parties&#58; (i) share a common legal and commercial interest in such disclosure that is subject to such privileges and protections&#59; (ii) are or may become joint defendants in proceedings to which the information covered by such protections and privileges relates&#59; (iii) intend that such privileges and protections remain intact should either Party become subject to any actual or threatened proceeding to which a Party&#8217;s information covered by such protections and privileges relates&#59; and (iv) intend that after the date hereof both Parties will have the right to assert such protections and privileges.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 7.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDEMNIFICATION</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Indemnification of Arvinas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Oerth shall indemnify, defend and hold Arvinas and its Affiliates and their respective directors, officers, employees, agents, consultants and counsel, and the successors and assigns of the foregoing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Arvinas Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) harmless from and against any and all liabilities, damages, losses, costs or expenses (including reasonable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attorneys&#8217; and professional fees and other expenses of litigation and arbitration) resulting from a claim, suit or proceeding brought by a Third Party against an Arvinas Indemnitee, arising from or occurring as a result of (a) activities of Oerth, its Affiliates or its Sublicensees in connection with any licenses granted to Oerth hereunder&#59; (b) Oerth&#8217;s breach of its representations, warranties or covenants set forth in this Agreement&#59; or (c) the willful misconduct or grossly negligent act of Oerth, its Affiliates or Sublicensees, or their respective directors, officers, employees or agents&#59; except in each case under clauses (a), (b) or (c) to the extent caused by the willful misconduct or grossly negligent act of any of the Arvinas Indemnitees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Indemnification of Oerth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Arvinas shall indemnify, defend and hold Oerth and its Affiliates and their respective directors, officers, employees, agents, consultants and counsel, and the successors and assigns of the foregoing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Oerth Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) harmless from and against any and all liabilities, damages, losses, costs or expenses (including reasonable attorneys&#8217; and professional fees and other expenses of litigation and arbitration) resulting from a claim, suit or proceeding brought by a Third Party against an Oerth Indemnitee, arising from or occurring as a result of (a) activities of Arvinas, its Affiliates or its Sublicensees in connection with any license granted to Arvinas hereunder&#59; (b) Arvinas&#8217; breach of its representations, warranties or covenants set forth in this Agreement&#59; or (c) the willful misconduct or grossly negligent act of Arvinas, its Affiliates or Sublicensees, or their respective directors, officers, employees or agents&#59; except in each case under clauses (a), (b) or (c) to the extent caused by the willful misconduct or grossly negligent act of any of the Oerth Indemnitees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Party that intends to claim indemnification under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall within &#91;**&#93; of first becoming aware of an action for which it will seek indemnification hereunder, notify the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of any loss, claim, damage, liability or action in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have the right to assume sole control of the defense thereof with counsel that is reasonably satisfactory to the Indemnitee, including the right to settle the action on behalf of the Indemnitee on any terms the Indemnitor deems desirable in the exercise of its sole discretion, except that the Indemnitor shall not, without the Indemnitee&#8217;s prior written consent, settle any such claim if such settlement (a) contains a stipulation to or admission or acknowledgment of any liability or wrongdoing on the part of the Indemnitee, (b) imposes any obligation on the Indemnitee other than a monetary obligation, and only to the extent the Indemnitor assumes in full such monetary obligation, or (c) would materially diminish or materially adversely affect the scope, exclusivity, duration or enforceability of any Patents licensed under this Agreement.  The failure to deliver notice to the Indemnitor within &#91;**&#93; after the Indemnitee first becomes aware of any such action shall not impair Indemnitor&#8217;s indemnification obligation with respect to such action but shall relieve Indemnitor of any liability to the Indemnitee to the extent the Indemnitor is prejudiced materially by the delay.  At the Indemnitor&#8217;s request and cost, the Indemnitee shall cooperate reasonably with the Indemnitor and its legal representatives in the investigation and defense of any action, claim or liability covered by this indemnification and provide full information with respect thereto.  Subject to the Indemnitee&#8217;s fulfillment of its obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Indemnitor shall pay any and all damages, costs or other amounts awarded against the Indemnitee, or payable by the Indemnitee pursuant to a settlement agreement entered into by the Indemnitor, in connection with such claim.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 8.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXCLUSION OF DAMAGES</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Exclusion of Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  UNDER NO CIRCUMSTANCE SHALL EITHER PARTY BE LIABLE UNDER THIS AGREEMENT TO THE OTHER PARTY FOR ANY INCIDENTAL, CONSEQUENTIAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES, INCLUDING DAMAGES FROM LOSS OF PROFITS OR OPPORTUNITIES, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, PROVIDED HOWEVER EACH PARTY&#8217;S LIABILITY IN CONNECTION WITH (A) INFRINGEMENT OR MISAPPROPRIATION OF THE OTHER PARTY&#8217;S INTELLECTUAL PROPERTY RIGHTS, INCLUDING ANY USE OUTSIDE THE SCOPE OF THE LICENSES GRANTED TO SUCH PARTY IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (B) A BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, OR (C) ITS INDEMNIFICATION OBLIGATIONS UNDER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> SHALL NOT BE EXCLUDED BY THE AFOREMENTIONED EXCLUSION OF DAMAGES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Allocation of Risk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of Arvinas and Oerth acknowledges and agrees that each Party has entered into this Agreement in reliance on the warranties, limitations, and disclaimers set forth in this Agreement, and that such warranties, limitations, and disclaimers reflect an allocation of risk between the Parties (including the risk that a contract remedy may fail of its essential purpose and cause consequential damages or other loss that are excluded from the other Party&#8217;s liability) and form an essential basis of the bargain between Arvinas and Oerth.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:10.91pt"><br>DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any and all disputes arising under, out of, or in relation to this Agreement, its formation, performance or termination (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall initially be referred to a committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispute Resolution Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) consisting of &#91;**&#93; individual representatives of each Party at the senior management level.  If the Dispute Resolution Committee cannot resolve the Dispute within &#91;**&#93; of referral, the Dispute shall be referred to the Chief Executive Officer of Oerth and the Chief Executive Officer for Arvinas for resolution, who shall meet and attempt to resolve the dispute.  If the Dispute has still not been resolved within &#91;**&#93; of such referral, either Party may institute proceedings in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The dispute resolution procedure set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is mandatory, and neither Party shall institute legal proceedings until it has been exhausted.  Disputes that have not been resolved in accordance with the above shall be finally and conclusively determined by a bench trial in a court of competent jurisdiction.  Each Party expressly consent and submit to the personal jurisdiction of any competent court sitting in Delaware.  Both Parties further consent, submit to, and agree that venue in any such suit, action, proceeding, or claim is proper in said court and further expressly waives any and all personal rights under Applicable Law or in equity to object to the jurisdiction and venue of said court.  Each Party hereby irrevocably waive, to the fullest extent permitted by Applicable Law, any and all right such Party has to a trial by jury in any litigation between them arising under, out of, or in relation to this Agreement, its formation, performance or termination.  Neither Party shall make any public announcement or press release concerning any Dispute arising under, out of, or in relation to this Agreement, its formation, performance or termination without the prior written consent of the other Party, unless as required by law or government agency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties agree that this Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of the Parties hereto acknowledges and agrees that the other Party would be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached or violated. Accordingly, each of the Parties hereto agrees that, without posting a bond or other undertaking, the other Party may seek (and obtain) an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement and to enforce specifically this Agreement and the terms and provisions hereof in any Action instituted in any court specified herein. An Action for specific performance as provided herein shall not preclude a Party hereto from pursuing any other remedy to which such Party may be entitled, at law or in equity, in accordance with the terms of this Agreement. Each Party hereto further agrees that, in the event of any action for specific performance in respect of such breach or violation, it will not assert as a defense that a remedy at law would be adequate&#59; provided however, that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each Party hereto also agrees that any Party hereto can assert any other defense it may have other than the defense of adequate remedy at law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:5.41pt"><br>ASSIGNMENT</font></div><div style="margin-bottom:12pt;padding-left:7.2pt;padding-right:7.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:7.8pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as permitted under this Agreement, neither this Agreement nor any of the rights, interests and obligations hereunder will be assigned by a Party without the prior written consent of the other Party&#59; provided however, that either Party may assign this Agreement to an Affiliate (provided that such Party remains primarily liable for all obligations of such Affiliate following such assignment) or upon a transfer or sale of all or substantially all of its business to which this Agreement relates to a Third Party, whether by merger, sale of stock, sale of assets or otherwise (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of such Party, in each case upon providing prior written notice to the other Party. Subject to the prior sentence, this Agreement will be binding upon and will inure to the benefit of the Parties and their respective heirs, executors, administrators, successors and assigns.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:5.41pt"><br>NOTICES AND MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All notices, requests, consents, claims, demands, waivers and other communications hereunder will be in writing and will be deemed to have been given&#58; (a) when delivered by hand (with written confirmation of receipt)&#59; (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested)&#59; (c) on the date sent by e-mail of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient, in each case with confirmation by one of the other means of notice in (a), (b) or (d)&#59; or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as will be specified in a notice given in accordance with this Section 11.1)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="padding-left:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To Arvinas&#58;&#160;&#160;&#160;&#160;c&#47;o Arvinas, Inc.</font></div><div style="padding-left:151.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5 Science Park</font></div><div style="padding-left:151.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">395 Winchester Avenue</font></div><div style="padding-left:151.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Haven, CT 06511</font></div><div style="padding-left:151.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">USA</font></div><div style="padding-left:151.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; Legal Department</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="padding-left:43.2pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With a copy to&#58;&#160;&#160;&#160;&#160;Goodwin Procter LLP</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100 Northern Avenue</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston, MA 02210</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; Robert Puopolo&#59; Nicole Daley</font></div><div style="padding-left:151.2pt"><font><br></font></div><div style="padding-left:43.2pt"><font><br></font></div><div style="padding-left:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To Oerth&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   Oerth Bio, LLC</font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   112 S. Duke Street</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   Durham, NC 27701</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   Attention&#58; Chief Executive Officer </font></div><div style="padding-left:43.2pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With a copy to&#58;&#160;&#160;&#160;&#160;   Oerth Bio, LLC</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  112 S. Duke Street</font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Durham, NC 27701 </font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Attention&#58; Chief Legal Officer </font></div><div style="padding-left:43.2pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.5pt">No provision of this Agreement may be amended or modified, or compliance otherwise waived, except by a writing executed by each Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.5pt">The terms and conditions of this Agreement shall be interpreted according to the common sense meaning intended by the Parties and in accordance with the principles of good faith and fair dealing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.5pt">The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement. Any reference to any federal, state, local or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.5pt">Every day commences at 12&#58;00 a.m. and ends at 11&#58;59 p.m. (midnight) New York time. Any reference in this Agreement to a number of days &#8220;in&#8221; which an action or notice is to be taken or given, shall be interpreted in such way that the term commences the day after the date taken as reference and that the action or notice shall be validly taken or given at the last day. Any reference in this Agreement to a &#8220;day&#8221; or a number of &#8220;days&#8221; without explicit qualification of &#8220;business&#8221; shall be interpreted as a reference to a calendar day or number of calendar days. If any action or notice is to be taken or given on or by a particular calendar day, and such calendar day is not a Business Day, then such action or notice shall be deferred until, or may be taken or given on, the next Business Day.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.5pt">All rights and licenses granted under or pursuant to this Agreement by Arvinas or Oerth, as applicable, are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to &#8220;intellectual property&#8221; as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that each Party, as licensee of certain rights under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The Parties further agree that, in the event of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commencement of a bankruptcy proceeding by or against a Party (such Party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) under the U.S. Bankruptcy Code, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) any intellectual property licensed to such other Party and all embodiments of such intellectual property, which, if not already in such other Party&#8217;s possession, will be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon such other Party&#8217;s written request therefor, unless the Bankrupt Party elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under clause (a), following the rejection of this Agreement by the Bankrupt Party upon written request therefor by the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.5pt">This Agreement constitutes the sole and entire agreement of the Parties with respect to the subject matter contained herein and therein, and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to such subject matter, including the Original Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.5pt">The headings in this Agreement are inserted for convenience or reference only and are in no way intended to describe, interpret, define, or limit the scope, extent or intent of this Agreement or any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.5pt">If any term or provision of this Agreement is held to be invalid, illegal or unenforceable under Applicable Law in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the Parties hereto will negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.5pt">Any mistaken reference to Articles, clauses, Sections, Schedules or paragraphs of this Agreement shall be amended according to common sense and good faith rules. When a reference is made in this Agreement to an Article, clause, Section, Schedule or paragraph, such reference will be to an Article, clause, Section, Schedule or paragraph unless otherwise indicated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">No waiver by any Party of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. No single or partial exercise of any right, power or privilege shall preclude any other or further exercise thereof, or the exercise of any other right, power or privilege unless explicitly provided for in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Subject to the terms of and restrictions in this Agreement, the reference to any Party shall include its successors or permitted assignees or transferees that have legally acquired its rights, obligations and&#47;or duties. This Agreement shall be binding upon and inure solely to the benefit of the Parties and their respective successors and permitted assignees and transferees and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever, unless otherwise specified therein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same agreement. A signed copy of this Agreement delivered by e-mail or other means of Electronic Transmission will be deemed to have the same legal effect as delivery of an original signed copy of this Agreement. For purposes of this Section 11.2.12, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Electronic Transmission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any form of communication not directly involving the physical transmission of paper that creates a record that may be retained, retrieved and reviewed by a recipient thereof and that may be directly reproduced in paper form by such a recipient through an automated process.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they will be deemed to be followed by the words &#8220;without limitation.&#8221; The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement will refer to this Agreement as a whole and not to any particular provision of this Agreement. All terms used herein with initial capital letters have the meanings ascribed to them herein and all terms defined in this Agreement will have such defined meanings when used in any certificate or other document made or delivered pursuant hereto unless otherwise defined therein. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms. Words importing gender include all genders. Any agreement, instrument or statute defined or referred to herein, or in any agreement or instrument that is referred to herein, means such agreement, instrument or statute as from time to time amended, modified or supplemented, including (in the case of agreements or instruments) by waiver or consent and (in the case of statutes) by succession of comparable successor statutes and references to all attachments thereto and instruments incorporated therein. The use of &#8220;or&#8221; is not intended to be exclusive unless expressly indicated otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Both Parties are independent contractors under this Agreement. Nothing herein contained will be deemed to create an employment, agency or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party, except to the extent specifically agreed to in a written agreement signed by the Parties. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their representatives thereunto duly authorized as of the Effective Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:80%">OERTH BIO LLC&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ARVINAS OPERATIONS, INC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%;text-decoration:underline">&#47;s&#47; John Domdrosky&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Sean Cassidy&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">Name&#58;&#160;&#160;&#160;&#160;John Domdrosky&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Sean Cassidy</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">Title&#58;&#160;&#160;&#160;&#160;CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;Chief Financial Officer and Treasurer</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.1.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional License Terms for Licensed Yale IP</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Oerth acknowledges that its sublicense and other rights under this Agreement to the Licensed Yale IP are subject to the additional terms and conditions, and Oerth agrees to comply with such additional terms and conditions, set forth below. Unless otherwise noted, the indicated Section refers to the appropriate Section of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Government Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.8pt">Oerth acknowledges that, to the extent that any invention included within the Licensed Yale IP has been funded in whole or in part by the United States government, the United States government retains certain rights in such invention as set forth in 35 U.S.C. &#167;200-212 and all regulations promulgated thereunder, as amended, and any successor statutes and regulations (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Federal Patent Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.18pt">As a condition of the licenses granted under Section 2.1 of this Agreement, Oerth acknowledges and shall comply with all aspects of the Federal Patent Policy that are applicable to the Licensed Yale IP, including any obligation that Oerth Products used or sold in the United States be manufactured substantially in the United States.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Yale Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Oerth acknowledges that Yale University (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Yale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) retains the right, on behalf of itself and all other non-profit academic research institutions, to make, use and practice the Licensed Yale IP for research, clinical, teaching or other non-commercial purposes, and not for purposes of commercial development, use, manufacture or distribution purposes.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Oerth acknowledges that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">In the event that (i) (A) Oerth brings a Patent Challenge (as such term is defined in the Yale Agreement) anywhere in the world, or (B) Oerth assists another party in bringing a Patent Challenge (as such term is defined in the Yale Agreement) anywhere in the world (except under a court order or subpoena), then (1) provided such PATENT CHALLENGE is brought during the period specified in Sections 6.1 and 7.3 of the Yale Agreement during which Yale is owed an EARNED ROYALTY or a percentage of SUBLICENSE INCOME, then commencing on the date on which such PATENT CHALLENGE is brought and continuing until, as applicable, either (x) the date on which such PATENT CHALLENGE results in a determination that no challenged claims are valid or infringed or (y) the date of expiration of the period specified in Sections 6.1 and 7.3 of the Yale Agreement during which Yale is owed an EARNED ROYALTY or a percentage of SUBLICENSE INCOME (in the case where such PATENT CHALLENGE results in a determination that at least one challenged claim is both valid and infringed), Oerth will pay to Yale an annual penalty fee of &#91;**&#93; Dollars (U.S. $&#91;**&#93;) within &#91;**&#93;, as applicable, the period specified in clause (x) or clause (y), and (2) solely if such PATENT CHALLENGE results in a determination that at least one challenged claim is both valid and infringed, Oerth will promptly reimburse Yale for all legal fees and expenses incurred in Yale&#8217;s defense against such PATENT CHALLENGE.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">Oerth will not bring a PATENT CHALLENGE without first providing Yale at least &#91;**&#93; prior written notice setting forth (i) precisely which claims and patents are being challenged or claimed not to be infringed, (ii) a clear statement of the factual and legal basis for the challenge, and (iii) an identification of all prior art and other matter believed to invalidate any claim of the patent within the Licensed Yale IP at issue at issue or which supports the claim that the patent within the Licensed Yale IP at issue at issue is not infringed.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.8pt">Any payments to be made to Yale by Oerth pursuant to Section 3(a) of this Schedule 2.1.4 will be made to the account listed below (or such other account as Arvinas designates before such payment is due)&#58;</font></div><div style="padding-left:72.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:50.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bank Name&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ABA Number&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ABA Number&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SWIFT Number&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Account Title&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Account Number&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Yale Contract Number&#58;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Federal Tax ID # for Yale University&#58; 06-0646973</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.18pt">Any payments to be made to Yale by Oerth pursuant to Section 3(a) of this Schedule 2.1.4 will be made in United States Dollars. If overdue, such payment will bear interest until payment at a per annum rate of &#91;**&#93; percent (&#91;**&#93;%) above the prime rate in effect at Citibank on the due date and Yale will be entitled to recover reasonable attorneys&#8217; fees and costs related to the collection of such payment following such failure to pay. The payment of such interest will not foreclose Yale from exercising any other right it may have as a consequence of the failure of Oerth to make such payments when due.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Patent Marking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Oerth agrees to mark, and to require that its Affiliates and Sublicensees mark, all Oerth Products that are also VALID CLAIM PRODUCTS and tangible products, with the numbers of all issued patents included in Licensed Yale IP that cover such Oerth Products, and, without limiting the foregoing, all such Oerth Products will be marked in such a manner as to conform with the patent marking notices required by the law of any country where such Oerth Products are made, sold, used or shipped, including, but not limited to, the applicable patent laws of that country.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Oerth will indemnify, defend by counsel reasonably acceptable to Yale, and hold harmless Yale and its trustees, officers, employees and agents, from and against any liability, cost expense, damage, deficiency, loss or obligation, of any kind or nature arising out of a third party claim (including, without limitation, reasonable attorneys&#8217; fees and other costs and expenses of defense) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), based upon, arising out of or otherwise relating the license granted to Oerth under Section of 2.1.1(a) under the Licensed Yale IP, including, without limitation, any cause of action relating to product liability, or any theory of liability (including, without limitation, tort, warranty or strict liability) or the death, personal injury, or illness of any person, or out of damage to any property related in any way to the rights granted to Oerth under Section of 2.1.1(a) to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensed Yale IP, or resulting from the production, manufacture, sale, use, lease or other disposition or consumption or advertisement of the Oerth Products by Oerth, its Affiliates or (sub)licensees or any other transferees, or in connection with any statement, representation or warranty of Oerth, its affiliates or (sub)licensees or any other transferees with respect to the Oerth Products, but expressly excluding all Claims to the extent based upon, arising out of or otherwise relating to (a) Yale&#8217;s retained rights pursuant to Section 3.3 of the Yale Agreement to use the Licensed Yale IP, or (b) Yale&#8217;s gross negligence or willful misconduct. Oerth will not settle or compromise any Claim without the prior written consent of Yale, such consent not to be unreasonably withheld, conditioned or delayed, if such settlement or compromise does not include a complete release of Yale from all Claims. Without limiting the foregoing, Yale may withhold its consent to any settlement or compromise that would in any manner constitute or incorporate an admission of liability by Yale or require Yale to take or refrain from taking any action.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Patent Prosecution Expenses Conditional Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that the Yale Agreement is terminated and, as provided under the terms of the Yale Agreement, Oerth&#8217;s sublicense under the Licensed Yale IP survives and continues in full force and effect (but subject to Oerth&#8217;s right to notify Yale of its election not to retain such sublicense), then Oerth will be responsible to Yale for the costs of filing, prosecution and maintenance of (i) the United States patent applications and patents contained in the Licensed Yale IP, and (ii) the foreign patent applications and patents contained in the Licensed Yale IP in the countries outside of the United States selected by Yale and agreed to in writing by Arvinas (as such list of countries exists on the date of termination of the Yale Agreement), in each case of (i) and (ii), shared proportionately with Yale&#8217;s other licensees and sublicensees of such Licensed Yale IP (if any) also reimbursing Yale for such costs.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">From and after such time as Oerth&#8217;s first Oerth Product commences field trials, Oerth will have purchased, and will have caused any of its Sublicensees to have purchased, and Oerth will maintain in effect, and will cause any of its Sublicensees to maintain in effect, a policy of commercial, general liability insurance in coverage amounts customary for its industry to protect Yale with respect to the Claims described in Section 5 of this Schedule 2.1.4. Such insurance will&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.63pt">list &#8220;Yale, its trustees, directors, officers, employees and agents&#8221; as additional insureds under the policy&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.58pt">provide that such policy is primary and not excess or contributory with regard to other insurance Yale may have&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.53pt">be endorsed to include product liability coverage in amounts no less than $&#91;**&#93; Dollars per incident and $&#91;**&#93; Dollars annual aggregate for Oerth&#8217;s indemnification obligation to Yale described in Section 5 of this Schedule 2.1.4&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.13pt">not be construed to create a limit of Oerth&#8217;s liability with respect to its indemnification obligation to Yale described in Section 5 of this Schedule 2.1.4.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">Upon Yale&#8217;s request, Oerth will furnish a Certificate of Insurance and a copy of the current insurance policy to Yale. Oerth will secure agreement from its insurer to give &#91;**&#93; written notice to Yale prior to any cancellation of or material change to the policy.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Yale Disclaimer of Representations &#38; Warranties for the Licensed Yale IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition to the Parties&#8217; disclaimer set forth in Section 4.4 of this Agreement, Oerth acknowledges and agrees that with respect to the Licensed Yale IP&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">YALE MAKES NO, AND EXPRESSLY DISCLAIMS ALL, REPRESENTATIONS OR WARRANTIES THAT ANY CLAIMS OF PATENTS WITHIN THE LICENSED YALE IP, ISSUED OR PENDING, ARE VALID, OR THAT THE MANUFACTURE, USE, PRACTICE, SALE OR OTHER DISPOSAL OF COMPANY PRODUCTS THAT ARE ALSO LICENSED PRODUCTS (AS DEFINED IN THE YALE AGREEMENT) DOES NOT OR WILL NOT INFRINGE UPON ANY PATENT OR OTHER RIGHTS NOT VESTED IN YALE.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">YALE MAKES NO, AND EXPRESSLY DISCLAIMS ALL, REPRESENTATIONS AND WARRANTIES WHATSOEVER WITH RESPECT TO PATENTS WITHIN THE LICENSED YALE IP AND COMPANY PRODUCTS THAT ARE ALSO LICENSED PRODUCTS (AS DEFINED IN THE YALE AGREEMENT), EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">COMPANY WILL MAKE NO STATEMENTS, REPRESENTATION OR WARRANTIES WHATSOEVER TO ANY THIRD PARTIES THAT ARE INCONSISTENT WITH THE DISCLAIMERS BY YALE IN CLAUSES (a) AND (b) IMMEDIATELY ABOVE.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt">IN NO EVENT WILL YALE OR ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER YALE WILL BE ADVISED, WILL HAVE OTHER REASON TO KNOW, OR IN FACT WILL KNOW OF THE POSSIBILITY OF THE FOREGOING.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.8pt">IN NO EVENT WILL YALE, OR ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES, BE LIABLE FOR MONEY DAMAGES IN EXCESS OF YALE HAS RECEIVED FROM ARVINAS IN CONNECTION WITH COMPANY&#8217;S RIGHTS UNDER THE LICENSED YALE IP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Compliance with Laws&#59; Export Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Oerth will comply, and will cause its Affiliates and (sub)licensees to comply, with all foreign and United States federal, state and local laws, regulations, rules and orders applicable to the testing, production, transportation, packaging, labeling, export, practice, sale and use of Oerth Products that are also LICENSED PRODUCTS. In particular, Oerth will be responsible for assuring compliance with all United States export laws and regulations applicable to Oerth&#8217;s use and practice of the Licensed Yale IP.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Non-Use of Yale Name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Oerth acknowledges and agrees that it will not use the name &#8220;Yale&#8221; or &#8220;Yale University&#8221;, or any variation or adaptation thereof, or any trademark, tradename or other designation owned by Yale, or the names of any of its trustees, officers, faculty, students, employees or agents, for any purpose without the prior written consent of Yale, in each instance, such consent to be granted or withheld by Yale in its sole discretion, except that Oerth may state that it has a sublicense under the Licensed Yale IP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law for Disputes Regarding Licensed Yale IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding Article 7 of this Agreement, Oerth acknowledges and agrees that any matter arising out of or related to Oerth&#8217;s use and practice of the Licensed Yale IP will be governed by and in accordance with the substantive laws of the State of Connecticut, without regard to its conflicts of law principles, except where the federal laws of the United States are applicable and have precedence. Any dispute arising out of or related to Oerth&#8217;s use and practice of the Licensed Yale IP will be brought exclusively in a court of competent jurisdiction in the State of Connecticut, and Oerth hereby irrevocably submits to the jurisdiction of such courts.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>arvn-20221231x10kxex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5c0b81e7763b49ddbe1c00dfd2607865_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 21.1</font></div><div><font><br></font></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.619%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">State of Incorporation</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas Operations, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas Androgen Receptor, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas Estrogen Receptor, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas Winchester, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>consent-form10kfy22.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i13e9f0eacd9c4ec2a9aaf3c38472f615_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 23.1</font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">We consent to the incorporation by reference in Registration Statement Nos. 333-234031, 333-234035 and 333-251326 on Form S-3 and Registration Statement Nos. 333-227555, 333-231388, 333-237215, 333-253721 and 333-263095 on Form S-8 of our reports dated February&#160;23, 2023, relating to the consolidated financial statements of Arvinas, Inc. and subsidiaries (the &#34;Company&#34;) and the effectiveness of the Company's internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December&#160;31, 2022.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Deloitte &#38; Touche LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Stamford, Connecticut</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">February&#160;23, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>arvn-20221231x10kxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id9117ec4a2fa4c6e868c4cea9b110b2c_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Houston, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Annual Report on Form 10-K of Arvinas, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;23, 2023</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; John Houston, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Houston, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>arvn-20221231x10kxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2e2105e481b242e3bdfd8ba66b4ffed4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sean Cassidy, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Annual Report on Form 10-K of Arvinas, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;23, 2023</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Sean Cassidy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sean Cassidy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Chief Financial Officer and Treasurer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>arvn-20221231x10kxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie7e4358cca444df98cee7292342e312b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;23, 2023</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; John Houston, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Houston, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>arvn-20221231x10kxex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0e48cac19e4043b0937bd8d76771f157_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;23, 2023</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Sean Cassidy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sean Cassidy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Chief Financial Officer and Treasurer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>arvn-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e632b970-0fa5-4bd1-afa0-85cac57f3761,g:02db76aa-3c10-4220-82b9-6cc6c0294fe6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arvn="http://www.arvinas.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arvinas.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.arvinas.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.arvinas.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.arvinas.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical">
        <link:definition>0000007 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>0000009 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreements" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements">
        <link:definition>0000011 - Disclosure - Research Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurements" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements">
        <link:definition>0000012 - Disclosure - Marketable Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovements" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements">
        <link:definition>0000013 - Disclosure - Property, Equipment and Leasehold Improvements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilities" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilities">
        <link:definition>0000014 - Disclosure - Right of Use Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilities" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities">
        <link:definition>0000015 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.arvinas.com/role/LongTermDebt">
        <link:definition>0000016 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.arvinas.com/role/Equity">
        <link:definition>0000017 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestments" roleURI="http://www.arvinas.com/role/EquityMethodInvestments">
        <link:definition>0000018 - Disclosure - Equity Method Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.arvinas.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arvinas.com/role/CommitmentsandContingencies">
        <link:definition>0000020 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.arvinas.com/role/NetLossPerShare">
        <link:definition>0000021 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000022 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000023 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTables" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables">
        <link:definition>0000024 - Disclosure - Research Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsTables" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables">
        <link:definition>0000025 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsTables" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables">
        <link:definition>0000026 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesTables" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables">
        <link:definition>0000027 - Disclosure - Right of Use Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>0000028 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.arvinas.com/role/LongTermDebtTables">
        <link:definition>0000029 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.arvinas.com/role/EquityTables">
        <link:definition>0000030 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentsTables" roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsTables">
        <link:definition>0000031 - Disclosure - Equity Method Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.arvinas.com/role/IncomeTaxesTables">
        <link:definition>0000032 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.arvinas.com/role/NetLossPerShareTables">
        <link:definition>0000033 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>0000034 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashReconciliationDetails" roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails">
        <link:definition>0000035 - Disclosure - Summary of Significant Accounting Policies - Cash Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails">
        <link:definition>0000037 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails">
        <link:definition>0000038 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails">
        <link:definition>0000039 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1">
        <link:definition>0000039 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsDetails" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails">
        <link:definition>0000040 - Disclosure - Marketable Securities and Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails">
        <link:definition>0000041 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails">
        <link:definition>0000042 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails">
        <link:definition>0000043 - Disclosure - Right of Use Assets and Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails">
        <link:definition>0000044 - Disclosure - Right of Use Assets and Liabilities - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails">
        <link:definition>0000045 - Disclosure - Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>0000046 - Disclosure - Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>0000046 - Disclosure - Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails">
        <link:definition>0000047 - Disclosure - Accounts Payable and Accrued Liabilities - Components of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails">
        <link:definition>0000048 - Disclosure - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails" roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails">
        <link:definition>0000049 - Disclosure - Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails">
        <link:definition>0000050 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails">
        <link:definition>0000051 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofStockOptionActivityDetails" roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails">
        <link:definition>0000052 - Disclosure - Equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofRestrictedStockGrantActivityDetails" roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails">
        <link:definition>0000053 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails">
        <link:definition>0000054 - Disclosure - Equity Method Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails" roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails">
        <link:definition>0000055 - Disclosure - Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxExpenseDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails">
        <link:definition>0000056 - Disclosure - Income Taxes - Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000057 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails">
        <link:definition>0000058 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails">
        <link:definition>0000059 - Disclosure - Income Taxes - Summary of Deferred Income Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>0000060 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000061 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareBasicandDilutedLossperShareDetails" roleURI="http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperShareDetails">
        <link:definition>0000062 - Disclosure - Net Loss Per Share - Basic and Diluted Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails" roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails">
        <link:definition>0000063 - Disclosure - Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" abstract="true" name="ResearchCollaborationAndLicenseAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_LicenseFirstLicensedProductMember" abstract="true" name="LicenseFirstLicensedProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_BaseLeaseRentPeriod" abstract="false" name="BaseLeaseRentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arvn_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_CollaboratorTwoMember" abstract="true" name="CollaboratorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CollaboratorOneMember" abstract="true" name="CollaboratorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CommercialMilestonesMember" abstract="true" name="CommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_IncomeTaxDisclosureLineItems" abstract="true" name="IncomeTaxDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_PercentageOfIncrementalBorrowingForLeasePayments" abstract="false" name="PercentageOfIncrementalBorrowingForLeasePayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_YaleUniversityMember" abstract="true" name="YaleUniversityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" abstract="true" name="GenentechIncorporationAndFHoffmanLaRocheLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_DebtInstrumentInterestPaymentsTerm" abstract="false" name="DebtInstrumentInterestPaymentsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_AdditionalTargetAndServicesMember" abstract="true" name="AdditionalTargetAndServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrentAdditions" abstract="false" name="AccountsPayableContractBalancesCurrentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_BayerCropScienceLPMember" abstract="true" name="BayerCropScienceLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" abstract="false" name="ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_IncomeTaxDisclosureTable" abstract="true" name="IncomeTaxDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" abstract="true" name="GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" abstract="false" name="ProceedsFromIssuanceOfCommonStockInAPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" abstract="false" name="ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrent" abstract="false" name="AccountsPayableContractBalancesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" abstract="true" name="IncomeStatementAndStatementOfComprehensiveIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" abstract="true" name="CorporateBondsMaturingTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_EmployeesMember" abstract="true" name="EmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_FoundationMedicineIncMember" abstract="true" name="FoundationMedicineIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OptionPaymentsToLicenseAgreementMember" abstract="true" name="OptionPaymentsToLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" abstract="true" name="ResearchCollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_EquityDistributionAgreementMember" abstract="true" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrentPayments" abstract="false" name="AccountsPayableContractBalancesCurrentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_PercentageOfMaximumFundingOnProjectCosts" abstract="false" name="PercentageOfMaximumFundingOnProjectCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" abstract="false" name="DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arvn_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_LicenseSecondLicensedProductMember" abstract="true" name="LicenseSecondLicensedProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_DefinedContributionPlanPolicyPolicyTextBlock" abstract="false" name="DefinedContributionPlanPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arvn_ResearchFundingPaymentsMember" abstract="true" name="ResearchFundingPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" abstract="false" name="OperatingLossesCarryForwardMaximumDeductibilityPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ProceedsFromMaturitiesOfMarketableSecurities" abstract="false" name="ProceedsFromMaturitiesOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CollaboratorThreeMember" abstract="true" name="CollaboratorThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_NumberOfWhollyOwnedSubsidiaries" abstract="false" name="NumberOfWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsTable" abstract="true" name="ResearchCollaborationAndLicenseAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_NumberOfMaximumDesignatedTargets" abstract="false" name="NumberOfMaximumDesignatedTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" abstract="true" name="GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_TwoThousandEighteenStockIncentivePlanMember" abstract="true" name="TwoThousandEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_RegulatoryMilestonePaymentsMember" abstract="true" name="RegulatoryMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="arvn_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_SuccessBasedMilestonePaymentsMember" abstract="true" name="SuccessBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" abstract="true" name="ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_EmployeesDirectorsAndConsultantsMember" abstract="true" name="EmployeesDirectorsAndConsultantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_PfizerIncorporationMember" abstract="true" name="PfizerIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_DebtInstrumentLoanForgiveness" abstract="false" name="DebtInstrumentLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" abstract="false" name="FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_AnnualLicenseFeePayment" abstract="false" name="AnnualLicenseFeePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" abstract="false" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arvn_SalesBasedMilestonePaymentsMember" abstract="true" name="SalesBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OerthBioLimitedLiabilityCorporationMember" abstract="true" name="OerthBioLimitedLiabilityCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_RequiredMilestonePayments" abstract="false" name="RequiredMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_DevelopmentMilestonePaymentsMember" abstract="true" name="DevelopmentMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" abstract="true" name="CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PiperSandlerMember" abstract="true" name="PiperSandlerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" abstract="true" name="CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" abstract="true" name="GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" abstract="true" name="ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_TwoThousandAndEighteenAssistanceAgreementMember" abstract="true" name="TwoThousandAndEighteenAssistanceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" abstract="false" name="DirectAndIncrementalCostsIncurredToObtainTheContract" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_SaleOfStockFairValueOfSharesSold" abstract="false" name="SaleOfStockFairValueOfSharesSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" abstract="false" name="IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_ProceedsFromIssuanceOfCommonStockGross" abstract="false" name="ProceedsFromIssuanceOfCommonStockGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" abstract="false" name="MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_PercentageOfLiquidatedDamages" abstract="false" name="PercentageOfLiquidatedDamages" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" abstract="true" name="ChangeInCollaborationContractAssetAndOtherAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_StockIncentivePlanMember" abstract="true" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_TwoThousandAndFourteenAssistanceAgreementMember" abstract="true" name="TwoThousandAndFourteenAssistanceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CollaborationContractAssetAndOtherAssets" abstract="false" name="CollaborationContractAssetAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" abstract="true" name="SupplementalNonCashInformationRelatedToLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ProceedsFromSaleOfMarketableSecurities" abstract="false" name="ProceedsFromSaleOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_NumberOfVotesPerCommonStockShareHeld" abstract="false" name="NumberOfVotesPerCommonStockShareHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" abstract="true" name="CorporateBondsMaturingTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>arvn-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e632b970-0fa5-4bd1-afa0-85cac57f3761,g:02db76aa-3c10-4220-82b9-6cc6c0294fe6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_277bca3f-45d6-4ff2-8ad8-fea25ff14ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9a980d13-2c64-4858-9fce-8c9335b61d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_277bca3f-45d6-4ff2-8ad8-fea25ff14ef9" xlink:to="loc_us-gaap_AssetsCurrent_9a980d13-2c64-4858-9fce-8c9335b61d9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_18e8f55f-118b-4f45-ae81-88e34d1fb437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_277bca3f-45d6-4ff2-8ad8-fea25ff14ef9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_18e8f55f-118b-4f45-ae81-88e34d1fb437" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6487e63b-5e9b-4dfe-93b9-6cb2341f558a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_277bca3f-45d6-4ff2-8ad8-fea25ff14ef9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6487e63b-5e9b-4dfe-93b9-6cb2341f558a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_c2d6020e-05dc-4cc8-9e63-be8d850579de" xlink:href="arvn-20221231.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_277bca3f-45d6-4ff2-8ad8-fea25ff14ef9" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_c2d6020e-05dc-4cc8-9e63-be8d850579de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b7492c1c-fe7a-4688-9b2f-c92c0792c49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8e0db2ff-6df3-4211-ace6-316a15e9a790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b7492c1c-fe7a-4688-9b2f-c92c0792c49f" xlink:to="loc_us-gaap_LiabilitiesCurrent_8e0db2ff-6df3-4211-ace6-316a15e9a790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_964090f3-711c-429d-a448-51022b5d0bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b7492c1c-fe7a-4688-9b2f-c92c0792c49f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_964090f3-711c-429d-a448-51022b5d0bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3931a3e1-5ce4-431b-9c60-da228a49de9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b7492c1c-fe7a-4688-9b2f-c92c0792c49f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3931a3e1-5ce4-431b-9c60-da228a49de9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_be6db38d-278e-40f9-a720-0db272fce442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b7492c1c-fe7a-4688-9b2f-c92c0792c49f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_be6db38d-278e-40f9-a720-0db272fce442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fc4fa813-1175-45bd-872e-de43dc6be4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d4d9d139-4f0f-4dc4-bb5f-538cdcca12ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc4fa813-1175-45bd-872e-de43dc6be4b1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d4d9d139-4f0f-4dc4-bb5f-538cdcca12ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4183c68c-4629-44d2-be09-e8132cd53913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc4fa813-1175-45bd-872e-de43dc6be4b1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4183c68c-4629-44d2-be09-e8132cd53913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_eab4e969-80ba-4781-9450-22ad0317270b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc4fa813-1175-45bd-872e-de43dc6be4b1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_eab4e969-80ba-4781-9450-22ad0317270b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_29ff789f-82d2-4840-b1c4-56ed5d4daa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc4fa813-1175-45bd-872e-de43dc6be4b1" xlink:to="loc_us-gaap_RestrictedCashCurrent_29ff789f-82d2-4840-b1c4-56ed5d4daa4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6dc01bfb-77ed-42ea-8243-3f1b932f0b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc4fa813-1175-45bd-872e-de43dc6be4b1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6dc01bfb-77ed-42ea-8243-3f1b932f0b9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_21258b20-48f1-422c-91dc-f405654a3cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fc4fa813-1175-45bd-872e-de43dc6be4b1" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_21258b20-48f1-422c-91dc-f405654a3cd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e1079ecc-783c-42fa-85d3-289ef161ab7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_15d986d8-3556-41f1-82fd-ce3587508e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e1079ecc-783c-42fa-85d3-289ef161ab7f" xlink:to="loc_us-gaap_Liabilities_15d986d8-3556-41f1-82fd-ce3587508e1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3813ffbf-c5ef-4f76-b497-d90163fd6089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e1079ecc-783c-42fa-85d3-289ef161ab7f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3813ffbf-c5ef-4f76-b497-d90163fd6089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5082a108-1206-4631-b704-adf0440a1f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e1079ecc-783c-42fa-85d3-289ef161ab7f" xlink:to="loc_us-gaap_StockholdersEquity_5082a108-1206-4631-b704-adf0440a1f15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5e2efcb3-4862-474e-9ed4-7d484e7d8698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_895edcd1-cf04-4d58-b2fc-e00a83b127f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5e2efcb3-4862-474e-9ed4-7d484e7d8698" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_895edcd1-cf04-4d58-b2fc-e00a83b127f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_40f446c5-9228-4008-95c6-11146b02362b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5e2efcb3-4862-474e-9ed4-7d484e7d8698" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_40f446c5-9228-4008-95c6-11146b02362b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8d0d4fc9-3c87-4418-b15f-7459642d94c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5e2efcb3-4862-474e-9ed4-7d484e7d8698" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8d0d4fc9-3c87-4418-b15f-7459642d94c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9b241d9e-8635-402f-b7c2-ecd3b1bfa731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1fbaf57e-94a7-43eb-9574-130d6ed626b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b241d9e-8635-402f-b7c2-ecd3b1bfa731" xlink:to="loc_us-gaap_CommonStockValue_1fbaf57e-94a7-43eb-9574-130d6ed626b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_430f0690-3b0a-408a-913d-c889c073b100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b241d9e-8635-402f-b7c2-ecd3b1bfa731" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_430f0690-3b0a-408a-913d-c889c073b100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d1006771-ff31-4930-b7c5-be58e76ae7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b241d9e-8635-402f-b7c2-ecd3b1bfa731" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d1006771-ff31-4930-b7c5-be58e76ae7ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_32293052-6546-4e4e-9840-751d6236c9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b241d9e-8635-402f-b7c2-ecd3b1bfa731" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_32293052-6546-4e4e-9840-751d6236c9e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7942161b-804b-41ae-aa95-ced20a508fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a7634d68-5791-4222-bdca-47d96b14eef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7942161b-804b-41ae-aa95-ced20a508fba" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a7634d68-5791-4222-bdca-47d96b14eef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0cdd9e15-34de-4802-958e-2ac1b45e074e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7942161b-804b-41ae-aa95-ced20a508fba" xlink:to="loc_us-gaap_OperatingIncomeLoss_0cdd9e15-34de-4802-958e-2ac1b45e074e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eea4d265-9361-409f-a099-ad9b4ca04bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_47ba1ea5-00a0-44cf-a901-03d8a23b6a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eea4d265-9361-409f-a099-ad9b4ca04bc8" xlink:to="loc_us-gaap_Revenues_47ba1ea5-00a0-44cf-a901-03d8a23b6a88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8cce98da-317f-4c94-aa3b-4019895fd8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eea4d265-9361-409f-a099-ad9b4ca04bc8" xlink:to="loc_us-gaap_OperatingExpenses_8cce98da-317f-4c94-aa3b-4019895fd8fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_07311e2b-d4a3-4815-b6af-91585bdb41df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9c54b1e1-1db1-4c20-ba50-58d2e2ebfe17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_07311e2b-d4a3-4815-b6af-91585bdb41df" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9c54b1e1-1db1-4c20-ba50-58d2e2ebfe17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6f57769d-9e12-45b4-b973-96156fb9468e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_07311e2b-d4a3-4815-b6af-91585bdb41df" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6f57769d-9e12-45b4-b973-96156fb9468e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5b261c18-8c6f-47d7-9d2a-2ae7c474e922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_07311e2b-d4a3-4815-b6af-91585bdb41df" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5b261c18-8c6f-47d7-9d2a-2ae7c474e922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_64a25e1d-2f5a-492f-b35b-43a9c02548ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2a3c203a-2aa9-4030-b63f-b86555e7a050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_64a25e1d-2f5a-492f-b35b-43a9c02548ec" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2a3c203a-2aa9-4030-b63f-b86555e7a050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e55fde15-0d0f-4ffc-86a7-94a5fc492b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_64a25e1d-2f5a-492f-b35b-43a9c02548ec" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e55fde15-0d0f-4ffc-86a7-94a5fc492b86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e57c41db-d984-40dd-9bf1-95230d29b559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2aab2662-2c8b-4e8f-ac0a-5855616c1927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e57c41db-d984-40dd-9bf1-95230d29b559" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2aab2662-2c8b-4e8f-ac0a-5855616c1927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a53e2439-21cf-433b-9fe9-6b6e860b8c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e57c41db-d984-40dd-9bf1-95230d29b559" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a53e2439-21cf-433b-9fe9-6b6e860b8c42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4855b893-ad8b-4fa0-a75d-4a433a70bb11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_36dd06d2-c4bb-4a69-b257-a9a3a507859f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4855b893-ad8b-4fa0-a75d-4a433a70bb11" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_36dd06d2-c4bb-4a69-b257-a9a3a507859f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_395528c2-347e-467c-b1dc-4c4d77fe269c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4855b893-ad8b-4fa0-a75d-4a433a70bb11" xlink:to="loc_us-gaap_NetIncomeLoss_395528c2-347e-467c-b1dc-4c4d77fe269c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_b8b5ec9d-9ab7-4205-a845-84dbb8e678ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_b8b5ec9d-9ab7-4205-a845-84dbb8e678ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_6baf70a7-be52-42c4-b013-052cfaca4fb6" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_6baf70a7-be52-42c4-b013-052cfaca4fb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_8528536c-207d-4e9a-8706-6c6e80b6437e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_8528536c-207d-4e9a-8706-6c6e80b6437e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_859bea28-ca58-4533-935e-34eeea64adfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_859bea28-ca58-4533-935e-34eeea64adfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_1365f32b-4fae-4e0a-badc-5c2f18b694d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_1365f32b-4fae-4e0a-badc-5c2f18b694d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_219ca505-9369-4d00-8628-9fd027bcc2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_219ca505-9369-4d00-8628-9fd027bcc2ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_64b2ccac-4e03-4aa1-8c4c-8fb4da1cbeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_64b2ccac-4e03-4aa1-8c4c-8fb4da1cbeb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_31097f0e-1107-438d-a5b2-2b5e12c6cf78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_ShareBasedCompensation_31097f0e-1107-438d-a5b2-2b5e12c6cf78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_40084f82-2826-492a-8b43-fc702789fc33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_40084f82-2826-492a-8b43-fc702789fc33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_0f8ee380-c290-4db0-bd21-9bad05bfc643" xlink:href="arvn-20221231.xsd#arvn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_0f8ee380-c290-4db0-bd21-9bad05bfc643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5110e86e-1f9c-4425-a7d7-94a6276e067c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_NetIncomeLoss_5110e86e-1f9c-4425-a7d7-94a6276e067c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6ddadf08-ec72-4f11-9d9e-bbba20da6453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6ddadf08-ec72-4f11-9d9e-bbba20da6453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_d37d48c3-9911-4c0b-8ba6-c5d7e43b7492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_d37d48c3-9911-4c0b-8ba6-c5d7e43b7492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9d22828e-3de1-4194-9188-2af75b9106b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_DepreciationAndAmortization_9d22828e-3de1-4194-9188-2af75b9106b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1b11b2e9-27e2-4f27-a42c-3a8cf5d9809e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d323fc-37e1-4b5c-bbc2-447e22dfff7b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1b11b2e9-27e2-4f27-a42c-3a8cf5d9809e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99124042-3b3f-46d1-8264-fce4edadf791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_2581fdf3-50cc-49bb-a698-1013008aeb08" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99124042-3b3f-46d1-8264-fce4edadf791" xlink:to="loc_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_2581fdf3-50cc-49bb-a698-1013008aeb08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockGross_daa9b9cc-a6b0-453b-b943-81db9515dd88" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99124042-3b3f-46d1-8264-fce4edadf791" xlink:to="loc_arvn_ProceedsFromIssuanceOfCommonStockGross_daa9b9cc-a6b0-453b-b943-81db9515dd88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_90638c84-f206-4614-b7d8-61a04aeb18e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99124042-3b3f-46d1-8264-fce4edadf791" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_90638c84-f206-4614-b7d8-61a04aeb18e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_479e059d-091d-4135-8e0d-76016055adc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99124042-3b3f-46d1-8264-fce4edadf791" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_479e059d-091d-4135-8e0d-76016055adc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_797d2ed6-167b-4598-a8ef-f978417a1a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1ac987f0-6497-440b-a004-17b023f9842e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_797d2ed6-167b-4598-a8ef-f978417a1a9f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1ac987f0-6497-440b-a004-17b023f9842e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a832990c-0cee-4ba7-849f-6810ca9c60a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_797d2ed6-167b-4598-a8ef-f978417a1a9f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a832990c-0cee-4ba7-849f-6810ca9c60a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2bcd3d30-fa19-46af-9051-95436f543491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_797d2ed6-167b-4598-a8ef-f978417a1a9f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2bcd3d30-fa19-46af-9051-95436f543491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc98d58f-79cf-4497-a063-3064ee6298c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d7625c87-8cad-432b-a52a-5e59964ac78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc98d58f-79cf-4497-a063-3064ee6298c8" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d7625c87-8cad-432b-a52a-5e59964ac78e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_863c1a13-4ee6-4a8e-b67e-9068189ba8c8" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc98d58f-79cf-4497-a063-3064ee6298c8" xlink:to="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_863c1a13-4ee6-4a8e-b67e-9068189ba8c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromSaleOfMarketableSecurities_80d9ace5-ac69-4c6e-8fa5-c08e76dd3c29" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc98d58f-79cf-4497-a063-3064ee6298c8" xlink:to="loc_arvn_ProceedsFromSaleOfMarketableSecurities_80d9ace5-ac69-4c6e-8fa5-c08e76dd3c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0deece96-bb88-42a2-83bc-bb77d0acdd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc98d58f-79cf-4497-a063-3064ee6298c8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0deece96-bb88-42a2-83bc-bb77d0acdd3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#SummaryofSignificantAccountingPoliciesCashReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0bb94364-9976-4672-abce-dc787a637cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb1c612b-3ea3-4714-a843-572d277fb4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0bb94364-9976-4672-abce-dc787a637cc2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb1c612b-3ea3-4714-a843-572d277fb4ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_20c1097b-13ea-4bb2-a35a-24ca19b7fe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0bb94364-9976-4672-abce-dc787a637cc2" xlink:to="loc_us-gaap_RestrictedCashCurrent_20c1097b-13ea-4bb2-a35a-24ca19b7fe5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#MarketableSecuritiesandFairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0de5e30b-3ad1-40fb-ba86-01156035b05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1abe594b-da55-48ed-ad90-98a658972616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0de5e30b-3ad1-40fb-ba86-01156035b05e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1abe594b-da55-48ed-ad90-98a658972616" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2500bb3f-36b3-4da0-ab26-24774a052922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0de5e30b-3ad1-40fb-ba86-01156035b05e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2500bb3f-36b3-4da0-ab26-24774a052922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5665b2c4-13c3-488d-a420-4c8dbcaba208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0de5e30b-3ad1-40fb-ba86-01156035b05e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5665b2c4-13c3-488d-a420-4c8dbcaba208" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fe8a35a6-dbe8-49df-87ca-7f1f4a929db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7b77f70e-741f-4014-9add-301f262abf74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fe8a35a6-dbe8-49df-87ca-7f1f4a929db3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7b77f70e-741f-4014-9add-301f262abf74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_491e57fa-c2cf-4a8a-8fa8-e91d7a685f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fe8a35a6-dbe8-49df-87ca-7f1f4a929db3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_491e57fa-c2cf-4a8a-8fa8-e91d7a685f17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e11451b-9d30-4597-9ec8-62f3f1dff02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c379d819-da4b-4f39-9e90-ddc6ae6033dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e11451b-9d30-4597-9ec8-62f3f1dff02e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c379d819-da4b-4f39-9e90-ddc6ae6033dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6955e242-85d5-49b5-a0b4-ff817a8ce9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e11451b-9d30-4597-9ec8-62f3f1dff02e" xlink:to="loc_us-gaap_OperatingLeaseLiability_6955e242-85d5-49b5-a0b4-ff817a8ce9e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="arvn-20221231.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_187bac2d-3c9d-4185-8668-e3413bf7a6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2fc85376-3eb1-46d1-a0c7-7f675247219c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_187bac2d-3c9d-4185-8668-e3413bf7a6da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2fc85376-3eb1-46d1-a0c7-7f675247219c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5d2b1ae7-0df2-4a46-b873-9ebd9d9b3040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_187bac2d-3c9d-4185-8668-e3413bf7a6da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5d2b1ae7-0df2-4a46-b873-9ebd9d9b3040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ebe1c40d-0292-4cea-88bd-7807509678fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_187bac2d-3c9d-4185-8668-e3413bf7a6da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ebe1c40d-0292-4cea-88bd-7807509678fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fe72ac44-41ac-4725-959c-6fef2ab68a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_187bac2d-3c9d-4185-8668-e3413bf7a6da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fe72ac44-41ac-4725-959c-6fef2ab68a64" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_508e72c5-956e-45f4-93fa-d1afe6d33805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_980a12fc-d22d-481d-98e7-de106e90770b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_508e72c5-956e-45f4-93fa-d1afe6d33805" xlink:to="loc_us-gaap_AccountsPayableCurrent_980a12fc-d22d-481d-98e7-de106e90770b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_b832a4de-5f69-4b96-ad64-1d79b56cc050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_508e72c5-956e-45f4-93fa-d1afe6d33805" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_b832a4de-5f69-4b96-ad64-1d79b56cc050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2ae2efca-354f-4ba9-bc5e-0c42417638de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_508e72c5-956e-45f4-93fa-d1afe6d33805" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2ae2efca-354f-4ba9-bc5e-0c42417638de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_c1adac83-03cf-412a-a826-3c479a6cffe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_508e72c5-956e-45f4-93fa-d1afe6d33805" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_c1adac83-03cf-412a-a826-3c479a6cffe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_0753df18-b4d7-4039-8e84-54df2ab16d8a" xlink:href="arvn-20221231.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_508e72c5-956e-45f4-93fa-d1afe6d33805" xlink:to="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_0753df18-b4d7-4039-8e84-54df2ab16d8a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_12006f5f-90e1-4851-bbfb-913849861c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d2f879c6-0acf-4a0c-b867-123cbef54a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_12006f5f-90e1-4851-bbfb-913849861c90" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d2f879c6-0acf-4a0c-b867-123cbef54a57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cebfc855-eef6-4542-93f9-cc29b4dc4349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_12006f5f-90e1-4851-bbfb-913849861c90" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cebfc855-eef6-4542-93f9-cc29b4dc4349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cad6001e-d813-4fbb-b64b-4867a261447f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_12006f5f-90e1-4851-bbfb-913849861c90" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cad6001e-d813-4fbb-b64b-4867a261447f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3c218dcb-566f-417e-9577-b136edd9335f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_12006f5f-90e1-4851-bbfb-913849861c90" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3c218dcb-566f-417e-9577-b136edd9335f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_719f14ff-f2e0-4162-b605-22020770d7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_12006f5f-90e1-4851-bbfb-913849861c90" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_719f14ff-f2e0-4162-b605-22020770d7c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f1926ab6-48e2-40d1-b442-385ef242f7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_12006f5f-90e1-4851-bbfb-913849861c90" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f1926ab6-48e2-40d1-b442-385ef242f7e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#IncomeTaxesIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7bd2f98f-bdc1-4c43-81e1-87e644fd840c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_53ae6c91-fa80-4ba5-a977-bacfe73979d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7bd2f98f-bdc1-4c43-81e1-87e644fd840c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_53ae6c91-fa80-4ba5-a977-bacfe73979d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d20c5ccc-dfe0-4100-b924-a10d7531adbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7bd2f98f-bdc1-4c43-81e1-87e644fd840c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d20c5ccc-dfe0-4100-b924-a10d7531adbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7a5f9f99-9fde-4748-9d65-31c4328a25e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_50005724-ceb4-46f3-bb4e-60dca0637f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7a5f9f99-9fde-4748-9d65-31c4328a25e1" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_50005724-ceb4-46f3-bb4e-60dca0637f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8eee9bc9-b48c-45ea-b92d-b11c8231173c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7a5f9f99-9fde-4748-9d65-31c4328a25e1" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8eee9bc9-b48c-45ea-b92d-b11c8231173c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6adeb038-0920-43b7-84eb-c1e7da2a8443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f70db085-d238-4a9f-bffe-9cfa4886f4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6adeb038-0920-43b7-84eb-c1e7da2a8443" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f70db085-d238-4a9f-bffe-9cfa4886f4e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6355ea3f-cca8-4427-a847-cbb787df2f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6adeb038-0920-43b7-84eb-c1e7da2a8443" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6355ea3f-cca8-4427-a847-cbb787df2f09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_38ccb34a-3898-4d98-a021-a1018676fecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e421c96b-b290-470b-b467-015bc619dce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_38ccb34a-3898-4d98-a021-a1018676fecc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e421c96b-b290-470b-b467-015bc619dce2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_b425720c-ec4c-40fb-912c-dbfb665bb970" xlink:href="arvn-20221231.xsd#arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_38ccb34a-3898-4d98-a021-a1018676fecc" xlink:to="loc_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_b425720c-ec4c-40fb-912c-dbfb665bb970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_c90f3026-10b7-4043-babc-bac3b20a6979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_38ccb34a-3898-4d98-a021-a1018676fecc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_c90f3026-10b7-4043-babc-bac3b20a6979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f994381a-ab51-4434-94c1-375a9a5463fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_38ccb34a-3898-4d98-a021-a1018676fecc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f994381a-ab51-4434-94c1-375a9a5463fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_60245ad1-7f85-4529-bef5-d2d934bcac94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_38ccb34a-3898-4d98-a021-a1018676fecc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_60245ad1-7f85-4529-bef5-d2d934bcac94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b2f2a851-47e9-49b5-8047-9aae6c98de73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_38ccb34a-3898-4d98-a021-a1018676fecc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b2f2a851-47e9-49b5-8047-9aae6c98de73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_f0bfae83-809c-42d6-a112-15bfd975e7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_38ccb34a-3898-4d98-a021-a1018676fecc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_f0bfae83-809c-42d6-a112-15bfd975e7a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e0f9ba30-20c3-4ebe-a832-8896ab40517a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_38ccb34a-3898-4d98-a021-a1018676fecc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e0f9ba30-20c3-4ebe-a832-8896ab40517a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_bf89d0b8-8de0-4f99-85fd-6012b4ede709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8301656d-39b5-4653-8bea-787c6e6db4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_bf89d0b8-8de0-4f99-85fd-6012b4ede709" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8301656d-39b5-4653-8bea-787c6e6db4fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b80f0f59-8ccb-45b6-8eb5-fb565bbb6d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_bf89d0b8-8de0-4f99-85fd-6012b4ede709" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b80f0f59-8ccb-45b6-8eb5-fb565bbb6d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_91af5ff5-4a35-4c2e-ae4b-f3a79abf2440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_bf89d0b8-8de0-4f99-85fd-6012b4ede709" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_91af5ff5-4a35-4c2e-ae4b-f3a79abf2440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0a8ddf2b-7090-43d2-80bc-05c0d23008d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a12efff1-0e4a-405b-8e6c-98de234fe542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0a8ddf2b-7090-43d2-80bc-05c0d23008d6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a12efff1-0e4a-405b-8e6c-98de234fe542" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_28b766eb-c586-4c95-a48e-30979f450b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0a8ddf2b-7090-43d2-80bc-05c0d23008d6" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_28b766eb-c586-4c95-a48e-30979f450b34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_48c9949a-5994-4ef4-ae67-42d329524747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0a8ddf2b-7090-43d2-80bc-05c0d23008d6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_48c9949a-5994-4ef4-ae67-42d329524747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3322f773-8014-4190-a759-4f279c3ffe34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0a8ddf2b-7090-43d2-80bc-05c0d23008d6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3322f773-8014-4190-a759-4f279c3ffe34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b44edb74-d4db-444a-89f4-807d72c465cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0a8ddf2b-7090-43d2-80bc-05c0d23008d6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b44edb74-d4db-444a-89f4-807d72c465cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a12c97e7-ce04-4ae5-ae6d-dc090c52c22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0a8ddf2b-7090-43d2-80bc-05c0d23008d6" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a12c97e7-ce04-4ae5-ae6d-dc090c52c22a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c9e00cf4-6eb1-4da9-ab8a-a98f7bbff6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_65f3392e-932c-4577-bc6b-7a34d522df1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c9e00cf4-6eb1-4da9-ab8a-a98f7bbff6d6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_65f3392e-932c-4577-bc6b-7a34d522df1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d6e7f46b-d22f-40d2-921b-d42c20643c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c9e00cf4-6eb1-4da9-ab8a-a98f7bbff6d6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d6e7f46b-d22f-40d2-921b-d42c20643c89" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>arvn-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e632b970-0fa5-4bd1-afa0-85cac57f3761,g:02db76aa-3c10-4220-82b9-6cc6c0294fe6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended" id="i3fa7d323c4d944f1ae78d639d7fc882d_ConsolidatedStatementsofChangesinStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8a1bf2a-2a8a-418b-ba0e-f08913627610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8a1bf2a-2a8a-418b-ba0e-f08913627610" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c68c389b-c7c9-4550-9369-722db067a06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c68c389b-c7c9-4550-9369-722db067a06a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_003de503-bb66-4b7b-a87b-dcec8815de55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockholdersEquity_003de503-bb66-4b7b-a87b-dcec8815de55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_156da260-1983-40d3-b897-28762653e790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_156da260-1983-40d3-b897-28762653e790" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3d26d9d0-3a37-4e01-975a-41aa3a72a418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3d26d9d0-3a37-4e01-975a-41aa3a72a418" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5a9e06e9-4b96-4b6b-900b-6caccf678fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5a9e06e9-4b96-4b6b-900b-6caccf678fe7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ee7c466d-2676-44d0-b1bf-3cebb80eabbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_NetIncomeLoss_ee7c466d-2676-44d0-b1bf-3cebb80eabbb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_58b69050-06e2-4c3b-96fe-e134a2feba83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_58b69050-06e2-4c3b-96fe-e134a2feba83" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_71f5e79f-a597-410c-8e74-07806a108e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_71f5e79f-a597-410c-8e74-07806a108e47" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f05e748b-100d-419b-b9ac-fce5cda85258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f05e748b-100d-419b-b9ac-fce5cda85258" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0e7ab3a4-f198-4251-afdc-026cc455d501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0e7ab3a4-f198-4251-afdc-026cc455d501" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_eacaecbf-2235-4c35-a07b-9258a9782ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2e6745e4-0dac-4fca-81cd-763de931004f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0ebc97ee-14df-4ed5-b1b5-dd5e6fccef80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f8a1bf2a-2a8a-418b-ba0e-f08913627610" xlink:to="loc_us-gaap_StatementTable_0ebc97ee-14df-4ed5-b1b5-dd5e6fccef80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9df11e58-8f0d-47ec-bcc8-8e98e6b8efa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0ebc97ee-14df-4ed5-b1b5-dd5e6fccef80" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9df11e58-8f0d-47ec-bcc8-8e98e6b8efa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9df11e58-8f0d-47ec-bcc8-8e98e6b8efa1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9df11e58-8f0d-47ec-bcc8-8e98e6b8efa1" xlink:to="loc_us-gaap_EquityComponentDomain_9df11e58-8f0d-47ec-bcc8-8e98e6b8efa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9df11e58-8f0d-47ec-bcc8-8e98e6b8efa1" xlink:to="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ed39472a-275d-4ad0-b828-a222733ff9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:to="loc_us-gaap_CommonStockMember_ed39472a-275d-4ad0-b828-a222733ff9f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5499c5f0-bd24-4ff8-9558-305f440e58ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:to="loc_us-gaap_RetainedEarningsMember_5499c5f0-bd24-4ff8-9558-305f440e58ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6406d906-6b7d-4106-af35-c39954f96316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6406d906-6b7d-4106-af35-c39954f96316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2eb30b7d-4127-4e9d-9ac0-1ce33aaf576f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2eb30b7d-4127-4e9d-9ac0-1ce33aaf576f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_77f7fff0-b795-4185-a0c0-cedc9ff2bd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0ebc97ee-14df-4ed5-b1b5-dd5e6fccef80" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_77f7fff0-b795-4185-a0c0-cedc9ff2bd84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_77f7fff0-b795-4185-a0c0-cedc9ff2bd84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77f7fff0-b795-4185-a0c0-cedc9ff2bd84" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_77f7fff0-b795-4185-a0c0-cedc9ff2bd84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cffebc6d-2de5-425a-8576-4dd19ce985a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77f7fff0-b795-4185-a0c0-cedc9ff2bd84" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cffebc6d-2de5-425a-8576-4dd19ce985a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_243f4528-31a2-40a2-8f02-15584cdc60e9" xlink:href="arvn-20221231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cffebc6d-2de5-425a-8576-4dd19ce985a7" xlink:to="loc_arvn_AtTheMarketOfferingMember_243f4528-31a2-40a2-8f02-15584cdc60e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="extended" id="i4d85affcae3c46dc8f72e98465f0ab3b_ConsolidatedStatementsofChangesinStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_36d6f372-1dac-4333-baf6-a5ef35b1bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_baf2d7a5-8f6f-42d5-9be8-27f198fe101e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_36d6f372-1dac-4333-baf6-a5ef35b1bc4d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_baf2d7a5-8f6f-42d5-9be8-27f198fe101e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8d80ee8-a77e-4252-bc74-c9de5b9785ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_36d6f372-1dac-4333-baf6-a5ef35b1bc4d" xlink:to="loc_us-gaap_StatementTable_e8d80ee8-a77e-4252-bc74-c9de5b9785ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3549d84b-41f1-488c-8ad8-357ab3f75ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e8d80ee8-a77e-4252-bc74-c9de5b9785ba" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3549d84b-41f1-488c-8ad8-357ab3f75ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3549d84b-41f1-488c-8ad8-357ab3f75ee7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3549d84b-41f1-488c-8ad8-357ab3f75ee7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3549d84b-41f1-488c-8ad8-357ab3f75ee7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e1e57d6-afff-404c-9fa8-237949c5741e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3549d84b-41f1-488c-8ad8-357ab3f75ee7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e1e57d6-afff-404c-9fa8-237949c5741e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_86644e46-f119-4999-b173-edc793bd417f" xlink:href="arvn-20221231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e1e57d6-afff-404c-9fa8-237949c5741e" xlink:to="loc_arvn_AtTheMarketOfferingMember_86644e46-f119-4999-b173-edc793bd417f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i61aed86e4ab0414793df4c69cf77b854_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_85dfd49e-3cc6-44ca-b5b6-afd4513453c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:to="loc_us-gaap_NetIncomeLoss_85dfd49e-3cc6-44ca-b5b6-afd4513453c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a40d92fa-b049-4b7a-b15d-f8b4dff55ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_DepreciationAndAmortization_a40d92fa-b049-4b7a-b15d-f8b4dff55ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_16c2825d-ff0e-473d-8b79-edefe5e3390f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_16c2825d-ff0e-473d-8b79-edefe5e3390f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_7fa8add1-e017-4e4f-be4a-09ad9a9e73c3" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_7fa8add1-e017-4e4f-be4a-09ad9a9e73c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_295c0e7f-7d59-438b-b0bf-fcebeb80f6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_295c0e7f-7d59-438b-b0bf-fcebeb80f6b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_dd651a47-f184-41a1-8564-c77e7be47671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_dd651a47-f184-41a1-8564-c77e7be47671" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_7d5cba71-3549-4d5f-a773-f1612579538e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_7d5cba71-3549-4d5f-a773-f1612579538e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_50da64d9-e9e4-472b-a1e0-3948c495f048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_ShareBasedCompensation_50da64d9-e9e4-472b-a1e0-3948c495f048" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_946a2d73-f755-4c19-8e27-2633634c4aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_946a2d73-f755-4c19-8e27-2633634c4aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e9f47bdc-d33f-40d1-907c-c9380f1cd0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e9f47bdc-d33f-40d1-907c-c9380f1cd0b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef058ea0-74f9-44cc-bc62-a04547440a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef058ea0-74f9-44cc-bc62-a04547440a46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_2d775512-1ef2-46de-8572-3b275fb77933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_2d775512-1ef2-46de-8572-3b275fb77933" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e5c758e9-e919-47c1-9d9f-e83bebd32606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e5c758e9-e919-47c1-9d9f-e83bebd32606" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_6d7a9d63-6cdc-4d73-8570-f9b6592758ed" xlink:href="arvn-20221231.xsd#arvn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_6d7a9d63-6cdc-4d73-8570-f9b6592758ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_08cbab93-c2ad-4a84-a3ef-6dcb70d50a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_08cbab93-c2ad-4a84-a3ef-6dcb70d50a3d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916fbd13-e7d8-46db-920e-c9e98881122a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916fbd13-e7d8-46db-920e-c9e98881122a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b7ddaefe-109e-4f80-ab91-bc02d953c080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b7ddaefe-109e-4f80-ab91-bc02d953c080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_e9a3796a-f10c-4acd-b3a7-35c0244767b6" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:to="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_e9a3796a-f10c-4acd-b3a7-35c0244767b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromSaleOfMarketableSecurities_739637f7-9e1d-4c9d-a9cb-9b26889cbf00" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:to="loc_arvn_ProceedsFromSaleOfMarketableSecurities_739637f7-9e1d-4c9d-a9cb-9b26889cbf00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21fb53bb-6f22-4e5c-a0f8-2493cca36b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21fb53bb-6f22-4e5c-a0f8-2493cca36b71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ca27b91-dae7-4094-b363-27a75067348c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ca27b91-dae7-4094-b363-27a75067348c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_76ec1e18-305c-4919-a47e-dddb01c92f3d" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:to="loc_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_76ec1e18-305c-4919-a47e-dddb01c92f3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_7c73d43b-3f52-412c-8036-d4298ef231d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_7c73d43b-3f52-412c-8036-d4298ef231d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockGross_2aefa7b2-12f4-4282-bc27-24c28693337b" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:to="loc_arvn_ProceedsFromIssuanceOfCommonStockGross_2aefa7b2-12f4-4282-bc27-24c28693337b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_981a2989-0b00-4e60-ad31-49e4cf9b7269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_981a2989-0b00-4e60-ad31-49e4cf9b7269" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16f7f397-fae0-470a-ba64-c5d691f50c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16f7f397-fae0-470a-ba64-c5d691f50c8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2362893-e95f-44ce-81b8-8dc18dda877b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2362893-e95f-44ce-81b8-8dc18dda877b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb88f5bf-a12c-498c-a7ec-488eaf7fe5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb88f5bf-a12c-498c-a7ec-488eaf7fe5a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a8bd6d6-817b-448d-9a06-d29c583d593b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e96b1378-fc21-4e61-af83-86f6e96e04ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e96b1378-fc21-4e61-af83-86f6e96e04ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_92997178-c164-4358-88b1-988e8081f95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e96b1378-fc21-4e61-af83-86f6e96e04ad" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_92997178-c164-4358-88b1-988e8081f95d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d903b492-78c7-4f2a-8a08-7aa7131ab5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e96b1378-fc21-4e61-af83-86f6e96e04ad" xlink:to="loc_us-gaap_InterestPaidNet_d903b492-78c7-4f2a-8a08-7aa7131ab5a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_4d62f556-cd73-40ac-a1d8-4ca7bbb01b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e96b1378-fc21-4e61-af83-86f6e96e04ad" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_4d62f556-cd73-40ac-a1d8-4ca7bbb01b47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4316ce0e-02d6-4d0e-957e-dd537de7b990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_StatementTable_4316ce0e-02d6-4d0e-957e-dd537de7b990" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5af9eb76-87ae-4b5c-b225-144196ee499b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4316ce0e-02d6-4d0e-957e-dd537de7b990" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5af9eb76-87ae-4b5c-b225-144196ee499b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5af9eb76-87ae-4b5c-b225-144196ee499b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5af9eb76-87ae-4b5c-b225-144196ee499b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5af9eb76-87ae-4b5c-b225-144196ee499b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_83524388-c4af-421a-b147-c649b20e37ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5af9eb76-87ae-4b5c-b225-144196ee499b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_83524388-c4af-421a-b147-c649b20e37ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_403e7f45-34f2-4401-8c5e-ff8a11f2109e" xlink:href="arvn-20221231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_83524388-c4af-421a-b147-c649b20e37ec" xlink:to="loc_arvn_AtTheMarketOfferingMember_403e7f45-34f2-4401-8c5e-ff8a11f2109e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityTables"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityTables" xlink:type="extended" id="i2631a0837dad4af08557ffa0befe28c6_EquityTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c3cce247-2776-4f02-8e72-6d35fa4ab60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f7135967-c85c-4439-88b8-bc96ea55621c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3cce247-2776-4f02-8e72-6d35fa4ab60c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f7135967-c85c-4439-88b8-bc96ea55621c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d387e382-860d-463f-b33a-b04d75c20592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3cce247-2776-4f02-8e72-6d35fa4ab60c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d387e382-860d-463f-b33a-b04d75c20592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_ad7c8d4d-9553-403e-aadd-095e7efc58a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3cce247-2776-4f02-8e72-6d35fa4ab60c" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_ad7c8d4d-9553-403e-aadd-095e7efc58a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63461674-b874-4eba-b836-3f6fadd8ccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c3cce247-2776-4f02-8e72-6d35fa4ab60c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63461674-b874-4eba-b836-3f6fadd8ccf5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b097a1a7-e4ac-45aa-a824-bae663923895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63461674-b874-4eba-b836-3f6fadd8ccf5" xlink:to="loc_us-gaap_AwardTypeAxis_b097a1a7-e4ac-45aa-a824-bae663923895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b097a1a7-e4ac-45aa-a824-bae663923895_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b097a1a7-e4ac-45aa-a824-bae663923895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b097a1a7-e4ac-45aa-a824-bae663923895_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d4db74f-42e6-4320-84fb-6db2ee0d06ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b097a1a7-e4ac-45aa-a824-bae663923895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d4db74f-42e6-4320-84fb-6db2ee0d06ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_82430a88-30cd-461b-aad1-a2bbab439455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d4db74f-42e6-4320-84fb-6db2ee0d06ff" xlink:to="loc_us-gaap_RestrictedStockMember_82430a88-30cd-461b-aad1-a2bbab439455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dd689d51-41cd-4443-b19a-8e7a4e79fa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d4db74f-42e6-4320-84fb-6db2ee0d06ff" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dd689d51-41cd-4443-b19a-8e7a4e79fa4b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i18f45aede6d24b0ba698102ad905730b_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:href="arvn-20221231.xsd#arvn_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_512ec60e-7df7-4372-b022-1eae21ecb0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_512ec60e-7df7-4372-b022-1eae21ecb0a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_efc267e8-3ffb-43a9-9af7-320a8523aece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_efc267e8-3ffb-43a9-9af7-320a8523aece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c90ca30d-8bd4-433b-8277-3ee469389d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c90ca30d-8bd4-433b-8277-3ee469389d5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_396bb2ab-797b-4847-b570-f96350261a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_396bb2ab-797b-4847-b570-f96350261a86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7254d716-3bfe-4996-9de5-3334a8e4f324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7254d716-3bfe-4996-9de5-3334a8e4f324" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1b8b56d4-ec58-4491-92e0-793e46af1c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_EquityMethodInvestments_1b8b56d4-ec58-4491-92e0-793e46af1c9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_da49baed-df46-4159-beb3-5914e30b075b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_da49baed-df46-4159-beb3-5914e30b075b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:href="arvn-20221231.xsd#arvn_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df924408-3c35-49b2-a4c5-63a2ea3ce9dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:to="loc_srt_RangeAxis_df924408-3c35-49b2-a4c5-63a2ea3ce9dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df924408-3c35-49b2-a4c5-63a2ea3ce9dd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_df924408-3c35-49b2-a4c5-63a2ea3ce9dd" xlink:to="loc_srt_RangeMember_df924408-3c35-49b2-a4c5-63a2ea3ce9dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa018ac2-464f-4cbd-8344-08f9f6be4c13" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_df924408-3c35-49b2-a4c5-63a2ea3ce9dd" xlink:to="loc_srt_RangeMember_fa018ac2-464f-4cbd-8344-08f9f6be4c13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87ced195-c3da-4be9-ace6-558c1b9f78fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fa018ac2-464f-4cbd-8344-08f9f6be4c13" xlink:to="loc_srt_MaximumMember_87ced195-c3da-4be9-ace6-558c1b9f78fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0fb99fae-4efb-4915-b562-bbbf870c65b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0fb99fae-4efb-4915-b562-bbbf870c65b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0fb99fae-4efb-4915-b562-bbbf870c65b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0fb99fae-4efb-4915-b562-bbbf870c65b2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0fb99fae-4efb-4915-b562-bbbf870c65b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0b89a291-357a-4459-a406-fb4e3a30e165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0fb99fae-4efb-4915-b562-bbbf870c65b2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0b89a291-357a-4459-a406-fb4e3a30e165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_9bbd7ec4-a05c-4f94-b245-de29d63456d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0b89a291-357a-4459-a406-fb4e3a30e165" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_9bbd7ec4-a05c-4f94-b245-de29d63456d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9642a429-60a9-4b40-b78d-a7c0254eee26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9642a429-60a9-4b40-b78d-a7c0254eee26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9642a429-60a9-4b40-b78d-a7c0254eee26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9642a429-60a9-4b40-b78d-a7c0254eee26" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9642a429-60a9-4b40-b78d-a7c0254eee26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_09bbf798-3494-4409-ad1e-37d0fe73e316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9642a429-60a9-4b40-b78d-a7c0254eee26" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_09bbf798-3494-4409-ad1e-37d0fe73e316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6eceeb3e-9a6b-43fc-8e52-50c139168226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_09bbf798-3494-4409-ad1e-37d0fe73e316" xlink:to="loc_us-gaap_SalesRevenueNetMember_6eceeb3e-9a6b-43fc-8e52-50c139168226" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395ce435-b5df-4007-bde5-ef0b71c2344e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395ce435-b5df-4007-bde5-ef0b71c2344e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_395ce435-b5df-4007-bde5-ef0b71c2344e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395ce435-b5df-4007-bde5-ef0b71c2344e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_395ce435-b5df-4007-bde5-ef0b71c2344e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b32ee0a5-4507-4c2f-a336-2a189251511a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395ce435-b5df-4007-bde5-ef0b71c2344e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b32ee0a5-4507-4c2f-a336-2a189251511a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorOneMember_69f0f8b1-cea3-45a5-98ca-882b16cf02d3" xlink:href="arvn-20221231.xsd#arvn_CollaboratorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b32ee0a5-4507-4c2f-a336-2a189251511a" xlink:to="loc_arvn_CollaboratorOneMember_69f0f8b1-cea3-45a5-98ca-882b16cf02d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorTwoMember_00fb092d-1281-499a-87d0-f13e9b93d33a" xlink:href="arvn-20221231.xsd#arvn_CollaboratorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b32ee0a5-4507-4c2f-a336-2a189251511a" xlink:to="loc_arvn_CollaboratorTwoMember_00fb092d-1281-499a-87d0-f13e9b93d33a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorThreeMember_fae88331-5db0-4fd3-8b22-47585c0a6106" xlink:href="arvn-20221231.xsd#arvn_CollaboratorThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b32ee0a5-4507-4c2f-a336-2a189251511a" xlink:to="loc_arvn_CollaboratorThreeMember_fae88331-5db0-4fd3-8b22-47585c0a6106" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d56cc5e2-0a06-4169-911e-f55ec8a61743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d56cc5e2-0a06-4169-911e-f55ec8a61743" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d56cc5e2-0a06-4169-911e-f55ec8a61743_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d56cc5e2-0a06-4169-911e-f55ec8a61743" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d56cc5e2-0a06-4169-911e-f55ec8a61743_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e911f176-67c9-498d-86f8-d183d4ca06d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d56cc5e2-0a06-4169-911e-f55ec8a61743" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e911f176-67c9-498d-86f8-d183d4ca06d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_29c828f9-7b89-47db-9af0-7ee0c3eb46a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e911f176-67c9-498d-86f8-d183d4ca06d7" xlink:to="loc_us-gaap_OfficeEquipmentMember_29c828f9-7b89-47db-9af0-7ee0c3eb46a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_c69c22b0-6d4d-455a-877f-d0089d2cd3bb" xlink:href="arvn-20221231.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e911f176-67c9-498d-86f8-d183d4ca06d7" xlink:to="loc_arvn_LaboratoryEquipmentMember_c69c22b0-6d4d-455a-877f-d0089d2cd3bb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended" id="ie2b2b68e4c5346df9aabf2590c08c3d9_ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_aa8b290a-440e-4c59-a3d2-9333a38bcfd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_aa8b290a-440e-4c59-a3d2-9333a38bcfd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_733ab55e-9b1f-4c6a-a0e8-d07f8d2cfe66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_733ab55e-9b1f-4c6a-a0e8-d07f8d2cfe66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_f50b5aed-9b7d-4a57-be35-0a38ebd5c230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_f50b5aed-9b7d-4a57-be35-0a38ebd5c230" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd7985b5-96b1-48f2-8462-275d9be6643b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd7985b5-96b1-48f2-8462-275d9be6643b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForBrokerageFees_be567597-d040-418c-9a4e-1326aafa39e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForBrokerageFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_PaymentsForBrokerageFees_be567597-d040-418c-9a4e-1326aafa39e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SaleOfStockFairValueOfSharesSold_a3d55f05-a97c-4c27-97cf-bbb2516f1e69" xlink:href="arvn-20221231.xsd#arvn_SaleOfStockFairValueOfSharesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_arvn_SaleOfStockFairValueOfSharesSold_a3d55f05-a97c-4c27-97cf-bbb2516f1e69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_04423595-7d5b-49fe-bfc4-9debb128387e" xlink:href="arvn-20221231.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_04423595-7d5b-49fe-bfc4-9debb128387e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_3cbac9af-944b-43b4-abe1-efc3f82c45a2" xlink:href="arvn-20221231.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_3cbac9af-944b-43b4-abe1-efc3f82c45a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_f406c77f-4457-4fa7-afe5-ccf9de85fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_ProceedsFromCollaborators_f406c77f-4457-4fa7-afe5-ccf9de85fdb5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_867880b0-397d-4c99-af5e-be14f7ca725a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_867880b0-397d-4c99-af5e-be14f7ca725a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_702c9949-610c-41bf-8d0a-64b7d553dcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_702c9949-610c-41bf-8d0a-64b7d553dcf6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_62c83313-226f-4bf0-b70e-fbc32f7aec40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_62c83313-226f-4bf0-b70e-fbc32f7aec40" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfMaximumDesignatedTargets_6b15b2db-4b40-4b49-b3ef-bae215b79f0b" xlink:href="arvn-20221231.xsd#arvn_NumberOfMaximumDesignatedTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_arvn_NumberOfMaximumDesignatedTargets_6b15b2db-4b40-4b49-b3ef-bae215b79f0b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5dfcec5f-78e4-4ee4-860c-9abf3ba042b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:to="loc_srt_CounterpartyNameAxis_5dfcec5f-78e4-4ee4-860c-9abf3ba042b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dfcec5f-78e4-4ee4-860c-9abf3ba042b1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5dfcec5f-78e4-4ee4-860c-9abf3ba042b1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dfcec5f-78e4-4ee4-860c-9abf3ba042b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c1cf182-a516-4e14-a4c1-9281ad8f6ea1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5dfcec5f-78e4-4ee4-860c-9abf3ba042b1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c1cf182-a516-4e14-a4c1-9281ad8f6ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_0983a129-7e1e-4dbe-befd-c935226808cd" xlink:href="arvn-20221231.xsd#arvn_PfizerIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c1cf182-a516-4e14-a4c1-9281ad8f6ea1" xlink:to="loc_arvn_PfizerIncorporationMember_0983a129-7e1e-4dbe-befd-c935226808cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember_62d0d80a-2c51-465c-a9d9-56f4702293b1" xlink:href="arvn-20221231.xsd#arvn_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c1cf182-a516-4e14-a4c1-9281ad8f6ea1" xlink:to="loc_arvn_BayerAGMember_62d0d80a-2c51-465c-a9d9-56f4702293b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_c4409658-b889-4f2d-a588-c88987a7e8ac" xlink:href="arvn-20221231.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c1cf182-a516-4e14-a4c1-9281ad8f6ea1" xlink:to="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_c4409658-b889-4f2d-a588-c88987a7e8ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_85702f5f-f571-4e3d-a9b2-2cdce2d8c4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:to="loc_us-gaap_TypeOfArrangementAxis_85702f5f-f571-4e3d-a9b2-2cdce2d8c4fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85702f5f-f571-4e3d-a9b2-2cdce2d8c4fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_85702f5f-f571-4e3d-a9b2-2cdce2d8c4fe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85702f5f-f571-4e3d-a9b2-2cdce2d8c4fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_85702f5f-f571-4e3d-a9b2-2cdce2d8c4fe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember_1dc1649a-615f-4688-a3b2-3c8a69fc09a6" xlink:href="arvn-20221231.xsd#arvn_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_CollaborationAgreementMember_1dc1649a-615f-4688-a3b2-3c8a69fc09a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockPurchaseAgreementMember_a0a49a21-5ef6-49d3-b6a9-a44cb5b20893" xlink:href="arvn-20221231.xsd#arvn_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_StockPurchaseAgreementMember_a0a49a21-5ef6-49d3-b6a9-a44cb5b20893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember_2ea1010b-85c7-4720-a276-1ca782527c68" xlink:href="arvn-20221231.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_ResearchFundingPaymentsMember_2ea1010b-85c7-4720-a276-1ca782527c68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember_832e6d00-d593-48fd-b867-144168eba929" xlink:href="arvn-20221231.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_DevelopmentMilestonePaymentsMember_832e6d00-d593-48fd-b867-144168eba929" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember_f24ae3a9-0a68-4086-ba59-c46aeb5f892f" xlink:href="arvn-20221231.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_SalesBasedMilestonePaymentsMember_f24ae3a9-0a68-4086-ba59-c46aeb5f892f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember_e3a7f202-b59d-4769-8503-b73ff09932c4" xlink:href="arvn-20221231.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_OptionPaymentsToLicenseAgreementMember_e3a7f202-b59d-4769-8503-b73ff09932c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AdditionalTargetAndServicesMember_0578a44f-d3d8-421c-bbfc-e3bebf985771" xlink:href="arvn-20221231.xsd#arvn_AdditionalTargetAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_AdditionalTargetAndServicesMember_0578a44f-d3d8-421c-bbfc-e3bebf985771" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember_db42fc81-63b5-4df7-875c-d9648fb2bd07" xlink:href="arvn-20221231.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_RegulatoryMilestonePaymentsMember_db42fc81-63b5-4df7-875c-d9648fb2bd07" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember_031336c1-d3a6-466e-b598-98422714896b" xlink:href="arvn-20221231.xsd#arvn_CommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_CommercialMilestonesMember_031336c1-d3a6-466e-b598-98422714896b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83b21740-f912-4b2f-9709-1d62f7f5e8e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:to="loc_srt_RangeAxis_83b21740-f912-4b2f-9709-1d62f7f5e8e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83b21740-f912-4b2f-9709-1d62f7f5e8e3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_83b21740-f912-4b2f-9709-1d62f7f5e8e3" xlink:to="loc_srt_RangeMember_83b21740-f912-4b2f-9709-1d62f7f5e8e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92c3ac2a-10b4-4d84-874c-5569f69b87f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_83b21740-f912-4b2f-9709-1d62f7f5e8e3" xlink:to="loc_srt_RangeMember_92c3ac2a-10b4-4d84-874c-5569f69b87f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59ee5ea2-1742-4dde-8e88-e010adafca49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92c3ac2a-10b4-4d84-874c-5569f69b87f9" xlink:to="loc_srt_MaximumMember_59ee5ea2-1742-4dde-8e88-e010adafca49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_677e9e51-1d26-4de2-a751-928b4c144516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_677e9e51-1d26-4de2-a751-928b4c144516" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_677e9e51-1d26-4de2-a751-928b4c144516_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_677e9e51-1d26-4de2-a751-928b4c144516" xlink:to="loc_us-gaap_EquityComponentDomain_677e9e51-1d26-4de2-a751-928b4c144516_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f5b9f073-addb-4754-b322-9088694a3225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_677e9e51-1d26-4de2-a751-928b4c144516" xlink:to="loc_us-gaap_EquityComponentDomain_f5b9f073-addb-4754-b322-9088694a3225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_18d61f7f-3244-4669-bf7a-7a4fdd4e88b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f5b9f073-addb-4754-b322-9088694a3225" xlink:to="loc_us-gaap_CommonStockMember_18d61f7f-3244-4669-bf7a-7a4fdd4e88b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_55b4db0e-32a0-4aea-a30b-6798d495067f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:to="loc_srt_StatementScenarioAxis_55b4db0e-32a0-4aea-a30b-6798d495067f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_55b4db0e-32a0-4aea-a30b-6798d495067f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_55b4db0e-32a0-4aea-a30b-6798d495067f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_55b4db0e-32a0-4aea-a30b-6798d495067f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ee004cf2-3e89-456a-b1e8-31b437adb2d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_55b4db0e-32a0-4aea-a30b-6798d495067f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ee004cf2-3e89-456a-b1e8-31b437adb2d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_dffe8268-2ec2-4e11-b169-b98e4a6b3d14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ee004cf2-3e89-456a-b1e8-31b437adb2d7" xlink:to="loc_srt_ScenarioForecastMember_dffe8268-2ec2-4e11-b169-b98e4a6b3d14" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="extended" id="ib1b1e37cc2a2459db886719f12ec6905_ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_00aad7c8-a66c-4407-94d7-d055c064e888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_00aad7c8-a66c-4407-94d7-d055c064e888" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_feb4405e-62e9-45fb-8a7e-ab15ed19dda9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_feb4405e-62e9-45fb-8a7e-ab15ed19dda9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a6a74f5-0f14-4fb3-aba5-233b4dac4ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a6a74f5-0f14-4fb3-aba5-233b4dac4ab1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_f6aeab1a-38b4-49d8-9145-413806be6745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a6a74f5-0f14-4fb3-aba5-233b4dac4ab1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_f6aeab1a-38b4-49d8-9145-413806be6745" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="arvn-20221231.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="extended" id="ieb6ff7b2c79d4311a2782d00be2155ea_ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_00aad7c8-a66c-4407-94d7-d055c064e888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_00aad7c8-a66c-4407-94d7-d055c064e888" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_feb4405e-62e9-45fb-8a7e-ab15ed19dda9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_feb4405e-62e9-45fb-8a7e-ab15ed19dda9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a6a74f5-0f14-4fb3-aba5-233b4dac4ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a6a74f5-0f14-4fb3-aba5-233b4dac4ab1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#MarketableSecuritiesandFairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="extended" id="i127e385099bb4958aa71d6f7cb76c25a_MarketableSecuritiesandFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_084ed708-9074-4bd1-946b-24108b6cbc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_084ed708-9074-4bd1-946b-24108b6cbc51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9c1c5c54-0b53-4a31-97f2-5755989bde30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9c1c5c54-0b53-4a31-97f2-5755989bde30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a07962ce-6fee-414a-858a-0bc4e2828952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a07962ce-6fee-414a-858a-0bc4e2828952" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ecba69fe-a0bb-47aa-97e1-9b4d95cd7135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ecba69fe-a0bb-47aa-97e1-9b4d95cd7135" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f6a7636a-46c7-474c-b8a0-d08a55fd342a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f6a7636a-46c7-474c-b8a0-d08a55fd342a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84a8856-557a-461c-a934-c51d169def14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84a8856-557a-461c-a934-c51d169def14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a84a8856-557a-461c-a934-c51d169def14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84a8856-557a-461c-a934-c51d169def14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a84a8856-557a-461c-a934-c51d169def14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5d31fe-a01d-46d7-902b-d8f666dde523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84a8856-557a-461c-a934-c51d169def14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5d31fe-a01d-46d7-902b-d8f666dde523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7c3db3a8-3bc8-46cf-af8c-6c1ab83f9335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5d31fe-a01d-46d7-902b-d8f666dde523" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7c3db3a8-3bc8-46cf-af8c-6c1ab83f9335" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_142d299f-8a46-4554-81b0-2af98da9534e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_142d299f-8a46-4554-81b0-2af98da9534e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_142d299f-8a46-4554-81b0-2af98da9534e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_142d299f-8a46-4554-81b0-2af98da9534e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_142d299f-8a46-4554-81b0-2af98da9534e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0674c079-37b7-4f63-bc13-8de8957435ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_142d299f-8a46-4554-81b0-2af98da9534e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0674c079-37b7-4f63-bc13-8de8957435ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_826b5673-950c-4c0f-ab8d-8a263fb3298f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0674c079-37b7-4f63-bc13-8de8957435ca" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_826b5673-950c-4c0f-ab8d-8a263fb3298f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_795452ec-c876-4a99-9a2a-159ec3cff752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0674c079-37b7-4f63-bc13-8de8957435ca" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_795452ec-c876-4a99-9a2a-159ec3cff752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9b0d5e7e-6c98-4ac3-8f8d-2c5acfc46390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9b0d5e7e-6c98-4ac3-8f8d-2c5acfc46390" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b0d5e7e-6c98-4ac3-8f8d-2c5acfc46390_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9b0d5e7e-6c98-4ac3-8f8d-2c5acfc46390" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b0d5e7e-6c98-4ac3-8f8d-2c5acfc46390_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9b0d5e7e-6c98-4ac3-8f8d-2c5acfc46390" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_8d90444c-14af-408a-b469-a88959ac729b" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_8d90444c-14af-408a-b469-a88959ac729b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_47f3f9be-1cf9-473f-a8c4-16c04ddbd479" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_47f3f9be-1cf9-473f-a8c4-16c04ddbd479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_810f42c9-921e-408d-9dfb-ab1d2391f3fc" xlink:href="arvn-20221231.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_810f42c9-921e-408d-9dfb-ab1d2391f3fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_8ffd132c-7da9-4ff0-a4f0-d67b782a76b9" xlink:href="arvn-20221231.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_8ffd132c-7da9-4ff0-a4f0-d67b782a76b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_f17611fc-c395-4d36-8099-2629acb0865f" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_f17611fc-c395-4d36-8099-2629acb0865f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_f7d8ba38-3118-4a6f-8048-c5c9e2bbe380" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_f7d8ba38-3118-4a6f-8048-c5c9e2bbe380" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_55abda27-ea6e-408d-af2e-2d923fe45292" xlink:href="arvn-20221231.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_55abda27-ea6e-408d-af2e-2d923fe45292" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_56d8ba54-ae91-4cea-833d-001e19fdd19d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:to="loc_srt_CounterpartyNameAxis_56d8ba54-ae91-4cea-833d-001e19fdd19d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56d8ba54-ae91-4cea-833d-001e19fdd19d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_56d8ba54-ae91-4cea-833d-001e19fdd19d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56d8ba54-ae91-4cea-833d-001e19fdd19d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ceb48ad-6239-4825-ad9e-cd3978fc17b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_56d8ba54-ae91-4cea-833d-001e19fdd19d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ceb48ad-6239-4825-ad9e-cd3978fc17b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_3f66e6c2-62e8-4ab8-bafc-2ed0f9dd0e06" xlink:href="arvn-20221231.xsd#arvn_PfizerIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ceb48ad-6239-4825-ad9e-cd3978fc17b5" xlink:to="loc_arvn_PfizerIncorporationMember_3f66e6c2-62e8-4ab8-bafc-2ed0f9dd0e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0a521b4d-65d1-42d2-9171-136d0d727c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0a521b4d-65d1-42d2-9171-136d0d727c59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a521b4d-65d1-42d2-9171-136d0d727c59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0a521b4d-65d1-42d2-9171-136d0d727c59" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a521b4d-65d1-42d2-9171-136d0d727c59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e71c781a-1761-43bf-a5f6-106f4a26ff59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0a521b4d-65d1-42d2-9171-136d0d727c59" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e71c781a-1761-43bf-a5f6-106f4a26ff59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockPurchaseAgreementMember_0c5b22fd-3eb5-4431-afcf-7840101090ee" xlink:href="arvn-20221231.xsd#arvn_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e71c781a-1761-43bf-a5f6-106f4a26ff59" xlink:to="loc_arvn_StockPurchaseAgreementMember_0c5b22fd-3eb5-4431-afcf-7840101090ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended" id="i87b33789ab694e428d95b2d7b74a0e84_PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba25ed7e-9da4-49ba-9836-d102610ce4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5067b7c7-3555-4867-8c07-b06fff5afa58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba25ed7e-9da4-49ba-9836-d102610ce4fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5067b7c7-3555-4867-8c07-b06fff5afa58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2b197fc5-9c85-4057-beaa-93a200ae80b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba25ed7e-9da4-49ba-9836-d102610ce4fa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2b197fc5-9c85-4057-beaa-93a200ae80b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_72c2b3d7-bb92-486b-9c7d-a1475979d3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba25ed7e-9da4-49ba-9836-d102610ce4fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_72c2b3d7-bb92-486b-9c7d-a1475979d3dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ee8ebf80-effb-4baa-936e-d4c0b85e0530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba25ed7e-9da4-49ba-9836-d102610ce4fa" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ee8ebf80-effb-4baa-936e-d4c0b85e0530" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa7e6735-2f17-42a9-be66-28967d4e47c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ee8ebf80-effb-4baa-936e-d4c0b85e0530" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa7e6735-2f17-42a9-be66-28967d4e47c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fa7e6735-2f17-42a9-be66-28967d4e47c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa7e6735-2f17-42a9-be66-28967d4e47c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fa7e6735-2f17-42a9-be66-28967d4e47c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d33cf4ac-0790-402e-b784-b1d1271e993d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa7e6735-2f17-42a9-be66-28967d4e47c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d33cf4ac-0790-402e-b784-b1d1271e993d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_c4d9b7de-98df-4577-9d3a-09219e7c3ed2" xlink:href="arvn-20221231.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d33cf4ac-0790-402e-b784-b1d1271e993d" xlink:to="loc_arvn_LaboratoryEquipmentMember_c4d9b7de-98df-4577-9d3a-09219e7c3ed2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_abb323b7-7945-47cc-a597-56e14d8782df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d33cf4ac-0790-402e-b784-b1d1271e993d" xlink:to="loc_us-gaap_OfficeEquipmentMember_abb323b7-7945-47cc-a597-56e14d8782df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2db37ddd-c221-4b96-93d1-c672d434aa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d33cf4ac-0790-402e-b784-b1d1271e993d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2db37ddd-c221-4b96-93d1-c672d434aa4c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#RightofUseAssetsandLiabilitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="extended" id="i45f286200c0a4e5192e604abb6814fb2_RightofUseAssetsandLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_6b8f9bbc-4d29-4378-ac25-92ba983bfe08" xlink:href="arvn-20221231.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_6b8f9bbc-4d29-4378-ac25-92ba983bfe08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_4c5d8d4c-cee3-4ab1-bff9-a247cbd82cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_4c5d8d4c-cee3-4ab1-bff9-a247cbd82cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecurities_de0808b6-30d0-466c-802e-2db91886416f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_us-gaap_DebtSecurities_de0808b6-30d0-466c-802e-2db91886416f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b9075cf9-c853-4058-9c36-9579873b403b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_us-gaap_LeaseCost_b9075cf9-c853-4058-9c36-9579873b403b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BaseLeaseRentPeriod_3aaa018b-98f7-43bf-85d4-112d54ed092d" xlink:href="arvn-20221231.xsd#arvn_BaseLeaseRentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_arvn_BaseLeaseRentPeriod_3aaa018b-98f7-43bf-85d4-112d54ed092d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_321794d3-d51c-4b5f-b147-bbde81f60da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_321794d3-d51c-4b5f-b147-bbde81f60da2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_cb56e061-0a58-4521-a4d4-041e87974b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_cb56e061-0a58-4521-a4d4-041e87974b49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f703a4a9-3c78-411d-94cc-90aa925164d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cb56e061-0a58-4521-a4d4-041e87974b49" xlink:to="loc_srt_RangeAxis_f703a4a9-3c78-411d-94cc-90aa925164d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f703a4a9-3c78-411d-94cc-90aa925164d5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f703a4a9-3c78-411d-94cc-90aa925164d5" xlink:to="loc_srt_RangeMember_f703a4a9-3c78-411d-94cc-90aa925164d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_920c7aeb-eef1-4ce1-a16e-59aeab82d5a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f703a4a9-3c78-411d-94cc-90aa925164d5" xlink:to="loc_srt_RangeMember_920c7aeb-eef1-4ce1-a16e-59aeab82d5a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e94f566f-a844-4d94-b914-2ef29247e884" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_920c7aeb-eef1-4ce1-a16e-59aeab82d5a3" xlink:to="loc_srt_MinimumMember_e94f566f-a844-4d94-b914-2ef29247e884" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dcfda809-4085-40dc-9716-ddadcf725704" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_920c7aeb-eef1-4ce1-a16e-59aeab82d5a3" xlink:to="loc_srt_MaximumMember_dcfda809-4085-40dc-9716-ddadcf725704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusAxis_21107835-1627-4b2e-b21b-6a7bbcb0da08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cb56e061-0a58-4521-a4d4-041e87974b49" xlink:to="loc_us-gaap_PledgedStatusAxis_21107835-1627-4b2e-b21b-6a7bbcb0da08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain_21107835-1627-4b2e-b21b-6a7bbcb0da08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PledgedStatusAxis_21107835-1627-4b2e-b21b-6a7bbcb0da08" xlink:to="loc_us-gaap_PledgedStatusDomain_21107835-1627-4b2e-b21b-6a7bbcb0da08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain_e04fa111-9926-4f13-9392-9bfcda9bc58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PledgedStatusAxis_21107835-1627-4b2e-b21b-6a7bbcb0da08" xlink:to="loc_us-gaap_PledgedStatusDomain_e04fa111-9926-4f13-9392-9bfcda9bc58b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetPledgedAsCollateralMember_6ba54ae9-7a9c-45ef-b9c6-9f4350d2cd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetPledgedAsCollateralMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PledgedStatusDomain_e04fa111-9926-4f13-9392-9bfcda9bc58b" xlink:to="loc_us-gaap_AssetPledgedAsCollateralMember_6ba54ae9-7a9c-45ef-b9c6-9f4350d2cd16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeAxis_21187286-695b-49e0-b6e7-9c47f0ed3987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cb56e061-0a58-4521-a4d4-041e87974b49" xlink:to="loc_us-gaap_PledgingPurposeAxis_21187286-695b-49e0-b6e7-9c47f0ed3987" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain_21187286-695b-49e0-b6e7-9c47f0ed3987_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PledgingPurposeAxis_21187286-695b-49e0-b6e7-9c47f0ed3987" xlink:to="loc_us-gaap_PledgingPurposeDomain_21187286-695b-49e0-b6e7-9c47f0ed3987_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain_4c120a2c-ca1e-47e9-acb6-61c745b47892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PledgingPurposeAxis_21187286-695b-49e0-b6e7-9c47f0ed3987" xlink:to="loc_us-gaap_PledgingPurposeDomain_4c120a2c-ca1e-47e9-acb6-61c745b47892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0017885f-a175-4545-a363-0bec6a187b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PledgingPurposeDomain_4c120a2c-ca1e-47e9-acb6-61c745b47892" xlink:to="loc_us-gaap_LetterOfCreditMember_0017885f-a175-4545-a363-0bec6a187b4c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended" id="i6fa748d75b244302b4b8388c86fe7464_LongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_affbb4a1-1dbd-44fb-967c-c154b9f0fa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_affbb4a1-1dbd-44fb-967c-c154b9f0fa2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfMaximumFundingOnProjectCosts_abc56180-a561-491d-b5f9-d7906c6744af" xlink:href="arvn-20221231.xsd#arvn_PercentageOfMaximumFundingOnProjectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_arvn_PercentageOfMaximumFundingOnProjectCosts_abc56180-a561-491d-b5f9-d7906c6744af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a47244ad-ce38-47e8-8cec-e856618dc3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a47244ad-ce38-47e8-8cec-e856618dc3bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm_756bc146-7622-4115-9f90-1ef36c7eaf1e" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_arvn_DebtInstrumentInterestPaymentsTerm_756bc146-7622-4115-9f90-1ef36c7eaf1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod_2a323c49-2561-4a00-b3a1-adb0cd621be8" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod_2a323c49-2561-4a00-b3a1-adb0cd621be8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_1e72afdf-64b7-4d2c-8797-4b6b3cc40e3a" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_1e72afdf-64b7-4d2c-8797-4b6b3cc40e3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages_2ce018cf-bc2e-4e26-a2b5-9bab4c87ec70" xlink:href="arvn-20221231.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_arvn_PercentageOfLiquidatedDamages_2ce018cf-bc2e-4e26-a2b5-9bab4c87ec70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_13d05a3d-cc24-409f-a8e4-e75d4c7a327e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_us-gaap_InterestExpenseDebt_13d05a3d-cc24-409f-a8e4-e75d4c7a327e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a70da94a-b00d-494d-8c15-3bb053c23a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_us-gaap_DebtInstrumentTable_a70da94a-b00d-494d-8c15-3bb053c23a6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_725c5f07-5051-458f-9d06-8d5603d8b4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a70da94a-b00d-494d-8c15-3bb053c23a6e" xlink:to="loc_us-gaap_DebtInstrumentAxis_725c5f07-5051-458f-9d06-8d5603d8b4bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_725c5f07-5051-458f-9d06-8d5603d8b4bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_725c5f07-5051-458f-9d06-8d5603d8b4bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_725c5f07-5051-458f-9d06-8d5603d8b4bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba3ab0cb-4da6-42d7-a0cf-7d8b24a9b54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_725c5f07-5051-458f-9d06-8d5603d8b4bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba3ab0cb-4da6-42d7-a0cf-7d8b24a9b54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_3fcd8ef8-8224-47af-a097-5d1c6f501717" xlink:href="arvn-20221231.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba3ab0cb-4da6-42d7-a0cf-7d8b24a9b54f" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_3fcd8ef8-8224-47af-a097-5d1c6f501717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_28e080e3-0c59-477b-bcbd-05a36ae07afd" xlink:href="arvn-20221231.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba3ab0cb-4da6-42d7-a0cf-7d8b24a9b54f" xlink:to="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_28e080e3-0c59-477b-bcbd-05a36ae07afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6513931b-0699-4dc1-9f86-3639085623d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a70da94a-b00d-494d-8c15-3bb053c23a6e" xlink:to="loc_srt_StatementGeographicalAxis_6513931b-0699-4dc1-9f86-3639085623d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6513931b-0699-4dc1-9f86-3639085623d2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6513931b-0699-4dc1-9f86-3639085623d2" xlink:to="loc_srt_SegmentGeographicalDomain_6513931b-0699-4dc1-9f86-3639085623d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_abf80aaa-05f4-4857-a55c-852317c1e9ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6513931b-0699-4dc1-9f86-3639085623d2" xlink:to="loc_srt_SegmentGeographicalDomain_abf80aaa-05f4-4857-a55c-852317c1e9ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_4d48e98b-31a0-4eff-a7f4-2c6e6e90681a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_abf80aaa-05f4-4857-a55c-852317c1e9ab" xlink:to="loc_stpr_CT_4d48e98b-31a0-4eff-a7f4-2c6e6e90681a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f349e01-1d29-44a0-b227-3821a46acee4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a70da94a-b00d-494d-8c15-3bb053c23a6e" xlink:to="loc_srt_RangeAxis_0f349e01-1d29-44a0-b227-3821a46acee4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0f349e01-1d29-44a0-b227-3821a46acee4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0f349e01-1d29-44a0-b227-3821a46acee4" xlink:to="loc_srt_RangeMember_0f349e01-1d29-44a0-b227-3821a46acee4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1834ab6c-047b-4f8d-9833-5288321d7ead" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0f349e01-1d29-44a0-b227-3821a46acee4" xlink:to="loc_srt_RangeMember_1834ab6c-047b-4f8d-9833-5288321d7ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c6939110-5176-45fb-b842-f6153ec6a4d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1834ab6c-047b-4f8d-9833-5288321d7ead" xlink:to="loc_srt_MaximumMember_c6939110-5176-45fb-b842-f6153ec6a4d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="extended" id="i8b96042c2aa34fb98ebaf7360c20b63c_EquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ec395bcd-16c7-497d-b71f-09b13d070e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ec395bcd-16c7-497d-b71f-09b13d070e8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d442805f-6ded-4a85-a451-1731f44bca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d442805f-6ded-4a85-a451-1731f44bca8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfVotesPerCommonStockShareHeld_147c0b22-7e63-4331-8113-189b1bda89da" xlink:href="arvn-20221231.xsd#arvn_NumberOfVotesPerCommonStockShareHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_arvn_NumberOfVotesPerCommonStockShareHeld_147c0b22-7e63-4331-8113-189b1bda89da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_322983f3-5cbb-4f78-aa57-6d7860490d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_322983f3-5cbb-4f78-aa57-6d7860490d5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_daeb29f7-c1f2-40aa-8254-04f64450460c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_daeb29f7-c1f2-40aa-8254-04f64450460c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_271a2852-ca1d-4d2b-ad31-19177bc77b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_271a2852-ca1d-4d2b-ad31-19177bc77b61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForBrokerageFees_36d037f8-b0ba-4f5c-943a-85e6fdb715f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForBrokerageFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_PaymentsForBrokerageFees_36d037f8-b0ba-4f5c-943a-85e6fdb715f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_58b65237-a69b-4123-9d9e-ea534ef3fed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_58b65237-a69b-4123-9d9e-ea534ef3fed3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_679942cf-e32e-4013-9fca-d01a19de9124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForUnderwritingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_679942cf-e32e-4013-9fca-d01a19de9124" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement_aeb06ead-4130-4070-9130-d9b5a7869a46" xlink:href="arvn-20221231.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement_aeb06ead-4130-4070-9130-d9b5a7869a46" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_23da8592-1ff6-477f-8532-6f465972bc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_23da8592-1ff6-477f-8532-6f465972bc8c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6e8fc82f-91dd-40ec-aab3-b61ba6a024bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6e8fc82f-91dd-40ec-aab3-b61ba6a024bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e825fe1c-b3a0-4909-b794-95bad59ea60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e825fe1c-b3a0-4909-b794-95bad59ea60e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_1552f09a-4749-46af-bf83-80a4abf637d2" xlink:href="arvn-20221231.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_1552f09a-4749-46af-bf83-80a4abf637d2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5003e395-f026-4cb1-bfe8-44028daea3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5003e395-f026-4cb1-bfe8-44028daea3f4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1accc2d8-9832-4136-9735-2e1b098a0b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1accc2d8-9832-4136-9735-2e1b098a0b28" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bdfec54-f67e-48ba-9ffb-4720b0ef757d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bdfec54-f67e-48ba-9ffb-4720b0ef757d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6452f975-7d98-4cbc-8d76-0628f0a3fb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6452f975-7d98-4cbc-8d76-0628f0a3fb3d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_20d90e88-dd9c-4896-839d-03923d18ed9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_20d90e88-dd9c-4896-839d-03923d18ed9f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0120f3d0-c918-4777-9ac4-97a9edf1a4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0120f3d0-c918-4777-9ac4-97a9edf1a4ef" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_eafc5d81-af47-46ee-807b-a956b101a74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_eafc5d81-af47-46ee-807b-a956b101a74d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a572acdb-b5af-460c-b41c-0265401297c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a572acdb-b5af-460c-b41c-0265401297c5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf1f36a-c5bb-477f-b64d-31fbeaa017ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf1f36a-c5bb-477f-b64d-31fbeaa017ff" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26b8cbbb-7e77-4c57-96b6-673763c1da56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26b8cbbb-7e77-4c57-96b6-673763c1da56" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0f68fe02-8fb0-4cc0-a7e7-bfb6c1ea7bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0f68fe02-8fb0-4cc0-a7e7-bfb6c1ea7bb8" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_18aee3d4-c9bb-4710-82f8-47646e1c6124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_18aee3d4-c9bb-4710-82f8-47646e1c6124" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_68e8af9f-956f-4e3d-a08f-7dfaa40cb625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_68e8af9f-956f-4e3d-a08f-7dfaa40cb625" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber_3851b714-6dd6-47ac-842b-6b37b4c8b52d" xlink:href="arvn-20221231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber_3851b714-6dd6-47ac-842b-6b37b4c8b52d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6ca744d9-1114-43f8-8780-b5a4980dbecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6ca744d9-1114-43f8-8780-b5a4980dbecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6ca744d9-1114-43f8-8780-b5a4980dbecc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ca744d9-1114-43f8-8780-b5a4980dbecc" xlink:to="loc_us-gaap_EquityComponentDomain_6ca744d9-1114-43f8-8780-b5a4980dbecc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_175a90b8-d3d7-4803-8972-af048fdd45f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ca744d9-1114-43f8-8780-b5a4980dbecc" xlink:to="loc_us-gaap_EquityComponentDomain_175a90b8-d3d7-4803-8972-af048fdd45f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f92f5bf6-ad58-4bc7-b700-b3b0fc683d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_175a90b8-d3d7-4803-8972-af048fdd45f6" xlink:to="loc_us-gaap_CommonStockMember_f92f5bf6-ad58-4bc7-b700-b3b0fc683d7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6e9afd54-f1a5-45c7-ae48-ee2df36f0d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6e9afd54-f1a5-45c7-ae48-ee2df36f0d50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6e9afd54-f1a5-45c7-ae48-ee2df36f0d50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6e9afd54-f1a5-45c7-ae48-ee2df36f0d50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6e9afd54-f1a5-45c7-ae48-ee2df36f0d50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40fd9b89-8048-44fb-9448-a391106cd4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6e9afd54-f1a5-45c7-ae48-ee2df36f0d50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40fd9b89-8048-44fb-9448-a391106cd4e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockPurchaseAgreementMember_ef35f089-2d38-4184-9b85-2fce85593e11" xlink:href="arvn-20221231.xsd#arvn_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40fd9b89-8048-44fb-9448-a391106cd4e2" xlink:to="loc_arvn_StockPurchaseAgreementMember_ef35f089-2d38-4184-9b85-2fce85593e11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember_f02882bc-cf3a-486f-94b1-095015f2a49f" xlink:href="arvn-20221231.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40fd9b89-8048-44fb-9448-a391106cd4e2" xlink:to="loc_arvn_EquityDistributionAgreementMember_f02882bc-cf3a-486f-94b1-095015f2a49f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bbcc5cd2-10f3-416c-aa4d-798a5743bef1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_srt_CounterpartyNameAxis_bbcc5cd2-10f3-416c-aa4d-798a5743bef1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bbcc5cd2-10f3-416c-aa4d-798a5743bef1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bbcc5cd2-10f3-416c-aa4d-798a5743bef1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bbcc5cd2-10f3-416c-aa4d-798a5743bef1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e215e871-36a4-4141-a9a9-b6f21c880ba5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bbcc5cd2-10f3-416c-aa4d-798a5743bef1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e215e871-36a4-4141-a9a9-b6f21c880ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_b93a0f80-334e-496e-9512-9a5378435feb" xlink:href="arvn-20221231.xsd#arvn_PfizerIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e215e871-36a4-4141-a9a9-b6f21c880ba5" xlink:to="loc_arvn_PfizerIncorporationMember_b93a0f80-334e-496e-9512-9a5378435feb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerMember_2ee07702-eb48-4c36-9125-1d196e8a83cf" xlink:href="arvn-20221231.xsd#arvn_PiperSandlerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e215e871-36a4-4141-a9a9-b6f21c880ba5" xlink:to="loc_arvn_PiperSandlerMember_2ee07702-eb48-4c36-9125-1d196e8a83cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b4ab93de-8211-4e3e-9cde-3bac35bfeda2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b4ab93de-8211-4e3e-9cde-3bac35bfeda2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b4ab93de-8211-4e3e-9cde-3bac35bfeda2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b4ab93de-8211-4e3e-9cde-3bac35bfeda2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b4ab93de-8211-4e3e-9cde-3bac35bfeda2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97e468ee-f145-4d85-88bb-0010dc888871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b4ab93de-8211-4e3e-9cde-3bac35bfeda2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97e468ee-f145-4d85-88bb-0010dc888871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_bbe65afe-84a1-4a1a-b37d-e50a29142605" xlink:href="arvn-20221231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97e468ee-f145-4d85-88bb-0010dc888871" xlink:to="loc_arvn_AtTheMarketOfferingMember_bbe65afe-84a1-4a1a-b37d-e50a29142605" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e74f03de-e319-4d4b-a7ea-4ee96fff2bb1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_srt_RangeAxis_e74f03de-e319-4d4b-a7ea-4ee96fff2bb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e74f03de-e319-4d4b-a7ea-4ee96fff2bb1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e74f03de-e319-4d4b-a7ea-4ee96fff2bb1" xlink:to="loc_srt_RangeMember_e74f03de-e319-4d4b-a7ea-4ee96fff2bb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8a2a25f1-9f43-4da7-8f76-92664fe90c9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e74f03de-e319-4d4b-a7ea-4ee96fff2bb1" xlink:to="loc_srt_RangeMember_8a2a25f1-9f43-4da7-8f76-92664fe90c9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9a1f4a62-93cb-4c67-9eb4-49cf9cf26f25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8a2a25f1-9f43-4da7-8f76-92664fe90c9b" xlink:to="loc_srt_MinimumMember_9a1f4a62-93cb-4c67-9eb4-49cf9cf26f25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f370625c-8e14-4ca4-8e8e-4158f25d1540" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8a2a25f1-9f43-4da7-8f76-92664fe90c9b" xlink:to="loc_srt_MaximumMember_f370625c-8e14-4ca4-8e8e-4158f25d1540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_0292278b-69ba-49fb-87ba-22e35f1def5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8a2a25f1-9f43-4da7-8f76-92664fe90c9b" xlink:to="loc_srt_WeightedAverageMember_0292278b-69ba-49fb-87ba-22e35f1def5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_c97f7179-688e-4514-86a0-8bfd600b418d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_srt_TitleOfIndividualAxis_c97f7179-688e-4514-86a0-8bfd600b418d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c97f7179-688e-4514-86a0-8bfd600b418d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_c97f7179-688e-4514-86a0-8bfd600b418d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c97f7179-688e-4514-86a0-8bfd600b418d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_361a94b4-8c92-41dc-930f-d480e9a11ca2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_c97f7179-688e-4514-86a0-8bfd600b418d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_361a94b4-8c92-41dc-930f-d480e9a11ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember_f0015ca1-080d-407d-970a-3a633c0b4ee2" xlink:href="arvn-20221231.xsd#arvn_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_361a94b4-8c92-41dc-930f-d480e9a11ca2" xlink:to="loc_arvn_EmployeesMember_f0015ca1-080d-407d-970a-3a633c0b4ee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b2cfb496-49db-4161-9797-aae5095c03b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_us-gaap_PlanNameAxis_b2cfb496-49db-4161-9797-aae5095c03b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b2cfb496-49db-4161-9797-aae5095c03b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b2cfb496-49db-4161-9797-aae5095c03b4" xlink:to="loc_us-gaap_PlanNameDomain_b2cfb496-49db-4161-9797-aae5095c03b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dc248e78-e3db-4a08-bcf6-6c5ac144b047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b2cfb496-49db-4161-9797-aae5095c03b4" xlink:to="loc_us-gaap_PlanNameDomain_dc248e78-e3db-4a08-bcf6-6c5ac144b047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_c1cac976-5195-4101-b45e-f58db30f3cdc" xlink:href="arvn-20221231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dc248e78-e3db-4a08-bcf6-6c5ac144b047" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_c1cac976-5195-4101-b45e-f58db30f3cdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember_6bfa629a-9f73-45e8-9bcd-c822fbf3af0c" xlink:href="arvn-20221231.xsd#arvn_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dc248e78-e3db-4a08-bcf6-6c5ac144b047" xlink:to="loc_arvn_StockIncentivePlanMember_6bfa629a-9f73-45e8-9bcd-c822fbf3af0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_483c4d18-bd26-4ffb-9e1b-00a5a20e539d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_us-gaap_AwardTypeAxis_483c4d18-bd26-4ffb-9e1b-00a5a20e539d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_483c4d18-bd26-4ffb-9e1b-00a5a20e539d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_483c4d18-bd26-4ffb-9e1b-00a5a20e539d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_483c4d18-bd26-4ffb-9e1b-00a5a20e539d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4e8d938-2e54-45f3-9151-774614fb1b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_483c4d18-bd26-4ffb-9e1b-00a5a20e539d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4e8d938-2e54-45f3-9151-774614fb1b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_73a0030a-0f5c-4d9c-8695-f747bfe6ea76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4e8d938-2e54-45f3-9151-774614fb1b1e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_73a0030a-0f5c-4d9c-8695-f747bfe6ea76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_94acdfe5-5a34-47a9-8a82-43a4144ff4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4e8d938-2e54-45f3-9151-774614fb1b1e" xlink:to="loc_us-gaap_EmployeeStockMember_94acdfe5-5a34-47a9-8a82-43a4144ff4e9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="extended" id="i035a43759a0a4cc0816be87104cf7bf7_EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6f059d84-7326-4c6c-ae75-36d62585facf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6f059d84-7326-4c6c-ae75-36d62585facf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2a930476-2007-4638-8885-e1ea0ed26c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2a930476-2007-4638-8885-e1ea0ed26c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0b0eac01-a08f-45d9-8f6e-607f5a49f956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0b0eac01-a08f-45d9-8f6e-607f5a49f956" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8bd01424-156a-4f15-9e90-a2ce47829334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8bd01424-156a-4f15-9e90-a2ce47829334" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0a4259ee-5fe4-466c-8b82-3d60e37d067d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0a4259ee-5fe4-466c-8b82-3d60e37d067d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_db5e2d8c-0b24-4a35-b62d-b86a3d4e1775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_db5e2d8c-0b24-4a35-b62d-b86a3d4e1775" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_4dc467d4-f1e1-4c36-9983-9be73514f022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_4dc467d4-f1e1-4c36-9983-9be73514f022" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_345a8604-8373-456e-aead-9c3d8b91453a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_345a8604-8373-456e-aead-9c3d8b91453a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f65f9c61-80e8-43c3-a41b-2541fe826993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_345a8604-8373-456e-aead-9c3d8b91453a" xlink:to="loc_us-gaap_AwardTypeAxis_f65f9c61-80e8-43c3-a41b-2541fe826993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f65f9c61-80e8-43c3-a41b-2541fe826993_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f65f9c61-80e8-43c3-a41b-2541fe826993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f65f9c61-80e8-43c3-a41b-2541fe826993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0a36baa-2640-4d13-974d-88f135a9ce53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f65f9c61-80e8-43c3-a41b-2541fe826993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0a36baa-2640-4d13-974d-88f135a9ce53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_647f139b-31d5-4d58-839e-b19f27d01777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0a36baa-2640-4d13-974d-88f135a9ce53" xlink:to="loc_us-gaap_EmployeeStockOptionMember_647f139b-31d5-4d58-839e-b19f27d01777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bbf7b8a7-e3b7-464a-9b17-1957f7a3c7c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_345a8604-8373-456e-aead-9c3d8b91453a" xlink:to="loc_srt_RangeAxis_bbf7b8a7-e3b7-464a-9b17-1957f7a3c7c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bbf7b8a7-e3b7-464a-9b17-1957f7a3c7c4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bbf7b8a7-e3b7-464a-9b17-1957f7a3c7c4" xlink:to="loc_srt_RangeMember_bbf7b8a7-e3b7-464a-9b17-1957f7a3c7c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a698d8a-ee93-4b83-aa21-f71ae5a8c8c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bbf7b8a7-e3b7-464a-9b17-1957f7a3c7c4" xlink:to="loc_srt_RangeMember_6a698d8a-ee93-4b83-aa21-f71ae5a8c8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9152c30c-39a7-404e-884e-5a000dcc4e64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a698d8a-ee93-4b83-aa21-f71ae5a8c8c1" xlink:to="loc_srt_MinimumMember_9152c30c-39a7-404e-884e-5a000dcc4e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ed0f1f3b-ebe9-4715-9429-92a95e80cb5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a698d8a-ee93-4b83-aa21-f71ae5a8c8c1" xlink:to="loc_srt_MaximumMember_ed0f1f3b-ebe9-4715-9429-92a95e80cb5f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquitySummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="extended" id="i578ebeb7057540878ff80b2f17aeeafd_EquitySummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8796af5f-4262-43c6-a427-aa77fdd994b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8796af5f-4262-43c6-a427-aa77fdd994b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a4c5c130-e835-40bd-9a99-d216ae7b3768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a4c5c130-e835-40bd-9a99-d216ae7b3768" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4997db20-5b7e-4670-9e41-cc63d05ef6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4997db20-5b7e-4670-9e41-cc63d05ef6f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_69d2eab8-5946-4373-a4cb-4457dea1f7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_69d2eab8-5946-4373-a4cb-4457dea1f7ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e394258f-f6be-41fc-8e5d-700c82c7519e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_85f4a4c7-4d0f-43b0-9c44-857bed5defd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_85f4a4c7-4d0f-43b0-9c44-857bed5defd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_84e172e0-618b-4a38-a3e2-f14bfeab93fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_84e172e0-618b-4a38-a3e2-f14bfeab93fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_efafafd4-20cd-47e4-9d39-d149f07d6059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_efafafd4-20cd-47e4-9d39-d149f07d6059" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_220f02b2-bfee-44e5-9c0f-0d2b5e4cd8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_220f02b2-bfee-44e5-9c0f-0d2b5e4cd8a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_46dd6a6d-4ba0-4855-afa3-9e68600c0df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_46dd6a6d-4ba0-4855-afa3-9e68600c0df5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_024207d5-f775-4f89-9dbd-0ce3c9320bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9d6db90e-d9cb-4492-a6e7-ea0c1846d782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9d6db90e-d9cb-4492-a6e7-ea0c1846d782" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d590e1ee-cdfc-4a0b-bba8-a0074834ed2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d590e1ee-cdfc-4a0b-bba8-a0074834ed2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bf0f3e4b-0003-4b9e-b266-b8e26aa14cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bf0f3e4b-0003-4b9e-b266-b8e26aa14cd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fe120a40-8dff-49c3-b60c-2f8bc788a79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fe120a40-8dff-49c3-b60c-2f8bc788a79c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9a376919-02e4-4799-9933-1f9818bdf332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9a376919-02e4-4799-9933-1f9818bdf332" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98763f69-4a5a-47f4-af16-6b0bcf0919e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98763f69-4a5a-47f4-af16-6b0bcf0919e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b0679f3c-00f4-4811-9db4-4f0e3bd64814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98763f69-4a5a-47f4-af16-6b0bcf0919e8" xlink:to="loc_us-gaap_PlanNameAxis_b0679f3c-00f4-4811-9db4-4f0e3bd64814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b0679f3c-00f4-4811-9db4-4f0e3bd64814_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b0679f3c-00f4-4811-9db4-4f0e3bd64814" xlink:to="loc_us-gaap_PlanNameDomain_b0679f3c-00f4-4811-9db4-4f0e3bd64814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e3e8b814-2eb4-4208-bd4a-3bff4c5da854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b0679f3c-00f4-4811-9db4-4f0e3bd64814" xlink:to="loc_us-gaap_PlanNameDomain_e3e8b814-2eb4-4208-bd4a-3bff4c5da854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_cf692909-2da4-44e9-a8e8-a319f64d8bea" xlink:href="arvn-20221231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e3e8b814-2eb4-4208-bd4a-3bff4c5da854" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_cf692909-2da4-44e9-a8e8-a319f64d8bea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7b88846f-9250-4a30-8159-d8c77e8e13db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98763f69-4a5a-47f4-af16-6b0bcf0919e8" xlink:to="loc_srt_TitleOfIndividualAxis_7b88846f-9250-4a30-8159-d8c77e8e13db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7b88846f-9250-4a30-8159-d8c77e8e13db_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_7b88846f-9250-4a30-8159-d8c77e8e13db" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7b88846f-9250-4a30-8159-d8c77e8e13db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b1914683-913a-4e58-ad0d-3cc3767bbe8d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_7b88846f-9250-4a30-8159-d8c77e8e13db" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b1914683-913a-4e58-ad0d-3cc3767bbe8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesDirectorsAndConsultantsMember_63438729-70d5-4e59-9cfd-032172526d7d" xlink:href="arvn-20221231.xsd#arvn_EmployeesDirectorsAndConsultantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b1914683-913a-4e58-ad0d-3cc3767bbe8d" xlink:to="loc_arvn_EmployeesDirectorsAndConsultantsMember_63438729-70d5-4e59-9cfd-032172526d7d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquitySummaryofRestrictedStockGrantActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="extended" id="i10a23005463145728271e2c47bc9e132_EquitySummaryofRestrictedStockGrantActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4541114d-1ac3-4825-bf3b-21c8f50020a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4541114d-1ac3-4825-bf3b-21c8f50020a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce9fabbe-7100-46f9-97ce-ea2bd9edf804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce9fabbe-7100-46f9-97ce-ea2bd9edf804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bb957ec-be8b-4644-8bdf-8d341826d22b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bb957ec-be8b-4644-8bdf-8d341826d22b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_45037b8a-7a66-4f30-95ce-988fe267e46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_45037b8a-7a66-4f30-95ce-988fe267e46e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_af396a96-8ed6-4304-9eb2-5aad010717d8" xlink:href="arvn-20221231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_af396a96-8ed6-4304-9eb2-5aad010717d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9a27aee1-b019-48bf-9ef0-803203dede18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9a27aee1-b019-48bf-9ef0-803203dede18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bdb588ae-3a68-4a51-bfd9-5f781a2ebfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4541114d-1ac3-4825-bf3b-21c8f50020a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7368616-6328-4a74-bf5b-cfc690849f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7368616-6328-4a74-bf5b-cfc690849f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_914e6a59-0b8d-4331-85f0-1978bbff3c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_914e6a59-0b8d-4331-85f0-1978bbff3c0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51984059-4cfb-48b8-94f6-b7d2b48e3153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51984059-4cfb-48b8-94f6-b7d2b48e3153" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue_db81db39-904c-40e4-a2ca-e3d50c19a687" xlink:href="arvn-20221231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue_db81db39-904c-40e4-a2ca-e3d50c19a687" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ae881bc0-84fc-4889-8c7e-27c97ee416e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ae881bc0-84fc-4889-8c7e-27c97ee416e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48e6a5b9-d37c-4ea9-aa39-3de11b2fe577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51df7f06-0492-44a9-a241-bd0212899281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4541114d-1ac3-4825-bf3b-21c8f50020a9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51df7f06-0492-44a9-a241-bd0212899281" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_753cba0d-6f10-4df2-a3aa-7c597c1a8b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51df7f06-0492-44a9-a241-bd0212899281" xlink:to="loc_us-gaap_PlanNameAxis_753cba0d-6f10-4df2-a3aa-7c597c1a8b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_753cba0d-6f10-4df2-a3aa-7c597c1a8b39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_753cba0d-6f10-4df2-a3aa-7c597c1a8b39" xlink:to="loc_us-gaap_PlanNameDomain_753cba0d-6f10-4df2-a3aa-7c597c1a8b39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b5a791f8-4e9c-428b-8b75-59c925ce37f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_753cba0d-6f10-4df2-a3aa-7c597c1a8b39" xlink:to="loc_us-gaap_PlanNameDomain_b5a791f8-4e9c-428b-8b75-59c925ce37f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember_5b370d0d-2759-4109-8960-155388208b0d" xlink:href="arvn-20221231.xsd#arvn_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b5a791f8-4e9c-428b-8b75-59c925ce37f8" xlink:to="loc_arvn_StockIncentivePlanMember_5b370d0d-2759-4109-8960-155388208b0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_cc3b8592-a300-4c22-9b35-e8be65356e83" xlink:href="arvn-20221231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b5a791f8-4e9c-428b-8b75-59c925ce37f8" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_cc3b8592-a300-4c22-9b35-e8be65356e83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_36446178-de2d-4c48-8ffe-06f5516cbbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51df7f06-0492-44a9-a241-bd0212899281" xlink:to="loc_us-gaap_AwardTypeAxis_36446178-de2d-4c48-8ffe-06f5516cbbc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36446178-de2d-4c48-8ffe-06f5516cbbc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_36446178-de2d-4c48-8ffe-06f5516cbbc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36446178-de2d-4c48-8ffe-06f5516cbbc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc0e34da-125b-4dc0-9a31-3590df6f81ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_36446178-de2d-4c48-8ffe-06f5516cbbc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc0e34da-125b-4dc0-9a31-3590df6f81ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_485e6f4d-3906-4f6b-8a05-1d48ea82c7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc0e34da-125b-4dc0-9a31-3590df6f81ca" xlink:to="loc_us-gaap_RestrictedStockMember_485e6f4d-3906-4f6b-8a05-1d48ea82c7ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bc5ae170-a953-4c26-914c-27a0328291bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc0e34da-125b-4dc0-9a31-3590df6f81ca" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bc5ae170-a953-4c26-914c-27a0328291bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_15b5b977-6f3e-4acb-b6f0-fbdd65a7dbff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51df7f06-0492-44a9-a241-bd0212899281" xlink:to="loc_srt_TitleOfIndividualAxis_15b5b977-6f3e-4acb-b6f0-fbdd65a7dbff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_15b5b977-6f3e-4acb-b6f0-fbdd65a7dbff_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_15b5b977-6f3e-4acb-b6f0-fbdd65a7dbff" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_15b5b977-6f3e-4acb-b6f0-fbdd65a7dbff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c7f60e8f-f139-430b-a395-fd113cd823d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_15b5b977-6f3e-4acb-b6f0-fbdd65a7dbff" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c7f60e8f-f139-430b-a395-fd113cd823d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesDirectorsAndConsultantsMember_4479571f-9131-4464-9ad6-1598144899fd" xlink:href="arvn-20221231.xsd#arvn_EmployeesDirectorsAndConsultantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c7f60e8f-f139-430b-a395-fd113cd823d0" xlink:to="loc_arvn_EmployeesDirectorsAndConsultantsMember_4479571f-9131-4464-9ad6-1598144899fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember_a9eaed22-6e61-4a56-929d-a72ca0c6609e" xlink:href="arvn-20221231.xsd#arvn_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c7f60e8f-f139-430b-a395-fd113cd823d0" xlink:to="loc_arvn_EmployeesMember_a9eaed22-6e61-4a56-929d-a72ca0c6609e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityMethodInvestmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails" xlink:type="extended" id="i47ecb5e5883b44a290f1e608baf11efc_EquityMethodInvestmentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_90f4ff3c-0756-4211-b1a6-c04a8b3efe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_90f4ff3c-0756-4211-b1a6-c04a8b3efe0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_bba4a21d-a67c-44fc-94c9-b5eee77446ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_bba4a21d-a67c-44fc-94c9-b5eee77446ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_e0cf4601-92a3-4416-8fdc-472e87c5e4d0" xlink:href="arvn-20221231.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_e0cf4601-92a3-4416-8fdc-472e87c5e4d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_904c83ca-09fe-4522-9121-9333400e33ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_904c83ca-09fe-4522-9121-9333400e33ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_30de94cb-4daf-4631-91f2-da126eb4a2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_30de94cb-4daf-4631-91f2-da126eb4a2b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_4868795d-89e8-4d88-aa6d-b0d796c949f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_EquityMethodInvestments_4868795d-89e8-4d88-aa6d-b0d796c949f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b5322e63-03f8-4915-a169-ec746cb78eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b5322e63-03f8-4915-a169-ec746cb78eff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_515a1167-e4bb-4d5f-a7ac-59f62197b7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_OperatingExpenses_515a1167-e4bb-4d5f-a7ac-59f62197b7f6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_27540f6a-7069-4316-898d-4d90966b5d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_ProfitLoss_27540f6a-7069-4316-898d-4d90966b5d64" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9c7b0d1a-2304-4c95-9e7e-c0b192933745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9c7b0d1a-2304-4c95-9e7e-c0b192933745" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2b44b60a-5b23-4666-9d26-8ae7eb82b0d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9c7b0d1a-2304-4c95-9e7e-c0b192933745" xlink:to="loc_srt_CounterpartyNameAxis_2b44b60a-5b23-4666-9d26-8ae7eb82b0d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b44b60a-5b23-4666-9d26-8ae7eb82b0d7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2b44b60a-5b23-4666-9d26-8ae7eb82b0d7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b44b60a-5b23-4666-9d26-8ae7eb82b0d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f00a23a5-ad88-4f1f-ac90-8be7d2e1a4a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2b44b60a-5b23-4666-9d26-8ae7eb82b0d7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f00a23a5-ad88-4f1f-ac90-8be7d2e1a4a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember_d1d51235-dd35-4d3d-b44e-f74bd128df4a" xlink:href="arvn-20221231.xsd#arvn_BayerCropScienceLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f00a23a5-ad88-4f1f-ac90-8be7d2e1a4a2" xlink:to="loc_arvn_BayerCropScienceLPMember_d1d51235-dd35-4d3d-b44e-f74bd128df4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fd72cbc2-7475-4930-8196-3f9669f420e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9c7b0d1a-2304-4c95-9e7e-c0b192933745" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fd72cbc2-7475-4930-8196-3f9669f420e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fd72cbc2-7475-4930-8196-3f9669f420e8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fd72cbc2-7475-4930-8196-3f9669f420e8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fd72cbc2-7475-4930-8196-3f9669f420e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f082f13c-a7a5-47d6-8ea2-a2414b36034c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fd72cbc2-7475-4930-8196-3f9669f420e8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f082f13c-a7a5-47d6-8ea2-a2414b36034c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_1e8826bf-cab2-448d-b431-565bb223acd0" xlink:href="arvn-20221231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f082f13c-a7a5-47d6-8ea2-a2414b36034c" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_1e8826bf-cab2-448d-b431-565bb223acd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_dbe59b92-3951-42e5-9575-f0eeb60fbdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9c7b0d1a-2304-4c95-9e7e-c0b192933745" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_dbe59b92-3951-42e5-9575-f0eeb60fbdc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_dbe59b92-3951-42e5-9575-f0eeb60fbdc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_dbe59b92-3951-42e5-9575-f0eeb60fbdc7" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_dbe59b92-3951-42e5-9575-f0eeb60fbdc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c23130ab-85fb-4c19-9b84-eefbc29a1bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_dbe59b92-3951-42e5-9575-f0eeb60fbdc7" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c23130ab-85fb-4c19-9b84-eefbc29a1bbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_c692e170-5816-4766-88af-bc13893ba7fa" xlink:href="arvn-20221231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c23130ab-85fb-4c19-9b84-eefbc29a1bbe" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_c692e170-5816-4766-88af-bc13893ba7fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails" xlink:type="extended" id="i185ac36e8f9149a4bc81b4cc2153230b_EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b0caf363-0ea8-4861-b1ae-12ca9639d708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_Revenues_b0caf363-0ea8-4861-b1ae-12ca9639d708" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f45b1ded-a3bb-4ab8-92aa-a674f9eb03f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_OperatingIncomeLoss_f45b1ded-a3bb-4ab8-92aa-a674f9eb03f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_67582df7-25c4-499c-a53b-8a2186ef526a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_67582df7-25c4-499c-a53b-8a2186ef526a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e9f6e64-fbc2-4d66-9ba2-f1c42a87a831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_NetIncomeLoss_3e9f6e64-fbc2-4d66-9ba2-f1c42a87a831" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5fb5e008-cf53-4aee-8077-f483c7e9ec20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_EarningsPerShareBasic_5fb5e008-cf53-4aee-8077-f483c7e9ec20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8f5f7fe2-2ec2-4fdd-83af-93ff8860377b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8f5f7fe2-2ec2-4fdd-83af-93ff8860377b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a0593756-6680-44d1-9b75-0e6260264b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a0593756-6680-44d1-9b75-0e6260264b7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d9944247-31fa-47c8-811d-c18fcd7ed5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d9944247-31fa-47c8-811d-c18fcd7ed5a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_6c8e7c84-964f-4581-8b99-78963b7835a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d9944247-31fa-47c8-811d-c18fcd7ed5a7" xlink:to="loc_srt_RestatementAxis_6c8e7c84-964f-4581-8b99-78963b7835a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_6c8e7c84-964f-4581-8b99-78963b7835a8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_6c8e7c84-964f-4581-8b99-78963b7835a8" xlink:to="loc_srt_RestatementDomain_6c8e7c84-964f-4581-8b99-78963b7835a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_543562a6-e9f3-47e7-9fba-26a22a6510a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_6c8e7c84-964f-4581-8b99-78963b7835a8" xlink:to="loc_srt_RestatementDomain_543562a6-e9f3-47e7-9fba-26a22a6510a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1265e17d-09cb-4bfb-a937-01d2ecd0cbd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_543562a6-e9f3-47e7-9fba-26a22a6510a4" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1265e17d-09cb-4bfb-a937-01d2ecd0cbd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_fe39957d-89c0-4afc-835d-775ded031c08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_543562a6-e9f3-47e7-9fba-26a22a6510a4" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_fe39957d-89c0-4afc-835d-775ded031c08" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="iadd52cd5c67142be9c857c5c7667e0aa_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:href="arvn-20221231.xsd#arvn_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5911eca9-309c-44c3-abe8-51d172349115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5911eca9-309c-44c3-abe8-51d172349115" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1cfa30b0-feb6-4bc9-9599-d3a79bd117ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1cfa30b0-feb6-4bc9-9599-d3a79bd117ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_e3eccae9-fa75-46f2-b4d9-d78fd25db471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_e3eccae9-fa75-46f2-b4d9-d78fd25db471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_d2a6322d-bf12-4cbc-837a-ac6899ca3639" xlink:href="arvn-20221231.xsd#arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_d2a6322d-bf12-4cbc-837a-ac6899ca3639" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2a083d83-8419-4f8b-89a0-ff15995dbb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2a083d83-8419-4f8b-89a0-ff15995dbb4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_35dbe69a-45b8-48b2-8a8e-fdffab0c6825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_35dbe69a-45b8-48b2-8a8e-fdffab0c6825" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6aa3b858-8fcd-40a1-ae2d-9ee6cebc5eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6aa3b858-8fcd-40a1-ae2d-9ee6cebc5eb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_84d3dac5-074c-4b87-8391-1a8111f8f7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_84d3dac5-074c-4b87-8391-1a8111f8f7ed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0b96d72c-22ff-4d57-a36b-3466283f336e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0b96d72c-22ff-4d57-a36b-3466283f336e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_a940faa7-1f00-44c1-b8de-ce0831b53fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_IncomeTaxReceivable_a940faa7-1f00-44c1-b8de-ce0831b53fd6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureTable_bb249e8d-8f64-4adc-a829-3f839953e794" xlink:href="arvn-20221231.xsd#arvn_IncomeTaxDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_arvn_IncomeTaxDisclosureTable_bb249e8d-8f64-4adc-a829-3f839953e794" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_42a0c8ba-8118-4065-bf51-63e7c2497ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_IncomeTaxDisclosureTable_bb249e8d-8f64-4adc-a829-3f839953e794" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_42a0c8ba-8118-4065-bf51-63e7c2497ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_42a0c8ba-8118-4065-bf51-63e7c2497ee2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_42a0c8ba-8118-4065-bf51-63e7c2497ee2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_42a0c8ba-8118-4065-bf51-63e7c2497ee2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_8da87c75-2a1e-4747-bbae-cd5a528f8495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_42a0c8ba-8118-4065-bf51-63e7c2497ee2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_8da87c75-2a1e-4747-bbae-cd5a528f8495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_29b7f0a6-ff2c-4ec3-b5c2-e8a772790019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8da87c75-2a1e-4747-bbae-cd5a528f8495" xlink:to="loc_us-gaap_ResearchMember_29b7f0a6-ff2c-4ec3-b5c2-e8a772790019" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0f76e86b-7c03-42f1-ab07-0fb37e04393d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_IncomeTaxDisclosureTable_bb249e8d-8f64-4adc-a829-3f839953e794" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0f76e86b-7c03-42f1-ab07-0fb37e04393d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0f76e86b-7c03-42f1-ab07-0fb37e04393d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0f76e86b-7c03-42f1-ab07-0fb37e04393d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0f76e86b-7c03-42f1-ab07-0fb37e04393d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a80822ca-d92d-4daf-8f1b-4b84d56758f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0f76e86b-7c03-42f1-ab07-0fb37e04393d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a80822ca-d92d-4daf-8f1b-4b84d56758f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4894bed7-46d9-46ca-a645-5676a49cb389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a80822ca-d92d-4daf-8f1b-4b84d56758f3" xlink:to="loc_us-gaap_DomesticCountryMember_4894bed7-46d9-46ca-a645-5676a49cb389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_b3aa4eef-be1f-41a1-b787-2fb299acb68c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a80822ca-d92d-4daf-8f1b-4b84d56758f3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_b3aa4eef-be1f-41a1-b787-2fb299acb68c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ib57eca3288c84c3fba22176a965ed0bb_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:href="arvn-20221231.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a5e6ce8-0c8d-421f-ba49-b5b38309f2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a5e6ce8-0c8d-421f-ba49-b5b38309f2a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AnnualLicenseFeePayment_1c2d693c-91d5-49b4-be39-4af125d154fa" xlink:href="arvn-20221231.xsd#arvn_AnnualLicenseFeePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:to="loc_arvn_AnnualLicenseFeePayment_1c2d693c-91d5-49b4-be39-4af125d154fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RequiredMilestonePayments_13c52033-23c0-4e2f-b497-f8c706b1510a" xlink:href="arvn-20221231.xsd#arvn_RequiredMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:to="loc_arvn_RequiredMilestonePayments_13c52033-23c0-4e2f-b497-f8c706b1510a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_29ed867e-5006-48fd-a8f7-53559ae0b1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:to="loc_us-gaap_PaymentsForRoyalties_29ed867e-5006-48fd-a8f7-53559ae0b1b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_d1baaa45-0590-4121-986a-61be83695635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_d1baaa45-0590-4121-986a-61be83695635" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:href="arvn-20221231.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:to="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a34600cb-6179-4aa3-b84d-9811cf94a32c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:to="loc_srt_RangeAxis_a34600cb-6179-4aa3-b84d-9811cf94a32c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a34600cb-6179-4aa3-b84d-9811cf94a32c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a34600cb-6179-4aa3-b84d-9811cf94a32c" xlink:to="loc_srt_RangeMember_a34600cb-6179-4aa3-b84d-9811cf94a32c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54f627d3-d3c3-4329-b78b-3e449cd878c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a34600cb-6179-4aa3-b84d-9811cf94a32c" xlink:to="loc_srt_RangeMember_54f627d3-d3c3-4329-b78b-3e449cd878c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_961cbfdd-c3c3-4815-aef0-296c3d512010" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54f627d3-d3c3-4329-b78b-3e449cd878c5" xlink:to="loc_srt_MinimumMember_961cbfdd-c3c3-4815-aef0-296c3d512010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa79b5cd-472e-467b-9b10-f43c112b8724" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54f627d3-d3c3-4329-b78b-3e449cd878c5" xlink:to="loc_srt_MaximumMember_fa79b5cd-472e-467b-9b10-f43c112b8724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9742a7b-44ed-419b-a241-25eff1764124" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:to="loc_srt_CounterpartyNameAxis_a9742a7b-44ed-419b-a241-25eff1764124" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9742a7b-44ed-419b-a241-25eff1764124_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a9742a7b-44ed-419b-a241-25eff1764124" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9742a7b-44ed-419b-a241-25eff1764124_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f1baf9b-4bf6-460b-81ff-f33d29a53b6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a9742a7b-44ed-419b-a241-25eff1764124" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f1baf9b-4bf6-460b-81ff-f33d29a53b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_YaleUniversityMember_dcd607e0-3572-46d3-bd15-9361cba52251" xlink:href="arvn-20221231.xsd#arvn_YaleUniversityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f1baf9b-4bf6-460b-81ff-f33d29a53b6f" xlink:to="loc_arvn_YaleUniversityMember_dcd607e0-3572-46d3-bd15-9361cba52251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FoundationMedicineIncMember_54acda42-f7ef-45e5-b3d6-cafa4fe0fa8d" xlink:href="arvn-20221231.xsd#arvn_FoundationMedicineIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f1baf9b-4bf6-460b-81ff-f33d29a53b6f" xlink:to="loc_arvn_FoundationMedicineIncMember_54acda42-f7ef-45e5-b3d6-cafa4fe0fa8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d2a958d3-d0a8-4362-8287-c7a0c2698c5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:to="loc_srt_ProductOrServiceAxis_d2a958d3-d0a8-4362-8287-c7a0c2698c5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2a958d3-d0a8-4362-8287-c7a0c2698c5d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d2a958d3-d0a8-4362-8287-c7a0c2698c5d" xlink:to="loc_srt_ProductsAndServicesDomain_d2a958d3-d0a8-4362-8287-c7a0c2698c5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a224918-5d5e-4e80-968d-cc6bf1ffd89e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d2a958d3-d0a8-4362-8287-c7a0c2698c5d" xlink:to="loc_srt_ProductsAndServicesDomain_1a224918-5d5e-4e80-968d-cc6bf1ffd89e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseFirstLicensedProductMember_d12928a6-fa10-495c-accd-7f2f0a31ecf4" xlink:href="arvn-20221231.xsd#arvn_LicenseFirstLicensedProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a224918-5d5e-4e80-968d-cc6bf1ffd89e" xlink:to="loc_arvn_LicenseFirstLicensedProductMember_d12928a6-fa10-495c-accd-7f2f0a31ecf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseSecondLicensedProductMember_c2b63be9-2ee8-4abc-855f-b2296e415607" xlink:href="arvn-20221231.xsd#arvn_LicenseSecondLicensedProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a224918-5d5e-4e80-968d-cc6bf1ffd89e" xlink:to="loc_arvn_LicenseSecondLicensedProductMember_c2b63be9-2ee8-4abc-855f-b2296e415607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10999837-34f0-4273-8641-ea580b7ea0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10999837-34f0-4273-8641-ea580b7ea0ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10999837-34f0-4273-8641-ea580b7ea0ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10999837-34f0-4273-8641-ea580b7ea0ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10999837-34f0-4273-8641-ea580b7ea0ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa038fac-2a15-4b7d-98cc-376078d49cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10999837-34f0-4273-8641-ea580b7ea0ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa038fac-2a15-4b7d-98cc-376078d49cda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember_b1e1f813-90d1-462b-94c0-2f7024923dc2" xlink:href="arvn-20221231.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa038fac-2a15-4b7d-98cc-376078d49cda" xlink:to="loc_arvn_SuccessBasedMilestonePaymentsMember_b1e1f813-90d1-462b-94c0-2f7024923dc2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails" xlink:type="extended" id="i420e87cfc98d4d2b99efb9229ed966b2_NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7cfb3e84-923e-4771-b2b2-07413576cea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ddc40742-a762-4f30-8dfb-aa72d92c8e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7cfb3e84-923e-4771-b2b2-07413576cea1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ddc40742-a762-4f30-8dfb-aa72d92c8e68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_363abcf3-17cb-4dc8-9ded-a3a48d5787fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7cfb3e84-923e-4771-b2b2-07413576cea1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_363abcf3-17cb-4dc8-9ded-a3a48d5787fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1652e14-f558-4c7d-83f8-e436e3efcbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_363abcf3-17cb-4dc8-9ded-a3a48d5787fd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1652e14-f558-4c7d-83f8-e436e3efcbd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1652e14-f558-4c7d-83f8-e436e3efcbd0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1652e14-f558-4c7d-83f8-e436e3efcbd0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1652e14-f558-4c7d-83f8-e436e3efcbd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93a36506-308d-4f4f-908c-8e101e8f9edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1652e14-f558-4c7d-83f8-e436e3efcbd0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93a36506-308d-4f4f-908c-8e101e8f9edd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_791ac8a5-1f6b-4245-b4b7-ccf80e7c416c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93a36506-308d-4f4f-908c-8e101e8f9edd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_791ac8a5-1f6b-4245-b4b7-ccf80e7c416c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ba9aedba-564e-419d-95c7-9a1836416f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93a36506-308d-4f4f-908c-8e101e8f9edd" xlink:to="loc_us-gaap_RestrictedStockMember_ba9aedba-564e-419d-95c7-9a1836416f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_42632b4c-21a3-4841-a314-b48b095ea44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93a36506-308d-4f4f-908c-8e101e8f9edd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_42632b4c-21a3-4841-a314-b48b095ea44d" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>arvn-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e632b970-0fa5-4bd1-afa0-85cac57f3761,g:02db76aa-3c10-4220-82b9-6cc6c0294fe6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_RestatementAxis_267ecc24-3b6e-4cfc-8ade-2d020fb91d12_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0f25a70-7e45-4b8c-b22d-e974c98bc92b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_832b3fc8-aaa2-4272-aa94-24151c172175_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_db9d98e3-d971-4f93-adb3-92a20fe878a5_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_2f9a4645-3e8a-4095-93d0-2c729fc3ac0d_terseLabel_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="arvn-20221231.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1285b6d5-cef4-4e30-9119-843e7c16664e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e0d764b2-7b97-478b-899a-923d3f329c35_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_aec6c899-7807-47b0-bc14-a071889bd0aa_terseLabel_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing 2023 -2024</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:to="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e5767356-f4f9-49d1-b9d2-3d78df8fc17c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ff03c10b-cbdf-4258-b93b-492855e92d39_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_34e0d474-6a67-4930-b87c-080ac196c4b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f69ee146-d41c-4ad7-841b-457e2e658bb4_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e263da69-a346-4a49-960e-8cebec3f7f04_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_fac2aca4-3a31-4e4a-9675-d5b97b37a7e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0e03d596-adeb-4454-9ffd-03b257d20400_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and leasehold improvements, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_54e03d2f-4c6e-42bb-8b86-2ea5591179a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_fe32b34d-94b2-437d-8015-44f8fa159603_negatedLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="arvn-20221231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7089773f-5eb7-4d09-a157-afb1b8426ce4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3ea566d0-bf93-4eb0-9e73-2ee63afddb8d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_2afdc9d7-8ec8-44f9-8d1f-79b9b6773503_terseLabel_en-US" xlink:label="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal deposit insurance corporation premium expense</link:label>
    <link:label id="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_label_en-US" xlink:label="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Deposit Insurance Corporation Premium Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_documentation_en-US" xlink:label="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:href="arvn-20221231.xsd#arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:to="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_863c6fbd-4694-41b9-b26e-cffea5ec3271_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetPledgedAsCollateralMember_77fab501-8061-4282-ab86-17d43d304cce_terseLabel_en-US" xlink:label="lab_us-gaap_AssetPledgedAsCollateralMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Pledged as Collateral</link:label>
    <link:label id="lab_us-gaap_AssetPledgedAsCollateralMember_label_en-US" xlink:label="lab_us-gaap_AssetPledgedAsCollateralMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Pledged as Collateral [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetPledgedAsCollateralMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetPledgedAsCollateralMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetPledgedAsCollateralMember" xlink:to="lab_us-gaap_AssetPledgedAsCollateralMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c364dd83-a695-4876-ae22-686e1f1ce0d5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_19f8934a-bf32-4f1f-aad0-0727db451c01_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_52fe5ef0-8025-4406-a1b8-65a79a6c62a5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9f9c2c1d-11b9-4189-8f31-b70a970f1c45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_27407c58-bdf4-474b-97d1-6c1a3ceab346_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_06ef3d14-92cc-4e05-aa60-82eace54ab9b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate per annum</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04686b3d-6ec0-4e1d-aa88-6696958356dc_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_51a2a34d-1b3a-48d3-a08a-50a8a8b7cf82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_0eb5c634-83ac-4c34-ab12-760accb28fc7_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AnnualLicenseFeePayment_ac23eaf6-6f59-49c4-af73-5c344faeb393_terseLabel_en-US" xlink:label="lab_arvn_AnnualLicenseFeePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual payment for license</link:label>
    <link:label id="lab_arvn_AnnualLicenseFeePayment_label_en-US" xlink:label="lab_arvn_AnnualLicenseFeePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual License Fee Payment</link:label>
    <link:label id="lab_arvn_AnnualLicenseFeePayment_documentation_en-US" xlink:label="lab_arvn_AnnualLicenseFeePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license fee payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AnnualLicenseFeePayment" xlink:href="arvn-20221231.xsd#arvn_AnnualLicenseFeePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AnnualLicenseFeePayment" xlink:to="lab_arvn_AnnualLicenseFeePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_deea7114-0894-4377-84cd-c63312925bdc_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_4a62667a-2ba6-4166-905f-367d11ed0bd1_terseLabel_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable" xlink:href="arvn-20221231.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommitmentsAndContingenciesTable" xlink:to="lab_arvn_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_14489e88-374b-4b78-a9ac-346ffc0b3371_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5f3218e3-ee53-4536-8de4-fdfb0828d64c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fbff964e-e607-44e8-9ee3-8d27609a1a8a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_be04531c-568d-4e88-a96f-b83218e10b7c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_61cbc6bf-5cb1-4dec-89d6-99fb45d37112_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_abcd5eea-a407-4154-a128-1e824ebae092_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from the computations of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesTable_7e7d5d59-0e48-4143-a705-ea7e73600cd5_terseLabel_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant of accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:href="arvn-20221231.xsd#arvn_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5d42d781-0d01-4be2-bc9e-a5d597dcdfc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of minimum future principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0b10b12b-def4-4c22-9d18-2cfa757b9437_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_bbd08b09-787f-4a3b-9063-98112ff545d5_terseLabel_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing 2024</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:href="arvn-20221231.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:to="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c1fd2a06-0f0c-46c8-9525-c4740163eb36_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_377f623f-6853-459e-8aae-64fc1ae3972f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_4e9df0af-40fc-438b-a1d9-c9198fb39291_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_95c4787c-bbad-4f0e-aa91-64e97c3dde3b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-recurring fair value measurements</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_6bd2f003-4d72-4180-b84a-f33e3c231b9b_terseLabel_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone Payments</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember" xlink:href="arvn-20221231.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SalesBasedMilestonePaymentsMember" xlink:to="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_403b7f5a-9fff-4c4d-b084-9bf8bfd0a53b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases for tax positions taken during the current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_30e14ca7-16b3-4878-96f1-f8e3f6a6d850_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_e5ebd977-83ea-4d8f-b901-c114ef331e28_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Use Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_82a23d87-c1d8-4479-bc15-ca03c8cf876a_terseLabel_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future grant of incentive units to service providers, percentage</link:label>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_label_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Grant Of Incentive Units To Service Providers Percentage</link:label>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_documentation_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future grant of incentive units to service providers, percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:href="arvn-20221231.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:to="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_ba226b78-1c9e-4fcf-a6a7-262c76054bc5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e05d81b8-4a0a-473a-94d5-acf338701178_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ffffb406-6d0e-4525-9f5b-1fbae4055889_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_bd6549c1-f6c2-4718-86e6-8c5f85f4e6f5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue receivable if milestones achieved</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_997fadf1-e6e4-4f55-9133-15393770f61e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_f464bcae-e836-4d22-a82f-9e53e856950a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecurities_8b1189e0-86a0-4a3e-b4fc-ff161a0c8132_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecurities_label_en-US" xlink:label="lab_us-gaap_DebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecurities" xlink:to="lab_us-gaap_DebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4c34097a-4109-4ca6-b330-d07264608c78_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_83a5e4c7-7e19-4afa-9bcc-01fd156edb5a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_2b583ee3-2aca-4c61-b204-dddea6ec10c9_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of restricted stock award activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b6ad3ff9-3fda-4f1d-9c3e-81bc06327609_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fdff2a88-8792-43e4-962e-6b63a5dbe124_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7ec2cc4c-25f2-4012-811b-1f4bc30eb504_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_2fe554dd-5311-4f7e-85ca-33e73400485c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_30bc8cef-c28e-46ec-a95b-1c79260ff795_terseLabel_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_label_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Additions</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_documentation_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:href="arvn-20221231.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:to="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a220f0c8-c0cf-4ad0-a697-b2c58dae939c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f7ad5568-4811-4d32-861c-a4d8f16b8d81_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgedStatusAxis_ae087b45-7bca-49aa-be57-6fd7023185c1_terseLabel_en-US" xlink:label="lab_us-gaap_PledgedStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledged Status [Axis]</link:label>
    <link:label id="lab_us-gaap_PledgedStatusAxis_label_en-US" xlink:label="lab_us-gaap_PledgedStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledged Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgedStatusAxis" xlink:to="lab_us-gaap_PledgedStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_f50a6ed8-3db8-4825-b45e-be9620054f20_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2c4bb276-1d41-4309-8ec0-a423ff732855_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term (years), outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_255c8f18-817c-44f7-8523-4b724a20099f_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price, issued and sold (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_8cc3d242-b69c-4fe6-93e7-100429e71e6c_periodStartLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_a05d4ee5-b20d-4659-9b79-b9942d120a6f_periodEndLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent" xlink:href="arvn-20221231.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrent" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_dfcec7c9-08c4-4032-9bb3-78f78d02338f_terseLabel_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing 2022</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:to="lab_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fc259ebd-47a8-463e-bc8b-272eada1c4f0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c19b93fd-a728-4f5a-b499-e119329e34f5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d7ee1ac7-26c5-4839-a9e2-12180362e360_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_e3f1d466-c901-4b4a-8110-d74275d7ffe4_terseLabel_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oerth</link:label>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_label_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oerth Bio Limited Liability Corporation [Member]</link:label>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_documentation_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oerth Bio LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:href="arvn-20221231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:to="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_4165b9eb-e75e-4287-8a27-d1f95c7e43e0_terseLabel_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing 2023</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:href="arvn-20221231.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:to="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cfa0bfe0-bb97-4396-9b45-d4b99df386c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_af9cd1ec-7736-4191-9927-6f4aa3a8eff7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40d1752c-c9ee-4801-b3b4-74fe25e988db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_e225f416-d7d4-4104-b5dd-922792f283b7_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_6c1309e8-7581-4d9d-80e4-b6adf675a040_terseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest payments term</link:label>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_label_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Payments Term</link:label>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_documentation_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest payments term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DebtInstrumentInterestPaymentsTerm" xlink:to="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_691e6360-5f27-4b9b-a434-adcee99a20e2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_31cd450a-81eb-4def-ba56-3e129a092598_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a7004569-017c-4e40-80e0-e71fcd0709cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_735d78a3-6701-4273-a266-c438d095cabc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f54c01bb-f261-4581-b2b9-a9b82ec300ba_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ea1947a3-67be-4afb-8a42-ceeab3d088b0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_9a63ecdd-c581-4180-8a56-d11dc351b840_terseLabel_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember" xlink:href="arvn-20221231.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DevelopmentMilestonePaymentsMember" xlink:to="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_df729a9f-feb6-472b-83ec-9ef7f0efd21a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4e553068-860a-49d3-8c7a-bf4f191ffb9f_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_b44f404b-b819-48af-8a34-251d1e65e642_terseLabel_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_label_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember" xlink:href="arvn-20221231.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EquityDistributionAgreementMember" xlink:to="lab_arvn_EquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2e063133-eafc-4c29-82a6-a743fcf4e1e6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73c33355-cfda-4a17-9742-b82714d733dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RequiredMilestonePayments_22e8ad37-0c52-44af-8dd4-b2674ca226a8_terseLabel_en-US" xlink:label="lab_arvn_RequiredMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required milestone payments</link:label>
    <link:label id="lab_arvn_RequiredMilestonePayments_label_en-US" xlink:label="lab_arvn_RequiredMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required Milestone Payments</link:label>
    <link:label id="lab_arvn_RequiredMilestonePayments_documentation_en-US" xlink:label="lab_arvn_RequiredMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RequiredMilestonePayments" xlink:href="arvn-20221231.xsd#arvn_RequiredMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RequiredMilestonePayments" xlink:to="lab_arvn_RequiredMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_c4deb6a5-35d0-40e2-840c-25cc1848fcb0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_39404015-bb0f-4af6-baf1-bab01754eecc_terseLabel_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities: Deferred revenue</link:label>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="arvn-20221231.xsd#arvn_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_92fb57de-d014-4c0b-a980-1c94bde00b3b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_198b18cf-d733-4998-8b33-8996ad969d65_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_df591343-cf73-44b3-8367-ab52017c7700_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cf56755b-3359-438e-bb6b-6e9d11cb5cb7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BaseLeaseRentPeriod_33e3bccd-1a95-4e65-a1a1-d3dca7afbfca_terseLabel_en-US" xlink:label="lab_arvn_BaseLeaseRentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent period</link:label>
    <link:label id="lab_arvn_BaseLeaseRentPeriod_label_en-US" xlink:label="lab_arvn_BaseLeaseRentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Lease Rent Period</link:label>
    <link:label id="lab_arvn_BaseLeaseRentPeriod_documentation_en-US" xlink:label="lab_arvn_BaseLeaseRentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Lease Rent Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BaseLeaseRentPeriod" xlink:href="arvn-20221231.xsd#arvn_BaseLeaseRentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BaseLeaseRentPeriod" xlink:to="lab_arvn_BaseLeaseRentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_2dcc69ca-46c2-4454-9695-13c13f4eb604_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease for laboratory and office space (in square feet)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_da68d91f-e7e2-4c22-938f-bac35ff87b75_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_17481c33-e6b6-4433-bccd-a207d988c4c0_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5ec28da-255a-40db-b5da-3ad1cca02a81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_04874a81-6a93-4626-8704-cada3bd1969f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_10e351ae-2860-4986-9b8f-120ad6d1b741_terseLabel_en-US" xlink:label="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label id="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="arvn-20221231.xsd#arvn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5968b583-3eda-4237-a106-47302a53511b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a00c6eed-ee28-445c-b11f-a9c2ebeded7c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_afc76ae0-789b-4033-82b5-31f471f66dc9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_366e3d1a-ae30-4041-9eb6-c3e7220570fa_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_94418469-cf92-4c12-afdf-0ac9a5fa6c7b_terseLabel_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing 2024-2025</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_label_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Five [Member]</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_documentation_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:to="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForBrokerageFees_a90eabeb-6dae-498a-bd9c-99bac47a8060_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForBrokerageFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial advisor fees</link:label>
    <link:label id="lab_us-gaap_PaymentsForBrokerageFees_label_en-US" xlink:label="lab_us-gaap_PaymentsForBrokerageFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Brokerage Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForBrokerageFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForBrokerageFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForBrokerageFees" xlink:to="lab_us-gaap_PaymentsForBrokerageFees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_94cca33b-460d-4bb1-a23b-23fd6c335e76_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1b635da8-ee44-4462-a5c7-3d662d68633f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f51f2c27-811f-440d-8c55-3c0d18a5b8a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases for tax positions taken during a prior period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_115bc3e4-de9b-491b-abbd-e6600e2b2c89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7489b198-165e-45da-b9f1-6619a2c7368c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7bc163b8-816a-466f-b56f-4e0e94bf1c89_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaboratorTwoMember_5a041a10-3be1-4795-92f8-b2fb3965947e_terseLabel_en-US" xlink:label="lab_arvn_CollaboratorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborator Two</link:label>
    <link:label id="lab_arvn_CollaboratorTwoMember_label_en-US" xlink:label="lab_arvn_CollaboratorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborator Two [Member]</link:label>
    <link:label id="lab_arvn_CollaboratorTwoMember_documentation_en-US" xlink:label="lab_arvn_CollaboratorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborator two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorTwoMember" xlink:href="arvn-20221231.xsd#arvn_CollaboratorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaboratorTwoMember" xlink:to="lab_arvn_CollaboratorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_ed20901d-e68c-467b-9310-7c676919cc20_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ad3f1f48-5651-40ab-8ba2-0b5c72aa57f4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of contract balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_efb1402a-6167-4a3a-9673-3f07e0b90e16_verboseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_f27d9a3e-cf1b-4f2f-8083-66e953055ecb_terseLabel_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing 2023</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:to="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_b6e13241-daf4-4ce5-a667-6d12777127b0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, offering costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock_867767bd-27a1-482c-9a5c-6ba28681c9d0_terseLabel_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental cash flow information related to leases</link:label>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock_label_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases Table [Table Text Block]</link:label>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock_documentation_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:href="arvn-20221231.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:to="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncomeTaxDisclosureLineItems_7356ffb9-135f-48ce-baa6-687cd3f0e109_terseLabel_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_arvn_IncomeTaxDisclosureLineItems_label_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_arvn_IncomeTaxDisclosureLineItems_documentation_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureLineItems" xlink:href="arvn-20221231.xsd#arvn_IncomeTaxDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems" xlink:to="lab_arvn_IncomeTaxDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_96967e0b-19b5-47c2-af73-20d41154e478_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LicenseSecondLicensedProductMember_3111dc2b-2d55-4340-ae7c-104c2b9c58af_terseLabel_en-US" xlink:label="lab_arvn_LicenseSecondLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Second Licensed Product</link:label>
    <link:label id="lab_arvn_LicenseSecondLicensedProductMember_label_en-US" xlink:label="lab_arvn_LicenseSecondLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Second Licensed Product [Member]</link:label>
    <link:label id="lab_arvn_LicenseSecondLicensedProductMember_documentation_en-US" xlink:label="lab_arvn_LicenseSecondLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Second Licensed Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseSecondLicensedProductMember" xlink:href="arvn-20221231.xsd#arvn_LicenseSecondLicensedProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LicenseSecondLicensedProductMember" xlink:to="lab_arvn_LicenseSecondLicensedProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_2e9effb8-8412-42da-915f-3c3a14d974ec_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional consideration received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5a0fd211-9ffd-4884-bea0-4d63d9bb37b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e5726f52-0353-479a-a645-ba4d16088845_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75b504c3-55b5-41b9-b6b0-c9be675c7534_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4444eaa5-622f-43f3-91cd-646ba53039e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_09052940-5952-430d-be70-0ad2009e1131_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7606feac-654a-442c-b274-fe2c90fab622_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f4a7e8e0-19a3-4966-897b-f64ddf376a38_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_ec3b9f90-5e0e-478e-9a99-cf7df8152f78_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e6f00fb1-b813-415a-8753-314424442a0a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4663051d-bbbe-4e93-9d07-0fdd74fe6ae6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_64411b08-21ab-4c44-ba32-7cd7ee2c7e21_terseLabel_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement direct and incremental costs incurred</link:label>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_label_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct And Incremental Costs Incurred To Obtain The Contract</link:label>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_documentation_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct And Incremental Costs Incurred To Obtain The Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:href="arvn-20221231.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:to="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a31c1b9f-b957-4da7-9a5c-e91f08566e40_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_08ce2310-827b-42f4-bd7f-588cefd80f13_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EmployeesDirectorsAndConsultantsMember_c8dd64ae-3c3f-4d8e-91a1-2569ba80a3dc_terseLabel_en-US" xlink:label="lab_arvn_EmployeesDirectorsAndConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees, Directors and Consultants</link:label>
    <link:label id="lab_arvn_EmployeesDirectorsAndConsultantsMember_label_en-US" xlink:label="lab_arvn_EmployeesDirectorsAndConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees Directors And Consultants [Member]</link:label>
    <link:label id="lab_arvn_EmployeesDirectorsAndConsultantsMember_documentation_en-US" xlink:label="lab_arvn_EmployeesDirectorsAndConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees, directors and consultants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesDirectorsAndConsultantsMember" xlink:href="arvn-20221231.xsd#arvn_EmployeesDirectorsAndConsultantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EmployeesDirectorsAndConsultantsMember" xlink:to="lab_arvn_EmployeesDirectorsAndConsultantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_da2bdfbd-6be6-403d-80f1-58b7ddc816e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assumptions used to determine fair value of stock options granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_a1eb594c-5049-4d7c-8586-6007e90eda46_terseLabel_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and marketable securities</link:label>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_label_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:href="arvn-20221231.xsd#arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:to="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7dba1371-edf3-46b9-a8db-957029b7d8b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of income tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66a115e5-b736-4e40-89f2-ae25b608b819_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c153f615-f422-45cf-8099-f01c7a66c49b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7d345f02-63b0-4de4-948d-c26077d1034c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense not yet recognized, period of recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_772cdcaf-4de7-4d09-b3ad-fb2b387ced1c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term (years), exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_19eb0bfe-bd77-46b7-9b7e-9ec9fb2f8473_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fe6e0fe3-010e-4943-9f90-b240e4289a4d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6e8be55-744e-40cf-bb93-c4062da07c38_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, issued and sold</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b0cb4a09-aaf9-4e94-bacf-694fb7e27f83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1686e46f-7d6f-4470-aeae-8e08ac048f95_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgingPurposeAxis_c89f1f89-0b5a-49f3-afe1-c21739dc6319_terseLabel_en-US" xlink:label="lab_us-gaap_PledgingPurposeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledging Purpose [Axis]</link:label>
    <link:label id="lab_us-gaap_PledgingPurposeAxis_label_en-US" xlink:label="lab_us-gaap_PledgingPurposeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledging Purpose [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgingPurposeAxis" xlink:to="lab_us-gaap_PledgingPurposeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_30dac30f-e5c7-44a1-8e89-88bcdae7afa0_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6b551d11-476a-424a-8617-1b99d4ee289a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_895064f6-e44d-4fe3-b3b7-603a3e1107a1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_7987f8ef-79bc-48c9-95aa-eacfc8abdaeb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of correction of immaterial error for the period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_451ac80d-098c-4d29-b1fb-ccc939ad1ef2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments (up to low)</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement_c0d66a0b-5b1d-4cd3-a241-601fa01e491f_terseLabel_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock aggregate offering price</link:label>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement_label_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Common Stock Under Equity Distribution Agreement</link:label>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement_documentation_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price of common stock under equity distribution agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" xlink:href="arvn-20221231.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" xlink:to="lab_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fedd980e-3c6b-473d-9d86-df719f2f0d80_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8ec4356b-4bda-4931-ae6a-db29aaa8e62f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d26f8c43-d2f6-4e3a-b8e9-5f7ae1ba0b47_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_FoundationMedicineIncMember_b6ceac78-ca0f-40b2-b780-bd04e99174e4_terseLabel_en-US" xlink:label="lab_arvn_FoundationMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Medicine, Inc.</link:label>
    <link:label id="lab_arvn_FoundationMedicineIncMember_label_en-US" xlink:label="lab_arvn_FoundationMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Medicine, Inc. [Member]</link:label>
    <link:label id="lab_arvn_FoundationMedicineIncMember_documentation_en-US" xlink:label="lab_arvn_FoundationMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Medicine, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FoundationMedicineIncMember" xlink:href="arvn-20221231.xsd#arvn_FoundationMedicineIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_FoundationMedicineIncMember" xlink:to="lab_arvn_FoundationMedicineIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_513497f6-57be-4d98-9e9d-71fc8b414c59_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ef561fc7-b217-430c-a438-fd424a4aaf9a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_7a75f2b6-cb9e-44e4-b362-d27010dc0bf2_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d4c0f82e-520c-4bb0-a8bf-c00b89455382_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b9586fe2-4304-4176-a80f-30f01e99ffa4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_09acfd2d-fdd3-4658-a628-bd8eb3f6ccb0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_36a8a374-7ebe-469e-b7d5-7d45e05d9f4c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d09a5ff1-3c64-49d3-8ae3-4c5818abadf1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_f0d7691f-1c68-4734-a918-e34fc51b2e9f_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Assistance Agreement</link:label>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_label_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Eighteen Assistance Agreement [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and eighteen assistance agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:href="arvn-20221231.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:to="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e9e08dd6-de01-4a0c-8981-81f1a00f3d9f_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, tax credit, research and development, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_14b53c80-9168-410b-a144-81e92c6d034c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal research tax credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LicenseFirstLicensedProductMember_c49cb331-bfdb-4c83-be71-f3bcb5a3bd25_terseLabel_en-US" xlink:label="lab_arvn_LicenseFirstLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, First Licensed Product</link:label>
    <link:label id="lab_arvn_LicenseFirstLicensedProductMember_label_en-US" xlink:label="lab_arvn_LicenseFirstLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, First Licensed Product [Member]</link:label>
    <link:label id="lab_arvn_LicenseFirstLicensedProductMember_documentation_en-US" xlink:label="lab_arvn_LicenseFirstLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, First Licensed Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseFirstLicensedProductMember" xlink:href="arvn-20221231.xsd#arvn_LicenseFirstLicensedProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LicenseFirstLicensedProductMember" xlink:to="lab_arvn_LicenseFirstLicensedProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2586af27-b06b-430d-a516-80b3df338ccc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_9cebdb34-1145-460c-b3b1-4d9616de8c02_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c10257d5-3ff9-4771-bfb5-cfabc9d3d9f4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForUnderwritingExpense_72a4e6e6-3c39-4f7e-90ad-68081675fb84_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees and expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsForUnderwritingExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Underwriting Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForUnderwritingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForUnderwritingExpense" xlink:to="lab_us-gaap_PaymentsForUnderwritingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_89df95af-bbf4-493d-8bff-09d3a142b17a_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_a09539be-c562-4c21-88f1-3d94d05cc915_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Tax Credits</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d21d063d-4deb-404b-b3b3-4c5447ebf146_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_c949faeb-ac54-4c71-b2cf-bf0847829999_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7e184baf-16d4-41b5-a795-b63b93579bcf_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0c23d882-9c02-4007-a16f-d7a077ab09d9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3d1cb435-be31-4c37-9fb6-2bf5be897a55_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, tax credit, research and development</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_8e315fdf-a025-44c3-98ab-7e10f6c0f0a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_ddbcc64b-bdc8-4190-9248-d5dbe2348a43_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">adjustments</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_eb2b8451-5f3a-469c-aa67-effe74793f43_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommercialMilestonesMember_8ab16930-08c3-43c6-a2b8-ee35a432bbff_terseLabel_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestones</link:label>
    <link:label id="lab_arvn_CommercialMilestonesMember_label_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_arvn_CommercialMilestonesMember_documentation_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember" xlink:href="arvn-20221231.xsd#arvn_CommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommercialMilestonesMember" xlink:to="lab_arvn_CommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_833c695b-bd5c-4562-9cb5-27c214bc0fa7_terseLabel_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration contract asset and other assets</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_label_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Contract Asset And Other Assets</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_documentation_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Contract Asset And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets" xlink:href="arvn-20221231.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborationContractAssetAndOtherAssets" xlink:to="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1a042161-75e0-4545-bde3-9ba06dc13d54_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_f57732ab-cfd5-4d31-b5c3-4fbbf1a4ca3b_terseLabel_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable related to collaborations</link:label>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounts Payable, after Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounts Payable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:href="arvn-20221231.xsd#arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:to="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_65c510ad-9387-4cf2-b9bb-32c760f0bf51_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d4d228b8-e7a9-40dc-8a18-9778cf4573a0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_afd43173-9c9b-4579-b8c3-2f9cd30da0e0_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AuditInformationAbstract_label_en-US" xlink:label="lab_arvn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_arvn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_arvn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AuditInformationAbstract" xlink:href="arvn-20221231.xsd#arvn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AuditInformationAbstract" xlink:to="lab_arvn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_d56a89c6-9083-4736-a44e-8f9e9bca8edc_terseLabel_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-Based Milestone Payments</link:label>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-Based Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-Based Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember" xlink:href="arvn-20221231.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SuccessBasedMilestonePaymentsMember" xlink:to="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f67a45e7-1a10-4e9a-b1e5-a44979d15d21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f858c89e-6b0b-4e9c-bbe5-183bbe432157_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_615a5a29-11fd-42b0-86b7-7a5ecf7314b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d13b0432-ee85-41bd-b2e7-8fc66ef0681c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_3c93f32d-ab0c-4eea-9cd0-cc02dac9f609_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_68460bf0-fcdd-413b-a776-4dba786065c6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_91f92242-b285-4313-b5dd-32889abb605d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_7bc6a845-da00-4181-92eb-16e195b97696_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_label_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand eighteen stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:href="arvn-20221231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:to="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d00da7bf-f181-4eaa-aa41-968dc6914d1b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_449a020c-08ef-45e1-812d-db0cd2e42e3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_fcf3cd42-453d-4583-ab04-412a1106db30_terseLabel_en-US" xlink:label="lab_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return to provision</link:label>
    <link:label id="lab_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_label_en-US" xlink:label="lab_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision, Percent</link:label>
    <link:label id="lab_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_documentation_en-US" xlink:label="lab_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:href="arvn-20221231.xsd#arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:to="lab_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_fe5b68ce-5ef5-49ef-8589-9cbb884ae31c_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to collaboration agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_label_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:href="arvn-20221231.xsd#arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:to="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_ad751b63-cf51-4b42-a974-882119a6dd61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_12a97922-1b52-4e16-a53e-5994f2fa3938_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0e96a829-c1aa-4ca0-8eb0-d57179e18b52_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1c63175f-c7d5-49b1-a3e2-ab317b12e2d1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7c4c295e-5cb6-443f-b071-f437102ea46e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_76fe645f-3ce9-47f2-be4f-e02edbde184d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_64686539-6823-422c-8234-fc32f9afaf11_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price allocated to performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_b9563fdb-6ff1-483a-a067-ad8f52090a95_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b1c26f89-c8d9-4be9-8b4a-beec91976ba3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4b52dc69-cce7-4760-a05e-58cf417d4e94_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_b55ac0b1-5976-4a76-89bf-e44b97fa3a38_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_fc96eade-9afb-433e-868a-d2778f3b69f7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_408b6a1a-8845-4aaf-b97f-0ad4c4ff6623_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_a7652361-9bf2-4d74-a952-180bc668b8da_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of collaboration contract asset</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_c43f726b-aa8c-4602-87e9-df7e6b87902e_negatedLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_50671d38-1185-47f7-be31-a8c31b1fb659_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a3592a68-e332-475d-aae6-a17a42798c92_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_e9645cc0-9dc4-45ad-81fa-186bde2e8a66_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_549e6fa3-3941-4af1-b279-84b429fe288b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_42805644-2365-4b8b-92b9-15b7056a2616_terseLabel_en-US" xlink:label="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating losses carry forward, maximum deductibility percentage</link:label>
    <link:label id="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_label_en-US" xlink:label="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses Carry Forward Maximum Deductibility Percentage</link:label>
    <link:label id="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_documentation_en-US" xlink:label="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating losses carry forward, maximum deductibility as a percentage of taxable income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:href="arvn-20221231.xsd#arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:to="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_052515ab-883e-46ab-ad8b-8585e533f8a8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d3a615d1-83ff-47a9-aac5-de2ea69babb7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense for options not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PercentageOfMaximumFundingOnProjectCosts_ec97c03e-8ad9-4185-b7a7-743db43d41dc_terseLabel_en-US" xlink:label="lab_arvn_PercentageOfMaximumFundingOnProjectCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of maximum funding on total project costs</link:label>
    <link:label id="lab_arvn_PercentageOfMaximumFundingOnProjectCosts_label_en-US" xlink:label="lab_arvn_PercentageOfMaximumFundingOnProjectCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Maximum Funding On Project Costs</link:label>
    <link:label id="lab_arvn_PercentageOfMaximumFundingOnProjectCosts_documentation_en-US" xlink:label="lab_arvn_PercentageOfMaximumFundingOnProjectCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of maximum funding on project costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfMaximumFundingOnProjectCosts" xlink:href="arvn-20221231.xsd#arvn_PercentageOfMaximumFundingOnProjectCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PercentageOfMaximumFundingOnProjectCosts" xlink:to="lab_arvn_PercentageOfMaximumFundingOnProjectCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_accede9f-cd3a-4439-9dcf-c3a7d6f7b874_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_dfa4dd4d-1f0d-470f-b80e-2412aa7e7e24_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_b5f828d1-30e0-4d23-9827-443a2f56cf2f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2a81f860-e409-4bd8-a19b-ac86299d86ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares remained available for purchase and issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6fe6c8c8-0fc8-4a72-bb51-c085ff24a5e0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_df737dd1-a42e-476b-a1e0-51739decde71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_abcfda98-8949-4985-af4c-092d15e0e3a5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_368df25e-5eed-4d67-a853-0c57e7ac293b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_dea2001d-d168-41fb-bb45-916e103fca8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_NumberOfWhollyOwnedSubsidiaries_ee43ad28-7fea-482f-804b-208369d0f723_terseLabel_en-US" xlink:label="lab_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholly owned subsidiaries</link:label>
    <link:label id="lab_arvn_NumberOfWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_arvn_NumberOfWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholly owned subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:href="arvn-20221231.xsd#arvn_NumberOfWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:to="lab_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_feb8823c-5bc1-4385-8741-08558e513df5_terseLabel_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash information:</link:label>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_label_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Non Cash Information Related To Leases [Abstract]</link:label>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_documentation_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:href="arvn-20221231.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:to="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_1fc70a07-9dd0-49fc-af6c-33bf4c9d51ae_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2c3aa4ba-e4fc-4c9e-a746-8d29024db52b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c3082157-b791-4eed-add4-369572943a91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_850d25c8-244e-4044-802f-f7d56a73155f_terseLabel_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Funding Payments</link:label>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_label_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Funding Payments [Member]</link:label>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_documentation_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research funding payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember" xlink:href="arvn-20221231.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchFundingPaymentsMember" xlink:to="lab_arvn_ResearchFundingPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_833844ba-b010-467c-b744-2cd06e9d49e6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0e705a6a-6535-4545-8139-382e2d07c202_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9bfb40f3-aee5-4aa6-a01c-439395647f51_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8450eb54-8454-41d6-9dbf-9e361cd18cf2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f9cf7ff6-0aa8-4457-b318-545582051e68_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c3770c6a-8897-4685-abdc-94cb2cc7931c_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ccda2280-1cb5-4efd-8054-a6e4ec8c77a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_fae3df15-d3fa-4a5d-a05c-fe1eab2709e3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8c0d2c51-a058-465c-9a9e-6050c1739316_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_a3ce0ae1-96cd-4dc8-8234-6ef033f6e202_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0029e2a9-e34f-40b8-8ea2-5752c008bbf1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_fa9aa4e6-fc71-444f-ade4-1477b9f5806e_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_label_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturities Of Marketable Securities</link:label>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:to="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0de450d9-3ca5-4672-9db0-1ff2f8446abf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CT_d63197ad-57ba-4690-8398-59de1ab2a217_terseLabel_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State of Connecticut</link:label>
    <link:label id="lab_stpr_CT_label_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONNECTICUT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CT" xlink:to="lab_stpr_CT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_b23130c9-fd91-4e8f-b7f2-c5279a88c6c8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_5b6fb2a0-1a3c-464d-b42a-12c1196e03df_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_StockIncentivePlanMember_753a8500-1fbb-44e4-8c48-7d5ed15a1505_terseLabel_en-US" xlink:label="lab_arvn_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Plan</link:label>
    <link:label id="lab_arvn_StockIncentivePlanMember_label_en-US" xlink:label="lab_arvn_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_arvn_StockIncentivePlanMember_documentation_en-US" xlink:label="lab_arvn_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember" xlink:href="arvn-20221231.xsd#arvn_StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_StockIncentivePlanMember" xlink:to="lab_arvn_StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_10b16a09-f50f-4464-9977-0266e2142154_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_8477d371-726c-47bc-b59b-30504e2a0fe6_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d8012be8-0a97-4c47-91c8-2331d501b2e2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5c7a8748-a12d-491f-b54f-9fa639b91f71_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_890e678b-0e79-489c-ac81-6e2eee1b0070_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a249d7d7-0c6c-46be-addc-637e86688943_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00693391-ab1e-459e-902e-c443f58798ce_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_71ad362b-9071-46cd-84f7-77e7de22f933_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_45b5e3f3-1f1f-4245-a5e5-4fada5be216d_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ff1a51f7-a1c5-4961-a50a-ee98ae7ce6e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_9742ff25-2013-47c3-9082-47ca84b33972_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_label_en-US" xlink:label="lab_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock In A Public Offering</link:label>
    <link:label id="lab_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_documentation_en-US" xlink:label="lab_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in a public offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" xlink:to="lab_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_360c39b3-0278-49b2-b948-736f27418285_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_28852486-1fda-4a64-a249-c3b3a384ce19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_288d5fdb-3f53-4511-a489-c95c426aa5f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6cb60691-6eec-4c29-807f-634d68340732_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_f1e887ac-c080-41e0-b920-aab4195596e3_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_a66bc727-ac6f-499a-8da2-b0187ae224f6_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8b774bf0-ea54-45fd-8258-d082562eb4ef_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_48901fbd-a2f9-4e8f-8fe0-53920948bd3b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_550d6339-7fdb-4d4f-8bbf-6f0c4037e787_negatedTerseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of debt income</link:label>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_28cd6093-f291-453e-997c-7332ae24d79c_terseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan forgiveness</link:label>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_label_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Loan Forgiveness</link:label>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_documentation_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Loan Forgiveness</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DebtInstrumentLoanForgiveness" xlink:to="lab_arvn_DebtInstrumentLoanForgiveness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5d9515b3-3c41-47f2-b6c1-68cc90ece98a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_1106e56b-f7f5-45d2-b87a-6c203ad7fc8f_terseLabel_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Inc. and F. Hoffman-La Roche Ltd.</link:label>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_label_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech Incorporation And F Hoffman La Roche Limited [Member]</link:label>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_documentation_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Incorporation. and F. Hoffman-La Roche Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:href="arvn-20221231.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:to="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems_45c19ab9-641b-4946-9d59-7fa8c1c36476_terseLabel_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="arvn-20221231.xsd#arvn_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_2f46795b-a2ef-4011-9a80-afd87eb582c7_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ab439247-f863-4991-b4e3-34f234f95d33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2d6dcc90-0517-44f0-871b-d243916519dc_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4d8b9a9b-8d05-4035-a1d7-e5edb696d2a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_9baf872f-6fa4-49b3-8035-8701c752e3aa_terseLabel_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of liquidated damages</link:label>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_label_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Liquidated Damages</link:label>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_documentation_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of liquidated damages.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages" xlink:href="arvn-20221231.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PercentageOfLiquidatedDamages" xlink:to="lab_arvn_PercentageOfLiquidatedDamages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3f87835f-9aa3-41d8-9700-ad4cdee64b27_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_be9141f0-cd8a-4df5-8552-4b304a41c81a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6dcf7933-7902-45a3-8358-ee60621e127c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_932695d5-3f33-4525-8dbb-ff56497f7628_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6d726ef2-b3de-48f2-b850-0a653a67e4bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9b0a88f3-f455-4b70-b8f5-8cfb07d99ed0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_dd9723ac-c16a-4c86-9c6d-f0f274625c10_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SaleOfStockFairValueOfSharesSold_959a032f-54db-4d52-8ddc-d071c4c86126_terseLabel_en-US" xlink:label="lab_arvn_SaleOfStockFairValueOfSharesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the shares sold</link:label>
    <link:label id="lab_arvn_SaleOfStockFairValueOfSharesSold_label_en-US" xlink:label="lab_arvn_SaleOfStockFairValueOfSharesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Fair Value Of Shares Sold</link:label>
    <link:label id="lab_arvn_SaleOfStockFairValueOfSharesSold_documentation_en-US" xlink:label="lab_arvn_SaleOfStockFairValueOfSharesSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, fair value of shares sold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SaleOfStockFairValueOfSharesSold" xlink:href="arvn-20221231.xsd#arvn_SaleOfStockFairValueOfSharesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SaleOfStockFairValueOfSharesSold" xlink:to="lab_arvn_SaleOfStockFairValueOfSharesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_167d9c92-cd47-4b28-b7fc-bcf586b041c5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_21cd0fb9-2eef-4013-b9f1-d6cfb66858fd_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables relating to research and development credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReceivable" xlink:to="lab_us-gaap_IncomeTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2e9b63ef-01fc-4a01-abcf-258a9a13dc16_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e713d4cf-c47f-4d7c-8016-d3562595197e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f8e65b49-dff4-44d9-93dc-e5af815f6332_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_29c2f540-c198-4abe-abf8-17bdf2563131_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_03f2ccf3-48fd-4976-93ca-a9368e4c3fda_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c1b6fefd-9168-42fa-8697-d5a77d382bee_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e33aa3c6-1498-4460-bdaa-fafd9a631096_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment, and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ac0a0571-fb22-46d2-a848-5efdf26c96c5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ae283c62-4bc6-43d5-8267-0784d6adf7f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2b3cf24a-b888-4a91-9887-3a249c9e8253_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_6dee0ed4-348b-4b9c-9884-828ea0d9d5c3_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8a46257d-fca6-449a-aa1e-842067d0b2fb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6d2f628c-c2cf-4a00-9050-e34a2e50c152_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_dcfc980e-34bf-4491-8e0d-ec7ad32ab7b5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e6d99534-1964-4d6b-a954-37376a055bae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_c79db84d-89a1-472e-b4ed-73f2f2c1985f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f365d8df-c55f-4847-8a8b-3a7aa92aa048_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f66d717d-0b73-405e-9ce1-a184a8d7ae4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_520dab2d-53b3-4a84-84d2-e4161598c8ba_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_795dbeaf-1cca-4a99-97e0-79e77c3399ba_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborationAgreementMember_160cfc78-da6d-4dfb-aa6f-551d34e053c7_terseLabel_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_arvn_CollaborationAgreementMember_label_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_arvn_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember" xlink:href="arvn-20221231.xsd#arvn_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborationAgreementMember" xlink:to="lab_arvn_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0099e258-1fb4-4e83-b482-19453b696a25_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a8008c01-669a-4afa-8db8-cc8bb1b0f8da_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_42024c51-8e3a-4083-8d84-fabb442bd2ac_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a7db3714-8bd5-461f-a6c3-3dc3a3207202_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_3d798dc7-b81d-47f3-bac6-f3b76148e48b_terseLabel_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems" xlink:href="arvn-20221231.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems" xlink:to="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_ce5f92c7-f26a-4577-a951-78fd1b482386_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in reserved shares of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_754751e5-aa07-4a91-a36e-ffd4f176a812_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 53.2 and 53.0 shares issued and outstanding as of December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d4df4145-4c6e-4ce2-9d8c-148aac2d941f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_434c34c8-1c65-411d-a956-42d3f0fd8506_terseLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current Payments</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:href="arvn-20221231.xsd#arvn_AccountsPayableContractBalancesCurrentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fe930630-e413-47c7-8b44-8d11bf854287_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_605ac729-5765-4ad0-ad1f-dbb4c0e96788_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities excluded from the computation of diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c1e6382c-9de9-4045-af55-1d886f012dec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_NumberOfVotesPerCommonStockShareHeld_19382caa-f3fc-4b83-b693-b2fa9c439a68_terseLabel_en-US" xlink:label="lab_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per common stock share held</link:label>
    <link:label id="lab_arvn_NumberOfVotesPerCommonStockShareHeld_label_en-US" xlink:label="lab_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per common stock share held</link:label>
    <link:label id="lab_arvn_NumberOfVotesPerCommonStockShareHeld_documentation_en-US" xlink:label="lab_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per common stock share held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:href="arvn-20221231.xsd#arvn_NumberOfVotesPerCommonStockShareHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:to="lab_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d71232da-1922-4a78-961d-629d4e2ce05d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f5c23965-ddf1-49fb-80dc-a58e54f6d76a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ae7f84b-e7e5-414c-91f9-3179469b8c03_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3a68320b-e503-4c4e-88ef-4d04b464e33f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3cae3e6e-b0c4-4801-a60d-3ea88d98c5a2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_d6683649-1088-4262-b0c6-dc202259f369_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_97c4f74b-75aa-45f2-ba55-35044e52247b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e3ca32d4-b4a4-468e-8070-d4ca4b4e33ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgedStatusDomain_51d79ada-d814-4baa-8812-48d0194d95ee_terseLabel_en-US" xlink:label="lab_us-gaap_PledgedStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledged Status [Domain]</link:label>
    <link:label id="lab_us-gaap_PledgedStatusDomain_label_en-US" xlink:label="lab_us-gaap_PledgedStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledged Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgedStatusDomain" xlink:to="lab_us-gaap_PledgedStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_0069dda7-5644-4995-8556-d1f11b251e48_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue_2375a015-7444-4103-a484-d714f786dded_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercises weighted average grant date fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" xlink:href="arvn-20221231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6ce62604-2edf-4159-8eec-aa8cdbac1768_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ad9a5ed0-b6b7-4e5d-8040-8763803b3015_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and leasehold improvements unpaid at period end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bd8f1199-90e7-4482-a158-a398ed558634_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6198a1f6-3e5f-4a06-b3bf-22e34fc8e32e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b6e5575-a437-4f09-80c6-650fd2276122_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a7bf89a4-c57f-40c8-a69c-e23d0c0665f0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d694dcc4-7272-4e62-8150-b408e1b6315d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromSaleOfMarketableSecurities_987d6c8c-2660-4c52-87de-1d75fb9f2b73_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of marketable securities</link:label>
    <link:label id="lab_arvn_ProceedsFromSaleOfMarketableSecurities_label_en-US" xlink:label="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Marketable Securities</link:label>
    <link:label id="lab_arvn_ProceedsFromSaleOfMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:to="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_faa24e78-9248-4c26-835e-8b5a15787d8b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e010f2f7-988d-4393-8243-6cb716017672_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_YaleUniversityMember_a6413cc6-81c5-4802-a0ef-86636fdc3204_terseLabel_en-US" xlink:label="lab_arvn_YaleUniversityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yale University</link:label>
    <link:label id="lab_arvn_YaleUniversityMember_label_en-US" xlink:label="lab_arvn_YaleUniversityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yale University [Member]</link:label>
    <link:label id="lab_arvn_YaleUniversityMember_documentation_en-US" xlink:label="lab_arvn_YaleUniversityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yale University.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_YaleUniversityMember" xlink:href="arvn-20221231.xsd#arvn_YaleUniversityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_YaleUniversityMember" xlink:to="lab_arvn_YaleUniversityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f9530b3b-574c-4d0d-b059-1ae40fbf03e5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f71787d7-3b8a-4c55-bf4f-8cbf6328724d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2b6d0cfe-b327-436e-91a2-deb5e1c43f12_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_bf3a17cb-0059-49a2-b5fc-704edf1c7e6b_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7e6f86d8-5c4b-4c6f-8a5c-f40a1c778e2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_9903aeb4-7b4e-4947-b8fe-c7779a7c026e_negatedTerseLabel_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_label_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_documentation_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:href="arvn-20221231.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:to="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2e638252-d615-4729-8910-5f5fe675d884_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e5c4f111-a110-41c7-a4f0-159220ef5e44_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1c3628ef-7cc6-4b11-9505-389df3766310_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30591c58-133b-4bd6-88db-c3312c7d04db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_79f260b9-73c1-4ae4-a1ed-61ed017219fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_b98c8e8a-a983-48ce-9d42-bd6e930be2de_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_eed9ed81-7bb0-4554-819b-e90ff12cc65b_terseLabel_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets: Collaboration contract asset</link:label>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_label_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Collaboration Contract Asset And Other Assets [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Collaboration Contract Asset And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:href="arvn-20221231.xsd#arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:to="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a6b28b90-0d4c-4753-81e2-fad1b7894cc2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ba787fbe-cf01-4e8c-a380-0d3629ca8b4d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_58f079d2-77aa-4420-bf51-8a5764cb7dd2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and leasehold improvements, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ebdd47f2-d417-4c7b-91dd-41cd6e424d5f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and leasehold improvements, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_26031bbe-cda5-4224-a2f4-192b4a98bab8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_ac0548bd-b575-499c-bd0f-00764da2fc9e_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_849b91bd-0920-4af7-8af2-24d0c68846c8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_bbef1b95-ffd0-4e77-8462-ccc0eda01129_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_StockPurchaseAgreementMember_b3e7c0d2-b1be-41bf-be9a-a0a897424ce9_terseLabel_en-US" xlink:label="lab_arvn_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:label id="lab_arvn_StockPurchaseAgreementMember_label_en-US" xlink:label="lab_arvn_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_arvn_StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_arvn_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockPurchaseAgreementMember" xlink:href="arvn-20221231.xsd#arvn_StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_StockPurchaseAgreementMember" xlink:to="lab_arvn_StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d89330f6-117d-4d1b-b979-e932b3435789_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ce70b25-467b-4a2b-9155-46215a84c2e7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_2c174683-5021-40e3-ba6b-1c8a3d8b359d_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3d5daba6-7e31-4978-9c88-166fa9400086_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_21573c7c-25d9-4813-a375-6e0bfb272148_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_4e0020f0-0e05-4bed-a670-d562d8c298ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_728bb2e9-631a-45b6-872a-49490352bd4a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_4d692642-62d3-432c-85a8-c7046de3158b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_4e7fce59-11bb-49d0-93af-a82796f0b8c6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_563a03ed-1c6e-4803-b046-818561e0fbc1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BayerCropScienceLPMember_ca0b9f52-3a20-4106-87f0-1ed085c63635_terseLabel_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer LP</link:label>
    <link:label id="lab_arvn_BayerCropScienceLPMember_label_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Crop Science L P [Member]</link:label>
    <link:label id="lab_arvn_BayerCropScienceLPMember_documentation_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer CropScience LP.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember" xlink:href="arvn-20221231.xsd#arvn_BayerCropScienceLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BayerCropScienceLPMember" xlink:to="lab_arvn_BayerCropScienceLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_db28129c-61e4-41a2-9b54-8015cea2a9ac_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_a4bdb831-dbfa-4213-b46d-465616756228_terseLabel_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense Current</link:label>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="arvn-20221231.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_08fda46a-7aee-489d-b8dd-3eac2aea921b_terseLabel_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Payments</link:label>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_label_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Payments To License Agreement [Member]</link:label>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_documentation_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option payments to license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember" xlink:href="arvn-20221231.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OptionPaymentsToLicenseAgreementMember" xlink:to="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_649d25f4-ec4b-447e-aa23-2f7d991f6aa5_terseLabel_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:href="arvn-20221231.xsd#arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:to="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_7ca9280c-1d11-44ca-89ac-fa29d740bd4a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ac6a3862-1752-4c87-9c24-96447d62c9c0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b8f10beb-ecbf-41a8-b3d7-088ca22359b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c35d3cea-9fc3-4f40-a2b7-21e226552adc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_ca9027b2-10ad-4498-b08a-797c72f84c74_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d68452e6-342e-4454-b8ae-8dd676e0815e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from balances held at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d99dca63-ec4b-4a2b-926d-3f97cfe150b1_netLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_NumberOfMaximumDesignatedTargets_bc0b9d50-38c2-4b20-ae60-99acd70bfddd_terseLabel_en-US" xlink:label="lab_arvn_NumberOfMaximumDesignatedTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of designated targets</link:label>
    <link:label id="lab_arvn_NumberOfMaximumDesignatedTargets_label_en-US" xlink:label="lab_arvn_NumberOfMaximumDesignatedTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Maximum Designated Targets</link:label>
    <link:label id="lab_arvn_NumberOfMaximumDesignatedTargets_documentation_en-US" xlink:label="lab_arvn_NumberOfMaximumDesignatedTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of maximum designated targets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfMaximumDesignatedTargets" xlink:href="arvn-20221231.xsd#arvn_NumberOfMaximumDesignatedTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_NumberOfMaximumDesignatedTargets" xlink:to="lab_arvn_NumberOfMaximumDesignatedTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BayerAGMember_1645f8e7-892f-47cf-8c1c-1b6487aa7657_terseLabel_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer A G</link:label>
    <link:label id="lab_arvn_BayerAGMember_label_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer A G [Member]</link:label>
    <link:label id="lab_arvn_BayerAGMember_documentation_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember" xlink:href="arvn-20221231.xsd#arvn_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BayerAGMember" xlink:to="lab_arvn_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5a3e97e8-67c2-45fa-b079-139ef21085aa_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EmployeesMember_fc5e5699-5bd9-4c34-b61d-1ebf834805ff_terseLabel_en-US" xlink:label="lab_arvn_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_arvn_EmployeesMember_label_en-US" xlink:label="lab_arvn_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees [Member]</link:label>
    <link:label id="lab_arvn_EmployeesMember_documentation_en-US" xlink:label="lab_arvn_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember" xlink:href="arvn-20221231.xsd#arvn_EmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EmployeesMember" xlink:to="lab_arvn_EmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7663f48a-6a12-414e-9256-a8724433d5fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_19de308d-7ef8-445b-98c9-dffdf9fae82d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_92fe941c-8bec-4103-adc1-383fa24adbe1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8eee373f-dc1c-435f-93a9-db09cd64a028_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9d0a102b-c049-4694-89a9-82fe21805950_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1b6102fa-18c8-45ea-b466-9abe394373e6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_36d8e31d-89f9-41f4-aae5-b66b41196694_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fef22d6a-fb2a-44ac-96c8-2c9448f83a8c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_84d166f5-d0bf-4b6c-b72e-53e3984d7e58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbe155f0-9358-42bc-8287-8969b90b09c1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5ceb557e-3a94-4b26-8cfe-2830a7cfa014_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_291b076d-3487-405b-a46a-def6eba0a684_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_e4b8449f-9300-4562-8671-eb9af367168b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_65f23f26-3349-4ff3-a09e-cbf140c81ccc_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_535033ce-4d5a-411b-ad38-b94d827f4f9f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_42fdd8f1-3c99-4efb-98a7-bf7043d9916a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_61d90b8c-5b71-4299-a20c-588f210f898b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e18a1450-4a95-45fe-b8d7-fbb248289f7d_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net accretion of bond discounts/premiums</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_77b466b5-59b7-4d63-9a37-7ea3094bae39_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaboratorThreeMember_f7d8922a-ad1a-4b26-a949-aeeb4aa407f9_terseLabel_en-US" xlink:label="lab_arvn_CollaboratorThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborator Three</link:label>
    <link:label id="lab_arvn_CollaboratorThreeMember_label_en-US" xlink:label="lab_arvn_CollaboratorThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborator Three [Member]</link:label>
    <link:label id="lab_arvn_CollaboratorThreeMember_documentation_en-US" xlink:label="lab_arvn_CollaboratorThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborator three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorThreeMember" xlink:href="arvn-20221231.xsd#arvn_CollaboratorThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaboratorThreeMember" xlink:to="lab_arvn_CollaboratorThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_295cccba-eada-400e-b0a7-c553f5202f18_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">as previously reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_bc667673-7609-4540-8b67-928c3a375c82_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35f6a49d-bc87-4c6f-a610-2ba5e680ec4b_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_08f51c88-f1c6-4fe8-8db7-f0601d6bf27b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_26a0a213-4698-4956-9dcb-350782c2d9fb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cd48d700-938d-42ae-a243-292416ee92e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_493e6012-a0f2-4bfd-955e-3505f98516e3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_13c05c36-0b15-4b76-9200-fef1de4c8f60_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_d99b15d4-53ed-4f88-baa9-ca43cdf3b34b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber_ab2d749a-3149-4214-a7a3-9bcc8de76396_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units expected to vest (in shares)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Expected To Vest Exercisable Number</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Expected To Vest Exercisable Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber" xlink:href="arvn-20221231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_9d5bf7b8-0edd-494e-9190-d66e6bf6734b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_63112d8a-abf8-481e-a3d0-d04dbe0f0b04_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_c4985e01-0042-4aa4-999e-2f6ebb2131bf_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaboratorOneMember_23df3a2f-309d-4bb5-9e59-339b5164882b_terseLabel_en-US" xlink:label="lab_arvn_CollaboratorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborator One</link:label>
    <link:label id="lab_arvn_CollaboratorOneMember_label_en-US" xlink:label="lab_arvn_CollaboratorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborator One [Member]</link:label>
    <link:label id="lab_arvn_CollaboratorOneMember_documentation_en-US" xlink:label="lab_arvn_CollaboratorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborator one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorOneMember" xlink:href="arvn-20221231.xsd#arvn_CollaboratorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaboratorOneMember" xlink:to="lab_arvn_CollaboratorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b4d2c334-65cf-4cbf-a7a5-c8503873db5e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_95854787-4fdb-4e6a-bf7a-bff4d2a75786_terseLabel_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance on outstanding common stock (percentage)</link:label>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_label_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock</link:label>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_documentation_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:href="arvn-20221231.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:to="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_337606de-6867-485a-b690-9dd7697ec8fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d06941a0-8b4d-426d-9c5a-331f6f0eb7bd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fd2c476e-f3b6-44a7-8967-67a3c0f5bb99_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_94ef7b8d-77b4-4411-a464-e550402bb515_terseLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current Additions</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:href="arvn-20221231.xsd#arvn_AccountsPayableContractBalancesCurrentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_c6bbfd66-a521-464e-826e-855d66a6248e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_c096add1-a387-4cc4-bec9-5059410e6fc1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_3bdfac74-53d6-4c2c-8efe-abe9baeb7458_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest, percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ef14cb5a-2f4a-4638-b52c-440398314663_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense, total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_09a2eb2d-4086-43e1-8807-15f4b0c1ada5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4ffd2864-9afc-4151-8512-615d959a5d01_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aa42854f-a172-4be8-a67d-d4c65b6e02ec_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, outstanding, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3d47402c-0740-4473-ace2-e788025b9253_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, outstanding, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PiperSandlerMember_7da87d60-1889-4d4c-b3a2-96b76004f39d_terseLabel_en-US" xlink:label="lab_arvn_PiperSandlerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Piper Sandler</link:label>
    <link:label id="lab_arvn_PiperSandlerMember_label_en-US" xlink:label="lab_arvn_PiperSandlerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Piper Sandler [Member]</link:label>
    <link:label id="lab_arvn_PiperSandlerMember_documentation_en-US" xlink:label="lab_arvn_PiperSandlerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Piper Sandler.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerMember" xlink:href="arvn-20221231.xsd#arvn_PiperSandlerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PiperSandlerMember" xlink:to="lab_arvn_PiperSandlerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromIssuanceOfCommonStockGross_a2ed6a64-a76e-4465-8e89-98570467d001_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock in at-the-market offering</link:label>
    <link:label id="lab_arvn_ProceedsFromIssuanceOfCommonStockGross_label_en-US" xlink:label="lab_arvn_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock Gross</link:label>
    <link:label id="lab_arvn_ProceedsFromIssuanceOfCommonStockGross_documentation_en-US" xlink:label="lab_arvn_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in an at-the-market offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockGross" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromIssuanceOfCommonStockGross" xlink:to="lab_arvn_ProceedsFromIssuanceOfCommonStockGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_960d8d8e-ec1a-448b-a0ee-bbb78272aa1c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_39b81013-552c-4c49-bc7d-797d7154c0e1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_91fbccc0-3332-40cf-8371-99dac61b7a20_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_ed0abb1c-28cb-4b56-aa70-022875cab642_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c652412e-e7ec-4697-bf73-e537f0247c5d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_9715ee48-85d8-4b0c-a3c9-bfd5562a00d5_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b077c03e-0bfa-4fd5-bc62-259efa7fa505_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_98161c18-d622-403d-86e4-0ab9ea33ceb4_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f8c2dfb2-8879-49ce-be58-2b4ed95dcb8b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes and loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_e73c5bd8-95c0-4c01-86aa-eaa13367ebf3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_fe8fc710-8746-42d1-8b2f-b7cad36d1ac6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in reserved shares of outstanding common stock (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c6596f9f-587e-4fa7-aed6-cf97315d097d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_cbbc9625-e1a0-469a-8719-a158a906f200_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue adjustments arising from contract modifications</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PfizerIncorporationMember_c869635d-0394-478c-939f-d54da84e42bc_terseLabel_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, Inc.</link:label>
    <link:label id="lab_arvn_PfizerIncorporationMember_label_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Incorporation [Member]</link:label>
    <link:label id="lab_arvn_PfizerIncorporationMember_documentation_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember" xlink:href="arvn-20221231.xsd#arvn_PfizerIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PfizerIncorporationMember" xlink:to="lab_arvn_PfizerIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_b254075b-b476-46e7-b7ae-6b668e611d01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration contract asset</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_21e5b80b-152d-4989-aec6-81566f6436ab_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgingPurposeDomain_29e87754-6ed3-4f3f-8cf3-de075058cd46_terseLabel_en-US" xlink:label="lab_us-gaap_PledgingPurposeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledging Purpose [Domain]</link:label>
    <link:label id="lab_us-gaap_PledgingPurposeDomain_label_en-US" xlink:label="lab_us-gaap_PledgingPurposeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledging Purpose [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgingPurposeDomain" xlink:to="lab_us-gaap_PledgingPurposeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_c65a63d6-fdda-4663-95c2-646026908452_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_c31b6a1e-d926-4bb6-8ed0-01c406ab3eed_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Table]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Table]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_e3b97ff2-ecaf-4e47-b1bc-b9f656f31078_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0f505ccb-7cfd-431e-a2c1-bae281faa8a6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b17f0428-09a1-46b8-9735-d83bc222fc5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of deferred income tax benefits and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_daa39703-0ef3-4193-b14e-88826bddf705_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_919b66b5-96e2-4817-90aa-9f4d081c0360_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_ea2c8e6d-093b-486b-8381-cb52286c03c7_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_fa384397-9b53-4853-9c67-6c7d58cb2bee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_20830652-f44b-4925-a3f0-58ddcb526f57_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3978694e-ac53-43ff-90ad-7af7599f565a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9c80312f-5c45-4356-87fa-f910f071f837_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, income tax penalties and interest accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_732016a1-e961-46ae-bbda-9932b988dd0b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d578fa7d-d404-45a9-8c43-483df885fb7f_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_1f8dc933-12fc-4c06-8027-978dc06f08eb_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9c2b9fd5-9ada-4c17-9eab-059e39cc6714_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_08218b53-d6cd-4aa6-84db-0b0b49d8b9fe_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a4a2e060-2d09-4de4-8cb5-63b330c41e2d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based award, vesting period (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_bc8e928c-7639-4c60-8f57-8188a852a61d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of common stock offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_a82a02e4-a90d-4156-a23a-948578e4f5ea_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees and expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_52e76e74-549e-482e-a81c-9499d5180e75_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_bec8557d-2e8c-46d0-ba2f-09e1e954eeb7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8ffbf84b-6eac-4d0f-ae82-5c35727ee761_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_88e52c86-5b77-4104-bca1-04bfd465535f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, minimum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f5319d19-e3a5-4a1b-bdf1-1ff2106d6cdb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_bf4242a0-85e4-424c-b08b-c4f859c4a566_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f198fed5-76a5-4a39-8421-82707e07bc96_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4e14b6ef-c016-4765-9e05-3b671749af51_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period balance - gross</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_9c42c252-2378-4fcc-b3a8-2c78e3cbb883_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period balance - gross</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_d22f8ee2-32b6-4f09-8bcb-c34e264913ba_terseLabel_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing 2022</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:href="arvn-20221231.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:to="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_e22f7666-23fe-44fc-9d64-b0092d4400d3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_cff6382b-958e-4b15-be56-f780961dd4e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12e7b137-58b1-4ea4-8a80-870c3bae07db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, maximum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_599e077f-8c4f-44ae-bfc7-55f4e2b895c8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_6e89ce7a-16df-4cf9-b362-93d69a30ab09_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_177ff909-70c7-411d-b959-5b051869aa32_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_833f8caa-2d58-44b3-a1b2-6c5170082c68_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod_eac2b276-d3f8-4d7e-93e3-f771f9ec91c7_terseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument amortization period (month)</link:label>
    <link:label id="lab_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod_label_en-US" xlink:label="lab_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Amortization Period After Interest Payments Period</link:label>
    <link:label id="lab_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod_documentation_en-US" xlink:label="lab_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument amortization period after interest payments period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" xlink:to="lab_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d1028ef8-385b-4665-bb92-ef504efeab9d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_66d9dba6-c7a9-4d6f-8224-a61fef652f3c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d2dad971-fdfc-4f2c-8a1b-cfc781db0c51_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_dd1762c5-9455-4144-8046-dca9daf67180_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_a77d4186-1ab8-439e-ad65-037adac8dbf6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5442a6fe-cae1-4e3a-9ea9-2fac8a31dd2f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_78887f62-566a-46bd-9248-79f605d5ed48_terseLabel_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone Payments</link:label>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember" xlink:href="arvn-20221231.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RegulatoryMilestonePaymentsMember" xlink:to="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock_13e6e387-13ea-4b8a-9e4c-84ae8a16c11d_terseLabel_en-US" xlink:label="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Savings plan</link:label>
    <link:label id="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock_label_en-US" xlink:label="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Policy [Policy Text Block]</link:label>
    <link:label id="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:href="arvn-20221231.xsd#arvn_DefinedContributionPlanPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:to="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_fd810f1b-a1ce-4d31-809e-29ac322a6d9e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91136fea-afb6-40f6-85b2-1082932417d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e2106c6e-bc88-4918-a89e-579a3d6fad4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_bd1f9bee-ad9b-4d63-ab90-8ce649b38e2d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_48d6cc5d-ada2-48d6-9232-9c9e863ac0be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a9771f91-7ba2-4530-8fa8-2530aab944bd_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f1a927ea-8f59-47d8-9b67-9a65083a5bdb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive units authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_449950c7-8b6c-4274-a5c1-4952cfbf9128_terseLabel_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of incremental borrowing for lease payments</link:label>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_label_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Incremental Borrowing For Lease Payments</link:label>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_documentation_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of incremental borrowing for lease payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:href="arvn-20221231.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:to="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_6710311a-0289-4150-a007-5bb692f45894_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_b7aca989-607a-4a2c-b34b-c60f68e46334_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_label_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:href="arvn-20221231.xsd#arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:to="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_55288d0b-e24b-465d-8100-a850cc01c678_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the U.S. federal statutory income tax rate to effective income tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8b3e7aa6-75d4-493e-a556-c493e2e11975_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember_d4b3f913-6808-43e4-99f8-d0457fdc5657_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Assistance Agreement</link:label>
    <link:label id="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember_label_en-US" xlink:label="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Assistance Agreement [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen assistance agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:href="arvn-20221231.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:to="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_701f63fd-95f7-4d7c-a6fd-2796aff68d55_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_da233306-305f-472c-a6b4-e056bd8912f0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_40035bd0-0359-4536-9eeb-1307db2adc21_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_21b44573-6323-4f88-99ee-d93da82b80b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_52b7acfd-a838-45d0-95af-57ab4e4513ab_terseLabel_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember" xlink:href="arvn-20221231.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LaboratoryEquipmentMember" xlink:to="lab_arvn_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_3177cad3-e0e3-43ce-a061-05a981fafa22_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00fa84e1-dce1-44a7-8c7d-6cd828c6d0e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_195d9aa9-9594-4a58-b745-bcf962a0dc88_terseLabel_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Offering</link:label>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_b2b90e72-d0f1-42e4-a326-8af520ee38a8_verboseLabel_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember" xlink:href="arvn-20221231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AtTheMarketOfferingMember" xlink:to="lab_arvn_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9609e4cf-11ca-4a0b-8276-3fe4a97d5692_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2299d327-9eac-459d-8368-d017f68be6ad_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_a8928752-06d7-40c0-bdf2-77e9c683d01a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2cea85c2-a71b-492f-a71a-747036ae964c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_dd79f1a9-67b4-4b4a-aabf-e0f8596ad2a5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees and other</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_06bebed0-8bd6-40f9-9104-dc24b3cd4d1c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c4d6fce8-a276-4651-9ff9-eaa6689f3368_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_237d86ff-8ab3-47f8-9206-43ba861e1932_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_908a8cc2-0001-41e9-8be5-17c1b59f87b9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance_ef66938e-874e-4319-8a92-fd8e26ac2b83_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from balances not held at the beginning of the period</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance_label_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Liability, Revenue Recognized Not Included In Previous Balance</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Liability, Revenue Recognized Not Included In Previous Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance" xlink:href="arvn-20221231.xsd#arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance" xlink:to="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5605e7f7-7bcf-4aea-ae89-68cddc88d2a9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7ec88bcb-b288-4df7-85e8-6205fd0799be_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from sale of shares in Initial public offering before fees and expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncomeTaxDisclosureTable_80b45a65-91a7-4688-84c3-e069b79b37b6_terseLabel_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:label id="lab_arvn_IncomeTaxDisclosureTable_label_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:label id="lab_arvn_IncomeTaxDisclosureTable_documentation_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureTable" xlink:href="arvn-20221231.xsd#arvn_IncomeTaxDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncomeTaxDisclosureTable" xlink:to="lab_arvn_IncomeTaxDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_4951566b-a763-4655-ac47-3ebd715b9485_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a03a8f59-21d7-410d-9cc6-340fd98c6e31_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1b0f8a38-529a-4e18-8e3f-153422510264_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8e901a54-020c-4a64-98aa-b568ad8a6f7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_6b70507e-135c-40e2-bbfa-35a9b0f3e48f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_cb75d714-e525-4033-b912-e4b60e031ed0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AdditionalTargetAndServicesMember_ee6e6c45-e563-418f-bc28-63b913f980e5_terseLabel_en-US" xlink:label="lab_arvn_AdditionalTargetAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Target and Services</link:label>
    <link:label id="lab_arvn_AdditionalTargetAndServicesMember_label_en-US" xlink:label="lab_arvn_AdditionalTargetAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Target and Services [Member]</link:label>
    <link:label id="lab_arvn_AdditionalTargetAndServicesMember_documentation_en-US" xlink:label="lab_arvn_AdditionalTargetAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Target and Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AdditionalTargetAndServicesMember" xlink:href="arvn-20221231.xsd#arvn_AdditionalTargetAndServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AdditionalTargetAndServicesMember" xlink:to="lab_arvn_AdditionalTargetAndServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cefdd396-cbcd-417b-a5fd-a207e66aba2a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_c6aef259-4574-4374-a26c-6fb6a9aedeeb_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_08dcf36e-a008-410e-93bf-793e36a54db9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_02d5da4d-8311-4369-af57-38338b2256ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted loss per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_87fc2b3e-fe62-4f90-8db7-cea56a83cb65_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d4e2e9f5-7134-47f0-8bbf-180c75ca5053_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8fb20a29-e7d2-4972-89df-1557c41f82b5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>arvn-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e632b970-0fa5-4bd1-afa0-85cac57f3761,g:02db76aa-3c10-4220-82b9-6cc6c0294fe6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="arvn-20221231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b07352e2-30fd-47a4-9e1a-8895fb67cf12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_DocumentType_b07352e2-30fd-47a4-9e1a-8895fb67cf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_893fa923-8502-4d7d-963f-ad6728942c9f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_DocumentAnnualReport_893fa923-8502-4d7d-963f-ad6728942c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_317c3ff8-c604-4393-bca4-6b869ad901e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_DocumentPeriodEndDate_317c3ff8-c604-4393-bca4-6b869ad901e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6c98f132-6a38-450c-9c71-93cacdf9efd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_CurrentFiscalYearEndDate_6c98f132-6a38-450c-9c71-93cacdf9efd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_512208f4-85b6-4f71-8662-5b834b93d48b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_DocumentTransitionReport_512208f4-85b6-4f71-8662-5b834b93d48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6dfdaa0b-36dd-4109-b9e5-947f6b9d58e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityFileNumber_6dfdaa0b-36dd-4109-b9e5-947f6b9d58e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_68a41718-c81e-41ce-a899-f71b710fe1dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityRegistrantName_68a41718-c81e-41ce-a899-f71b710fe1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_67cc5d93-abdf-4751-9987-2faed9f72968" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityIncorporationStateCountryCode_67cc5d93-abdf-4751-9987-2faed9f72968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_617733d0-36b8-4ea8-9bd0-f85eb387f802" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityTaxIdentificationNumber_617733d0-36b8-4ea8-9bd0-f85eb387f802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d9d44663-aefa-445f-9f41-56bfa8a14056" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityAddressAddressLine1_d9d44663-aefa-445f-9f41-56bfa8a14056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_efec13a4-bd06-4ae6-a2b2-734e36a916de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityAddressAddressLine2_efec13a4-bd06-4ae6-a2b2-734e36a916de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ddfd82e3-2699-4f64-b17f-1c0e34ab795e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityAddressCityOrTown_ddfd82e3-2699-4f64-b17f-1c0e34ab795e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6ec7a4b9-7017-45ed-a7e6-036c291c8830" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityAddressStateOrProvince_6ec7a4b9-7017-45ed-a7e6-036c291c8830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b96a7540-3d72-4d88-890a-9ac414b7fa9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityAddressPostalZipCode_b96a7540-3d72-4d88-890a-9ac414b7fa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_34a1fb50-464d-4dba-a09d-2e7db527e1bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_CityAreaCode_34a1fb50-464d-4dba-a09d-2e7db527e1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d3ce1bd3-3105-42d7-94a5-d30ce44bed84" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_LocalPhoneNumber_d3ce1bd3-3105-42d7-94a5-d30ce44bed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_672d9581-588f-447a-ac0f-227b2025bbf5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_Security12bTitle_672d9581-588f-447a-ac0f-227b2025bbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7956a5aa-d715-489e-8fb1-e50d1a5b2240" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_TradingSymbol_7956a5aa-d715-489e-8fb1-e50d1a5b2240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dd172f6a-8cca-422c-b656-9e84a9b237b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_SecurityExchangeName_dd172f6a-8cca-422c-b656-9e84a9b237b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_28c3e229-789a-4df8-ac1b-b6acb43da76a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_28c3e229-789a-4df8-ac1b-b6acb43da76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_ab96d1e8-3232-44b6-bac3-364dbb290777" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityVoluntaryFilers_ab96d1e8-3232-44b6-bac3-364dbb290777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_432aa7ae-0070-4ca0-bf49-fd1dc1f4c9f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityCurrentReportingStatus_432aa7ae-0070-4ca0-bf49-fd1dc1f4c9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fcce2357-9c1b-4395-b1bb-4df3797720f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityInteractiveDataCurrent_fcce2357-9c1b-4395-b1bb-4df3797720f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f6959ac2-41ec-41ae-95af-095048a516c4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityFilerCategory_f6959ac2-41ec-41ae-95af-095048a516c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_cf38fc2a-7d87-4cb4-99a3-509acb234e6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntitySmallBusiness_cf38fc2a-7d87-4cb4-99a3-509acb234e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b63b3ef0-444b-4466-860b-2463189ad708" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityEmergingGrowthCompany_b63b3ef0-444b-4466-860b-2463189ad708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_c2187ddb-aabc-43f0-a833-5456bba45edd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_IcfrAuditorAttestationFlag_c2187ddb-aabc-43f0-a833-5456bba45edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_278c33fc-1b1a-49f3-939b-6a1c9ade7e51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityShellCompany_278c33fc-1b1a-49f3-939b-6a1c9ade7e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_41e34eff-db3d-4479-864f-abc6eb736195" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityPublicFloat_41e34eff-db3d-4479-864f-abc6eb736195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9df37f5d-6461-4b1c-9fad-5f277f68b609" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9df37f5d-6461-4b1c-9fad-5f277f68b609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1eed2630-84fd-4e68-8d66-a0cc5e830e69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1eed2630-84fd-4e68-8d66-a0cc5e830e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ea3b7b37-eefc-472c-8340-fc4872f50f48" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_EntityCentralIndexKey_ea3b7b37-eefc-472c-8340-fc4872f50f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3828d089-d3ec-4bc0-b189-eb2dc13ac81b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_DocumentFiscalYearFocus_3828d089-d3ec-4bc0-b189-eb2dc13ac81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_af29917e-e955-41ef-b5c1-bce5b4b8897e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_DocumentFiscalPeriodFocus_af29917e-e955-41ef-b5c1-bce5b4b8897e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8ebee141-cd9d-43c0-b1bb-9098fc66d5a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1ae58706-3bbe-4782-b396-fc00c2f4a849" xlink:to="loc_dei_AmendmentFlag_8ebee141-cd9d-43c0-b1bb-9098fc66d5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AuditInformation" xlink:type="simple" xlink:href="arvn-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AuditInformationAbstract_aea2a5c9-492d-48e1-b598-c25ae9557580" xlink:href="arvn-20221231.xsd#arvn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_2f7b4412-8a25-4e8f-bb33-f55f33fb2a47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AuditInformationAbstract_aea2a5c9-492d-48e1-b598-c25ae9557580" xlink:to="loc_dei_AuditorName_2f7b4412-8a25-4e8f-bb33-f55f33fb2a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_1d338fe7-bb1b-4b9f-b2a2-9b29a3bc01c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AuditInformationAbstract_aea2a5c9-492d-48e1-b598-c25ae9557580" xlink:to="loc_dei_AuditorLocation_1d338fe7-bb1b-4b9f-b2a2-9b29a3bc01c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_c83f3078-b3e8-4ddc-9ff5-4d22cfa9e7cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AuditInformationAbstract_aea2a5c9-492d-48e1-b598-c25ae9557580" xlink:to="loc_dei_AuditorFirmId_c83f3078-b3e8-4ddc-9ff5-4d22cfa9e7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_96fe4170-a1a9-49d0-b30f-6cb0d0ece5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_06a7b49a-4678-4f38-8eaf-20bd79583a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_96fe4170-a1a9-49d0-b30f-6cb0d0ece5f6" xlink:to="loc_us-gaap_AssetsAbstract_06a7b49a-4678-4f38-8eaf-20bd79583a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_fbf30827-3073-4ce3-9379-75a85b5210c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a7b49a-4678-4f38-8eaf-20bd79583a47" xlink:to="loc_us-gaap_AssetsCurrentAbstract_fbf30827-3073-4ce3-9379-75a85b5210c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_96150bf5-ec51-4efa-af95-d002ab78761f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fbf30827-3073-4ce3-9379-75a85b5210c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_96150bf5-ec51-4efa-af95-d002ab78761f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_cf8677f2-d9b7-4c3c-8fd1-9f9fbe4b2d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fbf30827-3073-4ce3-9379-75a85b5210c6" xlink:to="loc_us-gaap_RestrictedCashCurrent_cf8677f2-d9b7-4c3c-8fd1-9f9fbe4b2d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_8c882738-8132-49e1-9856-53fcff661f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fbf30827-3073-4ce3-9379-75a85b5210c6" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_8c882738-8132-49e1-9856-53fcff661f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_61c66706-696f-4e45-8a4a-8f4a311a3e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fbf30827-3073-4ce3-9379-75a85b5210c6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_61c66706-696f-4e45-8a4a-8f4a311a3e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_62877a06-25bb-4400-bfc2-b1aac617df6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fbf30827-3073-4ce3-9379-75a85b5210c6" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_62877a06-25bb-4400-bfc2-b1aac617df6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c963a161-d957-4cf8-af19-3c881b6a84cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fbf30827-3073-4ce3-9379-75a85b5210c6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c963a161-d957-4cf8-af19-3c881b6a84cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf1c3de8-9623-47bb-84d4-10af6e8a2b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fbf30827-3073-4ce3-9379-75a85b5210c6" xlink:to="loc_us-gaap_AssetsCurrent_bf1c3de8-9623-47bb-84d4-10af6e8a2b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_63f88cf0-282b-48b8-bced-364fe6ebee09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a7b49a-4678-4f38-8eaf-20bd79583a47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_63f88cf0-282b-48b8-bced-364fe6ebee09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bfbdcb7e-4e5c-459e-a490-ace013203dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a7b49a-4678-4f38-8eaf-20bd79583a47" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bfbdcb7e-4e5c-459e-a490-ace013203dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_1ce44bc3-5736-449c-92cc-195acfee5611" xlink:href="arvn-20221231.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a7b49a-4678-4f38-8eaf-20bd79583a47" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_1ce44bc3-5736-449c-92cc-195acfee5611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eba7a513-350c-46d6-b630-5c7e6339a837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a7b49a-4678-4f38-8eaf-20bd79583a47" xlink:to="loc_us-gaap_Assets_eba7a513-350c-46d6-b630-5c7e6339a837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8297550-a63e-49c2-ab83-a89d0234bd36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_96fe4170-a1a9-49d0-b30f-6cb0d0ece5f6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8297550-a63e-49c2-ab83-a89d0234bd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_579eaacf-878d-4fa7-ae28-c4c4dd33f43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8297550-a63e-49c2-ab83-a89d0234bd36" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_579eaacf-878d-4fa7-ae28-c4c4dd33f43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ae2111c6-fe78-422e-be6a-a582d94b0cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_579eaacf-878d-4fa7-ae28-c4c4dd33f43b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ae2111c6-fe78-422e-be6a-a582d94b0cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f2b0490e-3f19-46ba-a7e7-d0c84ebf45a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_579eaacf-878d-4fa7-ae28-c4c4dd33f43b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f2b0490e-3f19-46ba-a7e7-d0c84ebf45a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_30e6ca39-204b-468e-80f9-5a6bc240c567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_579eaacf-878d-4fa7-ae28-c4c4dd33f43b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_30e6ca39-204b-468e-80f9-5a6bc240c567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7177701b-1b95-41cf-8d02-2acbf2d43c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_579eaacf-878d-4fa7-ae28-c4c4dd33f43b" xlink:to="loc_us-gaap_LiabilitiesCurrent_7177701b-1b95-41cf-8d02-2acbf2d43c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b337af53-284c-4617-8476-8bb641238049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8297550-a63e-49c2-ab83-a89d0234bd36" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b337af53-284c-4617-8476-8bb641238049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d505326d-0107-4ddc-bee2-ee68e2cb7928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8297550-a63e-49c2-ab83-a89d0234bd36" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d505326d-0107-4ddc-bee2-ee68e2cb7928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b10068bd-23f5-4b5b-b669-ffe3011052b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8297550-a63e-49c2-ab83-a89d0234bd36" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b10068bd-23f5-4b5b-b669-ffe3011052b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5925c1d0-e972-4a18-b7ca-c31b101f3aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8297550-a63e-49c2-ab83-a89d0234bd36" xlink:to="loc_us-gaap_Liabilities_5925c1d0-e972-4a18-b7ca-c31b101f3aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_90130df3-f6bf-42df-a1ae-bcfe6ffd73c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8297550-a63e-49c2-ab83-a89d0234bd36" xlink:to="loc_us-gaap_CommitmentsAndContingencies_90130df3-f6bf-42df-a1ae-bcfe6ffd73c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d8437cad-6d59-4be9-86f9-f50e6b0a8552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8297550-a63e-49c2-ab83-a89d0234bd36" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d8437cad-6d59-4be9-86f9-f50e6b0a8552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_42e16a76-3f0d-4135-bce1-83d21a458a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d8437cad-6d59-4be9-86f9-f50e6b0a8552" xlink:to="loc_us-gaap_CommonStockValue_42e16a76-3f0d-4135-bce1-83d21a458a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_949fdae4-0655-491b-a016-3e47466c176b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d8437cad-6d59-4be9-86f9-f50e6b0a8552" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_949fdae4-0655-491b-a016-3e47466c176b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8bb21909-e08a-4108-af76-2765a15145e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d8437cad-6d59-4be9-86f9-f50e6b0a8552" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8bb21909-e08a-4108-af76-2765a15145e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_67b18fb8-c6d9-4e31-b161-76389fc7ed09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d8437cad-6d59-4be9-86f9-f50e6b0a8552" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_67b18fb8-c6d9-4e31-b161-76389fc7ed09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6919932e-4b05-4eda-b9ae-0e5b656c9d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d8437cad-6d59-4be9-86f9-f50e6b0a8552" xlink:to="loc_us-gaap_StockholdersEquity_6919932e-4b05-4eda-b9ae-0e5b656c9d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7cfaa7a-5a3f-47f7-9504-953ef7ba01b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8297550-a63e-49c2-ab83-a89d0234bd36" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7cfaa7a-5a3f-47f7-9504-953ef7ba01b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5d094bb9-2a34-4944-ae28-801dc0eb16f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f4b40292-453d-4a38-9768-76855b5ab347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5d094bb9-2a34-4944-ae28-801dc0eb16f6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f4b40292-453d-4a38-9768-76855b5ab347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c0ef2e14-0dba-4da3-8240-3c007712486b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5d094bb9-2a34-4944-ae28-801dc0eb16f6" xlink:to="loc_us-gaap_CommonStockSharesIssued_c0ef2e14-0dba-4da3-8240-3c007712486b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f1233dfb-ad39-4e10-8fe7-a8459b3b26d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5d094bb9-2a34-4944-ae28-801dc0eb16f6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f1233dfb-ad39-4e10-8fe7-a8459b3b26d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_23388fa3-c81e-4d9f-ab2b-575c6d78eccd" xlink:href="arvn-20221231.xsd#arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_23388fa3-c81e-4d9f-ab2b-575c6d78eccd" xlink:to="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ebda9cfd-ec2c-4f7e-b938-37f94e2567e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_Revenues_ebda9cfd-ec2c-4f7e-b938-37f94e2567e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e8291231-0d5d-463a-af0b-20b10d39a026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e8291231-0d5d-463a-af0b-20b10d39a026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_47330e60-27bb-4f62-a2aa-b02ab7d45c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e8291231-0d5d-463a-af0b-20b10d39a026" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_47330e60-27bb-4f62-a2aa-b02ab7d45c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e2623e3d-7559-4699-87ca-4fcda0e02e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e8291231-0d5d-463a-af0b-20b10d39a026" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e2623e3d-7559-4699-87ca-4fcda0e02e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_216962e3-7571-4084-91df-118b5248087f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e8291231-0d5d-463a-af0b-20b10d39a026" xlink:to="loc_us-gaap_OperatingExpenses_216962e3-7571-4084-91df-118b5248087f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1f9e89fa-46b9-4716-be03-6ae2019dde5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_OperatingIncomeLoss_1f9e89fa-46b9-4716-be03-6ae2019dde5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c649d7a2-3678-41a5-b5d1-f1b8063311aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c649d7a2-3678-41a5-b5d1-f1b8063311aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_38f49bca-18ca-41b6-b609-27a00105eadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c649d7a2-3678-41a5-b5d1-f1b8063311aa" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_38f49bca-18ca-41b6-b609-27a00105eadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_15d1d0bf-d206-4370-b71c-6d5e89594acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c649d7a2-3678-41a5-b5d1-f1b8063311aa" xlink:to="loc_us-gaap_InvestmentIncomeInterest_15d1d0bf-d206-4370-b71c-6d5e89594acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_111ee5f8-6205-43b3-be99-3aa8ee1f6daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c649d7a2-3678-41a5-b5d1-f1b8063311aa" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_111ee5f8-6205-43b3-be99-3aa8ee1f6daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0e261520-04d4-4564-a40a-2f28b869e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0e261520-04d4-4564-a40a-2f28b869e0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c059f9ac-6558-43c4-81fa-2cc1dca1cd76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c059f9ac-6558-43c4-81fa-2cc1dca1cd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f2f8f6df-ccd1-4c9d-b21c-ac9035730846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f2f8f6df-ccd1-4c9d-b21c-ac9035730846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c076c0fe-1798-48ce-9fd9-058f810dc9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_NetIncomeLoss_c076c0fe-1798-48ce-9fd9-058f810dc9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_272ad89b-91c6-49df-8c08-e0126c22067e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_EarningsPerShareBasic_272ad89b-91c6-49df-8c08-e0126c22067e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_21542364-2aaf-41d0-a3d7-474c994d0e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_EarningsPerShareDiluted_21542364-2aaf-41d0-a3d7-474c994d0e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_37e849ce-6fec-44c9-9d29-e83e90a0a563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_37e849ce-6fec-44c9-9d29-e83e90a0a563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_770d462e-b3e9-4fc5-bf77-f666c49cb5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f39e967-41c9-4094-af07-3e0a0897c181" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_770d462e-b3e9-4fc5-bf77-f666c49cb5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_07648c68-6837-4417-bb23-659954583fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_23388fa3-c81e-4d9f-ab2b-575c6d78eccd" xlink:to="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_07648c68-6837-4417-bb23-659954583fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_09096f39-eed7-4faf-8eaf-20275d6de374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_07648c68-6837-4417-bb23-659954583fcc" xlink:to="loc_us-gaap_NetIncomeLoss_09096f39-eed7-4faf-8eaf-20275d6de374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4816993f-5205-4bdd-b30c-37ce9d0125d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_07648c68-6837-4417-bb23-659954583fcc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4816993f-5205-4bdd-b30c-37ce9d0125d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1c279d73-ac56-4ceb-9d7c-78d8d041e693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4816993f-5205-4bdd-b30c-37ce9d0125d6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1c279d73-ac56-4ceb-9d7c-78d8d041e693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1598e1ed-ac76-41e1-b002-da7dc31d6f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_07648c68-6837-4417-bb23-659954583fcc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1598e1ed-ac76-41e1-b002-da7dc31d6f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a4d2221c-e294-4c2e-8747-62ba08c34bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0ebc97ee-14df-4ed5-b1b5-dd5e6fccef80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a4d2221c-e294-4c2e-8747-62ba08c34bbf" xlink:to="loc_us-gaap_StatementTable_0ebc97ee-14df-4ed5-b1b5-dd5e6fccef80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9df11e58-8f0d-47ec-bcc8-8e98e6b8efa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0ebc97ee-14df-4ed5-b1b5-dd5e6fccef80" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9df11e58-8f0d-47ec-bcc8-8e98e6b8efa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9df11e58-8f0d-47ec-bcc8-8e98e6b8efa1" xlink:to="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ed39472a-275d-4ad0-b828-a222733ff9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:to="loc_us-gaap_CommonStockMember_ed39472a-275d-4ad0-b828-a222733ff9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5499c5f0-bd24-4ff8-9558-305f440e58ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:to="loc_us-gaap_RetainedEarningsMember_5499c5f0-bd24-4ff8-9558-305f440e58ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6406d906-6b7d-4106-af35-c39954f96316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6406d906-6b7d-4106-af35-c39954f96316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2eb30b7d-4127-4e9d-9ac0-1ce33aaf576f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a9a47ac2-0cef-4993-b4c3-b5c21ee65392" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2eb30b7d-4127-4e9d-9ac0-1ce33aaf576f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_77f7fff0-b795-4185-a0c0-cedc9ff2bd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0ebc97ee-14df-4ed5-b1b5-dd5e6fccef80" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_77f7fff0-b795-4185-a0c0-cedc9ff2bd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cffebc6d-2de5-425a-8576-4dd19ce985a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77f7fff0-b795-4185-a0c0-cedc9ff2bd84" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cffebc6d-2de5-425a-8576-4dd19ce985a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_243f4528-31a2-40a2-8f02-15584cdc60e9" xlink:href="arvn-20221231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cffebc6d-2de5-425a-8576-4dd19ce985a7" xlink:to="loc_arvn_AtTheMarketOfferingMember_243f4528-31a2-40a2-8f02-15584cdc60e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8a1bf2a-2a8a-418b-ba0e-f08913627610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0ebc97ee-14df-4ed5-b1b5-dd5e6fccef80" xlink:to="loc_us-gaap_StatementLineItems_f8a1bf2a-2a8a-418b-ba0e-f08913627610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8a1bf2a-2a8a-418b-ba0e-f08913627610" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c68c389b-c7c9-4550-9369-722db067a06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c68c389b-c7c9-4550-9369-722db067a06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_003de503-bb66-4b7b-a87b-dcec8815de55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockholdersEquity_003de503-bb66-4b7b-a87b-dcec8815de55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_156da260-1983-40d3-b897-28762653e790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_156da260-1983-40d3-b897-28762653e790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3d26d9d0-3a37-4e01-975a-41aa3a72a418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3d26d9d0-3a37-4e01-975a-41aa3a72a418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5a9e06e9-4b96-4b6b-900b-6caccf678fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5a9e06e9-4b96-4b6b-900b-6caccf678fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ee7c466d-2676-44d0-b1bf-3cebb80eabbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_NetIncomeLoss_ee7c466d-2676-44d0-b1bf-3cebb80eabbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_58b69050-06e2-4c3b-96fe-e134a2feba83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_58b69050-06e2-4c3b-96fe-e134a2feba83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_71f5e79f-a597-410c-8e74-07806a108e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_71f5e79f-a597-410c-8e74-07806a108e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f05e748b-100d-419b-b9ac-fce5cda85258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f05e748b-100d-419b-b9ac-fce5cda85258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0e7ab3a4-f198-4251-afdc-026cc455d501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0e7ab3a4-f198-4251-afdc-026cc455d501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_eacaecbf-2235-4c35-a07b-9258a9782ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_eacaecbf-2235-4c35-a07b-9258a9782ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2e6745e4-0dac-4fca-81cd-763de931004f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a937783-04bc-4ff2-a6fa-e3b667d22a1c" xlink:to="loc_us-gaap_StockholdersEquity_2e6745e4-0dac-4fca-81cd-763de931004f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b5801553-c641-4eb8-a56b-31f73204c6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8d80ee8-a77e-4252-bc74-c9de5b9785ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b5801553-c641-4eb8-a56b-31f73204c6d2" xlink:to="loc_us-gaap_StatementTable_e8d80ee8-a77e-4252-bc74-c9de5b9785ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3549d84b-41f1-488c-8ad8-357ab3f75ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8d80ee8-a77e-4252-bc74-c9de5b9785ba" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3549d84b-41f1-488c-8ad8-357ab3f75ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e1e57d6-afff-404c-9fa8-237949c5741e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3549d84b-41f1-488c-8ad8-357ab3f75ee7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e1e57d6-afff-404c-9fa8-237949c5741e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_86644e46-f119-4999-b173-edc793bd417f" xlink:href="arvn-20221231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e1e57d6-afff-404c-9fa8-237949c5741e" xlink:to="loc_arvn_AtTheMarketOfferingMember_86644e46-f119-4999-b173-edc793bd417f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_36d6f372-1dac-4333-baf6-a5ef35b1bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8d80ee8-a77e-4252-bc74-c9de5b9785ba" xlink:to="loc_us-gaap_StatementLineItems_36d6f372-1dac-4333-baf6-a5ef35b1bc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_baf2d7a5-8f6f-42d5-9be8-27f198fe101e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_36d6f372-1dac-4333-baf6-a5ef35b1bc4d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_baf2d7a5-8f6f-42d5-9be8-27f198fe101e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arvn-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1c4efa03-22f7-4a08-9f70-72e2062516ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4316ce0e-02d6-4d0e-957e-dd537de7b990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1c4efa03-22f7-4a08-9f70-72e2062516ab" xlink:to="loc_us-gaap_StatementTable_4316ce0e-02d6-4d0e-957e-dd537de7b990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5af9eb76-87ae-4b5c-b225-144196ee499b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4316ce0e-02d6-4d0e-957e-dd537de7b990" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5af9eb76-87ae-4b5c-b225-144196ee499b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_83524388-c4af-421a-b147-c649b20e37ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5af9eb76-87ae-4b5c-b225-144196ee499b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_83524388-c4af-421a-b147-c649b20e37ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_403e7f45-34f2-4401-8c5e-ff8a11f2109e" xlink:href="arvn-20221231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_83524388-c4af-421a-b147-c649b20e37ec" xlink:to="loc_arvn_AtTheMarketOfferingMember_403e7f45-34f2-4401-8c5e-ff8a11f2109e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4316ce0e-02d6-4d0e-957e-dd537de7b990" xlink:to="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_85dfd49e-3cc6-44ca-b5b6-afd4513453c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:to="loc_us-gaap_NetIncomeLoss_85dfd49e-3cc6-44ca-b5b6-afd4513453c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a40d92fa-b049-4b7a-b15d-f8b4dff55ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_DepreciationAndAmortization_a40d92fa-b049-4b7a-b15d-f8b4dff55ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_16c2825d-ff0e-473d-8b79-edefe5e3390f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_16c2825d-ff0e-473d-8b79-edefe5e3390f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_7fa8add1-e017-4e4f-be4a-09ad9a9e73c3" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_7fa8add1-e017-4e4f-be4a-09ad9a9e73c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_295c0e7f-7d59-438b-b0bf-fcebeb80f6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_295c0e7f-7d59-438b-b0bf-fcebeb80f6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_dd651a47-f184-41a1-8564-c77e7be47671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_dd651a47-f184-41a1-8564-c77e7be47671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_7d5cba71-3549-4d5f-a773-f1612579538e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_7d5cba71-3549-4d5f-a773-f1612579538e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_50da64d9-e9e4-472b-a1e0-3948c495f048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fa8ec84-57e3-40fb-a9ea-c536729d8be0" xlink:to="loc_us-gaap_ShareBasedCompensation_50da64d9-e9e4-472b-a1e0-3948c495f048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_946a2d73-f755-4c19-8e27-2633634c4aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_946a2d73-f755-4c19-8e27-2633634c4aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e9f47bdc-d33f-40d1-907c-c9380f1cd0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e9f47bdc-d33f-40d1-907c-c9380f1cd0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef058ea0-74f9-44cc-bc62-a04547440a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef058ea0-74f9-44cc-bc62-a04547440a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_2d775512-1ef2-46de-8572-3b275fb77933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_2d775512-1ef2-46de-8572-3b275fb77933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e5c758e9-e919-47c1-9d9f-e83bebd32606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e5c758e9-e919-47c1-9d9f-e83bebd32606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_6d7a9d63-6cdc-4d73-8570-f9b6592758ed" xlink:href="arvn-20221231.xsd#arvn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_arvn_IncreaseDecreaseInOperatingLeaseLiabilities_6d7a9d63-6cdc-4d73-8570-f9b6592758ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_08cbab93-c2ad-4a84-a3ef-6dcb70d50a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b7b732d2-be3a-416b-b5d2-59cb14778f80" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_08cbab93-c2ad-4a84-a3ef-6dcb70d50a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916fbd13-e7d8-46db-920e-c9e98881122a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe7f4e-f3c9-4dd1-aa91-95e677e1f279" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916fbd13-e7d8-46db-920e-c9e98881122a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b7ddaefe-109e-4f80-ab91-bc02d953c080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b7ddaefe-109e-4f80-ab91-bc02d953c080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_e9a3796a-f10c-4acd-b3a7-35c0244767b6" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:to="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_e9a3796a-f10c-4acd-b3a7-35c0244767b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromSaleOfMarketableSecurities_739637f7-9e1d-4c9d-a9cb-9b26889cbf00" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:to="loc_arvn_ProceedsFromSaleOfMarketableSecurities_739637f7-9e1d-4c9d-a9cb-9b26889cbf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21fb53bb-6f22-4e5c-a0f8-2493cca36b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21fb53bb-6f22-4e5c-a0f8-2493cca36b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ca27b91-dae7-4094-b363-27a75067348c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9514d5a-eb55-4934-9e2b-97918b079b59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ca27b91-dae7-4094-b363-27a75067348c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_76ec1e18-305c-4919-a47e-dddb01c92f3d" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:to="loc_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_76ec1e18-305c-4919-a47e-dddb01c92f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_7c73d43b-3f52-412c-8036-d4298ef231d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_7c73d43b-3f52-412c-8036-d4298ef231d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockGross_2aefa7b2-12f4-4282-bc27-24c28693337b" xlink:href="arvn-20221231.xsd#arvn_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:to="loc_arvn_ProceedsFromIssuanceOfCommonStockGross_2aefa7b2-12f4-4282-bc27-24c28693337b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_981a2989-0b00-4e60-ad31-49e4cf9b7269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_981a2989-0b00-4e60-ad31-49e4cf9b7269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16f7f397-fae0-470a-ba64-c5d691f50c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2754295-2dbd-431d-99c8-2aaeeb50f8cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16f7f397-fae0-470a-ba64-c5d691f50c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2362893-e95f-44ce-81b8-8dc18dda877b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2362893-e95f-44ce-81b8-8dc18dda877b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb88f5bf-a12c-498c-a7ec-488eaf7fe5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb88f5bf-a12c-498c-a7ec-488eaf7fe5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a8bd6d6-817b-448d-9a06-d29c583d593b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a8bd6d6-817b-448d-9a06-d29c583d593b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e96b1378-fc21-4e61-af83-86f6e96e04ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742d23e0-1994-4e4f-8311-87f2be6026b7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e96b1378-fc21-4e61-af83-86f6e96e04ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_92997178-c164-4358-88b1-988e8081f95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e96b1378-fc21-4e61-af83-86f6e96e04ad" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_92997178-c164-4358-88b1-988e8081f95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d903b492-78c7-4f2a-8a08-7aa7131ab5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e96b1378-fc21-4e61-af83-86f6e96e04ad" xlink:to="loc_us-gaap_InterestPaidNet_d903b492-78c7-4f2a-8a08-7aa7131ab5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_4d62f556-cd73-40ac-a1d8-4ca7bbb01b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e96b1378-fc21-4e61-af83-86f6e96e04ad" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_4d62f556-cd73-40ac-a1d8-4ca7bbb01b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="arvn-20221231.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bdfdf732-4e14-49d8-88da-ebbb6b2e0c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9f5229a1-b039-41b7-94bf-a7b855021b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bdfdf732-4e14-49d8-88da-ebbb6b2e0c40" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9f5229a1-b039-41b7-94bf-a7b855021b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="arvn-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_71860e46-3216-42f4-90fa-f5df95c09590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_60b1dfc4-b6fe-4786-82b1-1c8b7f83545f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_71860e46-3216-42f4-90fa-f5df95c09590" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_60b1dfc4-b6fe-4786-82b1-1c8b7f83545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arvn-20221231.xsd#ResearchCollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_dc2fe152-794f-4f0a-9a2c-20e939e588ee" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_619e2457-ac4e-4758-8d19-068ae140545a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_dc2fe152-794f-4f0a-9a2c-20e939e588ee" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_619e2457-ac4e-4758-8d19-068ae140545a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="simple" xlink:href="arvn-20221231.xsd#MarketableSecuritiesandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_146b6d8c-720c-4645-8124-a61f9b639194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a14e430c-533c-483f-80f5-5e1dfdbf1d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_146b6d8c-720c-4645-8124-a61f9b639194" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a14e430c-533c-483f-80f5-5e1dfdbf1d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements" xlink:type="simple" xlink:href="arvn-20221231.xsd#PropertyEquipmentandLeaseholdImprovements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_54cde51a-c0b9-4f66-b6e9-2829b81b9ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51c39b47-e4fb-433c-93c9-d888a1f69f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_54cde51a-c0b9-4f66-b6e9-2829b81b9ef3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51c39b47-e4fb-433c-93c9-d888a1f69f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilities" xlink:type="simple" xlink:href="arvn-20221231.xsd#RightofUseAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c13cb896-5360-4865-b378-164c46fd30b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_dce26d55-cc42-4f6f-ac69-5d67a32a25bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c13cb896-5360-4865-b378-164c46fd30b0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_dce26d55-cc42-4f6f-ac69-5d67a32a25bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="arvn-20221231.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b5c694d3-68d2-403d-b00a-67f0241b7449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2e0099ac-256c-4efd-a780-e42d53b686a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b5c694d3-68d2-403d-b00a-67f0241b7449" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2e0099ac-256c-4efd-a780-e42d53b686a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebt" xlink:type="simple" xlink:href="arvn-20221231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_419ff8a8-a496-45fe-ac1d-f3b832ab157b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_24acc2b2-e707-49d3-b708-269340855629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_419ff8a8-a496-45fe-ac1d-f3b832ab157b" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_24acc2b2-e707-49d3-b708-269340855629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/Equity" xlink:type="simple" xlink:href="arvn-20221231.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c22b3eb5-ea49-4d25-83ae-fba7cbf95c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8654a231-4f24-4710-a2bd-7c4c7be2ebab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c22b3eb5-ea49-4d25-83ae-fba7cbf95c34" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8654a231-4f24-4710-a2bd-7c4c7be2ebab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestments" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityMethodInvestments"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4ba67a8c-eb74-4f33-96be-511b6d131a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_a97dc162-143e-4941-8c56-b52f21f1a4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4ba67a8c-eb74-4f33-96be-511b6d131a76" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_a97dc162-143e-4941-8c56-b52f21f1a4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxes" xlink:type="simple" xlink:href="arvn-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f30a99c7-7880-41c0-8a9f-7590ead25f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_51c3fab4-f14f-4491-a61e-8d6c92b81f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f30a99c7-7880-41c0-8a9f-7590ead25f3b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_51c3fab4-f14f-4491-a61e-8d6c92b81f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arvn-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_38b4487a-cba2-40f7-8e6f-443cd1b4b8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ad2e5f14-426c-42a3-888a-5436137256df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_38b4487a-cba2-40f7-8e6f-443cd1b4b8c4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ad2e5f14-426c-42a3-888a-5436137256df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShare" xlink:type="simple" xlink:href="arvn-20221231.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6f452ffc-df3d-4280-9a00-dde1903a03e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_441ccb8c-614f-40d1-992f-aa8902110790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f452ffc-df3d-4280-9a00-dde1903a03e6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_441ccb8c-614f-40d1-992f-aa8902110790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arvn-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_a2b7f592-11f0-4559-8232-a48b2f83aead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_a2b7f592-11f0-4559-8232-a48b2f83aead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_cebc7471-246c-4503-8731-40775bd14cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_cebc7471-246c-4503-8731-40775bd14cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e13f399b-63d0-4a44-b085-2676455bd4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e13f399b-63d0-4a44-b085-2676455bd4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_f7e13f01-b8fa-48e2-b8fe-35b22361e7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_f7e13f01-b8fa-48e2-b8fe-35b22361e7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_baf89129-8999-46d9-8cbc-64c9e76b7546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_baf89129-8999-46d9-8cbc-64c9e76b7546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_382922ed-16e2-4e37-8f13-bbc337915f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_382922ed-16e2-4e37-8f13-bbc337915f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3da31ad9-17ca-4c8b-8720-4ece9bbda44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3da31ad9-17ca-4c8b-8720-4ece9bbda44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f7c5ea85-0035-4a27-9483-f1c0c64b8c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f7c5ea85-0035-4a27-9483-f1c0c64b8c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_5547f809-88ba-490a-b86d-b9c87c69e25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_5547f809-88ba-490a-b86d-b9c87c69e25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_4de6f299-524f-431d-992e-25546c749794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_4de6f299-524f-431d-992e-25546c749794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b93042a1-88a3-4827-9b39-8ebe22a1750f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b93042a1-88a3-4827-9b39-8ebe22a1750f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DefinedContributionPlanPolicyPolicyTextBlock_9a0411fc-db4f-414f-a438-f1f98acab412" xlink:href="arvn-20221231.xsd#arvn_DefinedContributionPlanPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_arvn_DefinedContributionPlanPolicyPolicyTextBlock_9a0411fc-db4f-414f-a438-f1f98acab412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f164424a-cd04-4994-aaa5-5243cd4470e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f164424a-cd04-4994-aaa5-5243cd4470e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_38bb0fb4-eccf-405f-843b-4d5614d60e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_38bb0fb4-eccf-405f-843b-4d5614d60e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_6cdc572e-32a6-4816-a3c8-dfb06c829456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_6cdc572e-32a6-4816-a3c8-dfb06c829456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3a07cc70-acd9-48d4-b33b-5188864f38c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f02d60f-ead9-4a98-8e51-8702ba9d2628" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3a07cc70-acd9-48d4-b33b-5188864f38c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_15e2de15-8d3d-4216-8571-875cb41cd2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_12154d8f-0dfc-4567-a059-b66018ce961e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15e2de15-8d3d-4216-8571-875cb41cd2e5" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_12154d8f-0dfc-4567-a059-b66018ce961e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9ed21c3f-c2b3-4196-b1a1-ac9ac8dc2a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15e2de15-8d3d-4216-8571-875cb41cd2e5" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9ed21c3f-c2b3-4196-b1a1-ac9ac8dc2a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#ResearchCollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_ce3c2a8b-e949-42bf-baa1-ede081ba1928" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b98dcf3b-80d9-4241-b556-f66b13e6d02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_ce3c2a8b-e949-42bf-baa1-ede081ba1928" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b98dcf3b-80d9-4241-b556-f66b13e6d02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_54eae8ea-03a4-4bd2-b1d6-bc0dcb7d2c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_ce3c2a8b-e949-42bf-baa1-ede081ba1928" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_54eae8ea-03a4-4bd2-b1d6-bc0dcb7d2c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#MarketableSecuritiesandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_42aa73be-8632-4e81-848f-1f61951376d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9b9f56c2-27e7-4049-96a6-b9e5026f179e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_42aa73be-8632-4e81-848f-1f61951376d1" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9b9f56c2-27e7-4049-96a6-b9e5026f179e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#PropertyEquipmentandLeaseholdImprovementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f241ff9e-107d-4fae-aefb-64f630e0bef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ac62dad3-aaab-4b66-a324-dbd1aeca9a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f241ff9e-107d-4fae-aefb-64f630e0bef4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ac62dad3-aaab-4b66-a324-dbd1aeca9a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#RightofUseAssetsandLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5604ea5e-5516-4f13-ae76-6152bf6adda2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_b04a1ee8-1bb7-484f-b5d2-dc4c6fccf9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5604ea5e-5516-4f13-ae76-6152bf6adda2" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_b04a1ee8-1bb7-484f-b5d2-dc4c6fccf9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock_7d582f58-6b31-4811-9bf3-0ca9609da989" xlink:href="arvn-20221231.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5604ea5e-5516-4f13-ae76-6152bf6adda2" xlink:to="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock_7d582f58-6b31-4811-9bf3-0ca9609da989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_bad7b4b7-0df7-4716-95da-bd2b11c2108c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5604ea5e-5516-4f13-ae76-6152bf6adda2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_bad7b4b7-0df7-4716-95da-bd2b11c2108c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_369d58c7-0c3c-48ef-b8f6-2944ed19d3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3f055403-a625-47d0-8181-133b854f6235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_369d58c7-0c3c-48ef-b8f6-2944ed19d3b0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3f055403-a625-47d0-8181-133b854f6235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9586d15a-7b00-442a-a7c9-a8504cab1f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2993fca6-db55-4212-a9d9-382abd47ccf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9586d15a-7b00-442a-a7c9-a8504cab1f56" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2993fca6-db55-4212-a9d9-382abd47ccf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30fd1f4a-90fc-4be3-aba3-3375f2388336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63461674-b874-4eba-b836-3f6fadd8ccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30fd1f4a-90fc-4be3-aba3-3375f2388336" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63461674-b874-4eba-b836-3f6fadd8ccf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b097a1a7-e4ac-45aa-a824-bae663923895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63461674-b874-4eba-b836-3f6fadd8ccf5" xlink:to="loc_us-gaap_AwardTypeAxis_b097a1a7-e4ac-45aa-a824-bae663923895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d4db74f-42e6-4320-84fb-6db2ee0d06ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b097a1a7-e4ac-45aa-a824-bae663923895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d4db74f-42e6-4320-84fb-6db2ee0d06ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_82430a88-30cd-461b-aad1-a2bbab439455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d4db74f-42e6-4320-84fb-6db2ee0d06ff" xlink:to="loc_us-gaap_RestrictedStockMember_82430a88-30cd-461b-aad1-a2bbab439455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dd689d51-41cd-4443-b19a-8e7a4e79fa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d4db74f-42e6-4320-84fb-6db2ee0d06ff" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dd689d51-41cd-4443-b19a-8e7a4e79fa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c3cce247-2776-4f02-8e72-6d35fa4ab60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63461674-b874-4eba-b836-3f6fadd8ccf5" xlink:to="loc_us-gaap_StatementLineItems_c3cce247-2776-4f02-8e72-6d35fa4ab60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f7135967-c85c-4439-88b8-bc96ea55621c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3cce247-2776-4f02-8e72-6d35fa4ab60c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f7135967-c85c-4439-88b8-bc96ea55621c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d387e382-860d-463f-b33a-b04d75c20592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3cce247-2776-4f02-8e72-6d35fa4ab60c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d387e382-860d-463f-b33a-b04d75c20592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_ad7c8d4d-9553-403e-aadd-095e7efc58a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3cce247-2776-4f02-8e72-6d35fa4ab60c" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_ad7c8d4d-9553-403e-aadd-095e7efc58a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityMethodInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_7d7dff33-5768-4e2b-9dc5-4d11b865d084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_0e580371-53cc-4673-a2bd-79b11b7d220b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_7d7dff33-5768-4e2b-9dc5-4d11b865d084" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_0e580371-53cc-4673-a2bd-79b11b7d220b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_eb28990d-1eaa-4834-9fd4-58e69b3a96cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_cd7d0c1c-31e0-4d41-8bbd-bb4f4b73acb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eb28990d-1eaa-4834-9fd4-58e69b3a96cf" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_cd7d0c1c-31e0-4d41-8bbd-bb4f4b73acb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_946e634a-6313-48b3-ad30-11ec99a25927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eb28990d-1eaa-4834-9fd4-58e69b3a96cf" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_946e634a-6313-48b3-ad30-11ec99a25927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8962fb95-ca33-46b1-bcc9-3245d0c686d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eb28990d-1eaa-4834-9fd4-58e69b3a96cf" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8962fb95-ca33-46b1-bcc9-3245d0c686d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_c63e4f49-5d85-44a2-bbc6-ca8205596c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eb28990d-1eaa-4834-9fd4-58e69b3a96cf" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_c63e4f49-5d85-44a2-bbc6-ca8205596c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="arvn-20221231.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_01b8576d-c379-469e-930e-014a3128a6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7f26d499-e644-4e05-b95a-655a69d7bccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_01b8576d-c379-469e-930e-014a3128a6d8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7f26d499-e644-4e05-b95a-655a69d7bccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b316c256-5545-4f5e-8587-5386720aa50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_01b8576d-c379-469e-930e-014a3128a6d8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b316c256-5545-4f5e-8587-5386720aa50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_667d3193-b8d6-4797-9fcc-ac3235fc4d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfWhollyOwnedSubsidiaries_6c90ed46-9110-46f2-be0d-c628c147010a" xlink:href="arvn-20221231.xsd#arvn_NumberOfWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_667d3193-b8d6-4797-9fcc-ac3235fc4d4b" xlink:to="loc_arvn_NumberOfWhollyOwnedSubsidiaries_6c90ed46-9110-46f2-be0d-c628c147010a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_8de8d7cc-84f3-42e7-a3d8-e2a2c311a168" xlink:href="arvn-20221231.xsd#arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_667d3193-b8d6-4797-9fcc-ac3235fc4d4b" xlink:to="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_8de8d7cc-84f3-42e7-a3d8-e2a2c311a168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#SummaryofSignificantAccountingPoliciesCashReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4cf5e14d-9570-4e1a-b0e7-ae2a221e8d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_863e41ea-754d-4d62-b6ea-047b7f554693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cf5e14d-9570-4e1a-b0e7-ae2a221e8d30" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_863e41ea-754d-4d62-b6ea-047b7f554693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_a0e81202-7521-4d35-9e79-b4f589c1777f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cf5e14d-9570-4e1a-b0e7-ae2a221e8d30" xlink:to="loc_us-gaap_RestrictedCashCurrent_a0e81202-7521-4d35-9e79-b4f589c1777f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02f88591-0778-4a72-b050-69dd6414f79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cf5e14d-9570-4e1a-b0e7-ae2a221e8d30" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02f88591-0778-4a72-b050-69dd6414f79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7d4c6b57-49a4-4453-83a2-58aa6f67b663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:href="arvn-20221231.xsd#arvn_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7d4c6b57-49a4-4453-83a2-58aa6f67b663" xlink:to="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df924408-3c35-49b2-a4c5-63a2ea3ce9dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:to="loc_srt_RangeAxis_df924408-3c35-49b2-a4c5-63a2ea3ce9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa018ac2-464f-4cbd-8344-08f9f6be4c13" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_df924408-3c35-49b2-a4c5-63a2ea3ce9dd" xlink:to="loc_srt_RangeMember_fa018ac2-464f-4cbd-8344-08f9f6be4c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87ced195-c3da-4be9-ace6-558c1b9f78fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fa018ac2-464f-4cbd-8344-08f9f6be4c13" xlink:to="loc_srt_MaximumMember_87ced195-c3da-4be9-ace6-558c1b9f78fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0fb99fae-4efb-4915-b562-bbbf870c65b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0fb99fae-4efb-4915-b562-bbbf870c65b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0b89a291-357a-4459-a406-fb4e3a30e165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0fb99fae-4efb-4915-b562-bbbf870c65b2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0b89a291-357a-4459-a406-fb4e3a30e165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_9bbd7ec4-a05c-4f94-b245-de29d63456d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0b89a291-357a-4459-a406-fb4e3a30e165" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_9bbd7ec4-a05c-4f94-b245-de29d63456d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9642a429-60a9-4b40-b78d-a7c0254eee26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9642a429-60a9-4b40-b78d-a7c0254eee26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_09bbf798-3494-4409-ad1e-37d0fe73e316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9642a429-60a9-4b40-b78d-a7c0254eee26" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_09bbf798-3494-4409-ad1e-37d0fe73e316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6eceeb3e-9a6b-43fc-8e52-50c139168226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_09bbf798-3494-4409-ad1e-37d0fe73e316" xlink:to="loc_us-gaap_SalesRevenueNetMember_6eceeb3e-9a6b-43fc-8e52-50c139168226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395ce435-b5df-4007-bde5-ef0b71c2344e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395ce435-b5df-4007-bde5-ef0b71c2344e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b32ee0a5-4507-4c2f-a336-2a189251511a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395ce435-b5df-4007-bde5-ef0b71c2344e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b32ee0a5-4507-4c2f-a336-2a189251511a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorOneMember_69f0f8b1-cea3-45a5-98ca-882b16cf02d3" xlink:href="arvn-20221231.xsd#arvn_CollaboratorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b32ee0a5-4507-4c2f-a336-2a189251511a" xlink:to="loc_arvn_CollaboratorOneMember_69f0f8b1-cea3-45a5-98ca-882b16cf02d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorTwoMember_00fb092d-1281-499a-87d0-f13e9b93d33a" xlink:href="arvn-20221231.xsd#arvn_CollaboratorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b32ee0a5-4507-4c2f-a336-2a189251511a" xlink:to="loc_arvn_CollaboratorTwoMember_00fb092d-1281-499a-87d0-f13e9b93d33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorThreeMember_fae88331-5db0-4fd3-8b22-47585c0a6106" xlink:href="arvn-20221231.xsd#arvn_CollaboratorThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b32ee0a5-4507-4c2f-a336-2a189251511a" xlink:to="loc_arvn_CollaboratorThreeMember_fae88331-5db0-4fd3-8b22-47585c0a6106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d56cc5e2-0a06-4169-911e-f55ec8a61743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d56cc5e2-0a06-4169-911e-f55ec8a61743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e911f176-67c9-498d-86f8-d183d4ca06d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d56cc5e2-0a06-4169-911e-f55ec8a61743" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e911f176-67c9-498d-86f8-d183d4ca06d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_29c828f9-7b89-47db-9af0-7ee0c3eb46a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e911f176-67c9-498d-86f8-d183d4ca06d7" xlink:to="loc_us-gaap_OfficeEquipmentMember_29c828f9-7b89-47db-9af0-7ee0c3eb46a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_c69c22b0-6d4d-455a-877f-d0089d2cd3bb" xlink:href="arvn-20221231.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e911f176-67c9-498d-86f8-d183d4ca06d7" xlink:to="loc_arvn_LaboratoryEquipmentMember_c69c22b0-6d4d-455a-877f-d0089d2cd3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:href="arvn-20221231.xsd#arvn_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_f925ef87-e55a-4127-9d97-8f88b883167a" xlink:to="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_512ec60e-7df7-4372-b022-1eae21ecb0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_512ec60e-7df7-4372-b022-1eae21ecb0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_efc267e8-3ffb-43a9-9af7-320a8523aece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_efc267e8-3ffb-43a9-9af7-320a8523aece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c90ca30d-8bd4-433b-8277-3ee469389d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c90ca30d-8bd4-433b-8277-3ee469389d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_396bb2ab-797b-4847-b570-f96350261a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_396bb2ab-797b-4847-b570-f96350261a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7254d716-3bfe-4996-9de5-3334a8e4f324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7254d716-3bfe-4996-9de5-3334a8e4f324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1b8b56d4-ec58-4491-92e0-793e46af1c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_EquityMethodInvestments_1b8b56d4-ec58-4491-92e0-793e46af1c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_da49baed-df46-4159-beb3-5914e30b075b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_07d14838-ba41-4f4f-a079-43e542d0f92a" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_da49baed-df46-4159-beb3-5914e30b075b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_11c01ff6-dca8-4719-b9ef-6a7ae74f3650" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_11c01ff6-dca8-4719-b9ef-6a7ae74f3650" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5dfcec5f-78e4-4ee4-860c-9abf3ba042b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:to="loc_srt_CounterpartyNameAxis_5dfcec5f-78e4-4ee4-860c-9abf3ba042b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c1cf182-a516-4e14-a4c1-9281ad8f6ea1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5dfcec5f-78e4-4ee4-860c-9abf3ba042b1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c1cf182-a516-4e14-a4c1-9281ad8f6ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_0983a129-7e1e-4dbe-befd-c935226808cd" xlink:href="arvn-20221231.xsd#arvn_PfizerIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c1cf182-a516-4e14-a4c1-9281ad8f6ea1" xlink:to="loc_arvn_PfizerIncorporationMember_0983a129-7e1e-4dbe-befd-c935226808cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember_62d0d80a-2c51-465c-a9d9-56f4702293b1" xlink:href="arvn-20221231.xsd#arvn_BayerAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c1cf182-a516-4e14-a4c1-9281ad8f6ea1" xlink:to="loc_arvn_BayerAGMember_62d0d80a-2c51-465c-a9d9-56f4702293b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_c4409658-b889-4f2d-a588-c88987a7e8ac" xlink:href="arvn-20221231.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c1cf182-a516-4e14-a4c1-9281ad8f6ea1" xlink:to="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_c4409658-b889-4f2d-a588-c88987a7e8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_85702f5f-f571-4e3d-a9b2-2cdce2d8c4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:to="loc_us-gaap_TypeOfArrangementAxis_85702f5f-f571-4e3d-a9b2-2cdce2d8c4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_85702f5f-f571-4e3d-a9b2-2cdce2d8c4fe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember_1dc1649a-615f-4688-a3b2-3c8a69fc09a6" xlink:href="arvn-20221231.xsd#arvn_CollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_CollaborationAgreementMember_1dc1649a-615f-4688-a3b2-3c8a69fc09a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockPurchaseAgreementMember_a0a49a21-5ef6-49d3-b6a9-a44cb5b20893" xlink:href="arvn-20221231.xsd#arvn_StockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_StockPurchaseAgreementMember_a0a49a21-5ef6-49d3-b6a9-a44cb5b20893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember_2ea1010b-85c7-4720-a276-1ca782527c68" xlink:href="arvn-20221231.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_ResearchFundingPaymentsMember_2ea1010b-85c7-4720-a276-1ca782527c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember_832e6d00-d593-48fd-b867-144168eba929" xlink:href="arvn-20221231.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_DevelopmentMilestonePaymentsMember_832e6d00-d593-48fd-b867-144168eba929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember_f24ae3a9-0a68-4086-ba59-c46aeb5f892f" xlink:href="arvn-20221231.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_SalesBasedMilestonePaymentsMember_f24ae3a9-0a68-4086-ba59-c46aeb5f892f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember_e3a7f202-b59d-4769-8503-b73ff09932c4" xlink:href="arvn-20221231.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_OptionPaymentsToLicenseAgreementMember_e3a7f202-b59d-4769-8503-b73ff09932c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AdditionalTargetAndServicesMember_0578a44f-d3d8-421c-bbfc-e3bebf985771" xlink:href="arvn-20221231.xsd#arvn_AdditionalTargetAndServicesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_AdditionalTargetAndServicesMember_0578a44f-d3d8-421c-bbfc-e3bebf985771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember_db42fc81-63b5-4df7-875c-d9648fb2bd07" xlink:href="arvn-20221231.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_RegulatoryMilestonePaymentsMember_db42fc81-63b5-4df7-875c-d9648fb2bd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember_031336c1-d3a6-466e-b598-98422714896b" xlink:href="arvn-20221231.xsd#arvn_CommercialMilestonesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a07d9d10-ec70-460a-b7d9-c3f9b8df96d4" xlink:to="loc_arvn_CommercialMilestonesMember_031336c1-d3a6-466e-b598-98422714896b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83b21740-f912-4b2f-9709-1d62f7f5e8e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:to="loc_srt_RangeAxis_83b21740-f912-4b2f-9709-1d62f7f5e8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92c3ac2a-10b4-4d84-874c-5569f69b87f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_83b21740-f912-4b2f-9709-1d62f7f5e8e3" xlink:to="loc_srt_RangeMember_92c3ac2a-10b4-4d84-874c-5569f69b87f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59ee5ea2-1742-4dde-8e88-e010adafca49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92c3ac2a-10b4-4d84-874c-5569f69b87f9" xlink:to="loc_srt_MaximumMember_59ee5ea2-1742-4dde-8e88-e010adafca49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_677e9e51-1d26-4de2-a751-928b4c144516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_677e9e51-1d26-4de2-a751-928b4c144516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f5b9f073-addb-4754-b322-9088694a3225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_677e9e51-1d26-4de2-a751-928b4c144516" xlink:to="loc_us-gaap_EquityComponentDomain_f5b9f073-addb-4754-b322-9088694a3225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_18d61f7f-3244-4669-bf7a-7a4fdd4e88b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f5b9f073-addb-4754-b322-9088694a3225" xlink:to="loc_us-gaap_CommonStockMember_18d61f7f-3244-4669-bf7a-7a4fdd4e88b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_55b4db0e-32a0-4aea-a30b-6798d495067f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:to="loc_srt_StatementScenarioAxis_55b4db0e-32a0-4aea-a30b-6798d495067f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ee004cf2-3e89-456a-b1e8-31b437adb2d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_55b4db0e-32a0-4aea-a30b-6798d495067f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ee004cf2-3e89-456a-b1e8-31b437adb2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_dffe8268-2ec2-4e11-b169-b98e4a6b3d14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ee004cf2-3e89-456a-b1e8-31b437adb2d7" xlink:to="loc_srt_ScenarioForecastMember_dffe8268-2ec2-4e11-b169-b98e4a6b3d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f4970c43-7ef5-4339-9c70-164fe584f177" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_aa8b290a-440e-4c59-a3d2-9333a38bcfd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_aa8b290a-440e-4c59-a3d2-9333a38bcfd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_733ab55e-9b1f-4c6a-a0e8-d07f8d2cfe66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_733ab55e-9b1f-4c6a-a0e8-d07f8d2cfe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_f50b5aed-9b7d-4a57-be35-0a38ebd5c230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_f50b5aed-9b7d-4a57-be35-0a38ebd5c230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd7985b5-96b1-48f2-8462-275d9be6643b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd7985b5-96b1-48f2-8462-275d9be6643b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForBrokerageFees_be567597-d040-418c-9a4e-1326aafa39e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForBrokerageFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_PaymentsForBrokerageFees_be567597-d040-418c-9a4e-1326aafa39e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SaleOfStockFairValueOfSharesSold_a3d55f05-a97c-4c27-97cf-bbb2516f1e69" xlink:href="arvn-20221231.xsd#arvn_SaleOfStockFairValueOfSharesSold"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_arvn_SaleOfStockFairValueOfSharesSold_a3d55f05-a97c-4c27-97cf-bbb2516f1e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_04423595-7d5b-49fe-bfc4-9debb128387e" xlink:href="arvn-20221231.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_04423595-7d5b-49fe-bfc4-9debb128387e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_3cbac9af-944b-43b4-abe1-efc3f82c45a2" xlink:href="arvn-20221231.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_3cbac9af-944b-43b4-abe1-efc3f82c45a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_f406c77f-4457-4fa7-afe5-ccf9de85fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_ProceedsFromCollaborators_f406c77f-4457-4fa7-afe5-ccf9de85fdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_867880b0-397d-4c99-af5e-be14f7ca725a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_867880b0-397d-4c99-af5e-be14f7ca725a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_702c9949-610c-41bf-8d0a-64b7d553dcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_702c9949-610c-41bf-8d0a-64b7d553dcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_62c83313-226f-4bf0-b70e-fbc32f7aec40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_62c83313-226f-4bf0-b70e-fbc32f7aec40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfMaximumDesignatedTargets_6b15b2db-4b40-4b49-b3ef-bae215b79f0b" xlink:href="arvn-20221231.xsd#arvn_NumberOfMaximumDesignatedTargets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f994e644-8137-4813-9f48-acd54a642f96" xlink:to="loc_arvn_NumberOfMaximumDesignatedTargets_6b15b2db-4b40-4b49-b3ef-bae215b79f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_08049355-c855-4104-af40-b1e748fbb028" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_8b146ec6-863a-4783-b691-dc3fd36e8c8e" xlink:href="arvn-20221231.xsd#arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_08049355-c855-4104-af40-b1e748fbb028" xlink:to="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_8b146ec6-863a-4783-b691-dc3fd36e8c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3d749fd0-085f-440c-b3b5-901298b48549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_8b146ec6-863a-4783-b691-dc3fd36e8c8e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3d749fd0-085f-440c-b3b5-901298b48549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_696caf1e-b693-48b0-9d68-770991ddec7b" xlink:href="arvn-20221231.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_8b146ec6-863a-4783-b691-dc3fd36e8c8e" xlink:to="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_696caf1e-b693-48b0-9d68-770991ddec7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_8e1fdf6a-65ef-4faf-be57-35b32ac28cb4" xlink:href="arvn-20221231.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_8b146ec6-863a-4783-b691-dc3fd36e8c8e" xlink:to="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_8e1fdf6a-65ef-4faf-be57-35b32ac28cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_be786e10-160e-4b81-bec8-04e1fea08456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_8b146ec6-863a-4783-b691-dc3fd36e8c8e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_be786e10-160e-4b81-bec8-04e1fea08456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_a31481de-74ba-47aa-a827-631100645b28" xlink:href="arvn-20221231.xsd#arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_08049355-c855-4104-af40-b1e748fbb028" xlink:to="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_a31481de-74ba-47aa-a827-631100645b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent_7ff9ea5f-1484-46f1-a6af-befcc7e21aa3" xlink:href="arvn-20221231.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_a31481de-74ba-47aa-a827-631100645b28" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrent_7ff9ea5f-1484-46f1-a6af-befcc7e21aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentAdditions_d47ffbe3-95af-4b51-b896-3c527137941f" xlink:href="arvn-20221231.xsd#arvn_AccountsPayableContractBalancesCurrentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_a31481de-74ba-47aa-a827-631100645b28" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrentAdditions_d47ffbe3-95af-4b51-b896-3c527137941f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentPayments_f52afdae-2b77-4c93-b312-eabe6615ce91" xlink:href="arvn-20221231.xsd#arvn_AccountsPayableContractBalancesCurrentPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_a31481de-74ba-47aa-a827-631100645b28" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrentPayments_f52afdae-2b77-4c93-b312-eabe6615ce91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent_9a9c9001-770e-42ff-9aac-5b0e623ebba3" xlink:href="arvn-20221231.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_a31481de-74ba-47aa-a827-631100645b28" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrent_9a9c9001-770e-42ff-9aac-5b0e623ebba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_3eaeaa7f-4e33-44ad-bbfe-0358f379f053" xlink:href="arvn-20221231.xsd#arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_08049355-c855-4104-af40-b1e748fbb028" xlink:to="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_3eaeaa7f-4e33-44ad-bbfe-0358f379f053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_f538992d-f849-4948-9b04-fabd363ff069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_3eaeaa7f-4e33-44ad-bbfe-0358f379f053" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_f538992d-f849-4948-9b04-fabd363ff069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_0c92a2e4-7841-4bcc-a599-d8f0f1ca373c" xlink:href="arvn-20221231.xsd#arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_3eaeaa7f-4e33-44ad-bbfe-0358f379f053" xlink:to="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_0c92a2e4-7841-4bcc-a599-d8f0f1ca373c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_6c93a7a1-c151-4f40-ab5f-7e77b40ac0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_3eaeaa7f-4e33-44ad-bbfe-0358f379f053" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_6c93a7a1-c151-4f40-ab5f-7e77b40ac0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_5ff79712-c823-415c-a0ce-2a248818da0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_3eaeaa7f-4e33-44ad-bbfe-0358f379f053" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_5ff79712-c823-415c-a0ce-2a248818da0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_3735ab56-4d7d-4688-ab3b-84b49dfebd65" xlink:href="arvn-20221231.xsd#arvn_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_08049355-c855-4104-af40-b1e748fbb028" xlink:to="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_3735ab56-4d7d-4688-ab3b-84b49dfebd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_be874f5a-ee2c-495f-b133-b8bbc38a5574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_3735ab56-4d7d-4688-ab3b-84b49dfebd65" xlink:to="loc_us-gaap_ContractWithCustomerLiability_be874f5a-ee2c-495f-b133-b8bbc38a5574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_bddde56a-824c-4a28-985c-e35bf64a7644" xlink:href="arvn-20221231.xsd#arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_3735ab56-4d7d-4688-ab3b-84b49dfebd65" xlink:to="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_bddde56a-824c-4a28-985c-e35bf64a7644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_19791f0c-03df-4ccc-8a43-0e224340bf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_3735ab56-4d7d-4688-ab3b-84b49dfebd65" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_19791f0c-03df-4ccc-8a43-0e224340bf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance_c3b0d11a-1730-431d-8684-8ad29dbcf50e" xlink:href="arvn-20221231.xsd#arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_3735ab56-4d7d-4688-ab3b-84b49dfebd65" xlink:to="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance_c3b0d11a-1730-431d-8684-8ad29dbcf50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d00a44ac-0b4e-4d89-9076-a87a9f1ad4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_3735ab56-4d7d-4688-ab3b-84b49dfebd65" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d00a44ac-0b4e-4d89-9076-a87a9f1ad4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_c3d79308-132f-40e0-b6e3-06aef54d3f49" xlink:href="arvn-20221231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a6a74f5-0f14-4fb3-aba5-233b4dac4ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_c3d79308-132f-40e0-b6e3-06aef54d3f49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a6a74f5-0f14-4fb3-aba5-233b4dac4ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_f6aeab1a-38b4-49d8-9145-413806be6745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a6a74f5-0f14-4fb3-aba5-233b4dac4ab1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_f6aeab1a-38b4-49d8-9145-413806be6745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a6a74f5-0f14-4fb3-aba5-233b4dac4ab1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_00aad7c8-a66c-4407-94d7-d055c064e888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_00aad7c8-a66c-4407-94d7-d055c064e888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_feb4405e-62e9-45fb-8a7e-ab15ed19dda9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_02bfd859-2da2-40ca-a37a-d32eadd0a5c7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_feb4405e-62e9-45fb-8a7e-ab15ed19dda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="arvn-20221231.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#MarketableSecuritiesandFairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cc4722fe-dbea-463c-8088-6cf1ffd23223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc4722fe-dbea-463c-8088-6cf1ffd23223" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84a8856-557a-461c-a934-c51d169def14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84a8856-557a-461c-a934-c51d169def14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5d31fe-a01d-46d7-902b-d8f666dde523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84a8856-557a-461c-a934-c51d169def14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5d31fe-a01d-46d7-902b-d8f666dde523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7c3db3a8-3bc8-46cf-af8c-6c1ab83f9335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f5d31fe-a01d-46d7-902b-d8f666dde523" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7c3db3a8-3bc8-46cf-af8c-6c1ab83f9335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_142d299f-8a46-4554-81b0-2af98da9534e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_142d299f-8a46-4554-81b0-2af98da9534e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0674c079-37b7-4f63-bc13-8de8957435ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_142d299f-8a46-4554-81b0-2af98da9534e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0674c079-37b7-4f63-bc13-8de8957435ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_826b5673-950c-4c0f-ab8d-8a263fb3298f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0674c079-37b7-4f63-bc13-8de8957435ca" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_826b5673-950c-4c0f-ab8d-8a263fb3298f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_795452ec-c876-4a99-9a2a-159ec3cff752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0674c079-37b7-4f63-bc13-8de8957435ca" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_795452ec-c876-4a99-9a2a-159ec3cff752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9b0d5e7e-6c98-4ac3-8f8d-2c5acfc46390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9b0d5e7e-6c98-4ac3-8f8d-2c5acfc46390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9b0d5e7e-6c98-4ac3-8f8d-2c5acfc46390" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_8d90444c-14af-408a-b469-a88959ac729b" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_8d90444c-14af-408a-b469-a88959ac729b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_47f3f9be-1cf9-473f-a8c4-16c04ddbd479" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_47f3f9be-1cf9-473f-a8c4-16c04ddbd479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_810f42c9-921e-408d-9dfb-ab1d2391f3fc" xlink:href="arvn-20221231.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_810f42c9-921e-408d-9dfb-ab1d2391f3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_8ffd132c-7da9-4ff0-a4f0-d67b782a76b9" xlink:href="arvn-20221231.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_8ffd132c-7da9-4ff0-a4f0-d67b782a76b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_f17611fc-c395-4d36-8099-2629acb0865f" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember_f17611fc-c395-4d36-8099-2629acb0865f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_f7d8ba38-3118-4a6f-8048-c5c9e2bbe380" xlink:href="arvn-20221231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_f7d8ba38-3118-4a6f-8048-c5c9e2bbe380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_55abda27-ea6e-408d-af2e-2d923fe45292" xlink:href="arvn-20221231.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd9bc73f-1134-438e-90bc-b43cd8e3b15d" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember_55abda27-ea6e-408d-af2e-2d923fe45292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_56d8ba54-ae91-4cea-833d-001e19fdd19d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:to="loc_srt_CounterpartyNameAxis_56d8ba54-ae91-4cea-833d-001e19fdd19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ceb48ad-6239-4825-ad9e-cd3978fc17b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_56d8ba54-ae91-4cea-833d-001e19fdd19d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ceb48ad-6239-4825-ad9e-cd3978fc17b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_3f66e6c2-62e8-4ab8-bafc-2ed0f9dd0e06" xlink:href="arvn-20221231.xsd#arvn_PfizerIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ceb48ad-6239-4825-ad9e-cd3978fc17b5" xlink:to="loc_arvn_PfizerIncorporationMember_3f66e6c2-62e8-4ab8-bafc-2ed0f9dd0e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0a521b4d-65d1-42d2-9171-136d0d727c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0a521b4d-65d1-42d2-9171-136d0d727c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e71c781a-1761-43bf-a5f6-106f4a26ff59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0a521b4d-65d1-42d2-9171-136d0d727c59" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e71c781a-1761-43bf-a5f6-106f4a26ff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockPurchaseAgreementMember_0c5b22fd-3eb5-4431-afcf-7840101090ee" xlink:href="arvn-20221231.xsd#arvn_StockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e71c781a-1761-43bf-a5f6-106f4a26ff59" xlink:to="loc_arvn_StockPurchaseAgreementMember_0c5b22fd-3eb5-4431-afcf-7840101090ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8023fc65-175c-412e-97d6-b6f4be628ae7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_084ed708-9074-4bd1-946b-24108b6cbc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_084ed708-9074-4bd1-946b-24108b6cbc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9c1c5c54-0b53-4a31-97f2-5755989bde30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9c1c5c54-0b53-4a31-97f2-5755989bde30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a07962ce-6fee-414a-858a-0bc4e2828952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a07962ce-6fee-414a-858a-0bc4e2828952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ecba69fe-a0bb-47aa-97e1-9b4d95cd7135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ecba69fe-a0bb-47aa-97e1-9b4d95cd7135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f6a7636a-46c7-474c-b8a0-d08a55fd342a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f42a6f1f-b64f-4a18-9a48-e962ca7de96a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f6a7636a-46c7-474c-b8a0-d08a55fd342a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cc5f63f5-2206-43fa-9964-681257c307cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ee8ebf80-effb-4baa-936e-d4c0b85e0530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cc5f63f5-2206-43fa-9964-681257c307cd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ee8ebf80-effb-4baa-936e-d4c0b85e0530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa7e6735-2f17-42a9-be66-28967d4e47c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ee8ebf80-effb-4baa-936e-d4c0b85e0530" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa7e6735-2f17-42a9-be66-28967d4e47c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d33cf4ac-0790-402e-b784-b1d1271e993d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa7e6735-2f17-42a9-be66-28967d4e47c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d33cf4ac-0790-402e-b784-b1d1271e993d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_c4d9b7de-98df-4577-9d3a-09219e7c3ed2" xlink:href="arvn-20221231.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d33cf4ac-0790-402e-b784-b1d1271e993d" xlink:to="loc_arvn_LaboratoryEquipmentMember_c4d9b7de-98df-4577-9d3a-09219e7c3ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_abb323b7-7945-47cc-a597-56e14d8782df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d33cf4ac-0790-402e-b784-b1d1271e993d" xlink:to="loc_us-gaap_OfficeEquipmentMember_abb323b7-7945-47cc-a597-56e14d8782df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2db37ddd-c221-4b96-93d1-c672d434aa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d33cf4ac-0790-402e-b784-b1d1271e993d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2db37ddd-c221-4b96-93d1-c672d434aa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba25ed7e-9da4-49ba-9836-d102610ce4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ee8ebf80-effb-4baa-936e-d4c0b85e0530" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba25ed7e-9da4-49ba-9836-d102610ce4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5067b7c7-3555-4867-8c07-b06fff5afa58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba25ed7e-9da4-49ba-9836-d102610ce4fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5067b7c7-3555-4867-8c07-b06fff5afa58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2b197fc5-9c85-4057-beaa-93a200ae80b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba25ed7e-9da4-49ba-9836-d102610ce4fa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2b197fc5-9c85-4057-beaa-93a200ae80b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_72c2b3d7-bb92-486b-9c7d-a1475979d3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba25ed7e-9da4-49ba-9836-d102610ce4fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_72c2b3d7-bb92-486b-9c7d-a1475979d3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7d378a8a-2b91-474c-abdf-08b64cfb93d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_01bbc856-602b-4833-b068-14e540948747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7d378a8a-2b91-474c-abdf-08b64cfb93d5" xlink:to="loc_us-gaap_Depreciation_01bbc856-602b-4833-b068-14e540948747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#RightofUseAssetsandLiabilitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_63efb8b1-b9a0-46a9-8412-dfdea1b697c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_cb56e061-0a58-4521-a4d4-041e87974b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_63efb8b1-b9a0-46a9-8412-dfdea1b697c8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_cb56e061-0a58-4521-a4d4-041e87974b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f703a4a9-3c78-411d-94cc-90aa925164d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cb56e061-0a58-4521-a4d4-041e87974b49" xlink:to="loc_srt_RangeAxis_f703a4a9-3c78-411d-94cc-90aa925164d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_920c7aeb-eef1-4ce1-a16e-59aeab82d5a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f703a4a9-3c78-411d-94cc-90aa925164d5" xlink:to="loc_srt_RangeMember_920c7aeb-eef1-4ce1-a16e-59aeab82d5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e94f566f-a844-4d94-b914-2ef29247e884" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_920c7aeb-eef1-4ce1-a16e-59aeab82d5a3" xlink:to="loc_srt_MinimumMember_e94f566f-a844-4d94-b914-2ef29247e884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dcfda809-4085-40dc-9716-ddadcf725704" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_920c7aeb-eef1-4ce1-a16e-59aeab82d5a3" xlink:to="loc_srt_MaximumMember_dcfda809-4085-40dc-9716-ddadcf725704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusAxis_21107835-1627-4b2e-b21b-6a7bbcb0da08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cb56e061-0a58-4521-a4d4-041e87974b49" xlink:to="loc_us-gaap_PledgedStatusAxis_21107835-1627-4b2e-b21b-6a7bbcb0da08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain_e04fa111-9926-4f13-9392-9bfcda9bc58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgedStatusAxis_21107835-1627-4b2e-b21b-6a7bbcb0da08" xlink:to="loc_us-gaap_PledgedStatusDomain_e04fa111-9926-4f13-9392-9bfcda9bc58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetPledgedAsCollateralMember_6ba54ae9-7a9c-45ef-b9c6-9f4350d2cd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetPledgedAsCollateralMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgedStatusDomain_e04fa111-9926-4f13-9392-9bfcda9bc58b" xlink:to="loc_us-gaap_AssetPledgedAsCollateralMember_6ba54ae9-7a9c-45ef-b9c6-9f4350d2cd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeAxis_21187286-695b-49e0-b6e7-9c47f0ed3987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cb56e061-0a58-4521-a4d4-041e87974b49" xlink:to="loc_us-gaap_PledgingPurposeAxis_21187286-695b-49e0-b6e7-9c47f0ed3987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain_4c120a2c-ca1e-47e9-acb6-61c745b47892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgingPurposeAxis_21187286-695b-49e0-b6e7-9c47f0ed3987" xlink:to="loc_us-gaap_PledgingPurposeDomain_4c120a2c-ca1e-47e9-acb6-61c745b47892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0017885f-a175-4545-a363-0bec6a187b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgingPurposeDomain_4c120a2c-ca1e-47e9-acb6-61c745b47892" xlink:to="loc_us-gaap_LetterOfCreditMember_0017885f-a175-4545-a363-0bec6a187b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cb56e061-0a58-4521-a4d4-041e87974b49" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_6b8f9bbc-4d29-4378-ac25-92ba983bfe08" xlink:href="arvn-20221231.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_6b8f9bbc-4d29-4378-ac25-92ba983bfe08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_4c5d8d4c-cee3-4ab1-bff9-a247cbd82cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_4c5d8d4c-cee3-4ab1-bff9-a247cbd82cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecurities_de0808b6-30d0-466c-802e-2db91886416f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_us-gaap_DebtSecurities_de0808b6-30d0-466c-802e-2db91886416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b9075cf9-c853-4058-9c36-9579873b403b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_us-gaap_LeaseCost_b9075cf9-c853-4058-9c36-9579873b403b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BaseLeaseRentPeriod_3aaa018b-98f7-43bf-85d4-112d54ed092d" xlink:href="arvn-20221231.xsd#arvn_BaseLeaseRentPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_arvn_BaseLeaseRentPeriod_3aaa018b-98f7-43bf-85d4-112d54ed092d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_321794d3-d51c-4b5f-b147-bbde81f60da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3367a15e-0040-43a6-bc0d-8d22dada6de7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_321794d3-d51c-4b5f-b147-bbde81f60da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_038a240f-8d8f-48bc-8bba-d33531d40b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d8179a1b-d08e-4d76-8bab-a11ffe9b4f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_038a240f-8d8f-48bc-8bba-d33531d40b55" xlink:to="loc_us-gaap_OperatingLeaseCost_d8179a1b-d08e-4d76-8bab-a11ffe9b4f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d57d0fc4-8c1f-492c-b083-6476231f269a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_9c87ef3d-698a-43ec-8e97-b504fcd52d36" xlink:href="arvn-20221231.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d57d0fc4-8c1f-492c-b083-6476231f269a" xlink:to="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_9c87ef3d-698a-43ec-8e97-b504fcd52d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_e158e271-ce36-4dc8-82fe-bf9bd84974e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_9c87ef3d-698a-43ec-8e97-b504fcd52d36" xlink:to="loc_us-gaap_OperatingLeasePayments_e158e271-ce36-4dc8-82fe-bf9bd84974e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_e65c3b78-08f2-4e46-9127-6b27287131b0" xlink:href="arvn-20221231.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d57d0fc4-8c1f-492c-b083-6476231f269a" xlink:to="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_e65c3b78-08f2-4e46-9127-6b27287131b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a9fb4b11-e617-4ad4-bd52-175a5a647b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_e65c3b78-08f2-4e46-9127-6b27287131b0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a9fb4b11-e617-4ad4-bd52-175a5a647b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3b6830a3-cc29-4695-ac3a-993265eddb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fc301338-3168-4d54-96b1-e344d09cf47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b6830a3-cc29-4695-ac3a-993265eddb5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fc301338-3168-4d54-96b1-e344d09cf47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e8a584f0-e543-4d9f-ac6a-0aa14e5219bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b6830a3-cc29-4695-ac3a-993265eddb5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e8a584f0-e543-4d9f-ac6a-0aa14e5219bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f743f7c9-c335-4ebf-beef-fe79668b4b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b6830a3-cc29-4695-ac3a-993265eddb5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f743f7c9-c335-4ebf-beef-fe79668b4b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e1f20521-99a5-4586-b7b9-3c0816611a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b6830a3-cc29-4695-ac3a-993265eddb5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e1f20521-99a5-4586-b7b9-3c0816611a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12194747-5120-45a0-895c-ff075e07e98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b6830a3-cc29-4695-ac3a-993265eddb5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12194747-5120-45a0-895c-ff075e07e98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_325caa1f-658f-407b-8707-8ec64fc4c058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b6830a3-cc29-4695-ac3a-993265eddb5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_325caa1f-658f-407b-8707-8ec64fc4c058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f534e741-db34-4cf6-9bea-34d491676e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b6830a3-cc29-4695-ac3a-993265eddb5f" xlink:to="loc_us-gaap_OperatingLeaseLiability_f534e741-db34-4cf6-9bea-34d491676e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="arvn-20221231.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_eac090e2-077b-4bdf-b4dd-b2c665e6629b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_51f737a3-75cc-4260-b1f2-97dd580413c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_eac090e2-077b-4bdf-b4dd-b2c665e6629b" xlink:to="loc_us-gaap_AccountsPayableCurrent_51f737a3-75cc-4260-b1f2-97dd580413c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8514ab85-33ec-4e0d-a242-dff3df046edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_eac090e2-077b-4bdf-b4dd-b2c665e6629b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8514ab85-33ec-4e0d-a242-dff3df046edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_8739d851-b1f1-43da-a1d5-808512967c4d" xlink:href="arvn-20221231.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8514ab85-33ec-4e0d-a242-dff3df046edd" xlink:to="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_8739d851-b1f1-43da-a1d5-808512967c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f7bc66ca-8f7b-4bd2-901e-c9705582ad32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8514ab85-33ec-4e0d-a242-dff3df046edd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f7bc66ca-8f7b-4bd2-901e-c9705582ad32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_8ec707db-8d30-4b49-9e0b-ba6c66df47be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8514ab85-33ec-4e0d-a242-dff3df046edd" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_8ec707db-8d30-4b49-9e0b-ba6c66df47be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_c8edd335-1f21-4931-ae6b-8ea833e23a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8514ab85-33ec-4e0d-a242-dff3df046edd" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_c8edd335-1f21-4931-ae6b-8ea833e23a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7a662c67-307d-4011-b418-803715be3b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_eac090e2-077b-4bdf-b4dd-b2c665e6629b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7a662c67-307d-4011-b418-803715be3b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4433a0ae-d386-4da8-89c8-c76eab86e832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a70da94a-b00d-494d-8c15-3bb053c23a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4433a0ae-d386-4da8-89c8-c76eab86e832" xlink:to="loc_us-gaap_DebtInstrumentTable_a70da94a-b00d-494d-8c15-3bb053c23a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_725c5f07-5051-458f-9d06-8d5603d8b4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a70da94a-b00d-494d-8c15-3bb053c23a6e" xlink:to="loc_us-gaap_DebtInstrumentAxis_725c5f07-5051-458f-9d06-8d5603d8b4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba3ab0cb-4da6-42d7-a0cf-7d8b24a9b54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_725c5f07-5051-458f-9d06-8d5603d8b4bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba3ab0cb-4da6-42d7-a0cf-7d8b24a9b54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_3fcd8ef8-8224-47af-a097-5d1c6f501717" xlink:href="arvn-20221231.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba3ab0cb-4da6-42d7-a0cf-7d8b24a9b54f" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_3fcd8ef8-8224-47af-a097-5d1c6f501717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_28e080e3-0c59-477b-bcbd-05a36ae07afd" xlink:href="arvn-20221231.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba3ab0cb-4da6-42d7-a0cf-7d8b24a9b54f" xlink:to="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_28e080e3-0c59-477b-bcbd-05a36ae07afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6513931b-0699-4dc1-9f86-3639085623d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a70da94a-b00d-494d-8c15-3bb053c23a6e" xlink:to="loc_srt_StatementGeographicalAxis_6513931b-0699-4dc1-9f86-3639085623d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_abf80aaa-05f4-4857-a55c-852317c1e9ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6513931b-0699-4dc1-9f86-3639085623d2" xlink:to="loc_srt_SegmentGeographicalDomain_abf80aaa-05f4-4857-a55c-852317c1e9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_4d48e98b-31a0-4eff-a7f4-2c6e6e90681a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_abf80aaa-05f4-4857-a55c-852317c1e9ab" xlink:to="loc_stpr_CT_4d48e98b-31a0-4eff-a7f4-2c6e6e90681a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f349e01-1d29-44a0-b227-3821a46acee4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a70da94a-b00d-494d-8c15-3bb053c23a6e" xlink:to="loc_srt_RangeAxis_0f349e01-1d29-44a0-b227-3821a46acee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1834ab6c-047b-4f8d-9833-5288321d7ead" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0f349e01-1d29-44a0-b227-3821a46acee4" xlink:to="loc_srt_RangeMember_1834ab6c-047b-4f8d-9833-5288321d7ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c6939110-5176-45fb-b842-f6153ec6a4d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1834ab6c-047b-4f8d-9833-5288321d7ead" xlink:to="loc_srt_MaximumMember_c6939110-5176-45fb-b842-f6153ec6a4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a70da94a-b00d-494d-8c15-3bb053c23a6e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_affbb4a1-1dbd-44fb-967c-c154b9f0fa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_affbb4a1-1dbd-44fb-967c-c154b9f0fa2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfMaximumFundingOnProjectCosts_abc56180-a561-491d-b5f9-d7906c6744af" xlink:href="arvn-20221231.xsd#arvn_PercentageOfMaximumFundingOnProjectCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_arvn_PercentageOfMaximumFundingOnProjectCosts_abc56180-a561-491d-b5f9-d7906c6744af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a47244ad-ce38-47e8-8cec-e856618dc3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a47244ad-ce38-47e8-8cec-e856618dc3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm_756bc146-7622-4115-9f90-1ef36c7eaf1e" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_arvn_DebtInstrumentInterestPaymentsTerm_756bc146-7622-4115-9f90-1ef36c7eaf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod_2a323c49-2561-4a00-b3a1-adb0cd621be8" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod_2a323c49-2561-4a00-b3a1-adb0cd621be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_1e72afdf-64b7-4d2c-8797-4b6b3cc40e3a" xlink:href="arvn-20221231.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_1e72afdf-64b7-4d2c-8797-4b6b3cc40e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages_2ce018cf-bc2e-4e26-a2b5-9bab4c87ec70" xlink:href="arvn-20221231.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_arvn_PercentageOfLiquidatedDamages_2ce018cf-bc2e-4e26-a2b5-9bab4c87ec70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_13d05a3d-cc24-409f-a8e4-e75d4c7a327e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6aba9f9a-7091-4640-815c-df7f76255163" xlink:to="loc_us-gaap_InterestExpenseDebt_13d05a3d-cc24-409f-a8e4-e75d4c7a327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e33563bb-113d-4516-a5c6-aa881e4a570e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d215956a-aa78-4fb9-a1ef-eb426c0b9835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e33563bb-113d-4516-a5c6-aa881e4a570e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d215956a-aa78-4fb9-a1ef-eb426c0b9835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f9094dfc-6a15-4e50-84ec-7b7727546f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e33563bb-113d-4516-a5c6-aa881e4a570e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f9094dfc-6a15-4e50-84ec-7b7727546f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c4d0161b-5677-49d6-a92c-69a0d7b84d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e33563bb-113d-4516-a5c6-aa881e4a570e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c4d0161b-5677-49d6-a92c-69a0d7b84d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0a89573c-a08b-45b3-948d-5d233783e96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e33563bb-113d-4516-a5c6-aa881e4a570e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0a89573c-a08b-45b3-948d-5d233783e96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_cef0f6db-828f-48ec-92d4-16d02c48d6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e33563bb-113d-4516-a5c6-aa881e4a570e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_cef0f6db-828f-48ec-92d4-16d02c48d6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ee1fd670-e6c8-4f57-a1d1-b531da560162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e33563bb-113d-4516-a5c6-aa881e4a570e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ee1fd670-e6c8-4f57-a1d1-b531da560162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_eb445938-4993-480c-b7fd-3e15cbd68072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e33563bb-113d-4516-a5c6-aa881e4a570e" xlink:to="loc_us-gaap_LongTermDebt_eb445938-4993-480c-b7fd-3e15cbd68072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5ab87c9-5e0a-4740-8f3f-0e7f9d61c806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5ab87c9-5e0a-4740-8f3f-0e7f9d61c806" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6ca744d9-1114-43f8-8780-b5a4980dbecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6ca744d9-1114-43f8-8780-b5a4980dbecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_175a90b8-d3d7-4803-8972-af048fdd45f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ca744d9-1114-43f8-8780-b5a4980dbecc" xlink:to="loc_us-gaap_EquityComponentDomain_175a90b8-d3d7-4803-8972-af048fdd45f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f92f5bf6-ad58-4bc7-b700-b3b0fc683d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_175a90b8-d3d7-4803-8972-af048fdd45f6" xlink:to="loc_us-gaap_CommonStockMember_f92f5bf6-ad58-4bc7-b700-b3b0fc683d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6e9afd54-f1a5-45c7-ae48-ee2df36f0d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6e9afd54-f1a5-45c7-ae48-ee2df36f0d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40fd9b89-8048-44fb-9448-a391106cd4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6e9afd54-f1a5-45c7-ae48-ee2df36f0d50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40fd9b89-8048-44fb-9448-a391106cd4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockPurchaseAgreementMember_ef35f089-2d38-4184-9b85-2fce85593e11" xlink:href="arvn-20221231.xsd#arvn_StockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40fd9b89-8048-44fb-9448-a391106cd4e2" xlink:to="loc_arvn_StockPurchaseAgreementMember_ef35f089-2d38-4184-9b85-2fce85593e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember_f02882bc-cf3a-486f-94b1-095015f2a49f" xlink:href="arvn-20221231.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40fd9b89-8048-44fb-9448-a391106cd4e2" xlink:to="loc_arvn_EquityDistributionAgreementMember_f02882bc-cf3a-486f-94b1-095015f2a49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bbcc5cd2-10f3-416c-aa4d-798a5743bef1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_srt_CounterpartyNameAxis_bbcc5cd2-10f3-416c-aa4d-798a5743bef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e215e871-36a4-4141-a9a9-b6f21c880ba5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bbcc5cd2-10f3-416c-aa4d-798a5743bef1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e215e871-36a4-4141-a9a9-b6f21c880ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_b93a0f80-334e-496e-9512-9a5378435feb" xlink:href="arvn-20221231.xsd#arvn_PfizerIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e215e871-36a4-4141-a9a9-b6f21c880ba5" xlink:to="loc_arvn_PfizerIncorporationMember_b93a0f80-334e-496e-9512-9a5378435feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerMember_2ee07702-eb48-4c36-9125-1d196e8a83cf" xlink:href="arvn-20221231.xsd#arvn_PiperSandlerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e215e871-36a4-4141-a9a9-b6f21c880ba5" xlink:to="loc_arvn_PiperSandlerMember_2ee07702-eb48-4c36-9125-1d196e8a83cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b4ab93de-8211-4e3e-9cde-3bac35bfeda2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b4ab93de-8211-4e3e-9cde-3bac35bfeda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97e468ee-f145-4d85-88bb-0010dc888871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b4ab93de-8211-4e3e-9cde-3bac35bfeda2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97e468ee-f145-4d85-88bb-0010dc888871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_bbe65afe-84a1-4a1a-b37d-e50a29142605" xlink:href="arvn-20221231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97e468ee-f145-4d85-88bb-0010dc888871" xlink:to="loc_arvn_AtTheMarketOfferingMember_bbe65afe-84a1-4a1a-b37d-e50a29142605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e74f03de-e319-4d4b-a7ea-4ee96fff2bb1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_srt_RangeAxis_e74f03de-e319-4d4b-a7ea-4ee96fff2bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8a2a25f1-9f43-4da7-8f76-92664fe90c9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e74f03de-e319-4d4b-a7ea-4ee96fff2bb1" xlink:to="loc_srt_RangeMember_8a2a25f1-9f43-4da7-8f76-92664fe90c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9a1f4a62-93cb-4c67-9eb4-49cf9cf26f25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8a2a25f1-9f43-4da7-8f76-92664fe90c9b" xlink:to="loc_srt_MinimumMember_9a1f4a62-93cb-4c67-9eb4-49cf9cf26f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f370625c-8e14-4ca4-8e8e-4158f25d1540" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8a2a25f1-9f43-4da7-8f76-92664fe90c9b" xlink:to="loc_srt_MaximumMember_f370625c-8e14-4ca4-8e8e-4158f25d1540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_0292278b-69ba-49fb-87ba-22e35f1def5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8a2a25f1-9f43-4da7-8f76-92664fe90c9b" xlink:to="loc_srt_WeightedAverageMember_0292278b-69ba-49fb-87ba-22e35f1def5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_c97f7179-688e-4514-86a0-8bfd600b418d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_srt_TitleOfIndividualAxis_c97f7179-688e-4514-86a0-8bfd600b418d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_361a94b4-8c92-41dc-930f-d480e9a11ca2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_c97f7179-688e-4514-86a0-8bfd600b418d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_361a94b4-8c92-41dc-930f-d480e9a11ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember_f0015ca1-080d-407d-970a-3a633c0b4ee2" xlink:href="arvn-20221231.xsd#arvn_EmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_361a94b4-8c92-41dc-930f-d480e9a11ca2" xlink:to="loc_arvn_EmployeesMember_f0015ca1-080d-407d-970a-3a633c0b4ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b2cfb496-49db-4161-9797-aae5095c03b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_us-gaap_PlanNameAxis_b2cfb496-49db-4161-9797-aae5095c03b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dc248e78-e3db-4a08-bcf6-6c5ac144b047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b2cfb496-49db-4161-9797-aae5095c03b4" xlink:to="loc_us-gaap_PlanNameDomain_dc248e78-e3db-4a08-bcf6-6c5ac144b047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_c1cac976-5195-4101-b45e-f58db30f3cdc" xlink:href="arvn-20221231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dc248e78-e3db-4a08-bcf6-6c5ac144b047" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_c1cac976-5195-4101-b45e-f58db30f3cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember_6bfa629a-9f73-45e8-9bcd-c822fbf3af0c" xlink:href="arvn-20221231.xsd#arvn_StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dc248e78-e3db-4a08-bcf6-6c5ac144b047" xlink:to="loc_arvn_StockIncentivePlanMember_6bfa629a-9f73-45e8-9bcd-c822fbf3af0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_483c4d18-bd26-4ffb-9e1b-00a5a20e539d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_us-gaap_AwardTypeAxis_483c4d18-bd26-4ffb-9e1b-00a5a20e539d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4e8d938-2e54-45f3-9151-774614fb1b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_483c4d18-bd26-4ffb-9e1b-00a5a20e539d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4e8d938-2e54-45f3-9151-774614fb1b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_73a0030a-0f5c-4d9c-8695-f747bfe6ea76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4e8d938-2e54-45f3-9151-774614fb1b1e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_73a0030a-0f5c-4d9c-8695-f747bfe6ea76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_94acdfe5-5a34-47a9-8a82-43a4144ff4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4e8d938-2e54-45f3-9151-774614fb1b1e" xlink:to="loc_us-gaap_EmployeeStockMember_94acdfe5-5a34-47a9-8a82-43a4144ff4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_787addb0-af65-405a-b135-fbf6e1a620dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ec395bcd-16c7-497d-b71f-09b13d070e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ec395bcd-16c7-497d-b71f-09b13d070e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d442805f-6ded-4a85-a451-1731f44bca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d442805f-6ded-4a85-a451-1731f44bca8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfVotesPerCommonStockShareHeld_147c0b22-7e63-4331-8113-189b1bda89da" xlink:href="arvn-20221231.xsd#arvn_NumberOfVotesPerCommonStockShareHeld"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_arvn_NumberOfVotesPerCommonStockShareHeld_147c0b22-7e63-4331-8113-189b1bda89da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_322983f3-5cbb-4f78-aa57-6d7860490d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_322983f3-5cbb-4f78-aa57-6d7860490d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_daeb29f7-c1f2-40aa-8254-04f64450460c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_daeb29f7-c1f2-40aa-8254-04f64450460c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_271a2852-ca1d-4d2b-ad31-19177bc77b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_271a2852-ca1d-4d2b-ad31-19177bc77b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForBrokerageFees_36d037f8-b0ba-4f5c-943a-85e6fdb715f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForBrokerageFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_PaymentsForBrokerageFees_36d037f8-b0ba-4f5c-943a-85e6fdb715f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_58b65237-a69b-4123-9d9e-ea534ef3fed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_58b65237-a69b-4123-9d9e-ea534ef3fed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_679942cf-e32e-4013-9fca-d01a19de9124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForUnderwritingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_679942cf-e32e-4013-9fca-d01a19de9124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement_aeb06ead-4130-4070-9130-d9b5a7869a46" xlink:href="arvn-20221231.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement_aeb06ead-4130-4070-9130-d9b5a7869a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_23da8592-1ff6-477f-8532-6f465972bc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_23da8592-1ff6-477f-8532-6f465972bc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6e8fc82f-91dd-40ec-aab3-b61ba6a024bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6e8fc82f-91dd-40ec-aab3-b61ba6a024bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e825fe1c-b3a0-4909-b794-95bad59ea60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e825fe1c-b3a0-4909-b794-95bad59ea60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_1552f09a-4749-46af-bf83-80a4abf637d2" xlink:href="arvn-20221231.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_1552f09a-4749-46af-bf83-80a4abf637d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5003e395-f026-4cb1-bfe8-44028daea3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5003e395-f026-4cb1-bfe8-44028daea3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1accc2d8-9832-4136-9735-2e1b098a0b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1accc2d8-9832-4136-9735-2e1b098a0b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bdfec54-f67e-48ba-9ffb-4720b0ef757d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bdfec54-f67e-48ba-9ffb-4720b0ef757d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6452f975-7d98-4cbc-8d76-0628f0a3fb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6452f975-7d98-4cbc-8d76-0628f0a3fb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_20d90e88-dd9c-4896-839d-03923d18ed9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_20d90e88-dd9c-4896-839d-03923d18ed9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0120f3d0-c918-4777-9ac4-97a9edf1a4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0120f3d0-c918-4777-9ac4-97a9edf1a4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_eafc5d81-af47-46ee-807b-a956b101a74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_eafc5d81-af47-46ee-807b-a956b101a74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a572acdb-b5af-460c-b41c-0265401297c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a572acdb-b5af-460c-b41c-0265401297c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf1f36a-c5bb-477f-b64d-31fbeaa017ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf1f36a-c5bb-477f-b64d-31fbeaa017ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26b8cbbb-7e77-4c57-96b6-673763c1da56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26b8cbbb-7e77-4c57-96b6-673763c1da56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0f68fe02-8fb0-4cc0-a7e7-bfb6c1ea7bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0f68fe02-8fb0-4cc0-a7e7-bfb6c1ea7bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_18aee3d4-c9bb-4710-82f8-47646e1c6124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_18aee3d4-c9bb-4710-82f8-47646e1c6124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_68e8af9f-956f-4e3d-a08f-7dfaa40cb625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_68e8af9f-956f-4e3d-a08f-7dfaa40cb625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber_3851b714-6dd6-47ac-842b-6b37b4c8b52d" xlink:href="arvn-20221231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_907aad85-8e84-4fe7-8e47-9c42d7543a37" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber_3851b714-6dd6-47ac-842b-6b37b4c8b52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15620065-2942-47ad-91eb-c60c95d1966f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_345a8604-8373-456e-aead-9c3d8b91453a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15620065-2942-47ad-91eb-c60c95d1966f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_345a8604-8373-456e-aead-9c3d8b91453a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f65f9c61-80e8-43c3-a41b-2541fe826993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_345a8604-8373-456e-aead-9c3d8b91453a" xlink:to="loc_us-gaap_AwardTypeAxis_f65f9c61-80e8-43c3-a41b-2541fe826993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0a36baa-2640-4d13-974d-88f135a9ce53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f65f9c61-80e8-43c3-a41b-2541fe826993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0a36baa-2640-4d13-974d-88f135a9ce53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_647f139b-31d5-4d58-839e-b19f27d01777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0a36baa-2640-4d13-974d-88f135a9ce53" xlink:to="loc_us-gaap_EmployeeStockOptionMember_647f139b-31d5-4d58-839e-b19f27d01777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bbf7b8a7-e3b7-464a-9b17-1957f7a3c7c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_345a8604-8373-456e-aead-9c3d8b91453a" xlink:to="loc_srt_RangeAxis_bbf7b8a7-e3b7-464a-9b17-1957f7a3c7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a698d8a-ee93-4b83-aa21-f71ae5a8c8c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bbf7b8a7-e3b7-464a-9b17-1957f7a3c7c4" xlink:to="loc_srt_RangeMember_6a698d8a-ee93-4b83-aa21-f71ae5a8c8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9152c30c-39a7-404e-884e-5a000dcc4e64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a698d8a-ee93-4b83-aa21-f71ae5a8c8c1" xlink:to="loc_srt_MinimumMember_9152c30c-39a7-404e-884e-5a000dcc4e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ed0f1f3b-ebe9-4715-9429-92a95e80cb5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a698d8a-ee93-4b83-aa21-f71ae5a8c8c1" xlink:to="loc_srt_MaximumMember_ed0f1f3b-ebe9-4715-9429-92a95e80cb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_345a8604-8373-456e-aead-9c3d8b91453a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6f059d84-7326-4c6c-ae75-36d62585facf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6f059d84-7326-4c6c-ae75-36d62585facf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2a930476-2007-4638-8885-e1ea0ed26c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2a930476-2007-4638-8885-e1ea0ed26c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0b0eac01-a08f-45d9-8f6e-607f5a49f956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0b0eac01-a08f-45d9-8f6e-607f5a49f956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8bd01424-156a-4f15-9e90-a2ce47829334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8bd01424-156a-4f15-9e90-a2ce47829334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0a4259ee-5fe4-466c-8b82-3d60e37d067d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0a4259ee-5fe4-466c-8b82-3d60e37d067d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_db5e2d8c-0b24-4a35-b62d-b86a3d4e1775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_db5e2d8c-0b24-4a35-b62d-b86a3d4e1775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_4dc467d4-f1e1-4c36-9983-9be73514f022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0157465-ed34-4112-86fe-b37fb05ff996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_4dc467d4-f1e1-4c36-9983-9be73514f022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquitySummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9d3f73d-c71d-4ebf-991a-cb1e59e63197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98763f69-4a5a-47f4-af16-6b0bcf0919e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9d3f73d-c71d-4ebf-991a-cb1e59e63197" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98763f69-4a5a-47f4-af16-6b0bcf0919e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b0679f3c-00f4-4811-9db4-4f0e3bd64814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98763f69-4a5a-47f4-af16-6b0bcf0919e8" xlink:to="loc_us-gaap_PlanNameAxis_b0679f3c-00f4-4811-9db4-4f0e3bd64814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e3e8b814-2eb4-4208-bd4a-3bff4c5da854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b0679f3c-00f4-4811-9db4-4f0e3bd64814" xlink:to="loc_us-gaap_PlanNameDomain_e3e8b814-2eb4-4208-bd4a-3bff4c5da854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_cf692909-2da4-44e9-a8e8-a319f64d8bea" xlink:href="arvn-20221231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e3e8b814-2eb4-4208-bd4a-3bff4c5da854" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_cf692909-2da4-44e9-a8e8-a319f64d8bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7b88846f-9250-4a30-8159-d8c77e8e13db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98763f69-4a5a-47f4-af16-6b0bcf0919e8" xlink:to="loc_srt_TitleOfIndividualAxis_7b88846f-9250-4a30-8159-d8c77e8e13db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b1914683-913a-4e58-ad0d-3cc3767bbe8d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_7b88846f-9250-4a30-8159-d8c77e8e13db" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b1914683-913a-4e58-ad0d-3cc3767bbe8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesDirectorsAndConsultantsMember_63438729-70d5-4e59-9cfd-032172526d7d" xlink:href="arvn-20221231.xsd#arvn_EmployeesDirectorsAndConsultantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b1914683-913a-4e58-ad0d-3cc3767bbe8d" xlink:to="loc_arvn_EmployeesDirectorsAndConsultantsMember_63438729-70d5-4e59-9cfd-032172526d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98763f69-4a5a-47f4-af16-6b0bcf0919e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8796af5f-4262-43c6-a427-aa77fdd994b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8796af5f-4262-43c6-a427-aa77fdd994b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a4c5c130-e835-40bd-9a99-d216ae7b3768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a4c5c130-e835-40bd-9a99-d216ae7b3768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4997db20-5b7e-4670-9e41-cc63d05ef6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4997db20-5b7e-4670-9e41-cc63d05ef6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_69d2eab8-5946-4373-a4cb-4457dea1f7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_69d2eab8-5946-4373-a4cb-4457dea1f7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e394258f-f6be-41fc-8e5d-700c82c7519e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4947b512-2156-4615-90ac-64b42d59be7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e394258f-f6be-41fc-8e5d-700c82c7519e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_85f4a4c7-4d0f-43b0-9c44-857bed5defd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_85f4a4c7-4d0f-43b0-9c44-857bed5defd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_84e172e0-618b-4a38-a3e2-f14bfeab93fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_84e172e0-618b-4a38-a3e2-f14bfeab93fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_efafafd4-20cd-47e4-9d39-d149f07d6059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_efafafd4-20cd-47e4-9d39-d149f07d6059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_220f02b2-bfee-44e5-9c0f-0d2b5e4cd8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_220f02b2-bfee-44e5-9c0f-0d2b5e4cd8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_46dd6a6d-4ba0-4855-afa3-9e68600c0df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_46dd6a6d-4ba0-4855-afa3-9e68600c0df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_024207d5-f775-4f89-9dbd-0ce3c9320bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f7bd099a-a9b7-46c0-ab58-43c9119a36cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_024207d5-f775-4f89-9dbd-0ce3c9320bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9d6db90e-d9cb-4492-a6e7-ea0c1846d782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9d6db90e-d9cb-4492-a6e7-ea0c1846d782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d590e1ee-cdfc-4a0b-bba8-a0074834ed2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d590e1ee-cdfc-4a0b-bba8-a0074834ed2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bf0f3e4b-0003-4b9e-b266-b8e26aa14cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bf0f3e4b-0003-4b9e-b266-b8e26aa14cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fe120a40-8dff-49c3-b60c-2f8bc788a79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fe120a40-8dff-49c3-b60c-2f8bc788a79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9a376919-02e4-4799-9933-1f9818bdf332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3078ec6-a320-4983-95e7-9a776c6d7a69" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9a376919-02e4-4799-9933-1f9818bdf332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquitySummaryofRestrictedStockGrantActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_867fbbfd-4104-4459-a45e-2aa6e5c4dab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51df7f06-0492-44a9-a241-bd0212899281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_867fbbfd-4104-4459-a45e-2aa6e5c4dab7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51df7f06-0492-44a9-a241-bd0212899281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_753cba0d-6f10-4df2-a3aa-7c597c1a8b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51df7f06-0492-44a9-a241-bd0212899281" xlink:to="loc_us-gaap_PlanNameAxis_753cba0d-6f10-4df2-a3aa-7c597c1a8b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b5a791f8-4e9c-428b-8b75-59c925ce37f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_753cba0d-6f10-4df2-a3aa-7c597c1a8b39" xlink:to="loc_us-gaap_PlanNameDomain_b5a791f8-4e9c-428b-8b75-59c925ce37f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember_5b370d0d-2759-4109-8960-155388208b0d" xlink:href="arvn-20221231.xsd#arvn_StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b5a791f8-4e9c-428b-8b75-59c925ce37f8" xlink:to="loc_arvn_StockIncentivePlanMember_5b370d0d-2759-4109-8960-155388208b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_cc3b8592-a300-4c22-9b35-e8be65356e83" xlink:href="arvn-20221231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b5a791f8-4e9c-428b-8b75-59c925ce37f8" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_cc3b8592-a300-4c22-9b35-e8be65356e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_36446178-de2d-4c48-8ffe-06f5516cbbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51df7f06-0492-44a9-a241-bd0212899281" xlink:to="loc_us-gaap_AwardTypeAxis_36446178-de2d-4c48-8ffe-06f5516cbbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc0e34da-125b-4dc0-9a31-3590df6f81ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_36446178-de2d-4c48-8ffe-06f5516cbbc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc0e34da-125b-4dc0-9a31-3590df6f81ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_485e6f4d-3906-4f6b-8a05-1d48ea82c7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc0e34da-125b-4dc0-9a31-3590df6f81ca" xlink:to="loc_us-gaap_RestrictedStockMember_485e6f4d-3906-4f6b-8a05-1d48ea82c7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bc5ae170-a953-4c26-914c-27a0328291bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc0e34da-125b-4dc0-9a31-3590df6f81ca" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bc5ae170-a953-4c26-914c-27a0328291bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_15b5b977-6f3e-4acb-b6f0-fbdd65a7dbff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51df7f06-0492-44a9-a241-bd0212899281" xlink:to="loc_srt_TitleOfIndividualAxis_15b5b977-6f3e-4acb-b6f0-fbdd65a7dbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c7f60e8f-f139-430b-a395-fd113cd823d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_15b5b977-6f3e-4acb-b6f0-fbdd65a7dbff" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c7f60e8f-f139-430b-a395-fd113cd823d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesDirectorsAndConsultantsMember_4479571f-9131-4464-9ad6-1598144899fd" xlink:href="arvn-20221231.xsd#arvn_EmployeesDirectorsAndConsultantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c7f60e8f-f139-430b-a395-fd113cd823d0" xlink:to="loc_arvn_EmployeesDirectorsAndConsultantsMember_4479571f-9131-4464-9ad6-1598144899fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember_a9eaed22-6e61-4a56-929d-a72ca0c6609e" xlink:href="arvn-20221231.xsd#arvn_EmployeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c7f60e8f-f139-430b-a395-fd113cd823d0" xlink:to="loc_arvn_EmployeesMember_a9eaed22-6e61-4a56-929d-a72ca0c6609e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4541114d-1ac3-4825-bf3b-21c8f50020a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51df7f06-0492-44a9-a241-bd0212899281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4541114d-1ac3-4825-bf3b-21c8f50020a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4541114d-1ac3-4825-bf3b-21c8f50020a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce9fabbe-7100-46f9-97ce-ea2bd9edf804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce9fabbe-7100-46f9-97ce-ea2bd9edf804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bb957ec-be8b-4644-8bdf-8d341826d22b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bb957ec-be8b-4644-8bdf-8d341826d22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_45037b8a-7a66-4f30-95ce-988fe267e46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_45037b8a-7a66-4f30-95ce-988fe267e46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_af396a96-8ed6-4304-9eb2-5aad010717d8" xlink:href="arvn-20221231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_af396a96-8ed6-4304-9eb2-5aad010717d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9a27aee1-b019-48bf-9ef0-803203dede18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9a27aee1-b019-48bf-9ef0-803203dede18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bdb588ae-3a68-4a51-bfd9-5f781a2ebfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_524649e4-0df1-48fa-9f19-39948ec7d0f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bdb588ae-3a68-4a51-bfd9-5f781a2ebfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4541114d-1ac3-4825-bf3b-21c8f50020a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7368616-6328-4a74-bf5b-cfc690849f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7368616-6328-4a74-bf5b-cfc690849f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_914e6a59-0b8d-4331-85f0-1978bbff3c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_914e6a59-0b8d-4331-85f0-1978bbff3c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51984059-4cfb-48b8-94f6-b7d2b48e3153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51984059-4cfb-48b8-94f6-b7d2b48e3153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue_db81db39-904c-40e4-a2ca-e3d50c19a687" xlink:href="arvn-20221231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue_db81db39-904c-40e4-a2ca-e3d50c19a687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ae881bc0-84fc-4889-8c7e-27c97ee416e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ae881bc0-84fc-4889-8c7e-27c97ee416e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48e6a5b9-d37c-4ea9-aa39-3de11b2fe577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32686d29-c295-4b54-9b38-47f646f91ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48e6a5b9-d37c-4ea9-aa39-3de11b2fe577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityMethodInvestmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_658a454c-691f-4c37-85a2-29e06cdc0501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9c7b0d1a-2304-4c95-9e7e-c0b192933745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_658a454c-691f-4c37-85a2-29e06cdc0501" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9c7b0d1a-2304-4c95-9e7e-c0b192933745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2b44b60a-5b23-4666-9d26-8ae7eb82b0d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9c7b0d1a-2304-4c95-9e7e-c0b192933745" xlink:to="loc_srt_CounterpartyNameAxis_2b44b60a-5b23-4666-9d26-8ae7eb82b0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f00a23a5-ad88-4f1f-ac90-8be7d2e1a4a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2b44b60a-5b23-4666-9d26-8ae7eb82b0d7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f00a23a5-ad88-4f1f-ac90-8be7d2e1a4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember_d1d51235-dd35-4d3d-b44e-f74bd128df4a" xlink:href="arvn-20221231.xsd#arvn_BayerCropScienceLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f00a23a5-ad88-4f1f-ac90-8be7d2e1a4a2" xlink:to="loc_arvn_BayerCropScienceLPMember_d1d51235-dd35-4d3d-b44e-f74bd128df4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fd72cbc2-7475-4930-8196-3f9669f420e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9c7b0d1a-2304-4c95-9e7e-c0b192933745" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fd72cbc2-7475-4930-8196-3f9669f420e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f082f13c-a7a5-47d6-8ea2-a2414b36034c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fd72cbc2-7475-4930-8196-3f9669f420e8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f082f13c-a7a5-47d6-8ea2-a2414b36034c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_1e8826bf-cab2-448d-b431-565bb223acd0" xlink:href="arvn-20221231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f082f13c-a7a5-47d6-8ea2-a2414b36034c" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_1e8826bf-cab2-448d-b431-565bb223acd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_dbe59b92-3951-42e5-9575-f0eeb60fbdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9c7b0d1a-2304-4c95-9e7e-c0b192933745" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_dbe59b92-3951-42e5-9575-f0eeb60fbdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c23130ab-85fb-4c19-9b84-eefbc29a1bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_dbe59b92-3951-42e5-9575-f0eeb60fbdc7" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c23130ab-85fb-4c19-9b84-eefbc29a1bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_c692e170-5816-4766-88af-bc13893ba7fa" xlink:href="arvn-20221231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c23130ab-85fb-4c19-9b84-eefbc29a1bbe" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_c692e170-5816-4766-88af-bc13893ba7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9c7b0d1a-2304-4c95-9e7e-c0b192933745" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_90f4ff3c-0756-4211-b1a6-c04a8b3efe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_90f4ff3c-0756-4211-b1a6-c04a8b3efe0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_bba4a21d-a67c-44fc-94c9-b5eee77446ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_bba4a21d-a67c-44fc-94c9-b5eee77446ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_e0cf4601-92a3-4416-8fdc-472e87c5e4d0" xlink:href="arvn-20221231.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_e0cf4601-92a3-4416-8fdc-472e87c5e4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_904c83ca-09fe-4522-9121-9333400e33ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_904c83ca-09fe-4522-9121-9333400e33ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_30de94cb-4daf-4631-91f2-da126eb4a2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_30de94cb-4daf-4631-91f2-da126eb4a2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_4868795d-89e8-4d88-aa6d-b0d796c949f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_EquityMethodInvestments_4868795d-89e8-4d88-aa6d-b0d796c949f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b5322e63-03f8-4915-a169-ec746cb78eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b5322e63-03f8-4915-a169-ec746cb78eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_515a1167-e4bb-4d5f-a7ac-59f62197b7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_OperatingExpenses_515a1167-e4bb-4d5f-a7ac-59f62197b7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_27540f6a-7069-4316-898d-4d90966b5d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6e0d80ba-203c-4345-8f24-f4f87eca3f20" xlink:to="loc_us-gaap_ProfitLoss_27540f6a-7069-4316-898d-4d90966b5d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_33655ae2-9945-426a-9d35-31536c2e23b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d9944247-31fa-47c8-811d-c18fcd7ed5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_33655ae2-9945-426a-9d35-31536c2e23b2" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d9944247-31fa-47c8-811d-c18fcd7ed5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_6c8e7c84-964f-4581-8b99-78963b7835a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d9944247-31fa-47c8-811d-c18fcd7ed5a7" xlink:to="loc_srt_RestatementAxis_6c8e7c84-964f-4581-8b99-78963b7835a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_543562a6-e9f3-47e7-9fba-26a22a6510a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_6c8e7c84-964f-4581-8b99-78963b7835a8" xlink:to="loc_srt_RestatementDomain_543562a6-e9f3-47e7-9fba-26a22a6510a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1265e17d-09cb-4bfb-a937-01d2ecd0cbd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_543562a6-e9f3-47e7-9fba-26a22a6510a4" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1265e17d-09cb-4bfb-a937-01d2ecd0cbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_fe39957d-89c0-4afc-835d-775ded031c08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_543562a6-e9f3-47e7-9fba-26a22a6510a4" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_fe39957d-89c0-4afc-835d-775ded031c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d9944247-31fa-47c8-811d-c18fcd7ed5a7" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b0caf363-0ea8-4861-b1ae-12ca9639d708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_Revenues_b0caf363-0ea8-4861-b1ae-12ca9639d708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f45b1ded-a3bb-4ab8-92aa-a674f9eb03f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_OperatingIncomeLoss_f45b1ded-a3bb-4ab8-92aa-a674f9eb03f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_67582df7-25c4-499c-a53b-8a2186ef526a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_67582df7-25c4-499c-a53b-8a2186ef526a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e9f6e64-fbc2-4d66-9ba2-f1c42a87a831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_NetIncomeLoss_3e9f6e64-fbc2-4d66-9ba2-f1c42a87a831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5fb5e008-cf53-4aee-8077-f483c7e9ec20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_EarningsPerShareBasic_5fb5e008-cf53-4aee-8077-f483c7e9ec20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8f5f7fe2-2ec2-4fdd-83af-93ff8860377b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8f5f7fe2-2ec2-4fdd-83af-93ff8860377b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a0593756-6680-44d1-9b75-0e6260264b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0fe5e506-2b5d-48de-8088-3ce6ab6c170c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a0593756-6680-44d1-9b75-0e6260264b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#IncomeTaxesIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_00b4e439-e545-41bf-855f-bebd9855db71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0f5e9bd2-062d-4c1f-9c83-e9ec9cd4d0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b4e439-e545-41bf-855f-bebd9855db71" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0f5e9bd2-062d-4c1f-9c83-e9ec9cd4d0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_81962b7f-a05e-4123-b13e-5e98965e71c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0f5e9bd2-062d-4c1f-9c83-e9ec9cd4d0b0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_81962b7f-a05e-4123-b13e-5e98965e71c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0e427c17-940a-4df6-a7de-eef65da9ad35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0f5e9bd2-062d-4c1f-9c83-e9ec9cd4d0b0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0e427c17-940a-4df6-a7de-eef65da9ad35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a4f152fe-cb8f-40c2-8740-6a64f941e022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0f5e9bd2-062d-4c1f-9c83-e9ec9cd4d0b0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a4f152fe-cb8f-40c2-8740-6a64f941e022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6c352a40-ab8d-4dc2-8b41-2e794ffeb53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b4e439-e545-41bf-855f-bebd9855db71" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6c352a40-ab8d-4dc2-8b41-2e794ffeb53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5f6c1761-bc62-4128-9e21-68244c385283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6c352a40-ab8d-4dc2-8b41-2e794ffeb53e" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5f6c1761-bc62-4128-9e21-68244c385283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f9c84957-8303-4b87-836c-65d92d8b5b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6c352a40-ab8d-4dc2-8b41-2e794ffeb53e" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f9c84957-8303-4b87-836c-65d92d8b5b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_181cc63d-acda-44c2-a92d-d1807062525d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6c352a40-ab8d-4dc2-8b41-2e794ffeb53e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_181cc63d-acda-44c2-a92d-d1807062525d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ff3bf61-8d8f-42d5-b534-eb15ba1d1ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_00b4e439-e545-41bf-855f-bebd9855db71" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ff3bf61-8d8f-42d5-b534-eb15ba1d1ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c2314f90-8ae5-44b1-bdb2-568f914d76b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureTable_bb249e8d-8f64-4adc-a829-3f839953e794" xlink:href="arvn-20221231.xsd#arvn_IncomeTaxDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c2314f90-8ae5-44b1-bdb2-568f914d76b0" xlink:to="loc_arvn_IncomeTaxDisclosureTable_bb249e8d-8f64-4adc-a829-3f839953e794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_42a0c8ba-8118-4065-bf51-63e7c2497ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureTable_bb249e8d-8f64-4adc-a829-3f839953e794" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_42a0c8ba-8118-4065-bf51-63e7c2497ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_8da87c75-2a1e-4747-bbae-cd5a528f8495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_42a0c8ba-8118-4065-bf51-63e7c2497ee2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_8da87c75-2a1e-4747-bbae-cd5a528f8495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_29b7f0a6-ff2c-4ec3-b5c2-e8a772790019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8da87c75-2a1e-4747-bbae-cd5a528f8495" xlink:to="loc_us-gaap_ResearchMember_29b7f0a6-ff2c-4ec3-b5c2-e8a772790019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0f76e86b-7c03-42f1-ab07-0fb37e04393d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureTable_bb249e8d-8f64-4adc-a829-3f839953e794" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0f76e86b-7c03-42f1-ab07-0fb37e04393d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a80822ca-d92d-4daf-8f1b-4b84d56758f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0f76e86b-7c03-42f1-ab07-0fb37e04393d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a80822ca-d92d-4daf-8f1b-4b84d56758f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4894bed7-46d9-46ca-a645-5676a49cb389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a80822ca-d92d-4daf-8f1b-4b84d56758f3" xlink:to="loc_us-gaap_DomesticCountryMember_4894bed7-46d9-46ca-a645-5676a49cb389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_b3aa4eef-be1f-41a1-b787-2fb299acb68c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a80822ca-d92d-4daf-8f1b-4b84d56758f3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_b3aa4eef-be1f-41a1-b787-2fb299acb68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:href="arvn-20221231.xsd#arvn_IncomeTaxDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureTable_bb249e8d-8f64-4adc-a829-3f839953e794" xlink:to="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5911eca9-309c-44c3-abe8-51d172349115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5911eca9-309c-44c3-abe8-51d172349115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1cfa30b0-feb6-4bc9-9599-d3a79bd117ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1cfa30b0-feb6-4bc9-9599-d3a79bd117ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_e3eccae9-fa75-46f2-b4d9-d78fd25db471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_e3eccae9-fa75-46f2-b4d9-d78fd25db471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_d2a6322d-bf12-4cbc-837a-ac6899ca3639" xlink:href="arvn-20221231.xsd#arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_d2a6322d-bf12-4cbc-837a-ac6899ca3639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2a083d83-8419-4f8b-89a0-ff15995dbb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2a083d83-8419-4f8b-89a0-ff15995dbb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_35dbe69a-45b8-48b2-8a8e-fdffab0c6825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_35dbe69a-45b8-48b2-8a8e-fdffab0c6825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6aa3b858-8fcd-40a1-ae2d-9ee6cebc5eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6aa3b858-8fcd-40a1-ae2d-9ee6cebc5eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_84d3dac5-074c-4b87-8391-1a8111f8f7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_84d3dac5-074c-4b87-8391-1a8111f8f7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0b96d72c-22ff-4d57-a36b-3466283f336e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0b96d72c-22ff-4d57-a36b-3466283f336e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_a940faa7-1f00-44c1-b8de-ce0831b53fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_1f51ef7b-7a9e-4f56-9d2f-5f2682b9bec5" xlink:to="loc_us-gaap_IncomeTaxReceivable_a940faa7-1f00-44c1-b8de-ce0831b53fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3ed2ee72-fe3c-4f42-a398-6317559cea83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_63ba32d7-3cd6-4dee-be9c-8166872180e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ed2ee72-fe3c-4f42-a398-6317559cea83" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_63ba32d7-3cd6-4dee-be9c-8166872180e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_128e4bce-f98d-4d8b-86ca-4b1109bdcd75" xlink:href="arvn-20221231.xsd#arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ed2ee72-fe3c-4f42-a398-6317559cea83" xlink:to="loc_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_128e4bce-f98d-4d8b-86ca-4b1109bdcd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_086001eb-6c15-4f48-9b41-f99d71796a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ed2ee72-fe3c-4f42-a398-6317559cea83" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_086001eb-6c15-4f48-9b41-f99d71796a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b1ee2e50-8bf4-47c1-a99d-db4c41c38c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ed2ee72-fe3c-4f42-a398-6317559cea83" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b1ee2e50-8bf4-47c1-a99d-db4c41c38c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_cc94c89f-03da-424c-98aa-f7d65a481f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ed2ee72-fe3c-4f42-a398-6317559cea83" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_cc94c89f-03da-424c-98aa-f7d65a481f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_ddea8a11-7573-484a-b51e-a63e58314d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ed2ee72-fe3c-4f42-a398-6317559cea83" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_ddea8a11-7573-484a-b51e-a63e58314d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3dbef02c-ee36-4afe-8d6c-30cd84beaae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ed2ee72-fe3c-4f42-a398-6317559cea83" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3dbef02c-ee36-4afe-8d6c-30cd84beaae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_88f69fb2-158f-4b2e-8643-7cd04465677f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ed2ee72-fe3c-4f42-a398-6317559cea83" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_88f69fb2-158f-4b2e-8643-7cd04465677f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cdd3c785-b57b-476b-beaa-6397048c9075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ed2ee72-fe3c-4f42-a398-6317559cea83" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cdd3c785-b57b-476b-beaa-6397048c9075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5241c88f-106d-4ed5-af72-c388e1523bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_72c6c48a-f897-4c39-a3a0-c176181f7934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5241c88f-106d-4ed5-af72-c388e1523bea" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_72c6c48a-f897-4c39-a3a0-c176181f7934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e7f88e23-401d-43ea-8fee-aca6b71e490e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_72c6c48a-f897-4c39-a3a0-c176181f7934" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e7f88e23-401d-43ea-8fee-aca6b71e490e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2bae5cb9-a34b-4057-ae5c-670252cc01ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_72c6c48a-f897-4c39-a3a0-c176181f7934" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2bae5cb9-a34b-4057-ae5c-670252cc01ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b324b4a4-32af-4948-bd39-fe5f1ce5186a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_72c6c48a-f897-4c39-a3a0-c176181f7934" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b324b4a4-32af-4948-bd39-fe5f1ce5186a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ee323805-e9fe-4deb-838d-d60847535be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_72c6c48a-f897-4c39-a3a0-c176181f7934" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ee323805-e9fe-4deb-838d-d60847535be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ece5f024-ce79-4594-9ea2-0ac8abedda1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_72c6c48a-f897-4c39-a3a0-c176181f7934" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ece5f024-ce79-4594-9ea2-0ac8abedda1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_8a8467aa-25c1-4c3f-a095-528c4b7bfea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_72c6c48a-f897-4c39-a3a0-c176181f7934" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_8a8467aa-25c1-4c3f-a095-528c4b7bfea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_555ed6f4-8fef-479f-b322-ca79843011d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_72c6c48a-f897-4c39-a3a0-c176181f7934" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_555ed6f4-8fef-479f-b322-ca79843011d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_619833b0-13bd-4acf-a3d5-bfeedd242fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5241c88f-106d-4ed5-af72-c388e1523bea" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_619833b0-13bd-4acf-a3d5-bfeedd242fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c4b4d7ed-3dde-4f39-8970-a29b7e8b1d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_619833b0-13bd-4acf-a3d5-bfeedd242fd6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c4b4d7ed-3dde-4f39-8970-a29b7e8b1d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_ef9c23cb-e265-4174-95f2-5a7ed6ca2c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_619833b0-13bd-4acf-a3d5-bfeedd242fd6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_ef9c23cb-e265-4174-95f2-5a7ed6ca2c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ab91610e-f0f3-43ee-a393-683f23a6fa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_619833b0-13bd-4acf-a3d5-bfeedd242fd6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ab91610e-f0f3-43ee-a393-683f23a6fa4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b11fcd74-8daf-49a5-8520-982f76e79263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5241c88f-106d-4ed5-af72-c388e1523bea" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b11fcd74-8daf-49a5-8520-982f76e79263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_443b57e2-5bcf-445f-bcf0-ad0431c08967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5241c88f-106d-4ed5-af72-c388e1523bea" xlink:to="loc_us-gaap_DeferredTaxLiabilities_443b57e2-5bcf-445f-bcf0-ad0431c08967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1cce48cc-2b0f-462e-938a-5e8a59b74554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b34c73b5-030f-4e62-ad47-8c10c9867eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1cce48cc-2b0f-462e-938a-5e8a59b74554" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b34c73b5-030f-4e62-ad47-8c10c9867eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_eda80a95-c783-4a9e-9fb7-6b090b350717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b34c73b5-030f-4e62-ad47-8c10c9867eea" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_eda80a95-c783-4a9e-9fb7-6b090b350717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ceac5e69-0a54-4809-8924-7b4ea897352b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b34c73b5-030f-4e62-ad47-8c10c9867eea" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ceac5e69-0a54-4809-8924-7b4ea897352b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_16313209-7f49-4e87-83d4-2865f82787b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b34c73b5-030f-4e62-ad47-8c10c9867eea" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_16313209-7f49-4e87-83d4-2865f82787b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b3807565-4cb0-482b-87ad-acd44938fc23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b34c73b5-030f-4e62-ad47-8c10c9867eea" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b3807565-4cb0-482b-87ad-acd44938fc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3e60667c-f58b-4de0-a773-6bb090cee8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:href="arvn-20221231.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3e60667c-f58b-4de0-a773-6bb090cee8ce" xlink:to="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a34600cb-6179-4aa3-b84d-9811cf94a32c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:to="loc_srt_RangeAxis_a34600cb-6179-4aa3-b84d-9811cf94a32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54f627d3-d3c3-4329-b78b-3e449cd878c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a34600cb-6179-4aa3-b84d-9811cf94a32c" xlink:to="loc_srt_RangeMember_54f627d3-d3c3-4329-b78b-3e449cd878c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_961cbfdd-c3c3-4815-aef0-296c3d512010" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54f627d3-d3c3-4329-b78b-3e449cd878c5" xlink:to="loc_srt_MinimumMember_961cbfdd-c3c3-4815-aef0-296c3d512010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa79b5cd-472e-467b-9b10-f43c112b8724" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54f627d3-d3c3-4329-b78b-3e449cd878c5" xlink:to="loc_srt_MaximumMember_fa79b5cd-472e-467b-9b10-f43c112b8724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9742a7b-44ed-419b-a241-25eff1764124" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:to="loc_srt_CounterpartyNameAxis_a9742a7b-44ed-419b-a241-25eff1764124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f1baf9b-4bf6-460b-81ff-f33d29a53b6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a9742a7b-44ed-419b-a241-25eff1764124" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f1baf9b-4bf6-460b-81ff-f33d29a53b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_YaleUniversityMember_dcd607e0-3572-46d3-bd15-9361cba52251" xlink:href="arvn-20221231.xsd#arvn_YaleUniversityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f1baf9b-4bf6-460b-81ff-f33d29a53b6f" xlink:to="loc_arvn_YaleUniversityMember_dcd607e0-3572-46d3-bd15-9361cba52251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FoundationMedicineIncMember_54acda42-f7ef-45e5-b3d6-cafa4fe0fa8d" xlink:href="arvn-20221231.xsd#arvn_FoundationMedicineIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f1baf9b-4bf6-460b-81ff-f33d29a53b6f" xlink:to="loc_arvn_FoundationMedicineIncMember_54acda42-f7ef-45e5-b3d6-cafa4fe0fa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d2a958d3-d0a8-4362-8287-c7a0c2698c5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:to="loc_srt_ProductOrServiceAxis_d2a958d3-d0a8-4362-8287-c7a0c2698c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a224918-5d5e-4e80-968d-cc6bf1ffd89e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d2a958d3-d0a8-4362-8287-c7a0c2698c5d" xlink:to="loc_srt_ProductsAndServicesDomain_1a224918-5d5e-4e80-968d-cc6bf1ffd89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseFirstLicensedProductMember_d12928a6-fa10-495c-accd-7f2f0a31ecf4" xlink:href="arvn-20221231.xsd#arvn_LicenseFirstLicensedProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a224918-5d5e-4e80-968d-cc6bf1ffd89e" xlink:to="loc_arvn_LicenseFirstLicensedProductMember_d12928a6-fa10-495c-accd-7f2f0a31ecf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseSecondLicensedProductMember_c2b63be9-2ee8-4abc-855f-b2296e415607" xlink:href="arvn-20221231.xsd#arvn_LicenseSecondLicensedProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a224918-5d5e-4e80-968d-cc6bf1ffd89e" xlink:to="loc_arvn_LicenseSecondLicensedProductMember_c2b63be9-2ee8-4abc-855f-b2296e415607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10999837-34f0-4273-8641-ea580b7ea0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10999837-34f0-4273-8641-ea580b7ea0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa038fac-2a15-4b7d-98cc-376078d49cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10999837-34f0-4273-8641-ea580b7ea0ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa038fac-2a15-4b7d-98cc-376078d49cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember_b1e1f813-90d1-462b-94c0-2f7024923dc2" xlink:href="arvn-20221231.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa038fac-2a15-4b7d-98cc-376078d49cda" xlink:to="loc_arvn_SuccessBasedMilestonePaymentsMember_b1e1f813-90d1-462b-94c0-2f7024923dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:href="arvn-20221231.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_eac94271-8944-4af1-94b1-e626a6aaaa67" xlink:to="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a5e6ce8-0c8d-421f-ba49-b5b38309f2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a5e6ce8-0c8d-421f-ba49-b5b38309f2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AnnualLicenseFeePayment_1c2d693c-91d5-49b4-be39-4af125d154fa" xlink:href="arvn-20221231.xsd#arvn_AnnualLicenseFeePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:to="loc_arvn_AnnualLicenseFeePayment_1c2d693c-91d5-49b4-be39-4af125d154fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RequiredMilestonePayments_13c52033-23c0-4e2f-b497-f8c706b1510a" xlink:href="arvn-20221231.xsd#arvn_RequiredMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:to="loc_arvn_RequiredMilestonePayments_13c52033-23c0-4e2f-b497-f8c706b1510a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_29ed867e-5006-48fd-a8f7-53559ae0b1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:to="loc_us-gaap_PaymentsForRoyalties_29ed867e-5006-48fd-a8f7-53559ae0b1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_d1baaa45-0590-4121-986a-61be83695635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_d3f580b8-b29e-4a01-96c0-299ad279b721" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_d1baaa45-0590-4121-986a-61be83695635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperShareDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#NetLossPerShareBasicandDilutedLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1ffe09b4-11c5-4aa3-8c07-e3578d25d329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02a25bb2-fe2d-4732-8e19-05e065befbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1ffe09b4-11c5-4aa3-8c07-e3578d25d329" xlink:to="loc_us-gaap_NetIncomeLoss_02a25bb2-fe2d-4732-8e19-05e065befbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_563b8527-ea82-4ce3-b495-352d8c9036ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1ffe09b4-11c5-4aa3-8c07-e3578d25d329" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_563b8527-ea82-4ce3-b495-352d8c9036ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f6e1f2bc-68c4-4dd3-82f3-79fbd45858dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1ffe09b4-11c5-4aa3-8c07-e3578d25d329" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f6e1f2bc-68c4-4dd3-82f3-79fbd45858dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_524cd453-78d4-4f83-9c09-c7fcb730232f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1ffe09b4-11c5-4aa3-8c07-e3578d25d329" xlink:to="loc_us-gaap_EarningsPerShareBasic_524cd453-78d4-4f83-9c09-c7fcb730232f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ca87313e-75f3-4b20-b557-553cd50a0c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1ffe09b4-11c5-4aa3-8c07-e3578d25d329" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ca87313e-75f3-4b20-b557-553cd50a0c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="arvn-20221231.xsd#NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fe7662e7-1e71-4bd2-8ab8-fe63552a81b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_363abcf3-17cb-4dc8-9ded-a3a48d5787fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fe7662e7-1e71-4bd2-8ab8-fe63552a81b7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_363abcf3-17cb-4dc8-9ded-a3a48d5787fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1652e14-f558-4c7d-83f8-e436e3efcbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_363abcf3-17cb-4dc8-9ded-a3a48d5787fd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1652e14-f558-4c7d-83f8-e436e3efcbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93a36506-308d-4f4f-908c-8e101e8f9edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1652e14-f558-4c7d-83f8-e436e3efcbd0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93a36506-308d-4f4f-908c-8e101e8f9edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_791ac8a5-1f6b-4245-b4b7-ccf80e7c416c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93a36506-308d-4f4f-908c-8e101e8f9edd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_791ac8a5-1f6b-4245-b4b7-ccf80e7c416c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ba9aedba-564e-419d-95c7-9a1836416f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93a36506-308d-4f4f-908c-8e101e8f9edd" xlink:to="loc_us-gaap_RestrictedStockMember_ba9aedba-564e-419d-95c7-9a1836416f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_42632b4c-21a3-4841-a314-b48b095ea44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93a36506-308d-4f4f-908c-8e101e8f9edd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_42632b4c-21a3-4841-a314-b48b095ea44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7cfb3e84-923e-4771-b2b2-07413576cea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_363abcf3-17cb-4dc8-9ded-a3a48d5787fd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7cfb3e84-923e-4771-b2b2-07413576cea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ddc40742-a762-4f30-8dfb-aa72d92c8e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7cfb3e84-923e-4771-b2b2-07413576cea1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ddc40742-a762-4f30-8dfb-aa72d92c8e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>arvn-20221231_g1.jpg
<TEXT>
begin 644 arvn-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,M!- # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "D[TM% !1110 44E+0 44E H 6BBDH 6BBB@ HI*6@ HHHH **** "BBB@
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M _-+FF@Y% ZT .S1FBB@ HS133UH 7/-+FHF< \D4]3E>M #Z*2B@!:*2B@
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MB5B"5KU7Q5;)>V+1EE#;2!DUX^LE[X8E=)<M;EB3@9ZTKCL=[X-\9O?,;:\
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M1%_>%<%]HO0?]8/SIXNKW'^L_6CZS$?L6=UYT9[TX,I'6N%%YJ /^LJ9=0U
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M1W\TD)P#D9ITEA<W?B]9O+(4"O6(=)M('=T0 MUH32K19O.5/G]:0V>$:O\
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M G&:XCQO<177B>UAN#F(OAL&H]9TWP];62M K>9VP:E=QL]>'B>U;3S=!U(
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MJMT(JKH5F2YHS3<CU%+3N(7-%)10 M)2T4 %%)2T %&:** %HI** %I**0T
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M4EXQ+/L7T-9UU?Q6XV1+EO454NKV2Y;;%]S/:G6VFN_S$&O*K8IWLCJC22(
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MX !ISX52?2N%N_%;Q^*&T]2,"@#N?+4G. <4\"H(IQ]GC9CRPS4RR*5R.E#
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MY31U#Q!;6\!?<"Q'8UQ,^HW>MW7EQLQ4G&*Y^]^UM'O!<@^]7O"FKOIMQF5
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M5F-+VB&JBL<E ,.I]Z]!T#Y[6N5ET&XMW^XQP:Z71'\BW*OP:ENYC.29<UM
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M2A>:DP*3@').*$[B;2///B!=SVL;F D&L?P++?S7#-*#@GN*[S6]#AU:0EG
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MCL;49VP 54NSQ5K_ )8U3N1G%<='XT:LX/QH3]EQ_M5+X04#2;H_[%1>-/\
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MKCN0ZQJJ:?"0&^<\ 5A:9ITVJW N[H'K3;.RGUJ],\Q/E@Y -=?!"D$01%
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M/2TW=2@UL9BT4F:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP&<8JQ;V,< &!S5FN2K6;T1ZV&P6EY@%"+@4A-*3QQ3"R@<US;[GIJ*2T%.
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M^U<Y<:+J%HQ*QN .]>N#BF2013##J#6T:[ZD.F>20:A?6C88N,>];MCXN>/
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M71Q5EJ6:4=*2E%=)@+1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKHZ6G4VG5Z!R!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(Z5W=JD'A32!U=ORJKHDYUO&=P>D;U _BR^;[JR"NL'AK1E_C;\J>-#T>/\
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ME>HMCB%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M;10:04 074?F1$5Q-] 8;ECZFN\89!KF=;M#G>!7#BJ=U<ZL/.S,9#4X <8]
M:K)UQ5E#7EH]!["6\ILKCG[A[4NH6N"MS%TZD"GR0B5,4ZUE&&MYN >!75!W
M5F<DU9W0RUG6:,-T/I5C::SYX6T^Y+#_ %78UH1,)%##O6$Z=BHRNAN.<51O
M+'>-Z<$5J;>]-QDXQ6E.;@1)7/,]8+QWBAL\-756EX!;Q\_PBL?Q5;@W VCG
M=2@2VT:;Q@;17KT6IQU,&K,Z:.Z![U:6X]#7,PW@XYJXEV/6M)45T%<Z!;CL
M:<S12##+FL5+L>M6%NAZTE2ML!9ET^WF4_*,UFS^'@PRA J\MR/6I5N!ZT*<
MHDG,3Z+-%TYJDUM*G5&_*NW\Y#U ICQPOU _*MXUGU X1XV[H:IW,!*GBN]?
M3+>0U4FT&)P=N:V58#SEHRCY7@BK<-],@V[C737'AAV)*H:H/X<NTY$1K15(
MLOF,AVDF8%CFKUNTB+PQJ7^R[B,\QT\6LRC&RGS1)N FD/\ $:#+)W:CR)?[
MM-,<@ZBCW0N+O;UI"2:38WI1LD[+1=!<3%(<"GBWN'X"5,FCWLG2.DY) 4F<
M4PL,5JCP]>MUB-3Q^&)S]]"*GVD0.?+>E,).> :ZZ/PNN/FR*L)X<MD/S$TG
M72"QQ2P2R=(V_*K,.C7,YP%*_A7>0Z=:P8QC\JL;XH_NJ*QEB&]@2.1M_!\K
M %I!6K:^&8;8YDVM6J]V!TXJM)>C'WJS=23*)TBMX!A4 Q1)=A1@5F2W@]:I
MRWGO4\C8C3DO 1UJA->=LUG277O522Y/K6L*0R]+=>]4Y+C-56G)[U"9":WC
M32 G>7)J,O463FCFM+ 39S1FF X%)EF.%Y-#=E=B';N<#K6CIVEO.X=N@IVF
MZ5)(P>1>*Z:&$1(%4"O)Q.+23436$ @MUBC"*,5.$.:55-3JE>)*3E*YK>PB
M+Q4X%"K4ZQTU$39&$S4R)3@E2*N*M1,VP5:D44@%2**M(S;$ IP'-+2XJK"#
M-&:3&*,T !-%)2YXH 2BBBD(**** $HI:* $HI:3%( HI*,TT4@I**!S36XG
MH%1O*D?)85#?78MX\9YKD=0U8[L;N<UWX;"RJ:G!BL4J9U;W\9X4T*6DY#5S
M%BEQ<)Y@&:T8;J6W/[T8%=:HTUHSGCB)25S7+.G\5*EX,X(JJE]%,ORMDTCX
M-.6&@]BU7:--95<<'FG^]81E>-LJ<U9BU5% $A KBJ864=3HAB8LU*.U0Q7,
M4PRC9J:N1P<=SI4U+89+\R$5Q%_$5O7/J:[EAA:Y'4T_TIC[UZ>6MQE8\O,X
M<T=#)D3:N:Z'3B3:@>HK%E7/%:UO)]GME/?%=&9>\K'/E[Y)&7J-Q)97>1G;
M6)J&J^<N I+-723Q"]4NXKFY;:.WO5SR-W>HI)QIZG=+&QC/4S8+"YEDW[6
M/M6[8Z#)(P9SP/6NDLTBDMP0H_*KB1XX"U\_B:C=2Q]-1QK]DK%6VM%MHPJB
MK:1L:E6$D]*M1PX[5SJ+;U.6I6;=V0+"33G188R[D #UJV0L:%FX KE-9U22
M_G6TLOF!.U\5T4Z)A*H5M1O)=5N?L=MD#/WATKI-(TA+"(' WGJ:CT/1UL8E
M=QF7W%;=;-);&=VQM.I,4M(8E+12<T +1244 %%%+0 E':EI* "BBEI )111
M0 =J2BDJ08M)12&I;! :92FFU)HAK5$W6I&J,UG(T0G:F&G'I4=9,M(::KW+
M;4J=JHWK\ >]1'5V+V&!-MG)GO73>&8]NFQ-ZBN?N$^2.,=6 KK=#A,.FQJ1
MR!7MX:-F<E:6AH4\=*2G5WG*%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% "&FBG8HQ2 ;WJCJ,'FPGCM6ABFR+N0BHJ1YE8J,K,X"
M5#%.5J1#5_5[79*7Q6:E>)5@X2/4IRYD7$Z5'<Q?\M$^\*=&>*F7GK1"5A3C
M<BB9;VV$,W^L'<U5@9[28QR9P3Q4]Q"RR^;'U]*D8)J,/I(@QQ76DI1U.;6+
M+"D,,CD4\#GI69:W#6\_D2\ 5L)A@".]8\NH[G"^)5Q>K_OBM^73X[FQCXYV
M#^58GB9<7J?[XKK($_T2'_<'\JZ$W%:&6[.%OK":SD) )6JT5T>C<&N_FMTG
M4JRBN7U/P_R9(03]*[J&*3T8Y1**77O5I+KWKGYO.M9"KC&*DBNL]Z[DE/5&
M=CHEN?>IEN3ZU@K<>]3+<>]-TD(W5N#ZU*+GWK#%Q[U(MQ[U'LP-L7/O4BW)
M]:Q!<>].%Q[TO9@;HNCZT_[2K<&L,7'O4@N/>IY6@-<K W)44GD6Q_@%9@N/
M>I!<>]*T@+YM+8_P"HVL+8_P"JXN?>GBX]Z/> ?_ &=;_P!P5(NGVW=!48GS
M4BR\=:EN0$Z6MLG1*E!C0<"JOF^]-:X J'*3&7!-2-<'UJ@UP/6HFN1ZTK28
M&@TYQUJNTWO5%[KCK5.2Z]ZI4VP-1K@#O5:2ZQWK*>[/K5:2Y/K6D:0S2EN_
M>JDEU[UGO<'UJNTYKHC20%][D^M57G/K55IJC,F:T5- 3O,?6H6<GO49)-)6
MBBD _<32BFK[T[@4:$MCJ*86YP*NVFGRW+9VG%8U*L8J[*2;*RQO*V$!KHM-
MTC 5Y!5ZPTN.W0$C)K3"#L,5XN)QCGHC>,.Y%&BQC:HXJ=5IR1\U,L>*\V[;
M*;L-1*G5>>E.5,U,JXIJ)+8U4]JF1:<JU*%JU$AR&@4X"G!:>!5I$-C0*<!3
ML4N*=B1N*,4ZDI@-(IN*DH(I 144\BDQ0 VEH*TF*0"TE%%%@%HHHI %%%%
M"4VG4E"&W8;2DX4GVHQ4-W)Y=NQ]JTHQYIHBK+EB<SK-YN+#/2N893+*"?6M
M"\F,UPX]ZA@BW3@#UKZB,(TJ-T?*U*CJU;'5Z8HAM0,=14\D*39RN:B@^6)1
M[5=A3(KY6MB9>TNCZBAAXJFD9,MC)&=T1Q3$GDCXD!/O6_Y7M4,MNK\%1712
MQ\H/WC.IA$U[IE&4,N:J2KNK1FL\<K6;.LD9Z5Z]'%4ZFC/*K8>I#4K^?<6[
M95^/2M*TU_&%DSFLII/[U5I2&Z<5TRP].H<<<14I/0[9-3AECZC\ZYK49@UP
MQ%9$<TJOM1B:UK>VFF4%T/-<_LX8=W-_;5,2K6(HQO/2M&5,6>3V%3VUDL?)
MZU/<0^9;.N.JXKS,3BU4EH>E1PCA!M[G(G5!$K)N[UCW5VLMPA)[U8N=$G%T
M64$KFJ,NC3O<)D$ &NOV\>30\>=&HZEF=WHKA[($5M1(#VK'T6'R+,)6] O%
M>#4LZESZG#IJFD2I&!4APJY)  ]:4+QDUS.O:T0?LML=S-P<&M(P&Y$6N:L\
MTWV*U)+>HZ5H:%HZVD1FF :1AG-1:!HHB075QS(>QKH@!G'05HW;8FP@QUI<
MTN!2$5!0E I128YH 4T9I*6D 44M I )10:.]4 44$TF* %HH[4E( HIW:F"
MD 4M)1VI Q*0T&FDU#&D(U--*>::329HD----*::>E92-$,:HS3V-1&LFRT(
MQK/G_>3;1VJ[*V%)JO9+YETQ;IBJHQO(<MA^#+?6Z]A@5V]NFR$*.U<AI,7V
MB^W?W6KM ,"O=P\=+G#5>HM**:*=728BT444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 )2=Z6C% !2'I2T8H S-3MUEA)QS7)NOERD'
MUKNY$#*0:Y;5K3RY-PZ5Y^+I_:.W#SMH4T/%3H:IQMVJRAYK@1UR19'S<&JL
MT+V[B2'A>IJTI%3*H92I[UM!ZG/-7*311WT.Y !*.2345K=O!-Y,N>N :EN+
M:2V;S8LGVIK+'>IDD+*O05LU<QO8YOQ*0U[&0<Y<5V,"_P"B0_[@_E7 :TTD
M5\B2 @!QR:]#LV62RAVG^ ?RJI*T2%N,914+(",=JNLE1%*RLUJC1,Q;[1K>
M[0_(-WK7)ZAH$UL2T?3VKT)DJ"6%6&"H-;TL3*#U!I,\K9I(6PX/Y5(MS[UW
M%]X?@NE)X!]JY6]\.SV[$QJS"O3I8N,M&9\I76Y]ZF%Q[UF2)- <.A&*$N>Q
M-=D91EL)JQK"?WIXF/K66L_H:D$].Q)IBX/K3A<'UK,\_P!Z<)O>ERC-47'O
M4@N/>LD3TOVGWI<C$;'VGWI5N3ZUCBY]Z<+GWH]F!MBZQWJ07?'6L'[5[TX7
M1]:ATP-PW1]:C:Z/K65]ISWI#<^]3[(#0>[/K4#79]:HO/[U \_O5*F,O/=G
MUJN]R3WJD9ZB:;GK6B@,MM/[U$\U5C+FFE_>K4 )3(33"QJ/?32_-4E8+DN:
M*8&S1NI["N/HI <GCFK,-C/,>$-93JQBM6-%<MBK$%M)<, H/Y5M67AW?AI,
MBM^WTZ*W "@&O-K8Z,=$4H7,:PT(</* :W8K6.)0L:XJPL?&!Q4HCKR:F(E4
M9T1C8B5,=:F6.GB.IECK"S8FR-$YZ5,B9IZQU*L?M6JB0V-"8J14J01\5(J5
M2B0V,"XJ0+3@N#3\5?*1<8%I0*=BC%58+A3<4[%%%@&XHIU)4V$)12TE*P"8
MI,4ZBD W%-(J2D- ##24XBDQ2 ;1FG;:3;18!*6C%)BE8 I,4M%%M ZA61KD
M_E69Y[UKXK!\0HTD 11GFNK"6YE<YL7?ET.51=S,WK5NPB!N<XJ6+3Y=GW35
MNTLS')DC%>QB\3%4^5,\;"X63J<S1HQ+G%:, JE$G-:$0P*^7W9].E:), ,=
M*:R T^DK511! \0(XJK+:HPY&:T33"N:%=;!92T9@3Z6KYV@5G2:/)NX-=6T
M7%0M!6\,;5@M#EG@:4WL8EKI<<7+J":T54!0%'%3^13TAQ6%7$U*CU.BEAZ=
M)$:)[5.T8\EN.U/5,4YU/DOCTK.*N5)W.8F;$A%4YB,YJCK%_<VEX5$7R^M4
MHM0NKJ50(L@GFNKFM&QYDJ4G*]CL-,;,-;4. *P(9UL+'S9<*!US5>;Q3 \1
MCMI%>0C&!7-"#G(].+Y8I%[7M;\A6MX"3)ZBHM"T5G8W5W\Q8[AFH-$T>2[E
M%[=Y#'^$UURJ$0*!@"NEM1T0MQP 48'2ER*;168Q<B@FC%% "9I:3%+0 E%+
M24@ &G"F4O-  >M+24=*8"T4E+2N 4"BDI7 #2#I112N 4F:7--S2&@-,:GF
MHS4LM(*B8\U(>!41/-0V6@IK'%+4;5E)EH;G-(1FBD+8%9LN**MT^V-AWQ4:
M-]GLQ+W/%,E/F7<:#H3S3-38 );*>0175AHZW)F^AT7AR#]VTA'4YKI >*S=
M'@\FS3W45I8KVZ:M$X)[BBE%-IPZ5H0+1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %':BD- "'D50U"U$T#<<XJ_2,H92*B
MI'F5BHRLSA)(S!(5-2(_2M+6+(@EU%9"MVKQ9P<)NYZ=*?-$O(U64;BJ"/5I
M&XIQ821:W;A@UGSV;(_FQ<8YJV#4B')P:VBSGE$\]UZ3[1=JC??##FNIMGFL
M88MQRFT=*YWQ3#MOE9!@[QTKI+6<BVBCG08*CDUTO5&2W->"[CN$!&!]:E9,
MC(K%DMBI\VV8M["K%KJ97]W.-I]ZR*9>9*B:/O5A724 H<T\QY%2TF"*!7FH
MWB#+@U<:/FF;#FIU0[F%=:);W.24&37.WWA*3!:( 5W;)DTTIZ\UK3Q$X; T
MF>4SZ7=6I(8$X]JJ;G0\J17K4MG%*/FC7\JR;KP_!,#@ ?05Z%/'?S$\IYZ)
MO6G>=[UTEWX3ZE"36-/X>NX\[48UV0Q5-]26BJ)?>CS*B>PO83S$:B(E3[RD
M5NJL'U)LT6O,I?-JGYAI#+[U7,@NR]YU+]HK/\WWH\WWIZ!<O_:L=Z0W7O5
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M/.OU.,Y:O3=/C\NW48QQ7=A5>5R,5:,%%%SO2TX 4M>LCS1E.'2EHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0
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M[MCEZU,*@'6I0:HD?124"@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M#P:=NJ*DR:0B;- J,&G!J8A^:<#3*4&@"2BF@TM "]Z4TW-&:8@IAZU)3&I
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 -[T444 %)2BB@!*,TM%
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M,M7H&I^%[+PS:2/:*0TJD'BL7PMX%M=9MI9;J,Y+GM[T+<'L8UOMUKQ(3:1
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M-]:]4G\+7-II:FV4F3;R/>N._P"$7UO4KQ4N(,(&!R![T=1=#U'P<(AIP,(
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M(U'M3Z6$+BEHI:0!1110 4E+10 F,T8I:* "DI:* "BBB@ I*6B@ I,"EHH
M2EHHH **** "BBB@ HHI* %HHHH *::=28H AEB#K61<0[6/%;N*KS6RR TT
MP.;E@!JG);]>*Z">S9>0*I20GTJDR'$PI(#Z55>/':MN2$^E4Y8?:G<3N93)
MQ5=H^:T)(R.U5F4YK*I14T73JN+*9!4TFZK++4#)7FU<%;5'HTL6]F-W5(K
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M-JCM5K%% %6ZM8;R/RYUW+Z5DGP9H;L6-KR?>M\KD4;2*2W S;/0=/T\YMX
MM/N-'LKJ42RQ99>AK0Q28H"Y7:R@:W$!3Y/2JT&AV%LC+%#@.<FM+%&* *%M
MI5G:2M+#$%<]34]S:Q7<1AE4%".14Q!I0IS0!3M=-M;/B"/:*;-I-G-.)I(L
MR#H:O8I<4V"*5QIMK<PB*6/<@&,57LM TVPDWV\&UO6M7;1MHV JW>GVU\H6
MX0,!3;6PMK%/+@C"BKA%,V$T 4;W1[+41_I,(<"DM=$T^R79!#M%:('%)@YH
M I0:1903&6*(*[')-:0Z5&!S4E "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M(: &E0PYJO):JW
M2K-% &-<69':LJXA(/2NM9 PY%9]U9AN0*I,EG(S1FJCQFNAN+7!/%4)(/:G
MN2T8Y3VIC)6A)#CM59XZ=D!3\L=Z8\2]JM,E,*\5A5HQF;4JK@4B"II1)5AD
MYJ)HAVKRZV#ML>G1Q:ZBAZ7S*BVM33N%<,J4HL[%4C(L;Q1NJMNQWH\RLVK;
MEI%C=1NJ#S*7S*BX[$^ZG@U6#T\/5")Z3-0^92AZ+CL2T9J'S*0R47%8F)IA
M-,\SBFEZ5QV TPT%Z;F@=AU-(I<TAH 8:;FGFFXI@,H%.Q1BBQ0PTQNE2$5&
MU $9Z4RG-TJ/- QV:=FF4X4,$% %.%**0T^XF*<%IP7<>*LP6<DA^[5*G*6Q
M,ZD8HA1/:K"1EN IK3M](/&X&M2WTZ-,&NJGA)2U9R5,6HF+!IKR8R*V+;2$
M4 LHK3CB51P!4M>C1P<8[GG5<9*6Q%%;1Q#Y1BI>G2EHKNA34=$CCE.4M6Q<
MFC-)15M6(3'BEIJ]:>*0Q:44E H$.H%&*6F-#ATI:0=*7O0#'4HI*44A"THZ
MTE**!CQ2T@I: '"E%-%. I .Q3E%(!4BBF Y13P*513\5(Q.U**#0*!BT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !BC%%%
M !BC%%% "44M% "8I:** $Q1@4M% "8I<444 )BEHHH 3%%+10 F*7%%% "8
MHQ2T4 )1BEHH 2C%+10 F!1BEHH 3%%+10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSY[5<P*,#TH HF#VI?(/I5W ]*,#TH I?9SZ4>1[5>Q28'I1<"GY/M2^35O
M]*,#THN!4\FE$-6L#THP/2BX%<0BE\H5/@48% $/EBG!*EQ10!'MI0HI]% #
M<"EI:* $HQ2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>arvn-20221231_g10.jpg
<TEXT>
begin 644 arvn-20221231_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHKY=_:O^*'_!0#PI\79M(_9U^'?]I>&EL(&BNO[(CFS,0?,&
MYF!X..*NG!U)63MZG5A,++&5?9QDHZ7O)V1]15YO\4_VO?V;O@KXA7PG\2OB
MO8:?J9"E[%(9KB2($9'F"%'\O(((WXX.>E?+?_"]/^"NG_1'?_+>B_\ BZ^+
M/B'-XSN?'FLW'Q%2Z77Y-3G;65O4*RBY+DR!P>AW9XKKHX-3?O27R/H\NX9C
MB*C5:K%I?R--_EH?M=X2\7^%_'GAZU\6>"]?M-4TR]CWVM]93"2.09P<$=P0
M01U!!!Y%:-?EM^QU\0/V[?!G@/4;?]FCP5=:MH$^IEIVDTQ9XH[D(H8(6(P2
MNS<!Z+7KO_"]/^"NG_1'?_+>B_\ BZB>$<9-*2^\Y<3P[4I5Y0A6A9=Y)/YH
M^[*^%_\ @K=X23XF_M(_LR_"'5?$>L:?I'BGQ9JMCJ_]BZD]K+)$PL!PR]QD
MX)!QDU]/?LH^)/CIXK^$4.K_ +16@?V;XE:_G66U^RK#B$$>6=JDCD9YKY8_
MX*^?#?0OC!^TY^RY\,/$]Y?6^GZYXOU:TNYM,NC!<(C#3P3'( 2C>AKEDN65
MCP*U)T:LJ;:=G:ZU7R.V_P"'+7[*W_11/BG_ .%Y+_\ $5ZQ>>(/@1_P3D_9
MNTC2_%'B?68_"ND:@FGVVH:I*]]=&6[N7=?,? )&^1AN/"J!Z5Y/_P .6OV5
MO^BB?%/_ ,+R7_XBN8_X+$?#?0OAK_P3'L/A3H5W>SZ=H^N:'IUK-J%R9KAX
MDDV R2'EWP.6[FD9GH%__P %@?V+=+\30:9J&O>)8=#NK_[%;>.9/"MR-#FF
MR5PET5^9<@_.%*X!;.WFO2_V@_VRO@_^S5>Z38_$"R\2W9UJV>XL9/#GABYU
M*,HI4$LT",%SN&,]1R*X'_@J9X1\,Z;_ ,$TOB+X6T_0[:'3M+\-6R:=9QP@
M1VRPW$'E!!_#MVKC'3%7Y_VJ_AU^R5^P#X&^,OQ0O9)B/ FCQ:7I<#9NM7OG
ML8C';0CJSL<DGD*H9CP#0!1\*?\ !5O]D[Q?\2?#WPFLSXRM-;\4ZE%8Z+;:
MIX)O;43RNZH#F1  H+ LW11R<"ND^//_  4(_9Z^ 7Q!;X0ZF?$?B;Q?%:+=
M77A?P1X=GU.\M86 97E$8VQY!4@,P;#*<88$\7^P_P#LQ?$K5?&U[^W3^V';
MK/\ %+Q5:^7HVB."8?!NDMDQV,"G[DI5OWC?>&YE/S-*7XGPY\=/'OB7]J#X
ML:7_ ,$[/V1/#5]J5EK\>G?$GXD>,?$LMK;7FIP;T\E(5#2.L9\P90@?[(!0
ML >__LP?MM_ 3]K=]8TWX6:QJ,&L^'G5==\.:_I<EE?V.XD*7B<<@D$94L >
M#@D"OGG_ ()I_'KP_P#!W]BWXJ?&KXQ^(K]]'\._%K7'O;IA)<RQ0AK5%55Y
M8@%QP.F36)^QQ_PNR/\ X+%_$>/]H2]\'R>+)/@];2:K%X&CN%L8O])L?*3_
M $@^8[B(IEFQD$8 &*\R^&JLW_!&?]I(*,_\7)UP\?\ 7Q8T ?I*_P 6/!L?
MP@/QR:\F_P"$>7PW_;IN/L[>9]B^S_:-VSKN\OG;USQ7R!_P4X_X* VNF?L
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M%.3X*>'/^$DT'Q3]B:\LM&\7^'I=.FO[=02TD(?[X !;!PQ4,0"%8A/V;6^
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MO!5U\++>.="B^2]G)8*TDC=B2&9RW4L2Q.>:\[_X(G?\HT?AU_UUUC_T[WE
M'U51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'L5%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]67Q4_9.@_98^*'[0GC3Q$L6O1ZF_BW6KE+G496CF,J1,T@(*#.T>@%?1-%
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M_!)J>#P8OP4\;_MG?$GQ!\,[2 Q:;X%N9X88EC7/E13S1@//#&=I$6$3**,
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MS[J6X;<$ 7AI2!@= *](HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+,D9)9@37WW^RA\<]._:5_9P\&_'+3FCSXBT*&XO(XONPW8&RXB'^Y,DB?\
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MK4FHCPI?),50I)(6>(.HCS&QR?M"DY^0CZ:\2_$3X$?&3QAXK_8\U'QD9O$
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M$*RW$@0'LN]V.!QG'H*XKX+00V4/[?UC9Q+%"+[59!$@PH=].OF=L>I/)]:
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M8DG  'T%?35?+O\ P1?_ .4:'PS_ .N>K?\ IWO:^HJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ H(# JPR#U!HHH XW_AGOX,?VY_PD/_  KZQ^T^9OQ\_E;L
MYSY6[R__ !VNR "@*HP!T HHK&CAL/A[^R@HWWLDK^MBYU*E2W,V[=PHHHK8
M@\B_9-_9"\)_LHVWC"[TKQ9J/B'6?'/BJ?7O$.NZLD:SSS2?\L\1@ (K&1@.
MN96YZ5T/[3?[/?@O]JCX&>(/@-X_DFBTW7[58WNK8*9;:5)%DBF3<"-RNBMS
MP<8/!KO** /G]?V _#-SXF^"/B[7OBIKNH7WP/L9[31YYXH<ZI')%'$#<$+G
M<J1(,K@DY)Y->^75K;7UM)97MO'-#-&4FAE0,KJ1@J0>""."#4E% 'BG[('[
M$WA/]B^X\6Z3\,/'FL7'ACQ+K+:E9^%M0$;6^C2L3N6W8 -M*;$(8DD1(<YR
M3C?M3?\ !.3X._M8?&WPE\;O&^NZK97?AN.&WU'3K H+?7;.*[2[CM;H,"3&
M)58X']_L0"/H2B@ HHHH \M_:W_97\+_ +7GPYT[X;^+/$U_I5MIWB6SUF.X
MTY$9WDMRY5#O!&T[SGOQ7J5%% 'EO@?]E?POX&_:I\;_ +5MCXFOY]5\<:18
MZ?>Z7*B?9[=+6-$5D(&XDB,$Y/>L[]J[]C+P;^U%/X>\71^--:\'>-/!]T\_
MA3QKX:F5+NQ+@"2)@P*RQ. -R''< @,P;V.B@#Y^_9]_8,M_A?\ &.3]I#XT
M_''Q%\4/'ZZ8=.TO7?$,,4$.E6C9WI:VT7R1,V6#-DY#-@#<^Y4^'?Q'D_X*
M4'XC:3KWBYO"D/PQDAUJSO))4T5+Y[F(6JVRG"2SE$N'D90=@\L$@O@_0%%
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MCOX;_L=W?Q(^,7[6OC;XDW6@ZQI]OX;L=;6&VM;(2SK&\TB0C-Q/Y>4$LA)
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M!*X,9\B-<,#T)ZL:^K** *7AK0X/#/AS3_#=M,\D>GV,5M'))C<RQH$!..Y
MKQT?L.>"=(_;./[:O@/QIJN@:U?Z5]@\4:)8QQFQUQ-NW?,I&X/\L1RI'S0H
M<9+;O;Z* /*?VQ?V2O!7[97PEB^%WC#Q!J.C266LVVJZ1KFD,HNK"[A)VR1E
M@0"49USVW9'(%=1\!?@QX2_9W^#7AOX)>!ED_LOPUI4=E;23 >9.5&7F?: -
M\CEG;  W.<"NNHH *Q_B)X-L_B-\/]=^'VH7<MO;Z[HUUIT\\(!>-)XFB9ES
MQD!B1GTK8HH X7]FGX$Z'^S+\"_#GP(\-ZW=ZC8^&[-K:VO;Y5$LJF1Y,L$
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M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCJO_  3B\!Z?;N!<:5-JMEJ$!X:&9=2N7VL.QV.C8_VA7S'KOAK4_B3\*/\
M@H%XQ\+1-<6-UXFBM[>:$961M+:66ZVD=<(03CL0: /4_@S_ ,$X-0^/W[,^
MD?M%?$KX_P#C\?&?QCH$>OV/B^U\57$":3<7$8GMK>*WC81K"@:-60#^^%*#
M:%]W_P"":?[2?B;]JC]D#PW\2O'K ^)+9[C2O$;J@7S+NVD,9EP. 701R$
M!G( P!76?LB^+] UC]COX;^,H-1A73S\.]*FEG9P$B5+*/?N/;:58'T*GTKP
MO_@A[I]X/V)9/%<UN\=MXC\=ZSJ6G[UQNA,RQ9'_  *%Q^% 'V%1110 4454
MU6'6)HT&CWD4+!OG,L>X$4 6Z*Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:
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M^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:
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MJ/8/V>OV6OA#^S5\$8?@'X T1Y]$V3?VF^JL)YM4EF&)YKEB )'D'!X V@*
M%  ]%HH ^/IO^"3=WI7AZ_\ @U\.OVSOB-X<^%&J7$K7?P]LV@D$4,K%I;:"
M[D!DBA;+ IALACNW%F)^I?AG\-_!?P?^'^D?"_X=Z''INAZ%81V>FV41)$<2
M# R3RS'DEB26)))))-;E% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH*T4>OB<PH8>@\)@%RT^LOM2]>R\O^&"BBBL#Q0HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %!( R35;6-8TKP_ID^M:WJ$-I:6T9>>XG<*B*.Y)KYJ^)'QT^(7[
M1OB)_A1\"["XBTR3*WE]S&T\><%W;_EE%[?>;H>NVN+&8ZE@XJ^LGM%;LPK5
MX45KJWLNK.D^.O[5\T&HGX:?!!#J6L3R>1)J-M'YJQ.>-D(&?,?_ &N5'N>G
M!:I8_"?]CWPVOQE_:9U8:MXJO"TVC^&XYA--+-UW')^=@3\TC?(AZ;FVYQ_B
MM\>/@W^P/H\OA/P0EKXL^)]U!LN)&&8=-W#H^#E!W$0.]^"Q4%:Q_P!F_P#8
M.^)'[0OB\?M&_MK:C?7!O66:S\/7;%)KE>J^<HQY$(_AA7!]=HX983*ZE::Q
M>8/_  QZ+_-^?]+U<!DL7!8[,WRP^S'J_)+]?^'7,>$_AQ^TG_P5!\>1?$#X
MGW\WASX>6-RWV*& $1!0<&.V5O\ 72GHT[# .1V$=?=7PI^$GP^^"?@RV\!?
M#7PY#ING6PSLC&7F? S)(YY=SCECST'0 5NZ;ING:-I\&DZ180VMK;1+%;6U
MM$$CB11A551PH X '2IZ]2K6=31:)=#7'YG4QB5.*Y*<=HK9>O=^84445B>8
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MB_$F?Q;:_#K7[GP#"LFNQZ+=-HL; $-=B%C""#P<OMZUM5B?$N\\5Z=\.?$&
MH> [03ZY!HEW)HT!3<)+M86,*X/7+A1B@#X'_8G_ ."9G[*W[5O[.^B?'7XW
M>,?&'B[QMKGG2>+[RZ\6W$<MIJ"RNLMJ\:D-&T9&TA\L<9X! KZ5_9R_X)I?
MLL_LK_$=?BK\(M%UR#6%L9;02:AXBN+F/RI,;ALD8C/RCGM7RY^Q+_P2X_9J
M_:J^ &D_M)?%'XM^.]=\:>+6FNO&-]9^)_(:/4/-82V\B",L'1A@AR3GG@$
M?3G[-7_!,_\ 9[_95^):_%;X:Z]XQN-36PEM!'KGB-KJ#RY-NX["@^;Y1@YX
MH ^A:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.!WST7\T[W3[V^N9=2T^QO)K6>\=+>>2$DR-G(4D9!?!!(!/6OKC3M-^-O\
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5'  %6Z**Y#YQMMW84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'5"G3I*T%8**\_\ VC_VC_A]^S%\/F\>^/7FE\V86^G:=: &:\F()V+D@
MEF/  [D@'YGT[_@L[X,N=-U)]4^"&I6=Y';,=(2'5TN([B7^%924C,2]R5#]
M.E=<*%6HKQ6AZF%RG,,;2]I1IMQVOI^I]$_M3?M4?#_]EGP&WB?Q3*+K4[I6
M31-#BD EO90/QV1KD;G(P,X&6(!^4?V:_P!F7XF_MT?$EOVI/VIYICX=>4'2
MM*(:-;Y%8E8HESF.U4YR>KG/))9JD_9A_9;^)'[:WQ$/[57[5TTTNB32A](T
MB0%%OT4DHB)_RSM%[#K(<G)RS-]ZVEI:V%K%8V-M'#!#&L<,,2!4C0# 50.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?+4Z/[)P=#_><3%>4;R?X;'N_P 0?^"BW[(GP]\R&?XJP:O<ITMO#]N]WO\
MI(@\K\W%>*>,/^"Q%KJ5[_8OP4^!&HZE<RG;;2:O=A7)_P"N$ <M^#BO5_A]
M_P $P_V1O NR:^\&7GB&XCQB?7]2>0$^\<7EQG\5->U^#_AYX!^'UE_9W@/P
M3I.BP8P8M*TZ.W4_4(HS^-'-A8;)OUT#VV08?X*<JC_O/E7X:_>?FW^TE#^W
MW^UCX=M_'?Q'^!%_9Z-X<2::VM;'17MC&LOEAW$4KF:7A%.0&P 3P,FO(/@'
M^SS\1_C[\1['P-X2\-WCH]VBZI?FW80V$.X;Y)&(PN!G /+'  )(%?LW16L<
M:XPY8Q2.ZCQ54P^'=*G1C%?9LW9?+KKZ#+>WM[2W2TM($BBB0)%%&H544#
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M.G-KR=OFVEH?>WPP_:T_9U^,GB!O"OPY^*5C?ZD Q2R>&:WDEP,GRQ,B>9@
MGY<\ GI7HM?BW\,_^$N_X6+H7_" ^=_;G]KV_P#9/D9W_:/,7R\8_P!K%?M)
M49MEU/+YQ4)74K[[Z&G#^<5LWI3=6*3BUM>SO?O?:P4445Y!]"%%%% !1110
M 4444 %%%% !1110 4444 %?.'QV_P""9/P2_:A^/,WQF_:$\7>*O$>G1PV\
M>E>!VUJ2#2;/RXPK/LC(<L[ L=K(#N.0W6OH^LOQQK&L>'?!6L>(/#NAOJ>H
M6.EW%Q8Z;%]Z[F2-F2$8[LP"_C0!0^&'P?\ A7\%/#:>$/A'\.]&\-Z8F/\
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M.0W_  QMJAA_X\S\1]9_L['W?(W18V^V[=6-X-^&W_!67X(?!5?V/?A[X<\
M:WIUA9/I'A?XKW>OO;R:?IQ&R)I;/:7,T49VKMW*NQ0?,VDM]+_LB_LW>'/V
M2?V=_#/P"\,WQO(]#LV%WJ#1[#>74CM+/-MR=H:1V(7)VKM7)QF@#TFBBB@
MJIJNH76GQH]KI4MT6;!6(C*^_-6Z* ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W
M_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X275_^A0O?
M^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^E
MK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
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M@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\
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M0#'KEV%?)7_#$7_!03XF?/\ $_\ :1^QV\G^LM7\1W<V/^V42B+\FK6\-?\
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MTLA_[8P__%FN"OF>"P[M*:OV6K_ YZF*H4W9RU^\^C:^>_VH/VJ_$W@3Q2?
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M;/)C"-'Y0]B7^IKZ4_9P_9P^'W[,7P^7P%X"CFE$LQN-1U&[(,UY,0!O;
M  "J. !W))/?T5G.O5J1M)Z'#B<US#&4O9UJC<>VGZ;A11161YX4444 %%%%
M !1110 4444 %%%% !17A7[=G[6MW^R]X!LO^$4LK:Z\1:Y.\6G)=_-';QH
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M=>)O^"P_@J%C%X(^"FK7S,<1G4]3CMCGM\L:R_EG\:]L\+_L%_LD>$MK:?\
M!73;EUZOJDTUYN/N)G9?TQ7HOAGX=?#[P6H3P=X$T;25 P!IFEQ0 ?\ ?"BC
MVN3T_AIREZNWY#^K\15OCK0A_AC?_P!*/C4_M[_MT_$?Y/A5^S)Y4,GW;E=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%0ZAJ.GZ5:
M/?ZI?0VT$8S)-<2A$4>Y/ I-I*[ FHKR[QM^V#\$_!^^"UUV36;A>/)TF+S%
MS_UT)"$?0GZ5YS=?M9?'7XH7#Z;\%_ABT*$[?M0@:Z=/<L0(T_X$#]:\^MFN
M!I2Y5+FEVCJ_PT.:>,H0=KW?9:GTK//#;0M<7,RQQH,N[L %'J2>E>>^-OVJ
M?@EX(WPW'BY-1N$_Y=M(7[02?3<#L!]BPKRJ#]ES]H;XKS+>_&3XE&UA9@QM
M'N#<LA]HD(B7\#^%>A>"?V-?@MX2V7&I:5/K5PO/F:G-E,^T:84CV8-6/UG-
M,1_"I*"[S>OW(S]KBZOP0Y5W?^1P>J?MG_$GQS>-HOP7^%LDDAX$TT3W4H']
M[9& J?B6%5Q\!?VJ_C*1-\4_'ATRSDY>TFN=W!]((,1_]]$&OI/2](TK0[-=
M.T73+>SMT^Y!:PK&B_15  JQ1_9E2OKBJLI>2]U?<A_5)5/XLV_+9'CG@G]B
M+X1>&MEQXC-YKLZ\G[5+Y4.?9(\'\&9J]5\/^%_#?A2R&G>&- L]/@'_ "RL
M[98U/N0H&3[U>HKOH83#896I02_/[]S>G1I4E[D;!11170:A1110 4444 %%
M%% !1110 4444 ,F@@N4\JXA213U5U!'ZUF7O@'P+J6?[1\%:3<9Z^?IL3Y_
M-:UJ*F4(RW5Q-)[G)7OP%^"NH9^T?"W0QGKY.G1Q_P#H %<[XI_9$^"&O:/=
M6>F>$8]-O)866VO;>XE_<28^5MF_:P![$<_K7I]%83P6$J*TJ<7\D9NA1DM8
MK[CXT_X8F^.7]O?V5_9UA]E\S']J?V@GE;<_>V_ZS\-M?3_PP^#7@CX7^'K+
M2M*T.RDO+: +/JALT$\\G5G+8W=<X&>!@=JZRBN;!Y3@\#-S@FV^^MO0RH8.
MC0DW'?S"BBBO2.H**XGXO_M&_!/X#V!O/BE\0]/TR0INBL3)YEU,/]B%,NP]
M\8'<BOE3XA?\%4OB%\2=;/@+]D7X,WM]>396&_U"S:YN&'3<EM"2% Z[G9AZ
MJ*UIT*M35+3N>CA,JQV-7-3A[O\ ,]%][_0^U=>\0Z!X5TF;7O$^MV>G6-NN
MZ>\O[E88HQZL[D #ZFOF3XW_ /!6#X#?#TS:1\+[&Z\9:DF5$EL3;V2MTYF=
M2S_\ 0J?[PKS/0?^"?7[7'[3FJP^,?VNOC#<:=;EO,33#.+JXC!ZA(HR+>WR
M/[N2.ZU]-?!#]B3]G'X!"&]\&^ 8;K5(L$:WK.+JZW?WE9AMB/\ US5:UY</
M2^)\S\MOO.WZODV _C3=:7:.D?G+K\CY9Q_P4O\ VY.OF>!_"=U_OZ;;O&?S
MN;@$?6,G^[FO6?@A_P $H/@-\//)U?XGWMSXRU),,8[H&WLE;VA1BS_\#=@?
M[HKZFHJ98F;5H^ZO(RK9WBI0]GATJ4.T=/O>_P"13T'P_H/A;2H=!\,:)::=
M8VZ[;>SL;988HQZ*B  #Z"KE%%<YX[;;NPHHHH$%%>=?$_\ :T_9U^#?B!?"
MOQ&^*5C8:D0I>R2&:XDBR,CS!"C^7D$'YL<$'I7:>%/%OACQUX?MO%7@[7K7
M4]-O$WVU[93"2.09P<$=P001U!!!Y%:2HU804Y1:3V=M&8PQ&'J5'3A-.2W2
M:NO5&C17/^*OBS\+/ V[_A-/B3H.DE?O+J6KPP'\G8'/M7FOBK_@H7^R)X4W
M1S?%N&^E7I%I5A/<;OHZIL_\>JZ>&Q%7X(-^B9%;&X/#_P 6I&/JTCVJBODS
MQ5_P5Y^"&G;H_"/P\\2:HZ]&NA#:QM]#O=L?517(-_P4]_:-^(3F/X+?LQ+.
M6.(_W-WJ9_\ ("Q5V1R?,)*[A9>;2_4\VIQ%E$'RJIS/M%-_I8^XJ*^'/^$O
M_P""N7Q3_P"01X8?P];2?>'V&RLMH/\ U\DRC\.:/^&$OV]/B7\_Q5_:6%O;
MR??M7\0WESM]?W2JL7Y-5?V93A_%KP7H[O\  C^VJU7^!A:DO5**^]GV5XG^
M(_P]\$J7\9^/-&TA0,DZGJD4&!_P-A7FWBK]OO\ 9'\([DO?C+8W<B](]*MY
MKO<?0-$C+^9 KQ?PQ_P1Y\%1.)O'7QJU:_9CF0:7IL=L2>_S2-+GZXKTGPK_
M ,$Q_P!DCPWM:_\ "&HZRZ8P^JZS+U]2L)C4_0C%'LLGI_%4E+T5OS%]8XBK
M?!1A#_%)R_\ 23E?%7_!7'X Z5NB\+>#/$VK2+]UWMX;>)O^!-(6_P#'*XJ?
M_@JC\:O'4S6OP:_9G%Q)G:F^2YU D^ZP1Q_EG\:^J/"O[-'[/?@G:WACX+>&
M;61/NW']CQ/*/^VCJ6_6NV@@AMH5M[:%8XT&$1% "CT '2CZSE=/X*#?^*3_
M "0?4L\K?Q,2H^48K\WJ?#W_  L[_@K7\4_^1=\ /X=BDZC^R+6SVC_M^8N/
MPYH_X8N_X*(_$[Y_B5^T;]@MY/\ 6VC^);I\?]LH%$1_.ON.BC^UIP_A4H1]
M(Z_>Q_V!3J?QZ]2?DY67W(^$?%'_  2!\6Q^%;O5=%^-<&J^(.'AM;O2V@@F
M/\2F7S'8,>S%<9X.,Y'*? __ ();?''7/'UH?C3I%KHGAZUN5>_VZG%-->1J
M<F.(0LVW=TW,5V@D@$C!_1FBK6>YBH.+:=^MM5Z6L92X5R=U8S46K=+Z/UO=
M_<T>>>%_V3/V9_!VTZ%\#?#2NGW);K2TN)%^CRAF'YUWFG:7IFD6HLM)TZ"U
MA7[L-O"J*/P4 5/17E3JU:C]^3?JSWJ="C15J<5'T204445!J%%%% !1110
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M+$T(;R1[.2%!9B  .2:XC_AI'X&_V]_PC?\ PLBP^U>9LS\_E;LXQYNWR_\
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M[X/VO8_!6PNY%ZR:M<S7>X^I65V7\@!1;"1ZMBY.'J.\JDWY))?CJ>)>*?\
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M-9G?.?\ ?'\ZWC5R^?PXM?=)?H0\^X@C\5"K\I7_ %/K;_AA;]D7_H@F@_\
M?I__ (JC_AA;]D7_ *()H/\ WZ?_ .*KY7@\+?\ !66T8);^(_$#\;09+R!O
M_0Q^M7K>+_@L%:MMM[O4G)_YZ+I3=/\ ?6MXT:4_AQ4/_ FOT,WQ-FL?BHU_
ME=_^W'TU_P ,+?LB_P#1!-!_[]/_ /%4?\,+?LB_]$$T'_OT_P#\57S<=?\
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M3X9^)-S\1/CCKFE6<NF6;#2=*U&2,QR.XVM*SL=A*J2 @R26W<;:^U;GX_\
MP1TB,0GX@Z8$085;9C( /0! :^<OV?OV?K_XKZRUYXCM;ZTT*&(F2[B 1II/
MX4C+*0?4D X QP2*]MLOV./@M:X\^SU&YQ_SWOR,_P#? 6N6AGW%F>TEB73I
MJ^S?,E;R6KMYWU.VADV29+#ZO2E+N]F[^;T+=[^UK\"[3(B\537!':#39O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S;]LO_ )- ^*W_ &3;7?\
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MHH Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !K8HH Q_L7C?_H-V7_@,?\
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M05[-17'/+\%5_B4U+U5_SN=D)RI?!IZ:?D>50?LJ^ ;?_5^&M,.,?ZQKAO\
MT*0U<@_9Q\&V_$?A30#C^_8LW\R:])HJ8Y9EL?AH07_;L?\ (T>)Q+WF_O9P
M,/P,\-6_$?@WPJ?]_08V_F#5R#X565MS;>'?#,?^YH,0_D*[*BMHX3"Q^&G%
M?)$.K5>\G]YS$'@K4;;'V:#1(\=-FE*/Y"K<.D^+[<;;?5-/08Z)9X_E6Y16
MT80CLK$.3>[/*/BY^S6_Q;OHM:U+7X+34(HA%]J@MB1(@)(#+D9QDX.0>>_&
M#X2?LUO\)+Z76M-U^"[U"6(Q?:I[8@1H2"0JY.,X&3DGCMSGU>BO/_LC+?KO
MUOV:]IWU^^VU_.US?ZWB/8^RYO=[&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C6Q17I'.8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&
M_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+
MQO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q
M10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% '+>+? ^K^.O#%_X
M.\57.GWFFZG:O;WMM);'$D;#!&0<@^A'(.".17RQ_P .>_#/_"2_;?\ A<%Y
M_9/F[O[/_LY?.VY^[YV['MGRZ^T**ZL/C<5A$U2E:YPXS+,#CY1>(@I-;;_I
M^1RWA+P/J_@7PQ8>#O"MSI]GINF6J6]E;1VQQ'&HP!DG)/J3R3DGDUH_8O&_
M_0;LO_ 8_P"-;%%<S;;NSMC%1226B,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E
M_P" Q_QK8HI#,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z
M#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !JUI4&OPR.=
M8OX)E*_((HMI!J]10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%>/?\% ?BKKWP4_8M^)/Q+\+7KVNIZ?X7G3
M3KN)L/;SS8@CE4]F1I P]U% $/B7_@HA^Q%X/^(\GPE\2_M,>%K/7H;G[/<6
MLM]^[@F!VF.2< Q1L#P59P0>#BO98I8IXEG@D5T=0R.C9# ]"#W%?-'[)?[%
M/P"N/^"?'A/X-^)_AMI-Y;>*?!%K=^([F:QC:>YO;NW666X,A&[S%>3Y'SE
MB8(VC&=_P1H^(WBCQW^PQHVA^,-0>[OO!VM7_APW4C$L\5M+F$'/9(I$C'^S
M&* /JJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'O^"@/PKUWXU_
ML6_$GX:^%[)[G4[_ ,+3OIUI$N7N)X<3QQ*.[.T84>["O8:* /F7]DW]MO\
M9]M_^"?7A7XQ^)/B7I-I;^%?!%K:>)+6:^1;BVO;2V6*6W\HG=YC.GR+C+AT
M*@[A6?\ \$9_AWXG\"_L+Z+KGB_3GL[[QAK-_P"(C:RJ0R17,N(FP>SQ1I(/
M]EQ7HGB?_@GC^Q%XR^(S_%CQ/^S/X5O-=EN3<7%U)88CGF)R9)801%*Q/)+H
M2223G->R11101+!!&J(BA41!@*!T '84 .HHHH *J:KH]KK$:174DJA&R/*E
M*G]*MT4 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
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MLT395U#*?4&O%=7_ ."C_P"PMH7Q ?X8:M^U!X4AUB.Y-O-$U\3!%*#M*/<
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M\ _AY\#_  ]8P?&-_B/8WVF3Z+;)'<V>BQ;_ +2]P8QD6^0K8;@K%-C@.#]
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M1M,A\G3]-LH]D5O'DG:H[#)/YT :U%%% !1110 4444 %%%% !1110 4444
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M6_&S?$+5/V6?"4NIO.9I#]@*V\DA.2S6X(A8D\G*'.3GK0!PG_!%[_A8'_#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDL/!OQS\(S:;X@N9#MAM]9TZ,213/CH6A5(U]3)(?7 !]&3?M1_!FW^->N_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*M+\?7?Q5TSX9>'K?Q1?Q"*^\20:+ E_<(%"A9+@)YC@*JC!8C"@=J ,ZP^
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MBCQ9K7C[QAX[@^S^+_%OBR99+B]M]NW[,BJ L4.W V#.<*"<(@7W.B@#Y,\
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M-?0-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>arvn-20221231_g11.jpg
<TEXT>
begin 644 arvn-20221231_g11.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **Q_&'Q \&?#^VAO/&?B*WTZ*X<I"]P
M2 [ 9(&!Z5@?\-)? K_HINF?]]M_A6,\1AZ<N64TGYM$2JTXNSDE\SMZ*^;O
MV@/VS+W3=3C\._!;5;62-8@]UK'DB7+'HD:N-O ZD@\G QCD_9__ &S+W4M3
MD\._&G5;6.-HB]KK'DB+##JDBH-O(Z$ <C!SGCS_ .VL!]9]CS?/I]_](YOK
MV']KR7^?0^D:*XC_ (:2^!7_ $4W3/\ OMO\*V/!_P 4OA[\0+F:S\&>*[74
M9;>,/,ENQ)12< G(]:]".)P\Y<L9IOU1T*K2D[*2^\\Z_;(_;"T?]C30O"OC
M7QCX&N]2\/:]XJM]%U;5[6[6,:,)LE;B12IWH%60G!'*@9RPKV0$, RG(/0B
MO+OVT?V>[+]J;]E[QG\#KB*,W.LZ._\ 9,DF (KZ(B6V<GL!,B9_V2P[UYQ^
MP1^UGI7B_P#X)X:9\:OB??R07?@'0;K3_&_G_P"MAGTR,K*7!_Y:/$D<I'K+
MBMC0[GPM^USH_C?]L?Q)^R+X6\%75U)X0\.0:EXC\3"[46]I/-L,5GLVDM(R
M2*^<@8#]UY]?K\XO@M\:?%?[&_\ P3H\>_\ !1/Q;H,%U\0_C1XJ?5].M;W/
MEI]HF:.PC?D$PQQF:X501E'"Y7.18\2:S\2O _PGNOC9HW_!:'0=9^)NG:8V
MIW'A67Q'HTF@WTR(9'T^*U5@0&P8ED7!)P0JY^4 ^O?VKOVK-'_96M/ ]UK'
M@^YU<>-O'UAX7MQ;72Q?99+H2$3MN!W*NSE1@G/6O6*_-[]OW]H?Q%^U#^PS
M^S;^T+\-]'L[;7]?^+^CSV&GW19K:+58DO(3$3G<8A<Q,,]2H]:Z']L;PU^V
MM^P9\*[?]L>T_;D\1^-KW1]9LE\7>%=;TNWBTB_@GF6-TMX(QBW&YU48^;:<
MAE*C(!]@>.OC1XH\(?'?P3\'M-^"WB'6-,\60WSZCXQL+9VT_0C;PF1%N7"%
M4,I&Q-S+ECQGI7H%?,/[0/QP^)GAS_@HM^SQ\*O"OC&ZM/"_C'3?$,VOZ0BI
MY=\8+!I82^06&U@",$>^:X?3_$O[1W_!03]ISXF^!_ O[1.M_#+X:?"S7/\
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MGC7PQX%OO$^H:9XOU:>T\/Z8P%Q?NHT_$49((#'MQ7;?\/&?VJ?^D57Q3_\
M R+_ .-U)@?1WP,^(?BCXK?"O2?'_C3X7:IX+U/4%F-UX9UIPUS9%)GC4.0
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M/?M _$GX;>(IM)US2?BAKDVG:C;A2\#F:R7<-P(Z,1R.]?9EQ\0?&2_L /\
M%5=?F'B$?!TZL-4POF?;?[*\[SL8QN\SYNF,]J .E_:8_:/^&O[)_P '-4^.
M'Q8GO%T?2O+5X]/M3-//+(X2.)%R!N9B!EBJCJ2!7>*=RAAW%?EQ^V_JWQ3^
M./\ P11\!_'?QS\8=8GO1;VS^(+#RH?)UR6:_1(Y)SLW!HO+)785!+G.>*^N
M?C'\./VU_ _P+\/?";X!_&^;5M8U#Q"%\6?%'Q<EE]JT726):26.#:D<KJ"
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MI,@ # 4D9)H ^R?@/\5K/XZ_!7PK\9]/T>73X/%.@6NJ0V,TH=[=9XED"%@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMH) )(^;M2^.W[ EQ\,'T;PO_P $LHY/C%)8^1;_  ZNO@O_ *K4RNW$DHA
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MN:_\/_&'@@>&O'4WAW3VN[C1;F*99(+QX4^9HBL<:$CIA_XBBMF^'?%.H?\
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M#(..":^N*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/7+-C=Z>TF\V=U&[13PDX&0LB, V!N7:V!F@#TBBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /@CPM\-?^"D<7[</QX^+/P0^%_@[0X?$VIZ?9:;XJ^)D
MMSY$MC90M#&MG#:Y9_,PCL[_ "@*.-Q->A_ S]NCXTZUK?Q-_9I_:=^'FE>&
MOBMX"\)7.N6LWAV9Y--UFR$64N;?S"S+AGBRI))W]%*LJT(/V[/BO^RA\;_'
M7PY_;I\+^()_#5QK37GPS\;^'/"3W-E/ISG"V<IMD)$Z?+G<"Q8OG"^66H_L
ML>"/&G[6G[:OC;]NKQG\,=8\+>"+GP,/!W@O3?$=H;:^U:V:19)KQXC\T<9P
MX7/WA*,$[#0!U'_!%?0K'2/^"<7@/4;= ;C5I]5O=0GZM-,VI7*;F/<[(T7)
M_NU\R:]XEU3X<?"C_@H%X.\+S-!86OB>*XMX(3A8WU1I8KK:!TR@ ..P KT7
M]DS]IV'_ ()G_#&__8T_:D^&WC1;KPCK-^? ^L:%X9FOK;Q-I\\\EQ%Y$D8V
MB4O(^58J%W $@A@.@_9J_8W^)?QD_91^._B'XS^&Y/"WBK]H35=1U.TT;401
M)HT#*_\ 9\<XQD,CL6*X#!=H(#9  /I#]D+P?H&B_L=?#;P9;Z?"U@/AYI4,
ML#("DH>RC\PL.^\LQ/J6->&?\$/=0O3^Q-+X4FN7DMO#GCO6=-T[>V=L F67
M ]M\KG\37(?!S_@I#JGP _9GTG]G?XF?L]?$ ?&;PAH$>@:?X1MO"MQ.FL7%
MO&(+>XBN(U,;0N%C9G!_O% XVEO=_P#@FE^S;XH_98_8_P##7PU\?JJ^);E[
MC5?$:*X;R[NYD,AB)'!9$,<;$$@LA(."* />J*** "J^H:KIVE(LFHW:0JYP
MI<]35BF2P03@">%' Z!U!Q0!0_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG
M_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG
M]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T
M&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,
M?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\
M,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_
MX3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&
MH/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'
MPQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3
M'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_
M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I
M_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I_
M_/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G
M:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
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M_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V
M**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!]
M(_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'T
MC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W
M_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;
MW_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#
M8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C
M_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_
M^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_
MY^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_
M )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P
M+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q)O!VA6\9EN+^Z
M1!U9[U@!^)-8VI:M\(-'R-6^)-C;$=1/X@1#^1:IE.$/B=A.48[L[2BO*]2^
M,O[-^E9^U?%16QU^S7$TW_HM6KG]2_:B_9RL<_9=<UZ]QT^S0R#/_?PK7-/'
MX&G\56/WHR>(H1WDOO/=**^:]2_;'^%$6?[(\(^)9_3[3?)%G\F>L>3]KK4=
M8<Q>%/A/>R,#@;M9EF/Y)&/YUS2SK+8NWM+^B;_0R>.PJ^U^9]645\ICXI_M
M1^(#_P 2#X/WD,;?=D_LR\/_ (\[A?TJ6/0/VY/$!S!IT]E&W7=/:Q8_[[8M
M4_VO2E\%.<O2(OKL'\,9/T1]3T5\PP_L\_M@:Y_R$_B<MF#]Y7UV9?TB4BIT
M_8:^(>LG_BJ_C$C9^]MAFN/_ $-US1_:&,E\&&E\VD'UFN_AI/YM(]P^)/Q7
M\*_#?PGJ'B6_U*VFELX"T5BMTHDF?.%0#.>6(R<' R>U?+?_  VS\<O[>_M7
M^T;#[+YF?[+_ +/3RMN?N[O]9^.ZO1;?_@GWX;2V=;KXCWTDQC/EO'8HBAL<
M$@LQ(SVR/J*\Z_X8F^.7]O?V5_9UA]E\S']J?V@GE;<_>V_ZS\-M>5F-3/:D
MHN$'%=HN^OG;_ACDQ,LPDTXQ:]'?[SM]6_;8\=>-'BT#X/?#.5[^6)?,>9&N
M75B/FV1H , ]&8XQR5%0V7[,_P"T'\9KI-7^-OCV2QMRVX6;RB9U_P!V*,B*
M/ZYR.XKV;X>_!#PK\/O"MIX;T^:X+0Q 7-Q'(8S/)U9R!ZDG YP,"MS_ (0?
M2/\ GYO?_ MJ]*&65<1%2QE1R_NK2/X;^IU1PLZB3KR;\ME^!R?P]_9;^#GP
M[V7-IX;74;Q.?MNK$3,#ZA2 B_4+GWKT0  8 P!T K'_ .$'TC_GYO?_  +:
MC_A!](_Y^;W_ ,"VKU*-"C0CRTXI+R.J%.%-6BK&Q16/_P (/I'_ #\WO_@6
MU'_"#Z1_S\WO_@6U:EFQ16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16
M/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#
MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
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M_P#$4BC7"A5 0 #KGNZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1=.G4JS48)MOHM3L:;++'#&TTTBHB*6=V. H'4D]J^+/B;_P5N;6M3_X0_\
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M;PH$AM[>((D:CH%4< >PHY\/3^&-WY_Y%?6LGP7\"DZLOYI[?**_4^(_ O\
MP2H^(GQ(UE?&_P"UG\<+V^O)<&:STZZ>ZN".NUKF<$+CIM5&'HU?4'P=_96^
M /P'B1OAK\-K"TNT7!U2=//NV]?WTF7&?12%]J]"HJ)UZM31O0XL7FV/QBY:
MD_=[+1?<OU"BBBL3S@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM'_LRS?2VABLM%T\.'>&UA0]V )?:G4\99V8 ^I**** "BBB@ HHHH ****
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M>DAR\A]V)-=/117.VV[L\:<YU).4W=OJPHHHI$A1110 4444 %%%% !1110
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MFTLPW7[B,9'P?[SX/=>U?3?A'P3X.\ :-'X=\#^%M/T>PB^Y::;9I#&#Z[4
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M_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\
M0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO
M_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\
M0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO
M_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\
M0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO
M_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\
M0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO
M_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\
M0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO
M_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\
M0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO
M_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\
M0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO
M_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\
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MI>/[,\*:;;8Z>18QIC\A[UI !0%4  #@"L?[%XW_ .@W9?\ @,?\:/L7C?\
MZ#=E_P" Q_QJ;MF+DY/5FQ16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
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M9CR2Q)+$DDDDFMRB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %RTJX'_ *$@K)X_ QWJQ_\  E_F0\106\U]Z/4**\?N?VX/@= 3Y4^K3?\
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MI3RMNN(](LEB8GO^^F,A;ZE!3]C2C\<U\M33^S,NH?[QBH^D$Y?CL>M>//\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW"'1+1_>M;_,X3P'^S!^SQ\,]C^"/@UX>LIH_N7?]FI+./\ MK(&?_QZN[
M& ***YG*4GJSQ*E6K5ES3DV_-W"BBBD9A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\
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M_L[^&?@%X9OC>1Z'9L+O4&CV&\NI':6>;;D[0TCL0N3M7:N3C->DT4 %%%%
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MLCQ,^.NT2*N_CGC-?-?QP^,7Q,^*6@VD7B#P7-I.EV]R7#)!*$ED(PNYFX)
MW8 ]37G>@7FKZ?KEI?Z!YOVV"X22T\A27\P$%< <DYKY[&\:2I8V,*%.]/2[
M::D_3:WS3N>A1R93HMSE:7E:WS/T!HKY_P!/_;BDLYOL?BWX9S02+]\V]Y@C
M_@#H,?\ ?5=3HO[97P:U/ U"?4M.)Z_:K$L!_P!^B]?24>(\DK.RK)>MX_FD
M>=/+L;#>#^6OY'J]%<KHOQP^$6OX&F_$32BS?=2>Z$+'_@,FTUTUK>6E]"+B
MRNHYHSTDB<,I_$5ZM+$8>NKTIJ7HT_R.6=.I3?O)KU)****V("BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*OA1J&7TJ_U:P;^%8[E9$'X.I)_.N;N?V*O$^B3&[\#_ !6:*3^$26[P$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'?L]:_\ %R_DN+_[1INDQ1$G4#;Y\Q^R(#C=ZDC@8]Q7SG]O\2?VU]7]DO\
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M\*"_:S@^:/XU;R>,?\))>G^<=']M9@M\%/[T'U/#_P#/Z/XGT-17SS_PH_\
M:ZB_>)\7]Q'1?^$@N3G\TQ1_PI[]L(<CXI9QV_MR7_XBC^V\8M\%4_#_ ##Z
ME1_Y_1/H8D*"S' '4FN-_P"&A/@O_;?_  CW_"P;'[3OV9^?RMV<8\W;Y?\
MX]7B_C7X>_M::5X2U'4=>\;S75C%:NUY!!JC.SQ8^?C:,C&<CTS7AM>+FO%V
M,P4X1CAW&^KY^J\K/\?P.S"Y31K1;=2_^']3]# 0P#*<@]"*9/<V]K&9KF=(
MT'5I&  _$U\S^"?@!\??&_A+3M7N?BC-96-Q:JUI9W&I7+-%%C"C9C:HVX(
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MC_GXU&4?^@%:]-HKKIY!DM+:A'YJ_P"=S*6.QDMYO\OR.-T_]GOX*Z;C[/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  @,"K#(/4&N
M-_X9\^#']N?\)%_PKZQ^T[]^/G\K=USY6[R__':[*BL*V&PV(M[6"E;:Z3MZ
M7+A4J4[\K:OV  * JC '0"BBBMR HHHH **** "BBB@ HHHH **** "BBB@
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M4444 %%%5]0U73M*19-1NTA5SA2YZF@"Q16;_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;
M_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-
M0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_
MWU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9
MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;
M_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-
M0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_
MWU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9
MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;
M_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-
M0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_
MWU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9
MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;
M_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-
M0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_
MWU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9
MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;
M_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-
M0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_
MWU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9
MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;
M_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-
M0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_
MWU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9
MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
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M_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM
M/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_
M +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L
M[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT
M*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_
M .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[
M]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3
M_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*F
MHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\
M8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"
MC^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^
M?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH
M A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&
M'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^
MSM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#G
MQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A
M_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM
M/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_
M +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L
M[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT
M*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_
M .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[
M]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3
M_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*F
MHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\
M8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"
MC^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^
M?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH
M A_L[3_^?&'_ +]"GQ6UM 28+=$)ZE$ S3Z* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG/9WWC#6;_Q$;652&2*YEQ$V#V>*-)!_LN*]$\3_ /!/']B+QE\1G^+'B?\
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
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MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV**
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M63.DBW*6IVN (U9?,9%)(/>0T ?>%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 V>>&U@>YN)52.-"TCN<!5 R23V%>'_P##R_\ 8%_Z.R\%_P#@
MV6MK]NSXC_\ "I/V-?B;X_CG\J>R\%WZ64F<;;F6%H83_P!_9$KX4_9E^/O[
M#7P6_9:\!GXK?\$[?%&MZ-:>'[4>(_BM??!RUN=.:[EPTLAN9AYDT2R.R"3'
M.P!0W% 'Z7>"/&_A'XD^$[#QWX#\06VJZ/JEN)]/U&SDWQ7$9Z,I[CBM6N=^
M$NI?##6?AGH>L?!;^R?^$4N].CFT#^PX$BM/LS#<GEH@ 0<_=P,'((!S714
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MX/VYIE_#JNFV^J6X(CN8$E0'KAE!'\Z )Z*** "BBB@ HHHH **** "BBB@
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M !1110 4444 >%6O[;'@1_VP?$?[&GQ4\+P^&[JQT>TU/PSJ^M:E']G\212
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MG+PQX*\.?LX_"?XG>)OB7\5/B/K]AI'AV?Q;XP.M7>A:4LZ3W%Q$HPEK#B%
MS[02N_!VJ^/T\LK.#3[.&PM5VQ01+'&/15&!^@KS3X%_L6_LK_LTZI<:]\#O
M@?H?A_4+J,QS:C;PM)<^63DH)969U0G&54@' XX%>H4 %%%% !1110 4444
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M))R30!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"C7[.WQ_^* ^"6FP^)_#'C"2U>YL_#?C;PY-IMU>0H"S/$'RK856;;D-M5B
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\NZ9_P $P/##?&3P;^TAXY_:$\;^*/B!X5UA;R;Q%K<\+)>0 $?8DMT18K:
M;I"!& VZ5B6/&/-/^"O_ (T^#/[1_@_0?V*OA_XHM-8^*^H_$/3H-(TC3I2]
MQHK[6\ZZN H_=Q+;R/G)&0X<9"$C[MKGK'X2?"K2_'UW\5=,^&7AZW\47\0B
MOO$D&BP)?W"!0H62X">8X"JHP6(PH':@#.L/@+\,K7X"0?LUW?AV.Z\)1>&$
MT"33I>!+9K (2I*X(8J,[A@YY!SS7SG9_P#!+/Q[I/@I_@;H?[?WQ-M?AD]N
M]G_PB*PVC7"639!M5O2F]8]I*;0NW:<8QQ7U]10!S_PI^%W@GX*?#?1?A/\
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M%AI,6E:HV@M&T.J6,<_G""56P<,V W)!"I\N5S7T#10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>arvn-20221231_g12.jpg
<TEXT>
begin 644 arvn-20221231_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBN>^*/Q:^&7P3\(3^/OBWX[TOP[HUL0LNH:M=K#'N.<(NX_,YP<*N6..
M : .AHKY\^'O_!57_@GU\4?%D/@GPA^TSHYU&XF$5O'J5E=V$<KDX"K+=0QQ
ML2>  W).!FOH.@ HHHH **** "BBB@ HHHH ***SO%_BWPYX!\)ZIXZ\8:K'
M8:3HNG37VJ7TP)2WMX8VDDD; )PJ*Q. 3Q0!HT5R?P8^.GPE_:'\&?\ "PO@
MMXWM?$&B_:Y+;^T+-7">:F"R?.JG(W#MWKK* "BBB@ HHHH **** "BBLOQK
MXU\)?#CPGJ'CKQYXCL](T?2K9KC4=2OYQ'#;QKU9F/3T]22 .30!J45X_P#L
M\_M\?LD?M6>+K[P)\ ?B_#X@U;3;)[R\LTTB]MRD"ND;2 W$**RAI$&5)^\*
M]@H **\"^*/_  5&_8%^#?BV;P-X]_:4T>+5+:8Q75OIMG=:@() <%)'M(I$
M1@>"&(((P<5ZM\(_C5\)_CUX0C\??!KX@Z7XCTB5S']MTNZ$BI( "8W'WHW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMJ-MJ#RO>B.\EMP65E 3(C#<$\G%?.O[)  _X+]?&( 8_P")'J'3ZZ?7)_\
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MG[/_ .T_J_[=5AXW^)?[:O\ P4KU?X5Z+HUW_H_@#PAJT.CRW%H5+$1'E[D
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MUL]+N].UOX1:2]JT[I+)(K6]M:R,K3QS(^XL#L'F,'9<-CUKXB_#+X:^!/\
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MJJ_\')$948W:)EL=_P#BFC_A0!^F-%%% !1110 4444 %%%% !1110 4444
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ME_PGO_#*OA'^T/.\W;]@/V;?G.?LV?(Z]MF*]QAABMXEM[>)4C10J(BX"@<
M #H*=10 5Q'@7]FWX#?#+XB:S\6_ 'PIT;2/$OB)IVUS6[*T"7%Z9IA-*9&_
MBW2 .?4C-=O10!5UO0]$\3:/<^'O$FCVNH6%["T-Y8WUNLL,\;##(Z,"K*1P
M000:\=\)?\$X?V%_ WC:/XA^%_V8/"EMJT,XFMYFL3)'!(#D/'"Y,<9!Y!51
M@@8QBO;*H:)XI\,^)9K^W\.>(;&_DTJ_:RU-+.Z24VER$20PR!2=D@22-BIP
M0'4XY% %3XB?#CP'\6_!E]\//B9X2L=<T/4XA'?:9J5N)89@&##(/<, P(Y4
M@$$$ UP_P\_8F_90^%?@'7?A;X%^!&@6?A[Q,$'B#2I;8W$5^$SL\T3%BVW)
M*\_*3D8/->I44 >+>$/^"=7[#W@71]6T'PS^S)X5BM=<@$.J+/8F=IXMZR>7
MOE+,J;U5MJD#*KQP*Z/7OV1OV9_%'PLTGX(^(O@IH-[X2T*Z-SH_A^YLPUM9
MRGS/G12?E/[V3_OLUZ-7A>M?\%+OV&]!^,"_ :__ &@M.;Q4VJ+IHTZTT^[N
M$%VT@C$!GBA:$/O.TJ7R&R#@@T >V:3I6G:%I5MH>CV<=M:6=ND%K;Q+A8HT
M4*J@=@  !]*Y#XJ?LV_ ;XX:WI/B3XN?"G1O$-_H+%M'NM3M!(]F2RL2A/3Y
MD4_517;U\W_'7_@JS^QE\ /BUIGP>\7?$^WNM1N-1DM-=GTO-Q#H)5"<W3(#
M@EOD*)N=6^\J@$T ?1EU:VU];265[;QS0S1E)H94#*ZD8*D'@@C@@UPGP=_9
M8_9V_9\U"^U7X)?!_1/#$^IPK%J#Z/:^3]H122H< X."3CTR<=376>#?&GA'
MXB>%K'QOX#\2V6L:/J< FT_4].N5F@N(S_$KJ2#R"/8@CJ*Y3XP_M0_ /X Z
M_P"'O"OQ?^)=EHFH^*[LVWA^RGCEDDO) Z)A1&C;1ND0;FP,MUZT <9K?_!-
M3]@SQ%XS?Q_K'[+/A.74I)S-*5L2D$CDY+-;JPA8D\G*'.3G.37K6O> / _B
MGP3<?#;Q%X1TV\\/W5C]BN-%N+-&M7M]NWRO+QMV   #&!@8Z5HZAJ%AI%A/
MJNJWT-K:VT+2W-S<2A(XHU!+.S' 50 22> !7D7P\_X*#?L5_%;X@Q_"SX??
MM(>&=3UZ:;R;6QBNROVJ3^Y#(X"3,>P1F)[9H VO@9^R!^S1^S4=4/P-^#^E
M>'CK2*FJM:AW-RBEB$8R,QVC<V%Z<]*QO!__  3[_8J\ ^.W^)?@_P#9I\*6
M&M,[/'=Q:<"L#-G+11DF.$\GF-5(SQBO3?&WCGP;\-?"M[XY^(/BFPT71M.A
M\V_U/4[I88($R!EG8@#)( ]20!R:X#X(_MO?LG?M'^(I_"/P4^.NA:]JMO&T
MCZ;!,T<[(OWG2.55:11W900,C)YH U?!_P"RS^SK\/\ X;:Q\'?!7P=T+3/"
M_B!I&UO0K2S"V]Z9(UC<R+_%E$53[ 5N_"WX2?#3X)>$(O /PE\%:?X?T6":
M26+3=,@$<2.YW.P4=R>37144 <7X/_9U^!OP_P#B7K'QC\%?"[1],\4^(%E7
M6M=M+4+<W@DD61Q(W\6YT5C[J*#^SI\##\9!^T*?A;H__";B+RQXG^RC[6$\
MGR-N_P!/*^3Z<5VE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@;Q!H]L9AK>F0RW6DRL%5O):<!XXV*N&1A*ZOR,A@ Q^SK_P4+\2_&__ (*
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MET^-R+7[8]JB*^0-C(D4SR \HHRV* /UG!# ,IR#T-%  4!5& .@HH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\O_\ @Y/ ;3/@
MTI'!O-=S_P!\Z?7TM\:O^"-_["7Q+^'NK>'/"GP1T_PQK-Q92#2=<T>XGB>S
MN=I\MRF\I(N[&Y64@C/0X(^:/^#D]@NE_!MF/ N]=)_[YT^OHCXP_P#!:_\
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M?$SXGZ9XBU&*XL/#NB65IJ5Q8S"-@DUQ;F17@8>88PC#S"9,!"-Q !]??\%
M_P#@J#<?L0?%;X>^$K3X8Q>)]%\86YNKV]L[UOM,< F1#]G0#;*[(Q*@L 3@
M9P<UY1X[_P""R_[2O[-7Q:T?3?VQ_P!B>7P?X4\26[W&DBQU9;C4D@! W'YO
M+D=24#Q$1,NX$XX!\_\ ^"GOA"W\&?M6?LA> OM-U=PZ3#I&G^=J,02>98KZ
MSCW2J.%<A<L.Q)%=!_P7[@AN/C/^SI!/&&236M25U8<,IN=+X/YT =-XH_X+
M"?M1? SXN^$H?VK/V*QX*\">-K@?V/<R:J9-0AM]Z*TKX)0O&)8V>%DB<!NV
M17 ?\%L/'-M\,/\ @H3\ ?B7>Z3=ZA#X=-CJ<MA8(&GN5@U82F.,' +L$VJ/
M4BMS_@XW _L'X-MCD:[JF#_P"TK _P""W/C;2_AI_P % /@-\2=<T^2[L?#L
M5GJE];0Q[VEAM]5$TB@=R50\4 >C^,/^"O'[5_[.'Q"T&\_;/_8>?P7X$\3W
M.RPU"TU4W-W:1\$ERI*22(I!:$K$Y&2!QBO9_P!O7_@I1X?_ &2K3PIX-^&7
M@:3Q[X[\>B-O"F@6-P1')#(P2.=V0,S!W8+&BC+D-RN,U\K_ /!;;]LW]FS]
MIC]G;P1\(/V?OB'8>,]?U3QE;:G!;:(&FDMXEMKB$(Z@;DE=[A%$1 ?AL@8%
M>?\ _!1?X5^+_@1^U;^SCXG^)_CW6/"6D6?PXT#0KKQMI,?F2Z1>63.ES)'U
M!:/SDE.,DAS@$B@#ZK^#G_!43X\>$_VBO#O[-?[??[,,?PZU+QFR1^%]:T[4
M!/:RS.^R.)QOD7YG(3<LA*,R!D ;<&_MC_\ !6WQG^RW^UX_[,'A_P#9\/BQ
M[C1X)-(_L^^D^V7M_<1-]GMUB5#D&;8I(RVTG )P#\[_ !0\#?LK_%3]ISX9
M_##Q3_P4?^)7Q=\1_P!I0S^%KG0;&SU6TT^:2>(^7)-'+^Z+&%&? .Q8]S[<
M<]E\:+&VU'_@XH\!V]W$KJND0R@,,_,FE7;J?P90?PH ^SOV'/C/^TI\<_A3
M?>+?VH/@4GP_URWUR6TM=("S(T]ND<;"<I+DJ"SLH(8AMA/%<9_P4/\ ^">F
MJ?M\W?@C3]0^-4GA_P .^%M2DNM4\/II#3#53(T8+>:)D\IUC61%.Q\><Q]0
M?IJODW_@K+_P4.E_8:^$%GI'@!(9_'GBX31>'_/0/'I\*!1+>.IX8J7540\,
MYR<JC*0#XZ_X*L_!']GOX2?M1?!KX2?L->"[#0/B8FIQF[M/#+,&@9IK?[ T
MP!.)MPD?<?FV?,Y(*&NX_P""B-I9_M1_\%C?A)^RMX^$EUX1TJSM9+S2#*RQ
MSO)YUU<9P01YD4,,9(P<)P17&_\ !-#XY?\ !-7]GJ^D_:9_:9_:D?Q'\8_$
M/F3WEU>^%]8N1HIFSYB))]D82W# D23 D8)1#MW-)V/_  4.OK/]EW_@LC\)
MOVIO'XDM?".J65JEWK!B9HX&C$UI<9P"3Y<<L,A R=K\ GB@#/\ B#X&\&?L
M)_\ !<CX;:+\!M#B\/Z!XYTBQBU'0]/)2V*WLMS9.@3/"^9!%,%Z!U!%?2.L
M?\$G? GQ!_;=\2?M>_M)^.[/QWHVIVCC3?!VJZ*8H-,91$D(9S.RSQQQ)(-I
M106?>1D<_-WC_P <^#/V[O\ @N/\-M;^ VN1^(- \#:192ZCKE@"UL%LI+F]
M9PV.5\V>*'=T+L /6H_^"PG_  4@U#QE\6)_V$?AA\18O"?AJ"\CL?B/XQ:*
M:3<S8\VV"VZO*8(E.)512\C QX"J=X O_!-72/!9_P""P_Q,N/V08C#\*[#2
M+J*[^Q2L]DR_N%41L205-VLCQ<_ZM6V_*#7N?PO_ ."2G[/GP4\3?$K]H?\
M;7\=:-\2QKC2:E<:OXET@V4&DQEI9;J1E-Q("S;DP^04$>%QDUH_\$OOC!_P
M3*^'FD6/[+'[('Q<;7_$NH0/>ZM?77AG4;:YU>:*/,DTDD]ND:*JYV1[L*.!
MEBS-\;?MY?\ !0GPG^W;^TG%^SSK_P <3\/_ (%Z)JK+J6MP:?<W<FM-"QS.
M8K:-V<,PQ"C#8O$C_-A5 /9_^#?:QU1_&?QLUSP%%?P_#676K>/P[%>LQ!E$
MEPR ;O\ EHMLT0D/4[H\YXK],:^<_P#@GO\ '?\ 8&\4>!A^S_\ L-^+X[[3
M_"-@DUY:C1+ZVDQ(Q!N)9+J"/SI'<$L02<]@  /HR@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\:G<JL1U ))KOZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=)^T7^W)\ OV9/$NG> ?'&I:MJGBG5[8W.F^$_"VBS:CJ,T )!E\J('8F58
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M1_M.?#BV^*_P4\7Q:SHMS*\)F6)XY()DQOAEC<!HW7(RK <$$9!!/:5\T?\
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MS@'@[F 4 Y) R1Z=^TI^V%\$OV5+?28OB?JNH3:KX@F>+P_X<T'2Y;[4=29
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MC^T3\(U^.7PJ\=VU[X:"R_:[^X!M_L31#=*DZRA3$4')W8&TA@2I!/D>D_\
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M ,%7M;UK1_B)^S5%I&KW5JMU\==*BNEMKAD$T9FBRC;2-RGT/%>T_'K]NO\
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M+DC<].KC?C[\5[/X+_"K5/'4[(;B&'RM-A?_ ):W+\1KCN ?F/\ LJU> ?\
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M":U^$Q^.T_Q"TI?!PTH:E_PD?VM3:FU*Y$@?N#P !R2<8SQ7QS^S!H__  5
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M>"/"-IH5U!J=[ID@L?%;RC2;G4([>V%G'=^7\QC8R3*0.H8CUKU;]M/X9?\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\Y_P#@I_\
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M _\ !,3QM\*] D^$?PX_;N^)6B_#4W$K0>$;"*S6YMHI'9WABOS&98E)9ON
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MD?=7(.U-MG]G']AO2O@O\5-2_:$^)7QA\1_$CXA:GI0TL^)O$GE1K9V(</\
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M>+9_/\5V.AV\%YIVHSY)-P;:<;4F)9B7!/+,0 6;/TS10!X)\#OV"O"_P!\
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MZ$UZ+17TAL9_A/P_;^$O"VF>%;2=Y8M,T^&TBED W.L:! 3CC)"YKPSX(_\
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M$_\ 96_:@\7?":7Q?=F[\4:-HMM!>:==W).7N(X)AB&5LL2RDX)X '%?3U%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y1^W/\
M\FC^/?\ L O_ .AK7=?"[_DF?AW_ + 5I_Z)2N%_;G_Y-'\>_P#8!?\ ]#6N
MZ^%W_),_#O\ V K3_P!$I0!NT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >4?MS_\FC^/?^P"_P#Z&M=U\+O^29^'?^P%:?\ HE*X7]N?_DT?
MQ[_V 7_]#6NZ^%W_ "3/P[_V K3_ -$I0!NT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#C/\,]%MM(F^(5[J/A3QG#80K#'J<+)#]F:54P&=))-VX\GRHP3A0*^TZ
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M44*"Z2,<#U)<DGW/->5G$LF6+_>)N?7EM^-^O],PKO#\^N_D>=_\/GOV(O\
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M_:04;_M!'4?\\\8781@#D5]'U^:XRG"EBIP@FDGUW/)FE&;2"BBBN8@****
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MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH
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MJLBJ0' /(!SBOL:_#N%GAXPIOEDNN]^]_P!#OEA(.*2W/V*^/?\ P4"_8K^
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MYK0_X0?2/^?F]_\  MJV**S;;=V(Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
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MMIK4YMC'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HI 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M/VY_^31_'O\ V 7_ /0UKNOA=_R3/P[_ -@*T_\ 1*5PO[<__)H_CW_L O\
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M1E _UDTF!GJ<*,*N3M R:]R$*&36G4]ZMTCTCZ]WY?\ #G0E&AJ]9?D?BO\
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M:/X]_P"P"_\ Z&M=U\+O^29^'?\ L!6G_HE* -VBBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116=XO\
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M06_[./['?@;4]"TF_M4_X2"ZDG"SNC >;Y\Z96WME)*\'=+C'\?E5]8?L/\
M_!.[X4_L>:*FN,L6O>-;F#;J'B2XAQY((^:&V4_ZJ/L6^^_<XPJ_G#_P3 _X
M:<_X:<T[_AFW_9_X2G[;N_L_^S]WS_:<?CLQ\^_&WO7[25\]G3>!MA:%HP:N
MTMW_ (OT.7$?N_<CM_6X4445\V<@4444 %%%% !1110 4444 %%%% !1110
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M%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MB
MB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V
M** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6O!_\ @I?\8=1\!?L5>-I3
MHES:3:Q8II$$DCJ WVF18I%X_P"F1E/X5](5\$?\%WOB!-!\.? 7P?T]V>;6
M==GU*6&/EB+>(11@@==S7+8'<I[5WY71]OF%./G?[M?T-:,>:JD>B?\ !(WP
MKJ/PW_8MT:\7PI=22^)-3O-6FD3:-P9Q AY]8X$/XU]-_P#"2ZO_ -"A>_\
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M%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\
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M%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\
MZ%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:M:5JM[J$CI=:)/:
MA5R&E(PWMQ5ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/
MVY_^31_'O_8!?_T-:[KX7?\ ),_#O_8"M/\ T2E<+^W/_P FC^/?^P"__H:U
MW7PN_P"29^'?^P%:?^B4H W:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M^%W_ "3/P[_V K3_ -$I0!NT444 %%%% !1110 4444 %%%% !1110 4444
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M>)E+?/),BC9<'VE3#$]-_F ?=KWVO/KT9X>M*G/=.QG*+C)IA11161(4444
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MN%_;G_Y-'\>_]@%__0UKNOA=_P DS\._]@*T_P#1*4 ;M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^='_!9W4[
M[XJ_M#?"7]F/19SY]XPE9(^<R7UTEK$2/4>2^/\ ?/K7Z(:7IECHNF6VC:9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P#
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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ML?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:N8@V**Q_^$'TC_GYO?_ MJ/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BL[Q?XO\,> ?#%]XT\::[;:9I6F6S3W]_=R!(X8U'+$_P!.I) &2:_/C_A^
M'_QDY_R*'_%JO^//_4?\3#[W_'_U_P#(/]SONKLPF Q6-4G2C>W]6]32%.=2
M_*C]&**SO"'B_P ,>/O#%CXT\%Z[;:GI6IVRSV%_:2!XYHV'# _TZ@@@X(K1
MKD::=F9A1112 **** "BN<^(7Q=^&/PG_LO_ (63XYTW1?[:U)+#2O[0N1']
MIN&Z(N?U)X&1DC(KHZIQDDFUHPLPHHHJ0"BBB@ HHHH **** "BBB@ HHHH
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M*0 K(4['!Y7[PY)&!FOF;_@L;^TM\$O#'P.O?V==>LHM;\5ZZ(;BRL890#I
M1PR7<C#)0G!54ZN&;.%)S^67A+QAXI\!^*+'QKX-UZYTW5M,N$GL+^TE*R0R
M+T(/Z8Z$<'BOKL/ETLWP$)U;QE%-)_S+I?TV.Z-)UZ2;T:/Z'J*^)OV<O^"T
M'P&UWX2177[1VISZ'XML-L-Y;Z?I,\\6I8'^OB\M2L>?XD<K@]"1TJ^./^"[
M/[/ND[XO 'PE\5ZU(O1[]K>RB?Z$/*V/JH^E>'_8^9>T<%3>GW??L<WL*M[6
M/N.BOSC/_!6S]MWXOGR_V>?V/%DCE_U<JZ7?ZL5'KOA$2?B1B@P?\%T/C?\
MZR:3PG82]/FT[3O+S]-UR/UK7^QJ\/XTX0]9*_X7*^KR7Q-+YGZ-LRJI9F
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MI6F6RP6%A:1A(X8U'"@?UZDDDY)K1KP,QS2OCZK=[1Z+_/NSFJUI5)>0  #
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M^./-F(,DI'1=P!'[NOT9MO@S\*;/XC1_%RS^'^E1>)8M*&FQ:Q':*LR6HZ1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^*_^"IGBR[_8X_96NI(_A=8:E$OQ6^*<:_Z-<)%(LG]G:>QXF<E5)<9!P/\
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MZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\
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M6E?^7Y_]P4?\1 ?_ %:5_P"7Y_\ <%?G'17PW]N9I_S\_"/^1_1O_$..#/\
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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M /0H7O\ WTM>5GF94<=54*:TCUZO_@&.(JQJ2LNAL45C_P#"2ZO_ -"A>_\
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M%&5VE?9K3YH[<WX3X@R'#+$8ZCR0;Y4^:#U:;M:,F]D_(]'HHHKN/G0HHHH
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M_P FC^/?^P"__H:UW7PN_P"29^'?^P%:?^B4H W:*** "BBB@ HHHH ****
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M_/K]:^CJ*^B^IP>\I?\ @4OT:/RG^WL2OAHT5_W!IO\ ]*BSYQ_X9._;0O\
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MBHN\7%*SYW)N\9;**['[._\ #VS_ ()\_P#1P'_EJ:M_\BU]'5_.IXDT&_\
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M.'4Y# %1C!W%?6OH'4O^"8NE;_-T#XQ74!'*BYT=9#^:RKC\J^AR+B?B/,L
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M4'^J/'O^"I'QJ^#?C+]@_P >:!X0^+7AG5;Z8:68K+3=>MYYGQJEHQPB.6.
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MJ07YR/G>>G_,OO1]545\9:I_P5K\11DC0_V1=6G]#>>,+.'/_?*R>]<WJ?\
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MBSU'XM?M^?LL_"'4O^$9U'XD1Z[K[/Y</AOPE"VIWTDG_//9!E4;V=EKC_\
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M8^+/^"BOP;@\,W\GA"#5I]5%J_\ 9\5Q8!8S,1A-QW<*#@GV%>%_LK_M:2?
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M45\'_P#(;^&!U39U_P")&L^[_P !&'Z4?\-]_'+PM_R4#]G\1;?O_NKFS_\
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M[.7_ $$]6_\ !4W^-'^LW#__ $%0_P# D'MZ/\R/;Z*\0_X>#_LY?]!/5O\
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MK1%_^^0V[]*^0OVV/VEK/XE^.M*TCX:^(6ETGP^5N8+ZWW*);TD'S%R ?D
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M)=&K3^U'WGHTUM*%KK=?F>=0P]2C)W46FK.ZO;5/2ZT>F_:ZZG*+^P)^S4K
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MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH
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MJ3NK.!C=AV.#CCC&<#/05V]%98?*<JPE55*&'A"2ZQA%/[TKB5.G%W21C_\
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MXPC#X58Q_P#A!](_Y^;W_P "VJUI6@66CR/):RSL77!\V8L/UJ]1764%%%%
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M:/X]_P"P"_\ Z&M=U\+O^29^'?\ L!6G_HE* -VBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIE9=Q^E &Y14.GZA8:M8PZGI5]#<VUQ&)(+BWE#QR(1D,K#@@CN*FH ****
M"BBB@ HK)\;>/O OPT\/2^+?B-XTTG0-*@($^IZUJ,5K;QD] TDK*HS]:J?#
MCXM_"OXQ:*WB/X2_$G0?$]A')Y<EYH&K0WD2/_=9HF8*WL>: .AHHHH ****
M "BBJ^KZOI/A_2[C7->U2WLK*TA::[O+N=8XH8U&6=W8@*H')).!0!8HKSGX
M8?M>?LN?&KQ-+X+^$W[0'A+Q#J\2LQTW2]<AEF=5^\R(&S(HQRRY ]>:]&H
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M9%==0 4444 %%%% !14&I:EIVC:=/J^L7\%I:6L+2W-U<RB..&-1EG9F("J
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M4:^+O^"0'QNUS54\+ZIJ_P"S;XXU)M0DDTFU>XD\"ZB^ Y:-03]E; &1_"$
MRZ8E .G_ &!?B1\3/V:OCMK7_!,S]H3Q%/JTFC:>=5^$WBB\/SZOHF2/L[$]
M7A .!S@1RJ#MC3/V77POJ?QC^'G_  4!_;X^"WCG]DLWNMZ-\+6U6^\9^.UT
MFXM+2"*YMTCBL%>=$:61R#E,?*LA(R/,Q]T4 %%%% %?5=6TK0M.FUC6]3M[
M.TMHR]Q=7<RQQQ*.K,S$!1[FO,_VA/C!))^R5\0_BE^SYXNT[6=2TGP;JESH
MU_HMY%=HEU%:R.I4QEE9U(#!>Y &.:^?_BUX3T;]LO\ X*:ZE^R[^T%/>S^
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MT_Q(THB_L6[\1V\=PLA.!&R%\JYR,*<,<C KCO\ @H-\4/'W@[]A3X@?$O\
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MP+\*?VEM0D/P[^-&GV]WI^H7*E5\+>))8U+V4Y)P@D4HK$X&X!A@1RFO8?\
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MI3WFKSZ7<6T]Y<N6EGCM[R>VAD=CRS-%%&2QY8DD\F@#QSQS\(?A_P#LV_\
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M?*'4D%6/ ?\ !&K5_%>K?\$_/"">)KB>X@LKO4;30;RY0J]SIT=Y*L#X/(4
M%%'9444 <G^PW>_$7]BO]HW4_P#@G!\1DU/5O"=Y;7.N_!OQ,\#R@:>&+3V$
M[J,*8F;.3M 8GH)8EKW_ ,5?L2_LB>./B&?BMXO_ &;_  =J7B%YO.FU.[T*
M%WGESGS) 5VRO_M.">!S7J!1"X<J-P! ..0#_P#J'Y4M #8XXX8UAAC5$10%
M51@ #H *=7+7GQG^'=A\8;?X"W.N,OBF[\-RZ[;Z;]FDQ)91S+"SK)C8S;V
MV EL D@#!/Q3^S)^SYH7_!6'X<:C^U;^U7\1_$]Y#J^N7UKX3\%Z%K\EE9>%
M[:"4QH/+C_UET<;VD?.X%<J>* /5_P#@J#X^\8V%C\*?@3H7CO4/"FC_ !1^
M)-IH'BGQ'I,_DW4-DPRUO%+_ ,LGF)"[_12#E2P/#_&?_@FM??LH: ?VA/\
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M]K+4/VW/ ?A^]U/X2?$.2.+XP:+IL)D?1[T-A-61!U4EF+?[3R@D&2/: +\
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MFQX9@I.<[\!)$S[UX4N=:O?"VFWGB2U$&HRZ?"]_ O2.<H"ZCZ-D5?"J"2%
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M=8Y9XW0D!HXVD<,/NE,]J\3OO /AC]OC_@HG\4/@U^TS<WE[X/\ A#I^D?\
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M/#OA#6U^)NL^'KM+JTATR2!A8PS31$H7^T2.0N2070D8H XK4?VQ?@=\&?\
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M$J^'M<@^(?\ 8]RDR1:*+?-L;DQDA?WLDFS<<EO+_P!G/J>F?\$U_P!F6/\
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MZE76O''C"&6"X\181D"Z=".557PV]@<[,,8SE#WOQ^_8+^ G[5OQ"\$_$_\
M:!\.R:Q>>#;.>./25GVV-Z\IB;]^F-TB(\9*ID*=Y#AAQ7LVG:;IVCZ?!I.D
M6$-K:VL*Q6UM;1!(XHU&%154 *H   '  H FHJIKVN:3X8T.]\2Z_?):V.G6
MDES>W,F=L4,:EW<X[!03^%?+G[9O[4_BKQ7IWP8^$/[+GQ(AT9_CYJ+K8>/H
M[?<VGZ5'!%-+) C@;;ATF14W8*G<,*V&4 ^KJ^"/@=\"-/\ ^"GNO?$OXO\
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M6H>'/"WQ-^)%OHGC+6-*N3!.]F5R+-91_JA.S;2P[(0<J6!\K_9._9A^&?\
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MS_\ M4_"'QAX;\2?#SP:^LWVH;[\O'-+/;QQ6\T"HK!YHY 6PVTQM%@D$D4
M;'[/7_!1[]G[]H?XHO\ !/3])\6>$_%K6C7=AH'CKP\^FW&H6Z@EI8 68. H
M+8)#%58A2%8CB]=\'^$_AS_P4>U?X=^.O#5CJ7@O]HGP6L\NF:G:K-;7&O:.
M )(S&X*$/9LCG(^9H^AQFN<_;8\(_M5_%#]MOX?^,_V=OV98M53X.V=U?2>(
MO$6K1Z=:ZO<7\ 1+6"7)>1(@A9A@?.2IV AGXOXN?M5>)?VH?V>-;^*%Y\)K
MKP=\9?V8/'%AXB\0>$9;D2_N(F87/ER@#?;RVOV@D<_ZI>64H[ 'O?\ P5.^
M(T7P5_X)]>/3X=M$AFU/18_#FD6=K&%&;UTM"D:C@;8I)" .FSBN5U?]KKX8
M_L)?#+P!^QE\-?"E]\2/BAIWAVPTNU\">%'#S+)' @EGNI0&6V4D-(=P+8;=
MM"9<=U^V=^SK:?\ !0O]E33/"7P_^(Z:+!J]_I.OZ/KX@:0" %9!(%5E)8PR
M,R\CY@N2!R.@_9._8G^!G['GAN?3OAIHLMWK6I'?XA\7:Q)Y^IZM*3N9YIB,
M[2W.Q<*#S@L2Q ,KQ9_P3F_8@^*7CU/C)X\_9?T&7Q#<2+<WAF1D228_,QG@
MAD^SSODG<65PQSDMUKVZRLK/3K.+3]/M(H+>")8X((8PJ1HHPJJHX     Z5
M)7C_ .TA^W-^SW^R[K-CX0^(.NZA?^)-2@,]CX5\-:5+J&HRP#.9C#$#LCX/
MS.5!VG&<' ![!7DOP(_;*^$GQ_\ B_\ $/X&^%Y;BT\1?#G6WL-4L+XH&NHU
M(0W4(5CNC$N^,]U(4L%WJ*O_ +.G[5WP=_:W^'5WX^^ 'BB/4A9S/:W=CJ$$
MEM/8W07(BN(V&Y,\?, 01G:3@U\0ZO\ L$_M%?LF_"'1_P!OKP5*+WXY^']>
MU+Q)\3-(L[@R6^OZ?>3&2ZLAMR',<8W?+U)E*Y98L 'T7_P471_A#K?PN_;:
ML$*#X:>,H[3Q3*H_Y@&I[;.[+ ?>V.T#J#P"">.M?0)C\"?"7P'>:EI&C6&D
MZ'I-G/?S0:9:)#"D:JTLCA$ 7)^9B>Y.:\_T;Q-\(/\ @H9^QY=7?AC4!<>&
M_B#X8N+.3> 9;&22-HW1Q_#-#)G_ ($@()&#7&?L0>)-3_:1_8._X55\2+N2
MW\1:+IVH^ ?&F#NDM[VT5[-V.<9=HO+E/3F2@#P/]B/]KGX0_LA_L4R?'_XV
M:E+=>-/C1XXUCQ1I_@_1X_M&JZK//=-!''%$.=A,((=L*#)C)8A3]*:+\#_A
MU^W)\(?#WQ!_;0_8\TK2?$CQR,NB:TR7%WIT/FL8D^T1A)%#)M=HCMVLQ#*"
M*YO]A/\ X)<? _\ 8PL;7Q3>2MXO\>+:K#+XLU>+)M$QCR;.)BPMHP,C()<@
MD%MIVCZ<H R/ O@+P1\,?"MIX'^'7A+3M#T>PCV6>F:59I!!",Y.U$  ))))
MZDDD\FM>O/\ ]HO]ISX._LL^"XO&WQ?\1O:QWEVMII.G65L]Q>ZG=-]V"W@0
M%I'/MP,C) YKA_V</^"A_P #OVD/B5>?!>R\.>,/!OC&TLS>)X7\?^'CIMY=
M6PZS1+O<,N.<$AL9.W 8@ T?B)^V]\*_A;^V!X4_8^\:1R6>J>,?#QU#2-7E
MG46[3F=XHK0CJ'D\J7:QP"P5!DOQI_MM_ N7]H_]ECQG\)M.!&J7NDM<:!*C
M;6BU*W83VK*W5?WT<8)'.":\#^/W_!+[7OVJ_BU\7_BO\6_%-K;:MJ5EIEC\
M&M3T^5Q)H"6D0F\Y\<@O<LRL <[?,9<%DV^A?\$Z?VMO$OQ\\":I\(_CC:?V
M9\6?AO=?V3XZTJ8!7N&3*QWR <,DH7)*_+OR1A60D [S]C+XOZ-^T1^SAX4^
M/=KIUM#J?B718#XA>&W5'-_ #!<(Y !.R:.11GH .E?,7A']H7X.^"OV_P#]
MH7]K_P".?CFST7P_X!TO3/ F@RW3[I;B0*;F[@AC7+2R>?%D*@)PY)P 37I_
M[''_ !8K]K#XS?LAW/[K3[K4X_'_ ()B;@&PU$[+R-!_#'%>(5 '_/0TG@;_
M ()0?LY:'^U)XL_:J^($4OBW5=>\1RZOHVD:O IL='FEVL[B+)$\OF!B'?A1
MMPNY0] &Y^SE\5==_;X\%>)-2^.7[)$.D?#6^F@/@NW\:117%SK<&&W7$UHZ
MD0C.QD;G(?Y68#<?7?A5\$O@]\#-$D\-_!OX8Z%X8L9Y/,N+?0],BMEF?H'?
M8 7;'&6R<<5U%<]\4_BS\-?@CX)N_B-\6O&NG^']$L0/M.HZE.(T!/W5'=W)
MX"*"S'@ F@#H:^>/CA_P5$_9+^ _CS4/AQXA\0ZUK&I:(1_PDA\+Z!-?PZ+G
MM=2QC9&1@Y4$LN"" >*Z7]G/]OO]D;]K#7KSPI\!_C)9ZSJEE$99M,FLKBSN
M&B! ,B1W,<;2(,C)4'&1G&:\7_X(\:SI>@> _B7^SEXOM8X?'W@[XE:H?&*3
MJ/.U$7$I:*]8GF17"L@;GB-3T89 /3_V@]-^''_!0;]AOQ-;? SQG9Z[!K>C
MM=>%M5TV4YCU.V99[8'.'AD$T:*RL%=0Q! Z5J_L7^)?AI\?_A+X;_;!TOP5
MI4'B[QAX7MK7Q+K,-BBW3S6Y,4]LTF-VQ)XY %X^XN1P,?.WCWPPW_!+']LG
M1_BY\/H/L?P1^,6MQZ5XRT&$8M?#NM29\F]B7I%&W)(' 595Q@0JOI_[&?\
MQ8O]JGXS?L@77[JPEU5/'O@B(\ Z?J1VW<<8_ACAO$90!_ST- '(:#XT\)>*
M?^"KOQ3^.7CWQ)8Z7X7^"'PRT_P_)JFHW*PVUO=7KF[>4NQ !"F:(^^!Z5V7
M@#XJ?LW_ /!5?1_%/@CQ%^SEJFO?#C1KF)=$\8^(;$V]MJ]SEUE:R;*3Q%,
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MKW/]GW]F_P"#'[+OP^M_AG\$/ ]KHNF0X:8Q#=-=RXP9IY3\TLA_O,3@8 P
M  #S'X5_\$KOV&/@W\1K?XH>"?@J@U*PNC<Z3%J.K75Y;:=,3GS(()I&1&!
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M67QD^+?Q:^*_B:VL-3N=.TS3_@KJ>G7#B31!:QBX-Q)CE2]RS*P'(!D9>J$
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MX/\ ACJ,>D:MXF7PY%JFI:QJA0M)&D<S!(8(R-I8$,Q .2&(3J?^">OQY_:
M\?:I\2_@'^TSJ&GZQXJ^%GB6'39O%>E6BP0ZQ;SQM)%(8T 1)0JY8*% #H",
M@D@',_#/PIXP_;4^,?[.W[?VCWFBS^%]'\"ZB=;TJ\E?S;/59XO)D-L@1E+K
M.&0LQ7"P>N!6!^U=X,_;'^(?[>_AKXS_ +.?[-&GW47P=T2\MK36_%FKI8P>
M(+G4+7#1PE"7EBACD(&2JB5Y 2,8/=?L/'_A1_[0OQE_8UNOW5EIOB!?&7@B
M)N =)U3+RQ1#M'!=+(GUD[U-\6?^"@OQ"^!WQGUWX:>./V&/BKJNE1&/_A$?
M$G@C1UU:+6<H-P<(56W.\X"EF;'+*O< Z7]AC]LT_M;^%O$.F^+_ (>W'@_Q
MUX'U@Z5XV\*7,_F_8[CYMDB/@;HWV28SR#&PRP =J'QK_8PU_P 1?M=>!OVP
M_@5XVL_"_B+2Y?[.\>I<6SR1>(-%*\Q,B$;IE*JJLQ  V-G,**<W_@G[\"_B
MOX:\4_$[]JGXZ^%8O#?B?XO:];7O_")QW E;1]/M8WCM8IG7@SE9&+X]%SAM
MRK]*T 4O^$:\.CQ$?%_]@V7]K&R%F=4^RI]H^SARXA\S&[9O);;G&3G&:NT5
M\O\ QQ_:#_:9^+/[2VK?L>_L97WA_0+[PEH]KJ/CWQUXELVNDTXW2[[:TMK<
M<22NF)"SY7;D<$<@'T%\4]9\8^'/AGXA\0_#S0H-4U^PT2ZN-%TRZ=ECN[I(
MF:*)BO(#.%7CGFODV^TCQG_P4"\??LL_M)6O@BSUWX:VVFZGK/C72I;J(6UC
MJWV5(82\4C9G,5T)%0 ,5\J3. >???V4X?VKM+\'7_A_]K[Q#X/U77[34G73
M-2\)I)']LL@!MEGB95$<A;/" #&.,\GS/]AK_BR'Q^^,G[&5W^ZL])\1#QAX
M(B/"G2-5S))#$/\ GG!=+(GUD[T >7_MJZGX\NO^"BGP]^(G[.G[*7B;QAK?
MPFTJ\G\::EH\26"7T5[:[+2R%U, DVP&1R%WX$C(HSOV\Q+XO\4_M-^/Y/\
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MT 5=%T31O#6CVOA[P[I-M86%C;I!96-G L4-O$BA4C1% "J    , "K5>?\
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M0_M"^!OV==3_ &<OVMHM.UJTT2[NM#\/:O'>>:^MZ%M\N)IT&?+.PE "V[8
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MS^(;_P 3ZE!)%?VSPVUAX<MK!XI'<SOA8'92(8QMY1Y0 2 C:_Q7_P",?/\
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M%%/V^OA9\9OV=M*O[GP%\'[;5;C6_B!<:7-:0:I=W4*QQ:?;><J/+L*[GRN
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ML5_\$T-1_P"&DO@=+J?B.:#4;OQSH6FPIJMYXBN;J[D6))3%O$SNDL,9)+!
M"2< FNH_X*9Z3J&D?!CP[^U=X'MS=:O\'?%=GXH@^RD%KK3-WDW\ 8<;'MI&
M9O:+K7J?QL_:&TOX2_ &Z_:#\/>!]=\::?#I\%[;:?X4M1/<W5O+M(F121\@
M1M['LH)QQ0!\"_ OXG:E^S#^R+X7_8=_X*(_L@>)_#WP\\7R76F2>.+O5X+B
MUM9;RYDN(EDB0%K/RRX8,[^8K1&0)\I"^J_!SXR?M/\ _!->P;]FS]H/X&>/
M/BCX'TIC'\._'_P^T3^T;@V7_+.SO(=ZF)D'RJ2W &U=R ,,3]JC]JSP%_P5
M0^#47[(/['WA+7]=U+Q1JM@_B37]3\/36MEX2M8+F.>66XED 7S?W>P)&6W!
MG 8G"M]]Z5IT.D:7;:3;R.T=K;I"C2-EB%4*"3W/% 'R]^PO\$/B#XE\8?&O
M]I3X[_"^7PO;_&O4;-+7P+JF#<6^F6MM+;JUVB\)+,LS%X^JX.>M?3'A#PCX
M9\ >%=.\$>"]$M]-TC2;*.TTW3[1-L=O!&H5$4=@  *T:I^(=>TKPKH%]XGU
MV[$%CIMG+=7D[#(CBC0N[''HH)_"@"Y7CG[:/[07C']F3P;X5^*>DZ?8S>&U
M\=Z9I_CVXNXV+V.DW3F!KF,A@%*3/#G<""&(X/->(?"OXF_\%)/VV_A])^TM
M\"/B9X*^&_A34+FX_P"$'\*:UX;.H7&J6T,K1"6^N"V;<NZ,,1*<+V/#-K?!
M7]H;2O\ @I#\#/B=^QU\=_"EMX3^)VD:==Z+XQ\.AR\4<O,<>H6N22T2S!&Q
MEMC!/F8.C, =M^SC^S?\2/ /[:'QR_:#^)&E:==6OC&XTF'P9JXNQ)=I8P6Q
M$MN$Q^YCWF,8R"[19(("L?F+P+\7/VJOV=/B_P#&G]NKP9_P3YURX^'?CO4[
M.[N;:YUZWTZ^M;&PBDCEOS8;7E9Y6=YV)  #$\J3(/K#_@G]\:]>^+?['WA[
M7?%=E<3^*?#-M/X?\5:>K+]H_M/3V-O*AW,%$DGEK)R0/WHR0.GDFI?\%7X_
M&/A/6/ACX?\ V//BBGQ5FCGL;/P%?>&F9/.;<D<LUQPBV_(9W8# W8! W$ X
M?X4#XD_LUZN/VS?V _AWJ'Q&^!7Q73^UO$/PTTK":EH%^24EFLX<D,0ZM&\2
M9Y79]U(W7T7X5Z-\:?VQOVV_!W[77B[X!^(?AGX.^&OA[4;30K/QG MOJ^M7
MM[$89"]L"3##'&Q(W'E@,9W-L]:_X)\_LW:W^R9^R%X.^!OBF^BN-7TRTFGU
M=X'W1I<W$\EQ)&A[JAEV!OXMF>]>ST 9/A?P)X,\$RZG<>$/"UAILFM:G)J.
MKR65LL;7MW( 'GE(&7<A5!8Y.% Z 5K45\A^*/B9^U%^VQ^T'XZ^!W[-GQDA
M^%_@KX9W\>E^(_%UOH\=]JFKZHREGMX$E(6"&,@AGR') P2&PH!])?'*[^)6
MG_!GQ5J'P;6V;Q9;^'[N7PXEY;F6-[Q86:)60$9RX ],D9!'!^;/A]X6\9_M
ML_&']G#]O/1Y-&NO">C>"]2EUW3+VX8/9:M/"(7-O&$97D6=60EBNT6Y.=VT
M5;_8K^-G[2'@_P#:H\;?L&?M2>/+;QIJGA[P]#XC\*^-H=.2TEO],>2.)DGB
M3Y0ZO*@'4Y63+.-IK3_8=_XL?^T)\9/V-+O]U9:;X@7QEX(B/"G2=4R\L40[
M1P72R)]9.] '!?M:>%_VN/'W[?GA7XQ?LX_LLQ:HOP;T6]@&N>(]9BTVWUZY
MU&UQY,+Y+310QR-C[H$LD@8J!\WM7[#G[9]O^UWX5\067B3X?W7@[QOX)U@Z
M5XU\)7DWF-8W'S;'5\#=&^R0#(!!C<<@!FYGXN?\%$O$7P)^-.N?"_XA_L7_
M !5O--@$9\*>(_"&AKJL.N90%@ C*(6WG 4NS8Y81G *?\$_/@G\5M'\9_%+
M]K3XW^#AX7\0?%[7+2ZM_"+3"272=.M(GCMEG9>//99"7 Z8&<,650#3^-W[
M&/BG7/VO? W[8OP \96'AGQ%I\HTSX@Q7D#O#K^B%>8V1,;YUVJJEB!]QBW[
ME%/NQ\*>&#XH_P"$W/AVQ.LBP^PC5C:I]I%MO\SR1)C<(]_S;<XSSC-:%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-7QI_;!^/>M_'G6?V
M8OV*?@UHWBKQ%X2L+:[\:Z_XJU5K72])-PA>WM<1_/--(GS<$!0.<X;;XO\
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M??"R?]LK]I_QCXDU[5_&.JZB?#-I8:]);0>%+&&\E@@M[:)/E$@6(.Q<,"S
ME2<LW0?MS^!+;]D?]K'P-^W;X%L(DT3QGK5OX,^,.A^6#!J=I=_)%=O&>&9
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M$?LUZI^U=^RAXF^%'ABY\C7Q'%J/AF?S-FW4+9Q+"N[^'?M,>[^$2$]JJ?\
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MDAAF*F:%7V-N3<H.T^H]#3J** (K^_L]+L9]3U&X6&WMH6EGF<X5$4$LQ]@
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MK[P+_P % /AFGV32/%FO6WA/XN:5!Q'>P7)VPWQ4?\M$*#)[M'%_><D [O\
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M;;QZMA_9?B33)VTWQIX=D4I+I>IQ<2QE&^8(Q^9,\X.T_,K  'D7[,.H:?\
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MJ?AW]@/X]>$HOA_K%Y)=1>#?B79W5POA^20Y<V4L 9G7)R$<J/[V]BSGVO\
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M5\??%.D72>*/ 4TKZ'J6GWKV[.DBD&&8I@RQ L6"$XR6!RKNK>BT44 %%%%
M!1110!X!^VE^Q O[2&HZ!\8OA3XZD\#_ !6\%R&3PGXRMH=X*<DVETG_ "U@
M;+#!!V[WX97='\[N_P!F']O7]K'7?"WAO]N3Q'\.-)\$>$M?M]8N]*^'Z7<E
MSXEN[<DPB9KCB&#)W$+R<D;1\K)]AT4 %%%% !1110 5P7[2O[-WPM_:O^$.
MI?!CXNZ,;K2]04/#/"P6>QN%SY=S"Y!V2(2<'!!!*L"K,#WM% 'Q;_PR)_P5
M%N/A_<_LN:M^UUX'O/AW=V3Z9-XRN=$NG\4G3678T.P_N"YB)3S&D+\YW9YK
MZO\ A!\*_"7P/^%V@?"'P':R1:/X<TJ&PL%F?<YCC4+N<X&YV.68X&22:Z.B
M@ HHHH **** (-3TS3=;TVXT;6+"&[L[N!X;JUN8@\<T;J59&4\,I!((/!!K
MY!TG]@3]J_\ 9BU_5-*_8%_:<TCP_P"!=<O'NF\%^-]&>_BT.9SEWLI!EMO/
M$;8' W%S\U?8M% 'E/[(?[*^C?LI_#R_\._\)?>>)?$/B+7+C7/&/BK48E2;
M5M2GQYDVQ21&G "H"<#/)))/JU%% !1110 4444 %>>?#_\ 9;^#WPO^.'B_
M]H/P1HEQ8^(/',-NGB%8;UUM9WBSB80 A/-8G+.06)W$$%WW>AT4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>arvn-20221231_g2.jpg
<TEXT>
begin 644 arvn-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /B!W\# 2(  A$! Q$!_\0
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M\OX;)"TO05+;SK<P+*GW6Z5YGKOB2YO;9TF@,+'I[BNFM=<CTSP[:,2&D9<
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M1=6WDQ.<*Y[T =C17/:KXGBTZ:./Y3O4-4FB:Y-JD[JT&R,#Y6]: -VBBB@
MHHHH **** "BBB@ HHHH **** "HYIE@B:1^%7K4E<UXXOFL_#%XR'#;."*
M/,?B)\29XKJ6PT^8JRGU[5YQ;Z/JOB1FFW*3GG-85U=R7=V;B0EF)YS7:^&+
M_4[G:ECI[21CAF6@9B76F:IX8<3,<8/! KTKX=_$J>:XCL-1F+.QPO/:I_'P
MBC\"6IGA5+K?\P(Y[5XO9W;V5^L\9(*GC% 'VC%*LT8=#D&F37$< S(P'U-8
M'@2]:^\)V<SDEF'.:P/B+]IE/D6\SQEE_A- CT&*5)D#H00?0TV:>.",O(P
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MBB/3T$?REN@'K0!T]%<EIOB][G4$M;F$0ENF?2NL5@R@@Y!H 6BBB@ HHHH
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MYK5E=7,T3)"V3@__ %ZZ'6O"(U*Z-S%<&&4_Q+UI--\+W-I,COJ$CA#T)ZT
M<REA#=?%FZ$JY^3^IK;\5>');FZMKJR9$D@'REC6I%X86+Q5+K7G?,ZXV4:_
MX?FU:6-X[QX0G4*>M &7X9UV6;5VTV]??>(N6(Z5VM<KH/A!=)U-K]K@RR,,
M'/6NJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,D<]*\,\8QVT6N2+:#$?-.T3Q9=Z1;W,*EG\]<=>E1Z?H^H>(+\%(9'#'J*
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MF@#G/$%NL?CK1T?'RQ@$_@*7XC+.\%HD## F&W\Q72^(/"(UFYBN1<&.2)<
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M(J+T48%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSM&C,=EM,ID_VC6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF2Q_-C:#0!ZQD8SFH+FX6*)F#KD#UKD;#Q,[:/=!E_>VZ<>I-8<']HZGI?\
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M#:X(\E,'VIPM8!%Y7E+L'\..* .!TV:RCL;F*_C8HXY %9&G7,$&K/#HR.B
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MEQOB5L# R* .#\0HQ\.Z> I_U@[>XK/UV<6MLDK@X5!_*O2WL[>1%1XE95Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 44UW5!EB *2.:.4$QN&QUQ0 ^BD+!1DG%(CJ_W6!H =1110 444UW5%W,
M< =Z '44BL&7<IR#WH9E098X% "T4BNK#*G-+0 4444 %%%(S*@RQP* %HI%
M=6^Z<TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A8*,DX%
M "T4U75_ND&G4 %%%(2%&2<"@!:*J)J=E))Y:7"%P<8%6Z "BBB@ HHHH **
MB%S"6VB0%O2I: "DP/04M% !1110 4444 %%%11W,,LC(D@9EZ@=J ):***
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M8YK48<]:LWBU)$X^Z*,4+]T4M "4M%&: "BBB@ HHHH **** "BBB@ HHHH
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MT <%8^'M6U#5(;[6 &DA.4(J._\ #^LV_BJ;5=/ 'FX!)],G_&O0,8HP#UH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI*6@ HI
M#4<C;5S0 \MCO31(,XS7%:OXE-K.R#L:RD\82?: "IQ4\R(<TCTLL*B-PH;&
M17*W7B)19(RL-SCIFN4DU^[BU$.Q?RZES)E52/6E<,*.]8FCZ@+NW1@W..:V
M0<\U:9I&5U<E%% Z44QA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'2FNP
M49)K(O\ 6%MP0H#&FHM[";L:S, ":XWQ7<P01-(3SFJ^M^+#!;9C4DXYQ7FF
MI>(+G4F(?< >QKKH4)WN<]6JK61L:AX@=("D;<,*X^ZNGG8ESS6I9VK72,7;
MIZUF:A (9V4'-=L;1,-9&7(>:A<_+Q3I<J33$/.#0V.UA1DU/%$">:LI GE;
M^.E5FF"\ 4FT6HHO16ZL1BGO-]G; XQ4-G, W+5%?MND)!XJ;E/386YO/,8<
MUMZ S%V)Z 5Q[,0V,UKZ5J7V4D'G(Q3OJ0FV]3HKV=;B38OTJND!1N*CCD5_
MG!Y/-7K*=&<JX'XU:DB9Q9U'AK4O+46S'AC6Q=V:1[I_[W(KB5D:VN5=<C%=
M7+J DTM2S<[:QG!IW14*BV./UV5Y+K(Z 5-I.BK?*7*Y*C-1(G]HW>S.,GK6
M_HSC2S/YG*@=ZTF[0L@BG)F?>10:=;LPXF'2N>DOI)I1N/>F>*-<%[J96'A,
M8XK(CN<,,MTK.$U>['532T.^CLGN_#[,O/-<6\S0W$D;'E3BMNW\0K!I1A#<
M_6N8EG$]P[?WC335V9R?NHZ?1]?O+4A48>7[UM7LT5XJ2G[XY-<-;2&-AS6K
M'=G;]^M%%-W1FI66IU=A;JT:RD\9KNM/U.V@A1 W./6O'OM\J+A92!Z5=TZ\
MN)KN,><V,U%6DY(J%1)Z'N-M<B=0RGK5M:YK2+HPVZ*XS[FNEC8,@([BO,J1
MLSOA*Z'T4AXI QS4%CJ*** &GK6?JEO]IM7CQU%:.WFFL@:@#P;Q3HUU:W3N
M5PA/%<F1MDWGM7T+XCT&/4;-@  P!->#>(-)N-*NF5E;;DGFH:U,7#4J-+]H
M.W/2B:,) ?6LV*7]YD-CFKEQ/O7 /:E8=C/;[QIT?SG%0RR@-CI35NUC<$#-
M-;DV+LN8U&*;&[,O-,><3*.U1F81\4I%*)H273I#MW8&*J6\I,F >*KW$IE5
M0M/M(V')I6"UBSYN&92>M0212$Y'2IG0 YS4D62V>U.R,[%6U\P3JIZDUNW%
MI<I;>:1\M5D1/,5L $&NJL-5MS:K;20*Y]ZAV!V.)4,),-U-3.-IYKH]:TU?
MDE5!'D9 JI8"! /-57)XYJ'8QFX[,M>'9M^?,/R@UZWX6D=@H7_58XKS2#16
M9@T3[5;GBO5_"EB;;3(@QR?6KB/#1DF="  *<M&VG <UN=PM07A46DN?[A_E
M4]5+^!KB'8K$9ZT <QX;D%IIEY.P'RRGM[FD6U_M$SW$Y^3:63![ULPZ,$TZ
M:V#8\PYS60?#]T6\E+ED4>G>KN38I65U<)X5O6!_>+(0OTYJ>W7[/ID-Q*3Y
MDPQ^-:46@-'9/;>9D,<FIM1TM3IL,1E">7T-%T%C!OK$Q:++=N3]H!^7GM3K
MS6)(M*L45OO\/51[::YO%@6X:2,]1VK:O?#IGM;<!L>7SBF!6TVRD;6(IH,_
M9L?-GUJ#1-*M[OQ!>O+G*/D<UTFFV+1QCDKCC%4],T>6RU2YG\PD2-G%*X6.
MC50J@#M2T#I14%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 4M)1F@ -0RC<N
M*E;I46<FDP. \2Z!)([2Q+WS7*+"L.1/]X5ZUJI1+61B ?EKR>_N5N+ED5<#
M)YK&2?0RFD$DVY5.?E3I4,EZETOE@\U5F!QM#TR&(QGUK)\QSRB^AUGAW5VM
MITA+<$XKTVW?>@/M7BL,_P!GN[<XSEJ]0TW6XF18V(#8Z5K"71FU%V5F='15
M.._CDX!!J?S1CBMS9.Y+13 V:=F@8M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW0YH 9::':6<HDC!W#UK3JE::G!<VYFWJJCO4@O[1C@3H2?>C4"P,"EK+>Z
MU9(_,X(Z5:.HV88J;A P[9I6 M44R.5)5W1L&'J*?0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBD- "TAH%(W2@!"<"LV\U6"R;$K8J]*3Y9QZ5YKXP6Y-
MQ\KL!BE<F3L=6/%=BSLHDZ5A:WXRB$31P2?.>E>=V\DR7; RL:GG7S;Q!GM6
M;D9\YK3ZI/=09D/45B(@$OFR]C5J\D$42*O)S5>0&:V('!-3N9R=RG/<[)?D
M/!-3MNGBXK,D.Q]K<XJW;W 6/'6@42E,A1\&F;>>*EN,LY-0H2'R:"K7'%&Q
MS3T!/2FS3 @ "I;<C;DT6#DN7[2*652L?6MZQLS;6XDN<@^U<U:WGV>X4CD$
M\UW2W]O+HRNRKDGO63LB.5(N:!JTC70BC/RYQ7HB$[,GK7F^FR16Q$RQC'4G
MTKLM-U:"Z0;9%)] :UIR-Z<D:Z\GFG]ZK_:(AR7 J6.XBE^XX/TK<UN2TM-I
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&,F#:<*.E.FO>N*"]X\\GU S73#.>:T8&)C'-9FH0-:7L@>,H2QQFF?;"L8
M.*]JE-<IZ,-CL]%U6*RF42M@9KJ3X@CNL1Q/E:\A2>25\AC7:^&P4"O(-WUK
M*2O*YT\FESN;;0[:]7SADD5TD2IIE@N#CBN7CU I'LB&,^E:5M#+=PGS)SR.
M :SDGU,F7=,UEY;L+NXS79PR;HP3WKSJTT>:UD,XD) .:ZO3M1\Q!&3\R]:S
MG'JC&4;['0BBJ<=P'(&ZK.2:R,VK#Z*:**!#J*2EH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** ,O6KYK*W4H?F;@5DZ=_:TYWR*-N:;XWDVVULH?;EP,_C4VCV;0M%)
M_: D7 .W-4MA=2WJ!U!+7,2C*C)JEX>U*[N6V38QNP:FUU/M$#B*_6,J#E0>
MM5?!8(LI-XW,'/S?B:.@=34US47L?)"'ESBKEI*XM=\W%<[XPF03V.7 Q(,U
MI:M?PQ:&9(I%.%'0^U%M ZCK._5;BY:0_(O-(OBG36;:)>:YJ_=X5LI-Y"SG
MYJGU!+)YUM;=4\PKG*T[(5SJ;G6+2TACEE?"N,K45GX@L+VX\B&3+^E<S:NE
MQ((KI@%A. &[T^T$'_"5"2#:L.W''2E8+G2-K]BL_DF3Y\XQ4EQK%I;)ND?
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M9(V!?>G4"BF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(23$N>M<Y:ZB#.%=<?6MVWNHY/E4CBLI7,:B+G2BD'-**DQ TM(:6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH RM7T&UUE$6X+84Y&*;:>'[6SQY;/QZFM>BG=A8PI
M_#%I/,TC,^6Z\UHZ=IT.FP&*'.TG/-7**+L#(U3P[::L5,Y;Y3D8IG_"-6?V
M,VV6*&MJBB["QS>MZ9:_9;>)R0L72LC2M%W>(([N++0 8R:[>2&.88D0-]:(
MX(H1B- H]J?,*QCW7AFSNGW-N!)YQ3K?PU9VZX0M]:VJ*5V.QA_\(S9FX69M
MQ93D4MUX:L[B\^U-N\SVK;HHNQ617M+1+1-J9_&K%%%(84444 )1110!!<[A
M$=O6O%_&)N?[3EW_ '<U[8XR*\_\7Z.9]TBKR371AVE(SJ;'C]V,=*H .&S7
M57.FM$&9T/%8[V32.2HP!S7H3EKH<NMQD+NB;CVJ&>4RYJVL.Z(IGFJTUJT2
M]:DU3T,SR\OS3MJ"IQ;N[X5233FMC']\8/O2L1S:D'!X%-9O+_&K21*%SUI/
M(,A/RU#*4BHC;WJVEJ0RDC[U6=.L1]N4O]WWKOY_#L5UIB/;@;U7/%3>Q:5S
MAKBP,=CO ^:MKP_X<35L!E)]:UO#WA6[N[D"Y#B//1A7J6E>'[?3D&Q%!QVK
M&K4Z&D#RW7?AP\-H6M(B7K@+OPY=V=Y%'+'C>V#7U0T*2+AE!%8VH^&+.^D1
M_*0%364:K*DM3C?!7@RR?3(YIE.X^U=A'X4T^%PR)^E:5AIXL8!$N,#TJ[S4
M2DVQD-O;K;H$084587VIHSTIXJ0%HHHH **** "BBB@ HHHH 0]*9C(YIYIF
M<4 5+JRCN(RK*.1Z5@?\(G;+/YBI^E=7C--(]JAQN+E3/+]0\#RS:@)%C.W=
MFNXT+2_[/M53;@BM8H#VIZC%-12)4$F.%%+32:HL?12 \4M !11FB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHS10 449%&: "BBB@ HHHS0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;1WMI=OH<5NQ:XJ;%W_,*+S2XS:,Z2*'KE;6VG6^DWL2%-::2')IGH4?B!E
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M6I*8M/KC6QTA1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *5KIEO:_<4$^I%6)K=)U <<#VJ6B@"NUI$T!AQ\IZ\4^*WCAC"*HP/:I:*
M*WV*'SQ-M&X>U0SZ3;3R;V4 YSP*OT4 1PPI FQ!@5)110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %(:6B@!N32TM% %2X)\MOI7!ZI937-]PN5KI
M]>U/[%%@*26X&*Y"6[ECM'G=R&SP#7503.:LS)O_ "K0%"<,>*YRX@))<5:F
M:6^O#\Q.6J6_MOLL."P)QTKOV.9:F4L.ZK$$:Q2BJS2&,9]:A:\PV:8TC<GO
MVVK@_<K+O=8DE0H3\M9]Q>DK@'K5-27ZFH9H6DO7B?=FIGU-I^#BLZ12*2,@
M4T2V;MI.8W5NW>M:3,X\V#DUS4-TJ@@UJ66IK$-I]*:$S9TO4ITO$0XZXKU;
M1Y'DA5CWKRKPZ8I[X%@,EN,UW<>H-8WQCP=G05RXA7=C6D['9"ES5>"4/$K9
MZC-3#US7!:QUW'9I:92YH =129H% "T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"54N[19T/'-7*2@#D+F*6RDZ?*:1)Q(,J:Z:ZM$N(R"HS7*W]E+9R%DSM]J
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M>::'K4YOA&[MMW=Z]&MG\R,'->55I\K/1ISYD3T445F:!1110 4444 %%%%
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M"<$C@55U"=+^[)!SFL+PW=@M)$6P&.*Z&:Q,)WKTSUKOI/0R>YO:*#96[$C
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M1O0Y*E1MV)$Z"GTVG5F8!12=Z6@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %(32TAH ,TM)10 4A%.HH 9MI=M!- .: $-1,F5(J=N*9D9H&<C?^'Y
M+BX9]I()KF-9\+7,LVV.,[<5ZH67!S7(Z[JZVMWL SQ6<DC6FY7.(/AY]/"/
M@Y[YJ#594DLVB!R]:=QJ3W;N,G%8-S$3<;-XR:R:.J+D)I41CW%A4]Y-M!&:
M/L4MI%YK29!&<5G33^>Y[4T#W,JXOW@D8@\9K)N]5DD<L,8JY?PERV&K#>%E
M8J:%$'(='J#27L0W$?-S@UZ381++IRN"6^M>4/ 8VW X/:M6PUN\@B$7FMMK
M>,K&6[/7-(>&4.JGYEXJ/6[Z2",QCM7FNF:_=6-UO+L59LFNCD\00W[_ #D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2!,SXIBR8P*A:*19-^6'XUK)8JAZ4RXB 7&*5GN5H):W=RX #$@>];$-TXC
M?J/6L.U)C?'J:U5!84^9HI6->/5HTB*G&?I4(O%E;.1S55;4,N34T-L,TI57
M)6'8DFMQ+&2*H1Z?)YN[G'UK5=60;14BQ,(P:E7*CHQ]C^[3+CD5?WC*LG7-
M9T,P1]CKG-:MG&#(&(^4FLYQN=<)'5:3<&ZL3%-PAZD5F:H%BGCCCD8@M@<U
M=E7;8-' =K$=13XM(>ZC@+N-P.<FB,0I\L).4CJ_#<+06(WYYYYK<ZC-9UA
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M.#S40E852*9I03XQS6]I=\8KJ)B< 'FN6B) Z5H6\VP\UK<Q2ML>GW=RE]9
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MN*T6Q%L\IR,#O73VMXI 7J:\^K&ST.NDVT:0I:B#;AD4X$UC8V'=Z6FYYIU
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MG/>L.4 M6G<S9!K'E?#5322!OFV$;:!49P:K2S'=UIT3[C6?,BXQ98& *C(
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MC"208#4<H[G<9JK+J%O!=);2/B5^@KCL:G;WK0F]+E>H%5[NROK[6+=TN/F
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M^%.E.DL(I(_+/W:MT4@,V[T6WNX$A8E0G3%.L=)BL1\CNWU-:%%.X6"BBBD
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M4$<JR $5-2*%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI/:G+"&4R'D$5R))'3S,QYRRG()JC<+,R!QG'7K6Q&JR705NF:ORPVR(0P4
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M=/-(< 'FGO;M*1ZYYJ6UA2(-N'.:G6XCC?D=:3)N;N@F&+",!D^HK4OX0>4
MY/:L&R=01(.U;4-R)3\PS4,M,+8_9B-PJ\\@E3( J&78ZYQ4MJH;@4TBE(6R
MT\7=PJX^8U:T[3YK35'4*=N<'-/M2UO>)*O0=A5K4]238&B^23N:A;G3"4G&
MSV)-6\.17NJ1W"CD+V'TI^D33VU]]G1<A6P:;I6L&&R:>X)<J:W]%:UO)FG2
M,!CS0EJ3/GC3:EL=1$,HI;KBK0Z"JR\X XJROW174MCR!:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *CYW5)4;,!U(% "\$TA0-U /X4SSHNSK^=.$B==P_.@"%[&&23>
M47/TJGK%FCZ?(H48VGM6IYB_WA^=13A)8F4L.1ZTTQ6/GG5;<6NK%1TR:Q-1
MG (V'ZUZ]XI\,1E7N$"EO:O']2L)DN) 5( /I7=3ES(YYIE$R!SBIH@ #4<$
M&'^:K]Q9,D(=>XK1@KE>$_ON*TY+=98??'%9=K&SOUYK=MHF\LY["G%#94TK
M3F:]PX(6NK&V.'  ^45DV^81YIJ&75QNV 'FM$C*32%GOG6Y88&*S;C+$MZU
M-<'>/,QBJV[<<51-RDX):H_)W-BM/[)N&14&P12#- R'[,R+G%)%'*7X6M$N
MKH *GMHUQS4V-(E8$[ IZU6GC+#BM&=%5B1BJ-U(J(<4BV9WW6P:&DV# -1L
MY))J+=@\FHE+H$=&6HY #DU=24?='2LQ!WS5F,D\"M*4M-3.K=L['P]JR6\G
MER$!3P:;XJBM9Y]]H=RE>3BL"$%%SU-6A=@P$-43LG<N%[69A21E6QZ4$,5S
MVI\YW2G!ZFGH (<&DI7"42&/(;FKRD%>*I\%N*MQ+5<UC!TR[:L XR>E>A>$
M6CEE57QT]*\\MD^;)KM?"MW';W"E^F*J>L#*GI+4ZB^MMCEE'%9X<AJGEU9+
MF4HHP,U3E<>>0.E>95IZW/0A/H61+FIDE(YK.5^:E$F.]9]#7<W[+4FB/)KI
MK.^2>,?-R:\_2:M&PU P2#)XI =WUYI:SK'4$N%'(K0!% AU%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 (:2G5$6P#0 XL!UJM+=PQ]6JK
M?2N(R5.*\_UG69TF(#D8K>G1YS"I643L=3O;>2-EW]>*\^U'0(&N-R,QW'-5
M#JTTO#2&G0W\LC?,_-=T*+@<KJ\[L;6C6-O9-F0XX[T[7+Z%8B(R",>E010R
MW$6?,Q@9YKGM9NA$K1E@32Y;RN;)J**TEQ&S;F;K5'4%26!F#'-94EP[OPW
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MGFL'2M66=0K'GWK=4AAD4"'4444 %%%% !1110 4444 %%%% !1110 4444
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M7<]*EL.I<XIG>G5@:CLTN:92YH ?FESQ4=+F@"3-+NJ+-+F@"4-3M]0@TN:
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M8Y0XR.E3 U0L3_HXJV&Q72>5)6)J*:K BE-!("EI!2T %%%% !1110 4444
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M4D#@$5O3=T>16I2A*TAZC:,4[-)UHXJS(53DTZFKUIU !1110 4444 %%%%
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M^<UH^(O!M[HTC21 F,GHHS7/0W3!MDL;J?\ :&* -0'(XI:K+)QD'BI ^>:
M):*3(Q10(4&ES3110,=FBFTM #J44VG"@0\4ZFK3J!CA3A2"G"@!PIU)2XH
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M#K4,;M)(-YR :F6AUTE=%GQ/;27ENT\"[N.U<M:QLI(/WAU'I7IEBUL;#;*
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MVGAS[Z5W47W!7!>'6_>J*[V+[@H ?1110 4444 %%%% !1110 4444 %%%%
M!1110 F*,4M%%@&XI>:6B@!!2T44 %,*9.:?10 S%+MXIU% %6XLH;F,I)&C
M9'<5P'B?X=V]XCS0 A^P48KTFFM]V@#YBU+2-0T:=E>$^6#U-5X;I)>C<U]%
MZKX?LM3B99H0Q(KRSQ)\.)[0O-9;54=A0!R*R5(K9%9\OGV,IBFC?(."=IJ:
M.X#'@T 7,T9J(2"I%8$4 +FG4WBEH =3P>*93A0 ]:D%,44\4 .%/ IHJ04
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MN ]B:M1:A%*?E.?QK9/0\=PD7N,TM0+,I;KBIQS5$V%HI,TM @HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!.U>6_$RU+6^\#^+->I5QGCFT\[3&.,XR:
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MEB:YC60<9%.=/W3)2O(Z6V\#)>Z895SOXX%:%E\-H613,[@UW>D^2MHJI@9
MXS6C@5YDEJ=J5T>=7WPUM9(BJ2-^%;>A>$;72XP&4.<?Q"NKVYHVD=:GE*(H
M;>*-<*BCZ"IP !2 =Z7!IH %.IO:G4P"BBB@ HHHH **** "BBB@!#12T4 )
M7/\ BD,='FV]<5OFJMY;I<P-'(,@TGL#U/!9MTDK(SD;?>J5PH' 8GWK?\86
M)T^\=H5*@MV%<QYF8SGK6$HF#A9W(&B,C8["HY(]G YJ<2@ U$) ?O4TA6*^
MTLW2M*U6)0,D9J!#&3@"K!@VKNIB:.@MKBU\G#%1@>E8&L.@G+1-E:K&4@XS
M5:>3>VVCE%8AY)R>]2@A1UJ,?RICL<X%4H@HD_V@KP#3EE;[V<55 Y&:5GP<
M \46!Q-"*^DC/RDG\:?(QG)D8\FLY-V<YJ0W!7Y<TK!RC9FVMC-1K(0:B=RS
M]:D5<FI:(<;%J-9'&5&:ZWP6/^)D%E<KC'&:PM,F@MXV\Y<YJ:*_,&H":W)4
M$BJB731]$VI'D( <_**G[US?A:_DO+!3)G( ZBNCP<5J=(X4ZFBG4#$;I7)>
M)='>_B.PM^!KK3TJM,0%)/I33LRHGC<OAP6P9IB0V>]8MQ;PI(P4\UV_C"9F
M=FA. !7$V;QM,_GC-=<).2-GL9T]K+("Z G':LP32I-L9<8-=DE[9P2@&,E/
M2J%Y96]]+NME"DGO5\[1-S._MV6SCV*>/K6EI=S'-()GQDG)K.O?#TJ1EG93
M6']ODL6:/<?2M-&BU(]5ENXGM<PMA_:M&WN9[N!4V<*,$UY=HVL2R7"HS'%>
MA:/JJ0J0YX/O7-RZ%+8Z32+:2.\!4L5^M=I'G8N?2N=T:Z@F17C%=%&<BL)[
MF%3<?WIU-[TZH,PHHHH **** "BBB@ HI"0*-Z_WA^= #74,,&N#\<:,MU:R
M2!>@]*[IY4 Y8?G6#K]W;MILJ9&X^] 'S[/:>3.R>E,V8K7U:,"[=E[FLQJ0
M$.*6E-)0 4444"$/6D-!H- "4444%!1110(2D[T4=Z 0E(<=,\TM-/7=ZT,&
M7--3?>QAF/6O2M/=H8<;<J!7F-JY2Z1QVKTJRN5.DJ[ @[3UK&1UT!SK%>AG
M( VG'2LV\TV-4WJ<57TV_,UZ845L,Q[5T5];K%: MCFH-(QL<?<@2V[1ASGI
MQ6;8Z2[W#99OSK=2P9Y"X^Z#5^&UV\@8-,N]HV.;O+*2SG4J6(QZUL)(YLXS
MWQ5BZMFF'/)I@LY5A S0R;Z"V+%V^8GK6C+;B6)N>@K,C@EM5\QCP*MP7P:-
MP>..]"1)B7%JQD*J"1201FUD!8XR:M&\2.3<W-0$-?3 IG:#39:TU-8M]HM<
MJ :HP6>9CGUK1ML1H(N]1SRI;Y;O31-K%.\4PRX!-7H5:2-0O7%8LMTUQ<9)
MR*W;2XC@6-B,XZXJ6;170VK2XCMK7RIL%O0UR^O+$[[D?KV%6]7O5=3=(I"F
MN>N-3AF*@ Y[TKFT8]2JDGE,.:Z[1]3MX]+N%=AN(X!KDY+5KCYXB *C!>&-
MAGIUJD$E=$MRZ37[N#P138RN[:'(K,^T$S'!Q6CI47GW W$=:&.#:.DT_4PL
M(M@0645T.@7T\#,7)(SW-9-GIEM%*92H)(]:F:;R7V+T-0G9ESY)*UCT.VUB
M*3 + &M=)%900>M>6Q>>SJT<@'(KOM)D<VH,CAF [5M&;9YN(PW(N9&SVH%9
M4NK1PN58XQ55?$$37J0C/S5?,<RI29T-)4*3JP!R.?>I P-.Y#30^BBBF(**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH 2C'%!HH X_QOHRW^ES,!EMO%>!1;]+U:2)^ #CFOJ6
M[@6>W:,CK7@/Q&T"2RNS<QK@%^P]Z );2<.@YZU;XKF-$OQ*@4GD<5T:-D4
M/J2-L-3*09!H ZG1=0,+J,_C7H&GSK-&"#GBO(K6<QGK7;^']2X"EJ .TZT4
MR-PZ@BGT +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4AI:0T 036T<RD.H.?45R^L>"
M+/4%8C"-_LBNNYI#P* /"=9\$WFG2,UNCNHKG7,]LVV=-A%?24T$=PA$BY%<
MCKG@JUOT9HH@&]: /($N0W0YJ=91CK5S5O!^H:;(S+R@[ 5A^8\3[)(W!'<B
M@9IA@U!JDLO<$5,LWK2$24&C<&H- QIIIIQIIH ;24IHH 2FD\TM-)IQ$!I*
M6DJ6K,=Q*FMI#%.I]ZAH)P0:M-W$U<U;QED4.I^8FIK="UNQ88Q6.+A@0,\9
MK;A?-BYQVKOI3T.:<3G+JY-O>/CI5::X$M&HHQG9@#5>.,YYK5ZF2W)X=HZT
MN1ORM6X[(R0Y'I6>RM'+BE8U2-B$>9$ ?2JEQ9D-D"K-INV"K_E!H]S"KBB6
MAVA6 (9G&..*V+>0Q3@*,UF07Z0*4'IBK-E%<W4PDC;"^]!)K36ZR*&=B">U
M2B"UBL&DE8;P>]4;N[6(*C,"R]>:H75W]H0JOW:=FT2[#;^\C_Y9X./2L*[N
M9) 0<U.YPQ!JLZEC5$K4S9%YI%C8CI5QH#D$BIXT0+C%(:,SYE. *O6T9*Y8
M8J00*9!QWK16%!%@"I-HF1<0*XX[5DSPD-6[*FPM61.2934LMV*;C J)0<]*
M?(_S4Z,@T)DZ#^JXQ4L (Q2(AS5J*$L>.U-ZC0R[@\Q01Z5G!65MN*UV.U2"
M:J! TF:RN4XZ#$M^,FI5!' %2,1T%6K6V:8@ 54I6C<R2N[%15<L.*V=-#1S
MQ') W"K/]E;(MQ'--@C;SE7!Z^E6IWB0XVD>E:9J_EW4,2/N!4=Z[VW;S(5?
M/6N%\,Z1"42:7;N'O7=1&-(U52,#WKS:KU.R&Q9'2EIBL,=1^=.R/45F4+12
M9]Z6@ HHHH **** "BBB@ HHHH **** "BD-+0 T\"HR34QJ,CF@#F]=\-PZ
MI"S'[V,UX_K?AZ\TZ]*+$QC.3FOH3VK,U+28+Y3O3+5+0/4^=9H#$N2.>]9[
MR'?\O-=KXJT*YMKR01QL4)P,+FN0FTN[A4YB<>^TU#1-AD$[!^:OBYRM8J2%
M796!R/6IQ*0E-$V+$C_,<=ZCQGDU )>>:;/<%5XICY"8M@U&6PU4XYV=CUJ8
M[B:9,E8=+*0O%5A(S')JZD(8<T[[&O7%#(N1PRD\4RX8AZO163]0AQ]*DET>
M>6+S@/E/M4ME&;& 2.:LG(& *2.W*OMP<BM1=+F, E['VI7,V4$+#K6[X?TN
M34K]5"DJ"#6:L._*XP1ZUZ=\/+!5=79>=O6JB7!'?Z18+9V<: 8.T9K3IJC"
M_2E'2K-QU+3<@=Z7(]10 IZ5BZO.T4+8]*V2P]1^=86M!3$3D4UN5'<\]OI&
ME+A_7O7&WI,<[E>.:ZO4[R*.X*XK%N=-><&4$;6Y%=<'RFSV,1)F<Y-217CP
M2#'K5G^SBD1((J@86$AW=C5NTC)LV)KF6XM]VVN4N[!I+@E@1DUTL-TB6VQJ
MH7=S&SKCUHLT4F0VNE>1")5)R*U=-\V:8)DCG'6HXI?,M]BFKVGP20L9>R\U
M5K(UB]#U'PMI_E6R,S'\:ZT?*O%>66?C-+2 (7.1[TLOQ%"C =JX9[G/-ZGJ
M!D5>2:0W40_B%>/S?$&1^DC52?QS.W20U!)[6;Z =7%1-JMJO645XA)XSNFZ
M2FJS>*+INLIH ]R?7;)?^6PJ!_$EBO\ RV6O#6\03OU<U$VL3-_'0![9+XMM
ME^XZFJ4GC4*>-M>._P!IS'^.D-_.>KT >KR^.A_LU1F\:AOXP*\Q:Y=NIIGF
M,>] 'H%QXTDP=K9_&L.]\2S7(()//O7-%SZTF<]*0$UQ,97)-5'IY/K330!%
M24II* "DI:2@04444 )11104%(:6D- AM%%% (#36QBG&FD9X[4,'N:.C11S
M7\7F-A<UZ%J$$*Z2BP/G'I7">'[=9[V/) &>YKT.1((82C%3@=C6$]CKH[F1
MX<6-9R& W;O2M?Q&)!:J4!ZUG:8J1Z@K;?EW5MZM<0R6[(!VK,Z)_%8P-+N5
M9#&<9)K4$&#D=ZYC3V*:B%[%C75RSI%$H/4U0ZBU2&3+#&FXL,BH6EB95P13
MVMS-;LQ(K!\QENS%G@'%-&3-N4)/%CC%<SJ,I@++%S6Q>R/!%\I[5C)LE9S(
M03]:NP(J6EO+=+\P/)K9M\VFU H.>#5"SNU@N ,X7ZUH"XBDDSC-0RPN+@P3
M^9VQ6/<7INI"N>]7[^02_NU!)JLVF>3&)<<D9I@O,JJ?(ZFM.RN5<'+=.E9;
MV-W?'$2L![BMZ#PW<P61E)!(7/ J7J7>VK%NFDO+8VT2 XYXKA[E);>X=9 5
M(/%=(NL'3KC#JX;IDBM$:3!K">8 NYN<DT6-%(Y.VU,PQ!>]:&F+]NN!')P'
M-6V\'R17Q#E"@[5U$&G6%O K)&!(@ZTT)R.&UOP[=6=\[V\;/'V-5[);RVE7
M?$5YKTR.]MGA"7"%C5:].E>7D0_/CCFGN%/FN4=+4S*#*Q7/O5R[M'C&Z-=W
M%&D1">7@83L#796NF)Y>)0"#TI<H5JL8O0\Y2[GCGPRD>U=GX<U1L"-SR3P*
M@UC1X!)F),'/)IUA9!766/ VT1T8JD_:4]1WB/"DR!R#GH#69I4CW4HD;(*G
M IVO3&X#1JV&7DYKEK35;BT<A7. :'+4UI4KP/11J%S ^W:2O:N@TJYEGAW2
M+@YKB=)UB*Z"K,<M[FNWTXJ8QLZ5<97.'$QY>AJCI2TB]*6MCA"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $Q2T44 -89KD_&6A)JNFLNWD GI76GI4+H)$96'48H ^4IH)=%
MU<Q."%W'K]:ZNRNUFC4@YS70_$GPD/+DO(8^5'85YKI&H-;R^1)D$<<T =R3
M\N13A]T55MY@ZCGK5C- #E.#6MIU\T,BX/>L;/-21R;30!ZKHVIB154GBM]6
M!&1WKRG2=3,,J@MQ7H&FZ@LR*": -BBD'(I: "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HQ110 W;05!IU% %6XLX9T*O&ISZBN0UOP-:WR,R *W^R*[@TW- '@6J^
M"[[3V9H8W=17.N9[=]DZ;"*^F9K:*=2)%R#7*ZQX'T^^#,D WGO0!XJDX['-
M3+,#UK>UGP)>V3L\. @[ 5RLT<]JY62-^.^TT : <'I16='<Y/I5A9_4T 3T
M&FAP:7(- "4TBG44@&TE.-)0 V@\T&DHO8! /F'UKH$FB%GL!&2*P*<)'3C-
M;0J)$2C<M2I$P.<51$"M)M'>GL6;G--1F1PV:W58RY#1LD\@L'Z8XS6==Q%[
MH%5XJX+D.N#UJ6W16C+$=ZUC43"S&6K@ (0!BK^%,)7IFL^YC( :+@]ZJ+=3
MM<K$">?:M;DL=<@P2YSQFN@TS6$BT\Q@+NS61>P,8%+#FJ%M#,9PJGBG;N8N
M]S0NO-EG9\D[CZUL6-CLTXROG(/>I8-/'D(S#)Q4UU.L5@T(X-4V%F<U>,/.
MX]:$ <]*BERTAI\3>6O-4["A>^I)/&HCX]*SEW;ZMO.')%+!&"^:DTL199<'
M%/:Z;& *GG"*.E4CMW<4KEI:E6XG(//>JC*'7=GDU+=D%@,4R)"W K%LJ:,A
MP=[9]:EMHRSU>DTUW.12PVS1-@TI22*@M-1<^6!Q4T<^U<XY-1RQD<T)'N Q
M4\^@[:C"C3L>M/2W*5<BBVK3BN:QY]2[:%1X".16YHBKDY R!6?QT-7;298.
M1UK1S3C8Q<6G=&I<WIB;8RC%0I>QA@Q"\5G75QY\F34&>U<TIR6QK&*>YV%O
MXG:  *V *T(O&TJXZ?G7G^<4N3ZUE=O<II'IL?CER.<5;C\;CNPKR?S7'>G"
M9_6@#V"/QM'_ 'EJW%XRA;JRUXL)W'>G"\F7HU SW%?%<##[ZU/'XC@;JZUX
M8-4N!T>I%UB['_+6@1[RFN6C=914HU>T/245X.NN70ZR58C\13K_ ,M#3&>Y
MC4K8_P#+04\7T!Z.*\13Q1.O\9J9?%EP.DAH$>UBZB/1A3O.0]#7C"^,;H?\
MM34J^-;H?\M30,]C\P>M&\>M>0#QM=_\]C4J^-KGO*: /6MX]:7</6O*%\;3
M_P#/4U*/&TW>0T >H[A2Y7UKS >-I#_RT-._X323_GH: /3/E]::Q7UKS7_A
M-)/^>AIR^,9)#M$AS0%SM]1:QBB,DZ1GO\RUYYXC\1V)A>*&"$^X45EZ]XDN
MKA#'YO%<-.TSN3NZUG)BN4]4*-.T@PN3G JDDQV9JW+;O(?FJ"2#:NT5*"Z*
MZS%B?:G ^:<&G"W*#/K3D@8-FK)YB2"!4)/K4Q S3D4D4XQ'-)$R8Z-3D8JZ
MD8XJ&(*J\TOFD-UXHD9,['2UADMBK(O3TJIJ5ZMJIME12H[XK'MM1D3&UL =
M:AU"[\YR<Y:L]0U$$L8D+\9SFM6'52\ A$:X'?%<P'.[FKMO(1]TXI]#)WN;
M/V62YO(A$G!ZXKTW0YH](L(RV PZYKR.#5I[5MZL>#5YO$EW=Q >8:<&;TV>
MOGQ="O5EJ)_&<*_Q+7C;:A<'J]1F\E/5JV.A'KLOC6,]&6JK^-P.A%>5&YD]
M:9Y\GK0#9Z=)X[8'C%9MUXV>964@<BN ,K'O3=Y[TEN$6= \ZWTA=FQS4LNH
MHD A4@X&*/#5K'=@*R$Y-:6I>&/*/F+M -=47W-]T<U)>L@([5G-=[Y#@5H:
MA820H2>@K+1$0$D<FM$^Q#1([-(,"J-Q!+N7&:G61D?<0<5)]NB=@N*M:@D7
M-(A;*[B:]#L='CDTJ9F."4XKAM/D7>N*[FS:Z^PL _RE:BJFD:I.QYAJ\,EI
M?-&'; ]ZS_-D[D_G6OXD64:FX;-8AW#J:XY7N<\EJ2;S_>-+O/K47O2@TA$H
M8^M2!O>H0:>#0(F!]Z>#4(-/!H E4T_-1 T\&D ^EIM** #O0>:** "D-+2&
M@!A%,IYJ,]: "BBDH **** "BBB@8E%%% "8I#3C330,2CM112 ?!,\$@=&(
M(]#6S'K4\NQ"3U]:PZ?#)Y4JL>@.:32:+C)IGJ.E1'[+NE&TD9S4-S<VZ.Z&
M7) JIH^IMJ%N(D;#8P,U4U*Q>&5F9@6/7%<\E8[82YM62:8BW.HJXZ UM:I;
MA%0[CP:P_#BO]N5>Q-:/BJ[,"(JGHW-$1N[9,UV!;$9YK%$3-<^8>F<UGMJ1
MD8*I.,5J6UY$51&')XH8-$^I2*;4G/05P\U].EPP4'&:] GM8Y&$?!##/6LV
M^T"!4WJH!JDV"..DFD*[\D5I:;?9^4FF7<"1H8MI)]JJ0*(6SC%7H*IKL==:
MK&O[YCGZUJ:2L&I3LA884XKAI]3D6WVJV*ZSP;:S1K)<.PP?FJ62KG;):V=B
M-@5"1[5674XHY'#A=N>XK$U74)//+HW%4H93*K&3G-0VS=)-:C_%&GZ?JD;2
MQ2*KD]%%96F3-9'8C%MO'--O&=7(AX6F6:E6)<')[U2-(J*1L&]DFN"[#&:;
M).T;@D\&G6X0L-V#5FZMHIHP% SBFT82EJ1K&+I-P. ?2J<]@Z/N#,0/4TY)
M7M?W0/3TJ?=-+&26^7T--((5'>Q+IUX$D6,8!!KM4O5>W4QME@.E><Q8%P=G
M#>M:UA=3K=(@?@T$U4I,W]3U$Q6^9% )K!TS76BN,/@ M5_Q0F=,B8$;MW-8
M4%HMP Z 9%9R;Z'9AXQE"S*VN:H)+US&W+'H*QY'\L;\<]:BOHWCU*0,>AI\
MGS@#VK1Q3B*G+EG:^A-9W$GG(RDCGH#7KWA>ZDFM%\Q<5Y)H\):^56Y7<*]K
MT:UCBM5VKC@5%*+N98^47'0V >*=2 <4M=1Y 4&BB@!!2TE+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%%  :9MYI]% &?JFFQZA9O"X!#>U?/'CCPQ+I%^TT*';NZU]+US/B?P_#J]
ME(I0%MIQ0!X%H^J;U"L>1Q7212!UZUQNN:3<^'=392"%R3P*UM*U(2QJ"W-
M'04HJ-'!&:?UH GAD*MUKH](U<QNJENAKE03NJ:.0QL"#0!['IVHI<1#+#-:
M.01FO,-(UAHV4%N:[S3M2CNHP,\@4 :E%(.E+0 4444 %%%% !1110 4444
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M$QNUFZ4R1&4=#5N%T P12R@2#:!3;%%7,TSG'!QBD60GDFI3;A7Y'6FNBHV
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M!J0&D!*#3@:C!IP- #J*3-+0 4&BDH 0U&14IIAH 924IIM "TE%% "T4E%
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M-MCYR+.*8R[CDDU*5IAHNQ)M$6/FY/%,QM)]ZE(IK4$M79'12FD- PHI,T4
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M_P#!"W<<EQ;Q_-C^$5X^CW&DWC0S @ XYKZUF@29"CC*FO*/'?@..X1[BVB
M8<YH XJQOEE08:M-7#"N#1[C2;SR)LC!]*Z:QOUE0?-0!L8^6@&F1ON'6G4
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M4VG4V@ HHHH 2BEHI )1110 4444 %%+10 E+110 4"B@4 +1113&%%+BC%
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M:::>1330 T4=Z*2@!P-*#3<T4 2 U(#4(IX/-("85(#4(:GAJ )A2TP&G9H
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MRV:GJI;3>;&K#N*MUTGCVLPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGPW%Y]PVYMI7I4^LWVT&,G-0^'YTCN&8CO3: Z.]66)O,+L<#UJO>2_:K95
M&X"JNN:QB7:A.W%0Z=<^>>_XTDQ-6,Q[217^8&G,)8X^5.*T=9D,419:SX+Q
M[A-K!B /2G<0^TN4\O# 9I9G+=!Q5>1$C;.TBK"RHR@ &G<$NI!#J:6,I;<
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M8R9UT&FO=)-<!MMJQ?,I/!K1\-ZE#:1#S]HY[U(TEA=V:!XR645CPVBW6IK
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M#U44^B@")K:%NL:G\*B;3[9NL*'\*M44 46TFR;K;Q_]\U7E\/6$G_+O&/\
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MPSIZ=(: /G,:!J9/%N]2KX9U1C_Q[/7T<NB62GB.I1I5J.B4 ?.J>$-38?\
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M;^$O)8W,*_[7 KC])NW0B.3@^]?0FK6"7MG(C+GY<5X=XBT.32[]I$7"CVH
MTT = ?:D\JJ^F7'FQ8)Y K1V\9H I&/!Z59LYVMY@P)I2E-"<T"/0-#U82!5
M9JZQ'#KN!R*\ETZY,$HY[UZ#I-\)8%!- S;S2U&F>]24 %%%% !1110 4444
M %)2T4 )2T44 %%%% !28I:* $HQ2T4 )BC%+10 F**6B@!*,4M% "8HQ2T4
M %)2T4 )^%&T'M2T4 -V+Z"C8OH*=10 W8/04;%_NBG44 -V+Z"C8OH*=10
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M>X'!Y^M:B3I(,J1^= $E%)D49H 6BDS1F@!:**0G% "T4FX49H 6BF[A1O%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &,,@@]ZX
M'QUX=6\M'E5>?85Z :JWEL+F!HV&00:0'RC<1M:W4D;#&&P*<&R*Z_QYX=-C
M>^8B8#$GI7%1G!P:0$V:4\TT=:4D"@0'DA1WKL?">A&XG1V7T-<[HU@U]>H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#,%W,HK9BNX95^5P:\2AOIHB/FX%;ECXDEAQ\_% 'JX(/2E[5QMAXH#XWO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* $Q2T44 (<5AZ]HT.JVK1LHSSSBMP]*9M&,F@#P2^^'=P-4&Q6*%NPKTKPE
MX732X4+*-P'<5UQC1FSBI ,#B@ 5 HP*<*2E% "T444 %%%% !1110 4444
M%%%% !333J:>M %#4;0W,)6N(U'0[B-9!&K'=Z5Z,>:8T0;K4.-P//?"GAV2
MWO!/,IS[UZ"J#9@CBE$:J.!2U2206*<^FVUQR\2'ZBLC4/#5O<Q,J*J\=A71
M\4#!H:3 \FN? C_;,KNV@]:] \/::=.M/+8]N];&WFEXI**0 >!5*^T^*]A9
M'49/<BKM+P!3: Y*'P=;Q7!DR#GMBMZUTRW@ VQ*".X%7L#K3A4QC9BLA H
MI:44=ZL89HXHQ1B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "DQ2T4 )MHVBEHH 8T2.,,H-9=[X?LKT'?#'SZBM>B@#S#6OAC#/NDAEVG
MJ HKS[4O".HZ7(0D<DBCO7T;WJO<64-R")%R#0!\R;[B$E9HBF/6IXKI3_%7
MMFJ^!--O@Q\G+5PFK_#.\B9GLE4+VH YA+@U82Y&.35.YT/5=.8B<9 ]!55;
ME4.'5@?I0!NK,#3PX/>L9;@G[IXJPESCJ: -,&G=ZI)= ]ZF68'O0!8HY'>H
MQ)GO3@<T!UN3).Z_Q&IENE')C!-5**R]C"_-8T]K*UKFK#=PR,-\2_0BJVH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2*/MBO*Q?S_WJ>FH3Y^]0!ZD/$4?H*:WB)1T45YE]OGS]ZIEOYR/O4 >B_\
M"1K_ '136\0J1V%>?B[E/\52+,YZF@#N#JR/SYV*A?5@O DS7(JV:E4T = ^
MK$G@U$VI,:R5-/% %YKPD<"H6E=OXC40IU "]>M!P.E)10 4M)1S0 44A(IN
M[- #J3K2$XJY8V,ER0P'R^] #;:W::0  XKIK*PVJ!26%B%Z#IUK:2,** $C
M0*N ,4_%**6@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS:<J/*>* '!A@TL:O*?E%6K;39'8;AQ706FCJN-J\4 9=CII8AFY]JZ"WL<
M8&VK\-E%$HP.:LA0!B@!D<810 *DHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***0F@!::[JHRQQ1DUAZ]>O;Q#:<9%)NRN)NQLK*C_=8&JFH60NX60GJ
M*Y;1=8FDO/*9N*Z^)V8 FHC+F%&2DCE[3PI'#>>:Q!_"NGC@1$50HX%6 ,B@
M**OE121&$ /%.P&4@T_:*"HQ0@.*\2>'GO7+1DC)[54T7PBL#B24Y(/>N^*
MCI4115-2XW8FAEO$L4010,"IL;17.:[KW]F@;&(^;!JE+XN0Z<[H_P"\ XYH
M<DEJ',CK/-CW8+C/I4RX->:Q:Y=R_O@_7FMG1_$SS2"*9\MG J55B2JB;L=K
M15>&4R+FI<FM$[ECZ*!THI@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M:M-#7AFX]JW8[=(_NBI<4 4XK&.+' XJT$"].*7%&#0 ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *0TM(0: $' Q7.^(+=I & ) KH@#BH;B
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>arvn-20221231_g3.jpg
<TEXT>
begin 644 arvn-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'B!P@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#GO$WB>W\.Q*\^[YAD8KCU^+VGL,K%<
M$>RG_"K'Q1 9K0$9!_\ KUI>!]%TV?P]&\ME"[$]2M %&R^+6DSS+$\4X+'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!YM\3_P#66?\ GUKH? 7_ "+<?UKG?BDP0VC,< =3^=6/!?BS1+30
M(XI[Z-'!Z&@#O+L@6LA/3%>,Z9\WQ>D,?39_6NS\0^/-+&G2Q6-U'-*ZX4#U
MK ^'^CW-UJ(UNZC*2,,8- %'Q5_R.6DY_P">W]#5_P"(MA<B0W94M!QPHR:H
M>+?^1TTK_KO_ $-==XD\3#3;OR+JS1[4 ?.XXH&<O8>+_#UWIBZ?<6D^[9L.
M1@?RKL?"6GZ;;V8-@%5".!D5A:I#X:O]*:XBG@AD*9PHQS6+X'-W#J3""5YK
M4(<-GB@#8O[#1]-U1[J_02,7W+L(R*R?%/BGP]>Z>8$M)]V>NWC^59FA-%?>
M)-0_M:\,2I,=BN>#TKIO%,^@VVC%+3R)IP>@'- BOX$G\[0-6VY"!/E![<BL
MWPAX>MK[Q1]HG0,"*N^ 95ET76BH ^7H.W(JGX1UZ#3_ !-Y=TXCB ^\:!G;
M>,/#-@V@7%PL7[R"/*'TKE_!VH2R^"EAE;+#/\JZ+Q=XLT^319[2VN$DDG3:
MH'>L+PEI<MIX)62=2DG/RGZ4"(O 4[6UMX@F4X*$D?F*YBQU[37\5->ZG!)*
M2.2H_P#K5T_@* W-OX@A7DN2!^8K,T1+/1_%#6NJ11K$!]]Q0!=U[Q3X;O\
M2I8X[&X\X)B,[3P?RJ/P=KUS:>&5A =%P>"".U=3JNI^&;.P>6%;:27;E$V]
M:K:0S>(?#WF"P2WR"1M&.U &5\/-$MM3U'4;J\3>PDW*?RJ]\3/#-B=%%S%%
MB;?UJAX$UF+0]2U&WU%A!NDPF[OTJ]\1_%%A-H@@M)TEDW_=% &Y\/D\O2PG
MHH%=E7&_#]B^F;B,$J*[*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !3'<1H6;H*?5/4R19/CT- &++XVTV*=XCD
MLAP<&A?&^G,<8;\Z\K\'Z(?$'B36%FN741RG'/TKOI/AM T9Q>2#CU- '7V6
MJ6U\FZ*1#[;A4&IZ[:Z6"9ST]Z\=MVNO"/BF"T%Q)+'<3;?F;I_G%;/Q.:1Q
MA9&7)'0T =K_ ,)SIIZ*WYU-!XQT^=PH.W/=C7/:-X$@N='M9FN7W.@)YJIX
MC^'Z0Z>TL5[*K#G@F@#TJ&>.>,/&ZL",\'-*\B1+N=E4#N3BO,_A7JT]U+J%
MI,[,+8[06/TJ/QWXAN;K4FT.S)\SKE3S0!UU[XTTZRD*,"Y!Q\IS4NG>+]/U
M&0(AV$_WSBN9T/X=H+59[F[D>21<D,2<56\1_#UH[9KBRNI1(.=J$B@#TIIT
M$)E!!4#/!K!N/&.GVTIC=6R/>N7\!^(Y-02[TN\.UH?W8)/)Z5L7W@*"[E:8
MW+@D=,T 6O\ A/-+!QS^=/3QMITC!0K<^]>/:CH)@\36UH+F3:\NT\UZA!\/
M+>-E?[4YZ'K0!V*7"/;"?HA&:S(_$EC)?_8U8>9_O56\172:3X9GB#_.L6%]
MZ\3MQJ%M8IXB9Y/F?;@GB@#Z-4AE!'0TI( YK*\/WR7VCVT@;+&,%JS?&WB#
M^P=&:=<%R=N* -#4O$-EI@_>.K'T5A69!X\TV>38$=?=C7$^&O"=SXBFDO[V
MYF16.]%+'!KI=0^'<$]JRQW+HP&05H [6VNHKJ,/$ZL",\'-35Y7X+_MG2-3
MN+2:*22$OM5W.>*]4[4 %4-1U6#38M\ISSC /-7)I5AA:1C@*,FO,VNI=>\<
MO:!C]E R&!XZT >EP3+/"DJ_=<9%250DO+32X8H9Y@F!@9[U9M[F*ZA$L+AD
M/<4 35FZGK5MI4>^X/&<=:=/K6GVUS';RW"K+(<*OK7F_P 8))%TAO+=E.[L
M: /2-,U>VU5&:W8$#KSFM"O%OA1J$^G!XKIV/GGY=QKV:5ML+MZ*30!F:GXA
ML]*ECCG8;GZ<U8BU2&6S%R@)0^E>!^,-1N=8UW]S(X6WD(.TUZ[X&!G\(QAS
MN)!Y/TH Z"QU2#4"XB/*'!YJ[7EMK>2>%O$GV:5R1>2\;CT_SBO45(89% "T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -D_U
M;_0UX-XVNVLO'-C.@)93D8%>\R?ZMOH:\4U]$D^)6EJZAE+<@B@#7_X3N]_Y
MYS_]\&NE\,>(I]4)\Q9!S_$I%=/_ &;9?\^L/_? J2.UMX?]5"B?[HQ0!Y7X
MPU:]U37'T>TEV^6XW ^F?_K5LQ_#;2Y-.$AMU^U,H.[CK7,WQ&G_ !'NKJX^
M6)R "?J:]>@N(_L,<I8!-@.: /*?#.IWFB>+;K2;F3-O$F%4>O-9GC=KB]\9
M:?:0/@3#O5DN-1^(MZMO\V!G(_&DUI=OQ&T53U ']*!G4Z;X/@T.&6_E1?M'
MEDEA["N1T8GQAJ4S7\R&W@D*%78#@''>O6M?A:;2IE0'B-NGTKQ+P5X8@U:Z
MOEGOY;:7SV"JC$9YH$=1XA\,Z9I=JEQHS0Q2JV2=X/ J_HM\OB;PM>+=9D\K
MY.?;BJNJ?#RRL+<27>LSA#Q\SFM3PUI=AIOAR]2QN?/5CDF@#C_!?AG3[GQ?
M/#)""D:[E'OS6IXV=K?X@Z/#&<(% Q^ J7P(RCQQ> GG9_C4/CW_ )*3I'T_
MH*!COBQ-*F@6(C;#-.H_45?T+P-#JNE1RZK&LLA0;#Z"L[XK_P#(%TW_ *^D
M_P#0EKTO01C1[7_KDO\ *@1Y3HPG\/>-KBTA;;;+@*H[=:U/'-Q)_P )-IV#
M]Y 3^0JE??\ (_7/^\/YFK'CC_D9=+_ZYC^0H 3XC[G\&Z>!]XR@#\Q3_"/@
M:#4M-\S5HQ*V!M/M2?$(A?".F,>@G4G\Q7:>#;Z"[TA#$P.U0#B@#SR_2?P1
MK@>W;R[621451[G']:]ALY/.LH93_&@;]*\E^)<J:C>VUK =TL=PA8#_ 'A7
MJVF*4TNU4]1$N?RH ;JTXM],N&/_ #R;'Y5YI\+8VU&2^NI?F:.X8 _\"->A
M^(8VDTF<+VC;^5<#\'9 MIJ2'AOM#?\ H1H N_%N5XM+L2AQF=?_ $(5U/A5
MBVE1D_W!_*N5^+JDZ38D=IU/ZBNB\'W,<FCH5;(50#0!Q'B2>1?$Y4'CS5_G
M5WX@<Z?#_P!<5_E6+XAO(IO%[1(P+"1<C\:VO'__ "#H?^N*_P J .3,#:'H
M^G:B@P9Y54D?4?XUZOJ^K+;>$3=JWS+$IX/M7*MI/]I^ +$A<^5\_P"6#7,V
MGB(ZM!)HI;+,=@&?3B@"#5+#S;*#62.;AAS7IG@#_D$M]:YGQ38?V=X-TZW(
MP4<?S%=/X _Y!+?6@9SWQ9MS%:V$\7#&X7)_X$*[CP[=_:]*A.?NQJ/TKC_B
MW(J:;8@]YU'ZBNF\(1-'I*;AU4$4".AHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KF/'_ /R*-U_GL:Z>N8\?_P#(HW7^>QH \P\(^/K+07=)[6>0XQ\B
MD_TKI;SXOV,D#);6-VLAZ'RV_P *K_#W1K2\+F:%&^7NN:]#C\.Z;&V?LD)_
MX * /-? NBW6H:_=ZM<J1'-\RAA@UC_$.\_L[XDV<X5CLBZ*.?X:]SBMX8$Q
M%$J#_9&*\:\7QI)\6[!9%#*8SP1_NT 7$^)C6ULN;>YP!_<;_"LN^\1W_CJW
M;3[.4QI)QM<5ZS'HMA<Z;Y9M8?F7&=@KR?6]-E\$^)X[ZWCW6J@LQ[#H: .^
MTS1#H7@^9' \X0$,1]*X_P"%J"YN9;B3EUF8 _B:]#LM1BU[PRSQD%I8CP*\
MT\-7(\*^)UL+K]W'(Y<D_7_Z] 'M=8WB>%+C0YHW&5-:5O=0W,0EB<,A&0:Y
M3QYXAM;#0YXEE'VCLE '+?"^5O\ A)=2@_@3I^5>L2_ZLUYQ\,]+EBFFU*1"
M/M"YKT>7_5F@#Q?P;_R436/]_P#I7M2_<'TKQ7P;_P E$UC_ '_Z5ZGXBU,:
M3H<EV3C8/Z4 >8^*KT:_XDAM#*H6VF&=QK8^(&G6J>%VNK6:'ST0 $.">E<E
MHWA"7Q1K5W?-<2Q*YW*5)KI+CX6//"8WU*Y93V+F@#I? .LK>Z)#;EMTD2?-
MS7$>*V,_Q7M(7_U9CY'Y57\"SR>&/$UY8SL?+W;$+'K6CX^M)+/Q-%KH7]W'
M'][MVH&>K:<@CL(D7H!5AU#KANE8OAK6+;4M)@:.0,^WD"IM<UJWTBQ>>60+
MM]:!%Z&U@@D9HP QZU8K@_!GB>]UW5;M9(=MNOW&]:[R@".:%+B%HI!E'&"*
MX?QAH6GZ5X2NA:0[,G/\Z[RN6^(7_(I7/^>QH ROAU_J&_W:[ZN!^'7^H;_=
MKOJ *VH2&*PGD'\*$UY9X=_XF7CF*_?EE)7/XUZAJP+:3= =XS7F'@@^3XA6
M)_O%R?UH Z[QT[)IN5./E-5_AG(TGAYRQR?,_P :G\>*3I9(Z!35'X63H_AV
M0!N?,/\ 6@#&^+$SQ:EHH0XS,,_F:T/B&<_#>7/]T?RK!^*E]#<:SH\4;@LD
MXR/Q-;WQ"_Y)M+_N#_T&@#AI=,)TO1[J$8\K#,:];TG7HY= ^ULV50!2<^U<
MKH%BMYX*.1EE@.VN0@UJ6Q\(7.E9/VEI"57//>@"R+1[VYURYG^:,J3'^0KK
M?@T,>$I!Z3'^9IDE@+?P.9R,220$M3_@U_R*<O\ UV/\S0,O_$2U$UK#,1S%
M\PJU\/;YK_0#(QSAL4WQZZKI94]64@55^%D;1>&7#=?,_P :!'<T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM.D\C<Y'K7H**$147HHP*=10!#=Q^;9S1_WD8?I7E?AU3X;\1FP;Y?M$I?\
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MMH!&@P!7,>&O#7V"\NKB;+-(^X;N<5UM !1110 4444 %%%% !1110 4444
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M^>\OYF@-#EO^%MZE_P _#_D:/^%MZE_S\/\ D:ZG_A1]C_SWE_,T?\*/L?\
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M_/:7]: .>_X6[??\]W_(T?\ "W;[_GN_Y&NA_P"%(VG_ #VE_6C_ (4C:?\
M/:7]: .>_P"%NWW_ #W?\C1_PMV^_P">[_D:Z'_A2-I_SVE_6C_A2-I_SVE_
M6@#GO^%NW_\ SW?\C3?^%N:A_P ]W_(UT?\ PI&T_P">TOZT?\*1M/\ GM+^
MM :'._\ "W-0_P">[_D:/^%N:A_SW?\ (UT7_"D;3_GM+^M'_"D;3_GM+^M
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M  MK5/\ GY?\C76_\*-L/^?B7\S1_P *-L/^?B7\S0!R7_"VM4_Y^7_(T?\
M"VM4_P"?E_R-=;_PHVP_Y^)?S-'_  HVP_Y^)?S- ')?\+:U3_GY?\C1_P +
M:U3_ )^7_(UUO_"C;#_GXE_,T?\ "C;#_GXE_,T <E_PMK5/^?E_R-'_  MK
M5/\ GY?\C76_\*-L/^?B7\S1_P *-L/^?B7\S0!R7_"VM4_Y^7_(T?\ "VM4
M_P"?E_R-=;_PHVP_Y^)?S-'_  HVP_Y^)?S- ')?\+:U3_GY?\C1_P +:U3_
M )^7_(UUO_"C;#_GXE_,T?\ "C;#_GXE_,T <E_PMK5/^?E_R-'_  MK5/\
MGY?\C76_\*-L/^?B7\S1_P *-L/^?B7\S0!R7_"VM4_Y^7_(T?\ "VM4_P"?
ME_R-=;_PHVP_Y^)?S-'_  HVP_Y^)?S- '('XLZK_P _+_D:/^%LZM_S\O\
MK77_ /"C;#_GXE_,T?\ "C;#_GXE_,T!H<A_PMG5O^?E_P!:/^%LZM_S\O\
MK77_ /"C;#_GXE_,T?\ "C;#_GXE_,T!H<A_PMG5O^?E_P!:/^%LZM_S\O\
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MWE_,T?\ "C['_GO+^9H#0Y;_ (6WJ7_/P_Y&C_A;>I?\_#_D:ZG_ (4?8_\
M/>7\S1_PH^Q_Y[R_F: T.6_X6WJ7_/P_Y&C_ (6WJ7_/P_Y&NI_X4?8_\]Y?
MS-'_  H^Q_Y[R_F: T.6_P"%MZE_S\/^1H_X6WJ7_/P_Y&NI_P"%'V/_ #WE
M_,T?\*/L?^>\OYF@-#EO^%MZE_S\/^1H_P"%MZE_S\/^1KJ?^%'V/_/>7\S1
M_P */L?^>\OYF@-#EO\ A;>I?\_#_D:/^%MZE_S\/^1KJ?\ A1]C_P ]Y?S-
M'_"C['_GO+^9H#0Y;_A;>I?\_#_D:/\ A;>I?\_#_D:ZG_A1]C_SWE_,T?\
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M^9H#0RO#OQ/U"_UZTM7G<K(^".:]^'2O)-'^#UGIFK6]XLTA:)MP!S7K8X%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHK
MB=;>(R.< 4 $\Z6\+2.P 49Y-8]AXHL]0U 6D/+'N#FO.O%WC'5=0%Q9Z;")
M(TRKL.PK.^%JSIKL8G+%^^3F@#W.L?6/$5IH\3-*P9A_"#S5_4)_LMA-/_<7
M->,V\,GC'QMF65UMR,?*3CK0!W%M\2=/N+@1>1(F3C<P(%=A:7<5Y")(G5E/
MH<UQ.N^ [/\ L:1HI&62),J5X)K%^&VK36URNCS.6;.?F.30!ZO1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5'/"D\91QE34E% '.7WA_3;'3+Z:
M"W"R.A+'UKSWP'_R-:_Y[UZMK7_(&N_^N9KRGP)_R-:_Y[T >H>)6V^'+\CM
M$:\R^%8$MPLK?>W&O3_$*&3P_?(.IB(KR_X9,+74UM&X;<3C\: /6M0&[3YP
M>ZUXWX<)B^*RQC[NW^M>Q:FXCTRX<] F:\?\*I]I^)2W2\KC&?QH ]K[4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-)E1^-<)X)\*IXA6>\U=1/\ O#MW>F:U/C)*8]'L<'K.H_45T7@.,1Z,N!U
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M$>ML>E<S\5,?\(O=>NW^E &SX$O3>^%+.1CEBO-=-7$?#+/_  BMGGILKMZ
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MRW?A4QPKN;?TH =\.?\ D$K_ +@KMJX[P!;RV^EJLBX.P5V- !1110 4444
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M==Z%IUZQ:XME<GUI+70=-LW#6]LJ$>E:5% "8&,=JJ-I=F]PL[0@R+T-7**
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MA?6[:^TJ/]\@**JD$^@K1UG2(-8LVAF'8XXKS+_A#=:T65X]+C>2)F+?,QH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5:L/\ CZ7ZU5JU8?\ 'TOU
MIQW)EL?3GPW_ .08/]RNYKAOAO\ \@P?[E=S55/B(I_"%%%%06%%%% !1110
M 4444 %0W-K#=Q>7,@=?0U-10!%!;16Z[8D"CVJ6BB@ HHHH **** "BBB@
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M*/L-O_SR3_OD4_;Q_E%[!]SPE]0\2O\ Q7'_ 'S5=YO$C?Q7'_?->_?8;?\
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M:'8+3[GRC_PA&I?\\9/^^:/^$(U+_GC)_P!\U]7?8;?_ )Y)_P!\BC[#;_\
M/)/^^11S0[!:?<^4?^$(U+_GC)_WS1_PA&I?\\9/^^:^KOL-O_SR3_OD4?8;
M?_GDG_?(HYH=@M/N?*/_  A&I?\ /&3_ +YH_P"$(U+_ )XR?]\U]7?8;?\
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M7?8;?_GDG_?(H^PV_P#SR3_OD4<T.P6GW/E'_A"-2_YXR?\ ?-'_  A&I?\
M/&3_ +YKZN^PV_\ SR3_ +Y%'V&W_P">2?\ ?(HYH=@M/N?*/_"$:E_SQD_[
MYH_X0C4O^>,G_?-?5WV&W_YY)_WR*/L-O_SR3_OD4<T.P6GW/E'_ (0C4O\
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MI: $I:2EH **3O2T %%(:!0 49HHH 6BBB@ HI*6@ I*6DH 6BBB@!*6DI:
M$I:** "DI:2@!:*2EH **** $Q2T44 %%%)F@ I:2EH *2EI* %HHHH 2EI*
M6@ I*6B@ HHI,T +1124 +124M !24M)0 M%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% "44M)0 M%%% !1110 4444 %%%% !1110
M 4444 %)BEHH **** "BBB@ HHHH **** "BDI: $HI:2@!:0TM)0 9I:3%
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M %)2TE !1110 4444 %%%% "T444 %%%% !24M)0 M%%% !28I:* $HS110
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M85<M;V&\3=$V10!8HHJI>:C;V(S,^* +=%9MIKEE>OLADR:T0<C(H 6BBB@
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M0!)^M=39:NDV,-UH ZQ) 12EA6;!<AP.:LALTADI:HFDQWI&; JA=7 C!YH
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MM S5W>]+NK-6['K3OM0]: +^\4FZJ'VD>M+]H'K0!>WTNX>M9_VD>M*+H>M
M%_=[TH:J(N >]/6<>M %W-&:@67-2ALT /S1FDHH 6BFYQ3"^* ),T5%Y@I?
M-% $M)FH_,%-,O- $^:2H3)0)* )Z,U#YE-\R@"?-&:@\RD\R@"QFC-0>;3E
MDH FI13 U+F@!QI,T4G>@!V:2BF%L4 /S1FH3)BF^;[T 6 :,U )?>E\P4 2
MYHS4?F"@R4 29I<U!YE'F4 3YHJ#S12B84 3YH)J(/GO3QS0 X4M(*6@ HHH
MH 3%+110 4E(34;/B@!^:-U5S+[TPS^] %O<*-U4O/\ >E\_WH M[A2;Q5,S
M>]-\[WH OAQ2%Q5'S_>D,_O0!>WBEWBL[[1[THN/>@#0W"ES5$3^]2)+0!;H
MJ-7S3B>* $9L55EE"\YI9Y,"L'4]1$$;$MC% &A+?HG5A5&76(EZN/SKS/7?
M&JVSLJR<_6N.N_'5Q(#LD_6F![JVNP_\]%_.G1ZU$W1Q^=?.I\8ZAN^_Q]:O
M6WC:Y3&^3]: L?0BZI&?XA4@U*/^\*\+@\>'(#2?K6C'XY4CF3]:!'LAU*/^
M\*8=3C_O"O'V\<)_ST_6H6\<*/\ EI^M 'L9U-/[PIAU6/\ OBO%Y/'F.DE5
M7\>.3Q)0%CVYM7C'\8J$ZY$#]\?G7ALWCFX8';)^M9TOC'4"WRO^M ['T,FM
MQ'^,?G4Z:LA/#BOG>#QG?+]]_P!:T[?QY,I&^3]: L?0<-\K_P 0J]'(".M>
M1Z%XQCN=H,G/UKO]/U(3*"&H$=(K4_=5.*3<*FW<4ACWDP*JR7 '4TR>;:#S
M7/ZCJ0B!RU,1L27R+_$*K/J2#^(5Y[JGBV.W8@R?K7/S^.4SQ)0![ -43^\*
M4:DF?O"O%U\<C/\ K/UJU'XW0]9/UH ]@.HIC[PIHOU_O"O*!XTB/_+3]:E7
MQE%_ST_6@#U3^T%'\0H.HI_>%>7-XSAQ_K/UJM+XVC XD_6@#U<ZBG]X5"^J
M1C^(5Y(_CA1TD_6LZX\=-N.)/UH'8]E.KQC^,?G33K,?]\?G7A[^-I3TD_6H
MSXSG_P">GZT!8]ZAU:-OXQ^=:$-\K=&%?/UGXWD60!I._K7<Z-XJ2Y5?WG)]
MZ!'JL=P&[U:1O>N6T[4!* <UOPRY% &BK<BBJZ-\ZT4AGB^J6T5U\7[N.9 Z
M[>A^IKT6+P/I\B1R>3&%(R5QUJ>3P;8R>)9-8*'SW')KIXT"1J@Z 8H I:?I
M%EIL86VMTCQ_=%6I[:&YC,<T8=3P0:EHH Y2[\#:=-,7B@CC![ 5?TSPMING
M'<EK%O'\0%;E% "%01@C@U@ZEX3TR_;?]EB5_P"]BM^B@#E;/P/IT$H>6".7
M'J*Z6"WBMXPD2!% Q@5+10!G:CHMEJ<96XMTD]V%8D/@73HYP[0QLH/W<5UE
M% &+-X8TV1%5;6)0#D#%:\48AB6-1@*,"GT4 %%%% !2&EHH ;333J0T 5IA
M65=0;@>*V9%R*J2)FF!Q>J:2LZG* UQFH>$$E+$1C\J]:EMP>U4Y;)3VH$>#
MWW@Z0,=JD?A6-+X5N5/"M^5?0,VEHW\/Z50DT9"?N#\J!W/ I= NH_\ EFY_
M"J<FFW2'_4O^5>_RZ%&W\ _*J$_AN-O^6?Z46"YX4;6=>L3"HS&XZJ:]FG\*
M1.,&/]*RY_!4).0E(=SRS:?2C!KT23P6HZ)5&?P<X!VI0%SB**ZA_"EPO\%,
MB\+SM( 4H"Y@V]M)-( JD\UZEX.TMX%4E2,U#HGA58]K,G/TKT/2--6%5 6F
M)LVM.0J@S6L1\M5[:':!Q5PC"T",B^SL:O+?&4D@C?&>E>LW<>Y37!^(]*^T
M1N-O44 >#W)9IB6J&M[6M&EMIV(7BL-E*G!%(H;11@^E+@^AH&)11@^AI<'T
M- "44NT^AI,'TH *7)]:3!]*,&@!=[>IHW'UI** %#,.AIPFD'1S3** +MMJ
M5Q;N")6XKOO"WBAY)4CD<YSCDUYI70>&K:1[^-@#@&@3/HG2KSS8U.:Z*%LK
M7%:$K+$@-=A;G""F223/@&N8UJ\,2,<UT4_(-<?XC0M"V/2@#ROQ3XBE65D1
MR.>U<9)JERY)\UJT/$L;+>R$^M8-(I$YNYR<^:U*+V<?\M&JO10!<&HW _Y:
MM36O[AO^6C55HH F-U,?^6C4GVF;_GH:BHH&2_:9O^>AI//E_P">AJ.B@!YE
MD/5S1YCC^(TRB@"47$PZ2&KMGK%S;2 B1N*S:* /9?!_B4W.U&?YL=S7J=A<
M^9&.:^=/!+,-0XS7O.CR'RE^@IDLZ4-\M4[J?8IJ8-\M9>I.1$U CG-:UU+4
M-N<#'O7GVI^.BKLJ'/N#47C>\82.N>]><L26)SWH&D=B?&MQNSEOSJ9/'4Z]
MV_.N&HI#L>@KX_E'8_G4\?Q!<G!4_G7F]'- 6/6(?'0;JV/QJ9_'" <./SKR
M+)]31D^IH"QZO_PG(S][]:'\<C;PWZUY1D^IHR?4T[A8]&F\>N&X!/XU$OC^
M0'[I_.O/<GUHI!8]2M/'Y8_-Q]371:=XRAF=095!/O7A>3ZU8M;AX)0P8\>]
M 6/J'2]56X (8'-='#*& YKQWP3J;31("V>*]3L9"R"F2;(;Y:KS2[0>:>#\
MM4KQL*:0S/OK\1@G=7-WGB&.('=(!^-,\079CB8Y[5XYK^M3-.R*U,1Z/<^,
MX$)'G+^=5/\ A.(L_P"L'YUXZ\SR-DL>?>F;CZG\Z15CV7_A-XO^>H_.GIXV
MASS*/SKQ?<?4_G1N;U/YT!8]O7QI;X_UR_G3CXSM\?ZY?SKP[<W]X_G2^8W]
MX_G0%CV=_&\08@2C\ZB?QO'CB0?G7CFYO4_G1N/J?SH"QZR_CE>SC\ZA?Q[M
M'!S^->69/J:,GU-,+'JD/C_)P>/QK4MO',3D;I /QKQ?)]32AF!R"?SHN%CZ
M+T[Q)'<8VR Y]ZZNQO/,4'-?.?AG59$N%0L<9KW#0;@R6ZG/84$G9(^11(W'
M6J\!RM22=*0%&[FV*>:Y35=8$&[+8K?U)B$->7^+99%5]II@.OO&"PDX?]:S
MH_'67P6Q^-><7DTCSMN)ZU6R?4T#L>WV'BZ*4#,H'XUKQ^(XR.)1^=> 0W<L
M)&TFMRQU28@98T!8]OAUY#_RT'YU,==C'_+0?G7D,6K2J/O4Z36Y,?>H$>N#
M7HO^>H_.E_MZ+_GH/SKQ5_$4B-]\_G39/$\@7AZ /:F\00C_ ):K^=0OXE@7
MK*OYUX>_B6<GA_UJG/KMS(>'_6@=CW^+Q/;L<><OYUIV^LQR8Q(#^-?-D.N7
M4;@[^_K77Z'XH=F56?\ 6@+'OEK=J_\ %FM&.3/>N!T+4_.53NKL;67<!S0(
MU5/%#-BFH?EILAP*0QCRX[U6DN .]1SR8[UDW5UMSS3$:1O #]Z@7@SUKF)+
MXYZTT7Q]: .L^V+_ 'J3[6N?O5RXO3ZTHO3ZT =2+I?6C[6H[US0OCZTOVS/
M>@#HOM@_O4?:U]:YHW9!ZT"])[T =)]K7UI/MB^HKFVO#ZU";\CO0!U7VL?W
MJD2Y'K7(C43ZU;M[\L1S0!UL<^>]65?-8=K/NQS6G$^12&7,TM,0Y%.- ",V
M!5626II.E9\S8H 5Y\=ZB^TCUJC/+S5?S>:8C6^T^].%S[UD^::42\T :XN?
M>G"X![UEB0XH\PT :GGCUI//'K69YI]::930!IFX'K3?M//6LPR&F^8<4 ;<
M=QGO5V*4'O7.1S$'K6C;S^] &P#3LU5BDS5@'BD,7- I*<* "D-+330 QVP*
MIS38[U-,V!67</UH$.>XYZU']HSWJBY):E7-,"YYQ]:!,?6H M*%H L>;3&E
M/K3,4TJ: %,QI/..*CVFDVF@!YF/K2B8^M1%#2;<4 7$F]ZM1/FLQ,YJ]!0!
MI1MQ3V;BHHZF*_+2&4+MB$->;^,]1:WM9""17H][]P_2O*?'L)>TDQ3$>-ZA
M=R7%U(68D9JG4DXVSN/0U'2+"BBB@ !(IWF..C&FT4 /\U_[QI/,?^\:;10
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MD_#.@S&979&'/I7M&A6IBA4&JFFZ*L07"=/:NIM+7RU'%,1=MTPM/=>*DB7
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M)BEH *2EI* "C%+10 F*3%+10 F**=BDH 3%*!110 8I,4[%&* &XHQ3L44
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M@ HHHH **** "BBB@ HHHH **** "BBB@!#1110 M(:6DH 2BEHH 2BEH%
M**6CM0 VEQ0*6@!,49I:3% !FEI,4E "T8HI: $Q24ZDQ0 E%+BC%  ****
M$HHHH **44N* &TN*** $I<44M #:44E.H 2C-+3: "BBB@ HI<44 &*3O2T
ME !24[M24 )12FB@ H%%% "XI*** "BEHH 2BEHH 2BBB@!"*3%/Q24 -Q1B
MG44 )1BBG4 -Q12T4 -HI:* "C&:7%+0 W%%+24 +2XH%+0 E%+2&@!***6@
M!**7%)0 E.Q24M "4444 %%+1B@ HQ1BB@!*448HH ,48I:* $Q1BEI#0 8H
MI** %HQ24M "44N** $HQ2TM "4E%+B@!**=BDQ0 VEI<44 %%%% !1124 *
M:2BEH 2E I*=VH 3%&*** #%)2T8H 2BEQ1B@ Q1BBB@ Q1124 .HI*6@ I,
M4M% "4AIU)B@ %+110 4AI:* &THHQ10 M%)10 4"BEH *2EHH 2DIU% " 4
MM%% !124M !1110 4444 )1BEHH **** "BBB@!*6D[TM "&DI324 %%% H
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M%&*6B@!,4=Z6D[T %%+10 F*,4M% #:,TIIM "T8H%+0 E%+24 +BD-.I#0
MVEHHH 7%&*!2T )24ZC% #:6EI* "BBEH 2C%+10 F*,44M "&DI:2@!:2EH
MH **,44 &:,T44 +1110 4E+28H 6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHI#0 M%)FEH *3-+10 F:6BB@ HHHH **** "
MDI:* $[44M% !1110 44E+0 4444 %)110 M%)10 M%)2T %%%% !124M !1
M110 4444 %%%% "9I:** "BDS10 M%%)0 M%%% !1110 44E&: %HHHH *;3
MJ3% "4M+24 %%%% "T444 %%%% !1110 4444 %)2TE !1110 4"BEH *2EI
M* #-&:** #-+3:6@!:*** "BD-&: %HHHH 2C-+28H *2EHQ0 4M)2T %)2T
ME  *6D%+0 44E% "T444 %%)2T %)2T4 %%%% "4M%% !1110 E+124 +111
M0 4444 %%%% !1110 4444 %%%% !2=Z6B@ HHHH **2EH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!*6BB@ I*** %HI*6@ HHHH **2EH *3O2TG>@!:*** "BBB@ I,4M% ""E
MI*6@!**** "EHHH 2BEI*  4M)10 M%)2T %%%% !1124 +124M "44M)0 4
M444 %%+10 4444 )112T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %(:6B@!M**6B@ HHI* %HHHH **** "DS2T
M4 )FBEHH **2B@!:0T4M "9HHQ2T %)FBB@ S2TF** %HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH @O/^/*;_ '#7@6O?\A%_]X_SKWV\YLYL?W#7@^NVT[:@Y$$A
M^8]$->A@-V<&.V1C45-]EN/^?>7_ +X-'V6X_P"?>7_O@UZ=T>=9D-%3?9;C
M_GWE_P"^#1]EN/\ GWE_[X-%T%F0T5-]EN/^?>7_ +X-'V6X_P"?>7_O@T70
M69#14WV6X_Y]Y?\ O@T?9;C_ )]Y?^^#1=!9D-%3?9;C_GWE_P"^#1]EN/\
MGWE_[X-%T%F0T5-]EN/^?>7_ +X-'V6X_P"?>7_O@T7069#14WV6X_Y]Y?\
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>arvn-20221231_g4.jpg
<TEXT>
begin 644 arvn-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *V!48# 2(  A$! Q$!_\0
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M>=3EF% K$]&:8) >]+D&@0ZB@44 +1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@D;:DJL?0&@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%(:  FH)9,#%++(%%5B=QS3L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNRW=KOLIE'=:\*\3V_EZHT;CUKW6%Q-#CN1S7FGCO0W%RUY&. .PK*M&Z.C
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M!6E.+CN<&+KJI\(OE)G.T9^E/ ]J**V//NPHH[T4Q!11VHH&%%+24""BBDH
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M(&^;%>GW%K'<VFV5=V%H X73?$-Y=:TD3CY"_'->C+T%>:I D'B6 (,#?7I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSD"I]*D@@MK>X>#&\C&10!ZC#M\E-IRN.*?45N=UO&1T*BI: "BBB@ HHHH
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M>_0BL^36PSJ58-T-.KA/#^NSI="VN@V1_$:[E'#H&'<4I1Y6 ^BBBI ****
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MU!6:-&5-1!VH?0U')=!XQ%&>2*L7I'EX/<<56TW3V7,CG/.13"ZMJ7;6+RX
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MB@=[D\=O%%R33C<0)P,9ID<)Q\SYIWEQ@\J#0-)]!OVMCPG-'^D2=1Q5E(T
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M8-07-#8]%#J3C/-.KE],DNWO<R;]OO6^UY%&0C, 36JD>5<LT4U3N&1R*4X
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M*>M-JB1:***8!24M% !1110 4E+10 4444@"D*@]0*6B@!K[A]T55NO,\DG
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MS@M6U61[H)$JL>G-5K;4KBWN$\V-%!8#@4E[HLL.MI'YX)8\5:2R$-\JW1R
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MEM=6$H^6/CUI6L5=&L0#VI#&M1I<1L.H%2%TQG(Q2V!"@8%%,2:-SA7!J2D
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M/6L>PL)+3Q'())-] '?1_P"K7Z4^F1_ZM?I3Z "BBB@ HHHH **** "BBB@
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M5 'GO@@BH?+>=OFX6IA&5.>HIS$;?O!/K2YNP^4='%%&N 3FD+D'G&*B5MO
M^;Z4_P LMR3^%+7J/3H-8Y/RUSWB[49;+27=>#]:Z55W# &/>N3\=)C17!&X
MYJ)O30WH*\U<\CEU!GN#,TC;LYZUZ3X(U:XN+<1\%<]Z\FGPK8 Y-=?X-UY;
M!UA=3UZUR4YVEJSV\7ATZ7NH]A4$'C[Q[4YBJ-R?WGI38+F.2R$R?,6&>*Q4
M:ZDU97*ML]*[N:R/G)JS.D@AS\S=ZM#BHXSB($U6N+O;\J<GVI;E)$EQ=I".
M3\W:J:B6[/S_ ':K7%O([)(QX)Z5JV^/+ 48XIZ)!U,Z*);:X..YK5'050NR
MHE3D9S5\?='TH8$%VV$&.]1,N+%ZBU2;RO+P/XJEF<'36(]*+:!U"P'RU>'6
MJ5@/W0/M5T=:4AHIWLBY0'UJ\G^K&/2LFX4S7! _AYJ_:S!X]I/(XK'J4M#D
M?&'AU;^/S$&7)KCK/P7?2W*J\7[K->M:C$9(E XQ56W#0+G!:LY13>IU4\5.
M$>5,ET735TVPCA'515^1!(A![U'%<*XYX^M3 YK1;'/*7,[F3(DMM*2H^7/%
M2_:)BOS 8J]+&)%P:I >1)L<9![TK6)'*P9?EZ]Z0;%.<G=4-U$\7[R(Y4]A
M3(IQ)U&TCUII@:"3EFVGI1/;),,XYJ!!SG-68YNQ%4FP:*:220/M<82KJ.'7
M(-+)&DHK-G2:!OE)Q[5JFF1L:)D5>IIOVF+UK+^:3DR<^E*',8Y0M3Y0O<U%
MFB?@8J*:S24Y).:YJ;4Y!?%%4J*W8;MQ&FX$Y%);Z$J28YHY81A%!'O4.%D/
M[[@^U:"3(Z\D?2E:%'&<"G?N58I",+_J>?K4$D;E_P!YP/:K;6CJVY6Q[5&9
M"C;7C+>].XC,OK!+E-JDT^QMGLT*D?+6DR)*/E(0U')'Y*$NX(I:;DV5[F;)
M?6RW/E[SNJ[<I</9Y@&<CBLJ[2(L;B-,_2KVCZDTY,3(0!QS6=W>S$G=V94T
MI;ZWN,W POUKHOM<*KECBI?+C;DJ.:IW]CY\+",[3BGLBTK+0LQ7<,QPC9J:
ML'2=-N+6;=))D5NT($V+124M PHHHI@(3P:YG5_/O)?+B&=IKI\5"+>-7+!1
MDU496!JZ./,=S GD,,9Y-:*W<<=GL_C45O/:Q.^YD!-0MIL);(45?M$]R%&V
MQS,$TT@,KKA0:UWU.$6\:IC=]*TULH!'LV#%1+IL(;)08[4.:8^5DMDQ>'+"
MK*_>I%54&%'%/0<UDRT65&!2XH'2EJ"@IK$!26Z=Z=6+XBNWM;0;,@OQD4 6
MRUG<AAM4^^*AM9-/:X:&,*77L16;X8M)! [RR[]QS6+XC2;2M1CN8I<>9( 0
M/K0!WP  X&/I7.>*=*N-4MA'$#^!K?M27M8F)Y* G\JFQ0!Y/;>#=3M<B*/J
M<]:UM,T'58;D-*IVY]:]"Q1B@".!66) W4"I*6B@ HHHH 0UR+_\C+)]:ZX]
M*Y%O^1EE^M '61_ZM?I3Z9'_ *M?I3Z "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ I#THILH)0XZXH0&%J?B2UL'VE^0<&I]+UZ
MVU%?W;Y-<9=1&'5;E[N,NC-\N14^B02OK*2P(4A'4=JWY(V ]#%+2#BEQ6 "
MT444 %1R('4@]*DI* //]>ATFVOP9I'5F;& *Z_2(((K1?(^ZP!Z5!?Z%;7T
MJR2(I(.:TH(5@C"*, #%-R;0$](:**0'/ZQXDM=*=5F<@LP'2M>SN4NH%D0Y
M##-4=2T*VU%E,J*2K \UHV\"V\2H@P ,4 3BBDI: $I:*2@!:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :PXJ!AS5
MBH''--"8WFFE0>HIU%4*UQ%4#H*,#TI:* L(5%&!CI2T4@&[%[@4NT8Z444P
ML@QGM2]*2B@!:*2EH **** "DI:*0%'4[AK>W9U["L_3;V>[7@9K:FB25"'7
M(-84MZMA<^7%%@>PJ;V>I$M[LAUC3[F=E9%Y'M4UDJV=D/M9P:TE+W"*W(S5
M'4]-EN(MJN:;TU1'+KS(@MK*WGG,L')SFM8VSNN#4>DV)M(L-U-7WD6,99@!
M5)V*2TN0"'RP .M,='/WN!3VNE<'R\$^U<YJ-Q>?:MJ;PN:&^XW)11T"R@#;
M'RU86JO?&XV@87VK?L8_]&1F'S$<TZ6W65\D4GKL'*VBI9$K;+_>Q5F)&<Y:
MIXX51<8IX 6@K88P(7"BL37K>WGL&2Z/6MB2=1P.36/J.FS7O\9QZ4-:#4W'
M8\=USPY+:3&:-#Y+'(K,AB)(6,'>#7M%_IZ16:1RQ>9Q@9%,T;P[92Q^:ULH
M.>XKE=*[N>I3S%J'*U=D'@V=VMEBF[+WKL62)/G('%48[.VL"2JJ/2JFH2S3
M1DH2OTKJBFUJ>7)MZLN2W33MY<//K3X+4+\S?>]Z2QA"0*Q'S$<FK+N$3)J@
M*]ZZJJCN>E/M]R6Y+56B4W$Y+?=!XJQ=N$@V@X-'D!RUU<7<FJ[4^X&KKH"Q
MA7=UQ56UM(BHD906/>KHP*FS$E8S-07S3C^[S409SI[K4SG=++ST%5X9$:V<
M;@35]!,T+#(MUS5ICM0FHK48@6G7!VP-6<MBD5;<;KF0MWIK(UO<@\[:EC 6
M(2=.Y-8VN>)K2SB894N.V:R?<VA3<G9'1G$L.ZJUJXRR'UKR^;QW,6*IN 'I
M5C2?'&V[43*<$\DU'.FSJ>"JI7L>F2VH)RO6HQ)+!]_[M.T^_BO[=98R#D=J
MLR(LBX(K0XI1:=AL4Z3#*FB6(2+[UFR1/#,2K84]*E59E&_>32OT8@61X',<
M@^7I3+BVV_O%^Z:L96X7!P&%4+K4?L*M'*I8'I0]%J)NRNR6.0JH+?=[595P
MU9MM<"Z3>J_*>@HO)'AMV=,G [4*5D%U:YI_O$.5^[4X9)5P>M<SI5[<7$Y#
M[@/0UT2KN'RG!JD[ZH$TRG<:=LE,L=302QNNQNHJZ@.S#56GM>"T?!]JU4KZ
M":[%:?2())/- ^:LW4+NXL62/ "GBM#[8\/R,I)]:9/;_;<,PS3<60UV"S0W
M%NLJ_>-3/<7%N/G& *;;AK,;0#MJX'BN%PP!IK1:C17BOFF&5IS7:*=LN.:6
M2T&W]U\OTJOL*'#IN]S3T#4F,$4J^8AK'U)[F53%;\]JNW2/+"5ADV'VK*L;
M.[MKK=+(S+FI=]B9/H2Z3&\2B.[&#WK4<6EBOF XSS5ES;,N\[0:PM0B.HML
MAEQMXP#4M(/A-FTO1<KNC.15U6W#!K%TJ%]/B"."WO5BZUF&V(! R:-4M2E+
M34U,"EJM9W:W46\58H3&+1113 **** "C%%% !24M% "4M)2T %21#FHZGC%
M)E(E%+2"EJ1B51U2Q6]MF4C+ ';]:OU5O;Q;*!I6Z 9H X-#XETIW2&/]V3Q
MD4D-IJFK7:MJR8B5@5XJ'5_&_P!JBD2&$Y7C(IWAFUU#4YEF>Y8)UVDT >CP
M*$@C4= H%24R-2D:J>PQ3Z "BBB@ HHHH **** $/2N1;_D99?K77'I7(M_R
M,LOUH ZR/_5K]*?3(_\ 5K]*?0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %)2T4 9M]I$%]CS!R/2I;/3H;)-L8%7:*?,[ -%.
MHI*0"T444 %)2TE '+:WX@DTZX5%(P6P:?/XKM;=4#R?.PS6EJ.FVUU&Q>-2
MV.":XF6U%M??OX=Z]B16D$GN!V6F:[;:BVR-\L.HK7KSWP_;3'79I8U9(CTP
M.*]!3(0 TII)Z <UX@U]]-:-4/5P/UK=L9S<6Z2?WAFH;S3K2Z(,T:M@YYJY
M%&D2!4& !QBH DHS1VJM=W26L1=R!CUH2 L[A1FN5_X2I?M&T1_)GANU=#:7
M27409"#D<U3BUN!:HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 2HW%2TQQQ0!!10>M%62%%%% !1110 4444 %%%%
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M1;_D99?K77'I7(M_R,LOUH ZR/\ U:_2GTR/_5K]*?0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M% !1110 4E&:,T
M %(>E+10!QNOW^JP7:+:J"F[!K;33UO[9&N%&_:,X%7I8[8M^\"YSWJ= N,+
MTIIV KVEC%:(%C'XU:HHHO<#C_$M_JMM)&+-007 /TS72:=)+):HTWWBO-/G
MCMF(\T*3GO4R!0OR]*0#^U8/B6"6>PD$>>E;W:F/&LB[6&0:<79W \P2:);&
M.T8'SE//%=GX:MI8+5O,SSR,U=.B67F^9Y"EO6KZ1B-0JC JYS30$E%)168"
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M&B@T 0.,&FU+(*AJD)BT444Q!1110 4444 %%%% !1110 4444 %%%% !111
M0 E+110 4E+10 4E+10 E+11]:5QV9%/*(8&D)P%&:\C\8>));R\>"%_W?L:
M]$\47@M]+F ."5->%O*7=F8Y;-<U>=M$>SEN&4GS,">Y.3[U&7+' H.6YH0
M<UQGT:BDK#L!13?]JD)W-]*0ME]HZ47!I6-;1]9DTRY5RQV9YR:[]/B'9I&
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M[Y3VJTHVKDT M5J5;N/HPZBI+**29AM&:5@7<+C.37JG@?P[;_V:)KB$%O\
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M*** "BBB@ HHHH :3@9KEM=\02VUU]FMCF0]JZAAE2/6N%\0V$UMJGVY4,@
M^Z!5TTF]0+>D>([@S^7>G:2<"NO1MR@^HKSW3+2;5;P2F)HMISR*]!B7;&J]
MP *=1("2DQ2T5D UD##!JN+&$/N"#/TJU13NP&A0HXH-+10!R6NZ%<7URCQ@
MX#9XKI+&(PVR(>H&*@NM4MK5PLDB@DXY-78I%E0,IR",T 24E+24 <EXCT.?
M49(VBSPX)Q]:Z+3X#;VR(W4+BH;S5;:S($LBC)P,FKL,JRQAE.01F@"444"B
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M##E:DM)8FN'3>-P[5>DMA/"4;H:F06NC)T.Y2>X==HP!Z5T2]:H6>G1VCEE
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MA72V16CW;F"UK6L_VB%9 /O#- %@4444 %%%% !1110 4444 %%%% !1110
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M_(RR_6@#K(_]6OTI],C_ -6OTI] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TG:@#(O]"MKZ17
MESD'-:4$2PQJB] *YS6?$DNG7*1+;,X+8R*Z"SG-Q;I(5*Y&<4 6:2EIIH R
M=2T*VU%E,N?E((P:T;:%;>)47HHQ7.Z]XCETJ1%2V:3<X7CZUO6%R;FW20J5
MW#.* +=%%% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI-#_ &8BJ=XSL^M 'HL))A0MUP,U)4%KG[+%GKL&:GH **** "BBB@ HHHH
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M'$S;BJXS0!>%%(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+10 E(:=1
M0!!(F>E0$$&KI%1/'D4TQ6*]%*5(--JA"T444@"BBBF 4444 %%%% !24M%
M!12446'<6DI:,4@N%%%%,04444 %%%%( HHHIC"BBDS0(6H;LX@(J8=:K7+
MRA,]:B0RK,F8XC[TR\L8KJ9%?N*L3855'H:SYM1(U&--M9.P-KJ3^1%;%4'8
MU++(@U")1CI6;=VUS//O0D FD-A<M?1R%FP*1%_(Z@'BBFP@K$ >M/K0T$IU
M)2T &:*2EH *2EI* "L36YI;7]['V%;=5;Z!9H&W 'BDU= ]BEHM_+>1 R5K
MU1T^*.*%510*O4+825D%%%%,8M%%% !1124 +124M #:6BB@!:**2@!:*2EH
M ***2@ I0,T 9J95Q0D B+4E%%4 44E+0 4444 %%%% !1110 4444 %%%%
M!1110 4444 (>M<]XG@N[BU6.V'7@UT)ICJI'S#B@#AM+\$P?9W:Z!#L<US]
MM"=(\52Q6Y.T$#%=WKNO0:?;,L3!I,<*#S7-^'=)FU#5'U.=2!)T!% ';?;X
MH+:-I3@E:@F-KJ477..1FK%Q8+/&%[ 8K&U72KB.W!MY"-O.!0!S^K>9#K%N
M6 $2GJ*[O394ELU9#E2*XC[-=:G<HKQLNWC)%=.[R:-I:A$,C*.@H VSTKDF
M_P"1DD^M9[^-+Y78?V=*<>U<\_BF\_MEY?L,FXGIB@#UV/\ U:_2G5Y\GC6^
M" ?V=+T_NT__ (3:^_Z!LO\ WS0!WU%<#_PFU]_T#9?^^:/^$WOO^@;+_P!\
MT =]17 _\)O??] V7_OFC_A-[[_H&R_]\T =]17 _P#";WW_ $#9?^^:/^$W
MOO\ H&R_]\T =]17 _\ ";WW_0-E_P"^:/\ A-[[_H&R_P#?)H [ZBN!_P"$
MWOO^@;+_ -\FHI_'UU;Q[I+"0#W% 'H=%>?1^.KR1 RZ=(0?:G_\)O??] V7
M_ODT =]1FN!_X3>^_P"@;+_WS1_PF]]_T#9?^^: .^S1FN!_X3:^_P"@;+_W
MS1_PFU]_T#9?^^: ._I,UP/_  FU]_T#I?\ OFC_ (3>^_Z!LO\ WS0!WV:,
MUP/_  F]]_T#9?\ OFC_ (3>^_Z!LO\ WS0!WV:*X'_A-K[_ *!TO_?-'_";
M7W_0-E_[Y- '?9HS7G2?$&YDE:,6$A9>HQ4__";7W_0-E_[Y- '?9HK@?^$W
MOO\ H&R_]\T?\)M??] V7_ODT =]1FN!_P"$VOO^@;+_ -\T?\)M??\ 0.E_
M[YH [ZDK@O\ A-K[_H'2_P#?-(?&U]C_ )!LO_?- '87.J6UJX65@"3BKD<B
MR(&7H1Q7CFL:IJNH7*2):2J V<8-;UGXOU""!4;3Y25&/NF@#TBD-<%_PFU]
M_P! Z7_ODTA\;7__ $#9?^^30!V%WJEM9D"9@,G JW%*LJ!DY!KQCQ'KNHWC
MQO\ 9I(P'!Z>]=#I_B^_@M44V$K8'7% 'I.:7-<#_P )M??] V7_ +YH_P"$
MWOO^@;+_ -\T =]FC-<#_P )O??] V7\J/\ A-[[_H&R_P#?- '?9HS7 _\
M";WW_0-E_P"^:/\ A-[[_H&R_P#?- '?45P/_";WW_0-E_[YH_X3>^_Z!LO_
M 'S0!WU%<#_PFU]_T#I?^^:/^$VOO^@=+_WS0!WU&:\_?QS>H,MITH'^[3(?
M'MU-G9I\AQUP* /0Z,UP/_";WW_0-E_[Y-'_  FU]_T#9?\ OF@#OLT9K@?^
M$VOO^@;+_P!\FC_A-[[_ *!LO_?- '?9HS7 _P#";WW_ $#9?^^:/^$WOO\
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M!BFVCI+JJ^;G%:B:,V_+R;E'05-+I",N8R%;UI<R"Q6FDLX[F-1G<3QBMSC
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M10 4444 %%%% "9JG=ZE!9)NE?\ 6IKABD+,.HZ5YQ=6>HZOXC:,O(D&/PH
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MHUN!NV2%8!FK-9^EF46ZK+G/O6A6J *6DHP33 *4#-*$J55H0#%2I ,4M%4
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M.7%L@"Q@[N^1712Z=;3ON>)2?4BG0Z=;0',<2@^U %H=**6B@ HHHH ****
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M@ HHHH **** "D-+10!F:OIBZG9O _1ABN-7X:VBG(4UZ+10!P5KX @M[A9
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MCHHQ4]% !1TJE>ZI;V2G>Z@^A-9\/B."20*Q4 ]": -ZBHXIDF0.A!!]*DH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>arvn-20221231_g5.jpg
<TEXT>
begin 644 arvn-20221231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %K!%D# 2(  A$! Q$!_\0
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M"KR2+(H9&!4]"* ''I5=KR%9 A?YCVJ9S^[;V%>3:EJEVGC2T@$I\MGP1^-
M'J\LR1)N<X%)#/',,HV:YCQQ=2VVAQO"Y5B>M5_A[=S7=E.TSEB#0!VM%%%
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M_G73>+?$;Z;91VL61(R###M0,S+WX>VL=C)=&=_.5=V-W>D\ :O<QRM82L2
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M7D>IZ3J_@[-X+Z22W#8\OM7I/A;6?[6TV-RN&VY- &Z_^K;Z5XSJO_(^6?\
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M#N/!D@O[9W,:]<FN\C\1C_A#8[W=^^:'</K6;\5;B+_A&I(LCS">!6$]K/\
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MN]5^\IZ*:]",:DY(IV!C H \WOO"U_-XD:[51Y>X'-7?&'A>XU*T66V&;A$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@ HH
MHH **** "BBB@ HHHH **** "BBB@!,4M%% !1110 4444 %%%% !1110 44
M44 %(:6B@!I4'J!0%QP*=10 A&>O2@*!T&*6B@ HHHH **** "BBB@ HHHH
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M1//'']Y@*9]M@_OB@"Q14:2I(,J<T\4 +1110 4444 %%%% !1110 444F:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M $/V:+^X/RI4B5/NBI:* (VB5SR,TS[-%_='Y5/10 Q(U4<"G48I: "BBB@
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M*[JU@F?)F*CFMP?#OQ.0#YLG(SUH ]Z_X2G2?^?N/_OH4?\ "4Z1_P _<?\
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M[1:/-*/O+&3^E $SZK:1MAIE!^M-_MBR_P">Z_G7S6_B?6=3U>6WA=BPD8
M^]:?D>*,=7H ^@?[8LO^>Z?G1_;%E_SW3\Z^?O(\3_[='D^*/]N@#Z!_MBR_
MY[I^=']L67_/9?SKY^\CQ1_MT>1XH_VZ /H'^V++_GLOYT?VQ9?\]E_.OG[R
M/%'^W1Y/BC_;H ^@?[8LO^>R_G1_:]E_SV7\Z^?O(\4>KT>3XI]7H ^@O[7L
MO^>Z_G1_:]E_SW7\Z^??)\4>KTGD^*/5Z /H+^U[+_GLOYT?VO9?\]U_.OGW
MR?$_J]'D^*/5Z /H+^V++_GNGYT?VQ9?\]T_.OG[R/%'^W1Y/BC_ &Z /H'^
MV++_ )[+^=']KV7_ #V7\Z^?O(\4?[='D^*/5Z /H+^U[+_GLOYTG]L67_/=
M?SKY^\GQ1ZO2>5XH]7H ^@_[7LO^>Z_G1_:]E_SV7\Z^?/+\4>KT>5XH]7H
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M7^S+7_GDOY5-O]Z7?[T 0_V9:?\ /)?RJO>Z;:?9),1+T]*OAZ@O&_T23Z4
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M_6OH4?\ (%/_ %S_ *4#/GG0?^2C2\?\O/\ A7TI&!Y2<#[HKYJT/CXC2_\
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MIXTRT_YXK^53@\U(#0!6_LRT_P">*_E6!XRTZV3PS>LL2@B,]JZG-8'C4_\
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M:_;/6M&[M2Q-4#8'/2F S[>WK1]O:E_L\^E._L\XZ4 0F_;UJY9W3.PYJO\
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MU)XP0'[_ .M-_P"$O7;]ZN+CT&]=@3FK/_"/W9&,&@#H7\8#/WOUJ6#Q.9G
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MW'A6VE;)C'Y54?P7:'_EF/RH ^>?)OE_O4G^FKW:OH!O ]H?^60J$^ K0_\
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M\@"U_P!RO$O'W_([15[;X9_Y -K_ +E S6Q28I]% AF*-M.HH ;MI=E/Q10
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ME7TK0VTFV@"DML!VJ3R!Z59VT[% $"1 5,%XHQ3J &[:;LJ2B@"/8*-E/HH
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M !1110 4444 %+24M !5>]_X])/I5BJ][_QYR?2@9\\:G_R4)OJ/YU[CJ/\
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M2?'FK#3M!D*-B3. *\>O-**6D>H2+S/SDT >S>#=4GU?P^+B8YD(KGHAKO\
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M]=J^@M4_Y%^X_P"N1_E7SUI)S\28"/\ GM7T)JG_ "+]Q_UR/\J /GWX=_\
M(]G_ *[/_,U]+5\T_#P_\5V?^NK_ ,S7TKF@ /6DHS2;A0 M%-W#UHWB@0ZE
MIFX>M*&H&+11FD)P* "EIFX4;J 'TE-WT;Z '4M1[QZTX,/6@"2FT$\5$TP
MH <:6JYN5'>D-VN.M %BBJOVQ/6D-XGK0!<&*Y_QK_R*]]_US-:8O%]:Q?&,
MH?PO?8_YYF@#RCX(_P#(Y'_KTD_FM?0U?//P0_Y'(_\ 7I)_-:^AJ "BBB@
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M*TN!<P"1>]>?>%OAG:Z.4F?YF'/(KT6*-8DVJ, 4"'4R;_4O]*DJ.;_4O]*
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M1'"I/]T5\ZZ+_P E$E_Z^:]\NH&>%<?W10)CVUA >M,;6T'>L22PE+GK4?\
M9TI[FF(VFUY!WIO]OIZUC_V5(>YIRZ.Y]: -J+6/-8!36I!.9 #6#9Z48W!Y
MXKH+>#8M !/(RKP:P;W4I(FZFN@FCRI%8]WIPFH QFUV7IDU&=:G/0FKQT12
M>E2)HJ#M0!F?VM<GN:8VI798 $UM#24':GKI29Z4 1Z=-/(!O-;L>=M06UHL
M8&!5X)@4#,V[=E!Q7/W5[=(YVDXKJIH0]9\VG*YSB@1S)U&[SU-+_:=WZFMW
M^RD_NBC^RD]* .>;4KS/4TK7MW);3!B?N'^5;XTE,_=IT^FHEE,0/X#_ "H
M\(T D_$2WW=?-KZ)U3_D7[C_ *Y'^5?/6C+M^(\ _P"FU?0VJ?\ ( N/^N1_
ME2&?/?P[_P"1[/\ UU?^9KZ2<X%?-WP\_P"1[/\ UV?^9KZ289% %*2=AWJ
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M$-6O]=%Q90,ZXZ@5S<6@^,88PBQ3A1TH ^BCJ-G_ ,_$?_?0IGV^S_Y^(_\
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M3?L\?]Q?RJ6B@"+[/%_<7\J3[/%_<'Y5-24 1_9XO[@_*C[/'_<'Y5)GFC-
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MX1[3_P#GBOY4?\(]I_\ SQ7\JU:,T 97_"/:?_SQ7\J/^$>T_P#YXK^5:M%
M&5_PCNG_ //!?RH_X1[3_P#GBOY5JTM &3_PCVG_ //%?RH_X1[3_P#GBOY5
MJXHX% &5_P (]I__ #Q7\J/^$>T__GBOY5JY%% &5_PCNG_\\5_*C_A'M/\
M^>*_E6IFES0!E?\ "/:?_P \5_*C_A'M/_YX+^5:M+0!D_\ "/:?_P \5_*C
M_A'M/_YX+^5:M% &5_PCNG_\\5_*C_A'=/\ ^>*_E6KQ10!D_P#".Z?_ ,\5
M_*E_X1[3_P#GBOY5JT<4 4+?2+2V8-'&H(]JOX&*** &&&,]5'Y4GV>/^X/R
MJ6B@"'[/'_<7\J7[/'_<7\JEI* (_L\?]Q?RI/(C_N+^52T4 1?9XO[@_*E^
MSQ?W!^524M $7V>+^XOY4?9X_P"X/RJ6B@"+[/'_ '!^5'V>/^X/RJ3/-&:
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M8HKG 8UR?CFXDG\36NF,YV-'S@_2K7BC0+>T\.6T\>0Z+G(% 'J+ZU:QZ?\
M;#(OED>M<?-\4+>.X:-;5F13@L.E>?2:W/+\.47>=WF$=?I756/AFU;P1)=-
MS(\.[- 'HVB:W!K-HL\1'/;-:M>/_"^YDCU!K,L2JYZU[!0 E+110 AJ*:9(
M(B[D!1W-35RGQ NWLO"UQ,A((':@#'U+XGP65W)!':--L."5K;\.>,+;7U&Q
M?+<_PGK7 >!](AU"VO+B<;FD4GD>U4?#.[3?B/\ 9(V/EXSB@#W2EIJ\C-.H
M **2EH 9(_EH6-<+K'Q%72KIX18R2;3@D5W,L8D0H3UKSKQ%JGAS3#<QSO\
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MSLM0F=B8@I*$GVK/TRS/BKQ=(US*XCVD<'ZT >M:7XGL=3)5)%#=AFMT>U>
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MA=&U+XA_;HQF+&,CI75ZA\+=-N;QYUW R'+8-='X<\(V6@0A8%Y'.30!T2\
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M10 4444 )12T4 )WI:** "DI:* $QFBEHH 2BEHH 2EHHH 2C%+10 E%+10
ME&*6B@ I*6B@!**6B@!" 1@CK5/^RK$W N/LR>:.C8YJ[10 @I:** "DI:*
M$HQ2T4 49=)L9ITGEMD>5#\K$<BKJK@8I:* "BBB@ HHHH *2EHH 3%%+10
M4444 %%%% "44M% "<T4M% "4M%% !1110 E&*6B@ I,4M% "48I:* $I:**
M "BBB@ HHHH 2@4M% !1110 4444 %)BEHH 2CM2T4 )2T44 %%%% "44M%
M"44M% !24M% "8]J6BB@ HHHH *2EHH 2EHHH **** "D-+10 E%+10 E'>E
MHH **** "DI:* $Q1VI:* $Q1^%+10 F*6BB@ HHHH *2EHH 2C%+10 4444
M %%%% "48I:* $HI:* $H[TM% !2=J6B@!**6B@!*,4M% "8YI.M.HH 3%+1
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>arvn-20221231_g6.jpg
<TEXT>
begin 644 arvn-20221231_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .$!+ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M28I:* "DI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BD-+0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,IC&<UT0$S<WXJ*64[:B1F(YI'!(Z5K9",R[+2'%1PVP49(K0\D Y-1L,5:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU4E3-=)%R!"0:OPGBJ"C!J]#]VADR-*&7"8JE<GJ:LPQEQ5><8R*@1ZC\+8
M"LF.2*]8KRGX7W*?+#_$!7JPKQ<3\9U0V'44E%<Z+%HI,T4 +1110 44E+0
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M.E>M%W.-E,C#59A-5G/-/B:K U(9M@J*7#$U&K<4I-381TW@C6AI&K[Y#\A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1FIA6+X>ODNK%%# E%Q6T*\V2LRQ:***0!1110 4444 %%%% !1110 4444
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ML-HZ,*VJ231*1[%;G=;H?45)45L,6T8_V:EK@+"BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %!Z44&@# \0:@;:W:-#\QK.TBV%P1+(,LW-
M5_%HD2[$ASY8'-3Z'>H8EY'2F!U<4*QJ !4@%017"N!S4ZD&D $9%59(QFKE
M-*YIW J(FUJMCI3=F#3^U#8$-S&'@<8ZBO*?$=N8;XAAZUZX1D8]:Y3Q'X=-
M^3,G4"FF!YBT0-0_9@>U:=WI\]I*RNAP.^*@51FFP*?V0>E-DLQMZ5I!122
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M.!GFM73-->3YG!H!Z["LQ !/>O6O 4>-/C?U%>736K->1Q*.M>S^$[,VNB0
MC#8YK5/0XJBLSH.U%':BF9A1110 4444 %%%% !1110 4444 %%%% !1110
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M*64$[R1Q*NX\U<MM#MK>Y\Y(P&QBM;%+0!D1Z';1W;3A!O)R35ZYMDNH?+<
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M&T=ZU;74VBL?*%BAX]*B\<Z7)J$UAJ<49*1G>PQ[5:L_$=C_ &?\]HP?'3%
M&-X;6^B\1JR1E(GDR0*]N3[H^E>3^$S=ZGJS3+&8XE?@$=J]87H!0 2?=KB]
M"_Y'"[^A_E7:2?=KC-"_Y'"[^A_E0!VM%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%)F@]* ,CQ,XCT*X9CP!7SU->C^UI"#QFO8?B#KL
M5KI$UKO&]UXYKP'S6^T,^>IK*;1WX:G):G?Z?<!P,FNCLB"17 Z3=\@$UVVF
M2AL<UD>AL==86RNFZI+FU9N%%2Z,RL M;IBC R0*T4;HXJE9QD<<VER,>AK-
MNK8PG!KN;B:&)3TKB]7NE9VV^M1-)'5AZTI/4QYF"U1)R]/FEW'K4*GFLK'8
MYFI:XP#5L28[UE1R[*?]IHV&M31+@GDU-$8RP!Q62UQQUJ$7;*^<TN:QK[)M
M&_=6*O%N45RU[$8V(Q726>H"1-C&LW5(1O+#I1)7*HMQE9F?89&0>E9VN;0&
MP1TI]_JD5C#A2-Q%<?>ZI-<NV6XJ%&Z-G4LRF''VEOK6E"PQ6'DB7/O6E;R9
MQ52B10JMNS+Y:@&HP<T\5D>BI7']:E2!WZ TMO'N85TNE:>DS -B@)5%%7.;
MDMG4=#5*0%3S7=:KIT</"@=*Y&^M]K$BFEJ9^U4EH8\XYS4MJ^.#0R$FFA"I
MJC%74KHTD?CBGEB:J1OBIP]9.)Z%.::)!5N&JBGFK*,%YI):BK321H1M@=:T
M+",R3K]:QX2TK@+79:%IK$JQ%==.)\[BZFYUVAV^R%21VK5GO?*&!3M-MMD&
M".U9^K)Y9-=])=#YVK*[&2ZJ?6LZYU LI^:LZ>;&>:I23DC&:ZXTS&XV]F#D
MYKG[M V:TIGSFLV<UTP1#,J2/!J%DJW*>:A-;HAD2P&0X S5F707, DP1FKV
ME1H\ZAO6NEU)X8-/"KBHE-IV0TCS&:TEA8@$\5&OF@]ZV9V#2,?>HMBGM6J$
M44MWD;+$XK5M8%0@XI8H,\U8"%:AV&7H7"XJZDPQ60&(J59L#K6;5RDR_=%)
M(B#BN1O8664X/>MN:YR.M9LQW-FJC$&RA';D\FKT4>P4BD 4XM5*(KBL3BJ<
MJ9-6&?BJ[ODU2B*XZ$[*U[.Z*,.:Q ]689,=Z)1N%SO-/U+"C+5N1:H,?>KS
MBWO?+X+8J[%JY+[5YKDG!%IG<3:@I'WJH/?IGK6;;V]S> $$X-7O[!N"F2:Y
MIM%@;]!_%5>354'\59][I%ZA^4FJ4>EW;MALUR2-(,UCJRYZTG]K#L:2#0)6
M + U;_L#:OW:AHZHR9)9WZRD9-;EO*..:Y=["2U;<N>*N6MZ0=I/-0S>+[G=
M65V@7!-4=:ODVX!%8HU 1IG=6+J6J%@WS4[D<B4N89J.IA,_-7.SZP2WWJR]
M4OI'D(4DUCO-)NYS18'49VMGJXX!-;L%^K*#FO+TNW0]:U[+5RH 9J3B7"L>
MCP:@R/E6J\TYN4YY-<59ZDL@'S5T=A= XYJ;&RFKW+O]EO-T6L^_T9E1@RUU
MNG7$>.:;JSQ.AP!THY%8(XB7-8\.U6$VEXX/3-5?,'8UM^+(@9R5]:Y=6;.*
MQG#4]:ABK1U+9<G@5W7@3PXUY=I<S)\GN*P_"_AJ?5KI&*$(#D\5[KHVD0Z7
M:K'&N,5M2I=6>9CL>Y)Q1H6T(@A6-1@*,"IJ04M=)X+=]0HHHH **** ,[6_
M^09)6!X2_P"/V?Z5OZW_ ,@R2L#PE_Q^S_2@#L*IWVGP7\>R9 WU%7** ,JP
MT2WL<^6HP>V*BN_#=E<ON\I0QZG%;5% &19:!9VC!A$NX=\5K!0HP.E+10 T
MKN&#TK'G\.6DURL^P!@?2MJB@#'&@6P</L&0<UIM$&BV$<8Q4F*6@#.L])@L
MKB2:-0&DZT7NC6M[S)$I;U(K1HH P8/"]E#(',:G!R.*VHX4B7:@  [5)10
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M [5'4Z)OEIGJ.@:+!IEFBJ@W8Y.*VQ38_N"G5T+8\:;;8HZTM(*,TR1:***
M"BBB@"IJ$!N+-HUZFN&@L];TZ_F:W3Y#TKT.C:/04 <3]K\1?\\Z/M?B/_GG
M7;;1Z"@ >@H XG[7XC_YY_I1]K\1_P#//]*[; ]!1@>@H XG[7XC_P">?Z4?
M:_$?_//]*[; ]!1@>@H XG[7XC_YY_I1]K\1_P#//]*[; ]!1@>@H XG[7XC
M_P">?Z4?:_$?_//]*[; ]!1@>@H XG[7XC_YY_I1]K\1_P#//]*[; ]!1@>@
MH XG[7XC_P">?Z4?:_$?_//]*[; ]!1@>@H XG[7XC_YY_I1]K\1_P#//]*[
M; ]!1@>@H XG[7XC_P">?Z4?:_$?_//]*[; ]!1@>@H XG[7XC_YY_I1]K\1
M_P#//]*[; ]!1@>@H XG[7XC_P">?Z4?:_$?_//]*[; ]!1@>@H XG[7XC_Y
MY_I1]K\1_P#//]*[; ]!1@>@H XG[7XC_P">?Z4?:_$?_//]*[; ]!1@>@H
MXG[7XC_YY_I1]K\1_P#//]*[; ]!1@>@H XG[7XC_P">?Z4?:_$?_//]*[;
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M)Z5,I#L00P^U:$-OQTJU#8D#I5V*V]JQE,I(KQ18'2K4:5.(,#I3DC(K-RT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%2MJ"Q1%!4=]J(?(4U@7-T.3FF[+848.2O(NW&JA,G-85]XC"@C=^M9FIW^
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M,4M%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7+L,9K-U8H=C1GO5'>L^2\+'BJX625\5H06:@985SSQ78I1*8>9FRM6T:9E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M34?V=KW_ #]-7?;%]!2;%]* ."_L[7O^?IJ/[.U[_GZ:N^V+Z4;%]!0!P/\
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M&BJ!P!71%'D5JCN9]IH-C9C$4(&*T50*, #%.HJ['/<,4M%% @HHHH ****
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M@"4G%9<.M6TURT*2*S*<$ ]*EU:]6RL7E8'@=J\.\,^)/+\6W@=G(>;B@#Z
M[45A7GB2TT_3EN9VP/2N>/Q)L=Q.'VCOB@#OZ*Q]&\06NL0J\#=>V>:UQ0 M
M%%% %'5_^03=?]<S_*N8^'/_ ""9O^NAKI]7_P"03<_]<S_*N7^'1_XE,W_7
M0T =K2TPL!U(%-,\8ZNOYT 2T52FU*WA!S(O'O67<>+;*WSNR?I0!T%%<>WC
M:VD.V%6S]*@DU?5[H9M!UZ9% ':M(J=35:34K6+[\RC\:XL+XHF;Y\;?I5N+
MP[=7@_TPD$^AH WI/$&GH.+A"?K67=>+1'_J(C)]*B3P'89W,SY_WJU;3PW9
MVF-JD_6@#GV\8WLK;5L9,>N#0\NIZD/DWQ9KLTM($&!$OY5,(T'1 /PH X)?
M#.LS/DWS >E:-OX5FP/M,V_US76X%+0!@Q^%M.'+P*35V+1;&#[D*K6C10!$
MD,<8PJT_'M3J* $Q2T44 )4-S"L\)1AD&IZ0CB@#Q7Q+I9TS5&F*_([9I8;R
MV:+'%>A>+]%74K!F"_,BG%>&SF>PNVADR"#6D4F!U<D44^=I JE+IV>]8J:H
M\9'S<5I6VJ+,0 >:MQ$1-I96=1US76:+HR@*Q%4;?;+@GDUU>D@!%%1)#1?M
MK!% PM:*6W' J>WC!6K\< Q61HK(QY(]HZ52D6NCEM0PK+N+)@3@5#3.BG*)
MBRY%4)I2.]7M4#VMLTF#Q7%S:VXD96XK-G9!HVI[\HA&:YV^U;;NRU0W6JHZ
MGFN6U.Z+L2#Q31%0EOM2:X8@'BF6EJ&/F/60LOS9]ZTDO@(>#TJ92L:4*2>Y
M?EG2),#BJ=MJ6RX!'/-9%W?,Y(4T6>2P)K.3TU.RE&\[(W)A]JG:4CK2B%5'
M HB/RBK2Q[ES7-*3/=I4(I;%7;STHVBIF7!J,U-SKC"*$IK\BG44#:NBNR9-
M1M%Q5T)D5'(N!5)G/4I*US(N$ YJKYNT\&K=[W K*;(KH@KH\3$U'3EH7EO,
M=Z4WI/ -9H5F; K1M;(DY-.45$BC5JU79$D4#W+<]#74:38K"!QR:S[. *1Q
M75Z3:&5EP.E9\U]$=;HVUD6X+<E,@4\J5-:\L*6T6.^*RY6!8XIM6W(B[[%=
MJ;@XJ4+DU(L7'2A!+8J!V2A[G<F":N&VW+TJA<V<BJ2!6T3S*Z.D\"ZB/[4>
M)CP!7J*G*@^M> ^';U[/7.3C+8KWFU;?;1MZJ*WBSR*T;.Y+WI:**LQ"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJ7_(/G
M_P!VN3\,?\A&NLU+_D'S_P"[7)^&/^0C0!VU>7_&'?\ V+;8SCSQ_,5ZC7,>
M-M#_ +<T<0@99"6% "^"_*_L*W\O&?+&<5F^*/$&I:;(1:V;RX/85RWA?Q0_
MAR62ROT? ;:IP>E==/XSTIHO,=-W&>5H XR#Q]>?VW!;WFGE';NPJS\19OM4
M6DR$?>EZ5C:A>KXC\7VTUE RQJ<'Y<5K^/H'2WTA"I)$O.* +'B;PV9-'BU.
MU7$\:#&WK3+'Q(+SPQ<6,[8FBA(.>O2O1=.@2?1XHY%!4H.#]*\6\?Z)=Z%<
M37%H&V3$YQZ4 =3\+3G17/\ M&N#=[M/%U\;4,3YW:NX^$NX^'\NI!.>M9/A
MR'/C2^+)D>?W% %]+KQ!\O[N;M7:Z#=WD&G337:ME5R U=(D,>Q?W:]/2DEM
MHYH6B*@*PYQ0!R#^.@DNSRN]='I>HKJ<'F%0*HMX0TYGW%>>M4?$-_!X6T:;
MR =V.* +'B/Q/;:1:M&C*93D!<]*X;P[HMYK_B&+6+L,JQM\H;N*P=(U*'6K
M\WNI[C&<%17J&E^)M+CV6T"X/3I0!U<48CC"J.!7-^//^1:FKHX91-&'7H:Y
MSQYD^&YL#)H XSX>^&K:=YIKF-9 W(![4GCW28M%9;^S01$,!A:B\"^)X[*2
M6*X5@!P.*/&&LCQ%<KIULC')#9Q0 GB"Y>ZTS29&)W%03^5.\5C/P\0#NPIW
MB2R>UT[2HBIW* #^5.\4*Q\ 1@*<[QQB@#1\!>&[673 ]U$LNX9&ZN=U>S32
M/&4LEJ/+7@8'U->A^"5(T:'(Q\@KBO%4;/XI?Y3@D=O>@"EK]U+JGB;2K,N?
M+D'S#UKOYO"6FIHDB_9H]XC/S8]JX/Q%93:9K>EZD%)CB7<V!782>.+-]&=L
M-N,9&,>U '!>"K$V7B!XP?\ EHV/SHOUN=,\8WUQ>6IGMW?Y0W04O@F[>\U]
MI0K#]X2,CWK<N]9AD\075KJ<1,0;"G;0!"T^AZJ%5?*M)>,$5Z;HJ)%I<*))
MYBA>&SUKQOQ99:5':&735D^TDC;BO3? _P!I_L"V^T9SL[T =#=P1SV[I(H9
M<=Z\6\(6%K)XPU#="IVS\5[;+_JF^E>*:!=#3/%]]YRD;YC@XH G\0.^H^-3
MHX8B%5#;:] A\):8VE+&;:/>5QNQ7 >(XGT_Q3_;JHQC8!>!791>.+-=)63#
M;@G3% '&:%<RZ1\0)[!'/DKP%[5[)$=T2MZC->.>'+2;6?'$VIA&$3="17L<
M:[8U7T&* 'TM%% %'6.-(NC_ -,V_E7F?A#7[NRL9HH;5I/G/(%>F:Q_R";K
M_KFW\JY'X=VT3Z;,[*"?,/:@!LFM:K=';]D=,]Q4?]C:K?\ )NI(LUWHAC_N
M+^5/V*.@ _"@#AX?!EZ"#)?R,/0FMNV\-6Z(!,HD/O6]2T 9B:#IR8Q:H"/:
MKD=G!%]R-14U+0 @4#H*,4M% "48I:* "BBB@ HHHH **** "BBB@ HHHH *
M*** &/&'0J>0>M>1?$'PPZS->VZ<>@%>P54O;**]@:*505/M3B[ ?+TF5.UL
M@CK2V5P8Y^M>LZW\-O.=WME )YKD+GX=:I;$OCA>>*VYQ&CHX,H4UV^F1@!:
M\ZTNZDL)?)F!!4XYKNM.U!61<&LY,:W.KAD"@<UH13*1UKFTN^.M3B\('!K%
MNQT1I\R.A\U?6FDH?2N:?4F4_>J!M7<?Q4G-&L<++H;NHV]O/;LC <UYKJWA
MZ,S,R-CFNCGU9F!RU8]S>;@>:RE-';0PTEN<3J.FM;H6R3BN6O6Y-=YJDHDC
M8&N O^)&'O24BJM%HS]Y!I?.*H1FHF/-1L:=KF49RCH/7YGS6G9K\U4($)K7
MMH\8K*HSU,#3>[-!. *LI*0N*KK]VG5RL^BBM"1VW5&:*3-)%A2BDJ:.$OT%
M-BO;<0-@56E)(-69(F3J*@9<T(F6JT,R9,GFJ,T8[5JW"8-4)5K>+/'Q%)-Z
MC+2$;N1WK8BC & *SK7AJU(SQ2FV:86DDBY:)EQ7<Z5&+>VWD<D5P]K((Y 3
M76V>H));A,]JF!MB8MK0=>7K.YYJFLP=@":KZC,8F/-9'VUUD# T.6I-.A>-
MSLHK5RH8 XJPD6#@UFZ7K0-N%<Y-7%O0[9K1,XZL91>IH1PJ>,42VBLN,4R&
MX7CFIWN4"=:WBCS*SL<A/9&/6(V3C]X/YU[C8C%E#_N#^5><Z3I@U'4]S#(!
MR*]+B39"J^@Q6\4>37E=V'TM)WI:HYPHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH J:E_R#Y_]VN3\,?\A 5UFI?\@^?_ ':Y
M/PQ_R$* .W%(P!&#TI:* ,#4_"]CJ!+&) Q[XK(_X0&#?DR97T-=K1B@#%TW
MPW8Z>,I"FX=\4NKZ##JK0F0#]VV16SBC% $5O"(85C'11BJ.K:-;ZM"8IE4Y
M]16GBC% &)HGAZ#1K8PPXVY[5#:^%[>UU"2Z7&YVW&NA HH 0=,>E.I*,T !
MK%US0(M:C*2G@C%;5% '!1_#>VB7:DH4#H!5JT\"16MRLHF)(KLZ,4 16\7D
M0K&.U0:E8IJ%HT#_ '35VDH Y*3P/:%?DPA]0.M6=+\)6EA+YI57<?Q$5TE)
M0!DZIHD.I-'O ^3I45WX=AN],6R?&T'-;E% %/3K!+"!8DZ 8K/O/#L%W>FY
M;&XFMS%!H S;S2+>]M!!(BMA<9(KG_\ A [?>?G^4_PUV5% '-Z9X2M=,F$D
M04$'L*DU7PM::DV_:JN3RV*Z#%% '(VG@>V@E#2L) .QKJ+>".VB6.-0%7@
M5/BDQ0 A&1BN9O?!]M=7HN!A&W9R!UKI\44 9$NA6\]B+:9%?'<BL3_A!+?S
M,[_D_NUV5'>@#/TW2;?38@D4:@CN!6@**6@ HHHH I:O_P @FZ_ZYG^5<O\
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M %S/\JYCX<_\@F;_ *Z&@#M**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %34O\ D'S_ .[7)^&/^0C76:E_R#Y_]VN2\,?\A&@#MZIZAIL&
MHP>5.@*U<S10!RL7@33HIO,&[KG&:N+X4L5D#JF&'.<5O44 8]QX>M+B_ANW
M7]Y$,"M1X5>!HB/E(Q4E% &59:#;64WFQ##9S6K110!FZGHMMJD92= <]ZR+
M;P-IUM*)%W'!S@FNIHH PXO"]E!J)O8TVR%=O%2?\([:?:UN,?.IR*V** ,F
MXT"UN+GSW'S5:N=.@NK;R9$!7&!D5<HH Y,^ ].,WF?-UZ9K?L=,@L(O+A0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""ZB\ZV>/\
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M3QA/"T3E-KC!YKH/!VCW&CZ88;G&\G/%=+28H 6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"*Y'QIX<76-/
M;8N7&3FNN[TUE# J1D&@:T/D[6M.FTV[:.12,' J"U!8YKVGXE>&+:2PEOE
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5)2>A(.I%. Q115"8M%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>arvn-20221231_g7.jpg
<TEXT>
begin 644 arvn-20221231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *V!.\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY$(3"$X KF9_']^;MK:WM?,DW8 %:'@O_D66_P"N9_E6'X9M8Y/$GF,,L)*
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ML/6$$/C"TV#&9.<4 3?%34]2BM##' WD \.*D\%:YK4D5O$]D_E8 WFM?XH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_(&3_=%=9WIS^(F.P4445 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\QCU8TVBES,=D+G/>DHHI7&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5FP_X_8O\
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M (0/4O[C?]\U]5_8K7_G@GY4?8K7_G@GY4<T>P>]W/E3_A ]2_N-_P!\T?\
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M4]+_ ,_TO_?1H_X4]+_S_2_F:!G=_P#"QM*_O#\Z/^%C:5_>'YUPG_"GI?\
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M_,T =W_PL;2O[P_.C_A8VE?WA^=<)_PIZ7_G^E_,T?\ "GI?^?Z7\S0!W?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "T444 %><_%/_D%1_6O1J\Y^*?_ ""8_K0!5^%/.E3?[U=3K<1:%L>E<O\
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M>*P^*IPO):I8?%TSRA<MS0![1%?AVX-:]NVY<UYWX=O)+K:S9YKT&S_U0^E
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M)#D&N_\ $U^NG:-++G&VLOP-9B'2(9BN&=<FN<^*&LB.V>Q5OF?G% 'E\.O
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M* &;11L%/Q1B@ 48IU)BB@ Q1M%+10 W%&*6EH 3%-(I])B@!NT4!13L4N*
M#%%%% !1110 4444 %)2T4 )2T44 %%%% !1110 4444 %%%% !1110 4PBG
MTE #<48I]% #,4&GTF* &4HIV*,4  I:** &&HR*FQ3=M $(4YJ0#BG[:,4
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M*$J@^E2+\--6)PSS8^M>]8%&!Z"@#R?0OA>L%PDUTSL5.?FKT^SM([.!8XU
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M ,\9O^^30![7BC%>*?\ "V7_ .>,W_?)I/\ A;+_ //&;_ODT >V4WO7BO\
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M^%LO_P \9O\ ODTG_"V7_P">,W_?)H ]JQ2UXI_PME_^>,W_ 'R:/^%L2?\
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M/^%LO_SQF_[Y- 'ME%>)_P#"V7_YXS?]\FC_ (6R_P#SQF_[Y- 'ME%>)_\
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MC-_WR:/^%LO_ ,\9O^^30![92$5XI_PME_\ GC-_WR:/^%LO_P \9O\ ODT
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M .^:\T_X6G?^DOY&C_A:=_Z2_D: /2_^$%T[_GE'_P!\T?\ ""Z=_P \H_\
MOFO-/^%J7_I+^5'_  M._P#27\C0!Z7_ ,(+IW_/*/\ [YH_X073O^>4?_?-
M>:?\+4O_ $E_(T?\+4O_ $E_(T >E_\ ""Z=_P \H_\ OFC_ (073O\ GE'_
M -\UYI_PM2_])?R-'_"U+_TE_(T >E_\(+IW_/*/_OFC_A!=._YY1_\ ?->:
M?\+4O_27\C1_PM2_])?R- 'I?_""Z=_SRC_[YH_X073O^>4?_?->:?\ "U+_
M -)?R-'_  M2_P#27\C0!Z7_ ,(+IW_/*/\ [YH_X073O^>4?_?->:?\+4O_
M $E_(T?\+4O_ $E_(T >E_\ ""Z=_P \H_\ OFC_ (073O\ GE'_ -\UYI_P
MM2_])?RH_P"%J7_I+^1H ]+_ .$%T[_GE'_WS1_P@NG?\\H_^^:\T_X6I?\
MI+^1H_X6I?\ I+^1H ]+_P"$%T[_ )Y1_P#?-'_""Z=_SRC_ .^:\T_X6I?^
MDOY&C_A:E_Z2_D: /2_^$%T[_GE'_P!\T?\ ""Z=_P \H_\ OFO-/^%J7_I+
M^1H_X6I?^DOY&@#TO_A!=._YY1_]\T?\(+IW_/*/_OFO-/\ A:E_Z2_D:/\
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MC_[YKS3_ (6G?^DOY4?\+4O_ $E_(T >E_\ ""Z=_P \H_\ OFC_ (073O\
MGE'_ -\UYI_PM2_])?R-'_"U+_TE_(T >E_\(+IW_/*/_OFC_A!=._YY1_\
M?->:?\+4O_27\C1_PM2_])?R- 'I?_""Z=_SRC_[YH_X073O^>4?_?->:?\
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M(T?\+3O_ $E_*@#TO_A!=._YY1_]\T?\(+IW_/*/_OFO-/\ A:E_Z2_D:/\
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M ,(+IW_/*/\ [YH_X073O^>4?_?->:?\+3O_ $E_(T?\+3O_ $E_(T >E_\
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MG?\ /*/_ +YKS3_A:E__ --?R-'_  M2_P#27\J /2_^$%T[_GE'_P!\T?\
M"#:=_P \H_\ OFO-/^%J7_I+^1H_X6I?]<2_D: /5K'PK96,@>.- 0<\+6^!
M@8KR;PQ\2SJ=\MO*S%BV,&O5T;<BMZB@!]%%% !1110 4444 %%%% !1110
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M</">E_\ /K%_WR*W*=VH P/^$3TO_GUB_P"^11_PB>E_\^L7_?(K>HH Y_\
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M_A$M,_Y](O\ OD5OTM '/_\ "):9_P ^D7_?(H_X1+3/^?6+_OD5OTM '/\
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MQ1F@#G_^$2TS_GUB_P"^11_PB6F?\^L7_?(K?HH Y_\ X1+3/^?2+_OD4?\
M"):9_P ^L7_?(KH*0T 8'_")Z7_SZQ?]\B@>$M,_Y]8O^^16]2B@#"_X1+2_
M^?6+_OD5%/X3TP0.?LL73^Z*Z.HKG_CWD_W: /G;2;5+7QRZ(  )\ "OHN#_
M %"?[HKY[L_^1\?_ *[U]"6_^H3_ '10!+1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G/Q3_
M .05'_O5Z-7G/Q3_ .05'_O4 0?";_D&3?[U>EUYI\)O^07-_O5Z70 444F:
M "EIN:6@!:*** "DHS10 44"G4 -I:*;F@!U)32U&Z@!U%-+"@'- #J6DHH
M6BBDS0 M)32PI-XH DHIF\4;Q0 ^C--W"DS0 ^BD!I: "DHI,T +2TE% "YH
MI** %I13:* '9IM+10 E+249H 6BDS10 M)110 4M%% !129HH 6BDS1F@!:
M2ES24 %**2B@!:*** %I*2EH **** "BDS10 M%)3L4  HS244 +1FDS10 4
M4M% "T4W-+F@ I:2EH *0T9I* %S244N*  =*#12T -I:6DH **** #%%%%
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M*0X$GZTP/2/MJ^M.%ZO]ZN"7Q K+D/5:?Q5'#U>@1Z2+Q?[PIPNU/\0KRO\
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MVG4TT )FBEQ2XH ;24^DQ0 @IXI *44 '>EHI#0 4444 +2 T44 +FD-%+0
ME+Q1BB@ HS1BDH **6B@ I*6B@ HI*6@!:3-%&* $HI:2@!*444O:@!#12TE
M !112&@".0Y4UA:E&60XK>852N(-X/% 'FFJ6,KNV,USTND3LW0UZO+I:NQR
MM1?V,F?NTQ'F$.B3 \@UK6^E.!R*[Q='0?P_I4@TI1_#0!PKZ0Q'2H5T)BWW
M:]"_LU?2GIIRCM0!RFGZ*(R"5KJ;*U$:C JW'9A>U64BV]J )8EP*G'2HT'%
M2 4ABU%<?\>\G^[4M17/_'N_^Z: /GVR_P"1\D_Z^*^A+?\ U"?[HKY[LO\
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MH Y#PCX431;-I& \UU^8UQWB3PY=7/C*&Z1&V*".GTKV4  8 IAAC9MQ12:
M*&B0M!IT2,,$"M.D"@#BEH **** "BBB@ HHHH **** "BBB@ KSGXI_\@J/
M_>KT:O.?BG_R"H_]Z@"#X3?\@R;_ 'J],KS/X3?\@R;_ 'J],H *2BB@!*6D
M- H 6DI:2@ HHI: $I:** $I:2EH *2EI* "BEI* %HI** %I*,T4 %%+10
MF!1110 "EHI* "D/2EHH C YJ048HH 6DHHH 6DHI: $I:** "FTM)0 48I<
M44 )2T44 +24"EH *2EHH 0=:6DHH 6BBB@!**6B@ HI*6@ HI*6@!****
M"C%+24 &**6B@ I:;2T %%%% !2TE% !2=Z6B@ %+24M "TE&:,T %%%&*
M4M)10 4444 %+12&@!:*;2T &*,T44 %%%% "TE+24 +2444 %%%% !1110
MM(:6DH 2EHQ2T -H%+BC% !0:*6@!M+10* $HI33: "BBB@ I:2B@!:2EI#0
M M%(*6@!:2BDH 6EIM+0 &H;G_CW?_=-35#<_P#'N_\ NF@#Y^LO^1\D_P"O
MBOH2W_U"?[HKY[LO^1\D_P"N]?0EO_J$_P!T4 2T444 %%%% !1110 4444
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MU]"6_P#J$_W17SW9?\CY)_UWKZ$M_P#4)_NB@"6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M.?BF"=)0@9P:]&K(US0XM9MO)D.!0!XWX"\:VFB6DL,X.[=7:_\ "T],]&_.
MJ;_!ZT:1F%RPR<X%)_PIZV_Y^W_.@"[_ ,+3TST;\Z/^%IZ9Z-^=4O\ A3MM
M_P _;_G1_P *=MO^?M_SH N_\+3TST;\Z/\ A:>F>C?G5+_A3MM_S]O^='_"
MG;;_ )^W_.@"Y_PM/3/1OSI?^%IZ9Z'\ZI?\*=MO^?M_SH_X4[;?\_;_ )T
M7/\ A:FF>A_.E_X6IIGHWYU2_P"%.VW_ #]/^='_  IVV_Y^W_.@"[_PM/3/
M1OSH_P"%J:9Z-^=4O^%.VW_/V_YT?\*=MO\ G[?\Z +O_"T],]&_.C_A:>E^
MC?G5+_A3MM_S]O\ G1_PIVV_Y^W_ #H N_\ "T]+]&_.C_A:>F>C?G5+_A3M
MM_S]O^='_"G;;_G[?\Z +G_"T],]&_.C_A:>F>A_.J?_  IVV_Y^G_.C_A3M
MM_S]/^= %S_A:>F>C?G2_P#"T],]&_.J7_"G;;_G[?\ .C_A3MM_S]O^= %W
M_A:>F>C?G2?\+3TST;\ZI?\ "G;;_G[?\Z7_ (4[;?\ /V_YT 7/^%IZ9Z'\
MZ/\ A:>F>A_.J?\ PIVV_P"?M_SH_P"%.VW_ #]O^= %S_A:FF>A_.C_ (6G
MIGHWYU3_ .%.VW_/V_YT?\*=MO\ G[?\Z +O_"T],]#^='_"T],]&_.J7_"G
M;;_G[?\ .C_A3MM_S]O^= %W_A:>F>C?G1_PM/3/1OSJE_PIVV_Y^W_.C_A3
MMM_S]O\ G0!=_P"%IZ9Z-^=-_P"%IZ9Z'\ZJ?\*=MO\ G[?\Z/\ A3MM_P _
M;_G0!<_X6GIGHWYT?\+3TST/YU3_ .%.VW_/V_YT?\*=MO\ GZ?\Z +O_"U-
M,]#^='_"U-,]&_.J7_"G;;_GZ?\ .C_A3MM_S]O^= %[_A:FF>A_.D_X6GIG
MHWYU2_X4[;?\_;_G1_PIVV_Y^W_.@"X?BGIGHWYTG_"U-,]&_.JG_"G;;_GZ
M?\Z/^%.VW_/T_P"= %S_ (6GIGH?SI?^%J:9Z-^=4O\ A3MM_P _3_G1_P *
M=MO^?I_SH N?\+3TST/YT?\ "T],]#^=4_\ A3MM_P _3_G1_P *=MO^?M_S
MH N?\+3TST;\Z4?%33/1OSJC_P *=MO^?M_SI?\ A3MM_P _;_G0!=_X6II?
MHWYTO_"U-+]&JC_PIVV_Y^W_ #H_X4[;?\_;_G0!>_X6IIGHWYTG_"T],]&_
M.J7_  IVV_Y^W_.C_A3MM_S]O^= %W_A:>F>C?G1_P +3TST/YU2_P"%.VW_
M #]O^='_  IVV_Y^W_.@"[_PM/3/1OSH_P"%IZ9Z'\ZI?\*=MO\ G[?\Z/\
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MG;?_ )^W_.C_ (4[;?\ /V_YT 7O^%J:9Z-^=+_PM33/0_G5#_A3MM_S]O\
MG1_PIVV_Y^W_ #H O_\ "U-+]#^='_"U-,]#^=4/^%.VW_/V_P"='_"G;;_G
M[?\ .@"__P +4TST/YTG_"U-+]#^=4?^%.VW_/V_YTG_  IVV_Y^W_.@#0_X
M6II?HWYT?\+4TST/YU0_X4[;?\_;_G1_PIVV_P"?M_SH O\ _"U-,]#^=)_P
MM/3/0_G5'_A3MM_S]O\ G1_PIVV_Y^W_ #H O_\ "U-,]#^='_"U-,]#^=4/
M^%.VW_/V_P"='_"G;;_G[?\ .@"__P +4TST/YTG_"U-+]#^=4?^%.VW_/V_
MYT?\*=MO^?M_SH O_P#"U-+]#^='_"U-,]&_.J'_  IZV_Y^W_.C_A3MM_S]
MO^= %_\ X6IIGHWYTG_"T],]&_.J/_"G;;_G[?\ .C_A3MM_S]O^= %__A:F
ME^A_.C_A:FE^A_.J'_"G;;_G[?\ .C_A3MM_S]O^= %[_A:FF>A_.C_A:FF>
MC?G5'_A3MM_S]O\ G1_PIZV_Y^W_ #H O?\ "U-,]&_.C_A:FE^C?G5'_A3U
MM_S]O^='_"G;;_G[?\Z +W_"U-,]&_.D_P"%J:9Z-^=4O^%.VW_/V_YT?\*=
MMO\ G[?\Z +O_"T],]&_.D_X6GIGHWYU3_X4[;?\_;_G1_PIVV_Y^G_.@"Z/
MBGIGHWYT?\+3TST;\ZI?\*=MO^?I_P Z/^%.VW_/V_YT 7O^%J:9Z-^=)_PM
M/3/0_G5+_A3MM_S]O^='_"G;;_G[?\Z +W_"U-,]#^=-/Q3TST;\ZI_\*=MO
M^?M_SH_X4[;?\_;_ )T 6C\4]-]#^=*/BGIOHWYU4_X4[;?\_3_G1_PIVV_Y
M^G_.@"Z/BGIGHWYTR;XI:8T+* W(]:J_\*=MO^?M_P Z/^%.VW>[?\Z //=
MO!J'C,SQJ=K39%?2$'^H3_=%<-H7PUM-%N1,LFY@<\UW:+M4#T% #Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *R-;UR#1K;SI\XK7KSGXIDC24 )&30!"WQ;TH,5PYP>QI/^
M%N:5_=D_.N1\"^"(=<M)9I).=U=E_P *IM/^>@_*@"/_ (6YI?\ =D_.C_A;
MFE_W9/SJ3_A5-I_ST'Y4?\*IM/\ GH/RH C_ .%N:7_=D_.C_A;FE_W9/SJ3
M_A5-I_ST'Y4?\*IM/^>@_*@"/_A;FE_W9/SH_P"%N:7_ '9/SJ3_ (53:?\
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M_=D_.I/^%4VG_/0?E1_PJFT_YZ#\J (_^%N:7_=D_.C_ (6YI?\ =D_.I/\
MA5-I_P ]!^5'_"J;3_GH/RH C_X6YI?]V3\Z/^%N:7_=D_.I/^%4VG_/0?E1
M_P *IM/^>@_*@"/_ (6YI?\ =D_.C_A;FE_W9/SJ3_A5-I_ST'Y4?\*IM/\
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M#\J (_\ A;FE_P!V3\Z/^%N:7_=D_.I/^%4VG_/0?E1_PJFT_P">@_*@"/\
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M .M5S<#=UH N@TZJ\<FX5+F@!]%-W4;AZT .I*;FC=0 ^BFYHS0 ZBF[J7-
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MZ@T 7J*1F"KD]!6/<^)=/MKCR9+F-6]": -BEJ"VN8[J)9(V#*WI4K,$4DG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M Z0T"HS+S]*]@MX\0@>U,1QOC&Y:&TD(/8U\]:KJ$EQ=O\QX)KZ'\:6QDLI
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M;-@.E '00'Y14]00?=J:D,=1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )2$\4ZF
M/]TT 9.H3;5-<AJ&I>6S#-=#K#E48UY9XCU,P,QS3$;3ZR ?O5 ^N*#]^O,Y
MO$C;R,FJ,OB"1FX8T#L>OP:V&/WJNC5AMSNKQZPUV1G +&MXZLYAR">E CM[
MC750??K#OO$BA3\]>?ZEK<^_:'85CO?W$AY<T#L>FZ;K)NKH -GFO4="RT:D
MUX;X-CDEN03D\U[SH,>V%<T".EMQA14MQ_Q[R?[M-BZ4ZX_X]I/]VD,^?;/_
M )'Q_P#KO7T';_ZA/]T5\^6?_(^/_P!=Z^@[?_4)_NB@"2O.?BR,^'2/5Q7H
MW>O.?BR=OATGT<4 1_#+0X(+#SM@+.N>E==XCTZ"ZTQT9%Z>E<;\,]>MY;'R
M7D52JXY-=3XHUNUM-*D83(3CH&H \O\  NZQ\274:GY=^*]AO;6UU"+RI@#D
M=Q7CW@2WGO=;O+@ [2V0<5;\4ZYJFB^(]YDD^SC'':F!OZO\,+2\+/$S*3R,
M5R.H> -5TP%[/S6QSUKU3P]XHL]0L(BT\8?;SEJU;G4;!869YXB,?WA2 \6\
M.^,-2T?44L[_ "OS;>37M^G7:WMJLJ'((%>#>+9K74O$4"V,8+++\S+7M'A6
M&2#2$63.<#K0!?U7_D%7/^X:\)T/_D>X_J?YU[MJW_(*N?\ <->$Z)_R/<?U
M/\Z /?+/_CV3Z4Z>411,YZ"F6G_'LGTKGO&VJ?V=HLKAMI />@#QKQGXACN?
M$ACF?]W%+7<Z1\0O#UEIJP?:4!VX(S[5P'A[PK+XIU>XGDY5FSDUW2_".':/
ME3]* //?$.O6$FO1W=A*&+29;%>Z^#-775-(1]V2 !7F'B3X7FPLVGA"@H,\
M59^%FLM;/]@F;YM_ - 'MM<!\5O^11N_]VN^5LC-<#\5O^11NO\ =H P/@_]
MP_[M>N]J\B^#WW#_ +M>NGI0!R7BOPC!XB1$FSA3GBF:+X#L-,AVA ?J*S?&
M'BZ70[F,;7VE\' -='H'B.UU6R$OFH#CH30!RGCCPA:_86N(AM91GBL/X7:U
M*97M'8D"0CFNP\<Z[:P:6T0D5F8$8!KBOA=I,IN9+H@A?,)Y% 'M8Z4M(.E+
M0 4444 %><_%/_D%1_[U>C5YS\4_^05'_O4 0_";_D%R_P"]7IE>9_";_D%R
M_P"]7IE !36&:=24 1[!Z4>6/2I,48H C"#TI=@I^*,4 1^6/2D\H#M4N**
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MVJ*&W"=JM@=J0SGM<LA/$RXZUY9J_@U+F9CMZU[9<0AQTK*ETU6)^6@#Q1/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:W0TII&Z4
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MHH **** "BBB@ HHHH **** "DI:* $I:** $-&*6B@ HHHH **** "BBB@
MI*6B@!**6B@ HHHH **** $-%+10 E)3J* $Q1BEHH 2BEHH 0BDQ3J* &XI
M<4M% #2M)LI])B@! M+BEHH :5S3"@J6D- $/EBEV"I,4H% $!B%,:W![5:I
M,4 4OLXSTJ:*+;4^VE H 0"D*YI]% $'E"E\H5+BEH C$8%!C%/-% $!B% B
M&:GQ1B@!H3%.Q2T4 ,*TWRQ4M)B@"/8*78*?BB@"(Q TGDBIJ,4 0^4*>$Q3
M\4M ""EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*,9I:* *\L6\5FS6(;
MM6SBF,@- &#_ &:I_A%.&G*/X:VM@]*/+% &2M@O]VIOL2XZ5H^6!2[: ,MK
M$'M3?[/4=JUMM)MH HQVP7M5Q$P*=MIX%  !3+G_ (]Y/]TU+45S_P >\G^Z
M: /GRS_Y'Q_^N]?0=O\ ZA/]T5\^6?\ R/C_ /7>OH.W_P!0G^Z* ):@N+6*
MY39*BLOH1FIZ* ((+:*W7;&BJ/85/110 E%+10 4444 %%%% !1110 4444
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M-]+_ +__ (]0!TU%<S_PF^E_W_\ QZC_ (3?2_[_ /X]0!TU%<S_ ,)OI?\
M?_\ 'J/^$WTO^_\ ^/4 =-17,_\ ";Z7_?\ _'J/^$WTO^__ ./4 =-17,_\
M)OI?]_\ \>H_X3?2_P"__P"/4 =-17,_\)OI?]__ ,>H_P"$WTO^_P#^/4 =
M-17,_P#";Z7_ '__ !ZC_A-]+_O_ /CU '345S/_  F^E_W_ /QZC_A-]+_O
M_P#CU '345S/_";Z7_?_ /'J/^$WTO\ O_\ CU '345S/_";Z7_?_P#'J/\
MA-]+_O\ _CU '345S/\ PF^E_P!__P >H_X3?2_[_P#X]0!TU%<S_P )OI?]
M_P#\>H_X3?2_[_\ X]0!TU%<S_PF^E_W_P#QZC_A-]+_ +__ (]0!TU%<S_P
MF^E_W_\ QZC_ (3?2_[_ /X]0!TU%<S_ ,)OI?\ ?_\ 'J/^$WTO^_\ ^/4
M=-17,_\ ";Z7_?\ _'J/^$WTO^__ ./4 =-17,_\)OI?]_\ \>H_X3?2_P"_
M_P"/4 =-17,_\)OI?]__ ,>H_P"$WTO^_P#^/4 =-2$5S7_";Z7_ '__ !ZE
M_P"$WTO^_P#^/"@#H\45S?\ PF^E?W__ !ZC_A-]*_O_ /CPH Z2BN;_ .$W
MTK^__P"/4?\ ";Z7_?\ _'A0!TE&*YO_ (3?2O[_ /X\*/\ A-]*_O\ _CU
M'2TM<Q_PF^E?W_\ QZE_X3?2_P"__P"/4 =-45S_ ,>\G^Z:Y[_A-]*_O_\
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M^%6ZE_T$)J]&_P"%AZ)_>H_X6'HG]Z@#SG_A5FI?]!":C_A5FI?]!":O1O\
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ME_T$)J/^%6:E_P!!":O1O^%AZ)_>H_X6'HG]Z@#SG_A5NI?]!":C_A5NI?\
M00FKT;_A8>B?WJ/^%AZ)_>H \Y_X59J7_00FH_X59J7_ $$)J]&_X6'HG]ZC
M_A8>B?WJ /.?^%6:E_T$)J/^%6:E_P!!":O1O^%AZ)_>H_X6'HG]Z@#SG_A5
MFI?]!":C_A5FI?\ 00FKT;_A8>B?WJ/^%AZ)_>H \Y_X59J7_00FH_X5;J7_
M $$)J]&_X6'HG]ZC_A8>B?WJ /.O^%6ZE_T$)J3_ (5;J7_00FKT;_A8>B?W
MJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ
M/.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!
M":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_0
M0FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?W
MJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ
M/.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!
M":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_0
M0FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?W
MJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ
M/.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!
M":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_0
M0FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?W
MJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ
M/.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!
M":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6:E_P!!":C_ (5;J7_0
M0FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":E_X5;J7_00FKT7_A8>B?WJ
M/^%AZ)_>H \Y_P"%6:E_T$)J/^%6:E_T$)J]&_X6'HG]ZC_A8>B?WJ /.?\
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M/W?_ $$3^M'_  I^[_Z")_6O; !Z4A^@H \3_P"%/W?_ $$3^M+_ ,*?N_\
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MO_H(G]:]LP/2CCTH \3_ .%07?\ T$3^M'_"H+O_ *")_6O;,#THP* /$_\
MA4%W_P!!$_K1_P *@N_^@B?UKVS HP* /$_^%07?_01/ZT?\*@N_^@B?UKVS
M ]*,#TH \3_X4_=_]!$_K1_PI^[_ .@B?UKVS ]*,#TH \2_X4_=_P#01/ZT
M?\*?N_\ H(G]:]LP/2CCTH \4_X4_=_]!$_K1_PI^[_Z")_6O;,#THP/2@#Q
M/_A3]W_T$3^M'_"G[O\ Z")_6O;,#THP/2@#Q/\ X4_=_P#01/ZT?\*?N_\
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M/_A3]W_T$3^M'_"G[O\ Z")_6O;,#THP/2@#Q/\ X4_=_P#01/ZT?\*?N_\
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M"+B4?QFNA\1Z!<6EZVU#@FL VDH/*F@8GVF;^^:EBU*ZA(*2D5&+24]%-/\
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MWJ -#-*&K/%\A[T[[:@'6@"_D4FZLY]13'#4Z&Z#GK0!H9I:@\S IOVA<]:
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MOY4H\-09_P!6/RH \F\+^%7@G1W3GZ5[#HUH88U&.U/@T:.$\*/RK8MX!&,
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M $,-O';J%C7 %.DB25=K#(-244 5X;.& EHT )J<4M% !1110 4444 %%%%
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M5']MM_\ GH*/MMO_ ,]!0!+L%*!4/VVW_P">@I?MMO\ \]!0!/1@&H/MMO\
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MLO\ GV3\J /GW[5XT_YZ_P#CIH^U>-/^>O\ XZ:^@O[,LO\ GV3\J/[,LO\
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M[,LO^?9/RH ^??M7C3_GK_XZ:/M7C3_GJ/\ ODU] _V99?\ /LGY4?V99?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>arvn-20221231_g8.jpg
<TEXT>
begin 644 arvn-20221231_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWXH^*7C#]G70M2^,%C=67B]YIUW7]L+:YGMP_P"ZDEA"KL8C(P5!(56/WLT
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M8I;.R\@X^4[KVW\O ^I7%>(?\$ZX;F/_ ()J^.&G_P!5(NO-;_\ 7/[-@_\
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M:#_9+_:L\/\ PS^.^O3>(=#UZ>WAEDOIEN%CCN)"D=W;SX#;%DR&4\81AM!
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M%Q$D5ROE3+#/;S;0 S*TB$'&?E?)/&-[_@C!_P FH:W_ -C;>?\ I+:5\_\
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MN2#@9YX]!7TY^S+_ ,FV_"C_ +%+2?\ TCBKXK_X+<?\D7^'G_8P2?\ I,]
M'@<OC7]N+X@_ ]/CA:^,+RT\):=:&=;>QEBMYIK>!?+ENC;A,2*2CNQ8\_,R
MKMQC[\_X)Z?M47_[57P+_M?Q (%\7:+>-IFJ&W0(LY"J\<X0<+O5L$#C<CX
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MS-\-?VDO$'Q%MOB-X;_X2*'2;6RDLE^W7-KY32/,'.8)$W9"+][.,<4 :_\
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MV>M3M;/2DO(CJL<PTTL9BA\L_P"E(S8V@_=XX- 'UO\ L(_ML?%%OV@+_P"
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MJ>,_#VN%Y7L+FZ6]BF1&0SQ+*55XI5$BX(.SYAPP!%?1?_!1O]O+6?@W\.O
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MPDT<$:Q*9-#M68A0 ,DQY)XZFO1Z* /SJ^!_[%/Q+^ __!0G6O'N@:-I]O\
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M)I;BS5/$?A-X+]-VGW*ZKF._;G*0?)N=AWXQR.:-0M$]F_X;VT#_ *%;4O\
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MNMI(TTGG.3$=GE^6H^\"<YQ0%D>G?\-[:!_T*VI?]_XZ/^&]M _Z%;4O^_\
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MQ&O^&=*O[6\:P6UU#5422YF7&5A50V_J #T)/UHU"T3Z)_X;VT#_ *%;4O\
MO_'1_P -[:!_T*VI?]_XZ\4B_9U,/PIUOQ%J>NZ=I.N:9?2VLNGW=XJJOE!M
MT1PIS,Q7Y%!PP(.>:-4^#OBCQUJWAFVAL/#6D1/X<M]2>\L@UK;16IW 37;,
M.921\Q4'/7H"0:A:)[7_ ,-[:!_T*VI?]_XZ/^&]M _Z%;4O^_\ '7@$W[./
MB9?&&@:!#>Z/?)KT<LFG:M9W9EL9_+0LX$@7.1C'W>I';FL[Q]\$-:^'_AVW
MURXU+1M7T^2Z-E+)H][]H^SW 4L8I/E #8!X!.,?3)J%HGTA_P -[:!_T*VI
M?]_XZ[Z\_::TRS^#MC\06T6[:SNKPV:V8E7S%(+C<3TQ\A_.OSNKZ-US_DR'
MP_\ ]AQO_0YZ <4>C?\ #>V@?]"MJ7_?^.C_ (;VT#_H5M2_[_QU\644#Y4?
M:?\ PWMH'_0K:E_W_CH_X;VT#_H5M2_[_P =?%E% <J/M/\ X;VT#_H5M2_[
M_P ='_#>V@?]"MJ7_?\ CKXLHH#E1]I_\-[:!_T*VI?]_P".C_AO;0/^A6U+
M_O\ QU\644!RH^T_^&]M _Z%;4O^_P#'1_PWMH'_ $*VI?\ ?^.O O@W\/?"
MGBCPKXS\0>+9M9CLO#\=M((]%>(2.)&=3Q(I!Y5>X[UL>(/V?+36M8\$+X&U
M"X-AXMMYY;2/Q!B.:%H5+.)#&I!!'0@8]\<T:BLCV7_AO;0/^A6U+_O_ !T?
M\-[:!_T*VI?]_P".OG^Q_9WUR]U35;8Z[X;MK'2EC^VZQ/J06Q@E?.(3+M/[
MP$$$ '!QSR,RVW[,_BUM:U6SO+C2-(L--BCFEUO4+T1V#))_JV27!+!L'''&
M.<9&34+1/>_^&]M _P"A6U+_ +_QT?\ #>V@?]"MJ7_?^.O$M.^$UKX>\&?$
M]]:ALM1UKP^-.>QN[2[,L $TQ#,-K ,&7'##(] :O>)O@/XE\7>._%HD?PAX
M<;14M)+Y;.1[/3XDEC!5TW)P !ELXY)QFC4+(]?_ .&]M _Z%;4O^_\ '1_P
MWMH'_0K:E_W_ (Z\4TWX/^)/!.N>)-)>V\+ZR6\,S:JMY=;KF VO'[ZU8*")
M<_=) '7M@UD3?L[^)+7PFNM7FH:'87#V9U!-%N]16._>W SY@C(QC'."V>V,
M\4:A:)]!?\-[:!_T*VI?]_XZ/^&]M _Z%;4O^_\ '7SM8_ 76M6\'2Z_IVL>
M']2DAL_M\VCVFHK)?Q08!+M$!@8!R1NSVQGBF_&;PCI/A.#P*VE6GV4ZEX;M
M-0N_WCOYD[[MS_,3C.!P,#VHU#E1]%_\-[:!_P!"MJ7_ '_CH_X;VT#_ *%;
M4O\ O_'7Q910/E1]I_\ #>V@?]"MJ7_?^.C_ (;VT#_H5M2_[_QU\644!RH^
MT_\ AO;0/^A6U+_O_'1_PWMH'_0K:E_W_CKXLHH#E1]I_P##>V@?]"MJ7_?^
M.C_AO;0/^A6U+_O_ !U\644!RH_1'Q)^TUIGAOX6>'?&\FBW<UKK,S0QVJRJ
M'C(W\D]#_JS^=<#_ ,-[:!_T*VI?]_XZ\Y^*7_)H/PQ_Z_I/_:]?.5 E%'VG
M_P -[:!_T*VI?]_XZ/\ AO;0/^A6U+_O_'7Q910/E1]I_P##>V@?]"MJ7_?^
M.C_AO;0/^A6U+_O_ !U\644!RH^T_P#AO;0/^A6U+_O_ !T?\-[:!_T*VI?]
M_P".OBRB@.5'VG_PWMH'_0K:E_W_ (Z/^&]M _Z%;4O^_P#'7AWP]^'O@2?X
M1WOC3QC-XB"PZO\ V:D.AM!DYB5P2)5]2W.[TXKLM(_9UT./XB:UH:N^J6%W
MX2DUK2'U"1K>6WE8JL9FVE1E3G.1MP>11J*R._\ ^&]M _Z%;4O^_P#'1_PW
MMH'_ $*VI?\ ?^.OG?7_ ("ZQX>U;P]:RZYX=N;'7%E:UUFWU(&P'E\R;I64
M8V_0YS@9/%7Y/V9_%+>(-'TZTO\ 0]3L]4AEGM]9LK_S+';$/WF9-N?EXZ*>
MO&<'!J%HGO/_  WMH'_0K:E_W_CH_P"&]M _Z%;4O^_\=?/5O\ =8O\ Q0^C
MZ?KWAO4[>&R_M"YUFSU(/I]M#N*DR2[?E((Z8SWZ9KGOB'\,]4^&UY8I?W%C
MJ-E?Q>?9ZEI=QY]M<H#@E'P,X/!X]* LCZF_X;VT#_H5M2_[_P ='_#>V@?]
M"MJ7_?\ CKQ?Q=\&?#]YIOPWN?!,NL2MXMGF@\O6&B+1E'1,@1J !DL>IX Z
M5TGQ$\$_#SQ9X7\=:]X<@U#3K[PG);Z>(84@BLIQYHB$@"KO=F 9BQ())'6@
M+(]$_P"&]M _Z%;4O^_\='_#>V@?]"MJ7_?^.O-OB]^S#-;>)]=E\'S:/'96
M=K'=)X?746DU'RA$IDD$;9)!;<1ELGL.@KYUH#E3/M/_ (;VT#_H5M2_[_QT
M?\-[:!_T*VI?]_XZ^+**!\J/M/\ X;VT#_H5M2_[_P ='_#>V@?]"MJ7_?\
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M.OBRB@.5'VG_ ,-[:!_T*VI?]_XZ/^&]M _Z%;4O^_\ '7Q910'*C]!/A/\
MM6Z3\6/&5OX=M-"O+"::*24332HRC8N2,"N;UK]N+0]%UF_TY_#.H2/:7$EN
MSK/& Q1BI(_*O#OV-?\ DNFF_P#7I<_^BS7EOCW_ )'KQ%_V$KG_ -&M0+E5
MSZV_X;VT#_H5M2_[_P ='_#>V@?]"MJ7_?\ CKXLHH'RH^T_^&]M _Z%;4O^
M_P#'1_PWMH'_ $*VI?\ ?^.OBRB@.5'VG_PWMH'_ $*VI?\ ?^.C_AO;0/\
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M?_$T?\,G_"7^[J7_ (%2?_$TK%<R/@VBOO+_ (9/^$O]W4O_  *D_P#B:/\
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M.AK/%';PJVH[1*"9#+NVM(&;&>A )(.:]]_X9/\ A+_=U+_P*D_^)H_X9/\
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MB%BT>+ARS=2Q( &21C'.?H?_ (9/^$O]W4O_  *D_P#B:/\ AD_X2_W=2_\
M J3_ .)HU"Z/GV?]I:&3QQINM1^$+>'2K?03X?GT=+U@LEN2Q^20(#'U4=&X
M!YYR,;3?CLOA?1DT_P ->'X])2W\1KK]H)KMKE(5$7E_9V!4,XQGYMP.#Z\U
M]-_\,G_"7^[J7_@5)_\ $T?\,G_"7^[J7_@5)_\ $T:CNCY3^)7Q,\.>-K-Q
MI/@.R\-ZA<W7VN\OUO)+B25R#D(" (U)))4 CI2?#?XT:A\*?#>L6WAVU2T\
M0:C-$3K3%)#%"G/E+$Z%>23EB?PX!KZM_P"&3_A+_=U+_P "I/\ XFC_ (9/
M^$O]W4O_  *D_P#B:071X#I_[5&HSZMX4UKQ%HZZ]K^@SW++J"SI:F>&:)D\
MID2+ VD@AAZ$8YS7._"/X[7/PPM]9T^;39-4T?5'6:6"VU"6PN(Y%/#)/%\P
M&.".^!TYS]0?\,G_  E_NZE_X%2?_$T?\,G_  E_NZE_X%2?_$T]0NCY]3]I
MJ5KSQ"\FDZE!!J;6_D36.OSI?6L<1R(OM4BR,R,<DJ O+-C&:Y+Q[\3+#XG?
M%2W\3:MIDUAICM;)=6D$HN)#'&%5MK,$R6 /7'7K7U?_ ,,G_"7^[J7_ (%2
M?_$T?\,G_"7^[J7_ (%2?_$T:A='QG\3/&C_ !"\=ZSK[(8DO)\PQ,,&.)0%
MC7J>0BJ.*[]?VBMMM;1?\(__ *GPB_A7=]MZ[@O[_P#U?M]SW^]7T;_PR?\
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M#:S-/%;W@>0[R6;<3CDY=OPIV!R/S1HK](?^%*?";_H5M-_[\O1_PI3X3?\
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M%?I#_P *4^$W_0K:;_WY>C_A2GPF_P"A6TW_ +\O18.8_-ZBOTA_X4I\)O\
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M\IXV'.T'=G\*HZ#\;M7M/$'BG6M<$OB#4==T>?27FEF$7E"0* X 4C"[?N
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MM-_[\O3%S+L?*_B3]J)?$.B^(]/?P_>LFM+ K6]UK336EJ(RIVP0")0B-MY
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M^$BN(KIL/N\PW$:JQ)Z,#G/KVKZJ_P"%*?";_H5M-_[\O1_PI3X3?]"MIO\
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M_P#Z]Y/_ $$T +H[%M'L23DF",DG_=%7*I:+_P @:P_Z]X__ $$5=H ****
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M\^YI_P#"4:S_ -!:^_\  E_\:/\ A*-9_P"@M??^!+_XUF44>SAV#GGW-/\
MX2C6?^@M??\ @2_^-'_"4:S_ -!:^_\  E_\:S**/9P[!SS[FG_PE&L_]!:^
M_P# E_\ &O>!XSUS0?V8=&U.QU2YM]0.I/$;D/N<H7EXR<\<#\J^=*]RU;_D
MTW1?^PLW_H<U>7CZ<'[%.*^-?DST\#4FO:M-_ _S1PW_  O#QY_T,]]_WT/\
M*Y3Q%^U)\0M$\7:%I4>MWT]G=;OMUWO&+0,1';YX_P"6DIV#Z&N.\:>'=0UZ
M"T?3M5NM/FM9/,:WAG,,=VI&#&[A2R^S ':>2K#@]W\,_AGX.\;?#W5[F-=;
MD&MLMK>R:E>&2Z@DLKB3:D<B_+B.<2,K+D$\^P^4XFSFAD%.$GAKJ37O6C;=
M.2[WY;VT/.K9C/"P56I.33TW>E_GVNUYJQT/_"\/'G_0SWW_ 'T/\*V-9^(7
MQ2\/Z;I>H7^N7T-EJ<9EM)A-&ZRJ,9^[G!&1P<'FOG;PGIG]KZO;^(],U;6D
M\-20DV5CJ5YY\ETK#B:88Q'Q]V,?,.K')V+]9?!G3[#XJ^!I/".K3K"VB7L>
MI6\C8_X]F;]\F>P^]^+CTKWXU:4L-#%RP_+%[II<R3V>E^MM.QZ6'E6KS=)5
M)<S6FO7L_E^)!I?_  O'6O*%I>WTC2VT=XJM>6Z-Y3Y",0S C.T\'GBGR1_'
M.'6H-(>\OAJ$\+W$</VVW^:-2 QSNQP6'&<\UU?P[\1'XF:U\3[E-+_MFTFM
MX;>UTL3_ &82PJ9%2/?_  9 SGU)I? ?@]_"_P 2I9;CP>_@W3[C0KI?LT>I
MK?-*59"[ALG:<,HP>./K7%*O[.4XSIP3BKVY5V3_ )KZ>4?F>M&ASJ$HU)M-
MVO=][?RV^]_(XCQ!??&SPO-8QZG>ZE;&^G6V@87$+HTC'"J64D*3[D=*N:=;
M_'75IKZ*TN[Z62QG-M<#[;;C9(%5MO+<\,IR,CFMO39M&T_X?^&XO!J7U[HE
M]XDMC?3:G*K3V<BR(50H@VJ&P#N!]N=W&?9_\G?/_P!?K_\ I.:T52\9_NX)
MQ4G\/\MNE]/O\S)T^5P_>3:DXKXN]^MM?N\CG/%OB;XO^!KJRM]:U34+2>]S
M]GC6>*4R8(! V%N<L/SJKXN\=?%?P)J$=EKNL:A87,D8E13+&X922,@KD=0>
M,UH?#'P[9ZA\7O$&N:LXAT7P_<7&H7,K+N4,LC;!@<GG+8 YVX[UT_CD:-\0
M/ 3ZG9^($\7ZCX<O3>7+"RDM7-I+)N:/:^20I'!SP!CCOT.I3IU84Y4HM:<S
M4>KV[I=+W?70Q4*E2G*<:DD];)RZ+?LWUV70P]%D^.7B#14U6PGU6:QD7>CM
M-$C.O7*HQ#$'M@<]JY6S^*WQ+U#5DTNWUK59M1:0Q"U5?WF\=5VXR",'/I@U
MZ'\1O _B;XE>+[7Q7X5U6"Y\/O%&UK?+?"%=."H RL"0R$').T$\\\UYQI.C
MZ%JGV+3=$GUQ_B#)<B-+A;B 6'F"0Y=) =^-HR&SUJZ$J-2#E*$+]E'X?\7I
MUV(K1K0DHQE*W=R^+_#Z]-SH_%VM?&;P+917FN7^I65K*VQ9A-%(N[T)0G:?
MKBN3_P"%X>//^AGOO^^A_A7N%WX(\7?#S1]%T+0+.*^4ZI#?7NMZM.GD/<LR
MA56/?Y@3=C)QN)Z5\]>,K74[_P"(&KVUU';RZO-J$D<D=B,Q-,7((3OC/3//
MKS58*5#$7O"#\TEMZ:V^\G&1KX>UIS7DV_STO]QV(^('Q+;PB?$7_"3W/V$3
M^1L\T>;_ +^W;]S)"YSU.*L:=X^\<7>BVNI7?Q%BTF&ZEDBACO//9V*;=Q_=
MP. /G'4BI%O/"EOXB30'UB_-LMF=">-=/0VV\MEI?-\\' G_ 'F[9T4#%8MQ
MH^DV_@_0;+Q%?7^DSP:C?0LMM8K< $&$/N)E0K@CL&_Q:C1E9.FE=_RZVL_+
MRU$Y58W:FW9?S:7NO/ST-'6/'7Q+T6RNKJ;Q5/)';7$<$GD2A^)$WQ2@A<%'
M4'!SVY JA)\5/B'#H,.KOXINDMI[AK>)"_SN54,S ;<;1N49SU-7)Y#<>/K_
M ,,7$7V:PU"QBTNU:1Q)NV1K]EF#  '>R(<@8Q(17/>+[G3]/\0VFBW4,UYI
MNB0?8GCLYU@9YADRL'*./]:6YVG(4=*TITZ<FHNG&]K[+:WYW_ SJ5*D4Y*H
M[;;O>_\ D:>A_%;XB^(-5M]/M/$UX9ICC<[@*B@$L[''"J 23V -:NF^/O'%
M]IESJ,_Q$CTZRANOLBS7/GMYK[2V5$<+'&!GY@*YW2M8\)V^@ZA:1SZSI%S?
MR[)72UBO&%L,$1"3S8>K#<QVC.%'8[K.L>#=$_X6I-I&GS7":1;RO+=F:()Y
M$48+R!3YC;@$7AB023C'JY4Z',XNFH]?A73?I;KH*-2MRIJ;ET^)]=NMSJ;[
MQ)\0+-;M5^(L%S<6]B-1^SQFX#O"5#@C= H!VD'#$'D5QG_"\/'G_0SWW_?0
M_P *DT36Y/$GB+Q?J<J+&USI=Y((U^ZBX&U1[ 8 ^E5?AEJ$VDW'B*[M]HGB
MT>=HV90VUMT8# 'N.H]"!3C1IPC+GIQ;5NBZ_(4JU2<H\M1I._5]/F3?\+P\
M>?\ 0SWW_?0_PH_X7AX\_P"AGOO^^A_A5^Z\?^(8_ NE:DFJW2ZM)?W-M)J8
MD/VIXD2%UC,N=Q4-*YQG'3T%;U]%J$.J>+/^$4C,7B5[BUEVV*A;K[.T):4P
M!>1F0J6V<X([9I-48_%1CU[=&EKIYC3K2^&K+IWZIOOY')?\+P\>?]#/??\
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MVI1P]27+[*/W+;:^W?\ S,JDJ]./-[5_>]^V_;_([S2?&7Q UF*S2#X@V_\
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M]P#3/^%X>//^AGOO^^A_A6QI^GVWC&34+6^<*F@:A/?3%FP6L6<F91WR'"X
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ML[G_ (7AX\_Z&>^_[Z'^%'_"\/'G_0SWW_?0_P *X:BCZKA_^?:^Y!]:K_\
M/Q_>SN?^%X>//^AGOO\ OH?X4^+XZ^/87W+XFO"?]K:P_(BN#HI?5</_ ,^X
M_<@^M8C_ )^/[V?H-\-=2NM6\'V%U>3-<7$B*SR/U)*@G]3745QWPE_Y$/3/
M^N2_^@+78U^1U/C?J?JM/X%Z!11169H%%%% !1110 52UK_D#7__ %[R?^@F
MKM4M:_Y U_\ ]>\G_H)H -%_Y UA_P!>\?\ Z"*NU2T7_D#6'_7O'_Z"*NT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R
M'Q?_ .26^*O^P=-_Z :^ *^__B__ ,DM\5?]@Z;_ - -? %??<._P)^OZ'PW
M$'\:'I^H4445]:?*A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7N&KR*/V4-$3/S'5F./^!RUX?7N%\VHW'[*JVNF
MZL^BWD]MJ-O#J".4-J2)R)=P!*[6PVX8(QU7J/EN(L7+ X6&(BKN,E^I]/P_
MA(X[%2P\G92B_P!#PN\$_P!DG^RB,W6QO*$Q(0OCY=Q'.,XSBN4\*^"M3TGP
M_HL-_P"(KTZOI<"QVMUITA@CM7QEWCCY5F=BS.9 V_<00$P@^DM1\+S>*'M;
MF35=9C:R1C MCK%W;!E3S3EUBDQ*/W:Y9A*./FD7)K+\77UAI/Q2\.6]_KNL
M0>(=:%U)IEO;ZE=I9RK:I*SDP1R& K@+U216/60<U\!6SS$X]1J5L)&:5[7U
M6NGX[7/LI<,9=3;IRK_A_7_!/$/ ^B:GH.F7=IJEQ:W+M?7$\#V<;1H(Y)#(
M%V'.S#.P"@D !<'L.AQ7M\7A"ZL?$MYKD.JZL]Y,)9!$^JW,MKM F!,=L9'A
M"CRARB.HQ_K$R:CTWP3<:%/JLUIJVL2O?)*6%SK%W=*%!G),*R2R",#RQ\T0
M(&/]8E=M'B+,J-.-*&'TBK+4SEPWEDG=X@\4Q1BO9[7P'-I6B:II=OJVMR6U
M]OD9YM;O+B<*GG<PS-*\D:_NQDQ,R\<R+S1<> YAX:ET--7ULV9DDN4D36[P
MW1VF<_+<B5IC'^[&0KNG'+K6O^LV:?\ 0.3_ *LY9_T$'C&*-M>T:UX#FU/1
M;72WU?6UMK,22026FN7D,[*OG\M-'+YDR_NQRS2J,<R+3_$'@FXUNXM)IM6U
MA&LD8VXL=8N[=75#,<LL,N)A^Z&682@X.Z1<FC_6;-/^@=!_JSEG_00>*8HV
MU[?J7A"ZO/$PUPZKJPO(@TD4=OJMREJRH)^?LR2&%U_=C)V2*<?-(M$7A"ZL
M?$MYKD.JZL]Y,)9!$^JW,MKM F!,=L9'A"CRARB.HQ_K$R:/]9LT_P"@=!_J
MSEG_ $$,\0Q1BO:]-\$W&A3ZK-::MK$KWR2EA<ZQ=W2A09R3"LDL@C \L?-$
M"!C_ %B5':^ YM*T35-+M]6UN2VOM\C/-K=Y<3A4\[F&9I7DC7]V,F)F7CF1
M>:/]9LT_Z!T'^K.6?]!!XQBC%>SW'@.8>&I=#35];-F9)+E)$UN\-T=IG/RW
M(E:8Q_NQD*[IQRZTNM> YM3T6UTM]7UM;:S$DD$EIKEY#.RKY_+31R^9,O[L
M<LTJC',BT?ZS9I_T#A_JSEG_ $$'B^VC%>U^(/!-QK=Q:33:MK"-9(QMQ8ZQ
M=VZNJ&8Y989<3#]T,LPE!P=TBY-2:EX0NKSQ,-<.JZL+R(-)%';ZK<I:LJ"?
MG[,DAA=?W8R=DBG'S2+1_K-FG_0.@_U9RS_H(9XAMHQ7M\7A"ZL?$MYKD.JZ
ML]Y,)9!$^JW,MKM F!,=L9'A"CRARB.HQ_K$R:CTWP3<:%/JLUIJVL2O?)*6
M%SK%W=*%!G),*R2R",#RQ\T0(&/]8E'^LV:?] Z#_5G+/^@AGBF*,5[/:^ Y
MM*T35-+M]6UN2VOM\C/-K=Y<3A4\[F&9I7DC7]V,F)F7CF1>:+CP',/#4NAI
MJ^MFS,DERDB:W>&Z.TSGY;D2M,8_W8R%=TXY=:/]9LT_Z!P_U9RS_H(/&,4;
M:]HUKP'-J>BVNEOJ^MK;68DD@DM-<O(9V5?/Y::.7S)E_=CEFE48YD6G^(/!
M-QK=Q:33:MK"-9(QMQ8ZQ=VZNJ&8Y989<3#]T,LPE!P=TBY-'^LV:?\ 0.@_
MU9RS_H(/%,4;:]OU+PA=7GB8:X=5U87D0:2*.WU6Y2U94$_/V9)#"Z_NQD[)
M%./FD6B+PA=6/B6\UR'5=6>\F$L@B?5;F6UV@3 F.V,CPA1Y0Y1'48_UB9-'
M^LV:?] Z#_5G+/\ H(9XABC%>UZ;X)N-"GU6:TU;6)7ODE+"YUB[NE"@SDF%
M9)9!&!Y8^:($#'^L2H[7P'-I6B:II=OJVMR6U]OD9YM;O+B<*GG<PS-*\D:_
MNQDQ,R\<R+S1_K-FG_0.@_U9RS_H(/&,48KV>X\!S#PU+H::OK9LS))<I(FM
MWANCM,Y^6Y$K3&/]V,A7=..76EUKP'-J>BVNEOJ^MK;68DD@DM-<O(9V5?/Y
M::.7S)E_=CEFE48YD6C_ %FS3_H'#_5G+/\ H(/%]M&*]K\0>";C6[BTFFU;
M6$:R1C;BQUB[MU=4,QRRPRXF'[H99A*#@[I%R:DU+PA=7GB8:X=5U87D0:2*
M.WU6Y2U94$_/V9)#"Z_NQD[)%./FD6C_ %FS3_H'0?ZLY9_T$,\0VUH6>LSV
M>CZAIR+&8+YHFD9@=P\LDC'/^T<\&O7XO"%U8^);S7(=5U9[R82R")]5N9;7
M:!,"8[8R/"%'E#E$=1C_ %B9-1Z;X)N-"GU6:TU;6)7ODE+"YUB[NE"@SDF%
M9)9!&!Y8^:($#'^L2D^)<SDK/#HI<-Y9%Z8AGEWAOQ,WAF1YX-/LKF\#"2WN
M[E7:2V< X=,.%R"<_,&&0#CBL8Y8DDY)Y)->S6O@.;2M$U32[?5M;DMK[?(S
MS:W>7$X5/.YAF:5Y(U_=C)B9EXYD7FBX\!S#PU+H::OK9LS))<I(FMWANCM,
MY^6Y$K3&/]V,A7=..76DN),S3<EA]7_7](/]6\M:47B-OZ_IGC&*-M>T:UX#
MFU/1;72WU?6UMK,22026FN7D,[*OG\M-'+YDR_NQRS2J,<R+3_$'@FXUNXM)
MIM6UA&LD8VXL=8N[=75#,<LL,N)A^Z&682@X.Z1<FJ_UFS3_ *!T3_JSEG_0
M0>2:#K,_A[5(K^V6-YHU=0LH)7YD*GH1V8UG[:]OU+PA=7GB8:X=5U87D0:2
M*.WU6Y2U94$_/V9)#"Z_NQD[)%./FD6B+PA=6/B6\UR'5=6>\F$L@B?5;F6U
MV@3 F.V,CPA1Y0Y1'48_UB9-+_67-+W^KJY7^K>66M]8=CQ#%&*]KTWP3<:%
M/JLUIJVL2O?)*6%SK%W=*%!G),*R2R",#RQ\T0(&/]8E1VO@.;2M$U32[?5M
M;DMK[?(SS:W>7$X5/.YAF:5Y(U_=C)B9EXYD7FG_ *S9I_T#HG_5G+/^@@\8
MQ1BO9[CP',/#4NAIJ^MFS,DERDB:W>&Z.TSGY;D2M,8_W8R%=TXY=:76O <V
MIZ+:Z6^KZVMM9B22"2TUR\AG95\_EIHY?,F7]V.6:51CF1:/]9LT_P"@</\
M5G+/^@@\7VT8KVOQ!X)N-;N+2:;5M81K)&-N+'6+NW5U0S'++#+B8?NAEF$H
M.#ND7)J34O"%U>>)AKAU75A>1!I(H[?5;E+5E03\_9DD,+K^[&3LD4X^:1:/
M]9LT_P"@=!_JSEG_ $$,\0VT8KV^+PA=6/B6\UR'5=6>\F$L@B?5;F6UV@3
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MM\0K;5_&VJ3ZSX4L+.X^Q^%[<26Z/<%[AFNY+B.0R2D! HQO4#@RKS6/X/\
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M6K2:IK6E?#OX1ZOXU\%>&[QM'OM6T_48%D\R,3*3;6S[WN5C5_FD+,5"9\U
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M!K<+GRKEDO(WCRLZ*SXW,'.8V!EC&#7RQX;^/?Q6OO!FFVQ\:-XDU?7OB/\
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MGF^=+_>\S'VOY_X]^/[_ .]Q_P ]DHO?WOVK_EIYOG2_WO,Q]K^?^/?C^_\
MO<?\]DH +W][]J_Y:>;YTO\ >\S'VOY_X]^/[_[W'_/9*+W][]J_Y:>;YTO]
M[S,?:_G_ (]^/[_[W'_/9*+W][]J_P"6GF^=+_>\S'VOY_X]^/[_ .]Q_P ]
MDHO?WOVK_EIYOG2_WO,Q]K^?^/?C^_\ O<?\]DH +W][]J_Y:>;YTO\ >\S'
MVOY_X]^/[_[W'_/9*+W][]J_Y:>;YTO][S,?:_G_ (]^/[_[W'_/9*+W][]J
M_P"6GF^=+_>\S'VOY_X]^/[_ .]Q_P ]DHO?WOVK_EIYOG2_WO,Q]K^?^/?C
M^_\ O<?\]DH +W][]J_Y:>;YTO\ >\S'VOY_X]^/[_[W'_/9*+W][]J_Y:>;
MYTO][S,?:_G_ (]^/[_[W'_/9*+W][]J_P"6GF^=+_>\S'VOY_X]^/[_ .]Q
M_P ]DHO?WOVK_EIYOG2_WO,Q]K^?^/?C^_\ O<?\]DH +W][]J_Y:>;YTO\
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MS'VOY_X]^/[_ .]Q_P ]DHO?WOVK_EIYOG2_WO,Q]K^?^/?C^_\ O<?\]DH
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MGF^=+_>\S'VOY_X]^/[_ .]Q_P ]DHO?WOVK_EIYOG2_WO,Q]K^?^/?C^_\
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MO[W[5_RT\WSI?[WF8^U_/_'OQ_?_ 'N/^>R47O[W[5_RT\WSI?[WF8^U_/\
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M-\Z7^]YF/M?S_P >_']_][C_ )[)1>_O?M7_ "T\WSI?[WF8^U_/_'OQ_?\
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M4OY&']EU/YT>B7O[W[5_RT\WSI?[WF8^U_/_ ![\?W_WN/\ GLE%[^]^U?\
M+3S?.E_O>9C[7\_\>_']_P#>X_Y[)7G<?Q"DU#Q+?Z;-!);V1:1O[8N+NS:U
MG;$N&VB=YB?WO!DC+#!^=>*CT_XC3:S/K$=U9S:8D>^2.6^N[%UO6S-@ILN)
M#N_> @S#<.SK1_:U+^1A_9=3^='I%[^]^U?\M/-\Z7^]YF/M?S_Q[\?W_P![
MC_GLE%[^]^U?\M/-\Z7^]YF/M?S_ ,>_']_][C_GLE>;Z=\0KS7M+U.=M+N[
M:^\PF+2[B[L'N+YF\W#(5N7CR/-ZRONXX<<5KW6H>+IO#-QJ9\(ZJ]Y+.RG1
MVGLC=/DRXF9C<&$X\P?>D>3KAA42SFA'246ON+CD]:2O&2?WG8WO[W[5_P M
M/-\Z7^]YF/M?S_Q[\?W_ -[C_GLE%[^]^U?\M/-\Z7^]YF/M?S_Q[\?W_P![
MC_GLE<=KE_XN@T6"]B\(ZKJ5S>NS2Z=#/9"> GS<-*9;@1L?W@Y#RMZ.M2>(
MKKQ99W-O';^%M2UA;X^9-+:SV@6!F,O,WG3J69?-Z@2MP=KCBI_MO#]G^!7]
MBXCNOQ_R.MO?WOVK_EIYOG2_WO,Q]K^?^/?C^_\ O<?\]DHO?WOVK_EIYOG2
M_P![S,?:_G_CWX_O_O<?\]DKEM4F\5+XF?3$\-W][97#[GUA)K7[*"PF^9UD
MF\XE?,')CD;^ZXHCF\5:AXEU#3)?#=_!9%Y&&L7$UJUK.<2X;:)GFS^]X,D9
M88/SKQ1_;F&[/\ _L7$=U^)U-[^]^U?\M/-\Z7^]YF/M?S_Q[\?W_P![C_GL
ME%[^]^U?\M/-\Z7^]YF/M?S_ ,>_']_][C_GLE<EI]UXLUJ?68[GPMJ6F)&7
MDCEOI[1EO6S, 4V3R'=^\!!F&X?WUJ.VO_%VJ:'J][/X1U6RN8W+1Z==W%DT
M]Z3YOS*5N)(\CS.LK[N#AQQ1_;>'[/\  /[%Q'=?C_D=C>_O?M7_ "T\WSI?
M[WF8^U_/_'OQ_?\ WN/^>R47O[W[5_RT\WSI?[WF8^U_/_'OQ_?_ 'N/^>R5
MQUUJ'BZ;PS<:F?".JO>2SLIT=I[(W3Y,N)F8W!A./,'WI'DZX84:Y?\ BZ#1
M8+V+PCJNI7-Z[-+IT,]D)X"?-PTIEN!&Q_>#D/*WHZT?VWA^S_ /[%Q'=?C_
M )'8WO[W[5_RT\WSI?[WF8^U_/\ Q[\?W_WN/^>R47O[W[5_RT\WSI?[WF8^
MU_/_ ![\?W_WN/\ GLE<EXBNO%EG<V\=OX6U+6%OCYDTMK/:!8&8R\S>=.I9
ME\WJ!*W!VN.*DU2;Q4OB9],3PW?WME</N?6$FM?LH+";YG62;SB5\P<F.1O[
MKBC^W,-V?X!_8N([K\3J;W][]J_Y:>;YTO\ >\S'VOY_X]^/[_[W'_/9*+W]
M[]J_Y:>;YTO][S,?:_G_ (]^/[_[W'_/9*Y:.;Q5J'B74-,E\-W\%D7D8:Q<
M36K6LYQ+AMHF>;/[W@R1EA@_.O%1Z?=>+-:GUF.Y\+:EIB1EY(Y;Z>T9;ULS
M %-D\AW?O 09AN']]:/[<P_9_@']BXCNOQ.MO?WOVK_EIYOG2_WO,Q]K^?\
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M=JBFU:ZENKB'3[*.Z%N0LKRS^4-Q ;:ORMDX(ZX'/7K36UB\N)Y8['3TF\C
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MU=['3HQ'@0HT4KVZ;(WV.Y)S@$=<XH4J+5U25OEOK_E_P <:R=G5=_\ AO\
M,\XM;62[\XHT2^5&96\V9(\@=EW$;CS]T9)]*@S7IUQI/VE+^_N5TN]MI]"G
MFM+BRT];4%EF5=QC"*%<9(W*.F.3S5F*U2V\3:%X;BT"QFT*]M;=Y+E[1&FG
M22)6EN!<$;EV$O\ =8*NS!'6CFH:_NU_PV_]:"M6T_>/_A]CRC-&:]!NM8@\
M+>%?#36.FZ7=37#7)FNKRPBG:=%F(5<.IV\=QAN@R,5SGC[3+71O&FLV5E'Y
M-I#=.L4>XML7/"Y/)Q[UO3C1G*WLTM^W1V,9RK0C?VCZ?BKD>E^#]9UI;1K.
MR,JW0D:-C(B#;'C>[%B-J#.-S87.1G@U)<>!]:M]0T^R^S132WY*VKV]S%-%
M,0<$+*C%"0>HW<<9K5\1Z3=:Q)X.TS3X6N)9-)C\J-.Y:65W)/0 $L23P #G
MH:V_#>I6L/C+PAX>T^=;RSTV]:22\4';<3R;0[)GH@"*H]<$]\#GE&*7-&$>
MKM;M?_@?B=$92;Y93ET6_I_P?P/,<U:T[3KG5K@P6L8EF$;R[-P4E44LV,GD
MX!X')QQ2:;)9Q7D;7\$]S:#.^*VF6&1N#C#E' YQ_"?ZUZ+<7&@M\7]"'AZS
M:&+[=:JY6YCF@D#>6"$5(UV]6#<MDD]*Z*M.E3T5-;-WLK:'/2J59ZNH]TK7
M=]3S'-&:GU"-(;ZYCC.8UD95/7@$XJO71]7HO7D7W&'UBLM.=_>+FC-)13^K
MT?Y%]POK%;^=_>+FC-)12^KT?Y%]P?6*W\[^\7-&:2BCZO1_D7W!]8K?SO[Q
M<T9I**?U>C_(ON#ZQ6_G?WBYHS244?5Z/\B^X/K%;^=_>+FC-)12^KT?Y%]P
M?6*W\[^\7-&:2BCZO1_D7W!]8K?SO[Q<T9I**?U>C_(ON#ZQ6_G?WBYHS244
MOJ]'^1?<'UBM_._O%S1FDHH^KT?Y%]P?6*W\[^\7-&:2BG]7H_R+[@^L5OYW
M]XN:,TE%'U>C_(ON#ZQ6_G?WG3?#5%F\?: C@,K7D8(_&OOG^P[':!]G3'TK
MX(^&'_)0O#W_ %^1_P Z_0:O@N(J%)5X6BMNWF?<Y!7JNA.\GOW\B@=#L6P#
M;IQ[4'0[)FR;=,_2K]%?*>QI_P J/J/;5/YF4/[#LMV[[.F?I0-#LE;(MTS]
M*OT4>QI_RH7MJG\S* T.Q7(%NG/M1_8=CM(^SICZ5?HH]C3_ )5]P_;5/YF4
M/[#L=H'V=,?2@Z'8M@&W3CVJ_11[&G_*ON#VU3^9E Z'9,V3;IGZ4?V'9;MW
MV=,_2K]%'L:?\J%[:I_,R@-#LE;(MTS]*!H=BN0+=.?:K]%'L:?\J'[:I_,R
MA_8=CM(^SICZ4?V'8[0/LZ8^E7Z*/8T_Y4'MJG\S*!T.Q; -NG'M0=#LF;)M
MTS]*OT4>QI_RH/;5/YF4/[#LMV[[.F?I0-#LE;(MTS]*OT4>QI_RH7MJG\S*
M T.Q7(%NG/M1_8=CM(^SICZ5?HH]C3_E7W#]M4_F9@>#;2*UL;D1H$_TF3H/
M>M^L7PK_ ,>-Q_U\R?SK:K1)15D9-N3NPHHHIB"BBB@ HHHH *I:U_R!K_\
MZ]Y/_035VJ6M?\@:_P#^O>3_ -!- !HO_(&L/^O>/_T$5#>:7<-?&\L;F.VN
M'C$4@FA,J.H)(. RG(R><]ZFT7_D#6'_ %[Q_P#H(J+4-<2QO([1;:XN[F1#
M(L<"KR <'EB /Q(_.N'&>P]FGB'975K73OLK<NMWMIJ[VZFU'GYK4_Z^_0A;
M1[R.87-M?JMXT8CF>>#>D@!)!VJRX(W$#GH><]:NZ;I_]GP,ID:>61S)+*P
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M3GMWJ2+3/+M[Z+S,_:G=\[?N[@!CKS47]O0R6EO-;0S7C7 +1PQ* ^!PV=Q
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M  X4445V&1R'Q?\ ^26^*O\ L'3?^@&O@"OO_P"+_P#R2WQ5_P!@Z;_T U\
M5]]P[_ GZ_H?#<0?QH>GZFEH_B;6/#K2'2M5OM,,GWS9W#Q;OKM(S5?4=4O-
M8NWNK^[GO;I_O37$C2.WU8G)KZK\7>$=<L9--'A+X:>$M8T][&)Y;B]LH _F
MG.X<R)VVGIWZUP?@.>QL?A;X[\3W7AC0;W5+34E,=O>6"RP0[F0%%&<A1N.
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MDEPXA;/7* X/Y5W7_"UO#G_1-]#_ ._DG^-'_"UO#G_1-]#_ ._DG^-'//\
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MCN3FFZ?KVI:28C8ZA=69A<RQFWG9-CD %A@\$@ 9'H*[[_A:WAS_ *)OH?\
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MONE_D>9T5Z9_PM;PY_T3?0_^_DG^-'_"UO#G_1-]#_[^2?XT>VK?\^G]\?\
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M 4444 %%%% '(?%__DEOBK_L'3?^@&O@6UF^S74,VT/Y;J^T]\'.*^^OB_\
M\DM\5?\ 8.F_] -? %?>\._P*GK^A\-Q!_&AZ?J?0OQ2^'^I?&K7+#Q7X/DM
MM5L+NUBCGC-RD;V;KG*N&(P.>V3UXZ$P?"#X<W-GJ_B_3%\37PNK(11M;>%;
MV));ODG*R2$ ;3P>G)(SV/@-%>O]2JJC[!5/=6WN^?777MT/+^N4W6]NZ?O/
M?7RZ::=^I]B>(88O^%G?":8---/Y5U"\]W)').VV(#$CQDJS EL[3C)-<AX;
M\5:KXINOC)I^K7LU_8PVETT-O.Y:.'89 NQ3PH&!T[@&OFJBN>.5*,.5RN[)
M7MM[SEW^1M+-'*7,HV5[VOO[JCV^9]07%MXL\3>'_!-U\-M8AT_0[*R2.Z1;
MI(DM9P,N;A3]\>H*MW..<UL^#=2FU+X?V<.B6(\3ZU:WTYU6/3]?;3G,S2,3
M,6CP)4;J,\8QC.#CY&HHEE?-'EYEH[K37KNTTWOY#CF?++FY7JK/73ILFFEM
MYGU39>+KR35/BYJL-E!HNJVFEQ*WV.Z6Y7S423$@D"KDXQVR,<\U\O7^H76J
M7DMW>W,UY=2G,D]Q(7=SZECR:KT5WX7!QPKDUUM^"2[LX<3BY8E13Z7_ !;?
MD%%%%>@< 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7T;I>DZ-
MJW[+^B0:UKW]@6?]HR.;K[&]SAQ)* FQ3GD<YKYRKW+5O^33=%_["S?^AS5Y
M&81<O8I.WOK\GWN>KE[4?:MJ_N/\UV.9_P"$#^'/_14O_+>N?_BJ/^$#^'/_
M $5+_P MZY_^*KC_  AX5_X2[4I+/^U]*T79$9?M&KW/D1-@@;0V#EN<X] :
MZ;QU\%[_ .'VGR7&H^(/#\UP@1A86MZS7+JQP&6-D!([Y] :<K0J*E+$2YGY
M1_\ D!1]Z#J1H1Y5YR_^2+7_  @?PY_Z*E_Y;US_ /%4?\('\.?^BI?^6]<_
M_%5C:M\)]=T7P%8>+K@6_P#9MX5VQ(Y,T:MG8[KC 5L<8)ZBI/"/PCU?Q9HL
MFLM=Z;H6CJ_E+?ZS<_9XI'_NJ<'/UQC@C.0:7-%1<_K+LG;[&_;X1\LG)0^K
MJ[5_M;=_B-7_ (0/X<_]%2_\MZY_^*H_X0/X<_\ 14O_ "WKG_XJIM/_ &>]
M8U#57TW_ (2'PS!J&X"&VDU+,EPI0.)(U522I![@'@\8JM_PHO4Y==?2;3Q!
MX>U&ZCMIKJ7[%>M*(A$5#*^$RK$MP".QZ5G[:G>WUE]]H_\ R!I[*I:_U==M
MY?\ R0__ (0/X<_]%2_\MZY_^*H_X0/X<_\ 14O_ "WKG_XJN6\0>!+_ ,/>
M'-#UR6:VNM.U=&:"2V=FV,I 9'RHPP/89Z'GBNML?V>]=N@_GZMHFG&*QAU"
M<7MR\8MXY-VT2'RR%;Y3GGCUJY2C"/-+$2M_V[TT?V>Y$8RG+ECAU?\ [>ZZ
M_P W8C_X0/X<_P#14O\ RWKG_P"*H_X0/X<_]%2_\MZY_P#BJY7QEX-_X0Z>
MVB_MS1=<\]2V_1KO[0L>#C#G P370^'O@O?Z]X5L_$$OB#P_HVGW;O'%_:UZ
MT#%E)!'W".Q/!Z4Y-1@JDL1*SVTC_P#("BG*;@J$;KSE_P#)%G_A _AS_P!%
M2_\ +>N?_BJ/^$#^'/\ T5+_ ,MZY_\ BJXW7_"E[H,MP28]0T^&?[.-4L=T
MMG+)MW;4EP 3CMUI_@WPROBK6#:S7T>F6<<337%Y*NY84'&2,C.6*CKWK7DE
MR>T]O*WI'_Y$SYUS\GL(W]9?_)'7_P#"!_#G_HJ7_EO7/_Q5'_"!_#G_ **E
M_P"6]<__ !5<MHWA$77B+4=+U2XET[^SXKB6X>& 3./)5BRJI9 2=N.2*TK'
MP/I6N&UETO79GM'NDLIWO;$02022!O*)42LI1BI!;=E>XZ9B7N[UY?='_P"0
M+C[VU&/WR_\ DS7_ .$#^'/_ $5+_P MZY_^*H_X0/X<_P#14O\ RWKG_P"*
MKC=#\,RZIK%S97,AL5LXIIKJ5EW>2L:DMQD9.0% SU85BUJJ,V[*O+[H?_(F
M3JP2NZ,?OE_\D>F?\('\.?\ HJ7_ );US_\ %4?\('\.?^BI?^6]<_\ Q5<X
MO@VVM=;TG3-3U9=.GN4\R]+Q@BRR"55LN,OMP2IV[2P&<YQ;3PKX8ET*XU9=
M?U9;6&XCMB)-'B#.S!CA +HYP%R<XZCGFL7=6_?RU\H__(&JU_Y<Q^^7_P F
M;'_"!_#G_HJ7_EO7/_Q5'_"!_#G_ **E_P"6]<__ !5<7XMT%/#/B"[TV.Y:
M[CAV%9FC\LL&16&5W-@_-ZFLW[)/]E^U>3)]FW^7YVP[-^,[<],XYQ6T:,Y1
M4E7E9^4?_D3*56$9.+HQNO.7_P D>C?\('\.?^BI?^6]<_\ Q5'_  @?PY_Z
M*E_Y;US_ /%5Y_I6C:AKMT+73;&YU"Y(+>3:PM*^!U.U03BDO-)OM.WF[LKB
MU"2F%O.B9,2  E#D?> (XZ\BCV,[\OMY7_[<_P#D0]K"W-[&-O\ M_\ ^2/0
M?^$#^'/_ $5+_P MZY_^*H_X0/X<_P#14O\ RWKG_P"*KA;+PWJVI7D=K::7
M>W5U)&)D@AMW=WC/(<*!DK[]*6W\,ZQ=7LMG!I-]-=PN(Y+>.V=I$8YPI4#(
M)P>#Z&E[*7_/^7_DG_R(_:1_Y\+_ ,G_ /DCN?\ A _AS_T5+_RWKG_XJC_A
M _AS_P!%2_\ +>N?_BJX?3_"^M:M#<S6.D7]Y#;'$\EO;/(L1'9B!\OXU8LO
M#8NM#M-2,TI$^H_8#!!!YDGW5;<HW#<?FP%XR>])TY+_ )?R_P#)/_D1JI%_
M\N(_^3?_ "1V'_"!_#G_ **E_P"6]<__ !5'_"!_#G_HJ7_EO7/_ ,57%6GA
M75M6NI8M+TK4=0"R/&/)M'9\KU!5<X8 @D9.,TT>%=::SNKP:/?FTM6*7%Q]
ME?RX6'4.V,*1Z&G[-_\ 00__ "3_ .1%[1?\^%_Y/_\ )';_ /"!_#G_ **E
M_P"6]<__ !5'_"!_#G_HJ7_EO7/_ ,57G,EI/###-)#(D4V3%(R$+)@X.T]\
M'CBM*S\&Z_J+W:6FAZE=-:,4N%AM)',+#J'P/E/!X/I3=*45=UY?^2?_ "(E
M5C)V5!?^3_\ R1VG_"!_#G_HJ7_EO7/_ ,51_P ('\.?^BI?^6]<_P#Q5>:=
M.#P:2J^KU/\ G]+[H?\ R)/MZ?\ SYC_ .3?_)'IG_"!_#G_ **E_P"6]<__
M !5'_"!_#G_HJ7_EO7/_ ,57F=%'U>I_S^E]T/\ Y$/;T_\ GS'_ ,F_^2/3
M/^$#^'/_ $5+_P MZY_^*H_X0/X<_P#14O\ RWKG_P"*KS.BCZO4_P"?TONA
M_P#(A[>G_P ^8_\ DW_R1Z9_P@?PY_Z*E_Y;US_\51_P@?PY_P"BI?\ EO7/
M_P 57F=%'U>I_P _I?=#_P"1#V]/_GS'_P F_P#DCTS_ (0/X<_]%2_\MZY_
M^*H_X0/X<_\ 14O_ "WKG_XJO,Z*/J]3_G]+[H?_ "(>WI_\^8_^3?\ R1Z9
M_P ('\.?^BI?^6]<_P#Q5'_"!_#G_HJ7_EO7/_Q5>9T4?5ZG_/Z7W0_^1#V]
M/_GS'_R;_P"2/3/^$#^'/_14O_+>N?\ XJC_ (0/X<_]%2_\MZY_^*KS.BCZ
MO4_Y_2^Z'_R(>WI_\^8_^3?_ "1Z9_P@?PY_Z*E_Y;US_P#%4?\ "!_#G_HJ
M7_EO7/\ \57F=%'U>I_S^E]T/_D0]O3_ .?,?_)O_DCTS_A _AS_ -%2_P#+
M>N?_ (JC_A _AS_T5+_RWKG_ .*KS.BCZO4_Y_2^Z'_R(>WI_P#/F/\ Y-_\
MD>F?\('\.?\ HJ7_ );US_\ %4?\('\.?^BI?^6]<_\ Q5>9T4?5ZG_/Z7W0
M_P#D0]O3_P"?,?\ R;_Y(]4TWX<_#R^U&UMD^)K3O-*D:Q+H4\9<D@;0S'"Y
MSU/ KU2/]C_0KB-98O$5\T3C<I\I#P>E?-OA'_D:]%_Z_8?_ $8M?H3H/_(%
ML?\ K@G\A7S&;XG$X&<(TZK=UUY?T2/I,JP^&QD)NI22L^E_U;/"O^&.M&_Z
M&&^_[\I1_P ,=:-_T,-]_P!^4KZ$HKP/[7QW_/S\O\CW?[*P7_/O\_\ ,^>_
M^&.M&_Z&&^_[\I1_PQUHW_0PWW_?E*^A**/[7QW_ #\_+_(/[*P7_/O\_P#,
M^>_^&.M&_P"AAOO^_*4?\,=:-_T,-]_WY2OH2BC^U\=_S\_+_(/[*P7_ #[_
M #_S/GO_ (8ZT;_H8;[_ +\I1_PQUHW_ $,-]_WY2OH2BC^U\=_S\_+_ "#^
MRL%_S[_/_,^>_P#ACK1O^AAOO^_*4?\ #'6C?]##??\ ?E*^A**/[7QW_/S\
MO\@_LK!?\^_S_P SY[_X8ZT;_H8;[_ORE'_#'6C?]##??]^4KZ$HH_M?'?\
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M_P"26^*O^P=-_P"@&O@"OON'?X$_7]#X;B#^-#T_4****^M/E0HHHH ****
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M*WDLA"H#'\SYPF0P&3C%6_\ AG_X@_\ 0MS_ /?Z+_XNC_AG_P"(/_0MS_\
M?Z+_ .+I1EA(M-5EI;[2Z;=?ZL$HXJ2:=)Z_W7U^7]7)_&&O:=)X9DU*RNXY
M=6\3>4=0A1QN@\K!EW*.GFR[7&>RUA:!XOTG2M2TZZN/"UI)]C^;=:W,R22R
M!<*[^:TJ<-AL! "0.V0=;_AG_P"(/_0MS_\ ?Z+_ .+H_P"&?_B#_P!"W/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P! -? %??<._P "?K^A\-Q!_&AZ?J%%%%?6GRH4444 %%%% !1110 4444
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M7<?U=Q5Y2_K[_P"NQYS-?WT$SQM>2ED8J2D^Y<@XX()!'N.*9_:E[_S]S_\
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M6)DL!YT,2N DYG WMN&.68J=_ Z8UC64I<O+KZ^G^?\ 6E\Y46H\W-I_P_\
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M_P#"6:+_ *7/_P ?L/\ RU;_ )Z+[U^@.BNTFCV3,Q9FA0EB<D\"OST\(_\
M(UZ+_P!?L/\ Z,6OT)T'_D"V/_7!/Y"OA>(DE4IV[,^VX?;=.I?NB_1117R!
M]6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8OA7_C
MQN/^OF3^=;58OA7_ (\;C_KYD_G6U0 4444 %%%% !1110 52UK_ ) U_P#]
M>\G_ *":NU2UK_D#7_\ U[R?^@F@ T7_ ) UA_U[Q_\ H(J[5+1?^0-8?]>\
M?_H(J[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '(?%__ ));XJ_[!TW_ * :^ *^_P#XO_\ )+?%7_8.F_\ 0#7P!7WW
M#O\  GZ_H?#<0?QH>GZA1117UI\J%%%% !1110 4444 %%%% !1110 4444
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M)DBVQRE?E$;K\^,<YP!C@YK:N/AKI,FI:=80^=;K>ZS#;B61BTL4$EO%+Y9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+X5_P"/&X_Z
M^9/YUM5B^%?^/&X_Z^9/YUM4 %%%% !1110 4444 %4M:_Y U_\ ]>\G_H)J
M[5+6O^0-?_\ 7O)_Z": #1?^0-8?]>\?_H(J[7R[J7[*WQ%\1:C=:K8_M'^.
M-#LKZ5KJ#2[2WMS#9QN2RPH2,[4!"C/. *K?\,??$_\ Z.C^('_@-:__ !-
M'U717RI_PQ]\3_\ HZ/X@?\ @-:__$T?\,??$_\ Z.C^('_@-:__ !- 'U71
M7RI_PQ]\3_\ HZ/X@?\ @-:__$T?\,??$_\ Z.C^('_@-:__ !- 'U717RI_
MPQ]\3_\ HZ/X@?\ @-:__$T?\,??$_\ Z.C^('_@-:__ !- 'U717RI_PQ]\
M3_\ HZ/X@?\ @-:__$T?\,??$_\ Z.C^('_@-:__ !- 'U717RI_PQ]\3_\
MHZ/X@?\ @-:__$T?\,??$_\ Z.C^('_@-:__ !- 'U717RI_PQ]\3_\ HZ/X
M@?\ @-:__$T?\,??$_\ Z.C^('_@-:__ !- 'U717RI_PQ]\3_\ HZ/X@?\
M@-:__$T?\,??$_\ Z.C^('_@-:__ !- 'U717RI_PQ]\3_\ HZ/X@?\ @-:_
M_$T?\,??$_\ Z.C^('_@-:__ !- 'U717RI_PQ]\3_\ HZ/X@?\ @-:__$T?
M\,??$_\ Z.C^('_@-:__ !- 'U717RI_PQ]\3_\ HZ/X@?\ @-:__$T?\,??
M$_\ Z.C^('_@-:__ !- 'U717RI_PQ]\3_\ HZ/X@?\ @-:__$T?\,??$_\
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MN)%O)KV2>:3>TCR*@/;(^YZG.?:O-;'X VFJ37D-C^T'K>H362L\\=K-9.P
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M $$5=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQOW#[1??P[:R^9B7[3YQ:-?)<?Z0?WG[F+]XV)1N&6^;._C?O'VC(^'/PO\
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MSD2_:?-+QKY,@_T@_O/W,7[QL2C<,M\V=_\ 'O'VCYGU#P;X;D_:6^%7PO\
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M$HW#+?-G?_'O'VC:FF^T>;^]^U>?OB_<2_\ 'S_K?W,7[UL2C?\ ,WS;M_\
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M3^S\+_S[0?VABOYV8LOAVUF+%9?M/FEHQY$@_P!(/[S]S%^\;$HW#+?-G?\
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M>?YC_P +&\2?]!63_OVG_P 31_PL;Q)G/]JR?]^T_P#B:/\ 7"=OAE_Y+O\
MY>7XA_J:N\?_ ";^K^?X'I=G\5-'\17&K0V6K6.J2VD3F_CL;Y':.(&8$$"5
MO*<%FW.V<Y;.[<WGQP?%O0]:TG5M4M]:TZ_TRU1EOKVUU!&A1#YN%+B5EC?Y
MSEV)W;FSOW-Y_G'_  L;Q)_T%9/^_:?_ !-4=-^,.IZP]VFG^)(;Y[64P7"V
MS12&&0=4? .UO8\U7^M\W=J,K?\ ;O\ 7I^I/^IT59.4;_\ ;W]>OZ'JMQ\6
M]#E\/W.NR:SI\FBN6@DU)-006TF?- B20RE5E^<Y8D[LMG=N;SS6/BYH>GZ/
M%JFHZSI\&FZ@C+%>R:@D4-VG[WY87:4C>-[;G!;=EL[MS>?YQ_PL7Q)C']JR
M?]^T_P#B:/\ A8OB3&/[5D_[]I_\34_ZX2_EE_Y+M_77\"O]3%_-'_R;^OZW
M/2M>^*FD:/-##JNK6-G-J41,,<]\D+7<;&4*(0TI^?,ARXW;MQ^_N;SY-4^)
MVF6WB!M"O-2LTUJY3']FM>K'<SHWFE5CC,I8/AFR^&W9;[^YO/\ ,?\ A8WB
M3_H*R?\ ?M/_ (FC_A8WB3_H*R?]^T_^)H_UPE_++_R7^OZZ!_J:OYH_^3'I
MW_"SM+U+Q!?:%'J5G>:TJ.MSIMO>J;DH!*2HC\UF1QO.YR#G<<[MS>>RS^*F
MC^(KC5H;+5K'5);2)S?QV-\CM'$#,""!*WE."S;G;.<MG=N;S_-/^%C>),Y_
MM63_ +]I_P#$T?\ "QO$G_05D_[]I_\ $T?ZX2_EE_Y*'^IB_FC_ .3'H\'Q
M;T/6M)U;5+?6M.O],M49;Z]M=01H40^;A2XE98W^<Y=B=VYL[]S>>7'Q;T.7
MP_<Z[)K.GR:*Y:"34DU!!;29\T"))#*567YSEB3NRV=VYO/\X_X6-XD_Z"LG
M_?M/_B:/^%B^),8_M63_ +]I_P#$T?ZX2_EE_P"2[?UU_ /]3%_-'_R;^OZW
M/1]8^+FAZ?H\6J:CK.GP:;J",L5[)J"10W:?O?EA=I2-XWMN<%MV6SNW-Y[]
M>^*FD:/-##JNK6-G-J41,,<]\D+7<;&4*(0TI^?,ARXW;MQ^_N;S_-?^%B^)
M,8_M63_OVG_Q-'_"QO$G_05D_P"_:?\ Q-'^N$OY9?\ DOR_K\@_U,7\T?\
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MK'&92P?#-E\-NRWW]S>?YC_PL;Q)_P!!63_OVG_Q-'_"QO$G_05D_P"_:?\
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MAZEKEWH\6L6-[JI5TFL+:^4W#K^]^18_-9ED&\[G(.[<<[][>?\ 0;?#VQ+
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MWG<P+;MQ^]O)G^D/^%>V.TC<WUH_X5[8[0-S?6IE]?J1<9;/S6WW;^?X%Q>
MA)2CNO)[_>><?LU6^I?V)<3W]P+MI+V\EBF602*T#W$C088$Y B:,=3TZGK7
MN=<QX"TN+2],N$B'_+S(,_C73UW82BZ-.TMVV_O/.QE95JO-'9:?<%%%%=AQ
M!1110 4444 %4M:_Y U__P!>\G_H)J[5+6O^0-?_ /7O)_Z": #1?^0-8?\
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MGBCD=E,A&,@,Q"C'\*X ]*J^%?A/X3\$^(=5UW1-&CL=5U,L;JX621M^YMY
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MO]E:]\Z3F+CY=F[9V'.W-='13GBL14=YU&^FK>SZ!&C2C\,4OD<YHWP\\/\
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MXAN+OI&[\^57_&YWY;"5/#J,E;65EV7,[?A8****\X],**** "BBB@ HHHH
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M[<G'8 9. !S795PX^M#$8J=2GLWIZ+0Z<-3E2HQA+<****X#I"BBB@ HHHH
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M6M--._9GA/[1'PAT?X27GAF+1[F^N5U/3Q=S?;I$<J^<87:BX'US7 7WP_\
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MHRQ1"<L .N!Q35?#RVP__DTO\Q/#XF.^(?\ X#'_ "/4_P#A4FG?]#_X8_\
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MGV&VN+F.TBD\IY-TKG"KA%)&<=3Q5PK4*DE&&'NWYR(G1Q%.+E/$V2ZN,?\
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MC_P);_XFO.:*CZQAO^?"_P# I?YE_5L5_P!!#_\  8_Y'HW_  J33O\ H?\
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M )\+_P "E_F'U;%?]!#_ / 8_P"1Z3;_  >L;F>.&/QYX:>21@BJMRQ)).
M-O6ENOV=_'*7$JVFE1WUL&(BNHKN%5E7LP#." 1SR*XCPM_R,VD?]?D/_H8K
M[VT'_D"V/_7!/Y"OK,FRG!9Q2G*47!Q:^%_YW/C\[SC'9)5A&$U-23^);?\
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M#^>?WQ_^1#_73,/Y(?=+_P"2/BW_ (9Y^(/_ $+_ /Y.V_\ \<H_X9Y^(/\
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M=^\^;Y@.N> !TXK7\8_ /P!X_P!>;6M>\-V]_J;Q^4]QYLL9==NT;@C ,0.
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M(SJ!DDJ%R#G@5[UX7_9U^'?@O7+36-%\-166I6DDDD-P+F9RK.NUN&<@C!.
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MYK<UMG[K][=:Z'@K*L?[15.>UMOWDWRW<;ZM>\O=V=E=^1XUIGQ=^(/BW2_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVOU.+$9_F6*:=>LY-=]3[-_X>!:?_P!"7<_^#!?_ (W1_P / M/_ .A+N?\
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MG0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KZ1US_ ),;\._]AUO_ $.>OFZOI'7/^3&_#O\ V'6_]#GKQLRWP_\
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M9F3<<'#;MW."3B?Q%X[\)W/QG\4ZK:Z]I)L[[P%) MRM\C++<$@"+>Q!:3:
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M&W\5K]>VQR_V:K?$KW?16UTV^1X[^R?H.O>'?@OI=KK\<UO.TLLMM;W&1)%
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M>=."W^S=:7Z\JULKVW[7!K&WM&<OO_X/GN97_#77Q9_Z&O\ \IUI_P#&J/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 8OA7_CQN/\ KYD_G6U6+X5_X\;C_KYD_G6U0 4444 %%%% !1110 52
MUK_D#7__ %[R?^@FKM4M:_Y U_\ ]>\G_H)H -%_Y UA_P!>\?\ Z"*NU\NZ
ME^W[\.O!NHW6@7VA^.)KW2I6L9Y+3PS<2PM)$2C%' PRDJ<,.",&JW_#R'X8
M?]"_\0/_  D[K_"@#ZKHKY4_X>0_##_H7_B!_P"$G=?X4?\ #R'X8?\ 0O\
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MPO+1/^@7X@_\%4O^%']L9=_S_C]Z#ZI7_D9Z)17G?_"\M$_Z!?B#_P %4O\
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MOVG6?L:VD=__ ,)#.FS:I"-Y:QA3@G..]?+7_"RD_P"A5\7?^"&X_P#B:/\
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M?T?O#ZGB?^?;^X[&BN._X64G_0J^+O\ P0W'_P 31_PLI/\ H5?%W_@AN/\
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MR'X8?]"_\0/_  D[K_"@#ZKHKY4_X>0_##_H7_B!_P"$G=?X4?\ #R'X8?\
M0O\ Q _\).Z_PH ^JZ*^5/\ AY#\,/\ H7_B!_X2=U_A1_P\A^&'_0O_ ! _
M\).Z_P * /JNBOE3_AY#\,/^A?\ B!_X2=U_A1_P\A^&'_0O_$#_ ,).Z_PH
M ^JZ*^5/^'D/PP_Z%_X@?^$G=?X4?\/(?AA_T+_Q _\ "3NO\* /JNBOE3_A
MY#\,/^A?^('_ (2=U_A1_P /(?AA_P!"_P#$#_PD[K_"@#ZKHKY4_P"'D/PP
M_P"A?^('_A)W7^%'_#R'X8?]"_\ $#_PD[K_  H ^JZ*^5/^'D/PP_Z%_P"(
M'_A)W7^%'_#R'X8?]"_\0/\ PD[K_"@#ZKHKY4_X>0_##_H7_B!_X2=U_A1_
MP\A^&'_0O_$#_P ).Z_PH ^JZ*^5/^'D/PP_Z%_X@?\ A)W7^%'_  \A^&'_
M $+_ ,0/_"3NO\* /JNBOE3_ (>0_##_ *%_X@?^$G=?X4?\/(?AA_T+_P 0
M/_"3NO\ "@#ZKHKY4_X>0_##_H7_ (@?^$G=?X4?\/(?AA_T+_Q _P#"3NO\
M* /I'PK_ ,>-Q_U\R?SK:KD_AGK]OXF\-_VC:QSQP3R><JW$1C<!T20 J>AP
MXR.QR.U=90 4444 %%%% !1110 52UK_ ) U_P#]>\G_ *":NU2UK_D#7_\
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MG_CWX_O_ +W'_/9*+W][]J_Y:>;YTO\ >\S'VOY_X]^/[_[W'_/9*/[/PO\
MS[0O[0Q7_/QF3=>';=OM&"7WB608^;>!]I^<8W;@-H^8>8!_SU2BZ\.V[+<
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M9QECGY1C@*,#%=7UFG+#<RJ<K<4E&ZLG=:VW7FWMYFOM8NE=2LVDK7T/0)]
MTC3?$UY\7XV1M-;1A=PQ]S<,FW]5PO;EC7B7BSQ1X^UOX3V1U6PC'AB:\:9+
M]4'F2N7=L-\Q(7<6P=HSCJ:TOBI\1O#</@#3/ W@V[NK_2H7\Z>\N@REOF+!
M,,JD_,<GY0!@8[UYM=>.-=O?"UMX<GU&631;:3S(K3"@*V2>N,D9)X)P*\_'
M8RG>5.#M=._*]'*5KW[K3H<U>M&[C%].FS;W^1A4445\T>6%%%% !1110 44
M44 %%%% !1110 5ZI\&TTR3P;KHLED:Z_M60WXD7<//%E&05^5N!%Y/..""<
MK]X>5UZI\'+JQOO!NNPVUCY,]MJLD=U)C=Y\OV*.028VMC$;1KTX\O.5^\/6
MR;_D8+T_]NCO_6]C[?(?]VK?UT>W];'H]Y^]^U?\M/-\Z7^]YF/M?S_Q[\?W
M_P![C_GLE%[^]^U?\M/-\Z7^]YF/M?S_ ,>_']_][C_GLE%Y^]^U?\M/-\Z7
M^]YF/M?S_P >_']_][C_ )[)1>_O?M7_ "T\WSI?[WF8^U_/_'OQ_?\ WN/^
M>R5^V',%[^]^U?\ +3S?.E_O>9C[7\_\>_']_P#>X_Y[)1>_O?M7_+3S?.E_
MO>9C[7\_\>_']_\ >X_Y[)1>_O?M7_+3S?.E_O>9C[7\_P#'OQ_?_>X_Y[)1
M>_O?M7_+3S?.E_O>9C[7\_\ 'OQ_?_>X_P">R4 %[^]^U?\ +3S?.E_O>9C[
M7\_\>_']_P#>X_Y[)1>_O?M7_+3S?.E_O>9C[7\_\>_']_\ >X_Y[)1>_O?M
M7_+3S?.E_O>9C[7\_P#'OQ_?_>X_Y[)1>_O?M7_+3S?.E_O>9C[7\_\ 'OQ_
M?_>X_P">R4 %[^]^U?\ +3S?.E_O>9C[7\_\>_']_P#>X_Y[)1>_O?M7_+3S
M?.E_O>9C[7\_\>_']_\ >X_Y[)1>_O?M7_+3S?.E_O>9C[7\_P#'OQ_?_>X_
MY[)1>_O?M7_+3S?.E_O>9C[7\_\ 'OQ_?_>X_P">R4 %[^]^U?\ +3S?.E_O
M>9C[7\_\>_']_P#>X_Y[)1>_O?M7_+3S?.E_O>9C[7\_\>_']_\ >X_Y[)1>
M_O?M7_+3S?.E_O>9C[7\_P#'OQ_?_>X_Y[)1>_O?M7_+3S?.E_O>9C[7\_\
M'OQ_?_>X_P">R4 %[^]^U?\ +3S?.E_O>9C[7\_\>_']_P#>X_Y[)1>_O?M7
M_+3S?.E_O>9C[7\_\>_']_\ >X_Y[)1>_O?M7_+3S?.E_O>9C[7\_P#'OQ_?
M_>X_Y[)6;9^)=(\3R:TFE:K9:N]G=7%O>K9W"7!AN$%RS)(%+_.H92=WF%0P
M_>QYH TKW][]J_Y:>;YTO][S,?:_G_CWX_O_ +W'_/9*+W][]J_Y:>;YTO\
M>\S'VOY_X]^/[_[W'_/9*+W][]J_Y:>;YTO][S,?:_G_ (]^/[_[W'_/9*+W
M][]J_P"6GF^=+_>\S'VOY_X]^/[_ .]Q_P ]DH +W][]J_Y:>;YTO][S,?:_
MG_CWX_O_ +W'_/9*+W][]J_Y:>;YTO\ >\S'VOY_X]^/[_[W'_/9*+W][]J_
MY:>;YTO][S,?:_G_ (]^/[_[W'_/9*+W][]J_P"6GF^=+_>\S'VOY_X]^/[_
M .]Q_P ]DH +W][]J_Y:>;YTO][S,?:_G_CWX_O_ +W'_/9*+W][]J_Y:>;Y
MTO\ >\S'VOY_X]^/[_[W'_/9*+W][]J_Y:>;YTO][S,?:_G_ (]^/[_[W'_/
M9*+W][]J_P"6GF^=+_>\S'VOY_X]^/[_ .]Q_P ]DH +W][]J_Y:>;YTO][S
M,?:_G_CWX_O_ +W'_/9*+W][]J_Y:>;YTO\ >\S'VOY_X]^/[_[W'_/9*+W]
M[]J_Y:>;YTO][S,?:_G_ (]^/[_[W'_/9*+W][]J_P"6GF^=+_>\S'VOY_X]
M^/[_ .]Q_P ]DH +W][]J_Y:>;YTO][S,?:_G_CWX_O_ +W'_/9*+W][]J_Y
M:>;YTO\ >\S'VOY_X]^/[_[W'_/9*+W][]J_Y:>;YTO][S,?:_G_ (]^/[_[
MW'_/9*+W][]J_P"6GF^=+_>\S'VOY_X]^/[_ .]Q_P ]DH +W][]J_Y:>;YT
MO][S,?:_G_CWX_O_ +W'_/9*+W][]J_Y:>;YTO\ >\S'VOY_X]^/[_[W'_/9
M*+W][]J_Y:>;YTO][S,?:_G_ (]^/[_[W'_/9*+W][]J_P"6GF^=+_>\S'VO
MY_X]^/[_ .]Q_P ]DH +W][]J_Y:>;YTO][S,?:_G_CWX_O_ +W'_/9*RO%F
M9+><@[_->27^]YF&NOGZMOQ_?S+C_GJO2M6]_>_:O^6GF^=+_>\S'VOY_P"/
M?C^_^]Q_SV2LKQ9F2WG.=_FO)+UW>9AKKY^K;\?W\RX_YZKTKS\P_P!UJ>AW
MY?\ [U3]3M_V5;C4[SX>65UK$?E:K<1K+>+C'[\JOF=N?FR,Y;IU[#VZO$?V
M5;74[3X>64>LS?:-76-5O9MX?S9PJB1]X #Y8'Y@6SZ]A[=7F8/^%IW>VV_3
MR.W'?QG?LM]]NH4445W' %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 8OA7_CQN/\ KYD_G6U6+X5_X\;C_KYD_G6U0 4444 %
M%%% !1110 52UK_D#7__ %[R?^@FKM4M:_Y U_\ ]>\G_H)H -%_Y UA_P!>
M\?\ Z"*XOX^_\DA\2?\ 7%/_ $8M=IHO_(&L/^O>/_T$4S7] L/%&CW.EZG!
M]IL;A0LL6]DW $'JI!'('0UA7INK1G3CNTU]Z,ZD7*#BNJ/!O &I-XX\7>']
M/\96TVF6EGI\,^A:1<+B&\94VF=R?O. ,A2. ?KNY'55\*P^,OB+>>)/#&L:
MUY&H-Y-[IP<16N2P_>.'4+D[<9!Z5]+ZOX!T'7;'2[2]L/,BTMD>R9)I(Y("
M@ 4JZL&[#OS@$]*?8>"=$TV36G@L%!UEB]^)'9UG)!!R&) &&/ P.:\266U9
M149-.SO=J]]+:JUM'MY>9P/"R:2;3\WZ'BVM>,-4\$_L^Z/9:SJ>W6M9!MXK
MAI/.>.V=LERRDEML9 R,GYE%0?";Q1IZV?C'P3X>\1@6BVTEUHVJ7 :+R@R?
MO-VY5*[6(;I_>->RZ3\,_#>BW>DW-II[)/I43PV327,TGD(^=P 9R.=QZ].@
MJQX@\!:!XJU&TOM6TR.]NK5'CB>1F "N,,I .&!!/# ]35K XA2C/F7NI*VN
MUK/7SWVZ(KZO4NI7VTZ[==?^!T1XIX4\/:3\,]>\.R^(_#5Q9ZI<7"VT'B&P
MU9KF*]F8=7C+ JISG[I'2O2=:^)=Z]CXHM].\.:[9WVFV=Q-!>7UALM9GCX'
MEMN.[/W@,<@&K>@?!7P5X8U9-3T[088;V-MR2/+)+L;.<J'8A3[@<5V]=&&P
ME6C3<+J*\M>G>T=?E?S9I2HSA%QO;T_X9'SKHO@OP==?"I?'>L76IZOK*PBZ
MN=4M;]_M44N1E$^8*"I..1_2M/XBZ'I2?$?X9:_9VTD=YJ5[$)9I97=W1538
M&!8C(!ZCD]R:[NZ^!?@.\U8ZE+X;M3<E]Y"LZQ$^\0;8?IMYKH]4\'Z/K5WI
M%S=V2R3:3)YMD5=D$+<#A5(!' X((XKGCE\_9N#C%/W=NK3U;TW:]?4A8>7+
MRV73\'OL>(^/O ^C7WBQ-,\(?;[WQXUTMS<:N;Z1QIL6[)\QBV!P<!<;L=^@
M-VZ\!Z'X\_:"\36FOV7]H00:;;RHOFR1X;"#/R,.Q-=K>?L]_#_4+R>ZGT#S
M)YG:21OMEP,L3DG DQU-6]=^!_@GQ+?"\U+1?M-R(TA#_:IU^5%"J,*X'  K
M-X"K)MN$/B3M=V:2>_N[ZZO6_D1]7F[MQ6][=.OD>9:;XJ7X7ZUX_P!)TF_E
MOO#NEV"2VD4LIE%K=/A5@5CV+,?E_P!GU!S/XD\$S_"SP?X+\4V,<DFH>'V#
M:H%/S30S',P/KAF('H#GM7I<OP?\-#2=.TNSM&TW3[.]COC!:D 7$B9VB5F!
M9Q^.>!S76:EIMMK&GW-C>PK<6ES&T4L3=&4C!'Y5M' 5'&49NUOAMT=[Z>2L
MON+CAY6:E\O+6_\ D>1^&XK'XR?$K5/$$\4&I^&='@_LVQCF02132N TK[3P
M>#CIR"/2NB^%.GZ;X)\"Z8M[;6N@7MY*T;K/&MM)/)YC[%.<%FV]!UQTKK?#
M'A;2_!NCQ:7HUHME8QLS+$&9^6.22S$D_B:H>-? ]KXW&CI=LBQ:??QWI!BW
M,^P'Y <_*"2,]<@8]QTT\-.DO:V3J:W[7;77LDK+R-8TI07/O+_/_(Z6BBBO
M4.L**** "BBB@ HHHH Y#XO?\DO\4_\ 8.F_]!-? =??GQ>_Y)?XI_[!TW_H
M)KX#KX#B3^/3]/U/G<S^./H%>L_ [X<Z9XRLO$6IW]C-KLVEQ(8-&@G\@W#-
MNZN#D#Y>WZ]*\FKN/AJ^@0->RZCXKU3PCJ@"BTO;"%W0+SO#[#O.>.!@>Y[?
M/8-P5>+FDUKNTNGGI]^AYM"WM%S*Z_KOH:'B[PS;Z]KVC:-X>\#ZGX7URX+K
M+I]Y.\BN.-K(TF#C 8DG &/QJ/Q-\#==\-Z1>:DM]I.LP6#A+Z/2KLS26G_7
M12HQ^N.O3FO3KK]H#1= OO"4 U"X\8MISRF]UE[3[/(4=64+&K8.0""<]=HY
M.3CF?^$G\#_#WP_XL'A[7;KQ'?Z_$;:."2T>%;6-LY+LX^<C<>1W'09S7KU*
M&$DY2<TWY.*M[NEDM):Z.QVRIT7=N7Y*VG9;Z]CI#\/=)T+XN/I6C>&M+U"V
M;P]]J:UU:XD,:N6P9 2LAW=.,#O@BO+/"WP;UGQ5X?77/MNDZ+ILLIBMY=5N
M_($[@D;4X.>01SCD5ZG_ ,+<\)_\+>?6_P"UO^)8?#WV'S_LTW^NW9V;=F[I
MWQCWKD+/Q'X.\<?#70-"\1:W<>'+_0GD"-%9O/'<1L<\!>C8P,G'.3SFM*T,
M+4DTFM'*RNDOLVU]+V]-"IQI2=KKK972[=3+^/7@?3? >OZ+8Z=9?83+I<4U
MRGFM)F8LX8Y9CZ=N*S_!OP>U#QIIEM>6^MZ#8-=2-%;6M_?>7/,RG!"H%)//
M;K6G\?O&&A^,O$>D3Z!>/>V=MIL=LSR1NC*RNYP=P&3@CD<5U?PS\;?#SP]X
M0TAKI-,M==M9C)=M?Z*][/,0^5,,H8",@8P23@CIZ\WLL-5QM2+:4%MJDNFS
MV,N2E*O)77+ZG!^'O@CXC\1:IKVG*;.PO-%V_:X[V8H &SR& (Q@9R2.*B\4
M_!W7/#,.DW$<^GZY9ZI,+>UNM'N//B>4G 3<0.2<^W!YXKT75OBEX9N-8^*L
M\.J9CUNPBAT]A!*/.<0E2/N_+R<?-BL/PQ\4=)\,_#'PQ:"?[3JVF:^M_)8^
M6W^I ?)#$;<_-QSG)H>'P2O#F[ZW725EIYK4/9T/AOWUOY_Y&[\.?V<C#XN6
MW\3S:1JD$=NSW.F6FH-]IMV(^1G5=I SQP2.:\#N%"3R*HP Q _.OH_PSXP^
M&>@_$K4/&2^++MI-120_89-/F'V=GP6W.%.X9&  ./4U\X7#!YY&7D%B1^=8
MXZ%"G3A&C:]Y;--VTM=K\O4C$1IQC%0MN^M^UB.BBBO&.$**** "BBB@ HHH
MH **** "BBB@ HHHH *]7^#^H/J'@O6;=[!85LM3EA218\FX'V-)?,/R-D@R
M%<XX$8^9<9'E%>M?"*;4[KP3JL5];XM8=2E6P/EYWP?9%8M]ULXE,PS@8V]5
MQN'JY-_R,8^G_MT?O_IGV^0_[M6_KH>@WG[W[5_RT\WSI?[WF8^U_/\ Q[\?
MW_WN/^>R4E]^\6[_ .6GF^=+_>\S'VOY_P"/?C^_^]Q_SV2EO/WOVK_EIYOG
M2_WO,Q]K^?\ CWX_O_O<?\]DI+[]\+L?ZSSO.E_O^9C[7\_\>_']_P#>X_Y[
M)7[:<Q^8LG[97CF'PYK>K7?QVA'BFWOYD@\%W7@^&6&\02R*#+>J@4-M=B&)
M+ '[ZD"OJ;Q[\5/B-\1OB1I'PT\#:CI'A+5;C0?^$EU_Q \/]JK "TX\NVC(
M:.?.\_OF:3 ((E3!KG;?]BSQ]H_@_7?!NG_&]H/!>K374]QHZ>$[=_/BD-QY
MI\TRNY;"L!(A=5W_ 'UQ7=>,OV3;9K?PG>^!/%NH>"_%7A;23H]CK:VT=Z+N
MQC,^5GA/RS "/(8;U5B"74*H7!*=M31N)R/QH\5?&#X&_"VWDUGQ[IOB34KS
MQ98V5MK,.CPPSW=G(URDIN(V+Q-(6W8DB#[1C$H/%=M^V1\>-0^"'@2RET58
MVUSQ%JJV%K<W%N;J.(,]R'G,88F9E4X7!F.XC$@QM./X[_96\5>//AE>>']:
M^+FIZWXAGUN'7SKM_ID<D8>V%T!Y5K%(% . 20TJ Y.],L">(_V7?&GQ \/W
MVG>/_C!<^++JWNX]5T+4;7P_;6$]C=0&Z/VAC$SBXR<Y^^H!QYJ8JO>UL+3J
M0?LF_%;6O'USXTT;Q3XSUWQ'X@T]EF;3/$GA2#0[Z")HKAA-)'$\HDW%@=S
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M7Q#*#3?'VEW7B;PG"MGY9@@C>[#0.P0F5Q&Z2"1_,8*/]:A!QZ[^T;\>M*^
MOA-=6O[4ZI>ZM>FTL+(W45NES,QN@'DGE)C5%ZF5C+CH)5.!7G&M?L%_#W0]
M2TG6OAQ ? WB32]1748=0$MUJ"30Q&X\R'RGN"/+=4 +(7 QS*!D'T?]HSX#
MZ5^T#X472[ZZ-C?V=XVJ:??B!;I5EC-T=SQ-N6XC(&&#>:".#,@XH7,HM=0=
MFSSKPC^V!??$?P9X]N-)\#1:EXT\,#[3?>'=-\0V^H0743+<N9K>\A659RBD
MDY1VRN!*I(JGJ7[;T&K?#OQO\0/#O@RXU?P3HR0;-1O[X6<NH7DSNK1I"T4A
MQ"+CYI6,AW*%5P&##7\-_LJ:KX-^%WBKPWI?C+2K;7]<4Q/XATWPA96!2S3[
M2'5(;4J&<J' F+2A"P(>/!SYU\;/V5+WX6_ 'XFZ#\.[G4]8\.ZTEE/;>$;>
MTDO)UN(;@K)<PNLK%E,<3,X5)5&"1*@!4KWTKC]VYZ9X7_:GU34O'5AX=\=_
M#C4O $7B2SN]2T74+N]2]COTACN9':0(K&-U5OX_,<$$>9'UKB]$_P""A6@^
M*/&-M;-X<CM_"6L:B;"TUAM?LY;^2:1IUAEFTT,TT:$R<R2&1EPN'7<*ZWP7
M^R_K#>,M)\5>/_B%J'Q _L;3KJWT/3;K3(;7[/'+%<)+).\>XW,FU<>: ?>1
M2J[<+P+^PGIGP]\<6U_;:_IFH^%M/EN+FQT:Y\(Z;->%0;AEWZ@T<DL@1DX=
M0VT;1YT90,#WQ>Z;]Q^U/XA\3>+M>A\'?"?6/&/@W3=5ETO4/$-KJ$"S/<!I
MU>6&T;<T\<?F$M*68J%)\Q 0:YGX9_M0>.M0\7?&)_'_ (6MM/\ "/A:XNY;
MB]MM1@N)+!HX9G2WV(':[9][$3_-M^4>8F=U=-<?LKZ_H7BW7)_!WQ6UGPMX
M.UC59-<O?#-K9QS^;,'G9VAN&9W13Y>/E$J ,VZ3FM"^_9>DN/'WQ'U!O&-U
M-X+\=I=3ZOX5:S23SYC%<QBX2Y+.XV;205$BC<=TH/(?OA[IR7PS_;NTCXC^
M.(M U;P]!H,&LQ75SI][;Z]:ZHTOEQ7$N;F&$N]N^QQCS?,;((\Q ,CSGX^?
MM6>,_B%\*?[;\.^"?$/A+P9JFN6HTSQD-66&>]47<P+/;HPE2-QYB;V:;YE"
M[_FQ7J7PC_8KM?A=XE6]U#7])\3Z78V5S:Z99IX.TRSN?+*7">;->1QO+.X"
M']XA(YYE7%<_J_["VOS>%6\&6?QAU)/ %C?#4=)\/2:1%((Q%+/)^]F23?.!
MMD"E<QJ9 2XVX,^_8?NW/KB]_>_:O^6GF^=+_>\S'VOY_P"/?C^_^]Q_SV2L
MKQ9^\MYSG=YKR2]=WF8:Z^?JV_'][,N/^>J]*U;W][]J_P"6GF^=+_>\S'VO
MY_X]^/[_ .]Q_P ]DK*\68DMYR3O\UY)>N[S,-=?/U;?C^]F7'_/5>E<N8?[
MK4]#LR__ 'JGZG:?LHZ6^C_#BPLI;Q;^:WA2%[Q3N%P555,@;'S!B,YRW^]V
M'N->%_LE:?8Z7\,M,M=.NC?6$-O'';W90+Y\2HJI)P,<@ \%OKQ@>Z5YV#_A
M?-_GVZ'9C?XWR7Y!1117:< 4444 %%%% !1110 4444 %%%% !1110 4444
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M/ '<BO!=2TG6/^%<Q>)+Y;U8?$>KI?ZX+#=Y\=@00D?'.P+@G_>%=C\.=/\
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MT9NI34GU"BBBNHV"BBB@ HHHH **** "BBB@#D/B]_R2_P 4_P#8.F_]!-?
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M3?\ (QCZ?^W1^[^D?;Y#_NU;^NAZ)>?O?M7_ "T\WSI?[WF8^U_/_'OQ_?\
MWN/^>R47O[W[5_RT\WSI?[WF8^U_/_'OQ_?_ 'N/^>R47G[S[5_RT\WSI?[W
MF8^U_/\ Q[\?W_WN/^>R47O[W[5_RT\WSI?[WF8^U_/_ ![\?W_WN/\ GLE?
MMIS!>_O?M7_+3S?.E_O>9C[7\_\ 'OQ_?_>X_P">R47O[W[5_P M/-\Z7^]Y
MF/M?S_Q[\?W_ -[C_GLE%[^]^U?\M/-\Z7^]YF/M?S_Q[\?W_P![C_GLE%[^
M]^U?\M/-\Z7^]YF/M?S_ ,>_']_][C_GLE !>_O?M7_+3S?.E_O>9C[7\_\
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M\3,IRK \'C//-?0E !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\L;?7[>(1QWD=]((E8+MW>3C&??.>>N>:UET*$?!OQ;%X>\1:AJ.D+K$,%O
M8DBCN-QBP65DW@Y..&4':"1740_LHV7V>.QFFUC^TVAW-JL9MC8))C.WRRWG
M$ \9QSUXKLHX7&<REA]79-MV>MVE9Z]M]#:%&M>]/5_)]]MSY_U#Q9K&J?VB
ML^HW)@U"X:ZN;996$,DI.=Q3."<X[=A1%XMUR#23I<>LZA'IA!4V2W4@A(/)
M&S.,?A7K^A_ G1(O"%IJFJCQ#K5W/-+#*GAJ**5;4HQ4AU8%FY!Z#\.Y\2U"
M&.WO[F*$2B))65!.NV3:"0-P['UKS*]'$8=1G4?Q+OTW.6I"I3LY/<TK7QMX
MBL;.&TMM>U.WM82&B@BO)%2,@Y!50V ?I563Q%JTUG=6LFIWCVMW+Y]Q"UPY
M2:3(.]USAFR!R>>*SZ*Y/:3:LY,PYI=PHHHK,D**** "BBB@ HHHH *]4^#>
MG64/@W79+6Z^USW&JR37<.S/V>464:A/NM_RS2-\XXW]5QN'E=>J?!M-,D\&
MZZ+)9&NO[5D-^)%W#SQ91D%?E;@1>3SC@@G*_>'K9-?^T%Z?^W1W_K>Q]OD/
M^[UOZZ/^O0]'O/WOVK_EIYOG2_WO,Q]K^?\ CWX_O_O<?\]DHO?WOVK_ ):>
M;YTO][S,?:_G_CWX_O\ [W'_ #V2B\_>_:O^6GF^=+_>\S'VOY_X]^/[_P"]
MQ_SV2B]_>_:O^6GF^=+_ 'O,Q]K^?^/?C^_^]Q_SV2OVPY@O?WOVK_EIYOG2
M_P![S,?:_G_CWX_O_O<?\]DHO?WOVK_EIYOG2_WO,Q]K^?\ CWX_O_O<?\]D
MHO?WOVK_ ):>;YTO][S,?:_G_CWX_O\ [W'_ #V2B]_>_:O^6GF^=+_>\S'V
MOY_X]^/[_P"]Q_SV2@ O?WOVK_EIYOG2_P![S,?:_G_CWX_O_O<?\]DHO?WO
MVK_EIYOG2_WO,Q]K^?\ CWX_O_O<?\]DHO?WOVK_ ):>;YTO][S,?:_G_CWX
M_O\ [W'_ #V2B]_>_:O^6GF^=+_>\S'VOY_X]^/[_P"]Q_SV2@ O?WOVK_EI
MYOG2_P![S,?:_G_CWX_O_O<?\]DHO?WOVK_EIYOG2_WO,Q]K^?\ CWX_O_O<
M?\]DHO?WOVK_ ):>;YTO][S,?:_G_CWX_O\ [W'_ #V2B]_>_:O^6GF^=+_>
M\S'VOY_X]^/[_P"]Q_SV2@ O?WOVK_EIYOG2_P![S,?:_G_CWX_O_O<?\]DH
MO?WOVK_EIYOG2_WO,Q]K^?\ CWX_O_O<?\]DHO?WOVK_ ):>;YTO][S,?:_G
M_CWX_O\ [W'_ #V2B]_>_:O^6GF^=+_>\S'VOY_X]^/[_P"]Q_SV2@ O?WOV
MK_EIYOG2_P![S,?:_G_CWX_O_O<?\]DHO?WOVK_EIYOG2_WO,Q]K^?\ CWX_
MO_O<?\]DHO?WOVK_ ):>;YTO][S,?:_G_CWX_O\ [W'_ #V2B]_>_:O^6GF^
M=+_>\S'VOY_X]^/[_P"]Q_SV2@ O?WOVK_EIYOG2_P![S,?:_G_CWX_O_O<?
M\]DHO?WOVK_EIYOG2_WO,Q]K^?\ CWX_O_O<?\]DHO?WOVK_ ):>;YTO][S,
M?:_G_CWX_O\ [W'_ #V2B]_>_:O^6GF^=+_>\S'VOY_X]^/[_P"]Q_SV2@ O
M?WOVK_EIYOG2_P![S,?:_G_CWX_O_O<?\]DHO?WOVK_EIYOG2_WO,Q]K^?\
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M/ NK_#CX.^*=!U70]1\.P6_C+5CIMAJ-M)!MLS(IB:)9 #Y9&2".#R>:^H:
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MGF^=+_>\S'VOY_X]^/[_ .]Q_P ]DHO?WOVK_EIYOG2_WO,Q]K^?^/?C^_\
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M\,?V:O@[X;\-CP+%>6=E*=>M_'!OC=6T;SF2"&'[/P&CA<HP?H54#@&OLF@
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M*EJM8_ZAO^NLG_H;4Q%FBBB@ HHHH **** ,7PK_ ,>-Q_U\R?SK:K%\*_\
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MO^AT_P#*59?_ !FC_AMSXU?]#I_Y2K+_ .,UX911[6I_,_O#^U,?_P!!$_\
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M-\Z7^]YF/M?S_P >_']_][C_ )[)1>_O?M7_ "T\WSI?[WF8^U_/_'OQ_?\
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M<[6O?J<[XV^'V@>.M2>_UBP^VW:Q.L,D<TB8B0W3 ($8@H"HR1YHXYE2HO\
MA'=-\$Z)<V&AV_V*SFN)+H1J[2 D><I92Q<[<11@[3(OR_ZQ<FNGO?WOVK_E
MIYOG2_WO,Q]K^?\ CWX_O_O<?\]DK*\6,)+><GY_->27.=WF8:Z^?JV_'][,
MN/\ GJO2O.S*M4E@9TG)\J6U]/N/0R^G!8R$TM;[]3LOV3;*ST_X::9;6%XV
MH6,-M%#;7;*!YT*1JJ/@#'*@'@L.>O8>YUX7^R2-,'PQTPZ,L@TEK>,V9F7:
MY@V+Y>[CKMQGEO3/8>Z5Y&#_ (7S?Y]3T,;_ !?DOR"BJ6N75S8Z+?W-E;_:
M[R&WDD@M^?WD@4E5_$X'XU^/WP#_ &BOCIXW^*W@S7X/$^H7'B'5/$*6NKZ+
MK'Q&TE+"6V,Q2:WA\/R".>W<*,*P);Y<J"7!KM. _8ZBORV\16OQ$\2>$?VH
M_B5!\;/B%HMU\//&.J+H6BZ?K##3U6&1'\N:-MWF1;2JK%D(N#P=Q%/_ &Q/
MVD-=U34/ ]AI_B3QAHOB)? ]EXAO/[&\?Z?X1TXRSH6#A;B)GO'W9S"CCA0%
M&2QH _1GQ1\5O"W@SQGX3\)ZSJGV/Q!XJDN(]&L_L\K_ &IH$#RC>JE4VJ0?
MG*YSQFI?B;\3O#7P=\#ZEXO\7ZE_9'AW31&;J\\B6?R]\BQK\D2LYRSJ. >O
MI7YG?$SXE7/Q8\*_L3>*/'/Q NO =QJT6LP:IXPLYH[:>#Y(H&E64KLA>0+C
MS,80R%NU4/B+X^U35/V9?VK?!-E\1-3^+?P\\,7&A_V%XMU:Y%[/(\UW$\\!
MNP,7 1@ &' QQ@,!0!^F_AGXE1^*?&VN^'H?#?B*RATN"WN$UR_L/)TV_$RE
M@MM,6S(R@?.-HVY'K78U^8?[0'Q8\<>'X?VM(]*\9>(-,30=%\'OI"V>J3Q#
M3FF^S^<;<*X\HOD[MF-V3G->E^$K7Q]^S[^U'X#\/1?$[QA\2++QKX2U'5+_
M $[Q7>BZC%];Q>:AM4  @1F(&Q>QP2W& #[QHK\9/%/QKUFZ_9STSXCC]I_Q
M8?B]KVNQVVK>!;;6?L\-I']I(:**R3$EJ%6-"900C E,?/7[,0DF%">3M'\J
M 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY]+;?J>MU6L?]0W_ %UD_P#0VJS5:Q_U#?\ 763_ -#:O>/GBS1110 4444
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M@QO!ROWA\56'_'W'WYK[2_9KT^SB^%>IR6US]JGN-5GFNH=F?(D%HBA/NM_
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M]^U?\M/-\Z7^]YF/M?S_ ,>_']_][C_GLE !>_O?M7_+3S?.E_O>9C[7\_\
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M3_#P/P!F\=>-?V\/$VL6/QF_MOPU)X8TS7'BCT.)(=5L9X_W4"*Q!@V%E;S
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MD^WI#CR5GW(?-$>U=H;.W QC%-UR/P%IOCCPO)JZ^'+3QC+'/:: ]Z+=-09
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MT_L^?M"ZK^TO\=/$VJ^%M97_ (5'X?T2QMEMXHH7%_JUR@N)&,NPN/(C(C9
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M&=0@MV:1_P"T)YK4P3'$I#8$SR;OW@ +HS#^^HYH_MG#[_JO\_PW#^QZ_?\
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M_'C<?]?,G\ZVJ "BBB@ HHHH **** "J6M?\@:__ .O>3_T$U=JEK7_(&O\
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MQY=JYSX3_LO^/?V=-!\%^,/"-A>:IXGGM3:>,O"$VHVTL=[$6N%\^WD8B+=
MJ#:59UP#B1"2&+S"R/4?''[5WB/P3XF1O$GPDUC2/ VH:PVD1^([O5+8SS3N
M]RD<PM 7+Q;BW[TO(<)\L@+**]W\=:]_PC?A7Q'K7D?;?L=G>:AY&_\ X^/*
M2\;.[$F?NX\S$VW_ )ZI7R+XPT_XZ^-/CA+XE\4?!N7Q-X4TFZEE\/Z)#XHT
M^"WC<&?&H2J3*UU(OSD2$GRP" V2&KZN^*&EW?B+X?>+]-LH?M5]J.F7R0P[
M@?.D:*]53DE@W)'[PF0#_GM'VN+=F2[:'@?C#]N#3_"/P\^%_C'7O#$EOI?C
MWS9KKR[UI6TX!IE\SYH?]("F3))!<!?E<-\H[7QA^TE!I?Q.U/PK9:-'K-B?
M!][XRBU>&^+)=+$UT%55$4BL&!SYV^4CLZC)'E&F_LY^*YO"/[.^C:SX:M[J
MV\-6]_%XCM7N+::..-XKE,X&1.O!!:/S0.[IP%P?#O[('C'X:_&3QN=)0ZWX
M"F\':OIGAV26ZB,EOYOG-':[6+LP5UE(E7?& 5S*C9*S>95HG7V'[:/C2;P/
M:>/?$?P1U#3/A]J*?:9=<L-?@OY KM<*L_V8QB1HU+,&D?<R[/OJ2*[3]ISQ
MM=>(_#_@CPQX1UFZMKWQYK$,\6I:;/)'+_9L+7%Q=7*2*VXXB &_,O#G]ZHR
MM>/:'X0^/U]^SY8_!9?AAIOA>T.GMIUYXIU#Q!:WD;P W'F21VUN"6^5I%$F
M9-A7[Z@C'HW@7X/33?&RYM+O3;\>$? 7A!?"VB75[;*BZDTL<QN+N%@K;]J1
M+$73>JD$>8F%($Y/06A(W[6'BCQE-JVJ> /@YKGC?P);SS(_B!=1AMI[PH;D
M--;6D@=[E%!;Y]SL"A'F(>E+XE?M7?$CP7XUL="D^!=Q<1>(KRYAT6>X\4VB
M2:B5,^)2@254PLF29'<J5(64=:S/ >@_';]GOPS+\-O#O@71?'?AVTDG_L;Q
M,VJQ68CMR]R0US:_,TQ0M(6>/=M 55D&,UW/QR^'/BWQS\2_@WKUKI4-TFBZ
MA=7NM/:W2,D.Y9<NA?#SH"C?.OF$ #+KT#]YK<-+FE\4OC]J_P +_@[8>)_$
M7@EE\9:S=+:0^#[75([EIKJ26[3"W 1A,%4%_,"2G@ 2(37<_#'XCV7QB^&N
MD>+]/C,<&MVCWK6S,9&CD NQ(K$@ES&X92Y60C;S+'T'BWQS^#_Q.^,7Q\TS
M4M%UM/ _AWPO97%UINLW%E;:J+^]D:X\V1;9G8G9&"HF?S-C+D2#(*Z7[,OP
MI\=_!/5O'WA/Q!=+XE\+W=T^LZ5XA2*& 7,KQW N ;9))-N'!8,JNB_-B6/-
M-.7-Y"TL=?XL_:H^%'AOQ_<^"]5\;:?;>(I99$DMW$CQ+*?M.U99PKQ+)\Z8
MWN[?,/WJ5I>*OVA/A[X=O/&EIJ_B:"QN?#J?:-5BNH90R"0W(BD4%&^T9+H
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MBXQ^_*KYG;GYLC.6Z=>P]NKQ']E6UU.T^'EE'K,WVC5UC5;V;>'\V<*HD?>
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M<5W^SS<? [X0W7AC]F_PUX+\.ZA=W8DNH?%OVNXM;F)E82>;(K/,[8("[B5
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MPK_QXW'_ %\R?SK:H **** "BBB@ HHHH *I:U_R!K__ *]Y/_035VJ6M?\
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M<T<[*Y4?17Q>_:D\.?#74Y[$^'O%GBUY+-]6N)_#FD-=V\%J3=8NI9F;RV0
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MF^=+_>\S'VOY_P"/?C^_^]Q_SV2@ O?WOVK_ ):>;YTO][S,?:_G_CWX_O\
M[W'_ #V2B]_>_:O^6GF^=+_>\S'VOY_X]^/[_P"]Q_SV2B]_>_:O^6GF^=+_
M 'O,Q]K^?^/?C^_^]Q_SV2B]_>_:O^6GF^=+_>\S'VOY_P"/?C^_^]Q_SV2@
M O?WOVK_ ):>;YTO][S,?:_G_CWX_O\ [W'_ #V2B]_>_:O^6GF^=+_>\S'V
MOY_X]^/[_P"]Q_SV2B]_>_:O^6GF^=+_ 'O,Q]K^?^/?C^_^]Q_SV2B]_>_:
MO^6GF^=+_>\S'VOY_P"/?C^_^]Q_SV2@ O?WOVK_ ):>;YTO][S,?:_G_CWX
M_O\ [W'_ #V2B]_>_:O^6GF^=+_>\S'VOY_X]^/[_P"]Q_SV2B]_>_:O^6GF
M^=+_ 'O,Q]K^?^/?C^_^]Q_SV2B]_>_:O^6GF^=+_>\S'VOY_P"/?C^_^]Q_
MSV2@ O?WOVK_ ):>;YTO][S,?:_G_CWX_O\ [W'_ #V2B]_>_:O^6GF^=+_>
M\S'VOY_X]^/[_P"]Q_SV2B]_>_:O^6GF^=+_ 'O,Q]K^?^/?C^_^]Q_SV2B]
M_>_:O^6GF^=+_>\S'VOY_P"/?C^_^]Q_SV2@ O?WOVK_ ):>;YTO][S,?:_G
M_CWX_O\ [W'_ #V2LKQ8PDMYR?G\UY)<YW>9AKKY^K;\?WLRX_YZKTK5O?WO
MVK_EIYOG2_WO,Q]K^?\ CWX_O_O<?\]DK*\6-OMYS]_S7DESG=YF&NOGZMOQ
M_>S+C_GJO2O.S'_=:GH>AE_^]4_4[']DD:8/ACIAT99!I+6\9LS,NUS!L7R]
MW'7;C/+>F>P]TKPO]DJ\LM0^&.F7>FV(T_3[BWCFMK8#'E1,BE$Z<[1@=6Z=
M>P]TKSL'_#U[O???J=>-_BZ=E^04445VG"%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 54CL7AC5$NY@B@*!A. /^ U;HH K?99?^?R;\D_^)H^RR_\_DWY)_\
M$U9HH K?99?^?R;\D_\ B:/LLO\ S^3?DG_Q-6:* *WV67_G\F_)/_B:/LLO
M_/Y-^2?_ !-6:* *WV67_G\F_)/_ (FC[++_ ,_DWY)_\35FB@"M]EE_Y_)O
MR3_XFC[++_S^3?DG_P 35FB@"M]EE_Y_)OR3_P")H^RR_P#/Y-^2?_$U9HH
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MAZ/)7=Y7[N7XR_R2[(****T/2/-_VD/^2!^/_P#L"W/_ *+-?CY7[!_M(?\
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M99#GYMY'VKYC]_<1D?,?-(_Y[)1];P_\Z^\/JM?^1_<7KW][]J_Y:>;YTO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKI]_:#4M0>*\;?*T^JW<TF<$961Y2RGD\J0>:)/V5HYM%DTU]2U P/+YS/\
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MG5C42<>OE8\NI3E3;3Z>9-1116ID%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0)YID6$,T15HUW;0K*WR@ DU<\"_#&W\$ZYKVMR:WJWB'6M;%NEW?ZLT <I
MKB)%2"**-5'F.>%R2QR363G25&<$^NFFO3?3MV>_J:<LW4C)]M>WR.THHHKS
MSJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>arvn-20221231_g9.jpg
<TEXT>
begin 644 arvn-20221231_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4O(?@EX9GU#29;[,K/8B6-)PHW;2Q&"1MSCT%>B?\+3_ ."AG_1.!_X*(_\
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MJ7AK7YDTZ/PYXCOK?4]<L9?+2[M(H[I2;G$;G"+C:9CDC?0!]Z4444 %%%%
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M1#1OV5?"_P"P[JOA7]D_^S(].L?CW9+XGM-*NII8[;6/,(N$(E8A"-J?(F$
MQM !KTK5;:T\1?\ !=#3K7Q[$DD>B? I[OP9'<#*I<O?%))(P>-_EO<@D<X3
MVH ]A_9Y_;^^ '[1WCJY^%'A\^(?#OBZVL_M9\*^-- ETR^EM^\L:2<2*.X5
MB0.<8YKYH_8[UKP=K7[ O[1L_P >O'GB.Q\-P_%OQ+%JVL:-<L]_96@CL_\
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M0\_3G&?2@#ZYHK,\%SZU=>#M)N?$D9349-,@:_0KC;.8U+C';YLUIT %%%%
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M>,$R3,%;&!T!)( )'#?&*1Y?V'?V&F=RQ'Q(\%C)/86Y 'Y"O69/#W@_6_\
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MOV?_ -MSX@^"OA_J>H2W;^#M,M;.62S,IRZ6MY,C26Z^A +="2S9)ZKX!_\
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M!.H?LJ:7^R7X7UK6-(T;3_$D&NW.KK)'/?:C?1L6>:X=UP[R$@$@# 50H
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MGB'QOXIG5[J:)<;8(E4!881M7Y!G[B@G"(%XKQ#_ ,$V=1\.>/O$/C/]E?\
M:K\9?"BT\7WSWWB3P[HMM;W=A+=/_K)X(YA_HTC=V4G' &% 4?4-% 'S3KG_
M  2\^!]_^QWJW['FC^)]>L['7]7CU;Q!XIFG2XU/4[]9XYGN)G==K.QC53P
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MHEI^T;^UIX]^)?@WPS?1W>B>"?$)@2WDDCXB-[)&H:]VCNX!.3GAF4_5=%
M  , 8 Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /D#7/C[^V
M+^U3^U+\0/@+^R=XY\-> /#?PMDMK/7O%&MZ%_:=YJ.H3*S>5%"S!$B7RW4D
M\_+NR=P5>M_8B_:F^,7C_P")7Q(_9:_:=T_15\>?"^ZM#>:WX?5H[+5K&YB\
MR&<(Y)B?9M+#@?O%P!AA7@?P]\&_'3]JW]M/XL_'G]ACXEP?![0]+U<^&/%?
MB"XT]-67Q;JEH #,+"8"*+RU(Q)N#$2!L$R2 7/V0[?Q-\!_BG\?OV8OC58M
MJOQCUCPE<^*9?B-%>M*OBBP\MXH=L;*OV4PO,%$2C&2X'$:D@'6_#7XX?M__
M +=R^(OC/^RO\2/!O@#X?:;K5SIW@R'7O#K7]SXD\@[6N)W)_P!'B=^!Y8W+
MAAABNYO2/V8OV\8/B'^S+XU^+'QX\/0^'/$GPHO-2T[XDZ/8MO2"ZL4+R- &
M8DI(!\@)/S!E#-C<<K_@C +(?\$U/AK]AVX\O5?,V_W_ .UKS=GWS_2OE7X@
MC4/^$!_X*$G0@WV;_A(=-V^7TW^;-]I_''6@#VWP5\2/^"L/QP^"J_MA_#SQ
M3X!T;3M1LGU;PQ\)KSP\]P]]IPR\2RWNX.)Y8QE=NU3O7_5Y(7Z7_9&_:0\.
M?M:_L[^&?CYX9LC9QZY9L;O3VDWFSNHW:*>$G R%D1@&P-R[6P,U/^R6+(?L
MJ_#,:;M^S?\ "OM%^S[.FS[##MQ[8Q7SS_P0Y#?\,;:H8?\ CS/Q'UG^SL?=
M\C=%C;[;MU 'V/1110 4454U6'6)HT&CWD4+!OG,L>X$4 6Z*Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=
ME_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&K6E0:_#(YUB_@
MF4K\@BBVD&@"]1110 4444 %%%% !1110 4444 %%%% !1110!\;Z3^SY^VI
M^Q1\8_'7B/\ 9&\&>%_B#X!^(7B"77[CPGK>N'3+W1M2E_UQBE93&\+<<'+8
M1%P-I9^N_9,_99^.<'[0OBK]M3]KG4-"7QKXDT./0M'\,>')'EL]"TI760Q&
M5QF65W122,@?.02'VI]-44 ?%/PW^!W_  4"_813Q#\&OV5_AYX,\?\ P]U'
M6;G4/!DFO>(&L+GPW]H8LUO.A'^D1(_(V'<V6.5+;5](_9@_8,A^'7[,OC7X
M3_'CQ'%XC\2_%B[U+4/B3K%BNQ)KJ^0I(L!900L:GY6('SEF"KD*/HZB@#X?
M\&_#;_@K+\$/@JO['OP]\.> -;TZPLGTCPO\5[O7WMY-/TXC9$TMGM+F:*,[
M5V[E78H/F;26^E_V1?V;O#G[)/[._AGX!>&;XWD>AV;"[U!H]AO+J1VEGFVY
M.T-([$+D[5VKDXS7I-% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !14-_J%AI=J]]J=]#;01C,DT\H1%
M'N3P*^:/VU/VH=-3PS:>!OA!\0+>>>]FD_MB[TBZW-%$H&(Q(G WECG:<X0@
M\'GDQF-HX*@ZDWMTZLZ<+A:N+JJ$%OUZ(^G:*_-CX1?%SQM\*O&]GXE\-:O<
M_P#'TGVRS$I*7B%AN1UZ-D=#U!P1R*_2>N;*\TAF4)-1Y7'=;[[:Z=CHS#+Y
M8"44Y73^6P4445ZAYP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%
M%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\
MT&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/
M]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_X
MT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/
M^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!N
MR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0
M;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V
M+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1
M]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_X
MT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+
M_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!N
MR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O
M&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V
M+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0
M!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_
M  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+
M_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;
M_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O
M&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &
MQ16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\
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MXT?8O&__ $&[+_P&/^-:T\GRZ%[PYF^KU?X_H9SS3'3VG9+HM#Q?X5?\$_\
MP3X!\7V_BSQ)XON-=^Q3":SLVL5@B$BG*F3YW+X.#C@$CG(XKZ K'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&NK#83#8.#C1C9/^NIS8C$U\5+FJRNS8HK
M'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&NDP-BBL?[%XW_ .@W9?\ @,?\
M:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QJUI4&OPR.=8OX)E*_
M((HMI!H O4444 %%%% !1110 4444 %%%% !1110 4444 >4_$K]D_PK\3_V
MH/A]^U!KGBC4$OOAU:7\.E:-&B&VG:ZA>)Y')&X, P(P1RBUZM110!\M>*O^
M":>IZ3X[\2^*OV8_VL?&GPJTWQI?/>^*/#>@PPW%I+=2#$L]L),-:2/U+(20
M<8P JCV#]GK]EKX0_LU?!&'X!^ -$>?1-DW]IOJK">;5)9AB>:Y8@"1Y!P>
M-H"@!0 /1:* /CZ;_@DW=Z5X>O\ X-?#K]L[XC>'/A1JEQ*UW\/;-H)!%#*Q
M:6V@NY 9(H6RP*8;(8[MQ9B?J7X9_#?P7\'_ (?Z1\+_ (=Z''INAZ%81V>F
MV41)$<2# R3RS'DEB26)))))-;E% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 445^;'Q=^+OC7XK>-KOQ-XDUBY(^TL;*S\TB.
MTC!.U$7HN!C)ZDY)Y->7FF:0RV$6X\SELMMM]=>YZ.7Y?/'SDE*R7SW/TGJA
MXA\5>&/"5F=0\4^(K'38!_RVO[M(E_-B*^+?@QXA_;%^-N@R>#/A[\0KI--T
MD)'<7D]ZD+PA]VQ3, 9FX5L $X  XXKT'P__ ,$[=0UJ\_MCXN?%NYO;A_\
M7)IZ%W;_ +;39)_%*PIYKB<7!2PU!N_5M)?\$UJ9=A\--QKUDK=$FW_P#OO&
MG[=/[/\ X3WPZ?KMUK<Z\>5I-H2N?]^3:I'N":\WOOV[OB[\0+I]*^"?P8:1
M\[1+)%+>R#WVQ!53\2PKUWP7^Q[^SYX)V2VW@*'49U_Y>-8<W)/_  !OW8_!
M17H]CI]AI=JECIEE#;P1C$<,$81%'L!P*OZOF]?^)54%VBK_ (LGV^64?X=-
MR?>3_1'RK_PJC]O+XS?/XU\;OH%E+]Z"2_6W!3T\JU!)^CX]ZZ#P=_P3C\#V
M;B[\?^.]2U64G<\5E&MM&3W!)WLWU!4U](454,FP?-S5;S?>3;_X!,LUQ5N6
MG:"[15CB?!?[.7P0\ ;'\-?#;34F3[MU=0_:)0?4/*68?@17;  # & .@%%%
M>E3I4J,>6G%)>2L<$ZE2K*\VV_,****T("BBB@ HHHH **** "BBB@ HHHH
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M7]D%;?1/C+X34RH(E$<'BJT _>:?=J"!(S*-J.Q!Z*6 V/'X=^SM^UCX0_;
M_P""K7@7XA>']$O]&U33?@M?Z7XK\.ZG;O'/I&IQ7LIFMFW*-P&]2& Y##(5
M@RKZ#H?_  5A^+7Q/LCXO_9]_P""<GQ,\7^%)YY$TOQ'YJVJ7RHY0R(OE.-N
M01PQP00<$$#;_9F^(.M?&;]JQ/B3\0/^"8>N?#3Q"VAW,<OQ%U.==TJ80>1+
MLB3S68  ,Y) 3 XH ^MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+9<100KW[LQZLQ[L<D]ZT;:VMK*VCL[.W2*&) D442!510,  #@ #M3ZWP6
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M#:%]W_X)I_M)^)OVJ/V0/#?Q*\>L#XDMGN-*\1NJ!?,N[:0QF7 X!=!'(0
M&<@# %=9^R+XOT#6/V._AOXR@U&%=//P[TJ:6=G 2)4LH]^X]MI5@?0J?2O"
M_P#@A[I]X/V)9/%<UN\=MXC\=ZSJ6G[UQNA,RQ9'_ H7'X4 ?85%%% !1153
M58=8FC0:/>10L&^<RQ[@10!;HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
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M^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:
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M"GFF?$M;G]K'QU\)-0\)?8)0UOX,AO5O?M/R^6<S0(NP?-GG/3B@#Z%HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN'QS)(W5F/Y#H   *Z"BBO;A"%."C%62/)E*4Y.4G=L****HD**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;P?:3 W,DN=@ .0\Y'^LD/58@<#CT+U])_!KX'^!?@?X;&A>$;',TH!OM1F
M,]TX[L>P'.%' ^I).[X0\'>&? 7A^W\+>$-'AL;"U7;%!"N![DGJS'J6.23U
MK3KVL'EZHS]M6?-4>[[>2[(\K%8WVL%2I+EIKIW\WW84445Z1P!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V
M**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!]
M(_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'T
MC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W
M_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;
MW_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#
M8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C
M_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_
M^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_
MY^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_
M )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P
M+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\
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M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M2"#P?WFWKQ6W6?XM_LC_ (174_[?O'M[#^SYOMMQ&Y5HH=AWL"O((7)R.>*
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MCL)A%^]FEY=?NW.FAA,3B7^[BW^7W['T17&_$;]H'X0?"I7C\9>-[2&Y0?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7DGRK[D/^T84_P"#1C'U5W][/F/P[_P3?TN:?[=\0OBI?7LKG,R:?:K&2?\
MKI(7)^NT5Z/X5_8L_9V\+;9/^$'_ +2F7_EMJMT\V?JF0G_CM>JT5T4LJRZC
MK&FOGK^=S"IF..J_%4?RT_(S] \)^%O"EO\ 9/"_ANPTV+&/+L+-(5_) *T*
M**[U&,59(XVW)W84444Q!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC
M_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"
M8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2N63LNRT7W!1117<<84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<,,,5W-Z1^S%^WC!\0_V9?&OQ8^/'AZ'PYXD^%%YJ6G?$G1[%MZ075BA>1H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*M:'\-O@'X/L8[;QK\.[Z[O=-:X>YN/#TT+@B6.61FD2&X0%3&Y(W*"I P*
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MO?\ OI:/^$EU?_H4+W_OI:V**8C'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MB
MB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V
M** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MB
MB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6K6E:K>ZA(Z76B3VH5<AI2,-
M[<5>HH **** "BBB@ HHHH **** "O%=$_:07XH?M:_$+]BW4/!9M;3P[X.M
M+^37X=3)DN5O$56C$7ECRRHD.&WMG'05[57YV?$CP/\ M<^.?^"M?Q4L_P!D
M3XUZ)X)U2#P'HKZM>:WH\=XES;^7$%C57BD"D-@Y 'UH ]._X<??L=_]#9\2
M?_"T?_XW7K'[*_\ P3V_9B_8[UO4?%OP?\)WAUW5K?[/?:]K6IR7=V\.X,8P
MSG"*656.T#<57.=HQX[_ ,,^?\%K_P#H_KP!_P"$/;?_ "'7H?[,7PF_X*2>
M#?B>NL_M1_M4^%?%_A86$R-H^C^&8;28W!V^7)YB6\9PN&R-W.>E 'T91110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445QWQ7^//PP^#-B;GQOXCC
MCN&3=!IMO^\N9O\ =0'@?[387WJ*E6G1@YS=DNK+A3G5ERP5V=C7G/QE_:D^
M%'P6CDL]:UC[=JJCY='TXAY@>V\YVQ#_ 'CG'0&O#M8_: _:4_:DU*7PK\#/
M#5QHNC[MEQ?12;7"G_GK<G CXYV1_-U&6KO?@W^P=X!\&21^(/B;=#Q+JN[>
MT,BD6D;]3\IYE.>[\'^Z*\AYAB<8^7!0T_GEHODMV>DL%A\*N;%2U_E6K^;Z
M'G=QXO\ VK/VR9WT_P )6!\.^%9&*2RI(T4#)G!#S8WSGL50;?51UKUWX+_L
M6?"KX5>3J^L6P\0:PF&^V:A$/*B;UCBY ]BVY@>A%>O6]O;VD"6MK D44:A8
MXXU"JJC@  =!3ZVH972A/VM=^TGW?3T6R,JV8U)0]G27)#LOU>["BBBO4//"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGPO\ LQ^ O"7[2_BC]JC3
M=7U=_$/BS0[32M1LY[B(V4<-OMV-&@C#ASM&2SL.N *]&J#4]2L-&TVXUC5;
MR.WM;2!YKFXE;"Q1J"S,3V  )/TH GHKXOT?_@K1\1?BE#/XE_9M_P"">GQ-
M\<>%_M4D.G>)D46D%^$8HSQYC?(W C&<CHP4@J/2_P!FK]L+]H3XV_$M?!'Q
M*_8.\8_#S3&L)9SXBUS4%E@$B;=L6T0K\S9..>U 'T+1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%9OBOQAX7\#:-)X@\7Z]:Z=91??N+J4*,^@SRQ/8#)/84
MI2C%7;LAI.3LMS2K ^(7Q1\!?"O1SKGCSQ+;Z?"0?*21LR3$=D099S]!QWKY
M_P#B-^W1XE\8ZN? G[-7A"YO;R<E(]3FM#)(W^U%#C@#KNDX'=1UIOP]_8=\
M8>/=8'CS]I?QC=7-U,0SZ9#=^9*PZ[9)N0@'39'GCHPKR)YG.O-T\%#G?\VT
M5\^OR/3CE\:,>?%RY5V^T_ET^93\7_M?_&/XWZS)X$_9H\&7ENC_ "OJ+1*U
MSM/&XD_N[=?<DGIA@:W?A1^P38_;_P#A,?CYXBEUS4IG\V73XKAS&7]993\\
MI^FT<=6%>^>$/!7A/P#HT?A[P9X?M=-LX_NP6L04$_WF/5F]6))/K6I3IY7[
M2:J8R7M)=OLKT7^8IYA[.+IX:/)'O]I^K_R*VC:+H_AW38=&T#2[>RM(%VP6
MUK"L<:#T"J !5FBBO6225D>:VV[L****8@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBFS3PV\9FN)EC0=6=@ /Q- #J*\B_:8_:<TWX1>%8D\%WNGZCK
M5_*T<""=9$ME49:1U4YSR  <9)SV(/BGPM_;J^*.F^+K=?B5J-OJ>D7$X2ZQ
M91Q26R$XWH8U7.WKALY QD'FN"MF.%HUE3D]?P1RU,91I5.1L^R**XR+]HKX
M%3#*?%C0ASCYM01?YFK$?QU^"DI(7XN^&AC^]KD"_P WKJ]O1?VE]Z-_:TW]
MI?>=717.Q?%_X2SD"#XH^'7W#*[-;@.?_'ZL1?$GX=3C,/C[17&<97583S_W
MU5*I3?5#YX/J;5%9L7C'PC-GR?%6FOCKMOHSC]:LQ:UH\Y @U:V?<,KLG4Y'
MYU7-%]1W19HIL<L<J[XI%8>JG-.IC"BBB@ HHHH ***X[QQ^T!\'/AOJXT'Q
MEX[M;2](!:V6.25TSR-XC5MF1S\V..:B<X4U>;27F3*48*\G8[&BJ>@>(-#\
M4Z1!KWAS58+VRN4W07-M('1QTX(]#P1V(Q5RJ335T4FF@HHHI@%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M6#\5=&TCQ'\+_$GA[Q ;C[!?Z#>6]]]C3=-Y+P.K[!W;:3@>N*WJH>*O$FD^
M#?#&I>,-?G,5CI5A->7LH7)2&)"[G'?"J: /ST_8C_X*B^#?V?\ X :%\ ?B
M?^SK\4I9O",+Z=I^N:#X(=[;4K1';R9VCD=)(9&0KN3##=D[CG ^G/V<O^"B
MGPF_::^(Z_#'P;\+OB-I%ZUC+="[\3^$S9VNV/&5\PR-\QW<#'/-?->K?\%+
M?^"D_B'PSX,^+O@/]E_X>Z+X,^)?BR'0O LGBC4[B6ZGFN#(+8SF*>,1K)Y3
M ,4 )QC@@GU3]DO]I[]O[Q]^UOJ'P _:U^'7@#P7%H_AAM7&GZ1]I>[U>)Y!
M%'/;2F::*2&-^)!E74NH(Z@ 'U]1110 45\?)\=/VU_VP_CKX_\  G[*?C;P
MU\.O!7PWUUM"O/$^N>'SJ=]K&IQ_ZY8HG81I"I&,]2&5@6W;4Z;]C[]J3XZ:
MI\?_ !M^QC^UC9Z%+XT\&Z7#K&G^)O#<;16>LZ7*47S6B<_NI%:2,$# .XC
MV;G /INBOBKX:_'#]O\ _;N7Q%\9_P!E?XD>#? 'P^TW6KG3O!D.O>'6O[GQ
M)Y!VM<3N3_H\3OP/+&Y<,,,5W-Z1^S%^WC!\0_V9?&OQ8^/'AZ'PYXD^%%YJ
M6G?$G1[%MZ075BA>1H S$E) /D!)^8,H9L;B ?1M%?$'@KXD?\%8?CA\%5_;
M#^'GBGP#HVG:C9/JWACX37GAY[A[[3AEXEEO=P<3RQC*[=JG>O\ J\D+]+_L
MC?M(>'/VM?V=_#/Q\\,V1LX]<LV-WI[2;S9W4;M%/"3@9"R(P#8&Y=K8&: /
M2**** "BBB@ HHHH **** "BBFRRQ6\33SRJB(I9W=L!0.I)["@!U%>2_P##
M=7[)G_"2_P#")_\ "Z=/^U_:?(W_ &:X^S[]VW/VCR_)VY_CW[<<YQS7K$4L
M5Q$L\$JNCJ&1T;(8'H0>XIN+CNAM-;CJ**1F5%+NP  R23P!2$+163?^/O F
ME,5U/QKI-L1U$^I1)C\VK/D^-?P;B.V7XM>&5/HVO6X_]GJ'5IK>2^\3:6YT
MU%<%?_M0? #321<?%/3&Q_S[NTO_ * #ZUG2?MD?LVQ-M;XDJ?\ =TJ[/\HJ
MS>*PJWFOO1+JTUO)?>>G45XYJ'[=7[/]D2+;5-3N\=#;Z8XS_P!_-M9LO_!0
MCX*1G">'_$LGNEC!_6<5F\?@U]M$/$4%]M?>>ZT5\[ZE_P %%? ,3$:1\/M8
MG'\)N9HHL_\ ?)?VK*F_X*06RM_H_P 'G8=B^O!?Y0&LWF>!7V_P?^1#Q>&7
MVCZ=HKY3OO\ @HKXJNG(T/X5V<7H)]0>8_\ CJ)45O\ MM?M'ZL^W0_A+ITV
M>@CTB\E/_CL@]#4?VM@[V3;^3#ZY0:T=_D_\CZ/^(7Q:^'7PILX;WQ_XJ@TY
M;ABL",KR228ZE8T#,0.,D# R,]15?PC\</A+XYT.[\1^&O'=A+9V S?33N8#
M;CLSK*%95/.&(P<'!XKX<^._BSXG^-_'C>(_BOX=N-*U">TC$%A-936ZQP+E
M1Y:2DL%+!SG)!8M]*Y_PIX%\6?$/4F\/^#M NM1NA$97@M4R0@(RQ[ 9(&3W
M(]:X*F<UU6<:<+KHM;_U\CGAF$7B5&2?+Y+7[CZA^+7[>^D6MX?"7P*T&37]
M3E?RHKZ2!S#O/&(XQ\\Q_P"^1Z;A7.>%/V2OC;\>M9C\<_M)^,KRS@8[HM.W
MJUQL/.U4'[NW'M@GU4'FN>^&'A/]J;X/QLW@7X(0V]PXQ)?3:4LMPX]/,=R0
M/]E<#VKL/^%G_M^?]$\_\I,?_P 57.E/%2Y\;S2_NI-1_P V>V\ZP^'CRX2E
M)?WFKR_R1[]\.?A/\/OA/I']C> _#-O8QL!YTRKNEF([O(<LWXG [8KHJ^7_
M /A9_P"WY_T3S_RDQ_\ Q5'_  L_]OS_ *)Y_P"4F/\ ^*KUX8ZA3BHPIR27
M11/,GCO:2YI*3?H?4%%?+_\ PL_]OS_HGG_E)C_^*H_X6?\ M^?]$\_\I,?_
M ,55?VC3_DE_X"3];C_++[CZ@HKY?_X6?^WY_P!$\_\ *3'_ /%4?\+/_;\_
MZ)Y_Y28__BJ/[1I_R2_\!#ZW'^67W'U!17R__P +/_;\_P"B>?\ E)C_ /BJ
M/^%G_M^?]$\_\I,?_P 51_:-/^27_@(?6X_RR^X^H**^7_\ A9_[?G_1//\
MRDQ__%4?\+/_ &_/^B>?^4F/_P"*H_M&G_)+_P !#ZW'^67W'U 2%!9B  .2
M:X/_ (:>^ G_  D/_"+_ /"SM/\ M?F>7G#^3NSC'G;?+_\ 'J\#\?\ C_\
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MQN2$\_\ ?(KZ&HJ?[.P3^PA?4\-_*?.,O_!.?PB<>3\2M27UW649_J*K2_\
M!.+1R#Y'Q7N5Y^7?I"M@?]_17TO14O+,"_L?B_\ ,7U+"_R_F?,,G_!-]0VZ
MW^,C+CH&T#//U$]-_P"'>OB>#FS^-F,_>_XE;K_*8U]044O[+P/\GXO_ #%]
M1PO\OXO_ #/E_P#X81^*5MS9?'+!7A/DG3C\'.*/^&+/C[;_ "V7QXP!RO\
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M7PC\4ZYJ<[V_A:7Q=KEU,/#NG*SB.&T2(QK$QC(#/@L3O.1YDF[Z<_9EU_\
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M\2*=L]_X'H_UDPR^.C57K!A_9U1[3B_^WCV[_A)=7_Z%"]_[Z6C_ (275_\
MH4+W_OI:\1_X::_:,LO^0K\%=N.O_$GO(_YL:/\ ALCXB67&J?"#:>_SS1_S
M0T?ZTY2OB<H^L)?Y!_9F*>UG\T>VGQ)JK JW@Z\((Y!9:B?5)Y%*/X!G8'J"
MB$&O&8OV[BC;+WX6,I[E=8Y_(PU=M_VZ_#+?\??@&_3U\N[1OY@52XIR&7_+
M[_R67^0GE>.7V/Q7^9ZG)+!*NR7X:%AZ-!$17FGQR_9N\-?&66'5;7PS>Z'J
M<$?E_:K.WC:.5,Y >/*[B,G!!!YP<\8EM_VX_AJW_'UX6UQ/7RXH6_G(*YCX
MI_MI:C?K#9?":VELD*YN+W4;9&EW9X5$RR@8YR<YST&.<L7Q#P_]7;E-379;
MOTV_-$?V1B:[Y)0T?<Z;X"?L\Z)\#;N;74T+4=7U::/RQ?7$21K"F02(T!.T
MD@9))/&!CG/J?_"2ZO\ ]"A>_P#?2UX;\&OVQKD7$NE?&.[0Q;-UOJEO:'<&
M_NND8P01T( QCG.>/2K?]J3X$7.-GCU%/I)87"X_..M\OSO)*N&3I5(P7:32
M?S3?XZD2RS$85^SC!V79-HZC_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:Q;?]
MH3X+7/\ J_B-IP_ZZ2%/_0@*O6_QC^$UUCR?B9H.3T#:K$I_(L*]../P,_AJ
MQ?\ V\O\S-T*ZWB_N9<_X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6G6_C[P)=X
M^R>-=)EST\O4HFS^35=M]8TF[_X]=4MI?^N<ZM_(UO&K2G\,D_F0X36Z*'_"
M2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q16A)C_ /"2ZO\ ]"A>_P#?2T?\
M)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_
M /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+
MJ_\ T*%[_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__
M  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\
M)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_
M /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+
MJ_\ T*%[_P!]+6Q10!YKXX^$GPS^)&KC7O&7P5:[O0 &N5F:)WQP-YC==^!Q
M\V>.*Z;098O"VD0:#X<^'4ME96R[8+:V5$1!UX ]3R3W)S7245$:=.,G)))O
MJ2H03NEJ8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL4591C_P#"2ZO_
M -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"
MA>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J_
M_0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T
M*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_
M -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"
MA>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J_
M_0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T
M*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_
M -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"
MA>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J_
M_0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T
M*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_
M -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"
MA>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J_
M_0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T
M*%[_ -]+6Q10!C_\)+J__0H7O_?2U:TK5;W4)'2ZT2>U"KD-*1AO;BKU% !1
M110 4444 %%%% !1110 53\0Z#I7BK0+[POKMH)['4K.6UO(&.!)%(A1U./5
M21^-7*^#/^"AO[(O_!1SQQ\>;GXS?LV?'?Q;)X/FL[:.;P)X3^)=SH=W&\<0
M61X0_P#HWS$%LD@DG&#UH XOXK?L@?\ !3OX6^#_  7^SS\+?"7ACXG^ OAS
M\0].\3>"-4GUB&PU2*"SFD>*PN_/EC1E'F$;D#$ #!QA%^@?V7?V=OVK?&O[
M1C_ME_MP7F@:?KMAH$NC>"O _AB4RVVBV\KAIII)"6#SOC;D,X(8\@!57Y+\
M)67@V'7(?!'[17_!2;]J_P"#GB*4[4T[XCZ]=6=O,PZM%>*[0/'Z.S(#Z5]D
M?LE?L=:M\*O&=M\8[3]OGXG_ !0TBXTV6&VT[Q'XP;4=,GWXQ,N'969<<,.F
M30!])4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !536M!T/Q)8/I7B+1K2_M9/\ 66U[;++&WU5@0:MT4; >)_$+_@GM^RO\
M0=\W_"OO[$N7S_I/AZX-MM^D?,0_[XKQKQ#_ ,$L/''@W4&U_P" 'Q\N+&Z7
M_4I?B2UE7T_TBW)/_C@K[1HKHABJ\%92T\]2E.2/B#_A*_\ @J7^SW_R&=!F
M\8:;!T9[5-2#@=26@*W&/=L5M^"_^"LVDVEW_8WQF^#>HZ7<Q-MN)=)G$A5O
M>&;8R?3>QK[$K#\:?#/X=_$:T^P^/O VDZS$%PJZEI\<Q3_=+ E3[C%:?6*,
M_P")37RT'S1>Z.%^'O[;G[,'Q)V0Z+\6=/M+E^/LFLDV3AO[H,P56/\ NDUZ
MG;75M>VZ7=G<)+%(NZ.6)PRL/4$<$5\\?$+_ ()A_LS>,=]QX<LM4\-7#<@Z
M7?&2+=[QS;^/92M>6W/_  3O_:E^#5P^I?L[?M EXU8M]E%W-ISR>Q12\4G_
M  (@&E[/"S^&=O5?J@M![,^W**^'_P#AI_\ X*+_  !_=?&#X2-KUC#Q->S:
M4& 4?]/%F?+!]V!-=K\/?^"LGP;UW9;?$3P5K'A^9N&FMRM[;K[DKLD_)#2E
M@ZR5X^\O+4.21]5T5\X_%[_@IO\  /P%HUI=_#Z27QA>7BEUMK-FM4@4<?O7
ME3<C$]%"$\9..,[_ .RM^W)\/_VG;^X\+PZ%<:%KUM 9_P"S+FX$R3Q @,T4
M@"[BI(RI53@Y&0#C-X>O&'.XZ"Y96O8]OHHHK$D**** "BBB@ HHHH ****
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ML,^ Q_KO&.KM_NB(?^RFK,7[#_PK7F7Q%K[<]!<P ?\ HFCZWQ*]L-!>L_\
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M=Q>GGZ>LG\G6O0P>*XGHX6"JX93=M^=1?SOU.>M2RR=5\M1Q7I='O=%?//\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBO>.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^0O\
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M2@VA?=_^":?[2?B;]JC]D#PW\2O'K ^)+9[C2O$;J@7S+NVD,9EP. 701R$
M !G( P!0![U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% %#Q'X5\+^,-/;2/%OANPU2T;[UMJ-F
MD\9_X"X(KQCXA?\ !./]EGQ[OGM/!]QX?N7SFXT"\:(9_P"N3[XQ^"BO=J*N
M%6I3^%M#3:V/BG5_^"8?QA^'-^^O?L[_ +04EM/U2.YDFL)<#^'S8"P?\545
M5_X6W_P4\_9\^7QOX%D\5:=!UGETY+U=G=C+:$2#ZR?B*^X**Z/KDY?Q$I>J
M*YV]SY%\!_\ !6GP'=2C3OBK\+M5T:=6V2S:9,MTBMW+(_EN@]AN->Y?#S]K
MS]F[XH;(O"GQ<TG[1)@+9ZA,;28G^Z$G"EC_ +N:Z+QY\&OA/\4(3%\0OAUH
M^KDK@37M@CRJ/]F3&]?P(KPWXA?\$L/V>/%.^Y\%WVL>&IVSL2VNOM-N#[I-
MES^#BB^#J;IQ_%?YA[C\CZ75E=0Z,"",@@\$4M?$#?L.?MM? EC<? #XZ?;[
M2(YCL(=1>T+^F;>8M ?Q>A?VVOVY/@.1!\?/@?\ VE9P_P"MU";37M2^.N+B
M -!^2&CZIS_PYI_@PY+[,^WZ*^8_ '_!57]GSQ(BP^-M)UKPW/C+O+;?:H![
M!XLN?QC%<]_P]V^'O_"6_P!G_P#"H]6_L3SMO]I_VC']HV9^]]GV[>G./-J?
MJF);MRBY)=CZ]HK+\'^-/"WC[P_9^*?"&MP7UC?VRSVLT+YW(P!!(ZJ>>0<$
M'@\UJ5S--.S)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCJO_  3B\!Z?;N!<:5-JMEJ$!X:&9=2N7VL.QV.C8_VA7S'KOAK4_B3\*/\
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M-!H]Y%"P;YS+'N!%6Z* ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !I#8^-F!5M:LB#U!M3_ (ULT4 ?/_[3O[&^C?%CX<:U
M)X<\%^&X_$YMO-TZ^L],2VFEE1@^PR+@$N 4R^0-W;J/SJ_X5K\0_P#A+/\
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MOH=Y%_Z'$/2O(/V4O^"9%Y;:C<>)OVH=#MI+;[.8[+P[!J+,WF$C,LLL#@
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M-_\ H-V7_@,?\:^/_P#A4G_!5W0_^0?\3?MF.G_$ZMI,_P#?Y!Z_YXH^V?\
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MXI3_ , D*M^E=M9WMEJ-NMYI]W%/$XRDL,@96^A'!KCE&4=U8SLT9GV+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q14@8_P!B\;_]!NR_\!C_ (T?8O&_
M_0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_
M &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?
M8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q1
M0!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_
M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_
M\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL
M44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C5K2H-?A
MD<ZQ?P3*5^011;2#5ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *SO%OA/P[XZ\-7OA#Q9I<=[IVHVSP7=M*.'1@0>1R#SP1R#R*T
M:*$VF!\A?\.B?AY_PEG]H?\ "W-6_L7SMW]F?V?']HV9^[]HW8]L^77KFK_L
M#?LDZU8Q6-Q\'K2+R8EC2:SO;B&3 & 6*2#>W');.3R<U[#16\L5B)6O)E.<
MGU/F#Q/_ ,$H?V>M6W2^'?$OB729#]U%O(IHA^#Q[C_WU7$7G_!*;Q_X5N&O
M_A5^T6UO*>4$UC+:,/3,D,K$_7:*^UJ*N.,Q,?M#YY'Q)_PH7_@J5\-/^12^
M,#:ZL?\ JU'B);D$=AB_0#\.E+_PTC_P4Y^&O'C+X('6HT'[V5O#;3#'<[K)
MPH^O2OMJBG];YOCA%_(.?NCXLT[_ (*R>)O#]T--^)W[/4MM,/OM;:D\##_M
ME+$3_P"/5W7AG_@JO^S?K&V/7M(\2:0Y^^UQI\<L8^ABD9C_ -\BOI+4=*TS
M6+8V6KZ=!=0M]Z*YA5U/X,"*X7Q/^RA^S7XOW-KGP1\.,[_?EM=,2WD;W+Q!
M6)]\T>TPDMX->C_S"\'T,KPS^W!^REXLVC3?C9I,!;MJ?F6>/J9U05Z%X=\;
M^"_%\?G>$_%^EZHA&0^G:A'.,>N48UX=XG_X)A_LJ:_N.EZ)K.BENATS67;'
MT^T"6O/?$/\ P2(\-^9]I\#_ !NU&R=#F)=1TI)CGM\\;QX^N*.3!RVFUZJ_
MY!:#ZGV/17Q)_P ,1_MZ_#GY_AI^TA]I@C'R6J^(KR#=Z?NG5H_S-'_"5?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M//C?\!?"8QTV:% O\E%>@44_:5%U879YI/\ L;_LMW (D^!GAX;CD^79!?\
MT$C%5)_V'OV3[@DR?!+21D8^1I5_DXKU:BG[:K_,_O#F?<\=F_8"_9"GQO\
M@Q:C'39J5VO\IA52?_@G3^QU,#CX1E"3G<FOW_'X&?%>VT4_;UU]I_>PYI=S
MP>?_ ()K_LB2DF/X?WD61C":[=<>_,AKYG^-'_!+_P"-V@>.+E?@YIMOKN@7
M$Y>Q>34H89[6,GA)1*RABO3<N=P&< G _1"BM:>,Q%-WO?UU*4Y(^./AC_P2
M6\'S>"(9?C!XYU:/Q!*S/+'H%Q"+:!3C;'^]A9I&')+ J.< '&XSZI_P2%\
M2Y_L7XQZQ;_W?M6G138_[Y9*^P**/KN)O?F#GEW/B=_^"3'C+1&,GA#]H_RS
MDE<Z-);G\TN&_/%)_P ,"_MN^'_^1._:HV!?NC_A)=2MOT16[5]LT4_KN(>[
M3^2#VDCXF_X4#_P5*\,_\@KXU'4-O3_BI/-S_P"!"#]:/._X*^^&?OQ'4(EZ
M?+H\V?RP]?;-%'UMO>$7\@Y_)'Q,?VBO^"H?AG_D*_ LZAMZ_P#%+R2Y_P#
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M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\
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M/X"O?B?\7O&-IH6@Z?L%WJ-X6VH7<(B@*"S,68 !02<]*Z6OS*_X+(?LV?M
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M\!VH U?@A^W+^R1^T?XA?PC\%?CQH6N:LD;.-+BE>&XD1>69(YE1I !R2H(
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M=6OP9_:M_9P_:Z\2.;?PQX8\4ZCHGB?4W!\NPCU&W6**:0C[L:XF+,>!@=R
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MH **** "BBB@ HHHH X[]H7XHQ?!'X#^,OC#+&CGPSX8OM3CB?I+)# [HG_
MF"K^->(_\$@/A._PV_8:\,^)M7=YM<\>33^*=>O9>7N9KM]T;L>I/D+#^.3W
MKZ+\;>"?"7Q(\)W_ (%\=^'[;5='U2W,&HZ=>1[HKB,]48=P:F\+^&/#_@KP
MUI_@[PGI$&GZ5I-C%9Z;86J;8[:") D<:#LJJH 'H* +U%%% !1110 4444
M%%%% !1110 4444 9?CG_D2=8_[!5Q_Z+:OF7_@B3_RC5^'_ /U\:Q_Z=;NO
MJNZMK>]MI+.[A62*:,I+&PR&4C!!_"L3X:?"_P"'OP;\&6GP[^%GA"QT+0[
MR&STO3H?+AA,DC2/M7MEW9C[DT ?(G_!)3QIX.^!GA+XD_L@?$;Q/8:+XG\
M?$;4Y&T_4[I('GTR78\-Y'O(WQMACN&0%*$XWKF[^P%?67QU_;N_:*_:X\(7
M NO"=_>Z5X9\.:K#\T.H-9VJ)<O$W1T#1Q,&&01*,5[W\<OV*OV5/VE-:M_$
MGQO^!VA^(-2M8Q'#J-Q"T=QY8.0C21,K.@.<*Q(&3QR:[KP'X \$?"[PE9>
M_ASX3T_0]&TZ+R['3-,M5AAA7))VJH R222>I)).2: ->BBB@ HHHH ****
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MG[1=U\.+O_@JS\"7_9DN-.?QKMU/_A9;^'&0J=$\J/:+XQ_+G_6[-_S9\O\
MZ95]:?&O]G;X'?M&^'XO"_QR^%VC^)K.WD,EJFIVH9[=B,%HI!AXR0 "5(R!
MS5+X%?LJ?LZ?LS6ES:? CX/Z+X:-Z MY<V-OFXN%'(5YG+2.H/(4L0"2<<T
M>@T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M((X(-<7^T1^TU\%/V5O O_"P_C?XTBTBPDG%O91")YKB]G(R(888P7D<X[#
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M1110 4444 %%%% !7Q9X)_X(\:E\+].N="^%7[?GQC\,:9=7\MX^F:#K"6L
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MV[^S9^P9\-_@'<^*_%OBCQ9K7C[QAX[@^S^+_%OBR99+B]M]NW[,BJ L4.W
MV#.<*"<(@7W.B@#Y,\ _\$P_&GPET:;X5?"C]NSXD^'?AM+=32Q>$-/AL_M%
MI'*Y=XH+]XS+"I9F/R '+$DEB6/>_LO_ + 'PB_92T#Q[X$\!:KJ=SX9\=W?
MG3Z'J$N\6*M"T,D:2_ZQPR,.7);Y>O->[44 ?*/@#_@EGIO@?]G;QM^RK=?M
M,^--7\$^*;&.TTC3-36%SH$:W+7#>0<;279OF^4 XS@5[)\0OV9_#?Q#_94N
M/V4-0\1WUOI5SX3AT%M4A1#<"*.)(Q( 1MW$(#TQS7I5% 'FFO?LR^&M>_9(
M;]D.?Q'?)I+>!8O"_P#:J(GVGR$M5MQ+@C;OVKG&,9KF/B%^P%\&?BG^RSX3
M_9<\:7VJO;>"=-L(/#/B>QN%M]3L+BTA6**ZBD4%5D(7D8*G/3(4CW*B@#Y1
M_P"'8FL?$37-%'[5W[7_ (X^*7AOP[?QWNF>$=6M[>ULYYHQA&NS$"UUCG[Q
M!.2"<,P;USQ?^RMX6\7_ +5WA#]K&Z\2W\.J>#] N]*L]*B1/L\\=P) SN2-
MP8>8<8..!7J5% 'EOQX_97\+_'OXH_#7XI:[XFO[&Z^&>ORZKIMM:(ACNY'$
M8*2[@2%_=C[N#R:Y#XZ_L%6OQ5_:5T;]JOP#\=_%7@3Q18:3%I6J-H+1M#JE
MC'/YP@E5L'#-@-R00J?+E<U] T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730383554000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARVINAS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2566120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Science Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">395 Winchester Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">535-1456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARVN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,175.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,271,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant&#8217;s 2023 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December&#160;31, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001655759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730383657232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Stamford, Connecticut<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730386427312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 81.3<span></span>
</td>
<td class="nump">$ 108.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,124.0<span></span>
</td>
<td class="nump">1,394.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">21.4<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,240.2<span></span>
</td>
<td class="nump">1,552.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,268.8<span></span>
</td>
<td class="nump">1,581.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">54.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">218.6<span></span>
</td>
<td class="nump">206.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">295.1<span></span>
</td>
<td class="nump">261.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">405.1<span></span>
</td>
<td class="nump">534.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">703.9<span></span>
</td>
<td class="nump">799.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 53.2 and 53.0 shares issued and outstanding as of December&#160;31, 2022 and 2021, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(965.4)<span></span>
</td>
<td class="num">(682.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,549.4<span></span>
</td>
<td class="nump">1,469.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(19.2)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">564.9<span></span>
</td>
<td class="nump">781.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 1,268.8<span></span>
</td>
<td class="nump">$ 1,581.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Contract Asset And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730383416144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730385066304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 131,400,000<span></span>
</td>
<td class="nump">$ 53,600,000<span></span>
</td>
<td class="nump">$ 25,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">315,000,000.0<span></span>
</td>
<td class="nump">180,400,000<span></span>
</td>
<td class="nump">108,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">79,600,000<span></span>
</td>
<td class="nump">61,600,000<span></span>
</td>
<td class="nump">38,300,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">394,600,000<span></span>
</td>
<td class="nump">242,000,000.0<span></span>
</td>
<td class="nump">146,700,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(263,200,000)<span></span>
</td>
<td class="num">(188,400,000)<span></span>
</td>
<td class="num">(120,800,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">12,200,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before income taxes and loss from equity method investment</a></td>
<td class="num">(251,000,000.0)<span></span>
</td>
<td class="num">(184,100,000)<span></span>
</td>
<td class="num">(115,200,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(20,900,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="num">(10,600,000)<span></span>
</td>
<td class="num">(6,900,000)<span></span>
</td>
<td class="num">(4,100,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (282,500,000)<span></span>
</td>
<td class="num">$ (191,000,000.0)<span></span>
</td>
<td class="num">$ (119,300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in usd per share)</a></td>
<td class="num">$ (5.31)<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in usd per share)</a></td>
<td class="num">$ (5.31)<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (282,500,000)<span></span>
</td>
<td class="num">$ (191,000,000.0)<span></span>
</td>
<td class="num">$ (119,300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(14,500,000)<span></span>
</td>
<td class="num">(5,200,000)<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (297,000,000.0)<span></span>
</td>
<td class="num">$ (196,200,000)<span></span>
</td>
<td class="num">$ (118,800,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382227456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-the-Market Offering</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th">
<div>Common Shares </div>
<div>At-the-Market Offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>At-the-Market Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 226.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (372.6)<span></span>
</td>
<td class="nump">$ 599.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock, net</a></td>
<td class="nump">431.9<span></span>
</td>
<td class="nump">$ 64.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431.9<span></span>
</td>
<td class="nump">$ 64.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">30.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">642.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(491.9)<span></span>
</td>
<td class="nump">1,133.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock, net</a></td>
<td class="nump">259.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">57.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(191.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(191.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">$ (5.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">53.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 781.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(682.9)<span></span>
</td>
<td class="nump">1,469.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">75.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(282.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">$ (14.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 564.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (965.4)<span></span>
</td>
<td class="nump">$ 1,549.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730388249856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, offering costs</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 28.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember', window );">At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382624640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (282.5)<span></span>
</td>
<td class="num">$ (191.0)<span></span>
</td>
<td class="num">$ (119.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of bond discounts/premiums</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DebtInstrumentLoanForgiveness', window );">Forgiveness of debt income</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Loss (gain) on sale of marketable securities</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of collaboration contract asset</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">75.5<span></span>
</td>
<td class="nump">57.1<span></span>
</td>
<td class="nump">30.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">14.0<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(13.6)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Collaboration contract asset</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(12.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(116.8)<span></span>
</td>
<td class="nump">695.5<span></span>
</td>
<td class="num">(13.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(273.5)<span></span>
</td>
<td class="nump">559.4<span></span>
</td>
<td class="num">(89.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(886.4)<span></span>
</td>
<td class="num">(1,744.6)<span></span>
</td>
<td class="num">(41.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">1,076.9<span></span>
</td>
<td class="nump">428.5<span></span>
</td>
<td class="nump">174.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromSaleOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">59.1<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">37.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, equipment and leasehold improvements</a></td>
<td class="num">(6.8)<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">242.8<span></span>
</td>
<td class="num">(1,313.6)<span></span>
</td>
<td class="nump">164.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">264.6<span></span>
</td>
<td class="nump">460.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of common stock offering costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
<td class="num">(27.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">278.6<span></span>
</td>
<td class="nump">504.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(26.0)<span></span>
</td>
<td class="num">(475.6)<span></span>
</td>
<td class="nump">579.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the period</a></td>
<td class="nump">112.8<span></span>
</td>
<td class="nump">588.4<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">86.8<span></span>
</td>
<td class="nump">112.8<span></span>
</td>
<td class="nump">588.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, equipment and leasehold improvements unpaid at period end</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember', window );">At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of common stock offering costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from sale of common stock in at-the-market offering</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 65.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Loan Forgiveness</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock in an at-the-market offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock in a public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturities of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromMaturitiesOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730390355952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation  <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases throughout the discovery, development and commercialization of therapies that degrade disease-causing proteins. Arvinas, Inc. has four wholly owned subsidiaries; Arvinas Operations, Inc. formed in 2013, Arvinas Androgen Receptor, Inc. formed in 2015, Arvinas Estrogen Receptor, Inc. formed in 2016, and Arvinas Winchester, Inc. formed in 2018 (collectively, "Arvinas" or the "Company").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated upon consolidation. The accounting policies used to prepare the Company's consolidated financial statements are the same as those used to prepare the consolidated financial statements in prior years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior period financial information in order to conform with current period presentation. Accounts payable and Accrued expenses have been condensed into Accounts payable and accrued liabilities, Interest income and Interest expense have been condensed into Interest income, net and in Note 11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, within the reconciliation of U.S. federal statutory income tax rate table, a portion of the stock compensation rate effect was reclassified to return to provision.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified and recorded an adjustment to prior periods related to the accounting for its investment in Oerth Bio. See Note 10,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity Method Investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further details.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the Company&#8217;s revenue recognition, uncertain tax positions and research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other biotechnology companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of equity interests, proceeds from collaborations, grant funding and debt financing. The Company had cash, cash equivalents, restricted cash and marketable securities of approximately $1.2 billion as of December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730388083872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies  <div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents and are considered Level 1 financial instruments. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease entered into in May 2021 and amended in August 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">108.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">588.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash in financial institution accounts that may at times exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and 2021, one collaborator represented 88% and 68% of the Company's revenue, respectively, and for the year ended December&#160;31, 2020, three collaborators represented   37%, 32% and 31% of the Company's revenue. For each of the years ended December&#160;31, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, one </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborator accounted for the entire accounts receivable balance.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's marketable securities are classified as available-for-sale securities and are carried at their fair value based on the quoted market prices of the securities, with unrealized gains and losses reported as accumulated other comprehensive income (loss), a separate component of stockholders' equity. Realized gains and losses on available-for-sale securities are included in other income in the period earned or incurred. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Equipment, and Leasehold Improvements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation is removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of long-lived assets when indications of potential impairments are present. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than the carrying value. No such impairments were recorded during 2022, 2021 or 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in assessing performance and allocating resources. The Company, through its Chief Executive Officer in his role as chief operating decision maker, views Company operations and manages the business as one operating segment. All of the Company&#8217;s tangible assets are held in the United States and all of the Company&#8217;s revenue has been generated in the United States. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition and Deferred Revenue </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues from Contracts </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, the Company evaluates whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent combined single performance obligations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company determined that the most likely amount to be recognized was zero, against which no constraint was applied. The Company continually assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company&#8217;s performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the transaction price allocated to the combined performance obligation identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on the Company&#8217;s best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale, or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s accompanying consolidated balance sheets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses direct and incremental costs to obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as collaboration contract assets and amortized as general and administrative expenses over the total estimated period of performance of each underlying contract.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Method Investments </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes its pro-rata share of income and losses in the investment in &#8220;Loss from equity method investment&#8221; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment in the consolidated balance sheet until such investment is reduced to zero. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. The Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the authoritative guidance for recognizing and measuring uncertainty in income tax positions taken or expected to be taken in a tax return. The Company recognizes interest accrued related to unrecognized tax benefits and  penalties in tax expense. Management has evaluated the effect of ASC 740 guidance related to uncertain income tax positions and concluded that the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has no sign</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ificant uncertain income tax positions as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures employee, board of director and consultant equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards. Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies equity-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">401(k) Savings plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Under the 401(k) Plan, the Company made discretionary matching contributions on behalf of eligible employees totaling $2.2&#160;million, $1.3&#160;million and $0.9&#160;million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites and consultants; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into consulting, research and other agreements with commercial entities, researchers, universities and others for the provision of goods and services. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires disclosure of the fair value of financial instruments held by the Company. ASC 825, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;&#160;&#160;&#160;&#160;Inputs are based upon observable or quoted prices (unadjusted) for identical instruments traded in active markets.  The Company&#8217;s Level 1 financial instruments consist of cash equivalents.  </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;&#160;&#160;&#160;&#160;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#8217;s Level 2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;&#160;&#160;&#160;&#160;Inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Common Share </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common shares.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reviews</span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new accounting standards as issued. As of December&#160;31, 2022, the Company has not identified any new standards that it believes will have a material impact on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730387888400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreements</a></td>
<td class="text">Research Collaboration and License Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-471 Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a collaboration agreement with Pfizer (the &#8220;ARV-471 Collaboration Agreement&#8221;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#8217;s proprietary compound ARV-471 (the &#8220;Licensed Products&#8221;). Under the ARV-471 Collaboration Agreement, the Company received an upfront, non-refundable payment of $650.0&#160;million. In addition, the Company will be eligible to receive up to an additional $1.4&#160;billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0&#160;million in regulatory milestones are related to marketing approvals and $1.0&#160;billion are related to sales-based milestones.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the execution of the ARV-471 Collaboration Agreement, the Company and Pfizer entered into a Stock Purchase Agreement (the" Pfizer Stock Purchase Agreement") for the sale and issuance of 3,457,815 shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;) to Pfizer at a price of $101.22 per share, for an aggregate purchase price of $350.0 million (the &#8220;Pfizer Equity Transaction&#8221;), less financial advisor fees of $4.6&#160;million, which was consummated in September 2021. Pursuant to terms of the Pfizer Stock Purchase Agreement, Pfizer has agreed not to sell or transfer the Shares without prior written approval of the Company for a specified time period, subject to specified exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the ARV-471 Collaboration Agreement and the Pfizer Equity Transaction entered into with Pfizer concurrently should be evaluated as a combined contract in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined the fair value of the shares sold under the Pfizer Equity Transaction to be $85.4&#160;million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the sale of stock should be recorded at fair value and therefore allocated the excess consideration received under the Pfizer Equity Transaction to the ARV-471 Collaboration Agreement, which, along with the non-refundable payment of $650.0 million, is being recognized as revenue over the total estimated period of performance based on the Company&#8217;s best estimate of costs to be incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the ARV-471 Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $12.9&#160;million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $12.9&#160;million in collaboration contract asset and other assets in the consolidated balance sheet, which is being amortized as general and administrative expense over the total estimated period of performance under the ARV-471 Collaboration Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the "Bayer Collaboration Agreement") setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC targeted protein degraders, that mediate for degradation of target proteins ("Targets"), using the Company&#8217;s proprietary platform technology, which Targets will be selected by Bayer AG, subject to certain exclusions and limitations. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $17.5 million in exchange for the use of the Company&#8217;s technology license. In addition, Bayer AG is committed to fund an additional $12.0 million through 2023, of which $10.5&#160;million was received from inception through December&#160;31, 2022, including $3.0 million received in each of the years ended December 31, 2022, 2021 and 2020. These payments are being recognized over the total estimated period of performance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated Targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no development or sales-based milestone payments or royalties received through December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Bayer Collaboration Agreement and a Stock Purchase Agreement entered into with Bayer AG at the same time should be evaluated as a combined contract in accordance with ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined the fair value of the shares sold under the Stock Purchase Agreement to be $2.9 million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the sale of stock should be recorded at fair value. Therefore, the Company allocated the additional $2.9 million of consideration received under the Stock Purchase Agreement to the Bayer Collaboration Agreement and added such amount to the total transaction price. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the "Pfizer Research Collaboration Agreement"). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized over the total estimated period of performance. The Company is eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. The Company is also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. In 2021 and 2020, the Company received payments totaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2 million and $4.4&#160;million, respectively,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which are being recognized as revenue over the total period of performance. Pfizer selected additional targets and initiated additional services totaling $1.0 million and $3.5 million in December 2022 and 2021, respectively, which were included in accounts receivable as of December 31, 2022 and 2021. There were no sales-based milestone payments or royalties received through December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Modification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the "Genentech Modification") with Genentech, Inc. and F. Hoffman-La Roche Ltd (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Genentech Modification, the Company received upfront, non-refundable payments of $34.5 million (in addition to $11.0 million received under the previous agreement in 2015) to fund Genentech-related research and Genentech has the right to designate up to ten targets. The Company is eligible to receive up to $27.5 million in additional expansion target payments if Genentech exercises its options on all remaining targets. Upfront non-refundable payments are recognized as revenue over the total estimated period of performance. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $44.0 million per target in development milestone payments, $52.5 million in regulatory milestone payments and $60.0 million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(20.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">740.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">742.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(120.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances not held at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(28.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">623.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">740.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded cumulative catch-up adjustments from contract modifications totaling $0.7 million, $(0.8) million and $(0.4) million, respectively, relating to performance obligations which were satisfied in prior periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of December&#160;31, 2022 totaled $623.7 million, which is expected to be recognized in the following periods: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">218.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">193.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">623.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730387927584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Marketable Securities and Fair Value Measurements</a></td>
<td class="text">Marketable Securities and Fair Value Measurements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s assets measured at fair value on a recurring basis.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024 - 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of accounts receivable and accounts payable and accrued liabilities approximate their </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair values due to the short-term nature of these assets and liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-recurring fair value measures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, in connection with the Pfizer Stock Purchase Agreement, t</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company valued the common stock issued to Pfizer</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at fair value. The Pfizer Stock Purchase Agreement contains provisions restricting the sale or transfer for a period of time (the &#8220;lock-up period&#8221;). The resulting fair value of $264.6&#160;million was determined by applying the discount due to lack of marketability during the contractual lock-up period to the public trading price of the common stock, which is a Level 1 input, on the date of sale. The Company accounted for the lack of marketability during the contractual lock-up period, by utilizing put option models, which are considered Level 3 inputs. Such option models included the Company&#8217;s historical volatility and the risk-free rate based on U.S. Treasury bond rates, as key inputs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730384216496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Leasehold Improvements</a></td>
<td class="text">Property, Equipment and Leasehold Improvements <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense totaled $6.3 million, $4.8 million, and $3.2 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730387938160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Right of Use Assets and Liabilities</a></td>
<td class="text">Right-of-Use Assets and Liabilities<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commencement date in determining the present value of lease payments, which ranges from 3.0% &#8211; 4.1%. Lease expense is recognized on a straight-line basis over </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the lease term. The Company considers options to extend or terminate the lease in recognizing ROU assets and lease liabilities when it is reasonably certain that such options will be exercised. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a lease arrangement, which was amended in August 2022, for approximately 160,000 square feet of laboratory and office space to be occupied in 2024. In connection with the signing of the lease and the related amendment, and at the Company&#8217;s election to increase the landlord&#8217;s contribution to the tenant improvement allowance, the Company initially issued a letter of credit totaling $4.5 million, which was subsequently increased to $5.5 million, collateralized by a certificate of deposit in the same amount, which is presented as restricted cash in the accompanying consolidated balance sheets. Once occupied, the base rent will range from $7.7&#160;million to $8.8&#160;million annually over a ten-year lease term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its corpor</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ate office, laboratories and certain equipment, which expire no later than January 2026. The leases have a weighted average remaining term of 2.3 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of December&#160;31, 2022 were as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730383812880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts Payable and Accrued Liabilities <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730384320304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into an Assistance Agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space (the "Project"). Under the terms of the 2018 Assistance Agreement, the Company was entitled to borrow from the State of Connecticut a maximum of $2.0&#160;million, provided that the funding did not exceed more than 50% of the total Project costs. In September 2018, the Company borrowed $2.0&#160;million under the 2018 Assistance Agreement, bearing interest at 3.25% per annum with interest payments required for the first 60 months from the funding date. Thereafter, the loan will begin to fully amortize through month 120, maturing in </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2021, borrowings totaling $1.0&#160;million were forgiven by the State of Connecticut as the Company met certain employment conditions, as defined in the agreement. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028 with a default penalty of repayment of the full original funding amount of $2.0&#160;million plus liquidated damages of 7.5% of the total amount of funding received.</span><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an Assistance Agreement with the State of Connecticut (the "Assistance Agreement") entered into in 2014, under which all the borrowings by the Company were forgiven in accordance with the Assistance Agreement, the Company is required to be located in the State of Connecticut through January 2024, with a default penalty of repayment of the full original funding amount of $2.5&#160;million plus liquidated damages of 7.5%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt as of December&#160;31, 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the years ended December&#160;31, 2022 and 2021, interest expense was immaterial. During the year ended December&#160;31, 2020, interest expense totaled $0.1 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730387888400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text">Equity <div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 and 2021, the Company had authorized 200,000,000 shares of common stock, at a $0.001 par value per share. The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. The holders of shares of common stock are entitled to receive dividends, if and when declared by the Board of Directors. No dividends have been declared or paid by the Company since its inception.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, in connection with the Pfizer Stock Purchase Agreement, the Company issued </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,457,815</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of common stock to Pfizer at a price of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$101.22</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share, which resulted in aggregate gross proceeds of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$350&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, less financial advisor fees of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.6&#160;million, as further described in Note 3 to our consolidated financial statements</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pursuant to terms of the Pfizer Stock Purchase Agreement, Pfizer has agreed not to sell or transfer the Shares without prior written approval of the Company for a specified period, subject to specified exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company completed a public offering in which the Company issued and sold 6,571,428 shares of common stock at a public offering price of $70.00 per share, which resulted in aggregate gross proceeds of $460.0 million before underwriter discounts, commissions, and offering costs of $28.1 million.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Distribution Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp; Company (&#8220;Piper Sandler&#8221;) and Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $300.0&#160;million of the common stock registered under the universal shelf registration statement pursuant to one or more &#8220;at-the-market" offerings. During the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, no shares were issued under this agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into an Equity Distribution Agreement (the "Distribution Agreement") with Piper Sandler, pursuant to which the Company could offer and sell from time-to-time in an &#8220;at-the-market offering,&#8221; at its option, up to an aggregate of $100.0&#160;million of shares of the Company&#8217;s common stock through Piper Sandler, as sales agent. During year ended December 31, 2020, the Company sold 2,593,637 shares of its common stock resulting in proceeds to the Company of $64.1&#160;million, net of offering costs of $1.6 million. The Company terminated the Distribution Agreement in August 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company's common stock. The number of shares of the Company's common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company&#8217;s then-outstanding common stock, effective as of January 1 of each year. As of December&#160;31, 2022, 1,986,565 shares remained available for purchase. During the years ended December&#160;31, 2022, 2021 and 2020, the Company issued 24,898, 19,357 and 11,046 shares, respectively, of common stock under the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Share Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Fourth Amendment to the Company&#8217;s Incentive Share Plan (the "Incentive Plan") adopted in March 2018, the Company was authorized to issue up to an aggregate of 6,199,477 incentive units pursuant to the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQ2Mjg_cc30fc57-88bc-4fe7-a68a-ecb6f7074afc">one</span> to four years. The Incentive Plan was terminated in September 2018.  In September 2018, each outstanding incentive unit was converted into a number of shares of common stock based upon the IPO price. Certain of the shares of common stock issued in respect of incentive units continued to be subject to vesting in accordance with the vesting schedule that was applicable to such incentive units through the year ended December 31, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s board of directors adopted, and the Company&#8217;s stockholders approved, the 2018 Stock Incentive Plan (the "2018 Plan"), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s IPO. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181 shares) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each year beginning with the year ended December 31, 2019 and continuing to, and including, the year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company&#8217;s common stock, 4% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the year or an amount determined by the Company&#8217;s board of directors. As of December&#160;31, 2022, 2,048,284 shares are available for issuance under the 2018 Plan. Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or cancelled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized compensation expense of $75.5 million, $57.1&#160;million and $30.2 million, respectively, related to the issuance of incentive awards, including $0.7&#160;million, $0.3&#160;million and $0.3&#160;million, respectively, related to the 2018 ESPP. As of December&#160;31, 2022, there was $67.3 million of compensation expense that is expected to be recognized over a weighted average period of approximately 1.7 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during each of the years ended December&#160;31, 2022, 2021 and 2020 was determined using the Black-Scholes option pricing model at the grant date with the following range of assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73% - 76%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74% - 78%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70% - 75%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 7.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 - 7.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 - 7.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 4.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5% - 1.3%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% - 1.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36.79 - $78.91</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$66.82 - $100.40</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.70 - $50.00</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the Company&#8217;s common stock has not been trading for a sufficient period of time, the Company calculates volatility of its common stock by utilizing a weighted average of a collection of peer company volatilities and its own common stock volatility. The expected term is calculated utilizing the simplified method. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2022 is presented below. These amounts include stock options granted to employees, directors and consultants.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,343,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233,961)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,814,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,601,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2022, 2021 and 2020 was $39.17, $52.85 and $27.45, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020 was $7.9 million, $46.9 million and $19.4 million, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $53.8 million of total unrecognized compensation cost related to non-vested stock options granted under the 2018 Plan is expected to be recognized over a weighted average period of approximately 1.6 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there w</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ere </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,540,844</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stock o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ptions under the 2018 Plan that have vested or are expected to vest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted stock award activity under the Incentive Plan as of December&#160;31, 2022 is presented below. These amounts include restricted stock granted to employees, directors and consultants. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date<br/>Fair Value Per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity under the 2018 Plan for the year ended December&#160;31, 2022 is presented below. These amounts include restricted stock units granted to employees.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date<br/>Fair Value Per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock units as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock units as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $13.5 million of total unrecognized compensation cost related to non-vested restricted stock units granted under the 2018 Plan is expected to be recognized over a weighted average period of approximately 2.1 years.</span></div>As of December&#160;31, 2022, there were 414,450 restricted stock units under the 2018 Plan that have vested or are expected to vest.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730387938160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investments</a></td>
<td class="text">Equity Method Investments<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company and Bayer CropScience LP ("Bayer LP") formed Oerth Bio, a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. Pursuant to the terms of the joint venture agreement, the Company made an in-kind intellectual property contribution to Oerth Bio in the form of a license to certain of the Company&#8217;s proprietary technology and Bayer LP committed and subsequently made cash contributions to Oerth Bio totaling $56.0&#160;million, as well as an in-kind intellectual property contribution. The Company and Bayer LP each held an initial ownership interest in Oerth Bio representing 50% of the ownership interests. A 15% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 46.5%, 48.4% and 49.4% as of December 31, 2022, 2021 and 2020, respectively, as a result of vested incentive units.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the joint venture agreement, the Company has no obligation to provide additional funding and the Company&#8217;s ownership interest will not be diluted from future contributions from Bayer LP. The activities of Oerth Bio are controlled by a management board under the joint control of the Company and Bayer LP. As Oerth Bio is jointly controlled by the Company and Bayer LP, the Company accounts for its interest using the equity method of accounting. The Company determined that Oerth Bio is a variable interest entity and, accordingly, the Company has evaluated the significant activities of Oerth Bio under the variable interest entity model and concluded that the significant activities consist primarily of research and development activities and, as the Company does not have the sole power to direct such activities, the Company is not the primary beneficiary.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the fair value of the equity interest it received in Oerth Bio in exchange for the license contributed totaled $49.4&#160;million. The fair value of Oerth Bio was determined utilizing discounted cash flows based on reasonable estimates and assumptions of cash flows expected from Oerth Bio. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $24.7&#160;million in 2019 attributable to the license contributed to Oerth Bio. In 2019, the Company also recognized $24.7&#160;million of equity in net losses of Oerth Bio reducing the carrying value of the Company&#8217;s investment to zero.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In connection with the preparation of the Company's consolidated financial statements for the yea</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">r ended December&#160;31, 2022, the Company identified a prior period error related to the accounting of its investment in Oerth Bio in 2019. Previously, the Company disclosed that revenue of $24.7&#160;million was deferred and would be recognized if and when Oerth Bio recognized revenue associated with the license. The Company has now determined that the consideration received for the amounts associated with the deferred revenue should have been constrained, because at the time Bayer LP had contributed only a portion of its full cash commitment to Oerth Bio, and Bayer LP had the right to all the cash contributed, but not yet spent, upon liquidation of Oerth Bio. The constrained revenue should have been recognized upon both cash being contributed by Bayer LP and the related cash spent by Oerth Bio on research and development activities. As such, the recognition of revenue is accompanied by corresponding equity method losses of the same amount for all periods presented. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company ev</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aluated the error</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd determined that the related impact did not materially misstate the previously issued condensed consoli</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dated financial statements for the years ended December 31, 2021 and 2020. Although the Company concluded that the error was not material to its previously issued consolidated financial statements, the Company has</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined it is appropriate to adjust its previously issued consolidated financial statements for the years ended December 31, 2021 and 2020 to correct</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the error and improve comparability</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following illustrates the effect of the correction of the immaterial error for the period presented. There was no impact to the balance sheets, net loss per common share, statements of cash flows or changes in shareholders&#8217; equity.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as previously reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as adjusted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as previously reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as adjusted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses and net loss of Oerth Bio for the years ended December 31 2022, 2021 and 2020 totaled $22.9 million, $14.3 million and $8.3 million, respectively. The Company recognized equity method losses of $10.6&#160;million, $6.9&#160;million and $4.1&#160;million for the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2021 and 2020, respectively. As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and 2021, the Company&#8217;s carrying value of the investment was zero.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides Oerth Bio with compensated research and development and administrative services through a separate agreement. The se</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rvices rendered by the Company during the years ended December&#160;31, 2022, 2021 and 2020 were immaterial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730383633664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, income tax expense totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.9 million, and consisted of the following:</span><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generated taxable income for the year ended December&#160;31, 2022 primarily due to revenue recognition for tax purposes from the ARV-471 Collaboration Agreement and the mandatory capitalization of qualified research and development expenses incurred on or after January 1, 2022, which, upon recognition for tax purposes, would create additional deferred tax assets. Under the Tax Cuts and Jobs Act of 2017, qualified research expenses incurred after 2021 are no longer immediately deductible for tax purposes and instead must be capitalized and amortized for tax purposes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, the Company had no income tax expense due to incurred operating losses. The Company had also not recorded any income tax benefits for the net operating losses incurred in each of those periods due to its uncertainty of realizing a benefit from those items. All of the Company&#8217;s losses before income taxes were generated in the United States.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2022, 2021 and 2020 were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities were as follows as of December&#160;31, 2022 and 2021: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred income tax liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company has provided a valuation allowance against the full amount of the deferred tax assets since</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> it is more likely than not that the benefits will not be realized. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This assessment is based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All, or a portion of, the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to utilize these potential tax benefits. The valuation allowance increased by $104.0 million and $74.6 million in 2022 and 2021, respectively, due to revenue recognition for tax purposes from the ARV-471 Collaboration Agreement and the mandatory capitalization of qualified research and development costs in 2022, and increases in net operating loss carryforwards, tax credit carryforwards, stock compensation expense, and research and development tax credits in 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had zero and $373.6 million of federal net operating loss carryforwards as of December&#160;31, 2022 and 2021, respectively. Federal net operating loss carryforwards as of December 31, 2017 expire at various dates through 2037 and federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such carryforwards is limited to 80% of the Company&#8217;s taxable income in the year in which carryforwards are used. The Company had $63.4 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$346.9 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of state and local net operating loss carryforwards as of December&#160;31, 2022 and 2021, respectively, that expire at various dates through 2041.  The Company had zero and $15.2 million of federal tax credit carryforwards as of December&#160;31, 2022 and 2021, respectively. The Company had $13.1 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.5 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of state tax credit carryforwards as of December&#160;31, 2022 and 2021, respectively, which expire at various dates through 2037.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company performed a Section 382 analysis to determine whether an ownership change occurred for tax purposes. Based on this analysis, the Company determined that ownership changes occurred on July 31, 2018 and December 31, 2020 due to various equity offerings, vesting of restricted stock awards and stock option exercises. These ownership changes resulted in Section 382 limitations on the Company&#8217;s net operating loss and tax credit carryforwards generated before these dates. However, because the amount of the Section 382 limitations (including carryover of the unused Section 382 limitations and realized </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">built-in gains) exceeds the amount of the Company&#8217;s carryforwards generated before these dates, the limitations will not affect the Company's ability to fully utilize these carryforwards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company complies with the provisions of ASC 740 in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. As of December&#160;31, 2022, the Company recorded net uncertain tax positions of $3.2&#160;million relating primarily to state income tax filing positions in various jurisdictions. As of December&#160;31, 2021, the Company had no unrecognized tax benefits.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's gross unrecognized tax benefits were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period balance - gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions taken during the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases for tax positions taken during a prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period balance - gross</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense. The Company's accrual for interest and penalties as of December&#160;31, 2022 was immaterial.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to file income tax returns in the U.S. Federal and various state jurisdictions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Company&#8217;s net operating loss carryforwards, the Company&#8217;s federal and state statutes of limitations generally remain open for all tax years until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization. The Company does not currently have any federal or state income tax examinations in progress.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021, and 2020, the Company recorded a benefit from expected cash refunds to be provided by the State of Connecticut, equal to 65% of research and development credits, of zero, $1.6 million, and $1.8 million, respectively, which is included in Other income, net in the accompanying consolidated statements of operations and comprehensive loss, due to the Company being a state income and franchise taxpayer in 2022, and a state franchise taxpayer in 2021 and 2020. The benefit results from the exchange of the state research and development tax credit carryforwards for cash refunds. As of December&#160;31, 2022 and 2021, the Company had receivables of $1.9 million and $3.4 million, respectively, relating to research and development credits due to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730387930064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the&#160;ordinary&#160;course&#160;of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred.&#160;As of December&#160;31, 2022, the Company has accrued $7.0&#160;million for such matters, primarily related to a contract dispute that is in early stages.&#160; Due to the early stage of the dispute, the means of resolution are unknown and could involve contract modification and, or payment of consideration.&#160; An estimate of the possible range of loss associated with the dispute cannot be made at this time and the Company has accrued its best estimate as of December 31, 2022.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical and Preclinical Development and Licensing Arrangements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under licensing and related arrangements to which we are a party, we may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Yale University License Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2013, the Company entered into an exclusive license agreement, including the right to grant sublicenses, with Yale University to develop protein degradation technologies. Under the license agreement, the Company is required to pay a minimum license maintenance royalty totaling $0.1 million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first two licensed products for the development of the protein degradation technologies totaling approximately $3.0&#160;million for the first licensed product and approximately $1.5&#160;million for the second licensed product, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from $0.2 million to $0.5 million. During the years ended December 31, 2022, 2021 and 2020, the Company paid $0.1&#160;million, $0.1&#160;million and $0.2&#160;million, respectively, under the license agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FMI Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a Master In Vitro Diagnostics Agreement with Foundation Medicine, Inc. (the "FMI Agreement") for the development and commercialization of one or more of Foundation Medicine&#8217;s companion in vitro diagnostic assays for use with one or more of the Company's therapeutic products.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FMI Agreement does not have a fixed duration, and the Company may terminate the FMI Agreement for convenience by providing adequate written notice to Foundation Medicine, Inc., subject to payment of applicable termination fees. Either party may terminate the FMI Agreement in its entirety for an uncured material breach by the other party, upon the bankruptcy or insolvency of the other party or by the mutual written agreement of both parties. Additionally, Foundation Medicine may terminate the FMI Agreement with respect to an applicable program, if (a) a reasonably necessary third party license is not secured by Foundation Medicine or if the Company does not consent to payments for such license (b) Foundation Medicine reasonably determines that further development of the applicable assay is not technically feasible or (c) following a certain number of years after the first commercial launch of the applicable assay for use with the applicable therapeutic product. Certain license and other rights and certain obligations of Foundation Medicine survive termination of the FMI Agreement. If the FMI Agreement is terminated in its entirety or with respect to any program, the Company has certain payment obligations remaining to Foundation Medicine and may also be required to pay a termination fee, if applicable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bavdegalutamide</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the development of FoundationOne&#174; Liquid CDx as a companion diagnostic for use with bavdegalutamide for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low to mid tens of millions of dollars, in addition to certain validation fees per sample and related pass-through costs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARV-766</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the development of FoundationOne&#174; Liquid CDx as a companion diagnostic for use with ARV-766 for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low tens of millions of dollars, in addition to certain validation fees per sample and related pass-through costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730387928400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;- basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per common share<br/>&#160;- basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.82)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the years ended December 31 2022, 2021 and 2020, and therefore excluded all stock options, restricted stock awards and restricted stock units from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730380801680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash Equivalents The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents and are considered Level 1 financial instruments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease entered into in May 2021 and amended in August 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">Concentration of Credit Risk The Company maintains its cash in financial institution accounts that may at times exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities The Company's marketable securities are classified as available-for-sale securities and are carried at their fair value based on the quoted market prices of the securities, with unrealized gains and losses reported as accumulated other comprehensive income (loss), a separate component of stockholders' equity. Realized gains and losses on available-for-sale securities are included in other income in the period earned or incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Equipment, and Leasehold Improvements</a></td>
<td class="text">Property, Equipment, and Leasehold Improvements Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation is removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived Assets The Company evaluates the carrying value of long-lived assets when indications of potential impairments are present. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than the carrying value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in assessing performance and allocating resources. The Company, through its Chief Executive Officer in his role as chief operating decision maker, views Company operations and manages the business as one operating segment. All of the Company&#8217;s tangible assets are held in the United States and all of the Company&#8217;s revenue has been generated in the United States.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Deferred Revenue</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition and Deferred Revenue </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues from Contracts </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, the Company evaluates whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent combined single performance obligations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company determined that the most likely amount to be recognized was zero, against which no constraint was applied. The Company continually assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company&#8217;s performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the transaction price allocated to the combined performance obligation identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on the Company&#8217;s best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale, or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s accompanying consolidated balance sheets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses direct and incremental costs to obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as collaboration contract assets and amortized as general and administrative expenses over the total estimated period of performance of each underlying contract.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text">Equity Method Investments <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Equity Method and Joint Ventures</span>. The Company recognizes its pro-rata share of income and losses in the investment in &#8220;Loss from equity method investment&#8221; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment in the consolidated balance sheet until such investment is reduced to zero.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. The Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized.</span></div>The Company follows the authoritative guidance for recognizing and measuring uncertainty in income tax positions taken or expected to be taken in a tax return. The Company recognizes interest accrued related to unrecognized tax benefits and  penalties in tax expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures employee, board of director and consultant equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards. Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies equity-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DefinedContributionPlanPolicyPolicyTextBlock', window );">401(k) Savings plan</a></td>
<td class="text">401(k) Savings planThe Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites and consultants; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into consulting, research and other agreements with commercial entities, researchers, universities and others for the provision of goods and services. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires disclosure of the fair value of financial instruments held by the Company. ASC 825, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;&#160;&#160;&#160;&#160;Inputs are based upon observable or quoted prices (unadjusted) for identical instruments traded in active markets.  The Company&#8217;s Level 1 financial instruments consist of cash equivalents.  </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;&#160;&#160;&#160;&#160;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#8217;s Level 2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;&#160;&#160;&#160;&#160;Inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques. </span></div>In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Common Share </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common shares.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reviews</span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new accounting standards as issued. As of December&#160;31, 2022, the Company has not identified any new standards that it believes will have a material impact on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DefinedContributionPlanPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DefinedContributionPlanPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730387919392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">108.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">588.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">108.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">588.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730387958768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of contract balances</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(20.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">740.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">742.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(120.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances not held at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(28.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">623.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">740.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Transaction price allocated to performance obligations</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of December&#160;31, 2022 totaled $623.7 million, which is expected to be recognized in the following periods: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">218.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">193.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">623.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730387927584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of assets measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s assets measured at fair value on a recurring basis.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024 - 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Effective</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 - 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730381741536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, equipment and leasehold improvements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730388813888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of lease expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock', window );">Schedule of supplemental cash flow information related to leases</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating lease liabilities</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of December&#160;31, 2022 were as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730384293168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of accounts payable and accrued liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730388090624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of minimum future principal payments on long-term debt</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt as of December&#160;31, 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730383455712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to determine fair value of stock options granted</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during each of the years ended December&#160;31, 2022, 2021 and 2020 was determined using the Black-Scholes option pricing model at the grant date with the following range of assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73% - 76%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74% - 78%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70% - 75%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 7.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 - 7.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 - 7.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 4.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5% - 1.3%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% - 1.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36.79 - $78.91</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$66.82 - $100.40</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.70 - $50.00</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2022 is presented below. These amounts include stock options granted to employees, directors and consultants.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,343,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233,961)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,814,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,601,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of restricted stock award activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted stock award activity under the Incentive Plan as of December&#160;31, 2022 is presented below. These amounts include restricted stock granted to employees, directors and consultants. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date<br/>Fair Value Per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of restricted stock award activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity under the 2018 Plan for the year ended December&#160;31, 2022 is presented below. These amounts include restricted stock units granted to employees.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date<br/>Fair Value Per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock units as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested restricted stock units as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730384286992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of correction of immaterial error for the period</a></td>
<td class="text"><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following illustrates the effect of the correction of the immaterial error for the period presented. There was no impact to the balance sheets, net loss per common share, statements of cash flows or changes in shareholders&#8217; equity.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as previously reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as adjusted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as previously reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as adjusted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730386415392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, income tax expense totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.9 million, and consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of the U.S. federal statutory income tax rate to effective income tax rate</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2022, 2021 and 2020 were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of deferred income tax benefits and liabilities</a></td>
<td class="text">Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities were as follows as of December&#160;31, 2022 and 2021: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred income tax liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of unrecognized tax benefits</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's gross unrecognized tax benefits were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period balance - gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions taken during the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases for tax positions taken during a prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period balance - gross</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382622608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted loss per common share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;- basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per common share<br/>&#160;- basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.82)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Securities excluded from the computation of diluted net loss per share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the years ended December 31 2022, 2021 and 2020, and therefore excluded all stock options, restricted stock awards and restricted stock units from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730385014912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Subsidiary</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_NumberOfWhollyOwnedSubsidiaries', window );">Number of wholly owned subsidiaries | Subsidiary</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities', window );">Cash, cash equivalents, restricted cash and marketable securities | $</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash and Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NumberOfWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of wholly owned subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NumberOfWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730479923632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 81.3<span></span>
</td>
<td class="nump">$ 108.3<span></span>
</td>
<td class="nump">$ 588.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 86.8<span></span>
</td>
<td class="nump">$ 112.8<span></span>
</td>
<td class="nump">$ 588.4<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730385092480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>operating_segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | operating_segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Discretionary matching contributions</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue | Collaborator One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue | Collaborator Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue | Collaborator Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense', window );">Federal deposit insurance corporation premium expense</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalDepositInsuranceCorporationPremiumExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730374990544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">43 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($) </div>
<div>Target</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,900,000<span></span>
</td>
<td class="nump">431,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Revenue adjustments arising from contract modifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,571,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price, issued and sold (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract', window );">Collaboration agreement direct and incremental costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SaleOfStockFairValueOfSharesSold', window );">Fair value of the shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Stock Purchase Agreement | Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock, net (in shares) | shares</a></td>
<td class="nump">3,457,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price, issued and sold (in usd per share) | $ / shares</a></td>
<td class="nump">$ 101.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds</a></td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForBrokerageFees', window );">Financial advisor fees</a></td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales-based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales-based Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Option Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Additional Target and Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Regulatory Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer A G</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer A G | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SaleOfStockFairValueOfSharesSold', window );">Fair value of the shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Additional consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer A G | Research Funding Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer A G | Research Funding Payments | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer A G | Development Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer A G | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer A G | Sales-based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer A G | Sales-based Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,500,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_NumberOfMaximumDesignatedTargets', window );">Number of designated targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Option Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Contract Asset And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct And Incremental Costs Incurred To Obtain The Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DirectAndIncrementalCostsIncurredToObtainTheContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NumberOfMaximumDesignatedTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of maximum designated targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NumberOfMaximumDesignatedTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SaleOfStockFairValueOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, fair value of shares sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SaleOfStockFairValueOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForBrokerageFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for brokerage fees during the current period. This element is intended to represent the brokerage fees paid by and between financial industry participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForBrokerageFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_AdditionalTargetAndServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_AdditionalTargetAndServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382585744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Summary of Contract Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward', window );"><strong>Accounts receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions', window );">Additions</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">19.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived', window );">Payments received</a></td>
<td class="num">(20.4)<span></span>
</td>
<td class="num">(5.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Ending balance</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward', window );"><strong>Accounts payable related to collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrent', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrentAdditions', window );">Additions</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrentPayments', window );">Payments made</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrent', window );">Ending balance</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward', window );"><strong>Contract assets: Collaboration contract asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Beginning balance</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements', window );">Additions</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Ending balance</a></td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities: Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">740.5<span></span>
</td>
<td class="nump">45.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements', window );">Additions to collaboration agreements</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">742.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from balances held at the beginning of the period</a></td>
<td class="num">(120.0)<span></span>
</td>
<td class="num">(18.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance', window );">Revenue recognized from balances not held at the beginning of the period</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(28.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 623.7<span></span>
</td>
<td class="nump">$ 740.5<span></span>
</td>
<td class="nump">$ 45.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, After Allowance For Credit Loss, Current, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Accounts Payable, after Allowance for Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Accounts Receivable, after Allowance for Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Collaboration Contract Asset And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Liability, Revenue Recognized Not Included In Previous Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730383561296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 623.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 218.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 193.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 90.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 55.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 34.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 31.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382407200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring | Pfizer, Inc. | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Non-recurring fair value measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,143.2<span></span>
</td>
<td class="nump">$ 1,398.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(19.2)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,124.0<span></span>
</td>
<td class="nump">1,394.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Corporate Bonds Maturing 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">802.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(9.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">793.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Corporate Bonds Maturing 2024-2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">205.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(9.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">196.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Government Securities Maturing 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">61.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">61.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Government Securities Maturing 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">73.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 73.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Corporate Bonds Maturing 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">784.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">783.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Corporate Bonds Maturing 2023 -2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Government Securities Maturing 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382141136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="nump">$ 23.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(16.6)<span></span>
</td>
<td class="num">(10.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">17.1<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730388133104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730381805056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities - Additional Information (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Lease for laboratory and office space (in square feet) | ft&#178;</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_BaseLeaseRentPeriod', window );">Base rent period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PledgedStatusAxis=us-gaap_AssetPledgedAsCollateralMember', window );">Asset Pledged as Collateral | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecurities', window );">Debt securities</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfIncrementalBorrowingForLeasePayments', window );">Percentage of incremental borrowing for lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Base rent</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfIncrementalBorrowingForLeasePayments', window );">Percentage of incremental borrowing for lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Base rent</a></td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_BaseLeaseRentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base Lease Rent Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_BaseLeaseRentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfIncrementalBorrowingForLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of incremental borrowing for lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfIncrementalBorrowingForLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgedStatusAxis=us-gaap_AssetPledgedAsCollateralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgedStatusAxis=us-gaap_AssetPledgedAsCollateralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730384295216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730388483568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract', window );"><strong>Supplemental non-cash information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new lease obligations</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental non-cash information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SupplementalNonCashInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730383395568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382141168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities - Components of Accrued Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="nump">$ 31.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development expenses</a></td>
<td class="nump">35.9<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee expenses</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees and other</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 74.7<span></span>
</td>
<td class="nump">$ 54.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382330592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfMaximumFundingOnProjectCosts', window );">Percentage of maximum funding on total project costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DebtInstrumentLoanForgiveness', window );">Loan forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember', window );">2018 Assistance Agreement | State of Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DebtInstrumentInterestPaymentsTerm', window );">Debt instrument interest payments term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod', window );">Debt instrument amortization period (month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DebtInstrumentLoanForgiveness', window );">Loan forgiveness</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfLiquidatedDamages', window );">Percentage of liquidated damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember', window );">2018 Assistance Agreement | State of Connecticut | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember', window );">2014 Assistance Agreement | State of Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfLiquidatedDamages', window );">Percentage of liquidated damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument amortization period after interest payments period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentInterestPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest payments term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentInterestPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Loan Forgiveness</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfLiquidatedDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of liquidated damages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfLiquidatedDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfMaximumFundingOnProjectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum funding on project costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfMaximumFundingOnProjectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730385119744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730377339584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_NumberOfVotesPerCommonStockShareHeld', window );">Number of votes per common stock share held | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259.9<span></span>
</td>
<td class="nump">$ 431.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.5<span></span>
</td>
<td class="nump">$ 57.1<span></span>
</td>
<td class="nump">$ 30.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation expense not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.17<span></span>
</td>
<td class="nump">$ 52.85<span></span>
</td>
<td class="nump">$ 27.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 46.9<span></span>
</td>
<td class="nump">$ 19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock', window );">Common stock reserved for issuance on outstanding common stock (percentage)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares remained available for purchase and issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,986,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,898<span></span>
</td>
<td class="nump">19,357<span></span>
</td>
<td class="nump">11,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,067,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares remained available for purchase and issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,048,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase in reserved shares of outstanding common stock (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense not yet recognized, period of recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation expense for options not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock options vested and expected to vest (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,540,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber', window );">Restricted stock units expected to vest (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation expense not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense not yet recognized, period of recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Incentive units authorized for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,199,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Annual increase in reserved shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,989,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based award, vesting period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,277,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based award, vesting period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense not yet recognized, period of recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arvn_EquityDistributionAgreementMember', window );">Equity Distribution Agreement | Piper Sandler | At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares, issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,593,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares, issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,571,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price, issued and sold (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from sale of shares in Initial public offering before fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares, issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Stock Purchase Agreement | Pfizer, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares, issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,457,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price, issued and sold (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForBrokerageFees', window );">Financial advisor fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Equity Distribution Agreement | Piper Sandler | At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares, issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate offering price of common stock under equity distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NumberOfVotesPerCommonStockShareHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes per common stock share held</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NumberOfVotesPerCommonStockShareHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Expected To Vest Exercisable Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForBrokerageFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for brokerage fees during the current period. This element is intended to represent the brokerage fees paid by and between financial industry participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForBrokerageFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PiperSandlerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PiperSandlerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730386248512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum (percentage)</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum (percentage)</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum (percentage)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum (percentage)</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 36.79<span></span>
</td>
<td class="nump">$ 66.82<span></span>
</td>
<td class="nump">$ 22.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 78.91<span></span>
</td>
<td class="nump">$ 100.40<span></span>
</td>
<td class="nump">$ 50.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730386224816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Stock Option Activity (Details) - 2018 Plan - Employees, Directors and Consultants - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding, beginning balance (in shares)</a></td>
<td class="nump">6,814,634<span></span>
</td>
<td class="nump">5,343,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted (in shares)</a></td>
<td class="nump">1,889,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, exercised (in shares)</a></td>
<td class="num">(184,160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, forfeited (in shares)</a></td>
<td class="num">(233,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding, ending balance (in shares)</a></td>
<td class="nump">6,814,634<span></span>
</td>
<td class="nump">5,343,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exercisable (in shares)</a></td>
<td class="nump">3,601,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding, beginning balance (in usd per share)</a></td>
<td class="nump">$ 44.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in usd per share)</a></td>
<td class="nump">59.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in usd per share)</a></td>
<td class="nump">19.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited (in usd per share)</a></td>
<td class="nump">61.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding, ending balance (in usd per share)</a></td>
<td class="nump">49.06<span></span>
</td>
<td class="nump">$ 44.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in usd per share)</a></td>
<td class="nump">$ 37.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (years), outstanding</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (years), exercisable</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arvn_EmployeesDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arvn_EmployeesDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730386227120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Restricted Stock Grant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan | Restricted stock awards | Employees, Directors and Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">30,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(29,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(1,320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">16.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">16.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | Restricted stock units | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">88,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">460,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Exercised (in shares) | shares</a></td>
<td class="num">(42,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(17,354)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">489,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 20.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">54.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">20.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">53.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 51.37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercises weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arvn_EmployeesDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arvn_EmployeesDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arvn_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arvn_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382349824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="num">$ (120,000,000.0)<span></span>
</td>
<td class="num">$ (18,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="num">(10,600,000)<span></span>
</td>
<td class="num">(6,900,000)<span></span>
</td>
<td class="num">$ (4,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">623,700,000<span></span>
</td>
<td class="nump">740,500,000<span></span>
</td>
<td class="nump">45,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">394,600,000<span></span>
</td>
<td class="nump">242,000,000.0<span></span>
</td>
<td class="nump">146,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">22,900,000<span></span>
</td>
<td class="nump">14,300,000<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">22,900,000<span></span>
</td>
<td class="nump">$ 14,300,000<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity interest</a></td>
<td class="nump">49,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage', window );">Future grant of incentive units to service providers, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 24,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember', window );">Bayer LP | Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest, percentage</a></td>
<td class="nump">46.50%<span></span>
</td>
<td class="nump">48.40%<span></span>
</td>
<td class="nump">49.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future grant of incentive units to service providers, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=arvn_OerthBioLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=arvn_OerthBioLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730386511792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 131.4<span></span>
</td>
<td class="nump">$ 53.6<span></span>
</td>
<td class="nump">$ 25.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(263.2)<span></span>
</td>
<td class="num">(188.4)<span></span>
</td>
<td class="num">(120.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(6.9)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (282.5)<span></span>
</td>
<td class="num">$ (191.0)<span></span>
</td>
<td class="num">$ (119.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in usd per share)</a></td>
<td class="num">$ (5.31)<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in usd per share)</a></td>
<td class="num">$ (5.31)<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (297.0)<span></span>
</td>
<td class="num">$ (196.2)<span></span>
</td>
<td class="num">$ (118.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">as previously reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(195.3)<span></span>
</td>
<td class="num">(124.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (191.0)<span></span>
</td>
<td class="num">$ (119.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (196.2)<span></span>
</td>
<td class="num">$ (118.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.9)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382317984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">12,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">20,900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 20,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730377224688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 20,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, income tax penalties and interest accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Effective income tax rate reconciliation, tax credit, research and development, percentage</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Effective income tax rate reconciliation, tax credit, research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">373,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage', window );">Operating losses carry forward, maximum deductibility percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Federal tax credit carryforwards</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">63,400,000<span></span>
</td>
<td class="nump">346,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Federal tax credit carryforwards</a></td>
<td class="nump">13,100,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">(Decrease) Increase in valuation allowance</a></td>
<td class="nump">$ 104,000,000<span></span>
</td>
<td class="nump">$ 74,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Effective income tax rate reconciliation, tax credit, research and development, percentage</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Receivables relating to research and development credits</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating losses carry forward, maximum deductibility as a percentage of taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730386225952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent', window );">Return to provision</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research tax credit</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">16.30%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(31.70%)<span></span>
</td>
<td class="num">(38.40%)<span></span>
</td>
<td class="num">(23.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Reconciliation of effective income tax rate</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Return To Provision, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730479927728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Deferred Income Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">$ 143.0<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">56.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">25.9<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">18.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Loss carryforwards</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">247.1<span></span>
</td>
<td class="nump">144.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, equipment and leasehold improvements</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(3.6)<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(243.5)<span></span>
</td>
<td class="num">(139.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income tax liability</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382393440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of period balance - gross</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for tax positions taken during the current period</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases for tax positions taken during a prior period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of period balance - gross</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730382231872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 04, 2022</div></th>
<th class="th"><div>Jul. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University | License, First Licensed Product | Success-Based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_RequiredMilestonePayments', window );">Required milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University | License, Second Licensed Product | Success-Based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_RequiredMilestonePayments', window );">Required milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Yale University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AnnualLicenseFeePayment', window );">Annual payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Yale University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Foundation Medicine, Inc. | Success-Based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Milestone payments (up to low)</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AnnualLicenseFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual license fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AnnualLicenseFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_RequiredMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Required Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_RequiredMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126928961&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_YaleUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_LicenseFirstLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_LicenseFirstLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SuccessBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SuccessBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_LicenseSecondLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_LicenseSecondLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_FoundationMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_FoundationMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730388466752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and Diluted Loss per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (282.5)<span></span>
</td>
<td class="num">$ (191.0)<span></span>
</td>
<td class="num">$ (119.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in usd per share)</a></td>
<td class="num">$ (5.31)<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in usd per share)</a></td>
<td class="num">$ (5.31)<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139730386103648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computations of diluted net loss per share (in shares)</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computations of diluted net loss per share (in shares)</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computations of diluted net loss per share (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computations of diluted net loss per share (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>arvn-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arvn="http://www.arvinas.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arvn-20221231.xsd" xlink:type="simple"/>
    <context id="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie2bf8d71415f4efa90cde8b45af0012e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i902528dd801a41cba33017f4bcccec14_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="iafe9691446164ba9bb2c4bf060b98b4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i62b9074c6dbb4f3fbdbff41dce34d514_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i00f51f7f7a9845899d4dd0c5fc38d3c8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5126550f14e04feb9ca9ca6b7e02ed04_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib59969a5f0034e8e9c7010fd7f0be379_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i35327f5dcba84428bcd65e20009ba82d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6be069e34bc4e4dab6470f86f377631_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2da99b1272604c40b299c7e2a492b717_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff0703d3445f4aebac374d380138baf6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0a5a6b31a7ca4b5e825ff2a8e5104399_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i58e74e4ca00a46a298dd26d104628c71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb59a32694da4a52a057a3d5d4602acb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9803bb2bac440b9a73f90689f2b195a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c3f132181ab4f2782eda83c630d9771_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d68e78d78a7421fa07de080fcab1007_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82f79a4ab8ad48ac808ede7cafff07d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic150bcdd10a44a698d262678b95dc444_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ae1926583c8447eb7a2bf92b4691763_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i189cf08cd0b147de9ee24b6f4241c087_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c56b6a959914b1fa1a46f86145ab11e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a8a21d9b2d1414aaf530880ae2aa161_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e9275d362a24c8a9d71ee61e0d22587_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20400f57ea38437d8f5a5a76227f5779_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i332f5a83e3e04dc99cf119f9afdf4c9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i515d8e18c44c4d4eb75265ed7439e978_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36d0618dabaa4dde950863143d4eba01_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id43fad10517549efbe1041cf1a7ac9c6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3328081fbb1245bea8d77942437e9fda_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic1c26cc298914577ad3d74291efe85aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i49058d6c0fee45bc82e5a3b3d793c61b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idec633905ec142408e34afcd540d6467_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idbedba621b114c17bd11d5578ed1e6c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c91e2ef842a460da45c1b6475a741ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49ca8da516e7499682d587c74985691c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i765b24d88e5044b0b3474cc202e4c269_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f3407ea1c884292b6b1262e24808e77_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i05529346f2bd43978586c86e2c968da8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2cf9012e2f3e483fb7f5830d388d4178_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c1ef30395c542ec9b2036e573ee37fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93dabaf08df04303b0314c7df4d8e165_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43bf74e98bde44c59baa52f0d2d487fe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3f476fc73a34c9e810fa5b3bfabf520_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id8bb00294943430a85af5e662821b3fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3c8b495cdfa84814911559b730f66a7e_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="id72a39411b0248c680378066eb3c8a44_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia18bd320049b4bbba687aa9d1e399170_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae355cb2cbd14a7ca7ce12fab1f7f070_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49f4a72ec629422dafd039f183564403_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i008bbd6d947d479fad8e8cd49d905905_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib894aa0b10644e20af715749fe409cc1_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i137647b8ea294b7f923d056ee2a3185a_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="ia0122cacce6947ffb02e9a5170ae43e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3f9942e42d3140f8a91bf2d658e6dcf3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5e7ec5fd01749818f635a4f60e5162b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic1c1ec77b77045b497b74778ed6dd646_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="if7526a5f18544f7e93c796607abcc906_D20190601-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6c577e36553475a87e391c1f798aa7b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i48ac848348704c25879ff7a321b30a93_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd3db3e1a3a44d7eaadb52f8b2021f2d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic37540796dbd46e89f0413e7111cb541_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i63bcebaaf3e442f0be53ff2a3cd2ab6b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id766159d435e4384b6f8955f4aa30c00_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i60b38ed093ce46b7bd1daba503d94341_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if3ae4abd92fa47a5b59e353890bedd74_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaaf06e4b711c47f79d1671a25c581273_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i41b133ccf8c94b249e0de13cf22af00d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1a14b1ae339242c8b514f80494ac7461_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8056d73a6e7d4769acafb7929251b89d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic134f4ad0212413fb29264d3665de649_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibcd68967c863457f9a819376746fa6fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i877187a756224a52a50870299413f7a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:AdditionalTargetAndServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i660d8e9f27ff4dc1a01397df66df2870_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:AdditionalTargetAndServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94762668373b4b67bb84c11c71e8cdb1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i759fe1462729496ba429f2526fc8aff5_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i9a9898905f154cf8b9795022a7300014_D20150901-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i8cc6a3e194a5420ea29436a5800706bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5473a14476bb4d1885b2439dc1d56870_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8eb28a02b3f4a66aeb3f487c3c1bb6b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i095c155f507a4c09a74c9bc2d95f96ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5bbb1ec29ec94c9f87ada6000b54a3fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i247c5fdfe9cf425da9589cd446cbbdb1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9ea29be677eb40da8b1cb7c47d711d2d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e801491e3064f7e8860d42f7cd1d807_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37df6405966e4a9bba28bd31c157a857_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3bd0aacedfdf49bf999f9c0416ec3008_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4368412362e45bba2473a1217491133_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i672048308c094a4fbb8e393353f2cc46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib73fa643c9664e9aa6e824a9828957e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i11ac1a1558a74e50b590271f7dea04b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2baa9d5c1314262a04322fd5725c7b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2517bd9479df46dcac4edde8de8fbf8b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e71741f7e2c4379b7adad37f613ae6b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5cb3556f23c44e99bce5894aafa9c448_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46cfa718400a42c5a9f24fb1d208bf44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49bcbdd1acfc42b186645d856f68c30a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice07d9029aa84199ac8be838d60ae4a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7090b40f62334eab9ab385c427bcecdd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24c2800943e64589bfe1be38fdfcdeac_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i058eebe5acbf4e69a811a1f3713b1674_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i65535f62f10e4ef4870538c48dee40d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida76e88673e6409baa83b50282beff61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0a77e93668514396822e5760f192b979_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a171973241c4a65b20f085ad93852a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i80ab38e360f943d6a594d05213ee4b3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i079086717708440bbc6bde6339a2c26e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i435f3577adb6471086574fa92705b9b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5bc16f834f8e48cca3a2cc04f3bdb2ab_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i75b6e519c7cb4a81826452584ae57c12_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgedStatusAxis">us-gaap:AssetPledgedAsCollateralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i172eba417a7443088682953acc866535_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgedStatusAxis">us-gaap:AssetPledgedAsCollateralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78cc6c1900c646e7a686f9fcfb72aaf7_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="iabe4cc386917403580675ce1a278cc64_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="if9675174a7b047df809244be6ddfdc48_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i076af9c270b244029a1fd9d8b3982564_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i6661ad55442349ec8d7ed679ec7f076a_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i53fe0650f7c54cf9ae9a1454d05ebdc7_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i3c91c1b5ea044c539a1158ebd4047fc5_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i477280be32f04a07b28c112beeada17e_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i1d949a3402824e308e36a3888973c554_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="if2470b93587642ee93b6862f8c50a373_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="ib169c00592d548a6a517237266872f3e_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3746b160a6d94d569ae602cad6e75837_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i991152e66e4e40e9bc87485ec165e1ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2470ca2aeec0492f9ed6572c69865095_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i96b0bd17747b4688858d04a773ba7ca5_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i7510f41e99a44e9ca02267aa1713991c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31413367d46d44f0931cd3029d3ff4ef_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ibe1acbc8a7b44d439c12403bc1c92244_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="iec89f9a651ba481db8272f35c6c0df8e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i639e7b73e496499384ef668da7babf51_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i49494ba6d0a5453c93d7b34884260277_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6dcf04ef5c59465f95dac5b9e575482f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia846f83b7f644f2a8e79d0645dc59a76_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="icfabad7e7058466fb197da797a83c8d6_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="if26c93c17a9d49abbe7e03e1fcfe3fdc_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i7ab2311054644dec946b5c3b15b4ac53_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="idf4d92b3f5524d2ca5cfdb2b7d2ecc62_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ic70f3f6fa6df4c48b0dda80d2a243089_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3160983fd398465eb653ad6cd4b8665c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3f56a6f1dc8a4a1cb8a2a3b2b8c32f00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if489ed4aaa6246e6bd13294c53489cff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaf5f5dfe6c4149dba9168a6e138aad59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf91003a0cee40d78e7d885446a5b900_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1574e37a15e549dfb509f0a9a114356d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i354e561295fa4c89814e4858d5d58e62_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09e4011096b842ed87640ac7cc8d1cb1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia382a82cd26a4f6289ea15987b91a7b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib731e741df304e76af7f4302010536a3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic8a73ff779bf416cb4eebeeae68b3d11_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e4ccd6ef3f64b6b9e8ca76e68ac3d86_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b0ed0665f494c7c902dffd54470764e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7a433e284fc436190fc991a5d7d1826_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ideae804a84b646ac95f9d6e31422f985_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife9054bd93cd4ee890d1bb3769253bbc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d25eae66f4940efbc51ec06b70565d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b0c4960152f4b068f2e7ff788c1f577_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07de6ac05c1e41a9b8b94c23de19c282_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3b24196f7ab4e96948b59541f2a2454_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i825713991b7d4d6ca930134e1ea64f3b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i64e8a70e80d34c36a994fb20b47a535c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9135a832bfa141bdaea8cd60e7266128_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idbbd49660da24081b31f3017c1fb0202_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81e6172dea754fde956550d07bd3297c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iee0ea6f5d3fd49e6bcd4ffc8b9e8f561_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ba241f8483c4d27abe31fc22d087023_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19ac2aec78b54b438d208831130b52be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9391f67286954fea9ef7f855af5453c3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2942bd6c0af14feca606f6c2cf37f948_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="ife636ddfe9704222b932ba3a4f39e4d6_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i0d437e8b17c84126a8ff5f6624f1cd05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d95876f6cfe490fb65fd87f81be2616_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc24f8c5be114f76ab380633238bd2df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i808530cbe2df478ca19263be75cce162_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ce462a88c514f3db5b77585aa66ba25_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b75291c93af4cb4b6f481d140f1d96f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a596c4754f948a899d60103c138350e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idfbc96733ba14eacba1def4f1f53391f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d1a440ff1814ec2b2967dbc51a0a62c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f581941be6141b8a521496421ffb373_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iecde1bb80509425b97c53198d17cd282_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i462d342906254aa08ed253bed2a62c4c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87ad4e65cba64ab792067ed0244886b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1330642a737d458aa14cb794d465bbbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f49b42bb24b4669b993f69de2a04054_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7a1938c4bd324660821a879962862c4e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i98620edc8ebd468da40a2ba163c12f1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief8ca6ef40ac464c81aebbad3e910b38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3cc8adccf5a84a7e82138a769bca1f6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadb5ee3cd631498e9f704ed1e3083c3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b912e140bd549c59a71222eff36d168_D20130701-20130731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-01</startDate>
            <endDate>2013-07-31</endDate>
        </period>
    </context>
    <context id="i0e872fdee2484e02a8eecae47bd8d71c_D20130701-20130731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseFirstLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-01</startDate>
            <endDate>2013-07-31</endDate>
        </period>
    </context>
    <context id="i71af99d94a15409d814e3bc898621bc3_D20130701-20130731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseSecondLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-01</startDate>
            <endDate>2013-07-31</endDate>
        </period>
    </context>
    <context id="i4c4e41fe7c444302a2f4e5632b5df43f_D20130701-20130731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-01</startDate>
            <endDate>2013-07-31</endDate>
        </period>
    </context>
    <context id="i2bcccb8aa5c3415c94857cd84457d1c3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc0e2f0ce3a94a72a40371967158f45d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id8f55863c58b46e580d64c087d73a211_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i496ab182e9bd4c7fb0d9db9b728a6798_D20220604-20220604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:FoundationMedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-04</startDate>
            <endDate>2022-06-04</endDate>
        </period>
    </context>
    <context id="i96d22ed283414299b6a543fcde594e37_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i131967269d424a0a9e25495c62957e55_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia927654c60d84e7a99159c1cae642735_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i008486f737c64fb5890db18235e070ff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia62bc0fe985a441ab8b2ca63ed56b425_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25d62ff1d49b406c840997107b6eae57_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iccb0fc5624af4bea97bb6b0b4030e038_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i73e8a5c5471147159a6cf356c1ed6b90_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ad800b817ff41fc9a94dc8de9936747_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>arvn:Subsidiary</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="operating_segment">
        <measure>arvn:operating_segment</measure>
    </unit>
    <unit id="target">
        <measure>arvn:Target</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="vote">
        <measure>arvn:vote</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV8yLTEtMS0xLTQ1MzM0_14b2ddae-cf81-47c7-98d5-ae5ab9d8d47a">0001655759</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV8zLTEtMS0xLTQ1MzM0_83b0dc65-1a21-4b72-98a6-676d092b667f">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV80LTEtMS0xLTQ1MzM0_92aef757-4fe6-4423-9b2b-56fe02c0c443">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV81LTEtMS0xLTQ1MzM0_1791d19b-31a7-4893-8103-14a29bdfb1db">false</dei:AmendmentFlag>
    <dei:EntityCurrentReportingStatus
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV82LTEtMS0xLTQ1MzM0_a4582ddb-399d-4cc0-8fc4-9158effd2106">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV83LTEtMS0xLTQ1MzM0_c646a26c-b17b-4f2c-a97f-40a76b70ffeb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityVoluntaryFilers
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV84LTEtMS0xLTQ1MzM0_b0d9abb7-42e6-47eb-be35-d2730678a5c8">No</dei:EntityVoluntaryFilers>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80L2ZyYWc6ZGI5NzM3ZmY2OGI0NDgxOTg2NTA0NTJjMDIxMWJjZmYvdGFibGU6MmVhOGE5NzAyNjFkNDdlODg4MzJiNmU1OTg1NzE5YzkvdGFibGVyYW5nZToyZWE4YTk3MDI2MWQ0N2U4ODgzMmI2ZTU5ODU3MTljOV85LTEtMS0xLTQ1MzM0_184484c4-9e33-4461-8268-ec5d72186934">Yes</dei:EntityWellKnownSeasonedIssuer>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i1e801491e3064f7e8860d42f7cd1d807_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzItMS0xLTEtNDUzMzQ_80a0dda5-94ea-4289-80be-96fd1a6d6b63">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i37df6405966e4a9bba28bd31c157a857_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzQtMS0xLTEtNDUzMzQ_c4a33286-7b0c-4eee-a3cb-a8307661d733">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i3bd0aacedfdf49bf999f9c0416ec3008_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzYtMS0xLTEtNDUzMzQ_e0292168-c96e-4d5f-ba05-c093d7e7280f">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ic4368412362e45bba2473a1217491133_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzgtMS0xLTEtNDUzMzQ_47d49ce6-4ac2-4cf4-8c09-4431b9c1f577">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i672048308c094a4fbb8e393353f2cc46_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzEwLTEtMS0xLTQ1MzM0_aa113f81-e516-4bb2-97a2-1bd04a7fe144">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ib73fa643c9664e9aa6e824a9828957e4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDgvZnJhZzo0MTFjZTU2YzhkY2U0MDA3YWVkNzcxM2Q0YTA5OTY1YS90YWJsZTo1Yjc3ZWY4ZDkyZWY0OWRkYjA1YWI2YzNkNWMzNWZiNS90YWJsZXJhbmdlOjViNzdlZjhkOTJlZjQ5ZGRiMDVhYjZjM2Q1YzM1ZmI1XzEyLTEtMS0xLTQ1MzM0_02f33142-358a-42b8-a9f4-12e89fd06b42">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:InterestExpenseDebt
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80NTUvZnJhZzoxNzhkZTQ3NzhkNzI0ZDg1YmUwMmZjOWU3M2Q4YTRkNy90ZXh0cmVnaW9uOjE3OGRlNDc3OGQ3MjRkODViZTAyZmM5ZTczZDhhNGQ3XzI3NDg3NzkwNjk0NzU_03bdee86-5a25-4b61-b9dc-62f2284faf92"
      unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF80NTUvZnJhZzoxNzhkZTQ3NzhkNzI0ZDg1YmUwMmZjOWU3M2Q4YTRkNy90ZXh0cmVnaW9uOjE3OGRlNDc3OGQ3MjRkODViZTAyZmM5ZTczZDhhNGQ3XzI3NDg3NzkwNjk0NzU_14f68dbf-8950-42d1-92d0-caa5a47871ed"
      unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="icfabad7e7058466fb197da797a83c8d6_D20180301-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQ2Mjg_cc30fc57-88bc-4fe7-a68a-ecb6f7074afc">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDY3_e2de66c3-4575-454e-bef0-10f50d2807a5">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6ZjBmOWI3MGJhNTdlNDVhM2JhZGNiNDdkM2ZmMjE1MjgvdGFibGVyYW5nZTpmMGY5YjcwYmE1N2U0NWEzYmFkY2I0N2QzZmYyMTUyOF8wLTAtMS0xLTQ1MzM0_287d7dd0-cb48-4aef-9f7f-5a77b1cadaa0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8yMzI_787d3ed9-c0f4-4e5f-ac8c-a78e3e4971b2">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8yMzI_453e4ca9-3580-4fdf-885a-ad2721154552">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NjFkYjRlY2I3YTk4NGIzMzg1YWM3NWZiN2IxZDZiY2YvdGFibGVyYW5nZTo2MWRiNGVjYjdhOTg0YjMzODVhYzc1ZmI3YjFkNmJjZl8wLTAtMS0xLTQ1MzM0_6f8106a4-df96-4a59-9ca9-feea10770331">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDYy_63452e43-4652-4082-bf1f-8c13d570baf7">001-38672</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDYz_cd3810f6-34eb-48eb-bfa2-0e7adade9d06">ARVINAS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8wLTAtMS0xLTQ1MzM0_f7ff6bd7-7cac-4626-91c7-f52adbbc4f4e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8wLTEtMS0xLTQ1MzM0_2aeb08dd-d3c7-482b-a1ff-7c095eb82f18">47-2566120</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8yLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MGM2ZWYwMmY1N2Y3NGY3NGIzYTEzYmJlNmU4MjhjMGVfNQ_10020a03-844a-489b-9f76-c272b8beca64">5 Science Park</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8yLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MGM2ZWYwMmY1N2Y3NGY3NGIzYTEzYmJlNmU4MjhjMGVfOA_2fddb7df-ae52-497e-a0be-d70e05514bbf">395 Winchester Ave</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8yLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MGM2ZWYwMmY1N2Y3NGY3NGIzYTEzYmJlNmU4MjhjMGVfMTI_5b0aa51c-3c4f-465d-8e76-707da5378d0c">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8yLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MGM2ZWYwMmY1N2Y3NGY3NGIzYTEzYmJlNmU4MjhjMGVfMTY_d26c9ceb-5491-4b34-974e-ebc8d50898e7">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6MWIyNjk5YWNiOGY1NDY2Y2E4NzIzNjE3ZmVhMGMxOTgvdGFibGVyYW5nZToxYjI2OTlhY2I4ZjU0NjZjYTg3MjM2MTdmZWEwYzE5OF8yLTEtMS0xLTQ1MzM0_2b4944d0-59b8-46e6-a49d-3a442897cd2d">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDY0_92c1d022-37a4-4ab8-ab83-78996e22b2b4">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDY4_3ec8e183-c0c8-4662-a6a2-5cd202f9c717">535-1456</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NGIwNzgwYjk0YzZmNDk4NjhlNjcxZDc0M2IwZmU5NjgvdGFibGVyYW5nZTo0YjA3ODBiOTRjNmY0OTg2OGU2NzFkNzQzYjBmZTk2OF8xLTAtMS0xLTQ1MzM0_d52d2b42-3322-4c9d-924e-a54a951bbe16">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NGIwNzgwYjk0YzZmNDk4NjhlNjcxZDc0M2IwZmU5NjgvdGFibGVyYW5nZTo0YjA3ODBiOTRjNmY0OTg2OGU2NzFkNzQzYjBmZTk2OF8xLTEtMS0xLTQ1MzM0_18cd75b5-1fe9-418c-a454-8db6ac822764">ARVN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NGIwNzgwYjk0YzZmNDk4NjhlNjcxZDc0M2IwZmU5NjgvdGFibGVyYW5nZTo0YjA3ODBiOTRjNmY0OTg2OGU2NzFkNzQzYjBmZTk2OF8xLTItMS0xLTQ1MzM0_de472043-4fb9-49f8-a2af-633ff8658340">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NWUzMjUyMDY0NGQxNDBjZWIwNjdlNzFjMzgzZGU5MmQvdGFibGVyYW5nZTo1ZTMyNTIwNjQ0ZDE0MGNlYjA2N2U3MWMzODNkZTkyZF8wLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MWZiMWM2OTYyODRjNDk1MWIxYTRjZjk4Nzc1YTY3NWRfNA_497d94bf-a3a2-4347-b78f-a5e2e49955b7">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NWUzMjUyMDY0NGQxNDBjZWIwNjdlNzFjMzgzZGU5MmQvdGFibGVyYW5nZTo1ZTMyNTIwNjQ0ZDE0MGNlYjA2N2U3MWMzODNkZTkyZF8xLTQtMS0xLTQ1MzM0_92d5f305-d5a3-4ed3-a711-0e86a6f7a09a">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGFibGU6NWUzMjUyMDY0NGQxNDBjZWIwNjdlNzFjMzgzZGU5MmQvdGFibGVyYW5nZTo1ZTMyNTIwNjQ0ZDE0MGNlYjA2N2U3MWMzODNkZTkyZF8yLTQtMS0xLTQ1MzM0_36901ca1-053d-4c8d-af3f-aba42aa55e47">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDcw_e417616e-a817-4831-8bbe-8b709283c0b6">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8yNzQ4Nzc5MDcyOTIz_d1f4f192-51c5-4ea1-86a4-27efa870f67e">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ie2bf8d71415f4efa90cde8b45af0012e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8yOTI2_c621de1c-7a77-471e-ad03-360d46ac94ec"
      unitRef="usd">2175700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i902528dd801a41cba33017f4bcccec14_I20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zMTA4_9478e652-25bb-40e9-a992-7c313128a0ed"
      unitRef="shares">53271491</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xL2ZyYWc6NzM2M2U4ZTYxMDQ5NDc1N2EyMTQ1NzFhZWI0NThiMDkvdGV4dHJlZ2lvbjo3MzYzZThlNjEwNDk0NzU3YTIxNDU3MWFlYjQ1OGIwOV8zNDU3_7ddd66a8-a112-4f44-ab4f-a0687c9c373e">Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant&#x2019;s 2023 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December&#160;31, 2022.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMDAvZnJhZzpjNWZiYjgyZTA4ZTk0YzYwOTE5MDkxMzkzMTkxZDkxMy90YWJsZTphMjIzMTAwODMwNzc0OWY2YWY2YTQ1YzgwZGI2YmUwYi90YWJsZXJhbmdlOmEyMjMxMDA4MzA3NzQ5ZjZhZjZhNDVjODBkYjZiZTBiXzItMC0xLTEtNDc5MTkvdGV4dHJlZ2lvbjo2M2IxODg4MGFjNDk0YjY0ODM4NDUzZGI4MmI5YjNjNV83Mw_a19e24c1-2731-41f7-aacc-a31e9b3beb51">34</dei:AuditorFirmId>
    <dei:AuditorFirmId
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMDkvZnJhZzplNjVmZmUzOWM5M2M0Yjc2ODg0NWQyZTMzMTFkZGU0NC90YWJsZTo5MmNjMTc5YzRjYWI0MTRhYTFhNzI2YThkYWIyOTIzNy90YWJsZXJhbmdlOjkyY2MxNzljNGNhYjQxNGFhMWE3MjZhOGRhYjI5MjM3XzEtMC0xLTEtNDUzMzQvdGV4dHJlZ2lvbjozODJhOTJmNTIyMGI0NWY1YTIxMGUwYzcwZDExNzRiMF83Mw_a19e24c1-2731-41f7-aacc-a31e9b3beb51">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTUvZnJhZzowMGRlZmU4MmNlMTY0MWZkOGE2OWJlNzM3MmE3MmUwYS90ZXh0cmVnaW9uOjAwZGVmZTgyY2UxNjQxZmQ4YTY5YmU3MzcyYTcyZTBhXzk2NTQ_126c3cb9-8a5d-4165-8f98-7a9c8b5fd1dd">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTUvZnJhZzowMGRlZmU4MmNlMTY0MWZkOGE2OWJlNzM3MmE3MmUwYS90ZXh0cmVnaW9uOjAwZGVmZTgyY2UxNjQxZmQ4YTY5YmU3MzcyYTcyZTBhXzk2NTU_3c3613cc-1728-496b-9790-2800e450091f">Stamford, Connecticut</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzQtMS0xLTEtNDUzMzQ_7d630db4-0cf1-4f4b-ad96-ed3ba03417a8"
      unitRef="usd">81300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzQtMy0xLTEtNDUzMzQ_91e0e4df-0163-4019-adbe-4dbb1a8c0c85"
      unitRef="usd">108300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzUtMS0xLTEtNDUzMzQ_5c7b3744-1709-4c5b-9a29-b5b837faa9a0"
      unitRef="usd">5500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzUtMy0xLTEtNDUzMzQ_efcfb5cb-ea26-4417-9023-f0ba1835ef01"
      unitRef="usd">4500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzYtMS0xLTEtNDUzMzQ_10585f4a-12c4-4d1e-8f27-423a26adaac9"
      unitRef="usd">1124000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzYtMy0xLTEtNDUzMzQ_92d79028-cb55-49a2-9fac-16a60d9d6d41"
      unitRef="usd">1394300000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzctMS0xLTEtNDUzMzQ_7674b7ed-1456-4c65-9c5d-5dfb16e4b6ce"
      unitRef="usd">1000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzctMy0xLTEtNDUzMzQ_d723fe78-3caa-43f0-9732-da88e422c97a"
      unitRef="usd">15000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzgtMS0xLTEtNDUzMzQ_d2b39128-77b7-41cc-8923-8328024f4aff"
      unitRef="usd">7000000.0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzgtMy0xLTEtNDUzMzQ_0d7a2df0-8cea-4207-b190-a172ca5c1e70"
      unitRef="usd">10700000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzktMS0xLTEtNDUzMzQ_12d249f0-7e12-41b5-a4af-37acd0027312"
      unitRef="usd">21400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzktMy0xLTEtNDUzMzQ_671e780c-8b93-45e4-9029-a85ea7dc3c42"
      unitRef="usd">19700000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEwLTEtMS0xLTQ1MzM0_c452fcb9-a1c5-47f2-a65c-c68b463df5f8"
      unitRef="usd">1240200000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEwLTMtMS0xLTQ1MzM0_4479638b-d4df-4235-843e-59c4775f0b84"
      unitRef="usd">1552500000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzExLTEtMS0xLTQ1MzM0_ef879659-d858-49d7-ac91-13c5271726ce"
      unitRef="usd">13400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzExLTMtMS0xLTQ1MzM0_dbae5bb3-6436-46f5-bd81-930b4de99435"
      unitRef="usd">12700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEyLTEtMS0xLTQ1MzM0_c0d6267c-11a7-478a-9c53-a8846f4a0ade"
      unitRef="usd">4400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEyLTMtMS0xLTQ1MzM0_69732df3-7b30-4c32-9329-89263bc17f6f"
      unitRef="usd">3900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEzLTEtMS0xLTQ1MzM0_9bed69a2-c8c9-450c-bf72-206e16f3974f"
      unitRef="usd">10800000</arvn:CollaborationContractAssetAndOtherAssets>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzEzLTMtMS0xLTQ1MzM0_0b52fa6c-8a64-41b2-932b-4a9756a95193"
      unitRef="usd">12500000</arvn:CollaborationContractAssetAndOtherAssets>
    <us-gaap:Assets
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE0LTEtMS0xLTQ1MzM0_00a102e3-9fe7-49f1-9224-1538ccc4b888"
      unitRef="usd">1268800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE0LTMtMS0xLTQ1MzM0_7aaec7fd-19a0-451a-818a-887af4eed829"
      unitRef="usd">1581600000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE3LTEtMS0xLTQ1MzM0_170d2020-47b8-49d4-bf4a-089e78075832"
      unitRef="usd">74700000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE3LTMtMS0xLTQ1MzM0_d4c7525c-4874-4adc-b4bf-d0dbea49dd45"
      unitRef="usd">54400000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE5LTEtMS0xLTQ1MzM0_5d66fe7c-47a6-4fc2-a57d-892eccfd266c"
      unitRef="usd">218600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzE5LTMtMS0xLTQ1MzM0_e75fecc0-a798-42e0-babc-f58bd85eca11"
      unitRef="usd">206200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIwLTEtMS0xLTQ1MzM0_982e2938-6d96-403c-a0ba-5e21ba81c255"
      unitRef="usd">1800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIwLTMtMS0xLTQ1MzM0_88182e5b-5060-4805-9024-4f6d85408926"
      unitRef="usd">1100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIxLTEtMS0xLTQ1MzM0_0eb74118-2736-4157-9fbb-12d434d3bdec"
      unitRef="usd">295100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIxLTMtMS0xLTQ1MzM0_1b70b382-85d3-474a-a49c-3f180490a39d"
      unitRef="usd">261700000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIyLTEtMS0xLTQ1MzM0_96d8a2de-f977-4e23-a6d8-e33f9cdfaf75"
      unitRef="usd">405100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIyLTMtMS0xLTQ1MzM0_83ca210f-1933-4be5-9830-fdc6d63f608a"
      unitRef="usd">534300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIzLTEtMS0xLTQ1MzM0_ee804a72-d939-448f-a498-fc7b35bd748e"
      unitRef="usd">1000000.0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzIzLTMtMS0xLTQ1MzM0_b1f93221-b0ad-41c6-a768-3990cdbe1c74"
      unitRef="usd">1000000.0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI0LTEtMS0xLTQ1MzM0_c3899974-2878-41e0-9564-b019d8dbe296"
      unitRef="usd">2700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI0LTMtMS0xLTQ1MzM0_4e99eb0c-eed4-4f9f-a4d7-fcbc52574796"
      unitRef="usd">2900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI2LTEtMS0xLTQ1MzM0_408491ac-2b72-4b6b-8e43-e5518920a2a4"
      unitRef="usd">703900000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI2LTMtMS0xLTQ1MzM0_2af84360-cc94-4c24-8930-151ba931a934"
      unitRef="usd">799900000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI3LTEtMS0xLTQ1MzM0_04c58906-f550-4b74-b63d-9e9e65257f7f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI3LTMtMS0xLTQ1MzM0_59d0e93f-cb66-42ed-890c-950219792799"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMTg_18ddcf86-68c9-4d6f-93d8-2a993901645c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMTg_6c783322-1ccd-4f3e-af23-07b9d280ada5"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMzI_37f07f9a-70d4-4bf0-b3a3-87484135b89a"
      unitRef="shares">53200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMzI_f71d868a-cec6-445a-9578-16d4de938e45"
      unitRef="shares">53200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMzk_31d73e62-680e-4952-b705-efe6d518efc5"
      unitRef="shares">53000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246ODdiOWFlMGI5OTc5NGUxM2JjOTNiYjY2NWM2MmVlMWNfMzk_92114ab0-e6ac-4c19-b707-6a999d55b60a"
      unitRef="shares">53000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTEtMS0xLTQ1MzM0_228b1ce3-42d1-4b97-865c-0ca28546075b"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzI5LTMtMS0xLTQ1MzM0_4a4a55cf-4eca-470e-b092-e4891c8bf335"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMwLTEtMS0xLTQ1MzM0_d69c8117-f0f2-4edc-96c6-0cd3af3a655c"
      unitRef="usd">-965400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMwLTMtMS0xLTQ1MzM0_f906eee9-5366-4fd5-9326-264f1bb68714"
      unitRef="usd">-682900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMxLTEtMS0xLTQ1MzM0_11661960-4da6-4789-8f2e-d5aa353117c8"
      unitRef="usd">1549400000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMxLTMtMS0xLTQ1MzM0_6dd6356e-377e-45c0-92b4-0f2f06979c83"
      unitRef="usd">1469200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMyLTEtMS0xLTQ1MzM0_3e2be126-1d67-4d2f-8345-a43c78bcf907"
      unitRef="usd">-19200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMyLTMtMS0xLTQ1MzM0_5ccec8c0-f755-4f99-a58f-5b51b69878e3"
      unitRef="usd">-4600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMzLTEtMS0xLTQ1MzM0_1026699b-dc96-4bdc-a584-13da55626c66"
      unitRef="usd">564900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzMzLTMtMS0xLTQ1MzM0_cf926d79-5f6f-49c4-835c-869615d4169e"
      unitRef="usd">781700000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzM0LTEtMS0xLTQ1MzM0_595dbc32-f946-4a0e-be4a-e32e9eb272e7"
      unitRef="usd">1268800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMTgvZnJhZzo5YmZkNWZiMGQyOTg0MGYzYjk0YjM2NGY3YTI5N2I0Yi90YWJsZTozNzI3ZmRhY2I3NGM0NzI1OTRiODAyZjcwOTRjMjU0Mi90YWJsZXJhbmdlOjM3MjdmZGFjYjc0YzQ3MjU5NGI4MDJmNzA5NGMyNTQyXzM0LTMtMS0xLTQ1MzM0_50e89839-7f50-4718-b4f4-66bd1a2afd45"
      unitRef="usd">1581600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzItMS0xLTEtNDUzMzQ_d0405cc0-07aa-43c3-8810-b7a1de8a365c"
      unitRef="usd">131400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzItMy0xLTEtNDUzMzQ_27a59a41-3e9c-4eab-afae-c430694b37ce"
      unitRef="usd">53600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzItNS0xLTEtNDUzMzQ_f9a1ace6-82c7-4de5-810c-d5eb7311cd95"
      unitRef="usd">25900000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzQtMS0xLTEtNDUzMzQ_cd3e1da3-022e-4748-a0b2-7ac906e7d18c"
      unitRef="usd">315000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzQtMy0xLTEtNDUzMzQ_c027d036-b38e-43c4-bc25-527c736bcbf5"
      unitRef="usd">180400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzQtNS0xLTEtNDUzMzQ_f7f47707-c662-436f-8d81-2e0e0a55df1b"
      unitRef="usd">108400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzUtMS0xLTEtNDUzMzQ_5cc2bbfe-5249-477d-9f6d-26255ed94aa8"
      unitRef="usd">79600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzUtMy0xLTEtNDUzMzQ_6fcaa43d-56c1-4a45-9e5b-ed8503f720ae"
      unitRef="usd">61600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzUtNS0xLTEtNDUzMzQ_39990306-7772-47c4-9a1f-11f049c0d8e8"
      unitRef="usd">38300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzYtMS0xLTEtNDUzMzQ_3b9079a0-681d-45e0-bbaf-12787a49bbbc"
      unitRef="usd">394600000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzYtMy0xLTEtNDUzMzQ_8f202e88-356e-456a-a08a-66ea0a2ea9a8"
      unitRef="usd">242000000.0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzYtNS0xLTEtNDUzMzQ_801b3f6d-095f-4e38-9f26-42649de442b2"
      unitRef="usd">146700000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzctMS0xLTEtNDUzMzQ_81206a4a-120f-430f-abc5-db5e0aaec504"
      unitRef="usd">-263200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzctMy0xLTEtNDUzMzQ_3dcfb84a-265d-433b-a546-c5465acd7f4f"
      unitRef="usd">-188400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzctNS0xLTEtNDUzMzQ_f4a5fefd-dacd-4063-bade-d324e8839210"
      unitRef="usd">-120800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzktMS0xLTEtNDUzMzQ_d8d7c3d6-305b-4b61-88bf-736218a4dcd6"
      unitRef="usd">200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzktMy0xLTEtNDUzMzQ_575457af-c91d-484f-9370-981597b4d3ba"
      unitRef="usd">2500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzktNS0xLTEtNDUzMzQ_9c3d2455-7a73-4151-944c-4ff3d348132e"
      unitRef="usd">2100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzExLTEtMS0xLTQ1MzM0_4ce8f9db-bda2-4c7f-9d90-c7bdb7e373eb"
      unitRef="usd">12000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzExLTMtMS0xLTQ1MzM0_7fff2e59-0ad4-40e6-85b9-d45d668def3e"
      unitRef="usd">1800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzExLTUtMS0xLTQ1MzM0_9064661d-d49b-4a1d-9c5f-a52b3fffb831"
      unitRef="usd">3500000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzEzLTEtMS0xLTQ1MzM0_7751f4b2-85fc-4ce4-9449-ac03644efd77"
      unitRef="usd">12200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzEzLTMtMS0xLTQ1MzM0_58dd0523-1baf-4c8b-b7c4-9b3f5e8955bd"
      unitRef="usd">4300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzEzLTUtMS0xLTQ1MzM0_ffb3873e-30e7-4f53-a7c2-feedf6b6b06a"
      unitRef="usd">5600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE1LTEtMS0xLTQ1MzM0_767b6a89-dbd8-4bc2-885b-1cafe0841e45"
      unitRef="usd">-251000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE1LTMtMS0xLTQ1MzM0_82f80a0a-34ed-48a9-b14c-160bd6edf1d3"
      unitRef="usd">-184100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE1LTUtMS0xLTQ1MzM0_fa0dc6b5-f030-4913-a9ea-5de101a68c3c"
      unitRef="usd">-115200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE2LTEtMS0xLTQ1MzM0_1ac26cb4-281c-41af-bd72-ba11758c04a5"
      unitRef="usd">20900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE2LTMtMS0xLTQ1MzM0_28473b9b-1bad-473d-a61c-e7f67f44a36f"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE2LTUtMS0xLTQ1MzM0_36dfbb22-190e-4a81-ac80-97dc5cebb38d"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTEtMS0xLTU5OTkx_d35c8fc0-052e-4803-b466-fd4b5d7ea055"
      unitRef="usd">-10600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTMtMS0xLTU5OTkx_0ef31a79-4a0c-4654-ae3a-4e8e45b8f226"
      unitRef="usd">-6900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTUtMS0xLTU5OTkx_4a677249-be61-4d21-903d-3627317af8b8"
      unitRef="usd">-4100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTEtMS0xLTQ1MzM0_f4edae02-d9c4-4b6f-adc1-baef9e24af3b"
      unitRef="usd">-282500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTMtMS0xLTQ1MzM0_ea199ab6-2983-4ecf-bc87-e989203e0782"
      unitRef="usd">-191000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzE3LTUtMS0xLTQ1MzM0_b1a1f235-82eb-4793-8672-496ce3abe554"
      unitRef="usd">-119300000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTEtMS0xLTQ1MzM0_c3ddecca-f25c-431f-9a36-b96a59fbd564"
      unitRef="usdPerShare">-5.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTEtMS0xLTQ1MzM0_ef7dae64-ccac-4817-8592-dd4f206f8054"
      unitRef="usdPerShare">-5.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTMtMS0xLTQ1MzM0_30c7ba46-1e7f-4bde-bd5f-718f18b2b76a"
      unitRef="usdPerShare">-3.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTMtMS0xLTQ1MzM0_65359610-9344-4823-9c02-79da7ecd2e8a"
      unitRef="usdPerShare">-3.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTUtMS0xLTQ1MzM0_10f3a8f8-b885-4347-b063-b8c928b18562"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIwLTUtMS0xLTQ1MzM0_7d6ada07-31b0-4e14-a465-8dbb9544d463"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTEtMS0xLTQ1MzM0_1b763ebb-02f1-4cfe-813a-cb59a5a69362"
      unitRef="shares">53200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTEtMS0xLTQ1MzM0_1c7017bc-0aa2-4c4d-8aeb-3f206265d4b7"
      unitRef="shares">53200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTMtMS0xLTQ1MzM0_8a2f453f-1e4d-4951-99aa-bff5e0fe3b17"
      unitRef="shares">50000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTMtMS0xLTQ1MzM0_e68f69d5-d3e6-46b4-baf6-7869500b88c1"
      unitRef="shares">50000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTUtMS0xLTQ1MzM0_0b1b4bf1-eaf3-4b52-87af-718db97964fc"
      unitRef="shares">39500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTozN2UyNzA2MWZlOWI0MzgyOTBjMjU4ODFhMTc5ZjZkNi90YWJsZXJhbmdlOjM3ZTI3MDYxZmU5YjQzODI5MGMyNTg4MWExNzlmNmQ2XzIxLTUtMS0xLTQ1MzM0_d0df61f3-4182-4446-a38d-c9204ea757e8"
      unitRef="shares">39500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzItMS0xLTEtNDUzMzQ_f4edae02-d9c4-4b6f-adc1-baef9e24af3b"
      unitRef="usd">-282500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzItMy0xLTEtNDUzMzQ_4320c9a9-107b-4efb-a453-b082b7b848cc"
      unitRef="usd">-191000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzItNS0xLTEtNDUzMzQ_b13ed757-aac5-434b-99e3-463b4b6cb6bb"
      unitRef="usd">-119300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzQtMS0xLTEtNDUzMzQ_fc04699e-d656-43fa-ae44-2cc6bf3a76c0"
      unitRef="usd">-14500000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzQtMy0xLTEtNDUzMzQ_1179620d-17cb-40f6-9897-e2852e4d5ffd"
      unitRef="usd">-5200000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzQtNS0xLTEtNDUzMzQ_182bfea1-1a96-48ca-97c5-5ca9f64e8004"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzUtMS0xLTEtNDUzMzQ_bd63c642-de19-499c-9fc9-5e894e400231"
      unitRef="usd">-297000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzUtMy0xLTEtNDUzMzQ_bbc1e1f5-c48e-493c-8649-062cf528f3bb"
      unitRef="usd">-196200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjEvZnJhZzo1YWNjM2FmNWEyYzk0MDUzYTQ1Yzg5M2JkNDg5NDhkMS90YWJsZTphMzM1NTVhMWM4YjA0NzdmYmVlNTA5ODg0OWY1ZTkwMS90YWJsZXJhbmdlOmEzMzU1NWExYzhiMDQ3N2ZiZWU1MDk4ODQ5ZjVlOTAxXzUtNS0xLTEtNDUzMzQ_5dc3ee13-28a5-4ab5-8274-69dbd558153f"
      unitRef="usd">-118800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i62b9074c6dbb4f3fbdbff41dce34d514_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktMS0xLTEtNDUzMzQ_18c82c5b-16aa-4ed4-81f6-bbe2d522c4ba"
      unitRef="shares">38500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i62b9074c6dbb4f3fbdbff41dce34d514_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktMy0xLTEtNDUzMzQ_82f4a1d7-b80b-43d6-aa48-1787ead37789"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i00f51f7f7a9845899d4dd0c5fc38d3c8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktNS0xLTEtNDUzMzQ_35f9f3a9-1aa7-42f7-a432-695de65df1b7"
      unitRef="usd">-372600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5126550f14e04feb9ca9ca6b7e02ed04_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktNy0xLTEtNDUzMzQ_b3377c13-6fbb-4725-ade8-01c123d3a284"
      unitRef="usd">599100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib59969a5f0034e8e9c7010fd7f0be379_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktOS0xLTEtNDUzMzQ_c4887f5a-99bf-4910-bfec-8177d489b053"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35327f5dcba84428bcd65e20009ba82d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzktMTEtMS0xLTQ1MzM0_4266bff4-17fe-4492-b259-9380e5b8ae4d"
      unitRef="usd">226600000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEwLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MTNlZmQzZWI1NjA3NDk1NThjOWE5NDRkZjNjNTc1YjdfMTY0OTI2NzQ0MTc1Ng_3b54a662-3c7e-4f46-b93a-44d66b9d9cde"
      unitRef="usd">28100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id6be069e34bc4e4dab6470f86f377631_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEwLTEtMS0xLTQ1MzM0_eb297cf9-ba04-4ecb-aede-b347ed841121"
      unitRef="shares">6600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2da99b1272604c40b299c7e2a492b717_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEwLTctMS0xLTQ1MzM0_d3b295f8-951c-4786-b627-52ffeb32503b"
      unitRef="usd">431900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEwLTExLTEtMS00NTMzNA_3af37ad2-4766-429c-bfd4-7a785dd0d412"
      unitRef="usd">431900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2da99b1272604c40b299c7e2a492b717_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzExLTctMS0xLTQ1MzM0_6aa049da-d176-45c8-94cc-11271f58e879"
      unitRef="usd">30200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzExLTExLTEtMS00NTMzNA_6e098030-a801-4f2a-882f-60bce2be5937"
      unitRef="usd">30200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="iff0703d3445f4aebac374d380138baf6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEyLTUtMS0xLTQ1MzM0_8a886243-2bac-4a31-ac77-cea97c6dff08"
      unitRef="usd">-119300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEyLTExLTEtMS00NTMzNA_1ecebc59-7eda-4a57-8cfb-d618e664d198"
      unitRef="usd">-119300000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="id6be069e34bc4e4dab6470f86f377631_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzEzLTEtMS0xLTQ1MzM0_2edcfc61-d2df-40a9-a28a-d77cfe64dd3d"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id6be069e34bc4e4dab6470f86f377631_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE0LTEtMS0xLTQ1MzM0_f9b068ef-83f0-4d0a-a13e-27b764816d3c"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2da99b1272604c40b299c7e2a492b717_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE0LTctMS0xLTQ1MzM0_946bc83a-4b1c-4f66-9ccb-57dd211c3cc1"
      unitRef="usd">8200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE0LTExLTEtMS00NTMzNA_791d4f7a-9d33-4455-b9d0-b98c893d6c8d"
      unitRef="usd">8200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i0a5a6b31a7ca4b5e825ff2a8e5104399_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE1LTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MjQ4OWExZDgxNDZlNDNmN2I3Y2IxMjM2OThlZDAxZGJfMTY0OTI2NzQ0MTc0NQ_9b03368f-2073-4371-ab5d-91082a0c1bad"
      unitRef="usd">1600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i58e74e4ca00a46a298dd26d104628c71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE1LTEtMS0xLTQ1MzM0_abe69aa4-b85f-428c-b788-d68ca4357028"
      unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifb59a32694da4a52a057a3d5d4602acb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE1LTctMS0xLTQ1MzM0_60b2de46-517e-4164-bc5f-ed8773d82790"
      unitRef="usd">64100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0a5a6b31a7ca4b5e825ff2a8e5104399_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE1LTExLTEtMS00NTMzNA_1d5e7bc2-6478-4376-9f28-2b9a680b629e"
      unitRef="usd">64100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie9803bb2bac440b9a73f90689f2b195a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE2LTktMS0xLTQ1MzM0_f9a75ec3-105c-4699-bb96-5f52cc1266d0"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE2LTExLTEtMS00NTMzNA_306f8a31-47de-4a46-a4b0-e634c4dd2d4f"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2c3f132181ab4f2782eda83c630d9771_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTEtMS0xLTQ1MzM0_7179a22d-8bbd-4506-8190-df1b15ffcaab"
      unitRef="shares">48500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2c3f132181ab4f2782eda83c630d9771_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTMtMS0xLTQ1MzM0_91cb7518-0f30-4af9-a117-2b696a0d9fb5"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d68e78d78a7421fa07de080fcab1007_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTUtMS0xLTQ1MzM0_388dda17-c7d0-44c7-81b7-641c18d8c089"
      unitRef="usd">-491900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i82f79a4ab8ad48ac808ede7cafff07d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTctMS0xLTQ1MzM0_85e0a7e3-1d51-459d-9768-cfb3c96fcbad"
      unitRef="usd">1133500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic150bcdd10a44a698d262678b95dc444_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTktMS0xLTQ1MzM0_b7b5f695-ddef-47e0-82be-83e519968a6b"
      unitRef="usd">600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE3LTExLTEtMS00NTMzNA_11b70b55-cd78-4036-b4bb-40aad42d486d"
      unitRef="usd">642200000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5ae1926583c8447eb7a2bf92b4691763_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE4LTctMS0xLTQ1MzM0_69669f4f-14ba-4c3d-947f-b728b794eb5d"
      unitRef="usd">57100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE4LTExLTEtMS00NTMzNA_552cf142-29a3-45f3-b09f-0dbb7e56ac3b"
      unitRef="usd">57100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i189cf08cd0b147de9ee24b6f4241c087_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE5LTUtMS0xLTQ1MzM0_f32fa8f3-e7a7-4be2-8181-d3d590796288"
      unitRef="usd">-191000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE5LTExLTEtMS00NTMzNA_cbad353f-289e-44ca-985f-194581d609de"
      unitRef="usd">-191000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i7c56b6a959914b1fa1a46f86145ab11e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIwLTEtMS0xLTQ1MzM0_c5a4dd73-be8f-4bbe-9dae-09fc3d6f4820"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7c56b6a959914b1fa1a46f86145ab11e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTEtMS0xLTQ1MzM0_f337cb5f-6158-47a7-b58d-0fa64b01e2c8"
      unitRef="shares">800000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5ae1926583c8447eb7a2bf92b4691763_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTctMS0xLTQ1MzM0_a8c9803a-dc52-462f-8457-b982097c902b"
      unitRef="usd">18700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTExLTEtMS00NTMzNA_63dc6636-e882-4d59-81fd-d75d658aff58"
      unitRef="usd">18700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIyLTAtMS0xLTQ1MzM0L3RleHRyZWdpb246MjdhZWNjOGJkMDk4NDAzZWJkMGEwY2FjZmI1NWI5OGNfMTY0OTI2NzQ0MTcxOA_9bd5dfd9-d3a0-4296-ab40-916e529d522f"
      unitRef="usd">4600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7c56b6a959914b1fa1a46f86145ab11e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIyLTEtMS0xLTQ1MzM0_d6525b4a-b6bc-4437-9b29-f4a94ad24929"
      unitRef="shares">3500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5ae1926583c8447eb7a2bf92b4691763_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIyLTctMS0xLTQ1MzM0_3500a271-36fd-40a6-a6b6-fd4797814aed"
      unitRef="usd">259900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIyLTExLTEtMS00NTMzNA_6343187a-da76-4519-b8c1-12ebcace7d9b"
      unitRef="usd">259900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3a8a21d9b2d1414aaf530880ae2aa161_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIzLTktMS0xLTQ1MzM0_7382e925-8cc7-445a-b070-93aafb2aa41a"
      unitRef="usd">-5200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIzLTExLTEtMS00NTMzNA_0e497622-14e2-44f4-9938-159d309fed6c"
      unitRef="usd">-5200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5e9275d362a24c8a9d71ee61e0d22587_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTEtMS0xLTQ1MzM0_1c4c21b7-5aea-4346-be5b-3aed6b0a5dc7"
      unitRef="shares">53000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5e9275d362a24c8a9d71ee61e0d22587_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTMtMS0xLTQ1MzM0_d8fa987c-23bb-4c0a-b3d8-43a1cb49db74"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i20400f57ea38437d8f5a5a76227f5779_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTUtMS0xLTQ1MzM0_c547ef64-213b-40fa-be2d-8cf360d42117"
      unitRef="usd">-682900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i332f5a83e3e04dc99cf119f9afdf4c9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTctMS0xLTQ1MzM0_a5a9267b-54bb-42ed-9189-7d72ef595989"
      unitRef="usd">1469200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i515d8e18c44c4d4eb75265ed7439e978_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTktMS0xLTQ1MzM0_8a9846b2-2895-4aa4-944c-b844298d2a3d"
      unitRef="usd">-4600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTExLTEtMS00NTMzNA_a36ef835-9649-4ad1-b1c8-906c80b0e671"
      unitRef="usd">781700000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i36d0618dabaa4dde950863143d4eba01_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE4LTctMS0xLTQ2NzUy_00ffe07a-c1fa-4d74-a1c2-5b29f10b7429"
      unitRef="usd">75500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE4LTExLTEtMS00Njc1Mg_5ba8ecc4-1335-4737-85f9-661071ac07e1"
      unitRef="usd">75500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="id43fad10517549efbe1041cf1a7ac9c6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE5LTUtMS0xLTQ2NzUy_c96741c2-5ed6-4c10-8fda-84dad8584f00"
      unitRef="usd">-282500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzE5LTExLTEtMS00Njc1Mg_1798a75f-f11f-4fbf-88c9-dff831c25c99"
      unitRef="usd">-282500000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3328081fbb1245bea8d77942437e9fda_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTEtMS0xLTQ2NzQ0_6dacf8a4-fbac-4333-bd39-878687602ecf"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3328081fbb1245bea8d77942437e9fda_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTMtMS0xLTQ2NzQ0_02f09ff0-3bdf-4755-88a1-8cb0755cb026"
      unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i36d0618dabaa4dde950863143d4eba01_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTctMS0xLTQ2NzUy_b8efbb94-ea0f-44af-839a-8aa0f3626df8"
      unitRef="usd">4700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIxLTExLTEtMS00Njc1Mg_9be8212c-7694-4136-baae-de11ed6c1caf"
      unitRef="usd">4800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic1c26cc298914577ad3d74291efe85aa_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIzLTktMS0xLTQ2NzUy_7ea6a979-6913-446c-a33c-0525110a25d8"
      unitRef="usd">-14600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzIzLTExLTEtMS00Njc1Mg_37606047-0ea6-4103-8567-0e1df77dda30"
      unitRef="usd">-14600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i49058d6c0fee45bc82e5a3b3d793c61b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTEtMS0xLTUwNDE0_97f05a2b-cb7e-4570-b051-ef18ae4da903"
      unitRef="shares">53200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i49058d6c0fee45bc82e5a3b3d793c61b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTMtMS0xLTUwNDE0_c4c5e69b-4207-4ed8-9b4b-192d0751e31d"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idec633905ec142408e34afcd540d6467_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTUtMS0xLTUwNDE0_0081c87b-b5bc-4047-be59-87b52964754c"
      unitRef="usd">-965400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idbedba621b114c17bd11d5578ed1e6c5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTctMS0xLTUwNDE0_56df5bac-379c-4a1c-a6df-5a210db508bf"
      unitRef="usd">1549400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c91e2ef842a460da45c1b6475a741ca_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTktMS0xLTUwNDE0_d03da82f-d436-423a-ab7e-b9d291c8500d"
      unitRef="usd">-19200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjQvZnJhZzpmMmYwZDM3YjBkNTU0NzQ0ODVhMjU0ZDkyZTgyMDIyMi90YWJsZToyYzQxOGU1MTQ2ZDQ0YWI4YWJjZDIxZjI0OGI3NDFiOC90YWJsZXJhbmdlOjJjNDE4ZTUxNDZkNDRhYjhhYmNkMjFmMjQ4Yjc0MWI4XzI0LTExLTEtMS01MDQxNA_e76faf5c-d748-45b2-b281-94d28fbcb887"
      unitRef="usd">564900000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMtMS0xLTEtNDUzMzQ_f4edae02-d9c4-4b6f-adc1-baef9e24af3b"
      unitRef="usd">-282500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMtMy0xLTEtNDUzMzQ_1699a791-4dc5-41d5-93b1-5f3891430fa1"
      unitRef="usd">-191000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMtNS0xLTEtNDUzMzQ_d040fc6c-fb59-4e64-a5f4-2678888c9720"
      unitRef="usd">-119300000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzctMS0xLTEtNDUzMzQ_5ee1f321-966e-4b4c-8bae-aa66a335577a"
      unitRef="usd">6300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzctMy0xLTEtNDUzMzQ_a58d3356-8cb9-44d6-b031-7d02ea5ce159"
      unitRef="usd">4800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzctNS0xLTEtNDUzMzQ_1ba28c20-02b1-4075-a318-fe9cd2a40070"
      unitRef="usd">3200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzgtMS0xLTEtNDUzMzQ_2bc25cbf-52b3-4fda-80fb-afcad42c0a97"
      unitRef="usd">-5700000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzgtMy0xLTEtNDUzMzQ_e7275afc-9b36-473e-a680-fe335870169d"
      unitRef="usd">-9400000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzgtNS0xLTEtNDUzMzQ_b0530c34-031b-4aff-89ed-3c401eb5a815"
      unitRef="usd">-1700000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <arvn:DebtInstrumentLoanForgiveness
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzktMS0xLTEtNDUzMzQ_6e939b72-70d3-4e8b-9223-61d08ea2f3d6"
      unitRef="usd">0</arvn:DebtInstrumentLoanForgiveness>
    <arvn:DebtInstrumentLoanForgiveness
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzktMy0xLTEtNDUzMzQ_b6204d81-ad6a-435e-abae-316ca1865bbb"
      unitRef="usd">1000000.0</arvn:DebtInstrumentLoanForgiveness>
    <arvn:DebtInstrumentLoanForgiveness
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzktNS0xLTEtNDUzMzQ_fd96c6e9-663c-4cee-88f5-9ab1ac5aac52"
      unitRef="usd">0</arvn:DebtInstrumentLoanForgiveness>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEwLTEtMS0xLTQ1MzM0_f67c9c8a-c8c0-4361-8f61-df45589a7947"
      unitRef="usd">-400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEwLTMtMS0xLTQ1MzM0_4febaec1-4332-4547-9649-32e04d6102e1"
      unitRef="usd">-200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEwLTUtMS0xLTQ1MzM0_550b6fe9-2c84-43ac-8285-eb541a7c7a13"
      unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzExLTEtMS0xLTQ1MzM0_5cc02937-4c41-4380-869c-f3d2da4e262b"
      unitRef="usd">1900000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzExLTMtMS0xLTQ1MzM0_5a7b1734-1123-4a0f-80c6-b05983ba0523"
      unitRef="usd">1200000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzExLTUtMS0xLTQ1MzM0_cf8228f8-71da-4105-8668-96b847f115e5"
      unitRef="usd">900000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEyLTEtMS0xLTQ1MzM0_10af3333-02ef-4a7b-9614-e8616de5472c"
      unitRef="usd">1800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEyLTMtMS0xLTQ1MzM0_23e95f18-f797-4b82-ba5d-cd5dbcb8abc7"
      unitRef="usd">400000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEyLTUtMS0xLTQ1MzM0_cd6f4550-ac16-4472-86e4-80aabf1d50f2"
      unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEzLTEtMS0xLTQ1MzM0_c86a0506-746c-44e6-82c1-f225be0cc735"
      unitRef="usd">75500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEzLTMtMS0xLTQ1MzM0_2c0bc726-2530-4baa-8742-a4a74ab803da"
      unitRef="usd">57100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzEzLTUtMS0xLTQ1MzM0_8e24c7d5-70b6-4bb7-bb77-a0ab9d7c5cae"
      unitRef="usd">30200000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE3LTEtMS0xLTQ1MzM0_c3f0c585-7397-4290-a33b-46064cad966d"
      unitRef="usd">-14000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE3LTMtMS0xLTQ1MzM0_9d1264de-3e9d-4bbc-a081-e456d89f37f2"
      unitRef="usd">14000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE3LTUtMS0xLTQ1MzM0_b1ed8c65-e79d-4d5c-9f1c-5598b93dfb02"
      unitRef="usd">1000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE4LTEtMS0xLTQ1MzM0_eceb95bb-7339-4082-a0f0-2343d17824ab"
      unitRef="usd">-3700000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE4LTMtMS0xLTQ1MzM0_a14af4ab-42ba-4dab-a393-5b87571ed1de"
      unitRef="usd">3300000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE4LTUtMS0xLTQ1MzM0_a2821e10-f1d7-4935-b951-3304f09fb20a"
      unitRef="usd">1200000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE5LTEtMS0xLTQ1MzM0_667aa357-8f06-49c1-b5da-c80a1210bf64"
      unitRef="usd">1800000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE5LTMtMS0xLTQ1MzM0_fd329bd9-de3e-4f00-9161-f0b7ad1da17f"
      unitRef="usd">13600000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzE5LTUtMS0xLTQ1MzM0_4715e2cf-0830-46de-bd0d-3afcb79e429a"
      unitRef="usd">2400000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIwLTEtMS0xLTQ1MzM0_2af7841a-1940-4dac-9a91-c848a0ad0916"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIwLTMtMS0xLTQ1MzM0_d18725c1-f3ed-4ee1-80ce-20e95ada24e7"
      unitRef="usd">12900000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIwLTUtMS0xLTQ1MzM0_07a623c8-ed7e-4fbe-923e-7aeefd7cd3b7"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIxLTEtMS0xLTQ1MzM0_de4b521b-2817-4fbc-9bb9-cd28fff21959"
      unitRef="usd">20200000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIxLTMtMS0xLTQ1MzM0_da9199cb-f9c0-4320-8b06-d8ac09f27076"
      unitRef="usd">27900000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIxLTUtMS0xLTQ1MzM0_3c4b1779-96d6-4684-83d1-903dc50c465b"
      unitRef="usd">12800000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <arvn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIzLTEtMS0xLTQ1MzM0_58d9a003-5828-4692-94ec-eadf34f8a0c0"
      unitRef="usd">-1900000</arvn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <arvn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIzLTMtMS0xLTQ1MzM0_8dc0e5ff-da14-4cbf-be7b-fa4a9f5946a9"
      unitRef="usd">-1300000</arvn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <arvn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzIzLTUtMS0xLTQ1MzM0_72b7e21e-3883-49c8-8292-072e803f0b53"
      unitRef="usd">-900000</arvn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI0LTEtMS0xLTQ1MzM0_3aebddc1-ad4a-40e8-b723-bbd1618dfe12"
      unitRef="usd">-116800000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI0LTMtMS0xLTQ1MzM0_8a5b1a53-e378-4590-a378-4d54ea0558fb"
      unitRef="usd">695500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI0LTUtMS0xLTQ1MzM0_fc10bca3-a45c-4e90-a05b-659ba78431ff"
      unitRef="usd">-13300000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI1LTEtMS0xLTQ1MzM0_99288040-b475-4ace-b694-f1e3f13e771f"
      unitRef="usd">-273500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI1LTMtMS0xLTQ1MzM0_05f629a6-40b3-404d-861d-d207fd8aef8a"
      unitRef="usd">559400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI1LTUtMS0xLTQ1MzM0_71c42d6b-5777-4240-99ef-bf56b3bc6d54"
      unitRef="usd">-89700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI3LTEtMS0xLTQ1MzM0_5378c39e-49b0-4382-a2fe-017fea4c6128"
      unitRef="usd">886400000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI3LTMtMS0xLTQ1MzM0_738db541-45e7-4644-beb3-7ceaae96612b"
      unitRef="usd">1744600000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI3LTUtMS0xLTQ1MzM0_4e38b4b0-bb41-47c9-9ac9-0691ad67be4f"
      unitRef="usd">41200000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI4LTEtMS0xLTQ1MzM0_cf1cd835-5758-4df5-8c72-904da749689d"
      unitRef="usd">1076900000</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI4LTMtMS0xLTQ1MzM0_c7de9af1-485a-4fc0-895e-02720e4b45f8"
      unitRef="usd">428500000</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI4LTUtMS0xLTQ1MzM0_c3bda442-3334-4989-b92c-4933e67e748e"
      unitRef="usd">174100000</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromSaleOfMarketableSecurities
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI5LTEtMS0xLTQ1MzM0_0e123029-11d6-4f3e-a0ea-6d259b5ed8c2"
      unitRef="usd">59100000</arvn:ProceedsFromSaleOfMarketableSecurities>
    <arvn:ProceedsFromSaleOfMarketableSecurities
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI5LTMtMS0xLTQ1MzM0_12eb7009-0250-4801-9400-859173be374e"
      unitRef="usd">7200000</arvn:ProceedsFromSaleOfMarketableSecurities>
    <arvn:ProceedsFromSaleOfMarketableSecurities
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzI5LTUtMS0xLTQ1MzM0_9b9cbb66-9142-4675-979a-33c8fc583228"
      unitRef="usd">37800000</arvn:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMwLTEtMS0xLTQ1MzM0_f1bb0f3c-1391-4819-8749-51c079da0897"
      unitRef="usd">6800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMwLTMtMS0xLTQ1MzM0_0eb7cada-2375-42f1-b963-e7bdc924b242"
      unitRef="usd">4700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMwLTUtMS0xLTQ1MzM0_27394e63-d171-4aa3-afcc-4d8aade3cb08"
      unitRef="usd">6400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMxLTEtMS0xLTQ1MzM0_96da0a27-9444-4bee-b3a2-e0912a02ee91"
      unitRef="usd">242800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMxLTMtMS0xLTQ1MzM0_44949d3a-d7c2-46d6-aff1-cceab791116d"
      unitRef="usd">-1313600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzMxLTUtMS0xLTQ1MzM0_c77e0ae8-f37a-4c5c-b831-4cfd20118f0d"
      unitRef="usd">164300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM1LTEtMS0xLTQ1MzM0_1fdd5953-66da-49dd-ac84-f6a58e5f5582"
      unitRef="usd">0</arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering>
    <arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM1LTMtMS0xLTQ1MzM0_fa02bcc7-f4ae-415e-8e7b-4af9b22ae2b6"
      unitRef="usd">264600000</arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering>
    <arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM1LTUtMS0xLTQ1MzM0_7f25dbb8-5ff3-4040-a2ef-cc1254ad6d83"
      unitRef="usd">460000000.0</arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM2LTEtMS0xLTQ1MzM0_7edda06c-7088-4df7-ad66-754be3033e11"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM2LTMtMS0xLTQ1MzM0_dafa4932-1725-498c-bf78-7884952a11ff"
      unitRef="usd">4600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM2LTUtMS0xLTQ1MzM0_dd9c23de-c05c-434b-81bc-508ae5f3acb7"
      unitRef="usd">27700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <arvn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="i49ca8da516e7499682d587c74985691c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM3LTEtMS0xLTQ1MzM0_997b5f24-e328-46ac-af5c-633da37c2778"
      unitRef="usd">0</arvn:ProceedsFromIssuanceOfCommonStockGross>
    <arvn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="i765b24d88e5044b0b3474cc202e4c269_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM3LTMtMS0xLTQ1MzM0_0bfa1fe0-1bef-485a-9459-d9f2e1ee210e"
      unitRef="usd">0</arvn:ProceedsFromIssuanceOfCommonStockGross>
    <arvn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="i0a5a6b31a7ca4b5e825ff2a8e5104399_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM3LTUtMS0xLTQ1MzM0_62dde33d-847a-4650-8bfd-c8dd467724de"
      unitRef="usd">65600000</arvn:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i49ca8da516e7499682d587c74985691c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM4LTEtMS0xLTQ1MzM0_88e59a95-5de4-4075-ab39-fda06ebe6911"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i765b24d88e5044b0b3474cc202e4c269_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM4LTMtMS0xLTQ1MzM0_e4f651a0-b325-4d15-b11e-68fbb77d9de2"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i0a5a6b31a7ca4b5e825ff2a8e5104399_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM4LTUtMS0xLTQ1MzM0_340472e6-033e-4acc-a9f1-8844334377f6"
      unitRef="usd">1600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM5LTEtMS0xLTQ1MzM0_dcd38552-e125-494a-9199-876a930ea5c6"
      unitRef="usd">4700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM5LTMtMS0xLTQ1MzM0_4079c156-378a-43a4-b226-bd21fda52a08"
      unitRef="usd">18600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzM5LTUtMS0xLTQ1MzM0_02759320-fac3-462e-a947-fa83041490b2"
      unitRef="usd">8300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQyLTEtMS0xLTQ1MzM0_09245a8c-6806-4eea-b556-25e6dbf80929"
      unitRef="usd">4700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQyLTMtMS0xLTQ1MzM0_c4ce39de-e200-442b-9d9d-68aabfb99de9"
      unitRef="usd">278600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQyLTUtMS0xLTQ1MzM0_ac21b24c-cc2c-4caa-93aa-02573b5c2c7d"
      unitRef="usd">504600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQzLTEtMS0xLTQ1MzM0_77cb38fe-76ab-45b0-b0ea-9e16f7f21c15"
      unitRef="usd">-26000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQzLTMtMS0xLTQ1MzM0_8ade6a0a-5c32-4dbe-98e1-915cfce4db2e"
      unitRef="usd">-475600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQzLTUtMS0xLTQ1MzM0_7427119a-0696-4f39-805d-35d48fa334f3"
      unitRef="usd">579200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ0LTEtMS0xLTQ1MzM0_9ad3843d-d048-491b-88b4-edadc8fc0426"
      unitRef="usd">112800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ0LTMtMS0xLTQ1MzM0_56d5c293-d918-432f-b1e7-3b1a12417302"
      unitRef="usd">588400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i35327f5dcba84428bcd65e20009ba82d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ0LTUtMS0xLTQ1MzM0_c27401a8-1152-4529-bda8-f612b1b9daa1"
      unitRef="usd">9200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ1LTEtMS0xLTQ1MzM0_db33a401-59ff-4763-b466-cbee6ca26c78"
      unitRef="usd">86800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ1LTMtMS0xLTQ1MzM0_db5a9b33-6229-4d8a-992b-163a057828cd"
      unitRef="usd">112800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ1LTUtMS0xLTQ1MzM0_cf67020f-493e-49d0-a5e6-575872be1fbf"
      unitRef="usd">588400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ3LTEtMS0xLTQ1MzM0_5458fed0-3723-4217-a952-83527ccddadc"
      unitRef="usd">100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ3LTMtMS0xLTQ1MzM0_c9f0f6c3-35ff-4c48-a7f5-4674d66f4101"
      unitRef="usd">500000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ3LTUtMS0xLTQ1MzM0_5f0d31af-fb22-4e03-bc2d-2360dd745f71"
      unitRef="usd">500000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTEtMS0xLTQ1MzM0_19de77b2-c929-4199-8cb2-e62405f231bc"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTMtMS0xLTQ1MzM0_b7362366-90ed-4a8e-a971-862616100190"
      unitRef="usd">100000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTUtMS0xLTQ1MzM0_f7d1abde-e51d-49dd-81e0-6d20986a6d4d"
      unitRef="usd">100000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTEtMS0xLTQ2MzI4_6b3bfbdb-8240-4292-b4c9-efa803e397c0"
      unitRef="usd">11100000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTMtMS0xLTQ2MzI4_b6876f7c-e6ab-46e1-afac-d46bdb5e0495"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMjcvZnJhZzoyOTljMmIxMzhkMjU0ZTEzYmYwYzlhYzEzYmVkYWJiZS90YWJsZTo5NmFjZTJiZDkyZmY0MjExOGQ4OTlkZGZjZTIzZDk3Yi90YWJsZXJhbmdlOjk2YWNlMmJkOTJmZjQyMTE4ZDg5OWRkZmNlMjNkOTdiXzQ4LTUtMS0xLTQ2MzI4_5e8b1156-a247-49b0-ac7c-22c0ba315b25"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzMvZnJhZzoyMGVmZGQxOGQwYTY0Nzg0Yjg1MTA2ZDQ5ZTdmYWQzMy90ZXh0cmVnaW9uOjIwZWZkZDE4ZDBhNjQ3ODRiODUxMDZkNDllN2ZhZDMzXzMxMDc_d2d3837b-ba0d-4cd9-91d5-5b0faaa0c694">Nature of Business and Basis of Presentation  &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nature of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arvinas, Inc. is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases throughout the discovery, development and commercialization of therapies that degrade disease-causing proteins. Arvinas, Inc. has four wholly owned subsidiaries; Arvinas Operations, Inc. formed in 2013, Arvinas Androgen Receptor, Inc. formed in 2015, Arvinas Estrogen Receptor, Inc. formed in 2016, and Arvinas Winchester, Inc. formed in 2018 (collectively, "Arvinas" or the "Company").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated upon consolidation. The accounting policies used to prepare the Company's consolidated financial statements are the same as those used to prepare the consolidated financial statements in prior years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior period financial information in order to conform with current period presentation. Accounts payable and Accrued expenses have been condensed into Accounts payable and accrued liabilities, Interest income and Interest expense have been condensed into Interest income, net and in Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, within the reconciliation of U.S. federal statutory income tax rate table, a portion of the stock compensation rate effect was reclassified to return to provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified and recorded an adjustment to prior periods related to the accounting for its investment in Oerth Bio. See Note 10,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Equity Method Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the Company&#x2019;s revenue recognition, uncertain tax positions and research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks similar to other biotechnology companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of equity interests, proceeds from collaborations, grant funding and debt financing. The Company had cash, cash equivalents, restricted cash and marketable securities of approximately $1.2 billion as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <arvn:NumberOfWhollyOwnedSubsidiaries
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzMvZnJhZzoyMGVmZGQxOGQwYTY0Nzg0Yjg1MTA2ZDQ5ZTdmYWQzMy90ZXh0cmVnaW9uOjIwZWZkZDE4ZDBhNjQ3ODRiODUxMDZkNDllN2ZhZDMzXzM2NQ_0cdbe1ad-6694-4a67-8204-64b09cffc34d"
      unitRef="subsidiary">4</arvn:NumberOfWhollyOwnedSubsidiaries>
    <arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzMvZnJhZzoyMGVmZGQxOGQwYTY0Nzg0Yjg1MTA2ZDQ5ZTdmYWQzMy90ZXh0cmVnaW9uOjIwZWZkZDE4ZDBhNjQ3ODRiODUxMDZkNDllN2ZhZDMzXzMwOTY_0a445600-5872-4810-8f42-a2ea5d082a5f"
      unitRef="usd">1200000000</arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzI3_3aea5069-53cf-48a3-9d82-dfdded15df8b">Summary of Significant Accounting Policies  &lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents and are considered Level 1 financial instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease entered into in May 2021 and amended in August 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the years ended December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;588.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash in financial institution accounts that may at times exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022 and 2021, one collaborator represented 88% and 68% of the Company's revenue, respectively, and for the year ended December&#160;31, 2020, three collaborators represented   37%, 32% and 31% of the Company's revenue. For each of the years ended December&#160;31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, one &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;collaborator accounted for the entire accounts receivable balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's marketable securities are classified as available-for-sale securities and are carried at their fair value based on the quoted market prices of the securities, with unrealized gains and losses reported as accumulated other comprehensive income (loss), a separate component of stockholders' equity. Realized gains and losses on available-for-sale securities are included in other income in the period earned or incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Equipment, and Leasehold Improvements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation is removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of long-lived assets when indications of potential impairments are present. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than the carrying value. No such impairments were recorded during 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in assessing performance and allocating resources. The Company, through its Chief Executive Officer in his role as chief operating decision maker, views Company operations and manages the business as one operating segment. All of the Company&#x2019;s tangible assets are held in the United States and all of the Company&#x2019;s revenue has been generated in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition and Deferred Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenues from Contracts &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under Accounting Standards Codification ("ASC") 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, the Company evaluates whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent combined single performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company determined that the most likely amount to be recognized was zero, against which no constraint was applied. The Company continually assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized ratably over the Company&#x2019;s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company&#x2019;s performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020, the transaction price allocated to the combined performance obligation identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on the Company&#x2019;s best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale, or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in the Company&#x2019;s accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses direct and incremental costs to obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as collaboration contract assets and amortized as general and administrative expenses over the total estimated period of performance of each underlying contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Method Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Equity Method and Joint Ventures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company recognizes its pro-rata share of income and losses in the investment in &#x201c;Loss from equity method investment&#x201d; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment in the consolidated balance sheet until such investment is reduced to zero. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. The Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the authoritative guidance for recognizing and measuring uncertainty in income tax positions taken or expected to be taken in a tax return. The Company recognizes interest accrued related to unrecognized tax benefits and  penalties in tax expense. Management has evaluated the effect of ASC 740 guidance related to uncertain income tax positions and concluded that the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has no sign&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ificant uncertain income tax positions as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures employee, board of director and consultant equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards. Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies equity-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;401(k) Savings plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Under the 401(k) Plan, the Company made discretionary matching contributions on behalf of eligible employees totaling $2.2&#160;million, $1.3&#160;million and $0.9&#160;million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites and consultants; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into consulting, research and other agreements with commercial entities, researchers, universities and others for the provision of goods and services. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#x2019;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, requires disclosure of the fair value of financial instruments held by the Company. ASC 825, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;&#160;&#160;&#160;&#160;Inputs are based upon observable or quoted prices (unadjusted) for identical instruments traded in active markets.  The Company&#x2019;s Level 1 financial instruments consist of cash equivalents.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;&#160;&#160;&#160;&#160;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#x2019;s Level 2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;&#160;&#160;&#160;&#160;Inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss per Common Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reviews&lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;new accounting standards as issued. As of December&#160;31, 2022, the Company has not identified any new standards that it believes will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE1_8ed964e9-f334-41b6-b423-5f4673075352">Cash and Cash Equivalents The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents and are considered Level 1 financial instruments.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE2_ab4ac742-50d3-4ee2-b4a3-aa09afe44e11">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease entered into in May 2021 and amended in August 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI3NDg3NzkwOTUxMzA_28f9ba78-7a84-46ff-846e-d94f26ad00d8">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the years ended December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;588.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI3NDg3NzkwOTUxMzA_96d93159-0d1f-4338-bbdd-4630f4798dc4">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the years ended December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;588.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzItMS0xLTEtNTk1MzI_7d630db4-0cf1-4f4b-ad96-ed3ba03417a8"
      unitRef="usd">81300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzItMy0xLTEtNTk1MzI_91e0e4df-0163-4019-adbe-4dbb1a8c0c85"
      unitRef="usd">108300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzItNS0xLTEtNTk1MzI_ca2a5900-11e4-454f-9331-de715c0d5d57"
      unitRef="usd">588400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzMtMS0xLTEtNTk1MzI_5c7b3744-1709-4c5b-9a29-b5b837faa9a0"
      unitRef="usd">5500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzMtMy0xLTEtNTk1MzI_efcfb5cb-ea26-4417-9023-f0ba1835ef01"
      unitRef="usd">4500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzMtNS0xLTEtNTk2MDI_b0c19611-9520-4385-bf12-417d9aa736ad"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzQtMS0xLTEtNTk1MzI_0d803d43-e319-455f-be93-a150b44ae38b"
      unitRef="usd">86800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzQtMy0xLTEtNTk1MzI_f73329a0-1b81-4dfb-9685-c18c350ef145"
      unitRef="usd">112800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90YWJsZTpmN2RmOGM5OWQxMDM0ZDYxYWQ1NTYzNDJjZGMxOTVlNi90YWJsZXJhbmdlOmY3ZGY4Yzk5ZDEwMzRkNjFhZDU1NjM0MmNkYzE5NWU2XzQtNS0xLTEtNTk1MzI_6a1c1043-8f1f-4294-8e52-a681003d1834"
      unitRef="usd">588400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzI4_1f4a17e6-2fdd-4199-bc33-df19f4af8e47">Concentration of Credit Risk The Company maintains its cash in financial institution accounts that may at times exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FederalDepositInsuranceCorporationPremiumExpense
      contextRef="i8f3407ea1c884292b6b1262e24808e77_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzkzNA_ece569a1-8550-46ef-ad02-3cb526de0e84"
      unitRef="usd">250000</us-gaap:FederalDepositInsuranceCorporationPremiumExpense>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i05529346f2bd43978586c86e2c968da8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzExNDA_262e9aef-f1b8-4acf-b0de-865db3927b55"
      unitRef="number">0.88</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2cf9012e2f3e483fb7f5830d388d4178_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzMDQ3OQ_1e2c84b0-91d1-4d52-8526-2c5e3e2c0d19"
      unitRef="number">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6c1ef30395c542ec9b2036e573ee37fb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzMDQ1Ng_e1652582-1033-4b41-9c29-3c1b201849c6"
      unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i93dabaf08df04303b0314c7df4d8e165_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzMDQ2Mg_925e0a94-c58a-4960-98e2-9d9848bc080a"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i43bf74e98bde44c59baa52f0d2d487fe_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzMDQ1Mw_8394ab9f-1106-4524-93ad-102779bcaf99"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE0_35ff9273-5bf9-467c-a9f4-963afff41aef">Marketable Securities The Company's marketable securities are classified as available-for-sale securities and are carried at their fair value based on the quoted market prices of the securities, with unrealized gains and losses reported as accumulated other comprehensive income (loss), a separate component of stockholders' equity. Realized gains and losses on available-for-sale securities are included in other income in the period earned or incurred.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzIx_fa7e37c3-0870-4426-8221-7e4abf8e19eb">Property, Equipment, and Leasehold Improvements Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation is removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id3f476fc73a34c9e810fa5b3bfabf520_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzIxMjA_8b16caad-53bb-4683-b75e-6ac07c6346d8">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id8bb00294943430a85af5e662821b3fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzIxNDc_12694f5d-3e33-4592-a0a0-21dbae363519">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzEy_6c6fba3b-2880-405e-aa0b-bda6580b219c">Impairment of Long-Lived Assets The Company evaluates the carrying value of long-lived assets when indications of potential impairments are present. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than the carrying value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI5NTI_12793652-4314-4f7b-a536-f9561b4e3359"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI5NTI_7068ddfa-5383-4d41-89a1-afeb6c19244e"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI5NTI_c607be03-7599-4428-878c-d73769877ccc"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzIy_7ece1e0c-8a37-4dcb-991f-ef5ad7ea7d55">Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in assessing performance and allocating resources. The Company, through its Chief Executive Officer in his role as chief operating decision maker, views Company operations and manages the business as one operating segment. All of the Company&#x2019;s tangible assets are held in the United States and all of the Company&#x2019;s revenue has been generated in the United States.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzMzOTg_97b7671a-bc76-4abb-b2b5-1d3d8fe12c9a"
      unitRef="operating_segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzIz_aa2c2cbb-3c96-4684-ab29-cc1743c32914">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition and Deferred Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenues from Contracts &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under Accounting Standards Codification ("ASC") 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, the Company evaluates whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent combined single performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company determined that the most likely amount to be recognized was zero, against which no constraint was applied. The Company continually assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized ratably over the Company&#x2019;s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company&#x2019;s performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020, the transaction price allocated to the combined performance obligation identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on the Company&#x2019;s best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale, or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in the Company&#x2019;s accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses direct and incremental costs to obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as collaboration contract assets and amortized as general and administrative expenses over the total estimated period of performance of each underlying contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzI0_f5121e0c-8af7-400f-ac8f-5422ecf74729">Equity Method Investments &lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Equity Method and Joint Ventures&lt;/span&gt;. The Company recognizes its pro-rata share of income and losses in the investment in &#x201c;Loss from equity method investment&#x201d; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment in the consolidated balance sheet until such investment is reduced to zero.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestments
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2Xzg2NDM_1c8ca365-e5e2-4a90-ab4d-55461c51975d"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE5_9b6e74cb-b53a-4132-a5b7-5f01f7527236">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. The Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;The Company follows the authoritative guidance for recognizing and measuring uncertainty in income tax positions taken or expected to be taken in a tax return. The Company recognizes interest accrued related to unrecognized tax benefits and  penalties in tax expense.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzIw_0d19a17d-6ca1-400a-8115-d45d55633867">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures employee, board of director and consultant equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards. Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies equity-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <arvn:DefinedContributionPlanPolicyPolicyTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzI3NDg3NzkwOTUxMzM_679ca02c-86a8-4be1-8f33-722193e8ad5b">401(k) Savings planThe Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis.</arvn:DefinedContributionPlanPolicyPolicyTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzODIzMQ_6f6c682e-4936-49be-ad54-f1074e969890"
      unitRef="usd">2200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzODI0NQ_fcfff923-c70a-4fb5-9603-06d6d90a1220"
      unitRef="usd">1300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzU0OTc1NTgzODI1OQ_1cc38a55-63b0-41de-a166-d585b5c6532e"
      unitRef="usd">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE3_158e9632-40f4-4264-b5ce-04d22f8551e1">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites and consultants; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into consulting, research and other agreements with commercial entities, researchers, universities and others for the provision of goods and services. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#x2019;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzE4_17f1cc0d-a34a-463a-baba-d46c81e12a20">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, requires disclosure of the fair value of financial instruments held by the Company. ASC 825, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;&#160;&#160;&#160;&#160;Inputs are based upon observable or quoted prices (unadjusted) for identical instruments traded in active markets.  The Company&#x2019;s Level 1 financial instruments consist of cash equivalents.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;&#160;&#160;&#160;&#160;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#x2019;s Level 2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;&#160;&#160;&#160;&#160;Inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques. &lt;/span&gt;&lt;/div&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzI1_cea6ec44-3f2e-4690-b3a2-f0966c9894dd">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss per Common Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xMzkvZnJhZzphOTQyYmVhNzkxZmM0OGY4YTY1ZjlmYWRhMDM4NjAwNi90ZXh0cmVnaW9uOmE5NDJiZWE3OTFmYzQ4ZjhhNjVmOWZhZGEwMzg2MDA2XzE2MzI2_4d001c28-b152-4811-a0e4-f4dd735b70a1">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reviews&lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;new accounting standards as issued. As of December&#160;31, 2022, the Company has not identified any new standards that it believes will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzkzNDY_779a8845-90ab-4dea-b2f1-afcef64e513f">Research Collaboration and License Agreements&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ARV-471 Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company entered into a collaboration agreement with Pfizer (the &#x201c;ARV-471 Collaboration Agreement&#x201d;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#x2019;s proprietary compound ARV-471 (the &#x201c;Licensed Products&#x201d;). Under the ARV-471 Collaboration Agreement, the Company received an upfront, non-refundable payment of $650.0&#160;million. In addition, the Company will be eligible to receive up to an additional $1.4&#160;billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0&#160;million in regulatory milestones are related to marketing approvals and $1.0&#160;billion are related to sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in connection with the execution of the ARV-471 Collaboration Agreement, the Company and Pfizer entered into a Stock Purchase Agreement (the" Pfizer Stock Purchase Agreement") for the sale and issuance of 3,457,815 shares of the Company&#x2019;s common stock (the &#x201c;Shares&#x201d;) to Pfizer at a price of $101.22 per share, for an aggregate purchase price of $350.0 million (the &#x201c;Pfizer Equity Transaction&#x201d;), less financial advisor fees of $4.6&#160;million, which was consummated in September 2021. Pursuant to terms of the Pfizer Stock Purchase Agreement, Pfizer has agreed not to sell or transfer the Shares without prior written approval of the Company for a specified time period, subject to specified exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the ARV-471 Collaboration Agreement and the Pfizer Equity Transaction entered into with Pfizer concurrently should be evaluated as a combined contract in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company determined the fair value of the shares sold under the Pfizer Equity Transaction to be $85.4&#160;million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company determined that the sale of stock should be recorded at fair value and therefore allocated the excess consideration received under the Pfizer Equity Transaction to the ARV-471 Collaboration Agreement, which, along with the non-refundable payment of $650.0 million, is being recognized as revenue over the total estimated period of performance based on the Company&#x2019;s best estimate of costs to be incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a direct result of the Company&#x2019;s entry into the ARV-471 Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $12.9&#160;million. In accordance with ASC 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized an asset of $12.9&#160;million in collaboration contract asset and other assets in the consolidated balance sheet, which is being amortized as general and administrative expense over the total estimated period of performance under the ARV-471 Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bayer Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the "Bayer Collaboration Agreement") setting forth the Company&#x2019;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC targeted protein degraders, that mediate for degradation of target proteins ("Targets"), using the Company&#x2019;s proprietary platform technology, which Targets will be selected by Bayer AG, subject to certain exclusions and limitations. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $17.5 million in exchange for the use of the Company&#x2019;s technology license. In addition, Bayer AG is committed to fund an additional $12.0 million through 2023, of which $10.5&#160;million was received from inception through December&#160;31, 2022, including $3.0 million received in each of the years ended December 31, 2022, 2021 and 2020. These payments are being recognized over the total estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated Targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There were no development or sales-based milestone payments or royalties received through December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Bayer Collaboration Agreement and a Stock Purchase Agreement entered into with Bayer AG at the same time should be evaluated as a combined contract in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company determined the fair value of the shares sold under the Stock Purchase Agreement to be $2.9 million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company determined that the sale of stock should be recorded at fair value. Therefore, the Company allocated the additional $2.9 million of consideration received under the Stock Purchase Agreement to the Bayer Collaboration Agreement and added such amount to the total transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pfizer Research Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the "Pfizer Research Collaboration Agreement"). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#x2019;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized over the total estimated period of performance. The Company is eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. The Company is also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. In 2021 and 2020, the Company received payments totaling &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.2 million and $4.4&#160;million, respectively,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which are being recognized as revenue over the total period of performance. Pfizer selected additional targets and initiated additional services totaling $1.0 million and $3.5 million in December 2022 and 2021, respectively, which were included in accounts receivable as of December 31, 2022 and 2021. There were no sales-based milestone payments or royalties received through December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Genentech Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the "Genentech Modification") with Genentech, Inc. and F. Hoffman-La Roche Ltd (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Genentech Modification, the Company received upfront, non-refundable payments of $34.5 million (in addition to $11.0 million received under the previous agreement in 2015) to fund Genentech-related research and Genentech has the right to designate up to ten targets. The Company is eligible to receive up to $27.5 million in additional expansion target payments if Genentech exercises its options on all remaining targets. Upfront non-refundable payments are recognized as revenue over the total estimated period of performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is eligible to receive up to $44.0 million per target in development milestone payments, $52.5 million in regulatory milestone payments and $60.0 million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's contract balances were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts payable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract assets: Collaboration contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract liabilities: Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;740.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions to collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;742.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(120.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(18.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances not held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(28.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;623.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;740.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded cumulative catch-up adjustments from contract modifications totaling $0.7 million, $(0.8) million and $(0.4) million, respectively, relating to performance obligations which were satisfied in prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of December&#160;31, 2022 totaled $623.7 million, which is expected to be recognized in the following periods: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;218.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;193.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;623.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i3c8b495cdfa84814911559b730f66a7e_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ5OQ_bdf09266-52fd-41f3-9250-c227aa7bafab"
      unitRef="usd">650000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="id72a39411b0248c680378066eb3c8a44_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU3Ng_67baaa15-a03d-4a13-be3f-91a897c7de4c"
      unitRef="usd">1400000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ia18bd320049b4bbba687aa9d1e399170_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzcxOQ_fad5213d-34e6-4243-bc56-6ed4ceea5b67"
      unitRef="usd">400000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="iae355cb2cbd14a7ca7ce12fab1f7f070_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzc4Ng_b6c5f6e2-bbf4-45aa-95fc-bb09d602654f"
      unitRef="usd">1000000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzE5MzU_d8e109e9-d456-4842-92cb-037fe66f1c99"
      unitRef="shares">3457815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i008bbd6d947d479fad8e8cd49d905905_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzIwMTQ_fba5ba53-aed6-4421-881e-3c6d616359c2"
      unitRef="usdPerShare">101.22</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzIwNjM_28ee55e5-65c9-4c35-9d2c-e2f492754bf7"
      unitRef="usd">350000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsForBrokerageFees
      contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzIxNDA_be82301e-c190-479b-9d71-456ed02300ce"
      unitRef="usd">4600000</us-gaap:PaymentsForBrokerageFees>
    <arvn:SaleOfStockFairValueOfSharesSold
      contextRef="ib894aa0b10644e20af715749fe409cc1_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzI3ODc_fc5367e7-c852-4e34-9a3a-b6ddbc65ecbf"
      unitRef="usd">85400000</arvn:SaleOfStockFairValueOfSharesSold>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i137647b8ea294b7f923d056ee2a3185a_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzMyMjM_de32ea44-bf1e-40d9-91f4-337e06c66cdf"
      unitRef="usd">650000000.0</us-gaap:ContractWithCustomerAssetNet>
    <arvn:DirectAndIncrementalCostsIncurredToObtainTheContract
      contextRef="ia0122cacce6947ffb02e9a5170ae43e6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzM1Njk_9c2e76d4-81b4-4960-a9cf-8369a0c5f9d5"
      unitRef="usd">12900000</arvn:DirectAndIncrementalCostsIncurredToObtainTheContract>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="i3f9942e42d3140f8a91bf2d658e6dcf3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzM2Njk_86d02116-d6b4-4318-a898-cf47068a2396"
      unitRef="usd">12900000</arvn:CollaborationContractAssetAndOtherAssets>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="id5e7ec5fd01749818f635a4f60e5162b_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ2MTI_84316c3d-59a7-4bb2-ae48-181d95411849"
      unitRef="usd">17500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ic1c1ec77b77045b497b74778ed6dd646_I20231231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ3NjU_ce29b8cd-2dd8-4bd6-b491-4003b364c051"
      unitRef="usd">12000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="if7526a5f18544f7e93c796607abcc906_D20190601-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyMzQ3Mg_e8024c3a-ae83-4717-98c0-c2fa7dba678c"
      unitRef="usd">10500000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ib6c577e36553475a87e391c1f798aa7b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ3ODk_21b184fc-6602-442c-b422-dce578b61a17"
      unitRef="usd">3000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i48ac848348704c25879ff7a321b30a93_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ3ODk_be33ac64-0e93-487f-abc0-2f4a654c3874"
      unitRef="usd">3000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ibd3db3e1a3a44d7eaadb52f8b2021f2d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ3ODk_fcae2e43-9e5a-44da-aabb-3e8408c777a4"
      unitRef="usd">3000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ic37540796dbd46e89f0413e7111cb541_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzQ5NzQ_03195cb7-3294-457f-8b14-2b79be58fc76"
      unitRef="usd">197500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i63bcebaaf3e442f0be53ff2a3cd2ab6b_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzUwMjE_1193ac6f-3eaf-4315-bfc0-2d346dccc6f3"
      unitRef="usd">490000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="id766159d435e4384b6f8955f4aa30c00_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzUzMDQ_019f3dae-590f-458b-b66e-2cb3a9302114"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i60b38ed093ce46b7bd1daba503d94341_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzUzMDQ_07ad0e90-3bfc-4cff-b702-1bdcd6534ed1"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <arvn:SaleOfStockFairValueOfSharesSold
      contextRef="if3ae4abd92fa47a5b59e353890bedd74_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU3MzA_738ca174-7b75-4b77-8d33-91343e914d7e"
      unitRef="usd">2900000</arvn:SaleOfStockFairValueOfSharesSold>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="if3ae4abd92fa47a5b59e353890bedd74_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzYwMzQ_0f0cc5bf-176e-40e7-9fad-5c12a7d2b6f6"
      unitRef="usd">2900000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:ProceedsFromCollaborators
      contextRef="iaaf06e4b711c47f79d1671a25c581273_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzY1NDI_1161ae91-c93c-4bcc-be4b-27671681717c"
      unitRef="usd">28000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i41b133ccf8c94b249e0de13cf22af00d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzY4NDc_11c78671-ae6c-44b6-8b53-65f86020a819"
      unitRef="usd">37500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i1a14b1ae339242c8b514f80494ac7461_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzcwMjk_73a1429e-cbec-4687-80eb-21815f50f3bd"
      unitRef="usd">225000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i8056d73a6e7d4769acafb7929251b89d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzcwNzY_e473dbff-449f-46ed-9f65-6c208c1e78f9"
      unitRef="usd">550000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ic134f4ad0212413fb29264d3665de649_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzcyOTU_631ed538-a5de-4e03-8598-97e4025d83c4"
      unitRef="usd">1200000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ibcd68967c863457f9a819376746fa6fc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNjE3Ng_88fc738e-451f-4947-a437-3c5a222f6ba1"
      unitRef="usd">4400000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i877187a756224a52a50870299413f7a3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNTM5MA_a56989ed-0b69-40a5-895f-00cc0723d133"
      unitRef="usd">1000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i660d8e9f27ff4dc1a01397df66df2870_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNDk3Ng_ad8fef0c-d9ba-4e47-9598-d33fad588fd9"
      unitRef="usd">3500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i94762668373b4b67bb84c11c71e8cdb1_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzc1NDg_05d90269-66e1-4511-b041-41b2b3090764"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i759fe1462729496ba429f2526fc8aff5_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzgwMTY_f83fe5d2-548a-40b7-9691-30301c042313"
      unitRef="usd">34500000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i9a9898905f154cf8b9795022a7300014_D20150901-20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzgwMzU_7bcc973a-9585-4cc7-affd-b4cd29b1c81e"
      unitRef="usd">11000000</us-gaap:ProceedsFromCollaborators>
    <arvn:NumberOfMaximumDesignatedTargets
      contextRef="i759fe1462729496ba429f2526fc8aff5_D20171101-20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzgxNjc_f14c16bf-ff35-41e3-9bc5-814a37da55d9"
      unitRef="target">10</arvn:NumberOfMaximumDesignatedTargets>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i8cc6a3e194a5420ea29436a5800706bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzgyMjA_f80cba16-237e-4e95-a233-c0b87ca6905f"
      unitRef="usd">27500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i5473a14476bb4d1885b2439dc1d56870_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg0NzI_dbee24ce-bff3-4fef-b879-7f05ac130ab1"
      unitRef="usd">44000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ie8eb28a02b3f4a66aeb3f487c3c1bb6b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg1MjE_1b1be1ae-3404-4d46-b455-7ef230dc0651"
      unitRef="usd">52500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i095c155f507a4c09a74c9bc2d95f96ab_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg1NjE_64429161-e637-4d6a-bd60-3ec8577bb0c7"
      unitRef="usd">60000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i5bbb1ec29ec94c9f87ada6000b54a3fc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg2Njc_1fe6c0b0-9509-45ee-9b6d-8039f7beb9e9"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i247c5fdfe9cf425da9589cd446cbbdb1_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg2Njc_3d72fdbd-726b-4eee-a1d2-9b2156f14341"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i9ea29be677eb40da8b1cb7c47d711d2d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzg2Njc_622b2a15-cb32-48dc-bcf7-dd28b09098d8"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzkzNDQ_df76fea3-1ed3-4c30-ad11-43bc79c2b11b">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's contract balances were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts payable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract assets: Collaboration contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract liabilities: Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;740.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions to collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;742.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(120.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(18.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances not held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(28.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;623.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;740.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzMtMS0xLTEtNDgzMTU_28755c09-e1df-4552-8d9f-603419f109d2"
      unitRef="usd">15000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzMtMy0xLTEtNDgzMTU_4e7f5009-35f1-4b82-9b72-80e4dc765404"
      unitRef="usd">1000000.0</us-gaap:AccountsReceivableNetCurrent>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzQtMS0xLTEtNDgzMTU_389a4d32-f814-4cf5-ab97-e93e3c0a5b38"
      unitRef="usd">6400000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzQtMy0xLTEtNDgzMTU_b6ffeaea-6a58-4de8-b187-b938cfd2ecef"
      unitRef="usd">19900000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzUtMS0xLTEtNDgzMTU_cedd0882-95f4-45fe-a6d5-5b454484bb90"
      unitRef="usd">20400000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzUtMy0xLTEtNDgzMTU_68ed6668-4c92-4bad-a2e2-db4f7c4d9b65"
      unitRef="usd">5900000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzYtMS0xLTEtNDgzMTU_c13833a0-2a73-4824-9f95-2527b8462529"
      unitRef="usd">1000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzYtMy0xLTEtNDgzMTU_a7eb2a74-8094-4ca7-b6d1-b3ac0d613140"
      unitRef="usd">15000000.0</us-gaap:AccountsReceivableNetCurrent>
    <arvn:AccountsPayableContractBalancesCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzgtMS0xLTEtNTE2ODc_a7f42c93-2ac1-40a8-9598-80aba63b80a9"
      unitRef="usd">0</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrent
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzgtMy0xLTEtNTE2ODc_d81c71df-06ca-453a-9c4b-c6970c68e4bd"
      unitRef="usd">0</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrentAdditions
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzktMS0xLTEtNTE2ODc_46105469-6487-4744-b4e4-1305686d263a"
      unitRef="usd">5000000.0</arvn:AccountsPayableContractBalancesCurrentAdditions>
    <arvn:AccountsPayableContractBalancesCurrentAdditions
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzktMy0xLTEtNTE2ODc_2111bb06-371c-4bb1-b606-12a2d73656d7"
      unitRef="usd">0</arvn:AccountsPayableContractBalancesCurrentAdditions>
    <arvn:AccountsPayableContractBalancesCurrentPayments
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEwLTEtMS0xLTUxNjg3_99435c8e-4b7e-4754-bbab-679fa025c642"
      unitRef="usd">0</arvn:AccountsPayableContractBalancesCurrentPayments>
    <arvn:AccountsPayableContractBalancesCurrentPayments
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEwLTMtMS0xLTUxNjg3_e6a2fe3e-9828-4d06-bd81-eed13ce5524c"
      unitRef="usd">0</arvn:AccountsPayableContractBalancesCurrentPayments>
    <arvn:AccountsPayableContractBalancesCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzExLTEtMS0xLTUxNzMw_01b3b3e8-edfc-4a2c-830a-39a7a46ede1f"
      unitRef="usd">5000000.0</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzExLTMtMS0xLTUxNzM0_664bf915-f0a6-4eed-9d77-a660fc425ea0"
      unitRef="usd">0</arvn:AccountsPayableContractBalancesCurrent>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzgtMS0xLTEtNDgzMTU_9d7a1eba-1707-495a-b88d-86ee68b77fd1"
      unitRef="usd">12500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzgtMy0xLTEtNDgzMTU_f497bc0d-c533-40d7-93c1-6c1df6ffbb07"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzktMS0xLTEtNDgzMTU_2ff718d8-cf2c-435e-8744-04bea3cff993"
      unitRef="usd">0</arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzktMy0xLTEtNDgzMTU_e45aeec4-e5ae-4c00-936b-fe38cdec3513"
      unitRef="usd">12900000</arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEwLTEtMS0xLTQ4MzE1_a0e76bbc-d408-48a3-a966-355df9fcee57"
      unitRef="usd">1800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEwLTMtMS0xLTQ4MzE1_b9ff27c6-5385-4c88-af1b-f2197357ead1"
      unitRef="usd">400000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzExLTEtMS0xLTQ4MzE1_4c3c6be4-9f02-4791-b792-50e53e084843"
      unitRef="usd">10700000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzExLTMtMS0xLTQ4MzE1_adf39926-23d8-4496-8744-ea248e63d8d1"
      unitRef="usd">12500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEzLTEtMS0xLTQ4MzE1_b1ed149e-8531-4a5e-85a1-0cba33352db6"
      unitRef="usd">740500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzEzLTMtMS0xLTQ4MzE1_a224ce2f-54cd-4685-888f-1ac28a77d8c4"
      unitRef="usd">45100000</us-gaap:ContractWithCustomerLiability>
    <arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE0LTEtMS0xLTQ4NDM5_7bc9953b-43fa-408e-8f5e-37415ec0a7aa"
      unitRef="usd">4000000.0</arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE0LTMtMS0xLTQ4NDM5_7b9df067-9f42-4e80-a54f-de7747a79e28"
      unitRef="usd">742100000</arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE0LTEtMS0xLTQ4MzE1_3b8c1fe2-0629-49fe-80b8-89b9fbc51509"
      unitRef="usd">-120000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE0LTMtMS0xLTQ4MzE1_60481800-6e6e-4ade-93ae-63685c35bf09"
      unitRef="usd">-18600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <arvn:ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE1LTEtMS0xLTQ4MzE1_4c83164f-6e7a-4aed-a7b4-fe3f2141a1ec"
      unitRef="usd">-800000</arvn:ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance>
    <arvn:ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE1LTMtMS0xLTQ4MzE1_998ebe73-de54-48ad-9663-5a1f8ab0e8ec"
      unitRef="usd">-28100000</arvn:ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE2LTEtMS0xLTQ4MzE1_e1fb870b-00c8-4daf-b4c0-7e694734809c"
      unitRef="usd">623700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTpkM2Q4NTFmNDRlODE0ZGZmYjI1OTM5MTEyZTk1ZTgzMy90YWJsZXJhbmdlOmQzZDg1MWY0NGU4MTRkZmZiMjU5MzkxMTJlOTVlODMzXzE2LTMtMS0xLTQ4MzE1_f9eab2aa-acbe-495f-8259-4a155a0a875e"
      unitRef="usd">740500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNzE2NA_0ed483b7-3721-467f-b6fa-1396e8741466"
      unitRef="usd">700000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNzE1MA_0feadc5b-3f89-4b58-91b1-8f9ffdb40de0"
      unitRef="usd">-800000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzU0OTc1NTgyNzEzNg_42966ae5-6b47-4943-aa9e-792205cd9638"
      unitRef="usd">-400000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzkzNDU_30935a90-1f7a-44d5-8d73-0f1a88d045c3">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of December&#160;31, 2022 totaled $623.7 million, which is expected to be recognized in the following periods: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;218.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;193.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;623.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90ZXh0cmVnaW9uOjU5NWUxOWNkYTU0MjQ1NWJiYzEyMzU5ZGYwYjBkMmRmXzkyNzg_2e3121ec-305f-42d4-8ba9-2b3cec350a49"
      unitRef="usd">623700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1e801491e3064f7e8860d42f7cd1d807_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzEtMS0xLTEtNDUzMzQ_124a5a12-c3d6-4b40-99f4-75487cc87d87"
      unitRef="usd">218600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i37df6405966e4a9bba28bd31c157a857_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzItMS0xLTEtNDUzMzQ_3cabfec8-d111-45f4-a495-834dbcaa1eea"
      unitRef="usd">193900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i3bd0aacedfdf49bf999f9c0416ec3008_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzMtMS0xLTEtNDUzMzQ_25d4d8b9-07af-4d0c-ab2d-497d9e15dfba"
      unitRef="usd">90200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic4368412362e45bba2473a1217491133_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzQtMS0xLTEtNDUzMzQ_ab87efdc-846d-4da5-802e-fe1c6cd0c3d8"
      unitRef="usd">55300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i672048308c094a4fbb8e393353f2cc46_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzUtMS0xLTEtNDUzMzQ_a5bd8f8c-1f1a-480d-bb42-59ae96f20bbe"
      unitRef="usd">34700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ib73fa643c9664e9aa6e824a9828957e4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzYtMS0xLTEtNDUzMzQ_3bc7672e-4721-460a-88b7-309dd225b58f"
      unitRef="usd">31000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNDUvZnJhZzo1OTVlMTljZGE1NDI0NTViYmMxMjM1OWRmMGIwZDJkZi90YWJsZTo3YTEwODI4ZmU1ZjE0ZjEwOWM2ZDllMmJlM2U3NTNjZS90YWJsZXJhbmdlOjdhMTA4MjhmZTVmMTRmMTA5YzZkOWUyYmUzZTc1M2NlXzctMS0xLTEtNDUzMzQ_2e3121ec-305f-42d4-8ba9-2b3cec350a49"
      unitRef="usd">623700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90ZXh0cmVnaW9uOjRkZDkwNTY0YmE2MTQzNmFiM2QxMGFmYjk2M2ExMGY5XzEzODM_c217fa0c-bc69-4cf4-9a3d-50a85082e474">Marketable Securities and Fair Value Measurements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s assets measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Maturity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024 - 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Maturity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 - 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of accounts receivable and accounts payable and accrued liabilities approximate their &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-recurring fair value measures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, in connection with the Pfizer Stock Purchase Agreement, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company valued the common stock issued to Pfizer&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at fair value. The Pfizer Stock Purchase Agreement contains provisions restricting the sale or transfer for a period of time (the &#x201c;lock-up period&#x201d;). The resulting fair value of $264.6&#160;million was determined by applying the discount due to lack of marketability during the contractual lock-up period to the public trading price of the common stock, which is a Level 1 input, on the date of sale. The Company accounted for the lack of marketability during the contractual lock-up period, by utilizing put option models, which are considered Level 3 inputs. Such option models included the Company&#x2019;s historical volatility and the risk-free rate based on U.S. Treasury bond rates, as key inputs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90ZXh0cmVnaW9uOjRkZDkwNTY0YmE2MTQzNmFiM2QxMGFmYjk2M2ExMGY5XzEzODE_1e7ecd58-a5bf-4edf-9f9b-83c78724f22e">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s assets measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Maturity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024 - 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Maturity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 - 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i11ac1a1558a74e50b590271f7dea04b2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzItNi0xLTEtNDUzMzQ_4d5c2d74-c1ce-42bb-8f84-f8d88b10961c"
      unitRef="usd">802700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11ac1a1558a74e50b590271f7dea04b2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzItOC0xLTEtNDUzMzQ_5f329dc9-a982-4621-94da-29154785d7be"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11ac1a1558a74e50b590271f7dea04b2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzItMTAtMS0xLTQ1MzM0_ad9ec5ce-8226-443f-b528-efd9b94cd36d"
      unitRef="usd">9300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11ac1a1558a74e50b590271f7dea04b2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzItMTItMS0xLTQ1MzM0_dfa754b5-fe3c-455b-9bec-77aa95751783"
      unitRef="usd">793400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if2baa9d5c1314262a04322fd5725c7b6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzMtNi0xLTEtNDUzMzQ_e9bc668e-f9f9-4dca-9e59-5c88e855ad2a"
      unitRef="usd">205300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if2baa9d5c1314262a04322fd5725c7b6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzMtOC0xLTEtNDUzMzQ_9b7298f9-7498-4d59-8d46-d4eac56dc744"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if2baa9d5c1314262a04322fd5725c7b6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzMtMTAtMS0xLTQ1MzM0_b700de2c-946e-4d8f-8014-856174e86baa"
      unitRef="usd">9200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2baa9d5c1314262a04322fd5725c7b6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzMtMTItMS0xLTQ1MzM0_8e3b75d4-c781-4ad7-af05-140f4440bf4b"
      unitRef="usd">196100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2517bd9479df46dcac4edde8de8fbf8b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtNi0xLTEtNTE0NjE_86df73e9-47bf-42de-9c3e-937e15935363"
      unitRef="usd">61900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2517bd9479df46dcac4edde8de8fbf8b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtOC0xLTEtNTE0NjE_f7d6e7a3-4e0e-4bc6-a8ab-6e9cbae22bc7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2517bd9479df46dcac4edde8de8fbf8b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtMTAtMS0xLTUxNDYx_d3ef11be-c25c-45f9-b45d-13e5fc6e0e1e"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2517bd9479df46dcac4edde8de8fbf8b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtMTItMS0xLTUxNDYx_cb781a15-4938-4bbc-a544-bddb646b4d1d"
      unitRef="usd">61500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1e71741f7e2c4379b7adad37f613ae6b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtNi0xLTEtNDUzMzQ_6944101a-2c3f-4f9a-a619-28f6af84c873"
      unitRef="usd">73300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1e71741f7e2c4379b7adad37f613ae6b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtOC0xLTEtNDUzMzQ_3c49cdcb-6d36-42d5-8b7c-bf98b42eca48"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1e71741f7e2c4379b7adad37f613ae6b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtMTAtMS0xLTQ1MzM0_c9f3e403-b82b-4d52-ba18-623fe8dfb938"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e71741f7e2c4379b7adad37f613ae6b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzQtMTItMS0xLTQ1MzM0_e63d3a36-94f0-492b-9e1f-f5496a07b5ae"
      unitRef="usd">73000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5cb3556f23c44e99bce5894aafa9c448_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzUtNi0xLTEtNDUzMzQ_d1ef67a6-4150-4392-ae73-56d5f83ef9d1"
      unitRef="usd">1143200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5cb3556f23c44e99bce5894aafa9c448_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzUtOC0xLTEtNDUzMzQ_14368309-fe92-408d-9d42-c8636bea6470"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5cb3556f23c44e99bce5894aafa9c448_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzUtMTAtMS0xLTQ1MzM0_3c8d882f-a81f-41e7-a635-7b5fca83392b"
      unitRef="usd">19200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5cb3556f23c44e99bce5894aafa9c448_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzA4YmM3MDYwMTg0ZjZlODQ4ODk4MjM4MzE0N2M1Ny90YWJsZXJhbmdlOjMzMDhiYzcwNjAxODRmNmU4NDg4OTgyMzgzMTQ3YzU3XzUtMTItMS0xLTQ1MzM0_33eede96-e97e-4b30-a166-3073ab51cb9e"
      unitRef="usd">1124000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i46cfa718400a42c5a9f24fb1d208bf44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzItNi0xLTEtNDUzMzQ_ba8e111c-352b-4c30-aeb2-daf5822e3e38"
      unitRef="usd">784000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i46cfa718400a42c5a9f24fb1d208bf44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzItOC0xLTEtNDUzMzQ_79e96c6c-33be-4e09-b07f-ab766849b594"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i46cfa718400a42c5a9f24fb1d208bf44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzItMTAtMS0xLTQ1MzM0_448f9b6a-2c41-4573-a635-072e87b846fc"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46cfa718400a42c5a9f24fb1d208bf44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzItMTItMS0xLTQ1MzM0_0f81d7e1-fcf5-4bb2-8ace-d8cc7dc8fbca"
      unitRef="usd">783300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i49bcbdd1acfc42b186645d856f68c30a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtNi0xLTEtNDg2MjM_84dbd29a-01bb-4ae8-9062-cabc460b9020"
      unitRef="usd">582500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i49bcbdd1acfc42b186645d856f68c30a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtOC0xLTEtNDg2MjM_455c6e0a-aac7-4d40-b1f3-cd48f99f3c3e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i49bcbdd1acfc42b186645d856f68c30a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtMTAtMS0xLTQ4NjIz_c2dd9caa-8697-4dca-9cd3-ecb74458ec34"
      unitRef="usd">3800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49bcbdd1acfc42b186645d856f68c30a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtMTItMS0xLTQ4NjIz_1b0e6e63-d627-4e81-956d-7f54d8ac3004"
      unitRef="usd">578700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ice07d9029aa84199ac8be838d60ae4a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzQtNi0xLTEtNDg2MjM_eee08b08-e27c-47c5-bd75-69f997b97aa7"
      unitRef="usd">32400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ice07d9029aa84199ac8be838d60ae4a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzQtOC0xLTEtNDg2MjM_35114fc4-2d63-4076-a848-c17b50e492ae"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ice07d9029aa84199ac8be838d60ae4a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzQtMTAtMS0xLTQ4NjIz_37b22a82-5285-413f-b92b-ebd8acf1e1e3"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ice07d9029aa84199ac8be838d60ae4a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzQtMTItMS0xLTQ4NjIz_7d1e7478-826d-47f9-bfdd-46425f30ac85"
      unitRef="usd">32300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7090b40f62334eab9ab385c427bcecdd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtNi0xLTEtNDUzMzQ_993ae1c8-ca96-427e-86d7-a7d7ac66c67c"
      unitRef="usd">1398900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7090b40f62334eab9ab385c427bcecdd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtOC0xLTEtNDUzMzQ_78fa3c9b-f2f6-4c4d-8d18-4fb4bd66c8dd"
      unitRef="usd">0.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7090b40f62334eab9ab385c427bcecdd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtMTAtMS0xLTQ1MzM0_9ad265a7-d72f-4844-a4e3-ec2a32f19e8b"
      unitRef="usd">4600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7090b40f62334eab9ab385c427bcecdd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90YWJsZTozMzIyZDc4MTQ2NWE0NWJiYjRkN2EyYmEyZjYwYjQ2Ny90YWJsZXJhbmdlOjMzMjJkNzgxNDY1YTQ1YmJiNGQ3YTJiYTJmNjBiNDY3XzMtMTItMS0xLTQ1MzM0_c4112134-01c6-4bdc-ac2a-db4bfc2d02ed"
      unitRef="usd">1394300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i24c2800943e64589bfe1be38fdfcdeac_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTEvZnJhZzo0ZGQ5MDU2NGJhNjE0MzZhYjNkMTBhZmI5NjNhMTBmOS90ZXh0cmVnaW9uOjRkZDkwNTY0YmE2MTQzNmFiM2QxMGFmYjk2M2ExMGY5Xzg4MA_8a20a5e8-3e31-4455-afd2-f69698e5075b"
      unitRef="usd">264600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90ZXh0cmVnaW9uOjVkYTZiYzcyMWU0MTQxMDJhOTI0MjM0ZTMwMzI5MmNmXzIyNQ_c234ef06-3686-487d-aa6e-26debadd09ed">Property, Equipment and Leasehold Improvements &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Property, equipment and leasehold improvements, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense totaled $6.3 million, $4.8 million, and $3.2 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90ZXh0cmVnaW9uOjVkYTZiYzcyMWU0MTQxMDJhOTI0MjM0ZTMwMzI5MmNmXzIyNg_6ac68c49-fc98-4688-b7c8-3fa6c5394b4b">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Property, equipment and leasehold improvements, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i058eebe5acbf4e69a811a1f3713b1674_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzItMS0xLTEtNDUzMzQ_ad8d6d64-fae6-400d-8682-8dba02964dce"
      unitRef="usd">17100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i65535f62f10e4ef4870538c48dee40d7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzItMy0xLTEtNDUzMzQ_f803ebdd-cdba-49f0-afc8-ec8e19c30de3"
      unitRef="usd">13600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ida76e88673e6409baa83b50282beff61_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzMtMS0xLTEtNDUzMzQ_f12d7829-2c39-4d61-b6db-ad0020798a65"
      unitRef="usd">2000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0a77e93668514396822e5760f192b979_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzMtMy0xLTEtNDUzMzQ_b5c9e6a8-2b18-44c2-9f46-f32d048ddc22"
      unitRef="usd">1400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3a171973241c4a65b20f085ad93852a2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzQtMS0xLTEtNDUzMzQ_dd416532-6feb-41c6-ad15-e7001ec9d29b"
      unitRef="usd">10900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i80ab38e360f943d6a594d05213ee4b3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzQtMy0xLTEtNDUzMzQ_5959742d-e809-4825-8562-407445035851"
      unitRef="usd">8400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzUtMS0xLTEtNDUzMzQ_5b3fc561-aeba-4355-b223-ecd4658c10e3"
      unitRef="usd">30000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzUtMy0xLTEtNDUzMzQ_76748954-2fde-4d7c-8c6b-65f219d35688"
      unitRef="usd">23400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzYtMS0xLTEtNDUzMzQ_3038be96-d1b4-48ab-b4b3-f02c86d83cd8"
      unitRef="usd">16600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzYtMy0xLTEtNDUzMzQ_f28b6e79-9bce-465b-9835-4049196a1ce5"
      unitRef="usd">10700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzctMS0xLTEtNDUzMzQ_e28cfca4-2c70-4126-bc8a-af2d4bcaedae"
      unitRef="usd">13400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90YWJsZTphM2MwNmFmOGU5NjE0YTY3ODMwMDY5MDE2MWU3N2ZhZi90YWJsZXJhbmdlOmEzYzA2YWY4ZTk2MTRhNjc4MzAwNjkwMTYxZTc3ZmFmXzctMy0xLTEtNDUzMzQ_0b47a4d6-a6ac-4f98-9bd3-120d15677c6a"
      unitRef="usd">12700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90ZXh0cmVnaW9uOjVkYTZiYzcyMWU0MTQxMDJhOTI0MjM0ZTMwMzI5MmNmXzE2MQ_63e8b1ff-0a0e-4f51-87ed-f2ac7e3bb6b4"
      unitRef="usd">6300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90ZXh0cmVnaW9uOjVkYTZiYzcyMWU0MTQxMDJhOTI0MjM0ZTMwMzI5MmNmXzE2NQ_c7b92378-710b-43b5-b21b-b52513074e19"
      unitRef="usd">4800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTQvZnJhZzo1ZGE2YmM3MjFlNDE0MTAyYTkyNDIzNGUzMDMyOTJjZi90ZXh0cmVnaW9uOjVkYTZiYzcyMWU0MTQxMDJhOTI0MjM0ZTMwMzI5MmNmXzE3Mw_654c9011-59e8-4cbf-90fd-b75f27de8e57"
      unitRef="usd">3200000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjA_af99682b-dea5-407e-9adc-fc1c1264e336">Right-of-Use Assets and Liabilities&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commencement date in determining the present value of lease payments, which ranges from 3.0% &#x2013; 4.1%. Lease expense is recognized on a straight-line basis over &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the lease term. The Company considers options to extend or terminate the lease in recognizing ROU assets and lease liabilities when it is reasonably certain that such options will be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a lease arrangement, which was amended in August 2022, for approximately 160,000 square feet of laboratory and office space to be occupied in 2024. In connection with the signing of the lease and the related amendment, and at the Company&#x2019;s election to increase the landlord&#x2019;s contribution to the tenant improvement allowance, the Company initially issued a letter of credit totaling $4.5 million, which was subsequently increased to $5.5 million, collateralized by a certificate of deposit in the same amount, which is presented as restricted cash in the accompanying consolidated balance sheets. Once occupied, the base rent will range from $7.7&#160;million to $8.8&#160;million annually over a ten-year lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for its corpor&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ate office, laboratories and certain equipment, which expire no later than January 2026. The leases have a weighted average remaining term of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Supplemental non-cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets obtained in exchange for new lease obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <arvn:PercentageOfIncrementalBorrowingForLeasePayments
      contextRef="i079086717708440bbc6bde6339a2c26e_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDM3NDA_fdf78db0-34b4-4bfb-ba1f-3bbfc484565a"
      unitRef="number">0.030</arvn:PercentageOfIncrementalBorrowingForLeasePayments>
    <arvn:PercentageOfIncrementalBorrowingForLeasePayments
      contextRef="i435f3577adb6471086574fa92705b9b6_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDM3NTE_04806e0e-4d95-4b04-9863-d3eaa7fe01a1"
      unitRef="number">0.041</arvn:PercentageOfIncrementalBorrowingForLeasePayments>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i5bc16f834f8e48cca3a2cc04f3bdb2ab_I20210531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDM3NjU_38a0578d-ddfb-47b7-ad1d-c7f653b6137e"
      unitRef="sqft">160000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:DebtSecurities
      contextRef="i75b6e519c7cb4a81826452584ae57c12_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDQ3MDA_ac4b11bc-36e1-4fcb-9d6e-cc3854631ec4"
      unitRef="usd">4500000</us-gaap:DebtSecurities>
    <us-gaap:DebtSecurities
      contextRef="i172eba417a7443088682953acc866535_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDQ2ODg_14f2c724-00c1-4991-8474-368cc5992909"
      unitRef="usd">5500000</us-gaap:DebtSecurities>
    <us-gaap:LeaseCost
      contextRef="i78cc6c1900c646e7a686f9fcfb72aaf7_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDM3OTg_6ce30116-7e2f-42e0-98ac-b2fd988c5987"
      unitRef="usd">7700000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="iabe4cc386917403580675ce1a278cc64_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzE2NDkyNjc0NDM4MjU_feb20691-af2d-44e2-9247-e86e5565f728"
      unitRef="usd">8800000</us-gaap:LeaseCost>
    <arvn:BaseLeaseRentPeriod
      contextRef="if9675174a7b047df809244be6ddfdc48_D20210501-20210531"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjQ_0fb40080-f91b-4191-98d9-8f33aba1055a">P10Y</arvn:BaseLeaseRentPeriod>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjE_9aad5514-4a93-4d8b-9cc3-f54d5473970c">P2Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjU_f90ca5ec-5140-4a96-aeee-7d8fa68d408e">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTpkM2VmOTFmM2ZjZTg0MjFiYjY5NzAxOGYyMzVhMjExZS90YWJsZXJhbmdlOmQzZWY5MWYzZmNlODQyMWJiNjk3MDE4ZjIzNWEyMTFlXzItMS0xLTEtNDUzMzQ_4ea2cf1a-0ce4-4b80-ba09-919e50e250df"
      unitRef="usd">2100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTpkM2VmOTFmM2ZjZTg0MjFiYjY5NzAxOGYyMzVhMjExZS90YWJsZXJhbmdlOmQzZWY5MWYzZmNlODQyMWJiNjk3MDE4ZjIzNWEyMTFlXzItMy0xLTEtNDUzMzQ_cc21dbc9-eb04-4686-82c4-d7afd975f483"
      unitRef="usd">1400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTpkM2VmOTFmM2ZjZTg0MjFiYjY5NzAxOGYyMzVhMjExZS90YWJsZXJhbmdlOmQzZWY5MWYzZmNlODQyMWJiNjk3MDE4ZjIzNWEyMTFlXzItNS0xLTEtNDUzMzQ_dd07eb4e-85a4-4ea2-8dfc-0bef99c6a93d"
      unitRef="usd">1000000.0</us-gaap:OperatingLeaseCost>
    <arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjI_38156d3a-6649-470d-a6a5-e7eea5b76cf2">&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Supplemental non-cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets obtained in exchange for new lease obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzMtMS0xLTEtNDUzMzQ_44a41232-34dc-4a62-9b0f-7f8931ba7dfd"
      unitRef="usd">1900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzMtMy0xLTEtNDUzMzQ_abb0f647-a84e-4131-b15c-f07d7f60c620"
      unitRef="usd">1200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzMtNS0xLTEtNTU5MTg_8f16c9c6-947b-4a6e-8acd-fff82c92e57e"
      unitRef="usd">900000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzUtMS0xLTEtNDUzMzQ_bb8dd331-3196-420c-9ba0-14076372a19a"
      unitRef="usd">2400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzUtMy0xLTEtNDUzMzQ_d3fbc21c-b789-4d5d-88e8-dc0015d8fd6c"
      unitRef="usd">3200000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZTphNmE0MDhkMjE4MmE0MTdlYTg5MDM0NTQxYjg4NThlZS90YWJsZXJhbmdlOmE2YTQwOGQyMTgyYTQxN2VhODkwMzQ1NDFiODg1OGVlXzUtNS0xLTEtNTU5MjY_8c1173d5-3139-4d02-86c6-dead8bd13d0b"
      unitRef="usd">600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90ZXh0cmVnaW9uOmY5YzI3OTNlZTRjMTRiODFiOWUwYzJlOTVmYjE4MDQzXzIwNjM_87cd55a1-092c-4a0e-9dc5-f27f2dd34243">&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzEtMS0xLTEtNDUzMzQ_1ef0e1fe-7523-48f0-ba62-f82a1fac4b5a"
      unitRef="usd">2000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzItMS0xLTEtNDUzMzQ_a6010bc1-2639-40e5-8219-6614fe30cad2"
      unitRef="usd">2200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzMtMS0xLTEtNDUzMzQ_57c14298-e13c-432a-97d6-d3cd154f3ff9"
      unitRef="usd">500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzQtMS0xLTEtNDc3Nzg_f506d7a0-35fb-46f7-8cfe-c463ed0848e2"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzQtMS0xLTEtNDUzMzQ_3758403b-a10a-44e4-811f-eef697bc467b"
      unitRef="usd">4700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzUtMS0xLTEtNDUzMzQ_0009160e-6d38-40dd-b65a-6f686973899b"
      unitRef="usd">200000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNTcvZnJhZzpmOWMyNzkzZWU0YzE0YjgxYjllMGMyZTk1ZmIxODA0My90YWJsZToxNDcxMTRjMDE1NWE0MzAyOTBhOWVhNmM3ZmZmNDZmMC90YWJsZXJhbmdlOjE0NzExNGMwMTU1YTQzMDI5MGE5ZWE2YzdmZmY0NmYwXzYtMS0xLTEtNDUzMzQ_2ed16eac-b749-4bd7-a939-68b52b09e077"
      unitRef="usd">4500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90ZXh0cmVnaW9uOmUwNmI1ZDY1ODE1NDRlNjY5ZTY2NzBjZTM4NTU1MTA4Xzcy_62d00a76-41a0-4eb2-a294-33a2801097b9">Accounts Payable and Accrued Liabilities &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90ZXh0cmVnaW9uOmUwNmI1ZDY1ODE1NDRlNjY5ZTY2NzBjZTM4NTU1MTA4Xzcz_562a451c-c9dc-4772-8432-4862aba91f7a">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzItMS0xLTEtNDc0NTU_cc3a57e1-264f-46d8-afd3-fed0f31e10fa"
      unitRef="usd">5700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzItMy0xLTEtNDc0NTU_b31ceacf-b97f-430b-a6de-d6a50e7dc2dc"
      unitRef="usd">31300000</us-gaap:AccountsPayableCurrent>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzQtMS0xLTEtNDc1MDA_3d71c5ee-63fc-47e4-a650-df9e707de3ad"
      unitRef="usd">35900000</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzQtMy0xLTEtNDc1MDA_dc8ed1c3-265c-4c27-b052-6a0b376a3f67"
      unitRef="usd">9500000</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzItMS0xLTEtNDUzMzQ_59f92d42-798c-4ffb-853e-76f5d32f909f"
      unitRef="usd">18700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzItMy0xLTEtNDUzMzQ_af025c09-bf36-4a67-8075-cd10e56f5cf1"
      unitRef="usd">12400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzYtMS0xLTEtNTgxMjY_b6842064-4c95-46cf-b851-e65e84a9b8d1"
      unitRef="usd">10300000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzYtMy0xLTEtNTgxMjY_974bdb61-fe41-4c0f-9e64-01f3b38d6809"
      unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzQtMS0xLTEtNDUzMzQ_98d259b8-4cdc-4e5e-b6ac-d1f1b628692f"
      unitRef="usd">4100000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzQtMy0xLTEtNDUzMzQ_7adc3e97-d110-4215-84c6-8833c6d74484"
      unitRef="usd">1200000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzUtMS0xLTEtNDUzMzQ_b154c7b6-4acb-433c-b48b-cfe2a202f0c2"
      unitRef="usd">74700000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjMvZnJhZzplMDZiNWQ2NTgxNTQ0ZTY2OWU2NjcwY2UzODU1NTEwOC90YWJsZTphNTJhZjkzNWUxMDY0NWVjODc2MWI2NmI5NmYxMDA4Mi90YWJsZXJhbmdlOmE1MmFmOTM1ZTEwNjQ1ZWM4NzYxYjY2Yjk2ZjEwMDgyXzUtMy0xLTEtNDUzMzQ_3350d8ad-dea1-4c40-9797-06327df13237"
      unitRef="usd">54400000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE5OTQ_069dc3f8-31b5-4737-ae49-a732450f05bc">Long-Term Debt &lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered into an Assistance Agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space (the "Project"). Under the terms of the 2018 Assistance Agreement, the Company was entitled to borrow from the State of Connecticut a maximum of $2.0&#160;million, provided that the funding did not exceed more than 50% of the total Project costs. In September 2018, the Company borrowed $2.0&#160;million under the 2018 Assistance Agreement, bearing interest at 3.25% per annum with interest payments required for the first 60 months from the funding date. Thereafter, the loan will begin to fully amortize through month 120, maturing in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 2028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In April 2021, borrowings totaling $1.0&#160;million were forgiven by the State of Connecticut as the Company met certain employment conditions, as defined in the agreement. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028 with a default penalty of repayment of the full original funding amount of $2.0&#160;million plus liquidated damages of 7.5% of the total amount of funding received.&lt;/span&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with an Assistance Agreement with the State of Connecticut (the "Assistance Agreement") entered into in 2014, under which all the borrowings by the Company were forgiven in accordance with the Assistance Agreement, the Company is required to be located in the State of Connecticut through January 2024, with a default penalty of repayment of the full original funding amount of $2.5&#160;million plus liquidated damages of 7.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum future principal payments on long-term debt as of December&#160;31, 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the years ended December&#160;31, 2022 and 2021, interest expense was immaterial. During the year ended December&#160;31, 2020, interest expense totaled $0.1 million.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i076af9c270b244029a1fd9d8b3982564_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM2NzQ_1232c0d2-8773-4e7d-9511-8e1a8c905f38"
      unitRef="usd">2000000</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfMaximumFundingOnProjectCosts
      contextRef="i6661ad55442349ec8d7ed679ec7f076a_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM2OTI_c0a267b3-dd3a-42c6-b88f-a2f7bb2de255"
      unitRef="number">0.50</arvn:PercentageOfMaximumFundingOnProjectCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i53fe0650f7c54cf9ae9a1454d05ebdc7_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM3MTA_8368e3ee-ae72-41e7-9fea-d6b9cbf39d8c"
      unitRef="usd">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i53fe0650f7c54cf9ae9a1454d05ebdc7_I20180930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM3MzA_1502110b-6efe-4451-b0ab-8dae70e798d7"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <arvn:DebtInstrumentInterestPaymentsTerm
      contextRef="i3c91c1b5ea044c539a1158ebd4047fc5_D20180901-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzYyNA_0bfc5f40-943c-43e0-845e-31736efe7aeb">P60M</arvn:DebtInstrumentInterestPaymentsTerm>
    <arvn:DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod
      contextRef="i3c91c1b5ea044c539a1158ebd4047fc5_D20180901-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzcxNA_e82b24e5-9592-4e28-9a67-af486c7564e9">P120M</arvn:DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod>
    <arvn:DebtInstrumentLoanForgiveness
      contextRef="i477280be32f04a07b28c112beeada17e_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM5Nzk_c30da163-25bb-4de6-8060-6d6c496a8323"
      unitRef="usd">1000000</arvn:DebtInstrumentLoanForgiveness>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i53fe0650f7c54cf9ae9a1454d05ebdc7_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM4MjY_0d16d08b-3a4c-46fd-90e8-60e424a80d14"
      unitRef="usd">2000000</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfLiquidatedDamages
      contextRef="i3c91c1b5ea044c539a1158ebd4047fc5_D20180901-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM4NDU_dfee313a-d795-4aff-8c11-066f77d25d0c"
      unitRef="number">0.075</arvn:PercentageOfLiquidatedDamages>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1d949a3402824e308e36a3888973c554_I20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM4NjQ_6fdafe3f-6b9c-4e24-8615-d2a3db49d7a7"
      unitRef="usd">2500000</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfLiquidatedDamages
      contextRef="if2470b93587642ee93b6862f8c50a373_D20140101-20141231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE2NDkyNjc0NDM4ODM_99df6030-15a3-4e1f-a865-fa2aaa695a7e"
      unitRef="number">0.075</arvn:PercentageOfLiquidatedDamages>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE5OTU_6f066fba-d929-4537-8e86-76f64c53e577">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum future principal payments on long-term debt as of December&#160;31, 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzEtMS0xLTEtNDUzMzQ_d36bb1fa-ddcf-4098-968c-98e845cb7381"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzItMS0xLTEtNDUzMzQ_3aae8e91-03c0-40f4-8f20-2b3158e53350"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzMtMS0xLTEtNDUzMzQ_671dfd94-6e3d-47cc-8e73-e041a6504414"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzQtMS0xLTEtNDUzMzQ_39d26d32-c671-4342-bd04-db56ee1c6e5b"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzUtMS0xLTEtNDUzMzQ_5ac83b32-f6ed-4254-9a28-e26ba9f4aa28"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzYtMS0xLTEtNDUzMzQ_fc45728f-6c5c-4ddc-b84a-0e053c4e372f"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90YWJsZTplMTVmZDFhZGFlZDU0YTE3YjAzYzFiOGExNzhiYzBkNi90YWJsZXJhbmdlOmUxNWZkMWFkYWVkNTRhMTdiMDNjMWI4YTE3OGJjMGQ2XzctMS0xLTEtNDUzMzQ_7a12c4fa-0e80-4da6-bb03-cf73dd26ae8a"
      unitRef="usd">1000000.0</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjYvZnJhZzplYjZhNzhjYzJjZjI0ZjliYjNmODg0OGY2OTJlMGVmMC90ZXh0cmVnaW9uOmViNmE3OGNjMmNmMjRmOWJiM2Y4ODQ4ZjY5MmUwZWYwXzE5Nzc_d8363b70-ab06-4b0f-a042-dfcb7b944bb1"
      unitRef="usd">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMTY_f95b013e-36fb-41f1-a08b-b70130e174d5">Equity &lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022 and 2021, the Company had authorized 200,000,000 shares of common stock, at a $0.001 par value per share. The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. The holders of shares of common stock are entitled to receive dividends, if and when declared by the Board of Directors. No dividends have been declared or paid by the Company since its inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, in connection with the Pfizer Stock Purchase Agreement, the Company issued &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,457,815&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of common stock to Pfizer at a price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$101.22&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share, which resulted in aggregate gross proceeds of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$350&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, less financial advisor fees of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.6&#160;million, as further described in Note 3 to our consolidated financial statements&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Pursuant to terms of the Pfizer Stock Purchase Agreement, Pfizer has agreed not to sell or transfer the Shares without prior written approval of the Company for a specified period, subject to specified exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company completed a public offering in which the Company issued and sold 6,571,428 shares of common stock at a public offering price of $70.00 per share, which resulted in aggregate gross proceeds of $460.0 million before underwriter discounts, commissions, and offering costs of $28.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Distribution Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp;amp; Company (&#x201c;Piper Sandler&#x201d;) and Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $300.0&#160;million of the common stock registered under the universal shelf registration statement pursuant to one or more &#x201c;at-the-market" offerings. During the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, no shares were issued under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company entered into an Equity Distribution Agreement (the "Distribution Agreement") with Piper Sandler, pursuant to which the Company could offer and sell from time-to-time in an &#x201c;at-the-market offering,&#x201d; at its option, up to an aggregate of $100.0&#160;million of shares of the Company&#x2019;s common stock through Piper Sandler, as sales agent. During year ended December 31, 2020, the Company sold 2,593,637 shares of its common stock resulting in proceeds to the Company of $64.1&#160;million, net of offering costs of $1.6 million. The Company terminated the Distribution Agreement in August 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company's common stock. The number of shares of the Company's common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company&#x2019;s then-outstanding common stock, effective as of January 1 of each year. As of December&#160;31, 2022, 1,986,565 shares remained available for purchase. During the years ended December&#160;31, 2022, 2021 and 2020, the Company issued 24,898, 19,357 and 11,046 shares, respectively, of common stock under the 2018 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive Share Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Fourth Amendment to the Company&#x2019;s Incentive Share Plan (the "Incentive Plan") adopted in March 2018, the Company was authorized to issue up to an aggregate of 6,199,477 incentive units pursuant to the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQ2Mjg_cc30fc57-88bc-4fe7-a68a-ecb6f7074afc"&gt;one&lt;/span&gt; to four years. The Incentive Plan was terminated in September 2018.  In September 2018, each outstanding incentive unit was converted into a number of shares of common stock based upon the IPO price. Certain of the shares of common stock issued in respect of incentive units continued to be subject to vesting in accordance with the vesting schedule that was applicable to such incentive units through the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s stockholders approved, the 2018 Stock Incentive Plan (the "2018 Plan"), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#x2019;s IPO. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181 shares) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each year beginning with the year ended December 31, 2019 and continuing to, and including, the year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company&#x2019;s common stock, 4% of the number of shares of the Company&#x2019;s common stock outstanding on the first day of the year or an amount determined by the Company&#x2019;s board of directors. As of December&#160;31, 2022, 2,048,284 shares are available for issuance under the 2018 Plan. Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or cancelled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized compensation expense of $75.5 million, $57.1&#160;million and $30.2 million, respectively, related to the issuance of incentive awards, including $0.7&#160;million, $0.3&#160;million and $0.3&#160;million, respectively, related to the 2018 ESPP. As of December&#160;31, 2022, there was $67.3 million of compensation expense that is expected to be recognized over a weighted average period of approximately 1.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted during each of the years ended December&#160;31, 2022, 2021 and 2020 was determined using the Black-Scholes option pricing model at the grant date with the following range of assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73% - 76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74% - 78%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70% - 75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5% - 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5% - 1.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3% - 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36.79 - $78.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$66.82 - $100.40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$22.70 - $50.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the Company&#x2019;s common stock has not been trading for a sufficient period of time, the Company calculates volatility of its common stock by utilizing a weighted average of a collection of peer company volatilities and its own common stock volatility. The expected term is calculated utilizing the simplified method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2022 is presented below. These amounts include stock options granted to employees, directors and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;br/&gt;except weighted average exercise price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,343,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,814,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,601,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2022, 2021 and 2020 was $39.17, $52.85 and $27.45, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020 was $7.9 million, $46.9 million and $19.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, $53.8 million of total unrecognized compensation cost related to non-vested stock options granted under the 2018 Plan is expected to be recognized over a weighted average period of approximately 1.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ere &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,540,844&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; stock o&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ptions under the 2018 Plan that have vested or are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted stock award activity under the Incentive Plan as of December&#160;31, 2022 is presented below. These amounts include restricted stock granted to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value Per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested restricted stock as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested restricted stock as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock unit activity under the 2018 Plan for the year ended December&#160;31, 2022 is presented below. These amounts include restricted stock units granted to employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value Per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested restricted stock units as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested restricted stock units as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, $13.5 million of total unrecognized compensation cost related to non-vested restricted stock units granted under the 2018 Plan is expected to be recognized over a weighted average period of approximately 2.1 years.&lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2022, there were 414,450 restricted stock units under the 2018 Plan that have vested or are expected to vest.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyODA1Nw_46d5460e-ada9-402c-ae2b-58d8e328a73e"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyODA1Nw_d9020ae7-949b-4583-91b1-309fa44f2b8a"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzY1Mg_18ddcf86-68c9-4d6f-93d8-2a993901645c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzY1Mg_6c783322-1ccd-4f3e-af23-07b9d280ada5"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <arvn:NumberOfVotesPerCommonStockShareHeld
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzMyOTg1MzQ4OTc5NzU_3ad6c560-9e57-49c2-b64d-45dd023a104b"
      unitRef="vote">1</arvn:NumberOfVotesPerCommonStockShareHeld>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzEyMw_d8e109e9-d456-4842-92cb-037fe66f1c99"
      unitRef="shares">3457815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i008bbd6d947d479fad8e8cd49d905905_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzE3Mw_fba5ba53-aed6-4421-881e-3c6d616359c2"
      unitRef="usdPerShare">101.22</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyODU2Mw_ab901300-e00c-40df-91d1-80c469b7b11c"
      unitRef="usd">350000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsForBrokerageFees
      contextRef="i49f4a72ec629422dafd039f183564403_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzI2OA_be82301e-c190-479b-9d71-456ed02300ce"
      unitRef="usd">4600000</us-gaap:PaymentsForBrokerageFees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib169c00592d548a6a517237266872f3e_D20201201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzE0MzQ_5436982f-b827-4205-b0f6-82c0e882438d"
      unitRef="shares">6571428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i2c3f132181ab4f2782eda83c630d9771_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzE0OTA_badb7957-9610-49b2-8041-961e6d1429a9"
      unitRef="usdPerShare">70.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ib169c00592d548a6a517237266872f3e_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzE1NTA_a06d6e33-0d22-4f5f-a88d-fbeb2f1b1dfb"
      unitRef="usd">460000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="ib169c00592d548a6a517237266872f3e_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzE2MTg_ac9be2b6-5e0a-4d81-ba21-cbe0f7a4f8d2"
      unitRef="usd">28100000</us-gaap:PaymentsForUnderwritingExpense>
    <arvn:MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement
      contextRef="i3746b160a6d94d569ae602cad6e75837_I20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzI2NjA_a925f84c-23db-47a9-8537-96b8b5799688"
      unitRef="usd">300000000</arvn:MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i991152e66e4e40e9bc87485ec165e1ad_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzI4MjA_77a773c9-98bb-46a7-a26e-8bd9051825f2"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2470ca2aeec0492f9ed6572c69865095_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzI4MjA_f0c8cd6f-42c0-4d0d-a9c4-b83765eb7a05"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <arvn:MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement
      contextRef="i96b0bd17747b4688858d04a773ba7ca5_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzMxMjg_bff78faa-7486-426b-9614-e6fcddf4f5b8"
      unitRef="usd">100000000</arvn:MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7510f41e99a44e9ca02267aa1713991c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzMyNjQ_be6dcc49-9abc-49bb-aa8e-572e99e221a0"
      unitRef="shares">2593637</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7510f41e99a44e9ca02267aa1713991c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzMzMzQ_a799a8fa-90d0-470e-b45a-155aea2e6b0a"
      unitRef="usd">64100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i7510f41e99a44e9ca02267aa1713991c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzMzNjM_49b560ae-9919-4634-94b9-7191b6da7682"
      unitRef="usd">1600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i31413367d46d44f0931cd3029d3ff4ef_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzM3NjY_87eb0f88-f3f5-4228-ad31-1c22afdf0d06"
      unitRef="shares">311850</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock
      contextRef="ibe1acbc8a7b44d439c12403bc1c92244_D20200101-20200101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzM5ODE_f2669101-eaa9-439a-8a3b-81c011958d51"
      unitRef="number">0.01</arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iec89f9a651ba481db8272f35c6c0df8e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQwODI_5991d666-f915-4426-9fc8-fc863ad219d3"
      unitRef="shares">1986565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i639e7b73e496499384ef668da7babf51_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQxNzg_8346b4c4-7aa1-490a-a54b-23489a22c25d"
      unitRef="shares">24898</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i49494ba6d0a5453c93d7b34884260277_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQxODU_0d327ce0-c3ae-4ea4-9708-748d9d6f7200"
      unitRef="shares">19357</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6dcf04ef5c59465f95dac5b9e575482f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzAzMg_cf60080c-1d41-4abc-ae16-e781aff25fda"
      unitRef="shares">11046</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia846f83b7f644f2a8e79d0645dc59a76_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzQ0MzQ_0e9604bb-8cd6-4388-af25-29cb70b778d0"
      unitRef="shares">6199477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if26c93c17a9d49abbe7e03e1fcfe3fdc_D20180301-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMjE_ced4ec46-9b39-4a55-938b-c78131985f19">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7ab2311054644dec946b5c3b15b4ac53_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTY_764b6596-119f-47b3-98df-02caf0e794f4"
      unitRef="shares">4067007</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="idf4d92b3f5524d2ca5cfdb2b7d2ecc62_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU1NzY_4329b552-f901-4b64-aa56-67cfc849cbf5"
      unitRef="shares">1277181</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="ic70f3f6fa6df4c48b0dda80d2a243089_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzYxMzQ_9f34e2f5-7a27-45af-9833-21f725c48b2c"
      unitRef="shares">4989593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i3160983fd398465eb653ad6cd4b8665c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzYxNzU_7692b14d-a3b4-4278-bbc9-e93698bae51c"
      unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i3f56a6f1dc8a4a1cb8a2a3b2b8c32f00_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzYzNDQ_2dd13f90-8b76-48a4-9d49-371267feee9f"
      unitRef="shares">2048284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzY3MDU_3bc7d15c-d222-49c7-a78a-a4f16a6b3de5"
      unitRef="usd">75500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzY3MDk_5277b792-e536-4d7b-9274-9a8cddaf4b66"
      unitRef="usd">57100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzY3MTY_04e5e249-8e33-4bce-890e-9e75739b2e5a"
      unitRef="usd">30200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if489ed4aaa6246e6bd13294c53489cff_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzA4MA_008f5773-09fe-491f-b516-62c3a856205d"
      unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaf5f5dfe6c4149dba9168a6e138aad59_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzA4NQ_ce561555-45ea-47e3-9e2e-816927e88e24"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf91003a0cee40d78e7d885446a5b900_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNzA5NA_2f51eba3-0e66-496d-a0c0-c3fdc7f3adc2"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzY5MDM_216a4418-a6de-4fa3-9eec-a9748f7f6ba3"
      unitRef="usd">67300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1574e37a15e549dfb509f0a9a114356d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNDkxNg_94da43db-3bbe-4679-b32a-cb5529934c65">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMjI_b29d0ec9-8372-4dbd-9e00-5218c259040a">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted during each of the years ended December&#160;31, 2022, 2021 and 2020 was determined using the Black-Scholes option pricing model at the grant date with the following range of assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73% - 76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74% - 78%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70% - 75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5% - 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5% - 1.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3% - 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36.79 - $78.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$66.82 - $100.40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$22.70 - $50.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpkMDAwZTIzMmY4ZDY0NzM3YjY3NjFmZjFkNWMxMzUzMF80_209d2b24-c2a5-47b6-9900-5d35aeae7005"
      unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpkMDAwZTIzMmY4ZDY0NzM3YjY3NjFmZjFkNWMxMzUzMF85_908911d2-b6c9-44ab-bdbe-5c1d9ca67339"
      unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiY2UxMWNiNmU1MWQ0ZGIwYTZkYjc4MDdiYmVhYTQwNF80_f63415e1-07f5-4434-a3ce-a5d0dd83cfab"
      unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiY2UxMWNiNmU1MWQ0ZGIwYTZkYjc4MDdiYmVhYTQwNF85_fca7355f-5344-4041-af01-0d843839ee4f"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiZDdmMmJlNTgyZWM0ZTQyOWRjMTlmMjI2ZGJkNjZhZV80_5bfafefb-52d2-4ae2-8a00-510f45194d53"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzItNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiZDdmMmJlNTgyZWM0ZTQyOWRjMTlmMjI2ZGJkNjZhZV85_5e35aa59-e22f-4d06-be2b-25bb7ac04d9b"
      unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i354e561295fa4c89814e4858d5d58e62_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjoyMmJkMTkzZWU0ZjI0ZWYzODVmOTU0MTUzYzI0YWQzN180_2db7606c-6a59-422f-bbed-ba9e6c821c37">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i09e4011096b842ed87640ac7cc8d1cb1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjoyMmJkMTkzZWU0ZjI0ZWYzODVmOTU0MTUzYzI0YWQzN185_dfe8172b-72b2-46f9-ac96-cba3bd9e1a25">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia382a82cd26a4f6289ea15987b91a7b7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjozOWY1YzMyMWFhM2Y0ZjE0YmFkNjEyYTUzYzg5MTAxMF80_6a71e450-f9de-4264-8294-09ca86785ae1">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib731e741df304e76af7f4302010536a3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjozOWY1YzMyMWFhM2Y0ZjE0YmFkNjEyYTUzYzg5MTAxMF85_88e8cbbf-4075-46ce-bff6-b53336f46be2">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic8a73ff779bf416cb4eebeeae68b3d11_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjowZjIxNGUzZTg0Yzk0OTI5ODJmZDcxMjA5MTQ0ZWQ3M180_20f230b3-76a1-4c05-ba64-638fe672df81">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7e4ccd6ef3f64b6b9e8ca76e68ac3d86_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzMtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjowZjIxNGUzZTg0Yzk0OTI5ODJmZDcxMjA5MTQ0ZWQ3M185_926a61d5-7773-4916-98eb-aa1ae168e3b2">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjoxNGI5NzU0Mjc2ZDc0ZmFjYTMwMDEzYjg2OTNlMDYzZl80_6a9a9b96-134f-4ca6-ba0d-e07afec20788"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjoxNGI5NzU0Mjc2ZDc0ZmFjYTMwMDEzYjg2OTNlMDYzZl85_be22e1e3-5c89-4592-8075-a88045406193"
      unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiNzcyMTBhZTc3ODE0ZjM4YWRhMTM1ODYwYmZmYzU0Zl80_3c31b9c1-a892-4b83-a343-810bcb80da05"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpiNzcyMTBhZTc3ODE0ZjM4YWRhMTM1ODYwYmZmYzU0Zl85_e470139f-3103-46ed-85ea-61f0c6192e24"
      unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo3MWE1MzhlOTkzMmE0M2I1OGMwYmU4OTk4YWFlYzg3OV80_8ceaab11-ed26-4b78-8045-6dbc5795630b"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzQtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo3MWE1MzhlOTkzMmE0M2I1OGMwYmU4OTk4YWFlYzg3OV85_66d93768-371f-4e0f-88f0-d86e2ee264d6"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzUtMS0xLTEtNDUzMzQ_3b6033b6-8e78-4989-b4ee-638fac28dbdc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6f7380290eb943568344b076b3cf1d42_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzUtMy0xLTEtNDUzMzQ_40bb031f-4e3f-40b7-96cd-66379fdc1ba1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i386aca24dfb7452b961230dff6bf4586_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzUtNS0xLTEtNDUzMzQ_eac6ddee-48a7-470e-8da6-24729a5acb5c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i7b0ed0665f494c7c902dffd54470764e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo0ZmZiNWQ5Y2E2YzM0NmZmOTZhYzJjZDAxZDQ4ZGQxM180_32f2991a-6817-4335-946a-2017472f9a79"
      unitRef="usdPerShare">36.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ib7a433e284fc436190fc991a5d7d1826_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtMS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo0ZmZiNWQ5Y2E2YzM0NmZmOTZhYzJjZDAxZDQ4ZGQxM185_934dda9b-d68c-4868-990a-d5cc680b2edb"
      unitRef="usdPerShare">78.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ideae804a84b646ac95f9d6e31422f985_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo1ZWJhMTEzMzg2YzM0NjIwOGNjMTlhYWY5NWJiYzc1Nl80_6c8be5e7-952a-40e3-b058-2aaccfd3985f"
      unitRef="usdPerShare">66.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ife9054bd93cd4ee890d1bb3769253bbc_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtMy0xLTEtNDUzMzQvdGV4dHJlZ2lvbjo1ZWJhMTEzMzg2YzM0NjIwOGNjMTlhYWY5NWJiYzc1Nl85_6ced06b1-705f-405c-bfbd-252e264a4646"
      unitRef="usdPerShare">100.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i5d25eae66f4940efbc51ec06b70565d7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpmMDczMTMzNDBlMzQ0Njk4OWYzY2M3NGE2NjJmNTQxMV80_8956db7b-b343-44c8-8644-23ff6f403f9a"
      unitRef="usdPerShare">22.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i1b0c4960152f4b068f2e7ff788c1f577_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTo2MGQ0YjQzMTljYWI0NzQ5YjA4MDkzMDY2MjllYTBkMC90YWJsZXJhbmdlOjYwZDRiNDMxOWNhYjQ3NDliMDgwOTMwNjYyOWVhMGQwXzYtNS0xLTEtNDUzMzQvdGV4dHJlZ2lvbjpmMDczMTMzNDBlMzQ0Njk4OWYzY2M3NGE2NjJmNTQxMV85_10ab2ca4-9484-48de-89b9-7fa0293b7d7d"
      unitRef="usdPerShare">50.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzI3NDg3NzkwODAwOTg_c2a06dcb-d22e-408c-a3e3-1e6b7b9a9a06">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2022 is presented below. These amounts include stock options granted to employees, directors and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;br/&gt;except weighted average exercise price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,343,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,814,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,601,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMTk_2a82e4a6-c4de-4613-9272-c0aa9b98ba4d">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2022 is presented below. These amounts include stock options granted to employees, directors and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;br/&gt;except weighted average exercise price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,343,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,814,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,601,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i07de6ac05c1e41a9b8b94c23de19c282_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzEtMi0xLTEtNDUzMzQ_8395540c-5213-4bcc-9685-c614f26e475d"
      unitRef="shares">5343254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i07de6ac05c1e41a9b8b94c23de19c282_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzEtNC0xLTEtNDUzMzQ_eeb53283-a339-4c1b-bf80-65389d09e135"
      unitRef="usdPerShare">44.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzItMi0xLTEtNDUzMzQ_9d1e741f-9ba7-4094-af4e-3096668d402e"
      unitRef="shares">1889501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzItNC0xLTEtNDUzMzQ_2f59df85-6fe4-4351-9289-8bcfa483325e"
      unitRef="usdPerShare">59.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzMtMi0xLTEtNDUzMzQ_d3a62e5c-36f4-4f44-8dcb-1917974e905d"
      unitRef="shares">184160</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzMtNC0xLTEtNDUzMzQ_ff3930eb-ece5-4a82-b535-130c7740c7bf"
      unitRef="usdPerShare">19.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzQtMi0xLTEtNDUzMzQ_093ab10c-c3f7-4e93-8115-453e09a9628e"
      unitRef="shares">233961</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzQtNC0xLTEtNDUzMzQ_a951eab3-65ec-4234-a441-be0a0cd67433"
      unitRef="usdPerShare">61.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzUtMi0xLTEtNDUzMzQ_1edd45df-223c-4ccd-b6fa-9dbc964e3368"
      unitRef="shares">6814634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzUtNC0xLTEtNDUzMzQ_3a6b36a5-8644-42a9-92fb-75ce70d38fe9"
      unitRef="usdPerShare">49.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzUtNi0xLTEtNDUzMzQ_bfaeaf4e-c6e6-4f1f-825a-a88c2b23d5c7">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzUtOC0xLTEtNDUzMzQ_28d3f07c-1e3b-41ec-9f84-25bf0ec235f4"
      unitRef="usd">34500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzYtMi0xLTEtNDUzMzQ_cb0e0f2f-f1de-4c77-b76a-5ad721b1d566"
      unitRef="shares">3601334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzYtNC0xLTEtNDUzMzQ_0a8d815e-5e9d-4d57-863e-e677d49bf9a0"
      unitRef="usdPerShare">37.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzYtNi0xLTEtNDUzMzQ_1e8d29e6-c682-4626-bf4f-9245c66f397e">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZToxZmNkZWZiYTQ3MGI0NDk2OWE1NmExM2M4NWJkNDZkNC90YWJsZXJhbmdlOjFmY2RlZmJhNDcwYjQ0OTY5YTU2YTEzYzg1YmQ0NmQ0XzYtOC0xLTEtNDUzMzQ_3d2d121b-3c12-44be-a136-0436b3acdb4f"
      unitRef="usd">33000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc4NDA_4d28d286-015f-45b3-82f8-a4968fb31663"
      unitRef="usdPerShare">39.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc4NDQ_f79f7160-70ce-49e1-98f4-407e6a0c63e4"
      unitRef="usdPerShare">52.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc4NTE_ce729dbc-0181-48cf-9fdf-4d6f2351424f"
      unitRef="usdPerShare">27.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc5NTc_74571ea5-e550-46fc-9e52-48df58f36e0f"
      unitRef="usd">7900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc5NjE_28825a2b-4dd3-40d8-b49e-808f8be75f8c"
      unitRef="usd">46900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzc5Njg_b50e9b7c-5f88-4376-b290-0638b9736a17"
      unitRef="usd">19400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i3f56a6f1dc8a4a1cb8a2a3b2b8c32f00_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzgxNDY_17f05e70-842c-4d12-9cd7-295e724b24fd"
      unitRef="usd">53800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib3b24196f7ab4e96948b59541f2a2454_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMTc_c3eb7e77-91e0-46a6-952a-be6af744c8c3">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i3f56a6f1dc8a4a1cb8a2a3b2b8c32f00_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzgzMTg_3d034661-16a6-4e6a-8555-b98c8d882709"
      unitRef="shares">6540844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i825713991b7d4d6ca930134e1ea64f3b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMjA_4121cbf0-69d7-488a-98f4-ed2ff1a282af">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted stock award activity under the Incentive Plan as of December&#160;31, 2022 is presented below. These amounts include restricted stock granted to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value Per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested restricted stock as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested restricted stock as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i64e8a70e80d34c36a994fb20b47a535c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzEtMi0xLTEtNDUzMzQ_db24c702-bc4d-4375-b144-bfc4ba0d8511"
      unitRef="shares">30625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i64e8a70e80d34c36a994fb20b47a535c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzEtNC0xLTEtNDUzMzQ_650269f2-5429-4e34-af28-5bdbdfb2d76a"
      unitRef="usdPerShare">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9135a832bfa141bdaea8cd60e7266128_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzItMi0xLTEtNDUzMzQ_1cea7725-1543-4c56-899a-db99a32f0d75"
      unitRef="shares">29305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9135a832bfa141bdaea8cd60e7266128_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzItNC0xLTEtNDUzMzQ_b34ce6c7-a1e7-4f2a-8bc4-dd91a44983c7"
      unitRef="usdPerShare">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9135a832bfa141bdaea8cd60e7266128_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzMtMi0xLTEtNDUzMzQ_38821583-7716-4ae3-b282-0436081ab94c"
      unitRef="shares">1320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i9135a832bfa141bdaea8cd60e7266128_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzMtNC0xLTEtNDUzMzQ_8e8f2c6d-fdd1-4c06-b9a2-d4f6a0e6d48a"
      unitRef="usdPerShare">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idbbd49660da24081b31f3017c1fb0202_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzQtMi0xLTEtNDUzMzQ_faaddd54-8531-43bd-9a3b-db14f58d017e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idbbd49660da24081b31f3017c1fb0202_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTowOWU4NjkwZjA3MGQ0OGQ0OTdlOTVmNjQ2ZTY4M2I1YS90YWJsZXJhbmdlOjA5ZTg2OTBmMDcwZDQ4ZDQ5N2U5NWY2NDZlNjgzYjVhXzQtNC0xLTEtNDUzMzQ_b73ade22-00f3-4dca-82cb-bac37114929d"
      unitRef="usdPerShare">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i81e6172dea754fde956550d07bd3297c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzkwMTg_94d505ab-887d-4c7c-9150-040850da293b">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock unit activity under the 2018 Plan for the year ended December&#160;31, 2022 is presented below. These amounts include restricted stock units granted to employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value Per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested restricted stock units as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested restricted stock units as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iee0ea6f5d3fd49e6bcd4ffc8b9e8f561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzEtMi0xLTEtNDUzMzQ_391065f0-a1a9-4fe9-b877-920bb7627f7f"
      unitRef="shares">88307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iee0ea6f5d3fd49e6bcd4ffc8b9e8f561_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzEtNC0xLTEtNDUzMzQ_e6fc6f25-144e-43f6-b69f-161af359cc5a"
      unitRef="usdPerShare">20.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzItMi0xLTEtNTExODA_79d83a20-9d48-4b8c-b08b-2d7be705538f"
      unitRef="shares">460763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzItNC0xLTEtNTExODA_407aab13-039e-4f3f-8a5e-2b98be4b8155"
      unitRef="usdPerShare">54.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzItMi0xLTEtNDUzMzQ_560befe9-6029-48b0-ab11-dde1f084af9b"
      unitRef="shares">42500</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue
      contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzItNC0xLTEtNDUzMzQ_8ffa7807-bd09-401b-ac7f-ff4ea412d202"
      unitRef="usdPerShare">20.04</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzMtMi0xLTEtNDUzMzQ_fcec601e-304b-4f59-bf5c-46832a3082c8"
      unitRef="shares">17354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ia342c776b5704bb28ffc26fed1e5be96_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzMtNC0xLTEtNDUzMzQ_9b6c9633-716f-46e8-aac4-7d2e9fbd438d"
      unitRef="usdPerShare">53.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6ba241f8483c4d27abe31fc22d087023_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzQtMi0xLTEtNDUzMzQ_95ab2bd8-e078-4c81-928d-19cd948b43fb"
      unitRef="shares">489216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6ba241f8483c4d27abe31fc22d087023_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90YWJsZTpjOTdlMWU5Zjk2MjQ0MDZmYmQ0YTE5ODMzZmY0MWRkMC90YWJsZXJhbmdlOmM5N2UxZTlmOTYyNDQwNmZiZDRhMTk4MzNmZjQxZGQwXzQtNC0xLTEtNDUzMzQ_cb0ada9f-2b53-4229-84a4-ae6e3d159643"
      unitRef="usdPerShare">51.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i19ac2aec78b54b438d208831130b52be_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNDg2Mg_8802c8c2-2507-4cc8-998c-a93ca25779f2"
      unitRef="usd">13500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9391f67286954fea9ef7f855af5453c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzU0OTc1NTgyNDg2Ng_83388bc4-26be-4df1-91cf-d7e756598c0e">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber
      contextRef="i3f56a6f1dc8a4a1cb8a2a3b2b8c32f00_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNjkvZnJhZzpkNTBmMDBkZTA3Zjk0NGJjYTQyMDE2ZDJlNzYyNDI1Yy90ZXh0cmVnaW9uOmQ1MGYwMGRlMDdmOTQ0YmNhNDIwMTZkMmU3NjI0MjVjXzg5Mjk_273d42e4-4486-42ba-a2b9-73e10eb7ee7c"
      unitRef="shares">414450</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzQwMTI_5a1b697c-103d-4eb0-95d0-ecc97a03a0d6">Equity Method Investments&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company and Bayer CropScience LP ("Bayer LP") formed Oerth Bio, a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. Pursuant to the terms of the joint venture agreement, the Company made an in-kind intellectual property contribution to Oerth Bio in the form of a license to certain of the Company&#x2019;s proprietary technology and Bayer LP committed and subsequently made cash contributions to Oerth Bio totaling $56.0&#160;million, as well as an in-kind intellectual property contribution. The Company and Bayer LP each held an initial ownership interest in Oerth Bio representing 50% of the ownership interests. A 15% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 46.5%, 48.4% and 49.4% as of December 31, 2022, 2021 and 2020, respectively, as a result of vested incentive units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the joint venture agreement, the Company has no obligation to provide additional funding and the Company&#x2019;s ownership interest will not be diluted from future contributions from Bayer LP. The activities of Oerth Bio are controlled by a management board under the joint control of the Company and Bayer LP. As Oerth Bio is jointly controlled by the Company and Bayer LP, the Company accounts for its interest using the equity method of accounting. The Company determined that Oerth Bio is a variable interest entity and, accordingly, the Company has evaluated the significant activities of Oerth Bio under the variable interest entity model and concluded that the significant activities consist primarily of research and development activities and, as the Company does not have the sole power to direct such activities, the Company is not the primary beneficiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the fair value of the equity interest it received in Oerth Bio in exchange for the license contributed totaled $49.4&#160;million. The fair value of Oerth Bio was determined utilizing discounted cash flows based on reasonable estimates and assumptions of cash flows expected from Oerth Bio. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue of $24.7&#160;million in 2019 attributable to the license contributed to Oerth Bio. In 2019, the Company also recognized $24.7&#160;million of equity in net losses of Oerth Bio reducing the carrying value of the Company&#x2019;s investment to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In connection with the preparation of the Company's consolidated financial statements for the yea&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;r ended December&#160;31, 2022, the Company identified a prior period error related to the accounting of its investment in Oerth Bio in 2019. Previously, the Company disclosed that revenue of $24.7&#160;million was deferred and would be recognized if and when Oerth Bio recognized revenue associated with the license. The Company has now determined that the consideration received for the amounts associated with the deferred revenue should have been constrained, because at the time Bayer LP had contributed only a portion of its full cash commitment to Oerth Bio, and Bayer LP had the right to all the cash contributed, but not yet spent, upon liquidation of Oerth Bio. The constrained revenue should have been recognized upon both cash being contributed by Bayer LP and the related cash spent by Oerth Bio on research and development activities. As such, the recognition of revenue is accompanied by corresponding equity method losses of the same amount for all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company ev&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;aluated the error&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd determined that the related impact did not materially misstate the previously issued condensed consoli&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dated financial statements for the years ended December 31, 2021 and 2020. Although the Company concluded that the error was not material to its previously issued consolidated financial statements, the Company has&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; determined it is appropriate to adjust its previously issued consolidated financial statements for the years ended December 31, 2021 and 2020 to correct&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the error and improve comparability&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The following illustrates the effect of the correction of the immaterial error for the period presented. There was no impact to the balance sheets, net loss per common share, statements of cash flows or changes in shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as previously reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as previously reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses and net loss of Oerth Bio for the years ended December 31 2022, 2021 and 2020 totaled $22.9 million, $14.3 million and $8.3 million, respectively. The Company recognized equity method losses of $10.6&#160;million, $6.9&#160;million and $4.1&#160;million for the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 2021 and 2020, respectively. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and 2021, the Company&#x2019;s carrying value of the investment was zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also provides Oerth Bio with compensated research and development and administrative services through a separate agreement. The se&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rvices rendered by the Company during the years ended December&#160;31, 2022, 2021 and 2020 were immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i2942bd6c0af14feca606f6c2cf37f948_I20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzE2NDkyNjc0NDYxNzM_aa066498-07b2-4cfe-9894-ab48fb6ef1ee"
      unitRef="usd">56000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2942bd6c0af14feca606f6c2cf37f948_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzE2NDkyNjc0NDYyMjE_c75d14a2-f96d-4bfe-a0a3-648372f19779"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage
      contextRef="ife636ddfe9704222b932ba3a4f39e4d6_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzE2NDkyNjc0NDYyMzA_640dcbc3-f513-43ba-9de7-7a0bb1f5481d"
      unitRef="number">0.15</arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0d437e8b17c84126a8ff5f6624f1cd05_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTg1ODA2Mg_1ca5d975-61c9-4c71-9de5-ca8749bcb7e1"
      unitRef="number">0.465</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i5d95876f6cfe490fb65fd87f81be2616_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTg1ODA2Nw_6bf88a75-6a2d-46f0-bb79-3e2fd5c97a62"
      unitRef="number">0.484</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifc24f8c5be114f76ab380633238bd2df_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTg1ODA3OQ_73fcad42-49f0-408f-853f-41133f341100"
      unitRef="number">0.494</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i808530cbe2df478ca19263be75cce162_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgyMDg3Nw_3ec6fe28-2003-4cd3-9415-8068b1ae663f"
      unitRef="usd">49400000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i7ce462a88c514f3db5b77585aa66ba25_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgyNTI4Mw_1291042d-6461-49f4-8f62-945597c8bad8"
      unitRef="usd">24700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7ce462a88c514f3db5b77585aa66ba25_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgyNTI5OA_af93bac1-b9a6-4e75-856f-98be292d7be3"
      unitRef="usd">-24700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9b75291c93af4cb4b6f481d140f1d96f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzIxOTkwMjMzMDA3NDU_d6ff3a96-059b-4b15-8d62-86de7baa1838"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i808530cbe2df478ca19263be75cce162_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgzNjQ5Mg_91770998-506c-44dc-977e-f94df41393f9"
      unitRef="usd">24700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMyOTg1MzQ5Mjc4NTI_3a1f796b-09bf-4203-9a70-75f9ea019e58">&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The following illustrates the effect of the correction of the immaterial error for the period presented. There was no impact to the balance sheets, net loss per common share, statements of cash flows or changes in shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as previously reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as previously reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:Revenues
      contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItMS0xLTEtNjAyOTQ_b7fa807b-416d-49bc-be3e-bd9db0353033"
      unitRef="usd">46700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItMy0xLTEtNjAyOTQ_8c70fd93-6285-4beb-b62e-b2184cdba88a"
      unitRef="usd">6900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItNS0xLTEtNjAyOTQ_cef98cbd-de1a-4336-9c4d-0e7c88a531e8"
      unitRef="usd">53600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItNy0xLTEtNjA0NDA_91069843-22ff-4e28-ac92-12f75c5c94b2"
      unitRef="usd">21800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItOS0xLTEtNjA0NDA_f4270fb6-6b53-416d-b244-eea329a70297"
      unitRef="usd">4100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzItMTEtMS0xLTYwNDQw_b6117a08-bd1c-4445-98be-49b934790d14"
      unitRef="usd">25900000</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtMS0xLTEtNjAyOTQ_7d9478e2-6106-49bb-ba2b-635b4798bf20"
      unitRef="usd">-195300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtMy0xLTEtNjAyOTQ_6734c19e-5941-49ff-8bef-6feb2f1d8b57"
      unitRef="usd">6900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtNS0xLTEtNjAyOTQ_4b77cac7-d2ef-4f3d-a612-758093f35e45"
      unitRef="usd">-188400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtNy0xLTEtNjA0NDg_939b5356-e5ab-47ff-8a37-be10b455cbea"
      unitRef="usd">-124900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtOS0xLTEtNjA0NDg_20ad8e2b-0728-4103-9891-4bb228e6cafe"
      unitRef="usd">4100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzMtMTEtMS0xLTYwNDQ4_4db3c6f4-23bf-41d7-84c7-24cbd978262a"
      unitRef="usd">-120800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtMS0xLTEtNjAyOTQ_7fad1350-443c-4405-a949-a73e64b48165"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtMy0xLTEtNjAyOTQ_0a96589d-f092-450f-b45f-ed155ccdeb06"
      unitRef="usd">-6900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtNS0xLTEtNjAyOTQ_b1373366-c2e9-4e1c-ae5d-9c1e67582c99"
      unitRef="usd">-6900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtNy0xLTEtNjA0NTY_4f519021-fd47-41e5-89af-bfb06b83eb64"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtOS0xLTEtNjA0NTY_75c0e1e7-80fe-4a7b-8286-7cf4bd1b7eb6"
      unitRef="usd">-4100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzQtMTEtMS0xLTYwNDU2_47ab6f9c-0522-4567-ace7-ecef2f2af1a0"
      unitRef="usd">-4100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtMS0xLTEtNjAyOTQ_101db2ce-6dfa-4b62-9e24-984eb4019206"
      unitRef="usd">-191000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtMy0xLTEtNjAyOTQ_a02cbc19-cb5b-47d2-85b0-a01376b686ef"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtNS0xLTEtNjAyOTQ_56f5a753-85f1-44ed-a992-3220c4d6953f"
      unitRef="usd">-191000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtNy0xLTEtNjA0NjQ_a965e58f-260f-4144-aa06-34ed3f9093e0"
      unitRef="usd">-119300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtOS0xLTEtNjA0NjQ_bf32ce17-dc15-4af6-a0c1-0645107e8c92"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzUtMTEtMS0xLTYwNDY0_e4ba3875-d6da-47e5-9182-005a62ce5982"
      unitRef="usd">-119300000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMS0xLTEtNjA0ODQ_1dac6700-b626-4455-9654-7f94aa7acd68"
      unitRef="usdPerShare">-3.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMS0xLTEtNjA0ODQ_b2291695-c9a6-4c01-8de9-64a8c4557a14"
      unitRef="usdPerShare">-3.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMy0xLTEtNjA1MDY_143605fa-6d36-456b-919f-41d7438da439"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMy0xLTEtNjA1MDY_a47af6ab-44a5-4794-a8a6-e5a8673ba398"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtNS0xLTEtNjA0OTA_4ec9f07f-0f25-454c-b8f7-fb25519067df"
      unitRef="usdPerShare">-3.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtNS0xLTEtNjA0OTA_7287cc69-44e6-40f3-a079-1bb1301f1d46"
      unitRef="usdPerShare">-3.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtNy0xLTEtNjA0OTU_631fb358-7e74-4e2c-8a5f-8383942113b3"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtNy0xLTEtNjA0OTU_9c473465-f848-491f-9050-f67d26cc9a46"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtOS0xLTEtNjA1MzE_03bf57d5-6413-45df-a57a-a152997952d7"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtOS0xLTEtNjA1MzE_2ff51ec5-3ad0-4c4e-9fcd-5372584b8f8b"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMTEtMS0xLTYwNDk5_64359b54-fdbb-4432-adfb-ea9a13e0c657"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzYtMTEtMS0xLTYwNDk5_708d9e00-5ca7-454a-b2d9-3b06879108d0"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctMS0xLTEtNjI4MTY_d613cc2c-36a6-44d2-bc6c-d1736b8f2c71"
      unitRef="usd">-196200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3a8e5aa0da1b4ac5ada599f62e05ea8c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctMy0xLTEtNjI4MTY_0cef6ff8-135d-49e0-8bd1-1e84c527a3c5"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctNS0xLTEtNjI4MTY_7ad94e3d-d99d-4cd3-9fcf-a7523f45c07f"
      unitRef="usd">-196200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6a596c4754f948a899d60103c138350e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctNy0xLTEtNjI4MTY_1bd04a5b-9497-48a8-b37b-c9af7f84307f"
      unitRef="usd">-118800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib4013772253f4f3592856bf3febc66a6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctOS0xLTEtNjI4MTY_9748fbd6-3410-461f-99fd-d81e1c67cdfe"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90YWJsZTo4MDE3NGQyZmRiYzA0ZWNmYjEwNmYzMzZlZTA2Y2E3ZS90YWJsZXJhbmdlOjgwMTc0ZDJmZGJjMDRlY2ZiMTA2ZjMzNmVlMDZjYTdlXzctMTEtMS0xLTYyODE2_403b0def-0295-4a4b-8f94-f17e18cf4f09"
      unitRef="usd">-118800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OperatingExpenses
      contextRef="idfbc96733ba14eacba1def4f1f53391f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxNzQ_3c7bb7eb-9def-464b-ad87-471831ce1796"
      unitRef="usd">22900000</us-gaap:OperatingExpenses>
    <us-gaap:ProfitLoss
      contextRef="idfbc96733ba14eacba1def4f1f53391f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxNzQ_d5315e65-3027-40dd-a6c6-0f3319a45b1d"
      unitRef="usd">-22900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0d1a440ff1814ec2b2967dbc51a0a62c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxNzg_70627fc3-51dc-472a-a763-a3647742b85b"
      unitRef="usd">-14300000</us-gaap:ProfitLoss>
    <us-gaap:OperatingExpenses
      contextRef="i0d1a440ff1814ec2b2967dbc51a0a62c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxNzg_a4e31c76-b3f3-473d-b602-072a1858fa95"
      unitRef="usd">14300000</us-gaap:OperatingExpenses>
    <us-gaap:ProfitLoss
      contextRef="i8f581941be6141b8a521496421ffb373_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxODU_7eb37fc2-38c1-4467-a3c8-f28af2ca169a"
      unitRef="usd">-8300000</us-gaap:ProfitLoss>
    <us-gaap:OperatingExpenses
      contextRef="i8f581941be6141b8a521496421ffb373_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzMxODU_de03e16f-401d-4adb-a3bc-e128c3a117d3"
      unitRef="usd">8300000</us-gaap:OperatingExpenses>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgzMTE3MQ_87bfd27b-e721-4cea-b925-8277fabf8267"
      unitRef="usd">-10600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgzMTE3OA_b1373366-c2e9-4e1c-ae5d-9c1e67582c99"
      unitRef="usd">-6900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzUvZnJhZzo4MGZlYzA4ODVkMGU0ODhhYTA5YTViMzQyMTAwYjkzNS90ZXh0cmVnaW9uOjgwZmVjMDg4NWQwZTQ4OGFhMDlhNWIzNDIxMDBiOTM1XzU0OTc1NTgzMTE4NQ_47ab6f9c-0522-4567-ace7-ecef2f2af1a0"
      unitRef="usd">-4100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzUxNTc_b78b39ec-48b5-4df1-97b1-be309b0f290c">Income Taxes &lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2022, income tax expense totaled &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$20.9 million, and consisted of the following:&lt;/span&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generated taxable income for the year ended December&#160;31, 2022 primarily due to revenue recognition for tax purposes from the ARV-471 Collaboration Agreement and the mandatory capitalization of qualified research and development expenses incurred on or after January 1, 2022, which, upon recognition for tax purposes, would create additional deferred tax assets. Under the Tax Cuts and Jobs Act of 2017, qualified research expenses incurred after 2021 are no longer immediately deductible for tax purposes and instead must be capitalized and amortized for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2021 and 2020, the Company had no income tax expense due to incurred operating losses. The Company had also not recorded any income tax benefits for the net operating losses incurred in each of those periods due to its uncertainty of realizing a benefit from those items. All of the Company&#x2019;s losses before income taxes were generated in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the years ended December&#160;31, 2022, 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities were as follows as of December&#160;31, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(243.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company has provided a valuation allowance against the full amount of the deferred tax assets since&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; it is more likely than not that the benefits will not be realized. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This assessment is based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All, or a portion of, the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to utilize these potential tax benefits. The valuation allowance increased by $104.0 million and $74.6 million in 2022 and 2021, respectively, due to revenue recognition for tax purposes from the ARV-471 Collaboration Agreement and the mandatory capitalization of qualified research and development costs in 2022, and increases in net operating loss carryforwards, tax credit carryforwards, stock compensation expense, and research and development tax credits in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had zero and $373.6 million of federal net operating loss carryforwards as of December&#160;31, 2022 and 2021, respectively. Federal net operating loss carryforwards as of December 31, 2017 expire at various dates through 2037 and federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such carryforwards is limited to 80% of the Company&#x2019;s taxable income in the year in which carryforwards are used. The Company had $63.4 million and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$346.9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of state and local net operating loss carryforwards as of December&#160;31, 2022 and 2021, respectively, that expire at various dates through 2041.  The Company had zero and $15.2 million of federal tax credit carryforwards as of December&#160;31, 2022 and 2021, respectively. The Company had $13.1 million and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.5 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of state tax credit carryforwards as of December&#160;31, 2022 and 2021, respectively, which expire at various dates through 2037.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company performed a Section 382 analysis to determine whether an ownership change occurred for tax purposes. Based on this analysis, the Company determined that ownership changes occurred on July 31, 2018 and December 31, 2020 due to various equity offerings, vesting of restricted stock awards and stock option exercises. These ownership changes resulted in Section 382 limitations on the Company&#x2019;s net operating loss and tax credit carryforwards generated before these dates. However, because the amount of the Section 382 limitations (including carryover of the unused Section 382 limitations and realized &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;built-in gains) exceeds the amount of the Company&#x2019;s carryforwards generated before these dates, the limitations will not affect the Company's ability to fully utilize these carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company complies with the provisions of ASC 740 in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. As of December&#160;31, 2022, the Company recorded net uncertain tax positions of $3.2&#160;million relating primarily to state income tax filing positions in various jurisdictions. As of December&#160;31, 2021, the Company had no unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's gross unrecognized tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning of period balance - gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for tax positions taken during the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases for tax positions taken during a prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;End of period balance - gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense. The Company's accrual for interest and penalties as of December&#160;31, 2022 was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to file income tax returns in the U.S. Federal and various state jurisdictions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Company&#x2019;s net operating loss carryforwards, the Company&#x2019;s federal and state statutes of limitations generally remain open for all tax years until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization. The Company does not currently have any federal or state income tax examinations in progress.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021, and 2020, the Company recorded a benefit from expected cash refunds to be provided by the State of Connecticut, equal to 65% of research and development credits, of zero, $1.6 million, and $1.8 million, respectively, which is included in Other income, net in the accompanying consolidated statements of operations and comprehensive loss, due to the Company being a state income and franchise taxpayer in 2022, and a state franchise taxpayer in 2021 and 2020. The benefit results from the exchange of the state research and development tax credit carryforwards for cash refunds. As of December&#160;31, 2022 and 2021, the Company had receivables of $1.9 million and $3.4 million, respectively, relating to research and development credits due to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzYwNDczMTM5NjIxOTA_d271598d-a408-4697-a983-dacb5edc1dcf">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2022, income tax expense totaled &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$20.9 million, and consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzU0OTc1NTgxOTE3OA_1ac26cb4-281c-41af-bd72-ba11758c04a5"
      unitRef="usd">20900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzQtMS0xLTEtNDkwODU_403fe743-0268-4624-b6da-8554cb967687"
      unitRef="usd">8200000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzQtMy0xLTEtNTk3OTU_a7b08920-f6f5-4853-8a73-66d699fc31fe"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzQtNS0xLTEtNTk3OTU_76380a49-94e3-4804-85e1-e4b9d0993ff6"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzUtMS0xLTEtNDkwODU_01a2d31b-fd24-4c9b-8d7c-469c7b0f4069"
      unitRef="usd">12700000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzUtMy0xLTEtNTk3OTU_c673126c-5d79-4a8c-8bc0-6c69f1961b87"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzUtNS0xLTEtNTk3OTU_b9b1a0dd-ccd8-4b49-9fb8-5e293c23c44c"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzYtMS0xLTEtNDkwODU_d80d72f4-c3db-493f-acfd-195413e61bf5"
      unitRef="usd">20900000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzYtMy0xLTEtNTk3OTU_8db670cc-0f94-48ca-8829-32561d7c0883"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzYtNS0xLTEtNTk3OTU_c7b967b8-6d58-47b1-8f97-c43118fb1ee3"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzktMS0xLTEtNDkwODU_312bba93-79ac-41a9-9bac-7799624f20c3"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzktMy0xLTEtNTk3OTU_847b73a8-fb51-4be9-a401-3fd4bcf37c83"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzktNS0xLTEtNTk3OTU_23ff2359-6710-4f4a-93ab-48e26ddc69e4"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEwLTEtMS0xLTQ5MDg1_e18389fd-2505-47fc-8992-a5d95573b35f"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEwLTMtMS0xLTU5Nzk1_d64bf7a4-0807-457a-9ca2-2b43ddba0d45"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEwLTUtMS0xLTU5Nzk1_b278cbf9-894e-4799-a5e0-ab93d737f8ae"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzExLTEtMS0xLTQ5MDg1_494c1c3b-0c14-422c-bda2-96681c4335f5"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzExLTMtMS0xLTU5Nzk1_88ad1597-a844-4b80-aefd-1b576f55143a"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzExLTUtMS0xLTU5Nzk1_add484eb-fd52-462a-8135-ca4d27cd255f"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEyLTEtMS0xLTQ5MDg1_1605394c-d02a-4acc-8a8c-d63affb6081a"
      unitRef="usd">20900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEyLTMtMS0xLTU5Nzk1_b337b5a3-d877-4552-bd46-efc9859a0226"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YzUxMzE2NjUzYTU0MTRhYWRhZTNlOWM0MDliZmU5MC90YWJsZXJhbmdlOjljNTEzMTY2NTNhNTQxNGFhZGFlM2U5YzQwOWJmZTkwXzEyLTUtMS0xLTU5Nzk1_2dbab1fe-ad17-4555-b29e-dbb8e4333a36"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzM5_83bb080c-2fb7-4f36-9de1-17c346296621"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzM5_cffb05fb-2e48-4825-9c2c-46869ad23eae"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzUxNTk_7c59cdb6-9de3-4d74-b992-6730794d390f">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the years ended December&#160;31, 2022, 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzItMS0xLTEtNDUzMzQ_8fd68f2f-f68c-4f6d-9fc4-27b3a6bcc0fb"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzItMy0xLTEtNDUzMzQ_9eb121a1-ada4-400a-a411-e658cde89c60"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzItNS0xLTEtNDUzMzQ_91a1a12a-683c-4dd1-8cb0-7151b12d5240"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <arvn:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMS0xLTEtNjIwNjI_ac743d8d-585b-40f8-ad94-4ad2d46d3be1"
      unitRef="number">0.036</arvn:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent>
    <arvn:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMy0xLTEtNjIwNjI_af3cfd5b-1db4-4a67-aa5b-e77ae39160dc"
      unitRef="number">0.011</arvn:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent>
    <arvn:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtNS0xLTEtNjIwNjI_a9afea5d-e499-4a1c-9fa3-ea904f5991cd"
      unitRef="number">0</arvn:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMS0xLTEtNTc3MzY_28a90526-5e38-4404-8b39-089deec04210"
      unitRef="number">-0.034</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMy0xLTEtNTc3MzY_c7ca9f25-0a86-4100-b8e5-5c0920255557"
      unitRef="number">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtNS0xLTEtNTc3MzY_e9cb9005-d2d3-458b-9f31-2fd79155d9b6"
      unitRef="number">-0.041</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtMS0xLTEtNjIwNDM_d3ebcc13-6be9-45bc-9b64-b61e4ba00f8f"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtMy0xLTEtNjIwNDM_b0bbebc8-842b-46b8-8e65-d79edf83f1ec"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtNS0xLTEtNjIwNDM_6b88b7ed-a721-4d8b-8b96-832cb64099b2"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtMS0xLTEtNTc3Mjg_8f4da429-441d-45ba-888b-f59c9cd5f6c6"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtMy0xLTEtNTc3Mjg_7a350c9c-d294-46a6-8ef2-7a1050bc046f"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzUtNS0xLTEtNTc3Mjg_f9d8cfcb-9bb2-4b54-bfdf-970dd1b959b9"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtMS0xLTEtNTc3NDg_e871306a-4d42-42eb-8b13-5db8582eafaf"
      unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtMy0xLTEtNTc3NDg_9402aaac-a9cd-4e4b-9fd2-1911447173e9"
      unitRef="number">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtNS0xLTEtNTc3NDg_f463ac27-71b7-4b5f-88af-76c116045bed"
      unitRef="number">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMS0xLTEtNDUzMzQ_d2916356-5b45-4056-8652-4ab1a1378b51"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtMy0xLTEtNDUzMzQ_549278a5-82b3-47c2-96d9-23c4339b63bb"
      unitRef="number">0.163</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzMtNS0xLTEtNDUzMzQ_8dde8bf2-a5ed-4e16-988b-1e299ad53fa9"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtMS0xLTEtNDUzMzQ_0042f7d1-45e0-4a22-b351-92345efe9af6"
      unitRef="number">-0.317</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtMy0xLTEtNDUzMzQ_aa4acd44-4b57-4fa2-b21b-e6977f0cd11e"
      unitRef="number">-0.384</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzYtNS0xLTEtNDUzMzQ_6a8f07ba-d9b2-4ae5-b2e1-7b7a684f2928"
      unitRef="number">-0.233</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzctMS0xLTEtNDUzMzQ_b267f625-66c5-4561-b80e-1219c3295db7"
      unitRef="number">-0.080</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzctMy0xLTEtNDUzMzQ_d8e0af36-1591-45c2-9023-22b526f967fc"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo4ZjBhNjhmM2IwYWI0YWQxODRlYzIxYzkyMmUyMDk5ZS90YWJsZXJhbmdlOjhmMGE2OGYzYjBhYjRhZDE4NGVjMjFjOTIyZTIwOTllXzctNS0xLTEtNDUzMzQ_88a3df87-58d8-41b5-8b04-c2f8a859b681"
      unitRef="number">-0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzUxNjA_ca7b4408-355b-4f6e-b72e-1db5e0eedb0f">Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities were as follows as of December&#160;31, 2022 and 2021: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(243.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzMtMS0xLTEtNjE4OTY_031bb08a-9dc1-4ce8-9c4b-aede3e2cb586"
      unitRef="usd">143000000.0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzMtMy0xLTEtNjE4OTY_e5a164bf-cae0-454d-8652-402f747d9164"
      unitRef="usd">10000000.0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzMtMS0xLTEtNTQ4NTU_40577d60-0eca-4c33-9c67-131c4adf4712"
      unitRef="usd">56300000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzMtMy0xLTEtNTQ4NTU_8ddb73af-3efc-49ee-8308-17d874e7e6f8"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzUtMS0xLTEtNDUzMzQ_ff461316-d514-4576-84a1-6808199c4ce4"
      unitRef="usd">25900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzUtMy0xLTEtNDUzMzQ_36af6637-b04b-4109-94d5-a2734d246f08"
      unitRef="usd">15400000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzYtMS0xLTEtNDUzMzQ_454c98dd-1286-4cdb-88b7-94d17f003616"
      unitRef="usd">10400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzYtMy0xLTEtNDUzMzQ_2a94dabb-5da5-43f1-9866-c08049f168df"
      unitRef="usd">18800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzktMS0xLTEtNjE5MTg_4a2ac154-b066-4f91-a8ff-48d78d9811c4"
      unitRef="usd">3800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzktMy0xLTEtNjE5MTg_faa4a6dd-c685-4a81-aa4b-4d590187dde9"
      unitRef="usd">97000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzctMS0xLTEtNDUzMzQ_fc4efd40-11c6-4b2f-b118-0742fa22c0de"
      unitRef="usd">7700000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzctMy0xLTEtNDUzMzQ_fff39374-1734-4b04-9f2b-60a0cc18fb3d"
      unitRef="usd">3300000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzgtMS0xLTEtNDUzMzQ_37d79aa4-d4a9-4865-9f4f-2514b72468cd"
      unitRef="usd">247100000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzgtMy0xLTEtNDUzMzQ_6890c31d-9a4a-4d1b-b765-6d50c28ffdbb"
      unitRef="usd">144500000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzExLTEtMS0xLTQ1MzM0_afc7b5de-96d0-4d45-97fb-df32028d126e"
      unitRef="usd">2600000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzExLTMtMS0xLTQ1MzM0_017870d6-9703-4fa6-bd5b-41f772220299"
      unitRef="usd">3600000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzEyLTEtMS0xLTQ1MzM0_7a28ccc5-4dfa-42c3-b8e8-ac8abf50a5cc"
      unitRef="usd">1000000.0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzEyLTMtMS0xLTQ1MzM0_ccefb878-0794-4db0-8a48-c448a5ff747f"
      unitRef="usd">1400000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzEzLTEtMS0xLTQ1MzM0_626e97c1-7c6c-4cd6-ad92-67943644e230"
      unitRef="usd">3600000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzEzLTMtMS0xLTQ1MzM0_028bdd74-6f04-4875-9c7d-1321f0a0523c"
      unitRef="usd">5000000.0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzE0LTEtMS0xLTQ1MzM0_a29b8e44-5065-4e32-8cd5-a874468c6afe"
      unitRef="usd">243500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzE0LTMtMS0xLTQ1MzM0_0ad1edb5-0d61-48f9-9694-6c544b420a21"
      unitRef="usd">139500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzE1LTEtMS0xLTQ1MzM0_5d5a07a8-b9eb-413a-ab00-c300452031ba"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTpiOTUxNmU3M2FlZGM0OGE4OTBlMzk4MTlmNThjZTAyMC90YWJsZXJhbmdlOmI5NTE2ZTczYWVkYzQ4YTg5MGUzOTgxOWY1OGNlMDIwXzE1LTMtMS0xLTQ1MzM0_2bb9a656-1f18-4865-82b1-8fd974a0f138"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="iecde1bb80509425b97c53198d17cd282_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzEzMzI_08598f9d-5c16-4082-8027-f6585c49e374"
      unitRef="usd">104000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i462d342906254aa08ed253bed2a62c4c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzEzMzk_9b76c230-be8a-4fc8-823f-d7340178eb26"
      unitRef="usd">74600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i87ad4e65cba64ab792067ed0244886b2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE1MzM_34eb6349-cc3f-43be-a66a-e42445a490cf"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i1330642a737d458aa14cb794d465bbbb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE1NDA_133958c6-1b6b-42da-8da4-10769daef10a"
      unitRef="usd">373600000</us-gaap:OperatingLossCarryforwards>
    <arvn:OperatingLossesCarryForwardMaximumDeductibilityPercentage
      contextRef="i0f49b42bb24b4669b993f69de2a04054_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE4ODM_a5aaf6f2-e503-4742-8f8a-96adcc9618ad"
      unitRef="number">0.80</arvn:OperatingLossesCarryForwardMaximumDeductibilityPercentage>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i7a1938c4bd324660821a879962862c4e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE5Nzk_d6096a61-06c2-4b58-8144-596ba25f1548"
      unitRef="usd">63400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i98620edc8ebd468da40a2ba163c12f1a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE5ODY_1d401019-24fb-42b0-bb9f-a7f288198218"
      unitRef="usd">346900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i87ad4e65cba64ab792067ed0244886b2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzIxMzA_9bb72b9f-8090-4d2f-b411-3999044cb110"
      unitRef="usd">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i1330642a737d458aa14cb794d465bbbb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzIxMzc_eb00a9dd-5237-415a-954b-bca8f3e41ef8"
      unitRef="usd">15200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i7a1938c4bd324660821a879962862c4e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzIyNjU_62d60203-4669-4890-8425-f777973ba624"
      unitRef="usd">13100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i98620edc8ebd468da40a2ba163c12f1a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzIyNzI_f4255030-f5bc-48fd-afa8-083ec97e1025"
      unitRef="usd">4500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7a1938c4bd324660821a879962862c4e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzE2NDkyNjc0NTI2Nzk_e7137c61-0b94-4913-ac4c-5c4f811b2899"
      unitRef="usd">3200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzM3Mzc_88c28761-7d3d-42d9-9620-abd557e0ca4a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzMyOTg1MzQ4OTM5MTE_6154a4ef-2b3e-445d-b4e1-90facb409e1e">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's gross unrecognized tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning of period balance - gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for tax positions taken during the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases for tax positions taken during a prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;End of period balance - gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzMtMS0xLTEtNTc5ODI_a70bc16e-9a96-45c3-af9c-741934e2b10c"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzMtMy0xLTEtNTc5ODI_3df9ee3a-d864-49d0-971c-ba30585c4a9f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i35327f5dcba84428bcd65e20009ba82d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzMtNS0xLTEtNTc5ODI_01366704-bc61-4ec2-90a7-ddc4c98806b8"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzQtMS0xLTEtNTc5ODI_16639f59-8087-42e7-93a7-f3bdaf6b62df"
      unitRef="usd">4100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzQtMy0xLTEtNTc5ODI_c0f75ef6-f23a-43ee-9af6-892eba1be01a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzQtNS0xLTEtNTc5ODI_370114b4-cdd0-4752-af20-997848c7effc"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzUtMS0xLTEtNTc5ODI_5465b89f-2ffd-4ece-a1e9-eea56c4504cd"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzUtMy0xLTEtNTc5ODI_70cce9bd-11cd-4613-aff8-8cdd4028fc4b"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzUtNS0xLTEtNTc5ODI_977427ad-1e0c-4121-bb74-7594d0d917d0"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzYtMS0xLTEtNTc5ODI_42f5a7de-8aab-4752-b61f-b06b1f45f1e7"
      unitRef="usd">4100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0ae6f33336fd4929b4de48a65cfd91f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzYtMy0xLTEtNTc5ODI_76774876-34d6-41b7-b605-d46229c20bd1"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0c3c730cf6ec499aac36b9dae0dfff96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90YWJsZTo5YTdlMmRhNGU5MTE0NWY4YjljY2M0Njc0NTY2MTk0ZC90YWJsZXJhbmdlOjlhN2UyZGE0ZTkxMTQ1ZjhiOWNjYzQ2NzQ1NjYxOTRkXzYtNS0xLTEtNTc5ODI_e55543fa-c559-474f-aae4-a6fb729607c2"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzIxOTkwMjMyNjYxMzY_d2e7e562-41be-4fa4-a261-350dcc8ca8c7"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i462d342906254aa08ed253bed2a62c4c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ2NDc_0ad998e5-a0d8-47f1-af97-2ad0b1b649dd"
      unitRef="number">0.65</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ief8ca6ef40ac464c81aebbad3e910b38_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ2NDc_cab7a289-dbc8-42e9-b6c5-c940d2d1911c"
      unitRef="number">0.65</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="iecde1bb80509425b97c53198d17cd282_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ2NDc_f9f9ab72-2275-491e-b216-838c60ff7255"
      unitRef="number">0.65</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ2OTA_400ffdc2-329f-43b6-958d-1450df17fcfd"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ2OTQ_5e18b903-fac5-48c6-bcb6-89b4b2ddac8c"
      unitRef="usd">1600000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzQ3MDI_d3b1bccf-db2b-4855-8d1b-5d857d8306d1"
      unitRef="usd">1800000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReceivable
      contextRef="i3cc8adccf5a84a7e82138a769bca1f6f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzUwNjc_b54827f0-b4e4-4af3-86e9-70ae67434e79"
      unitRef="usd">1900000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable
      contextRef="iadb5ee3cd631498e9f704ed1e3083c3a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xNzgvZnJhZzo1OTIyMWRhNGM0Mjk0NjgwYmNmYmM1MWI2N2VmZmQzNC90ZXh0cmVnaW9uOjU5MjIxZGE0YzQyOTQ2ODBiY2ZiYzUxYjY3ZWZmZDM0XzUwNzQ_5b82fb92-a7bc-4691-a9f3-d0ae494db291"
      unitRef="usd">3400000</us-gaap:IncomeTaxReceivable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzgzMg_a4a747e5-7a0c-43ea-841c-87d827ab5000">Commitments and Contingencies &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the&#160;ordinary&#160;course&#160;of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred.&#160;As of December&#160;31, 2022, the Company has accrued $7.0&#160;million for such matters, primarily related to a contract dispute that is in early stages.&#160; Due to the early stage of the dispute, the means of resolution are unknown and could involve contract modification and, or payment of consideration.&#160; An estimate of the possible range of loss associated with the dispute cannot be made at this time and the Company has accrued its best estimate as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical and Preclinical Development and Licensing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, under licensing and related arrangements to which we are a party, we may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Yale University License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2013, the Company entered into an exclusive license agreement, including the right to grant sublicenses, with Yale University to develop protein degradation technologies. Under the license agreement, the Company is required to pay a minimum license maintenance royalty totaling $0.1 million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first two licensed products for the development of the protein degradation technologies totaling approximately $3.0&#160;million for the first licensed product and approximately $1.5&#160;million for the second licensed product, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from $0.2 million to $0.5 million. During the years ended December 31, 2022, 2021 and 2020, the Company paid $0.1&#160;million, $0.1&#160;million and $0.2&#160;million, respectively, under the license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;FMI Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company entered into a Master In Vitro Diagnostics Agreement with Foundation Medicine, Inc. (the "FMI Agreement") for the development and commercialization of one or more of Foundation Medicine&#x2019;s companion in vitro diagnostic assays for use with one or more of the Company's therapeutic products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The FMI Agreement does not have a fixed duration, and the Company may terminate the FMI Agreement for convenience by providing adequate written notice to Foundation Medicine, Inc., subject to payment of applicable termination fees. Either party may terminate the FMI Agreement in its entirety for an uncured material breach by the other party, upon the bankruptcy or insolvency of the other party or by the mutual written agreement of both parties. Additionally, Foundation Medicine may terminate the FMI Agreement with respect to an applicable program, if (a) a reasonably necessary third party license is not secured by Foundation Medicine or if the Company does not consent to payments for such license (b) Foundation Medicine reasonably determines that further development of the applicable assay is not technically feasible or (c) following a certain number of years after the first commercial launch of the applicable assay for use with the applicable therapeutic product. Certain license and other rights and certain obligations of Foundation Medicine survive termination of the FMI Agreement. If the FMI Agreement is terminated in its entirety or with respect to any program, the Company has certain payment obligations remaining to Foundation Medicine and may also be required to pay a termination fee, if applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Bavdegalutamide&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the development of FoundationOne&#xae; Liquid CDx as a companion diagnostic for use with bavdegalutamide for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low to mid tens of millions of dollars, in addition to certain validation fees per sample and related pass-through costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ARV-766&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the development of FoundationOne&#xae; Liquid CDx as a companion diagnostic for use with ARV-766 for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low tens of millions of dollars, in addition to certain validation fees per sample and related pass-through costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="iafe9691446164ba9bb2c4bf060b98b4b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzE2NDkyNjc0NTQ0NTg_a0a7aa4c-6fbf-41fb-9cb4-e9c6ce9d7271"
      unitRef="usd">7000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <arvn:AnnualLicenseFeePayment
      contextRef="i6b912e140bd549c59a71222eff36d168_D20130701-20130731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzMxOQ_7ae996aa-ed53-41c3-b05e-1ea5ad54be0d"
      unitRef="usd">100000</arvn:AnnualLicenseFeePayment>
    <arvn:RequiredMilestonePayments
      contextRef="i0e872fdee2484e02a8eecae47bd8d71c_D20130701-20130731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzU1MA_7244c149-2b66-45b4-bfe9-f6e26ca2435d"
      unitRef="usd">3000000</arvn:RequiredMilestonePayments>
    <arvn:RequiredMilestonePayments
      contextRef="i71af99d94a15409d814e3bc898621bc3_D20130701-20130731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzYwMg_96e21f8c-7758-4e6d-92f1-28658ccecf69"
      unitRef="usd">1500000</arvn:RequiredMilestonePayments>
    <us-gaap:PaymentsForRoyalties
      contextRef="i6b912e140bd549c59a71222eff36d168_D20130701-20130731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzgyNA_80d2f22c-4669-43d5-ad07-faefc1d87298"
      unitRef="usd">200000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="i4c4e41fe7c444302a2f4e5632b5df43f_D20130701-20130731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzgzMA_8000bc70-10b2-4fcd-8681-13a246fdef50"
      unitRef="usd">500000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="i2bcccb8aa5c3415c94857cd84457d1c3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzU0OTc1NTgzNDkwMQ_0e98b6ff-eafb-4a01-a636-cca58f4a8b6f"
      unitRef="usd">100000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="idc0e2f0ce3a94a72a40371967158f45d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzU0OTc1NTgzNDkzMQ_b54079b5-0946-4107-bceb-bfbe4bbcd1a5"
      unitRef="usd">100000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="id8f55863c58b46e580d64c087d73a211_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzU0OTc1NTgzNDkxNw_8a4c645c-5d75-462a-8f62-6d3ae2934d55"
      unitRef="usd">200000</us-gaap:PaymentsForRoyalties>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i496ab182e9bd4c7fb0d9db9b728a6798_D20220604-20220604"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODEvZnJhZzo4YmMyYWZmZjBhMmQ0ZTBjYTAyZTQyMTdjNmNlNTYxZS90ZXh0cmVnaW9uOjhiYzJhZmZmMGEyZDRlMGNhMDJlNDIxN2M2Y2U1NjFlXzE2NDkyNjc0NTAwNjQ_27728292-3df0-48ef-8873-c15dc2818e3f"
      unitRef="usd">10000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90ZXh0cmVnaW9uOjEyNmEzYWFlM2E3MDQzMzdhNzExMWIyODliYTYxODk1XzI4Mg_986253b3-14ef-4d63-80cd-de43fbf0fac3">Net Loss Per Share &lt;div style="margin-top:6pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share was calculated as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars and shares in millions, except per common share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per common share&lt;br/&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported net losses for each of the years ended December 31 2022, 2021 and 2020, and therefore excluded all stock options, restricted stock awards and restricted stock units from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90ZXh0cmVnaW9uOjEyNmEzYWFlM2E3MDQzMzdhNzExMWIyODliYTYxODk1XzI4Mw_b8c2899a-e50c-496e-a7d2-7f6c6505e3e1">&lt;div style="margin-top:6pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share was calculated as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars and shares in millions, except per common share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per common share&lt;br/&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzItMS0xLTEtNDUzMzQ_f4edae02-d9c4-4b6f-adc1-baef9e24af3b"
      unitRef="usd">-282500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzItMy0xLTEtNDUzMzQ_1b234317-f74f-4e32-8073-e77079a8e9b1"
      unitRef="usd">-191000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzItNS0xLTEtNDUzMzQ_6d681472-c811-427b-bbc4-8b5889d84716"
      unitRef="usd">-119300000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtMS0xLTEtNDUzMzQ_5d8e0e19-7a4c-42ea-8414-4452563a594a"
      unitRef="shares">53200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtMS0xLTEtNDUzMzQ_ca7357fb-7480-411c-a635-7d0763115e3d"
      unitRef="shares">53200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtMy0xLTEtNDUzMzQ_39b64c60-1933-42c4-9dc1-1ec7307a5ea7"
      unitRef="shares">50000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtMy0xLTEtNDUzMzQ_782eef24-b23b-4ee3-9661-18567b9099b1"
      unitRef="shares">50000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtNS0xLTEtNDUzMzQ_9ccced41-83cb-4308-be44-26aba2e9b478"
      unitRef="shares">39500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzUtNS0xLTEtNDUzMzQ_e492034e-c525-4161-a0f8-63dd7c35da5b"
      unitRef="shares">39500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtMS0xLTEtNDUzMzQ_0d095c59-9423-47b7-a163-cfb14774b60d"
      unitRef="usdPerShare">-5.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtMS0xLTEtNDUzMzQ_d50862b3-4dc5-4bad-95ac-ebe81214e160"
      unitRef="usdPerShare">-5.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtMy0xLTEtNDUzMzQ_9f82e83c-e29d-408c-a73d-e12e8f344bf7"
      unitRef="usdPerShare">-3.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtMy0xLTEtNDUzMzQ_edb18b11-8db1-4e04-80fc-007f33f14faf"
      unitRef="usdPerShare">-3.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtNS0xLTEtNDUzMzQ_254167c3-8fe4-40e1-a6c0-3e2f96633a59"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo3MzEwOWYzYWVjZTc0MTMwOGY0ZDI0MTJlZjFjZTNhNi90YWJsZXJhbmdlOjczMTA5ZjNhZWNlNzQxMzA4ZjRkMjQxMmVmMWNlM2E2XzYtNS0xLTEtNDUzMzQ_d20ccf03-08f7-4025-8ab3-a4d2f00235be"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90ZXh0cmVnaW9uOjEyNmEzYWFlM2E3MDQzMzdhNzExMWIyODliYTYxODk1XzI4NA_21e6c148-8089-4181-810f-9b605a4607d8">&lt;div style="margin-top:12pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported net losses for each of the years ended December 31 2022, 2021 and 2020, and therefore excluded all stock options, restricted stock awards and restricted stock units from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i96d22ed283414299b6a543fcde594e37_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzItMS0xLTEtNDUzMzQ_df5d4a7c-c2ef-4cb6-bef8-6fa08d3df087"
      unitRef="shares">6800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i131967269d424a0a9e25495c62957e55_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzItMy0xLTEtNDUzMzQ_907aedc2-e77b-4f05-8f89-6821a765fc53"
      unitRef="shares">5300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia927654c60d84e7a99159c1cae642735_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzItNS0xLTEtNDUzMzQ_c4db2122-9ad8-448a-853d-6cee35d99f22"
      unitRef="shares">4300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i008486f737c64fb5890db18235e070ff_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzMtMS0xLTEtNDUzMzQ_4eddca7d-7596-4e9a-bbcc-a800736c99c2"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia62bc0fe985a441ab8b2ca63ed56b425_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzMtMy0xLTEtNDUzMzQ_2d0688e7-3eea-48e3-9928-14367d1f8eee"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i25d62ff1d49b406c840997107b6eae57_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzMtNS0xLTEtNDUzMzQ_b896f662-914c-47e7-90ba-14fe3c0a6d3b"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iccb0fc5624af4bea97bb6b0b4030e038_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzQtMS0xLTEtNDUzMzQ_674cf69b-2b08-456c-8b4c-3cdefe2aebe1"
      unitRef="shares">500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i73e8a5c5471147159a6cf356c1ed6b90_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzQtMy0xLTEtNDUzMzQ_2938d5b9-2ddd-4323-afbf-f35eef105d3c"
      unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2ad800b817ff41fc9a94dc8de9936747_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzQtNS0xLTEtNDUzMzQ_34130a63-ba14-4759-b1d0-278c49c26eba"
      unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzUtMS0xLTEtNDUzMzQ_30e47cfe-d8a3-476d-a233-cc4912c5519a"
      unitRef="shares">7300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia9b34aabf560460e87638e54eb236a17_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzUtMy0xLTEtNDUzMzQ_98811fa3-d2e5-41fe-89cc-506d7a489cbe"
      unitRef="shares">5400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i02b37884dc3b4dada48e5a69bd661d0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5MzZlZGUzZjIzMDQxMjM5YTc4M2EwN2U3ZjkzYzQ4L3NlYzphOTM2ZWRlM2YyMzA0MTIzOWE3ODNhMDdlN2Y5M2M0OF8xODQvZnJhZzoxMjZhM2FhZTNhNzA0MzM3YTcxMTFiMjg5YmE2MTg5NS90YWJsZTo2MTgwOGVhYmM0NTc0Y2Y4YWYwZjJmZmJjZjE5NmI1NS90YWJsZXJhbmdlOjYxODA4ZWFiYzQ1NzRjZjhhZjBmMmZmYmNmMTk2YjU1XzUtNS0xLTEtNDUzMzQ_b8e48c24-d07f-471b-b0f8-435d4a764c8b"
      unitRef="shares">4600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>91
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M7QO5%I0AL0JHP0'4H!FH*6$1E=-AB&!25?:I$TK[J:EV;M+&MX5F2*P";7B
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MGN#)ZQ=?^,-.FR]FZ]6>/K![IK_N[R3<S8Y>,EZP4G%1(LFVUY./^.HF#,R
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M<VK=W&BQKP]^-T)K4=27.T9!MC& W[="Z-<;<Y9\_-_!^C]02P,$%     @
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MELJXX/IG#PO(,N-)C^.?QNFH?:8Q/#X^>/^U(J_)/'()"Y%]2A.UN1N%(Y+
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M#L<0>2BM(9)Y#$MM/$12+YA:B$4ML<A*K)I.5Z7(#^3.M/)H,( ;%K@,8X5
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M1[VL]X;J$R6VU6[)HU!*Y-7A!G@"I0'H^RLAU.'$/*#=H9O_!U!+ P04
M" !%BU=6[.FCT+X(  #"5P  &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;+V<;9.;MAJ&_PKC=DZ3F?@% ;;)V=V9QN9%,TV[DVW.^7#F?"!87C/!X +>
M3?OK*S Q%L):2.YI/F3]PG,]DK@M"=V@F^<T^YSO&"NT+_LXR6]'NZ(XO)U.
M\W#']D$^20\LX=]LTVP?%/QM]CC-#QD+-E70/IZ2V6P^W0=1,KJ[J3Z[S^YN
MTF,11PF[S[3\N-\'V9_O6)P^WX[TT=<//D2/NZ+\8'IW<P@>V0,K/A[N,_YN
M>J9LHCU+\BA-M(QM;T<_ZV^I890!U1'_B=AS?O%:*ZOR*4T_EV_HYG8T*TO$
M8A86)2+@?Y[8BL5Q2>+E^*.&CLXYR\#+UU_I;E5Y7IE/0<Y6:?S?:%/L;D?+
MD;9AV^ 8%Q_29Y_5%;)*7IC&>?6_]EP?.QMIX3$OTGT=S$NPCY+3W^!+W1 7
M ;IQ)8#4 :050*X%&'6 T<Y@7@DPZP"S%6 LK@18=8#5+M*U2L_K@'D[X%J&
M11VP: 58US(LZX!EWSK8=8!=R>%T_JJ3OPZ*X.XF2Y^UK#R:T\H7E8*J:'[.
MHZ04^T.1\6\C'E?<K=(D3^-H$Q1LHST4_ ]7<I%KZ59;[8+DD>5:E/ OTO#S
M+HTW+,M_TIP_CE'QIS;6/CZLM5<_OM;R79"=#GP?Q3'7</Y&^_'R[<VTX&4M
M,T[#NESO3N4B5\KU>UH$<4?82AWV<S$N=FS\/L@^\X[BM^V695'RV,%9JSFK
M=+_G/\6'JF(=X<Z <*UWH=P7*A>&Q_TQKD[5FFVC,"HZ(-X+D,TF*KN9(-;N
M@V@SYF=I%1RB[M;VOY75O\ZT?YU_X\1,XVW+N_5=V=\^,>V7-&^=GRG_!9Q_
M!N3\,R!5&O-*FG?L,4H27D+><\9!$C+M%:_,2=>OM:#@[1U.-$-_HY&9;G?)
M6<DOAZRW^2$(V>V(%SYGV1,;W?WK!WT^^W>7R)&P]0FVJ&#EV/=T9RPGULWT
MZ5+/R(PN$N8A83X21D$P0;#&6;#&0,'V$>F):5U(@9#Y9"YJ8:7,/%1])YA]
MD7+6DAXRG2O7<&PL2+N*GGR89=L373S*1Y:,RBEG%PD%$9AG$9A5D'%%!#0)
M^00WYYT5/_/5J]=71^O_?4CC6.,3Q.<@V_R_2QPFL@=#PM9(F(.$N4B8AX3Y
M2!@%P0216V>16\J>CN;YL>S@JCEI>)I8Y:7"WV@)GUI<C--=HE:RAXH:"5M;
MTK L]<2.? QIC]PNLE >$N8C810$$R0X/TMP_AT2[)+=7#IQIJ%/[-9 .Y>&
MA+DYF=F7_\2(M;*<0WM"),Q%PKQ>S></;CX**J0@HL591 NEB*I1>5PNS&Q*
M#1WX!4Q07CQUR6<A3]EG$])2CS+=T-X("7.0,!<)\_HTK(_,2$$P07++L^26
M2LG]RL?'6+I /DEL*;7$6-?MB=$2F3+!4)$A80X2YO9K#0^9TT?"* @FR,P^
MR\Q6RNP#RXLL"LLEFFI4U)[X!^6EZ0MS,R5UZ-P,"5O;DAQF$[,U-T,F=)$P
M#PGSD3 *@@DJU6?-4O=,J=/[+ T9V^3:-DOW&OO"LC#B%\]\3G>2;7HHQ^/\
M)=FJLPS5+92VKFFB<MMK?="4+I3F06D^E$91-%&^%TZ-CI!OIV1U21;+B6XK
MILHK=6$&ZQ))<Z T%TKSAC>U#RT 1=%$E39&BJYV4CXF&0OBZ"\^&7@,>$?Z
MJIR OM9*7_LIB.+@4\S&VS0;YT',M)R%QRPJHDZ/[9TN.Q=29[92%V>P3I$T
M!TISH30/2O.A-/K"B1>5V3@FNMHR<9)-/X./S#K5B'0#5E#:NJ8)"R:RQP?-
MZ4)I'I3F0VD411-UVY@\NG)YO:W;7EHUY<5EDT@K2.K$@T5HOFCU01.Z';4<
MF[:T3NAU'*?KAM'^??C0TM&.K+.+!7Y1#(T9HEO_H.6G0^T1*&T-I3E0F@NE
M>5":#Z51%$V4>V.\Z-_CO+QXI8XT)590VEJ7/0ZI1W*@*5THS8/2?"B-HFBB
M:ANG1U=;/</]0ETV)HAE2X:A.N]@"4)-'RC-A=*\?LWK0Y-2%$T48>/]Z&KS
M9XC?J,O^A[5HWPZU4B<<K#ZH&P2EN5":UZMU?6A.BJ*)XFL<(5UM":F<QSIT
M+IAMMB0VJ*$#I3E0FMNK/3QH3A]*HRB:>.MVX^L0M:_SK?ZC&COXGFVHD4.Z
MC)S6];L#3>E":1Z4YD-I%$43]=H8.01BY+PH7Z1ML(+2UD1V06:395N^4!L'
M2O.@-!]*HRB:*-_&X2%JA^<[?$@B+^SKR\FB-?2K\P^6(M32@=)<*,WKU;H^
M-"=%T40M-IX.47LZ0+>1=#PZ8DE+YNKR#-8FDN9 :2Z4YD%I/I1&B>R>"6=>
MU&;CVY!!OHW";]0[]6A*EP56^^Y,=0D&J_'EC XTHPNE>5":#Z51%$W48F,;
M$?5#-&H/L5M_EM0?+I:Z/%A#39^:IO(0H0E=(C]B,YXOB>0A=ARGFW-;NG<<
M6CK:53KSFHE(&E>%S/]!$Y% 718H;0VE.5":"Z5Y4)H/I5$4391[8\<0W),W
M1'8*%I9TTYDZX6"10GT8*,V%TKQ>K>M#<U(4311?8\.0;W\&AW0\=D*6TB.>
M*W6*P7*#&B]0FMNS13QH5A]*HRB:*+C&>B%JZP6UN@A].@=*6Y.NYW.DQ7&H
M20.E>5":#Z51%$W<UJ0Q<PS(0SI=DC5DS\1L+SJOU.F'*K&F7=O5XZ1$:$H7
M2O,ZVZR]9 A-25$T46"-^V*HW1?@DF&=25@RU$UY/QVHM0*E.5":"Z5Y4)H/
MI5%#-KC$4R^JLS%7#+6YTG_1D'0J4K8 +$-:Q%:78; @^^1TH#E=*,V#TGPH
MC:)HHAXOMAD;]-!,+PUV;*XU-Z5[&=6)!XM0O;U6K4'L5F,=AI$]M]H/BGL=
MQ^F6:;>/\Z&EHUVETVW)U9A>;!U:[F[[/L@>(WYU$+,MCYM-%AR0G3:,/;TI
MTD.UF^BGM"C2??5RQX(-R\H#^/?;-"V^OBDW*#UOVWOW-U!+ P04    " !%
MBU=6A+T'OHX"  "W!@  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;+55
M74_;,!3]*U:&-I"@^>C'$$LCT<(T'JI55&S/)KE)K#IVL-T6_OVNG30KT%:;
MM+W4]O6])^?<VYS$&ZF6N@0PY+GB0H^]TICZRO=U6D)%=4_6(/ FEZJB!H^J
M\'6M@&:NJ.)^% 0COZ),>$GL8G.5Q')E.!,P5T2OJHJJEPEPN1E[H;<-W+.B
M-#;@)W%-"UB >:CG"D]^AY*Q"H1F4A %^=B[#J^F0YOO$GXPV.B=/;%*'J5<
MVL-=-O8"2P@XI,8B4%S6, 7.+1#2>&HQO>Z1MG!WOT7_ZK2CED>J82KY3Y:9
M<NQ=>B2#G*ZXN9>;;]#J<013R;7[)9LV-_!(NM)&5FTQ,JB8:%;ZW/9AIR <
M'2B(VH+H;<'@0$&_+>@[H0TS)^N&&IK$2FZ(LMF(9C>N-ZX:U3!AI[@P"F\9
MUIED*H66G&740$86!A<<D=%$YF1:4E& )DS@A4R7I>09*/V)W#ZMF'DAIW.J
M,+<$PU+*S\@%>5C<D-.3,W)B:V:,<QR4CGV#/.W3_+3E-&DX10<XA1&92036
MY%9DD+T&\%%@IS+:JIQ$1Q%O(.V1?GA.HB *]Q":_GEY<(1.OVMZW^$-#N#=
M:;VB(@7;Y516%?Z=M>WP.09R4$P4&-9F;^L:Y*%#MJ_H.AGT1K&_WE7S/B>Z
M[(5=TBO.@X[SX"CG:W.!H[Z84;5$;_G>\MS'\"B.=:4K7=,4QA[:C@:U!B_Y
M^"$<!5_V#>8?@;V2/.PD#__;F(XB_VT3AN_F&>[,O-'F[WA !:IPUJB1X$J8
MYD7IHIW[7CO3>1.?H"LW)OH;IK%TG'W!A"8<<H0,>I^1D6ILLCD863NG>90&
M?<MM2_RR@+()>)]+:;8'^X#N6Y7\ E!+ P04    " !%BU=6HK:*%ID(  #%
M*P  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;+6:;8^C.!+'OPK*KE:S
MTB3!AD#2UQVI)^SJ3KK9:6UK[UX[X'38 9S%3C_<I[\RT.'!A=,YY>;%="#E
M"O_"5?6SX?9%E-_EGG/EO.99(>\F>Z4.-_.YC/<\9W(F#KR ;W:BS)F"P_)I
M+@\E9TDU*,_FU'6#><[28K*^K<X]E.M;<5196O"'TI''/&?EVQ>>B9>["9F\
MG_@]?=HK?6*^OCVP)_[(U1^'AQ*.YB<O29KS0J:B<$J^NYO<DYO(]_2 RN)?
M*7^1G<^.EK(5XKL^^$=R-W'U%?&,QTJ[8/#GF6]XEFE/<!U_-4XGI]_4 [N?
MW[W_6HD',5LF^49D_TX3M;^;+"=.PG?LF*G?Q<O?>2-HH?W%(I/5_\Y+8^M.
MG/@HE<B;P7 %>5K4?]EK$XC. !*,#*#- #H<X(\,\)H!WD<'^,T OXI,+:6*
M0\046]^6XL4IM35XTQ^J8%:C07Y:Z/O^J$KX-H5Q:KT1A119FC#%$^=1P1^X
MJ4HZ8N=LF-P[O\+$D,[4^>,Q<C[]^+/SHY,6SM<TR^"FR=NY@DO0CN9Q\W-?
MZI^C(S]'J/-5%&HOG5^*A"=]!W.X]I, ^B[@"[5ZC'@\<SSRV:$NI<@%;3X^
MG"##HX\/=RUJO-/M\"I_WMCMT#'?53'?E2)W(+]+IM+BJ4Z05*5<WF!AK]WZ
MN%M=/&[D@<7\;@+50?+RF4_6/_U  O=O6,BNZ2RZDK->./U3.'V;]_5O4#@S
M(=&)6H]<5"-U=7Q>3^F2SA:W\^=N+&JS5=>,K$C?*$)\$;*:>2>SWM4O3E>_
ML$Z&^^1/* !U/BH!538619QFW"D:6?JL_ASK6?/I*"&%T^)GYU"*YQ2RR]F^
M?7P"+:XY@:[I++J2L]XM"$ZW(+!.H(B#TSAE=8\J$H?EHE3I?ZH36!AK=V%G
M)@2=:5!'Q[3Q9\O!C#)MO!G%IU-XTA*>3086QR6OQ$"!WPH0E*0R%D>88G-0
MFJ?''$V6T+B<Q2P<R#)M5C-_(,NT(1T_/5G+DZRE51:T_R= AX++JFLE?*L@
M"V*1<TQ([2OH7( [D&%:3(?I;G/2T[ Z:5A9-?Q3)_.G)Z:S%^Z-9)#DH 5(
M[#M7; M'DL?'LLI>3-7*"*L[#/T&LZ$#8:;-M.NHIXVX+6*X5G7WG9S1LDK-
M8E.QFT+%<IB47.$DX2*39350A1H-92%&;L=37U:'G,A%L@#%,K8597T":K4J
MH>;6 E%]!+GTY5"?:63<VJ@Q^L"$)+151ZWJ'I6(OT\U4B>@)8=UAAPM>HVK
M[D6&"Z.3(E:+<#;,+<3*<\=*'VFYBIP!JSTKGKC4]-IIB=7<J^IZEK)MFHVW
M1W)5P+JJM^A:WOJA;1F+V"'K/JX;B 84GC[K<H5&T#<F*1G6*,1F.C2*4*.1
M^=&B%K%BQ/J;VO.RHP"O2 ND*P_;(&(T]88,$&%69'2:M[A"[+SR4/(#2Q.'
MO^J$Y?7<%I4VZ!\EH*2MX)K0,44J$F;ES8*A0,2,CO:2EF&('6(VEQ;9\&S#
M)R:43 D==IK(ZJFOID478F>74^H<V%O5YBO$!$8[\EY)0I4MC<NF1D??8%:A
MJ<VT@@@L1^2U5$/L6//M5&DS#HWDK"($/Y".CUH9^86BS$C/IRW*4#O*1'S'
M(8T2J!2 G$>TT%&3-F U&!B)A-@%*Z-M1J@[;VQM25M\H79\^>WRA2.JU@24
M*0T]H_LC=HN%N4# W"U78VL$VN(,I1=MK*3%,Y<?61=3*R9=VOBOZBVZEK=^
M3%NFHE:P6#\<RWBO\_J2I4KCLW^#EX&Q7,'L2.C[1J/!#/W15DI;K*%VK/G*
M5"/C,GV^64K=,##*&&+GTZ69_8B[T)^-\ YM>8?:>>?QTB4F-8$%TI<,59E6
MH;$<0XR\<*S;T)9]Z!GVZ4Q'J&10O]3;9X?_=4P/>04^&O-U']J+#.I=KJM=
MO=N-ZD7X!:GAB)4_1,((]S7"0K1E(7I^0Z>JX-VZW59SK,2A2DW^H3XUI6*8
MY"'DAQB2P!]M6"TLT>5%)7R7%JR(/U+"K1!V<0F_IK?H6M[Z,6T)C=H)[:$4
M,>?)>U.4\@@AY?5N1I[KK2B]#8 &=746K*G)8#1 "KCIR0]&T-IK2<VSD]H#
M>ZNR?B %CH'@]*2)A<0SOW%L4^8A3&8*PZP OD=8QFO)S;.36_^F\5=>QFE=
M]AJ)!S7V=,XS\<HH5QO$B"Q-=:;5<N:YW7\C7<IKJ<VS;T*A%0[+>U2KN9.$
M:#6-:(B(1?:NW.X=[POL/.ZS(Y06^"GA<:G[DB[9]2>]3:5U?Z[5ZQ[V# V[
M:#:KH!*H,HWU(UO]/2K>,S=):# 4CZ%3N##5FW:+<#6&6%Z+6)X=L38?EOC9
MV?*GM"CT78=YKO;<@?Z>B@35CC 3,1L:8K98+HT5"6(&W+/J_1L)1$MCGIW&
M+@D$USLZ9T-@(M;2I!?$"@E4A)CU ]57W0*;%U@;^N/Q<,@J F-9]1PJ$_)8
MUMWGO==#)M0OMT!%PQ]\6Z'PXB??U_067<M;/[XM'WIV/GP'8GDY$3O'HMI'
M9*J99'K:H>$W8<\U5@6HT7"E<\:H'X,6&CW[#EL%C944F$8PF137"84J.?]H
MT#.WR0RQT1FCOHX6U#P[J/5U*/8ZTO-,Y"+$O!]GV2VRFO3?Q6B1S#_S'%!-
MH6I-OU9+3N=; V+HNQE61Y<F]56]1=?RU@]B"W\^^?^L@GPK5%X<TVMZBZ[E
MK1_3%C-].V;^[VN%QK&M:)PWB7R3+J=D#"[]%B[],_MSO77"^TL%/87 F:S.
MRGHCZ"09%5O_W,HF]JQ)U)AT7Y8*%K.%C:?FG?<;<UX^5>^)2J=Z=E*_*7@Z
M>WH7];YZ W-P_@NYB>HW2ELW]0NN4)2 +R6TPQVX=&<A7%]9OS-:'RAQJ-ZB
MW JE1%Y]W'.6\%(;P/<[(=3[@?Z!TYN[Z_\"4$L#!!0    ( $6+5U:IDC93
MQ <  !$3   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULK5C?<]LV$OY7
M,&RGU\XHDB4G:2:Q/6.[:2\/:3QQ<GFXN0>(!$74(,  H&7=7]]O%R!%>V0W
MG;L76P1V%_OCVP]+GFR=OPF-4E'<M<:&TZ*)L7N]6(2R4:T,<]<IBYW:^59&
M//K-(G1>R8J56K-8'1V]7+12V^+LA->N_-F)ZZ/15EUY$?JVE7YWH8S;GA;+
M8ECXJ#=-I(7%V4DG-^I:Q<_=E<?38K12Z5;9H)T57M6GQ?GR]<5SDF>!?VFU
M#9/?@B)9.W=##^^JT^*('%)&E9$L2/R[59?*&#($-[YFF\5X)"E.?P_6?^78
M$<M:!G7IS!==Q>:T>%6(2M6R-_&CV_Y3Y7A>D+W2F<!_Q3;+'A6B[$-T;5:&
M!ZVVZ;^\RWGX%H555EBQW^D@]O(7&>79B7=;X4D:UN@'A\K:<$Y;*LIU]-C5
MT(MGO\O8>R5<+2[Z@+T0A+25N)!!!UJ]\BHH&R6E\&01<2+I+<IL_2)97SUB
M?;D2[YV-31!O;:6J^P86<'7T=S7X>[%ZTN(OJIR+X^5,K(Y6JR?L'8_Q'[.]
MXT?L?? ;:?5_.;Z9N'0V.*,KF1"#1$SCIWS\JJVTI99&7&-1 9XQB'^?KT/T
M -A_#J4H.?#\L /4=*]#)TMU6G1TEK]5Q=D/WRU?'KUY(KSG8WC/G[+^/Y?W
M_V=='! ^][=(9YB)=Q95A8X4)<[0I33/0@0GB+5V496-=<9M=J)T;2?M#EU7
M02:J2D0G=-MY!SL;$1LE#'J<S^YP*A<G]'6M/.W7WK7076NCR2>LD+=&U^I9
M;,!H45E:K'10Z/, >][UFP94QJ:Q7KI;Y7<S&+D%G754?;8!QUKE"1892N0!
M=+SL-!N2$3H;+RLUF']62DK#1L#[J+0-\P?I:&00M>N]V#;.F)UP6XN 0[\.
MNM+2P^Z;04-\Z' 4G3LH$UM#6EOTR?)X-@J>V\J[C;+BHRI5%YT_)/]B+_\6
MN/Y+^9<S3L*@\T5;7!TAJH/"K\2/X"PF9>00N2RR7B&<YSP7EZG,Q4_S1Z#T
M"5)9Z!\!R1^:%H?48W^&?7]*X [-U>$_NP$-\DG''=@V-K@:2M?;F*H![W5G
M4#6$C:Q2ZK&/X),N>?C9:GIB!F#OSE%](%+\6'R>7\_%;^?G5\5/G!18,SVJ
M3FKYF*1QK]8LB8U'2PUP& -C2.K0!" <&R3?;0%@N46S*!1*&8UK@G/1=\Y.
ML@/!.:=N&BZV2H)H'U(WY32QOW\WQ:039(L#"/(NJ(-6_]H6LHPR  T[)3U"
MOU0^8KS #% :&8*NJ?D?A-U2:_%)I(AVT&YJ7=LTOQ!Z8,GY2GD2STA(,"A[
M[ZFCLW8W@1SR/Q2ODSNY-BI!OBQ]CS#4'88DHHR]0[!<T1I!  <=5)=9W6C)
MI(1"$"!09+0/0<>U27!<RP<]?LX#[9FP*F8@BM]!-&*Y9,R1Y4_R#B[/./B,
M;*38(6-P:& Q!G2M*FH%+E(/%M@-SD5Y)\ \] -!@0> *#\A0&BX\H:)&TXF
MHRRO0,IE%%M 95_6!!:O<%'85$P0>QAQF_$H- *.29PB(Y]13WH0LOH#,Q/S
M\@,PT#EFN#/B_2X !+C]M,7ED;21CP^ 72,NM)N+:Z5R]HYFXNW7GICCO0+&
MJ32##J62+-6])^H'X0.U)B3?4P=,[X8AG!^^>[5:_OSF6YKL '6-?(/PX!=*
MCU:PN#J''+3R!CV7.PB>ZI9)B^$7,(IWJ9/XBI*I* D(5$A*:IMP2PIT QH7
M>CHE ^8;F &*%KE#(KXT&LB?^+<&6ZG;X89\W+L^[,GW0";_AA-,5+(#L@ .
M;,_HO:"',&+"($]5Z U%2D-#FA@2E8W.I7JV#CT6],8R&]E[SC/1C?27W08:
ME&=F?@("'LFP?6I#F$Y#:6^'\E&W=2[HE)2$?0P3OFQ2>293R<!(<_%1AYLD
M_'DP1$1SOZ-H3%K_P<5W:&+;MVN$#R\]:P?<*48R8SK&]J&Y3.]1 9]PC?$(
M-\M7(/IL)M88I5 &07=4:L49RUN5^M*M.4YP^=>>6$)6%0>+^M2]33:0@*")
M06MT5YXH.^*0-#B*2)5 4Z,3]VNHM0D'S\*KZ(U*PR"AXI:.RG2 QZI'2E#?
MBL$%"\QD48,#PY!OTK5X_1P3PD=J:V$LSV33<T./:2*$NJ>;?CHX)JK?[)W*
M<P?0K!X#3'8QU9<GR7+ 5X(X. ALO:_57+R[9TE4#F6CFMSS*R?'JTT/TB3"
M'[*#>H*V-::1-0!N^2Y#5&E8BFJ$,+?.D,$@::!"6F794,/31HTAG&\]^/3)
MB8J;<>H9#<#DV&":"'[WE'W* >&>\D$O!A87^A1"+DW)*!=(+&0%JS:21M')
M;BE#(VKCMH&A0#[A/SI-<;1U3R\R]Z\D'M:9>%2:Y-PXD=,MA'IJ9#6_4 SI
MJ(5*5XG.ES:0@HA* "6D^&A2EFLWSO9X@T!OYU;(/;^. ^79S4.G*HYEEB*B
MPU! XL,9$0>:HJ2L\B;92JCC&(-"[G@@(3>Y]G=,;XCB^^5\!0(PAM^160!O
MY8H98W@SGQ]Z=UU,/E, ]1O^&,.,:V/Z8C&NCM][SM-GCKUX^ECT7OH-WIF$
M4354C^8_ORA 5?P!)CU$U_%'C[6+T;7\LU'@%4\"V*\=>B4_T 'C5["S/P%0
M2P,$%     @ 18M75A& ZW*\%@  -T,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3 N>&ULK5QM<]M&DOXK*&UVUZZB*(FR'9W?JF0EWO-5LG%92:ZNKN[#
M$!B2$P,8!@.(EG_]/=T];P!)1;G;#[9$<%YZ^O7I[H%>[VSWV6VT[HLO3=VZ
M-R>;OM^^/#MSY48WRLWM5K?X9F6[1O7XV*W/W+;3JN))37VV.#]_<=8HTYZ\
M?<W//G9O7]NAKTVK/W:%&YI&=??O=&UW;TXN3L*#3V:]Z>G!V=O76[76M[K_
M9?NQPZ>SN$IE&MTZ8]NBTZLW)]<7+]\]H_$\X%>C=R[[O:"3+*W]3!\^5&].
MSHD@7>NRIQ44?MSI&UW7M!#(^-VO>1*WI(GY[V'U]WQVG&6IG+ZQ]7^:JM^\
M.;DZ*2J]4D/=?[*[?]?^/,]IO=+6CO\O=C+VV>5)40ZNMXV?# H:T\I/]<7S
M(9MP=7YDPL)/6##=LA%3^9WJU=O7G=T5'8W&:O0+'Y5G@SC3DE!N^P[?&LSK
MW]Z*, J[*F[-NC4K4ZJV+Z[+T@YM;]IU\='6IC3:O3[KL1_-.BO]VN]D[<61
MM2\6Q8^V[3>N^+ZM=#5>X R$1FH7@=IWBP=7_$Z7\^+R8E8LSA>+!]:[C*>_
MY/4NCZQWX)C%?U\O7=]!6_[GT(EEO6>'UR,+>NFVJM1O3F B3G=W^N3MW_YR
M\>+\U0/4/HO4/GMH]?^GK/Y5:Q<WRFT*U5;RR_>_#^9.U;KM7?'S1A<WMMFJ
M]KXH:^4<EL$$Y8HRS.%?=#9'-;2!*V"AE=Y:9_K"M#"T]K-+$TQ[IUVOJZ+7
MS=9VJC/U/0V[PV]V</@5(AL:6G!6;#O3R(C&MAK_J^XSO)N2HV# SO2;PG9F
M;5I5X^M^Z$Q/A.+P_:;3FB:2VMJNJ+4#'7W1PQ/1]]NA*S?P G,^;*FZ[IZ8
M$T[1X0@=$0KB>AI@6P>^58J>+56MVE(7;*T\EG0$7*:1*V4ZG*<>A(X'&(:'
MJI.E3:4[+/R#OM-U<5&L<*"V-#A4QI!Y\0F\ZTQ))+#(LL^\>B0$B^/ ?:\[
M)@%+0QKP,#7([U1MOM(A[C&HU%W/*M(S4S+!T5&< J^$(R3[CJ@G,@=X@8Y'
M8+G&LSMJS-]=4:LEA-M;Z"&=TJZP!98C@P)=X'H!(OG$INTM;?>CNB=?<"%<
MP7DKX?WUL(;O9#<ADEKA%'9'HNK5LM90$GL'[M&).PU6EJ8VBN.$9_[L,.>[
M?=Z)P$FI>/D_D#KH9@[8'F(*:N,V=M<>U!G7XP?+,6K%"@=Q.)"P\EZKSA5R
M<+A'W2S!X^ B9XDY^.7\9?%?&"W>>#SX2452[LB2$&7J&HQP3WD)68%F)\/?
MX\PWQ=7%_!(_+LZO^.?SJZOYLSU%>SY_7CS#OYO'\Q<KOYA?T<H7"_XI*]]
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M^:+14F]4O6+SKHUT@M/II5:#:=\LYHMP!W-6?$/W*OTG/NLWY_-_BP_^+Y=
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MO6WXUXU&T.]H +Y?60C9?Z -XM_*>/N_4$L#!!0    ( $6+5U:'=\RWW0T
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MT$)(S?XV!R?!P!V<XN*[P],WMK-/2M!-P;%90G>(?>Q$@V=D<05$FYHPE=[
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M'OK0C\7U\,C4]G>[( E%E.HV*Z+8$8;!A2EBW)Q&/'-.;,]:OP=HXJ%Q<5=
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M:R2"AASG!$1XE_)H+!&0@52 -+2DDN\+"E!+!%W:?"+53Q>PP[0Z9:IN.X0
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M"NN5.GZH45]O?)5.D;T<)-L@[&^-@N32Z73[2%(]F_LP^/" G7=39Z=J#CJ
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MEHYFT<W00JQ3BMPQ=$ )M3 4:G[\J&$OEH!50#.-+,B\&GM>8Q>5MWK>,/E
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MTP(\7QCCZPLZH/DCV<U_ 5!+ P04    " !%BU=6OF_^7'L)  #0&0  &0
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M5_+'0F'\\+0 SS<.MX[F"QW0_1'G\@]02P,$%     @ 18M75K;WE(%^ P
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MR-+MQ')SZCL_2Q7QV:R\K_6&A?VNE:8'I#)9\'XUE>(GN(!B?W+R5(1:Z;7
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M&-VI6R%"(>R+MA9G##M?B2@**S<Z9$]J,["D#?)(C^@@4N[LK:J!5^/\6,T
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M"'4\.02'*,28 ,$)CAA.CPE^-D-3J(W.3XY"7ZM)MTUK/DN/!7\K&88C^9T
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M65I-JYS\[&39; :H')9\+7G.4R8M3--4;:3E<@T+)7C*T<#)-5L)-.]'H:7
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MTH7KNP6]<% [ UK/E;+[@0O0OIDFOP%02P,$%     @ 18M75AR_]H$=!
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MW/KC161%"E3<<L2ZY504H,>XGD0;YWK54%&#)DP0TP *UG94//ZD7SHD>U!
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MD4>[D>W#FNB:I3CSZ.5H5(_H)9\^1./P\Q[>HX[W:!]Z<DL/-6L$@LRA[G+
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ML@?(GDMIM@L;H/L%)?\ 4$L#!!0    ( $6+5U81K(=XBP,  ",)   9
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M2E4\5<CQ5!\HME2"SC"7&^!"M*XGEMKC4+$L*;=+[*0?J3C-3^B [XVT6(1
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MI"]<T6J3,,<-<5RUQ,*- 6OF3WT:'D 65 K]48@KBRTM\"7/!595\:\SJ11
M<<1HGZH\HRH_)GX]5>MG7 W&6%S],8KEKM:.(?P1\V?>C'U6QNQ-=XB_WTXQ
M@%)04Y08DG"_Q#]+B 6C*4K/'XV\<6O>C6F?LVN-QVYMMR<,OA6BS,6M#> )
M=*U2')E1>0#J,20UE%,_I&>E<RPFQY44#X?67.IR='],XSX#IMTJP0"78$S
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MZ#E"*#"Q+@.C98=S%,(E(AK/3<Z@A72!A_M]]EM?.]6R9@;G2OS@J<VFP<<
M4MRP4M@'57W!IAY/,%'"^"]4C6\O@*0T5N5-,#'(N:Q7]M+H<! P&)P(B)J
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M&PKM=3\0LJX'1GVPJO!-NE:66MYO,YJQJ)T#W6^4LON# VBG=OP74$L#!!0
M   ( $6+5U;G2DTBQ@(  %T)   9    >&PO=V]R:W-H965T<R]S:&5E=#,U
M+GAM;*U676_:,!3]*U9639W4Y8NDI1U$:@G3]E )@;H]3'LPY@)6'9O:!KI_
M/]M)(R I155Y('9\SLF]Y][8Z6V%?%1+ (V>"\95WUMJO;H) D664&#EBQ5P
MLS(7LL#:3.4B4"L)>.9(!0OB,+P,"DRYE_7<O9',>F*M&>4PDDBMBP++?W?
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M]*^,F"P/\W*BQ<J=5E.AS=GGADOS_0/2 LSZ7 C],K$'8/U%E?T'4$L#!!0
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M0'T*\<1 W=\Q)E]/D@<4/XNL_@=02P,$%     @ 18M75K<D"Q3P P  61@
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MU0BH:!P+S8R$E@DN6 #OD:P*@.H!/')H=U@_SE&K=BPTDQ5=M[MPX;Y_6BN
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MH4U-NZ\&MRI7V*\UF:BW)+#03,ZU-O!.JJO)0Q48J&@<"\V,A-8BWJ%=33"
M-7E-"<)H_?X;Q_)I/LZF)4@?JZD)!K)^D&UGBQ3'<F@RHZ5('ZVI"4:RIJ:E
M1<JIMP!Q+)\F.UHT] ]I8X*-K0G9HO7- ZFN7+%\;@GI59['SWX]X<:7#^K
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M8U-VN<*3+4@3@,\70NC[@3D[E6?EX!]02P,$%     @ 18M75N'TA'"- @
MP 8  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULK55=3]LP%/TK5H8F
MD%CS28=8&JDE3$,:4@5B>YCVX":WC85C!]O]X-_OVDE#@<)XX"7QQSW']Y[K
MG*1KJ>YT!6#(IN9"C[S*F.;,]W5104WU0#8@<&<N54T-3M7"UXT"6CI0S?TH
M"(9^39GPLM2M3566RJ7A3,!4$;VL:ZH>)L#E>N2%WG;AFBTJ8Q?\+&WH F[
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M"EF"TDR@YPLA]'Y@%JB^"(W_ U!+ P04    " !%BU=6;^3%+(8"  "A!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6RM55UOTS 4_2M6F-"0H/EH
M-F"TD=IF"*1-3)L&#X@'-[EMK#EV\'7;\>^Y=M+0C7;:PU[BKWN.[[DW.1EM
MM+G#"L"R^UHJ' >5M<U9&&)10<UQH!M0=++0IN:6EF898F. EQY4RS")HM.P
MYD(%V<CO79ELI%=6"@57AN&JKKGY,P6I-^,@#K8;UV)96;<19J.&+^$&[&US
M96@5]BREJ$&AT(H96(R#27R6IR[>!WP7L,&=.7-*YEK?N<77<AQ$+B&04%C'
MP&E8PPRD=$24QN^.,^BO=,#=^9;]L]=.6N8<8:;E#U'::AQ\"%@)"[Z2]EIO
MOD"GY\3Q%5JB?[)-%QL%K%BAU74'I@QJH=J1WW=UV '$IP< 20=('@/2 X!A
M!Q@^%Y!V %_JL)7BZY!SR[.1T1MF7#2QN8DOID>3?*%<VV^LH5-!.)OY/C.]
M8+<(;(((%AE7);L0?"ZDL *0O6,S73=:@:)#"KT *C0[OZ=7C\;C'"P7$M]0
MW.U-SHZ/WK C)A2[%%)2:W$46DK471<675+3-JGD0%)QPBZULA6R<U5"^9 @
M)(6]S&0K<YH\R9A#,6##^"U+HB39D]#L^?!X#SQ_/CQZ0LVP;]K0\PT/\/D&
M(/LYF:,U].7\VE?BEB+=3^'<Y P;7L X(+M ,&L(LM>OXM/HT[[RO"19_D)D
M#TJ7]J5+GV+/OC5@N!5JR:1_BPN-=E_U6I83S^*L<YTE ^K\>K<H_\?$@_1A
M3-[&?-R-Z2-: >'.QUN#67H31$ILI6S[@O>[O<].O+T\VI^2_[9V^8^F->]+
M;I9"(4E>$&4T>$\YF]80VX75C;>(N;9D.'Y:T3\$C N@\X76=KMP%_1_I>PO
M4$L#!!0    ( $6+5U8?#7=')@,  %$)   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;*U6VV[;.!#]E8&V6*1 8\GRI=VL+2")MFB!!@UB9/>9ED86
M$8K4DE2<_GV'E*+8L6+DP2^V2,XYG#DS''*Q5?K!E(@6GBHAS3(HK:TOPM!D
M)5;,C%2-DE8*I2MF::@WH:DULMR#*A'&430/*\9ED"S\W*U.%JJQ@DN\U6":
MJF+ZUQ4*M5T&X^!YXHYO2NLFPF11LPVNT-[7MYI&8<^2\PJEX4J"QF(97(XO
MTKFS]P;_<MR:G6]PD:R5>G"#[_DRB)Q#*#"SCH'1WR->HQ".B-SXO^,,^BT=
M</?[F?VKCYUB63.#UTK\QW-;+H,O >18L$;8.[7]AET\,\>7*6'\+VP[VRB
MK#%651V8/*BX;/_94Z?##F \?P,0=X#X-6#Z!F#2 2;O!4P[P-0KTX;B=4B9
M9<E"JRUH9TUL[L.+Z=$4/I<N[2NK:943SB8^SZ *N#<(E\:@-<!D#C\X6W/!
M+4<#Y["B:LL;@<YPU=2U0,J\90*NF2GA*]4.?)=M#;IDWJ%@%G.P"GX@)<7
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M,ZVW Z%[#Q7-D-;SH %]*"V TD(4K6VK9EO!-N:.\ZEW_']WN<PA>GL-NML
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M1F$ ^OLYY^KEQCR@.N2;_@=02P,$%     @ 18M75ID@,A"B!   ]!0  !D
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MDN_XZ5<H.S3)>&L>I?EO<BIBIZK%]2&5/"Z3U7$<)L5?_W,IQ%D"M3L26)G
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MYJ>O^0TG^^P\\H5P3J+L<H<]'],T0'R^)82?;M(!RC/PU7]02P,$%     @
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MX-5.B^I$LF6YE>")2<FR\G !5"U,"P-U?\:8?#DI&FCVNTS^ U!+ P04
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MPACH\2WGZM0P$[3OO\7_4$L#!!0    ( $6+5U:US6XIQ ,  $<-   9
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MRJ U0%6JK/=EQ\C<5< G:;">NN82GTB@K '.SZ4TVXY=H'YT17\!4$L#!!0
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MP.B#@$$9,#BT2\,R8'AHP*@,&.5C7PQ6/M(ND60V2?@&)5EK1<LV<KGR:#7
M+,YFUJ-,U%FFXN3LAD<1DVJJ2(%('* ;'DL6+VGL,RK0B4LE8:$X15_1TZ.+
M3KZ<HB^(Q6C.PE!-##$QI>I$AC+],N%-D=#Y(*&-YBK%2B O#FC0$N]^$N]H
M *:Z^FH(G.T07#M:XN]IW$/6X PYEN.T7=!GX6$/]>TLW.ZW78\^W*7^-KPU
MNW=XN-T2C@\/MS1CV:^F4S_G]0^83E?OIM/?=ZHYNI4T$O^T]/6Z8 _:V5F-
MO11KXM.IH8JHH,D+-6:__F*/K-_:5(.$N9 P#Q*&@6 -M0>5V@,=?7;'A4!^
M)?%;FZ9:0E=-(6%N ;O(8=D#^&4VGI@ONT)!IL- L(90PTJHH5:HOTA(T5.L
MGN&)8+)5)RV@JTZ0,!<2YD'",!"L(>FHDG1TQ$H[@E0;$N9"PCQ(& :"-=0>
M5VJ/M3?P W\CH7Q#:_*62=XFJ1;055)(F%O ACN%UNK9>Z7V@#:XK8U3M6F,
MZWDUKN=="B/Z%]TQ7WTWT3.$62+D=C= ]PD/4E^J%H^I[U,AOEZ3[+AZ$Z;J
M+5W=;?>%-FWOQ-?:7G05!Q+F0L(\2!@&@C7FQ44U+RZ.6%TO(-6&A+F0, \2
MAH%@#;5MJ_X*MO3UE?Y(6:)NYZBZG=>:VUE/ZZIP2=M]$^TW2Y\+FM #I6$H
M6E.Z'0/#_MD2_DC5QTD 5</U_>@L.B3-!:5YH#0,16O.#Z>>'\X12WD)AQ(=
MDN:"TCQ0&H:B-46O;2A;ZWMTKN>@SE-)&^_4<[LWW*_HH)82* U#T9KBU:Z2
MK;>5YBQF41JI,GV ;Z%G=98.U&$"I7F@- Q%:VI<&U+V\)A5&=2M J6YH#0/
ME(:A:$W1:\O*UGHDLZLX3DFXK<1HP1,4%N]FK2*#FE0E;;<HOW,87-"4'B@-
M0]&:VM4&E/V_'2@]H;-@XQ;!G'W!(%-ZH#0,16L*5CM;MM[:FI/7#D]14(,*
ME.:"TCQ0&H:B-36N72K[F#:5#>I3@=)<4)H'2L-0M.9JA=JK<C[QJCZOQ'I"
M5V5+6M-XW_^> 4WI@=(P%*TI6.U0.7J'JJ[$F*=Q0/(E57,:,%\U/$.WL=_[
M24M*G[BSSJ"6%"C- Z5A*%IS0M26E'-,2\H!M:1 :2XHS0.E82A:4_3:DG+T
MEM3\G1.%3M(UDAR%?'/:*G3_W?\%;*M9=F_T23O+!VI*@=(P%*V0S]Q9,AG1
M9)DO;LT6,Z6Q+)8.5D>K!;17^;+1O>.N?8F+9; UIEB5.R?)DL4"A72AD%9O
MK!Z@2;'0M=B1?)TOS'SF4O(HWUQ1$M D:Z#.+SB7VYTL0;7<>/8?4$L#!!0
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M,HB%HL#R\@RWD&6*2>;QLR&UVO]4P.YXQ_Y9%R^+><0<;FGV%TE$NK N+)3
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MW?X*TVO'S8G:QN(R90N6CNJNGHZK9F ;-FI]@<,N<E-=?@3S<9@? 0R+@RG
M?)P7%N=_FD\/G8_#,&T]+])#?7JHC_/R(:/J@\7Q^R3V\L\T2:(HCK&,CD9>
M!2,L;W$,7S\;I@T\L#@0Z7FYQE<;KY#]=8"MZ;X*P6:*5R(V4SS7@/CS!AY)
MXE]M+ YX8*N U0[$]\>!FO+[1!&L*J8->X)Q)$DP!&K17Z-QC&0GAH]_?;"G
M)(J2Q(\ YE<011@"3R..8 I  X9$4;4/[NQ'X6J?"M>_7@[_ %!+ P04
M" !%BU=6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M4$L! A0#%     @ 18M75@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !%BU=6]$.^LNT    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !%BU=6F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( $6+5U; )Q*D# @  /0P   8
M      " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !%BU=6'DF;,CT"  #!!0  &               @(%.$   >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 18M75F&MW ?(!0  1Q@  !@
M             ("!P1(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( $6+5U;&1JN*?P(  ),&   8              " @;\8  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !%BU=6Q]0WA;0%  "M
M&P  &               @(%T&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ 18M75NSIH]"^"   PE<  !@              ("!7B$
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( $6+5U:$O0>^
MC@(  +<&   8              " @5(J  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " !%BU=6HK:*%ID(  #%*P  &
M@($6+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 18M7
M5JF2-E/$!P  $1,  !@              ("!Y34  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( $6+5U81@.MRO!8  #=#   9
M      " @=\]  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ 18M75H=WS+?=#0  'R\  !D              ("!TE0  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !%BU=6UYZ109D%  "3#0
M&0              @('F8@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( $6+5U:KHKO"]0(  " '   9              " @;9H  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 18M75DY; A->
M!@  KP\  !D              ("!XFL  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " !%BU=6GH4%6K("   T!@  &0
M@(%W<@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $6+
M5U:Z\GB0M 0  -(+   9              " @6!U  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ 18M75NIX-;][#0  3"@  !D
M         ("!2WH  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " !%BU=6'$S!Z*8)  #3&@  &0              @(']AP  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $6+5U9S[0!9N@P  %0F
M   9              " @=J1  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ 18M75KYO_EQ["0  T!D  !D              ("!RYX
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !%BU=6MO>4
M@7X#   #"   &0              @(%]J   >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( $6+5U;UT,2;2A4  -Y"   9
M  " @3*L  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M18M75O&Z?B8- P  /PD  !D              ("!L\$  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " !%BU=6'+_V@1T$  !;"@  &0
M            @('WQ   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( $6+5U9/5@ER?@,  (8(   9              " @4O)  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 18M75DH5#*C+ @
MC@8  !D              ("! ,T  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " !%BU=6$:R'>(L#   C"0  &0              @($"
MT   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $6+5U;^
MO 73QP(  "(&   9              " @<33  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ 18M75FC*=F]_ @  E 4  !D
M     ("!PM8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $6+5U9"NO14I0(  ,$%   9              "
M@0'L  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 18M7
M5N=*32+& @  70D  !D              ("!W>X  'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " !%BU=6^_=1S3(%  !#(0  &0
M        @(':\0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( $6+5U:.R#R?(18  (&, 0 9              " @4/W  !X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 18M75A@S):K4!   (AD
M !D              ("!FPT! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " !%BU=6MR0+%/ #  !9&   &0              @(&F$@$
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $6+5U9:L7IO
M6@<  ")"   9              " @<T6 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ 18M75B2>"<9? P  -P\  !D
M ("!7AX! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !%
MBU=6X?2$<(T"  # !@  &0              @('T(0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( $6+5U;2>/W^-@0  !T2   9
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M970T-RYX;6Q02P$"% ,4    " !%BU=6+QJF?=H%   <-   &0
M    @($X-0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M $6+5U;=8EOBB0(  .0&   9              " @4D[ 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ 18M75AG<9TF'$P  9"P! !D
M             ("!"3X! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " !%BU=6/&L%'U($  #P$P  &0              @(''40$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( $6+5U:9(#(0H@0
M /04   9              " @5!6 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ 18M75AR\L!PM!   'Q(  !D              ("!
M*5L! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !%BU=6
MJ&9JY[@%  #'*@  &0              @(&-7P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( $6+5U:>TC[-;04   \?   9
M      " @7QE 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ 18M75LGW=RX+ P  ^@L  !D              ("!(&L! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !%BU=6D2+$ZX %  #[(@
M&0              @(%B;@$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( $6+5U8[;4W]O@,   L.   9              " @1ET 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ 18M75K7-;BG$
M P  1PT  !D              ("!#G@! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    " !%BU=61C.Z>AL#  " "0  &0
M@($)? $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( $6+
M5U;K0 GR/ 4  'HL   9              " @5M_ 0!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ 18M75E27)$4T P  ?PH  !D
M         ("!SH0! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
M    " !%BU=686\E*Z0#  #!$@  &0              @($YB $ >&PO=V]R
M:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( $6+5U9 OWGK1@,  ,H4
M   -              "  12, 0!X;"]S='EL97,N>&UL4$L! A0#%     @
M18M75I>*NQS     $P(   L              ( !A8\! %]R96QS+RYR96QS
M4$L! A0#%     @ 18M75M7R<#;V!   %"H   \              ( !;I !
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $6+5U8G9=6E# (  (0E   :
M              "  9&5 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( $6+5U;NU>T8Y@$  /4D   3              "  =67 0!;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !' $< :!,  .R9 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>221</ContextCount>
  <ElementCount>345</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Research Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements</Role>
      <ShortName>Research Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Marketable Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements</Role>
      <ShortName>Marketable Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Property, Equipment and Leasehold Improvements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements</Role>
      <ShortName>Property, Equipment and Leasehold Improvements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Right of Use Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilities</Role>
      <ShortName>Right of Use Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Equity Method Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestments</Role>
      <ShortName>Equity Method Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Research Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables</Role>
      <ShortName>Research Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables</Role>
      <ShortName>Property, Equipment and Leasehold Improvements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Right of Use Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables</Role>
      <ShortName>Right of Use Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/RightofUseAssetsandLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/LongTermDebt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/Equity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Equity Method Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestmentsTables</Role>
      <ShortName>Equity Method Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/EquityMethodInvestments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/NetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Summary of Significant Accounting Policies - Cash Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Summary of Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Marketable Securities and Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Right of Use Assets and Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Right of Use Assets and Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Right of Use Assets and Liabilities - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Right of Use Assets and Liabilities - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails</Role>
      <ShortName>Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Accounts Payable and Accrued Liabilities - Components of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities - Components of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails</Role>
      <ShortName>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails</Role>
      <ShortName>Equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails</Role>
      <ShortName>Equity - Summary of Restricted Stock Grant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Equity Method Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Equity Method Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails</Role>
      <ShortName>Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Income Taxes - Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Income Taxes - Summary of Deferred Income Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Summary of Deferred Income Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/CommitmentsandContingencies</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Net Loss Per Share - Basic and Diluted Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and Diluted Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="arvn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:InterestExpenseDebt, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  arvn-20221231.htm 4</Log>
    <Log type="Warning">[EFM.6.05.45.cover-page-fact-not-visible] Submission type 10-K has 4 cover page fact(s) in ix:hidden that should be visible or referenced by an -sec-ix-hidden style property: EntityCurrentReportingStatus, EntityInteractiveDataCurrent, EntityVoluntaryFilers, EntityWellKnownSeasonedIssuer - arvn-20221231.htm 4 - arvn-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="arvn-20221231.htm">arvn-20221231.htm</File>
    <File>arvinaspfizzeramendmentno3.htm</File>
    <File>arvn-20221231.xsd</File>
    <File>arvn-20221231_cal.xml</File>
    <File>arvn-20221231_def.xml</File>
    <File>arvn-20221231_lab.xml</File>
    <File>arvn-20221231_pre.xml</File>
    <File>arvn-20221231x10kxex21_1.htm</File>
    <File>arvn-20221231x10kxex311.htm</File>
    <File>arvn-20221231x10kxex312.htm</File>
    <File>arvn-20221231x10kxex321.htm</File>
    <File>arvn-20221231x10kxex322.htm</File>
    <File>consent-form10kfy22.htm</File>
    <File>exhibit1034arvinasbayeroer.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>arvn-20221231_g1.jpg</File>
    <File>arvn-20221231_g10.jpg</File>
    <File>arvn-20221231_g11.jpg</File>
    <File>arvn-20221231_g12.jpg</File>
    <File>arvn-20221231_g2.jpg</File>
    <File>arvn-20221231_g3.jpg</File>
    <File>arvn-20221231_g4.jpg</File>
    <File>arvn-20221231_g5.jpg</File>
    <File>arvn-20221231_g6.jpg</File>
    <File>arvn-20221231_g7.jpg</File>
    <File>arvn-20221231_g8.jpg</File>
    <File>arvn-20221231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="813">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arvn-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 813,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 221,
   "dts": {
    "calculationLink": {
     "local": [
      "arvn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arvn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "arvn-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arvn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arvn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "arvn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 544,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 9,
    "http://xbrl.sec.gov/dei/2022": 8,
    "total": 17
   },
   "keyCustom": 40,
   "keyStandard": 305,
   "memberCustom": 39,
   "memberStandard": 28,
   "nsprefix": "arvn",
   "nsuri": "http://www.arvinas.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.arvinas.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Research Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements",
     "shortName": "Research Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Marketable Securities and Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements",
     "shortName": "Marketable Securities and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Property, Equipment and Leasehold Improvements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements",
     "shortName": "Property, Equipment and Leasehold Improvements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Right of Use Assets and Liabilities",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilities",
     "shortName": "Right of Use Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Accounts Payable and Accrued Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Long-Term Debt",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.arvinas.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.arvinas.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Equity Method Investments",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.arvinas.com/role/EquityMethodInvestments",
     "shortName": "Equity Method Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.arvinas.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.arvinas.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.arvinas.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.arvinas.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Research Collaboration and License Agreements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables",
     "shortName": "Research Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables",
     "shortName": "Marketable Securities and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables",
     "shortName": "Property, Equipment and Leasehold Improvements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Right of Use Assets and Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables",
     "shortName": "Right of Use Assets and Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Long-Term Debt (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.arvinas.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Equity (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.arvinas.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Equity Method Investments (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.arvinas.com/role/EquityMethodInvestmentsTables",
     "shortName": "Equity Method Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.arvinas.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.arvinas.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "arvn:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "arvn:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Summary of Significant Accounting Policies - Cash Reconciliation (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i0c3c730cf6ec499aac36b9dae0dfff96_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i0c3c730cf6ec499aac36b9dae0dfff96_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Research Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i0ae6f33336fd4929b4de48a65cfd91f3_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails",
     "shortName": "Research Collaboration and License Agreements - Summary of Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails",
     "shortName": "Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i24c2800943e64589bfe1be38fdfcdeac_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Marketable Securities and Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails",
     "shortName": "Marketable Securities and Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i24c2800943e64589bfe1be38fdfcdeac_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
     "shortName": "Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
     "shortName": "Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i5bc16f834f8e48cca3a2cc04f3bdb2ab_I20210531",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LandSubjectToGroundLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Right of Use Assets and Liabilities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
     "shortName": "Right of Use Assets and Liabilities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i5bc16f834f8e48cca3a2cc04f3bdb2ab_I20210531",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LandSubjectToGroundLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Right of Use Assets and Liabilities - Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails",
     "shortName": "Right of Use Assets and Liabilities - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails",
     "shortName": "Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Accounts Payable and Accrued Liabilities - Components of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Liabilities - Components of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i6661ad55442349ec8d7ed679ec7f076a_D20180601-20180630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "arvn:PercentageOfMaximumFundingOnProjectCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Long-Term Debt - Additional Information (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i6661ad55442349ec8d7ed679ec7f076a_D20180601-20180630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "arvn:PercentageOfMaximumFundingOnProjectCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails",
     "shortName": "Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
     "shortName": "Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
     "shortName": "Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "ie6fa461cbdf54025b52ab83381dd58c8_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "ia0a99c647f184a9ab5e6769eafbbd9bd_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Equity - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails",
     "shortName": "Equity - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "ibf40c4a4c35741269074c5b864fba1ac_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i64e8a70e80d34c36a994fb20b47a535c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
     "shortName": "Equity - Summary of Restricted Stock Grant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i64e8a70e80d34c36a994fb20b47a535c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Equity Method Investments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
     "shortName": "Equity Method Investments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "idfbc96733ba14eacba1def4f1f53391f_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails",
     "shortName": "Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i67f3345958fe4cb09d464ed14886f52e_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Income Taxes - Income Tax Expense (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails",
     "shortName": "Income Taxes - Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsDeferredIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Income Taxes - Summary of Deferred Income Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Summary of Deferred Income Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsDeferredIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i62b9074c6dbb4f3fbdbff41dce34d514_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i62b9074c6dbb4f3fbdbff41dce34d514_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "i0ae6f33336fd4929b4de48a65cfd91f3_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.arvinas.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "iafe9691446164ba9bb2c4bf060b98b4b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Net Loss Per Share - Basic and Diluted Loss per Share (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperShareDetails",
     "shortName": "Net Loss Per Share - Basic and Diluted Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "ia9b34aabf560460e87638e54eb236a17_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "ia9b34aabf560460e87638e54eb236a17_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Nature of Business and Basis of Presentation",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20221231.htm",
      "contextRef": "icc0f8a5c31cd4c03b62024ed8dec8f8e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 71,
   "tag": {
    "arvn_AccountsPayableContractBalancesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable, Contract Balances, Current",
        "label": "Accounts Payable, Contract Balances, Current",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AccountsPayableContractBalancesCurrent",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AccountsPayableContractBalancesCurrentAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable, Contract Balances, Current Additions",
        "label": "Accounts Payable, Contract Balances, Current Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AccountsPayableContractBalancesCurrentAdditions",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AccountsPayableContractBalancesCurrentPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable, Contract Balances, Current Payments",
        "label": "Accounts Payable, Contract Balances, Current Payments",
        "terseLabel": "Payments made"
       }
      }
     },
     "localname": "AccountsPayableContractBalancesCurrentPayments",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current, Additions",
        "label": "Accounts Receivable, After Allowance For Credit Loss, Current, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received",
        "label": "Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received",
        "negatedTerseLabel": "Payments received"
       }
      }
     },
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AdditionalTargetAndServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Target and Services",
        "label": "Additional Target and Services [Member]",
        "terseLabel": "Additional Target and Services"
       }
      }
     },
     "localname": "AdditionalTargetAndServicesMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_AnnualLicenseFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license fee payment.",
        "label": "Annual License Fee Payment",
        "terseLabel": "Annual payment for license"
       }
      }
     },
     "localname": "AnnualLicenseFeePayment",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At-the-Market Offering",
        "verboseLabel": "At The Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.arvinas.com/20221231",
     "xbrltype": "stringItemType"
    },
    "arvn_BaseLeaseRentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Lease Rent Period",
        "label": "Base Lease Rent Period",
        "terseLabel": "Base rent period"
       }
      }
     },
     "localname": "BaseLeaseRentPeriod",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arvn_BayerAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer AG.",
        "label": "Bayer A G [Member]",
        "terseLabel": "Bayer A G"
       }
      }
     },
     "localname": "BayerAGMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_BayerCropScienceLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer CropScience LP.",
        "label": "Bayer Crop Science L P [Member]",
        "terseLabel": "Bayer LP"
       }
      }
     },
     "localname": "BayerCropScienceLPMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities",
        "terseLabel": "Cash, cash equivalents, restricted cash and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndMarketableSecurities",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Accounts Payable, after Allowance for Credit Loss",
        "label": "Change in Accounts Payable, after Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts payable related to collaborations"
       }
      }
     },
     "localname": "ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Accounts Receivable, after Allowance for Credit Loss",
        "label": "Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Collaboration Contract Asset And Other Assets",
        "label": "Change in Collaboration Contract Asset And Other Assets [Roll Forward]",
        "terseLabel": "Contract assets: Collaboration contract asset"
       }
      }
     },
     "localname": "ChangeInCollaborationContractAssetAndOtherAssetsRollForward",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Contract with Customer, Liability",
        "label": "Change in Contract with Customer, Liability [Roll Forward]",
        "terseLabel": "Contract liabilities: Deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CollaborationContractAssetAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Contract Asset And Other Assets",
        "label": "Collaboration Contract Asset And Other Assets",
        "terseLabel": "Collaboration contract asset and other assets"
       }
      }
     },
     "localname": "CollaborationContractAssetAndOtherAssets",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CollaboratorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborator one.",
        "label": "Collaborator One [Member]",
        "terseLabel": "Collaborator One"
       }
      }
     },
     "localname": "CollaboratorOneMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CollaboratorThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborator three.",
        "label": "Collaborator Three [Member]",
        "terseLabel": "Collaborator Three"
       }
      }
     },
     "localname": "CollaboratorThreeMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CollaboratorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborator two.",
        "label": "Collaborator Two [Member]",
        "terseLabel": "Collaborator Two"
       }
      }
     },
     "localname": "CollaboratorTwoMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements",
        "label": "Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements",
        "label": "Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements",
        "terseLabel": "Additions to collaboration agreements"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer Liability, Revenue Recognized Not Included In Previous Balance",
        "label": "Contract With Customer Liability, Revenue Recognized Not Included In Previous Balance",
        "terseLabel": "Revenue recognized from balances not held at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedNotIncludedInPreviousBalance",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Five",
        "label": "Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Five [Member]",
        "terseLabel": "Corporate Bonds Maturing 2024-2025"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Maturing Two Thousand Twenty Three",
        "label": "Corporate Bonds Maturing Two Thousand Twenty Three [Member]",
        "terseLabel": "Corporate Bonds Maturing 2023"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyThreeMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four",
        "label": "Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four [Member]",
        "terseLabel": "Corporate Bonds Maturing 2023 -2024"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Maturing Two Thousand Twenty Two",
        "label": "Corporate Bonds Maturing Two Thousand Twenty Two [Member]",
        "terseLabel": "Corporate Bonds Maturing 2022"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyTwoMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument amortization period after interest payments period",
        "label": "Debt Instrument Amortization Period After Interest Payments Period",
        "terseLabel": "Debt instrument amortization period (month)"
       }
      }
     },
     "localname": "DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arvn_DebtInstrumentInterestPaymentsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest payments term.",
        "label": "Debt Instrument Interest Payments Term",
        "terseLabel": "Debt instrument interest payments term"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentsTerm",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arvn_DebtInstrumentLoanForgiveness": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Loan Forgiveness",
        "label": "Debt Instrument Loan Forgiveness",
        "negatedTerseLabel": "Forgiveness of debt income",
        "terseLabel": "Loan forgiveness"
       }
      }
     },
     "localname": "DebtInstrumentLoanForgiveness",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_DefinedContributionPlanPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Policy",
        "label": "Defined Contribution Plan, Policy [Policy Text Block]",
        "terseLabel": "401(k) Savings plan"
       }
      }
     },
     "localname": "DefinedContributionPlanPolicyPolicyTextBlock",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arvn_DevelopmentMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestone payments.",
        "label": "Development Milestone Payments [Member]",
        "terseLabel": "Development Milestone Payments"
       }
      }
     },
     "localname": "DevelopmentMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_DirectAndIncrementalCostsIncurredToObtainTheContract": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct And Incremental Costs Incurred To Obtain The Contract",
        "label": "Direct And Incremental Costs Incurred To Obtain The Contract",
        "terseLabel": "Collaboration agreement direct and incremental costs incurred"
       }
      }
     },
     "localname": "DirectAndIncrementalCostsIncurredToObtainTheContract",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Return To Provision, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Return To Provision, Percent",
        "terseLabel": "Return to provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_EmployeesDirectorsAndConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees, directors and consultants.",
        "label": "Employees Directors And Consultants [Member]",
        "terseLabel": "Employees, Directors and Consultants"
       }
      }
     },
     "localname": "EmployeesDirectorsAndConsultantsMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees.",
        "label": "Employees [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_EquityDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Distribution Agreement",
        "label": "Equity Distribution Agreement [Member]",
        "terseLabel": "Equity Distribution Agreement"
       }
      }
     },
     "localname": "EquityDistributionAgreementMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_FoundationMedicineIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foundation Medicine, Inc.",
        "label": "Foundation Medicine, Inc. [Member]",
        "terseLabel": "Foundation Medicine, Inc."
       }
      }
     },
     "localname": "FoundationMedicineIncMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future grant of incentive units to service providers, percentage.",
        "label": "Future Grant Of Incentive Units To Service Providers Percentage",
        "terseLabel": "Future grant of incentive units to service providers, percentage"
       }
      }
     },
     "localname": "FutureGrantOfIncentiveUnitsToServiceProvidersPercentage",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech, Incorporation. and F. Hoffman-La Roche Limited.",
        "label": "Genentech Incorporation And F Hoffman La Roche Limited [Member]",
        "terseLabel": "Genentech, Inc. and F. Hoffman-La Roche Ltd."
       }
      }
     },
     "localname": "GenentechIncorporationAndFHoffmanLaRocheLimitedMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Maturing Two Thousand Twenty Four",
        "label": "Government Securities Maturing Two Thousand Twenty Four [Member]",
        "terseLabel": "Government Securities Maturing 2024"
       }
      }
     },
     "localname": "GovernmentSecuritiesMaturingTwoThousandTwentyFourMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Maturing Two Thousand Twenty Three",
        "label": "Government Securities Maturing Two Thousand Twenty Three [Member]",
        "terseLabel": "Government Securities Maturing 2023"
       }
      }
     },
     "localname": "GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Maturing Two Thousand Twenty Two",
        "label": "Government Securities Maturing Two Thousand Twenty Two [Member]",
        "terseLabel": "Government Securities Maturing 2022"
       }
      }
     },
     "localname": "GovernmentSecuritiesMaturingTwoThousandTwentyTwoMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Statement And Statement Of Comprehensive Income",
        "label": "Income Statement And Statement Of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAndStatementOfComprehensiveIncomeAbstract",
     "nsuri": "http://www.arvinas.com/20221231",
     "xbrltype": "stringItemType"
    },
    "arvn_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.",
        "label": "Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock",
        "terseLabel": "Common stock reserved for issuance on outstanding common stock (percentage)"
       }
      }
     },
     "localname": "IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_LicenseFirstLicensedProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, First Licensed Product",
        "label": "License, First Licensed Product [Member]",
        "terseLabel": "License, First Licensed Product"
       }
      }
     },
     "localname": "LicenseFirstLicensedProductMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_LicenseSecondLicensedProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, Second Licensed Product",
        "label": "License, Second Licensed Product [Member]",
        "terseLabel": "License, Second Licensed Product"
       }
      }
     },
     "localname": "LicenseSecondLicensedProductMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate offering price of common stock under equity distribution agreement.",
        "label": "Maximum Aggregate Offering Price Of Common Stock Under Equity Distribution Agreement",
        "terseLabel": "Common stock aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_NumberOfMaximumDesignatedTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of maximum designated targets.",
        "label": "Number Of Maximum Designated Targets",
        "terseLabel": "Number of designated targets"
       }
      }
     },
     "localname": "NumberOfMaximumDesignatedTargets",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arvn_NumberOfVotesPerCommonStockShareHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes per common stock share held",
        "label": "Number of votes per common stock share held",
        "terseLabel": "Number of votes per common stock share held"
       }
      }
     },
     "localname": "NumberOfVotesPerCommonStockShareHeld",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arvn_NumberOfWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of wholly owned subsidiaries.",
        "label": "Number Of Wholly Owned Subsidiaries",
        "terseLabel": "Number of wholly owned subsidiaries"
       }
      }
     },
     "localname": "NumberOfWhollyOwnedSubsidiaries",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arvn_OerthBioLimitedLiabilityCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oerth Bio LLC.",
        "label": "Oerth Bio Limited Liability Corporation [Member]",
        "terseLabel": "Oerth"
       }
      }
     },
     "localname": "OerthBioLimitedLiabilityCorporationMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating losses carry forward, maximum deductibility as a percentage of taxable income.",
        "label": "Operating Losses Carry Forward Maximum Deductibility Percentage",
        "terseLabel": "Operating losses carry forward, maximum deductibility percentage"
       }
      }
     },
     "localname": "OperatingLossesCarryForwardMaximumDeductibilityPercentage",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_OptionPaymentsToLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option payments to license agreement.",
        "label": "Option Payments To License Agreement [Member]",
        "terseLabel": "Option Payments"
       }
      }
     },
     "localname": "OptionPaymentsToLicenseAgreementMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_PercentageOfIncrementalBorrowingForLeasePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of incremental borrowing for lease payments.",
        "label": "Percentage Of Incremental Borrowing For Lease Payments",
        "terseLabel": "Percentage of incremental borrowing for lease payments"
       }
      }
     },
     "localname": "PercentageOfIncrementalBorrowingForLeasePayments",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_PercentageOfLiquidatedDamages": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of liquidated damages.",
        "label": "Percentage Of Liquidated Damages",
        "terseLabel": "Percentage of liquidated damages"
       }
      }
     },
     "localname": "PercentageOfLiquidatedDamages",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_PercentageOfMaximumFundingOnProjectCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of maximum funding on project costs.",
        "label": "Percentage Of Maximum Funding On Project Costs",
        "terseLabel": "Percentage of maximum funding on total project costs"
       }
      }
     },
     "localname": "PercentageOfMaximumFundingOnProjectCosts",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_PfizerIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer, Incorporation.",
        "label": "Pfizer Incorporation [Member]",
        "terseLabel": "Pfizer, Inc."
       }
      }
     },
     "localname": "PfizerIncorporationMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_PiperSandlerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Piper Sandler.",
        "label": "Piper Sandler [Member]",
        "terseLabel": "Piper Sandler"
       }
      }
     },
     "localname": "PiperSandlerMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock in an at-the-market offering.",
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "terseLabel": "Proceeds from sale of common stock in at-the-market offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock in a public offering.",
        "label": "Proceeds From Issuance Of Common Stock In A Public Offering",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockInAPublicOffering",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ProceedsFromMaturitiesOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from maturities of marketable securities.",
        "label": "Proceeds From Maturities Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesOfMarketableSecurities",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ProceedsFromSaleOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of marketable securities.",
        "label": "Proceeds From Sale Of Marketable Securities",
        "terseLabel": "Sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_RegulatoryMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payments.",
        "label": "Regulatory Milestone Payments [Member]",
        "terseLabel": "Regulatory Milestone Payments"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_RequiredMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Required Milestone Payments",
        "label": "Required Milestone Payments",
        "terseLabel": "Required milestone payments"
       }
      }
     },
     "localname": "RequiredMilestonePayments",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreements.",
        "label": "Research Collaboration And License Agreements [Abstract]",
        "terseLabel": "Research Collaboration And License Agreements [Abstract]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.arvinas.com/20221231",
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreements.",
        "label": "Research Collaboration And License Agreements [Line Items]",
        "terseLabel": "Research Collaboration And License Agreements [Line Items]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsLineItems",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreements.",
        "label": "Research Collaboration And License Agreements [Table]",
        "terseLabel": "Research Collaboration And License Agreements [Table]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsTable",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchFundingPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research funding payments.",
        "label": "Research Funding Payments [Member]",
        "terseLabel": "Research Funding Payments"
       }
      }
     },
     "localname": "ResearchFundingPaymentsMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SaleOfStockFairValueOfSharesSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, fair value of shares sold.",
        "label": "Sale Of Stock Fair Value Of Shares Sold",
        "terseLabel": "Fair value of the shares sold"
       }
      }
     },
     "localname": "SaleOfStockFairValueOfSharesSold",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_SalesBasedMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestone payments.",
        "label": "Sales Based Milestone Payments [Member]",
        "terseLabel": "Sales-based Milestone Payments"
       }
      }
     },
     "localname": "SalesBasedMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental cash flow information related to leases.",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow information related to leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercises weighted average grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Expected To Vest Exercisable Number",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Expected To Vest Exercisable Number",
        "terseLabel": "Restricted stock units expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsExpectedToVestExercisableNumber",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock incentive plan.",
        "label": "Stock Incentive Plan [Member]",
        "terseLabel": "Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement.",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SuccessBasedMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success-Based Milestone Payments",
        "label": "Success-Based Milestone Payments [Member]",
        "terseLabel": "Success-Based Milestone Payments"
       }
      }
     },
     "localname": "SuccessBasedMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant of accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_SupplementalNonCashInformationRelatedToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental non-cash information related to leases.",
        "label": "Supplemental Non Cash Information Related To Leases [Abstract]",
        "terseLabel": "Supplemental non-cash information:"
       }
      }
     },
     "localname": "SupplementalNonCashInformationRelatedToLeasesAbstract",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_TwoThousandAndEighteenAssistanceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and eighteen assistance agreement.",
        "label": "Two Thousand And Eighteen Assistance Agreement [Member]",
        "terseLabel": "2018 Assistance Agreement"
       }
      }
     },
     "localname": "TwoThousandAndEighteenAssistanceAgreementMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_TwoThousandAndFourteenAssistanceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen assistance agreement.",
        "label": "Two Thousand And Fourteen Assistance Agreement [Member]",
        "terseLabel": "2014 Assistance Agreement"
       }
      }
     },
     "localname": "TwoThousandAndFourteenAssistanceAgreementMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_TwoThousandEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen stock incentive plan.",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_YaleUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yale University.",
        "label": "Yale University [Member]",
        "terseLabel": "Yale University"
       }
      }
     },
     "localname": "YaleUniversityMember",
     "nsuri": "http://www.arvinas.com/20221231",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r286",
      "r312",
      "r536",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r339",
      "r494",
      "r506",
      "r533",
      "r534",
      "r549",
      "r556",
      "r568",
      "r620",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r339",
      "r494",
      "r506",
      "r533",
      "r534",
      "r549",
      "r556",
      "r568",
      "r620",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r241",
      "r496",
      "r551",
      "r566",
      "r615",
      "r616",
      "r624",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r241",
      "r496",
      "r551",
      "r566",
      "r615",
      "r616",
      "r624",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r331",
      "r339",
      "r370",
      "r371",
      "r372",
      "r469",
      "r494",
      "r506",
      "r533",
      "r534",
      "r549",
      "r556",
      "r568",
      "r614",
      "r620",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r331",
      "r339",
      "r370",
      "r371",
      "r372",
      "r469",
      "r494",
      "r506",
      "r533",
      "r534",
      "r549",
      "r556",
      "r568",
      "r614",
      "r620",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r286",
      "r312",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r153",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r216",
      "r255",
      "r256",
      "r406",
      "r429",
      "r430",
      "r431",
      "r432",
      "r449",
      "r461",
      "r462",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r153",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r216",
      "r255",
      "r256",
      "r406",
      "r429",
      "r430",
      "r431",
      "r432",
      "r449",
      "r461",
      "r462",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r203",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]",
        "terseLabel": "adjustments"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r340",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r153",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r204",
      "r216",
      "r406",
      "r429",
      "r430",
      "r431",
      "r449",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r597",
      "r598",
      "r600",
      "r601",
      "r602",
      "r612",
      "r613",
      "r664",
      "r668",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "as previously reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r205",
      "r340",
      "r579",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r242",
      "r243",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r552",
      "r567",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r242",
      "r243",
      "r518",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r552",
      "r567",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r205",
      "r340",
      "r579",
      "r580",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r606",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r533",
      "r534",
      "r673",
      "r675",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONNECTICUT",
        "terseLabel": "State of Connecticut"
       }
      }
     },
     "localname": "CT",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails",
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r564"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net accretion of bond discounts/premiums"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r2",
      "r127",
      "r142"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees and other"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r78",
      "r159"
     ],
     "calculation": {
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r162",
      "r502",
      "r512",
      "r516"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r25",
      "r28",
      "r114",
      "r462",
      "r507",
      "r508",
      "r585",
      "r586",
      "r587",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r8",
      "r564"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r594",
      "r595",
      "r596",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r99",
      "r100",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r85",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance of common stock, offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Compensation expense, total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from the computations of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetPledgedAsCollateralMember": {
     "auth_ref": [
      "r422",
      "r560",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset pledged as collateral.",
        "label": "Asset Pledged as Collateral [Member]",
        "terseLabel": "Asset Pledged as Collateral"
       }
      }
     },
     "localname": "AssetPledgedAsCollateralMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r125",
      "r141",
      "r160",
      "r184",
      "r225",
      "r235",
      "r239",
      "r252",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r422",
      "r426",
      "r441",
      "r564",
      "r618",
      "r619",
      "r671"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r155",
      "r163",
      "r184",
      "r252",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r422",
      "r426",
      "r441",
      "r564",
      "r618",
      "r619",
      "r671"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Non-recurring fair value measurements"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r248",
      "r262"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r67",
      "r247",
      "r262",
      "r497"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r55",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property, equipment and leasehold improvements unpaid at period end"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "negatedLabel": "Amortization",
        "terseLabel": "Amortization of collaboration contract asset"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r48",
      "r157",
      "r535"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r49",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r41",
      "r48",
      "r54"
     ],
     "calculation": {
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r41",
      "r120"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Research Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r131",
      "r148"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r267",
      "r268",
      "r520",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r594",
      "r595",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r564"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 53.2 and 53.0 shares issued and outstanding as of December\u00a031, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r29",
      "r167",
      "r169",
      "r175",
      "r498",
      "r503"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r62",
      "r63",
      "r117",
      "r118",
      "r244",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r62",
      "r63",
      "r117",
      "r118",
      "r244",
      "r517",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r62",
      "r63",
      "r117",
      "r118",
      "r244",
      "r519",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r137",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r62",
      "r63",
      "r117",
      "r118",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r62",
      "r63",
      "r117",
      "r118",
      "r244",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of contract balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r315",
      "r317",
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Contract revenue receivable if milestones achieved"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r315",
      "r316",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract",
        "terseLabel": "Revenue adjustments arising from contract modifications"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r315",
      "r316",
      "r328"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r315",
      "r316",
      "r328"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "netLabel": "Revenue recognized",
        "terseLabel": "Revenue recognized from balances held at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r593",
      "r656",
      "r658"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r402",
      "r410",
      "r593"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r593",
      "r656",
      "r658"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r61",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r183",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r299",
      "r306",
      "r307",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r126",
      "r129",
      "r140",
      "r189",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r448",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r122",
      "r123",
      "r283",
      "r448",
      "r545",
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r20",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate per annum"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r21",
      "r189",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r448",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r21",
      "r86",
      "r87",
      "r88",
      "r89",
      "r121",
      "r122",
      "r123",
      "r136",
      "r189",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r308",
      "r448",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "DebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "negatedLabel": "Loss (gain) on sale of marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r593",
      "r657",
      "r658"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r46",
      "r110",
      "r403",
      "r409",
      "r410",
      "r593"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r4",
      "r5",
      "r128",
      "r139",
      "r396"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r593",
      "r657",
      "r658"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r108",
      "r655"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r108",
      "r655"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r108",
      "r655"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r108",
      "r655"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r106",
      "r108",
      "r655"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r108",
      "r655"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r102",
      "r654"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred income tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r108",
      "r655"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r108",
      "r655"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property, equipment and leasehold improvements"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesSummaryofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Discretionary matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r46",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r46",
      "r76"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r344",
      "r375",
      "r376",
      "r378",
      "r383",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r176",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r206",
      "r208",
      "r210",
      "r211",
      "r212",
      "r216",
      "r431",
      "r432",
      "r499",
      "r504",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in usd per share)",
        "verboseLabel": "Net loss per common share - basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r176",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r208",
      "r210",
      "r211",
      "r212",
      "r216",
      "r431",
      "r432",
      "r499",
      "r504",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Reconciliation of effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r185",
      "r388",
      "r411"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r652",
      "r659"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r652",
      "r659"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r652",
      "r659"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r652",
      "r659"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "auth_ref": [
      "r652",
      "r659"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r652",
      "r659"
     ],
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Federal research tax credit",
        "verboseLabel": "Effective income tax rate reconciliation, tax credit, research and development, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.arvinas.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation expense not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expense not yet recognized, period of recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r651"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation expense for options not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r85",
      "r152",
      "r171",
      "r172",
      "r173",
      "r190",
      "r191",
      "r192",
      "r194",
      "r201",
      "r204",
      "r218",
      "r254",
      "r314",
      "r379",
      "r380",
      "r381",
      "r405",
      "r406",
      "r430",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r462",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r154",
      "r184",
      "r252",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r154",
      "r184",
      "r252",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest, percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r70",
      "r226",
      "r582"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r40",
      "r72",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r433",
      "r434",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r297",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r434",
      "r466",
      "r467",
      "r468",
      "r545",
      "r546",
      "r553",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r436",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Marketable Securities and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r297",
      "r332",
      "r337",
      "r434",
      "r467",
      "r545",
      "r546",
      "r553",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r297",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r466",
      "r467",
      "r468",
      "r545",
      "r546",
      "r553",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r438",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.",
        "label": "Federal Deposit Insurance Corporation Premium Expense",
        "terseLabel": "Federal deposit insurance corporation premium expense"
       }
      }
     },
     "localname": "FederalDepositInsuranceCorporationPremiumExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r249",
      "r250",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r308",
      "r313",
      "r428",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r543",
      "r608",
      "r609",
      "r610",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r46",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment of long lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r225",
      "r234",
      "r238",
      "r240",
      "r542"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes and loss from equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r30",
      "r46",
      "r70",
      "r132",
      "r149",
      "r223"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Loss from equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r185",
      "r389",
      "r394",
      "r401",
      "r407",
      "r412",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r186",
      "r203",
      "r204",
      "r224",
      "r387",
      "r408",
      "r413",
      "r505"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "terseLabel": "Income tax expense",
        "totalLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.arvinas.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r170",
      "r385",
      "r386",
      "r394",
      "r395",
      "r400",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReceivable": {
     "auth_ref": [
      "r138",
      "r583"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.",
        "label": "Income Taxes Receivable",
        "verboseLabel": "Receivables relating to research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r652"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "verboseLabel": "Effective income tax rate reconciliation, tax credit, research and development"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r588"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedTerseLabel": "Collaboration contract asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r495",
      "r588"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r35",
      "r303",
      "r311",
      "r547",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r177",
      "r180",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r33",
      "r222"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Lease for laboratory and office space (in square feet)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r458",
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Base rent"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Right of Use Assets and Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r184",
      "r252",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r423",
      "r426",
      "r427",
      "r441",
      "r541",
      "r618",
      "r671",
      "r672"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r130",
      "r146",
      "r564",
      "r592",
      "r611",
      "r665"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r156",
      "r184",
      "r252",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r423",
      "r426",
      "r427",
      "r441",
      "r564",
      "r618",
      "r671",
      "r672"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r129",
      "r143",
      "r296",
      "r310",
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r83",
      "r189",
      "r621"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r83",
      "r189",
      "r301"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r83",
      "r189",
      "r301"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r83",
      "r189",
      "r301"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r83",
      "r189",
      "r301"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r83",
      "r189",
      "r301"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofAnticipatedFutureMinimumPaymentsonLongTermDebtExcludingDiscountonDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r269",
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r41",
      "r44",
      "r47"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r47",
      "r133",
      "r150",
      "r154",
      "r166",
      "r168",
      "r173",
      "r184",
      "r193",
      "r195",
      "r196",
      "r198",
      "r199",
      "r203",
      "r204",
      "r209",
      "r225",
      "r234",
      "r238",
      "r240",
      "r252",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r432",
      "r441",
      "r542",
      "r618"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of restricted stock award activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r225",
      "r234",
      "r238",
      "r240",
      "r542"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r454",
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r452",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r589"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r457",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r111",
      "r112",
      "r113"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized (loss) gain on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForBrokerageFees": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for brokerage fees during the current period. This element is intended to represent the brokerage fees paid by and between financial industry participants.",
        "label": "Payments for Brokerage Fees",
        "terseLabel": "Financial advisor fees"
       }
      }
     },
     "localname": "PaymentsForBrokerageFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "terseLabel": "Royalty payment"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForUnderwritingExpense": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.",
        "label": "Payments for Underwriting Expense",
        "terseLabel": "Fees and expenses"
       }
      }
     },
     "localname": "PaymentsForUnderwritingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of common stock offering costs",
        "terseLabel": "Fees and expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, equipment and leasehold improvements"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PledgedStatusAxis": {
     "auth_ref": [
      "r422",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by pledged or not pledged status of asset owned by entity.",
        "label": "Pledged Status [Axis]",
        "terseLabel": "Pledged Status [Axis]"
       }
      }
     },
     "localname": "PledgedStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PledgedStatusDomain": {
     "auth_ref": [
      "r422",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledged or not pledged status of asset owned by entity.",
        "label": "Pledged Status [Domain]",
        "terseLabel": "Pledged Status [Domain]"
       }
      }
     },
     "localname": "PledgedStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PledgingPurposeAxis": {
     "auth_ref": [
      "r477",
      "r560",
      "r565",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by pledging purpose of pledged asset owned.",
        "label": "Pledging Purpose [Axis]",
        "terseLabel": "Pledging Purpose [Axis]"
       }
      }
     },
     "localname": "PledgingPurposeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PledgingPurposeDomain": {
     "auth_ref": [
      "r477",
      "r560",
      "r565",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledging purpose of pledged asset owned.",
        "label": "Pledging Purpose [Domain]",
        "terseLabel": "Pledging Purpose [Domain]"
       }
      }
     },
     "localname": "PledgingPurposeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r584"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Payments received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Gross proceeds from sale of shares in Initial public offering before fees and expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r98"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r154",
      "r166",
      "r168",
      "r178",
      "r184",
      "r193",
      "r203",
      "r204",
      "r225",
      "r234",
      "r238",
      "r240",
      "r252",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r421",
      "r424",
      "r425",
      "r432",
      "r441",
      "r500",
      "r542",
      "r561",
      "r562",
      "r587",
      "r618"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Equipment and Leasehold Improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r77",
      "r158"
     ],
     "calculation": {
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, equipment and leasehold improvements, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r79",
      "r147",
      "r501",
      "r564"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and leasehold improvements, net",
        "totalLabel": "Property, equipment and leasehold improvements, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Equipment, and Leasehold Improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, equipment and leasehold improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r101",
      "r151",
      "r680"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development Tax Credits"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r581",
      "r590"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquityTables",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquityTables",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r90",
      "r145",
      "r511",
      "r516",
      "r564"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r152",
      "r190",
      "r191",
      "r192",
      "r194",
      "r201",
      "r204",
      "r254",
      "r379",
      "r380",
      "r381",
      "r405",
      "r406",
      "r430",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r417",
      "r660"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Milestone payments (up to low)"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition and Deferred Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "terseLabel": "Transaction price allocated to performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r174",
      "r184",
      "r220",
      "r221",
      "r233",
      "r236",
      "r237",
      "r241",
      "r242",
      "r244",
      "r252",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r441",
      "r500",
      "r618"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r456",
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Additional consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r244",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Components of accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Securities excluded from the computation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of deferred income tax benefits and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and diluted loss per common share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of the U.S. federal statutory income tax rate to effective income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r73",
      "r154",
      "r184",
      "r252",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule Of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r203",
      "r204",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.",
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]",
        "terseLabel": "Schedule of correction of immaterial error for the period"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of minimum future principal payments on long-term debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r54",
      "r124",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r341",
      "r343",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails",
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to determine fair value of stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r559",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Share-based award, vesting period (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in usd per share)",
        "periodStartLabel": "Beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum (percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum (percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum (percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum (percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Incentive units authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock, shares remained available for purchase and issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period",
        "terseLabel": "Annual increase in reserved shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, outstanding, ending balance (in shares)",
        "terseLabel": "Options, outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, outstanding, ending balance (in usd per share)",
        "periodStartLabel": "Weighted average exercise price, outstanding, beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Stock options vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Annual increase in reserved shares of outstanding common stock (percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r348",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (years), outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price, issued and sold (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r55",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r85",
      "r152",
      "r171",
      "r172",
      "r173",
      "r190",
      "r191",
      "r192",
      "r194",
      "r201",
      "r204",
      "r218",
      "r254",
      "r314",
      "r379",
      "r380",
      "r381",
      "r405",
      "r406",
      "r430",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r462",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Consolidated Statements of Comprehensive Loss"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r218",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r6",
      "r7",
      "r85",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r85",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuances of common stock, net (in shares)",
        "verboseLabel": "Shares, issued and sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r6",
      "r7",
      "r85",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r85",
      "r90",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options, exercised (in shares)",
        "terseLabel": "Proceeds from exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r85",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "netLabel": "Gross proceeds",
        "terseLabel": "Issuances of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r85",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r65",
      "r564",
      "r592",
      "r611",
      "r665"
     ],
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Federal tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r249",
      "r250",
      "r308",
      "r313",
      "r428",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r608",
      "r609",
      "r610",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r384",
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "End of period balance - gross",
        "periodStartLabel": "Beginning of period balance - gross",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.arvinas.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Decreases for tax positions taken during a prior period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, income tax penalties and interest accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases for tax positions taken during the current period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "(Decrease) Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r207",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r206",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding - basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=126928961&loc=SL5834089-161433",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r571": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r572": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r573": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r574": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r575": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r576": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r577": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r578": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001655759-23-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001655759-23-000010-xbrl.zip
M4$L#!!0    ( $6+5U8:=4:/^PD  .M&   >    87)V:6YA<W!F:7IZ97)A
M;65N9&UE;G1N;S,N:'1M[5Q;5]NX%GX_OT(#:SHP*W'B)%R2,*S%A+3E+!I8
MD YGGKH46R8ZV):/9)-F?OW96W),G%M-2TE*X2$ELJS+OGS[V]*F1[^<7G3Z
M?U]VR3 .?'+Y\<_SLP[9*E<J-_5.I7+:/R7O^Q_.2<.JVJ0O::AXS$5(_4JE
MV]LB6\,XCEJ5RF@TLD9U2\C;2O^J@D,U*KX0BEEN[&X='V$+?#+J'O_KZ)=R
MF9P*)PE8&!-',AHSER2*A[?DQF7JCI3+::^.B,:2WPYC4JO6ZN1&R#M^3\WS
MF,<^.YZ,<U0QWX\J>I*C@7#'QT<NOR?<_6.+U_?W7%:O4I<=#!JUNGVX1SU6
M936OZE#'\>J?;%AD!;J;=U0\]MD?6P$/RT.&\[>:-<O>C^+VB+OQL&57J[]N
MY;K&['-<ICZ_#5L.+(=)>.P)V%_ZW!&^D*WMJOYIXY.R1P/NCUN_]7G %.FQ
M$;D2 0U_*RF0<EDQR3W34?%_6,NNP>SZZ\BLJ 'C^#QDDQ6:-768C"D/8=>P
M"NYQD"P//2$#BFHC0ZK(@+&0L,^.G[CPU),B(/&00<N0#W@,CQV:*$;@5PZ=
M13PD.WR7A"(F, BLBOJ$ABXT0BOTP'?C<<2(\')3Q4,:ZX>2W7(5@^G 5U2V
M(K"(2((B8WA)$D>$GEDN]2T"EI$,? 9]<"YUIP@\$M@SX$K!P,HZJJ <IO1E
M1 U*E\?Y9W,:G5*3MJOOKJ6#A5KJIK*VJU:]-K>=+]G4@HVNU1(7[_$$W-+5
M+MX3%JF36)"36\F8\=8-7_S.F^W#6JW:GMF$;K7;NT76_]]$@0..'ZNS=;ZV
M;A/I>AYS8G[/R"E@PYOMO<,V>;-M[U?;Q3\GNUX'^)XRAP4#)DG-+F'$*N3:
MC]%<1%T7PF399U[<JNF -#^2:>(A0FJKK'NM2;\]&NBP< %8RX$SS / .K2T
MVJZNF&)4.D/@'KY/!T*::(81[YP#)D%DS'9!=C"^I5 QO\E2"A?ZY5C<,N@M
MR8A#1(TDN^<B@5 X<0%5(MR#GN,2AD>@08[D XC/ ^:+48E,392-_T4T^D9S
M>5&VF,>6Q5:YVC(V UEJB"SV 9E$J%G,?#6)PB9Q267,F5H[%BTSN$L/1I+D
M+'2L3-VF;:)FC2PG\A[,6)&+B!FP BC!=TK$>[/=.&C?Z4\ZZ5?*#YBVOAK.
M(PP'/4TAA%Q.8#QC,IMK37FR91-7I]T9L#0UKC1AB&:;Y/O6TK[_IF%"Y9C8
MC:]E-\\OD-50OKDKOWG?O>J>7)O GP(54 <UQ#Q*DP:3>#,9:$O$+P^\!%)N
M*M&C='L(J7-H: STI*1/)7 1LJ-YA@=3XQE!?H3=^23[QTLZ%DNV=W%3(GT4
M[]N+JVX)MRZD"QZ @G4<$00"S5W+ V@8ER">:98VK1#@<VPP)A3%AK3- \XH
M1LKP"%(,[NS# FB'G1Z/I(\=^KE585OK0\MV3E+-B:!<YJ24OY6 @"2^AO3+
MN$D?W6V="&^1#HUX#.K\!Y9CO#]1F"8DL3ZBFS@T6B98MAI2WR=#>L_2HS@5
MI6PQ8#2$[>-A7)II@/VK!!(?,^HL(BP'A"(F]_)LM_:CV.X#-4$-YW2Z7DLN
MB(_U(FRP_E5,L]ZTBE%-ZSFXYC([VQR4K!LY]$2,AQ@JANP#.08-QT3HLXU(
MBGNN4J*1,[5\W#0!4]\0X-U"FNBD8&5BZ@"C+[RJ<4D#&%<JP5@\X2_7R0"4
M%2>:V,":N,-(E$B5Z)L&049##FCV9KMIMW__'?ZIM],9!@B$D4\=&$V?QDSW
M>1Y9+\XKR#H=<OHL:V,$DNF8K3>O,LEQ*;6I2<8-=)%%YCXKLTJ-O+.VK^_*
MC'RGK/%A<[GVTN1Z+7UGXC3&>(WK"!.=L\/*2Y^&P#[E8R:!14>1SQTZ\)FF
MP<A^I4M#\"/M%M=(%6"FNK6WP)]QD3G'S4V+:]%L(A5+*(B/MX?H]&&NJT5F
M\60R[Y[56((C$1WK/,=-6"IP/=?4BU8-.TH&[\^M:Y6,I@%D,ES-.LP&RQ D
MHMQ%-<!X P:C+M+AO/8<(?0IC<X6)*-*A"#^,?SZOT1G&C M"U4BV</]*2@%
M>9LPPN'AO4"DXRH#1)AI?C5:()C(6.0M7K+Z5/)XO$K/"C9: Y'C>/C;O-)U
MRJAS(62<8WC(U<Q907VWI.-!3KYZEI1[3DC(,@4$5&._-DTS2VID,'7NG0?=
MK[*7N;EI?I2 NFR13$!>> FN'3<=T^-2 ?3@M21VTZVP_W3V@OQX*>5X>0RY
MOC&\Y0L,^8IBI823G9!L$D?N?L80@\;//D=@Q@K 0@&>@H^#E8+AG@"\.#XC
M-4('XIZ59LS?P(YD 1:%)&$@7%,4@DX.+5X"3V$LL&=L8?HR :;MZX(0YFAR
M50(FYD/.*,=3G>![",O)W&#V+M=,#"EI"6M-YO:@F:*;):JEY<E *I$#%%DD
M3/E12S*()K"$I?4X Q''(FA5'UZA R5\0)BY5U8YWA/KO5E([2>=_ME?W8_7
MQ&X>- ]KC?W&O64O*FPQGT/Y  ^WK#R L')7IAX$VQ;U1W2L\I(I4-14O)[F
M$;G_<SO/5*"E9$31?O7Q)P0G7?I3(I$889M$]V#N>.+Z41JQ9[/E$EBSKE::
MA*K989=G/Z^')WG=-'Z4T- 1"58AH4FL^=ROOPAD4[)DD-H<XZ,AAHF^T@$K
M=*;6#T!,@1-"J\EB,BI+D3>F=^$<K%N:RDS$>NPQ>0&S'P9Y![W#S[2<H901
MV\PM1,@R]JNP H1^V0V>MM1MTPKD%NOT^NQ=[Z3_\:I[3<X^?.B>GIWTN^=_
MD[<7Y^<7-V>]=^2B1WK=__3)Y<F[;O&:Q^<,G=]>5OF.2AI :@.BG)'B8;%8
MF7E$M68?V/OK=-+Y"]&%ZVCJGZ)B>#&4X:EU8A<2S%F/W)SU>]WK:Z*O5"_>
M&H;L)D!":1(/ ?GP*D4R9*9@1]HWS.5^FG=.E5CH<\@,;1?R7II=Q^I;1),T
M:FI.1I"!0^[XB/KE@GZ>*<.JSKFFRU7DTW&+AUHX U\X=VT@+9 U4#_UV5A$
MJ4(;^Y:]5\_I]/MI;$E1Z.)REB<3VC/2_8(V^N=X9>&&+M]1^I-<,PC6':H4
M=\??!^J*+'D58WILO>[7UO=NL#XO)4<X .JS4J^ONGRDCI];C_-G$NM91Q__
MLFFE*77>7KQ:T NVQ)]DF]E??2Q;YZ>L!+&J2Q#KG_(_&[*/IU++SFF>I>X^
M85 L<KJWD#L&]'/9D,4#:[]9^[6-V8%IV#<-\^QRT1]7?@4QW5LK,9TJQ]YP
M._MY^'!G2*4O(*LB)[X/MB/"USCX,MGRJZHW*U;_..3X^J_+$GG/J$L^,)<[
M, (Y90K"R\NVGPW1ST_B#M],75\>>RW,:I>?4[_><VSB/4?]A[GGJ)C_!D;_
MAS3'_P=02P,$%     @ 18M75CC0DO\+@ 0 G<TC !$   !A<G9N+3(P,C(Q
M,C,Q+FAT;>R]>5,;R;8O^O_Y%/4X]Y[;'6'AG >ZMV]@@[WI;0D;9'O#BQ>.
M'*%  [LD >+3OY4EB=EML"6DPNK!EE135J[?&G/E6G_^W_-V*SL-12_O=OZQ
M@E?12O9_7_WY_]1J_WZ]\S[;Z+I!.W3ZV9LBF'[PV5G>/\R^^- [SF+1;6=?
MNL5Q?FIJM?*:-]V389$?'/8S@@B]=;!8"X(2JR6JH6AXC5F/:R8:5%/<&<=E
MI%+@%P=KB'@KA3$UZC"J,4+@#+BN)IP3#A'-8A O_)K15 0?:"04,4RH-E)1
M@V2045/'5'KL81_>#MZPTUOS(?_'RF&_?[+V\N6Y+5JKO>!6#[JG+^' 2Q@N
M61F?>-Z[.O'L[&SUC*YVBP,X!>&7_ZZ_WW6'H6UJ>:?7-QT7)E?U^B?%_?=/
M1VX\(.]U&<'RQD/**\:/H2_'9UQ></ZM<S&<VVGEG9"H=?D"<-S?>MGQK<7+
MT<&K._=K,,X;MY^,^^K&+_N%Z?1BMVB;/L D/9?7D*I1?/GV1?_R'M'T;/D\
M^/'FQ,+]CN^;6JRU?ED>'9_Z[9,20:^_9_YWLWB+1(-^\<VS]4LX>FU6[C_Q
M[Z8$4(I(#5^^K2E..S?N C_D'=-;==UV.2T V<OYNS,S-]\D';:F=_4FO=J!
M,2=WIWQ\X&K:UUJF<_"/E="I?=I= 7X(QK_ZLQWZ)DN7UL)_!OGI/U;>=#M]
MX/):<W@"SW"C;_]8Z8?S_LMRQE^^^J__^J\_^WF_%5ZE%ZM-7N#/EZ,?_WPY
MNK7M^N&K/WU^FO7ZPU;XQXK/>R<M,USK=#L!!I"?KZ430S'ZF'L?.N5'.-X
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M=TN?.\#FM+0]17QY*03FVC/* Z,J59U6FJ=^<88BAZJ0D[LX<'A:>3/_ *I
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M$.&6$V,5I0I[SY53%2#<8WA_^V0VA9?G3T@1)56(:!2L3BRG*&,626&I P>
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MH?F4 C,J@ A&WN"RJ8+QAFL=!0F(I]RI*E-R!PB83MF.'V ^B@_EK&P61;<
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M2T1XL$V]2/($I.;/C'-I-B[-QNFY[04,+T_![&^;CM&T>E6V'1M'8.L=[;3
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M^6\8&)U*I%6:7S$:W0;'0\@6*J?11=0Z$7]U=>-]-#,TD2K=2>WTFLU-7!9
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M33RH85@P]U$1U(0O5W.0#56), >@%5EUSN48G+_I@V! S.%PXQQ_UP#:N,B
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M7)-F03V.#M^I]6M0Z_]?*=UT?K=TN%RB_@T(EA?6$>M+46XQ@HWKM&'R(NR
M6UF42^[[*RUOVX4!VM@W<%R8+3EPJW(/C)?P-Z? \+_#O 8-B=@#,](HS"56
MYR,.,!1=* 5U-91J$NBM;!3R3(988HV[*!%U.W=5"M$QD]8HSQ@'N.ZZ;5V+
MZ?ONY[>O?W2IQ'>T,DK\R2?A+2<VD]=&4'-3IK#"3:6"F U4?WV"R(9#J!9!
MB,@;MSAY$KQSF5MW_C6%>V!3]HEC +.0"1IJ4$E*B!N:/ZA^B!6RT.H8VXAC
M66I6\O,M+\HB(!B1-GN^B5 <FDM6"S8(6N9!>CD4P1Q^-]F0E9R35M+P(F%
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M)1S=@1(N\[4_K2J.[WHT%1M-KZK59'=@U9TDW.911*C$FQ"&353=ECY\=!<
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M+21&^:3RB+YT42Z6)0O:WU9+#T7 3)H=7 < KS1A-&&2U+,&"L&IH %%RFL
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MQQZ4Z9!+!\DO%M-HPAJZ3;@+1!%]6\4-98_.DJZU+M&#M=*801,'OU9^S7[
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MX73T[&F/%DP'ZH>OL,_SM&9T6CS]S=-AID,I6F/R@2WSY_%8^4/K!1"^".D
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M/JD93F\]>_WRS<=//8FZLX;@A)]"C:H5O8S5E>OQ$ZR=6Y96IUKK-DY&1!8
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M;[+6&6\PMV/6>QB2T$J2@J8Y#V=II"&MCLJBA.]^>0N)Q2FD5V_I+;PQ]N9
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M[M +*AX/5R7M-OY'=\++PR_2!@GFS RO3-B+M*M6*M'-AOE5X5 @0<@4Z.U
M'+*(T8XS'35&>[V&-I4[0R8[S<9%K-W(ZMCC3ETZ!-+Y/_^J75+Q4WSK'EGZ
M]/N'Q_?&K=ZIX9).= ]4"&F $*:[.;#F9W&/;O9.UG_:Q]'',N7[\6,4G\G)
M-" '@WDW4Q'<J'ZLY(6A'$FQ9DP'I4G\)URQ37?3=B0V@ATCEKQ>[3!\ R99
M_Z@2QHF;'QJHT2T]J%(09,,LN[ O=K=T[!UD4U024P.Z26]Q+O==76A4QQ=3
M08UJ4I,>G.@0[4RT0?Y?IK,5_7YS=]EG$J+G99_4Q/NN!VW7\F$[5B0#RI*+
MRI;8J5A&/ :5J;L7]SI*M+42U$+MI=%?"UC/X?E0.O;P_EN[]@RSVQHMIP-#
MJ9K"WS:PV78[ZHBV<<#CB!&!ZUU!+8?<Q(RL=EU<7!FXP"%;[^@D=^*2TCA/
M^-)^^.VC%SB,#[X;D3-=[^N&W6KY"V7II*H03*3C!QQH:WT,-#'&MZ!]FJG4
M[J^*5;X0G:4(BRS$\CW$HL<FXBK@G]^B0>^[?!LTB1I7O-;1"AK63JZIJU1Y
M"#+<K.<+L)G1A;>J:LU5TVBN5UYJKHC*UAIQ)8+J)!-E:CR7\$1C"."P\70M
MT3@K&?7?*WJ5 !M@11/>R'Y8 G)K5*1MJE(Y -B69(EM'@89)8TI2)+&2@XP
M.R &,6YAD^T9X5<NQ^]O>TKQ%NN8H*S)BWF2Q)W'$H$-)5'+BN$.U9+NO&'S
M9JQI%?BY"?3\Y%Z(A2NFY*JJ29RO@!H7W+X\G=TWC8;R;=/ OKB49N:&@"6C
M1>*CD6Z6P9"1L63-K8X9O-B0AUD:E:0^AOY*"FF./PLA#_M!F\5:FYE<98MW
MXJDS >N"81P -9HV'H_\LB5#@,:3@\Z0D&7%J"T<65H,<F7H9@]=P]EXX!H]
M/'&6KXR\!!7K/'R$/+59N_F&22T2;,9*)C<CVXNI.HXD#B(E3GRAID$,;N/%
M)3[O>%.PAM*CNLW6HB@BN=W+RZ*N2EXZ!O$S:XW V6AL+ZN^L&D(ZF ])J&(
M_%+LF]Y _DTP''TFB-J+-E?&+Z]?_^,4:X@@L\L8^F-D:^Q75);'B5>X3S]I
M'@C3DED@4@CHB]9P_?3V%;=$-S"B6+Y3J2^'PZ]E',V4E$&UF+G8IL09I)6S
MG+50F:1"?,46=4ZV2:@S,OZ<QN"6_+?%MJD:&LXBI(#'I%_6U?2"=!4*6!76
MS 8[U%51SA?9<AD3NAT[UF>O:)PE;%ZAE821H!EJM@(V]65QR7R</V^66=A(
MT2:KA*ZC6%J\2^K\M+.:KIJKPZ?9/Y3R'%GVD"VS?NFZW-KP2&:<A;%9J$L]
MMVT3.J*S'R*$A%(@-TY?JIOLE804T&JV:&K5P!TGEY_:8^2)13:.YIB@K&@9
M)T6576;% C$=>>^ G;=?O+UEFK%?I=AW>M.,8X@%+9YRL^7Y2J?'#!@XJU@Y
M\:1>??+^CI]!53U49#9 ;[KRV 8'GNM8W#TPNE8U6U+AAPRF]@"D73B*VS"T
M"R5NR@L<)'!>60&##J%148EM*[Y_^!<UP&\,E-0"(OG%Z2"11N^%1/J(;5SZ
M@4?/2;^"$G<CA5MD$_60L-[&!!S+)KJPUE Z6I Z$C:!QFZ7T6:EZ%-7W4)&
MJJ&.^(Y"93?3'ZAK*!8920L)6+[.:G5F10G:IJ](]R,VDIX!O1#RZ46)7$(:
MP]NGU,>YY]TDE<3#WY75U1$G[HT=5AW^":<&:1'80)SGY4SM,1KF5/#OA=_M
ME>XV612TJO%"5H Y)BF+8E\ IJG6MB5@%)M)!%13BP@Z($+5,/GG6H?+K[':
M57C1Y9S3IKP@="T6R3"A[7<-$^_A#;K!D,W'!D3FMI#F)8OA1AHO",I6,A@E
MWTEL;W,%58J<"R70@<.I*+EH-@^%Z0NN?*6K%$D:E+#Q-]E4Y'4LFF:3-RW7
M1#;RDEYQSDCXK%C*#9>%\^#PE_S.28+' #!>>N%.I)X^_)"4+-XX$QE@JH!F
M2CMI3ZESF';,E:W,\N@(,KW@\G:T%('GC8>(3W76P 1BCP9AU2EW(%Z/SC=9
M34/)S;8L@RCVY'B1?IWD=J 9F\ZM<&&IZM\@@9-M(I R)[D4]+4T\%DQ72=5
M?=TU:ZSH.%XXJTW=;#2$I+O"%K"^ HO/^>EX$'_;D,G/[U(,K'\CMDR9G;:Z
MX.%12:[9I>^&-!L[B5HO*>X:$N7Z,(F_T75.-KK9?'&SQE('OF0<I2PJ"2>?
M[6QMZ"^F(L6L4$5W*YEI<5REB^_?LQ+MKN]+>YG[8Z\/<RE#MR4ALX83D$=L
MWDCGZR/:_UN$HLS+QD5T[W]K@O+/XS?'ML'CT?>G#)\J-:M OR_C9SRM!_0%
MOEO5R^I(^IWO[C-Q1]Y8).#!O>_M27</M[I=[^M7>@XD&8_9G_G9'XS-9$Z4
MW4@UF3&+HK)B,+ELJOJ<[J+_6H"=*V>Y(/*\(KW1_!">$6P@>=B\8!=<Q24Z
M:ZD21GUVDAPX"B77Z7,.7V9L?0Y".'8IOH$-'U:$8Z<)6?T8-IK]=+8W&CS6
MRN:>WA]M)L5_-LSOBS1(DTO$L]Y,(Q4A$B7<?:97?=W?H;ZTVY@J+_>[5(/Q
M$+^]'[Z7/B;YJGF4R3+HQ.+ 9;X(>83<CL9&_D47[L_%:I4O1K_0AC.>B#[Y
MU\^_C/L60PVUO,XGBTIR;8]?__ARQW=#IVL:=K5:5XWXOQ(DHK\^/WLU\&O#
ML(N/+<GZ6;5A,VA9E.R:7U1+-EGQG!=/7ISV/NBF"A<_ 6$@R58CH3L55C&%
M_B>C*?^S9)@A6>W209[_!BZ=H#:%(2=<#7UB18([K6DW.,C. 4SQ 9C"8IFM
MUXB:P(H+51PN=3WL)N)1&Y8I[>"9HUZV(V@__S*PSY&21M\O-*2&^5F2E5E)
M9<J&(\IV <8@O1TWYD7;,+1A463CT8O\]V):C4>O-S01^O<;<ODN1O^@LY1%
MX:)EY5^^64>GMF_EOO1LY?U[MSU;^:D/+/M2II]3N?NQSOY;D/O[."NS&?W[
M\451TO][NN'XP7CT,]<]_8/^9TP>\(Q_\/>,1AWE-9%3$=Y^<247>H[F!TA2
MK6KPI"".E)>@4I[G6O:VRKC% S##=E94RN&:Y;^OBEJKA^[?#^&1=?8N)<+2
MWS"[/OUFG8-%MQ'++)M.20FLX9FB<%W]$*1+H,%NJT;2:V+TEFS+E=<M>KMK
MDJ&E*<0 :%WP79TTK%(^G@#U*+PA 6([7,-9UEW#Q1_7UMRU=_#G;&64L:8*
MF_R+7EQGY[0\DOR6+49D9E%=C8 -_3AIP4'CN/\(ZUCEOGPC3%1D^S^N%MJ8
M@:?ZZ>O8;HSYY*-;+'R^JS)(B#S<]]B]UM#=]_S#HC54(%N<O9:Z''#Q'AUS
M([J"(QE$L^#>Y-(^,?D:4JMME!,[B/EJS5$K?;1P6A; @56A@B5H(/=(*$)>
MH%3A-JVSWCK;SVI6W./13Z1BLY+&]1-Z\OQ8%VN T'_>E.?D%(63_YQD?=M1
M &""06QNP0K/:805GO*&MNB_\J'(?E049EY]-%WUO*FS?/%'=-8?O_1$H[-Y
MS1);6#A6K\&R C"T,+(RNA,?_K$[\9#.<]8ZS9_UAB;GL/>@?YC+D,HTA(#N
M.YUG2\1%@'>(8'*_OX<\@F.4!<W7JH1;MHDTKF*-??L'K;&OHO>!HL?QA%LH
M>R)O?0[O)Y7*\2<0R]L<3]58\N.8T/NT,)R/'YVW<'D,DG>BXZWT(B<7K3*B
MDNRB]HZ>5U,@-BU*J8$N]'Q!$NI]3JVOGE3S*PXLDI[O$4/6&782$,'89')Y
M&MS3UQ8OJMR1L%AS)]\&_^=.Q%JD.8:$!S6\X&Z,+)_>$W,YS:'NSHI]=_]:
M4WL\.GD0OJ0ZZ7$EB @^\N#!D]CBJ\=</)'\ED=Y_[OO]HM(']*=<W(_N72D
MHOOC7CM9)*/6_>^_/<@!V  S80BA^%'@C?"=%T$2V;I"A5)R,%7!#<,'A0J>
MG9>JKDB<G.XC$=>N* UD6]*ID.)]OCGR61%O.YFX7J@=C[#%M)Z"!=Q%Z2Y<
MCCDWFR7 \OO?D=U0V=_>\Q9L78)O8YE"SZYQ1X>^/>,/;-&[1D7'7)",T\Y\
MNE,,]OG0]F4+FE$IQ1.[#L>GW(7W-9%[=L% (7V;,'@$9.U.]EX[%5Q?O>8(
M68=/MU)<?SXY?W#OCZ_PO&(2FYXEWJ5EY-KY?O\5WJ6N_;K'!A@'M8;%_,.6
ML$=-?WHA_<CK>W(#NKCX_0-%M*L$OOB$X<G7A&$K8;C_B>LW L?D7FT;\E11
M%\URMUF0Z[_:P,.JEWJ;SZJ&,;2A'O^PCR0(,3_H4/HOD$>3?+[W\K>UW%!?
MYY1)*OBC9-^'AM2?\K*Y@96'Z/8M?$]F9TBTKUO(SW -OV]VN[4R6)JR>'^1
M%'>JWPQ7*_SA!UGA9Z^5K-'XPZ.?6;:#D0B9(*%D?N.GL]*_NP$K_4-4P<ZC
M?I75'%&Z-1KSP0U()_<'^$@+=1B6X$T<\?55OOA 8WO/>^=#/.G;?VNP([W.
M/_*5_:=;NJ\!TWT#ID]W!4QO*BIZC86S5TSM]&8BHWO$/]F(>O"WDS]+W/-:
M)7&Z%R[^PTW\3>-6U8A<RFIM+;=1] C6$>,CS$I_,W(3\R-KHL,-P0\LRC04
M"[W>NAU0W9H\<Z'4#PA">=<W&&J?7O1OXH[\H%#H'BOLO]"SPG_0Z;4#,>SL
M/G7.[OB:C%7Z3*CT'2?HT'SGO0.U/;7-;I>DRU-T3D+OC"CZ[65>U?DJP[4
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MAFCL)Z[UEWZUD X(!>#JJ5A+!ZR>(!BU!9.%VQ#2UQ9$ZTIJ1+?:OL% \&C
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MK+E('MBD(XLXQX??1J_G^#:A3J,_+XKPB\_6?7> V;K/)#MZ:7J.+@OUE]5
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MAW>%K0YY-M0G&9X466U,FR/ITGD%7O![%.'<MKOEK<Z&%^+YZQ\9":J(NX.
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M6J_A@X*IF'&.F-Y>_[E-/F"C>4<KSNT&DB'"7L\6-G_+) D%MF(!.=:B88C
M"]9F$T+95NAWC VC4U#,@BO1Z0IRV.?C]):<#]>>8N!\="*CR"1H9Q$N:VY@
M%;8.PBCVCY XT#A<%W:Q[,$%%0"HTN,JX=71'BXAE)<>/"$]IW/'=7?T4<:=
MNUXP9HB<A"&A,NF-2]'"0ZXKZS^3HB>U>"GV,]2P,7#-TCJZX>8UY@QWA'EH
M0!F:*B\6HWA4F*.8IKH(67@]/7OOWZ$?G?NWX.@H8-4 *4/;-\MICZ1UFMJF
M(J9H+30L^AQ:<@WC(KLA[S,B7#"?+>VOQXR>,R\X-C4@9='K98)TZ:$JE8'!
MD^P_[(:K"P=8SE-P\9,> 3G_10'280!)5QE[W-IJ[73\K;$(![$HE9YQ91RD
MD^/,37;8]5U=Z,U!=^N*?S=K6]N@9F%(?>OZD38;="-;,70UX0!@_T*:EO#U
M/S/RCKG8X8M/+SZ\[>E%UFN?=$E@]S "25&D?1TX)"\!C#/+TI0/50L3Q<&Q
M #TL9ZU^XQS?MF\(NQD:34[RA89\?I# KH_&&@*V5?FOX _MQG9LD(];<V=<
M@\SO.:OJBXG=L8@X\UAWPA1^ MWR56;5G!WV$-I/OVXK*:]Q[9?[TS\]C"*N
MK46PM7W(N1>5V2@*3!X9.FKIZ!5I6>8<$,S OFX&TV4'EV]EALUF+F4=$#(M
MW B+T 7G<SX$;[-6Y2C:2^M+:)("^11,V8;NAD7 BP=<+(X%@K? ;B9UGX*U
M8=AMBQWG!6U#A<2/5,GP53&18Q%:" ;<:6<!K3Y<.^_-_)0[T[5,8F3U&-C*
ML']];*<X>/+>T,A+.GPS074>NG)ID91. <>^/$IFA&+N(&@]S4:.1S^9/3].
M%T..>B*T,8RQM2O-[!B+%LZ]U^8"^GW>6^S/!H862UN&]=>T\MA)[<(N?1I;
M!C*NDFM4D*G)I"7[@:0ZF4J  ;E3"0\EI9:*-M>PL43A>\@K-[&M7,OE" 5$
M,9+4@Z(SL\H1Y.PKIR[$UXY"O9%TH.>NZ@V;M2X1$:0'74?G;8>"9J-@UG.
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M1J7%VAC)M856P2X.W--J%LX$ )0A*A"_WX]T"RR BE[C"D'6I1<9]XRCZ36
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M$:0A$B9D"<C,%8A)(VBTBUVFW>7U.3&8DM"TYWE2$KK#@>Q]EIMYZ+(1_AC
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MJ#8?9:.A$^_QHY.OD3<P!N-]T6<Q#B]-E;,[QB/_F/EZQMC*SW@IKHB3J*"
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M>2?/M90GK0KY$R]_>D[]D5DNZYP>O4+XIEPDW#_#T7?>-$C3A1D&64 \P,/
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M-YP^<3NY@B:-#M$AM.04+B()P 4J\H9 9'RO.!E\&5MQF >I_U.X+@F>-AC
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M4 ?<@=]+HOSQ%Y\H_P*=L7?,44^K[W3@++SGJN8=81F9AAX BQP+R(C4R>)
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M[31, !W/3IZ"M.41<]2JLBB;]['O?_/T:WR_1_*2BQ@L)PE2V!6JK!A&?.<
M>0=:0;NDO\CX9_[H8+VQQI6T*Z%J5^;G=0B#.!B[5.1PF[;S,VE+V '%$1T4
MM .D'KT(:[]F*8+P&O/(PFC5?2&YHK^APFM:&"O5'2D@AK7KP!( ,+EG]<%N
M[I?:1+X"&X8I8_H/EVF5I?]@Z#WG^@MW">(%W/,Z#F%8*BKJE?2 9&O(W*'S
M4/NV^KBU@>07)M&]#L)T[C':DI-"CJ+HQVYW+5+V[#@)T[U)EI4@\N-NW>^1
M,(5C9'F]B/WHT57W607U6:F;BS(=:!Q.))G617A?3D+<:'U(=2\.H.'!12M=
M2$?3-*B,2--FEHN0&_-C97'\-,5%K3,NF>/0>)RVXK6FWA9XS4QV_6Y4N>"Z
M^MSD) I3VO&0>^8^]$<',]X3Q[VV?N@)B+Z/FK,VG#\RVEV7FCO 1JH2<:92
MIO&/2^>15+,PB8 , JX ':E-&%T"<]VH1GX]R""AKEKS:Z<B=#EW\NNR+LB]
MKRV4)958(U=,-9E[B<Z"DH2F,W%#_C"F#N.RY4@,8-1[P*O+0H@I4S\?)X]Z
M*6'Y)86RGF_Q<+RLIT+XX)Q[Z"<6'_HG]9)1_5AO<_WODYY7@2\Y6_@_5)I!
ML$G4S]-CJ20LMS2@I3(?Q*>DF)XFE(ZM*)=%_C7MC:NRBS!CO (FP/IKKAT(
MCL /%3OH/3._0;,>_00E 32]KZ*4<"K,XH\4YZR[1SMNXPEVH\F+<U7MN8%P
M*]J96W^">1J7T;>[NZ[N.XX#/I*/_RI2S4P+J;V%,?VS%[V\$V[PQY'7H6V7
M$-))5(2()\9!:KA#3*/Z0#M5?QTP]GJ^P_ #ABS+5K8#?EQ:\K3&+\@B<!$L
M";]R?3JZRVX#]8"8T.1L!QUONO!I'Y/HP([.55>>6ZK\).TPS2KR]9)RVZH,
ME]3Z69JG\ON:BZ/DWJ@JMZBJZ@ZV>AZ.R+#+79 J6;^PXV/ G!SVG=5SO B6
ME9D OR0QSG"CJKD*0UB1BRMSQ6U\49:-IY$\X.':[O-7,S*X88YCJ)P>S?='
M*G@*"W0\^R#S.KYL6EI]'7N!0VHMRG,&'[ G'ZLJR\,'G!;U^+V4CY[<EX_^
M*2S/>V^J)#OJW)+3044&P<Y;K:?>"2O_6K++HR7\40HO"^ 26[--P&N'?,Y(
MDKYDU&2DFW8A2'),.-DD<;"B]XF8W^X%]LYU8WX[X>2-NR,)H]3XFC#B?0_[
M+?2PG_4(AWFI&*R&$/=A@BF/.FC(H<.."VE109+=!IPO=#""*&FI,\<?0MX<
M3%%CG(*IE+0_1LNPQ7M=2#=S2N_7P#5KX&-_?\(9BRF@,09=3_]I@'\?8MH2
M"H:@(!Y#I +K)2RU ,4U*DR4YJ3)H\^$[3*+9%:89RT\2-3BXT6CLBR^H#N&
M&\S2OS[YZL53_/40FE K(F,YWC^%^[HVK3\U(4Y\DPSJ._ Z+ K;#MYB*N]/
M_[7#>R[^].:=\0^*]D$Z71/LQ4(&VX/TA!^$/2DLK'&,>BD"+('K?F_.7"PT
MVUPAGE1L<PGE(JVK7G-1TYNZJ<+Y_0:_T0:WTYU)?N703;<Z13G)L@@#&'9J
MB TD>.#>1>*OL(5'\+FPZ!S =TEPMY+(SF=+;#)X#E>@S_0H.D$0TSVU#9(^
M%V(O:;?(I">6K (P =B?26:Z;K:@+F-"A\%NIVU-]1K5UL SMM(@Z0@_^B5W
M,C#'<KFPT(Y G[@FI]*](/3,'!E0["WD_!3:UXJ4LOV&Z_I+]+:_:T.TMS5+
MZ)SO[XE8]ZII/_5B_[^$45HVZW\K9>^/@]>SXXX,(''\>!G7L+"V3?.)0<84
M<O\Y&%HJ%3TYR<(B??Q(\#T_V;CVQJZE!CEN6H2ZBRC&";*6D*Q$"11V#2F<
MZ?A_;$DXGJYXUH3C2I(CI_K[3+%#[B]\HA.&*1?.*V,W1;IE7H2U64N/DKX$
MO\,)-W;C H7P#L*2A].07_I-;M_E][4;A^\L=AV8_\NP_DO.2ZP(Z;+%2Y!6
M-OF27)R<;<-W5BN01__/+NQ]1KOAF^'=S\/1F]@P[M=:Y*T#TFL_[$2<$0:<
MPL<LK3 .Y@7E+N9RNVJ\'T2VMDO5L,,7EH K+[:^"L.MD^=HECHOU\B2\>-E
MZ>R$RQ>?@.PA,K$U]?;,B5$6W,)-[_5I(BKMI[(FH7G3DH$,2VGQJ4NH:<(*
MOY3,,(AV%DJ'Z!/.O9=/B(QI_:D;D*A<X'7"![W5PB_WQHPE#<,/(_/D# RK
M'-JR??/#^U,FS%P7 [)SHU)+:%-4#A-D+^&%%RQ+\R<JD<Z^:TN*C86@DG_Z
M*KP(U#(^+)IMQ<TKR]G/.<4Q?-B$@: *Z@*LOU=8.!TI:5 &K)Z];J&V82KI
M"LQ*#QV.BZ+"Y^#G[Z3@QMN&7IPG#Y2>4C)(Y!P++X#>D5;KX]F##Z_Q'U^=
MO#AY_G#V()Z(#VU,?WCS/E/6=JY!K-!XS9?R8\F/$K[/,LCUHFF#BR?GLOAO
MR=C@DLURGY DAU-]Q_XO;Y4)9U;T=HHC9!J9YS/6;GZ1(;YM-?C?]!CZ4+)H
MJ"^U$Y\X!>,.XANWT,K.:-0"4A_<AEO/[^._',?"+/VE!Z#-$@3M2/= #!=[
MK0*3A=?,-?4C%R2$(60Y@\>XZ]&##!^]2_D1PDI;JCO8^0(XPR_$FZ%Z!!@"
M<FL2II"%2%K0S=8;13;4HZ0:KMR>^7 JDQ!(FU^T,YZ-0Z0QL(*VXS+H"23;
MU !;\CDG;%,6_YI89<R>:^\<PP#VBSJO?CJZHIANLH)NFXE$P;@TWSOY1F#1
MQL8?$XF*?;W^37]"$];+8L'>N7A-3P8D$RMW-#!AGU8XK,V:^-P/"BTU!F+B
M&>+.WN!A3;W:99E/#^Y=0;-\S^AMJIYGXCO0._6;8T\92!^.D6\FO'R8:B%J
M,]A=IWQLLMSUSR-%(#/??Y(@L/\(\5S#J?6GE^_"D87NBL5%6=#&?]_LP^].
MNTZ<9/([:;'@J7/N!ZN;*X<2&'T575W,QK0+WB3A-HS4H VCO>+D.7JHXK88
M%>3"P[YZ=9J-GUIZGE,=GL[&U:X2AX!>D _;WB_PSJ(7:BJ1@H-+A"<(4A,3
M-(^_9I#GJU/%V71&;P.J6J$"-9SOKJ5<;>SUC8#:+#KEN"N/ \@;;33ZRT,S
M.U_1 \C[[FJ%@]VWD#U_>E\#_.59B>N-Q9VH[7V\\#1H&4L"D"1YU73,WR-6
M)S-@D\+W-!4%6&[DLB2)"TGCE9?E<D>==$X<R<F.Z0^%)I$Y&%-"7/H5F2.)
M\B7T<F KL;7/V-:RU<(/2G+'E\4150OY<6;=(EA)-L=K-C UY=9 M^(3XTWM
M-&\E$&# 8O*N_EV2WR>M3'&LG$01CV-'F(:M:CADSB'J0?/\4(9K7EVH&%)O
MZ"ONT6#\";]THHOLKQ,G2DVL/J?7U++S%"#-X(*?[U 1X#?;JD)Q5RQVZ)*3
MR'/%9$AY)1U[O7&+#U@W6U/F,G,_Y]R3^.'!?<*0"-##E#Q1E"CJ\_R<3X.R
M71Y12F"O[]*TG5L/R+SJO$O!AZ-@<;_\\9H.+"K0"@Q-P"0_]<L9/QU_..;'
M9EJWKG^ )<UR6WVB</ZVYS2?X9[XA(["R[+1:%K6 7L>;@<9;= * 3A)>@!S
M%%R:)\^??OOXT2P8BDKPJT__DXE5P.M\7C5S9IHN*$D@>3A"J#(',6'EV_[P
MT<SB>*=H^!*<," (D,(-N[)X8=G"G2X(26*'25EHC^.60H;EN=2?" PH%(^:
M2$&J*HY6AFS4[&\[BM7QZ!2VZRH106,T)=9=A"<L\W4XN#I'2 4_87QLB>MQ
M6 )D^R/11$ZOW+3:(D!$B4>H.W5"FK%@;N5\J]H:E)X1,H^&Q0*7(*F<[[H2
M>N1(=\!\>+/3D$@1 1TXX6K?WDA)S\L"@1XXEO&F$PY?TLGSNIZ]76P;<@=#
M9/4X"X=HT<%NS+ZC_T&*@1/0Q>=@7P1<NV1Z+S-,LA&/:.?I81S6YL)5!RS)
MC/Z*\+B7DG)L"Z3'^3)-<B6]R(?@X5=+2Y9S,S6*2Q=NNI6F$=UBY,TN]C'^
M4[?V\$/2 67A)@W(\>RU8*$Y#"""":2[I><E)E9T;4+>BZEB^(LX94C+1KZP
MH+[58#*YDA5L6BL@XUTMYI5,.!IR&>P< M0=2UYJKZWD*"B"C@M8,_WNH+_1
M&OP2_;HP,>B^?2G3Q[;XU$2O->US5_:8GE,;>2].2)7K^:[M),E/E"0%Z3RW
M>_A,U5[)+AF8:>??_GCV@5+W\32,#?3L)?'82"N#\B6*6HF X]*;TV,5K@N(
M2@_+P6WH@FHCV9)ZVE_?H"E8'FGP64.Q3VWOD?F-O&P9_FM*D4-"<GKQ7=LR
MDMUC7H7Z!7@DZW(6_\XTH_>.'!#%H6B]Y+1*AP)D[#))D@KJ9=P&_3FLYWZA
MRK6<@!+G!AE$A<J-RX]1(4\)Y.3I2SI1</YU>^)6C5.</BP.OX;%L9I*K"&.
MI5$D'>[+-+$[DO0;Y0=07L7<*W>7T@<496)9GXM/U_"(^5*-KSPR]Z:UA7RU
MEO^61S5_3SL3RLK12BCAC?;@RQ=]V[W6F!BS/VR9HI[^]"!?E9]EM)NK6H?)
MB\(Q9Y0 SM1EPK@F=?[+IMJMM2L+EEF11TR:L._(,Q+7"G*A_N<=T98M"E4;
MJ_=N?T5<@Q#PLM?"IUR^IN_QJ';XC4-G4DM5DACOM'#9(4YKVJWR#VE%BLY>
MUVBU#5.VV7)VMB9*(%F)*,J1+!QUZ9''G\V0^&9Y$<I9J>_)$0BEG<-0=PO)
M<2^+>9CTMNR8;3D84/!S42)VZNWY,%R&60)P! S- ";5R4.1+<&O!#62.2N"
MEA<W9W&*V<9)Z9,<Q@)UREQ<TTQ'G2J9>PA@QV(KW96E4@K#MN"9"QCH, 8U
MM]5).?E=$Q8U:S(5FA+LM>*YLD&7G/#L1RZ8/Y;-45V<-]M2*Q@,YAE^8G3P
M/,G"%>N-AIEYQ033DE3R6KTD1+/#)!$="KG90PX"/$!.?&=%Q47H,'C'!05>
M[;P,?SBGT=I>T9W"9CS"CF.GB(95_SV\,.%$=1BXBTIVJQ3HM?NB!LV=V$EN
MVK8%)<VE]*ILO*+=Z0\']JCC/9^J,,%]8[NRRB^;%H?0T!S;X='"[,?N&1@T
M6X?E*A(S8N4WG3MJ;PX3^A<Y,N->V:NP)IM]H55['"1G.>N3O8'9P##<":>,
MP0GJZ__7_W7R_-&W4E\*41!(T)<\19]+J@T&:_#TY!F"O"-H 18Z&.$0T@[O
MD4^SWD6>/'D4/PSW08OP>2[1 "EIYNWB0FRG:^%UZ2#$Q$\>^>M0)4P31\O+
M'"9V69 ;)SLU?8AOGAUX!D7A,:*/!>Q:T9JRISB>_0C:0"Y8QHOE( X71=!"
MM'V#PT:-7;6D0%QQ,K>TYR50+>?:8*;@E^/9SV1&*JKP\)Z^*KAI,1?(BZE2
M2^(B>9Z;!4"_>17NYR(A[J5"#JM2[M$I$4YGY!OHOY7A &1!&0ZQ\S;GS]K"
M&O0BU)/\)Q+C!E^US5,(*R^Q;\D/WA%N9D%!=.\0S2$'8*<)!(JI%RT\;UZB
MJ+- C@KI@>"+ $@DN3&D8H 36$/^&.=F?5FV38T5;2SOZ0(BXTXW44"IDK"6
M+8[]HM4- (=;"#?/&R[8RH[!8 1O0\2J^<S5H:';4<#.\#1I;B:0,GT@@<9L
M4VZ Z<9O5SL HRW2IKO1KJ?G%M\*+O^BW95;=S<J/Q/-<E?(88E",SB=[/X*
M_X[)6&;TXHRT3Z1E]R6R9U]\B>S7EB.*66ALOWTD0.FM'2W 1^TM(XW0K('$
MEUW8!Y+8O"BJC=N:$AGP9E0N?$IW030/>,9R5?C>@+#.QX#P\WSQB1GGCF1X
M5OB_;_^U@_5)(8E]0,EC'A]-$59@[BM@6Y1C%\9!PE)B@2'+,P/R!:!9<FK5
MK28V.;I07FO9"$!Z(WVEZY[?(D#D-QK-CZT[:Z0/0,QK<LQ\*O9ZR#3A?*\%
M/@/96YPY.$X(CTA>M1>.(TY,E(!PBW!R@)AO*_?M,CZ>R"N/L27J,)2I%<T_
M;F\'!/]HM:L7<NOP=516 >(1;T4K$2TQ"RZAOSUK<#3L:O%Y7GN2AROP[.V*
MY)7_%R5BR]JZDKAG6THP^F+Z*BB94/41R97=NF,@Z<B)J+]<%<62YINKHX*\
MU'PX0=TRYTA 7 5%3@/7( P2.)WV"G&HV5U(ALP_J%1(=^?GS!;$D4RYQN<Z
MV9=-A7_0H89,/B842,WP6'^/OK ]O9HC-'_!=]!OA#FYY/4B%<;X$7NH/NW%
M=54]GMG)\6-A7>R4:XFR1D;JZ7*$L($%^$XZ-_1N,>9U4^_77*7.Q<G7][GS
M>[F_KCF_LH[J,,F*E-5D1X!C5:7M>(0<"3;+&\0RU.B0*24KU=0U;W+V]K]?
MOSPZ>3$C3XT(N?GF2R(G@9Y>&Q=5"'$JXC/A.@_"\&2>&-Q*"?,+2N[PPU!Y
MLED6E;L8<A;+\AS>*X4P[&Z'E5T5GP$FY-!+ZEYT,]HAX3+P<V,RER_&RNR"
M>VH($5L(#3>=GWLBW4?R<<=JO,$A)PTY>GS.LG#&[3/#^B4]P 014KX&=*"6
M3545?'@LY5*SBQ)^M;BPDK(1ZR)U,>3AV0Q* 4Z]3<K&<(J+K@L'FL*)UNKN
MO2VG<0#>B-SK7[O)[3_^GYHGLFWFU$;:U/-&X!/AC4(8M';E6(H+*!]WP1I6
M;2$DMQSD)J4SO-RN(C-R=P)&:V1+-BH'',!J%X+:%OXPA&1REHYM\9CXC &\
M(4( 23SR@7TD_Z3LL?>/>C$DY8B+?"DM2FU3(6-R63A?*TJ!J)4F[D @%A;(
M/LHR7UHU$*Q*AGVO]APRT@7K'3P[;-!U40N(G*,PEY3I/Z+&0.P?HE9!2*N6
M)15[)W\^Y46N6(-EK1V.6&6T1&,UA&A8-+BG"ZV*=<Y&A[H@1=M/'SA$_:7X
M"<7V@E@0:0UO[LHBU3!=PW-#C9(9V\>CO;0VZ&46;9D CY!@6%IZ89_UW",R
MD+!DNIJ3H%X[PTFTD.$&,K8N2Y$Y R!EC6TXQTK0'SBO!GIS\2[\#^H8*I:B
M,%5^9EU$>S:@7"2%KNZG^(*ZX,A+@81\<!*K/'R'RG^N52K>D"(,>AS9K[:(
MT'I$CAEM L&VQ<9<7_&4_$@\&C(K,&K?.'874VI6E;A$<D[Y/-!\5U9+)K;7
M7$\\JKDW0!>Q)3ON"B;^YT()"CCM*)4I:>00IK1T$1H"3HX6FC2*&O:P'#&G
MW)AC(](N9 =?OWEW>O:1-/4R4>L(5I1[,>PZ ,R44,/=:^C.9*DQI+(:VI\8
M.#;[,1Q_/^3$N$QKY'CVIQ*..@*(*#RVEO F9N2N>-(DI+_$4L=4(]=86<\?
MOZE&(0B&>"$A.K[(J]5PI-CPEAOMY)8(#T@[^"V5B.G$7'-X]XKK;;JK=2JV
M%F9(+?<T#%*=)TV@(+4$>;VY^X1?#[-5%,Q)P[218>,\^/#QU9N':3BE#: C
M8XJ<WA9TB&X8;XRY^55+-Z>&FW@=T:AWHE#S%FU"D,9 X&X@-#C;[-E5S8+)
MF;>S9[,//.&S=SF!SFR^,I*0KJG4$"XP>_3\V<D)YW"#K2\V%Q0*B.\05ON#
MQX^>/)P]>_+LZ.3IL^?\O:MBCE ]^ $M>%.#-;ZZ.LYYR1V')?#%0_Y.'K-Y
M@XJO06DR"Q :_YJ4$:-.;)(SN"!D+)^\IPQ=?0_J'^ XOJ<H_.31T5^RV?_9
MA>U=D$\U\OG_"5,@^?7^I]\<_85/#=)JH.94:1-25L%6OD_!UI*,Q6K7UF5'
MK?%>)^Y#(2?8R9,'^4-<\>39@^5#:X/Y+'!.Z6<Z>?'D:4H1H2A!]T5\H6O(
M=4;P3['1' @#8$"Y=QIU]F W8:DBXS;$2-!RKF] M8O,O4'Z*6GJ*H*9WF8G
MMDWHV?F9/%>_/.\'TL/K1_&,,Z#)@&"SFUO*:S1=0LWOH.@^-LH,>..KD1)M
M"?$..GB9>D>"B[#_PD4H6<R<V VWJO<>H^>%<[(T/I <9IU MHU(69K,7MN5
M_RM?;[Y%!W2>6<,99(N1RN:X-EXW>/0[TI+F8\9_TM3)*(E 2-+C/-\[I5]I
M> [?2S9%LB>8W.P"V!NZ&K,>]37)8A?]P8N->5#E\O_^CS)_\>1YL2R>K!X_
M>?3TY/&3%_G7WSS)'WU=?+UZ\63Q])O_[^3%?]SX1+JF\_GW4FUZ_L57FWYM
M)^(UX?I.3H]G[TD7^7MPT?\"+K;?#&,\Z>:O$*T@0BL8?DBR6&S6(AI;?.-!
MRHAM6\_K!Y5=LR D.27&(?N-'!O#,?0>Q[/_M]FI7:#"-F<(U30P;G3B62))
M+*AA@Q$Y9Y Y4S/&KD].WWL+1R$<<U["NAXT-MZ)YK=SHEM<]D.S/L&VA/U1
M?&45W@[VK@"C3)%SV%]U!5<X;G)W$<R"7I7T<?&(CPWW\6QV&@'(4R-'!EA2
M6&&P/]6$!,6YQ.<HHTLBV-AP)[#2Y=HX ARS.4,)+1YA@085$0'2.5DXK&Y>
M&]25U:>0=.-G7G ,-&L6X3FRX5D,U@$J2#+<']DZ%NB!PV;3$M4>&/=)?. D
MN":O4'%D"N<#JA&9ME]).K6,86ZRK/EJ2\A"LI.X#PMY#11H!84'6G^1%V9/
M5_#*&+^L)<&;_U_+;9Z@F\7\O)>E'98$Q03?VWB_DV,-0_(C*:01:-RM207*
MW=!:_L8-&#];N0S;89E0C51 FXDH'L\OZ(9(Q.-GA@MSXRA^K5]'4L"4\9"K
M#?.9%MHE%A?E5&WMASJM8KX2Q/B7<_A<&\/6A0W<MJ%BY7+VA\??/#Y^IMV!
MV>P/)R].CF.W((W%'TY.7AP_L3\I1($'B\G'IS",G$*DBW !3AA+H+#71T),
MX1\AA;U;"_$>:?0M2FSK/[QX_NSXJ3X7A!^7$,C2##Z96A71X;A.NAPY*:I1
M!:A>!#]Q62B:A%-DKJ,I\H-IJ,H_U/22@E^(?DR$:R%3J(4Y6+$*.$0%4$.1
M@I*RAA$#5ETL*!4PI<C"/! 2C10(5<*9=R[,""XJFF1OL;C(1D8E>9?]"SB4
ML+M ;UOY1"QO,;\[@=;O3#?&JCKQQ)!E"%3RX?W(@U!KQHZ/-8RXWN2*!T<:
M+$G2D<Y!:0_@9CG -.YIFV^%T3,B^V?O+FC$3[YZW"-9FER'L]/W_WWT]&LR
M"OKC^<AOY5O<G+B>J]@.G,M-7LV;11E^-$^OTER0 P?,92?!^^#'N9'9(J>$
M N8Y7 \N&/#5GLB3X"?Z+!S.4Q?%\@B.AZE;9;+,N2-T<)5?\C[ R] )PTE=
MP1-3;I$6L^&JZ3 JMCGYO:1!^?Y_S[Z:_?#J_6.$@1W&._B<W]XO]]]ZN<_S
MRR41+.ZVX2&7Q>P!K823DT</D_4VN@?Z/QU=SG/2'2E:B.#*N9R(KE'Y&=]T
MRV61JUK5$35:=U+$:!!%R=)!5F]]]O[=66]Q W'?LM21:[><W(7=35]E?%]V
MO7V9#A,0/?$5Z7'OU_QOON9IB7_]_/G]W/QKYD:T<\+0OWO_]N/IV>PE-6,"
MS? *)45F(>"N!;=%1WGN@"XL;&8!0M!_.+?PVWO/Z3:FCOM!N.B=;SA^+&,(
M,3&?]X-_*X,/TAA'I"B=]8/.2+]!$&L(1ERSHQPU]5E%[R?I5B:)J'FD0=!4
MBLGM9C;65$<@X64MZU5+?LV.%210\5H0JFVW@6A8"R671+DBV8(L+F1<J$72
M*^O($JZ8!45X&X;+Z7X=W**ES&+*35H"MIK,9GQ<L5"8\:8 X5?P/5=-53;W
MTW KTT# 9>]#)!3#L323^ ^16B"3;6B*O@RTJHN*V5AO#,6[GZ-#_N!R&=.4
M%!/% @QGLJTIWE?A/.;2IJ7?BJJMX.,(#->7.J21UJY4K !W29=014*%=584
M<7A7X)EO??J1RU&6?YP7^T9Z!#A=JL#(E6+>C3-%J*"!M/F>^LAIM%Z2EOFI
M:WH7C,WW+T^SE.0W$NX[>0(P8QM#IQ=[2/D&I:]#W)>9%_<VR-.P'"D)8'A,
MFI'-HM!S*ST!-=&*5/D>U[6#W,[)35NFDEVC;!7@[#&&)ZT IVZ7@H]&4MA:
M.12X%^!.6*QCN>W?/=+DZR\>:?*;;_KOBD4.^-A*NSR$,G:BTJ\DEX5(K8^S
MNJ1GJEB(*'M.M:^6'>(-J90)G]>6%.C/L0^-E"F2-<7*2&'%$?2^@C00S"\L
M0:^?$P#,;LCUSEZ-\Q7!C=F$+2>^E*ES+!BSJ-S>L3)O&XUDCW.+> K^QW";
ML"X 98@2,)G;55Y6Z+$TQ ,[&VM?D*T*X79<HDV(2=ZE0]: !&B@YF8R&.[P
M!V+DVE&C#3\/42GD4&WG@KDR.?2@$.:<^K-R0)LB)V&F?5&K?9(W:P@30;W$
M]-I4GHREM?2\/)Z=&N9!*H&C;\9OQ6U9N<(= 9Q@R54A7!W")+BI_A_!27PA
M0 $NV,>*[S75WECCGQ=N!=V1>OXO?VG>1VZ-ZX^N&ZC1W4Y;K*B7G2)6S0CD
ME=0(8/22DK<IA65L%\;R*L/3/.'U[<FAQ"Q.7=#%<F6I=*%\-I;9$5-E'4R@
M"(ZW1=$Y&#HR9:[V+"/&D"<F3!X;-"W%#(O99GN/9[.?"[<$,1@F+-@EO2>(
MA MO@#/WR_XL*O"+8 .^)%\#LS!MX3\>-JQLW:GEU3VJ)[N)I.7#K(CDV%*]
M&>F9=3)+]BK^P>6UI/=-M"J8 707-:UT*<&1C1W22G0[H#./L6OT+WTF?"NP
MRB0CKC[G-,AB*;E;9L$ZD'O/>FZQ=WZ%6ZALEXQ.=RNJIY)J3T8A5N52R6,W
MO':")M1P)(H<E=#F^(XZ%?'?_U#*[*X$?:]72?53W,"IK/&5F3&TKBG1WJII
M^S)3[/5%(\-X-_2-N6W 7)-]G[*_G^#:Z+T&CY:X<0C4Q$4;VA 345%1]+$K
M=SV7#];#^6+QE!4*!UX";F,H]LDCBKS+<W<\$!@FO*@#(%W[JCT/[_5J& $D
MGBBS?M-MJ%-(!K^G;87(.V-2R4SI*\E^0*8'17SOKT;ZV?'^FA@X3V9Y[H[+
MI/D+G[^)Q ,#\!B<\5JZ?XS:KZG/F_Z!<HBS+OE- J8@@UN%6*<8/61ZL(DL
M0I'"1:3*GEFI%W=!TJ>I%T([';Y7%[LPNX5Z+GSNQ\XI>\AIVL<$VQ37\\@#
M<U.Y2%$01G&\Y&:'#9$RI(\37V(L2Y-TE[$5FSQ5K*QWX$2\&@*%4Y,[6.^Z
M9MJ(P=8+3QV1F?.D?<D*+N9A&.6XS8\@RM$,ZNEBT:")3BB'HF&*%O@:$S6Q
M[IWX]C]LM)":K$4<EK\=S!*L#'SM+46EMV/9KND;E.5Q;08;I 9P1$NP:#D.
M S[?0*EVP W@C 16]56)W =U[TU<IR$FW^KRQOR[O[E7]#/#M!=Y=Y'A_P,)
M?0DF+%"!,0M]P5]QKXK)[V)_:;/J,<3^X>3X\6RN0/0#6/$A02M6ZS_]1(?N
M.<)-0;LG,>EQHR9X:-T5CM(\E8T"+"?<Y#E>#%&^\#E1!$2!R9JA>""?7F\<
M8P9M&N;.Y\#HJFV47@ G$JU$S0GI<T2^1>HP5M[ D;2_).)DP]BOW9-C4#@Q
M0(\'>G5I1W(QUST.^U8*?Q)]G+=(1LI9@="=F['DX%//HW]>@ZM"T=A]A*9W
M,:PK7F=^!"#F0,[#B[EKW=?E;VWJ(6*77;<";H+N,W]LRO,:^(1ZB-Y/YZU-
MIY&&98/13DQLF*ML>J+4YP C1=%OG[U1>&"!P TF^?=2'?WF2Z^.WF^QFUA,
MSA+'@IGOQN,PY]TJW"=LL-?UXABX!O[#MY"$KHF^B3_#WOG^>/9#LUJ1!,5?
M\_?-(MSBK]OE<>8$!2KAZI  )N_BA1@#]5V^#UOR]$^X&?YQ;U-O;<)Q(F9:
M+.?\PA9)2J) B%6DMK@LBZOI3,']E-SNE#!+@T 85M,A^'C%YA]-N&37IX32
MJD5PG0JP:=ZC?/]U"T(J#BQ'1,RM,NI+E1Y,:B4'"ESW<_=%;.80<&QRWI&K
MLE*[2^V%8,VC_9MOD5?>L+H8M\(KEL;8_ FKNE#'=1SM+0DY=I=7A7;1[\>_
M?J0YVT65E^35WA2"?+\4KED*/>B4:]QPU8($!S(L=W-H,B\;QX@_5$*+:HI$
M1&$2:$@ALP61_+'6RY,413MRQ$R:D[N2?WT=59J<#/A$#"]Z![\$[$#%:U:W
M9O7N4H2-1,(E@3TJJ2^'H=O\4[@MTX0P)@<('\M&CD!8&#2C0!X(B$,LC],9
MOA0P7??I(98\_BFI'TT5A9PL7F:U;;V@/XY4.N3M+BGI1R5U/=$48KD,,VP'
MFYUF*03FRF!'L3(U]_=-!&A78*4)%B^"BW@'_--EH,XCA5*19PBZL[C%*32N
MT[H@_]KC0*->+O-<#<L_B'[TR?L<DG0I5!*].9'L\Y)+9]$42!G%J*=83(5P
M],4YJF1,;J;'CD-5:0%!.5*(K:I$[XJ\DF;)AHCRF.BGU/_=@2V\S\NNAU32
M@86$)^"CR[+::5M 'TH:JRG]Y@ZG9;\3;;)P__"'<"S$0EH#[ELQ^**C_(^:
MXM\<7O!3V$@5TYF1O70P:\$#Y+5#N+FM-PV_[)6HA9K(REO8SU%;(T]8%8@%
MGCF)#&*<]?B%NFQ 212W2MB+9935<M%5TG<9)BRL-3H,>BBV8!PJ5A[2/:PN
M>3REM"$CW[,G (F':W,SED&)"93,V<U8M<(V9DBTBDQ8*VCD9<7F!OP1Y$J?
MX9RJ+>8Z]LC^T#'W$"D=;E3*P\1OH>6"(8]5Q6RPB53+IKFJ1:'"2*3BT4&;
MT/0(+JQJKJJ?KFK)>M@LZ5>5_T/"T#I3FC96]EB%BB[!D@]I=F,+''M"=;B[
MA(]/OG0\>YDL+G;C>4CLCWQ$1=9G?EBP5$;!37DL?0D"5(:?DS8!%?ZE[T$-
MCX8(S@$EQR,JAXNB0,8[,^\<OB[I;)QOZ7$^,;"'#%4\/T8JMO@[P?&95C*8
M)((2+V]&O?Z;FRJ&; P6MQS\JEAV ], _^,76H81?*N=\ZQCGYP6U.3 0L>3
MQT:FED0M:4<D.&L^GM)BQO@)$T$>_,@<8/ >L[JZNC/1=R$/( 8AY-S\9LS[
MO_#D)Y\5NRF!*5R4'?*A]+;@9R^W84[)#0K^M_D__5Z2 C,DWGLOQVY>XY;)
M^=A^034;WXIX@LOR[O$I.G]'WX_1&M!@E.&E]<H*&8:7W@8[:PV-JEAD0P7X
M"/93*_Z9M2&Y^&UI+"%2\17TGDN92OYE--]2WC!LS/A0WK)A]$%CM]TMR]L"
MLC/ L*(F,.)8/XAD[T>RPE"4R7\\QN?CA%'= 9S[\6SV0W-E?7'&D[@O"$ 6
M3CNV?\O^:3/>Q@*W([UW-AVT(@$6!R1/XDS06,CS<J#$8\SI;#>^>)S@!76-
M-N7,"U) R<0E\7[E 2H-UWD28W&ZE^NRL.'K)U2.2>*B"\<^7+!,>@+0N(A]
MDA@/UH  %[ZS!&9"VF@4$@/<65<D_7=83=KT1@S)*R,.G55-&*5V:-\.6)@)
MDW)/1X\R^(LOL@S^FRJ9]$79<F*;)H$CM>9,X#@X:E4L5J2JZL8.7Y0FX<8<
MN78S9Q!D?\9^6TA=T&H(MIKXRCLZ?A1RF,43'-::I5;M') V?=1&$1TP(SFG
M]?B_5TJR_W,OBQ3L8:V,T\&PH/FC*2E?PA)RVI$JS)N3"/-5L^ <0?P)N'DX
MJA+VB/%!*(68UIF'M!>,G7[WJ'<EKYLV*XR1JF/.!A3L/6[>546,2+V>.E*%
MH2F2EFOZGOXG7922B?0W_*]DV!*% H-TKJ6:RF4W@H []@L(_3;]5&1R #A1
MDI;BS]VFT19/0[#1+<9ZPVG_-,N.([JEKFA73W99.:]A>D<\]#,([;">6OYY
M5N57G3!B2)\V.1KK*)#9BG!J6\A?(! P%MDG A(C"^MNA+##\;G!&S>C.XE5
M>#Z&JYSMI)[XYV;>J4+3XT<G7V>2\1CB>6BU?CS[\ZG7<%)BE[.F#7'U9=D&
M\W9:+C.B[B\+0?B]"O=OUB&:%HVE/0L]A4<\.WW_Z@/_*]VTA%-A,5TAC7E=
M2SKKO02^9PVKWI^\^.;YJ*H4?4'>-SRTBG$0/7AXNW,Y [87G!Q,>E%DO&%?
M5&\OC+P0U$1X1LZ-&9J#Y#JQ^P%+ULL1$9;2C%<5Y4&!:E_-GCS[3S8YJ^!!
MV5\?G_RG9;]PGN;^%DN[)WFJ1'0_X!H/E_SFT7^B;993A$=LZ,([T%%#&DMK
M=JKE!\'@==(.HU_B:M:\" _,I6J(;O5D6$^^GCV0U"<9+QQ!HT\D+2Z+X-"7
MW!MZ10RXM*56%!&%9?RP5P^)MRY5U%%7X*R@8:D%!TKV3]/V/#@'*"I\7BOF
M3SFP1!*_LSG4:%=B4J;*6]+R::&T'NZ\9IT%*-$RA?LM^]M?BL=G(N)QP^:=
M\6F$0 C(;,F>=C?1'B_4*+2P%+,J3'?'&L?07D5FH:CSA4A7DJR"ZBN<Z&Y&
MEVG8:)#8[KA)BW;\ZWHEEWIONT5MSNOWP8)=D<$@XA!1'D<C"EG6<*?3W3DU
M_W._#:[V_M0KV9/.=7K3U"B$W5M\7E#"D;Y%:C70K*UG6CMF;9>VV.S"$LUI
M>P0KRLUMI+G0YF18_2KDQTBORQXSBJ32$$^&A%J78TI7K?.!:\\>4,0L#T;I
M"3H65I1/H=T%+3]^7&T"/W I8L!2V3S4:YNZV/MLO*!9'JCMS>OTXLG%MN%L
M6SVD9#;*L&PG@\TGNK U=0=]-AF4CQ>[+I.BA@V0L,. 0YAVL;PC_.-$>Y><
M.?++(,<C^>'!%!V'E60H2M(X1GF*RSCQ8-SR:A$Z0#CD,>?L5WB9]J0JNP/U
MX5T$XUQJ*Q.N8;>3KJ;('&K=O&3*26/8Q'/SQ3;63-BE&A'5&G41TM[3+3UK
MQ#V(RD1XW"L:.RDBJ>HRB-6EEA.NR+1KS=0 N;&!8Q/'YZXDEU_S>+,;SE$J
M?=KGA=IM2SX^$C\#L1Z?Z[1OA^<FCLN]G)5=+_O9.]BPXBG[M.W]RI4;[DB^
M^49B.74(^(HEZ&:N&[AL]H?G3Z)\#ILTS=!#<.(&EW#W^^5SD$-;Z/C%\!%^
M\;6.9R^91%"%B7JZ1+-DI#A5*\M/6C;)M0Y[E:K&!46DX=7US7I#  LU]CX2
M*??\28YDZ==P>;5"U8:3_KPNS6/%T;EKZ51T@D':\'^6H.=.M5!J_G (;9=L
MA,TM,^\XQ,Y5V%S%@6UB[:DFM<41)7NW?\Y#O!TNK9VOJ7GWND!E'?O81QW>
M\ 6M^<?H/9<QPI8?<N8DK$QIE7YD@6)$IE9<>$P 4NI=1R$1,L><T1I!*C6K
M55<DB6F945CETJBC;V:5?_-\4G)^\12*5/'LR3>/U=>@\#"30[AE?U4Q]^+5
MQ5T:SD\NYR<>"BY]WJ!,HSJY$=G ?I!)Y'+>*!RET6]#Z%,L>6&<B^(YG*)G
M(7B3WY,+!_([*("0=Z;8"[M3^$;B66K*B27@J,A=%!P \E+,^KZ6N>VNUD-X
M*+I;,!='XM+=Z( RX(7^BM90ON6:"_LYLMQP]:;;ZA=ES4FD*'GDI.$="W32
MZ(LZN7<7:\V@N2BZMPT7+KF"58&LK(V(C3+B'9VQ,.)(/[AEA>GY\RY,:XB*
MOV%Z6S7)%+H<SWYLMI0>AOJ+&O#X7"D BGR*0R\JWN(NQ4@.UGKJ/%,"$[/C
M[NI,'.=+QB")+H/?7]\V<&(X>J-+V"^ND/GO6VG=#V\GS4J\4605-+LM@1AC
M'YOD61G5L2R8#D.H$,)T]Q\/D23$/=MB:;0KO65.?^*21#GA"_1,[>^].O;U
MHR^R.M8[A'[5(4D-8=DYZ5<U98BEF"&%H/[^N!W6-H*%*9#5Y<Y*+RP8?T9+
ML@GA^+ED">[&\?R1-8DE_Y*#5)@WL+B5KEU1C$9$M'6[#GA\',]L>82H>,Q.
M.GIP5R^DD83!96ZL4CL"C/9AU.1R["U^E5X6+#?"!K>KQYRJPPX5"8-&@>G@
M]T($5IV)WZXP8F[+P9Q_S 4*@+'SN7.D[?44TVRXDZW>45? .3DI2.-=ZUT8
M.BVM%&BNHV?7)>)NIOSS.$.]*"8YSWKG(7N#H]>+M+1TP-7%S#3FQ./>=8*0
M$N^'[Y;\+*]YK>*GQY TYOR-K5@'X@\^U4"@U[-)188JVB"Y&22?=I@<G>C)
MI>[;C?,R7[R>-,WQRP18]C+E>"'4VSL)S,X,.G4W]*3!?DR *]+8E)=-470]
M0IL1Z!GS,$G24/2Z7,?:)HPDTGO(#J*)B!Q&<=ZH'2I!5++ZFB=U+YC&I2_K
MBYQ,^2EX_!<D$P$?TJ'.(@UOPL%Z1S);;Z\=RGRF[F*UYT*#?2_AI%+DF*.F
M=IA40H3T9AB$6G68I0KJ%?D&C8:V2H[#6B^;5A>+L" Z,R'0P[XT(B5T1C0O
M0PST CFS*>(6MDF+B[ .@M<]Z];$T+YNJB*LEB)9NY!" @'S>9LOI0:K[H!?
MFV&>H?&<_@"M.Y0P1#V)VO_8UE[LUNA?^G'T&77 MON-![H:*ZP<$C_5P#I]
MV"JRF@5+8N\"^OH08E5[C?E6Y,BI',#*K^B)X3A22K0X;=9)%YXQA \$^I:2
MJ.QO'SXG^$ZAM)9H2,%$"=&U D#U@0O:Q/F"+]SE*X'&'*87(&+%H8 )G8V'
MN)DAK()H8?CD4<4['Q'H')6UT_[+J>L FAUW2-%[N^'UW,(Y[; *,Q&#D5-7
MO"UQWI5<V'1J&1_VRR1;HC8-^Q)J1ZGO%&LT+)J[ O4Z3=,#[-U$VCS4FD Y
MG6+Q&3/7/T D>=>-GV"IVHC2 J9#>'512"6R\*#Q:U0J,R74[,(FJ_)6VJTW
M!<&YN16W;[',QG>9\KIC#,2.#!YU9&ND:Y(68+V?]9C*@L.W[C2/)!F;-#_C
MV%P/Z:JF["'#UI+8,^D+6H*PI FK(\OW4L@3T$ #B/0E]YT-M8S2YE^"1$<\
M.+]P?]$DE]QUQJ21""F-;+(!N!^3.#18/6:.2#T^+;2@5*>0>J%URE@^1Q8.
MK9>DA?F.E#M_9O+; M3/DL@;$8 9)\I-12<GCHVF]6MW9''1O@+)8]=D:2BK
M#80N\T)Y%CH$[X1S>%I-*TUS:CO*4)AP!_W9>1!:11M52 ^;L8S-*BA\5GLE
MU09=L9-.?_7^?W_UPZOWCX]FE,+KMJ*6#NMT@/7R=K79CV>STX.RSDCX;UGW
M*=G5R3C] VHP6>3724D*L,J041ZC))">&L<->U'DEV6UO\9!1P,IV; =4W^,
M4'>D>@Q3C3T?AXUI8Y8J):]5W98A?RT?'4U5-5?W;+:W)L\\TD8UT7(VQE-R
MS^IT*[. 'OW-5E UXA5IJ_FH>#9PO.PEHDEW5'#R?G9NAVAI[BFR/&66]GA2
MA$WQ/1$"M$Q+OY7*)T^IS4[Q.5BS#HU$!YHB[R?N5B9.>07&FV./N'G3=8"V
M7*1).FNGQ<N9[@H9CY3KV9,57:</=<_R^_7)EU[ O=]GU^RS9,-<W^GL-Q$G
M"/-=O;CHM1J.\4XJN]>2M4TB89@F3TP%$5HJ'KT7Z>[NK>OMS+HP<M2+?A P
M.4O462!Q'^.^UI3ZDBAC5].9R,GJ:)TW^;ZYG[%_N2/CAQS9MV!N!18O5'-M
M4:[GI))#Q^C]?-R2?^+85ZW_8NFY;J0(@(1=U5<_[&(X['AV[PE6;^M8<Z G
MR:F'@7:\J5P%*^\0:^G*)9&,9G*@KNE2VJ5+'*])7ZF-G)%9%#<ZG"=%!C]<
MZ@!]R[796$N"X7Z]O&J2?+TS&>R7[>X\R;P))1O5I4@]=WO!YV&D?16BUTQK
M=ZX72BCVC9:!VP%V-:<*?>'#S57,8\?4#T(@U]8U[^7-A4VV7S))(Y];XOG]
MS?/@6O>]IJC<'XC)["^E1($Q!)U#65$!B*+(@@ &!PK8W>PB/)5EV>.$N.HA
M@^ZNJX4CW<I:96;?0-8:#II84F8A<=0&IPC=CV??%2O8C(,"Q]Q],Y:=LO2\
MU[H=/'$4P%8J)72A8#OT:V3HN3;**%]$QS92Z,!!H("6U.7EA$ 4*QM=CR/$
M5OGAIQ9JJOC84QS0FF=%C5WX5Q)EN]<_ONPFX1Y: /:$8ZB+X:CZVRXL.Z6#
M8@U,0P.ZCELM9[MDL'!81@4/:=PZ^ JP!FE]N^2K?__RU#_MQ-)0K/WP3;$J
MV4'26>2>9GL>SSDH-_V%3X][.!.H<\&UZQ8#VBL7RZ/@QG?%&SCKCP$:F>6L
MR5+ W+*@<QVC9$C?#%L#M)^Q].1/"?ZZ[]C-.T5UV7EU:H:P5UGJ;S6Z&1>[
MT%^Q)V@JR\W+\]O9YTZX>A=.).H&]AQ-E\@$+D7!A'9P @7)AH:%=B1[.C@R
MN8;.A?X>V'?:8/:9\*<]G7O)QMLNKXB1$=Q76"W;G11R181HW@#7;<3S;(O^
M#AIM2=,'[XS6V3E?2$$$H!(;8, B\=_@,UJ\J"UOY/#E/W?!R-V'U;<RW<-.
ML>CGMN1IZ;8GP\-[-B?PG#$A][CR>Q.(QJ]\L1V!Z:#PTX0WECK#^#3?I[-N
M9YY'I- G_#K1YX5P=5V<Y^KT4N-#S04Y(S]+A#*6Q0(2\(WS5#JA55>:_4S(
MWWB['U!JIW,B7+NI#RIDWR^.6UD<B;AGA!N9F,EJ#&-W< %1(S#ANJ-2<\05
M9K.B;INJDC!>DBC]Z\M5NJJY&KT*W IB[*5_TM-B";:$W]LYC&K_LCA1*#X,
M%Y7 IW_E^T5U.PGT7=M+E?-1H$9!#Q0XP,+ F0@>.D590-R*K;3/Z94(<^7:
M*$6[99B%<](M]W-[FUZ#4N%S<R>0B-S8#23@C0T&F1<E(K*..4_,M2JU\S[G
MP#+9^,SI*8RUC73K[6KGE%P4>46KBWK)[E? ;Q FJ .@'1&C4<*-5M$U:Z4F
MY6AB#T:I]9!-N5\'MV;E)WP 6 ?JH>I*EI] EDH;;%R#=TR[7^1DU\/3A56Q
M(";H?(?>^8G ,IO=?!E.F2G&/-_C,V]M1;CDT7G5S/,*TV*-SDXDMR%8RR+]
M@DZC_I/!FRC9 -'$#BIS44KJ8)N?PQPLRXXH]6*3X02!9<G$46VSDV8_4).W
M)>>T#3[^N\>:/;Z36+-?ESU$(EET*_6E-'P.E)<9I\!4Z3,*TOKRP6KL8M].
M+L8OR!2!>O:W,$7AQH<%@#'&OS1^38B]TM"3Z[<BYU%\SA=%.P<.?4XAQZ)M
MC"/7B3Q&;2^AN+U'G]QJ @/X89P?H!/<'JI=FO.AV BO(^,R5+]XT82C*VIR
MXBA34)C2FR-^[;1"8CRPRS9?YS@-$;9^DAZ>=21Y0><>]Z!7=Z9O./83>F7<
MFR4 !3<D];;IH1<]A^U%T\4((U*$DX=0K*F/E_4N!_V-X^I(-Y_Z_J-F6DEU
M"A&<C(KOMH5THA(8LTO :5;Z&TC\UTWPG.D%_*=\Y99?0>KUE)8MVMH4ZNX+
M8;=B4^92"A%FH(/ C?OFE'_M7- F.2"G?9_:NVW<<[JV$_&:5@L$P3!M=I7F
M7CTA.ZD M$V^9'=GR^1C$"/MZ BXGZE_R4QQ=WA.I*N:*S5Z-P\TW3'M?-)F
M8E*U*D?.1\M5#HZW>S-V:T>*YW5U'?)$IQLMF_H\:;XR3,O]+-S"+'#5(G8&
MA&%>@QR*.7\N%(\DW.*'3OZ[XH:_=<Z)KZ,SSIEA@D3J:>$(^\FCJ)";<[!<
MXS8QM%( ]J3C%SO3/"KW1G<3#I%SALT)!C1+M0#G!9NY'?I7EP;;G1>.6HI8
M%187Q7)7%:YL>#S[X/4?>L^T'P&WJ&@AC2J'>MU%TVZIQ8N0NT(MS["ZF'.,
M13661%&T!4WE+Z%BR:G3Q;1[B=](8%CSE@D+I"4F_.7_9^]M>QPYCJS1OT)<
M/+BP@9JQ1K9E:04\0'LD6;-K60/->(6]WXIDL5F>8A6WBM4M[J^_&2<B,B.S
MLMCL44LS7!%8>#5-LE[R)3)>3IPC:WWI(;SK3I&+9=T_I"3[\-,H6]FD]4!E
M,31$"DK%E[*KOF%X:Z$4*[[%A:.S;E=1&7HP98W_8=;X3=T[>]^ DFJ@7-%:
M_M%IR9S_J6QTP %O#J$_<&"*07\_T28&74ES%+"X7H<.?+?5"/0N#UH/H.!&
MS84Y@:J6M, *\V1R]6/A?CYR\TC7DS!0^& 8">%Q)!'HM9 .RF=8@[0^EE1D
M"1IHE)UW-P]#XUOF:'&#&GFK'#+"O40*N8NFWG UC[ =);[YG/C2:>1,&Z1Y
M;IV%<DVR0X,;?#8"@4N'QF//W(GRT"!:/ 2H/Q,W*@M5KA*9$.H4GL?',NL(
M Y"Y<\>;7."O:WT,9=YQ&^"-YU\G04J>3TIOA)U+[AVW)K!I"WDG]*&T%?V+
M!+FYRP')@7O??\0>R%!5[X+_Z#6VB5QH0-E]NAB6X^$$C9:<+8'O-O2S6G5D
M96/<0.QP>A-WS4('I0L"=4:*.@$@/)Q0NIA&IU>;!5V+"EJ>D_".NX#G:JG<
MA31;1N4%R&+JI+&R#CHT*8_;.?QH?O#U7%6@7B<"!<)TSM#_;-L/C(%9SI?7
MZ_3JU& ID1SLSS!TJQK% <1G<W.+&3PQO5CIZ<3ZH#M,_NSL<.HYF@6=KTB^
M* BNC8,TRXQ+&^G[&BG(%\]<HB%)FEN<I("&'H&R0:L$_@UR*SX3T>)@\#RB
MS$EXGF=LZ@[D4BE\N%A$FK]*W7\7L6G'A)^IR%J1)5?/NRN%M+$Q?-FMX.]F
MEH:$Y'I4.X?PGFEO=\1&3R)\=!8_XU8-C0$W>C(PI8J>C#R84O(>^.T:U*M
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MBC=I]T+H.#AU'_D;&1XW0M)5:VY:J,ZNA/ZA8,Z57[SZOCQ*I<+6.^+11.,
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MG;:CO+6Z)]-&BL'X&>RR!**LL:6\727=D<+YW7E?8P#L81>$4DV;:M+JH9\
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M"D#HW8Y(2P[=ZIW8NGCN(Y9D2>OX.P"9($0_<6:4^S7E</:LQ6:/^0:Q33Q
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MZ4*AEST<0SH0WHOF^^F!W2:]&'A")KP]=4**8*0:(2^&XO?\9#S)9\R-D)
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MKU/R!%-BZ74"V?D.:NEBMK@>0:A)X4XR#H6VBDS,G;-O0[D1$DI?<J8-1QE
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MW2IO#CY(SIYV+"?T?/$2^=)AD3_3?0K60+VLD\[D/H5D73F@TO8_]\">P#I
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MB:\9JX&:*/_T:_>F8"1]L^H.#1^ZZ\6/%$(*$X,;,HHP5D2*43#OJ%M$_^C
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MQL6>9S;?'44/6Y"7 ? UL!!]WVWJB6RL-GP-(4%G3$MVJ'V-1>)YK6(F<7Q
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M1 +<8S&6<)70@[01?/"M(N\PG/XPMW#R_6*Q/]:75K???$9\B8=;B:OXWKT
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M447ZY,X.S9NF"@KERSRK->U;+&W+RKD4:\S LB>JI@_ZC2KH>Y\LD> CFR9
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M,IQ&;VAPMP/&[M&^4)^]?C>_?0D7CQU1CKYYJI/7M@O,L[J[2"8OEY@M,RR
M"J5R1IDOMQ>RXI.CHU.?[OGII[-$SF/FTZK^'=@=.;Q$F83*PEA>H[9:D1;W
MF,;X<;397*%HQL_-5)04(O,A@U1?M]:\7$Z-QB1CD14-%4QDZB1B*!Z-Y]38
M<MH)XX036.<\9$P_.\4[R#Z4\0"NJLJ=)RDD!P=:&P6*2 RSAWF#LR3409I=
M;[ROPERWJ/A2/1?T)L^:Y=>CQ9B,DDY B1G7SO.BM2:3N0'G32@6$L!O_G&6
MKR0&<DYWHWM")U67X90;3(I!_D&5F!FPNO5L^4BUVF[.V\_<H'NF!L!$UGR
MN"H97P@F,T_.$=%B\K^Z3:@%]<\L=-(WB:DL))0VE# @(]8JN9  ;$*(TS=Y
MJUM2U$1!V1.8VC-*0.7E[";8E>W] &NB%K*/FM.D8P68>LA[]#!/$(*?QK.%
MR/T$--[)T3$G=LN#D#1Z-74^E":,HBJ"VR-JI9\%LE9] -^,&ZA;%>OT08&
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MNX&93O1D&MW%AU<%)0!'/%GCO_IK?*,G%7LVYI>6O\G[8[4DZDELJ+9!:-_
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MO^;"T&=.DVW'%".*N9$LEZ]1F-B'^4)0A0XAO=P<0=.)F4^CH,39:@,0G96
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M;X>PS0UK[YH\]#>[[@",M9\9G0/NRP5;#N#(B\Y?S+1*G>7K"WY\V52+(O-
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M-SRX-YWADCAO;:3FJ3_+>WO_5BP@;4('N>- &U-0CH@J EMLWI1HS2!Q/0*
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MWX)=&:A:"KH)AHP2W2%505D/T]#YLFJX)))!M\Y?MX3RXK!!S00WWN;>F9N
MZ@.%W5]5S]@U<@^]N?6K)(^27J!P$75/&]T2);^[5!YSZI,^=E+K49V4Z!JD
M354(T;AMD0MY:P-"AI3PND)3F5-6<Y7/I%- </LU%'&9UBV'K#EHM"_@DY^J
M.F=(NH9,A,LA1,08X:0A3D]=P50:? 8X)F07Y:VD+4^.3G4S?)#T>X&QG9N0
MVX_IE2HIO=^;0((AZ6V&87_4BL?C\1PWJRK1!3#D*3I7</\^SB#XUC6=Y']M
M>TVXUN0UNP%0 %S)27VS31-Z"SX%EH!'*^HEN_%HB4P;9'<<@:*08ABS9#V:
MH'Q <TI1,L&AL9NS-ST=7D9PHZJV8$8&?VF3Y54W713-96@7R8>2:6>G=('%
M !W&HR$)SY<C1<V9@P)=08N&FG= (E9.&"I0^C@-KH0DLAG^CQ)VE/XALFV+
M;IG'\+,] 9R\8Q'&-$QM^AB)0%S8W9IFWP*>XCV00+#LWCB0SV\B;UC'=7H1
MD6F,.O0_I,//E,'41/2F^TE8LXA79%EEVAQSM&&&CDMV/A3+6YQCX)\:0SP6
M2,*0*3R*>0S8QKZ$@6Q B >\4+EE0=2OYH!OI4 :OT SD"QCB5+F >/5U8&$
MX\/;5:'M*9>_UD)&Q(*\(, *:?%IA"H,@#>6%P^6H\^[6DF*0LC=SJFJ^X<&
MJ#V>W/ZHJIB$"+VO0@ROK0CV9-6ZI#C \52!^TQX&'@%DYV2&JI>G&3&>*&0
M#XQ$NR"-B;O-B?6>:*.?G$U^'5)-HSR@3P]>BUM@ZFC"*3M.M%#1%8!G%#97
M@CMX 18\&D*VFS-1'HE+AV<6L/6T(8 ]QZ_DO)EP$$K39A01K=1,,!L.?=DW
M7R?N,%[DP[$QQR!W6R%G&_^J*#)G92A]^O49LK_:MVV1YF@9X/@$ABY/5W:/
MIGA\U]$4G_HH!P<IE* DG(5D#ZZ3NLD%F)>%>PV2YJQK#O?B%I,D;!$RQ;6@
MP+5W3?B(^1A'GZ5MF)":+1:>PR;PT T10_OBM[TL)S]0K/3DZ/A;7. 2T3E.
M3A\\2DZ/3[>I-K>6WZ5K<A5>E9-7L[8BC7.<A(?1:F4 [XZM+!D0+YQ1-'E[
M<!IM&&ED 9L*UE=0!7NSIF^=OD:JW*W%R;%=V-/DP</'R9/CA]<L[.NY>V.]
M+VU;\C&&Q<$5Y,MBC?ZW=W6U"M4.>BEKZ)&ZVK0"0(J1('(RQ:(/%>_RM&3C
MH_S!-54HMG"E*JGV \@.F%V#;6+0%HKSG6)JA3?)^?20<_1,U!Z0U%J#O0QP
MA=)DV4M!7OYW#C7Q>%.R3K@P9V).$ ^4.^W&$51K<*>F-PB700G&R5CAD8'"
M:!Z&ZRR)F[5H>S 25M2P-V2%S/K&NXBT#9J< 90.YM* #D*STGPY,6U5M.N<
MFF8;C-[ 1'?I!HHH#'E]XN/T/ I%M_&"#*RA4??VIE[(YSRLQR=\6 41M!"
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M'*ACV?MM P2Z,SS%MPSOJ"R7;ERB:2.O<LI<78@%NB/I9C5SB_,V#-+ X*+
MSK7VE;GI9)XFK:C+S_A$F5XA]-1DI&X8:&*BY8/?[CHR-=:BK#/7H7I3RQ<^
M4FC9?5^,.BDYS:70>E$5[3Z;RV:?P]3#K=H'OC"3FB\NRS1B.AY2-F@'.9WP
M+F(G!0:/<T)R;7;.QUVOH=VVE)YR=<F)37/59./!\VL>MK.K_4G+.%]Y0H3G
M6F*_%Q)F*(3<V#T]0-.C?(%DN<-%1* $H&7CP*9&F#BF;T_3OW+=)3,&6%Y
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ML21KRN]S6JN0SM*C!B_K^#(0S5#_8FZNUCG;49IN/GTSHB;@%Y[,-2@BDNM
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MF]65 ](%?"KZ5(X)2(&@&T+]0%K$BN8 C:X>]D\; 5DO0OJ8T='FH/@*\N?
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MY6^RKB2)T3V. S$:<4E04J3I)5]0 3A$^"*.^1"E7X!T)BH[GY@@65>.DF7
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M*5J:O=_GW^G4]=-.97G[>:X"/'6N?DH\O?MY]\%N= ,0$(O^<:7><?'=G@X
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MFB]I,^8HK?D0%A:QU6&!**@. =AFMJ95'<_.QS3WMCH,H)5II;LZ%J"1ZA"
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MW_RWH?^4.'@^:L>^Y[/(Y[$2=B80YN45JBH\O%J&-RN&WW:&=\,@YOA*T 2
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M\AYX_#?VXML+ X(%-FMX[Q(-CY<_!=0Z-J4/7LNI&]KC6LO-?6S==A9K+?<
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MI&D=8%5=2:LD5?/&'R1\1.(9*EA.=>4@OY:)=4R_-A4;J98&;)H]#C4GXGE
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MMZ?3H1=D5!PG2B7<U(V/- 6OX/Z---EX!_8 .Z3WDP4]BN(1\L7,9C>O*-7
MF)UJL/U) \6<"]3T[Q%%!?-R/<X$\J2H*!;]R@V06QB-/R4C\'#,"T_P&8\&
M XP&2N^7$ 7$>YE8&>+^X@G_:+J2-@<3J5-7E%UR!N$J8O2\9-R2&GUPS #5
MZ#0@5!Y*5!)H(7A&.$25+IP-\.*5=&4QT6\DQ0ZAE<QV2PF/&HFK3%.?$ ?Q
M--@1E&V804+D\P^PX.EN"G7M[P!7NYXG0R52;-,WWI=ZK\6LDGK5\I<^?I4Y
MZ9&2J23'Q"0?URU2!8),[; 'AC 9_*P?HO:)SLEXR;,J3-<T&Y/YFGIK*F'S
MA<Z54@H:'\H16X05?1@[.=VJ4P;P!=ZC5 ,!,80W)I :@ SJQ2*J-^%:1:VB
M" YFBO\$)Q[2VH43G'Z2TVAR#M8)8L.%Y'VZ,Q>04^!3HVO*@JJHL@14>8KF
M7LS0'9@$$FXYQ16R9"HBMB*=.S5+VG>KP)BF4>;;=)J:4>+;M!IX5'Y P59D
M^%S^F53)"#M0,<&/?_&[O$F<,GSRY?%P;0898'?<8;PD9U7D%),4*J3Y_6%Q
M/EZLLV9%,&LC&# T94"2PHAI#(5 6T70ODNU]''JR,L9:>(*KT1<2Q,;693J
MUSXEM@E!DX1.9)1RE-/S)DDO5<LKHBHY4?4Y)XHB&S UQJ2!EK/YTEQ*3-8$
M134, MZC7XV3 %()N8')K9KWI  *+:N0H!*3BCQTO$J/8O:5BFA?(]%F]TT:
M>BK;I-<QS1T?3^G,57-*JA NZ#&_&GJ!* F8_/'HP1,Y#KQ8Q,IT+_R>7$7>
M_3EMY3^2D,IO,.- B/7W@CV!?WCI3K 7WV0GV/#V^/-9[T?_FW7</^D=7UQJ
MQ]]__#K]?&"<?O^S=W)_;![W#^ _WVXOSQWMQ[^ZFMO_.V#?G='I]>[MC\]_
M]W]<7-U=&M]^GUS_]?M'_R_K\N+2ONQ_,X_OW3M8[]V/BT_=?]W_,DXN_OJI
M&PW7=-N."J?HJ9;>L-56QVFI3>:XK;;=\73/PYYSO1 S&I3_ M#\H%R$@(=<
M^?+EZZP.K0LV47\YZB*'[OHIZTLH4BE>)75]^VFZ9D,W75?5FT9+M9Q&6W6:
MCJ8:+4WCEJUICM[9^7@^9'T0K5X-TPH"U$7=T?!!RBH%!15G=V\6%R2E%1@.
M0ED53Z02)P[LV$?A!R3?F"V 7E$DR)P="5JFZ+15MD$?K1>?V;%[]O?1R>YY
M33DZV:LKNR?[ROFW3^='^T>[9T<'YQLR>&1N0]R%X6%CAH8TFG7'F?WQ8X>&
M@&ZNV;-_.N^Q\S^SM,9Z%KO8X)2G3B%Q-F0*B9AJEK.4EIE&\H)SR]*-+5X1
M1UM]XR%/RB!VW&4RS[Z/^6P "&_'MO_@.+/%.^R7Y:I1%5[)'A?I>K/A!Z4O
MPPNK:L4"I_5<8I#VB8D5.8FWEHD3*^]]M]X5/E-GO>>^Z3U1:$$AY6$NXV!5
M;:O*\HQ5=K$3,=B7N\EB(4;- --^$I@ =<-Z8]U!QM6;A;:L*>4=/_K'DS:6
MWU"$3RW!CJ1GZQ CN1BO& 6^\&N-8F]GW-'%.MQI.+IE-?2&U69.NVVX5KNC
M-;2VTVI;[9]'F7_+XZ[?9[WX_W94._%VC6+UBK'!>Z2:W<##_SG(2&9WN,>B
M"/NP_,UZ(PYL N<"OVJ\N$?L*O&(V9?]'[].OO_PCS__=7=Z<:4=?[Z\O[S^
MI5U>'QLGGR_-RXLC^\0XTB[]=/+6_<G]D?FC?]:]-([,D\_'&OQ=/[TX\T_W
M=^]^7+NW\.?KX^MOVK$_.7GKV#R^]OH_/A]>7UZ[&JP?_O[-/OE\9!WO_]D_
MN=^%/Q_?G5S\=?>O^[^&Q^=CD[=^-KV&J7EM2]7<CJY:':NM,L]IJ-PSVTPS
M+;W)6CL?6WK=3!QH"0U\%#ZJIY!Z EM+D/PJ97(%-UL -QKCC8X)_]?H>)9C
M.&W+XU:+-6RWXSEZQR2XT2NX>2&XN1N'&T?G&K>\CJKI#5.U--T!N&ESU?+:
M;9VU7,UMV3L?=:U5*KQ990OY<JIH9SP>1CYU?$ E;::R;2RWZ4+4W$"0695.
MDQTSXHRT<"I060I4ODWI,+;;;)M-RU+UIN:HEFNW58<9CMJVVRVSV6',8=K.
M1[MN/Q52YK#UNE281:W/5\J8JY+^%6.NA#$GI#WON)VV[;95SHR&:H$QH3J:
M8:H=K<WTEFGSCJ;O?+1*Q9C;[XXY9M$O+@.!:3NK1TG\1>VD#02654G\[+"S
MUF$IO(C\3WC;[^'[8-17O9!Z>^/#*NQ9"GLNIY0"7;-;=L=BJ@X7!_:%SM56
MQVBJEF$"&#&/,=<!2Z.F&U9=*Y&ML>IXPROEWU4I!A7_/A?_3GH*#*\)RD)+
M==NVK5J@T*M.A[FJWF -S7.\AF?IR+^F8U6^@F?EPMVDH95(1T?>J/P%Z]$>
MDJ,^2T_ZA \KZ^0Q".-.ASX:3:O=Y)ZJ6S98)V[#5AW7]E3;Z[3U!K?:#9<#
MPCQ=.ZC<!F7CSU5I!Q5_KI(_)S0 KVF8'=YLJ:;+F&J9'4UUFJ:A>JS5XI9A
MN$Z3 7_:I6+0[7<?G%)[XDSV5ZZ#-0E_.N@,6>(*6AX)+5=3HM\SVJ:C@W'1
M;+:;JJ6[KMIR#%-MF49+,ZR.Q3J=G8_-RC&P?=RY*M%?<>?JN'-"\&M>DQD>
MB/N6RT'P&UI3;>N.IC*]:;C,=G7>U#!)H-XL$7MNO]W_=;Q7CZA)H'Y@25-T
MF:M;>0/6HQ#("S@0Y[\;>(1!(B.^PI['8,^OZ;"!X1F6 ]C3Y+H!FD';5AEH
M ZK99*ZG:4;3U(V=CX9>MTID=%1>@5*I!A6?KH%/)W2$1A.T@)8&>GO;,57+
MYA:F%C@J:]F<-3W7="W@4]UYNHY0/N= V2IU+L(A3I%[N@ZP</W3-J'.RF(%
MX_A2Q297!3X'MP@\0E'X2S^^/]9^NI9M=+#+#=-=6[6:'4-%,:&Z#;BQANEU
M[$X+@Y.&I=6-%1DI"Y>G;HIWX76Q^<I"#A6;KX_-C\?9W+*:3L-LM54/2Q8L
MP[35EF5RU79<J]FT.UJ[92&;V[;Q]!S&9V'SC:\5GN6:P,:/.+8<JTL':?_I
M'K;7QP'GBM_'UK3)K+" #RLGQ;J<%.(JOO98, 3;YR"YD!->63U+(M+O*<6#
M=UH 2;:C>BT;&Z!Y396YCJ[JIFL;3;UIB)P%LW)/;!^'KLX]47'H"CET0F?P
MVHS;[;:I-BRSH5J-CJVVO9:N.J:&%^8XEHD5CD;EF'B&5 71#3JX$HJ 0B>!
MO79Q!-?3_13;"#(K2UY(COX+GOP9+N:T\RWF9+Y4*+,<RMQ-.R TKV$TFJZJ
MZZRI6LT6P]Q%4V6M%D".Q33F<:RL>K(:4"4PE(U#5Y; 4''H2CET0@]H8*ZB
MUS'59MO45,LU#5 !# ?SC!IFV]6;G49GYZ-9=TK$H5OJ'=C#'HKM4 R&R$8!
MD@*02V*HDA?6H1"PZ"9X/W8#>_(""&C&HZ,5["P'._=3BH'3YEX#BZ7<ENNH
MEJVY:KO3-%1#:W =Y(;3M#J4.]4JD?E1.0A*H1E4K+I>5IW0$+2V;718PU7A
MBBQ,-2(-H:U:S&G:#>;8NF.2IV +VR.4,X6A6 -88QQS4QO(+;CE#<?3U69F
M5+':%:*I-J7X:!K3-8.;JM/A3=5R.KKJ&(:EZK;9<EVXMU9+I&0T6D_7?38I
M):."KU<*7ZO-.*G@:[7P-:$,-AGC;K/CJ;K#-+#;=*:V]!;\5ZO).A;G7LN@
M=C5V2Z\W-@*^-MZ95*PI?O'%-$5?%L#$P]#]A2DF/(K_F])/AG=/Z56?NQ03
M3MX+1]BHZ^GS"1:UG=>PQ"VU&9(!!;V,(AXWI6"%HR/6]HSM+V]+V]H,V!TU
MQZ/AYG)6?>Z.GV)U;X<65;2Q#=>55MVPYZN@H=W VQ44E!,;50G0HW0F<\KD
MTYN:!]<"ZE*S3<EPEMK&CG]:R\':H*;=,HV=CTVK5*DV*Y+7%>IL >JLN@U1
MA3KK0)W)!#_+;=J&[:I6JVFI%O-<%01$1_4TK\T9H)!GV3L?[17DWI3/;5]B
M]6V?=SA0N*=$_(8'H\>U)-SBM*&5C662(<'O_K"[-P+KM\^C!&;N*I!Y%,C8
M4ZJ-[34:'=X$D&FRAFIU7$-E=M/#["'N@G0P&@T7VQ"T5N8,*I''^K6SZLI&
M&E6LN@Y6G= '>-/N $]J*FLZ8(487%/;K.VJ';O5]EHV=YFNXWS6QLHJ@4OD
MG2VQ0I"XYP9A1 P7=I1PHAX@\>K,=MB^TDRB]50!5-CS).PYFNY#X+0,;CAF
M2VW@S$9+,UV5:6VFVMS0VZRENX:-Q495LM_VL>AZR@ J%GTRBTZH!ZV6#DQJ
MMU4;T%.U6IJ-C8HLT.D;H!U8&M8#((OJ)6+1+0W8C?<IFA/2J;J8K%LQJ!R3
M3T6:Z=X &F\W+5UOJ483*X]UNZDZG79;U0W/,BW/;,.%@"'BV$_'FDW*?ZN8
M>=TJ1,7,*V#F";5!;S>UMMDRU);MF:K5M)C*+,=5S8[>TBQ'8Z;C 3,W])4U
M0:ZRP5XJZK#%5LJS1!U.PL"M<.<QN#/=6, !JX09'E<[3K.I6MPP50;_I'+3
M[#BNUV&=IKWST=)6H$14/H6R<>NS!!XJ;GT"MTXZ%TR7&;K6477'!"VAS6W5
M:9F:VO'<AM<P.PVMQ78^VN8*1B16[H6'&.U+&%PI0Q[U@3?:C^LON,5!S95Y
M#N"4+^"0]^&,*RAY+)1,-P[@'.P*UC14SS$=U;):'30X6FK';;9-N^TUK=9J
MIB%6^09E8\V5^0$JUEP-:TY(^;;><4S 1K6M,0^GE354UFRT5--Q--=K<]UM
M6F5CS2VU]R<["E89!"^305#!RV/A9;IRWC5;CN,T+=5H-5L +UQ3';MA =KH
MCM<"?#&<QL['<C4LK0S^4DG^BDM7SZ63LPBXX_"VYJJ<>Y@]X*!^[C5!/V^[
MMF$W<50!<NF3^PD^GZ'O^?&@Q^YPL7P^8S_7-S?>,S$O\:%*>"A'PD.%A<MA
MH3&EL5A:RW)TYJI&NVFH5KO15EO<,E5NVWK+,31F,#"(FMKJNJM6F0X;S<5K
MR'2HN'AI+I[0: S6:5EF0U-=UP&-QC4LM>68FJK;.@"MJ<-_D(L=9T.X>$M=
M'GMAO^\/:7 2M<1 QH+E\L"=IT@LUT9FQFTD +<><?T[]M\'?N__=H;1B$^'
M,--=[P;>7G[/%><OQ_G3C1LTR[5;CM90.[:M@?QN6FJ[87JJPQW>0&.FT^P@
M5TTP?1D:'JV,4I<1216E/ANE3L@HV_$T[I@=U6TW&EC<AR6X8(0[-ER.TW0,
M$$\S*75+K<GS@HYG5>.KE4AUS[])'BQ_K^*7W^LF5E@^N]@/ ]'>KJ;\,0_9
MOO+HO,LBOA*E^^CDL CAPH#([BN+3J/S(1MR[V_6&_'LU1+IM KI%D$Z^\O%
M[AC2?3'/>OP?9W<_OGN#MF$U3O<]__3[8>_X\Y%]>N'";[_]/C;^O#Z]./$O
MKR^-D^^PX_[?O>/O)QW8\T^]Y7ENI]50&S1WP&MT5,?T6JK!',=T--#&;'>^
M?)Q!18]SP%14M)%4U'";+=,T#%5W74^U.B976<<P5:W9=CRCI3&/_7_VOK2I
MK23;]J\HN/?=UQWAI',>7!U$4,95CXX&/.!RVU\<.1K90N)*PC;\^K?S2$R2
MP,@Z$D>0U5T4:#PG=ZZUA]R#V-C"FQA/9Y]./= ZL?W6MRS?9ZU;-]X@RWVP
MM*SERRU7[:_![F!P&D,QRQYRFYWO?F(J896,10KGLQ20+'+,,J05UYPPX;2Q
M=Y#5:O?,P>EP, 3'&XR!LG$>>.,D18*6VB(?/;@#7%CP!)1&1(8\VY/I6/7^
M8C-:?4S34PZFS+?'ZLO/+KS4O.WU]1,C0;$H*1A1.")N!$5.88%BBC((HF/R
M8EY>6MJ>*;S4G(UC0(+<.HRBM!YQ3TS>. I)L+Y-$,))7-4!S$@1G.:ET39J
MM2M.&,W'NQ)URPYR)YV=Z..QB_U1')Z19ZVLW:H7Y^WTK 6?<!+A [_%SE5N
M'+BW)?=FB09#Y<P4,,X-QHGP-*7:$1\9XC00, ^-0AKX$F%OJ19<8B5<]D)*
M!=RC ^42M.48E->GIZ3VCQC0>>SW"ECG!NMD7ISE5H!X$(_>(J[ <'+84 1B
M,\1K!]($F^E__DL#E?[6(, ^_HZ\V]Z?'I]V<I0-L)+:OOTTBN+^MA(C8 !W
M![]-$L^;.+1P1>&E[7=AM0;7A+ SDD&AG+DH9V^ZZUZ0QFM"%$HX4>"=X)&1
M7H)]$)A-#+1%CG4;*6:T /][J9-;7[3^NG50T+HZM$X8",E@&6,T2+!\A)^"
MR&-V):*2)^*<U(KPC2VI9Z7./PA:'W]KWFVXT+R^MM,ZL>V VMV6MR?MH>V4
M,KHES26Z7/%7L."[W1>CY2Y#'6NDGNF.?(1(24QN^QER%W^E#=*)1A2$M4PP
M,"%\-9-6<-.H:2$EF-"H8$(![TK .V$WR! D$S(BIE1$7'B,#'4<@<T/_&L4
M^  L@Y=+LWAG_Q)8^,7 0F]X%/MPG\<G_7@4NX/VM]CJ] 8+5;BM#1<]:*3A
MFA0.LA!>7)?!;A=$$O\-@MB/PX-T:'\40IJ/D*9;\[%(723@N9 @%9@4-"'-
MN$"6,Z^T\^#H*""D66Q4H@YKC-S:HPX%N<M&[F05 6Q/K\& 2$J(7+MOD!4Z
M(>$$<=)HI2.8$GS&+*]U#D TK6YA5 4_U[SV>S@N3ZN0MJYXQ/4:DI>5# K+
MS,<RTQW\"*92&N-0\'D8D L^LPQ'A 4KA*322[FQ)22OK4=(,ZKB:XQ"/"TP
MUQ6?*&"N <P3)@-8\U0&99!(,B%N/ =C7WBDI9%$!$ZDB1M;2M?0_W\E8'ZD
MM9!3G76J%,C[V!CW[%4P6L7G#)8]]$Y=)XY$L@!1K=W@]SH79,T9>PG=B+:[
M819_E]!R;>0^W7%1&!&<9Q0EP\%2LSEG+7*+(J/11$<5C3F2\XQ*O?CHQAKA
M\\"1H$*9A3*;T/JI4.8**',RA(:C-IH9I%)N&:.(1HXGCJ1T@5AJ0;BB.DH'
MBW@ZC+9^E%G9R_\86OBZB\*9:\TACFW_<[L[^FYZDZM\A,W?KQN-U><\SZ?.
M;7\W/BG.+4)B;%F?3^5L]RQ7#75[0["-A[W6\"AF?%:K51W@I7;7=GV[BLS!
M U4?FYL%0]?N>_PE/!]*GO0&U:GX\W[LV%QH]-OW=A@>P47G*[C^KK$ \=5;
MK(,+.!W>_I:E+^B=R_='"[7X1-74M9_Y.BL6L8;)&")+E&$.%&:LTLQB%54R
MS'/]B5"R<?&NH_Y5:Y'/8'#TH_V*;()[>VX[W^W98.,?-_<8;+#KZSVY5*,%
MV?JGZ\/[9ESK+=M5KV*[WN:S5:N[_>:OW?WMM\]:N_LO-EO;^SNMM^]^?[N[
ML[O]9O?EVUOWWLHQ=^=-O+B.H;>7R,FU>>-FS/""RAF]<;K3R@<[K?O>(]Q1
MQ4!70*HH#^ZL8T\&\?G%+[]=]-)M=ZLKK=[TV_C#QNC+6VC26<\K.'KZ:G=M
MXM$.&\<*QM\\?GJS>FJ"OT?/";I)&;OU:;Q);GWNKH\E?!.+V]]ZU\?>_1S'
MLERLN)_ ?A(\FC-&5*>]JN=7D*/SWY"ATQ^'B\8%M]T6?&$G _=9*_[P$4P'
M@/+HZ98]!@ME.)@Z$+Q<#R(67I#E*T!]KZC:AVC[K9?= -0V56@\HYAXG;?'
M[ 6X%[O?I^7:?6W4:6VVDF6Y<Q%R**N6>[Q/3[@U7RA2%NI^"X5O+-2*3B66
M&B&9?:MO9L\C7F);\#4/DCWR,)CW.&DK/",^<(^9DP &'H,.T>NDXZ>=3+>8
M8(+N=X0PWF -ZC&;OV<4VB(?WN]_V:-_'.^_?WGVX?PKWMMY=_[A\#7Y</X9
M7O^OK_L[G\7^SM'7O;?70EOTW=G^^3;=>_^Q<_!^%^^=?SX[./P]A[/XP<X?
M1WN'7GS\\O'K_HS0UL?#7;:W\^''Q^-WXL.7U^<'.[MBKPIG?>9[[U_^V#_O
M'.\?OZ;_.=\=A[5>#O?AFO;.7W\*F&,!XD%868LX\PQI33!RRI(0M64R5Y,2
M1A8O$5FG80:%J9XH4UGC&+?6)2$QESAJ)9F.@D='F;1$54Q%+ICJ'I'[PE2_
MRE1G-YF**BN,Y02Q:#SBT3IDDXW(<X:EX8XI'ZLN4S4'X M1%:)J(%%A"CM>
M:QX\<SS88#G0E)7&!2E)P".3"E\0%2Y$M32BVI\PJ9*QQ/HHD:8^5\I$@<"B
M\BB(Z!0C8 (; =Z@*(-E'MA+O1JG&W^<Q.X@#GYMD$"-LSX>_6>LOC[T 6C\
M31Q$V_='57P] *]V>B<YA/HDRD(?-BPP6OCM;MBY6O:7(W07Q3:78GL]%2OP
M@442+$,@BXBXXAI9["A2UN<N-RH0[3>V&!&-F@5?"D&;ZA@7K-:(U0EOV6.J
M F82.9!2CNMQY#P52%#E%9/.@R WMHC&M<7U"E8;@]4E^(8%J_5A=<IA5(FK
MW##=2TD!JS(A'33()N*(K1 A$0=8Q;I16%U]H[@' -V?L0L^8J<RY&TX;G?;
M@V&_RO<LO>*6;,N/EQXH9_O&PA?6^176>3=ES0OOJ7,I@DG #5CS*B"39$!4
M4B%B,&#LZ3P >?%X>ND-US2PUF[,%[#6#-8)<UXF;RUG 0GI">*6"V2B< CX
M56"6%,4V;FS)&JI/"EB;!M;:K?D"UGK!.FG/,V,,9E@BI138\PI\;V-)0H0D
MS(W'04?0K$QOL@:!]?$F(XZZ)/2F#GL6B<8_K58MM=OVER=O8\HIA\[S<<Z'
M*6N>.8.5L1A)30+B(F+DG 7.H4HKRXUS+L?FS:PV;TT\=7Z 2.#3PG3M+D#!
M],*8GC#Z=8*5CUJCJA$T%](BB[5%4D:++8W69 ^=<EK;>5O!]%ICNG9/H6!Z
M44Q/^@8:$\=RF T;D:?&,8U,HA)Q*KD)D7/JZ,86X7+QSFHE.VPAMZ&J54_]
MWO&%ZW!7T>/3Z.XX3]_H&GR&6QI(7Y+25;/H0DMST9*?<A\TH5A:;L%?P$!+
M#'Y8YP4*#CP):Z,7F(.I(6?-EK]_E^C2N/510+L&UZ% >WG0GO B6/#):8 V
ME2( M)E#5G")//P0U@>5>,J90+.R"PJTGQBT:_ @"K27!NVIQ"%N18HIH  X
M1AQ+AIP-$04&EI;6S  + [0IGM''LV'0?KS'#]60DU:[VO6MOXT/'VYOI%-'
M8*1\QA-)3[N^MYZUNO'7*DP>\=EY_2=7><7W>]W>3756CLY_1:-]G6Y'H8/R
M+$C$L'"(.TF0UBXAQ20EVH)=$N3&%F[4R,.2YM+0 ZD"U5JA.N%7"B6X4#8A
M;_*)L^8)&:8P,IH(H\![8,YN;-%-4:#ZV*!:_SE3@6J=4)WT$PVH5,J%0,HJ
MAC@1!!G./>(IL<"X)HS&#%72(*C^Q'Z_Z/D+%QOO1O<ZO_))5,OOYO:,<3!<
MV(]YQ!5]M?LQN]UOL.2YBF]$M1="*%P[%]>^_#$U7H?[J),)#KE@*>)>@5T4
M#$9>N>!49(K%7,U77]+.FJ;F/$:8UN[#%)C6!M.)D2X*#!4:A4'8!HXXSOV:
MA#,H< %6+/!J8J"&26T3L I*&X/2VMV7@M+:4/KN)DH-ECP+!6!I'.(6?C->
M)&0%R! 0[#3(9HLM'F1876%\\[R,1G@N:Y,7."XGNG;R\L2S A_2C2DQHYJH
M=WJ@NU*").XHF$7)@Q\3>0X:&61!;I+SF()2E1]3UUE,R1U::VS7[OL4;->'
M[<EYECH$+"A#)-<(<J\=<E69,AA5(FHCA L;6[RV N4"[;6&=NT.4X%V?=">
M\)C )V):L8@8C@KQ)!BRRE.48@Q).NFPM!M;HK9&(24M\-?<B/TX;'5RB9&+
MJ=>/%PF"0_LCCN;R=2[KCV(UXKEU'(='O0 OO @V//$&!LVH1KI*9_X#9/4"
MOK3=/87UNYJ4]WLEX-'K#K-X]]K=7A\D>A$FVNZ&FY\RFNF]5\G[*K94\J7G
M)$<R[=-(Y:35!@47-.(.>%%KX1#Q-D6L.8F\:LU/9AS.W#]ANA13/PK.6%Z9
M4^&,)G/&A*^D:=+88HL8Z O$M37($>X1&$M@_X)110++]5-\1OI,X8PGQAG+
MJY\JG-%DSIATPBP.7CJ!$F88<4/ "3/1(A$BB-Y*[5F>JDC$0N74Z]3@H>DI
M:!?.UT5WN"=12+-B#VH6H0%1C4,_O\=N3.UR9CXG^= I)X=83Z5W'%%-/.+$
M)N2"HLA90I30'G.;G1P\8_[8W$6A:QJ^71N$/FSNV2T !3/CV [A*W\,GZ?V
M#["*SV._5X [-W G/ VJN6+.N'PJ YZ&8@%9"1".*DF5.+=,IHVM__DO#>SZ
M6X-2]0N FWG*4@"\; !/F/U,AN0<I8@8'!&WFB#K-49&!2]\=([IT$0 /XDR
MDW\O]3QE;0BIB:<F)0Y1"R&Q*U?@G3@X_/KC4V "!.4QPB)/;-28(<>E1"EP
M)X**%HL\!0[/. V>.PRQI@'*1PG<51U=%.#6!=R]F\#%,3%BE0$C H,/+P5'
M-C*+>-21"Z<3I7)C2R[DPA?<-@ZWJSH^*+BM"[?O;N*66ZE4GJ?FHB2(!TJ0
MP>#',TD5(\HF[71.K*SAJ+!IP7WZX';_W8E6RTELFTD]#?%X_GM)M[SN++L\
MMP;V6FEO68/[<G&,"D*Q$5,4C.>Y&UA"-GB"G(W)1,IM8FYCB^I9388:UM^R
MIAAI(:VG2EK+<^D*:=7CNHU)*UIBC'424:,9.&P^(>>U0M%H0S&+6.D\X<,L
MEF-:2*N05O-):WG^;"&M>OS6,6DY8DFB3"!-HT-<&8:TS,-+C?2161>%X#EA
MS<PH"6P8:97V"V41'G'Q&,;7B\=.8A]N[?@8:'AP9/NQA5K.#MJ^JB +[<[I
M,(8%\DD98##T3ETG/E9]/.<]KYU"?A7[;_/&J#<$0F_5RR]MOPNK-;CXWIW1
M'KS4T+AHZ'MHZ-WO4[$0SP*LO[<H4>$19R0A8YE$SD@K3')!2'YWNM%#;X7?
M,S&5C;#H1HA)!1LE1[ 98"-HHI 6AJ(0>*)8)HVSJ28VV?090ZVU!G?QY .?
M(Q8-5S3<@O&R0FO+IK6)L!G#7CG+)2)1)<1=B AT6D**Z$2THT[EOA5-W@C%
MU*EI*TC!A)$$(\,X!PU'&3(>4Z1,L"KZ0*.VN>FCGBZ>*QJN:+BGHN$6#*X6
M#;=L6IN(L1*<F 6/"CFM!7AP7"%7C6S4WE#MB!:2_I*&6]E&*!JNIJV@@@0Q
M8848<1CQ2#@"TT<@'9PS@O/ )<L:#J^AAGN\G7_?5W_$T+)P+?9SO!%Y';1Z
MI\/!T';S3=PG#/L+[09']SPEM464?5,4X*VT-UK<91>C7XAV>R39_=-C%_L'
M:4QX%?D-#J[D6PX<YV/ Z2DI!/PY%IU#F":"N$\1:<(L\DX8FY47NU,9/NBN
MF-H.-PVDLB=^=4]XA8ER'F%;3<[A 6D;'6(YKIFGUW.G-K8$F]$TI=YFEHOQ
M[!J541>]LN0>"H5!ELL@D[W:+$U<L(1(!/+@)@\Z--8BEY*(.$7FB&KJGBBV
MQK)V190Z21,$"BQ*Q*7CR-DDD=+2"(S!'?<$] J>D9!9]$K1*S7HE=I;>Q0.
M63:'3$1LL"...W!5HDT,<2<HTGGXM2(Z.*.,Y,DW=5<4:V,Y>R+@D"3)VX%H
M\%<XE\@R#5QH*.;1*J&BWMAB9D9UTF/0*U6@[Q]#"Q\*_PWM;UO_A!\7UWQL
M^Y_;W5&2+ZT42?7*RUL:71O<3L>>#.+SBU]^NTCD;'<KTJW>]-OXP\;WF>M,
M)ZZLNO+1T[]];X?A44Z4W,15LN1%,'+\S>.G-ZNG)A9Z])R@FY2Q6Y_&F^36
MY^[Z6,(WL;C]K7=][-W/<2S+Q8K[">PGT>D'#$+K"[NC^ICG[2%\A;_/T6'(
MT.D/6NUN"[ZEDUL!3YT)7-XJ$0O?ZS607WN+C[G+<,U+<6<X_D.T_=;+;HBA
MM1-]S+INQ**,/+N\_XJ6UE[RLQ?@!4@ZUT[8?";Q=@C_J;HXM'JI]:)W?-*/
M1[$[:'^+K7_/*'^?Y1)<Z0N\J<2-THP92N.W*>FO9)'N7)(<UZWQ3F_U@1[;
MHI&R:/,O&KZQ:"NJ-H$U:W;[C.E3YI^*^+&F(?W\QIL8VBBM-);EJYX<@=](
M]@__.MI[O\<_?-G&^^?A^,/Q7YW]PVUQL/,9'[S_0#X>?OU^^9X+7_7XY?G>
M^3L"W_7CP_E1&^Z+[=./[8_OWY&]G:_@Y[X&'_>OSL'A]@_P5<=^ZLOA/ES3
MWOGK%772^ 4$K$\>96&Q1\MBI;=&0UGL[":+<4:Q-]8@@I5#/":'+!<,.:RI
M4TYS[?WBK34*BQ466T<6*\TVFLEB^Q.VF",L!B44LM97>> .&1,9XA+DYJ1W
MTKG%>VVLD,56E/&[:L_W8'@TZJYP+9*6/>'G]XF5_/+I>OF,AYA'L+R]-9O7
MWW7[$;[Y/(;6W_*>^GOKLVUW6T#P]IMM=_*A%TJ]/AK8?&06_6F_/6S'VX.X
M3[5A\O+B#Q7Z;X311RIP^T(^()XLG;>7PMD.7TY'C91!7QZD0_OC5:^?;V![
M..RWW6EUE'G8>V7[\)*B1>?2HJ^G(QH>7#70FRA((4&+)HMLY!Q1[Z5+S"KI
M,6A17D= HT&F_I-'_/)\]8+XAB%^POLG1!F@]X"(\N#]XR21T4:A2+6@D0>1
M4LB-3VH8J5H _T#9DRN8BE9@WBR83[K'1%.7HB6(6 .*77N+C )'67AKDN11
M8\PWMO ,O3YG#EWSYB@TS0-^,>7[UIJ@B&_F*#Z1T.125J:))-\,/VX&TU^P
M>*'JN:CZW90/!CJ8><DI"I$8Q(WQR"1OD(C:\ B[(HMIBQI58ZOS>@"S'AW1
M"VT6VGP@9[C09HVT.>'(.N=))$D@#[X,T";S2$MN$);4)T%U8M4!D)$+N;*%
M-@MM%MI<\4EYH<WZ:',R,"! 7#$2ABAX"HA;EZ=5*(ZD"2X(H8E@*9^;ZTW]
M2&ASK@J[Z23YNO%W_\(DFFNUWL;8LCZ?G]ON66Z*U>T-XZ U[+6&1[EWUK7B
ME=3NVJZ':X!KO2ACN5G"<^V^QU_"\['N26_0S@)^WH\=.P3,757__9^;I4IC
M2>*KMU@'%W ZO/TM2U_0.Y?OCQ9JB8DZIFL_\W56-&(-DS%$EBC#'*C*6*69
MQ2JJ!)8%UY\(S8WA1^\ZZE_5.WV.R/6C_8IL@GM[;CO?[=E@XQ\W]QALL.OK
M/;E4HP79^J?KP_MF7.LMVU6O8KO>%MJJ5G?[S5^[^]MOG[5V]U^TMO=W6F_?
M_?YV=V=W^\WNR[>W;KV50^[.>[BK_NO(=C_'JB;P[;#GOQ[U.L!6@__Y+TV)
M^JTUFO_;NN]]KE/Q+J>;H-IK+S%5O_RI=S]'.2_76JZU]FO5F^P7/_5!UM7<
MKRA\?,XR80E0-:*H^]3UCIPZ/,.KJ_YN=P-0Z'-DIEEJF26&LUV:V>=9E_=H
M[E.[W)1RR1=5J]1[9$[>)ZFPW_L^>2:^!DNP[?WI\6FGTM8[,;5]>]AZV@L"
M5Y@M<=NI[,=7MAT @*T7]B3[&$][::[ME6IQJJR%ZK<;(8;JD7N6]S_>U3KL
M#<=[Z+JQ^W^K1T:F[JQ*[0DM0OC]M4BSND/\I"]([D$];E%]KQ8ACZI,?]3[
MJG0WF)=_CGNGW6%-I++ZEZYZ\N<UUWG\$2B__KDYF;8KZQ&CN9<8?[<=V_6Q
M9:N@P%27G!;%Q,QHE3-GVN'"IRI+/T.87*TZ>CI*Z@Q6W,O@'$\LN>!2XB3X
MR'@0A'_:S:O[\WS$D65<*:XF]VU\/3XS.#G>._[P_>/.'OOPY?>O^X?O\/[Y
M:WRP\]?1WI=W^./.U[./AY_/]G9VS_;:ESWZSN![?QS\^8[L';ZF'W=>P^.[
M')[[\G%G]P=<+S[X<Y?M[_S1/G@QV:/O7U_V=U[RCX?O?NSO?/RZO_/FZ,.7
MHZ,/Q_M?][[\<0S7Q3]\\7@//N\_YU^G,E2(]IIZX1"1UB(> T>:)(F<BS0(
M2CUW>924KBV;L$FGJ35F%C]ZB$\?$M:%[^LFZ<@8W6BE7O_8#N%+?@R?I_:/
M&-!Y[/<*VN=%^T1BA::)6Q(4<AH[Q%F0R%JN$5%:11N84MKDL(JFA/Y6 /\4
M #]76@!.@B25E#6:"VU,X"%@+Y)G.C"O;T?\+=D LZ!?(#X7Q">3 )A()K'<
M L1:A3A-"EG.*))&A"A%2"3/"&&*;LKU*)XOV%Z%,A>$2B%P(CQBGJ(SWL+_
MI5,1TQCP0LJ\('H^1$]F0S+0RYXP)),#I:VH0#9$C3#Q((_ +-5YGKDQF],#
MS8O*?MJP=K MI+$B8<QXU-'D"5(X!96PBTR9 NN5P?I@0E%[KK5*PB)C7$+<
M$(Q<BA[<;Z4"U\9AP7(97P%U ?5-4#/!*.R<X)W5G%/M?) B4K@H X_04$"]
M.@=[<D0?IU+F, BXU"DBS@U%C@J##-,X"J=MY&%CBU(YP_QN+JY76KX[.\UN
M=&^_W3@]H&1EQP?3H!4 VMW!X#2?'U2G!Q?#;C.JGK6Z<9@?A#6)_>_]]C"?
MM[9">^#SN='HS+$]?C>\<S#*2OSOAZS[OZKB'QSVKE(/<M;!;G><<U!11K[K
M&"[N_46^^)L1N^[I,0J](1I_6V&5N5CEY?=_'V[?8)5_LS>=^/_>G'U\'TX<
MY7+O<+_S\?CU^<?WNV3_RS9\YU>R?WCT!>Y;P&=__?AE_\O^H2<?OH2T=_@!
M'QSNTGQ_>_#8_N=/S ENI:2(>04<E;A$SC +; 5;QYE@?(BYU_$,T^/B='R!
M,[$9U+"6>GGFF5>0+F)I(N/.<Z!ZZR17.&F9P(>3C,P-RFN VSGMPX*]@KOH
MC0>8[<?OU5--:CFY+@B;T-O14:-\,LA9S!&/WB$;0T2.<16#YH10LK%5@]:>
MK1G796[ANJ!V?(119%-D4V2S'"^4!FN,(U11B;GG& C4@#U!+?@\3HU+ZVM0
M=7_9SFDLFN[7-9V?&,K(0%(B:60$\8@K#=:?I H)FE)TC J<)UUP1C9-T77K
M@-G"I\V5S4/Z\X5/E^0Y_!A[#WC_<.]\?_L3L^#=V4"!3*5$G!J/7 H<*:NT
M" $'3FCS&+7.'N*4S@CN_:Q>K+9F??>#8@4'<.\&,50]ZV-W8(?M.TJNUJ*?
MZ#)51.GU6F139%-DTTS9/*2K>J^CDARBK=3-BVO:YDW\W]/VH#V,;V/_6]O'
MD4WV)OK>YV[U*95Y5JRR^:RR'U->KK06<Q,L"D2!328\^+O<>T1@%Y D=-3*
M;&PQ/*.#7$%[ ]%>F+BYLFG\H75AXE4R\91_+",V&C.,K :Y\D0MTIHF)+'S
MD;HH#%.-X^*:4E[6QCV^;8SY8XS*E8AID4V1S7)KQ5+""K/ .!>)6U"_GBD>
M&&@ IIU-\O$-6UT+_7SV[\-W-STE;;66E#-$04:(6T:0]4HA'ZU17@80I%Y\
MVFH!:"'/(ILBFV;*IAF]T8MB6TRQ33F>)/KHO#!(Q6!!M0F%M$\.!4ETE)('
M8IJEVI[:F>R;.!CVVSXW\:O*)EK?X &XD:=P)MODQ/(KN50OV_YN^Z$:T_!'
MKY]B>WC:+YDC\Q+4^53..8W!)R\)"C0DQ+$UR%)M45#*IPCT%%C(%:"\06&Q
M$@8O1Q1%-D4V139%-D4V3ULVI2I\=E7XJWX/%CD,6JG?.V[%'['OVX.8Z[M'
M3D[O)!MQ@U)#VP17IWKR8"21EV-1A>+;S.?;X"G?)AF'I8X):98PX@%;9 F+
MB"JG)-=$!N9K&5)? J3-U35%-D4V3ULV3:VG+5JO'JTWD75LN'1>YU8J+M?6
M)BF1\=XAH4*@A'CF/=G8THLGNA7T%F9]VK)I:F5M8=::_(G)PUQE2.!)660"
M8XAS(9 S <,/[;5A07H=FL:M*QJSLW81DA?76N55;?!BR*.W[! -CR)JP>5_
MK=KGI9C1==E,[^*!7VR89P'TCA&KO.5.1$U%2M0"%Q#,F3&E8=ZZT@7Y:<,\
M>#W<XX^/.Y_SYW7V=_:/]^DN^T!W\WK1@\.CSL>=[1\?__S79,,\O/_ZDW&8
M,:D3[ L%U,,40=:)@ S!FEKLB;- /61&<[ :^N6M651ZOEB?T%'QR+W%V')I
MJ=%@*,L @)14>U7ZY34&8!/Q/>NB--9RY+1(B(.PD ,;"P6I@5V94)CJC2U:
MV]BH<I;40$^GR*;(YFG+9IZ"&">,950:<$&Y%6 W"&59$(%+3*UWI;]30S3=
M9"<![&B(7")!<K=D(D'G>=!Y,6BE6-!4&;RQ)7EM@QH*9 N=/E'9/*0W7^AT
M28[#5%5&$%$Y3Y'D2F=O6B*3J$;4&2LU=I*:V#A"+;E.LR-Y[[K]")=^'D/K
MLVUW6P!:^\VV.]9U(DJ]/AH 7%J#Z %2PW9\0DE/Y?"HR*;(ILBFR*;(IF&V
M<\SMF)S+#1\XQV!V*98,EAK,,$>,L'/;S@?#H]C/S;7Z\2AV!^UO<53(?&4=
M_+]>)Z_BGV CY.KF@^[;2Y, ;GT 3UTWNJM:PT/[HYC;\YG;]-^'7R?S<*T2
MT3-$L/"(2V.0<T8BD03UGE I RYYN(\1Y+5GO120-P;DTRWHL4PZM^[A*D3$
M+9?(<H=1E(Q['@(-/#4-YBM*CKG\TFM>]0T?VJS,A58S,?V[[513(&V5T;(3
M?3QVL3^2"R//6AF=B^<///HYN3/S"ZAGB3!*-+&.)ZHTC<%JYB7#P2A%\JC<
M^W#?*&&I"A&.4@D.3H>#H>WF)2O\-1]_L:ED D64L90&I)T+B LLD28&HY"(
M(R(E;VT>2:1KRR8HL[#7$^,SJB9J OBL6=C7,_12^T<,Z#SV>P7N<\-];Z)*
M@GBG!-$()X;!6$D&64(4HDX::4%NR8G+6,/C1?Q]+ZDPPGP-VGB0.BH=E+:*
M4Y(L!IL8:PQJQ!&,U>V4<$M?MEG<4#A@3@Z8Z#K*M [! NB]"L !W"M0^4XA
MR8DG.FB/M0&5;V;-S+I_:[;F@K^ ^Y?4O:8)3$5NG;:!:^LUUC%$Y6W*_89#
M;>J^).0OBO>)+"HM(K8J,D2"(&#BFX",DAKYY)@W,OE1"OTSPEBQ\@OL)V#O
MB<#.AT"PY=Q*HP.55"KMC B><[X([ NRYT3VQ F#4TXD:00*(2;$5<1(4Q>1
M9E$08Z2VTN70XW1Q3$'UTT8U]LPKAGV2T7-CK/5,.A-LQ '4N9$%U:L,R4VE
MZ8$YCIT0R(><IH>91(X[E_N4@NU%P?R2(:?IT=K&]JP"V4]MK$^M4V_7[+"T
M9*L4V139%-D\)MG,85X)&XFA4FCF-0>[W"E+73+4<6F(DJQ* "$7"2"DS%I<
M-ZN-3]>J&2E-X@D1[BSBG@5DN$K(*:J=,CPZ 3:;4(N75A2T%R9^VK*9@XFM
M<8Q;ZY*0F$L<-;"OC@+@2)FTX]9^A8G7FHFG_&<AJ$^$4T2-98B+Q)##)B$<
MG%-12.N9:QP7/[4!1 M-O5VSXMI2^%QD4V2SW-P3HHU/6/N '<FIV"9&RIU,
MG'+BL;Z/IB_# >O7SV(J_R0QFJP&G1R558B[2)$FFJ# @C!8&4EU'@UHR"9>
M//^D +209Y%-D4W#9#./8JO!A2V*;2F*;<KQS*E43+"$J#8QIU9:9'*31F*X
MT"1(;$)LE&I[:F>RM4Z]?2Q1LYGE6\H+Z:0UPAC"'4F66"Z3EH0+ZPB)<P?.
MRM3;U1+4[O>I8B\O+ ]!,>2B3F!YNXARS@_")GD6P%72M*I(;U(?]Q(&+T<4
M139%-D4V139%-D];-F6FRT--O5VS\$J379TRI:H&W^;']-1;QI1W(B%)A$8\
M'RTXH0/"R4KN,(G4Z^S;Z 9UMBT!TA*\+K(ILGDD2<IE-N/RM=Y$UK'5/C<4
MM2AX01&7-"'-A<J3&2DVRAM,W<86T9NJJ+UU@&^AUN;*YB&SC@NUKL"AF#S-
ME2QX*9E$46L@UR ,TB0%%)0(H#9M2D(WCES+M(Q[S[V]'&[;'H^'_;7AM@]3
M8E"&VRZ?%,Y^/MPV''U\O__EX,]_?=W;^<KW=[;//[Z'W_]\^?T#_>/+Q^-=
MLO]^5QS\N3\YW/;'P?8GXX((*1@4F,6(4R.1=1PC0V04U 1!:=K8XLL9;KMF
MP><FA_3*C*I?!]A$& \4*Q6.6^2D\XASII!QU*#$K>$V4&ZHV=BJH5%5.3)J
MKC]39%-D\[1ET]0P7M%TOZ[I)D)W3&!LJ2*(2? I.;9@_('-@E+@RBA-N 4O
M?HL*,Z,-:\%L S%;^+2YLFEJ[*[PZ0*>PW2\CC.BE47!*HFX( 8Y[0DB-#IO
M?53!N.8Q:DEJ^NEXV]PF8)GC;=?L(*(<$A79%-D4V139%-DTK5B966TI 4.+
M!L+!A[5),*PUMI%:2R3Y]6+E,@.S&9;W^50;>L4TC88*I+U7B'-AD<,*(\-
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M]42Y0$@00ND82)1>+&)OEJD$RYA*,&9+(4,2N:2(*0-L:8E'%AY"X+@3')S
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M3VZRSI=#NT>)U]I-_GOAM60&U83C2>L_R'S,CI'U1"(.:A:L_\C!?\^43(+
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MV:@K,NTX:%[G,FR5-\A8^(&E(39(Y2)/&UO\4;;N;:3AOV>'X\U=K^F_9GD
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MQ8.4B8/0,O&(0CR%>!I'/$O(QR[$LR3BF0C)B(0#(S:AY"A%/&*&G*<!@<;
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M1U%#PFP0S8.3I=(+FY__-)(JCW((_C;@,;DX2X#1F^V54@,Y2;/3R.I,/.L
M_V3826E9);TTD0)@,!EY<LNI^I=Y:5@6_'"22 6)"S'[)*\S#'#M@^LU2\WD
MLVE:=U8O7W"2TVH;FF8E ;GAZ BFM++@,E-U+OC?3\R 7O=3@!FH&C^7#(!%
MD5LC;NLN+<<P1V@X!U%-;DS ODP[K0WPP3"//C$/X++T+7-VUNN&I<?6.GU:
MG]*@KHQ4  =K;+?7!>A(C-<N/"^=S!E#/P/P@QF9P2L'FOISB?,V9$)%->YZ
MP!4U%F8GL1J&S2O4T[1ASF%,PT0'J>:[VH7-FEVU!C?S(3[ZCGH[.Z?GEA5>
M'V;C8L8263[>FV#</*!4%.%2P<KI*K/<1C 8,^.OOQ(F3/Z+LCZ"A3W1L 9K
MV[&Z:1Y)*5L+V)_'D5OOQFDO=L'F7#?<#;!7<Q&K394)VCF..(1SUYT.8.9/
M+AJM9>VI4M<\K4Z(YL3<[?P.;UW*QG10'8Z9;-V<Y4OX-9L?&->\P'^<^M(Q
MV)WKV Y#;/9L?HB?SFIO5/.VM#!/!>1OGCF_U -Y9P,:5@ZY<M9*W>+*XQ@,
M^!3GSM!?"G.Z* 7#/W<]@-5M]5>SS &KE6.X)G2SQF*66%J@)<%JKZ'2;MQO
M626;R5!6^6YT^4+:P_+&6=F2B6DVGIU%%>/N[S6#/\_^VA)-0\GLRW?K!Y/*
M/&1"P6@(TU31WFH%<F[FX+=R@V;59MCXDYKUFUNSO.Q@?3=MN%UM$NW W@BS
MI2^5I-HR2 = O6:Y[-+2[K^!UECJ_:6"WVB"BVKD#&C*[N#I6$L>M 9&X9E#
M![.YBKQ/=Q^O,PMG.FI3*R1I9PL"D T"5(KE3%%::TQD8V0\S:B=2(JS,B/=
MRP8-36>2B*-+Q\ZJ9Z#R=MSB\96BE#3&3* T/^7?\TJ.0@:5FL]BQX#<66I,
M,M#@=>U/*^L[+\[#.I11T4/GW*GK1Y@LN>4!-@[6&00V?QK#@\89X_X%EZXR
M-Y=+B;5,3M0A>,NIG-=2,Y<<L 5Q1 G#!2:$QR(J2PLG.'RSH [^V13,N]9Q
M>Q4L/>BR91S.!D8C\#\M\=0&%5"'\;)=,&^J;?!G=&/^>^;++6WS,DHR<W_9
MB]FA-'-T3,<-3,R.'1@A*'APU4XRI4;SGK_*$W!SE&IV_)P24IM.Y8GR9.S_
M%_WY%.UY@ZY<W(O:G@.E['-HYFTTYZ9WHRYLR:Y9XM#/CB90!TK+LSLKH[9\
MC"7Z?_Y+Y7?)Q1W+-2XSQCOCTQ F3V9>CY9,JN3XK/(LLDR!IE?F4IC>3 ,<
MVEJ!RD5K2O,K_SJ;2S.>[8Y:7:Q)GHWR4R4ME/!2VWMSF0:E87\^G/;\DOLA
MZ<B#JE!.2J$ -2"?K=43*J_%PKW@DFX_:;-IUG8[ATG]/N^.8:-EME#Y=F6J
M\%EVS5_6XC&OZL^]8!D.7<B],+73NW07&0]8WQWGXAF?PVR"&QTOZX2+6GHU
M!PO:02R-ZJSO]R[F77Z[MTB\^(XI3*]R*O1^]F^]'GR&"<T(^ -7+7B-CZ,@
MM*(NQ0+!_H_(P(0BP2D-+A:\H'I9+1!1*^4BMKI@G!:@(#C!*!<:SGJ*=;$<
MERTGOE/.?&=NZN^2P+16$;E^I(MO1H6*3H48,4@9"=%:S40DGFL!RE+BS3\2
M[#;E1V+.K9_-8/J]LAY3@6' C90O=VJ23ZTVC#/LIBR[U'TGLY-<.M@R;&3'
M90J<,,JV(Y Y+Q_Y2"6_=!8E**'F']F@_C=\:PIOU<C-"K0]-J_M>HG::'@F
MI^?9:(B2T0\:@RF](E5*X%P!ATH+F4E%^DN:.8I_^3.G#2;%L"P$42?XS;Z<
MOPA37+EX%M25<2+8U"&\)=+88FV*-)2JW$42NU%R[0X'/I]"ISF7N_*P+(YR
MTZ#J=]JL/'52>+Y7<7CGKDO:GY^ZTFER[TV$UC#5-IPR+<-[Y00ZH0=[^\?$
M*6>8%"B(0!$W&B-CN4="P%(X070A_+/G::I6Z\H^,O/K==Z*1^9+R_':OWPE
MCK65H>#.(BN809PPBHRP!1(1DU@(6E F5TY<6'OE"8?36'"#4QE: =>P*)BF
M;I4&O2VZ:KGV'5C\\$2(3R]&G[L# R@-0]\M[;:<R3=,WH_A>:8!3.VXZ[MF
ME(S;Y'F8&49E]*(.NM9IXK%63!+0EZI)GI9)FI:=9.FD:^&#2?9N)SVCX'@[
M](P7BR.?7]"'9TG5%)9)(G67L[N3J.TE7Q"F<]Z4G'=!U'Z*.<_-@O5<I4.F
M.Z3#-/N?*L]SZ*=*Z*,+,.4C/"CDRO V3,Y#6,J3K$/HIJK!D.Y6Q:#BQH'!
M[P-8_!F1.)<PR/=,PSQ/G+J=[+A>J1Y3<1U +L/ E!$0>.(HLWT[+SHS/GYR
M7)]GI0#& D>ML;TNJ >^#.(G/6#M)):Z2'<T9U27)( <Y"^S0A>TLE1<H9M#
MP&L?7NDVN4I%Y8_H9ET$;/X9V2"EGR;EO*QJGASV*;*7\VEF@=EUPSU/@>MT
MY1Q988U-?X-N'H_N2MJ@)%]W""S80G'8RWF]&9RFL%5&L.>S[^1DVBVMFI*X
M-G/6YBR''%E,O\TB[HGW,X=9G3K:D!CMGT*NTS$?A+.A^GNRH4J9#+"]!IM5
M^-KH IB$XVM65@1NELK"-?LV[Z@P"+%;;:7.&8A^K_$RPL>58VB=TK.?$SBR
M IS<N37EK=RL8'LD1QW(5P6_LVE:&$T=8%L[':7&7[.+&A)0]<I;5$4T3\!@
MF"D2#P_C-2GCNMG,P'E-:=;=AU1E_T[FY:\I7I"6%.0L2]9A9H6^&( ADT)J
ML,52V:0?VF-V?IS*N!M2>"2=(<EC9I B1"#/A1=",J;DB@=L6[36TCBM D/S
M*_TD--@%7EC)$P&PZY_UAA<A['3L$%2*M+'*T$2.86742J67TJX,\V_OYMX^
MGQ>Y;F9-A%[J55U^=C(R"QSEA(#Y;SD6-U\LM#K,*_>&R;K.;N?5QN?7A:H6
M>79-!"#SN@ \&HKO<ARD4J:ROA7GM!IXKQBZV44&CU_WYZQ 3L]*#TMZ\>K6
M@#&EAM>\+2ABB=V4A@KV0:I[7!:>GG_'\F2HO(_ST0F7G$$EUV6R_JA<.Q_-
MP_.QF"F@M3MJF0?:G$EK'UOJ4+;AI2_K3]NJ+RW08>N*MN,K)+F1I'+.;N3.
MJYQM8S@14B[HH$POG=$I\]JFM>J>=2N/88YSCDTOF0_SY=+F F2S^KO#F]ZO
M%NZ&0;-PGZ]3>;^3()89?1[\O%?F.N?LGJ[-39+2@=SFXN>"$>Q@[X3!,\X/
MC][!\_>/9:&=P=0A)8U"W :"5&0,%3"UF@5EO%BI*6LCQ@6SW,4B53S$BD5I
M/9>.1ANHU,LG.\?D7Y]^ZOQM/H-E,>Z<P7)\1UGYU\[& D"=Y@*&54(^<G-2
M"E QFY^*DOIW*)WRU0Q6D/XZ64Q@^30YDB^'*>4J?52%-*KO)\&O8A<58V?N
M UC4E :0K>Q:0<B^+M ;X(RL:P:DP'M_VN^ \32?]%7SJ"L0JI+VP>)L6)N#
MTHF0C?45&[Z;%(^4MK"(S.7A"@9C[3Q99\F]:]BZ<V^S>&;VC6\J%\ U"8'A
M5(=CK8[X5W.>*WO;<&IZ,2L%O6Z9HCV;CY)L"I?=IE'?-^;VK_;%W0!J+^$D
M>=OH0C?KSO=4F^/>18.1PSUXGS?',DHG%0V(:R;A7S8@@#F.(L&IX8O42N-G
MS^GN:A^9T@SM)Y9.4M-N(Q/?6#FIE8G[DPE\\.8XNM2HFC+D"C!6>;0":8D9
MPM)+K[$AL%^?/2>[[&J9R$AX&['XQM)XK5C<GUB0U*_..09(+I!D%B-./$ %
MD1)YH8053@I&0<'!N_H:L8A79.1T-B;CS#>VNPU![4?BDY,MYY-?RP]?KMBJ
M3*$"5L$6D7-G !NDIC$"'B@5J+YW"N#;*EOGQ<#OS7)UJ@[ /[!;\Q4[)D*!
M>L HXCARQ*GD"$ @(,P]I5$)05(KM^UT:[Z=3\*:6]A.M;+C)V&"O=V42M90
M@N<K4-1J/*I=+_6W=JJOY=I-R4.3*S34P:6=E H'MR[MG>36O,*+]$M9W2+%
M-;--MC'9;7Z$)8N[M/'FTU;K'.GNJ*JBD(:5^5OS]/KF$</1B1G4M.]9UM].
MQ?:J,J%@4,DO.EYR]8Y_J2IME"2R\:2D*B2K#J9EIQY[$QHT@VE,_LVR7D.=
MOS^>3'TVKC(;/-_S\T^UBVLI]WMC$8!9TN]RXO_, _=+61NDN?F,"S]8F.9,
M_YN$7B^4OMBSJIG%;N?ERG4P&8/*PLX#O$$=CR;I<# N:>IS39R>FK,TG]@Y
M #NLY2*O_,(TE)VLEHO)S'4C3T&O4E#KZW+&*.B\R;TP6]5\H[G^#(DN,*X\
M JLU978[?V>QG]\<LUR@1,=QR7O=*TL03LM^%68,TIY^'PPGW:J68.4HG67>
MSG)N7\X<L;,LVT8^9D[]P7QYPYE;O4R\S7,'.!/J3ZNB%ZXS,>-/X_E<_F8#
MEPR.^8**6> 2A[5B430MW.?R_S^#VC@<+6#7NLR:V=;L3F;U,LIWS^]9[O2%
MW)3JE_7;MGDA&-O'5"L@DY;.8>[3?U,Y')CD;HZ0IR(0P^FXD8DRXE!%&YKT
MU!E^S3M?YMXE-T\*)36VJ98SZ?;3[RFEH_9]5YR2QB=>SEV:H@T!E+/<.<7/
M)9",&MI!\[>YB/]D-G?U1-9?ARM7[I9$J1&;?D,XF-5\J*)+36^6\^'H4ST]
MS8%0O\X\H,_GT%71F;()51-IJM8*)@F.LUF6\%*EB"%8HJG#]5PKU'&*RKG\
MUS+5IJPY/QMKR81/U6_6&2'S3MS[54Q_,]W1OU/H<+^,:\XZP_WH;OVLGO)C
M4D2P5[%'AG&#N&0&]!9K4')&*U!-J:%XI3]<8:3#07IM'2R'M$X3PVR1>AYK
M(K:V?F 2ADZ6ALZ<.#P5FNG?+SM'H%JYCJ);PO3<-)_96NB.76\XGD\B>;BY
MVJDC#>/LT"_'4>/G(IT@=E.+K-Q=(Q5.FE;)NZG&:G6:-N=+6@%%Q9;,?3/N
MU[-Q/\9,ES&?\?RTYD.F(8VFV%5N6(=Z23N>(WK"F31*9WKFK<ZM5#[JYN[7
MGPE7J1R$P:G)K-JYU5V(+:7[K=Z@+NZ7N^?EP>0GK1O04@7LBAKY\XVAXLSX
M=/K!*\?)SQHO@0<2_('1X\\\]21K%?27TL^X^N_7@[/I9%XER8K4T";M(NO(
M,*U5B]ZJ-^^_IH/R\ _^IY*HGHOXN*7]!'I%U>36E'IIV>$7%F1M&<MJM!LV
MYYQ"FKO1I(6'-4R?P?V>]@K1KUJAQ37)I*M*IYN?MY79WUESX6S]-M^ENKPB
M7(^RZ53?.IO]0Q]ZE?MCMKERF87N_TS#?')E"B3/5]T".V+:/ZO8G FS9[)7
ML6FJWM"I<HU)ID#.BAOF%/'2 IJ[I/IN-I+RK$SM.+DQRLH4^3"8IMIEN>_>
M0N?#E-8^(]WO7B&E="%MM)9-F%%X>+=W4=J0H[,\OC11E65KAX/*>GVW^_<N
M&+-@^ Z:TF9@! S<Q5RSZ)N5--A>N68WE^N9M3X=S*UESI%HRDJ.0DS.FFL-
MIGEYRN):MQ:?9QR4-0ZF);LK[86FGD5.T9F3A8M2$F9'2SGDY*4(<9C/C*:B
M8VFPS^^%N1U0YC)4;L>*&UD_.5^2ZF?-NG U7;>J#TNW1[4[9[==EI*GG;UP
MK9GQ_/6@F?"<;M0LRZ(Q/YUT>]F47PM&E5A\@=F\#/.U81:PIQ3/0<5M6?KF
M@J!6WUW,73D;CL=5(?_&"U([D-)/T]Q1PZ0^T6X4?'?2&77'GVJVX2)#<_::
MCYVH^<J,TL2/_PJC3'1O;>K]R]?DV 4C@^,<L9@((U)C9)FA*&(MI=-*\]3=
M<SMMY , O)S<?A9&:0/U8;/DM7T:5O*O9@QRGOC:O?HE7/D29:)_MR1$3RM=
M(=>63-#17%$9?>5#@D<&SN5$8QOD1BGE:3Z['YPQL-=3)?O<'*:,<\SJI^Z"
M&=S+SUH8T>I09I6#[^;!":EV4CT>GYX/>MG.PLT[JS>?=9FL[[_TP&O<>"VW
MH.(6T"WG%CPZ5^ @G,]2A/\:#0?#E-4U5S*H/47@%*''W&-,'%7(DM1Q4Q&"
M# X<13@]"B9L@<W6$@=@C>=[?2RN\M>9,EO1G\65V=,O/*CLJ<'Q-[_BS0Y+
M*M+_WVM<]^%=AZ.0FZ==\>![>NU'>-<![(>YB@[CIO=-(@. B9HBRR^N2%Y=
MM&?*5-S)?,'L].?TD-F=ZVQY&WHI]%=ENU<I9#7W(K?I3$G,:[*:9LZW)K_I
MZY2 #-]&,QE\ (V880['@H93B!E<A")JYK@Z)EP\>_C6G[=$ +;;N>?3\>6L
MX.'G\&+&9)C%4[;E8#S8>U<=C$-R>/3OWOY1[R,<9.0@D:./_MU]W]]/SR.'
M_[SM[__^^OS#WA^?/BP?C!_?B8-_WGTY_.?@T_NC=WC_XQMR\,\?W?>7K^#Y
M[\2'W]^?O__XZZ?]_MO^?RX_71[LO3\N"IV4%H$T-A9Q'PRR-*;^Q"Y$R8,@
M+*YT/',Z*$=X)-QP3["24@LPQKS!1A2I0]KB.=I0QEZNE)K_LRI;_J*)M%^=
ME[2^D.^UXUD</[->I!0KQ5S!07?3JM#6>TDHB<%&_1B%?]?OD!=O_XUX098F
MKIFL)V%$OAYT_IC",9^8U4M-CW+="5_2G\QR(X*F.T6F5?P5X9&CA12K:R:G
M3KOJG$U'XZDI.[^L=M_(J=$PB.H!Y\-1SX-ID#SA*'QQO6FN'#<KJU^1TNKJ
M<DVI]E W@VH:=FVB!R4^W*@;)BDG*C>#G<*MZI>9?\%J<_BD#N4[SS+)9AE8
MU\S""A&GK#F<\MO*_EH[2XVWYNE:MTFC8$Y9KH7ST2A0K[DF1 AM"X:CE*8(
MN30=P<5UV1/KNE/F9N0'8?(TDB8>'LK?B,,WQ]9'K*F42-#H$2>1(4T%1H[2
MPIC"FFCLL^=2X%U\=:K$;@>V;#(65C/AZ_ST)DVO;$.49 KD*?UF9I>"KG,;
M ?(%-4QS0BR<\LI)A5FAL)3!@F@9SM?7-D3J[@5(_W "](X=G!Q+D!%CB ##
MF($ &<*0!143:6*4+ER*%+B4@,4WB(^M,FU*6F_=GVRU:5[#9IQC&><(S+IR
M\#.ZZ@H:[G8.XUSIZ37/O&5^(%'6,XHQUY9;:XU4L'&T)X%I30J\00!;!+L#
M 71? ,&B\8(2D#W&@T2<<A! )R0"4X>[$(RPLDBY[-<B6-GQ<$WONJH07<,N
M+>.7F6!_EKBKI@H&WDIL A/"6>JL!_VS</!/(!3 EL0BXHUBT^+678@-!]RR
MTHDH T76IIP@80S2(CKX%6LO,96"QX1;FX2FQJTEV5@/1T\PR2 )=*7=EK&2
M\#]5M\+>8O?'S+*>)[>7;/0<NQ@DR%W(.YGD=).=S?B<\F9LHJMGAG[%/ >5
M.IQ5_3I?Y9\7^B;!KLWL @\6Y*AK4UP)AG=>:B%5/DZIA>2^2ZOO [NXJ4XW
MJSR]VE.IK+7GR^27F(+ X_D<DXTOE7D_J2IB3LK(/JA1E2-TU;L^/:FI5;T9
M2RC#9%G)L)K$TV'/EV5XTK<6^MV7,;.Y25F%VE0+:_BIZC*S[AZYXQ@HF;5I
MEEUN\,A-XRG#>,EV6[E5R319$*!9Z\%L%.Z477!RL[12!N<Z8V:KL)F2\;"7
M2F4N6'\E66I0/N-BI\KJ*#/'RANN$>',]:N*<32ET]=(\&9I7*CR-1JFPADI
MKZ#D/M3CK=(;8+Z>B!PNV!]KLL1**DAPT_E\H%L9PG.8N.2%^#L74?MK.G*G
M9MXQE2WS9_5%F[[U[*=FL9)<EV(P3NZ'LISM1KVB# LOJ19<1] H:'"2:DZI
M-]%CIB-13$C.,:LJ5NBJ8@76#%]3]SV/^W7VD>_E,/=?.<*=.0GC@W">/QK?
M3-UX[%KP#Z]NI/=Y=^Q5@*D..M52!#55<0J&MK,([-48I(S$:?WL.=OAHMA1
M1*QH'7.<@+798Q5/($O8O#NH7*3&K0726@ECXHU6;4*O<]K4W*+E&AA869O*
M;/#"\T*#(JZ"<IYKK[& ?RKGS9)\T;7U.<>E>/V5QC-[W \K,Z_/]X_ M+%@
MO1C!D D>9(93@I0B 3$GO222">THZ*B8[-+5FC<SFLM.U?2L8TX <4X2"?:L
MQJ";"<#=(LRJ\;L!8')>RQR^_+"&[NOS@X_[QU2%($002 JG$7=,(.VI0X%&
MKFDAN(U@Z;*UOKI.;>3.8T.%!%4'FJ-9^^ :+G9R8[&Y,*3QG[OCE-@12BAZ
M5*GYJW+8_#8<_3H:?LITJM_"30^B'U"*X)DOCFU0E&% $4<T!MU'6Y"B@H )
M+(/'\!%VJ?;?KKRNBE89%:F;'4_[9?U54+S^!ONEK)"3:STGA:<)I23MN3G$
MKE&+=NHOY.)[Z:^^+#(/)EPH:\S7O8_S[<J#)"M[H-)7'1+/1ZDK\:"Q'Y8.
MT!(::^]BLN&[_9K!MV")S+[QI VT.7)\4U7V&AVX:8VP$2X6M>'YR%NJJYX[
M B?*SOBT;F0XJ^*>RRHV7:V;3/MUC;QFW(V_&X;%RZ'/:2MY%/^J0WQ_OVST
M'8GE=B0+OIWO9%I[[:JJ#+7C[E&:<VR4CG55GRLE=)SLZ5GW]<V"4386N,TI
M897FQF!+,!P*@6(3"R(*.#L"Q]HY4IT217U*; P-YJJR?P/4'\8,,$T:.OR>
MW^)O>(GVJ-AP5, XW'%T@LDB%,BI1'\,C"-M4G:Z]-XZ*8*S\=ES)38&=VJE
M(VL1N4E(U?DL2W\N\[*HB(XGW;.J74KE1&DB^F6 <0D4\C?.SF +E@E*,XQH
M&D%4O7G ID+;TIYGMOUA<*]2S8V9(7=X/J@VTF-D$D^N.2JR>R(52\E']@S0
M9^V$)\M9R+/$K%DK]M(5DWK7-QDX)80W5(,;@LN-7#B5I\[TAB 7C=C<#8&!
ML$+RPJI@0*FU12I%Z3%H4H$:ENK'W0V!X8?%H?T+N-^Q#XP&PSFR$?16CKU&
MFD2.&"L"EDY*Y^,FDD*GT5=3P?^0H&&N#8$9-ZVR;]F3>,&'NNR-L:DO3GV'
M60FC\C1\8I6G7N3"UV6A(3@UI[W))A\4#&]T4>J MW:M-N6;;M9[>^$<V6GJ
M&)E54W7GZTI!&TPH=7">!*EY$:/%-&@C2(%-X"S(&Y>"+HO;YY<JF\W4KY2K
M6+VN7OMH>)C?"Y2Q&@E:U60#))"#CY^.M:.AD)XC12Q'7$N,C'81*2:UP4Y$
M[<6SYX1>5^%UK5:1>P9OB[*0^[1W7LPZT>W5;=2R!#VVEC /IH,Z6_N6),"H
M-:>!4\\(3^QM36RD7@H5I'>174>AR5ML 67J/91G#;9=GL-R"MMMM6%;T;2M
ME/2IB+E$7J9M!2H,,DHKY"(OL%2&,BUOLJW*^-L\[C>F_:SG9E6BL)3L:[LB
MUPZGYA@W_=2:H#K%JXH%52FTE" ^GI0$_J9MS"T/^.E-R;)MA>?U69ALR[,P
MKR7T+R4 %,*1Q L*BD9NX O8%(1*:H@*!?-D>Q( ?C47.7/\B=/_!Z$#&I9>
MC<&7[_?B]^4H_ TR1<KXQ[,K9^C93ZFU;]T]=W*Z5ME=1+>L-C3#@L%4>6$7
MR4F=:HOT*Z[_) Q[%ZGWV 1FNV2CN-,N&'NI>S%\]Z^WAT<O7E:?YK) <$DN
ME7N2ZC>5-3)3L8S@N[DQ6ZK:E3^;E3G-U]97CCO_>G:4_S)^]M/.7);[50D&
M9P!(N?1GKM$!*WUR4<-O=:\9K27TRAZB]J*9@$V\II0647?<[,&43$S%Z9HE
M)BS$!ZY<I0?+4? B% $T2H])P;4B*DHF#(\2!T$DM4D](1K+Z\)5+</W*W(4
M*(SG6($B(AWS2&A3(&XM16"%*404\5IP0A37H)44NVMH$W,*"4C@:<KE:\@V
M5>F8=;MA)O@@J1E#EA(<FLU>UI#HIRA3MD&3N'U#0H,CC@17%+8H,!>6:_B)
M%X4*7L+9Q&56AEG+)[\7:6,'']\=NT"U5<XCZGUJK>8E@F7([5"999([+$C6
M@:^(LD].1\/IR6D*@+*=)&,E>-Y&$&(AJ#0B$B4XCT70H*9H*7%AK', -\D#
MD6#GQLVH_AH-70A^_-MHV)]AZG#4FD2;\EOJKC+PV1NV?W(<%*;<,0/HHU@R
M"0JDE4O)4M$4WAI9J)3K@M?@T*)U=)[]CM6)E2."W4$55&Y$9U,6^HQH?:NP
MFG2B* *30C!>"*/@9PU0$PNM4IY7FZ9RG[!RN/?IF!(+YU1T"/8P360N![!"
M*?(NB$)920PIFL(O-^+3*.,45XPK."D<%6"^Q%@8!@]BV.C2;7*#AF3MDG[M
MDMK F'&2(PSHC& =(@)PQBC9AU( 4JB"WVI)K6?>LD ,,YS[(ACCK:"I]Q"L
M9*0^+^D-FHFU2_JU2QJ="31PAG00!G:I![ WUB(6%,<*]++"\%2#8O7LO_X/
MC7;00']22F<5_6_59:SN:[#04'@EOG4[G]>=1:2L<9].1BE%'55^@IC_[Y=[
M\QH0ND1TZH[+9)_-2<>WTLI9(3@&_<NG%K%!Z8@Y8:$@A#@+%DAK ]YGGOK!
MY9MCS(@6SA:(49WR]0!KE24<45MH&X2*KDB>:7V=$3B?NM8DZ,WMHH'_"O&0
MS+I@C8DLP,$>,0R(Q4@-<YX:*UL7P7UJZ>?['U\=$Z+341P!J$U,@0N!;$Q'
ML6=<>N?@(_;L.==7<J-3ZM6Z_,V9>&2V:$X#2Q6S,Y)6#K$KZA\ %*U!H9U$
M'D@U*<M4-D#BZWQ_33NTLR97LM_U*'GT>JEM\DDW.]QZPW,0C:F=_:V;G:2C
MX87IE1V?2FNT;RZR!V_FJX.O35WEDWO0P&(-WZ-4(#,5.KU-!0@IB=">,P'G
MMN)61J6% !7,,.PPOB92OR;=Z8:&<NQ^"1Y=AM'P!TY4>9?>X1C +3)O A(:
MP^X3RB(K94#460:62#)#;J<(2VR9"AYKY@*7MK">>&.-P,QKSCAI%_4!%K4P
M'@P;C!@@*>(N1F0+,%V)]<Y+P7A(,:_!\ :*[T*CO]%U( O?:+!JIBM?[1=Y
M(F2JZZCX5T8\RN#VYES3519^XZ1NZ)O]4&8X?",7_^^7+;/^(9CU&]?Z]L3Z
MR$S@QGI-H^&%$5;HP 13&K15[PM^.T9;2ZS_VII),*;C@BEG2,%180N!N"T*
MI#QC2!/&6= D^7Z>/5_'LNFTE/H?FE*?4:7DTR_Q(A;(]5\9?+PSC&@2>V<P
M\7*>Z/^V.M7_"J,Y1G\+&NM!X_WY?O* 1.R<L!&10B86?"A0RKE'PA%J"D_!
M\)'7@$99E.?J?(NKCIP;JB@^B6W9_KJ?P*.^M'1"3N92.#)$W:RQTH.SJ*K$
MDPUU:)\<GZIQ*,/^+:XLJ7J;RKNK=5:?W7#>GOVTD?=SPSM\/0,HEV&M>$ES
M4#G7H/AK4@9,Q#+ 84Z(XT4LM">R((8*)Q2A1<YO)ZH"3Z+:@/W=XV2Z]S$A
MDAA0HI#3#.Q6ZQRRL"R(%K <4I&"% YP4EWC"4QKM,(:NA5CJ$Q_JQA!I4PW
M+KQ9K_9QT^1RKG34#7? O02!.D?7^BZ_N6PK)Y8PYEQ43G-+N0[8!\)<I!1V
M$?8M'>$>=PD_V'.P2URA8$,@$R3L$FXE4E8P)$54$E-L%$GUB*X+IRP!;-U&
MKY;';FP*9GU)5<]R9;WDXJGZ =;^]$G%*EU)^[S1#E@-^B4#H%?R\;X^Z$<,
MX1:@A#%-.74P/81'A;GFQA5<DE9([[%&Y_G^QT]@)\,24!V0LP&$5"JPDW$
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MP83IPD<I?:2J:AEP@S.Q7?]O6O^]3PD;C5<Q1.R0U]; "0G8J-,)Z1E+#2D
M.GTRGZ^QGN=\LI366AY9 LRZT&+B157MZGT=E$_K6.F!IFIM/M? L.$.-[>N
MPD>W)ED!]DLJI6(%L]S*PEK%77(AD%3QU[9\G/M5RN#>)\=8>(TIH(V4(97K
M) 19S.$G8JEE6.-"\K5\G$?EVSQHR.;W,$BQ#-@M^W.%(9]*A.8 -) ;16C
MGNR760)I7X/).<F:QN%9R3VM@C1E.X%-@;HR5K-^PI[]5(9UFD]WP!)UN_E^
MO^UV_N\P1M"&T)^F\W;H4H>!B8?[#4'Y204]9C=-"><FC327Z^B<I7:SP^EX
M=M^Y?GT+;[A41):(^5#1^C%O,(VOB03=NHAQ(70,A$M:4,TU:,"<PHDL*%@H
MRL0H<I"G(%60!WZXMHAQ:Z;<#@Q/SO>/WA]'Q6(0GB+!%9R_V,+Y*S5!##-,
M'.9P ('^Q?A5!_"_YJ)_MW7^:0/JG])81"*XB\KJ0@O 15,P0 >2F1)$5,6L
MB6C-U?N0@\MWQT5*ABY8:MZD!.+.@8T:HT>6.T^U)4Z1 'KXE8KX&A)$ U4S
M@"I#@N*G)J+7X-":H-[\Q[E\=>ZTDN"^[ 9:.1(KK_-&N2LMRKN%H#E=+#/Y
M#J8)90_COOG2[4_[>XV3LZX:,B]_<+JY)(/GPY$?A\$/K).=?#GXZ(XC 358
MVHAB9"!^)#"DK0-;D'##"F^$2&; ) Q6I6]2YXW<.-QZ*V>!<]*P0#0W@E.<
MRY,R:83"N,#2NC8X<8^B<;'_\06<4-A90R2BK$@^5"V0H8PAAZTJG)'I['CV
MG%X78)US'X4O("/C?%A5)7[FPJPSN%D?:1V6'<A&H5\W&:[E[UVI(FW4D,H.
M=]]>,G69YM462JL*I?$M+Y3V387/MB??XLZP5? <E^:%M)9[HI2PE#/M'?%"
MJK;EZ[UB*SZX?'WL;0B4.]@0<.XB'D-$ *H:%1$+XT#A,39%)OA56E]JCU3A
MZ+4,@=NU! XJ6*H,II:E0A#2A/0#@#YSQ%;9P*U\W)-\D)P-;(D-Q 3$..:(
M>YY*. F!BA IP]YAF4HX"7K-V;NN&_ B:^0V8H$UX*A(M)7"<(>U*;@#99%Z
M+:*6IA6+>Q6+ Q +R<%4(I*@(%D!8B$-LEYBQ()3HBBLQ:YX]EQ>1Q>9M?!<
M)Q:+'(Y;T3V^SC<OK+4D.*J#TR!1417&&PFGJ15@A%21\]8W?U^219,=2&*0
MH-ACI 76B(L0P Z4'JG4X:RPP>J@;Y4 37F12D[&H%WD5'BCA=+.<RZ=M6W
MY4$6E?F"1F\]*JBT8,'!HAKB*:PL)4*"Z<\XN=6BZF2&VR"+(EB.O5&6.%LX
M7OB"P(U]NZCWOZB24@N6BT#.,HJX\@Y9%POD/546:ZR55S?+:K\RS7UG7GE(
MK<JO/#/N( )7CN5@"D_INB56G4M%]85C! #$868E7,^#5R!:*JJP5NQNJ'.\
M&/@_N\9V>]W)Q5'R&QS!8W_M#=VG'TZ^/ET>[+TY]K&0,1B&2/ L->G$R'A"
M$&?6%=I12XA]U@FP"\^2]V$T#5ML/K_,F2]-<?[*DO[?XUEQ@*I$_[C46DPB
MR_9ZP_/QS[?)Z9MDAU/CPQFE6C>YOO;9./Q<__"+[X[/>N;BY^X@#S1?]$MU
ML\KQDUP>G\-HT@6,JYPZ>?[*CV?>D%U<>D0F(_B?KY]<?;R;/_KOB5_]3!:[
M6F_^&.^2C9]==5L"AJK8?.E5M[WZ,X[E_0R6W>BV_YWGMYQC6,8D#__?,_9L
MYM+R*3+\,^Z0+ ;U_9JOZI6OTK,OZ<N_K'CMEI>]7/&[V2SJ.NX!X?#*\Z2;
M1O9O,0MK7JT7XHH\W\N+W3S9/K_JOWS:DZ.,"Y5=-/YIX9W7OVJUM?/./YMT
M<J./3AKU+T]@?=/1>"?ON%'<OY^)(K?9 *MY"0YTVABO>M?[WAG7\XWRJ[Y8
MI>#=1$0VO?#=R,YUT_DM][CE"&^]\E5&RM+*=_)_V2.+P'HL_#6 _I$#:I4J
MM"P MWE7W-D&65__HO_U32\V_T*9![$%;W0;WZT),C+X/QD]UV#$<Q^X,E*X
MZ#6)-ZZU?37W^HF[9]__\\?XP]'9IWWZAA\<_=8_V'O;.]Q[A3_\_J'__N-K
MN->^V#]Z=?'AZ!/Y<'1RN7]17?.?/TYMW_<.^V\N/^R=D/U_WN.#W]_Q_:.W
MGS[T/W3WP0S;O_ST9?_HCUX:S^'>_N5_+O<G^W_C+W\>O9H<[,&]CMX=4U4(
MX;!&@?A4A5!0I+R.2&+&B8X$:T^?/2?KDD5+T_I;)+R&J5M(^JT >.F1RR#>
MHLSW@#*.N8)A%V5P7&MC')-6>Q.PAU?5\J;EWUN4N4N4N5A$&1Z**#"@#!.1
M(&Y5<@@7-"6F<^\**3CFZS-_'@]D[D@#S\^F8BN!XT7%DQIO5,#I[=YW+4H^
M05#Y*N_OQKJ/J]#R(K&17B2G7])^?QN.7HX"+,6?P_&X@IQF:5KLN17VO%G1
M<)C2AGM&452$IY*\ AFK"Q0T"\QA(RQ3SY[+C1FY-\:>*_;_?2DX-[52?]!M
M;+1EW!@;A<1<XJ *R500/%C*I"'%C4LCM-OXX;?QD@IA98S!!(,2(1N!*:F0
M):I 5C,%!B6%18FIE\7&+LN/L8_OTI>SI3K$7W4\M@[!?I4N<5.+:UM Z%]/
M2IFHUZBN(-N"T:W Z-V*3N&"]U@E*T;$U%@G!F2D%TA8+CA7W%J-DU-_C5*Q
M$O-Y0@Z3'WXK/[Y"T6[E;]W*2WJ%3%V"I025PFF*N#4>&1HH\I;'PG&OK13/
MGHLU:L6C[.2[]$JP8ML"A)EA\JK,?;]M:.C&T;;OQYU[NU?>1O"]#?;&D++5
M.9=$PC;5UE+';<026ZTLOW$J0.OHO3,T?;^J&!&F&#,8I:1^Q!7E2$<M$!6T
ML(I+^*^^$T?OK43_D=TP+63]H)#51L"W$;*6%$!3@/9N"HX43DU2G2F0E9X@
MRXS#7A)&.+Z;"/B#8-8=N9RV2R]<)(Z=F8M,?JY+B$R&'3=?L6ES..L&\W!/
M?+*;6M9W/\*[M!B^.S[938,?6_*BMSYGV]-T@\_EKQ)#ZAR=7ZN4C+4E/==D
M@K6'[4T.VY.9?7#TBA[N.3AL(Z=.,[ /'$DE8%59 E1A8XUD%OX+]D'N#T-_
MV:) S@-9 BT./04<^D;&68M#CX!#%XLXY%6JP^LCPM(9Q$4JAN>X14[J CNI
M D]-4K8/AWZ @/*WD=*>6O3IT>/(5P-0RU_Y.L3YM*+Y<$FPX*D2-5<%X@7G
MR/+ $6%82"4]E<RD.-,V46#;L/$6T]!NO'%;%>)N-O22"@$+1:S%$K&"I):9
MEB KX5="#?4%DZG1V9VI$%L:0=Y2%:+AI/6-WYQ<^H.28A]#C:@7I 6C.P&C
M5^<)B$H-X]V7@X\G[%AKSH1+?:=LJIQ;"% OK+%(%CH:3(63G&ZC0=,RW9^L
MBM%NZCO?U/N+FSI(0V-@ 6E%$^<=M OK%4$A>,)<$()RMXV;^BZ]%-\72>W&
M(;SOQP-\NU=^ZCC\C22U6_F&6WB]#;Q^6="9+O?/CS&QS+*@4/ 1+#A#'5(,
M&\2T*4SJC!Q(O$N7S':0U;ZQ*$(+7=\I=+7A]:<(:?OSD(:/)9PZ41.!(C8R
ME=_U2/NB0$9*'!VG(AA\UTZI+>.S/9E":/7FZ)A4%';\\U+;0;?P\1V52&.P
M"GXX3>RY;:V1=J,AMD72VO)%[:D;;MK@HCU6OXZU5E'$X0@U)%B#2($+Q+4P
MR"KED9(A2&6+(J:&3F1=:Y0G'[QM4>9[0)D[*I)V\S8ZK5+_[5RU"GTBUX5U
M&.13,(8X]@72S!$D'?%1QF@M;@/-3Y&K]AW'H^XVR+P1=L:O!VX4S#CLA?*_
MOPU'S9H<#1<,JJ:->QNPNG..6UU,-L:"**^0B]0ASD1 *A'=,+?!, <GC6;;
M&*]J@]!;&(2^\TW?;NZOX[M5FSMP80*HCRC ?Q& .@8U1%H4 U,.5I$)PK(1
MU!9@>U@=I#^$(5QF<?\A*/./4GNML8#,66[Y<AE\#5 OA^/)_"*T2//59+8W
M?/_R%3DV.*0^T0YYCA7BRC!DM)2(">&CC@ /HDA51-1VU&1J:?);5EVMW:P/
M05*K-JO5,=+"2228$J 7*(5,)* 74*(+)HI@DG-T:THAM@74VFI$/V8UHKLJ
MH-:&FNZ%E%;!*7?,21M2W31,$2\T0;;0% D<! M8<<63F85WBR=1CJ@MH=:"
M5AL?_^Y :TD'-#XRK:E$E'DPV+B6I>,W&,I5D/#'NPJ0MS74[H9SUJL:D'?#
M^.?.7HAA- J^,PJ?PV#Z=?TX5]F =THVNZGQ? ]#;"NHM96+VL/TFL/TSPI0
M+MK3]':GZ>6*"6!)\(3K@)1@!'&3PJC"$(2=-;!X@GHKGSTO.+ZSX_0):?HM
MT#P%H+E'OED+-%\/-,MJ.Z7<!1J1X,XC+I5 2JF(B'%4F:+PRO%GS[G8)5N$
M,S]"2+=F,ZR4-NZ8AM#P0\1ZMXIRUB!/2T!Y +C"\WK1P=Z^."ZLTUHPBSB+
M!G&L0"^*H!RQ@A,1'#:%,0!7;0FU[V]SWS^UK-W<#[RY]Y<WM_81RP+IR"GB
M06%D!(_(AZ+@A2ETH"H9/?3;E9$MC29OJ3+RMO0)IOZ>PY-!XE)TXFC8KQU%
MX\YIZ/F.F70FIZ%C&S_2,.8_G,%#AU_7$_2I,64?F)<VAM>$GVYE,E5K^;99
MRA:WOD$IR384L\J1&"C"DFK$=02E!%N%E+8Z6B>(P*GC%<5KU)*;$V"VST_S
MPV_A.U!)VBW\V*I'WL*P?HHHC)$,,B!N?$":F8 DDPH@6MB8M[#:E=NQ@W\
M#\BU2L=@.+DWQ>.IV5&/JWA<;U&M0-;!< )65F_J@W\]^&L4/G>'TW%5(ZB%
ML]O!&5G#(%.,2#"=9"@,P%GPR!26IT2=2 DGA@27"+DM>_Z[VMEWKX^T._NQ
M=_:2HJ*U"C84#'E8UY07XY&6DB%A"("ZA35/.YNJ-2Z2EFN_Q5S[<MPK9*0?
ME]3Z;1.RC4B^)3S]-GC^E6!,5]2L0*)5!;8(8Y>*<YN(+&C4J A2\X)QA36
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MPT7^9P'B2+FG&F/#691<:.-2)"XRG4+R(5I?$D=L&+Z%.!; D;6E"U7IC=;
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MEZ5ST&1#W*H7[OS=ON7L2G.W^;WK8>Q'Z:WURE_40LV@7VO?K'];EP5&>Q"
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M@TT80Y#FBF>U<.^%,=1@DX7<;[*)0I1XF+M6%4PM-Y0HF$@+8'/4KB'$HB7
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M'S5FRK:__6Q\WSVJ?_]XU/S^]U%CY\^#^DYHU3> 27S?XODZVY\^']8_?:7
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MS1I2]F;N_27VBYE\!DCX8OO;_5)#ZF_;/HF7MZZ,XPRN1^K[>T3G$EDM$1
M6/U!)F18T(A:8YC!L'R%OSE-<\V$/@4$5!-Z^X1*GP5G*47$^X!X B9J(=)!
M&.*H0#4&E!<YE()X]@[K_!@B\!_Y51>"8<6J+^5##GKM$/L% LS'@N*LTJ10
MZK4V]*,W?'3C*4Y1-HISFMOI;[A!EH":=B;_-[;G:$*!)SGM]<,@=M^Q6=7/
MMG?V21W&"^8%(?JW/6:#]$)B9*)0B!M/D9,<+$R$@"FS!'.W\J'7C;-&E">X
MD)&+UA^4YC)C+0<P%X7W:+=KG1B'Q3GT;%SYMV-CRU3TM-\:#F,^@UXHW>3S
M2^U6/,F?'7_OOA8ZTHZH0<#0@I@@#%9KK53>] #N"(;6MOGP^NAX_.\]VP_%
M8;T6?'/8Z\.-&[W+;P-'AHNY./E5> G'MA6F3]@/6OG<?&N8'\?'XV&9T%CD
M;-_213%32J5E[F]&\2"_A"\)+MLO([?:EY.^/["#&T0$!B<YWGCVZ&@Q LQS
M@8.BT4MJ.*7!IH"9240S(3G';*3;9<:Z7>9:#=Z+\\/Y]6P53U^F2$M-NY(5
M-^)I\:L[BGB]/SS;/*L#$=81WG0T*' A$=><(D.]0YBI%*5,Q!NS\H&M<J%6
M-9D],+Y$0G?701J@V&@Y%4S\N)]UT%\DFW"O( !KYX(,AJO %40G,&/:Y^23
MP0+^5P8!TXN%SBR5XMV4:^5+?@,53SS?9+  DK,"_L<@P ^P #@E2&L246YJ
M!TR+"9-;/1%,UNALO<0R6?\%&5T=B=C ?)^T1U(R=A]<QWZ6DH&A#099<#WK
MJ;]05FTAM<>'>0TD[^@TBN!I09_Q\EM3+YE(^49A^5AG<@X?HXBQ1QP'B)5)
M@#6$/9?&*4<(Q,ILCJC[%<V9)5I(J[5VA!626EW;]:TLJ!9^M 9 4HM&RV]^
MO<QLW(XWL3[V^K_W>T>Q;_=C;JQ:+9'Y2V2+;J_ON:@IP^!&/#$8@=]VR(1\
MI$#(F$-#6"PQ]S.6MW7&R,HF)_W<V1LF:>#[+5<">B/'CRQSF]Y)/UM 4=51
MR#5=6NX@IX6*R5NB];66XYG!B>T.\^BOM)NY->H9?0!^7$JWEKU!X#*#6 B:
MU89]&%D:"?V7G*<(JGHGPTS\X!,7L?)Q;CH"+VET[W$PE6-R6QL<@QVG%MS@
MN/ .J[7!B2N:3N2;7?PR=R4I(M/!&PA-QWM=HS*2R9<"?/JX';-Q 7\^<>V6
MS_V$XECMNN0;<T+2G"< PUQT+\P1:3P&>DN#R EO*XBB3%$IM:*)C8I/8.#S
MBT^J2/&QB3(N#B]P)HVF"3E-%>(4"^1PDDA3CZ/6E#,=5C[(5:'(*L]*XW?;
M(!E%95-6=1&EW2=FHI[E-H1$$^MXHDK3&*P&1L]P,$J1(F::,9LJ9KJ3*6SO
M@'NSP2DC%#(R-P,WC@+AXR3_-<I .#76K'Q0.:,^)W]^WT!E$1KT0 B90X-&
M _G8[W6R2615SRVX/R#OE\)VMT>F6_&B:RP'PH;U/8LAK(Z,(1PH13R)+$VH
M THN.IJ((R$Y($82SRF/'=>UU5Q,N0]8H=B:_7DF1ZU!V0%VM0 7\#\CS?>R
M]5T)*D7#J)>WI$M"_6W\!#"Z46%D93[7F ^M[^SO66]<I$XB$;%%/&B"G*4$
M>1=Q4I8G'>C*!ZIOKHJ\ U.;+=5Z<F(VOX9K5->VT1H,@?R?%-9ZP8@'K[NJ
M*S<&.=D_&0SG%%--M]:\\3V4&R=?6MFU_ 5+O@W__[]LY_BWB\O],PM;4?S;
ME<\4/R.__5*@Q!\0D0#W_]@:GN]#D ND=7R%M8MOEY\9?ZV(SB :+E#G>"*H
MF>7#'7M6PE!)B7.T4O89:G5B$0;!_Z]>Z#J7K2G*ZYX<Y]\O EA,<0F@A6U.
M&@<AC8T24V\!=Y703(TRQOHZG"KVB4==#=?'[GCLW0H>5-2^CK>-"PPK9V=R
M<BX%MRM NR9/T#@$?VBHR"<($&7!(:ZL03H+O!KIM!/*&*GUR@>&Y_G#JZK-
MHSCV"K6&N8,I*=;19?\[,)T?L3_(^8&#V$ZC#_7+BMB+E,$5@^YU8XZNB^Z;
MHZ5@AP@NA@!GCB+,\=C'#F9.*XR/02Q=\>82Y416%PR0C2%$T"AEY)'C:)S7
MBFL1/9$B$AM&2;Y1)?M=2L3N$R#/$6=\?P'1%J_#,E;**L6\04;G]D?2*F2I
MC$B[O$U'-"QRNNA^>19/]Y;:&#WFAB83@Q2*>@C"I<!&S#VN4$WRTTURPE[[
M7 W(:9:W"S@@:SQ'#IPJK#NG+!8K'[J]N]>*%ETD1KFR,4"W!A-MJ1XKJ_CD
M/&[;#WNC_KOF(42N;-PQ_Y<KO\SA>;<Q+X@*V^%:[@4O$!4<+*<>NG-]VX5K
M6QWQOIRPRF5)O2+S.V9H=C)WL6"("<X>NT"4XLIQ</A:Z(!Y1A1GE;?%'C\Q
M!%>,[64+ &'\^WLN):63M0@\K@0HD"ZGO3B*,OD0$D_"Z5PP<"?&=ID2G;#9
M0H-7_3:8*F,9!0=3U@\A"%"Y. I$+MC7G'.BM<LCHE?J[!;/SRM!<.(D&F,Y
MC\9;<#]264L484!-_"V'0ZO\_*-7IN;V+R[*X#T'#F*=STE9AZS5$0%G@)F*
M %T6KWR@J\*P5<G43?GY#&]3@41.T8ZV>RYRLCEPG;"D!5'O@59TMQ3M%>"K
M@.T:^RET"RQ$FQ:0#1D<\IXUCLAQ81$1PD8+T8;#=N6#Y'-R:U.;UMW":SXP
M[_KXYG&A.W2!-ME"BC.[E65<9QF-P_H>8(F0V$8$[]U =,,X,MP9I("4.!FL
MDCK7R,VI9KA(NA;EYV.@R)O^K6Y1K)#QXQHJV+J2'9RBPC?J2;RGYH5FR9L7
MWGI:>NITM5 *4TVD<I1PIH0N3F1'IIG742>]/*>K"W*"7#[H7YO4 GBDG/QS
MBR<4S8\WB\[),4[7X'QIVZ5YKD6.6!!]E>S: %';"'9N?>!1,%I^[J\O7U9^
M6;T\H9%:_<%PHEZAX*L36=:+;Q5$*G9]_A0LBG'/Q@LN[LX Z8I]Y/99IE8_
M6D4SQF.;!7=:Q[9@77$TS,'E 'K'Q[W^,#O0LTS$CL<CGPY$%Z/VC'#"F%2!
MR\!YPB:+93!,36 I\9CF=X:^^8CB'_8X6V%)YO^,,+,_8OC8ZW\L6H"-_7!%
M[J]QP?#GYIY6T>&D-4HL"8@ZJ48V,(*(I]2FD("RR94/C)!5/:?6=GZ<^;^O
MDOS21Y>-'*^-3?_W;&!03&=1-]<:3>7<9=#J>G!  )97,S9%X^+)(L"+;Q1+
M(ZM3Y4<H=BN*\<3_GL!?;CH\.;<7I8O$>N>U58[SP)GQA'+,G"?>4,KY%)W,
M?YA;'%3D6K9&S[+5O9MM_QF/\XN"X83UP40CR^[VR3 WB,TK_DJ<LCS=+)_=
MW,7VQN9>HE*:/!?19@$&9BS2ECFDB<>$&*&#(, XK^^%/9U*@9]U4>_R;4^=
MT8^ XSZSPU&OP0N4SG\ICFCFA,I:;?V&3H2+;N)$KTTR5@KB+-<DY+(ZFICP
MTN.0Y8CN>AK\4G!HDH:L]_NVNU]0Z=_/9C2)UD]M/XP/ X]D)'[85CMKN('Y
M?H+OWC$/^/X0^>OI]L;6GH!@*$@I43)$Y(-#$IGD :"]ELP&2L!E@HFN&BU7
MA9P].3?&LW[L6* QH6;'[[_ TK$_OW8_]3HCS,'2>(\3SS\HNI"92F:B<HI%
M;B0WAFE@ 5)JB/J<=4F01]Z&&A.R4MQ@]!(R&ZNR?]>9X\_&^?Z>9EPZ[CG*
M*1+$#;;("NX095P;2ZFG(@#)YZO:S);F+@I=W,!_G94!PST$\X8%Y>!&&E8!
MIDH]\OYS91.+V\3VQK<]'!A5/F+DF8V(1\N145CGG8M@@DP*> Y E%EE8DXZ
M.&/(@E 1?,( #\(+PZ5(1@3KA<OJ"()KFAYY7Z RBX<HHZR?U_?W?)(8:^P1
M"1Q0(V\<V$@DBDH3FQ(5*62M6K**^9SD7FD$JSD(."[I4_ML=::^?TXPL#S[
MV@LF28#X9W6,'Z/#1:\J+Y)G('<)&A[4UH$"AB+)>G4+YX(NSWO.43KD\E?Y
MARN_7.146MU:W<(BG)-VR8*V$\IX<-."BERS=;Z@KIKF,FGF5))9N,OJJ P$
MPUP$0"&KY"ACP9Z-1E=J;+<YI^(X$8Y&8NX@IO/YX#W3.HLR"42-=PH[I73
M^3@1,6:5JSG^J75AB-E !C-9A:N&NE;[%+NYKC=#U/17BSJ<_1SSQ$)QI]LK
M#P$/#\ VDVV-!9_ C$,L=R\N-6_<6/.F8[L0U(\T>;(8Y(\X&%XF!X'J@R7E
MOQ?E)U<6?U990JV?Z* 5 !]^?4_&0'-1A?<,)R\4TCKO7:>HD)7:HN@=T!2L
MN$U^I*14@.U$_F>NU&^B$DBI)\J:P(UU+JJ(623)I\A2*#8/,R@43&2,#H\$
M!\6__BZGOJ0K9%91*YST+Q2UWMGR/SJM'V[N^1AX]!R"9L<,, \A$,26#GE@
M'HP8+1(Q*Q]2/MU<1+W3PKYEMO+J&B_\S,3F8FMZ,V"M5INS05#D=R9S0U?A
MH;@J6%>6P+^H8YN;)[U">\J-H9/C7NEYM[YLEX<:UVI_P(4@Y!^GJJ[Y_BA8
MA\^-Z%51F#$%7!=[9WE!N#AY2GD,/KFRS7NPM2(S>[%],/[UP!_$<-*.&>O*
M1[7'QT"&BD1$/NQ\ B]G^K:3!Q5NJ#2BKY;G%4RUW!*Z:F*OA>S=L EV0?(N
M'%<8B[6-N5QY;F[>=ZYJSQ5GZ//'+]C]O'<VN8]6<L;QR4\7/6#N1/;U8KE<
M_*B;_?!HI5QS4@'^\A'@M?87(D7J;"ZA_;(]O;\Q7FWE\KO<@[N:A[MN3Z-X
ML&(O8K2=.#CIY*O^D_RR:#6==1 ($RPX$%A@AQ ZN]QI@@C'(7QFU9;;2X3)
MS3TEN9/"2$2(28@KQY#1(:%\EBIAB#)XXBL?^"J6:A7C&^OI)H']M]IQ^V10
M^R?]I3";6_W(/\L@:3&;"HD'0QU+0E >8,!9,]A1IP*-WDM:V=2SVQ2!Z^QQ
M1HV#.4$I"_" ?7%DK9!(*I^\YA#Z))$W#:A2JT3/.<1:SO8O=V,'XXCF$KJF
M@+GT^3GXF4<<.IT86@"R15U"UDX9!5:+8'-QA_CSN)6/^U]0LWR8K% \S<(V
MIZU!OG^_GTE$/WL3GPVIW<Y_!&-*L34L94+[<;PK,J,6:O.M(@1J$'J#'[;M
M2^ NI20FHT-;+);\3O-6\N55:V6OH]$"9;\4F8EN-W]HO'M=&_FGLOPC%,<Z
M+S<(P:'!S;OY[5T0K>OY$3&%FQUQN&*/IU=Z7KA;^R13T=4KE\@?F>98F;^.
M=\3S9W/<6N+)8HCA%4XLR60E8(?GVN$0K,:!6LH9UJ:(F,PH=TO,4VY+;I>2
M.MO9.,8[[0-X[O(/6]TRJ*J 9C[0-'_F[(I)C$>:!%(VB[4(F\!Y,88H28J*
M/+_49^=EM,D%X7>L&)E[,N&&S:.YE1B,2 QC28$9S?.Y*2D*(>7 G992^%LL
M;;Y,RWWL;*(0(TT48A3.;G2:YCU78C1_9HUK)8%'$!Z098XC3I5&SGF#HLEJ
M0,Y&D07^^/65&+<4%,T_[#(9C<]#W M4S(X$0+J3M3_FY.9N#WD>MZ8#")>T
M,I'@M>66>*<MA1='G?:,)HRKFHYE-?;SQL;7/1H"84#-D'8JJR'G#=/ #6**
M4*E2C-&D?(0&<[U*]:S1CTT\<YN[AY%KM3^NA*(37&QR'<3RX*3-LSR8)%9C
M-G69^5J]RJ?@]Q>4ZD(.[\#^R%<MM-C320Y\XT\ Q-:@Y%KY@I?DJQ!YZ[6+
M6^430+8_G/.0J8@$2MI9+*IRK*\V"S2Y]&HC?9Y7D0#Z.,J"/+!>"""RM]\M
MMNS\Y*L8-Y9<\$3/O?KOW72B9[W=[OEL[_/1LE)4NAGR6'WCVQYS7@4B/ HT
M"W(9KY!5VB++$P%7YEB($)$JL3:G@NWBP-<B5F"-8]SFTC&)<X\MK2334?#H
M*).6W%8[5%G!XUO!T9Z@2CEE*(J"@>,+RB%#%7@_JSW$@8D[*5<^"'7;V;\"
M2%ZTSVQE#0^TAIWF'N911 J\1V>E/NY\1-K@B$Q40C'C*$Q1%B5:FU7$O\2$
MJT5!_;)!ZCA+<4&'KF2M2KJP>IG^6,B4$M<F!H 6*RDOSIP11@WW(E= ^I0J
M]_)RM6:\OKZ'L4Y"*8:P21$\#4G("2*1I)Y9+8 ,Y I5O#:;29\Z7KR0MTDB
MB9"B])QP$YPU1&HK(V':VB!,Y6U>T"@:7_=\%)(((1 7T2*N(@.4H8 W1((#
MBEH##F6CF,U0/<SON&0(QLQB'R/'0>FH@M:"<VF%,Q"H5W[GQ>Q"--;W:!(D
M.@M@$240$B,#@KG*E<PI>)68#;DMRZUV<8L;NBQ(O24+E%/1L:B.6 Q\[M.R
M;]:V+@J=8_]'R\?Y%M;(%2J#?,*L\*([/8AR)W^?=0X:O6$SPN#&85UECM?0
M(%'?J.]1"( X)QI9&<!A)9NQ*7IDC>(ZJ23!/E<^2#7'"&L3&C]S0^<B?=,:
M%'_WPXOZG8F(N_<C*U;5RCB_.!Y4M-X8GS3.V95<?O$3IJK8HKNI'(X(Q2-3
ME@@(M$Q(3H /QM980C@3,LRE1L]D@^5NSL=>?_2C_+GY!7,YF_'N3'$"&3>.
M?C;V]PR$23R+A3+GP"JE,L@Q:I'/^\K&,.YEWD*^I%'CBKDR&U3I:,S5T:!X
MR74T;M7%F-+1D-X3 J[246T@IL:&"R.*TZ5$4B/M]3H:2YB(+:O*1OO"5U_9
M#:AWKWSCU#;,J#IRM)\RL]M2#&PTKMQ!K-RE@>"V4_YL)^?&=V!$O[>+<]WO
M#+QRJ>_6GJ,FX.@-TDQ1Q(,+X$<Q1H(2[:DPF&.[4HO -HXS%O1/XK7&^>*9
M]5Q".'$@8%S"6VY:EG-^4783RH.[97EQNE]"ON"<$_N:)X/Q6>#?V]8?(3#0
M7E;_*^]=U+KD#W1Z(;9'13'E>&JY.=2$?$D/XI73_-%B1[&@$Y=F^^M==VS@
MW0^+[9\+[.^'V,_:R6U[/(B_CO_P6V@-CMOV[-=6MWBGQ9=^&UULY# R5.8:
MZQ:PSI$S**:Z_/4EBJ[A$DF'??@GC.\\^O5:\:M_#</L[[A<8Y1?^VN\1J[]
MW4V7)7(-)NQ>E[WY=QS+:K"4WNFR_RJ,H30(L+ELO/__"ENY]-LAIQ-_Q352
MV.SX>A<?)6+FL_3X9_[T;S/<9-I(2_M\'!32MRE/%:;?G%]2=K%H'^.-7'YT
MM*:+)7\\K!6-YFKYR7Y[!:\J0^J5]W+?9WP'+XI4+^IN+PHOLM)F6PIX'V-*
M-SUK.Z897_B83WH[V2D>=7.<G/C1RS%?NS4\NXN)7/? ]YKV&U_%_!"RJ.)]
MUA>U6 %DE,ER2;P+27!,A1/4.LV8)B$([?4M&U6/5P#Y$8ALT?=X(F(9S_G?
M%U/^)Q#'>JO[-LHAF]\_#W9W>K3^">*6PZ_G]9WV8?/[%FZ<?Q7-PW5>WSB"
ML39I_;#=;N[\?E3_8_2=_WP^<)W0WCYLGNYN_-EJ;-1_;G]O', U6&.CW:IO
M[)_"^$\;A\VS[>]_'\#U3_]SOC6L_X5__GMG<]C8^)9%=G^$3W_S\'\_MW=I
M^X<[/#ZJ;ZR?[L)SUCM-OKO1A''46?.P"3'4Q\[NX<>CQO?ZS_HY?/>CQGL4
MFT =Y<A3*_*)%(F,R8%48%FB-P)@Y5J-V73D/VIHP2+=UVBC;Z5D]Q7;J-@S
M6!M" D5.0L3/N77(!1>1\"08;Z5B++>&G%43^<=4*NP>#F81"E(YJ9L!0";%
M-*8&1V?R'H%FG#NLI&,^D<#I+1OGE9-Z30!P=B, M)KTV\_Z]T:KT?E&ZM^_
MXMU/6Z?-G=VCYB&\IXW0:G;^/H!G.6UD)Y4DXT1$@K#*2J6<<629C\B*@$/0
M8#[6 0#,.S&PJ)-ZC39:.:D7MU&QE[Q53(B$!%@,XKEUL4U@)3AHSC0S,?($
M-CHKE%<YJ:5R4DQ+ZRWE(3G%!75&PAK'(27I$A=:WE+%4SFI5P0 C9M9:FMW
M(W3J'1CCSO[9[O<ZWH5Q;W__\Q#&U:D?;M'=3Y^/&H>[![M_@Y,2+MD4DT."
M E7E-E*D;8ZD<L\107+?5)8;F#^"DWJ--EHYJ1>W4;$G(D3U5A@4*4VYW:!$
MN?<U@F#<*>LQ#R83J=ES&?.<U,))RE'?TU>4I,Q[I+5_%CNLO]PK3?G 1UXR
M%SJW)(()G@MNJ1')<J^-)CSRW&Y0!*&CI'<IB<C@XF[''[<(_NS W+VYHJ_G
M19_Z+7F<WAD@SU%]Y^A\]_LW#.\)[WYOGF]O_-W9WOD&S_\-WL\6W/_K>8/D
M7&-P2F+ID<P0Q#,$.1<#<M9$Z34EGJF5#Q/'PB[*S-"-I8C81(X)P;G!-:<Q
M:"4YMEYYKP/Q;KZ<>&6![\X"Q5Y(41,%#@_^ 8XFDT'6&XF\L\P%$XFE.=M]
MV69S;($/B-&F7,"]8K1WX$8LT]1JZ@.5EB=)M8F6"*.5,\0J-_\,9[6(7\DB
MOC'3TH/G:Y+F>?VL_OWC 3PW+.1-W.Q\!.*Z>=8L%O&^J.^L_RRVK*15)'*!
M43*YAIY*CC0U'&'CK99*"QM)=B-L03?B%"-1<1(2PSPJ:9-*G.7X"0LF+:LL
ML++ G\6&E-91>^<@@L)*@!OQ$3D(OI$3C#&9N(2@JG(C+^)&<C<NEI)2QB5.
MI'<\1A>CC5([%@B9FQJI%O'K6,0WYT)ZI_!N?C;R.]K9Q\WS([R]LR6V-SYW
M=C<\O*]U6,!?@1]^9?4B&L&),NP8 J0GB'LL(! !7R*93E$J&I*^EQM1D7L?
M9,S2=]Q)9P KK))@@-:S<$URKK+ =V>!8L\ U94D"*3R$79NB$1&Q]QBG>2.
M*3HR=V<W\G8K!O]L#8YJJ1]CEDF/_3@8UOIV&!]2-?A&'.#SU%VQ)]TMR+/[
M$29W:S2WU7[6O='IZVVY$D"F+=$X_X;KAQ[&ZO%NYR.,O7X*8S]O'N[3[9U&
M&\8#;[((LXPU+FM5,PY,UUO@MQ8'%+&R*7J*E=;Y4.B<S8+G+@U\ 1.MMK->
MW$3%'H19-)+(D/#:("X,13I'9%9KS,&0)#%LY0.?HRFT)$47[\L1/;"VJG)$
MKV>5WU)9U3CW9_6=WP]V=SP\YR;>/:SSYO<_#^H[=;*]T3QM=G8[34"!PA$Q
MSX@SGL"RA@7.P2\@RSA#FF#GG<;!YA)U_"B.Z/69:.6(7MQ$Q5[D"A-F$F($
M0R0G8T ZBT])DK '+T0+R2DR1]6E<D2OK\:O<D2O9I7?DJ]A]>^;I'Y^T-[>
M@?MV-G&=;I'M3W58W=\X_ Q6_$=X-_ML.U?X:1^M=82@&*@$1Z0TRCP3R>"\
M4$9(AMU\ ;%G+_&K'-%[-%&Q)V4P3$F=Y>4A:(\X(:T31D'+2&.DD@>9'='=
MSDJ]@PH_>-A6B-U0.VO%=K@VJ4@7>VA<F_/H92>@EW_V-WAJ<V,TBQF(*@1:
M#(&^3>=D]IB3F,&_D([@XKC1!N5MU&)GS'JJ@PL>_-PU,IG3:VA!L"A6#E[&
M=?./QZ@ OI:DOU^$>15'[BJ$>1#"7 VV]SAV#K."H;!<1>,4,M(')"53)@5/
MG"45PE0(LQSQ?H4PRX\P4U'47K1>A@"DA6NK$%<X(AVL1)0K:JRPWHF*P[S=
MHI'-4=^QLE/K>ZX5N5%<_DOL%T UW3[<X1BPE")QP[WR!E, RR XK",E>9PO
M,O_4,%G.Z)<\H:^^J^#SPF/SMFUWO-O9;36^P[WI)FV>UW&CL]O9WMD]:)Y_
M/MS=6/^YN_&5[WZ"=Y<K)QE-U!ABD=0$L)4Q@0R7-K=650"OR5AE5CXPN:;,
MK(H]NKG=P346Z92%^T2J>?*<26)P\GD((JA -)651;YCBQ1[AO$0K'$H2.W!
MY4N=5<PL"L)[J;&C,>1SS7K-S#8;JS;@7LK-A&BCQMSJW+0>&+H1R009&<E'
M0PU,Z]9+Q/O5HG[ HK[YE W9_?[YH+ZS";_;+Q?UX=;I]J=&%BLX:'YOBL;W
MSZWFN2>-H@#1:Q=%5,@(:A''D2&'A4;46N^+5M\BK7R0<DW/Z1EW/S>3HL&"
MNV"8#SQ&;7 @SK'<L%HPYWQED>_8(@589*;%CB"%14Y;"8]<<@%10?/6FN4
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MWQO9.%7R,$<>?NZ>2(Z#=YZA) C+U7<M,B$J!*3/.9($UR17FYP-G_UC'D:
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MF$..BQ43O_>M%^AUOME3=^.Z5/.UF*B54[:0?+VA6:D4L%+ EU3 U]O^;)!
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M3%JB*IQZ+IPZF")4/B:CO0LH1&(19TPBXWE ."H/$"48B;KHW[/D9A$54%5
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MXR#TY40RDAP3&JFH>&YGZI&V(B$-JV4X& GFV./B><\E!Q4M68XD&%@LQJ5
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MW;MDF10OG$WAN^*"H9*<P?0\G]G]=/#;LNPNWE"[^_A6[OOB1#/GL,8>T>3
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M5"(1F4:<8XZT8P9A;4*,'G/@Q]DGX\]59W)-8.'% ^"O%$">[I)5 +(>CMD
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MW/HUWB:W?G?7;0G=-N;VK^^Z[=W?<2RKP1JVT&WOJ91P;\T3(F9^.^=X:^G
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M(^;?$^&#-[@L)U5_IWG4CT5TO *"K,093M:@Y>EYM, IA*'5(^S/'";8[;G
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M(HI<,G">F2"P888([SE1609$(=,L-RI1,:J8)BN"BHU>:/3"_72_:_3"?8J
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MF( T"429+$DU6.ZYDS>$UEF&A/SQV#K[-03%H<>NR-[%ME"842@;XD6(ZA*
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M<V3M75MSVSBR?I]?P:.7,Z=JY6OB3%SC;,FWK*OL2"7+DSU/4Q )2MA0A 8
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M#T\$8_+)^MN/S[[^]=KWO\CEM[GW_LGR?[]_=3[>]$5Z+'_RG[^_>I<^XDF
M\72^"--47S ?_SQ??OAJEL)B.>=WXGITXS?J3[#^&M2/@ N0_*>O\_SX'W][
M]&@U'=UL@F^Q/*I___GVY:57AN[S>!KF/Z79R9/Z_T^>S:;SV62<JW!_#9.*
M^]U'Q,6<T"^?MOCV"7]Y/!^??)K@^K./'99?'M.SIH1"""Y6&/[/S0][<@XO
MA4DZG2QGXQ7]?/;("J8)4ORZP&G&U82LWSF9I4M?FE1QS+KU;TY"Q,GRT]'I
M'#Z$\&GT=#ZG1X^$M3$%64#I;$"5(L"%[*!@$+H4KK#XR[-2AS"G,2Q%5\(\
M+N5W]M@G=;J>X&0Q7W^RG,#EY%U^\VK&#L7_[+3K:/6.?/".92Y!)*- .>W
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MX__!O+XF]6PV7SP]J8KN?Y;2'$47-:::#@W1@A),0W!*@U,Y1H?&NM!Z K:
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M<7G2Y,]I=U:MHUZK6'5(J*7/.#U8>Q4A!ZU!.<RU\PD#[X+1SEMA>.ORR$V
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M!1>U9X'B3H,SAGPXJ;BD0".8''Y$(WOA/?\/0_>>QH8C49+3TAJ06+M/UXN
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M/1L@F>L>2)_8MP\3-US@NH#W!492%\G>U9-^/0V3EV21\1><(/D2EI01Z@Z
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M?W0/GE(#&6J8[I*;D+X<3\(D;58,"JN5\!I$CK2N2EI<O4\T"4) TA7-AS1
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M?IH;<EY^(+-\NSU$\F\D!YTC U6R!!=KLV.KG4XL&,[Z-;._88 ':,][:F^
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MB"IQI73S;D>W GJH&VI[:S0\43D'MX9IE?O2!]1 5_D; 1WFPKZAX:9#:7V
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M9^F>E^'DV7P^GB_")%TK8R]+[198'#A1G1D;R)EAM=1.YLD4S;CEME<8L.7
MAW8/[VNNZ9YTW?I*X2K6VCCT=JS"U1?G*($E75O"VT@13LQ0/5\3D!'X?F^
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M3-[Y\N;>PKSI^F/,WRP^U1* RP!B_@)77[R:G)<!9-DS= YRKGU.G#?@I,_
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MYA[S0-N=)E !E0-$D8LTA67-&IM[(Y#'[3CL;IL!*@Y>%OW9)/\VG81OW_E
M7\U#Z@Y,5OSN W<@5V)+J(=Q,AH8>3V!:@\6&F#3V1:V8B7[Z#PX6G9!J1+!
M*_HJ=*7/3<H*>W6X^MX(=8>K<G@^;6.8UC5SKSP06V_4AD7JP@B8R)* <:>
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MM$@:M P\*@XI&9F9QF)*ZU/O[5$^\75XXQY3VO-*$-):P?'BC.0[GV8CX[/
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M/F50%A7X+#UDKGQA-ANF]WZSU$Z\IQFUZXPZ$-4.L3_=)>JY-/VD%8(5)J(
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M4O=Q,OX_S*-:R.)D"L!\H5!4U^0%+@B\E%(QAE*NMM,Y>#O:#>'%&=<1%#5
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M'XH/OQ%*K 59N>S*_>8UMGX>I9ZKXCQAHXQZ<B]MW'I=;?J;%<03D[0Y4T%
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M,3?R"9<0O@29(==EX,'TV*Y =)0^:VEK.Y1<@&ULR'51O,*_F>LBJ9!SS@1
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MN;NBP44#JB(TF3%*-\\/=.J)?Y;1@Z7YO/,A]?1L9;^ZIQG8*N]'B>PF,Q_
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M6C2N*$G9;AOFN^SYA#Y=C889>X4'ZEUAONUQ;Q'Z05KY",F>N\YL2_M*J'
M0SFE&C9[\"])]TOOE2#.1059E46(!*\GO.:KD-,KQ'/?GU;:1>PP[\BE*\(@
M!\+>+<ABQ!] 3%S'].F$1Y]S1DS;+7#'J%JR@SX9&D.0EU,/W_]"UB)^WHLW
MM(JLMCZD3>B7E>6E.;WA51:0WKS>:RZ.S-4FSNG(*&\33AF_9;B>/.QF^3C$
MU2/RCJ9W04;GIW"3R1!KP8!BZ:W[#X/4R5P+,/!TZW-2&4(XYX'\5* .$= \
MR B62T>4W"J<R\["I9(&FXNUY97"4LH4I&AZYQZ5^08-^"E7.FJ7)O=V%A=H
M-%SCT6S73+!^1I>WCPZ.5YL=3PD\[X<96^*5$I,L[[JVC92SV.55YZ4'+FJU
MMLGS/ -9F64@N4^F- )+W4)[)7V?R9E7>2UINX;ZMU;L*=W$I,\+&?#,IGNY
MZ&45;:LY]B';^6CF[:.U4/6%VLBZA?98L^'W_!*5J<*5O$];O;ZDA.B;&70$
M+!M"5WM^K?E?DT<UI<)2F."N8%C?R\.Z5.C)L8!=6[27"/3RG9GX9/%Z.U=X
ML[\#)SGIBW2X^R',U7O0'(#="EDUC?2BHCEA[B$=^AB WGA-9;"EBR%:))&3
M,8FJ,[?JZKA&%:<P<@^+3O.JQ+N^Y0YAU^F<IRTU_S %*H@[S^,9^M3JK<ZD
M-N4\*H2"F<#5(RO$+HV]9M TQ(P>P&*&K>100SSCKK1(*6RCBP.9=D1#?)HE
M7H@5@Q7HXJ!,"E!ED%1._GI(6VB:I3)Q!69_4^T +G6F-AQCVGD#>3%EG#'W
M?B==5EG!I)A7:8XP["2#4L(OVKU(VYJ9A"3.[<#R9G8)5I;J/F>7Z#>J0^"U
M&('Z*DU?%N&\:,KHYMD7N*A#[AG?!QUK;/V(SPXEQ<>KY2_%TZ!0%QPJF/#W
MP.*)6Q>I[P302Q:[&31V/$7CW)4E<-XD2;8$?KZ(C(3ZL;#$&47XE_!:_O@\
MR\K#78JEV82T2X>V,8P"F.;"#3TUOM!F^95>THIFE9*9OR\S9NS3H"<ZFW4>
MD([V-)MR ;?$=W&7T(CE@X+Z2&KT[HV<=+3>D@L._] 9*=HT=).4Y8[286D2
MIS%DOBH?[W?"YSQ1OY%4/ *Q&!ZH/.:EW2U93A'K3@.!M:=$YPME6PEIX0^&
M^TE6U*&.;;]_\:Q:_@&$-%V>:!#)<E\.FZIX)'M^J^QQR,K3AH2=*.#\/:@F
MF9SQW/*Z_ _ \7X!_D;*$-];4]]RRDK4L*>1HBZR.)@F85?@N'](4?U73G>Z
MWWCQ>-&65_Z-5R">?CEG*4C8,&B%GY(W%^@Y;1C:^&S:N$<J=:((U:;>5'^@
M_7OR"ZKIZ1#9ANB]_CBE2'P.U%\T@%+BSA(Z<RE;N3I4*N=(J6)&"9[* H<L
M\P2?322ZS(V23'*7223::ANE+#W/SFM/LZ*A>*QR:/^H$]MR9- %DU?4&RD/
M=$0DL%BIOU$N,;%-RS4]KTPY12T](G\PS"<L&# /.Y:26@X,KOV"^-L=.Q[0
ML\DQ?>U3V4@'KQY.CTM%W"_2M(Q+I"M48BX@&=B9[C&L] 8X'+_GCD[07GG>
MS16$(5M+,E""3R5M33<7=L,C<MS@T0M:@T8K4BX:4RWS)V5?2)_.;VZU83=K
M"]/0&3$@&).@7F2.)>6^1;T25AY?+PX#H1.=;J9/L7PR3-3=W*.-'%1X5O&$
M!@0I/:C(-MA%<KQU03X P?[RBF(;.C3=D@+L "X=#2BF6A=%2=%[U@M#R2%1
M40U33*.TJ%* ($_%%ZHBJ*$"B7 U@S+'TM=- '@JPB"8-Z+CW&((%3D[%X<'
M. U"<$K@D)WQ/"EG=(K/NN@#"@^7>DGI?3&)MZ@HNU/_M1*R%8?$);L2?:_+
MIZNO_IX(P>#E1 V'#(!^WBBWMS*1>FH1)K'9[*#!4C%JO=<IYG;FW1A,3Y#M
M) IT^3&/0 [$VX0:](2BYK?![,^?LWYXSZX,WC2,T@" X]4&)0I4"FR>&CX@
MIS%#S%@Q]3X7D1KY5'(58%/-1S[YIP\OF!T@J/!^WWD"FUU665T9H+K++#G
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MC!4!QO7Q<?&N):X5+UOT,VS(">,$]+S&("#>G7<P[P4+7]-]MY(7AO_1$]=
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M5/I(D0.EN !F_1A,'Y[QXKW:OX.6?7B65^5,UO8E0V 7%SP+,/S9BYO1N5=
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M,&^;9R%GG"VY[0^JBE3JG]E7?6CU&:]&C-VUX"E6EFZZ&_?YD<ZAH-_;0X
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M(X7 &;%CL#?,,E.6"^OZX%Y'>T-.% SC#*SZO.&Y)O+U;*W(KW\8L7>2+!8
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MI)4N,N%81%=;7?@#SL1D@IC6Q-B@FS[E#%V< O;&W:SWJ @DW_M7'FP[<A1
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M'+_^_0I1'/G'Y!6)[^S'_=E]6]K;E]IG=-G&_D*:D))*USUJ43'(^E:N*Z&
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M _V?VV)D:A6/3<A-M?@%R&&P=302JLZ>NDLJF&.2U@#C"3DSK$0# B][P5^
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M,;&-9RIHW.D4XX.JG3^5-?MN$?J\L.[VNU(1IT"OR1FQI''D\UNY-C[.=R2
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MN2",,MK,$$E^.7[=.E0;L\P;.,94EU*W L\K,TA>1"W=VEG;^%C:/9NU4AK
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MH!'GTG.1J2KFB'Q[,E_]2#GD0].B2]Z#8,E 0XRR8<@%(^22_K;-*7:D**2
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M/<2F*V(CDY>L:(2+8%_W@$R9^<HHL57>#"#0W+,HJJ#SO+[$$=)JD2%30'D
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MF'F!#%PYX&<RCA:PL[M$=O"!.9,_^/B&3ORUS__MA-W_@EC_S/TW4$L#!!0
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M*U":<- ,L]*$$V^@>_RYBBS&2Q6\]E?R5;IG9X7@B!^#/X/$T =_Z;)EX9F
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MAE[ZPB* SW!2]XB7E^WR&/R^9,*Z1Z%*8#C-[N)%R9BY/J.X-(BG^Q/J-<:
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M/T;(/.!'%!RW/IIKN1;IY"6_/3ME3GP8.WN:"'\Y%Q^?4'$3FO?6Z7QH8*B
M66C071GD>GJ,8%IYPE4^3B5>/9[$CC/X7=[O30P%4EF<=YG_='+==)]MH^7-
M^)#+HB)<5[(O [LF2MJ$,5!MO\?&@7*LG9Y@)+??I4BJFJK4UEM_YA0\4CH9
MIJE3GV:4;049M1P:-0$ ;BP10I5"G:*7X7P+A&>9P.!<^N\ZOQ'?(_$$>?:*
MR'+7>?5K+<E)W;=>/B:GG?E^Q^+=N(ELD>#X?<0!T-J&Q&@G!*8'[ T.JI^X
M']GR1+7SGEV9[S6V\TT&BB\$<Z)Y)#?<C]"S:4<)F'GQ/FR3V5C*?=[?F0?
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MZ8=_!T92U=67(U5JMFYM7"VU#M4G+JB_2OD:-XSS6IX5Z,74I3>GG?A5(Q4
M/32-"B6\^;TKLM569UX_IHO=&Q.-9M>0E1%J?=+ZPTV8:$ U!K4HKT%9@G#T
M$BS;KV$1/>496>%1YN)_U2S[:,X=Y9 VC=">06'N]@_J'!N_Z=$TG5 "(A9Z
M8J;K6&!;_'XW59:H&[Z1HK"9]5[B+L>=<QLA)9:G6E36BFPBUZ>J&G\WY#HT
MD3\*CC_.E[4[U9856Z+$JQQ[P,H,0)9OQU#%D;84K19R< ZI;RA_8"C!R+JR
MJ=07'V1B/OU7M_+R>K,'1]#16MY;5J*'/H5<-B"RF!SG&FA(=40%D?(&=^6W
MVJJ>+">L)BQ?F:CD%XAZ\$FCH3UC^OM)E4'5&Z<AR]LFRM\O_N??OCE&,(&8
M_SP-TKC15VB(QZ4:V6!*7?R75.NG/5LFLF27K$/6[78Y@PP_19+=2\TDV-:[
M>.A/:%HKB+GR0=9909G)-1M3J+LECC_VVUQ?8WV;K1W')1_%M&0K<Z[M5^[.
MM5-.D1!$,UABAQLD7:^&!SG1LV\+B__W_,&3$]O6T2K)<>QU_2L'AN\NL'.<
M1'B^BH:BZ5B,QP@FG@6Q:_02J"Y+O4D/"$.JG]XC:KF1!;5-A9[XS2[E-HVC
MLG2\X_0OG]<'%JA/H(HTBQP&OQU:V?_L?FI![R.:=K9BP*<]*WLSZXW6).>J
MNN<J]8^M$[,>*\:-L+0#S.2*"===7 .DIPI"20"/$N"QT(-3.[>/=]B4OO<,
M#?=YZQT/D?46Y!U3W*I[%7UF]^&RL.[N0RP_2H>$O=B5OS/1IZ14]R6H.MA$
MS$:Q@8^_/6:0("*><2KP6Z<U@\\_"M_>B>G#U>.(4:NX1"4>LLUV\]FQ6-T+
ML2[((G=5J9"691^9!ZY_[P'"57XOA,ZO&'2/)4+J$;U!\BNXWG29K]\C5%LS
MYLY 4-GUVN&J62V+RNTZVJNYIP$/0<@<$Z#<)(T1DTGRUT$>PJX8W%]?KH%2
M-Q)5]DIWV*/PB!U';,=C@/QYIFS<1,F?:L\879*GOV4"OIJ!E&"R1=)NPT=#
MEY2/1R:/BPJ24R-?!TO[W7'(C3$=_FX#:9#>'L'CYJ0I/I-,P$<3TQ\V+>?S
MILQYUOJ-TRO9<8_<HY+1'@XJ_6RKK376K/WB8LVZ;!0/:3D#YH^9%:=@INXO
M.L_UC<YL'YYJ:,?5+\TW=I8]O]F28@91>4U6CHLUT#IWNN8FR8(FGDM8)> 2
M&<<9$["&C52&QMC*/+8!";.:P<?.C=BVR,R'D,]I&VW%'S8?.B@FQ U-G*+)
MKC !D4!G1++>+K]_<UM&QAXT"Q/FJ9#C6!^MT+LM<,'Q6.RUM!7?4G\[GEPL
MJ[8W*/V0)@N:R@P3F.?HQI%8H.MUV[8^'.)/M2AX'KS<GN8K4[DH3-$A)<9A
M HFVE X23^IO8REJ?\2Y661[WX,WLA._$^W.N0Z7!%OE\88=W?!G D69[;/J
M+WAKB.)VM?F]%L?J>\?KA5Z(F&.<?T*^+E.NDW#;OJ130RNV<30;3,77KTL+
M"Z4[94EU]3:'0GA-N-E.*SB\&3?A0F82W:C<M,/T"KT@M:&VW/IJI/60DI*K
MGY(AB57_LWH:9N\/GUH150GW,;15#@WR7IBE;*ISK&ED@JK0>C)T<^8RO1+'
M:D*(N)&!;TA]^<.=:JG>#^N/U\VZDY^5#KU67WH8BGT TE=LI,8HSF2#OF4^
MBZKO#Z2ZQ/-G;!*['P11J):KJ?\;>^\9U=3WK0MO1$%0";U#5%!00$2:""18
M:")@!:1%! 1$ND# D( (2!<04!&"(*)20@=IH8<B(%UJ2.@ED@!"-.WB[WRY
MYWWO.>/<<__W/?]QWM^'.4;VF&OMK+WV6O.9SUISK\F'<Q:4@=SC%A(RS+^Z
M'2S/WK?71U[<],MDZ#IV%LQ%MZZK1;?M0 3+$F').\O]FA/TU'.*R?PF)?=O
M5YD9Z;PQGPC?@5'M:#:(,^D$EW8%]\HPS[GZP9^FY^:ZZ@<W9/K3_;Q.\G2)
M*&KMYVWCO8C1SPF%JD!G"U"E^0E,"28N$,4/44&.-FI04_RSU\1#L)'K_I61
M$Z.=)A<ZMHQ>Q$V9+RSL+^/7"YB3DR&A)UIW5,C*I)NUG,]_Z-PM@IMW0/CJ
MW-%<U+'66\\QCW?OL;_K/&Z4P>XK^7@VKBKD<GO683(J4>T!>2,!<>K#FO63
MVKKOJZ,J4RU?\T^WRQXPYGSAT[XW6KJM473^5=U (C:<J8OP87Q"N,]AQ.":
M;<(3D9D?5V_8-#\J:9EL+PP8*.Y,PA_^P?7@='V<),/FWPM'S428,Y+WIATL
M+NLH3 AA0+5Q1'T"WFW<=/.83V=G_WJV-N@5 ,K0.?QXKT^*,Z^^S.OE4J-G
MQGT>R+67K+S_OD[M#?W:!C?<I%7Z )E1'8&0RIY8>>/QYE%56=DS0TE'K?/L
M7V23@Y.-==X,Y,2D366.OW<4?9]<QKTICW52YNJE.??07-=F%(?]I1Z N>,Y
MKPS\X%=QS[MDY))\G(.X?FU<=DZ@!G<MF"08J6&5DW7R*7QD8+@@-RZ2\Z-,
M#2;U$7;V)?BP6O^X(PY:QI-!L6GS@9MT0.02[U8]Q[$;YY[K%YRYLK_XL$MG
MO'?3MER!^.^R&""/4,0#.DSU,R=/5_3+!H?$60QTG=0\UQ'&=OZ''D8*7++T
M]''BY'GF1",[Y4-!MKOE;\OO.C=RK'!BI6,"GM-;IR3"Z:62G\!J\C[)DPV-
M,< F>E)DCT5:DE+):<H1,V<I'+FYQLZ%DP]K#;Z\/Q=;<*C&>%+6.0QXZ6*[
M,YW4*32,.$!5(2B/XV?'(IE<<#$G9@]Y-%4JM2*%;='LMO-B2/:132V71X"F
M5E-Q;0R@ ";*A3]BRB"@8TCP0Q'?R<FU6O713!URJ+U:ULGHUWX=>O<-0A3N
MQP $U -TV 7P>@]9N16]3T>S:'I5 R)1[N[N/KEP0_&S4]"Y9D"L)ZF)9,4"
M)%'.J$-T/VHSN6=.N)KH3E/HC[S0,/KN@[5UCNB&]./HN\Z*7$#090F?X;%/
M-_0D8:0#Y$,$#$F+G&))5:"X&SUI$+&*MH"=-$VY>+S$=3&:'& 4Q\[^]'SS
M?GY0V J8;#)MV&8]%E7( EQ9P,06#B:@<XR@L(Q1 W.XES8+E??RMID&'=\W
MEF&X2WG[ FGA#+6ZH0>&,F>@/$P9^J44@C^VI>%)^VAP'KJ-=,YMCCR?C'/=
M43C=,/F0_^2^IJJ54]RXI1<Y0'LI3._&GF-B3E*G<5/]YG!MF> Y?&CC*7<6
MP-,HXQI@ZNQ"W',O!1_45,BBRZ=:CX[KW"OGY9(*D@4.0,=I._L'&H7I#J@)
MPSEP!XR/?IT:6<6!,Z>(1%N<SQDDO>+M<O/@'>>8_<JUG[S.H0G9R/Z8O:^^
M>N?1'S^#IN8.YO5//$)]PP)NH)[;7VB@&&2G=X9:]_M.OI'?"7LI%=WU+Q&J
M.\%_E=>F3A*A\73H7H?_8LK":^U0-R(IO"?>]UF]FIM@4]@"-Z2T!^';O,;_
M1 ^P00XSAV "V\H",+PMW80\@REX:#'F^E3;6,"\ENWXG_+HO?(A2M=7K3TS
M"U?&Q TP#D=&\H:5CXP4?;TX]T;CP%TI*][NBT?#FSE"H;HLP 'Z7:2C$<*(
MI@M]I%]@E"./P<&MC6>_Z>-B=)1R*_C;91.^)E<6EBF_=EED2SM4(RP[QRFT
M/9;PYXL>_ $=$YJ@+;.ED2]YMQ4ID#4SH>)_S\(D>\!>/V"PW.A@D&RR8JD,
MM0]H8I]0 X%<I04'BNC:A!">?M,ADLRXFZ/#HQ>MW"S GP^X(]UTIQN@[ T,
MKYVS5'?:33K7$/,@=>@6MM1#V,8DGKTMV/TTS*U:8_9TOP"OWOUW+Q->.<;Q
MO@^.>K:=:7F1W)CY;BWK>(9E?7E9S*$B"Z)0@@GN#O<#?SU!5;Z:",#I+7"^
MB%N>O>OGQKA"R]Z[(:7F(,>WJ/G7$ZT&=,294N%&5Q+7!R\-]LN]:8NG;6GS
M\$!NV)?N^8\1%%4".I2I0@7=HCI3M%N%:_LB"B=%U:4ND(R-K[\PE#E@Q2MV
MU\AYS_$Z*O[+ZT^$GQ7=@!KBS (.6C:AJ/(N[5Y<<"T3I>K(B+9 @VX9%J!8
ME']"7$BJY(OT^WETB6LVZ 0CA07<WWB*+L5'J1]1)D2D,A8_%4V%Y+8AY<>*
MF4.?'@XY96Z9A+TXI,+]SE(1=^!U]"+R,.("-?X]<P8MW'C4% .O11VT7[:^
M)IPVL9V<]RSX]<VA,V@)1!%W2XE(JL'A<J,O)T1!V?+90*C!04SJ7N.>.AC/
M;O"Z6V#+T23G.7QDUA&*^G9Z\-)3Q(5[3QXGFYW0N&F45UC-L\PE*MITY\;/
M.X)LY'XZ'XV@'&K>#$J$LBMO"S:06Q!N8]O&:I-+Y[@*TV9F0$I="^6BS5K]
MR,I1-S3YJGN\<JLO0C!VIX>:C.>R>P6*,M4Y&G2X/?Y=_:&ED%<IX;P=MY/>
M)KNO[DT8U68FCTT;.2I";5K^H0@F"*DV*3I+,VV=0PP^8D?$AZ5KR;&?K/CX
M!^J=0>/]K?@RV/H>H]]S.K9:LHXVC*BQ )!29S5V6$C8#;'VJ5C"6T\D\E58
MV#?N[:ORV?MB_I9_!@$E(,\@0ACUR%/,R:QSC#=01S0?E?WJ$(*3T'!NS;:.
MDH7V.>-9G/[UMN4SE:[XX8C3''Q?2/98FK(KNCH@ZK.[ /-[HS;5__-W]4+4
M]Y[9 I-76:<NJ[SH=M$_$$#JT ZWUT&336#2U+J="&H^Y0D.78F->WQ$#O=[
M2M/;#7JD4N:#K<[U@KQ:NZESVD8R\57/AP]T*9I?M.UOQDLA4 ST'CHIQZ#)
MYICG>!'U1/!*++ELHQT,JC?%]"RNOC"XW>;ADEZ8[Z<AR@+Z%4/?[7SDZ&^%
M)8"K]TS*5.-Q:C]-@6Y$]@J%@-UJ1_HR9SO]-W@J&?W1.N&5Q7*^J %BX&R0
MHR\A4K1X<3MQ/':'$D[<@^<Y6"Q86D<7%*5C3,[9NCG4*+N\H]1PM+;TTJ8:
MVZOD9+;-?>9?Q2YK:$IBJ#) &9AL:AZ)=9A,5+ZSI<$"4#3KK8"0+8;" NRY
MS'46\(R3R<W_^"C^P9]]9-/)A6W\8N\.&B?ERCZ)$*+(,+E;*:VSGYG?42"=
M6[-2$F;#C] 69%R+>S](MQ7OUJK,W_.DYGR658>EYXCV&,/>");WQ[N>N-R*
MKL2L;Q#0B5EB91H^:VF//+=W4H+*:^,G3A'DV(\Y&;"5:)X9;>HUIYV(/48[
M35<5]\27HUH:!Y#]Y1_Z2UJKI;^W([;VJ+_6$19PV..S*&KN*]UP%%5>NHN(
M'W#TJB(-L^WH"N[17,$[IA92]UV_N>XF76IN]%-\$B;(YAF#HXG$LX!ES3WK
M%8JCN_[K*_;[?^O_UO^M_UO_M_YO_=_Z__;ZAZ.I'-C#"?ZQU),WL4=CE-Z+
M PWZ@M?9_@WAQ+U @!BU*$<6$,^\0 E<;R#T@^A7R<IM1]PJT\C]S^E&$R$_
M(I!+NUFWB\7$V;-$BH?U6TB*#*_U*)H\W6F@\?R>3]G#*/+W$)XC@F(?=VYG
M2!UJ;9\O^:;VTMGA4?'<N;ISQQR'3GO;!.$&AZ]SMD./,#E1S7I8!T$*J!DS
M#B,LA>N@R+LW1CW]01S&&'A8X1F$YDZDXNC6._ *G\RFAE1OFM;-2<M!Z /0
M]W/@*%BY<CQ2@ ZG2-K+4)3;8QM,KE-3"JV*V]ZL_N(V*A&^?JDC?^$^9]_=
MI\67$G,_9H.BZ!+D229W#_GRGG>'PX(06K-'O,Q*RD)D6EB T(^?N]4IYD//
MQP5,7"J^O)'O&YG\8GD_?-'C1&,Z(PGU8(,'V04MQT8BV> /J#.&[\9+ZH;%
M=2,W5PW=7#(\S;X-:O-^T;9\.#^GOJ+V;_;RW_*W_"W_ +'%MF-B[86I6@1'
MHI> 6F*C^>G!0>!P2M?3@#@RP"Z;!>PVZ>HC\FDHNBE9:/ZW?2QG]'VW;<T:
MCVL%H)-23"ONWK=>!U0J7,2:FXDU?I+7R#7&9F#AZ#.DQMA/D<??KPSNJJ<,
MG-GXJ8V/Q%?M$44=#^(K'54BZ)!Y;DB9@U#>I#U7[ADS06AWWCEXOXS<6Q[W
MR;4M]]FL=]F(1]3X?#A[,^3X4Y/)@K#6%+[;L-=37NP!(_L)OG#,H/5BM\*B
MD(-Z;*RI]9@%*@ ]) >2?*Q\^+:D]8]"YM*]G!B%L0N7_@G6(O[IY;6?GX>S
MUXF%A19]02/[N\[>GV,XC&7)@-0:M)VI0AX+W1:K-R7V6BMHG^?L5XQ*TTW5
M6WBUPYX"4X>GXZ#"T$=0 6BX#KO+F73"<UF.U;O&W)8Z.NN0+4GG^U(,GQKO
M.95A<M53VZ$G^IXLH"OH[<]2OKR<47.G1W08XT/]+8JR'0N(,*7I3-J:GV@5
MS1_QZ)"^,5"?@QK)WCB&J^*46X12Y=.;+Y,O-TL?'BJFFQ^8*?@\-=U;:(,[
M_TNC\)+2<^2#Z];W;.,$$E))* FLVT8XJ@0=M4B]2W[8!^*#,Q?VV4\9;Q45
M9$7Z-FSM>@POU?&]L,E@9*#N@:3ICRF7D=]80%7?NY @2/:5T1GINM3D(!PY
M([YFTY']1U.=T:Q4ML>%A?&0J_YIFN(;D-B<;1B&KK4M=A*F>,!J\=6N$Z9'
MNGAU9O77!@O@0=PBUS$%P-2[%SCI"GAM6B#M_B1-9OT7?B=1!5'OR"BT)(T$
M85OZQT$[GE0EHC#%I146(2R._'!Y?V/0AYKDHZV</:K:OX+$P"?/RS[&&&',
MA>S5YPNK-/O+@[6*K"[XN.GK[@9N-XYRR^=\,?\''K+\WU,4$JG-E.IF-,=C
M*$F9S_97M=\I&L_K0R"-61:P7K"*"_OA#5*@Z3&'WW"V/)\G]T?NMTY_;GM/
MC\>Q0NY=BI3- ">D9@[BF$V7+QG:7L-.F.QT4JS*2^*X>C_D';-,I\6L:@';
M5KR>.H=!M8AZ@PMY5[&6+6?<?H;(K"TML(##OGU%5RM#$J3\3)E@,B+259J;
MBJ99K^&((FW3-RI07.-IKGH>286.:;R1<]F_\CS/;\3G]C,O,"<M+:O/(KM1
M)2)1"V^"IB:Z,&XW?@39Y#)>,=B4?'&A7#<!?DM=RJ&Y0!P+H,KWQV7,HM;7
MLDVSX=P#J<H?4G:-OH5'/,DW$_*&F#SN\Z';^&)MF#WH,G#+QKAC*WB<*5!!
M\RSWYQ7'//?,D0[I6KT3_.O&4@[[=WZK+?N$0V?>I>7?+%CZO.OU>R (;!S9
M4Q)T.*1*>3=UYK-N_0(3-KB%^M[/Y)HDH,,V+U*@Q+56#'748.M%)Z(G1*5?
M]L/&SQ27POQWM!I:[S9)T&+DM-E[S,F@[_4/9"3NCA0I8'NZ B[J"]Z6;/Z/
MX53/ZS<S$\:#PB]RA/FR%TI4PS;TI/EH/L@!B"HUZ/TR%H  BH$PH4;9OM^H
MB&/0<RO7V9@IG_O.!K3O<XZ\.#5[[ZR%T"*:K(\56KW!;#)L8VI1E*9IWZGI
M=Y-WKS?6!#DY)5PK%_8UGA48K4_<\63D,<]3%>8XXZ%NV$0LV1R<4+N46'_7
M9T>;2ZW_0)VUZP5)CU=J-,=C%O/T3<C(#/5\GXD)"]CO0\T@FH.1G?;RC(Q'
MR$/PVO$SBO3+@>YSVIF:GDDZF[4=BH./MKP/?U%(2*K. SR97;!RJ6JZ8"LA
MX1WM 7(8S4MW]=*Q*<(GLJ]8BT0OE5:1^]#[-[QXJQ-4*[JE-7O.WIN\>#2Y
M;1M<[D)*H<C-XM?S*/A6O%B]H5P,X@Y-]^%$9(9[X:KL:_4,;PP#+4MZFQ9X
MLW!<J>*4;)4QB07,QHI/)Q3LM91(ED9[SMJZW7I89?V,,S+2>;@8YLZ#<\QU
M9+R#J:PUB@\S9>E_XN'#X+B6 ?7V^+'HG.KJ-WRI2155:39%[_U;>,VT>5W9
MAYF'64#S>750(KX<DD331URELH Y"@7=<6%_,",QEH2XX[//35.$+YI41*R.
M?^;.S1%_%V!2;X:[P@+_'.C,'$2>9'R&.H&.T*]2UMB))BXU@_4&JV&(GCJW
MPP]L>=@>\W7J 1R^0)/0*+*S4?F;>N+W#0(V+GO8P4Z'KCWX(2W F_^$B?SN
M#]VJU'LAW.BK9"SUV \T''K_KHZE>AW.@PB56KN0AF[PJ14XUY[$ O9%X AZ
M8(=_B42X/>(P>C*>(S%(4%%BZ1RNAD]/>+D050K',\,#8-3#J([$_^EWJ(;\
MW[J_=7_K_M;]K?M;]]?U1VJBY6B]3*XY$<Q/Q9J6EU69#MF:L[$9YG_1!213
MFMY/Q-1]-WU?W)=FS"_KML>LLM,>G >"W_S:F(.1;A108RWWJ(\E#:JO1&+T
MO'(>\;#TD:MM_KUXJPE(8A!ZJ.G$Q [P1(9]"@'3ZIPL):CYV[D_?4$!A\:J
M'B:9U<0Y5;_3X;&< Y$._#F!B:<DHPEU^,?V!C]"KS;NQ'R6 <4YZZD%Y\+2
M_DM8E=E228'YTS6%,_EE+6X\Y1L+X"UFEM7#\U]G:M\]L_9'C2WZ6[^%<4 =
M^KGSV\T3K=\&X^+.M!J_=[UN)/NB9TP>=!,T\[KQ#E/RK2=E@X.NS'B/FLUO
MU(DE&K;'&Z!XZ)"R&@?'P\#SG?#(A!$)AE.4J-MW7AY#[2N.V7\BE[UBH>!Z
M,Z@K9I+3(NM)[-)=4H64N?<;0C FJR#QY%'(ND)XPL$;F]43XL@(8OSQ%BGE
MJPU#'D4>.59%)-)Z@"&_?,OGCP0]=H GE418=O#MMN_AJ5QE 47XU]LOLCB/
MYJU[!Z3:ET\KR^\B4>1N: 266X>-#&NNFME']2!TJO5J#/L(7E92F'U@++KY
MPZ>'W]RLB7NY +QNK\D"LJ?3F>Q@2N[_?/')HSH [O=VU;C;C/3SWQD322?;
MA1)WE"58P#?/'A; ED@=^%=7WSC^T?J1HM-'D&*2:R+D:WG(BX(V1FILP?\O
M8J_0#-%&G&24L !7T'/QJ+ *<+P*0HGJX7I<?P1Q6H<%\+FWYQBD/^K;YS90
M4'[\)5Y&-%92(4Q/>JR(6M[2*"[?*$/10.>_AH[$3@['!@[YB!6DI:>E[W0%
M.?A+DCN_)%C9GBOYN=_;?9ZDS3R82F.K,PZ9P^ZGIK3_?DF?6I.6I61NV7[]
M3OOQS9@_!?]C.( %D(WZH[!<RC9M+* T$;<!1IP<O5/=+A59,I&0KK)=4_Y%
MCG1H*#)%NB,4\B6G!CJ^B)J08?)&;V,F'K:V8LDO5B9B)R\7P.U=-&H;/B9H
M)&QTO^"H#E!<IO#KN?:<FNCF#-([$.2UCOKK3-H+U M8COIC1'>&=:^_>P$E
M\--QQ;JED/4:/0ZV%?L\?0!12<103V;EOZ=NM#6>9KQB >Y@<<3I(80;8K=1
MGCP3?EA3.'G:2$5QI^6:^OO$X3+^BQUG]WW< 8VO[5A3+]/4$7Q1L^!0-4/T
ME7'-G8S50KF,VVD.T8M?[@-)\Y+2P,2^4$% 5S@&H/[VHLI.SZ02UEA .(P'
M^VCC^8PD]<9GVZMC*-"C":[]U[O;\ZJ>_M!SBA'NV??J4:1VM?!]9![5A8QO
M1G$RP2O@0TRI99^56ND(!ZFL#&<^64/^PX=3>E3FTV339).-94<7_N\>?OS/
M(T&)N/Z)/R&*'"2P<>GF3RGDE:\:W"Q 44Q2IRUD8$IY!M*T6(IYGAOY8?5V
M@%%,ZK&K.H,!AN84<^)2.)*7BEC+4L"VGC\^V'W\\)@B-$)DZ(,563LK=:LW
M*X4"VVFG<%&48S!F4;-K7&)AT\\=;PR?7.>2[0@T@ML'>^>]@;6FCRG^P+HI
M3[*WX\??"!X\8:7LI%+1-7)=?H%WV^J;ER]<<OX7*)&IB=@;[D^?P4OH;(S7
M"'6YJ'IVERKM<:--1U>VICU>SG?^E\?0B=*^=41CB.1)!:UT72_?F)617]A-
M%A"ET;-9:.$[;=QX564:.[9MP (ZL)/JC^9C=VXS0M6XBC?.Y&F,062&<O&*
MFXZ@G0"F3&B@K28WVZE0]D1S1MP>S\O,DJ(JJ$$%F>?J+[" >&<O76&#+8_M
M+JZ^V]6_Q\N[7FY# S_\B0QRV8%2831%N/LZ4K12Y/?"\$5_&._TE?V[G)^N
M2/ZZX9+#_EU8T<!]5&':+_\JNBR[2#"8^K8E4CJ\Y9Z($J2,=O/G>CV6\#1&
MOA D^!]>DYG#)@XPOZ&KY$COBI'=X",H5]- 0E0X4AK^H/4F1>,30>O:A0\%
M(4^^O(L^:6&1<"+>U]OGQ62XIQWZOF4OM *W'D'3>P@&%V$?LH#O_7/"*028
MZ)1KZ?+,J4&$B=/0RIOIMY[VFB$QO9*?WG)P^^X+O76DGKU/;0^ *JKI MI$
ML]19S,08,6^W#14..5EOHRM##,CG8GXC3\^%=/IS](A$?V',J4H?VE=WS7\"
M7D<$Q68PN6FS:/:5+,WAQ,@-))<=K"NW^9/QCD0T<_+LW:\7ZZM#L@&J'. 7
M\UN5Z-4*94<XD3D*R%BB993'3X]#-N7N'@8M"\B[O+O[?0L/'BX\Z'Q/E%=/
MG<("UJOWZ#B!D0U]@)GT,J F%B#L$CN@/ BMV8)ISA;?53_2\':=87IO9)_^
M>#2?V#PW(5'20T](CW.RXG]YU,9_8^$'NM1MK$;5,*"5E#7KF7='\O(JG)=J
M,EMRY'\88]XTRB(>4R-H!M1HIB#B4$E-[+44A:"0KQXZ0<V!7K^<1:IG/*.*
M)X@=CI_N$3&%60,VY=PC!'WW@B=G"E<@%Y@C6Q<_HB/1^WE7K=LV@_@?:@S\
M*A#(TKC$@<#M 4.J]%+^@<]6=#E&(D(#*X9RR[1Z.'.Z7DDCD5"S*&"J.!TH
MB<X,@ZK%;QY;^5*U!"96XQ+#42601.5G=-ZT1D4J>F]<18L^D-+T7J9J79RZ
MPK,[6WK=HO2O%%'?M8F&I$-$"LV .3$1_[.YP?E-?^O8HYONJ:N-OG%!O(F$
M".^0@ 0QAW.UJ1]*@\)9P.%@Y2TD:O"GMYBBK;"V*J*$IK)*3V:@"&,J!&@4
MN )-%^+$)2'TJ&B49A1$VFJJ^ON[4#[>Z]Z.518LP.[4\E!)DY;4,_]=RQ;T
M,S2HD8MZ;K()=@2AQ9.1;W-X/<YY$7&X2R;+KD_+L?_B-S:;6L^,?-<)A+A9
MDL.1HJ(*$Z'*RHJ+,M&"#G=N>V?S %*G@W^>'O57LS[Q;0S\>KCCA)E"\MN
MF/'@7:2#OJ"%W*O_G?<L%$LYB1*>H%\8^X%@Y^XJQN5,:\1* )?MGENU'-21
M;)RIK+1"\V_H6.8CM"@<[V:U+T*^<$0'GHQG,VTQJ8R(4P@?.R-X/Q3"R?B3
M[.DUNJR:9$/37D9+(37AN [I,Y2J+TO&1%H/1GC*4.E#=EEMST/*IR,2!@:#
M8$6?++9]C:F,M]C9-["R_G4,10IYFGY\P+]3/:(T[9OQ1W@,<1%Z^IJGA.Q]
MU<V$)Y8]Z%)E.O_<SD/&YT; #5J1W@Z.16J/(=R(HV_6.C1'D7*;XKJ7>QV4
MZI_+*$J)WHN27<IB T*T:.JH9E46X((=MR1:TRVH[AAXQ]PM&RZ/_<%+SR=6
M06=,ZQ):PA=_&?# LT'O7/\)%M+_/UNPGT=%8ZNP;3T;PK8X\B;SB.;5ZLSD
M20V?GA,MX?$_G#C%UB(ZV#K,K7<3$V 5FL^0W"N1"NDVT_==MUSRKE"]7%ZP
M@'U/?NJ&S2?VHB68 ];2B43MC".J>IHV<@ZJ^M!T<8V@VYWW]5;Z\Y&5A =>
MX-C/)53AJ=2I0I)'46!>[8H?Y[.O?J=G6ME%3BG9O;$@!4R8;$ ^#:J#XU!5
M!L6U#QJ*)U8FA.,E?1\FMS3:JCB!9P25TE]$/'**L 77X9]36VGWQJD>0SMW
M&:';QI5';OZ&E</@'[JA&D]>>U\.R0S]]7Q)]>UQX.H]!UP2_?P(RM5KHHJX
M,6O9%,NU31*X <^CJ,\9W505GU>><+9/BFL\;ILN2_[.AOS)2,4Z8B)80!DV
MDME/Z''XZ#YVX\ (0M^?5\!\*H<'\;%\@&T)*+W/AC%7Z$GC>(.)M1W):Y@F
M39)UUX5M(KM.%1KH^A&EOS60)C/HV+S%/1\\GRY0<)&JY0-J]XK'\&#G[L)(
M?#B%H-'?CYXM>2LQ:Q%O7X, QHS!UD\I04N/JRF?%+K>6M4_D)&Z.USX@P4<
MF$^_LC=C+W;_[YIR(1NK(<?1QQE%Q]U?OS,I<(GX4)7B]%SL:IH%4UBL4S?^
M;B$L&B(VC' CK\'( 4F?,PXUV.C7EE4V[E^<,79PNGM^:4$1)/V2[5<^$1J&
M)>NC(IF:(QZ5T,DEG,7OJ?0$_]@&S8Z4*9VA^8USYEZN+09]OH$";\?*D4UO
MS.D";_KGZ'[(K[#*W00==V+B^I,7M2>Q&+LIFPQ4RM<4IZJ!XH5?WH$N69$U
M^.]^<S@Z/VT6UZ2D/.N%.P^1=D5JDU^FK,R<-74Q>$J>AAFJ%J9SP4MK;65^
MWBR^&G=&Q%-A!3N^-K=$%^@A*K?IDY?6AXC*@!W\U;C)Z79"[W%Y3T0$[E6@
MXM6 S2]BV]F@P)Q_@BS7__<E875UM&/"9'+R%2%25EFQK.:./KML,AS@V7ZT
M/Y6(K> DV3C/?L$WH0[?\8?R=C)->OF#DB:TSD\ +.#N&?C$><YB\QY;7#M^
MXE8[6LA_@WH;73Y2V89W/:D=?Q.P,(XRV.S"I8MN'&O>;IHGP2T)N!;E[Y,$
MQE@'-$Y\H3Y]IV319M2N1=.A3;@S*$CB0W 6<G6Q/HA8,+=ZX;QNE1]#9IH%
MV+O(Z3YR-G>.7,MC ?K3;W%12+X_!Y)&*:/<E"?68#<=6("1AB9F4> 8[1V.
M7IF:L*_MO-36 $IMXS%M<NVUOQ*D8]/][H:4TE(R_[7XMQ&R3B+-^T/-K7_/
MF0TA_V0$OM.HBG)_2/(CL(#(B0,#MV]K68G0HK-.U/IWV*3&@:\I,#;(:X2Q
M<(@ 50/7! &^O1NJ*((HI>U\2^Q]E77WU7R:EFRRZ9/OBA"P7%[7@2#=/8AK
M7)J8/>U -8O-]PPN+T_&MKI/_.BW0Q5CU5#-<I#]>U[ +?)0&T2-\B/)[P-8
M<-JZ*C/?WN#FC?V'SIQTTBG>.@5(\O-*/Q/XF2IX^_;'U=ZNGSJ' \[ UVT+
M>N_V,,60;']VZL+^4]$E+* ]_O26+?4NT4[ ?&S(N*:>S)CG?9AL7/IH>M;_
M;BSJX*7++E4*V9B#U'&:!U5D)X0:'S*K//&$T%A*P'/@G[_[UGBTR\EKV^Z*
M,7?0"SO1.V_Z+LH8BQK?+LCQFF)K G[!F%P42@:32W46/YY_F2S27N 54>L5
MKZ:6W-_N2XVZ6E&;O$.2O3?&-UUVP;9M[G!<0K=@A&B'PFKB^!JQGRZ0VP'C
M'3-@O/KI%7D+_G;\ZFJ6X)#'_3K:>=SK+7WQJAE+F?,K=Y$"5.<]-_TU9>9-
M+?8I4X+9;YU7?G)# W?YVP+@J$,R?YDP.YOP,Q5#]]UC?69,7/ 7BE=45(O=
MH;9+JE[[I=F^*3X8R9O1V[RC*',N=)XMLB4E+DN>?95;(9R1A3P#Q\UY/96C
M[,8T'G:WYZRJ&;9[+*79EGP</VWU?.Z4OPX7NJQ<ZT60H@D0%OVK1+L;D,>H
M4-=H+L@>6+E!OGL.PI<ZG0,/9FZJG&A$^ZD:>SO*[;LL>+7OH]%1+38SD([X
M.D2<?H/J1TEL$9Z!4._,>:BVB:O/Z#?FO9]1'% !!_GF1W(^S=\O?5"0K4$_
M2*X#/(G=XX7L<R>H090G<\RPG+5'@ET?3+6-%=DB;W?+6&SZ'I1!3CT%7;;/
M(&#YJ8$=U@?0,?4RQ>.K;QZ\\RS_OGHAI+OW0-NU<\4)SPI.21T\GWUHV#(.
MGL[D/D;C@T.).F@NA GM&MRZWSYR:7U7N R/_,$5-N&8['WX1HF.D,M^:1Z%
M\?MIIXAW9Y/LI"[+Y#J=U3VHVPY<^*^.E/F'B\(+*I92T(SE>*Q,,N>;#DJ_
M^8G&DW$(I$%HP-;FUDES?FG2&BDPBY-<7$\Z]])!VDU;QJ^=>8X\%EK!1?_7
M,3F&%H[?>4P10T1S"80EHQ1AQCQ"EGI?"XL@+7 L&AL?JOXK)D>Z@'<.4C,E
MT@K93RVB.< S==PI^S;M5%MYC?0+;^P3+ XR$F00?2)?+J%M/:3'YQ(E$%*,
M% B_"?&(Q^R@FJFZ1K/'P:_5M_C:7+F^EC5J9[4E [)!7/?]HN_:JZ$VW5C
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MBY?PQ^9Y9&\>.OR";?WEGE.(&/E$!S-2H??!(@@#1CG4%0TV#/*9B_=5]<'
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M;1N_SVVK(D#XK/;IJV%?*JOZ'X4MF@\GA76VA- (_3RN$-YO13HJA)#CAXY
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MXB3Y47)W.JC-LR&0K;G$%AKF"-Q3RM"_T&<Y4-B[Q_M&E9=JN2KONYUMR<K
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M;V+\(RT1G: YF=,D#*M,H?&),6/^!" \+J@'%AJ3NJ]?&EUO\LQ?Z<< #@1
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M2GS,M'6K=UU==4UF&B3Z%>30'^D%7M.K<]7_W!().<*WB.!ARAGXV,@,X95
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M.YI?@OJG5OS/=MV=4S2,<BQIBZ)"RG_9H,_Y:H? W5-$3S:4*RFH/-DA+%R
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MNYL)Z,;+#;>,YO<Y$MO_2#P.RI6&$:MZJ: OFL!QE=E;88RCM7\ZE*Q$+=@
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MN%>Y%1%+OU*58L0MC%1+Y-2^=4J+#[C,J:Y8T/49]RFV*TIT8P::^9YE#)$
M\1X@,?_2H6<%)Z[VWU.W"):+G?YIP/4\TTE3???U<<-=-N2=L+^7AL'F:F 7
MI:4)L[_>B%+0RM*MJJ)"DU*^4>929Y-'&JQL7!-C^&Z]WV5OP'?5CE1EBFPP
M0._R\Z/T;VQ2I7]JV<9-.$_1SD7,&CZ^/K8>[G%]:B)\(C<8_K*3;H@\#2JQ
M@=V7F'GU_M1><LQ6FFDP6:W>U@!7;+<G^GO_M0$?X<MCS7RK1$<#1X?6U?$W
M3TY WVQ^7\+)F8LB;I!JXBB&[M2I%%Q2O9V?64_"*]V,H)"]:FO*44!HT:49
M(T_=BJA.WF)4/QJ*Y*,?0\H/-^@A;>J\!S:2(OLG+!_JK[3(5[A9X=J44YU.
M;'4V\J1%H:081T'<JS_;0C1P(X.8^0%O%4S [+=@ELNPGO]\9Y]_EOTG>P>#
MH_?#=>2,%MU?&"D% ZB<_K];7J1/#2#SM<"B6+N^@AAJ1+M!CL3#PF7)^RE$
M_R+WYH-1KRIUK@.[>7(W/F3BCN$('Z&5-U:XL$@!:L>*--T"><]M2OT$5>XH
MXS@%&G?UZ.BE<0=D^=ONB:,_MFSX#E ?7?<OO;@"0-\%G<ZPJK0:<SG[/=("
M*\YI,(0"-E!>$T/E8DG=PE?SQ2@.*WTV6+<::6T2>[6BM@6$JUD0HLD\^X,2
MEQN,09=VEC$SI]Z=@(W-R1IE6)> 1W9Z+;^LU^..K+K9GGJ!IB"7<8:4S15X
M+DX(Y\<1?&DM>/#0U-;R6RJD<;@":57==V<CTJ6IHZ5,OYOV*:R]UAX1W[=^
MV%4";GCOV@GXEU=1J&)K#1=A#<KI#ZFOG_1_E%)XI$!ZZ6'"!G@8()JJ380O
MPRE+1#;01L<:MLK<B/-*I:+Z#OT^6Z=W=.V\97A@5=",B/D9?BG]Y8O_NIAA
M5$-2;0L\FK7_$W6K+4WN5YY"?]DIUVKYR]1K\3KT(D%H=IJ/M&JY?I]+ JL?
M71'[D.Z O <&475)AHG#:RTPR*K6*KXQZ_[9G!'GNDRSBF[U;( YP'.U-%5H
MV(.[&KC%V,_\C/9.&X>U:A.AT3@%/<U@YU-C[5EBV'VM\?65RL%']**$[,Z>
MD,O9O ]>8 DDY#/,OX K% AQOI$-0"XU45-82J-XWXR%FD[Y[KPD"390];4I
MV=MM1OW:)W6Q4<)QV G4*)0'YPL=%Y*7)&*: U+/(@2;MCKO-I@-;M"O1WK.
M*<WN*5O&KS9+A3?-?+OV^^I1C3?<_2@I),<U4/-[G0=1$HB> ;?:ONJQ#?_S
MI*Z@4P&O]_C$!0%&9W^M:UV<C_9[ATV"$6*GI0>0DG0CA@TE--7;X+YC^]2=
M[X,_Z)BNQ.E.R:#&SN;D7)?Q>W^S7,YY6#, >^]%B:;V.;K\C^&>S!'4V8QO
MCXL%Z'9<-;ER-W(]HTPS2%B&F!)- U0EVYG+,\XP\QDF[_P"[6:G?)O#7JY@
MZ)7A1YHE:'??7/]JW\0Z1LEJU=X[AAAHS#M4/GPOQ498,[;PG;LRY8HB^:ZQ
MB)2W<-/B'JP(,QOMB7^ J8A;7B]">'5LW5>-?W.]8; ^@(P6]A6VVGD>KOSD
MS>=C5<^MXA\IYF*_=S==Q^:A"7D>1AE$R>4+="MD),7IY7 VA0050V2X@DX^
M]Z1WN5H+/OWM]/GBC4MD;OH"^8,=L'-YGB7@2-\]-MGI&TQW0>@H)WP_%>=\
MI80[&F:\"8]#"]<+4@.::N#[63*(=[UN?9LJH>5#>MMA+<==;HZ6A+64: _*
M,)J9*:CCK';T;C;@A>=SH-JS^,DDG/28ZR5[PT266FVSK-O$GKE,DIVL89A4
M^'E-TD'\O?"K6JOJ&P4$+1S%JPV^1P\JPNK56?A%Z*+#8"<==G5JECD;A&I(
M*#L)U_RF/RY2W.+EJCPA'_DWOEJ.#;3B$_'[4(+@27('7L(T^!TBPJ9:\?I@
MB%];[(&.U5<:J.MF3[WS&D>$*9:T66;Z'QJT'_<()<! ]%5WNRK=D+EROMY0
MY.#O'T]^%/T$C%0L@+M^ZK0D9K(>=-R/7-B2EH 1KG>N14F#Z*"P4!9/W<]'
MPU^J)RM64GVO?.-;?:ZTVSLP]"-%OJ011BC*T6Y9PJ;B 98"$D+93(9*X4EF
M*;1L\Z3;3R;'%BH"Z/:34NW6#2=K9*,K'%*YH[DV1]JQXQ "9GF>^)0:UP%)
MR'&,K=I^^[ML;G UM+KU>>>I/I_9JT:*%@>"+[)VHP9AE?,KNF\GEZ!<+(T%
MEDIBYU./CFM&HFYW>@:4STA8\?'M?LK],)DPTLD&:O.PA( H-D YAXV%54-6
M[-]9HRD?M?DF;X[[_Z"15LU$W=;?/IXR*YI<W>LOLQV?;"& 4*NVI$52:YMQ
MXP4L@<H ^@E6NT%?X4-30\+A#380GW>@IM) V"_L@K1I_".A8N72LIF*9X_1
M1>V!19>XU[[_>\PA T=8 G8A?I0;M#)F+LP/*V)42^F(-;U0M)"G.C@)U6HV
MLYGR3/3=0Z_X<$BCX\&#R2C4]])>:5"]&2J,U(X@8!1 SQ;7_DVUOUQVKA?>
MJK0(S.X9MN51.&'>RCUXEJ\#3KD$@8(P,JP1)\#JQ.RM=RU<\C@"OB:;:4V<
M'M@H:?T44NF*'-.6O69RS;UX/>^HW4*I[7BYI7P5?X  4>E$D1D@)3Z+X\%Y
M0L8,:7>IRBP=4)VB>K(OQ)=\<^)\M$3Z/1OZMS1U79O"+Z^!+:S3WR]@_[R6
M=-DQK7HM)D^YCR7N-SSNDK"FI_[)U*1X>I=G50/"]6HVI32T-.82HZQQX;Z+
MI36 "H:,P5D"(70M5'O>41#^!L03(D!G?(M,-SY^WM[?V=WQO,C$]ZT+53U1
M=H%+CZ7+>?<'O@=H$%#)(6M%/("N"-Z:)[VK(-HQH%H/;R/Y _);C/%-4IGH
MXQ[2O.V>H?YC>2EY0YNAN%<+TT?ZL$@=DJ:!>C?L?%7Z,*LG9#*CY>!3Q&C8
MWC?19OLN4K0?F,I3NIH-%':!:&*7NY+-@.+O>TR#[V9/W#K20XN6CSG.GY 9
M_#>.: G"5VFW237L8?!1L]JEO6S-I2EMM$(YQY^NB@^F1%D\32Y4K#"''IY
MJJ)C\>4CL4B'DKKN#XC?OHP+6(^NKLGN4'I!J)G=;PEHA^K72$ER  ]H3[)]
MM,80).,@$[>^F!??N3IX;^G;EG60]&*RR<,+"'B+ I3B$EO%!O@0CJ<>.OZL
M>B%5NC$A>'%"ODKXP"FRQ9C31<!L-^"1GZ@&_(UQ:W? ?BLO06D"G]A OS_\
M&(<OB:!G97 0-K!$OL0&!LJF(EU"_ ,B_%5>3JHK7[ Y?VG4^]B3: CQ$F:?
MN23###0D=#G&H05-%;U>WPSEM;SQ]E??=F"S]Y,WD2436LL=DSG =@!+X"4;
M4/&BN;.!RNA^W,8MEU&G7L0\T; E("%K1Z&8S"&/H[=&%&2&"H;T^+%7A88E
MGSP^CV #7P@/'KKO^]O2%J>NK02Q@<-7F9GHI:XV],Z=6W2!SVO[D8= ?Q)6
MX29<S-264"?8NQ_TN>'.?2D/&!CE'_#.-V#)+S5MBG&M=ZS,_CF,GA/!^=K1
M<9C]#;R(WD:[?%#$=O :92TU9F+"H63V49B_?/V-'SJ'!A3F9-V"N#,P.>;'
M;V(HYT$<H0##XV_J188_$D&P'$0]S"%UY1\'>;/V'NP)J$IZZ[,N*+7U:%2G
M3IJ$<US*&VX011I0H:UFDJ3V.LYC847 4&EBWV;Q*UY2YZ&3Z:7^#,5G\>:O
M^GAKXP:N./"VF3IJ5BZ>[%$L^OK\FJ!C57@,=W!E:%!>4/+0E[]I=PW6'%S-
MHK\?K^<4\35W539@3\1^*,& &$H)L;<=PW<%:0Z6$2;VH:WJT@T_#^BK63W^
M]HW8]\PLL%%X58W[&YI00$7:O6#Q+U'%S47U^X9Q1+'SN&N].?Z6[7>:5^9A
MU]=W@J^$+6^6<A!B,L>Y6\A"N8<[*(\$&O8]0F1.;Z]LE74\QOF*8O%TE^PZ
M5HYDD\?ID:%BL:!V12LN\="8#N"^2_PBCN* 'C5QHU8B3P[!?##\]L7U<[Z0
M48&)3D4CC6%"_*6,SN]R,_-E0""&8KT&7H)2&CVDS(_[D6\'K.&(DJR?O;EZ
M&+.&WMSUVK7EE<H[^"S_2)=SXZ[COK0GERY=[N#9;U/1LE=-7,E:2N!5(
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MG )=AA AW)?!T-_VV'WC4[[#*-WT:V^F;CW^M8,>RYS_WI5[YVK475=J7PY
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M^X;>OW(*<R//).:Q[F>EP&MS<E?)#SS><L1.,X<C<E5ICT<0'.-9W&"66]W
M;:3MS<=7X)?>9WL*'CDE$,=S0XU/Z6O8O;.\DLUK7*,,#? &$1]K[+Y<:S M
MUU>F5Q?Q(HHGO2- P.K#*#EH#W^'M'X;JA/^$1?#81KPN!UL"YX?S&$#3K5#
M]>?"R[K,\^,_I$\N3TF- N,&>\/FOIY.!+9Q)!Q#M'G?#?*9$DX [X%501/-
M14%L:]!!Q&L&;*^A@7&E6G.W9FG+M2QL#^3\&4-=W3NL;DSYC19T5)BY.C4@
MT=2U#$%O5S!YN,S2I@8D'7+5TO:GK="/'8FJL*SEOMH3^"KWX.XM8S7NF5Z
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M3/8?^\?^L7_LOZ!QL<?^&U!+ P04    " !%BU=6TKRO1;[2   _-P$ %0
M &%R=FXM,C R,C$R,S%?9S$Q+FIP9^R\!U"3W[LN^M&E"](1H@*" B)= 0F*
M-/D! E*D12G2I"@B06)"D=X$%:1&0$1%0:1)#1":(")=0@DA B)$$DO\).W&
M??:]_SUW[IRYYYR9L^^>Z\J\F959*\GSKF^][_L\*X7UD;4"[#UG:6,)<'!R
M )?8-X#U%1 Y[1_A&P $ .S&P5H S %.CC_MSSWGG\;-]>>>AYN;BYN7AY?W
MWXR/?P_;^'AY]PCNX1?XT]@](4$!H3\/_KS(?WLJ)P\7%X\ 'R^?P/]P8_4
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M]<#%BO/" P_59$_4E^K!P",HDB;%RHZM#GY1;[.YV!60V-\M=%=6HYGAV5^
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M1_-BV**PW;Z0^]7'^:X-;,D=UP(W@3EI\7NCN@TQ=W?O]0"B#>P=^2[X*A,
MH50<V%7' GH=F,+PDO[BYE_I\]W2^&4PA.8RN39A:'VIM3F'!S[*_>T7KQ.'
M$+\P)B:4)KKI\0Y&OK C ?_EP"B(=DAF"E#X^@Z*)OY80 N_3-03\\'%^V=(
M?B.MW\6:E-M>[N-1OL[/X*Z,AQI# R/8A+B^'PJJM [M).%BDJ(%(_:&EIM2
MA'8-2IYZ-'<6EMB]:+@CSI%W,.MYZY+RS]K="-*682[T\BSC 8*#9D2W; .?
MFLJWID2+BB[!78,.3!WVW!>JO_A]F%/Y*)<U']ZOV2!Q$9GH: 8IA4HQ11!.
M%#?Z7GDLD^L#@J-V,11WL[!F<2GHVN:WVPU^F8Y+![]=PQR]TR8S?-XAI)46
MB[@$PTT1-GHQF12$'I@:2S;"#TH[TCW(2]UYUR*0B :^>1S<-XP47O/^]WVB
M:J+,$^A9]FJ^'5](G*/>!!_0](_]^4SG*R.U^:0>0]?K%89BF',5J3#J[[2D
MO*=@PL8D-"I:R48YX($YMX4&_"3$%1'*Y@9IT>.@.JPG=_^FHN+T,;U0%&=H
MXH9+QHAY!$?^\NV,;V&XY-?'91*C8)X39I##R"E328IE-3L?7V24F#C7P,.9
MQ'^FFG(ECE4\[;VRP_/LMI'+:>7XL#/]\89B^9%'4%>U!, J-S8%R6..EA^:
M1!BBHFLV[\%+O[A1J>%D7,3K--7B+P)#;Q)Y5W6L)'\^D. @;_2AXTV5P0::
M#7,!+=(\=HAF^XKRM:QJL]V^/B;@T&EUFQJ?@?7!?E]'^?9[K2=6%)O=J)Z,
MSG 6$# >[Z&U74/9H2+ ) A;6'"SM<;']L#4&Q&"X]&0--?]U4T%K7N>Z&25
MNQ^S!A(M";";;*^*T9S0 -%L3%,N73QN=;P7(P:W)%I09E]2#)UGMIN6+)4X
M1V,E9EMY];7BG<[D6[X.O.*N\)%[,A@BSP(NA:D2-'P4V9=:_'O$H'K8<4^;
M%5'0F:-XR_D"_X/[YJW#P<<7&C&7"38]T.K[Y_G&ND7!LA?(?@S980N6B6=7
MPD!-K;/3>ATN77-T?G*ME?NEUZ&9=T6&B\\\JC3J'.N,=SW##^S[P9>$L LF
M.NP)]M%^U9JOIA]F(/C1MT1^0B7;2_U2WET9KHRWX 2YRA(DDK%NH.VJ783S
MJ\F?"]="G[]][*7A/!;B'CM+F_<,.9=0>1T(RS>8=4Y1D"JK^;@IAY!S+0JY
MZ^G1U^")E>D;S !<N%X!'&80-K1>;U2(:#9,=)6,WR:1 ['=>BVM%*?;58/=
MVF14:D!7Q]2-QH-9V-"FYYGI!F_?WCCZ_+@E8S2;ILE<1+\VW!Y;L=-=J>^%
M?L02ZQ[XSNUIE6Z%B4J,Q45^4O=:LMM86Z04?'YTV>R\Q&VB!8 (I-F(2B('
MV=SFO#QT(9,I^;6MG@ZEI";RI71&&Z;>H':\F0CW+?)/I! <BBK5]P=9;Z8R
M#V7,=RM0["O8.U*&T<'<3P\@\R68G/8C-ZZL%53$0=)^,@[;2L[^#'TSJ9^Q
MI,)1YO>->+W_6D.O8)O@[2X+0/);('T?M*];C8P?R,5Y[/3[R&->93J!F\^]
M-B=]YCMMHP6MP0*='C[S^<(#<[,WSO.]19/M,>Q-C<4WU9.@3[>8\IB&UFGF
MD?0?\SL:R\H=F?OH%%U V<=*/6\L$B-HHKZ:+3B ;O5IJ&,'R_NI"SD7]19J
M.PQSC)N\=4"I](<<!V1EU>_JJ'_%;9AJP]F*=Q7:!Y5$F$Q^K4C<\B&O4<O"
M3@TBWGPJ7UIUO<IY,[&GE/.:&60/L@=#=JH7H(LRTA'2Y.^K.[WU$,C>X%U=
M"X*U'E30(58TG41_:Y(4JG?IT54D:688-^R $,)(,=^AY1'[V*$1#T[4TL^0
M]5?AWU=K,H<R]46%W!<Z?TG!@F<TBL)&#FAX.QGDI>AT#)\X:D;SI!X#95<A
M\U54;W),3[WD%ZK;;F[*C]F6]LZI7[]U&@JL1B)<KE[N^23RX L[A+4&Q^=;
M^]$-L]GD>NHF(Y<I;:/PZP[]Y.4JNC79(-5_9/=K[M&A=</[55&+5DI2&J=]
M;QK[GSU-0_>6:TPB8@B:AH/%>]](W7J9Y>8Z&G/UP\BS0RD"E#?"\EDKM<"%
M1-%#3>S,E]M]!+0=B(&1/<93D+HMY,&*P[EAY!2J8+:K\1'A)J>BB.'L:JZ0
MAD7,D9.?;LU]U&,G9A/VGK9F![L<<@JS1Z\,MK)<(YS;#P7@&?A^Y)ZV-Y'/
M5*;Y#B\])%>0'^\;!(EO!=_,H<$XIB#/RKC YP9X#/4^H\14%30?<IWX[9&:
M&M9Y4/-=C&["VZ;[Q\4MAQYHYG2Y(X:V0]2XV*)A/I60.Q2!&Z6..X!JJB0^
M<C<+Z.F&D-\G'[M'KN_%39*F#484 KK;<ID7=95?9S_FC*G3:4A%(<E6)#LV
M^9%'3B./,QX0R<<Z_)Z!YM;-T_ZS6B\G-)KW7'$?-B!U1)&"!?;%&RH)47RJ
MO7)3NX7@@5@6((,PIPPT*UC2O"@B98$U4MUE'IJF(PMQ*LWMS^OZ@_T+7#4N
M%GV"&GQX_DA>T92<G-H/X=SRX9Q1\6^>_5%29KKVP?]%U-F)!D70#R;*'(8U
M5^.W1=ER@ZK'>-HM#%]#7%P9K>UP$+8CU MZA4@M'VV._53 UY2OW=3PW2#,
M]]'EZ^;A+C1<!D"?8.0Q)>#?J3.,+!80PJ96<NM9[9",3A@EPJ4M[.BZ8\NH
MLV5KNZW;M<&9<I6L5A/.V'I[,(H=RH=F];3FOV)7CM703B+.P+)WW5+OG77@
M90%]ZM 'IWY$ICEMD4Y\RY^^JQ*H^:UN.QS0IHY_K**Z4U#;;Y_273HI@6E-
M2Z<1<10K)XIIJ1[Q<!CIJ_41B9(9%%S[_6+NF= E-:YU+5 I-:73BB *JCK$
MFYQ:'1==WHPAV]3&4HVRJWKUXIH]6[R'5XZ/W+6T.I"TW%WV[UI1O02\1ZYA
MA^B+,+8ND38W'@H^DB_&O;;']WA43J>;C46 1[:&A:K]BPN5OQQ\*TY.%>IY
M%ZVAR4-0'M0&UI&] 9-0R9$8:92?[;"BIA5!H(@XWT*T[VSG^!6XH]3"P1W-
MG>67M9%;%50/V8>--3B<6;-]/V+VR.'N0&^3(5E[Q")I]TMN:;<8<K#P7B<N
M=V#MN%5C6'=9X W!K^/+,5[QP&>.D^,GAD[-T;7'>V%LM8@B7\(3?&HL9,+E
MW[Z:=H'Z5X>_MFG]+E"4H_/X=QONQ\3^5&Q$HB(7Z'P[ZBG<<GE-N2/-2KO\
MTYNC(I:Z4\5D45"]KH8"'8  >A'SA2M?$YYYA\(D.YV#*Q9]+EZT4;YU.[4X
MVV3*B%/IGX=YF7L%;%1-Y';;,WY^OOSY<O#1&[Y5DA-!.1>GRRY&V2VA3P1#
MR3804+6@J-HSN!'Y;E=_:F'AL5UTU+5(_X?/X[W3[G,.R9JN=Z*I&F2^=!;@
M%[&@181LQST!=5U2V32:Q!8MD.7JTO' ,"5+J=#3Q_8(-VUSE"A?S*E.06Y4
MMASXK<K<DT=PD "UJ-P??D!DP-#SDQ'W?*;GMYN-#1-=G".M5?9S<NS/.5DG
M3TT%XXAX4'6(U%;-_(CG-)&N#4&),)67CY510ON6(5.?WAC,J6JT9YS>JPJ]
M]4_"KUD7Y=N/W)9^G.?+0.(QP#[J"T9NYT7RUFGS8R\//]1W$!B7,J^KB$@G
M416?>]47.)Q_W0Q'T?=9CJZVDC0I4P.HUI@A/%=(L6(U7W)3/2\8:#][U8?_
MD)CG@&FUD5+\39L; WGQ^TTR/V;0PC, BD,ZC&R?^Q%-%,V)AJ3#Q-E<H4O>
M;2XZ^&Q[3E64!F$CLH+#V)_KZ]/](C-;Y5+D]TDK]4*;R\+DEN("CRMYEX4+
M2@+%C"\E*O/O]U,N/?IT?_D,,@/XK<OD7R+ ). H:C'CJ;YF'#:&:H!##TB6
MV+WI;(3G?S5Q^-[_#LB+W5]GI3^%ZO4T.54/UC/YB10E+%/JPXZ^.JW$F"/"
MKV;!9.J<957(4,@!C8] .9^9W6UY"R#6M(L<PY2&;5NI]HRY9-_O/@2&%#OF
MPX<-&FU\Q;P+ZQR'?:'S]0^9 *K7O!X54#_?:,,H8AHBQYE0B)2)<%5=4C4<
MYD >&'CG06F%'9VTC4N;KCH[K"3T>WO G(+N4GLD^@#JBP?@&"HGFU?&+<$;
M5^?N1&NZ]:_5=[JLEO&=3;_2'EJ;*DR%3^_7RY3K?\$QN'95_'CH9T@"1NI&
M1 X+X.O4IY1@V\-FRE+3?P3IJ]MZ+G7?<!Q)Z.N>=(OD*Q57=QABBO_Y\D"O
M7&LBBJ T?2.A-O@;SJ#FL75Z]-771YPHNE7/WW"O/#AA\K.J1Y&'/(05Y?R,
M%Z9+/LD\!3&;7)GZT7%^H+,6[N<^<3W65]+2YE.Y'1 Z][9<@%R?<9"->A(^
M-.@,#V?HI7?S+"Q8/&\NR0Q\",,UI-EF5Y/Y%TI7%-6WC-2X/FDMH+%($U":
MYDG78S\M 802UNM7R_9A<:?P*<P#F^609MWEWB?OO GM.0??9>[/'WYG'.:3
MD*D%H?"M^OY15YA@K3O+^T"5%9AX;BI,Q,03DHGP6R7%F!</XD)KKS&S _84
MN3R^OC S>$+</_+QW%+3>0[88>10.9OGLZ4ZCS+C*=VBEDU=YARFU\GCU##&
M0,ECPSB-:M$U8^!UF#)74ZEB\\\R"8YO@=MS[%T5C">[L "<[8!':LK.RN1/
M!>F^K9HOSA?;>V\XVR5X61V4]WK&O7]?XO%@/&>G^FH<!%0O'-*2\@&O,Q6.
MLA=<Z*9':4MXRR^15V:R3F<,VKCWQ]O(U+\(8NM&&*@B2I> ]$$;4[<O5].A
M()X\-1@Y?_H9["U!.-2<_&Z.BNN/B-Q1:3<QN_/&YEV&(S7[1>H)_44XWPIZ
M,,R->H91BPJN3V,!PLVG!/NA\GI=ECL6Y!O4[;E9'$(JAC]P?T/"FW_Z GFT
MRR56PGMVH4S^*9H&B*4:,@KUZA-\3E)$2IZ'&,AED_H+BVWNO0THOI)G]EW2
M\\!^1?7%SUS?<[:H)RFHOHB/Z!4T*9-V%&',' *?D<?[9HMS.BI/7YH87S4^
M62GZU,-K$(A5&1WN@90('WJZM$:B3:VT#IS2(@;V=8FNEN=5A<A=]9A)M-^]
M\C*([#7_=M):Q0I(M1*JR=KO[[_7P9%-EF_3(N"V [?FZ!)15 ^*2#8A^\R.
MPY2^\(TO;K.S3C;"CX(N"01$\_B]Y9-/>Z^^+<>.&HD_&X@YPD=]RRAJ1MVY
MY5.KB*[#7A-Y1@BS]#WC&7)<W$_#\ERMNDE O,K9Y'CE2^!</ M8J6V%\G?J
MA[&E(I7(*#<]"'<>:O</#7MJ\P2\O*.AGWXA[#LI((UTZ9-4STABI$)\?1/[
MO5*[]\,]B8%T"2OJ$#F5Y$#1)8@TKC@D0P7/SBER3W0Z1WP*\5BO.K;H_9;/
M/>_<V95OT!L)MCO7,=8V-&<X4A2'TYJ7(_:T;]]Z,)3\>$X3<5JE7=@4/C'A
M(W%]H=CB6!%P*5S6)..GW">'WERA,<H TO2+7$Y%S M/,*S)3F<V=FZ[_7;G
M/8VI)C4),>67^XV7BG(.FG58KI@9?0%%J>?!<0A=?,&>8KB=2;-&&%*N;QH@
MU3JG317 6BQS/_I\T^SV,1D=,Z&C"\<D<BZ0!5?RXCUW1M2XOM=3U1HH6J1[
M%%WJ] >3*(+QSAX?D#IN/37USTSE0M03"_V4*IZ&,MZ;(PVQ]IOSK[MJGS *
MH.$TS+S?BE0V38V.9*"[#PQ1C'L-H!]Q@:D_8(+C,=)I3H><<+:V:=.#CO<N
M'>L'3BLI9?S"S-=3+U)2>QUP4434D#"JWRAL&4TQ=YFL:\JTU54M"VIYM:B4
MWJKF=>]H7E-YZHGZJ$>B[(A=R<))]Y>)4J]2@L%&@N"8J'<W6/_2!^:^[*D'
MC^5I\RWI_A:QR"64E,-?7Z=6&2_PU_[WF/JG^GW,#ZCF5I(=S1(<77';#EUU
M$ $-L1#AK\X.E,!^X3AKHZQ6CV?<S64OVRX]S!6J\[SK=A)X&CY*-0,Q-'<O
M^EE*S3:#Y@U7/*(/X7\A;638[RUJ6;Y@3>%Y7%L:?FVMNL\_W *Z+&]5<#'>
M-*FR^R@82L%260"CH[ ?)LL" E#IBL)D/BS)T*-MJE-6I(LPBVFCJ-Z]V=S_
MU6'7Q)XNJA'N=1PKN;B<1]-&+A]'F#.*$*$4/^)0:@5Y(]U4PB?$(Z:_3'&@
M];&TJYJ/9;RNN).9J9G-[R2U*X.K'#_")"E\B=W*J%YWY F$)&Q!E+"1@>"J
M"L9EW_NR+ /:Q1(VWL213@2L7HR(X=LW*C-"PM7<8@&U;P5_8+:S:=;P*&HS
MHXRN2_F.-;!\?^KZ6/9R^62$08QCAX6)\HJ_1EJ/ >\:[J/L(U'K__0?[OW7
M,*[OTDS^#;(5D060CCRE7R&/(">8*F 40=.8*-(8]0R:4&T;YN<Z\R0:O^[]
MZDJ&3%6&R:'<LNKK#IQ=H2NM_1B<$D%T,"(30W;8R8)*:B'B&"7DP8T!18!R
M\TE\B'#(R,'0N!19G3?YIYO357]=C4IQL<]U891A0L?G(=04"F;0X>-<W[(<
MI?4.4R6$RX4"28@F7=J<DY)[MNC?UE*:)&LCJ'L\/)8+HA:RR0+\(?-1Q"N%
ME/%!6(L;*3"N$M47L\K048#8DW^E/@Z^^D/AL($K#?J0J-/1KJ0M*^MTVGCX
MO "*;,GA#UTI1@LCL:V*/K7K84QVM6I>WZ9M[+J-8/9:5K" /6SJH/SY=/<8
M"^ 7*6D=W<2,E9"@.49S'0A#4(%-=#@9=YS[H;R8 %1JN1"%!6"7K"ZV39O(
M'NY:Y7W51L;C9!H]W]]!/3Z;._PQQL!]S38,9LUX"+TTC%1 ONO6!QTHQ/YK
M\-Q^C-2QGYKFJ_8-OAWBH;6?CASJN7A:4 []( UR\HI FP!PRI!J*V5.=0&O
MZ"UAKK" Y-N5#'2@'?IR:OBIAHS?&\P]U^69,@L7CK. H2(P]P6;]/M]_2U?
M.8@/6ZB5[\4(8U9>8+A-!>JWX\B_L.7 [(\M0=5)$RV*SPXL+E:/<2([3Z\E
MSK:H,HODW?'@IIKIE4G/3=2\-#6<O+%]CV8,!JY(IT1D?[JE4"+8=;KJ8\2Q
MQS<+8EL^D825&@3O-=^LL]<U4[SWYS,=%WWWZ/2JTU7+%H*\O]\U?.5V:5?C
M@FS[&+* 1TN%3"X(I>H_/GB9\7?T[^C?T;^C?T?_COX=_=\P6NMQ08ZN<W)6
M:Z7H'#U1K>5NR$\)P-'BK_VUO_9?SF!ZR \PLN-G4R'D!VE,8TT""[@"38.(
M-8_IFK=._W0 SS3];)/*>V=]_HO(&C'XK<SO@9O0UWB2-Q&*TW6;^8&18(Y
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MPW0F2(7E6>^\',4H>]!C&KH'GLY=]CNE_&YWQ\\/[X0%Q8HYPYO!VP_U?*]
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MW./7XA)FK]QD)>^Z']W.N7[093: 3L<S]GE""3S]T/FY+3:P>SQ84S$?1;O
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MVSB6Y$Q+UZDD\]->??@UW2![ZBAE)$Y6E6MJJUG;D663^O-90N$MF_CTN^Y
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M]/68XLU+DOP\YWF<S/_Q<X+__?+9P>&"USZ'6^8);:%@^=C=7S;E?W_@Z7.
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M\.AML<U\]!X&OWD^)BT0D8FY,0W=S3G-DY!CB,O#UFULH!S=O@^W_..!:^E
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MQ6]&=TGB:1+D[9IB P<<R-_CTM(OG49/T^_B=1.6 1YFV@I$E(/WQVJUJ6R
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M9'"K3<",=;^&:<ODT7Z$'*';H#5M$YODG#W:Y1>H>;9$L;>F0O^UR0?!;C9
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M%MVQ<SUZNXC3_?,72PYGMWG]>YZTM,]N6+ !_BTJ:1!#7&X'N6'AM+<M;]@
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MCBR>\4K5,<!YLJ3-KFC4VWN]X9T\IO#LAO3,*6YK+T<9NCFJ40?C AWOLN*
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MT+/.N<3/2!3M!B7+B!9/)($;*JE=69IY7PR]?% /'\E*COU25'O 'XM&-1>
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MHY29A5[01!O"@GN0.\"6WUOJ8R$+-K#73Q ?K_F2GK>DIS_6P:P7.<P(S4=
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M%='.Y#&'D6KZ?C:-',2>SB0/P][DGKX<9+HWKM4&JZPXMI1>.]]O]]'X]\)
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MP9!C/!]K>$3Z;S19X5G]=!0;&,-ZT(-SV( /W05%,O0GX8U6)I[-/9O3]2/
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M SV<TIG&!JCB(,$#&E300HM<^WU667LMI2GV91U87H';$@(AGHM-5=$<;R[
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M[P@";9+YKSVGC]G(7>\_M&3"&VD<Q'%'%T+ZFDG<1BI45=I)*'DZ?)=4*PN
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MG/2X&7H;98A>3/YNX9EE%QJJE62G-:K*<<,.(W<[AT;O$H ZNP JP[,^4\)
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M?IC\?_@/_^$__#^%B&#\_P!02P,$%     @ 18M75@MG;]F&%0( '7 " !4
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M8E?!DNC5"T(*)Y:$/@RB-BE* 'P%BQ"/%3\$4F6?36Y6SZI _/T=7">6DF]
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MK??7)/V/R">J"RWQ$/#1S.HV<$B%BV+]=GDW[_P,YGOIX2J@A <XC\R9/P$
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MX8N*-K3'&F9,GU9K0MQ.)?V<;BENHW]YV_7D? &YT;+E)4XW7#XXCSGCI@T
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M=X,?>@G&YPV>8WI=NIE12O_^58E"@$*D/3*"&&$F^J9QZKCH7PTC:\;-+8?
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MQ2&Q1+B%J-\?QK;1P9OI516B^^G()[DXN?/G!0 )I3P'1UL5I9E!889< @X
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M\1#<+)Y0$V;P_N.$?%!B+#VC[6G>$:7;7#HW-KE.\$5C%-A62$V AZQ 6QE
M/XZ#)__)?WK:R,+UE6+N22&IUZQ?JO%GIWA),AD\MG(0\?U#4&C0MQ9%B##2
M8(QI6MS5\+&R+B_TH(+ALT0S2J7*''A+&2+W7QJ1P&KGP'MJ.@?/R6NCDI]R
MPV*4 ]]F;OE=GO4^":'Q.TLP1:>@"> 6Q_4MAMLWOU P%]LPF'W(1QI[*WG@
MFDZ;V*XKGGS=]O9ME_C;MQ$6"H-HP@S])JM(LQ6JQC8-[E8IV!$A>/O/R[<7
M<?5&)1N/FR::M!N:#03S.))G.%9N1@:G1]6K(\TX1OZS>/3Q<HC%@BNL1<A@
MNSGS0(@$37K]RXYVAT0:E@K#?&NC1&24 8]HUO2[U!\5M3 .$+U-CTYT+63_
M^>ZJ6_2!&+G8R3$#=+-G#Y$ Q6TC2DD1_6J:^&F/<<%-XIE.4?JFP\EA)1S>
MB3>^Y[JX7C$PRXCB $U31:I"+U&I&Q)\7+ONTN4_;44_VE.] L_D]-6-)8K;
MW38])LLU9T=%DP,Q."6(B!<3,F[0=<CPF39&)R7\Y@4]LS .->EJYHI^=V-H
M*V_M/-.$@ZS5)&R2! [[",(]<4]-=%BKPG4B''][*V^K=6Q^MY*MQ-&GX31,
MGSP; L H+\SPQRW&],1+R[[KC\F#8X4N_GZW6<$;P]TI#**@)%"C4%YHT(;V
M[DE CXIUI$Z5E!\M9L^YM$B5;2H$WU ;.5H71LY>-V-H,A4!#A-08,LQ^;[>
M,Y)J?VI86M$W=$V:NT[3;>X@K[1Q&K^0W.J?<US^UK2+;"$&0P%YDW8?8"Q&
MK"^3/\ N%\-,5\[+U_(6&K%^9>AW1^X^&*PHOR\GRU5(JN<!K,C89'VF#)71
MUXE*+?WFN#P;4GRIV(Y7Y#GY/(A'*Q>QE.MVER,8L4&P!$S3[]#S3#G IQ0(
MC$H-R'-7=GN;OF'XK/5_L\ -W9?<W6&LUUA2(8=<I&SPT0;[T,I11EQ ]$BX
MD5?)]H!\TFD!MO1U1%K9W:?W5/*IR[.^K<:(^G+=E\(09>IHBHW22P+"LT^9
MKR#_C=?) PT3S6ONB2*(P=-.7_DNJ<=?Z\"D<O:VAYCQ_> 8TH=VD1R=71^*
M4BO\_'4K:A_K8!_@]ZZS)CHD6>Z>(?8@>_35@*IOH^6K!>?FYWS[QGQ]YAW4
MCP5<.:5YF/PTT4X@42Q6 ;<%Z*RL7Z96+THCW8$'#"L@X,S,JV<C+=W)G]MF
MK[.9)@V'1<3[Y9PVTNA'='F,!DH$J3%XM(@_H#G(5G@WW?S  7QD#W1F<N,"
M0N=,4K(CK[JMYM=XQX/M$HGP!O#Z"\91( VM@)0%Y%X%'Z_%AZNL>E";\ZJL
MOI_.];B1"8NZP-4SM/CA[/_::^K_G8.)W0,EY?6$FY'&<WJ[9CBFA?RU\Z=M
MH![01*\?HAF1-VO)H\)(J0FF2<W\92?S%W<=VTMTFCH(R+;#767I[U7RGR::
M?25E%T-)2W21<J;*#1N1#_<PC!58_6N(,4<OANV!KF"XD="IJ%$>9 !,)NS)
MMR&"0VI%\$Q"79TEQL#;^8 7Q>_;_&<<SU%>DJ3$_D-F2=34KC)T_0/-K!>C
MV'6&%@P7(IRXH#+<9GBS1B>+O/PH+O<MO?'H^9$;&M%RI?O9ZFA6,^00$.;'
M>LGF9O>B"40AIG6D\8>I^IUK;;FG),6TDD(HH<C1Y4'3P1&O#>VN)+H@*XMM
M[(_N/<*&($^FV'7Y75STR)%!W,'C3^].%Z.+S)R5=ZZ:N1[179WC4A(M^PUM
MR$Z#2)UB2/K/ S-LX1B*1,K*J>QSV1>!@'*WF^K+:DNW"VZ[?)J!W&D?.2K^
M6?&MTDN)<9@@NM<1!4*4TK7;61TW2GY/X%KELUD5Y9W5?KW(NH8'CT4?A2@[
MVI]Z(IBCN,%+6>Y D]YAVWPQ8AAZ12,KGL,/R!<.#3(?'9K68MBE?/G-'#53
MFGN_O,W+QT6Q\7P.I-.CJ+Y$ZFF,8BBTL?4#Q4@2$1>A.KCH[(G_>\3;M]E8
M,'S3^^CB#<]4FW?+O9J[INCH#WGT<,X:UZ&&P'P<+?S,7[;0G>:6]6H1+8SP
MF'/!]*A\CBDL?/(H'21[11,96W)+./XLZHI'_(D4BB=3+HB$[D-_>X_#MO)C
M7L-#PRBRDD 0SO1HXF)80[NK;&VR5-F9+'5;Q=OO8R)\ 1:6*?>>_@Y0JD$$
MX;%MCNL>W\6HX/2Z7#4HWCN08M/J,W/;[/3GI7>^#9E=E9;5<AY'/+K"V")*
ME"UY]A2T,:8',R<_3!YH(V,EU& 7?89%^AIA-]L,(N@A'_TMAUIS&TUZ#DR\
MH3W? Q%*X+/@ :(XTJ@4>8DSOVKD&0#S!I%^/FT1A^L\E/^F/#+ .#/1+?+6
M=<^$E'\"!'&?M<_P:D:"P'!TK^W^@8@5N$&@/R*E6[H9"%!(_0-7]'E6/3=G
M/<TX<ULH1V+VJUCC>TWIE^]X24$"%LOJUIQ[#+/'L4V>_;5@-U;#'NA:+!),
MADG[?!C(U8\*;)_,!=G.HR(,'2^<LSE]>KA=)HMK>[]MS-9# Z82PP,UY,_-
M<)N:/W[FN -F)=2$MR0P[>_(B?&W9-]'P^+X'#\!IL*FX"V(&7OD"4SQ>I[W
M9/Y4BNB;%5<2^Q[7!**4+2+$.(\4!=Z3==&AH]]J$'H])9;MX&^[IJ%OW$ZJ
M//A9JT=Z:J188(FX?/"V2JO];3#51T)U#LGQR<2'3"Z@\'[9PJHD<._;ZIUO
M7AHAFQYB7BX!&:K<ZS*AV1?T[K+%K7@8 J2Y@)RZU7^@5!&7'LYU\\"<ZW]%
MX"! C*;C.['TOH&Z[A%7OM-LLA5RM6WJ]+BNVD=WFW,"I0".+4QC>+)'P)+-
M*J-S4+HZF@^0P>]:ZUN(N+G/+Q <>P]]RLUU2K,+=L$O74\8T)O= T7 @<..
M^UJ_&B:,L"(7)I31MK*8<9H1PL'R5KR.6J;&3BO1MI][%Q('TDR7K/0R9C[M
M%SU%S%EQ^- ;:% $+U*#A>D^\ TQ"I^R"0RO[ U_S5_LBB@@+$IFO;SE[+<I
M=?JT +F1GR]V#\24A9/AZ6Q>U!2V*3N5K0/L>E$+<H*H%-NO=5WA98,_7,O\
M+YN5?\[9X2O=SKV8D:M*DM;E6<4F8:CNL&QU&=;K+FN&!9N(;A)%B[<8*34Z
MDA^$G9WDI3=^WFH\^CPB!Q5TP$K_8:DIOZW*[8B-?<'((2/K;0Q_Z'HO1T;,
M4H&&37.$UCBT::N,$;C!PKO1[T>EGEM2:CVL:=#\G/NVQ,@>2-9&C*''=&=5
M0)28QC084Q:]Z-E/Y&!DR"GHH[I[*BHG/"9@Q<Z+$-\\1Z/-=,7S&-"ZURYD
M_NXL,KBA=1)-6LSFFEO UU67G=(5-=O6SH]>1?.?0PN#&-9T56"4X8*\"UQ\
ML$@D))$N(*$S!CL?PPWNQ3=IPF[E#/3=R5UZJ[_^,OE JTQ_)(9ZCF.].F\J
M&<@%0!,V";%PYLQ"'/"YD+OF3OT;(F8\=293T>!':MZGJ,SK]M9@];O@<ZCB
M^CPTJ09+/?<+?;7^H7R<8[RT$C-VD6SN#][^:A.'U)5U1:PBKI5/G9<07=$Y
MDE'&0ZD'CHSV@F>WR#H;]M0PLLZZ!>F]&,_BM=#(9^]AHDW\"<5AZ'?F/3*I
M;4+@R'];D2-.NF'M'.-\3+C,GD13O8@/,8UMV0\+_:7&:S:N=XV+UC2,_(Z=
M\53JY8W-.25Z/4-5A]=390_$^Q58_J^LJZ2^C/4&'8(AY# =:=EXR/7=0L]N
MA6E#A[0;H_^DZLPJNM[NR='JR4D\+[[P16>_FEB\NXE5B"8U0H6PH1'@5 .D
M9M5E[_+O[Z[=R.+/< N)?,X-*U1]-V3[D<#D1KP4W0,]AO!3@];W,SZ&@/#7
M3/ZOBU1V N7%P0$#QU,3'UVOM37.SQ[G'17Y82?;&R=PSOZ!9@VZ5P<I1!.@
M+]!T-NXSG('-T<$XRXI@BALUNOKU/R\GE$X["P:9-8ZJ1G)BFST?)E9)E;E
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M#3PFG1J&N+A/GPBX+:3R-"G1(=9B\KRMJD /9C: CF 5W31LWHKG[)PY6LR
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MPP2$N=KR-O34E]B_OJUW10=<ZM;O#5N$ 0:8OB]Z [2R:65X+^/+J3[JO.B
MA65[Y^477)3/DJ_;5#/3[HN"XE9ZH(!NT/HNPY9ISR'1)\H'%^&BB(X-Y<U1
M',J*NDX(7%@7%@HY(!UX'73XJ-A[X4%%#\WYM4_LXS^)C6^!-NI</UH-VG2
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M+I^U$VBO3\$&H[G1O>=1FJ@1MB[@20O P9OX<TAKH^)?PBO]G:M"IZF_HM?
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M86@@C@_C%"#'WJMK  F4>AF8;-R/.LM_MVN[[-[,;NN)JJK]V]=DFA5#EYU
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M_T>7(UMP@W$M#-JLL/Z'@.ZOET&D>] >E(^\J@R+8S>\<57+ZYLY(Q70<>1
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MSA\SYW6]EG.NZWF>USG7.5>\&.49L>:5\1FAV;G'KA^+(,IES Z=CPO#=:Z
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MBML1>W7DZ+FNB'MABW0'3GR/RN:&@XF[W89Q(BXBYJ$\<$_\GFFVM"G+8H,
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MDHCJ8@XL'=6%/,\3SENGLEG1@$/B.3U!]4:L/=['TX^]WX"_KKC_]+>)T7)
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M=GHD]VRI4%TU\_,N6;]W?"/T>(]X>AZZ_UZ#.G]]_E5%.6&)*^>%(7FW[[+
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M@7T_M46"G%H]?%-PBQ[6*\EZ8JVV52T&KJ$+O'I(\)!H_(0OCZ:K&5]MHKZ
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MASQH##U?G(EXY]</D%+6UHJ>X@NX:_!;2;H$?ZQ((_<?2;H7Y06%MI)TW_P
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M.0H=!RH)&:;[MCGOBBJF J<#T&=RL@3.*]H]/ZKL<4 .V(47X8E&\#%A\F/
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M N@K5)/<U4 3/-EAS$?E_+Y2>D#5<G+$A$A,TM,;9>^%6-\,FL7[]S18[+[
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M<MFZW=JU'C9/13=S99-+!I5O71VWO*:W])!^+N+!-="BMV;=4.(HK-(OZAL
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MH::OKA12E<NI13Y!3L4S#,BUU1M_5LDM0<"^#V<!0X [X<70=5#J19[IJ65
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M9EQI_B'5Z\ADS)'O9X\'AAS@/7L& NS264?F8"Q4'V)*L_LH:&>XR"*?4BX
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MZ>XK#7 :ZF7BXSW1;07^1O2C.<3VNQ/B,<K>1<YN]89]PI6QV _A3X-YS7(
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M@G(&^X16B'OB'G\%^<<$JG"/S67UT+Q+XP)IG)$(J5G^5YBJD=]YKSN^%G7
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MIWF&*V<>:.69KTC8S#F*UB5XE,\<1/E:/C=02X/L6/Q+H:YFA-T_ZMB_K#M
M$L6>!,K)*<2=DFK!]C?*$OV=S'75C3IN=IHA8BRO.%:,0]\_',%,6$U,6[;[
M.=W0._59Z*+=PXX53;5#'FH""\^A_]WO$?>:/R_ORB<NDW=[?W@^/35Y,R&$
MY,9GW:%H]5R[Q\IX:,\IE]Z+X\>>H ^C3^!F/ML(]+NY8]E<8"=X&J>O?GTE
MOBWRI3R$3<''L3?.1.3.X9F-)_'Q,E'/@UC6XPL1ET@8ZJFY1MAAG*N*S?0
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MI&@#V/&UI2'*UQ IS,[PFFX3M.3]F8/QB JFE!7]*"#(X$/R3T"#T?.BN!S
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MWG3U,"I**2*JMK-^6:X_S#2TL?3GD5L31F[!KP^\.9;6M,%V2W^W8-.KG%@
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MB]-(>])9:-*CBL3?G^2:?U8Y(X\%WKUVZ6#7R:$G,"&Y%W&\:NK^4:&E]$=
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M-#,>(FWS2:L><G QUPW3R*2+\CJ&AR#C.J2FM LU]3Q^YJ#UJ-N2<J"-/5
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M<'S'B8FLHN;';;_W0,H(&<>.Q^05C%&L[K?7.;K?),X?1='Z]+V^?UD'QNP
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MQE(1HV.FW[)@*K^[6 D'>#+=4'"!+P@BI"?3FIL$:*^QME40(V[+(*ZU]=_
MP))4:'[\V--/>Y&WWU9\ ;*,;^BSO$>NH(4I[H0#DA283(1AWS1F![1*B>7:
M:MM/?N>//.&=83V>)QOJ]P5+4BZ>7H/QH+!/#X&&O,&0><O>%06"\8<_F:EA
MF=SSOPTB!@RY7'$M,+SR+9>NN>W;?3FR_..%7D\Z1(^+HMEHS'!-TE&985X
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MW6U/N0C.KT<%"5RT=A0M?>9J'>SC>;&/TXICY&3/R>L"T=;=3!D<I!"Z*4I
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M^@(10JBL$BY!%RW/@U3"QNH6B@5Y*O">WRJOCNCQQ2 1IR=H&9JNA$5:Q&G
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MOU62!S$OG:)<D9R8%+;#8MIVS9_S]/?8.R:^7,-J X*<-U]TN>ZBXUVA_8?
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MBV,+L&@87PZA ,,2?&@^Q8/LH]3)-C:8YEK1@ UAS\XNKHQEW.61=/S2\*0
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MB.GE0TRB%0X#4 (F/8[V':%.B^E%*=/KZC=SJRO6#SY,2Y%_?QA]>)3[8/I
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M?6W.W_%&MMG'(^\<#B@HH#,NG14ISSSYIY/U;R2P(^MQ,("CBKKDXL4BRYV
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M2>6W#F0U-:?/S8,1&9![S-- #,'E/ENT&4!29P=B%55R7@ZH-<]&K]R6OF0
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MSXG:\E!] 8DKO\0K]=%I]+5_X/3&D^Y&&1/_ZW &:4Y=UU>@UJ-48#%:$WW
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M=TW>Q*7\\'[1/7D=^%8S>%L^]]6 XGXIWO:*V".06"_]"%3E3LR-1_";4OZ
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M3W*)T^O).?,4O[QG/8I?,S!8IF(.H^,!/F;!WSX0RYZ("@]DAY =S/\)##6
MNS-?E+XS^E07,'>>AZ5*N#"/B_&;7'&- EF,+3-'P(Y-QN469I+:(!?$9'%:
M-+/I/N:L[/[B(WG4AJ*29)<>@;4OL E#?#@6<!A<[83IU$[S[T.>#Q#UFC+&
MHQ \ O"J9-5CD_G*AU'^Z;?I8V053,&'IBDCOEG?2([SG@8T6*;=ESWFTV[$
M*OJ<=5!LFU@Y:5/;-%079%?7=-S</ %73=W]6F'E4ZRZ3I_[N[-C(('[2>+X
M]69XM(D_;XQ]@4%/<L]6=;Q!4-3=_@E+DU\5E[.@J"@QS5I[S$Y:I9:8>/BY
MPZ(LK^2+_^AL4 H)A>IB9%\<=1*6;[R'/6HD1HBT/7P<V//@J%P]?*VC6> M
MHC#Q_99"1-F=4 U)YA\#&2\QJKCE7;G)?0W3442_[0$AH"[SCZ&M4K ^*J%%
MLS302@21 <QV'\BFH?.?&R8=3*<:_ILREW\(NU)WUF5LX2A@\R(W?(&Q[H!A
MM&-'0K$[>AT</F<(JQ[.M3W/8 81R!XWI'\#V//GXU(:_QTN_PU TK_IQI;"
M9?18*F[*EEZ7"Z\JXL$T^9J5D[(Z*4F!EGM<T#-7AXY=/2)T8 1+B2%^'I%G
M5([&.OI_=O;.;YC9"?(4JM0N*PC54 0N)Q?_JNU_E?=>:T9=$I7P?X-FQS0'
M#%7=N?53P_I%Q1<UD+H4;?ZY>K#*?^)\^7^'K-J0UCG_B)TQ:-*C@<L#[6EF
M]YCS< 5,0FZ -$;XUCC,PY?K,Q\$TZ8NW)2H708@5/\?L-H3%BLNY7;-;.I3
MAQ['I5API6,)VJ[D!^%IL892@I%3_]=(@QR3H5R9$67"\_$>#:GBWV+XGP&/
MC39)3(PSJG@]_W6& Y6['&NOLPS@NF$TRX_]4<F ](OL9WST Z/>O[ZFN:#6
M\%Y4TQW/I;A0U7JN6KL.DPJ-&V-[K!#-6K39X$NIP-G&YX)$L&(N"%^HSX;O
M&,HTP'BOH]4:A1;)DMB8;;UNBK]=DHQ$5,F?(>U*4GTE-?@&_F7-63$;=)-Q
M-@K2;ZZ;J79PQ!3^7H(U .$S6O'./_)HBR=\G\*@2HBTNF34YT!U91IC!=$.
MT6YLA=GDNP2YS#6U>ZFT"ULE627ZPR0$?.>8POG\YMUM&&_-O^+&6#VEYRG%
MMB;VS1FBFPPVZ<\]/*AC?8["+]SL*&]JAGM+4*Y*[<UF1&7L%X)R=%_UVJ,%
MB3'1D0X6GA'<[O^!HQ9ZY]C\]M EQ;FEIZ':*;F>$TAT*=M?T#1&9XC'DD7*
MP]5!H0KGU[]96S0XJ@KL)AO)B&QJ2*!\RM%9F-IMO<,"Z52X8LXD"7;AG;98
M"KO[.OZ]#S</'CL0B!)VS.E?X:Y5DD1?&\F^W/SEVYC.FFKOXY.'JSW8[\JM
ML,V)0T(E0H:P.*&8LB&7POO<(U$DMY["BPO#EASJ"YS=#A*6+J=NJ!02S=*N
M&"RM5$(*7H)CNE5@.FB+YJVWS H=.GG<6R*>%28Q)WJA:7;M2U+B[Q\N0#V[
M3DD0+1_VA&NH-8WE"H?Y.QK"UO"V.GB6]Q7/]!_@<X?LH_,-\F%KWR_V'PB1
M=M\$_WISHP''7(_U"!WX.1)FWP B,/I8X,G!09]P@2&?A\DP04&L?CVU:29$
M4BTPO:AV@C_J6_<#]\N6% B>^P S.4'K9(PLTO]K,RVE@9=@<!3P>CF1A:9Y
M#7^-B/54IE7BEQW(I-'\ V=W>@3JC)Q>J+VF<#P]VQ_EBN'"OJ^*=95]/80C
M00;\*CHA+$,L*O,&#K.;1MQU]K?D_\TAU@<R?O?EGNNA"?<^-9>S@+&L:FEA
MW'W.#O,N7.)CD!C-<SD4,OVQR0+N>0>>=(D%_H+_=YOE/X/7OE;D:6?E9&.%
M?,-T+*3CR$VMS_BQC?6X1'?-\!JD0$^)&,'?MH;_4A"GY*2*7!?.Z0"]AA1H
M\Q(O_-SCU2H)>P2DM6:H$'IF_9<HQ\R@R6&DF6"%=MR3ZAUC)\AUW?JYGT&%
M^P=+YTZ6W22)_K*5Y3U]O@GE#CWITH#FBSQ<K97T_JWQN30:#]JVAIM'0 T:
M!M?B8N2D!P9R6T<=[&[N+B\GVUCU8MZO!3"#&L\(!%<ZLTWW%WIV5UUJ^^UB
M$_;4%A;WC.U+1H6X=XIT9V%<!R(2O"2L>63 D?M^+O2G#&_-,-;F;,*>[RL)
M:6,'/P07G5(]3&Z^=8L=5U%)66U7OXT;LMNL31[/A[3K%RR(\M'=W(J4M%JD
M^82A/Y8OC9>-,/,0#1*(;?N:;*;"ORL1J7]E!@FNZ=]+:10H;-%%NR(EC&B[
MTD4%&68K%SC_;?5BY$]3UL?T-7?59*PI6@+OAT"DNQ:Q-=W:#5RB9+QLGTSN
M,CR=/5! ($22JC8Q9CNON4DWWQ*G&3373(Y+(&)]]2;MJF%WH(P_''P95U+T
M"-CY),7.4VE;@VJ.YQINH%<1HXD$[W5DC ..X5[II8ZWB\WW;!/6_VP2\'^@
MD!VL@<KA(LXY>\CN08((XF9P"Y:D+#Y_.'UP=WJ[X;JS;ZQ9;DL6%^OD]-%8
M[C7[BV&FP]G6UEC9J8%;2[D$=EO<5%7PT^RE4T$SI_,\[O;#9^YTZ,FP/P]3
MZ1]MW5C6'QU<4%*K.I@<X/^ 6@TS5?GDX:3UD6WL$NBQ"J",$<+?8 6OZS"5
M@C-.'P&"/29UV,2V:;@-$MUTQCS<7^IE!@=;8*KQ*Z^=$D*D9;#F9/ -F<9W
M#YH 91^?V47I-BBZMV/'U!I>;JN^[UBSV&5+!CMYLB_:"A1IY>_*=S9OP-_0
MFGYR5+O'BN_I,229)-,Q%>D=QY4P?BM*-Q]S]9T 2P>X7/J1%FOP1&<,3O"G
MS200V\/%BO;Q]S"K>AA=B"7'U[7.8W6M;]2::*A<)*G2MAE=V@.%#6.L:-M@
MU6W7Q3,24$62!XMH,3ME_W<N3)^_M<E'RQ]\ CM^05H%2SF3!@I[./O2?PP8
M<:LJ-&=WG=PI@7E9)48!VQ>=>+&O-1L;4.)YDI7A#,VSVY&K5\RM88%D:1K'
MW;:OV7B5PHQ3C,]ZPC#1]5DBG&-3*7W5T,:R*_7W/EHE]%PY0,]THO/VAL2+
MVY+7Y[*]. Z6^G<O![A1W> 9N_Q-,8WU3C/Z2S1+:$\DG4GPNL"[\N9O9F<^
M\N_D4)^()NZFL2M\Z=]$5M6'L*>192JY<AE38:(\!1BJ[:V7C3:OD<'?JAA-
MB(WD2D4MQE-5B..?%?77%A@.\!TDOE13N.)OY0I=2R71H>&S8JB="^+CRXQT
M=/ :<555Y*?\ ']K_?D@Y.7W[:H^_#ZR_"" I)KM.L7*M=&3@9,"G0$ ?-TD
MJ4KKZ/*<>U"L(%Q?L[,#A;=HZIKJCK?G.0UKU;P(#@S[MC:LKSRG&/.GTPT=
MWY[GX6H.4LH7XI04@*[AZ A5/$.#W3!KO/0:06K%"AO^BYS,RQ_FB1T3Z5T2
MGD^.:T3UJ'I'!8L[*^J4[<]AP62FEM(N)MI 6L:O$KB)TJ3]2)62D=Q,3N[.
MDUFA/\]R,KRW+3HL<?KPJZX&]<;-V,ZE3"#3FI]H!JO*@$K%^D1G@9^9;[X@
M.Z%E,^@C%&E/S5#.A<3[Y_. /?TM?VI3L?8DOOKZ>[OR?^[VU[?FM!\1,&4M
MF()HJX"]9=#+J0O<!M'ON4UV?PD3! W_@2.95LIS\-,F)M8WW;&(\NA?.:S/
MD PNFXXK N>L4D/MNKAEQ2\7G]&?$WVWU4]9J4;XG$>0(N3[UVESV@.[@P1@
M\<]AJ9T6YO&G(SX 7$U/IPRT9S?@.+5-3;);YJQ[8(\\VUYQ'61R'15 L120
M_H&\[;OOQ2.  9Q+#BV34'\KY"RH0+K@W]$FN[41_J*MQ-V"G]NFJNBPO'G3
MW^AERZF_)!7:CVMH_@@\?9#SW^XU%G7&X[T$V9D)YHJ1X?SRV[-6'WRBS8NN
MTH-J#THW_:19??DDNJ978M:@Z>C2O2$),K7OYS3WV"YD1?6#OY+VL)U"01"M
MX^H(/9C(/L'+=(>$A,T+1)#8LY:X2O ,G-L, 6Z>.^1XO64F2#0>/;R*O\*7
M>BJJ7D HHDJ4O![)!#VARJ]'$U<;VU@)$G/S#>+Y'J#,_-[W^<>PMKD-/;*M
MX_B#7$N3%GE^JYX'>O.D!S0WUD66GN2K4M $YK]\SK8[UW/Q@DKCA?HM4WN,
M'0='KK:W!SY82;)1BNNJ1*KKXQD=]+/Y7R@J-I@ZD9^\O%Z['3E:NLJS\A9&
MR.7QUI++GDT.VR.00)_RW888#B_S8!5-B$"3I.Z3I&IL=LGNH=;G[7?K\\FW
M@X?+W(K#SWI\SXQ0J&CT1"6$ED1_%>RN\B'-?L*5SBCR*5_\.90X\OW%[JCY
MM?!I@)R,4GH(&\$$G.,$>0BAK#(BY[R;_//>&M0P"S-U*(F.^.KJ,A?[0O/6
M_>W8!MT,G%HLYK*#-+8PO7"GW7SWQ&38S,.[FOX#CE3($UDXS[-!OIP/5N3P
MLRK\@;Y8I_72DNR/GFO;=?2=7"@+\9>1V-0CM./ZP(4B&[B[I7;6W=K*-,PQ
MO['T/PPDY1EI CP!K,MTS*9AI(1(7=<?!83[CA=\(H(':BO;)73">X1C$E;8
MMC;9!>)]SYL.:"*'"Q4K?1-8T<\SR2-!PP[DKPYE )^<4']^:D+;Y/Y*.G/!
MP4O^^O50.HTM^3_C3KX'-%._(5^A I/?3#])[FL,V#@1.,JGJ)82(NUH2IW:
M922QYGY]+E@J*E39LRXVIU-^FST<@S/_".S#BP.B%D=L1%.6EE58T:'1Y.&K
M#%#[E4(U-.S+:IS:XK>7>S^UZ#>U7X1<1% KI@[;1>I+Q\2[&0=3QD+5O\BK
ML9#0X, HA-^EM!Y&+?")>3\-2.:1E6RX-T)XEY>3JUB_7DT\OTNFN;A,GV.Y
M,:&3SY "M1B2*@A<^;[_SN"OZ?0Z!]J[4M"X.SG+7^(T[:S^K2GL60%L=M\Q
M=+K?8B1X4>6WTM<WQM&1]7Y[U@5H]-BAMAD;<K,RY1$B]7BCZMH)]VO%_%@*
M8"L\D612%"3=AM% &QL]K3]H6=WVXL#H$^DK&F2PQ+ !GZB"@%23+^?G$.^$
M1Z";_/F"6VLQ6]TM=M6S4TWP0A;'>SP?8XW?U#UQS*#@:<NZN/YMMNN?!7&2
M1(DEAEUHE<>_!G\%N31Y5JL+>WS3P$(?A_%0,@Z!5U(G*WR#):G<_)SX1\_E
MM8X<VS2A]XZ48/V<N5T3UJ]K 793'7T.;1))F>'249\<:+M]WM;I]X_YUE),
M@-.E7>[KR^,9#%";!DLU%I7J3RB';-6%OO\6A^U-VJ2JO;*&%$B)!"MG*M;E
M2-,MRAI>?& &I1\?-(30(PQ(C'2I$(VP?<OFZ56GXS)^5TQR.Z<+M?P 5%T:
MG@39-WO,H)$V+D2%,M7<-CDT.3##)?C0ID- 'N9'SM8G^PH:'#$@..H+LLYP
M$]^P>2'F7;;0/;N.Q_=,W9=3\&D1/2/7[;[$T3EQWN=1B4RW6:"H+_[:M8W=
M8B\ 40I5G8I1]0LL-4R&G)=MU39\I4DB?!_.EC@5)'JZ:_! ;/EU404%E!78
M*A?!-)&SMU;)$P#!>3/@>\YK9@_'% K%*G]%3A$5IDS;KX<)@UK$:\9!D4+7
MR"M:V_%R?M]U'8NGS,ZH&?389[Z,50\@+OKONUG\'P +EWA>(: H-,:\;,DN
M8T+4U,*"(O6,/7/B8-<X;*BJR33!-GB2[XC7&QI-OWDR%R3(X;E)5U5#U)9.
M@30@%GAS(0!!^!F9*9%9M'1FLJ*2$JTJE"PH/0L]F"R@)(Q#E::*-24(-]#M
MP0FG9 :-<D+_V/.)8%II-C,8KOE%K9[@)W&\*GS8]?/3L7G:)'G@4'(P'6W*
MP?LT<H3V]^^#>3BXO<P#/2W>&(%S."N(^HOY/DB=XMJZ6B#K>6-]8R(1%8.%
M<5!<RLAULMQK+PQ\]N*E]SC,H(S,OH8T87Y(I>V#F7\["^/T5OUTNI&*R38)
M%6QQUQ<[1EO=)S7QR$1=O]K&B78=H0&FB ).Q:25PQ96IOQ^_NP_Z$=UM)GT
M_H X98A"%_WM+%]U8R0^Y3U+'TRJDT=7)(>38@$Z4O+NP?F, 9R9$$BM,$B8
MU6@^A/E%+1P33?\TB.7\12W:($>A8T,96JDRED!;'X  ZVO5-2CXSX2"XM;4
M4/3;DF0*EQ5>K.K^(-J<NVIXW>+6 :&(]6J*"5YH3TDQPJA!556S#;_DS&V5
M,(^F^IJ'*S(Q$6AA:ZS_2CF7F6[7P)A 0Y3Z4R'E ,R3>_<RD8Y6,@K2!7B4
M]-FA</NH]Y;G+H.>.-T+3^G1S-%C?'S[Y)<R_SIY!RD)ERDL8\KB76A_R0Y)
M--(F1'HX!D%TR!BSR&FGN(J900G7KOT*,%+/!,I3'O&4U1GB2\_+].=2M3M5
MDYH3_][AXK\+0Z:H=_&1D @-V575(B\/K-0$99HD^92O[O1JX-SK=9+=%FW"
MK+?MX":("0F+.-(75/H_=M^I9F>5K9R$RX<QFC03GNVJI"Z0KI^:Q^KSWM$_
M*>]WY7HC#X036S*"D2$2E,$0#J>^!M^2\(SN>?JSR]!-7RR=/')RR\]2IM)D
MYX;.K"V_,EP;9 I-4@"?5)@%O;8O>8H0)V_PD;:H4G%_Q\O&F>KGL/R_0._=
M)G2*?YC9L>9YJW\*F)!39*IK:%).ZH[K^*P&SEZ463>HB/8T\/$?7>64\XW7
M,LV_ON10E'&J*S<+/J^6BI:OC6SD@+Z/RW(OX^2[5:J^F*#+=9&DV+C.&3><
MYOP&TUG2I(C:/J=^ONCMBU;;JG,F)(IQ;LTW+.+L7^$-%W-F%>)S$-<3'8!%
M9LY$ 6>JX!''\ A+C"X3!E?Q+]/%HZ7>WE)1KN1,M.VRV )C\T:FC;&@^S6P
M?B+[08%1&4;P+U3 QRCH>.'[A%$72R(:==S%C%0+44G8U%^A?=\$011PV07.
M',/&>;,?^P/Z63_UOZ)02?F8Y6\\V4I1:V/#"66&]> N1?7M2-1%TY7]GY99
M^?-HDD*<ALDP2ASA=WL *WF'?<DC4.5P5VXKA82"U[4O2:6W%F L)HQXF)SM
MG1I;]+XJY;QXQG2"_9LL7T2VU'/-:[M=R#V:,'-4R7KV+"M8@3'1E+U8MB&F
M>4_^J;%R$3M;X0KY7Q9&.^3AS:40?MU\)\YW9O<(L.WY@9U48YI,SL(<4626
MQQM#A\X%OEN3&LH78^\%_O2Z!MQ,@/76_D#G^:Z$?1-:.^QOX J&:9^@/N[[
M0F\ST_Q2%_S,,_:M@6KQZ]1*G$QF#6TA:0I<WW.R3]MC*P=2X_B#8.7N($$C
MMU[+G1YL_KSW$=_DZ3K8DMN3%9OC51-IDP\8@MWB+GZ#%.N>DWP<IT[UK1(L
MQB900:&NDQE0$58#@\OI*$5-5=\L0"_@UG>OK>4 N<&JODJ'=$\HLUPQ&ZA/
M7VFY"SU$Q'3G_='!4[PLV4O%7[C/.:%8=-S\T")!^%.Z]*=-TF*90 VGKM<
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M-K1B/?75B^Y9W.;RVY(=0$64D5=.TA,JPMJ-']'S'YJ.EF\6)@&B [[*5=
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MGTOWH'272I+J:2"7'G<+_^#%&U9$1^5DE+Y9[B_S0PL=\9]&2TK;WMYA$$X
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MW^G*3B";=V%YJ4^H(LV$CEJQ6J[C3M6%3IX>(75;N+ 9W;VZXM_-4',:+9\
ML5^ 33(AJ8K,@>L_*#T,C2IBOL7M!I;[FQ60SM2[6.90=7^6,3VB%L=6"CVO
M+M1L5*3];A;K?EDOU$ON2.L^IY5,Y-9&G_W>R4LLQ$Q=%4?1[M$B;7I)'4%P
M]QI]K/'Y6VBT#.C8IG#6=O;Y$E76.$55^*D^(7/&.IF$1NH:@4QA'63#E=KG
MX,L2?^74D"BX19]0OGG]DX![<:>A9MB*R0,%O/V MGM.IJNG?T\32*V^#?ED
M',>1KW%?J+V*_:RB !&RY,$M/ /L4<7QG;YET(9;'Z#FY:!J-_T!$EB*Q;&R
M00;/%_5W5(VJ. Y609"AC1/L]NQ=9B]^-3J??,;RM:3G;$9B?S+*;5J1-(8K
MAC)._@"'0/Y_X$CF/XVTS @2/C)U#@^KSWB?''K$0*()\U2UM^^6)D=DZ,?T
M:#6N(TCRC"_8&3%R3QNJ$OMBAE1]VVS8#1P3D!*2^XAMSOF3C5GEQG#!\O$<
M$]!5N7=?TE5<Z<&]DU5:"<F=5J4IH!M"S<R,BU)?VD#;[I_1JM4UH0T&:5#V
MOW#,+;V?1PPAXE\2=]&/]]Z#)IY;CS]2P3R9A+QOV^@G:'4PU)4:#*XHWWB0
MK_$VK)=YJ'-//_\$-E>#<G2',+/Z191Y])-LGM05!'!- :M=(/.@P>5*E#/D
MT7T7)R+@,H-*OP6=+S.$1N$9Y;YOV<RCBRAE!W0T'5#6X%YP+=^]8,O;?1.$
M;3>N1@L8_DS5$ZG&=RJQN(R78"P.PUE!J[Y:+N-DYO<TFK'S])(=8L2N18Q;
MQ^T1^!P-B(N"OYN67QLJ[7)0GE83MUY) Q:Q&SKQES7[N&H;I4FJX7G,>L"0
M,3\7_J^O@!!0SF"^>@SZF8!J,S,M=G 5H=X9?NH+B+.@7]JV]A6VMNJ,2-<R
MG)A<&O)V6Z4BB7=(GG<*%FR2QC5RD^;_PN?;P2]JP![NNGHT*1*"_9VPJ25Z
MEU?%=*C1]7R$/2^G,)B2WK]+:,,.T['_K QAT'Y3$51J1=.98QZD[0 ?2=HE
M%5D%2.K8'/D;:2F_3QH]^2D_WGUA93G^>46#@=EXH_7XY_,&-[5'*[^@V9D^
M<OUM-XEB<XMYA9U)A>KSIP(@8[OM']BYHVD;?LU7MUOS9!YLB;' 6J;%Y9M#
M5<K5:41&9J69G2?J3W'2U1WJS1X713^2D+RJ9_X16M5N 6+."-3M;D><".^*
MBQJ8IJ?Q4ST.8=[T\.71'PN90]=!09U"RR7M4QUUF>*D$4D;W6.IS3+K@.)+
M0V8^/,99:ND_:I>P %U88_FK8FYSV  L$US11%CTD/!<-]$?ZG=B=E^/:C2U
M56<7'?9@0XY03FTB D<(?SXJ*$JC'5.78V'IJ;%3C-*V O*+?7"5@6'B2HEQ
MKY +Y;]VE!T0'3[R5[URU>8!HLNG]'[A4H/*3XO$I8U,CQV\%2> '>*"G[)G
M[7,9FI^)#>=IEZ+5G"G.-55Y$8^MI97; @CYR[O+1B.":FX>YY@\GSGFL!LM
MMT7'RWO2O2M XZ>"=-4U<S[CY<VF.K:^-&H2;32='W]24U"&/1XL'[,,+@M%
M6U#(#KKC*-75])NTB==Z<)+LKA4O,"5Q*1,+K>IH;[KM=,I!=5ZDF2@QJRG6
M9-[#QYLP\0W:*5X8\I01F8]U_E(H]+-H'G4+5K<M#I]S@%^ Q$R=R9X<F^["
MK\))S',]1%B'>;!U'/UJ&OGW<4A\IUOSB( =*P)*0<9@K<(3EFVC.:U;^@TF
M^( +"@?&S) "=LM*;V!Y6MG646;YXOB)W,#NUI*%T$OLN+20CC34=N&"'&9!
MU'^CVOVNP]%@?ZUN:Z'<R=^[@*K'-CRHZ=$'7<A+_Q_R.60#97?II*^ Y=01
MTXMR;3DIP]P5LWYH:7=ANN?!860T2@Z$WP<&2SX%;/TJ8LDJF#V<L >UU%*:
M_O@I9_S2K<Z+FJ#=C4-.';+4<[9?@%TA',Z:Y(NTU&E*1;^MB%)P'IXH!$>I
M8% G/Y5"ONWRWC'.:U0LM/@D:6XFF,B)JF=^,NXH'.<$+0X"HI,2C?DC9 P_
M2QOHZ_\/CE_Y!X,+A[+EG7,$GOZ8A""_Z;Z!"W<Z7L2Y8"1G$F:@Y\*JI*]A
M2^\F.@1;8R#@:(][!QT]/3'=V$XUP^-!#&E<BB"4.)<S=%\9[^N/AF1I;4=-
MF&0S>CS4CN&@NT(6"D_QOH^U6%^U1E6"M+QU 3,>7T+PCFT I'_AN'2U24Z"
M>Y1UL!N.Y@L1"_O@/FLZ-(V3LY^?B>3I9GJ$4O7/Z20 S/%$2U5(W&VQR'[Z
M'[LTN&1]7@G)D W_+H:]+9>WH>A51 S(4+6_2@%<I94!U]P[S]G,,73PE<\8
ML0;52MWK21Z2!C,\_UQD2(,.6AU\4V#W%%2O&6WCZ&M<H0>M%@M6#)F5&.@0
M8;XR8/=[YW]HYOE$?)&[S1[>&,LCH/-MTNW$^_+KUS,"YX]9['01R9#)?) ]
MP8OG)N20=TFD,>EJF>QO4C9:$(_//)&)/UZPUR]_27#WS*[R;9C5OC.NS?O\
MYH3*_M NY9&JF3NY4O4N"]=BLQN?"1T0Y4[9]"%T'D U:F )]L=^(PPQ2GAM
M\'E_U_:K Z8.3"'7-;0;;0/@>^%#)6)U9Q=QN=/YS-\AW^@F=N$-NC#H@.S%
M7*5R)6CDE7TL,-5+NOLO'(E[R.61=+K-U)@56^<*R![ZI'ER(TM42"Z0WH(<
MH^-U .;TH2Z0(OIL2CG>#DA2#]EMK4@V-KNPE$4T/V$T89M'-#(6D=JC.&@>
M?QM3U6XCD$9,7$A-:#S9>JP#I3,?,P!FAFU&@:6=OJ0'TA%] &946H:U*A9?
MFR9T^K4F(<L:F'3<Z'B*^1_"%OUR'I_J)%Y,0BN;W8>(BNII/_MWI)2QQ>',
MH_:S#'YE6.0Y)EWMS$>IATFY0IPCL24T%$(C/KH6#@[]>%:MSO,J+08:")R_
MW<]TK".#WO(*9[?=,]OY3YX2,9J]VH37RQ++.G'J&U^+(?"V#FOYCG9LQU1-
M) 3K8^J+9"W6'P0+,)O;6?<^Z:TGFD66)ZW/CW'@)V4(W*]1S)O5<3?5*4 +
M(!_?Q4:9(181BK_?Q3FQ)]/2GFIPJJ;SH*PRU.^5N'X+^0Q(;-,^WS<S -VI
MBO,.:!6"T9Y[$^GPY^YO^A9WRG6JA"#.3CSW2M)D"\@,2 /;461R^)[-'U!&
MH"0BL39N\Y)-5E/W&+_?[!_@!Y,4%#_BHZQV\EF6G(E78"9IZ]=4 3SR:!<M
M=D#O\AD_O5!-/6<(<RQEG_E&GG<0^(I)&I>LJ8H)\&;:AGB):*VHJEZIS5_X
M=1D%N/>H!!E/::1!B8>87?#G$O!MDYYM@L"6AA)_%.?!W:S(:])[8-_E>Z[+
MO*1D&U"O==Q1OVIWW?=\Y@EC7F_#Z_U=F);<TR4K_L)QLTAJ([Z;E5A"][S3
M8//G7R5WQ<U$,)7GE8 ^KLA!=:O!$&^KY9RVFJI3PP<_U"2?%/.L)2HV"/%!
M!4XBYM(41%]+FY16+<;P>SX2.D:8WINC'-G6,/-SIPV!_W\ID/"G#GE+V1$8
M?M(T AS3GFXM\_@1;YPZMVX[>PD6T>)!K8V79>+M%D3K-@95FAJNF[+I2\5=
M=&.FTL>60V>ZS)3I4AL=/US?+*;< .-=7'9 VHDC5R@-EJ/,7>@N%4U';L98
M8 +V&^/E%!6CQ*YL 7_&W"?MGSNU)_VVQDT6-5Z?K(9@-SK^PEH E6<.<I)U
M3QA=@(UVU4W@X*<KQLWB1W[8-?:NQ$6#C@F/O;6GF3J*X%4%R3I"S.983IF"
MT*2/I2F :6*OBY2#!\T[$2V=UG'T:*Q)#2E-8>1HJI8AW=.)L]B+<MHRT\R8
MG#V))LS7^6I4$_./7&$NMGU--UX\!8/F'U:DV9.JP>^;UP$E1_;)\"M?R9IO
M?0FQWDP D+&/(QKV\9D8MD7&T0IH9SV^GA!6.R.KQ=2#QEI"'2_K&"Q>2U%.
MT9(\+ \1JQQ/"@8P#D2<;/9HW M=F='XR(&2"JPY7?+1M5>+[^^\9]: M,@B
M53HT,[RL'PNACPF56@%(B*K B5CIH[]XR1TL4R1EX) <3]CQT9>)B'QC+'BW
M@\_,-Q MR<2_1?$T+B]J4-/)W<BD%FL8+(*'0&[:\3#Q86LP$T-0U^PQ=?TV
M9.KI%'N1AVJ3[JLK$_>SCDTJ4].EA4M4O?T+&&1-YXLH?9K%]6MC++\-4_N^
MUO7K18::O!8V0),62K6,\.D9E-K0Y.+0].11<IX)(6<!E/,*F+:M?":^4[HB
MJG?(0F4<0^H&@P"L'^?<!\IUYRX\0^G;!]JW>+"3=,55Y AR'Z>*]XKXUT4+
M%D#Y\!Q.YGG(AB6GJ,* 2J1/\P-)BA(,!1>LXOG:TA-,OP<-;>)2_#88!J]S
M=7")%H3QPG?Q82:.-T*Y4(?IX<0*^"/\/&QL[$]KN;F#TO>^<[N/E&'A[,.,
MY&JOSJ@.;!Z=Y5IF[V95[>*;FL@AXOD+95PO+8-)&PFKW:KN)>#";6 V/BL*
M:$H#Q?NK?#E';L>8V@E^%0D9'"(4CL@W4-KJ0/N2\4ZWP^#YWB?.1,_PX F_
M-?%YDCY#XL[S;XASU/.-P.RLU%R>'NVWZ3P7;/AWX2][Q,;Q\0-KL.?I%\Q7
MSJ!P/YWG[#NA:3!MTZ=!%9-2O;7?_4"* G#'5LFAB4??C0U43 XUX%N\5/CG
M;[;HE94#CK9N2L,G5-2#=]%66FIY3C3?JG=8/1K=N!5#G.L@'H^2QUA> AD;
MPA)Q?W,8_^P7R_OF9D7L*;:1@GSC3U=C0$A>YC?A9C7!<[)I&Y *=S\?IFIP
M8LW#=(@D7LD(2&_PHHQ&'78\?D%19U_>EF4>'AFV39:FVKPLLGJVL/TP\4L_
M8O7L3DL.M#K*>A<CY&HX:U#MXC!/T5:/K5""CV%.,T]DJVFI:BH1>WK*C3*U
M<;*O>7.F(%_9XHVS!B2,EGCY6(<5$@.S4AAR7=Z*8U8/WA=6/F#[Y.FY4RV#
MIRX,JYAR*5IIZ7^2G@I_S6#<C!$X(?82]V1 '%X]P OI"ES7,]#7*T5BB3U2
MQ/W$[EX/"X>5J1+& J<%=I+4@>2U)%,E;G:C=]EX=]AQ9IH.C?"P$(QJ@?YE
M;4A;[(<6@>.-I!>\SQ=I*WW,!V9+J/4%"UUU'?57?BE\O\*GYSK@G_JUI@?\
MX+\^W)[PL(6"E?;A6GGCM*" 79J4X)+.863!K-53.QWOY?>KA1W?=K(1VEZ4
M63#JE4U?F&7A61++4?73\0X7]Y-:O=+,EM>XW+*-K\-<V\WC^]:'<F(/.UL/
M'FC901]F\H=D=2BI4AK^\X]P_DM05GP <J5,Q$0\RB.9Z)ZS;7+77*C%I&_G
MA9@A;C]ZZ@R/'1'R6>7(,)F?6\?+\*:7VT%?B;Q5F?[(,QEBEK\\*F+=(-)8
MO?M"_)SPI:FG6NA.R_>R&WUGY5E3=M;'=TW70,@W)4I0[>B$60H=ZBWC$Z..
MO/PQV,I1UI;L$Z/6_8V-9DX9%B@,WN;E32WK7V3 IQW-0IC35L!OF="<KE_,
M]LV5?Y[1H'%"#E>.KUG[C[#,7$GL$#.7$GS1 K<P1H9!0X;&ERWC!'T?HF&F
M;84N[892^!?6F"_+GTH!374:IQ8R[%*&@J[T+8E^[ D_.P9#V)\T\Z""W^=R
MF@YH-R;X\V"Z!"1,7^\3+E(6*D+!OA*5G-!Z'D1X2/WUVUBNWFJ'=OB+]J^_
M ##+-,R,V^P_3&(8VAI.*]Y7%9[G5=70$</=*7AZ=C4QO@815)2J>V+0E@:
MX9%GG'[K3:LF+=II+Z0."K,A#+)GB#L"5&18NJJ4POJV$H;Y>"J@+_6:+7\(
MU8@.009/HGP9J]I@A9#3GV3K'YGR/&2M4J>CH?PU0Q#2\\-##K+/"7BC*&N
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MZ["'VCZ99?HPBY;[P8E:CB;M0PX?C_5K' VE6X+NXB94%P-4<L?R2"ANVCY
M% OL'1GI<[5G! 5/-T']CRR)**5:M-2+@F0^^ASZ<,Z#M-UES.S_PB&Y# >2
M</A@6V5IRN3SRU7J=-4=K'TWJ:;XF]YO&F_.,5YGK9/)Z*A2\'#,FEYZ(VT)
M&(VSRP>=M]:VJ\H;[#/A?*1_&V^4,1TL="LKE@N@S]=4\\P98T$+A4<RKY_P
M4&;G;-!\1\Z ^M1V&IV]A.]0#[9V@VEYT(XCMU)4]#F@=B9#X+W8_ 1.$TN7
M+VSX/J:>-!PDDA7*'2H/A<_!K9FYBG(U[RC6OT$-S,M"#?D J51LDS(F+^.Z
MF-$<4OB%X')?D'NJ(6DFM_O7P+HLE7S[ :]]J[FV"6OF./I?96)O/&ZJ7#]6
MLS.T(+ZM-\B;R)IP199V+29GFQ77%4*P)PZ.SAQH9[<E(0^+[NDAF5F(V)74
M?E$P^\KF21* ^?G@]77=\(!X_R3((]F&?*G*+_OXB&K;;B>0",5]]-B#G8D>
MJV'O1K1J@ZZD7LZ-CB0>86\2"%UT_B$KJ"\U3+44!/MXT1\@Z/BN0;YEDWHQ
MP:UU\D)I!HN9QID:QP6V]_B8')<(#\3O"9M2ALYA,V/+J9SL-7E+LOO^Z3G3
M_R$@9@_4BNX[23X/(PC^ G\F(4,X&,+8+]S67L]__L:S[:MCA*H6^TM&!UW5
M0X=B8!!34^U+4_\?3RU!AXAF!X4E"_WS4_,KX88[:C>>41;!H%K1WQM/PZGY
MEX.]2\YHX2-S@J1-B7FD)N1#'F/4]FLM8#6M!!/GG)RQO-GIDP1/4H@2^V6#
MD^]JK;1>)E)LW"@-*N+6] ,&=Z[A>D.0Y#9^]$$SB7#DJK)Q"M]PEOZ!"_>+
MW [4RV,5R_W7O,L[A VJ?<.L''GTH?/LVYVVQI(W0N\LYLR#4ICDUE/??]LH
MG_%O;6 H>A4VX0M1M)$QKF;COR_&9>\^^5Z/!J)-2TTK!PCO6V//KW@@$U"'
M*T@U2]8-/^Q6$'N\C*0U?D=Z<JJC:]:@7E@(FT/5=6^1DIF+V,&L,A.K@56N
M.T3X9SK</1OFQZAS.OQ=1OK#-UP"Y-N$DZ^M;6AW*#*WYO8J'K/:!@&W/BSY
MZCTK<.1@JJV?_JD8@Z\^%'9H8>A&O=_%Y,:=#C.!OAQHMZJFLA7B;FP6=2O^
MBO!G+2]2^ML;\#\J5U:,JHH(O\[Z/F]*$!JIKBHBQ6($5IM&%/@;J6IZN_1M
M2= Z<KP>D8;[&Y:!(K\^2R$M56:<VP6([ZK?/\W?F"F_#QJ[HMH27V/KF*FW
MND-NTJ+VC=YEQL "7+I%^F6Y.48XJ';71,X0HYX8Q7QR:&;4L!G%I[3QX*N*
M QMIQ(XH,P,AHI2+U;!3:G;U41KUD8_%/(6'+\3!V\9PMV."SRGE GX*;YH=
MTC.4L24"FR4+@LHSGON2\W'8#U,]!UCQ3$09FY,-F'9C3W2#D?OK3E)5#LV.
M#@R0Q[U ;:*3*90)?R#"C"G>!Z^-NURV>-#$HI5[1L]"(K JLZ*1C6^JQZ*M
M(=/)62FEQRT6MZ,VD^:+TQJ=+WWZ@K6FH6?$A0&R0GG"_(,/C(]7^(B_3)DL
M:JF90<:+.,A3P&(61#Q2KW>V&VD_XRS2'?:MVRSSU@@L[;Z?'@%8;9&S%W@^
MI]D^*>W<6.T=#]Q,X.VEK58<%()-0E219 2#_R(ACV=9[G1H6AM8.4I'1XAF
M*7<Z^-;IAJ$R!%T6T5U\B4,5?#'(E+53VNC82<P!X2'VNS5$=:H^==R7.C5/
MC2:!89O=)TH 07/R-^#.>V%K5R8Q(G.4@?BC"$'&LA,4PVXKQ,<[5TCGJ:JC
M@CC_ RQHDH;JJ6G#QAT'IA3QA.^KC_'7O+M2.5%K@M?J,+\:D(G</MUHSG11
MHK?T7'8]9Z)W)6+AG+"0#/E(["G2' 8OMBO7"*1UFM2#C(ZF2KU0#NS/6G]L
M),KTI7\" G[Q21SYX[S9P\&M$[@EX?:CTFE*UN27S=HWACX[=*IZ%25:V&ID
M>N9HH\#MA"65P;FT<[H2ZZFU5.<@QXNI2^P6P(^_^#0,_'(;T*OJF-B&\(E*
ME^8@=TC#R%+X$VP9=H?RC=9KMK52/*<DSQ!A-3 TT[9/D^:@C(F6JHR<N)>)
M+/KGD^#_.92)M>CC>]WH0B=^>DX'YWYX2W(90#?A\^KIY[(/4LER,L8C.E;G
MN15I&V&U(X1UX-)E[=HDG1#QR*\926IIZ\H^/Y\7GY.G0CV\Z0($"9RGR7GX
M !N/)U9,&=-3\ZXF(!/2Q-;$M$P ^JVB=+88?D\ %:?_A>BIJ>S7SZ$]4/GM
MOF]2E8O-6LN4[&F/+>=9>(&%'-UI/MB6RA;.+1*/GE9N@F@QDR,-9SJ:9T8C
MR@\S*VS?\"<8MH/FT2;1,.(+QH2',$.5@-:71H)#^[X/0\P[O#N*BUOB]S.5
MX2K.1O V?$4/HF(47LFO$KEI>;VB*F?=D0F-MW;PO1;5W*D+]7+[BAQV[<?/
MS7BJZPXUT3%RO"K6)KT*"O641?7L[+^^Y9]\D.IS#.TV=;SQ\HMPX0'&U>K:
MSI(@<]^U&9BAGMF;9TE.H5Z*E;H6)##'Y-&_*IFFHU#/E)Y9[TGCD^U.Z4=!
M7.E+9.[G!/+)8E'8=*]=8"\)7D"U/[ 9J-<1WH](A?I:=-)C8FU>'!.^;5.V
M\@NLKES!-\5_\ME,P\F!:<$RP_8!(V+(P*R+W4?=A;)$A50&_NJ@&F+B\*#]
M,2'_)"!O!S(>5%[&Q.?ZZ+^/W$N,ZYV2X/A31D?0<4=\C%&:P!&@S!D&X_[]
MC(R4)$K]5Z-!./S*R^1X\1[:-$"7Z1SPI&CKR><O@_WV%ZAZ"=_'\=]GQ9(W
MKN>&Z>B:*,D=A@![<F<GO7?D X6:?7L@2I!!WXT>P\/UTS0ZK.++KR1?@;5T
MR+H".21.7?N<40C%V$8"'>%,) A)N2MV;4KB2UQ3*85".#_SN:&1BZQ87CUZ
MI6.2S3@+HFU3UMQ6V?^-8;ZGZC+R<92P"CUC^;/'K3:P?9<)P@ $0YX6<MB7
M<FR/5&ID[;S]14;=+N&;Z[]3'BM571;!K"JL-@.W)'LB4@M;*QJ=E"%I$*+Q
M$:NF31UVQ\(RX/H=U"H:.R05:<TZZ8>F5P1"?#8ES>]NJ(A7<ES=GW_M_'J!
MN'D8F_EFF8;S#/?PA3P2^9"H/(0G,M1YR;V/6(-_F!$!A^_I!\A'X2%2(3$Y
MX<S%KLU#O5'[9M$P.;)8S)^N*?!_E].L/4&+SE 2*.-7@:O(S+0YP82J*W"=
MCX%<[#HK3X11;#+Q"1X]P,>OXNYF_OW%<9)D$Q]KJ**Q,'Z1$\/GH'LI?2Q+
MDBDYJKW3K&>@5N+9'\'J:/Q8#<,X>[>,+4 2[^N,#>B6:%<3%*?Y6_D#9\.=
MX[5T=F,J][U5*1_+#-$V?/UN='2\V_W^04_.0T@23'RL=+++3WF$Z%X/45\!
M2RA'9VA&?<6M#3%JPXO/(&)K$^6?*<[G<C\!=]#*[4HL&@ 905VVL^&\H?MN
MW&RN+"23 CLVFV=^UZ5>[EZ2B$PRU"-:U IHPV<:\P44MT;;OE4KC31MD./M
MO:S(B.2,N2ZW>7?T3W)B_".AM/_G7^N?$*N24]72B-0H8G7")2>"7+Q@*$OM
MHIK2O)RGVVCRSV<6T%U,J2)5!^M*X\W>[5@\&#-)EBI[*>YT:CW4\[7?[L?G
M'TTA) .OV3Y !>PW=)"P?CW.GWV52?,C=L-4W1XJ3CF= 4AH1Z0]@3B21^:)
M9/(G?'_DW0NR00V\-%U=-V>350Q"Q6:+.&\GUWNWN!;Z^&@2@NREKUTH,W"]
M8>8[LTP5W#2R[+68##'-,V"W%<(/P;B'#C![G9S)D/24'30MC0X))UW^4IOD
M MGP&*6F$8A,WO_$QTF*=1\R[!#X=70C\C2;,<2TM.7\UE_0,@)FF6)I8>%V
M=*&6W.$K:N[%\<4KB78TRJTOZ=U^?<C&ZYMDV4)]46NAR6 4+6WV,#"G2A&;
MU4244/S4!^&R3#*$(UD/>3?/M]?OT#SM;XZL, #8.G>F;]P_:634RZAGT]C*
M^$8[#UUOT >,2(1!^0!CNWK<63*Y'N1+5Z'K::I^J?QNF0^BD@!9R?I\S",Q
MHOM@T\^? HDO>&23<)%;A4;<UC/ K,PCP1-1ZSP1SX0G:]T',^H(K+)D2@HY
MM'8&S2*,[_CS$[8Y+Z243NT'T_V2ZF%OQLA.Y!9B9*+V80F"MTBYJNR_/A64
MM =RAT3-%M_E1EI(!UZW[(;"Q7=R-X/%ERUYPSJ\16]GE^1RGT]K_"KBM,)K
M VK9^0L<$.EK60V4\HM LF+1@*[,17'A+L**>:/C1Y+P7P[\Y,;,:+./MO%\
M$HGCC#^_Q)46^0.!$ZI'H2FQ69*UF6GMZ"\25).W?8Y/%K9[!Z* Y;4O^JEC
M'.&JD@:??QAXX%4=REQ9QF>F_(R?8+^MU'%>XMKIJ+T),AW3V7JZNU-]A=\4
MC,6N&HT#\E R;%8'GO[Q6B"'3+.^]K%9TU>L#3WMW]C2G^U;3=26#[P&5.#:
M2>)VS1SCLYQE$+,N-1P/,_&9"_HEUB\@?VND[TX*&UI!J3-'.]5[ZR1'F=.1
MPBD/"EL4/OV>$#]_/[TAKA[62/4CMEQ>OV/)'(+MS#QM?G_< _D%^\V,(8C,
M5,V63-G"7>HDR12CC"T78"L3?IU%Z5%>%A$W*_21:O"V5+&I72V 1<$F8UEA
MM5[A7+!TRPI4?LM4"Y'P_1QW%%Q1:LN672$Y195RS9 ;"?Z.VD-L>N\!@'5G
M0?5&%97"]S'Q;>R% @GB^[_GK-&%/G14X%]-.BJ)CZ4.MP<R\%TU)JS:^Q%Q
M9AXNL\6'?1NY:P6/,B98#75,CM@"0]'$AX:/POC$J?<-%ZS<.#SYCXBC25<)
M5!E9>-A?OW#@)8*/E8A'L<XZ7RP4[5OT4DG60I]XK2Q6+=P;AK]E=U:C1BHF
MU=$&5+,U(^RR-YV_DW019@1SPE\3$X95-QG*Y:['5(IA*2RE1N[UR$&GWC.Y
M)MN5#XI%Q RSSA=5:FYGU$%:F?[%D3 N&6U)@CX!M!T?^PU 7J,:I)?8$MOR
MWDO NY*[YS:A#I!^KA!#8];F709(_5@-V1JU.KL'Y[CKQ/3B6-$? 5GN62W6
MBE][R]42RHDXAS_EP"O4W$UKG!+##EERFW\WR86*YT4^&JU]LG3'8\<BO-&5
M?"\H?-(QTWALM[TLW476@0^4-*68<?FEXX)RH^)L+=G?+:3">!-X(+2?4N)Q
M7UC/6IQ*ZCXNBHJCT9 +;67)PU1C5#![I5B#<ZRV!G5,C S;GR7AB_CG>U#^
ML<8.RAPF_H)2_VM+B5PY_@L3N>>X/N[3!3'I>.-H5,C)8<B9OE^=Z?1.YN8N
M'LKSX#H&<^W>:B8'8 =4I=G@("UGQPR?3;E?*"=X$_C>7*]IQW0&75'U"TIC
MJ6N4.UAG.&"45O>7Z<I?OO[%G]?0I2U<@"YFRGU[$:4C7/8 </\LC,\V0>NF
M1D)M<DU5YW'V?)TK;\Z<?2_3@6."K'*@9JE8]*JZMO&.?>,18?H3EI<_\E^+
M@.1@VG";*-DHDS+GU!B-C8HHW"8(7:XZJ,UW;?%.I" ^>M"T>;:NQ52XRKK(
M 5'4Q@4B6:B1?E]33=XG\KOEN< (>Z&PT0#-]$$@VZ0$>3OR[9&-2U\2GYU\
M:(]/NK5X+CXTPEOG)65&:?6>JJOIS*5KJD(0^2:F2P"@TIZV&OINY%ZSQ_%<
MW:;,T/12UULT[5-W'$4)!_23_%9IJ9YE#E;%:]M36A\,TOR%K@O;K0&F V5I
M$RS84.4#7C+YG$; :?>V[$KEF6A#TEV"^:9+2+WC#,,BO6!,?NE22_5%&_X-
MBJ !JH%0E2)J0#)E1NERU8:WE$5QP/?8. <Z#JVVZTI(UZU]KE#++ZNV[HR3
M 'Q60R6"?B4I,$U^;44,AA[\7\Y"CLU=,E@[47@^L--5XVLM8$$W#V=.#5>C
M0OA6HQ/X?@J[R4YPB&YW7H"E _+)<W'AC,<\LG-CO%UX',9GQQ5(XTG+;2G:
MBO ^H,NUJ$<F+Q0"%^P;ED#M9WYP:HL;?4"C.8)IL5YC33IYVH+CP-T5S)9D
M%_=( OOV*YSB[6?>Z\IQ .V-#5US9]A$^^/@0>DO_:8!AV\$KE U?-9)0RP_
M.<2=UYT]!M]M&:X&028W+HYUNL:O49V\752I-IAI@2<0E_-:2@/0WYSOWM\5
M3C"Y3K&,[7XQQ+W[0]?Z+YQ X'&2"&#JYXO2G!M0[2AP.M8--%DQG+R:X%>#
M(^D^;P*K:%'*^7QN?NJ(D>(7(@+NZ8+W? ]]4KI*/.5JZ+9%=E!(F1*^ D@+
M%O7XJAJHIRSZZ=.%[M+K2NJ3TVA#'2E40GBH[0],(^-2BG<0)=;KV7FMQN/H
M*; >ZXC>)_TQ0WX.KY#6S#*1-/DKBQFD^O*[#ZLW=;_#R0?]*SB6(WO,9(W7
M!LMA,>T-P@NG>#NH^H>W/D!W0L,PJ&7_&E575\>]+<ED.5JS:C<;EK:9%'=5
M(J9:>K0TO>*WU<#U_GY7,(;=IOW!!W+KQ355QL;-E[;S<V0DH'8G?%/QTO5X
MF7V*GV4$.D[TR&H!78F/-J1-82)2%4;M/\SL6*+%;JU$>/[0&/J@Q@B5]M[+
MVNY939W&E.5E5">^4C2575AUJ1S?1AG!O]+]N \UG46D*A'./HI4@LC2]H1:
MWJT04Z*?[ &?%+*KOYN9)<R KJM\VCN,9#_HG\DV0^ZI)ARO(D[$!)[]D)\S
M\KR/LH^XKJP:!%+&Z6LD41K.:-0\#:.,./];&3K_-^9\2\7^L&4Z2N?_$V(O
M%?MG[[[_YJ[,F'<O#) Y'ZKR-'N(UH5J%B2"E%,-_A(O-FRA\Y&S)BE#9,$P
MA-&F"RF+D=D*G1L;#)KPB9&#%G5&6'ENTM8%;+ (AB8)6^UH6.U1@[ KC-]4
MG:8X9 Q5V5)Q5C%9O\'V-3MY5>9V7)'LK10THULFCLN,MAO)+3%W(<8KH57U
MLM#VC1(<]YV*O A1Q">$+P->.=B^H:F5)1F,('!C;I[+^2*+;2W 3<??R/9-
M[3:'&-$]0#3[UB3FS3+<D/.;=VAN9<AB_7\5MW-%NVD+\;\_(H?L3XX;)'<[
M*CU0966^JB=M4IT04V$\P2NWB#.[;8!.OZE+FFVA10Q,ZY;*FFG9P;CV]/4(
M&VR;-':(\*(L>3=&<"0'G028/L7L*HHQ\&FVY$SR#PZ69T2W"S>.(*$>8 T9
M1O*KG!J(D0:;*N<%IH[&N3M+AHQEX-.'3T^%\\SL/&HM5[A7%R7KF1M:NO F
M*=KQEMI00&)VNQXXQ:&NW\S"J[X?3!7E#(#@U*O:SH=Y+YZM=1Q:@U8>,:1:
M.R-&J(+O-65@&J/-%\V_Z+[.A]N+;%95;H5@>5A;#!U#,/^]43T-I8J=_\?,
MT7LDO)0M./VC2(\ T$8KUZ$C8FKV:'"UB^VRDLB9IW%+NJ(:'R,&4N>ARJ'5
MIWVH.7].'8&E>66[CVU&]76F]DK6&U*G=4HY']D/B5M[G.A(GX>X8#-_J\1L
M>3!.,P0?CM0V"J6T&EDJ28\,ESL=!&K!_'Y(.[>L?=KBI,_5FC8\4<>/4"QO
MT+(FE7'-:0?.A=MG7UYE/^.":<>K"1\\($*Y6Z\^8+ C+92@I?2\I.%*G7!K
M]9T*H8C]A+A^\=!U^B,DH?>;S'R&^4H9S).6"#AO'E0 !?WV<[;R,=_@DV@T
MKLB,+>,T*+XS?MB'](%_??K3QM.+ZAXC_8E'V86M^A5='=W@,*Q&<*L7ICLL
M]CI?'_X(,_WON#XP-$#@>(4\U/34/7!O>CO/G1;XF3DJYN7,,-6DS6T20_"<
M!%YZ$KK<H6K8+S**/.Q075?#*EKL4DQFYH!UD;T<.?.4]W^'P_^#MQ8QF2F?
M<9?2LM!,5;@M)[-KER>S.#FE*+9#=4TSG$$!;K<8$[+1BKK!AB/&Z60PW#(Z
M261M+I>ZD3'+1M_.N&2M#P9:V%<$&IQRZ'3833Q;*EU,4Q4T91QISL-<[W1T
MK08IBY0('A7,O?IBK!XA\^AA<>4H&VQ@CGD6_9SA=IN'5+)62Z3M.9]DT[M4
MWG*QB"@MD#WNA'3:OSW0XQ^-)Y3V"=,(G+C;T3KUP;:&7 VVJ7%5?XFT8&^I
M:^#V$GHWOSIB(F.GQ!V;(0C+2PLR%N)!PP+'Z0W-ROVD._G%C;UU[%>6<QYE
MT"+OHVAT%BG=N>XY6UW5GI+&"_E*#BI7*'Z ]#N@_.C?:#23$.G.F0EY:>48
M:K4*F\RUR4,T2KE\$%4?4QP0@E86P$]I]^!(CV5/'\,B'H)$UWYZ,:M4W<WM
ME]G%H<U7E;^*5$=D9TX6J;5)_9&U.:]\88,<FH&ISKO&;FJX^ZH5Y2T>#A;:
M_;+D+56],.V]:S"#R%KQ@5LD%O3;R$*1QF?"4@/?P=,MK=A^W$S>QGB:;"K'
MSX$(7F4VD4(@![GJB5+ITUE!8$6 !M(Z\G/*?'('.KID@\_#0TJ:+V2[+P9M
MXLEU?_?W0%]F9L13*'EYV'N_\N7WD.@/AZ9Z6F@0(9PSW.=GOA:^8S2S>T0-
M;V3[RCQ79JGUW'&4H[6U[:W*5X)A65.;XN+%-4)H:*:-CJ?U&VC8 MV@[8"3
M!"D5O+I$8L4@ RWBP71<OKSG8]D(A>?2A(_S=F,VQ1/VV6/K3+%+_N_37SZF
MQ") OFX%T2QOZ12?KR#VCNK>G-4^&:7:^?Q"S=G$B>ZF+EVWT^,0?7N)K-0=
M>IP4ZV"8E&&S>C/T=XX3KP#[WUI =N P2IR)A5)_8%:/J!BN^+H6XJWA29%*
M3GG5S9^GPU[%3I88#@F?J)HK[OV*C D-;%J6OI07I46_7!?U(?Q\0A-6N=(T
M%+1OLU]G 1S,/9+=Z'8Q.YNX&CR*X/C*W%ZW1!5LDA3RN6/RDUC@8R(>!*;%
MA#AUABK_99FUVT0<1VA(JB58KE3+:^H&6JZ[(YP(#Z11HCR6XVV875JS/E#G
M03C]BN\;C+N#2G/$A36#N7S$9V1 5\#,8T%BAEYDX2.Y@80FH;[T08%J!N7-
M2,NEP29KMT=-O 1FW&DM8.+6Z<&/PN0BP74UF*,5E90\!]HZ,._9;A+,^B8:
M^;^(>\^HIKIO7QA$0) B)0A(DPX1E!(Z2)$2D!8@0!*0#B'TT+& "$BD5PE5
M>DN43BA*[YT0)!21$J5+$[$\SWW^YWT_O%_N/>^YYYQ[/\PQ]EAC[+7'7GNO
M.7]SSM^<"[+^>'2>@),>E5PM.-L4'R?+OF)?J2_8Z!:85=+&J%$C-A259$6$
M.!P ]7UVUF\K(D+.B6=(H!>,LWFARE;UW;\'0"R\RC4EJ27+6FP)!!.O<3D:
M@68[^J;:(A3-@%H7-&?"9*,1-,U9RO^NH.@':&@75D#.\E"2F<:%6O:KKQ:<
M2Z_: R@=49VM3X:/W- .+ G5*SK2;^[?)1%>WM!ED!!OWL<WCL?$8O>KL^O=
MKX'5B[H]A7(X?4[T$?7\C(:HD-6B[&['!]EY9,Y_-;X178=0>]4F6#4P-Z\:
MIB^#I#K;[ ;BK:]%*H67,%37UM78J_O"7X]'TE@USY;Z>5(_,:72PE2#3-B7
M]8GV9ZL0<)0O.WU&L(TF@R*U)N"A=RM3@&RIQ)_=@A7=ALMX_6M1E&BQTM)X
MRJVX"7E@JHUBID,OU41C[3_3F.K;QG\GKV](S4XWU/TOJ$N\,$EJ.1/]VSO:
MS!)8GFC.[.+:E4NNE,T62?'5. DWF+*TPK1Q#_'Q@V\.$7(WP/513[R:Y^+]
M5CP:M[)6=HW[.IT3%JVP-IW\CQU%7U2*/E:.'")JF-SN/CEX?4/?R?%Y:K\3
M$?JVU6FB,Q7G7:WOK5>]E@#[.8H2%O>1@VUK?0)U?RI*J.JV+:1@MR2#.(NR
M<3+-7!T1$3SVW4#]:_T4SS!AI6.^#"H'@F/!W-V7A_C\T9>QQ9$]Z1GVW+(W
MQ=O.@':^,Z;B#!=58IRMO.:$RE]"K:>>*D'R0-KS'8T_,>_-<;:D%FB&"\;(
M(M#N^</6?4J!$"Y4BC\+>[149G[[9$)UM(X<AA&U9@92(S0[P%)WP&3@TUL@
M[* ]PN^L)ELRA%:5']>6R 5.IV'%=JA4L LY.WJ6X?<&H!JQ*:@YF4P?)X_V
MNCZY2'[K\K7M-%,UK-3"E-__=19Z?$Y&-".SC(@%#=K 0$I>G?2T+#*M9]#.
M#=(^1\C;X#<??5%:[.J("DC6H.CL04&K?O:R2TH-E++6(I5_ .FU:03O$(1X
MF(1PJ;=]WR2O71"\9Q^6N3SH9R%85+_+>_84+OW6#_BRHS,#.<H4:.%3(S5T
M CI0$/NXM'+JH#_8*LQ\8.?(V[HR<1CEYM&&KU /),='J+RL[A01VV#ZR._=
M,ME4FS/HN_0 /S%@Y;_ F$UEX6FZ&UBYW=5W*UI*T,KMEL6QS;G(]D1/&"AG
M2B^D,M)ZI_)5T%J3W.B>A<;8.*E$0G%%T-@#(Q<C^S.(;:V4AD8\;83V'OK!
MI-9\C'$CEP^VADBI?."Q8YKVBLUX=N)6*\J/?#:A6V#CJVZB3'-G^6E+_7<&
MU VRCE9I1DYE#6_HHK!ZJ'@.S^^+2W/8R,NNY&VWWPN+2-B]MK843R<TN4/H
ML&?YVVJ:G=TF14*XC30GOX\H2/%^<7>[_V69T&:+AN+7SH]MDW#[O%'>&T-M
M/*P7.H/Z8:Y7+9OT"GL@R/5ZIB&S/T %6)?;R_W''*:.E- PN<.[AQ#=FHNF
MGIIU\);IM@&%CR16D[TMKV4.:L]UM+87X0:TU"LY>Z,U"S\R]V_&P,C0=BL_
M.':4&%CMD*C]5<X"KB=93 VG^@G-,5/+R9[=5Q.OSK6(AF<Z4.T@S.-\\RP1
M;9\=&I_,(CC FBS&B>(RG)86'O^5?]IMGFJ':WS69R_<+&AM'O/Q/OV,!9=M
M"M<=":W/T-;/=M3%:S5_^VTA'(!<VBAA-F?6'J4NEU"<F*-$"TBM>M]#+I70
M=1Q/&\?N'[.;#?ZN[0^2YN$VR+M#)TE:WT<+2,_Z'NZ[B='MAP)Z'F,?NX@>
M].(7!\C[)K<>X!E$&MZJ%D&+'L<68,_N?0OM5*T2>\+X<W!NC)')"3/8VHH4
MZ^'SZ$@,7M_)N!=HWP3/AS+11^Z:D;D5+^[4&UP].29UV'8TI(+UPR['-@%C
MS4-V88=;T. V2 ,9L0[9IKB#R<JRK**(C*JD1??/?Z"20P,BFL#G;;0KH&"U
MAQ"9OL*JJPLVS[WZDI'**'X'RANJKH$IG4'_K[Q$A9Q$096-]L*@):PYB%7E
M *H!]$<SDRC,\5K9XY "!X5P8J[J[O$[36G8\T^'5[R]3U.V9/Z]CD.W*TJC
M>6+M?JYF+4+KTZ_8D59O\U06%O8<)_Z6J^E'BQ;9"Q6<F#[H,"@_>9S.M-@
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M?)@'%$2:TO3ODS,)$ZD3=8^?7RLAA2#/FTV5U#VMT[5E4FB])U'BN9^K96S
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M<5AK"M^V41;01]LJ"=O%NHJW5.ZW@"PM#5EELC)&/W"N3ON%;G1RN-5==P]
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M*0O@E&6V#.]%+ S*3+C+Q@5T+H/\N(U4 9S >-Q+$8/D2!H;\:06?9SPEDY
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M]IM(BJ@+Y1V#&<8Q@OD'T<JFL6G>W%]N$Q1+,Z'"Y5AU0V)%IW-F3-%0IXS
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M(>E8A4\M]O9DHU;5+VNOC:6\/8:O7V[%#'FOU,2M& !U;P70F4?&?[^?ZP4
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MTJXDGG;1)6MC'?I>0P@V%*V4P1USLO'ZD*_9\S_,KTW^O 88>(SY+[C*VN9
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M(4A_:DH^P=VW-/:*YOXG3/N.?2!#@.,[H:;8-TRNYE>F*BY(193D,^$CF9@
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M4$NIH5.M@3@FV?@&CSGO5]=+IS@XMY/-T//O#8NWO\/V#A\I"YMB2H5='IT
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M:]G;[+\NX\;?O3C/,#!B\\F,133Z:NNNMKINR<(+N:QEQ)\5.#?J;OT!Z9F
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MW*>T(V!$OF*=V]I>]B*\)9U8Z-!T-($9R*O7GWNSG?L6W2FS*W[E*<2(0FV
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M_[:<CF3A;Z<?<Z2,A5,N&'Q8Z3\ ;D;46AP%@N^+A4L9UZ8< 3XB]!_  MT
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MKRGVM:2U;ST+TV-ANA]HRU,&]%3K_//.#>EA#.<,[R0)@%&,WGPF X'6;1O
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MY8])[FQ/!(8ZZ*X?'YHY8Y@9/*'E:*Q.![KY;QP$M&!7V!VXWC@"H*9]TQ#
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M_1-I\V\V%F.3BK&OU0'WO7 @DS=(^H>&\:/^3?YCVC]7TP./JP-X;J 61W\
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MY3FU>%>-6497;=V*.!Q;>["+2;WDZD+1=Z!T*NI&+AZJN>?R9(EI.MEA 16
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MN[M=>>M6'$KU3 'S*\BF0V:)BI9,\N2L3JB_4FFP$P.?%,IC^<7& W8*I&D
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M WD%R_666IH7I#2EG)$N.;5S:A[GQ_V<OAOSG EVIW1!,3"G=N2V!^=/^=>
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M]VB4O_C=Y(2]=Y3'G^!N/S<,NVJ:Y,UV!LL?5>"XCZ%$AG_XRE$ 9?M8BM^
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M>1EU;\)_IZ5^1/'-\IB^VO;%->!T\V"\5/WC!XHY7M/OQE("WUZHIZ.VSF6
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M+T'>6ZIV$J2^(V(KC62]&WW&O8!7 KC=W%IU\RFR2R 'NJ,]GX[3O.D/0KV
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ML5V6R=KRI&7;5D20V?[T01WIJPD4&2'&ECQ4O^PIJ3[5/YQ:LI60(6O \!J
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M^V7)8ZY/NB(]\,*!RZFF-N]^F/G)V;!\;PG,CMD>&D4HLCS5^)*<+"B97?"
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MAV+J+Z;78)E="UGR#[6%8AIE&GUR'*UD5=XJH[ILA"*3^PS[7$]M:[RDC$H
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M3Z-C&:X1%1I!;HPE.RN"X-H4&C/L862CRGV;ZZ?@01 8HN[Z-^H3&*LKH47
MS&#<KN0A,W<'&>5J $<0ZU+6!/6  0%*G\"OH1B! !Y1*D$ZP#ZNZS$>%**S
M-,I5!\V^H2M!.'H] QH\)ZW_4$1'E6BH$(' 9&[>D*=T+C1W <2I7$TDG#V.
MONCCGG%MVH"'S/I%.6.;QT7B"1KL['O*U'!5@V8;\-0Z92KSM87#%WO0W:!#
MJ,X(.@VV!1.)B]N50 30*%=].$@;JL01@P$"PF/SVIYV![$"U,(V0J1*&_8%
ME&E<FLOB278&U)]'UV3 IPTJ 3,9^@V/\T0]&HRY!I0+A0V]_5):IG&)?24
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MMRV_Z5_GZGJUP9]KE\1Y-U0MM3%#!HPQ4-$-XB\JQK0W&YA )5^OI0)J>4&
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M&C[NSGWX<Z1@0U&W_\+L'?*$8^[D-D8[[D(WUU1+?%7V8[$<>:")1I78T=+
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M_O.ATSF^+_L_7O*_TGIKI*"Q@-RK)KH8>E)^\/P1.^;C%ZT-C7RC>E9]^]:
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M[DH=:M:).4KO:5LBQ9-'8"@AS0'X5#[V-$]Q48D(!62GTQ)(M5<O\ R?OR^
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MN#Z<1J1J4PA)CO03)1,TC*OJ3DY/3B11(^>_;XDI1!\BU0]B$:LW@#6'WS>
M(XFE:Y.VXK8N.;D*_M[SZ_B-7]J_R%QVX;WPIM: @WAWTQC#IT=\-1&QWZV=
M74(4.G(/*[-N (_KCK@63VL@!^'N)5W9!^.-:XO@WI1WNOV=UPBT0@T!F _*
M8KK#C9)%:%F;N48\D]K3W19KTWV '2751TC7?G\/'=IB>">45 QBR]=NVI$
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M=.0BC[S^P87[>>D4^PW [+U6Q+\D=3F=#UKTH:6:;+>Q!06I"?3*$!'W$J6
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M3UOC<\ O'IQ/<NX<ES*]P8:DAV6-#ZCWS6>U[\3YYKA;V5(.U71GL OGM%7
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MZ*36X:4R==>*PCW! SRM'4R7S)1$J%X^$4,9@"@?6K5U^K>19S^?(89?3$'
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M%1UBO*Q4[L4<[T).GN2*L(/$.;%=)1G#NV?F&J%?+;:6K>C>O(G6KF#.(N]
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MH.!?@,!D\P0"7CQ#G1UVKYKUQU XWZ1!CJW'$.MXT+*EEM_EM0/= .C!"[3
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M,$ 2WRJ5_"4FGS59.^V"NA%VYJJS#Z8$P,-,V=M<[6>?8AR2PVXU(P*)IU+
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M#/6D!(UC+R9L'N:A;)<="<&IUAF$NL*7@.3^V3:3""E<.HQJ8N\>1\-8#H-
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M1H2+:E+@G@OZ:4_A_?%QK#>_N6[Y?GX3%?J9CN-OWT15_B=F_O\!<.?I& 3
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MW/_>N^]BKYP?4[6UH21H*/*.6GO\J@\%S)'LO1/SH@<[H;R <UBBNK$8?S_
MD'Z+>YJ.@[  ,C:]+AU5#$2]\YS6PW+K #E[AW!6NVH^WVI2'!@-3(I!,L]9
MMYB$')!RS)7>7K9& -3_0$O-V9D8H,HQ3'[D!:C./!&+T-S,E*I.HAL.FCWI
MA3*2SW.ZB"^]$ADLR\SPWA(<N(T&^/M=>EJR!,PS7LW(&9I&:L=GXX_Q/?F
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MDSI:.Z]F?+;] A+S:RY/ LT;.TPZG8I =8JW+0@&ZS^X(=-6'68D-SPMV5A
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MZ_6UC1Z1(4YOLX-+MR6T_DB)A*',>H3?=$+BH$MZ60< 5],(HR;U^E*R$O@
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MQGL/&$MXW.LW%9%6_%C4<+O">S?-X'=1#I8MD=H$=5X20<9 M7  5N+3MZR
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M_/PY]!8MX"D]BC1?W;VY6[^]KP]ON/K2R1&C%G$[3#:@M X[&<D2O>V0O&L
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MQ11Y@15515XT,>JO1ID=XL1I.WKOYK1!PA+^1)^@.Y_0YMUPEKFX)I]2EG;
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M08_J+ D)T_@IB!'BM1)QH.3*$WVM]LF1\,X)/6R%V>,DKL+)VGAZ#J\+'P@
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MXI1!!FB,P--&.>%+)$8TGG,$H- T)D/51>XE3:)JF87<701S3D;FOR2G*D;
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M8&>M03@!&,E8QVDL;A)MPK:;$G$[9AW1RT^%]G[6I?CMO6\D ,O=,[MIAU7
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MA14!J,V%3YKNIN%]6O>Z3LMNX.E3>/ !4^#U$-A?JX 9PQ^#N@D U4[CQ,:
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MX#$8@34!1;M,?F--6V+!^/NY0&83H/ NT5$9I:9)<AT5P(>8#4;0-+';]94
M[24?[/K8 /62#RZ(3#1ID^#YJXS L(BJ*@H TAE+-,_Q%<@I[NLLL/^\TA,H
MYS2(G$8K$0 3 E#H3URW3@;_B539.S#]*[@Q_0INKON:6AO-H6)K;&;[>P2
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M\0YE^=_C-^?T:#33K^RU0L6SANR^Y')>$=C(7J.4H,_@9Q$7D^)S>$ZL&RE
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M"S%V%"T*=HF''>F>47';NM( 6P:7>V'^F72G'U1*W=(RJ!06?NSXT82?P$+
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M97UZ4O6)FBRW405POL35'&TH)Q]OM_66C?B1S8=QNB$[]*C4K[TW;YB8B<*
M*!U,L&V^A<@GOL3&G]9([0(8X]"#TC2A?*BK):FXBB]J6*TG]9UPW26'.2S7
M6.<43^3:5I!G.E6.'X]I2@SMTV>=8TL6YJQ-B"&/:CJ<EWJ^+Y\0NJ5 (1I=
MF7R>,M6]Z>&WTA$S#\$AFIF79#,0+6 ]/"U4^NWWEK=)-V6$A?*Z-]I\[XY:
M/PO2Z!#Z+@FA-!O%W)WW/'6A038'<\>%VY+G4YFPEAJ5;#JU%3WB21A@&@1&
M=H_OL1=OWNAP,/WIQ^T0:S+H29OJ&1Z)("BX]'P=D[?:4,#2[&JV*?>4]2FG
M!K?1"3>IR63UP,R:%?^:6!.%Q3A3.)D4BU]WOFEK8\C44)4DP4)\?%8.[LE>
M^GI$/ GGU=SO Q+F3>//WXA,#5=IL*U9$.]_-!_2/%-&UJK"61W>),<8G&?O
M2NO.EQ(+[Y0DF-]Q+'U0T%![BN'#MR^%7GFA;Q!(_M7S+L-2TVF48[\[VO1>
M_GCQ)/9IFD-GKW!G6+4%EWDK2C';V0]!L& *#5U\+'Z36V\T"/;(V]A_W+3N
MV=Z].\35D5:)]\]BI7YO/MP>F,7V$2B>B%Q'?#T3$UP,6#F\YD;TGH%]3%0L
MOV'O)U36ER/V)NR-O,W;:I6)I?/+)[:0XD)4_L8OY]XRH -Y4X2J[ZKT;:93
M>]?U+;TYMV83H\R>6W8>7?&TDE-D7MR9"O84O;_>NT!C;]9:E#E#4H )KB^;
M\^))6!2O>W':)9W:QGOWT?NUH9N#D54EOGLNMY.4C#::75*1218>KU%P@@=T
M;%@[\^F*TU_TZ@*G^H9,%"89T1OIU!9EM4$[M,(76#06'48]U>MUM>RM(EN-
M1-YS/KR>*]0_2S231C>H>  TRFM[#%N)IW*TUE"K8WQ9Y<PM8@1(.2ML5G0C
M7I\+-CRW719!-I^EPDK,1@QX,C6%T+')-(<_.VO%$./[\Y?3J<%YFGSB.R,N
MED4H4;(ACR><243G^EO6-9BNLCI*T.@&SBEW7EHI'IKWH_%F -.>3Q^632#4
M%8]6-BN\89XAC;$T+!^6+>,R/2ZTJ7VTOTTZW:$^D+^01B4Y:FHE04)GJZ#'
M&17E<^/ND''" SFMI6;ZZ0R,=DZ;?=ZHIGC"FO6(N* 9]3.Y^Q)O8I-D% AA
M=>7OPEJ)@WC("L6:B!1L44Y[SY8@"Q^PC^??;X5;3<S:^(4S%[(N!PI7? J9
M3F5KV7T&LY@3,Y^#W+E]^4$3H0)S\689:KCJ04."<<OG_#U=6,'P:&Z67%W;
MLQ%5;\=G$_(B=/8\SY1L%Y(K2CV\>LW>2O>J2<>E!BBS/R@F12JPP+BA$DV,
MIF]\)-"*.9$)F^15C+R4>VJ?G@O5#R0_#AP2G):VJ$9>RM\3[/GM2%%0HZFP
M))-.]0[9:.0>M^VV^B851)D\C[#VTD<%M%Y+4DD3G42#=A!)U;;3KW4?ZP3$
M%\S:$7VIIGPC&EPQ7&16]BN45T:DR:L&&8;8K+1^@I)E2V(V>M/N/M'QLJA]
M1BX:6W1S'1[DY9?FS/O]::2G)$$#BU'OU\UR"Y]\,UF'(4Q2P8_QKU9L;T*%
MF&;SI) +6*+>C41-[A-R%TB$1'4QT#RS$>'2FK"S$<G I(^*DTC=D];6DSQ)
MQ8^];B*N3%1'TCM*C\(*!JI%;(M^D)L83S'/+1D,SS*NV*GKW-C-3(&0 6@G
M2G7A6N9'(73N;L4'0-!.SO.G6VUN<V<<(1Z34F-VKRG+NI<BQ$1;?6&D>AB3
MW)$QA6]5.L$B@<IL!K"!&Z;A(:,Z?NE].]*55&_?,6N<IY)YD^_#<(\Q\CWP
MOFFFV'QE)FAI3ZE<F$7ISK=V0'WR9+(%NVY69O)$+;5&D:W?T[TQUP-@5JT&
M8N!O?NO:T\>727]9JO_\%7<%39%XX>1IK>^0T\KTCV4&KG.T?["E"^O"/*<3
MNJS\Y8?0IY0O1N+SR_GB:6(I+@45I:=,%L[[;$#XFP!/9!ADZE;WVM*^X.O*
MG$M[Y^%.(7XK[/US6V-4[VK?OJ^(N?9#:>D6F/CY<NS*)HGID89B]+6C3CM(
M%_%SF[PEE2I5@#$UT:7?/MGD91RLP'!G8CLO=O#B/5E)[9]M3,B.0N.M[+O^
MLJ4AOR%O^R&A6:CW6&:U;S^'];Q05?"0:TBYT:"TDSRWEB )7GQ!X,I^L9U5
MZ+Z573IELL#1<QE+Y3 9,.X!(4$!3K&XL'73K(*YM_-N#\V^IQ>5X/X-C@M%
M+N1$(OE0)YR/RQYBVH&QLN=I+O9U9OHE'DL]:?IN3Z!\;26ET7H&0#I-' !4
M0[,7/=T6(B+M6!"X YC$I#GT>L3>!5R1C&L:IR)=+5U1%O(-R(&'K>5?IB/6
M/AAG.#!J^CJL?.L.DBF5^X"Q<.QY:Q2=)<8WG4YUJ9Z)R;-OB=/&XWV"^<UE
M$DOU'(_2;Q_OL)/R1 KU[,G^_,1&PDM3P*NR9O.NX@ (-C)]M68I&'-^'160
M>CVDQ, $71'ZGE-5_8O01BFL++P5<571OT2]H8YZ$1%:O9_]+76MW>WG;8(Y
MY2<QD?W<FWD&%NX9!B.@.BU<'EFHM%JVT_@\NBO4O"$9I8G64=>*9[!7OOTZ
M8;[VW I#;<'CF2#?L>;"V7&*^R*B2KW\5N=DMR/MB$+13BD<82)2IPR?WMKF
M6RD>9X 9)2F=>1\D<'/L:C-!R4PC.VWYP.)W\=+[A$*)Y1@S6[96R936YH?I
MR< $7P_?>XS'FY9!.EOF'6,8F'R=_RD@,O3(A.[L [Y4I*O[Q"?Y&J%%JK2/
M)>?VA!"[VE;PQ.M<D@3:$\\0L0Z4GHA%6992Z)OGY"KONQ83QT:=,RL.JVQ+
MKJ,8BD8Q^BC^OEB5G\8F>B-F.=_59$D,-^@))FN)!T3NBSC^_)!@97WYXE>V
MPM)GW16B(7#'"!MA*ZZ<QU[!]:/2T^@9B\\M#W](=6-<ZZ5-3YR_;:DN*TG0
M+0J0/<8?:D7$$YQ=#;E[X1I0PF$6V.#UY)HC.[6\_;R:JT5-([D+^=5]2D]L
MWDIS\^I2WBBO^5H[X+G\[%<RLEF(.&[Z1]ENC6#C]?V8R:*B\+08GI0BXSR,
M^V=3MV><;61QYV9X7Z$@A#]@Q=-:>1ZR+>FV:9A5+.5=[!DS=3JZ0C^#-*T-
M.,7E+@^O#MZ?A633CZ!!']U2/"JO2FC4B,,^18J==2B\2(S_KP=2V1)S^TLF
MB+YDQ?1U5\M+D]Z^D.O]Y^)4'XW)LINT>R%#JAGL2\H\M4F4@LH>+3_SNE<S
MU+'[,BY7%W#QXPG[#3]E[RX1)%JC;;M@P8 ,%<Y9D6_DNR[);Y&^9K&Q%;2X
MC/A5'@-WRR+\T(>YGEO\A<^OWC6BBY0A=^YT6]:(Q?:#BJP6U,?KP>SG$+T*
M\@I,XIF:U2M?26N\%$L"8; <WP :3V\WY!G/E2+=Y*F6E,]\?"3^LG#BX=J,
M2?+=>%+;E]&^GJ5.-YYQ:'U9V7JVN'ZRS+$ZYHFN4Q=AS]W$Z"Y24K1T__3*
M1EL^WZE;?L0#;Y:JZ45^O:13#6?F2UYOOWX]W.!=[-"=>)= 2R=(/29Q-N1*
M2&=&.@4$J$>^/A\[1Q]ODI+67//96'XBC=P4X]7WE7#U*Y]213<9[C2U/UW6
MAT>1))Y4-%2:!0X5^X5C/]H<Q]U4OZ13D3?*70LMY"X_\\+]=EJU4*<"F^MC
MJCP76R*)R]9<0ALEJ+6)VCEF-?/FZ\5.'E:?$^48+>B7^;B3@;4:ND<]2CQ0
MJ883^L"WG>2TK^[1\Z^%RL+Z&S_%KU8C[Z&@P9M#Q<-C:MDZ,[&";*03[14)
MZ^YQ0>)?MQ[:$16O3(F0A)^X?U%YSG2]43F$00U I2E3*AA+E.8F>;0[/5;0
MFK*%L</RN*3J,4E?3A7.DZ#)MU]\)?%7J(16!%]%LZ78]Q8MQT4'(12LD72F
M7SW%8Q)9N(VA.7MB[[7[JJHH+*C48(5('P';-_9UUC%*-WH"4M]7E9IHKJR;
M9<]:7R1 <#BL#4I69:_<3/URAMU>42EAI&&E%H(@CO,,<2;Q-G:L92JW8'BT
ME/9)ST4YDJGAXVBJ)=T']5=$A9/V"OV0(&<)3,GJ(M&O;ZEGO6]N^S$US6C$
M_*;5>.@,JUQ9#EI""-W3,*8@H22Z](R>0%OY274#"J'3YG3N1.$JK'>!J='T
MK&E_7-.Y-MH Y;/&P17:ABOG1@6)6II]B_@F#"EYBPJU"(9L6O8%F":P!63D
M&OVU':PUI/6UK,$-FV]HG5<?]A'T4#W!%2[@GO\O-"I^TESB60L7;W5Y$Y8U
M<K/51'7=8[W=RZC8QDG$@DD^!%7=O/5E:.K7!/#B11<)TY,*%D:DP5N6:'[!
MDSLW2PE'>/)"7\N^$'K E];\*8K,@VY<+4A_;JU5R:$9J4#D+.56TQL=Q$5/
MT(ZIM:Y#-\>?.[_9_HWCBN5@7K,50E71OQ2R,N.??&;"TR^X76VD8DY0VE^1
MF(A-EYO_VZQ W[?3/O=KL^A/3OEHYEXI^BX]FFD5<=H2$K0R'H9L>Z%=JY=G
MOU6JA:R^5*CI/GWK-Y=42M:>3*S%58MY#?>@44R7!'6SL'K$DF,JPW4136[C
M*Y.4EX>@9$.<K3FOE4AP?WI91]+TQHSD.=RK$&AZZ(8EZ"NY]T2H24E'/2J'
M4.;E_9S +_*#&NP>LA#3#>8*,RC&6/BUPV]&#*AL*_V5!\7CP0= >8*2)?6D
MN1:&R-!(>EBC0H%V29D:HTI>,3^R)$\A3+!7] /V>B4O^/8*]M59VA*R")N/
MK(#6/S5-"#U"]YSCOSAIML-5B.**L?#>%X&K,E$5H0?B<86%^!ZX&IC+!,Q<
MQ0;8UK)+A).+WZ8CGT<Z+-$#3Q*/*TQQP^CO]=RW><67.,AN"!&B;2DJ_,#\
M]Q]V:8$LQ%3_*D*-Q[%JQTFCWWTD&GZ #JY=#<<YYZ\C2UK$?PW5QPFG)8_K
MJ/TW-1QY?)U,E(/IT=$GW-.NM8Z_1/<<S\X]YV^QU!WP[Q.@BG@%[/ZZPO]W
MU2Q>)5HXP;)J<(S<CC6'[_5B.JY8+@S0P4T&?C#X?U!+ P04    " !%BU=6
M?<2MJ.'E  #]"P$ %    &%R=FXM,C R,C$R,S%?9S8N:G!G[+IU4)OON_\9
MW&DIA (%2J%HD"+!H4C1XA(@N$."NY06*5""%)<@Q3U!@]-"BY>@(3C%'5J*
M%6K[.6?WM[NSL[._WY[9F>_9/7L]\_KKON>9^_T\,Y?=U]^%O^N N]KJ6NH
M @("@-T_#^#O,D 50$Y*2D9*0DY&1D9!04Y)S4!#345%S7R/_@X#&\M#=C86
M5E:.Q\*\')R"7*RL?%+\@D]$)20D'O+**$B+R0N+2XC]VTL(*"@HJ*FHF6AH
MF,0>L3X2^[]M?_L =.1$KXD;B0@X 81T!$1T!'\'  \!  (2@G\WP/]B!(1$
MQ"2D9.04E%3_;,#<!1 2$!$1$A.1D! 3_[,:\<\Z@)B.Y-XC4652>D-[,DY?
M!K&HM!)R+I6F?J#1]+?'X@Y^T124C/>9F%FX>7CY^ 4DP))2TC*RJL_4U#4T
MM;2-34PA9N864$<G9Q=7-W>8?T!@4'!(:%C,Z]BX^#<)B/2,S*SLG-P\9&E9
M>45E575-;7-+*Z:MO:.SZ^.G@<&AX9'1L9E9W!Q^?F%Q:6-S:WMG=V__X/#L
M^_G%Y=7UCYO;?]-% " B^&_V?ZJ+[A]=A,3$1,1D_Z:+@##XWS;0$9,\$B6]
MIVQ(9N]+SRD61<Z@DE;2U$_!)6[T#>C@-TW)^%AB@_OLWZ3]N[+_,6'1_R%E
M_ZNP_TW7$H":B."?GT=$!W@*N+[E*XVD_$_$O12<H1+Y./ Y>W2=ZBOBDS:I
M45;(_:3+=\<H<8+&F>BZRP:>;^\QM>8A'YF\7?RI7[?IZQB0?=@C.C"(:'[8
M&BH7]Q>@;9+G@CF_NTW7WR"<88Y\F'#6__BG7=\(+P)PB5#I5^:IIH'KB;2<
M^'H=)..Z7O>WWK#S3([Y:,Q$"GX*9#C^_,"I 8KLF=_ E_@'U\$2)&*S6*-.
ML&$0/L*>>9^^#2</^IE*+48UZBK.GD^;BF6![FB+<C$@A#7JAYE%.:S&<Z,:
M+?R8N?_0C:@8N<EWMR<Y4N!1M66S]YUA5*AP"1IFPX?/7NH;9959,@] CT6P
M;-(P\MF<&"G)^+D1H>(""H/5%X%\:.]/HG\!K@>G7B+W#-_U%F75+_5&"T,/
M.9ZN%5-=F/(%PA_$+=.,>ZU%U7[6?M.=%VEKK'3/T *+/JCVF4^-.?U8U8X3
M\HH_Y=7X"PB8(D%"40HGF,;Q6<X[_@;"G97=GI8CB>S]L0 W0\/ZVJ-.3="A
M0.L2)HGLWJIZ_&HUX0E0CT9O8GOS0>[*+<@%M<<9R8C@*R;\KTA:!Q2*Q7\=
M*JSX[!/&5WQ'^&RW^':HG;3PP9V5S^?4<V]9]IL6]BEJED_N#43Z6E5\B!?Y
M9;D)KUL0WHYE.B6!A_W<>-_I[S3UO%[_<<B.%E,Q[5$_M/;+#QA0*(_PQ=PN
M.W=K9^^/[-3E/5\@?&/G5Q=C>W#%JJ9V\5)%[79[:O\9]'YFK!$93Z0$^ XA
MN*C >\M=<2JQXWRMZEO;!P7\6^Z*V9>7JM1F[JA#QC+5PIZY)8.T2>BY+569
ME:["V)W5C?CS8IJ'<4^_,\W]!7QY.M%KC FU_73GAAKV%W Y]1<@>ZF'(]CZ
MPKAGZ>DP8[9?]P<X<L@.ZGH_*W3BP'N\T6UF?08C\*VW&%JE_ N(]=HONMO8
M\2T3OLV;U[K1A 78?J.I+.JR2U^FWB8<N,45/4TKFV4HX3JPHDVLL0YY.L#Y
M<;LIVFQB:XKR^)=G,-MN+.MTH\"JJ!+KGWQ?_F_<RU_E8EA9\?JO+\(;[FD)
M!GNL&46LL$S//MU6[OX+",'_!7S*).3A"&0@&#N4=5JCPT^?%(X[XN9]:S[7
MV.Y+GKB/IBG"!GX@GKY4+*T+2;3*U_WV)\^3"BA>;?VIG8& 59&Z+7WJ<_7X
MIE<'C?D?MCFGF1>:;9*G0[P9K$C<3 _H5:CS54U@'F61CR;:!4]^TN,,9]'A
M!O%0_'(C\A]B&9_]D7?Q,QOD >!BO[3OX;^_@/^JG8=<%U826L/(J]'FU\%0
M3FM64@3*YW+S4G4AMD93'MOO$\VSRI0[.+@8");1=1&E/ZRA/Z)$C4 ITP'7
M9\:??:LU^\CD?,)=\A2K E$_C!X_RHN'U*[1?9N;*".N%++>^/0PD^Y(Z3Z8
M3B3FDBJH)35WYP5KP9E-=X4-U3+Y#MGC:FS(5>=&4&M'VT^]>A>Y'Q#.7M=/
M_WPIUYEI\;0H!&"A%,$'^"\( 8W_>Z%9KTMK'LOG#F);O0$!N<6TMOU_V&1Y
M<BAURB:)J-4"=I29!H7YW8C& QN(K$?10I=OB (B/\P4X^6)PE\U<-]N[1B(
M(R]U#!& [SG?VA.$K2SU1J\,A\D*S!S+?SBPB6C"W<RHE8\.U0):#<CNK_\%
MT%BYM5_//H_D\4B*@+>6,1B0T6R)4%D=A57T#G!X)OE;JR>XX&5-(%^O<U!N
MTPC U@OG]1^7W4'9P,$1)F,+PQ!+TPA&.?ZQPNC>APP.D=)R3RFM^C?RCFGE
MAV6 -1NZM!'L8BV.%8%,90P$PS_J/N6P]$25#AOBZXX4:?_,3*-*0#]_W-^Y
MG??7^N?(X4]I0VI7%2>[GO)6\I^]D.]LQY]XEPZI>F7P])H1)AF0D6S:DO0>
M_P5X-6_N1U+P(@84F<X4CE\Y];IAF]:W9GH=_SF"3 3O1T@V5!/CM.=%XY?#
M3C77VIWCR51;UL3KVV!2/@@(??EN':5]>^F*UY334Y^UR?$D7.YKJMY0%[ R
M5*)28S @^*^.%@+*!RBO^-?G4_\IX:<1 C 8JOW__/<P,C(@JA&WN(VKHDE2
M*[<#Y><,TM]7M+AQETPT\#B1,T1N>_ZR8.+061A%I\]</>BX?M;W%D6!,/1=
M:5>3,+JJU#1$NMO)(;#O\1R8$:%S0]_RQ1HD*$N1RV$E8JE17M\C;5>COV(<
M<>6W-JR&1VQ7GKV0^3UKTK;&G]"T"[Y_QV6B-&FS5CD".! ^':>(@1Y9MF#^
M BPY?NUWD>CIX+!"]L.;EA2RVD]E>VDKB+>V4U\&^#_J,K8LO03>&R%?1X3(
M,$S32,@BM/GNMOX?M'$+<3, 6DV,=-(>N7(0',))SP>7 DL$9I+>AE4P]NWO
MH_66A[I>3,9P>UK")=N?^M[^G%K'K[L;ZE(S.;'.UBKQE2( _Y^E_)]"J+B[
M*P6_6NX?2>K>/M]DWN><U4@2RHOH\>9>&5J;^Z.S/N,U."0E#%LJ^W+XM4W%
M_EC.&%>MO2>Q2,4G])EE82W(%4RF#>.+/HL+J;E(]CO2SWOI$C"IC16>70V%
M3X)Q[K?W))0:]QA.'*7 7"_O,*F?14_'\I2]&T+$4]'ZKS4UM$;=N]=9SYUG
M_^YS=D::=O*E;%[@S\2I(%*=6Q-#9<$O$A.61P9+S^D,S( -%-3\DIZ4[C3Q
M^NIL &!^C7LD45M[S&OMB:YW,J,UKL_H/;9V(OOV.+.\@/<%PTR/3NII_%A6
M%]M>GX I768^V9JX6?_XN,GM)K1M7R1&XXCY4^*W7-X1-%E3#S=^KS+NGV'9
MR)D*HL!Y%A4]H" ?.B%OL1$!B5,BA9X;QS:W^]T9JJ)+,C'BULZ0+*0,6EAL
M/AM<36#WE\B]1!<-;YH8>T+BV2]W,S2*YBAIJI+FGPEH?A=ETO8V7BX[2ZY/
MZ!9XRC*#F:\_);N=8SY!?OMIBE0G>&ZF85^UFB2Y^91E/WEQ>ZZ*Z3B<V/]Q
M72<3G9$9G6.MOC- ZX[V@006 MJYL=QE@^N9P0LJ"QGR2E.IU'C<L  A[D<^
M9+Q [7-33$M23SJ:K*0R(YP@K-H6UH87S<XV)0[BZ5CUWA3*)!_UV!L'[BY5
M)30$NEN.^S$4#76YVU<(6="ZLVDD]KB"EV\DO4;(F&TN!Q/0+IZS<J*\O;)+
M7.)1!1F6AOO?4\FA)R9;Q+JGKGU8YI%-#.J2JOH-OSAU.,[U>9X,WRL!DI8&
MTZ=9/&5"0\%A9(F*Q^(%17G@Q4_5R^,$%B;S"9$CB]L05%R9+\4-ZY_ 45F6
M?=-).PBU&*V[OQ5-U1MO^@=O@0ON[4?!E 6_%G8[=T@1(M-JP'^];_Q_'"TE
M*BUU]V9)+@<^(NQ++MAI G>YEVJX6=XG J'>3MZ">=VM/!;;>[(9@TX:3 ]@
M++C]V$Q=!4GA++^KP&A"J1<#/@(]]-P]ELE.JY/<X^L9WV,&/9G$^756IK;.
M76DU'L^7+G&6 ]YIGY_<4V:&GCS*6Q--R:U0(*%:";R(B@(.'C$.)LI^T] Q
M,Q/KQ#JM6F:3<7;F'1B9:<C9U\B+>?B%7*+1PT80P"G:Z%S?;C#3WT!58;#.
M+Z3&8S^6UW^*^[U1 <OGSBXR^7GYI2G3[3E^#.ZROD*\*^4!*MGR<_&;<6R4
M32CJR\VU+DL!&G;:5/=9S",YA<;?TC+($L6-KFQ)U,]B"4JW0ZRVY4=A_>^V
MT<"6QI\3&,Q-O,'M:*BT4)OXZ0D0[_BK5.7QD>'13V3@FZ&0UXW+GX,63*11
MOY]^//[ABA*Z-R%=2AR%W-]R-MGL.IC1^7:T:2GNV?I&2&FLYJEVV\SCYY&
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M$*6T=]'IW&X@@T90?5=:(5'4?737R:'NAE#<*CT]NZ(<KAI4#Z(:R$U?/3N
MO)A+<@7G5*_6-S7O8?RQ^3/0(H57\GAH2;J8,DV:3<WZ*Z#0!;^GW)\+VM &
MA3.VMU][!MG.+<*$+K)9TL4DQ?H"T5XNY6$3KP4,NU9NS>\J21Q656HZSZ[[
MSZ6R=%IK?MNN/V9@$:"JJSZQ"V5K9'!)7G@3R*;"IKA8F=4(:* ^:T_:P:%9
MR*UN8+[]=8KR9W5KXU=M7[\'K,_GMZ0'TX\V/*>);^_EDM$,'UM)UYJLJ>0/
M\LY,^S'[\JRN[0P@;A,O(.8U]"=F4^XW*U]R A%N/J+LQ;-TBZV4G3B*P= P
MU"/'!U[&T;(0^C(*PNKIB\NL;;/LSX(>Y#",C>VW9:OT?51^>E#2N4V)C9JY
MG_:P2O!]#$,F)O?COWH8X[]'XR_3^X4;1P-LVI =?W:Q#XQ="A]==YTVT<B>
M>NJ;H7!>7>74*W %@YQ1??W+@$HC18<PW! KY=5&:5,,/W!08BZ!GJV6=!,E
M)OALJ"Z49],G,K"J.]NS5ARY+^$I7M:Q6^G7+" *EA "VR?HR0P&WE6+'31I
M?<,!H)QOC\KU 2'\<(M )"#<-+B%9@FSM!AOJ/E(85#CB7E?=M^KH!;>1A./
M-.L7J4D0A5^JI%EH$BKFU^+5:#2-DJ#C;H-BT?IP4 <8XRXW$I-AT6$5+)N'
MD1?VMT+W;E(XO*YMNJF]@8!&-QO!=<H2+X(JCJ/W.$7*X9.B;V705<]QP5M"
M5JUM?B#ZUKE"10C"[@Z*M8T(%[#<LX4\$-KFU@#W'Y@]R M%+V'/F:KM/%2Y
M'%&6ZF!UREZ6# L),96_ "&SU P(=2!QM1HY]5'V#;P =]\'/+620N.XPB&#
M=6?@\;T."O^2!A&L'R(#UBF@_7P-^XHL';JXBN.%<B\J>PC4W"(IYT*'@59+
M*4,ZB4ES&D=F.S:ZIOP94![._"%S4PNAA!-++5KWW07'"C/I>O\C>$PZ*%R[
M)V4J&D910H1QQ68=Z+ZW]PB4K6SE_2?K.;&BV3H-<H0L;;Q9TG6U;B=%TS7F
M?3[2$(;3F($;ZB3W.%L<V&!+.-F[$J\DR:#[K33<W%DZGVHVJRTL23M7-( S
M"R.IFE51,5; *A>HF8:MLR,K90D#Y7X]8OCA3,>'DQ_SD6H6,0,$<2OS@K7Y
M'PLG3N5B?9-P7HD%\U+PVIB)PZZEXF5\!00<H.O6=E-LIN_HP_66>;/GEDU#
M[!*U &8=3IX3KOBTL'#HW,NZCG]Q#8C!.H.OPG%"P467PLX"C\_'QGUH3"1/
MN&5<2#I0SQ]K,1$9AR-K(;B=0 4.+#U-SV:'R[2+K@50@V PW/EW 9Q"<6[@
M\)&GJX5*=#!E' :W'ZLQ<AQFDQFG(+:J;Q!S8WHX-BU"LH.@^\5!.8>:WI[T
MA4_\X8._K3R -4E2%; <8Q0<EG5BRY%*'9<-[WZ%;GJ?=+<ET#I"1OY)>BMW
MN"0GE LKT@I3M&3*JP3.-,*N-AYP,9[J4E+O-JA+UQHTUDTCR_@9LQ1UYMS#
M\:^?=U%.ODO"Q:9L;3AF-$C_!3B]@E[3S?08;Y@\/9-V5X#T-IJ]3?PQD>O!
MT&IH51'[KR]:_B\AUR.- (V^YX4+Y-SM>_O)QP>.$ZF\"]7<OC#^5;?K37_H
M9QL2]4GTD9,T:E\D;-,E&4UIFOU0R*1I]Y%9N%EUTEAZ]6Z+L+X5)*M_T,7Z
M";FNZ7'TI]9JB&52.^SD!&@*( )^<C=[Y +&J8:WTL)Y;N):Y=AD5S35-=%M
M0VMKTG\<Q&WL:=O.OM%8)PX8_06$_ E\?2!I.JF1#@J2=V@YS>:+.K!JA9X7
M/7_9.HH)ROP^EUX^'.".E=V.A-\WZC!-^O6Q;K*&9!)[#O%(!)]OI6)JDU^[
MUNL'AI"S$EF;9GW(88D6 +%)J_2*P2$2E+)&"Z3-OS#O?$F5-S&:F\59! RS
M1!G=K<Q/A5S 1?@5,NTC8:%K^D&72<]6>D0>"I"AD1I=/!]1F3Z-.$]6-,A1
MAD^WNM"P_ 85)NU[&H/+(PDLSC2K!50#%. \8E=J8!R=R4N<.+[",E4#"B&,
M/03H.FD7(W'O,WQYFB>A2WPZB6-8LW#'[B@HGRRDL")]1.PC:JPO)1C.>6Y:
M 9XZ#*IAV@)&";!4=\?P:8H;O-Y%B:WC!/L@U:K/B2OS*X9YZE:U@5I8A\F0
MYY[&N@LTH,^#2RJ7]<W?M5\>@!W&9I[GD?IC V^#XF+535Z:LL_T.[X.MWA_
M]>D&$K@DK=JIV>!J3<BCPS2\8PZ=C-URLX6M;\T4^$J&)0Q\L_R-]4>@$6:8
M@-O=>#!FV9X6)%2?*S+> 9ZG4(>6LD<O;+GVZC])4U<SBV*Y1RJ-8AK35N+I
M6=&5X5F<5>-W<WWYXQHL(:8=_QB?;XE>(S'.DB2R>5$^:<1 U7:;STM2IP86
MVOIJ]E"B0L]]VE:,O174F)71(O?L_:,6Y!P&-WE=]SK18'4-<XS^3-M:/UUJ
MZ.HFDDB]^[:-];+>O.HF;-:I$[36DED?:/2IYL'9EQ,%N-Z\*;DRC167[<D?
M 3=\T,->@TIO03'-B_QDNQYS05DS_KJUFYB=/>2@M?/NC<D>&%-E_KM"5>L6
MW]0M7<LW>VVX_(-S_7?LZWBR-KBK-7Y]IA[JZIM.*X.&CI&V =0'(D /AR1S
MPF(CDYD[P'-Z\UI%"F[=JZP/$WHL0NM69"GT<PK,GG"ZR!Q!Q=R;+34_*BEC
M91R(,.&9C@RMTI;.HHQSM:?E8'?9.2UC\(S:R-U4V"]>1'$9:8/JM9O3R$R<
M%8] UN@A;%PT!VCCFX2(8B_[U@:@'$W1;#!OX/]AZ_=.\.D 25ACPWWZLT*#
MA4"&3#-902B_^']KG62V @S5&/Z3058!<#YZXS3K1/5[]A\/0F,DR7*Q]2$7
M?J@+44OYJ/);\MV.K>3: ._\GO-V:%P7WPL5EY1WS'>%8=<Y@XI+"V_F$9CM
M,YOD$=%3^RUP3$3_LK7GP"NN"%#&AUUC1$(O8%P+2B$&@LT:T )XFJS%#;E:
M15)U=7A=JQ?GRQ>_0NZI@.X-'<M&ZH.K'R+V.::>1Y-!M;RU1: 5NW8N;^S3
M3^V>!.%:XQ*[/(Q6=3M'N>3-K)WM9Q%U%0ODCC:@XG:"D$%_7)H[7;XO$ZO)
M,W^SO1U8T0K&*7?(\['1&ZJY:OO1NC,ET9F,K,A/X2*PB=X614N[('3OR9!
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M[@//Z]5W*?#*$"HC]8 4]D;E^9'X?],)GK<NTZ&TFV8;JUUQ#'"Q-I=PK3"
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M0HVP/G( /5+0(TZ=0#OARZ+253YDZ&JRVN:SZM5W-'ST&^6FF.8RI'T2/C*
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MK5Y$ASF>4LN\69Q0,)D/I.V)]#N,@J<C$W7QR$P<'!5/7T 1P,"5NFH,/Z?
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M1L,^:JEXQM?V;J(=WNDR;:9P"F(,""&Y\U9[QGS<!ZK\AC@1I1![,G2Z/I?
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M4QPQ,I>KD4Y5]KZ6730+EB)I_IN<^VL@_4$NL+FRJW8]PQV$ "O/EY;';^T
MVXL&D@F ,30[>@Q7D_-%LT!!4(_"*H@Y+DBG3(=EG;CZ<\7DZGSP2S73X.D
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ME0=[+(IS]O\:9L0YYO[-1LJ)D\,]D[CX34B<M2SG]N45<&'5-QW_0E>=T 5
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MRA,R8<<*7UBV6">B7E&CO$</7=C4T4><6V$S]J</5"E>FA5X:L3=TH#1G3Y
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M7GR3UH^;S0>7]GERP[<G6%W-#MW?]1>5\[?9F\V>^DE6$@0"':]^6.R]*Y6
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M/4:QYW=Y>Y_Q9"S#8 8Z@J/,H'?\2I9I%BU&0E94_/6F:@R2%9?8X>W\25#
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MRX=^MZ7@1F^D+0%9LI!V<(D>+LJ]7NT=/(Y8&#O/B_V<F&LN?55UJ#NONT"
M.):C86B]3'K>8AKVTQ<0*/E5VES? \D.&72+P,$MALN3^D^PS;+O6].1=2+!
MW&>$9"/6U<U:<ZX;R%$[W\I3H\_O?$FAR]7RBG) K.AH_::X-^#^$",REC5Y
M([\/C ]4-&!Q:__\!ESI16HT<68MCO'VB5 LDT?N#WX:]HY? (R0!%WU'1&4
MI?2Y.I% 58N %)NG"NGACCG,NX35$6<QL/8*,FVMQ#JCTI/U7%80;%B.5WLO
MB]L%3'.6;WC,V+QN#%:Q3:?D.? FN2<F.DA538KGF8>TIS2^$"$KAUL-#@#<
M$1Q9'L4=3X<M0(8#(@_A1QJ*\YS[MGZS#$38'C'2_<[+K-ORIDO-]?-N9MZ(
M9QWGE\@1#FW Z<@C&'D>O[-UU)KZ7!/UQ2HG/5)3%&%S(8+&$TRY:S#F8O"+
M,9,]T4XA..5[TCF+:G>,)NJ])L?';NC-IDSN3PD(QL4G1*^;O/R >JZC2MLY
M:2!<>R:_^W/_OSL"_"\*W6991S/R6)ZOG@'L@Z0KR039?KN'6:-[JJ=T2F#=
MLHBC^XMJ3)C1$G!\,106G/Y%.]IO038++;M<+]V[O;[+GS2#NLBSC#QJ'' H
M7GPS&JR4]U-& X1[T247[WQ2;?QJ5YX5+F8V^Y8WOX;MGG4$742VO9,0*<"8
MDQ^8]XY*%&]D8%;CA_N1HKQ)@%TO0#[2?86'/N7;.7/DH^@,_Q@[#)9\:1,*
M.YIX8%K\R6'*2\@HI"(-F\W^)Y#72?@P=N\V&&)&PQ-Z-SO@]AW&7,JEQP'B
MRN0@IWT1<4D5?)$4M^?PN+.5(S,KJ.3 .IX5E:,))?[*CB\ASO:Y5=(#U%LK
M@ZF?\MV=1DV!3,621)3O/N,F-/%J%V=#7P\B$Y7+?$OUWZ[@?X1:=GZ<G[,^
M#HAHT$-@>=T+&1,=EUM[,-WZ%P^+/0JRQ.?PI6+B\\_;QM2SR7#$L[/-G3%E
M]^6.2-2Q2,"U] 5]<94 O9*,NT[N3SL]15LX#CP*)VF]ELO6+V;$0]NF@OD+
MV4:8/(AUEME\*+ W4]=PNZCD;I$[QG@WE9YFO= ]8/*WYY=#9Y#:"[;![ECD
MI%QC41SUOJ=I7,JNARS)JIEX12)["&3ND7EKW6SUM ]78FMC$%;7>U;G65TT
MS=+51:5TVV3,J<WX%1BR^;;XN4F&B* L[)3[T-VC8CQ\-;<7K-7JBEHO9SFA
M\+-^4VN&D]L!#4%O9,@>3@(@UVLS[0?7[1--GZY$T"T61^'\'9@1<)J7\TE>
ML'0C?9\(W7K9XUEZH?QE,P(049X'?LY[% ;RKE<!:CIQ$!P]"/Y[.[@ZK]4-
M"/Y1/R/6+]RD/AR,:C\TFAJ&/M&4R#PMRI@L6# *P).LT&:,S:#[Q.<RDG[I
M8%&"A+.NYJ;Y1*B]HRSVLW/VZ ?SS[U;@ 4&O_MGHET!4S<RB2(V@6!\<,WY
M\"X?9$* [0=,$^Z+;+/8DU*WE"2X:\L($:HJ^>%J/5=W9UR0Z3'8J <\\P23
MQVUAEXGN0.F]-D/9!&A3EVG7#E^NS=+26EJ\4/\W==_ Z%*!;Z$@,M^"%H'5
M"'R@^%+@10+ LKE<^"4H5F8[6OWG@]O+!+L8@9*W+J:V?E.":KL]\CH?,:W/
M TH]:&Z<$A) CFZ;ROU9[K;(0Y23L0!H->-&I@QU?599G8R$'^Z1[+_(5ON_
M+J+^3+4'O58TM=7GJ;_>GD_OBGU-^3M)^-^*\3^KE_^C:ECP?/UZ"94J,OAO
M1<#CX=T'$50'$B\]_J+ZH\6D_2&\_@<J[7]$&1:\^A>V_U!B4O^SZ:U_FA;^
MK9C^WZ1;_YGTZF_2WQ?_@RK]&_7R_ZK_"[=N_;^"_3^-_U9F$B[K_C']+]9(
MU$H+.KWU6_0"6QHO/U+7'>(QW>^LM$AD<)ZI>7T\$+C;<YG4"81',2O^[/6-
M=S7W<1W[5/% 9I!1VD9#E9QX WPOW4&M^LZ#_1AR &8$-,I^GC)F]@L$_*UO
MISZ?EC9OKPPF'\3F?%:RGN"K-$U^NCW?+LQ"#C>O,ZA12[(HO8&D_;%99Y:?
M<5B;DO\ U8_0[]Y\(A>'A1Z26G\[4V\IXQPCG6..U6>TQ1IK@)D#1J_*WC69
MC(LD=/DI?,DPT *,:^/6Q$DM6IFK]N6UAPY\,5RVZTT=YOR@7Z6"X[55SN-V
M>V3;;POJ"EU=4Z<3H\]U(1L?PV3'8:/G:"]Y"_,'7(9C72]1%I: Q,]I_K>!
M\TT?=WI:Y59^$QL%2N!4 B;7OS%4#66/&,;$Q3X,P16>U5F@&EZ!0K3 :] E
MK<J=#,.WD-)5SWBMI5Y2V9WQOZBNVQSSG]<OYQ=6+AD66LEOH3]X/ZE'GU@"
M_&>K2*\;Z=?C'3?!7<K2OL%-Y=1UB^^.J.4[>K_B:[?R%4?,?NG;S.VVRZ)
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MAP.^[U6'T?=1=_3QG(A;+>TT]_\'F8#\PJ_PUL(7[G@G^]+G3GKD?#PLK"F
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M."7B&NX'(JTJZN344I[R@CRW-_3FP]=WDE%77Q#BHR"#UN8VG4#7OGN"N1O
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MS(Z?_2'OAT!F^C^L*PYL]+OP?=Q8L_6#!QES!X<VVUQ$,SUN:YEUB_],!A3
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M]I12&Y%&_L04CR40$WJP[3[%YP:21EUQ];-L@ET?GTR%ZB!,E-PHWS+WWU8
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M2P(*#MP!URU)/-'']+5:H+!2I6]HI*L.V.!:?&W:@R0N[YEDLCFDJS98[4
MNIXQ=9PGW3,6FT3\&"$>'O&N#F7]5:- DRR@Z;+NV2X%^:N K"7)E)6H'EGM
M8OSJR94&LK3&R/1O?HMQJZHK:" [\AAEPI(J!'&K5]"]@3S8VJA5V;R;]_JK
MW9:@Y5AQT&,OJ]L.$_+[LM4BD[_Y3*@*0M(!PSKFI'V:'LTEK^7W-K7(62;>
MK@/DT&>:S%%L"L?$OO\NQ)#%Q=5QB@'C/)CF)"#^7W8:QHJ&F"0Z50$O:'?3
M\/KA 03 *W$\,513N05XGJ*7\LXME:\)Q:9E1 !J2J*G(L-C"@E D!N\1PPT
M_R4:%Q1$ (PG1J61B[OPHYG1_ 1@R!.Y,FUZHHL )&DL*0!J"@RA&38.EGFW
M!XSL(*6 C;9!%+*B^>5'$DZ<E<' LP>VT!/8!LCS1J./88-\-.HWT[)NRV8;
M'WAQ,?@Z-\C*FGGJ8/[)N>.:LC:1Y;-5?D_"SM/5+HB!6AN->'&*>?Q@Q92X
MQ3HG*8N[7W/Y*8;5:UZ(@;(5%/ACN!$G7;4B!^W+#B#.][BQZCV9D&?+97A-
MG*K4W WP=XZ'[;6KO*0<!DD6 _5JG8LTN&>;J\>NFQS:P=().7B :(@/K>*N
M3CDZ/+!C9R)#U5MTM%#O'E5[:)*-(S)=G,*#Q>XK0BTBOUS$^I@=QN9VHT(#
MAE'2+(C;O<X%]RZ?"E;@GZ<X(.B^/AX,I\N8VKDDJY@7NW#6($9;\[GE<H"<
M'#T: YT@M1R/>\*Y7I8D:PR^,=C(OO.V"OF)9H:Q\<1$3<RS;O55\&4RI<5,
MQ4Q);")Q#'B$SP$9]&M(Z?9-&^BDOT'LJXF_3@!VE0\Q"JVV]IB>/*0M?$;)
M#WN_"2E[]R/?,[JSB3!Q#\7GF+BIZY@V"]R!K!%IR!=Y]DL/C!]46TLJ#+BW
MI]?TNZ)6?>>2$F?2;&EKX;S '-C1*3'$QE2QI-##CS0J]Y/&YR\"%;3O$IMQ
M_!P/V7SG,+LS*PTC&7J,70F  59?XL%ESD!%*?U^&!</]8",H6=;6]-163+7
MV[$#JSG%5PQ&;7ID#!)9BRTTI= SDZ:OV\F_/'9L;WK$,#";^[G:)+-R\)[H
MO&0:#*L@F!UP[(O^9,E!AZ<OX&& ;=V@.55EFRY>O/C2C7(&@9I;YCRO9&7Y
M!'!\3NE$2GE&IW)Z$_6D:N8" 9/Y?A43&\M/I7Q5GI+]N_!=^^_O!DWQ]>*D
MS;[9.!DY04%E?>-(RL\E>J[?1H=8IKN]1X.L!V34+UR]= V"D'>C:0^X<K,_
M GE*7\#3UI#94=?9GD+]\'N1FR)>O*SV$".AS"]G=D?!&??!O*,\C0Q"%H-@
M?HE:?7/Q3RH=OTXO:Y+?PLO09:Z\N_V^>M+Y.KW;<*%''U7/ON,]RWIUD$KZ
M],YL<'L32C:[,L+N.OK-(D/GD96B09SH9;M^>27KKY!=RKL=38M7Q?@_59.Y
M"28/^MC=>#OLE*D]JUZL;MWO@5X>?!,I^\ZTV/:2W$-06\TL#>0\GVK7 "E-
MF^H<+,O(8DW'6T_LQC&S,"68'\CL4WF_=#Y5M$BD-T<7[;*-B>0AQJ22.[B4
M;+%QMVX>OZ K\#T<;B3WI-H-,38'L'Q\%N+SGB06CV^,2&;:8=WLC^:?XD*R
M (M=BA_<OJ5I[!DG:>.R76#(MB[PG\E0J]8L"7])-H$^>5S@5$U6UT>BG.+*
MG@I!,F]-G#-.B+G?*GZ]VOK8=^S,#5EG[X.G"( LKQ,VR#YH,6S0P[ IZ)$V
M%7N+W,%.GP^Y^Z/WV@61G#(1+5AI<L'P>]'T]]%SQ7-3+F>JOK1K!)O"<6+Y
MCS-\)+M,Y3L2.#2]>%#O/\GD<!6LG7JCA5 ^)0=G&1</6'N<-68J@QV?FQ,X
M<5,:),^.\;2PA:PT+K>H#Z;JP2=L1J8G^;+;S!.>3/BVZ2A4U#28U4C4Q.6T
MS_:D.(>4(5>=&\;XM%DG;D]P8F[(-B'O2I3&IR(LT -EP:2>0^WUU0,ZK74W
MY"C<ADK.GCVFR0=3M IUR_*-:C6?LA<0U752./#)<4RC3833UEWS(.^(H?*C
MF]BJ]?O6(;#E4;C4?!^#:;=A\:2 $6D49^G>_=*+&-KG!F^.1B];PJ6>B1<\
MP=:,F$K5#-BTPKWJ;,YC$T:CU#0AY36IBDJ]R<A<^M6^=-<T.=ZG0H=3SGD:
MB[YC%*@#/$X;]'?Y(KY-%CJ:N/1WO17,R[:(7&"%+YX:DW][.9@CI<X5LQA7
M>BG%)J*TU+*C"9S$F.+1[->YTKZW*-8B.=5AG+]G[.Z$7$M93K\3,:\:5M<@
M%%M4ES"['W9GIA_I5'1OYW<V=0_OQ=561@+CL:'.9_DDWKX'(=0Z@VNT5")%
M?SH%^4^6VRA*JWBN1^<H 80(+WEXK.AJ UE)DZ]N"7'"ZUK A*%RBR=/I?(C
M#K'W%T"BP: 4>E6P<Z+&C><:XH$"HU;7: ";-\OB[G)A899=*/%4&'$$4UJ?
M^LTABZP1Z!&\[!!Q5M< J0]'SLG!UUPR,9,$H.7(:DR99S8!>#!+ "9*O2#V
M^.?P'BA(P*V\*D;I=A=IT".G3.7,8]C\FMM/"4 .-]AO!G+3%G<"&G2]Z3+U
M3'6Q!58MGNP0LR-^-H/^E8EDT GT:4NJH4O%*F6"I[X\1>QO@$#2K+)=E8SS
M]Q2[V0ZFLBP)[1XGGU=3.?<MD[*PE;@P$9HE*U;VS%41 1L4&"JP/XNY)+.'
M,1>X5B8SZWG;X:(Y 9!F2XB9J:^<1P*%+=1/.D9NB[]5O*,]F[IOB']Q0>"A
M&DV:=2S8$J\+>M/K>;RYMR/%OANRO_VI!MN(+T[91VWY8$NHZ<G! R]R[:G/
MCX?8AQ\V7SR 8K9+0EJZGA^9:C0OD>K2,%:J]H>F=:G(KDWT7LE2HZ%T-0-X
MJ^5)2HZIEZ#;:RB:7NB1SGGG@,;#R\#-G3V[^I9;[33Z\Z(=K[X^-E5C9DR3
M>$^LWS9Z3,MI,4D<QF3U+>_#F,Q5AP868-9.Q":3!IL\2=?U?J\?L_B"0$"O
M<YS]. H?-C]$)5<^L!1U_!''HZ/',[U\O-\G9)P]ZKNL ZZ7.]S]5J J8$_^
M^:,=XIVNVA\^C?$FRJ#<,B7<8*:S3B]\PVZ>:<^H(,L-V?U("Y<,JL&=:@NO
M49]K?3%%B9ZY^]69RL5+ZSU%RXBD> _VV^RBW556Y4?!(0$^QA*Q_5?D*$/V
ME$MSCT!!35A&/;6UW0 K/V-D5YL&3BUNQ>"!IV1K5*5>2(7^\;/D-FV+^CWQ
MHN[I1V7@E:%?9UO[+8[W=;?G<^5?V6^9SO&QL;?,JC1D4L;4*2_>5W3P8*[+
M-==CIH4OZ=D4Y95)S8/9&VF&CH&%"^"!U^%[[[$S%'$$>Y6SS-?QF;24'$NE
M,AR[_,#%[FW&8(V!C=OGQ_$Z3Y/@\4<E36^=K;OVZ9*WR7!IDE,F%$M,FS :
M_*3'N3'EC=79YO"?A,\=;1V!0XFS+ ;8:@O(M/\X ;AG1)P,Q+Q#H>?+;_7-
M41'7%POAS!A*FJN)20E>C[UX)X3$>G*,*">N%L397)%-Z>V4:"!WR-;I#+/5
MW3^0(]%\LP%\X2['0)H9VA(ZU0**]KAZF)3NW#$6?FWZAVM\R<'FJ2+4"QBE
M0YZRN[T_XY+P%?>4=JT8:)NQ/XS2E$WV><^V5[05J6J!.]@0N@3Y8JQURUWS
M (9:39:%^]R>V+F,^TV<+"B>>TSDZ=4%4.H'M_5?9@KL,QIR3K_:2AH3O+\D
M\M#93WPKVH+^>_"@90.%%UI?T)>.PK-B:WK6>"4:#\(K5PQ47KAKNYDUA;WZ
M JML/*8+"U.QQU317SXR9@Q_R$V')C]UQ?: IC#BW++U\78&(6O@?8O Z:03
M#-7C<DSH+V]YGJX:8%0+&;2>Z[R%OIJWQYZT6[*P&-/.]+VHA<]<R#RQ*K6B
M<XMJ3)[=SN%SK3&R%1_FYSRS<L36#Q[FP6J8&7_2;L\W#.V!K!G2:Q_2-&>\
M^!H7V#AM!_7 3.G..?*.>>FO]^@T^>R[=.;P%>NVD_U,=&UY$?&GI,BAMUVK
MRS_?*GK\B/.M7-C-<EI%-QV3D<.1DD.Z-(F)2PK"[()]M*'VE$C>YPZ?R6'.
M-![/7YA.-;.>41R/\8F64_]L$P;C-_<7 O>4O%*A(RG%C<Y&]T-'%^ZV#'%@
M!!VC=L]T-#^X7G \4^G>#0Q[JVK3)[/]E(W I6"H_<#\@8.=)?EO\'O53^K;
M)7*57M6K31NS#3_UKAD\\LD;)C=_ZWB<Z9V@M4J3;TY)!*"(!YY]$%;!#7YM
MV+_J4\&2+(3*8)0V$U_@;!J$5_!*-!V$$RM'Z#^GSG+)9(B:^'ZNI\Q]H._T
MNLY=LO'2D2G*4JM$?B4_$I2 U8R; ^A^2X\BK8@(+TXMUP&M$NH:!PF?P.]?
M/6\?D>X0@J5R#-G37JQV*;-%SS$^<<GJ[DSC9QE8@?60W*XN''EIP)C*6J?[
MF#+\-DK&JX1#?C7AF44_"9>V[F*FB1T/[0Q:>2%'_V,G4-W@%/0R!B5E8$9I
M*R^;PNIQP=='_U6<R+-NCY9V460BHYF/L7]&O]ZA/&IW'? =*<.1Y\D#S=TW
MQ-M8Z<94^>_$DTB6OWS!5*4?55?[V0!A>]M=AZ66;LD2?,?F_(DQ!,(Y=8J9
MH:S3.G3)VI+_)OM#5-1'@11>+ /4*M?:FERL22>0BQO$8UD%!0ICQ2A/R9.[
M)5)>D?OUBPM4$>:6H(7'"<,!#>!L1:O"&!0;\7<\!J*ES&,)VD5<V26$H@'O
M<4UKMA9, VEA7-W12/46D*"5J-94/#D*NI"27?8Z,E?7OJP?0SV664$?JGNY
MM1&)?K'XOL;7@7F@X%-NH;_9<,+!QB=&"GA>"]PA.@+@7=(]+EJ^E.SO<%UC
M5A.2@*Q08,)+H37H*V(?\]5]B9RP9TUEGU/#L<43 %YR]RM]_A<Y? XK7$QY
M4O@:PM$>^GIWK/B[*:& %8,$K*%ZV U&<A_VH 1'ELC.LV&/S=AK:YIRFN,Y
M@Y(RD(.]&DOJ:MMK1.#/]U<,_C00HPX3!]H\T?Y$V"3E GH>Z8^<$\A?K4 =
M+[_C39W5UA^6:$Y*/6O<CS6,>[ 4/9?AV'\VW<+"GCO2M6%RRJ:I_I[8*]%O
MM<CI%&#6GLE5SU/ C:PJZAKK$?%>K*F!ET7E!<GW9@P?/%5G:<IB9KJZZ#B/
MP'CJG) T3H6<#>T?M$4[&B!15DU40BS*F=5CJ:.&YC3VS+ >V+N28S4LAU;T
M<]EP6MDDJ_?)7/#TLV'IPU'^,OZL/@'"58 +@\G "I768U,&5?L]5K.GC;JK
M7N$7W8X$R!@Z)EG?;-;@/R%K\$">O=S+D:'ZP?7&IT'\[1]%K8*274M./EZ^
M-V;2%Z/@ +O5D[&+_^*(^)>B([@@AS6->0S---8@GZO&R5[PJ\,\R^=<-L%5
MY=9;"%^IUU%G53(3TH%5WI&F@FEVUTNR!F=#3I\8'O1% _ZO.J\^%#@8^2E?
M6O"L@I/<D>+5?8$'?0.H#0*PHJ8%#<X16467]D@T1D[A'-*5!".^*/;[ ]>X
MP:+];5%--DOM+W<?DB0O)@#TIAG/8M4$'?)>XFC,.9LX'V4PMW,5UJ-9:N]_
M^JI79D$<.K_,3+S"1AD^/FMPXT2F4NB ;.RYNVH. 4XI<N0SXJ5K*=T]IUG=
MEQ@ZB4OLXJ;RD4\\/OTW5F;S9R\6!O0?"D9*K>R57BR;F5JTQ84-R\G.B$E=
M%N[NK&:DB2*S<H6=GU]@Y@B;JPQ@D7?$,V6CIVLB8DX\RWQ@L@CESAO'4-NQ
MI8[(2I]C,;A_]>G-4RH?I0V*NK AK]/T3SDP+2O->FA"(CVU<^[W#O1>[@]X
M.I!87N"&9S.R_PK 'J0%L5@KF;8.YN61M5X>+^6+FR6/<B( =^8YIS#XVX^8
M813(P?[RGDP;-KXW^#U$"%<BBTTZI+1!EC%H@.^C-P\!J.6%+Z4VIFY?)Y'0
M;@VU+_GJY.B1M>LW^9H]-$DO:U^*B\.07XJ QH2C6-$(!#?(LDH "E3P<JD^
M;;J$XK.-O7*N2R4/Q?E)\=T3.R8,1:NU'I0L$20/2JJM4U;@XB81B$'E<G%7
M :)V7*^U!T*A(/9&Q<Y0Z"44&73EA)H\W8N!YWQUYPX\(?+H4NR,MF.U),DZ
M-::2W9EN!^V)0?'=&HD_>T\M1^<5AJQ*L5+\,"<4=#[DD78Z [3I)K%_J&TJ
M)W>7_!XW,^@3R51I*PE-$D5A'4I+ID1*0)&!&?&P61D*HB-YG,^5T*7X#KAS
M(8Z7UU-'M8%46M'Z7-O#P\HQ*"@E1?PD49*!4,MDBH0&\ U*XYAGBMR@)PJL
M9/!U09D2M2^A 6'%1C4%X!CT4G@XBA[:Q+/P"$,^"26#?M4>0%%K;3PN];UH
M:S?*[U+;\<7.HD.1V*0)=E#D6= $"Y]()-J0696G(Q8*4"*X,>0L >@GT)X<
M$(5.9/!NGE7+*D!1/U(_H8IH%" A3DNC2Y4,8$MYUG3U).^DPH'+FA#:M+$H
M[_[[N75!U"2?^$PB'*R9%E(&&D^,G=E-)R/!B+6N<'5#%AN_R#9R2A1(\6WR
MV7]M9OS!$EPUL$3D#OX\/JS'_\I"_"KO"I&5??_=!Z_G:KX8'[X?^0+D5V5#
M=4%:]_T>*!"<T*BO'YF*=HT3WKH/K=UB )^=/K*:@)+[TPJ$X4]WTC"[;![.
MYMU<^1;<-KKKT AZ?.PH-_B50?^->"H8MRIF1==_IEG_"/6\V83)HH\B!(.A
M/=)0QIC&N$N\69I!<CFU^>ODP6P?LT!YDG1M3?*KJ7$GDE\UOL,,.5>YY27.
MU,4^CL]VD[W&U\Y#9%L5\0J1-G0H03,:,8Z3GOG6=?:!>03_X&I%\5=:56Z2
MM+:4MKV&2:^NU) 44,' XOEWVY:L7LG:-"4+RU/[R!2$>?%<#KQ\,DV$IR4'
M]*7W$-9=<!&6:\A'+A!%I@*[F<$51MW_ K/;IODH$=-:S5_]PJ."N5=3T?TX
MI<_)XNE6@D82#7R-R0[RS.Y<D47FT?LIA7/TXZ&:Y(JE\5RIEV9>?-3U,=KG
M_UEE82*<\QRG;7N*]@5-R -BELEB9"FM^_ <Y1@LG](.IQ5JQ"4A=)BG3=ZC
MB5K5XX0^<^?DTZN'!Q, 5X-3 W9[K(OXPZV/7[Q/Y@35A.SZ7 \A !>4#:WV
M&SA):6]N;FS><,,ONHN[C5111*D?OL%SB+Y!D\QT*]X[E\LK>L4C*F?>4ITZ
M)O!)W2EZ)L\4[UI' #PC@6]%JK,:6$,19#US^72H$D[@#@&($D7V<:%DLZ&7
M2G3P^]X3@*VZB.VZ3&CN /('&WB_;3EN]@E^60PT^=#@'E'33\CEP6-K<^N[
M7"\)P'RU_>I0 R2WT828CJBN$("1@+ZEM[$_F,NSMZ.%?ZJ,^ZEEGHY'.YK(
MMB-TLT>BS'N1FTT[>6S>W*G:$BYB)]=/"J[1/^0.PAH*$0 9XHJU3!WP,&;*
MI-_12=,.J<&=LVHF1WXOJNJLZ0Y6L)_LB9B%_Z[NW1D#-/(WIM%NWS!;Z ^+
MJNP0E6& Z+1#/]2@W5''O:'&BU^IT<7]DXJ-.S3"T-J(A:USO?QKXQQVS?P!
MAI][U.?.9-C1XSK7BS^XQF_(^DMD=/YDMB,[ 95*!-3/S7:H;\(C;,)'[.62
MQK;ELHYL<74E=O@;*.:$_5:4WX,T3^OWGO]'<+KR6S'^_\[^HYVI_#[I_!_6
M6EG!-?%WO?'?B[Q54^<ZB\W<C*([ ]F#:V<VXM>,2BVOQ R_+^TQ = A=FG5
M-Y,;MQVF\?K/T+/V6,3TC_R6.[1=FPC]NI[@VK\+:X7LMX5OJ7$3_5-:%-H9
M^R^W-NC$!W>DR\O1##V#5^;,AY!.#>3B?]RW>U(BP+\2A*YZ>^^5E6.M^$+
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M\1RQ$T:-.ZW)LR-0]-?$&LAI=P32CMX6!7X&4=Q.$QF3<?W)K[\*U#]EA(U
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MO:T#SO>H%:7N(N>A+I"U)&FSXBUXZMY@ 05)2Y IC% /I*I?)UE,L7&(^-Q
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M1)^&\.F_E)%=/TGM'9;Y#X>)'\]<)>%S0(;]<-S-X?7G<D5*FON/;AZZCA]
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MMX<5(FTC! ]^M>)&SD-I\6:?U?W-39*<-?NY%K]D(T<80%P+7;?$UD*S%L#
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M.FX.L[T?56B><E+-:9_IPX-7V^QF^PSJ\ZC>\%?#C1:%V;^RN.Y9[UGIU+?
MY24847N>P/>%]$<L9@F,7)&Q6K=O2=^QBN%$70AYK3WR"&KD'R\6QGATW;Z9
MT,#)'B00OQ,MZ$N,&:XOB:!6F11</!H9=MIH9:)GR=CK0[:\IQG'+,,+T^1K
MRJD"D'/C#QQA 9GJ&B-O0A]CG4*23QHE<0W'U!W7Z485'CJ00ZS\I/:R&&Z4
M![D-W@ @DV9>PPY7$DL]&'QQ8F5?)@)74EED,#+>IV>[;V(5E[-J<PB:@M:?
MK^8PS]ZF[[_^;ND*%D'DU\UEFC8(VP!JK.J6,W3K4T(_MM.4O+,[=_7 YS(_
M@SXN^T8"7U9 =D:+;TH$<1!B!Y/\.G+5)_NV."R-(\,CZRE8S<W,-M/[T<&'
MX1M C@@7LJ>,U"CNV=.O3\RA\*J[R<#.X3.\ F97VFERPB_"*S6(.&V"WJ>D
M>I&I#< 0*NGJ?=\\.6@>S:0>86 2,('D5%(^""K'/=(<#M8X32S,&IHRGG+-
MV!5O0]D]!7$-TH]73\POZ'QXH2O&S<&(6@EWB:M@H' -"\:],LXY+[P^MJ=C
M_9DOYL[S29.F+AC4-Y[4WXU1INZWQ 9YRM@_7O-N,+)>"CW&AF9,.4[IE=']
M0H"B>?0M=VSO[2HU#-NA2WS2'9-ZQWEZ]=2Q4NW4Q0]E;*5?35XTO[:<LO_B
MM,9+NQ!2MS/DUF!D;^K7<9E=07M2Z2CUBQ9<I2JX-_Q0+.+S$ZTZ5WZ[_Y9,
M)[R)]]HI6.H5K-@FM4U4G^E;%;]R:P'L'\&FU==@B]D\72'+F=P93-.ZS^Z&
M:5053(OYXLZ4A2YFW$++V#SCZ+=8[3K9BN:RYUP\2-.?>9K]F1Y4'+#YT+^K
MSU8H3;#[C6SFD1B.<FQ_W'$".S ^)&$4L-5[I#N@WNA\V(J+BV&;G_HK&5/4
M?9BI#3NS@O'W,]M2QM3%&/6"&.4!S]3A$Z*Q\F6W[U+2S7"*UO6TEB7R<FDI
M[ACL+G^#VFUC/BZJ+A@J!=A0]KW953IE9CN[OU[4=J;)Z=J 1(X3M?=S\3=P
MH9+[BA*Y<L.W8B3N?[54</G"2RF@,",S'7K/M&^:XFS))6PPR7J;A- GC=GH
M0;&E0TR<KZPM.0OKKM =EW44J"@@]17^)?-);(N785RF0^K&>AV+EE=<:=5[
M%=1]J2N'; B*@.?5-R!,88PBYFO:?MK[^?L>!QEKO^:&):'13%R5>&T&%EV5
M/!YM-S.7-'R@<<)NH3M24\>P50G=\(_,;L2AO)WM)('XHB;@3P#W4P,[AQX<
M=9VSP@4,P1EY@FP_/K5<S'FCB5_23-&$L<D>K&*1M&K5D)5#KN3KEU1U>QRK
M#(^S*&6CZ:_T&O9\=JGH+FUOS(H2<\B0$_UZ5NT^41[.AX_OPSBAM0$.3H+Z
M'0G">P=Q?M*!UX[*V+\D0. \UX=[RWV4>UK!!I6]C3S!![B2Q$"C[&VU2AX"
MHX\+$D3:F.OPM2_IT6.=IJ_GKE#;C_$/!@K &Y,\%M!,@C.:08JA9^>M[LW&
M[_(J@M ?*BB[*-<TM]KM%+0!.&\ Y6;E/8@SYJRJZZBAKNN&8;D";RL$!F-F
M][YQ$:V2KAWH+X>&[>_7B .XJK$E [1XC,/)5XEWL?I'%O7$0-W':I0H*:LT
M!,IF!D)TY8KG(I^/5CJO>M5AUY3N?NX_S_;:T*)20*7[<M?4S><GN#G# 9MO
M,Q"#[Z$'#))^7&OM@&ZGC1F/^@S_=AD)A*1<LC]5Y6YE4=RFDN5"ZX)!2(<8
MS&#:^(Y"55KOU&BC!M<%L-:=>FU]Z0H/T.L]%M(3PG0*T$\)XSK5P=R7R0'5
M%4S%%6>Z$MY/KO< <X\JV#C@-.,7VJXG]<O*X3"5 06+Q"D1]^ZV/C2C>:TL
MI[%0B8F;Z8+6%(KB:6'AGA%D.R62VLVH!1%_2D<2%^4=].J-=';SXP2[98%0
MRKM1X2ZI1VX2"FA7QO \YJ(<I"[&*+J?=OU=,Z2Y,FZ-47K]E4YN6!">EVWX
M!9Z5*Q3.GTZDODR@F<OSDI2$.U]P2%* ([0$XL63\*)O2O5YO66C)LNHHX62
MM,,L<LXF)3O2&GTH*MYSO9[RZ-PLHTQ6V.SQZ.-1KTP^ER?*&KTM+]R[KQ[P
MEAFX?K-8\!433[8QGE,7<HB0A;L;?7/402G6".ZN1?-(?@A,CQ)>R%R690B_
MO@)567R:FDYDMQ_/5.Q#*X9\\.;T6='\="'BY6@KA*\!4]FL?I1IIDL@"0TO
MA1UH"ZZ0+#KK7#C.TG$-09=F;<']FLK^\)"+$J-B/8NY3:'':U>!T>D]WH'#
M C@K.>3J+>([E62+DG756A<3$9X3MF$KM6O'1]=NQ:SQD_Y6OL.?.[ !9$*B
MQ G<+-!NIF9$Z9!0FHFP7F;;OM?.-958\YWR&X!TR"=#')%>0;]W-R&#JNU@
M;MHKK*9L$@?@$ML%WZ$Z>DF8;2%WN<:,Q5CH9AIWS_4B+R*D>"Y[A'5*CZ"5
M]L4)I=+W+.A-L"(Z4[*O)):%M0U<YU\\[+ !]+@YCI<]F\025(>XW9Q;LYK$
MWR90JTEI23W6.["*<X,$6<GH)Y7,N&>FV23O/Y.-^2I;6.PR5/[PKC.</U4L
M+NB@*6ETME]J.B1WZF00IK+GS>%W 0)-_I3)8G1A;]HPE3?ZI<_1%(H<< IS
M-.)0II4))PVS)O::F%:_]>:I"IE->?Z@&49C:2YIY_G@K.=@QL?XKNO,TBO0
M"EOYNH1^<5;=]4Z-N82UD#FT58)=S%K#?$925RH*H7YA;F M;2[YG:*6#<7;
MF!>-[P7MVXD0E=8W$?T5+6<%J7QC:N,4!^_Y=NZ3J=8X]F52:\+QW#[]:[K7
M*#+LWL_%WKLKN[20%&]WO:LM1U27T>I,B]7#@?Z'[$Q9)YPJ=7AR79:S.',>
M/Q[L--H)]D+O&LJV"IAP-XI?@;6X?FQ,JS1YILQU91*+D!%0B/'6-3TGRTT0
MB&I/O'0G=@)8QPTI,:R]G_'%&INZ87/L)#X_9WW2];)R*=>WJ\EM^F*0^.$(
M&#O<=CE5_)7,Q%T-OEMJ[$#UZ./N267EP\^P:H77WC%&@MIA@=JZ7;L#>F+O
M-?SSBQ0_?I$W9S52R2G!(M+5"]5=V6^E?,IGP,EE2URP-+LX+*/V\JV;FD+G
MY$%(I99L"7I]=5ZB0JFWL2GS)/Z&@B-KNQ17-741Z_I$F?CE8JFLAFSQ]VPO
M!>V])UHO-QY+H9#R"_?0"EBMK9H]' R5\2&FY+15VW@RWUU>WLME0GHW+G62
M9V(,>/^Y4O'<&X5DW"W\*8FCI3L^SIO-HQN*F%LH)(U=@IF%&LC]\=2IXY&3
M*/Q2Q'J/W%];31%H#10,P[NC#)C'^B9)UT^J.(]UU .*,V_D;M S25T2G(R/
MPGFC-&Y,JKE;F<5'O2:(XG(^/9\SD]?)NJON(<N+G7(0RV!5NSF"M@/F-@"*
MK\]GCW;9!9KB\RY7%A9V'9Y+!3YZ,8_T[RB.7S:N* &FA.ZYZ!-T<^UBA4.7
M'QU9.]/ F7&].HMPHJ!"<%:43SK,@#O=FU*O$^0'%7_>9K2HR>2=V*;U++1@
M-J2WU:C0T8.#*OC1:&@8.:5=?874R"Y5Q2Z=U@U 8-[A(ZYX'&?O9_?B:>-!
M@R#O(GM3U3HMH;!++][,G\05>.NS'<3LL6IUEFRG6C<@GC6 ?F6?><)$5"PA
MIJW@RNT&YNA*21T9[N98PIQ,PR*T%2$SUT:4B1C7B-<&JXVB4XW@#2\"!.)G
MBS+6GR0V#Q7=8_(%9O/8\+>D$O:R?H;WU0MY22K6"3-=M,VBZ='B+.&6[7[I
M[5?S I]F4!*OH1<G(=XG7'/&$Q4%50'F!W9/8O?:=_2]4V$M>'3-H PO:F"J
MJZ38]P!@_LQU!&]V3;#'^]R-(&F]A.#8-\;0=SQ.<7"@G:8(!YHU)LIS5"_;
M5^DWMCA#F:L_:I>1%\].R#*MUQ*G?*?MYH2#!C;[XS)?+9JCP]6TKX:/G(\[
MHQO/%RN,^"+6Z'F39D+@]&NNXS%RI6$. 2DSSKO<?6E"ISR,#PG'(D:>BH&:
MO4=J6*HOVX?>PFK'"S ->1;R14UQWJ8X)Y%;VR YE<UN?/Z(_M4=E]B'J_;;
MGHQ[=#STD'^-#Q@T99DB='!<]<_.HQ,7 ;F9..)9UPV@TNR1F?6/:QB5^"W;
MKD@0UZMQQ6@9?O)>\+"#"RGO^/!)8! D6H9/&BUUH201P0[61:!UVBD-KR:*
M,"QDA//P4@CSZJQ88I+K6;?WE-/%@+5VG#ND T(::<-H["QYY&6C$0(K<F*S
MK,P\O&CJ*:[(3M8,VU3$P1,H%>GK\5&7Z$1@>S)!.B %/AN*T[":+)G,Y^,&
MMB(PML]- ;QK='LP>7M4>"GYU26@9?S994:0(>8*>;%4&\IH![;3UC:$+(76
M5Q:D3HQ5,47"D@)!VT[%;#;!.6$W",::M-,(>21GARD;9:S?3/@ B?*8HI7)
MJ((MH!D5UZC\#A(R)<2.-GQ8%\B?VX^YG]-U-Q(TVHEW/+4!1%O.94)G[LA7
MRQH2LC!<'9IV-]\S+*1R[U? 1+_CI4=.<(?MH.Q)O/7AF%T1C9V<Q)1KH^:^
MXY*X:#OB+M5'#Z<FS=Z3!S<O4CKU;J_84-;O>\G+<4;<QIL/'$#J5MS6A*#E
M&L1FM0#2^.:J.?5QIJ:+."[ZQB%UO[#8<WN6[9)C3\(]$=*23%35\:6Z8;@,
M;\WS+"[I],A>4S;06E1^VOO0Y_6 S=D]AB\SC6YR)$GKU^12R;FP?!*[Y;S?
MUVQ96@_Z)3!PRG/:BGX?TOH=S;)MZ$BGX@9P]='Q,)%E^R+C/>,J6#K2<('I
M=(R\5-64:6<!^@%#CJ>K;2;\5JC[3-B) F!=$F>1QYR7_S'5N([95R^G0H<M
M*(#Q"U;QO<;7J&Y-6DM,1MS9^,@ZB_68NY$!#U?UWQ4NI:P=*P0N%=!P\I?W
M/L8I+05Q\E-:1V 0(H=)CM>S6=#BON",KW[8[BE*)%"X^R7S<;Y,$<WD$__*
M_H]OO]1B.15;CA3 K:?..-$IQ8<&Z3X:]8X!5V1>7[G+Q3<^\NA5*3<UQ1L?
M;![<9@0OIL><?X+Z(/[EI+?/Q?S\A33YH6[(JU4MJ7C3*^CFL)VZI@SLHB\N
M9>3."8$49_3P!5I)7XF1M+.5!K6N+!\R[4]"F#0P@-9BGEM)>W<#GQ[WS!S-
M6D(*96D;7O'<J35EH\7P4Q AEA<%E4*7*3_E1M,67:\_*-2 B1XARB23W$44
M-=514H^AO'6FXF_G:/XKUML+@;ZKC-O?4E3F47<L93DN3]14'JZ8'TX^J3XT
MQWVNP7N,E_(M070H:]YI]/VCG=QG=F '"(=CL7EG[DY=,6Q:%.\EG"GV7F@_
M<JY:V,6T79Z3"G"K8IUY*WDT,Q@B<J KD'<FI:K4<:*6P0\Y004&#<:84707
M3-ZX]K;^[ B#+:16]G!YG:O@1!JJPKX?R3?!.X<C#=G;:N!,>VO.NKA>3)8F
M?)@WBP%;\-: 7H)G1%1AS'DC)]^ILTXTR_N8Q0S1ETA?B''@N$:3X_OI(,E<
M0)QED<$&)<PU_F<QPH5^UC=V6&1+&:!UF&ER %<NVID5S#7NO3RXWE9Y3S "
MA'D" Q=*R9<_CSXL6NIBIGQEL'<*6F_K!E;_1*$),5IR4W\G^EAKA_[U^K+I
MM>X6[S7E.(.9Q?H"_HL/G:D\(LE$?99KJQD_V#3[?Q28&XE=X(>AW5/0C);U
M\?N#S K>C7SF%#&SBM^+=;=E$\3JG].<95^6M W7M -FI<RI)GPK!^UG^=,E
M/L8N!M"<#U',-TRB3)/63X=)TGD PG;_Y*>JWR;P(>?Z243L[D :_6K7R2F)
MY#.3WV^ =H$+M"AT=-/1.^I9MY^!:)/K)9& (Y^+JCP@EL/3',##"Z+ #$<C
M 5N33CJZZ'OM.V0-4][QJ^E<A^UF#1;)>36EGR$" U>UBF)2D4*%LCU:O" @
M62 V  RBB>3S?ZHS'(W@WG/];)AN"Q@$"M4ZS)8QJ\ +>BJBL9EMI&! \$+!
M0S3M$IWIC00D+P7W;K%XI8ST>D#N$YVWFNZL*HR67)M_^MO?3[^]85=)U<@3
M-*Z_VF+!47AM^&'C+G)\J*L9Q#T:[*ZHH9R<( Q*4(M:Y9WPLIW3\^.2^JAH
MJN,]P!O[W7ZZ\/PNSQR'@C@;BC#/5WYZ=6ITGCW>8 "D]BV(]??O8#:4HV^@
M*Q (^<R Y_:9 =F+WU,[!WV//8,N*41^.J6"?#.F8.?+2T$KE%AL^CPQ?8E9
M!KR5,?J?/@R"K62O&!E.(]Q(DKV%./S34C4[WF%8E5-*,XKG&F=_X< &4..4
ML@' 2<#1C+'(S_"ATY@-\CY*E/8&L+,J9GT#(/@B).T$'FT -P=4B1L 44:1
MP+-JL+P!S$X X^FYUL1] <)K&P!^$3(3-PXG46Q(ITQ-+$W JR]43V\ (UWP
M/[*H_LXAZE<.*F0.TKP_77ZCE4>F58/Z?O6GK\C .,69W_Y4L90?T&&<0LPM
M9#QP\H,D$G2!3>B >X&!Z \XJ._809W:)FVD^IIOUA?Z73I:-.KR;M#O%?Z9
MPZ_,?^;1];<\_GI-X+]6A"26E+\BEG^#KKR_5]V<_'XPY/O5KQ7T_E/URJC^
M_$1M\]/1-DCH-WZ_,DG_+]O#9L7-?ZFXP/>*F_])Q>%_K+?.#^FC&:/_U'C5
M-C]R_77-;E4C[QOWFHCOBODNQ)A_AR7^'X__*(]#6\[G;]T2R1J2ZIE;?IC:
M=Z<Q@V9\@/R\ ?QB=3';S5!902#N3]R&D)#;=T//@/^,[7OFN]'J;T0ON.%[
M54^4#'3!?1'2M_Z0#J^U3+W9%-^7C(H2_6C0H?_M9.Z_%&Q6?+B/<LVSH>F#
MO'NASA*1@[6BZ2X+0EJ5R"SST54$N:2GXT=N>3E=U6.'Q'WE"+ .2]>44O
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M(0L7_H*KYM'2^;:S:DP'XH:Z=KC0$C(C_$^;S.XF9/6VQ'+5SB6O@>%]D"C
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MPI?>0.Q^6Q?DQ,50 YAJ)]9JB)U^Z8<2"*$M7%/TM.11/<6MU&0<4(OB3J^
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M([NUI.E'&*ET40Q<K5/20WXLN$90?]@5[][B=6$LS$CSXID^RT2E/).!!P?
M1AU9K3-/EY'2K$8T@5V+MNH<@2,?OHK@=8CL54?>=;[%Q=NN"5^6_8UY YDK
M(5>CRHMC')Z7:-84)G"$'P#G&S ^C#0?"Q;4(JB69FO"".T'-Y/G/(M_V-4
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M4RTYU$0_:B^'#Z"])G)W\J/B(7P(*%'M;9$&_Z6&4?VSK??3C]^Q*SG%9S*
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MUM'\S4OAM#;Y$P? 8U3'6*2.19"O;Z0\.G#X Q?-6"UV6$@.Z6?MEN>:"BJ
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M+S,%V+]'I%BA4L#E+Q*0 O"NA+2RFRM.]M%%$C>97:A#)YPX9 T3.%VYLWV
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M$@_#ZT.,J3C+#"*0[4@U*CM12X1N3WU=X@JE[D+KLD 5.)ME_H@<Q]RH8\\
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MV^X6:1;XR=#SGY>-6=)[2[M1>Q[^Y?;D/\F2RYTD0M'O(* ]AGK2H)E !+"
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M?S+27:W&!=X<O<ZW,V(CN^^K8(% U\IY$@%*\H?X/5!3%-:40XXD1)-/",?
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M%:/[9>4EM&IGXA.7%L6*"V#=&FSU%MTG1=WBWT1ZPC0QY*_M)6K"U#)&R]Y
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M9\?'(%(N1'/_*EWWNZZ?9&PTHOBI^[?,%A2-/1YMEWZ'FA/!84F:1'!SW2&
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M-&G#><XWYD* XT.'@(2P'0OPDD;^GSTV^+/9LW3\O;+S/U/*^\LI^7V WTF
MWQ]WN2VPD-SIGF0<N]Z[]L%8>TNA'91Y;R_KOOO,E,?=7P,V#N]B=;32%B[8
MRNW_B]^;ELK_OJ:*!0'1IZH#_X/5:7^=U5FMF*((BJQ*GO=J2D.*+T,N:N%9
M+3S-XYJMI_4E_RQ3]:18#KU? K;_H!B\QW'4Y%&] ^S_XH.QY$7J+[%#ZU=P
M_:<B^_%7=2BKE7A61Q53M>_:IP6U,U6G?J^N*X>83##/549,VR "OR9*-=$L
M60HK@[ RXUW[&#]#+^<(WCV^E/WUYI'M<KFSKM7QZP>SE[KDS_54(" /_X%8
MPO\-Q$HQ13'Z=X=+W656,T1>V;076%@:R^R^W$-+L=; -I5Z/C>NW_!0^Q5<
M?PMB :.8HG!OL\#O%:M9]Q:WT_('W]9_NO"EM;OIGGT-4]G!TH/-JMQB+2PP
M?-#4W*SU5.;X-ZO@37\WJ.B=B7+.FZD]U0^[&J$/!-S/C5[\YXS^=!;^+*.E
M@ +,-79,=WX>LZ6)>>6R;/CZ&K4#^1(M_3%I#U.:-M2"/^J(-7X)V*O4$20E
M&O3Y T)!F?DO?RV^%?0+]$#Q_!*P1ZP&_<,Z_BJKTR9_P12X?@G7WV,=T%]B
MQZ/T7P'VGZKL_T=NG[$\<[Y4%B^AGU515P?9N/ZZHBZJCJ:ZT6'K29OA JYM
M*Z"#7#W7REKJ\QY6"Z6?=''\IE TK:UXK7\\D,][3PKK8/O$^L86S73"_&HH
M*W./DX:66FEU]?QV7BFGT&Y6S%\MME9(*E7\A=KS'8DS*[7)W:OEV@6JRO'9
MQ__#&YX=><.Y_[Z;75)OXN@%Y4&'H,2LH7%I,I7EXZ>>O>[LFO9>^9\[@3GX
M>I CB?4@*GP=#=Q4F/AK)S2)I P+$A^2TGYB"%,'^.2F]2!K013YJJC@7I9=
M1H\ _&M[K#IU-9(OH]DT+,*'0<J*8>:KG:4Z5S-FI!AR\X_U@V,&J&&VG=/Z
MQ58I"\+=N@[T!53FP3.*]9'_B_ )%$S!RDUS3&*7OHVGO$Y(/2)*085]@VO7
M,9VDMO^^TMT=R:U$$WT+WZ[LEI,T##[7Q'1J%%A,FLCLYAU)0')UHE*<],?2
MNA=A1S)9%;9V" !0FS%^5G%[/'\=/0L77O&,)GFN-$+LA]W$G@YOW^RV*97[
MU6FO)SETE;[NYODK'"G!PB$@ZDW_XX:H;PHE2*^ M8'EOEX[H:<Y?SRQF%5O
MW7T1_Q]2, $+[B4PKIEK^)".-.'[7WU#R#SUU\B2]"BC61OK.'BAR6^WTHBQ
M9OME^NA_8^^]HYK:NG[A*"@H34%$.DJ5*KV#B'0!Z=(5D!9"Z!VB("!=0$"I
MTFN(E-!"[[W7A!IZ[Z$%N)SSO.]SW^?<>\]S[_O?-\;WQ\X8<^VL->?<\S?+
MVFN/M;9^_4Y:<8T!B\0=XK&(4E\4LUU-M[A!/D',T.*PU@WP?Z]N*S80K=7)
M\TAX.\*\-X-]++?TH<A(U7:\+%DE",GB6?9?7@.?F'".YXZ;5^]59.<P?5R*
M-%S?IKP)!P MBP/:N5I<RJ"%R^/,"V>2J:M;?X*<#/K?WIZD:A-X#:"P3:2#
M>4M_<37D^#%=[N4ZTQ:K[G53*#XW#&'L/!2[B0DBCFT4!L%A.7M][3D^C 5U
M2V6E*;2YI7\L@[%8"M\EBWKANTZG5O5! 3-+7X:5[OT3Z(M7"N;_[=CIB/R_
MPXL2F@/V6'\:U0%> *F\,UQ<4>4JPGQ^;\EW*)PB%O_QT.LSAX-;U4W=_4=,
MP,-P,]9@(9V;_UT3&OY?H2423&Y+QSPJT.4C#+D3[?D$2$%F "]:_:,J2+7[
MY[J5QF5UT#_]+V3T;X"N337.7%DW,/"__02JV$J]9M\2+E5&.W #=%Y&'B:G
M.77K'J^I'[>36/^C+B#9A<H2K8:Y1N"]JZW:BRRT<HC\8ZTSC"7U*$UX1;.2
M5.'/]P4.#HNA_3FNP=]I-.<&:SPE/?J4&@:PD1,8R.\1D(\.NFMK]VK*V;.(
M\R3Z&C!0V]P^A.O9U6^FF"8JO2DV,02?IR_S\Q^6@A?U9&R(T<YFYU$7%H*4
MWUE\Z_PM"_BPK/+LD^:C14]1W%3XT1VG90W; '!U,9!I,PMQYY&&R1 Z\/_]
M>.V4/!NWFHQ?55&.X3M*Y*%B=#]U-?&E957_Y4_IM6/<CT^G)E$*S@[1(1;\
M;\Q>:RKB/'VW-+\?.=81&H<_4O'4A$?%,/'23:D2CEEW-K"UUPLH,W'#*H%<
M#%4$?FK0AO>4*K'$+;F9>'"W5HA*6-4Q]P=;N7PK9/KZ09V+*<@JI/D:X.[T
MS;%Q45 ?'M;%8@@$21KLFY/VT9Q0DS(H >QU[&++%R-3'(=32$**=!^ [9^.
M6,T."0CSLZ<L4@)B#XEE.K?D/ LJWBUN93_).VL?F@.6Q^W6S$B.C8B).@JO
MJ%8N[5P#\" _.6=I1W(J_&>@GT()?S27/=?T^LVP*GDX(7&<(4TRJ0 4H%.*
M9F'H'.[LWU)@2# S9*R4<,O+&2O.KJD*5B^-7#/\5EI;=B;K>*L"UCTEPEB,
M)^DU8GB#BM1W6RY'29V-20-5!YU.Z17<Y $/\ <8G">&/TJ4\H&G6*YHGU=Z
MLR3J1E8HY<0-J_P>;A6T!TN'K?H>L58,<H*H%!1GLF+XR;HX!QA+SQ^;*6%/
M"U7-<>,A%AYQVQ6>?H9.0HM/5DJ#O^8@$F<Y".A%5P)S>@_.5.C&D3I?B0*2
MC_!R%]^8/C15 CL*>.GJCOVT)U]%HA)B&,\4_<1CZFQD*>,UPP)%UJW*F2VA
M[N5V1^[F+HZD[K$3?3"UY4D?Z0_WNW-8DI41U-M\M1W@$QDG!\G@;"7S#*3-
MH4 )9P0'4;W%B$011?&@40S>;W3!-- 9OEQ7%Y$X73Y^#;#69T[HD:/$(72+
M$</<_?4W8GC[%(=/< EZ;(T);8]-Y6'<!T5Y^0UZ%&95]D<GZTH"WE:^F%98
MD5>45&2(_/*PDW'460<J0$W]//$=VO+GM_9A58[NWJS(>V9*-,1U'-+:^[[P
M[T.R-.,JG-&<<^L3_C-N%8Z13V*;%NDC./W8*>(Q/.9VE6"7@]="O4*,#*+,
MGQA@M/)>D6RITL_SC0]%NK- &/L3)?VI.7VNBBKY2/87PQL\_3WG@W7F"Q>T
M4CH>C-%NCE0"_5WTX.A[[+5>M[1:<@Q0<T8F"O>S^QHU. -$[0CO9[- /05;
MA_3?M3F .O61*@%/9K6%1L_4T+=HW2+]JG1&:ZM=\0X,1)]&"G],7+S/EW78
MI=WAQ)_F-9[RYH[4NV%_92[4M W+]^+%G2D$2TJ-L:?H=V#WCB8"V* "/4:9
M*=:*?R#J2*'A#(;\7"X:6+;O=_?T1"4?)KOF9P^#6(+>I=)V<:8"?3K$3\\^
M]\O,NZSK/Y9B4S7@.'VLHB4AM/(6(VSFTM1Y,:F)SSA2M5*D/ZO89_LU")CY
MOA2'<RNO(Q*_B7)@_WUB<R0K5S[YL8=<LQY2?-,2"IQ;SG?*_1IV@JHY/-MU
MG#"A";C@WD&.0;P= )[<3)Z4O[WX>3GE^3OJWI7M749$- \\4E]A>RK19=SZ
M_AC_R;> RVD=7^EW#37U"']O:A<5BQXEL-,PT>JW- %@OZC$?O2F3OG<8ZZ;
MA#7Y>62YRL(]W,#T7I >C73W_>,M$EG]]@H-RI'\[EAPO'" KF/LE,C:65K?
M]X50Q^_@"IC)9G%==,GE3Q"&S.HFT66FS4_[.D^(;FIV 1^-R/(76X2)4[.&
MA],/5U^H&IQ#2*:G-Q[OW]%]WV!9X] 7<G_Q*87]"U'<522LK]"XR]61..TC
M[3#J06GMR)DI[W]Q[<7B5/$[[ Z)$=^_VU4S]V&2]=@CCLIL4>",,D_EB(\L
ML +[\T*7^LI-I_^SE0H=IUKN]^;](.-U7SI0QQU7W*>9<#9L^V"^*C%8/I5J
MRF6.1"E7W_HJVCE/I["H=Y2BN/&V9T46X_W5XD4/W7;3N_=['IT,_L1X)OXP
M D.>[Y>I=,^%D5RLV4=N2@BI2,Q9:!8PNT_C2CI[AT_U=K?B]B.FZ,LXH5=#
M;]:Z:WVJ<4E%:&@"0N'FEHF^R;K[\<^IM@D[F"[2G+6&3 (EN.YK8;[/?X<"
MLT$"UP#F$YJ#?%%N??',;__^>S5#_?H^5T*4[)D]K/RDJ9_CR(_VZHZZZ> I
M-\.5@*2T%LIE[O,5^1XL:,M5_6L]4YI\ZB5.RP?+7]V?#@^)(EOGPQ=>XBX*
MANWSS_=%!6/Y\4*QSXMHO5LT?RNX=?R\)W&[]59T*@G _V6;%T6[.L 60LTP
M6&L\CXG2KH@9?(6Q=(E BW)A7W/+F#VQ$L6!:HV7QY_R7TAOB!%7.Y)M>BU=
M9)1$OKQZ*\X' ?QD<HRYZSVFV:9MGWP)77VNWZ)*?CSB:H\N#,SYOK %Q6_?
M\-HX!Y8UF/<Q7*9=,1AUAM '6X#V[\5=#>&_RLWM:Z"\!EB)8HK5P/> 0E?/
MQ C6$QCU23U-S1[&/K6OO35JGGS4(<FQ)ATU*S)1RY_O\6Q":<S>98UJ7'0&
MM,3&9)=WMG\2A#<CX3R,* Q+$1O A&N(RQ&GNR_LQ<<H#7:M5+P\09+,$QDY
M2[RV*8A[EA@3J]N@,-JO;T^GY;+ DF@CCBI8\ZE&1P5<O=@SB1>D-7\=/][#
M0!FON'PO-:F"%]6%D^S<IOH+2[9?&5+^?;1\^[:G799Q%U.,PD/7=AD=MSN?
MMUZNU#$:[DVT02E:ZI_5[+-4E\ET"CL:SV;EK/"UD@<7-SI'5+]9(J0ZDJ:W
MOI+<IP^MY<WWH- Z\.'%>/Q\0\%!\[S?7<QJ51/A\&)&['ZUI8Y9S&I0Y0E\
M>8@5;.P=2U/_/<FG;!AITU=H>Y7&V"%%Z",Z(GBX: AYN.XDN1)G82*2[?G,
M^N.MPV]9%GLB@BT>T@NPD%HO9A"!8N*Y2"2=<0_-^^/VDZ?.G8NB*_6%\1=J
M]:<A^Q1;1-1]Q($T>F!ZV1>D>^I.%-92/SILT3[\-C"/6(S;T+84_8Q@?2'8
MK?E*'/@9M]==E-&3$7>91"/Z3/=%K^VLCM"*PRG,>E;XJD(H_G9<IKJ?B6]E
M7$K4K7V\S\>[]S=Y;<1R$AR!><HO0VD1O=4BU/>7A"4<U 6'N_;P.O8N8R'!
M+/2VH.BK*V[B>V?UD-C<??-4L7U3A>)TX@#WO1'U_>QM:$?HN!+$9XG7>$@L
MO#*?17# S>2T3W<O-^B*61]KT3 J"))7V"OLXGT-_#58:T'/I<FY_,2G6H3>
MY<"Y.QYL&'^U40HV1.J"O!L<%N,T5RIK=X:')R*&_4YF?>H*?03V64+258MF
M;69-DHAZ]'OX!LBVXM[E:Q:T1OUXF&R>FU=(1=)L^M@C2:5TU&7F:;'=[D=K
MKJ5#M#IO@OAORL^-R.E%&CK@)); ]\;#]/9Y%G;2&=X)&A86A@GYA?!U.BDT
MW)^1_C2:^B+6(!A-\<7GUKSJ*W'JNKN#*^A7N'Y >94$7"$_-<> GE0.Z KY
M60H',T_H#F89OMO@2ZSS.;.[8*9J^R/PT&3\ B[E,N:"J"/1K![9G0<">]QY
M>PB.=6GEM*$#- 8;%5+<8_,3+!?RQ0G<W)8S5>*K,22YN>J_BL1.\GL2[ZO#
M0%'W@?&J#!FA'*_^]]^U=NAJ7 ,(4S)HG"^+YLYIX MC.P:5V$3[L&O !\MK
MP. *C/6%LDF;]*IIK.0; D<,%,*('5HTL(R%0-_LK6.$*0Z?41J(6QO(:].^
M"\0#6$%9DK+F-DF[R /CVHZBVS^Z5(1D?909^PJ8)S&8/K5:Q-NCCQ2 6CP^
M^)!@M]'01N93S#OGKWARNRZX WDGMPE">)KA?<\<&$5N[)NFSBM\CB!-7^I
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M(5UPZJ8=IC/"(]!E01W-PS7+\F$#YU;B0)\W)'#A--8Q;VT3;4HX=UJI/N<
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M=+1;]$ZRU7]Z%\P>GL(;#$'@9T^_9NZTYW*<I%R.5<2O^^ZNV,YYW&]I32/
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M$?F7P:/_:M\69\6^!\-<E=E)'4Q8?6JL>W5DT^)Q'I_YU=2Q[_K09?&V.Y-
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M9!7(LVTUJ8GG<L9QQ$W=>9"6O2\1L>S6I[Y?#AXY*0E/YU97TJJ'JT$895E
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MEA.MJC_0ZF;4+<J_?2. J>V#9.![N[;3S]CKV#C;;EB.G?J6SPB1">U7%.7
M1CHGD'++)8PJK+&+]_'/OYU#(-#/"80JO$98P,]&!$_BKL]"Z&/V..5O-\T5
MS?6?J+ ]VB9D.Y@>Z@IP>YBJ7^+"A6SM/?C9K\HJ(GJW\9H8G?0^UZ#5L-1]
MF]RM.EC174BX,W&AT@WMZ9P&P?JZ.JM?RETAQ%N=]#5L7?,EM^WN94L\_)[O
MG&W<4]3Y3%WH[/M!;#9_X3-6_8^O9?'Z^CWC7I/8IW.2A<>'#_=T7P::&]IU
MJW*J@8&23%[LI5#AMM9#LVFI,\*5/E;5MFPS&7WQY==B,D'%[/DE\M^F"DPW
M5;):7#[+];!41[D<^3?LD/9[KZ6.J[ 9<X2B'RY<=J&!U# ___'K=KS%[,I5
M'8_!GQ2WCI88U@ 6P<G(&A0DNRO?;NSN^=B67U&+T\/8<#5*<E ;7^+3^;(]
M5K$N8,)C\\>PI>^--.K,6NTA2A65PX5;!5)M'G?RD N)JU:0$"Y^$ME/Y(3$
MFX2 HVD=B_IT+I^7*MG*[)R6D88A 7 OUB8!EPSCXX\._C>Y.D[K9T3&Q)S,
MKPFYY0F5M9H0W@CUK@JB69W^O*XX'!L%;4]VUYI$FAEM&)OF?(IK@'ADSZI)
MN=ZE#/%(F(Q]([[,*[O19G?[(/63SSVXA_/6LHT$>81);7RU#71KU2UF<QQ7
M2]D<EO"R7HJ](NDR]'E57L,G9<,AMI6<H7O 7E(L?\,X,=\O3P'0^MCC]6&1
MQ: \151PCO6@J51IXTX^HH_+^.*><<;'RDC[V3L!2GI-\"#2$RU3$ZEP9MIS
M>7("ID^:BZ9F6ZK1SU/TFE+4P^FYEVL\0_B';VD0K!A5:"^'E54U(WA,^^C!
M9)MC$BGV(LB<E::O+<1>5"U%V4PD)@R82JKV4JCWN+J+GYNDZ1._8+:B=FO&
M.\OH5IM&G<P,;F<_ B$8)%D?@R-KWN6Z8+W&T%5% Y^L&@]/J\OL'^)LEO.G
M?<\QW*.\]-IQFX>0K32Y:\[2?2,E;#EXA18N,GD$XHNEZSG;"XWO=QY6_@I[
M!"/"?7PE=OZ?_$E\-/4+>"B\#C^Y),5$&%\1#D"7[UA@ 284Y[=1&JR8AT#%
M #@I%D"26\ WJ$!UL#9VDU+KZ7]UH_U3K?C/S_;K_JFFT^.!8)Z.8P$G>QR8
M(/L=[3'X,C$4"S [A*ZSOR'^YX-*_>OS [OGR/P5\F;LJX 5T"@A2:X-XTUB
MWJ'9Z18;^KB>V^2"E==N"_8#"N;V.^8H<%7S.H8%.B]<@@50/&76&P1S0EN8
M_36Q@*PLU%LLX,T8'*W._-\]_[_8D^G\+Z>2GF2$S97EML((%DH^5M+![9P9
M-_F-)]2YC#6='<A?4J;!0OJ)_?FQ@%O@"-POY:&",:AP--=N#11Y27<IX8\\
M4\M-D9&7R+I7^7)Z:!@!CSWVH#J*1M\/%,0",K,622\7^?:S,'?A=%C H-8!
MP=4!#<I@%%J!!2"2SCK0B+2+;.#:YF7&.;.2%E@,"_A%LP2\X)1AP0*:'F !
MMX$+=PXRKJB8[T+GR* AS#O ?W]SPW]?]=]7_>^ZRN#/QUC"@5C GZX)(%R
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M-;'.[(UQ/MFS0U)A;TX[+]-SQ4]+A$M1>'8%ZC[$T3L$L$T*(RZI V2?Y3:
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M@8\@FR*^HWA;X >*>7_U)PU+C\I17QL6]:IAEXA<KU'2F$TDZP^** 6&B?S
ML"_C=PS[&XJ.7''Y_ME7Y-F!S:P9@\^'2/WFEP^((-H+X^QH=@#BLRD9##.I
MLC)=;7.<)IGHM0<_TA)-3HO4=IU05:_S%AMDI+R)R>.[Y72__]URGO@-VQ=C
M'\E='J C9R7XP'*N51;]@F#>7RWG@ZVW)N"=JWC*OB4/@LZ>QDV8DP,C3+BG
MI-KOUA(YZS>,W9NG(9Z\'<]^>$:M?\,7J-,+M4QO<V) 8^Y.O?D.7Y,PYN_7
M,D[\ZAD?;%5I@XGMBIDFY5.('GZ!#9@37W/\=TJXBRLJM9V3YU1L<N;KQ+R)
MFOD-ORXH2E0/9'9C4 YP1G.'+RM"#RBVA>2G/3]Q4Y#G3*L?!&"Q-RNT.E\\
MBGKE=ZML@!R]$CGZH062:/_%FJ"6[;=8K33)Z)*8%K";Q?<),>,WS/I3"?R!
M1Z7_PO&_</PO'/\+Q__"\7^&8Y#7;^YJ/HLJW@>$YI?N XY>W]X;PIZU^NJ@
MP:_&=RF7K6R&5UTX7.O$;MC)+?YOV;J2W!UGXC-E=1,$_?_U1]_#!S\Y8-#Z
M,=0^H- ;N'G&P"&>_%E<X'W WD[,/D!) F"'6C_VCORNUSY@\S3Y[;"#M^GV
M=A#D=QD\_E?_QRLC@@"MWR0X[0/N)R.(@,'9#E@ZU&<?$"TR#<%3C,&_'4,)
M@S<[&?8!GCDDD2^[YY9P[S;)OU@WMOOE)QYZ^;N?PK<2TKW<Q,A)N0:9GII\
M-7-!5<<(RM6:#\'%#)U 02D/9-S28@0MJ>4V>4U57SYI\ &U<6R"5+5_"99.
MIL:A)>U!%/*AZ/ (C"H".&/"!E?P\T$:-0!7NPB"WYC,UMJ/>94"3]EO#\IK
M?>.I>\;WXO3YTZ_L'W*F&@:DH)LJ3A"J/X).'1UL0IS5+@ /H->"P$$K(G2K
M*9;AQ"<=-0MGLZXGSWD;WW0LFXUXEBA]6AC9U'48YX%N\"ELE,$(4CX3/'^>
M-WY /J347SHD+T,%GMA6 IZS?9B@RSS/=)9T 3?=($6BZA<L&=ID6\(PM8D;
M:1[N.AIN<4\C,4J4(O6Z6OOGC/N/\PS<853&J'Y8X?$ONG?'T;,%20X#V9ZG
M7(\]2)@[E:8BU-2&TBSMU30>M!R6&-H4.>WW:B&I-JODA-TH7@[#LQ&ZX7K2
M*:ZLK4MHPWF\F=B 84(WE+W??9& 472U&VQU)3V'>^-?H+R&8IU9(,GR.'2-
M7SKW9%?]/H .*M*]*E@BH^^]=9D9C6[6L>VWIN)_RL;I\#G-?Y+IOO[)9WK^
M8Q[BFML(Z1V4P\9.$SX4/CU/A*Q8$)<L=%!SD&3RH#V] >R!]<C"6-N2DBJ7
M\QJ8G&Q6H(73(B-'&MNPEDVD$VM\#:>Q%%Z.UR7-E!2TCR6)26CS9]A?<JPX
M=LW,:$>TI?U<HGL--_X.[H@ACBH+>@?KUX83O]UW,;XC?X5'FD;ATWJZLM-L
MO/?QSNF+757#UO-G"*M3A</ES1.BN @LI1E69!E+ARBL49VB:GW4X53C28.(
M.<9RX4:00- 5F9,\\F'%9TY]'%/HN@X:WIA"-/C)?Q4NSOZV!VFB,?CHX[<=
MY_M:.>^F54'O;J#^@*W\[2@!)Z'R.7E%(X4//=9;U$ "7@5MW@CO:O:I 99R
M?G0R:=@;* 5/Z\ S%UQ,.MZ8FAB./^"NM%6[RVP1[>PHRX5I<^Y2]%3"RD\#
M&^@"F0:V4P6Q3G7(JULO!Z/RP#S^7F?:*014.KFA[PZ](*U%GVGGVR')3HH,
M[S37B># ^!N:4^3*V.^)A-6=1VL-Z,OY$:1=35\\<'.,4GM/W ?(1IJ1/&AB
M2.\$QWAWEI%88%,JVQJZ$7)F@=7S6=WEA;W^9$[JCC<?A.9Z\T^G,TKUA'*(
MB8N*%_'&C>A!:JZE$%7I]@&*7^IJ0_8!R/ M*NV1WH^*5W"YKQ?JF+"T<3FX
MBYIT=P8D,1;3':7Q S(:(5.'#4"\K?#$#%T3X*485W'/.AKBZSI:@DHQEGTN
M=+J:K<V/=;Q DK%B0U M@/[<JY18[$N)](?130^;'B/GX:' 8NTFQ(C /5S:
M5(IO_8AT $$ISW"A3.YF2E8APQ#JM.:\Z>CN-TQB2P*S<&OP>=&.&HE4O^FN
M8<\FUNP&34@3\I2[GV5]'5=ONP>K#':G4?ZJ<9>NCEB\B0Z_2AC3I<XC:GIA
M_M=75-RWSI%KI;2UK$H@V/:/P#'>:VRFWM&C4PQYG1@>1YZRRO*)PVHS=*+0
MY'LIO5)W4AK<7H:N*>C@P5!FR#'PSL0Y;(9<<RE#7%]\O*ZA6:.S5>0)*\.R
MLI-^DU4J\B;SAU[,=^YZ3GF$3L-'<Z?<\[,.'L-STIYI@NX+T"W;;J_/."6_
MP>_5<@G^]FV+L:]J.GJ1+IYBWB>N#F(.K1E,=V%XIR+X]*MPH R<OKS3^1(-
M&4>HLKW'O=+6C7NBL<X7N,^?K/SDSE/<+HW4:1B]!5[A'"QB=Q!?A#Q%G2D!
M<=KO<2!RT:,(3G/<0W0C:U!,=M.5QG?MG(ZNU=5'GXMC=E\40QN/=:T2NIJ1
MY<$?D72+$^QEY0/.I<DTENW@VNML\F_H!\98]$PL<RQ&&\[S,\=4I+3%)Q6&
M*7(0K'%N6),I,N4WH"GM.<1["+89)O9RYF_<WSC1(K=]U2^LW^#=43_/][IH
M[):-BE'D/D &J[U<C(5HKW4U.'$WI+(7#1SV8ERJ']1*&A.ED2(MJIO//IEH
M=A2(O7!H([ZEG>>N@!<U\):=!GOH >IVFHF%I"/F(/.1)NQAMK:0 OJ.Z?+B
MJHNS&?8,W %!8TI B=Q:69YBVYV%!_@'T,.#(JS'8=Q&"?&=&O7.7!4EZA=T
M+J\'M 5&PGS$!'>Y3HCC]P&I=;P$5AP&J_J!DU9!%'V\).(BW?&1L2'C-LLI
M 5G2H"M#<8;060N]$XF*3FDOBL_:L+A8;Q\C)KJ+E,(Z?([828T@@Z&<U!M@
M3_U!J<5\Z'/G9Y?2-ZZLLZP;/;\2_<D%']ONITH'GRRL4/S1.B/])"!!%I<X
M.2X'IR#H:UX$C]NPRSH;W$RRK;:A!PXUBC]($\R>JWA0 L79 )<JR18 72;]
MA$TS^3;.>DI(NHDDD6Q0TD/_V5"8XDKHG%=KV#R'_9T6$3:YZ+'B8Q<A?+A0
M/!?A+JX5.]TRTC^12!O\"NPYDI?DM^Z@WT.5$]V=O_PQ\O)P*S2Z9<Y1/::F
M*E0N620 SD#B+?^(H,:E3\)B)H$T."EUI\[LS*6R06V)=R85@6E!LBKC/9,A
M9LOMEC8LT,]U:<'DP]C!OS.<[S@20[D6;(B+D6[ :Y\S6N00L.<878Z?4F)O
M?_Q)L8MZ5\Q[UZE&GHG7?U5!&S[5TJP=!#KFG)\/M9]ZVC.'*J](97_7P3_6
M<MH%FZYBRI/>;AK/4S==WMZU2M+ *>&9H=?*^PG2DT!6$UQ^#7?&HJ;O=H=X
MR\![>VFWQBX>=7"V-_72>0\7PS*XCY%W% 52>Q%)4W-S"C(R2_#.,1R=P)FH
MK954Z2-XQ!M[S"?:)!""+@'B5VXQE,5STU3+)K1SN L>8R^<? U#A:*P++%P
M,.2)= +KU1KXJ>65[(%>J59J\0 NVRC&RW+$>+..5J2SDN4&K6T_9$3^Z_A@
MH[<"%6=DW@KA]GIIX7#^ (C?6YR+$=L5'Z(9/YJ"J8@_XBV#_%BP#[!&LIN3
M6LI ='D$62>G:3I&KSQS\#HO)J]HE*LBL:;QPD/>1S>>.H7'/^#2:U[N0&;#
MNI LDB+^/G0?0PE4:?95PA$YQ/?:#,9+[\;8'Z0E&>D*F#C.\EF>U\4\5KKM
MM 'TJ4L_J,IW"N#<P*9B7?$&4-I]P-,"$&WK]!";/CC'D8.SV+09<:$X+41-
M26U(?+K#YA*9UWOY%#V"(U'V= $@.JBU=&"-\G2UO)\C(7JT_OVG %<7;OL[
M-2YJTOX=W/?]6^;/=4V#\5=P'7"KU9->QZX>HT*>Q04TW7'@$$AB:[M;>K.]
MY],GDBM]^[,+MU_9W%]\*]K0V=FG2 &UZB&(8\4GG2,FA>C,NFL\"\?,RQ$K
M6V]:O<;+*<"F)1$N+QY4:CS\=O9]:]7=11GX[G; TA!B%]=9W(@LFV]X.D@Z
M[^6KUG=T)3/-WL!3RC/B[-RH;BISED>YUJ<[,Q*!VZT;CO;B^)7JKT#,Y36R
MQ>!(L,S4GDJ1TF:7BB^ORDJP*E:BG69KY6%<%6>P#5=D"5!TV0?X1DF'+**+
MT<U"E/5 1AB''<>9LH$2-/-B?-$(KNJJ<_?M@>?>KAD7^CXQWRH23!X2IS?E
M=S925E\ L:-L0*<)MW!/,@R];-C8^>JK^)Y("E&I]0EE1,K,UKU0IS?B41=S
MH;#6N!*1[;T/,+8"R0H>XR3YO=HC<9-@XE\(?/@;4 Y<Z)3?W88DRD@A23^+
MGLM6\<?C#0/;[=X7\U97#G,_5A<,;( .H;N0 7R8@#7&Z1MU_?#)!TI"+T\W
M]S*45*GS&-VNEXF^0A6JPES9<-^9CVL.GDS@Q?,2]!,:=+/2TW'Y[MJT]DQE
MYN>"-J:.IJ8_\/3 2AQFD[\7 8UM:+O(^J!!1;2IOG6Q"K6\,PT*REUC,EGS
M#)1 LW=\[;@XK=&G .3(H47.CW6Q>;\W^604TZDO;/18/C%F-J:=AGLODGR<
M7[EMQ1GH"'J,8&N'<34(:A6M1,L+E!K0Y^6?,QJ!Y@#&:\JU7YQ#;N&K1##L
M:P%-(T(%A9FX#PX>QD'9M*%T,?8/HSO<@<DSHR$OF$([M:S=AV"01-0LJEG@
M*S"TAS08EN,  W2[BS"A':0GA&+JM_=F%#6WJ@Y!3C:Y9/9IU&99V:O,.XK1
MU%!^(\EZN>GU$MBPMBWF"K5KJP&DB[CT>SWN9F<^;OO$&L3,==J$2KT82LR"
M((6/6$&;/L90UV4&C_>2;8 VV0:,HM;BO1276D:0 18#-U=#\@5IB./Y[V5O
M/DFZ>6-#6<*U7;V3)4Q&\)X:K>T:,]Q!8UB!:1]PPI-P(1I<!0]34)O@6-.*
MRB[R7[H7<3MGKD/@\Q*5?-2'Z]?NFW@]M%IX! P>F6] #WM.!8=LA654X>*F
M:01T!B2KFYY7^,:7(JU?\K16BW(?G7FYPF5M*D@RF(($I K@$&L&VS YSJ"8
M*>V&)2#=!TG.8R9+#3?P?J/7;SL7HHX9[E0V*^*)@QN>:A-':'J2CB(:]P'R
M<D/[ +#9]6EU+&.B= /5/ Z1"2Z3HVD)=-QZL<)= 4;)M,R,-[-[ @HT8OD]
M 29S$'$6E).FQG44-K,\@L30E282I'.^CTT#2^T3%3]G,PH!LT1 WV'FY"62
M1T\&GT]\UO:%U$4^/8D'>A3'B>7Z!CO=BR&H3K&KV)=PGC!T>#>67_ ME3=D
MO.8SKU=K:YNL%> P%!,]BQO=OHN%Q:Q1-DRP?\%..]GL TQ86R(=IP?JFD2>
MS5ER:QPVC0?67!]]J,)\EHN^;;YPF7"U#D!NG=UAWGF,GVMZX3,).A;<2?@)
MKVWT;9,. =72_O3^F'M7/M_W/^ME,A/;<6F1^;VSY9AFLY?X=MY '0=4(487
MRQ0@B3B+LU3M!ZE@^<)G!M,W.'93PHM&1F6%OP694NH>ZZG4&ZN_K3W<L&V"
MI4W#3C<9YZ,?LTT&!VTZMF;:73&ORX2XY7K3"QZCBG?;+A1HM_U<S!^OM"%^
MU,>'<]D7RVV,I0SB-,"Y6]*%W\<>[Y.$AY8KBIJI+;%=M&?G+A8<CBONRQDO
M$ZF>.[RTR$PFN> M@NI&<7>I]BA3<UC&MRI,X8?1:K*9Q\48.C&I5)#Y._%\
M5=]834@H>UIH5D17NSK_!XAF8^B)!/@U8H[D/H"3<*>/P#TI$BQG&\K8>R_F
M=F42\)S1J)E:B*$&CSXBT?#R%1A6.OB\BF'U"7D*G-,T,@3$KJ"#%6D<,:M
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ML4,[Y^1/[4Z(,DLMU*IHTXZT=]Y V6]H--?=#B!RD39VQ&#8HDMC5]!2GOL
M#NPV(G&+[AC.67O$9-*@?A]P;)@?!YDD(>'YXZ-&8^H7FGMW<\ .D>MUO$+<
MJ/:.:ED=/B/8^R1(B3>J%F^ K!,9TR#C&;@$=V-:-:&/V >(0T?+R:\DDF+
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M\\OYJY;15BVFKQS#_?B=X$W&?(%<D4X0PW?=DU%E/$F!/=?RQEVHHF) A^R
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M)NN*S*CVTQ.QQ\MN:5:_L:$F,C/1U,B'8N&3%KCG\'9];?PV\N"F.44UZOL
M)2/@Z@@<*TGHI>6_-]G*?&N@?)B4!\/>#2"6C,U?*ML96X%*8]FN(SZ^+RT/
MP;AWB*B7:)B,&SJ<EK&Z%Z44?2/&ZF%*8_$TM5&%4SM?K2L6HIS0L".WG-2)
MO/AL]E6,KJ;2T9+$C6NA/%?BC&!N\3PK;;8><QN$:1*C="CPFP ?$:]-NHC
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ME='MG4S-W[:3%](#TW HO(=QD,<IAV?3]+1B%^.A;SVTQB^DV,]WOFF6H^@
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M[I4GNAF3NU[R0O6J297OVW^0P$KUG]>Y3%O)%BB>*_[D..EX>NK/QX%IF9$
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M#R7<+M$L<CAY).\UE^+XW&P^S?!^P766>[5^_(D _HQ$Y^A3+>K-SX=:6?"
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MY:B]M\-RA5[BE/AHU<DRSZV'*F2,:.MH(8X>]OSNOS3;+\9\J>1_V[[A*,:
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M#=_JL4&-L#JD<_JJH68.%-9$W@\%EO)):!0U<<GU;J):LRM^CH1 =TV:Z4F
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ML$6PG)1T-&O:*;QAR*+ [5$_TN+5H-/5J\H?11O/V":DG+ZN])4#13S1(B"
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MM(.Z-/:?GSMEY2NS\(L;BI/>TASX2E?L>VW^> -H(R^>=>^ "XC,+$8V7KU
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M,.#3ZCI3\.?#@UJU/K;\%2%Y[R4IP2QU/KZ4X.S,E5W0@@<=0,""SD$77.F
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M<SG?Z=J:PF@'BJL?5[F3 MW<?AM25E7&4$_03KU(_P6B2EPIDOM)QL0G 71
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M^+S6\3,$I$ET'O1Y,Q^G6@F^YK\2TL'GHM]^(GX.P<4;$'?U\5R[ LECF:2
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M]Z)D0V64I^=,8W(_2PQEP)H>\-EKZ;;N^"%)SE9N RNYKW.TVSF1ZX@<&(0
MAB%A$>G,Z(NY;T1>45826^\>>W[V@?@*H+ZM_<YI(XWM7#R+?DO:6;+3I ,9
M["0\9&HCF60R8BW5\>%X_NYSTZB2H!0?KJ^(U&N"#"ZX^Y &B@9U%/G$7,$$
M/\YWL+DKQUJM=/ED%G2L>PGI+8AS9(&6HBU;%QM];=7:Q&@1+;'\.TN^\V,<
M9INW-L0'/>=FR^+(:(F%]8T'?":E)NXDY-ZZUP+XX#>\+A+'O[17\<;><9J\
MM8#^YGJ\>,@ @7S%C7),T%2%C1NW.+4%X\'L5#;BBW2VE2A!)R/95M>.!V"9
MMX=0LP#[N=$#]=UX940:/"@8+R%]1A=_S"<R>TA8.6X]Q*I-4.)0@QU3N[82
MGX>EFBW1M,5.%1DS=F](I*XB&B5Y\=H;Q8 $+4"ZEUF9GEU7VP2F%IZ3TS5D
MY_H= ;^9  _84]W1B"'*IZ4'$PNGL@->:[]V[B1*IOODF(L [QS;.8B 6-XC
MAQ<&60R5P_WT>U[(R;*J#%JP<5Z4C;/?>?E*EMD]]SE(DAR)9WJM9NF?.^X2
M$-_EE?M)W\K^MS>9@)G[G_A"5;;AJ3K3X3$^;OQ;-8C3/W2=+OJ[%_(]7JD[
M=J6 :QYMI+Y\=V[ 7%=_0O_CGHWMF?+:\DTI^PN=$S4XK,&'M1W6?++.Y(HG
M51K)*:N;WRWZL9O-2SI1)/;FD?-K2G>Q&8TT'WU\^!NJ3A95C&!85V03"633
M+&CSN!9X\$R#0^LL_PEQ;H&9^][%8I/@&*K,E,'Q.=P=H@5JJF97E.%P'KT4
M1?G4'SK>J_]J.KY<($SX>#\YFFC:@+Y62]AYE8T9<*^5!WMB.??*7T]X1YE7
MK!YVXK9/?V?_+.L0Q^#V1\\FK\LI\!81WD(Q'SC*SFUUSG7UX:*M7E<V/)CU
M>OKUOFNXLW9!H.C8\J'>ES]D=A1/)D/-&TFST9"D2#7CZ57PE'KLX!,A :Z/
MQ,_ZVYIS>K/C7W R%_S.-8S*Q7PN1U\.TB;\T #TJ[%,CM44[E_FW,RMK3Z9
M@W[8<+4]F]HF-@NX;U_GC\3&R(_A3MA /(.UK:[9.*M]A5_]).&05OF-6RST
MJ41/F_VE";/)5>_U]BW/!$3(LF&X?$!O313(,%EA9Y?+S%@KJ'?VY?^H=3D@
MMZ&\7YC@7BV9J%U-&WR+>\/Y=+/EG0/'KLUSSOANI?,IC#K>DE''>RZU4AAU
MO,*0QFW2:%'LN&[T1!#F88RFJ$*%#*]VG=+&9@*E:>@;9N9^'9"TL+X/ME_=
M$-QQP6%U4-LE"SOI__,D_Z\R8_]_-6<-&?8Z\J]6'?]JJG[]WQ3_OT+1PBW]
MC3?L[#>X:$+!B,NZDX\'.*#"C_GI@TI-S\ZX(]*;>8YB?N_-KNZO^']BD?@7
M#Q#^Y;K_V8E_4_PWQ?]VBNW$1PZHE#!,E[\( Q"OJG?W*A@HDYVF!2#T!O^"
M9!'BW"-]_VZ_781PG9__>U=$>B&X;6?S"J.>WD( K](!/OD+?K,,%LSV#7$D
M\\J!=0T!*UM7MEUK>+.K%'Y:$',9[>0>\B1J]F<M7%VK0S)'#JPR/J-3U$6*
MMK4WKTN&0!6>%@@'3P)V[X?<M]&H"T=9?@BCG4N=& /W?UUM@W+C2G'!U8P(
M9MOVW]VA\O^2KI9*# RS<2M(EPZXQZ@&M*5\/_YSEJ>I_/[!IA8>]>ZD_ 92
M,N_+$Y(V(XH S:5LMJ_\+ _LD@NUO:=K#((7NK/O?<)79S74'LA7C%&SG=H'
MMEKT.R<F!@3)+5AK->)Y6\U&G3Q#-I_)LL<<V%N;\3$G%&G(DB/]\48G77FP
ML7F*\8&Y3&S6,U_VI\/O5*EZO VP[-O#///F]VW3+Z_[LGFQ;T3@6YRS4-S!
M9T<N+S74G*).GNU+?S"9>M8@WAHBR<[O&(E[PY_J)'S:D^OM42["567$&2LW
M*RUM U75\4*<O@O<36#"SNE0X[?L9*.N/0$I.*3)C&"T0LD:<55)&W>U.CHA
M\2J^&[*:6GJO-,[FB</)J/0/6IJ$Y!:>@!%R6X.& )'K7*2;R%!TP;VCD>TG
MTVO'J\R*ARY40R'8TD7@2:IBYOBBHL+'0.$],R.6>%VO:VDW-/P W%_G/9;[
M/Q4*G"><>XZ':_=1+/J%ZJJ1.C%BL>\!Q5?;KRO=UU2[JFY@78]GS])P7,N&
M%P^587N"JR^B$29+EF.&-3Y8&M-OD-R7:NK95#ELK:KT:ZJ\AU/!O7M2Y0(7
MO@Q^G),8>>\#Z3A8X)5>K:.WE>J*MUT>)F?B# ES-4[!GT=^&!R9W7[5896F
MP90X%K.R/RGS]2A\0?!($,=4M)6\NJKF*][A,<];&]^NM'9[9@R_U)CTL*WS
M?O EX7'_T^J(#6QNH XH@3J2<UGNQ3TPV(CL$+2<299NP(*.)[4%M SE%BY+
M'*NN&I0"XU:-]6/?&;T7OVRH+-A73KNX$& 2I$-V1(R,Z?+/Y02>3G1V]//3
M,AOF.B=T7B K_L?'M37T$?*I30N5=VA>I*+(SMNB938-XM'AD&3_8I@9(00&
MMUWD5/35%QZ]G>86:^EP&G7HI<D!OE/'A"+F8T# 1Y/3[/OCU>7;8(/1[>T+
M#V8[.AS["8$K$!BLEC4+!"FYUG,L&+W3%NV-4N2I0L>V)I];29>)O/_T*2=O
M">Z3HGLM4P9YDQ1*E/^,<=S/.,SC5IN'?A([]24,*'2J&>OJ3U&G @>DQ:K3
MKV^*?1C5Y5U-.B1IJ%L?SV]@@PUA(HLUHQHW37I#^CV%;MW<+_#9-;Z1UUC)
M!Y!0?%8H.O9"0WC5[U%<(*5FN7"(]ENPG?MJ"SC0>WG&/S$9GT,&P2%T@&X?
M>!9-6$NZ'S>J)?G9V-6;;/[\+DFRC>'2G ;X>O!&AWL(90VT$T2#*$_=/$AP
MF,MSHZYK<GR=K,7<KP6>S2,#[F&8J->NI:KJEY6[*1J5U<60&URN<YX1]7UC
M]=Q), ;"A[7*=ZX8;4WWL@\\_L/Z7FNO_EEO1Z'#(>;E3SGX'+EK;*90.H&+
M,T5H_'1XPL>DC@X;.B!V)H0WHFU:K!ENVGRVY6CN5*H Z\H8UYRFL*G>Y#5$
M.0&BM/A5J*]:^J5*2/)D^L'%R$ WUT]V$WJ]U3T\8[IJ:?8KIBGGW.J8[GD7
MHYH$SO51>;-:<A:&(AWM>>4D-3_LVL?IRPC31/,@V'H26I%'Q;94TCJ8ZI?-
MA9);89IA HH+1VU_Y=KAOT;HSZZ#Q^?#*;9(;*E>Q]>A:SE'>FHQ/=28Q AQ
MQ)WE_ZT3C8">^O5P%:>HHEJM?-QP5W%73O,K%AYF:MC3KIK"L+<:=CB$WH;+
MF@8/^ODANXX\,L*,$)-W,%)_[)CM=VG5IA75;LCD_< TG'K84W/\7+SU6M_B
M?"XN8^X[JOQ>^_+>>D8&?OWDV/(H*3H+$EB_E_YRNR-T^4JZO^K78J71KWWW
MIP^\$0/8$_.H!@1%6\)$K'^^%"F^J.'^E'167W%GGS44JW599F\:8>C:7XQY
MS,)Y'4UX=^A.)3'2N>=2W9!=_\H&NX_C"9Z*4]?/IVR/*BLKS4&GQ C )APK
M^0LDT+::R$_#L%7$,$L)<""CR^)6IN>%/&;\^(]ZV=7I<>DJZW8ISN#A:XL.
MY8G5JOREN5KC52%ZH[XVR\.+K$WC8C?(E7L6T5-PZ3L58-;@?+B/ZYN3+K-?
M' X7A?L97E6=C-CH.1'$.Q1D/K6-U1C+7JA^4OH>/COH3GVN&JH],#G_5D=I
MQC*?#FC\04BG2LT/T0%(#/YND#I)$+C2#RT>3TWV=5_$<>T4W^AI#CE%;&NR
M/72#> [E,=6QSSQSK->JEOA#NTWMR,)P_;<V9;6Y<OA)*=UK'WO;VQ>ER]R"
MI<$&QU.<=4>7X0E]JP,=Y.W)8,7Z %JD?:Y5\(N.G!;Y=G^XZ"/)J1@K6*Z[
M!+ !PX1DY7%.Q";N383=QYI<LQA"[4S<VY1-.9W''M_CCLPE4EIY!*-J=;*-
M/MFIKZ96)/.7J<56RY;6I/#7.TS&Z' ,4N6(J*8>5LC-6Z[9_5(^8U9126[0
MS+J5S=.[IB<SGD4]CSIC>&QQN6OERZ '\N+H'1N7N,6RX8ZX=X7?;#WW4@3#
MT<?(L&;KSW6YE\J^U/;Z[A>KCD3\7^R]=US3V[8O&D1%09J*2(U*4VG2.[$L
MNH#T#M)+A(AT"$1Z!P$!Z4KOH=?0.PA(#3UTI"<@$" DC[7?N^?LM=\Y:]^[
MWN>\=^]]^X_?AS^8<XXQ!W/.\1V#40 ,DD& B+?6K%%/>>_BF)"2 A1QCHQG
M/O76A:^Y=QVJO**E.3ZG7IU[OIIZ_MYCN8E6&YNSE!)IOER,WDJ*-B@+8Y(*
MN!TMULDF?]["RP$4YJ3L -YUSKB%XT-W?<W8%:])@I?@$J0-8 5$!Z^H:T$B
MC!OLP<%MG!TIS;5&;)9YR>-2:91!%T<M&:<,+10P:Q;*\ 14YZ$M?3;U;.7<
M9D*ROW?N?,@IW83K)X&>JU'@UKV[K =/(P"=E$/-T>CA"&FZGZ#;U91TO.$\
M,\HRK"#3.-4OWFD9UVI%->HLW@)$CX0. SM(TF6-7YC);>BN?'N9)BH;"?=X
M-^8ZB@0?'+%0TSM&:'(W;OM,LF2&<7:+_F,YIW_[FDP6\5_/@OV.4MS*=+4'
M-!+NQICWU0'-%: =!\+R_#1#HM3128XQ:S3;)C=RQ_<0=PJ[O"'ANBY/M%M/
M/5 DTS3AWI-#; *W%LTA6MU+6ZNH [[H//P\L.7,>G85M#?14AK\=<'G/S7;
MU$U\, X$P'\,4W,0_SF$S6Z^0#<"MR7W+TW(TW]T%<PX ;]4^$P;BP5W)"^4
MN&%FJ)=3O$YC*:_-NTO3F2)><(7=JBWT?67O^C"4B^A\ZSF\ .&%T5@6Z82$
MTLMUJ!+;B<L%5!M$DN!O&\$Z*2F/"UO)5"0;;7IM-H8.S]=MG]UXI-E6ZHHZ
MYL(<1R]>N+4UP+J/_=L\JY :<S:;2Q)NA\N?YCSR!OD;$]K+;C]T,2( O!V-
MD!$M%K-6M>BT?5])@WQWWB[C>Z,JT>8E)55NF7O= M+:[JH#SZY(!C%,Z/H9
MO<PWO)U6+>C P8+)ZC*Y+WT=QUT;IX?92UE65CSL2A#6GODN+OELV,V:Q3 [
M=UF8]XZ\@2MKB/1(A"(ES:S/-)!9B-*/^6I%HHSNK"'F7F'-O5J1>^M;HOY2
MO1[?34.3XE5HKYO71<CS5:U@]X^U,3K1TG3&[C!];'W!ML_##(-@$_%=?!)C
M3' -[7,/[7+YN\0?%<B?$L<U\;>FLUPD0FTQQ!TG,V[1^&>&V(JMA3TIG9?C
M]E"0O:E4Y/CUGQ??(EXOKW"(G6\1]21_*3RI+JO:>G'.CM.>1'@[K2@S=$D+
M(*%RR^12"59CD@I+\H(2/Q_9E-Y79G64S%3N\IUKK;#>[R9-]JG%>'5EH!N;
MQ7Y2;\W^BB3IH"S<K-FV)SMU UK7P41KING5;W(X)?W^W_(PL=*>)5#KI9(%
M8(LZFWDP.A&ES0^QP_JUSQ2*YJ:Z[*2'J>I;Y<UY$!5!UB9\'X@.6<38A"#3
M:!14$?MM>1)YDD%O4V$;;GT,$MA9,JN/&$;TXMTX4S^VNB51"NYR/K1U6JN^
MJ,59B^QTE)16>K '8HP7%H;5*L<=BA>=)XMST\;GNR.:#41O5XCTKBG&%@?0
MF*A.2,I@G);S=JE7@#?<S9=#T*[Q.;;",Y\B$5*V!24="G<C=MS\NIJM'[T<
MM9\_&0?(;G0.3T%>8 /1(NW2UU-T=5U09 9<PLSLRE*O8[OHZ@Y?_19]R!)@
M'/VHZ&F&T/.G#MB68U-,)4X;B7-<A(>SM(OH5W]VK300"5H:#RA_&??$>[1_
M&M3(*DY"UI@D*Z!FZ_)T^YM.*[#*JC$;:[+"GH2A-V#8OP,5YSG1#PQ1H\B'
M0UQ8;^]>JV01H9N9FJN+E<X;Q--O@6ZS5*%KVT$D=C7&]!CIO,S!%=@];)9Z
MY3ET6_!@CD]^=]I5@9V5U,+^_/V-6*ELG<QM J#B6J</41UZ,#HD![F'4%B6
M\';JUL<W"51/PJ\USDD4VU)9KG9__?"SWLS2,,9HN'MX^D UQ)BK#),7B-!P
M680PV1X?SKXJUI_)6743#E)*=$ZXSOHZR[;#X=.3!U7^=A]W>3(;1(<9L!PK
MZ\&+Y*['D,ADC[J1Y::6J /*F[-*// K,A)[==I6,C'Z8B_[J&(TY<GDA3\R
MG0MA_7M.,FYJ++MU9H1FH&-M&M)#A7.=ZP4EO%0KXFFY#B5[&_,LIP@ X?;K
M!$ +'<U/9F;LJV4F4"LS_P^<,H9, ]-=LBSJ@)A7QT^R1MX,VN/EYW0_>4Q,
M%#7V:(-5B9H5*5+J\SV1-J-2.@GM.=958F\+9E2;WPK-6X/O?DU8E[LBF$BJ
M^]CDF6!_%LMWM?@\:Z^O+:]"+]*:I=S/NXRE[YE0]9.+],P8(4,1'*33IU8W
M6+S*?DA<9=>A;I!GA?'Y11_EO^@IQ8^T,%?!/S;?,=+'CV\E-E1O5I55B*@9
MY'S_[O#1@^/SEPG:@OB(NI]L&K[&CB4^;3!*9RDEA<EFQN=0\F5E7C4C6:;G
M2B[YK#\Z'21[H7EU+ ,NS\D>ON?[_M4"*'>1)4V\:5)%&4BKU-P@+'+L%EEH
M>[)\K4$K0<#935*YWH'E@:F_Q]>H6[VBWYP>5X\SI4ANMX-JKIUTPJZ['Z\H
MH 7U$R,EGTF/>2_-BW0*GP70JO'/U2<O'-#$6S_.COOLVK^HF!V65^ S^\,.
M18&#7+XFS;?J)G!WLE@9A!C.EZQYOGD(-%39DLD\['RTLAX?$?PA4(?(GQQ&
MCN]/AOO[T+H7=7B:1%05V<,,->Y@@Y71@?&^2H+G\B[R]HI!'[ZU?JGZ1G:%
M69+Q%'EYL-1/EB"MP- &RH[&-%5=]%Y5@L:LN^S"J%+?Y#*#7X5A^S;G/0W&
MUT,T;&I^O^43J3?]*@6Y;N2ZFQSG30CQ,NFZN_7 *(1X 3++2A)-2C+C//OJ
MQQ*_@B22F+)O%)N[:.-!?&U7/6*.2GE_(P#\ FVD'V,BJRO=/TC ;H+I0\NJ
M)AE,*A/P"MFVDW168Z\$1[[Q.[$&R1KR,+F1;D-ISWFWR5>X.;J,0=C ?.AS
M?/=8:<DO*>'MUT'('<P 3;L2ZS[SBA/[1$\RT4F,8ND<[Q5\NZ=U!XK1P&06
M?&:5M60O;1">PD2_T2[^#AGXHLX2E2_X0>F!K K3*WL&N32ZYZTG77LI)\!J
M4 A4>7G7$T@"Y9B4-%^<%]%*5!J7? 7.?UXIU6H[L18T4BN(Z5F_/9I@]DWA
MD(H*G(2U/G_COOT&X];-@2$  DNJ"( ;6/WE/8/P67M9LE N>E$KY]HIWYG=
M#"]JT&#M&K.9M8LS$EC1W/+-O=8PHPU%4YU!YBZA.V&!Y(4*@*T9\>_:-JQM
M'.C21E03HS\K?A1PB$O^T7R1F%V'.>GT?H$P=Q'QP[DF:FSA:<""<<-?NISN
MURG%#JU8C;Y0>Q39X_SU -C,O-D'%;AHK(H.P8N&/Y] 2%WWOUY),S&4X06!
MZV]%\B;2=-;7!]W>=SAG-!\\9'@0S0?H/<R(SJBVCL _A#[!SZ+W_:"OEGBO
MVR6OY8])6@A9!GE-T#I=&7:(8).?\PAM2H8DO=P_+3?.04<?<U9CC9:UFL:%
M+C@ZSXPBXP=+DZS2*<:X]J 5B3?7!ST8(5Q[5X +#UG2+0UU0$7X]AG< @WD
MNA[.=#RN]9Y(A]HH5(H]YJX?W]W*OO/I6.5#WYKG.4[T240\PHO#+:;GM=)U
M?^ZF\SE8<$I; /?Q&BU8T6]O;,UB+G8&HD^WFCBU_]1M6('0"^7>8-T_-%;P
MW#M\AC0!::.B]ZT,8<-:FX;UP><EJJ\J>0D S[PMUXR*J(0S4$<XV1/(/3S8
M79T6H5%G2*.E\> =M"UDZ -JWY5YQ9CVG,WV6-RD@YL?J=(@,DDUV\/4-/V\
M&:H85L!!S/B1\EHSXJU7CL?4W\)=9K]-1^)%^GQ>R-S5L6W]K^CS_?]17W#!
M?\\=R 6?700'_O)*T]#(V)D4WJ+7<Q78O>H[\H(C5IS4YP_MP;MPW@1 [*ME
MU;/EC#,^,.D1TU.! J91R)ZL"^L*"=L(4TESN:5+=FX!S3@D#P&R,4A#<21&
MSE9N1ME1DF/CE#&NT=>+LN<N2MN]V\5J^!UFNE1O$6U1VJ%+>-M\'M^[A[\>
M\1I*ZTUOIUS@Y_;*05,P(>G(EB_*J2K.?X@/)W&KF0:KMVC"/-UY(!WNZ$B^
MHW:4,*HPK^MS%9/./[UK+'<<*<,VJ-+'CNHKFFU00'U?.?L.+W:N:0G$ZV>\
MT>:-^+T\\XV6H&IR>3G6BA=D56 F1!SYDH)1&]'##V*21'-A:*-+S0):,NQ:
M5EIKTH7*%>7@Z[A$/#!35"_E>B2N+&:<!+J"*)PO5[$[XPW[10 0,;UX5UH2
M(5&*6+)@M> \H".RG\/-G[EV@1F="P>F\_-K2DN/)H2+2^#I#5)D6G.HI]H-
M^"HICK:%A\R/T?-!66M]=^->1C[J@[ 2>[PQL/ET18<CB(ZD7)  N.->J8CV
MCG!K:$).<V<GO=4YF#_83;WUF*-VM-P4(P3WLT1'!\(SZQ+PQW,&74((F:^4
M=^T8N-[[I#IOAZT2 +83;EB817E+PH96+2EV:.SP[4J3LU:G8@*]AGX_IXF!
MX:@6XQ,Q;GTI%GV,;-+2;*0X^<N-G8,MD2N3$] :"/^K$9\WCD>B- -V*&9)
MLF]V2''[X_I5XUEYLP0!6[&9UL6( !;,H,=)%$)B.9*VRY@HSA@#P[&^EZZ]
MW4-Y;*'=; #S>JP@Z1@&7Y* 76+RE65-YOOBMV>5"NXVB+=^*1M""U]=Q&0T
M[1H*\4U<Y+&:VML7-F(AH]HX%0^SITX?<NR]/4VRI)(A0*P/<,=PRU&^83Q=
MR[^]Y-'0W'NZ%\1PJ"8]LA-%[NYS=C9ZKCXM%<'IZ%S^@BOS*BO ,/-3=NRS
MF\,L81@0H_LE_&D]@W504FSJ)S-IN= A&C?-VUE+-??(A@'I)-6N)M<=[K3I
M=Q<LEMA=]>^,9%DH_:H FAF)54VI#V4+%C,\EH[4N67IH74L$!8^9C0QIU%S
MCAI3V<E'YF_TL4$.:WJRL:K=]')1@I4%-HDP^XK#6\:0SQA<!]W]]Y2.,S7@
M/I@5[)0*3@#L<#M=XDEDB4Y.8-'37P_5#:J<1U(*E!6.?D]UB/3[QT+%_^/I
M#D8@?SQP2UJX#,FS8U4=)L4\/C_$0^=K011UA_2#CP:2YKM.+7YP;';F)P%
ME=M8<VY?[*FR:8_H ";[6G"E!'/&Q,2,"1U./>6#&PMN5+:L3F^\\2M0DS6
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MJ3R4W.?M6PK:L9=H/E$1=RF5#CO5=^&0-42[PD8EO_2U'<HY_7!NB:2?:"(
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M'=2I0PJ=KCJUOT^F8,"@-/O%;]%9Q_C*YRO1.V/GE]@/S;L#7^$-8N868>;
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M"BL!D%5HR#YN6A]F'TGTH%=TW6*]GA-RR=W($6M+V:AD2J.'_MZ,_)Z5?:[
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M:ODQYRSVS#,3U3HF43&G:KA/GL0*)'B&)*J:HV622WK6M5R\@]5)_DLH^1C
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M$Q ()(0/=SEGOV?O_7[[O./L'V=\^T=&<H_['IDK:\VYYIR9:UZ7W#/[]J:
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M<B.A%'G\YE]],*4JHG1](09V4IC:)R1J38D1^?.%?1\]BW-#98WN\@LKFCY
M[6YUFO5?7_)[OK_/EE$5AS8:2#>(+/4$!\F59P>"W;^Z'QUJ^! "-Y.+R8^)
M4UA;5N(@O>4\_>,)_OKJV.E=R'9%I;'Q7^\O?;Y#597204@K5]<[,"8\R".I
M_R0KR!"]A;[,L&])\;L\MQRZ8[GR7MS\ZMO.1XH,-X_*UK-N'MR>&?89P/OX
M9DC6K'Q=/\J9/PO=^B-=0.?\DR* 5S+,B':2&<5$6\.&77\8T[K,X-ORDJ\O
M&E]^;A@[6?3^P.<S:R/0^<<RE)WA+-MJ+N764'4"4XW?!E?;I&!;BB6W6\YW
MY.=/!78T7^V7ECY\.#'6XAL4TKOU<2[(,C:N6?<7/(52$>C>%7NS(NG9WZ.B
MWH,A-2DZP+/UV*3W/05\&@G3,-T$;O&? @29^T\!!S1GCN6'8SM0;+ /JD-.
MC3\%+)3"HOY@?[;L[7W_?UDV/M<;10[MAUN03 _<QY?JB48P6:L*Y/QZZIR@
M6(8"QMU8X4K=%U^NL'#NSL$3#,'XS]/H+)+> 7AB$TLT+1UP]STHW98W7VF.
M<H3&T'RZ:=",[DAN\^ZCE"5TIX-VOOPYWI8Q?R)P($E-X1/X0='^LO / NYI
M_8,(?VG'_/O_@]3W/Q+_1^+_2/P_6.+?PXG[W_5Z5L6AQLAAX ')L/\GJ>9>
M#?.A16Y47L8IH-5H7Q4X>VMWZ#'1KLAZK5[ 8&); I>%_,D0]$1&]/[:Z(]7
M4W_8,<=;5 \,)@NF-:ZM(=_4ZQ6K+XGZ3%?E&4=7B]Z4H>HZ6=#C4R&\VI9?
M_9=_V; !=K _Q]9,15WPV1T'?+(9O0=MC/B3ACCA^17P]S4O"=(VI]OHU:!O
MBTN_$1GMX+%H&#=4@'"[(8IL%(0G83QR\B5.QJ)K;>DZL<H:/U9N)WOR.^T]
MCW@22'?E8H>' 1X/ C@29A)@GLQ7P>P@KO9ZLKQ(I-R(-S9),X9_RLTIZ?#Q
MC:H+C!%I+1V*#?//Q&H7-9:!#"U\S3:M14ETO^P>S:RDK)K64$:C!B8=H$$I
M5L)S#T=>I7OI]LL;V1(M%QF-2,(D2WQ4Y/8I  -\PZBR^GA" DU2D ,D">7
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M'SCL.7&_#WJY%%3,*TC[AR"B#K]3C&T?HP#S5F'V+U0IS.3X'6ZH?*H%,:2
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M^V@^O,LM\G;[J(_A96[8\4PMF8Z"A-&Z^$ BKURH/W@L3W9I<)U[/S-"[2)
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MC]+&U\(O;[=Q@*^)CXN@\K^;&H4_;G!R?%)CQ^J=:\#7KN#5[#/^ Z31%E6
MS[1\7"PJY!%:R([N'@JR$74)2 5;'O.)?*(,AJE/J=EB&<]M+W3?I70F.)YY
M'HM-38?S;O0"1Q]YR@ ZUWF>K7+*G0*XPP;/+,$@HG8>ZGH-&"TNK_](7<I
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MU'&"K,G4A!WCM@)GF-[^E>7MZ%C;&. 3\>%R<@>'MS'_J"P<1&!^4VL;"V2
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M8UCGDTG%+'S%P=EL;2&2,%8M%X4,K/4Y]1O'\[9*#$\EB=&&=!T=+V:5<)5
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MK8]6]+K$)M@;<#'V8X'62IZ=S;EB+8^H:I=28EQB"&\?ZPLRX($M#5Y=,U,
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M5D/$<;8O0BX%6^ >ELY;BC*NV?R G9:_F@QS<7X5GHEQ%&M2W;[H^]"C5_;
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M9-_(J2"7@PA\JP9N//0^&[<MKXYD;C$UN)D-EG2:,[UF!\R%;%Z-XPIHV[^
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M?YW2F2##>C2<%'R' H%Z?Q:V#4)/43L,(I[.(@.B<DEL#'-PXJ$.&?#4D S
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MJ(T[QF$"[N4V<Y-YU^=H]O>BCSTI74FM],1"[C9C;5\T2_D6NZ;XH=B;W[?
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M%IF1.B=X<>'U&8V>O8FZ3QO\.9';G[/_R==N?\E?\H\(%7GRWP!02P,$%
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MX0(B9GO><[[7Q%12L*S8,V-_E$ G]W01^L+>T^O8I6=$#JP_9+;"NL._#6S
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M%JQZ%?AZ'/A_\7=H?D"]F5\;UQ.!Y>'\%!.*T;6ZT,UWR\W5R0-0 19P':N
MF85S=^ACQCIT]G",_2]1P<C'AM\8Q\FF/^X@+M3D#SFTVI6VN%P/4WRBOASX
MZ$OF+X[=<BGGDSS_,;</)U9[\?.-(D$_E;4[33=<OELW8M?+3$N%;S_97,UP
M,T.?NK'FK4^L;7[H^>IA=>$O-_,\31V]7H!/<YJ/!8B84229$E#0F@60_-FS
M';P-:R,QBF;[81L=2*:9-]\R"X R/RO@XQH<X;U,H>)YQ[S!/@;M3U!IV;'?
MOUTU19I'&X-7HW]2/=I>VA^XP0(Z'W8L)W5<UC$LA;;MG>0^)%PF9LOMC-0
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M\A!VZ1&T*7&T7S$[K0#9YQC9U_+\&4ZLH1UAWSIIJ)C8\&;L:=RD=3#A4I:
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M:R!J9N-Q=7-=<K.<DH/],<L!?B*;O_[[\N+AYN5QOZKR=,P:""-01K'_>89
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M"U]R>LO0^?OD\-^MYE<%KT_TCCT=VU)/C$>ON.]RZG N2&?3#!19P,?K0RR
M(QL<^U\<?>3M^]?_K_]?_[_^?_W_^O]_X)\V6X:F>B)[?NDOP].*H1./A'^;
MZ'%7K*E$FBP=\#]V-MNP*/^Q<\;S#>G_B;WW@&JJVQI%MR*B"$1 0&I4$! $
M5 24%AL@(H(%:4I40)H0E18@) @B M(%%(0H5:5$NM1(5P%!>@])Z#41"!O2
M;OSO&^]\___>_]_SWCOWG7ON<&3,C+7'6G/ON=>>=96Y?'Q/6G:,'V?B46)O
M2\X2(T>B'I_=< @Q_7401CER\2X;0$E,N\-<X<-L@/3E5]T^AJ8FQ7A#[6X/
M7SVZY-(.^"N<9HYGT-/*NZJ^PTH<YP F7"=N=\(DQ231-Z&"(;SP^%QP^T.>
M:V[AU-PE:0KLBV1/$U;(J^^U_GI!/L'Y)?1<W$Y9ZO8:03;@"!T>($VLUJDR
MK&QU_&#]UF;O=>GHV.;G&/G"U 8"Q0RR;3:_!!EBFVSU:"/^OO,]&&7_5P3#
MOV1KW 4.GCQMZ8?_Z0KO*]Z"->>UTPW0N'-J^S'U1KJ"]Z<[B6P@:%WEYC6?
MK(IBE2KAP:#JH;JG1PHQ+-&*I1EJZA0%'@P_4YR\W"D=/!*<7N?^4XYY7:9O
M108"ZN2@8&?J^+I0L-QC^U<+2M\>AEG2.\"46?UF,F:+?P@S<9SCPNIGQN 8
M_DNJ73<9OI#".[-L8&<$^K$O0U/?O8CY5%\5R9K3@$=A)20L?Y#W/38).$ ;
M.V*.#;I[NQ1.,8MY8@X^#I3KR#<..(J,L4A:\XNMN/51Z:EL.6^Z3DB'_\Q@
M#8(-G*U68^R$D8W^>F'3\^W7K!UE&I'7QX*]>[-ZV8N6%C];J@LG6C*$V4"]
M_C9J(#Y2UYA$C_)=O+X[?W&X^<[SB[E*#INC=0("IW9$/SZ%>_M?#+04YFL*
M\X>$1.T?@BU\Z'C>--!LDI)?V/%?C<T4)G#=BVBEBT6Q@5DM1TZWMS*<__W5
M_Z7>M3]Q)YXOVCL2E+^&/Q"ADB4!U!KL,]_VGP#/2\8E9@)#F0JCO04#Z>9N
MZ8J]0G1B7S9#^V:4Q,'RM,)WR'0C.0\^KNW'C!3+YGLY$8<*,H^U._?#G+X.
M52T"?Q\VW-J"Y2TE2,#U5B)TM=XV\C=G55SC,]'[E,#O(KM^]&GLHQ? 1[T0
MFC\SJ6XOJP.^XR[(,\$O./-3TY29LY6W>[KO\*M[?H5607)^/#Q!FD%ON0&(
M04:0OGXJ:[>6;S;2GPU,##3B1G1(6F'Z^UR3A<H(C2.:P6?WG2AR<7];'2M^
M*+3X2X[DP>BEYE?8#VAQAA8%7L\&PK:,&CC__E+^'F'OK(R<<H8N& LVA7#)
M_6KW.QQ^.%PNWEBC\G^\V^!?&^"I4#&T*CA JH@J9)B23.]-QI06%9>L7HSN
M/G:EUV#V\_YO\U>,)P>24^['MMT5);=/%8^XKP]4SDYMHJBK\=>*X7J=W?[O
M2% 1I'W#32=SJMGS?*]!'D8YOOIB\NH]91(A1.8@LPBM.7L"J4Y<:5+.ZO&*
MC1NU,_./K3FX\>#ZL9WWB;: <!! CEB#0CA2I./-[[I*MR?--%>GCH2Q@5LI
M_F(^;*"\QP';K,SK5Z@@QGU48^=*7VDR0]CFM0^47TMB/;[B0BJ&(D!OP5:8
M+;(!HAYE;FNIOT*;.N6B^;000TAPC5O>C=.J8U9S]-V9JD#E"6S]L[C54A.Y
M:^-?]6A-(M>I1Y4'4&)T&59G^NXAE8J@=[U.\$UDO]1H AL $&,Q]0;^>M'8
MN]G#V=&O'?EK!%\8\0D^-9#Y\E")A4L=8!VVX/ZMCR,51J9>8L),OVTD, 5_
MX1A*,2-M9*U.,ERR[HFCVGBPR7H%MYYNGKGQEK[>PEN*+T,XY@O-0Y6!(=>:
M6+Q,ZQ1YZ>8NKE>O$*#5*Z*Q%BIB_NT3:K0/H35NB@=WM&DTVR:EO:TVL")Q
M*#V-VDO9V4H9:'37D#>K]O:&#!_FZ=7-?H7>8?G@WY8U!%TU\+\Q=RU3QN:1
ML9^RE/"':_DXS9%57L6,T@.*&1' WP/*;1@7M1'E"<ABGI,K5D3WUHQE[[.3
MB#W.M Z_C_.F\<"S8=VB'<%:Y;V=W$]PUW"I;,#%;%B-=I 9BCYB2E5O31=3
M9QA1APV7Q,)*/0,+X".-0F>R'&+D@2*ET-&(]OPS]P6<N2*Q+%XQ.@(LOAY(
MB63M-B$'I"E&=8TA*YIBY\1.J-USGPR-2,>VN/X(9P/<U_MTN7VE*Y:P=$G&
M!=#$1?8C5*C-8:LP9H]PS/CM\Q*)6SL0*,M/K.\<EIE97*';.V]4<-!J[JS"
M7=PKK+HT=.S=WUM)38@?]/"9B9JW]HQ[$[PSIYI^D7&JB)E=2A@2OM%==J3F
M?"'RDKN_N/XW2:M4C42B@X]:M9\B0;5AEUZ .8_C!$X*J4,R"LVO05#80+.H
M1'_,^X;#1;UK;=DINWOZ;AOSO F9/<L39Y/8CE(%U2BXB;3H#]FHPQ25L+#%
M];3;ZZ;GVDPBOS]9'C]%]A,]_LLH,?S$>Q'C'62YA)ZN_TP3_V\%5^%P:Y>D
MQ_/:4:,W:11#AQ2_+-ZX]^)'FRB =,=]<*8U71AT)U8RK,EZ]Y65E1^M&A^<
M&BD^%&T=XR@U\#U=CHIO08RD-N,F.H%ADTSP7/\=C^R7L:F>L:N?Z,O^^9<>
MPK:30\1C<D-+#U7FT"((K.VK.L<^GR:IG=:W4IED P76)=1,6@[G-CA!;#"A
M1"^M]\/C%IT"N]%]\=ZS([M;$_:N'*S7;US1;V7M_N"N'^DPC&T^[;XN_;KW
MIO1)D]WVC.-374':'J<[;PDD+F.Y63N18A.(L)WA1&7I :$@Q/J17O'E5[[V
M0T:.4I /<C2+;V9*5JE]K0'=@:K=,?$5T]YF)Y"8,:+>8&'5[<V2./ XQ;X!
MRE5S0%>!>#+)[,1UC:FI^IVVKR]R>=[Y?3A%9I#>-X7"C(CUN9[0_8IGK67;
M/USSOC^CY=,0H9CW=\OSOY-M4J<@ZAIH2C_!4;I6* LR8MCI9FE7 <J-LG*Y
M @P@U3KZ#)_YI*,R]>I-U*=J_2&!B_M;+HZ_J^LIM"7S!-4)(%?J?96IK?4V
MHF7OYN)JU^9(_)K*K]R?NEKG;#?0L;XA_/FQ(A?'S+H3!@>:_6>><Q3S _@0
MM_N:V8LZX>M*NUX:\404 ,QIK,_;)[(GHMXOGIW-#AJD@KZ+2W0K\#SM"QL(
M+D"*D<3"UDR8DC=ZT'O@<VAERG*N![4SR_61W??[Y>[?M;;57KQSFN^$2(C2
ME@#'6G#?!<NH^E]!/"WP]\Y#U&4J)E0A_4(WPVBZX"-<Z?3Y0VHOR1YGI8[7
M[Y#:>V:$^;KNP )<'._:!"90N5B[PPI1)ZE[G'V/MU'%KJ?Y7GIU=M*D6&[5
M.@A0CS]S64"1:\%5\;^OO_S?&HBL4ZA BMH7+,<@NR)3%G[4OH;0T E<,=I3
M>-H-GKQTG@=ON+[]3B@T\(S%UZ@0BE(ZU(>ZLA!:QN-UTV^V.ZZO^GFK0MTV
M\0DT#^O;N J838* MZ&E?1T=[157Y"M^+D?+O?*^?FS_+S)7UGFIAP]W]DR2
M'JTK6,Z#!AWZN*Q % -/C#&!A#QUH:-,2K55B]=^K1ZK@5(&R&)+%:2OK(.H
MJ_C42Y0L(4'''0<^%CN]K+@^<*KQ\M"D;\O/=:>0&G$B)HPE4T'!A:PY/WB@
MDBQXEG=CN=V_1&;QL9G_S_+R\N+RZ!\_Q@X]D]N][^H!"P,N #@%"/1N$;B#
M<I_6C$RGCIOYLDR^MHJ\2)?_:9*TQ[D@>?-31H1R#?G_4[^V@%&Y2%LK, #G
M(G/ZLY6728'$O/2]FPEW3&Z&)]U4&=EE-5/VH%^AJ4/2A IMC-F+#+C54[AR
M%+=F4AW09L(]IDO552V,BUZ^$9O9&P$PF,RPWV<G0/<SME'4KH"VE!6:%)A(
ME:T?WQ_OKM.@K]]5ZE1N>J_AR.V[OJ%QB0Z\FD76DH?]>!\KS[&!H3;:=["$
MVDK2!B5;X$4\30A@2.-%"78O,KWW\'N'ED-?KZYJ(K<D-K$T&+,&YHP?ZISP
MB:/(MD IIIAH_^:*4'LW:8A-#X/'>T=RTJ6ER5+*28?SBN>XN.//7/SAA\O"
MW,>-9+:P@5*QIC+.&[.:,*(,;H]^H5$, NQL/#%LO=/T<V2[(U> TQ/"SB#]
MT(P(1:X)L81Z:(5O"SX"*@QS90,QOC)BH#IEH448J=-0)VTFQ@;N#<Z+T>;Y
M.\;:&RZVYYL<.?MY;[%]4*YO$:L9OQOE3==VK=.L^8F&62,)$P;-6?XQ086J
M-89;::R77Y^.-A0_5:1M\E<(23V )Q]=1'MSE,1=5BN<6U^9<0V<\J9?0)[K
M;/;'/JU3<O4/# O3/8-U+NEY6EQBXE7>^:KMA[W%*F]"^9A/RCR:'Z52#(IS
M- XW.$*71@'&*BA!$B:D$\<&&K3V+=*&#7$'H\<NG W_M9&?/Q+P[.R&O3D@
M3C^,;O<A4*Y#GFF'+;VF7T.=I[ZKH7I4H'4AV<YV"NDM(XW:*.':FG/CIW[T
M*"()1^M#W'<$FPAWH3NPY69-V!!,<7(K!H*Z3Y5*/T*U7%S/<Y5P+RQY'^_0
M[]Z IZ$2RA];CUTJ<2CORHH?4N!X/L%'W7RT<0SAR"_^@=5/'F6;?AQRW2LC
M(9Y\K3(P7T<Z.BJ&%HIJ+03=KH,)E$P6+S<9NN?"@*B6G7S$^+BSX4W#[F%K
MC_*X@5UG3RV>?0NY#JK_WK34JP]#MV\9+8E0E<F<K]3:@MD_*[A TU<KHUHT
M[<X:O66H4%X1,:XIF*\HH>' 12=>XG\72. $A71C,)7VGAFKJT55;LV'A*ND
MDR]1)3]RKZHN91U__? 4=Y?100 0_\H%6%K3#X'X,_TP>_PSUHF0JZ%>JY25
M2RG60U\N)A[-)'RF#5L\65,*5.:$<!-A58$3S' 'ZJW^%>F*YPS?_'D;]'K+
M[.4V42,&KQ@T% @,_3?'0^2Z19A5RDD)O4GS3X@W;3(3!H!M!H=Q_CJV\-<+
M8/!/[9_:/[5_:O_4_DO49I-4+&TH29&/2&I"8./EXJ+2%[7-'4TZ%CPSWQ:!
MR80G'?*]%N.-QA4.7M%S$LD^O!]/&)\"+#O@I3Q+H7EN_IT,)<A0PVEOZ6OS
MYQ&J.(?4KQYSB.C<0L=90 Z#?&RG ?9QPL82JA1^%PLB5^2</UA7*_CJ0I$3
M]_3=!"F[\+[J8/35)=AV-G!?!_/$QE,S--#QT<=1^9&.FP'7'.XRF[YM"NN%
MV9VXLE/7F/1(_,V8KO)4;G\@(Y.%Z5E_=RX:+G)]+TX_;FE&[=<QSCUP@S,F
M(.(D9J^^PDE_7/@DXK20X>JA(L\?9V$+ASL/=P),P@K4)Q]3A"2P0GS@(!^F
M)>8OY=K+FJ+/A))+LO+Q,$T_\(7!+=,K_M$K6X/_9:?.'M-4_$]O&?2G[N^J
M*W Q=Z-\G;'"!SLJ_]J5,7SV[9[>_YBE)H&\(F:-@E%4R\@=AL/&!6NF\M,L
MY%VH;CB?J:P2/3:+MS\?\7S\T$_=@Y0-.ZI3^ /^_K3LV0%+_]#W+TZG["(Y
M>0TC'WR,"QDXN8WJVP"1Y@3RCAC7F# ;I]:5L+H3H-;$"@1,D?5]YZR=ECBZ
ML7=8])!F7-.U[>UOI98G]_KD^,0X,E-JH!P?]OA/_<,%&TN65"=B4@G1[-/W
M D>BJ3Y)N>3AHZGRN0-G2U%#,]UU#LQPAAJGM7L?B\ME_ @SM>8L!== $"A[
MG5M',0I%(7Q]_3RSYGY]7Y$Z<E1SN6/O-^7IXW=V$0WW!6K1-9 !+%Z_')2)
M+7:XM16^6P.R.S#8O)_%]VP=@>[YM>FD?B;R$^<Q>J?>0MXY9T0 FP-D,X;P
M+X@8PZF6F<$&G B_-W5=)9O>_ZE28Q1(G+U;6=(ON%-P6>6^I(P! $Q$OVXQ
M=N5$-HZ0P;9Z6'%O^@'J-1!O0\6\8,"]DF64J;AP)R$[>/%VH6/[MNV[M'LX
M1*_XHL6>12]SGC8[I=_9)N?]S:(9)B3<4 RMB)K;4*#5DMP90(KAGSW6^,A%
MI3=$J/.!7*/-1:;)03DI>T IY@XS'>^(>PHKL:S?C]X&<EWP6S--P+C4?6SP
M*S.^OS_=+>G ;IFS]1/\;Q6WG>'ZZ?P6$I/#>8[IV)R=#![4H"S0?H!1Q,Y0
MB>RF E\*K>-MK %?OHVML^KDSHOO'GPZ\NRK??6C^PKS\&<8?H88!4-DQ5'P
MQ/$PF=1WLS<%A^;*KPI=>'3@RS?=$AGC>YR?7+RIQ_\"R^?^86#YBM7%!LIX
M0O2YYIYU#&E(HY&K3EFM"LKI\9>,1LWZJGUEE=;G[G[03I2./YEIF.T?L:]O
M1!L301!#02ANC6HDC*1KL-R4>X%]HZD7&QB-\ORVKKNM-PY^;,0:Y<:L8=BI
MJ8VMP;@';Z'>/;X7(YV<B]74KAB[1?LA$-. '9HAF2WID;S -OKY>;'C+M>(
M^5[+]@'/2Q(OP#?M(?AQC\S"K2V<X4\OK,"<N;._:"I_6EK^/9T -V2#G*L.
MH&T9_8&D[MMQDY+9K><X35=3 SU[/3.35&U\$NUP68$Z>!AH+TO,Y40PW PY
M2I/=/HIA;'G_7'NQC.-GE*=<5-\KUOFW *#\-B."1MQU/?B%1;SNZTO7$UZF
MC? J9KR/_4><._E1YDA192_C^/NY<A_1Y.NWK$SWW:R8ORRL?G";'-='H8?C
M37U;%'@TH;BU)1(+G8=*XQVPPZ*K]>E'>YN,;+O*!D?,*:SRGQ=B,TT\AC2+
M_1ZU/',^=NGM]W@3<YY.#%"W&U/OBKF_LD.M$1J6@!+%-B9Y?A^63R@@$&[Q
M*XG%O;$U4+P1EW&M22WEQY<['E]$5F EI@3&OE^(<%=L670R)1[*41.W.R=:
M:K7P+ILH_'J[I=-X)SIQ9@!;VLH06?DBX(43Q=3KHQ1(<_L6;]O7LW0BAH?M
M0U9W%4I/77T#?06Y5)0SCZ%888=YSV:[HB5 # 5JD QUZ:U9'RA+O#[PS2"N
M8#5F)51V0';?MO5UD7I6)PQ8,QN:J1<&+:]0PY[K&F ^N*J]7Q@_1#5\O^%;
ME;C0*N7.T8PA#E<S6IY86 !<IQ5J_ND[+?_Q$,%BM9H4)U_K73E441&L+K?:
M>>!&U)EO]Q6"@!7X488C\WV-)[6M*6RB8K''T5O.4J[5-^\<K_'#M/UY4G['
MHI<?FGVBCR+;W:6DA),*%I.6-J6M;AV^=6-)6FBL-JX?W0TK-\ _58,2<^NS
M;ELV)1A/&GOO0#_PB1>.>IZI_Z"2C#@@4WF@X"HS'68?\*KL.-6>]L2G3Z/M
MM?Y/T=>^"BE%IV=0DS/M"<QTBX!)YG@KS8.94'.$HMVA,6;5_ &,O\@& M^?
M0"4-264=6)..Q+ZN?=+L/_6HJ_YF\PVK%_<7B&$7MS8P [D6#VX?U=,RVE-A
M[8U.BP6 +QS;',"3](^=9;5B X*Z=Q&4#2*KFDRO-OH<>?YG8=GN.R^(65;W
M7'AC'HM!HX '5^')^H<H8BVX_4CE"86E)6HR+8IZ)8\$>PZ7J#FFPE#(G3?D
MY[G8O5QH=Z$\>@R]^C3Z6/O%'U;'?-JPV;IBL&;$4"Z+]S*>9P6MZCI^A )K
M,56SH@JD9BYX^L4C$5>#KYXL^D)H=&T[:'$&F'0ZO.<43_^-W_19IJ!LF$4<
MRXD+8AV![T#9@TO$3@'7%>=DD]SY9-+IRT>ME,E=B0\"E5;J\<.I-!_F.P2N
MM#,8MK]437C4)4ZN@C(G%GSSB51L_N#L[AWH?=L(5^V,J6&T%68,"P"_H650
M=B ;>.M<-<)]PB7A2K<)<#?QQ/.^FC?!NP@5!T*Z!G) 1%.=-#7IB1,)MVNA
MW#_G]7O;?)IV-/9QR=E'PGQYF>^4OAN=$U#<OBY"ECG\.R\ONLD. L8H-,"%
M6#TRHB4#[RKI>LWY%83JX#L^KR;?<.U[ .&VKN<)B:!994<@DY!RED;F7V>'
M^"#G((_."/PC5.<_#Z98!Q@NH"VE7%@ANL;-T?[ K8(/":A%O8S+E5MD$>$/
M5U[ZY73;.9X3_J!JE8>7133I'^JJ4<CL)$&$YFDTS9O?J@+R/IP[)/ F830=
MF#?^4B@ '5ZE>5;VK'A+(L+[7Y0?%TM2"+::3)"ZI^%U_:!"\<ROZ3HG)@[C
M&BA,SBY/(V)V6,^+;CF&MB>,?D.*Z/?);W^W*VM"D?#B31ISIW+S&K^8.56F
MTHG(E._+K:JMO*A"/!N_W Y 7^.26JC[YDA^Q[Y=TEOOV\388 V>?B5K2ZV/
M1"[E1+9O23;)' <[Z5Y@)4-V(M+:"\$S?)F_/7[F#C"I.XG)CUVW>O*%W%4;
MJ$!QF\ \0?. #YSM!(O:NX,09>)!ZF.GEEL_21&-N.:-=>KV4GR?H;B)=,P>
MY'FC9RT-?3[-.Y2?+!O/M_LGG99;+]"F??+SSX2Y6Z_>"*@;-RG6S;^I-5Q_
M+:O2I3"-0?#A"*Z_T?]Y*-H_"FYP6-H^;VYUSB8MRW/D]KF?M\XJ33D8[C@1
M-[KWXJ&<?'@XG)*,::@:8 -$8(19RPSW9H97[Z?#X\>O>+9N==0BWT*"6"<P
M]:<P#]3"?/QY&A!#!%H^Y0(!@CI"3C43 =4;X8*3\9(%HM.[[2Y.6&=$&*9S
MN^R/;7X, :22-LR&>&BV8$@&P[T7Y@H=KJ!%_.3PDDGUSRN)V3:SVV1[O)2W
M$\=UO!J2CGYQ_'ZP_L'R49L:+=H^CL3=1S=@2SL7-[,89F!/UGS=,3 4M:H5
MH]"'L@P064_/.>R=,HZT3Y30--R_V3*]_T%:0UT:,QTSD8(MPB\64?G12B@(
M:*L?5ZCRLCS23^&Y6J%1HKQ6X;<<[QGG&?%]VY9_[_]&.\SC)5C\;G#*-8Z[
M+P^&TY7 2+)*?X),PEND9R,:2CGJ/S.86?&T8/379J,#5Z?I6R;I=I"T:>!I
M^B'63S90Y!15PT]&2+)^P':6L@$N,*0AZ01V/WB-W""ZI9GG-B47_>&1E.ST
MK<R@\\=X#BSIWFQ=)-#M&1)@"!5+\JTOL*SW1S2N[ =-FG [<W/GQ<P-]"N!
M'QT&5WI/Y EXKNXM?(I]8_D<=;R'<9QN\GOJ5%\529ZH98C9"96#YW152)V"
M+EEZV<L%ZBTB7+@V93GCTM@K^C\,_<2!.<Q$+'9G#82,&QQ@B54T0W:[H ]0
M8<WN;C?[=&T_N&ZA?(7LN )TM\N?X'I5WF3K-+;3D)Q@9T+!D@:>8QS8P% J
MK1E4G]"[$N"F%FHG5\T&GHK43#MUO^UE- 6?&GSS1!CW"C9R7Z' ?X A)$8V
M"ZK90Y>$!!&$&7>S04PSE-<[RO8RU>=U'J$5<?B56,D/^;L'H54C!V^S =_C
M%;J6\0QYT(P$&6ZE.3*+T.J@L,GGS\5@'LD$#YX-BZ]?MSK9>7P"V?LB3AE[
M%%.>#SE_!FK(^H8I,ONB' ,JM#YE\8-88GF"GSL)N\-F#(R>=ML_') Z4NV=
M9!MR4+*FV4_?Z(?YH3M1F>($BF',\W%%*F'Q>*8S^EBOS#*]?KB/#83Q][XP
MT;W9/;W7<^A0G"QTL47Y/,V46<X)_T8PH,) */HXF$"R2W!!$.$[;(:1\?UN
MD[:1;B,FCA&V&,6T<7MM5.2+SUY* D1K-D QQ(2A%2AJBVH9"^EJ/>D_Z"T2
M'6S@>53^Q_-REB=(\O6+5,-X".V6.4_?C?\C^<!MF0&KJ$-5\1:[AF1N9)O-
MG1&=S<> 9]=B-C=KV<"7\DS6WD!9%AJ!H:B\_[VVCO,)H!Q7 YM*8.QQA1%Y
MNF$STQML8/OPOXT(_$'\@_@'\0_B/PDQQVQBB7=8]',EOBKZY+4?*_Y?%*6-
MY2B*7!X1%#80#BUM79RBK+27Q30/5(W-.P0F7*A4!P(GO[[P')B6\[=\:4PE
MT,)!(G(8\047YENN&5K.+')T&<*,IYL6*?2(;^ TZ]Q#,E4O;&8/:^,;S]=%
MVT;DR=ROM!^WD5V($03S&O4A/;:65/CSHVLC%@MZ2]^;*M>XGW^C+=C)4J$L
M7@@EMU'>!+IM+AE]J$I\CU((PAV[,>J!J#\6Z/:24K'(3\9)$!2>H_50YNG&
MMLEE):\+Y5LW+G<S/JSQ-H[7QGQA \6X>GA8SFG&:6)PQ=5HM=Q7W_0#ST,Y
MAG';EWR]'$0D>.B#474_W(?@AY.W?@9.SNNW&6RL;,A V<!NZ%(G_2*J2N1I
MNNC/W+F3=_/ME?RAQTM.AD!'O^HG]J+T?Q^M@M1NN9N'NDEUGZ[TZJBS=;MV
M-_35.M_F"5CO/HUE/"5D#KJZ&L &GK@;,0YL&3$8XVQ@PM:B4:&QTG/ (PM?
ML[:I@C_AE&)Y=2KCI5@2&T!/2:M/M#8$0AO502U3,""K.6?,4&B^U_J#\+:O
MXQ?;8A^>E8L]<_JC_@YF&FL/2KT?\EQ79&*/B4[W+MN<>.-T78J/N'BYPZ-?
MY&AES[_PQ;_CB37]@K J5,2"NVAZ6K0:PJ[#4T=OW7\K==]-V%^HO,H&=NG'
ML0&8%AX4[2N**S*P9P,-D"Q,9\<*B[L,^I>7.R/Y7Z#V;ON#^2^ :=-=ND=%
MQBB^WWJP:F*S1!1: -C]Q] RWRS\&E@."=,_@/TB&#:0<*':77#_=HG%<^,7
M#U P?A4XD0IKE@KK*X?;+*^S"#4! 9#%S;J11Y*)SN\&?3\I?SWX^/%I4A!,
MAPW<@X&'\8NV=&MTIXU1*_1%2D4XRI9<X#B=T+*1C)9/T8F\;=9Q5Z/FYP>^
MZ*?V0JC6%:^[<%-6!YQBLC(D23,!D_"B+#[D=8N2_J0&V^,:TY4:#7[7W,<U
M3[>@KW:@X)Z4$A8_O:;7J6_Y=Z+#O2:^7E/+'EG]ZS?C;^HFW=?<M%]V&\%/
M8-.Y.6)LCL300F*N,J-9ZO-5*R^>13W^<-?O/>'2L][%5=L'71\G434SNET\
MH[]#$+^P5MA@-<V2F>U]48,0#>-:@^UU%?WYG-CK<<!Y^<*=R8,IAPJ_"CS,
MBCV!G!RPI500H8W08/V]85]@NQ@\V:"O8<4]ZMR6:4:CN&?4CQ&C'S-<1X?L
MHTV];ICSQ#/N,9]B'" QK./PYU Q%H#$V/3W'DBXGK(SVKKAA>++IC9.J+N3
M.0@(A(C,I4M0.L-0DF^MP>L-VOSIR3DNM 7N9VFY(T>/V39E\CY_OOWCDZYM
MEN_?0L2I,(9P*^T0-;G)"2PB88:P#14IBQ7R)-*\"9^1;M/DMZ,'GF??\SO<
M%6^L<!KG$*'X-OQ.L,8% ][G(=O.S *+1WK_^6N"_VYP *M;T7P4T71ON 0R
MH_5R"(_;^*V/")KY%2LZ8(I$-)F!BKY!)\,E+X..Q.H._]FTHM$K_#4[TK<!
M(;),S<) MP3AZ(:[8BOWDY/AU9XYSX2%PS'5D9AD0M&:P2.\(-X9^A3*FTBF
M)D<M':P\RP9D]FJE/33+37KMN%7.4XO:I)F-Y-'BIJ>M=94SS1@*WD\=S3ZU
M_]JN]SB76MA&[&0(]Q!S@KZ]1QD,J.F>]4[KW"Z,0*37A!X>6?CLU/T9C8]N
MQE3]+&:YS-8M#0VLZ\I#F:0"@O,\BQGWA(0=66E.5^LU>U:W#:5265V9\+Q0
M[:[+E&S.!4$GZ+4F_X@?831G9CX:=KF"#4C6':A+N+,HN:C^74Y)1Z3\Z?->
M-E!SWG^@5T:4XO2T1C"77[:>)5G<H_),G3^QN&7_UAO(*WJZVY68Q:K/48^\
M;^&K:@=9DF&T4&V)NQ_>;];"R463,'Z.])H]00._EE=*%09PUW>,NAV5.Q.8
M <C#QOD"%_H+W-T?N'?_^#Y\ZE[4N=9]%T5N^ .GMF=EU"KM?Z OH5N:D5$3
MS5NV8)DX;XPWSXA0]CSP/WM([+VW^$G0:W.Z+RM4Y9JHELK#,R\,MXU:I6N2
M3W?N_Y W31A&L'B5*3,3T"8]DPE<)/X^(K).:<0>.HQC*$S,XKPVR2D'FG=$
M/0Q]SE_V;%S Z.2V.C8@@I](L86\IBI,W!]%C91%2>YG W5YC2Q!Y H-":58
MF*J?889KJ G G6T(C:E#K,.M$YE\*3<\#0XQXR=/BC^_Y?CT@?DON6V5\C4X
MEAB"(=3#BN.FFK$!?A4\&Y"WQ*/K8:7PQ7<%C+.?06.Z-KI11@>T5WWG>'AL
MN:  I5_1H^*QPZK!6->SNAHU<R_6Z-:]WP<Y_M.''_].*$&=)ZOM0AI"2L&\
M9FV?US+J=2S:*8XXU7W%G:):+I71=9!PKT?@=],K%@L"B?=_.<U.*D'I\Y\*
M(AK-67+=Z\[#Z3*UB&#^+=E^9]PK[Q50<5&L CI$$$ +V]F9'FQ2P7AQ0>F.
M>^]A=N93J>=9O)S.C=F#%"E5E)M=R#G\:62A:C$>G0=:IJ_F2_ID96LQ!RM8
M1J[?BXSMLM_B:[KU"^6VQ?_>+IE M6S%A*!WC];)@\F9(U^Q_MRUUH>AM(X3
MA&P4 V9O-FQ/,A9"V8+#0F+T_I5 /:+9U2E&7,P74E4G+QNHUZX3=-%QI!H]
M+XNR.;L1YV""3&5M?UO!@IDLO,Y&$,VG5A.8HN_6']0E4Y7AWY77_:%'4=9@
M(QD6B5:OHEH^U\A[9OCY?E&9L*!TEM^FH%C&A'UZUF2ZJ;]1 R026Z[6A-@3
M\XRP![?L02IV+W']$3YS5I(Y.$ZZ'LKE)M+:^2+H(@"QI!(8PIG$_MJ\ HYO
MP+#V?6L;NZ-<S<.CY\F+3-V(MO2:I)F1B'5\"'2G[D&*3@-7 UK8V&'UL+J=
MW:V]CI4O@[0T?V\TX#W%-1J/0LF;O68^OE:@M6_#99X)F\CL:YI^C>F[]\%
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MU\FZPYCZ<VM6A9)G017BD?7("O<X./S"-V$M]SBU%3F&CP2IAXA8DJ9?;->
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MH8]9&1:\U9+'X:(=3.S:(C-JO9KA15=-$8-MK'?CYF"?DA?).;$>-2I^**.
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M\A72^A:S3)Y>L&$#E%D,J !E2M 2V4"([0H+9F=$B:0AF6D8>PBHU!]&&9F
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M:^XU,AT%T]JGAL:N:%_EI Y-!A8)KC5DLP!.0?+!OZ[%D^GWTL']U:DRI2P
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MDC=<#(&7C]QIRA=QDGX1+*!ZX>Y.@M.?V>?@"Z]=X[&/C["-Q0GJ_P;"IUC
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MY/D6OG,M6E-S_[:YIJ)S4M^ZPB&;RH<5\:<@-WGPQD(9;GB3ZOV+W,O0C'.
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ML6'9%)]J[_/DY?3":74W?@G1EK8+'+K<1^IF_!/<M[VH]D,[.YJ/XF-7'K,
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MFR%"8)SF5!U:( $'N 9XA[W^(RY$*_$MJ:]+1:5?^YYJI9/]H_>:3_%$9ZT
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M=JC>%*.__R%XCP74& 6\*Q\H)]78C(Q+?KE>FY4L?;!01^_8880VDBU^0AY
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MNP*ZEAUW+B]-U:3%>[6NM!V,BYA]2V-8F[!A5*W0!MS)1$Z?+V'<&*$Q[ 5
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MUGL]O@CE86O.L=52OCQT[[QV?(_K[9Y!U7-2I_GY=S[DC4LCCWSA /5Y.')
M- >@7L EPFLAR[9O+-#4*FW^<6^B_S?ZU(KI'M>UUP\F3(O'5X3]]VW=3S,3
M##M8:TZ/HM6WX8D%;,'J ,9)=H=A7U&<B1'YT#H'N)^G5%=M*.X7>E'6Y'Z\
MZ%O5LO*9RIP'Z.*..\4NO*M?_S/26< 1MJ!-L!_5BU[.>@[WPTD<KZ=V)II<
M+)[+4Q\:AQYI,[6<N)[B(\"HK#B@V1D3,QZ-^EK6*PMJM$'%D=J19*PB>)UP
MJ7_CX%GG[9M%OM5F=Y[T#%OQ*9Z$M?,.G>?O1%!=(% 0/@UOP0NROV"%FRX5
M+;H?!O.G38^,G1E<+VU_'UQ]"3FJ+7?-^)K;V[4\'9NY,BOB.W.%FMT!@A25
MD\6F@(SD3SP?_CIDU(A^CZ;*/@IJ4-5/]07[3'N/.<1*9059,CYC-/0LBQKR
M@4V<X]\O<7JF=^9!8ZM8J."9_;=N'R-[U0^_L "0+(86:HRT"^Z'3B(.OYV>
M@)RA9GRDE#NMG:79QS79OS53ZWCRL])A(#P%VQ@L_Z+17*/B7)O?9S0YJ]([
M%"J/]_X80 Y"(=J$L/*ND%U:)9G7-U.RHVK+@:W32,)FV.A/GA;<2Y0.JA5:
MV=O9*_T'[-$"Z$@JN[+<D&1\,4Q1ML(P#6+PRG/MG0XL:APXP>.>0\;QA1E1
M\ E+S#U_*OP14:D%\[3PD!,W<[T?F.V8/?;726 F*\I&];<WK\._6- E:DQ/
M  ND6Z'1;%V0H.D]2X#)- ]-)V_;JNH8OT*W/#[,-IB"4ZTA\:O4,?H^:F]R
M;6AX;:^B'3PE>'$T//))!2GH=N=;V"D".+.)>\7T)V-W(ZVI+[@<#QE*8?@[
M6WW7^K8OXT6XXER%BNF%I#N^ 4*@!X$M2!W&DE=WSXOY;#ME>TCF/;OF^\RC
M+E9UM[RW\>&2:/Z7+X6&_D4:O2<XRS[]PH/=Z@S=UBK]A0"5[9D%SA0.P$+Z
M0;>#&W$E*^7EJ_Z%U8T)-U*\O]K*"2<ZZ)@Q-?90BMHX0!)^%U/6A[I*\8K7
M#-(2;?E\:_WC">@1F;-9^IC:2,^)QXSLDU!E=*N:B0]Y-29/ LQF*"$M:::)
MJ5-H &DY-.,/O]A@K1BEZX81F8G\3)*[ED%YL#?_V.2'1@8/XA(RF-6(]\81
MI]ND=RRVA6XV."<BCY<0ULR+#5Z4J'6U3RCP6NW9)<MWYJC[)JV+?IB5 _>Q
M\R6U8^78_-XHI:%R#W%"\?BI_O'PJS,J-GLT3O ^UY#892__=*6)GPSA0QZA
MYN1&L^5!>_N^=?\3VD<ZSPYJ.<E<NY(54A*M:Z.:5YAUSN:E2,3?FN\F_3T'
M>/@.U07?^#F%9QD91"5<V;P/VX,TI#EC]+53%%6H;@FS]Y&ZU14Q9?: SQ+?
M?-4%.;3H!GD[!=B:IO]F/>0 ?F@B[S2<T'L?P6OB15;M1^Y66= !0SM/+2^_
M^?Z[S;@N8U+OETRV#R90I/Q]S)?>;JB\OCUX"(F@7NB--<P[2L.U[39!'TC&
M0?DG?ESRY;5-%/<R(EH,5&TEI$6VW9*92*,ABC9Z_1"[F^7",%.*J30/-^YM
MC20CC86I<Q%#?;QW;V3OMW$R9(M];8>>]^9U)<Q7'(B[GJ?^:'1COY?8D/LW
MG80BHDE;S(?1QF.]QSI\)_Z& ""4N?#O'OZGO/L1#O"N(IL#O*:.C#CV,NU!
M1^KLM'U<!0R*=*+Z)^)?N7V1&Y]_^E#9^L:-.W-G\MY?%=C<RU-9R $^'QYC
M?QSD &:2M,ZEUX+L/C3U+U(&ND:QDK&(2!Q^E+>+6F6S)B!W9"2M.4TMY5S4
M$9F(D='^CDS+2LM\QY."_->NK$:SQ9&Z("*JPA<-08H7S4LKJGTO_&ZP5795
M8&0S2\(]'$([KIH5-<=;\'<IS+BG</(K?'T9HLHR-1]Y'$0U6(RT(^3/^3<9
M2#466_E?>]/Y7@,Q::MRN-#:GN>)N=@X95]S+NX8V,K8SZ4.4*8-?RI;GRG.
M=1[)M<:NDM7US=_+XJNL=C2^3]O3;VX]JUCFS=O" :[C1%"="&##;S4%+<X!
M_*% & >8AJ3)6B4W>89.N_)GCJ9,]72;C'\"]O]U.-K5EUKR=E]4DKMZ$7>4
MC3C -84#;)&+=JR<)@613S5=6DW]\V?V&3D(OMODXW4?/0E5Y/Z;# >8P?R!
M<E6L*2A+V@MQS=F4.DTQ(@3$GPAF9U,[6T/V*=2]+;5[NZ#C0^5S3?UR*EG]
MVL0/Y1EN%XW\_]&YE2X0*Y[E^X2>F*R.DBQ_\:*Q-S30.,'ZNH5F3SL5 +*B
M=KJ4P Y0)^.FM446%,5HYW)$Z$]*?G1Y%?\8/S*WHI0C:",GNO"U77S.FW>M
M] +K%0R*;G6 *4^Z,A&L N91ZB(=3:7C?HZ%G6-\&B:BRJ=]7EUM<\T)E[+V
MUXN5!NBR=YOAK] ^O4F/.$!M[U)X,:H'_TZ[ P>,CJD0?1J2Z.>JLBZYSJ<4
M13U:W'\H-:*DHF_7S*1>;. 0FE #OXK8UB?MY #DUWYXT(AAS(2P\LJT:_"Q
M<*%UC+#KPD75>NJ\U"NU%T-B93\63JJB]'FV/G& G0?! .ZG$.C#$((*(#V'
MV<*=7/5:-P^4+0=A>>>WXYUU!'[^5>_"W! 0MY;]TF.ZN.Y!1U:S\I=0"E8!
MC/.^[+W-M/--#[O@<==>:*;)*KKLN -%Z>5-YN!HYG_4D>XND=V"EC*1OH:;
M&[23'YAO>+C#^DE_O8I89-SGBL2_A0XP[S]UH=F3E:@O^XXD4&<IV_/2"''D
MW>-UU*'+*_D*M8G/%,GEZ'#-M)+,_2:[/(7- ^-]9_X7)U[D; =D%$*_ 7*
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M&/VW3-EPL1U3&M/[O[9'S+RJ]E<XZXN.OS[2,:V!;O5D[])?D.PE1 5&Q+7
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MNJ-X__XMQS_RC_PC_\@_\O\L:,[H?P-02P,$%     @ 18M75D'N_QE%!0$
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M.7$?J+J;VY3?W7B+[3VWOO6N0HET&@B0/3X5^;<J[D2=ENZ+(<D+^O"_T(O
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M+2OS0D= VN98/P6JV>G<!51C[\O; N0ZDG0K)/C0!Y5]6-(9'%S%(IWJ9MH
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M19%@SJ,E._W/;=/3%Q)I>,$_="2,S$-CXCOZ;L<B\*U28<2XQ2[P[H,3!P[
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MU)S7L_=&?LA69,4RLKS-RRHKQO:B-Q4,A9&>BY1KQ[;0AT3$!'(:8$)(*N+
M:#MKT^G<YNI69KU>;J4&K=B#_62,!L#0$NP8UK$MOI<C.B#^RQPB9]%?!EU.
M'/ME#L)AY)?%NT-]Y]^KD[SVY/NUR+^KLWW^^$16SPL>Q#)51 1Y('46Z9!
MF@H,(YD0X5-UW$9&R?O/]#,WXFD\Q%M902TL:*2U]:(_#FT_OS@$;&1*&8C5
M '_Z7B0N\*D_WN[$?O6]RAWZUO<_/L 2]R%79]#J6/R;X!G+5CH]9K/II3$3
MA"4I9,23$'DT@#1)/4BYAP3&?H($,C:M]70T-QK8B0I:6:]TDMK31W$[7 T,
M7H[0&ID#3@(UI*QL'V(6!B9'R$UD,;+_U.RL/@9H])IQ^MZ?SBYCH,6>H<7D
M^6%GN(Z-YI84-T6U1^-5E..M**HXR$7DAP@G:M\4)51 Q'$*L< <)KYD*44^
M8I%5;))!GW-CT+=[*5.>2%N552=.V91<^_?4"50L[Y9-X#<[P#D&=62B[5X#
M7 $EL(Y;K$5N0L&5T'70N+L#G 5$CLYO)CU.>GRS@.#EZ<WFU>%<E-7N-W7)
M:^T5*=0Q4=?"+MDR+S>%V-HUA(QB14 )I(&?0!1Z#!(4IE!R':&!=%H.JZ@,
MJ][GR$^-\)6_VY[X8"?_8%.3W=B84]8HB$] 7J[ 'D1BUJ YI#/SOB<G-FM8
MCE&<?2/VEJKK#<_4*%?9$A.21#*@,604J\V5.H%"&L8!Y$'B^1YG'C5SZGO1
M[MP(JA'-,K]D%ZCS=J:!ZH_,%D::6UF1CN@YR&K4;6<R*]$1X;M6H6._MK\3
M[CC\5G?.OXGU0\X_5@G?*Y>P@W\50G=9I0_@B'DR#02, K6G0)1ZD*140N9Y
M-,4HBL+4:$9>*LC<IO!.ZJOJ8[;*UW#QJ/1/_RFQ'IDO;&&VNN9V@=$%M^(7
M=3_9);H+D+IW[D[:&W:DVJ:LVNU?.D%"%$=I+$6@3T\((C^)%=-Y$H:>]'R!
ML93$R!YNU-O<Z.QHK?AJ/]])2/>;(%J+:DMH=V#J1][L@.0,S['-YCO .I*"
M/T:)JC("Q=&!I[^O20\X1FJ_/-"8O71AOHS#@&P/$R9YP*'D/(0HCE)(XB"%
ME*>"AC)FC%HEN_GG"7O_(!2 9%DEU<ZW4=K+"X/A+XY]_Z<(=9\FJGVR(/:Y
MQ*S;AZ@[CTC7![N[@N@8G*_/CS1?+L*8I"1,$$R$OE**L8 TX1%,.(J$%W$L
MS<HW'K0\-T)HA .U=.:6CWVXSML^!H,P\J0VU-_*_G%4UT$6D/V6)K.!'%6@
M:P4Y_L!0E[@/V5)\WM1^!VIICJ3TM7N\VO%CM3RG1*@UFD6IGQ)*N#3*4'.L
M\;E-O<:A2PL(:@EM'=XZP)V?@9? ,?(DM$!B@#O;H<H7^+!U&IO8<>U0C4-O
MM2//#'!1N_N>WSWDFU*=-:]7_'U5ZDJLKLLR*]>Z2,LV*J:-:?%X$F-?0I_%
MJ8YI09!@/X4B1))%/@T$-H\(M>Q\;I,Z\/P4[*0=%"AHBW__W!\;U;$7Z.\Y
M:$4'2G;0"G\4Y2%^<+9P6_C&C0C[1/YR&OYU"[_^?]'"3W;P.X^='(A;KV>=
M;9O3>=L-U';/ V]H&\-L*^^EU EJOFDWO_Q1W)$?NJZ +CJ\8MDRJ[Y)]8]O
M"\&S=?E%E$)U\; 06'@IYS'DPO,A(AZ#*4Y]F/K2)YXG0W6NLBNS-4P0FWDV
M3=FMK1X@JQ0!:_(#%#J@N=C3Y:KZ!:O4N5*_J_6I)B87W\0R?ZHO9G8U:BPK
MW@\;6!_1*&2I![&O=P"^1R'Q$5(#*W# 8NZ%ZKB\JF)P^9VY76W$T<7UZ![(
M-+[I;3MHNY&<9(S,+''C3ZBQSQ+;F51K4"6FU#J +R]FDO[%VV8FM8I<:;].
MUK==LS;H78:H(V/?0"$F-01>!M1+(^&%K0TX-GW*F$[L^R$KRG7S=WY;Y'S#
MVITC0YC1,/0AE9Q"Q-(04I'X4(:4T8B$E =&57+,NIO;T:@1\@I4(H-69M (
M;;%C/X^TP9'(*7XCD]H9Z(:<>LYC:''.<8KE1">;H9^CW4G&&)G>L\OY5J8[
MK1AKM'<^,7]KJ&_^8<*T3QFABNK7SY^56INBT)F3@BB-B0P22#V=\R'T."21
M'\/4HR&789@R9G2Q8]GOW+AXF[:[J'/.V3K;FX%MMN4< <*1Z?AXJL<KL)7Z
M"NSD=NE:;P64,Z=ZLUXG=J>W@N+0D=[N]6&<=,U8L1&\;3@3Y=NZW>L5WW6R
M#4K!3%!.0P1]'T40Q1[3U1E\'= 8^S$7*?.LTN?:=3\WAFJD!\N=^'8D98F^
M&5>-A^G(E-7"V9%\E/"?80 YHBK+SB=EK&' O"2N@:T,S0U>'XI5V^]VQL6F
M?LV"^5X0:9^84.H"XTFBC[4T@DP2RC#7MEPKY]S>WN;&3E].6%YM,W?W 6S&
M2,Y@&YF ]A#K2-I6I7*9*-L $6>IK_OZFCB9M8':A^FI35X:6$:VR6S_(2^J
M])K?M0O[MO[5(@D($K&(8<A"Q1\R$1![A,,X]5(_3B))4RO^Z.]N;@3R033.
M_&WE.LNRLOW8FE&'.\1&YHY6T*I<35=4]^1AAHFK"K3]G4U;C-9(\8.ZM&9O
MV4=(WF5K'9#T<<5UX?H-659!=BGF$D=$0DJE=@\,.4RIE-!3^PWBHX#ZB5%.
MA9,]S(TF*B%U#LF=F-9AC<>A[*<()P"-S H#L+&*1>S5_X(@P^/M3A8]V*M6
M-RRP_\'+CA3-%0/Q<!1B*B"+X@ B%O@P3;7W+\>(>Q%CV#>Z$#O>_-PF\\DM
M\.XFVG(;\ ).NQ/#[&ZYMOCL\-B+LG&84KL?"\>'@RFO:/H5.[7]=Y-N6Z=8
M>D-*P76:3+7^5Q=XG4(W;YYWCS0;AVL]KG5\\<=5N2ZJB[_R9OT@BKL'LKIY
MJJJ@_:J:6)<?5W45M 4/?.[%:NU'7%"(/$2UH;0*$D H$53Z*+9*V3V1X'/C
MHTHZP:LD<55RN-(R.]QD(VY&;',<QY$IL]('5@J!KM+=BF6 /H/N<XWFH%+]
MJBUOT]$>5.J#M=(?- !<@1H"H#Z5V_Y:H?9YRR<>-E>YSZ<2>]K\Z1,/QD$.
M]JG['[R/71<94^S9E(_1/F1??V_]O##"DJBUB:@522U+VC0>,'5JE5Z*DC3
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M7,O6, Y\^V;Q?K>7H>\HP?4,WTUH80<;4($#U@8=<-<2?N\ = -:B$"#$:A
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M->D7_X$6E,T\B+UYL+N563,/;*-(K#4E'+G.927@L<.M+.$Z[RTN5SPFL(V
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MQC$[T/4X(;&:U?4AXK!][7H$^:@%7I]C7>F)[G>/GZC2+!/8K!D"E\8;E:6
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ML+%9?'FF2I'(%'+$%<2(:\@599 EC- 2IU@H)Z-T<:2QF:"#0N2-M!ZY4IW
M=AN;J'#U[=6<02JD+U8G9![Y8[&@&RA!K(;PN85P0V\;B]W6!8[.'*_.!PR7
MQ.6BQUZ6EM,-4>DX_L5F+[MN9,MM:!G/",VR1!<0H5)"+!&'G)84*IJE/,-9
M7A(G6QHLP=AL['ZKXX9.MO)25N$;2?]Y<=M@]HKV(";Z- 5'I<!-0[S1Z  V
M2O3.O7$9OWY9-SK&'P/?QF5X')DV'!XT<'&^C<;95+;5>EFML:LJ6_;^D<T;
M"3\MEEI-UTI^GM<Z3 JARH2G.<1%R2%FJ3VKS^U?4Y0S@D6JRI:5U=&&#B>]
MDSW8IV[MV?YN1'R':NZ V7>TTR.;T;],!7BM/]@!H*E&6!L(MO7AVY?&O#,U
M#B.H#P^?O/>N' ^0_*]14QX^)=&JS:\0(6PQM+W5[M7RR;:,G*0"E;@@&<R3
M%$&<J QR5G"(!&&9)#S+J?3)+-M]^-@RR>[M&'Y+QQY6;K8]%(&>C6_5&M'*
M!:Q@\:SA*74CF:N]1P]J3TXI=?C!G[PF,"O#?O%?%_--(E*=T-N4&4\RF4MF
MODI8JLQ\H[0DD I"("H*S2A.DH047ND9G<.-;0->K^_32L2 [,X+V+I]T_$0
MZ_DKK\':E;2M&OBI$?:\[^R?Q.&$2JQLCN[!ADWK<%+\*+_#[:XP$U(SQ59[
MYYJO\O9E_;A8VI;/$[/O+#-1"ICFDD),4 995N:P4 G7/"U3A+U2/3K&&IOQ
M.$F@RS;BAN\IN_!VLRF14.S9H#0 _J@!K 4%6TGC&1,'.")9DJZ1!C4C#BH?
MVA"76\(,R*T0RQ>[Q]B4$C5='"98)4F:Z 0F*LDAYDI"5I0)E'F12B)22I3P
M,1]G1QJ;\6A6SH!JR/-@NMF&*!#U;!D:&0^J$ALYX]F%BU!$L@KGQQG4)EQ4
M]] B7+XA].B0K:NXA4WPL,^^G5>1C:5Z-.[*ICAQTP"V3 GGJ:*PR!"#..<%
M)&7*;%LRFF1YRB7V:U'I-_[8;,>'Q7RUF$VEC9"#C2XK>VZXIT75,,GW\-!O
M9ER/#GO#N_>#PT;R8W ;V^30 SG@J# (KV@'A7ZC#WQ,& 3-\2%AV&.NK)5K
M]F.K"98%30N<0N/F9!!GJ8 D9P2*,L&%5!G*"?<)C1Z-,,KXZ$XUG&KD#*R'
MVP*I2BU43B%"G)L%02:09DQ#1M*2%CKA1/C%KZX"<M!2PU@0.H:IK@&F[\C4
M!I-?+F$27D%XJ'?LXL'-\]^G;O!0O;,E@T<7^E<&_,K^G#Z]/#5IC7F1L20S
M.S\D"@4Q23+(C16$!)&\0"K17"#7O/^])X_MTVV$<T_@W\>I^SN]2ON>O\]&
MKHAU/6>UO2*=?O]Y@R7+GU1C-Q7^] 4!B>X_LS>U_+!<//\04V7D^O*M>;,$
M2SC5>0HS9NOU4&+W5[9#FI()R461%5GNG.1^;I2Q?8V5G.#+-X_L[+, =G^:
MT6#I^3.M$;$R@D9(\ 5\"TEC/PN41PI[#, &2E_? K?![5NLU/5+,'2FK9^]
M>;B4]4OR[Z6K7[PX./[\\O0RL_&2ZJ#LQ$[/ADJ^*K,=O&=_3B1/"4JIL*UR
ML+&'+(646[[K!.5"L911YAN5]AE_;)9R1WRPJ Z!Q5XD9.8=9O*=$.?(=E\P
M]Q_OWB!<'[.?C#7]9,7_6T6F9.-11H>HL? 0\.)%R+U&'SIN'@+-B6AZT&,"
M/+TF</]=K92Y\?%V+C^J5S5;5.0/S0:N/35BF$M.,@0EUPSB%)GM%RXDQ(79
M?15E7J2ITPF^[\!CLW*MS!5SF=Q*[1EG\<;?P7?L"=6!#O$VP%I^]QW!VV#-
MQ7.]Z_#U<#E[PGD@+[3%>WGA10:B5B&6AQJ 6J?3ZO.\X?S8 "WW7-N0^P,L
M?YW7W3)ZW2^^3(5]\F$I<4*T9+A@L&3*QMRHA)Q("3/%1,H4HRER;^;B-N;8
M['W#-7.1<RX88P?#'A^YWB/M>Z"!^P5H9+ZN[MT14@];'A_:@<QX _%S"_%Z
M 68-Q-'KXOU ZK3:CH\:SF#[Z;9GJSUOO:(1EUD5;.."U7<EU/25\9FZU<;X
MW<YFBS]LF]E/B^6'I9+3M=T9?-_I)51@*M-<8Z@$YA#C4D'&T@RFNI24(ETP
MYAZRO5::L9GV5@_C"K6*!+1X"IX;!\,_).(]+PG;YDX;V+?:W !F]0$;A8"V
MK5,JE:KTI.L[<05/4T [KB&F:_">7"'3%KDUU[6X.O7G"AYD^"9=U^)QLE/7
MU0\-K!YA*[O;L7_8<M17-E.5$*OU<BK62I[^]V\+X_2\34IAMB(D$1!)A,PR
M)Q@DE FH64IEB1/?S,]KA!G;*K>5&EAY/6M,KID5MW#\4%CWO;Y91G<;2JE^
MV)'T!AS,P)FK:HW [\V?]^K/-?C9?/+_%3%C- ;6L4I@KA%EV!J9"* =%='$
M>&9,0WN[_L"6R[?I_*%BP)DP4;",%"E$99Y"+$@)J4@QI(791,@B%50DUUO4
M@U''9CHW7VO5KD%MY8YA1 \1O\9:7H'C^YE%M@:MU#6[5M]V[@Q*O1JTPS%'
M8+G.P.!FHL[='&:+/L_%TK:6^*CJ/S]O6L-:'M</+ZOUXDDMOTP9G\ZFZ[<)
M)QHE7'&H!-<VXX) GLD2)H0(EJ993KE7&K?G^&.S3Q^55LME=9;SJN8='U 4
M\-T,5(^0]FRJ6LG!3ZWL?ZM[43?=I_\P\H-6@1NP42&>V0K$+I(!\QU]4%,6
M",VA40M]3&!"6=72NCUA%EDN,Z$8I%ID$&N<0);R$J9(I6F1YRF3PJ>89^_I
M7J9IL$*>Y@@9L.Y&[0[@N1F?8$CZSG&HY.JC-/F4PK&2K?:>/6PJU2FUCA*E
M3EX4[(BTM<O?V%3:MHN"T20MN=D!)4Q"C*GQ-1+"8$E+4:::8%%B3U_C8(BQ
MN1.5B_YL9*O"N &< R=0='8:KL"F?[]@PRX K'B1VU2>5S[>PGXXP-!K]QD%
M3RS/YZX,Y23J6-V_UUZS[6K\,*]H<V1!<)ZJ F8X5>:;SS'DA"E(I"S*0B4$
MY5Y=Z/R&'YL]: 2TQZ.-A#4#.6<S>Q"P H]J)NTV?OVH %</T_G<[N47NOK%
M<S?G:93IHE0*5F3-Z7;%<YP6$F;:V&BM4)YP-)FK];M-UH:F>#WX5/4*O&.L
MJK>WO^^@U:4MGXWIUX!_OPQX  ]5"&[1J*F\!A^8K2H$F&,"JZ"G!*3O?'VQ
M"4!WNBG-_*A6TX>Y3>R_9\L'X[M.N$@XE7D",R)2B'EJMH2J2""E3,@RX5I*
MZ9R><VFTL2TOM;QVN9 ;48W76<GJD>!Q$>1N8Q4=NIYM4X/:G09MN?166G ?
M'SV/])>8* Z4WK)]!Y\:-(_?Q5A9E*[P=&:I7'S(<%DHKOKL99DXWQ1:N'[[
MSR8)&!4XUT25D-!40VP<0D@$$A#Q I.2L;+(2[]J]?;18S.D=5WQ+?BG;^GU
M!BL'$QF,0,_V<*-\< 'Z!@7?JO,0- 8M-;_]9]3R\D-]+]>4;^X8N)#\4-+C
MZO&C*_SLC533R2]58\D?3VPV^_EE-9VKU6J2LTS14A%8E-:ARS6#/"DI1!E5
M.D4)R9E3(MJ9YX_-\M0B@DI&T KI]OV=0[#;%$7 I6=[Y >)\U=X0?$3F[^5
M$G]_6+S^A[FSWO>9'[;;O7//&^1#O:!,^[5>NNS_K^[=FMO&M771]_TK\+:Z
MJXQU> %!8#WL*B>=S).SN^-4XIZS5O6#"E>;IV7)BY3=R?SU&R IB;(E"J!
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M\&S5 \8H8S8.K5$*<*O5P)VZZUQY;MM'F(&1V=B*WN1(7C56< 6VXEN\=PJ
M6@/PQZTMVS!."OE0%$/O^5V'?QL'@"<X)[T!OL\9V&BMN%L5NA!LM6FK?UBB
MMLGFA>I\9E1&+(X2#D6$*$28(EME@T)BK.(D)E%&,Z^<<+=A9TR$'07 7@.P
M5<&SIYK;)+AQ77AH1V:X,U :2AN#S/Q@"M4XS6W0:?NE>0'QJDV:W]W#2&I[
M /--E<^%4'7O6<."JF[(IE95;4A^7J^>564LR6M;DJBJLQ"[OW^_KC:?UYO_
M5IM.-'O,L:$US6!,!($H4\R6ML:0&CE2BHP5J+RRRD>3=&Y4V)5W5S9XM=Z
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MBZN/A>_72PD^/3R6ZV?ET7MAT*2XD?Q84(],W7N4:\%KA/=X[V4?R<DR!+5
M_.HU]*2L.024EUPXZ!EO;AU_6FW*8E45HBE[29",,=89E)$MZ<>Q@#Q/%,Q2
ME5+SRUQE7N=LHTDZ-^Z\OKLKU1W;V.+LK9S-"=P56.]U>#,3^L4T3VY%#Y^\
MOZ<A?05V&H>NICKZK,S/FGXAY]_5H#X.]X@V]8D! YO5M^9Y;<2^X"K.,AU!
MFF8$HH0+2!)BD[XQY32RP1I>$7D.8\YM(?AUO;J#OQ;/=?V'U5UAC_[K<^.!
MB1(NL%]H+P\#<V1BO@#'<#;Q:V3&-H4[(\[# GX-@;/A>^364(6I7[=%661"
M\2S+%4P91;9Z#X9$: 43DD8L%YI%,5JL:AM-NK&/R[!.7\RN\-A^\!$MT:%]
MM+S0=J.<8 B^:<WI([V6QJPR?1JBT4I+'QGRC>M)GP;A?!'IGGO]ZTI\LS%>
MQ>9'G/#;8F/>_(3&/,IM74-D+!L491S635FETEAQ%C%,G,Z0CCU\;L9,+92-
MK8J3G_C/8"NN>TV)5^CU\\:EF(S,#[YP>-63.*7WH&(2KQXV626)4VITRTB<
MO&:@.TS<*_FT5#?Z]]4^SN66?7^G5DH7FVY?M#H6=^]I5H@3A*B-)H\BB#*<
M0(+S&"I.F4[-WS!Q:JE\N2AS^_0[@95/'55L(6K 6V4\W5G#I\G17S4)^&,[
MI%HE+/!=-6S%:[!5!'2/:4<-,+\<TU#NI.&"3.LONABP5PZARY\XT./#?MC'
M569/9TRJ\HDMJVM>U=5:%SC32:K-'BM-;?2YUBED$550<!VC2)!8"+]ST]-C
MS8T9MZ+6)W=;8<$?6W%]_3L](#OZ=<) -_:QYU#4_+TYY_$(Y<7I&6E:[\UY
ME5]Y;1QN&48;ORB^^;0RCZIK)?U:K-2GC7JH%EF:16DJ%$0R8Q#%L=DXR91
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M-"<0:6'6PY01F(B<J%1P3DC:8OUAY1@9%PSI[8CCX6P+C8V,L-M*& "SD5?
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MF6LCP2L3R23-8ZBE[>VH$P&)+?4AM,A)+'ED=FR>]3##0#N-5:5562H)RB;
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M1]WA,(DY0EF>0IPF*42:$$@-,T!)4\E(PDG$G2+:/,:<&T=TY 0[0;WZ1_H
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M*6<$QRJFJ=\9MLNH<_NF=T+7!YL=L?]C&X_J\+)?, ENA! <VI%Y(@BJ_F?
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M)>:WYUIYE+D-9VNRQKCYS18:/YG/S\+L WY=+-<3YV4)7D@RKTR RC:#-[)
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M7\,T__+G5YROD!R\#6NW)#9)WLC #:<36M<3NA9X%NY!DM'ET02GTE-IR?M
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M;'T15M,T$5:$['P$7YM-DG-<P"7F !D7)@F*CVSK"7D/$K(56/QS LOA\N[
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M(R&/G<AQ-;[!R2BX5;6"@0M0413PEGG@V8ABBT:'S896C-R4]TA)/OO)M@=
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M4=-.6NDW-+GB9S\O-N:<L?8V=$*1$(*HTSQTG1^D8S$J6*.VRXMI3UL7 <J
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MKK=Q8\-+O@/7M0E>WEP%+V\B11VS:IR__)D^U;)E,MR;5G1IH]\FP9>H(N>
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MV333@0?\>3[;%"74YN4_KY>K^6=<7 6U[_ KSM;X#M/\XVSZ/Y@GM;+:R12
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MZN SKT$+EU2TL1!+@\.L4C+N)>$9$76PV'L$S]\6=4B[UAJS*:JF6;3=6U^
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MG$-H7$KZ-FX"S)81S<WV73!M#3E@H!C))T*5:U  A#,1QM$82/'4Z<'J=4&
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M3LP;\#O')0K;&(B=3?P%N$X8\_B=R5G]QRSI?0J_D/4Q]>XRMIS8TJ#;82G
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M$M7Q1AC=LI9@M4=*HNX2"M-C>M)+!HI[JLRB[GMVEJS(+[K=5X9[Z:9M!"+
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M:^##LI8!'HH1-C,TA7RMHBSLUL6,?9=*Q(+X5H<U_A 8A+?7@S0&<X;ZD+K
M[B9:2GNV]QP8@9KCAC'88$]O5 K[+[X;W)&YL=? ! DH\R]7[(Q!]P^L?7Q'
M86O>G5D6@>X3RO[H5!J#XS9#1$"A NLKUGZ;>KR?+K)CWP7333#]^78$T]=A
MVYL,KROJC90L#(GN=WH--(GJ"E(X0M@.$FUUXZ\A_MEHE: ]GE5A[?GFF>@(
M.3\"X%R@\YKI_$Y/KS4P;B76U#$X@]REP^0]83?[6AEU2Q$%LDYW2S.8XXQF
M:I%;K=L:57LU0_P\O3_U94&9-L_8&D+S#BA"9R%ZW?13@W'I6! #:.@V<'/
M#0^;6(-/( %DLVB]#K@<MK,"8TBYR@X=RXK\<Y9JC;":$YD\<(YW5<??L D2
M]1\1;8%]#7%I]MBW#1VHD+_$TVM+ <T/G!G(GG/C3**<0Y=?X&WXI?,4\5PM
MN/0!>3"F1HB1#/*3?4FW>((Q)WI^NRCP+[P<B*]"-PM\"F\#!(V$58'M#CEN
M2 _&(SW-@QOD+ASI*M ?304YW,= -!6-,25,QM&FC;YLJ3DEET(DPZ8P@LM$
MR3,1)-E-L=;CW!P'Z\HR9PR!5PDL$Q8&DU/U-SCX&+E<%!=!4:@9GB4=FF/
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M"BM4"IO^3*>9C13!!TU\+E/Z1GB\<P87-$$0C8D04&@-&$25H^I($345\5?
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M]"SJ>9X)@R&V$")ZNP)&%;DP0X8#2"PSYMA6([ZHT1HZM.*'[:(]Q_C&F%G
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MO]O_&'-_HCO0&A'[.^"6K61-AMF<(;63JD#U'0W=RJ:T*HR$ALHLWU1:>##
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MS/_W_P%02P$"% ,4    " !%BU=6&G5&C_L)  #K1@  '@
M@ $     87)V:6YA<W!F:7IZ97)A;65N9&UE;G1N;S,N:'1M4$L! A0#%
M  @ 18M75CC0DO\+@ 0 G<TC !$              ( !-PH  &%R=FXM,C R
M,C$R,S$N:'1M4$L! A0#%     @ 18M75I6Q&) U%   ;>,  !$
M     ( !<8H$ &%R=FXM,C R,C$R,S$N>'-D4$L! A0#%     @ 18M75F56
M3"3T'@  SC(! !4              ( !U9X$ &%R=FXM,C R,C$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( $6+5U90YRGXUV0  /AX!  5              "
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M2P$"% ,4    " !%BU=6PO5UPBZ!   ;M@  %               @ ''G L
M87)V;BTR,#(R,3(S,5]G,RYJ<&=02P$"% ,4    " !%BU=6'60R4=#4   O
M\   %               @ $G'@P 87)V;BTR,#(R,3(S,5]G-"YJ<&=02P$"
M% ,4    " !%BU=6]Y\PAS1Q  "@@@  %               @ $I\PP 87)V
M;BTR,#(R,3(S,5]G-2YJ<&=02P$"% ,4    " !%BU=6?<2MJ.'E  #]"P$
M%               @ &/9 T 87)V;BTR,#(R,3(S,5]G-BYJ<&=02P$"% ,4
M    " !%BU=6,@',]?Z2  #J\P  %               @ &B2@X 87)V;BTR
M,#(R,3(S,5]G-RYJ<&=02P$"% ,4    " !%BU=6,1N &YNU @!%C@, %
M            @ '2W0X 87)V;BTR,#(R,3(S,5]G."YJ<&=02P$"% ,4
M" !%BU=6@1.)#);Z  !A9 $ %               @ &?DQ$ 87)V;BTR,#(R
M,3(S,5]G.2YJ<&=02P$"% ,4    " !%BU=60>[_&44% 0"JWPH %0
M        @ %GCA( 87)V;BTR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @
M18M75HOST,>:GP  ;2P' !4              ( !WY,3 &%R=FXM,C R,C$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( $6+5U9@VO-XQP(  !@/   <
M      "  :PS% !A<G9N+3(P,C(Q,C,Q>#$P:WAE>#(Q7S$N:'1M4$L! A0#
M%     @ 18M75NQNB%AE"   =2@  !L              ( !K384 &%R=FXM
M,C R,C$R,S%X,3!K>&5X,S$Q+FAT;5!+ 0(4 Q0    ( $6+5U;8QZ8A6 @
M '8H   ;              "  4L_% !A<G9N+3(P,C(Q,C,Q>#$P:WAE>#,Q
M,BYH=&U02P$"% ,4    " !%BU=6S']BDM,$   ^$P  &P
M@ '<1Q0 87)V;BTR,#(R,3(S,7@Q,&MX97@S,C$N:'1M4$L! A0#%     @
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#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
